PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Chao, JF; Li, HT; Cheng, KW; Yu, MS; Chang, RCC; Wang, MF				Chao, Jianfei; Li, Haitao; Cheng, Ka-Wing; Yu, Man-Shan; Chang, Raymond Chuen-Chung; Wang, Mingfu			Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells	JOURNAL OF NUTRITIONAL BIOCHEMISTRY			English	Article						Parkinson's disease; 6-Hydroxydopamine; Resveratrol; Pinostilbene; Neuroprotection	AMYLOID PEPTIDE NEUROTOXICITY; TRAUMATIC BRAIN-INJURY; LYCIUM-BARBARUM; PROTEIN-KINASE; PARTIAL NEUROPROTECTION; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; MECHANISM; ANALOGS; ACTIVATION	Resveratrol (3,4',5-trans-trihydroxystilbene) is a phytoalexin with emerging lines of evidence supporting its beneficial effects on cardiovascular systems and inhibition of carcinogenesis. It has also been reported that certain methylated resveratrol derivatives are more effective than resveratrol in the prevention/treatment of cancer. However, little is known about the impact of resveratrol and its derivatives on the development of Parkinson's disease. In this study, we compared the neuroprotective effects of resveratrol with four methylated (fully or partially) resveratrol derivatives against parkinsonian mimetic 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in SH-SY5Y cells. Release of lactate dehydrogenase and activity of caspase-3 triggered by 6-OHDA were significantly reduced by resveratrol and one of the methylated derivatives, pinostilbene (3,4'-dihydroxy-5-methoxystilbene), in a dose-dependent manner. In addition, pinostilbene exerted a potent neuroprotective effect with a wider effective concentration range than resveratrol. By using high-performance liquid chromatography, we found that uptake of pinostilbene into SH-SY5Y cells was significantly higher than that of resveratrol. Enhanced bioavailability may thus be a major factor contributing to the neuroprotective activity of pinostilbene. Moreover. Western blot analysis demonstrated that pinostilbene markedly attenuated the phosphorylation of JNK and c-Jun triggered by 6-OHDA. Besides, mammalian target of rapamycin kinase may be an intracellular target accounting for the neuroprotective effects of pinostilbene. Our findings demonstrate the potential of methylated stilbenes in neuroprotection and provide important information for further research in this field. (C) 2010 Elsevier Inc. All rights reserved.	[Chao, Jianfei; Yu, Man-Shan; Chang, Raymond Chuen-Chung] Univ Hong Kong, Lab Neurodegenerat Dis, Dept Anat, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China; [Wang, Mingfu] Univ Hong Kong, Sch Biol Sci, Fac Sci, Pokfulam, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung] Univ Hong Kong, Res Ctr Heart Brain Hormone & Healthy Aging, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pokfulam, Hong Kong, Peoples R China	Chang, RCC (corresponding author), Univ Hong Kong, Lab Neurodegenerat Dis, Dept Anat, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China.	rccchang@hkucc.hku.hk; mfwang@hkusua.hku.hk	Cheng, Ka Wing/V-9433-2019; Wang, Mingfu/D-3136-2009; Chang, Raymond Chuen-Chung/C-1107-2009; Li, Haitao/D-8440-2019	Wang, Mingfu/0000-0003-1469-3963; Chang, Raymond Chuen-Chung/0000-0001-8538-7993; Li, Haitao/0000-0001-9160-8334; Cheng, Ka Wing/0000-0002-1201-312X	HKUUniversity of Hong Kong [200711159028]; University of Hong KongUniversity of Hong Kong	The study is supported by HKU Strategic Theme Research on Drug Discovery, HKU Seed Funding for Basic Research (200711159028) to R. C.-C.C. J.C., HI. and K.-W.C. are supported by a postgraduate studentship, and M.-S.Y. is supported by a postdoctoral fellowship from the University of Hong Kong.	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Auger C, 2005, J AGR FOOD CHEM, V53, P2015, DOI 10.1021/jf048177q; Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567; Borsello T, 2007, CURR PHARM DESIGN, V13, P1875; Burns J, 2002, J AGR FOOD CHEM, V50, P3337, DOI 10.1021/jf0112973; Chang RCC, 2002, J NEUROCHEM, V83, P1215, DOI 10.1046/j.1471-4159.2002.01237.x; Chao JF, 2008, FREE RADICAL BIO MED, V45, P1019, DOI 10.1016/j.freeradbiomed.2008.07.002; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.3.CO;2-5; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Deng SL, 2006, FOOD CHEM, V98, P112, DOI 10.1016/j.foodchem.2005.05.063; Fang XY, 2005, INT J MOL MED, V16, P1109; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Fujita H, 2006, BRAIN RES, V1113, P10, DOI 10.1016/j.brainres.2006.06.079; Glinka Y, 1997, J NEURAL TRANSM-SUPP, P55; Han YS, 2004, BRIT J PHARMACOL, V141, P997, DOI 10.1038/sj.bjp.0705688; Heynekamp JJ, 2006, J MED CHEM, V49, P7182, DOI 10.1021/jm060630x; Ho YS, 2007, BRAIN RES, V1158, P123, DOI 10.1016/j.brainres.2007.04.075; Kumar A, 2007, PHARMACOLOGY, V79, P17, DOI 10.1159/000097511; Kumar P, 2006, BEHAV PHARMACOL, V17, P485, DOI 10.1097/00008877-200609000-00014; Lai CSW, 2008, BRAIN RES, V1190, P215, DOI 10.1016/j.brainres.2007.10.103; Lai SW, 2006, NEUROPHARMACOLOGY, V50, P641, DOI 10.1016/j.neuropharm.2005.11.009; Lee HH, 2007, J BIOMED SCI, V14, P819, DOI 10.1007/s11373-007-9179-x; Lin KF, 2004, EUR J NEUROSCI, V19, P2047, DOI 10.1111/j.0953-816X.2004.03245.x; Lu KT, 2006, J AGR FOOD CHEM, V54, P3126, DOI 10.1021/JF053011Q; Lu KT, 2008, J AGR FOOD CHEM, V56, P6910, DOI 10.1021/jf8007212; Lu ZB, 2006, NEUROCHEM INT, V48, P263, DOI 10.1016/j.neuint.2005.10.010; Ma ZZ, 2006, LIFE SCI, V79, P1307, DOI 10.1016/j.lfs.2006.03.050; Malagelada C, 2006, J NEUROSCI, V26, P9996, DOI 10.1523/JNEUROSCI.3292-06.2006; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Matsuoka A, 2002, MUTAT RES-GEN TOX EN, V521, P29, DOI 10.1016/S1383-5718(02)00211-5; Murias M, 2004, BIOORGAN MED CHEM, V12, P5571, DOI 10.1016/j.bmc.2004.08.008; Orsini F, 2004, J NAT PROD, V67, P421, DOI 10.1021/np0303153; Ramassamy C, 2006, EUR J PHARMACOL, V545, P51, DOI 10.1016/j.ejphar.2006.06.025; Rivera H, 2008, J APPL TOXICOL, V28, P147, DOI 10.1002/jat.1260; Schneider Y, 2003, INT J CANCER, V107, P189, DOI 10.1002/ijc.11344; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Stivala LA, 2001, J BIOL CHEM, V276, P22586, DOI 10.1074/jbc.M101846200; Stojanovic S, 2001, ARCH BIOCHEM BIOPHYS, V391, P79, DOI 10.1006/abbi.2001.2388; Suen KC, 2003, J NEUROCHEM, V87, P1413, DOI 10.1111/j.1471-4159.2003.02259.x; Suen KC, 2003, J BIOL CHEM, V278, P49819, DOI 10.1074/jbc.M306503200; Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885; Wolter F, 2002, J NUTR, V132, P298; Xu BJ, 2007, J FOOD SCI, V72, pS167, DOI 10.1111/j.1750-3841.2006.00261.x; Yu MS, 2007, INT J MOL MED, V20, P261; Yu MS, 2006, INT J MOL MED, V17, P1157; Yu MS, 2006, APOPTOSIS, V11, P687, DOI 10.1007/s10495-006-5540-1; Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010; Zheng LF, 2006, FREE RADICAL BIO MED, V41, P1807, DOI 10.1016/j.freeradbiomed.2006.09.007	49	61	64	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0955-2863	1873-4847		J NUTR BIOCHEM	J. Nutr. Biochem.	JUN	2010	21	6					482	489		10.1016/j.jnutbio.2009.02.004			8	Biochemistry & Molecular Biology; Nutrition & Dietetics	Biochemistry & Molecular Biology; Nutrition & Dietetics	602OT	WOS:000278149400004	19443200				2021-06-18	
J	Haselkorn, ML; Shellington, DK; Jackson, EK; Vagni, VA; Janesko-Feldman, K; Dubey, RK; Gillespie, DG; Cheng, DM; Bell, MJ; Jenkins, LW; Homanics, GE; Schnermann, J; Kochanek, PM				Haselkorn, M. Lee; Shellington, David K.; Jackson, Edwin K.; Vagni, Vincent A.; Janesko-Feldman, Keri; Dubey, Raghvendra K.; Gillespie, Delbert G.; Cheng, Dongmei; Bell, Michael J.; Jenkins, Larry W.; Homanics, Gregg E.; Schnermann, Jurgen; Kochanek, Patrick M.			Adenosine A(1) Receptor Activation as a Brake on the Microglial Response after Experimental Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						adenosine; A(1) receptor; BV-2 cells; head injury; Iba-1; knockout; microglia; neurotrauma	CONTROLLED CORTICAL IMPACT; STATUS EPILEPTICUS; CEREBRAL-ISCHEMIA; MOUSE-BRAIN; CELLS; NEURODEGENERATION; ANTAGONISTS; SEIZURES; LACKING; RATS	We reported that adenosine A(1) receptor (A(1)AR) knockout (KO) mice develop lethal status epilepticus after experimental traumatic brain injury (TBI), which is not seen in wild-type (WT) mice. Studies in epilepsy, multiple sclerosis, and neuro-oncology suggest enhanced neuro-inflammation and/or neuronal death in A(1)AR KO. We hypothesized that A(1)AR deficiency exacerbates the microglial response and neuronal damage after TBI. A1AR KO and WT littermates were subjected to mild controlled cortical impact (3m/sec; 0.5mm depth) to left parietal cortex, an injury level below the acute seizure threshold in the KO. At 24 h or 7 days, mice were sacrificed and serial sections prepared. Iba-1 immunostaining was used to quantify microglia at 7 days. To assess neuronal injury, sections were stained with Fluoro-Jade C (FJC) at 24 h to evaluate neuronal death in the hippocampus and cresyl violet staining at 7 days to analyze cortical lesion volumes. We also studied the effects of adenosine receptor agonists and antagonists on H-3-thymidine uptake (proliferation index) by BV-2 cells (immortalized mouse microglial). There was no neuronal death in CA1 or CA3 quantified by FJC. A(1)AR KO mice exhibited enhanced microglial response; specifically, Iba-1 + microglia were increased 20-50% more in A1AR KO versus WT in ipsilateral cortex, CA3, and thalamus, and contralateral cortex, CA1, and thalamus (p<0.05). However, contusion and cortical volumes did not differ between KO and WT. Pharmacological studies in cultured BV-2 cells indicated that A(1)AR activation inhibits microglial proliferation. A(1)AR activation is an endogenous inhibitor of the microglial response to TBI, likely via inhibition of proliferation, and this may represent a therapeutic avenue to modulate microglia after TBI.	[Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.; Cheng, Dongmei; Homanics, Gregg E.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Bell, Michael J.; Jenkins, Larry W.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Homanics, Gregg E.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.; Dubey, Raghvendra K.; Gillespie, Delbert G.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA; [Schnermann, Jurgen] NIDDKD, NIH, Bethesda, MD 20892 USA; [Dubey, Raghvendra K.] Univ Zurich Hosp, Dept Obstet & Gynecol, Clin Reprod Endocrinol, Zurich, Switzerland	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Shellington, David/0000-0001-6708-6978; Homanics, Gregg/0000-0003-3641-8153; Jackson, Edwin/0000-0002-8101-6009	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 38087, NS 30318, DK 068575]; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [32-64040.00, 320000-117998]; Oncosuisse [OCS-01551-08-2004]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK068575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038087, P50NS030318, P20NS030318, P01NS030318] Funding Source: NIH RePORTER	We thank NIH NS 38087 (PMK), NS 30318 (PMK), DK 068575 (EKJ), Swiss National Science Foundation #32-64040.00 (RKD), 320000-117998 (RKD), and Oncosuisse OCS-01551-08-2004 (RKD) for support. We thank Marci Provins and Cara Mulhollen for assisting with manuscript preparation.	Avignone E, 2008, J NEUROSCI, V28, P9133, DOI 10.1523/JNEUROSCI.1820-08.2008; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Dare E, 2007, PHYSIOL BEHAV, V92, P15, DOI 10.1016/j.physbeh.2007.05.031; Dzhala V, 2000, ANN NEUROL, V48, P632, DOI 10.1002/1531-8249(200010)48:4<632::AID-ANA10>3.3.CO;2-V; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Fink Ericka L, 2004, Pediatr Crit Care Med, V5, P139, DOI 10.1097/01.PCC.0000112376.29903.8F; Foley LM, 2009, J NEUROTRAUM, V26, P1509, DOI 10.1089/neu.2008.0747; GebickeHaerter PJ, 1996, NEUROCHEM INT, V29, P37, DOI 10.1016/0197-0186(95)00137-9; Gimenez-Llort L, 2005, SYNAPSE, V57, P8, DOI 10.1002/syn.20146; Golarai G, 2001, J NEUROSCI, V21, P8523; Gundlfinger A, 2007, J PHYSIOL-LONDON, V582, P263, DOI 10.1113/jphysiol.2007.132613; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hammarberg C, 2003, J NEUROCHEM, V86, P1051, DOI 10.1046/j.1471-4159.2003.01919.x; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Jacobson KA, 2001, HANDB EXP PHARM, V151, P129; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Lai AY, 2006, CAN J PHYSIOL PHARM, V84, P49, DOI 10.1139/y05-143; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; Olsson T, 2004, EUR J NEUROSCI, V20, P1197, DOI 10.1111/j.1460-9568.2004.03564.x; Sachse KT, 2008, J CEREBR BLOOD F MET, V28, P395, DOI 10.1038/sj.jcbfm.9600539; Si QS, 1996, EXP NEUROL, V137, P345, DOI 10.1006/exnr.1996.0035; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Strong R, 2000, NEUROPHARMACOLOGY, V39, P515, DOI 10.1016/S0028-3908(99)00156-2; Sun DQ, 2001, P NATL ACAD SCI USA, V98, P9983, DOI 10.1073/pnas.171317998; Synowitz M, 2006, CANCER RES, V66, P8550, DOI 10.1158/0008-5472.CAN-06-0365; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; van Muijlwijk-Koezen JE, 2000, J MED CHEM, V43, P2227, DOI 10.1021/jm000002u; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wollmer MA, 2001, J NEUROIMMUNOL, V115, P19, DOI 10.1016/S0165-5728(01)00257-0	36	61	62	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					901	910		10.1089/neu.2009.1075			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400012	20121416	Green Published, Green Accepted			2021-06-18	
J	Soane, L; Dai, WL; Fiskum, G; Bambrick, LL				Soane, Lucian; Dai, Wei Li; Fiskum, Gary; Bambrick, Linda L.			Sulforaphane Protects Immature Hippocampal Neurons Against Death Caused by Exposure to Hemin or to Oxygen and Glucose Deprivation	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						Nrf2; oxidative stress; ischemia/reperfusion; hemin; hippocampus	TRAUMATIC BRAIN-INJURY; ANTIOXIDANT RESPONSE ELEMENT; OXIDATIVE STRESS; INTRACEREBRAL HEMORRHAGE; NAD(P)H-QUINONE REDUCTASE; TRANSCRIPTION FACTOR; CEREBRAL-ISCHEMIA; DT-DIAPHORASE; NRF2; ASTROCYTES	Oxidative stress is a mediator of cell death following cerebral ischemia/reperfusion and heme toxicity, which can be an important pathogenic factor in acute brain injury. Induced expression of phase II detoxification enzymes through activation of the antioxidant response element (ARE)/Nrf2 pathway has emerged as a promising approach for neuroprotection. Little is known, however, about the neuroprotective potential of this strategy against injury in immature brain cells. In this study, we tested the hypothesis that sulforaphane (SFP), a naturally occurring isothiocyanate that is also a known activator of the ARE/Nrf2 antioxidant pathway, can protect immature neurons from oxidative stress-induced death. The hypothesis was tested with primary mouse hippocampal neurons exposed to either 02 and glucose deprivation (OGD) or hemin. Treatment of immature neurons with SFP immediately after the OGD during reoxygenation was effective in protecting immature neurons from delayed cell death. Exposure of immature hippocampal neurons to hemin induced significant cell death, and both pre- and cotreatment with SFP were remarkably effective in blocking cytotoxicity. RT-PCR analysis indicated that several Nrf2-dependent cytoprotective genes, including NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO1), and glutamate-cysteine ligase modifier subunit (GCLM), which is involved in glutathione biosynthesis, were up-regulated following SFP treatment both in control neurons and following exposure to OGD and hemin. These results indicate that SFP activates the ARE/Nrf2 pathway of antioxidant defense and protects immature neurons from death caused by stress paradigms relevant to those associated with ischemic and traumatic injury to the immature brain. (C) 2009 Wiley-Liss, Inc.	[Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Anesthesiol Res Labs,Dept Anesthesiol, Baltimore, MD 21201 USA	Fiskum, G (corresponding author), Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Anesthesiol Res Labs,Dept Anesthesiol, 685 W Baltimore St,MSTF 5-34, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu			DODUnited States Department of Defense [DAMD17-03-1-0745]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 HD16596]; Maryland State Stein Cell Grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034152] Funding Source: NIH RePORTER	Contract grant sponsor: DOD; Contract grant number: DAMD17-03-1-0745 (to L.L.B.); Contract grant sponsor: NIH; Contract gram number: P01 HD16596 (to G.F.); Contract grant sponsor: Maryland State Stein Cell Grant (to G.F.).	Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chen-Roetling J, 2006, BIOCHEM BIOPH RES CO, V350, P233, DOI 10.1016/j.bbrc.2006.09.036; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; Danilov CA, 2008, GLIA, V56, P801, DOI 10.1002/glia.20655; Danilov CA, 2009, GLIA, V57, P645, DOI 10.1002/glia.20793; Gamet-Payrastre L, 2006, CURR CANCER DRUG TAR, V6, P135, DOI 10.2174/156800906776056509; Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Kalda A, 1998, NEUROSCI LETT, V240, P21, DOI 10.1016/S0304-3940(97)00914-2; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Le W, 1999, J NEUROSCI RES, V56, P652; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Levy YS, 2002, NEUROTOX RES, V4, DOI 10.1080/1029842021000045624; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; LIND C, 1990, METHOD ENZYMOL, V186, P287; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Marrot L, 2008, PIGM CELL MELANOMA R, V21, P79, DOI 10.1111/j.1755-148X.2007.00424.x; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Platt JL, 1998, NAT MED, V4, P1364, DOI 10.1038/3947; PROCHASKA HJ, 1987, J BIOL CHEM, V262, P1931; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X; Satoh T, 2006, P NATL ACAD SCI USA, V103, P768, DOI 10.1073/pnas.0505723102; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Soane L, 2008, J NEUROSCI RES, V86, P1267, DOI 10.1002/jnr.21584; Song LY, 2007, J NEUROSCI RES, V85, P2186, DOI 10.1002/jnr.21367; Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	40	61	72	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2010	88	6					1355	1363		10.1002/jnr.22307			9	Neurosciences	Neurosciences & Neurology	575ZK	WOS:000276112600020	19998483	Green Accepted			2021-06-18	
J	Kharatishvili, I; Pitkanen, A				Kharatishvili, Irina; Pitkanen, Asla			Posttraumatic epilepsy	CURRENT OPINION IN NEUROLOGY			English	Article						animal models; early seizures; epilepsy; prevention; risk factors; traumatic brain injury; unprovoked seizures	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E POLYMORPHISM; TUBEROUS SCLEROSIS COMPLEX; TEMPORAL-LOBE EPILEPSY; MAMMALIAN TARGET; APOE-EPSILON-4 ALLELE; RISK-FACTORS; HEAD-INJURY; SEIZURES; RAPAMYCIN	Purpose of review The purpose of this study is to focus on recent advances in understanding of the genetic and epidemiologic risk factors, development, modeling, and prevention of epilepsy after traumatic brain injury (TBI). Recent findings Epidemiologic data suggest that the epileptogenic period after TBI in humans may last longer than previously thought. Depression was found to be an important risk factor for posttraumatic epilepsy (PTE). Once PTE has developed, it remits less often than previously reported. Moreover, patients with PTE appear to have a higher mortality rate than patients with TBI without epilepsy. In animal models it was reported that in addition to rats, also mice develop PTE. Furthermore, the immature rat brain is sensitive to TBI-induced epileptogenesis. The development of a lowered seizure threshold after TBI can be alleviated by pharmacotherapy in rats. Summary These observations provide small but encouraging steps towards a better understanding of the mechanisms of posttraumatic epileptogenesis, which is a key to developing a cure for this condition.	[Kharatishvili, Irina; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	Asla.Pitkanen@uku.fi			Medical Council of the Academy of FinlandAcademy of Finland; Sigrid Juselius FoundationSigrid Juselius Foundation; Citizens United for Research in Epilepsy	This study was supported by the Medical Council of the Academy of Finland, the Sigrid Juselius Foundation, and Citizens United for Research in Epilepsy.	AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; Anderson GD, 2009, EPILEPSY BEHAV, V16, P501, DOI 10.1016/j.yebeh.2009.08.025; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beevers CS, 2009, CANCER RES, V69, P1000, DOI 10.1158/0008-5472.CAN-08-2367; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; Eftekhar B, 2009, J NEUROSURG, V110, P319, DOI 10.3171/2008.4.17519; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; FERGUSON PL, 2009, EPILEPSIA; Golarai G, 2001, J NEUROSCI, V21, P8523; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Gurkoff GG, 2009, NEUROSCIENCE, V164, P862, DOI 10.1016/j.neuroscience.2009.08.021; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2009, ENCYCLOPEDIA OF BASIC EPILEPSY RESEARCH, VOLS 1-3, P1229; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; PANTER SS, 1985, J EXP MED, V161, P748, DOI 10.1084/jem.161.4.748; Saccucci P, 2004, NEUROGENETICS, V5, P245, DOI 10.1007/s10048-004-0192-1; Sadrzadeh SMH, 2004, CLIN CHEM, V50, P1095, DOI 10.1373/clinchem.2003.028001; SALAZAR AM, 1995, NEUROSURG CLIN N AM, V6, P715; Shavelle R, 2000, J Insur Med, V32, P163; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wong M, 2010, EPILEPSIA, V51, P27, DOI 10.1111/j.1528-1167.2009.02341.x; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; Zeng LH, 2008, ANN NEUROL, V63, P444, DOI 10.1002/ana.21331; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009	45	61	68	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	APR	2010	23	2					183	188		10.1097/WCO.0b013e32833749e4			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	577BU	WOS:000276196700015	20125011				2021-06-18	
J	Schonberger, M; Ponsford, J; Reutens, D; Beare, R; O'Sullivan, R				Schoenberger, Michael; Ponsford, Jennie; Reutens, David; Beare, Richard; O'Sullivan, Richard			The Relationship between Age, Injury Severity, and MRI Findings after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						age; aging; traumatic brain injury; magnetic resonance imaging; brain and lesion volumes	WHITE-MATTER; CEREBRAL ATROPHY; PROGNOSTIC VALUE; CNS INJURY; HEALTHY; ADULTS; DECLINE; VOLUME; INDEXES; LESIONS	Age and injury severity are among the most significant predictors of outcome after traumatic brain injury (TBI). However, only a few studies have investigated the association between, age, injury severity, and the extent of brain damage in TBI. The purpose of this study was to investigate the association between age, measures of injury severity, and brain lesion volumes, as well as viable brain volumes, following TBI. Ninety-eight individuals with mild to very severe TBI (75.5% male, mean age at injury 34.5 years) underwent a structural MRI scan, performed with a 1.5-Tesla machine, on average 2.3 years post-injury. Lesion volumes were highly skewed in their distribution and were dichotomized for statistical purposes. Measures of injury severity were Glasgow Coma Scale score (GCS) and duration of post-traumatic amnesia (PTA). Logistic regression analyses predicting lesion volumes, controlling for participants' gender, cause of injury, time from injury to MRI scan, and total brain volume, revealed that both older age and longer PTA were associated with larger lesion volumes in both grey and white matter in almost all brain regions. Older age was also associated with smaller viable grey matter volumes in most neo-cortical brain regions, while longer PTA was associated with smaller viable white matter volumes in most brain regions. The results suggest that older age worsens the impact of TBI on the brain. They also indicate the validity of duration of PTA as a measure of injury severity that is not just related to one particular injury location.	[Schoenberger, Michael; Ponsford, Jennie] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia; [Schoenberger, Michael; Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Clayton, Vic, Australia; [Reutens, David; Beare, Richard] Monash Univ, Dept Med, Monash Med Ctr, Clayton, Vic 3800, Australia; [Reutens, David] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia; [Beare, Richard] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [O'Sullivan, Richard] Epworth Med Fdn, Richmond, Vic, Australia	Schonberger, M (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton Campus,Wellington Rd,Bldg 17, Melbourne, Vic 3800, Australia.	michael_schoenberger@web.de	Reutens, David/C-7226-2018	Beare, Richard/0000-0002-7530-5664; Reutens, David/0000-0002-1652-9369			Arlinghaus KA, 2005, TXB TRAUMATIC BRAIN; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Cook IA, 2004, AM J GERIAT PSYCHIAT, V12, P190, DOI 10.1176/appi.ajgp.12.2.190; DeCarli C, 2005, NEUROBIOL AGING, V26, P491, DOI 10.1016/j.neurobiolaging.2004.05.004; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Farace E, 2000, Neurosurg Focus, V8, pe6; Fotenos AF, 2005, NEUROLOGY, V64, P1032, DOI 10.1212/01.WNL.0000154530.72969.11; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Head D, 2004, CEREB CORTEX, V14, P410, DOI 10.1093/cercor/bhh003; Hedden T, 2005, CURR OPIN NEUROL, V18, P740, DOI 10.1097/01.wco.0000189875.29852.48; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hinman JD, 2007, NEUROCHEM RES, V32, P2023, DOI 10.1007/s11064-007-9341-x; Hugenschmidt CE, 2008, CEREB CORTEX, V18, P433, DOI 10.1093/cercor/bhm080; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ketonen LM, 1998, NEUROL CLIN, V16, P581, DOI 10.1016/S0733-8619(05)70082-7; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; Kolb B, 1998, ANNU REV PSYCHOL, V49, P43, DOI 10.1146/annurev.psych.49.1.43; KOLB B, 1995, BEHAV NEUROSCI, V109, P285, DOI 10.1037/0735-7044.109.2.285; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Malloy P, 2007, CLIN NEUROPSYCHOL, V21, P73, DOI 10.1080/13854040500263583; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Pfefferbaum A, 2005, NEUROIMAGE, V26, P891, DOI 10.1016/j.neuroimage.2005.02.034; Pieperhoff P, 2008, J NEUROSCI, V28, P828, DOI 10.1523/JNEUROSCI.3732-07.2008; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; Resnick SM, 2003, J NEUROSCI, V23, P3295; Reuter-Lorenz PA, 2005, CURR OPIN NEUROBIOL, V15, P245, DOI 10.1016/j.conb.2005.03.016; Scahill RI, 2003, ARCH NEUROL-CHICAGO, V60, P989, DOI 10.1001/archneur.60.7.989; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0; Tate R., 2005, BRAIN IMPAIR, V6, P75, DOI DOI 10.1375/BRIM.2005.6.2.75; TEASDALE G, 1974, LANCET, V2, P81; Terry RD, 2001, NEUROBIOL AGING, V22, P347, DOI 10.1016/S0197-4580(00)00250-5; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	55	61	63	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2157	2167		10.1089/neu.2009.0939			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200003	19624261				2021-06-18	
J	Afari, N; Harder, LH; Madra, NJ; Heppner, PS; Moeller-Bertram, T; King, C; Baker, DG				Afari, Niloofar; Harder, Laura H.; Madra, Naju J.; Heppner, Pia S.; Moeller-Bertram, Tobias; King, Clay; Baker, Dewleen G.			PTSD, Combat Injury, and Headache in Veterans Returning From Iraq/Afghanistan	HEADACHE			English	Article						headache; posttraumatic stress disorder; combat; physical injury; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; CHRONIC PAIN; PREVALENCE; MIGRAINE; IMPACT; RACE; IRAQ; POPULATION; SYMPTOMS	Objective.- To examine the relationship between posttraumatic stress disorder, combat injury, and headache in Operation Iraqi Freedom and Operation Enduring Freedom veterans at the VA San Diego Healthcare System. Background.- Previous investigations suggest that a relationship between posttraumatic stress disorder and primary headache disorders exists and could be complicated by the contribution of physical injury, especially one that results in loss of consciousness. These associations have not been systematically examined in Operation Iraqi Freedom and Operation Enduring Freedom veterans. Methods.- In this observational cross-sectional study, a battery of self-report, standardized questionnaires was completed by 308 newly registered veterans between March and October 2006. The Davidson Trauma Scale was used to determine the degree of posttraumatic stress disorder symptoms and combat-related physical injury was assessed by self-report. The presence of headache was based on a symptom checklist measure and self-reported doctor diagnoses. Logistic regression analysis was performed to predict presence of headache and determine odds ratios and 95% confidence intervals associated with demographic, military, in-theatre, and mental health characteristics. Results.- About 40% of the veterans met the criteria for posttraumatic stress disorder; 40% self-reported current headache, 10% reported a physician diagnosis of migraine, 12% a physician diagnosis of tension-type headache, and 6% reported both types of headache. Results from the logistic regression model indicated that combat-related physical injury (odds ratio: 2.25; 95% confidence interval: 1.17-4.33) and posttraumatic stress disorder (odds ratio: 4.13; 95% confidence interval: 2.44-6.99) were independent predictors of self-reported headache. Additional analyses found that veterans with both tension and migraine headache had higher rates of posttraumatic stress disorder (chi-square [d.f. = 3] = 15.89; P = .001) whereas veterans with migraine headache alone had higher rates of combat-related physical injury (chi-square [d.f. = 9] = 22.00; P = .009). Conclusion.- Posttraumatic stress disorder and combat-related physical injury were related to higher rates of self-reported headache in newly returning veterans. Our finding that posttraumatic stress disorder and injury during combat are differentially related to migraine and tension-type headache, point to a complex relationship between physical and psychological trauma and headache. These findings have implications for a comprehensive approach to interventions for headache and the physical and psychological sequelae of trauma.	[Afari, Niloofar; Heppner, Pia S.; Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Afari, Niloofar; Harder, Laura H.; Madra, Naju J.; Heppner, Pia S.; Moeller-Bertram, Tobias; King, Clay; Baker, Dewleen G.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Afari, Niloofar; Heppner, Pia S.; Moeller-Bertram, Tobias; Baker, Dewleen G.] Vet Affairs Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Moeller-Bertram, Tobias] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA	Afari, N (corresponding author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,Mail Stop 0738, La Jolla, CA 92093 USA.		Baker, Dewleen/O-4957-2019	Baker, Dewleen/0000-0002-1736-9838	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AR051524, U01DK082325]; Department of DefenseUnited States Department of Defense; VA research grants; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01DK082325] Funding Source: NIH RePORTER	Dr. Afari is supported in part by the National Institute of Health (R01AR051524 and U01DK082325). Dr. Baker is supported in part by Department of Defense and VA research grants (Merit, HSR&D, and Cooperative Studies). Dr. Moeller-Bertram is supported in part by a grant from the Foundation for Anesthesia Education and Research. Drs. Afari, Heppner, Moeller-Bertram, and Baker are supported in part by the VA Center of Excellence for Stress and Mental Health. We appreciate the efforts and support of Mr. Michael Kilmer of the Social Work Service, and Mr. Glenn White and his staff at Member Services of the VA San Diego Healthcare System. Portions of this study were presented at the VA Mental Health Conference in July, 2008 and the 24th annual meeting of the International Society for Traumatic Stress Studies in November, 2008.	Adeney KL, 2006, AM J EPIDEMIOL, V163, pS221; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Boscarino JA, 2004, ANN NY ACAD SCI, V1032, P141, DOI 10.1196/annals.1314.011; CHIBNALL JT, 1994, HEADACHE, V34, P357, DOI 10.1111/j.1526-4610.1994.hed3406357.x; Corbie-Smith G, 2002, ARCH INTERN MED, V162, P2458, DOI 10.1001/archinte.162.21.2458; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; de Leeuw R, 2005, HEADACHE, V45, P1365, DOI 10.1111/j.1526-4610.2005.00269.x; Engel CC, 2006, PHILOS T R SOC B, V361, P707, DOI 10.1098/rstb.2006.1829; Gerber Y, 2007, MAYO CLIN PROC, V82, P933, DOI 10.4065/82.8.933; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Ifergane G, 2009, EUR J INTERN MED, V20, P182, DOI 10.1016/j.ejim.2008.05.001; Katon WJ, 2006, J TRAUMA STRESS, V19, P611, DOI 10.1002/jts.20147; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Lipton RB, 2007, NEUROLOGY, V68, P343, DOI 10.1212/01.wnl.0000252808.97649.21; Lyngberg AC, 2005, EUR J EPIDEMIOL, V20, P243, DOI 10.1007/s10654-004-6519-2; Maisto SA, 2000, PSYCHOL ASSESSMENT, V12, P186, DOI 10.1037/1040-3590.12.2.186; Moorman PG, 1999, ANN EPIDEMIOL, V9, P188, DOI 10.1016/S1047-2797(98)00057-X; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nash JM, 2006, HEADACHE, V46, P1377, DOI 10.1111/j.1526-4610.2006.00580.x; Orr SP, 2002, PSYCHIAT CLIN N AM, V25, P271, DOI 10.1016/S0193-953X(01)00007-7; Peterlin BL, 2008, HEADACHE, V48, P517, DOI 10.1111/j.1526-4610.2008.00917.x; Peterlin BL, 2009, HEADACHE, V49, P541, DOI 10.1111/j.1526-4610.2009.01368.x; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schnurr Paula P, 2004, Adv Mind Body Med, V20, P18; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1001/jama.279.5.381; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Tatrow K, 2003, HEADACHE, V43, P755, DOI 10.1046/j.1526-4610.2003.03133.x; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x; Wolfe J, 1999, PSYCHOSOM MED, V61, P532, DOI 10.1097/00006842-199907000-00018	37	61	61	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	OCT	2009	49	9					1267	1276		10.1111/j.1526-4610.2009.01517.x			10	Clinical Neurology	Neurosciences & Neurology	500OC	WOS:000270311200003	19788469				2021-06-18	
J	Potts, MB; Adwanikar, H; Noble-Haeusslein, LJ				Potts, Matthew B.; Adwanikar, Hita; Noble-Haeusslein, Linda J.			Models of Traumatic Cerebellar Injury	CEREBELLUM			English	Article						Cerebellum; Traumatic brain injury; Animal model	DIFFUSE BRAIN INJURY; PURKINJE-CELL VULNERABILITY; LATERAL FLUID PERCUSSION; HEAD-INJURY; ROTATIONAL ACCELERATION; RAT CEREBELLUM; PARASAGITTAL ZONES; AXONAL INJURY; TIME-COURSE; ALDOLASE-C	Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide. Studies of human TBI demonstrate that the cerebellum is sometimes affected even when the initial mechanical insult is directed to the cerebral cortex. Some of the components of TBI, including ataxia, postural instability, tremor, impairments in balance and fine motor skills, and even cognitive deficits, may be attributed in part to cerebellar damage. Animal models of TBI have begun to explore the vulnerability of the cerebellum. In this paper, we review the clinical presentation, pathogenesis, and putative mechanisms underlying cerebellar damage with an emphasis on experimental models that have been used to further elucidate this poorly understood but important aspect of TBI. Animal models of indirect (supratentorial) trauma to the cerebellum, including fluid percussion, controlled cortical impact, weight drop impact acceleration, and rotational acceleration injuries, are considered. In addition, we describe models that produce direct trauma to the cerebellum as well as those that reproduce specific components of TBI including axotomy, stab injury, in vitro stretch injury, and excitotoxicity. Overall, these models reveal robust characteristics of cerebellar damage including regionally specific Purkinje cell injury or loss, activation of glia in a distinct spatial pattern, and traumatic axonal injury. Further research is needed to better understand the mechanisms underlying the pathogenesis of cerebellar trauma, and the experimental models discussed here offer an important first step toward achieving that objective.	[Potts, Matthew B.; Adwanikar, Hita; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA	Noble-Haeusslein, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, 521 Parnassus Ave,Room C-224,Box 0520, San Francisco, CA 94143 USA.	linda.noble@ucsf.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS NS050159.	Ai JL, 2004, PHARMACOLOGY, V71, P192, DOI 10.1159/000078085; Ai JL, 2002, NEUROSCI LETT, V332, P155, DOI 10.1016/S0304-3940(02)00945-X; Alavi A, 1997, J NUCL MED, V38, P1717; Allen GV, 2001, NEUROSCIENCE, V102, P603, DOI 10.1016/S0306-4522(00)00519-4; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BOWER AJ, 1981, J NEUROSCI METH, V4, P181, DOI 10.1016/0165-0270(81)90052-2; Braga LW, 2007, J CHILD NEUROL, V22, P1084, DOI 10.1177/0883073807306246; Bramanti P, 1994, J Neurosurg Sci, V38, P117; BUCKI A, 2006, ACTA NEUROCHIR WIEN, V148, P93; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Carulli D, 2004, PROG NEUROBIOL, V72, P373, DOI 10.1016/j.pneurobio.2004.03.007; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHEN S, 1994, EXP NEUROL, V126, P270, DOI 10.1006/exnr.1994.1064; Culic M, 2005, ACTA NEUROBIOL EXP, V65, P11; Dayer A, 1998, Eur J Paediatr Neurol, V2, P109, DOI 10.1016/S1090-3798(98)80026-3; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GRAFMAN J, 1992, NEUROLOGY, V42, P1493, DOI 10.1212/WNL.42.8.1493; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hattori N, 2003, J NUCL MED, V44, P1709; Holmes G, 1939, BRAIN, V62, P1, DOI 10.1093/brain/62.1.1; Holmes G, 1917, BRAIN, V40, P461, DOI 10.1093/brain/40.4.461; HOLMES G, 2007, BRAIN, V130, P4; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; IWADATE Y, 1989, Neurosurgical Review, V12, P500, DOI 10.1007/BF01790695; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu Y, 2007, J CEREBR BLOOD F MET, V27, P1724, DOI 10.1038/sj.jcbfm.9600467; Louis ED, 1996, ARCH NEUROL-CHICAGO, V53, P450, DOI 10.1001/archneur.1996.00550050080027; Lupi A, 2007, CLIN NUCL MED, V32, P445, DOI 10.1097/RLU.0b013e3180537621; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MATSCHKE J, 1943, PEDIATR NEUROSURG, V4, P330; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; MYSIW W J, 1990, Brain Injury, V4, P247, DOI 10.3109/02699059009026174; Newberg AB, 2000, CLIN NUCL MED, V25, P431, DOI 10.1097/00003072-200006000-00008; Niimura K, 1999, NEUROLOGY, V52, P792, DOI 10.1212/WNL.52.4.792; OHEARN E, 1993, NEUROREPORT, V4, P299, DOI 10.1097/00001756-199303000-00018; OHearn E, 1997, J NEUROSCI, V17, P8828; OHEARN E, 1993, NEUROSCIENCE, V55, P303, DOI 10.1016/0306-4522(93)90500-F; Park E, 2007, PROG BRAIN RES, V161, P327, DOI 10.1016/S0079-6123(06)61023-6; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rossi F, 2006, CEREBELLUM, V5, P174, DOI 10.1080/14734220600786444; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Sarna JR, 2003, PROG NEUROBIOL, V70, P473, DOI 10.1016/S0301-0082(03)00114-X; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sherrard RM, 1997, NEUROREPORT, V8, P3225, DOI 10.1097/00001756-199710200-00008; Slemmer JE, 2005, PROG BRAIN RES, V148, P367, DOI 10.1016/S0079-6123(04)48029-7; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2007, EUR J NEUROSCI, V26, P649, DOI 10.1111/j.1460-9568.2007.05708.x; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; TSAI FY, 1980, J COMPUT ASSIST TOMO, V4, P291, DOI 10.1097/00004728-198006000-00002; Tuzgen S, 2003, NEUROL RES, V25, P31, DOI 10.1179/016164103101201085; VANGIJN J, 1904, BRAIN, V27, P522; Welsh JP, 2002, ADV NEUROL, V89, P331; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; Xu ZJ, 2000, TOXICOL SCI, V57, P95, DOI 10.1093/toxsci/57.1.95	87	61	63	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1473-4222	1473-4230		CEREBELLUM	Cerebellum	SEP	2009	8	3					211	221		10.1007/s12311-009-0114-8			11	Neurosciences	Neurosciences & Neurology	489PP	WOS:000269433200008	19495901	Green Published, Other Gold			2021-06-18	
J	Scherer, MR; Schubert, MC				Scherer, Matthew R.; Schubert, Michael C.			Traumatic Brain Injury and Vestibular Pathology as a Comorbidity After Blast Exposure	PHYSICAL THERAPY			English	Article							ARMY MEDICAL-CENTER; HEAD-INJURY; BATTLE CASUALTIES; GLOBAL WAR; BASE RATES; REHABILITATION; DIZZINESS; GAIT; SYMPTOMS; RECOVERY	Blasts or explosions are the most common mechanisms of injury in modern warfare. Traumatic brain injury (TBI) is a frequent consequence of exposure to such attacks. Although the management of orthopedic, integumentary, neurocognitive, and neurobehavioral sequelae in survivors of blasts has been described in the literature, less attention has been paid to the physical therapist examination and care of people with dizziness and blast-induced TBI (BITBI). Dizziness is a common clinical finding in people with BITBI; however, many US military service members who have been exposed to blasts and who are returning from Iraq and Afghanistan also complain of vertigo, gaze instability, motion intolerance, and other symptoms consistent with peripheral vestibular pathology. To date, few studies have addressed such "vestibular" complaints in service members injured by blasts. Given the demonstrated efficacy of treating the signs and symptoms associated with vestibular pathology, vestibular rehabilitation may have important implications for the successful care of service members who have been injured by blasts and who are complaining of vertigo or other symptoms consistent with vestibular pathology. In addition, there is a great need to build consensus on the clinical best practices for the assessment and management of BITBI and blast-related dizziness. The purpose of this review is to summarize the findings of clinicians and scientists conducting research on the effects of blasts with the aims of defining the scope of the problem, describing and characterizing the effects of blasts, reviewing relevant patients' characteristics and sensorimotor deficits associated with BITBI, and suggesting clinical best practices for the rehabilitation of BITBI and blast-related dizziness.	[Scherer, Matthew R.] Univ Maryland, Dept Phys Therapy & Rehabil Sci, Sch Med, Baltimore, MD 21201 USA; [Schubert, Michael C.] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA	Scherer, MR (corresponding author), Univ Maryland, Dept Phys Therapy & Rehabil Sci, Sch Med, 100 Penn St, Baltimore, MD 21201 USA.	matthew.scherer@us.army.mil					Argyros GJ, 1997, TOXICOLOGY, V121, P105, DOI 10.1016/S0300-483X(97)03659-7; BARBER HO, 1969, ANN OTO RHINOL LARYN, V78, P239, DOI 10.1177/000348946907800204; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BERMAN JM, 1978, J OTOLARYNGOL, V7, P237; Bockisch CJ, 2004, NEUROREPORT, V15, P2617, DOI 10.1097/00001756-200412030-00011; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Cancio LC, 2005, J BURN CARE REHABIL, V26, P151, DOI 10.1097/01.BCR.0000155540.31879.FB; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; *CDCP, BLAST INJ ESS FACTS; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 1997, WORLD J SURG, V21, P240, DOI 10.1007/s002689900223; Chandler D W, 1997, J Am Acad Audiol, V8, P81; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; CUDENNEC YF, 1995, MIL MED, V160, P467; *DEF VET BRAIN INJ, 2008, OIF OEF FACT SHEET J; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs Veterans health Administration, VHA HDB; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; *DVBIC WORK GROUP, 2008, SYMPT MAN MILD TRAUM; Fife TD, 2000, NEUROLOGY, V55, P1431, DOI 10.1212/WNL.55.10.1431; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; French L., 2008, J SPEC OPER MED, V8, P68; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Furman JM, 2000, PHYS THER, V80, P179, DOI 10.1093/ptj/80.2.179; Gajewski Donald, 2006, J Am Acad Orthop Surg, V14, pS183; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; GIBSON W, 1984, VERTIGO; Godbout A, 1997, BRAIN INJURY, V11, P629, DOI 10.1080/026990597123188; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; GOTTSHALL K, 2009, ASS RES OT MIDW M FE; GRIFFITHS MV, 1979, J LARYNGOL OTOL, V93, P253, DOI 10.1017/S0022215100086990; HALMAGYI GM, 1988, ARCH NEUROL-CHICAGO, V45, P737, DOI 10.1001/archneur.1988.00520310043015; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; Herdman S. J., 1990, J HEAD TRAUMA REHAB, V5, P63; HERDMAN SJ, 1993, ARCH OTOLARYNGOL, V119, P450; Herdman SJ, 1998, AM J OTOL, V19, P790; HOFFER M, 2008, ASS RES OT MIDW M FE; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer ME, 2003, OTOL NEUROTOL, V24, P633, DOI 10.1097/00129492-200307000-00017; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Javernick MA, 2006, MIL MED, V171, P200, DOI 10.7205/MILMED.171.3.200; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kerr A G, 1987, Rev Environ Health, V7, P65; KERR AG, 1978, PRACTITIONER, V221, P677; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Maskell F, 2007, BRAIN INJURY, V21, P741, DOI 10.1080/02699050701472109; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Mott F. W., 1917, J ROY ARMY MED CORPS, V29, P662; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Murray CK, 2008, J TRAUMA, V64, pS232, DOI 10.1097/TA.0b013e318163c3f5; Nelson J R, 1979, Adv Neurol, V22, P107; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pasquina PF, 2006, MIL MED, V171, P206, DOI 10.7205/MILMED.171.3.206; PEARSON BW, 1973, ARCH OTOLARYNGOL, V97, P81; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Roberts R. A., 2008, BALANCE FUNCTION ASS, P171; Rustemeyer J, 2007, BRIT J ORAL MAX SURG, V45, P556, DOI 10.1016/j.bjoms.2007.01.003; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; Scherer M, 2007, BRAIN INJURY, V21, P93, DOI 10.1080/02699050601149104; Schubert MC, 2004, PHYS THER, V84, P373, DOI 10.1093/ptj/84.4.373; Schubert MC, 2006, J VESTIBUL RES-EQUIL, V16, P1; Schubert MC, 2008, ARCH PHYS MED REHAB, V89, P500, DOI 10.1016/j.apmr.2007.11.010; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Semont A, 1988, Adv Otorhinolaryngol, V42, P290; SHEPARD N, 2008, BALANCE FUNCTION ASS, P359; Shumway-Cook A., 1995, MOTOR CONTROL THEORY; Shumway-Cook A, 2007, VESTIBULAR REHABILIT, P444; SHUPAK A, 1993, ARCH OTOLARYNGOL, V119, P1362; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; SMITHWHEELOCK M, 1991, AM J OTOL, V12, P218; Springer BA, 2006, MIL MED, V171, P203, DOI 10.7205/MILMED.171.3.203; Sylvia FR, 2001, MIL MED, V166, P918; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *USA MED DEP, TRAUM BRAIN INJ TBI; Van Campen L E, 1999, J Am Acad Audiol, V10, P231; Van Campen L E, 1999, J Am Acad Audiol, V10, P467; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; World Health Organization, 2001, INT CLASS FUNCT DIS; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; 2001, PHYS THER, V81, P307	99	61	61	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	SEP	2009	89	9					980	992		10.2522/ptj.20080353			13	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	499XN	WOS:000270260200013	19628578	Bronze			2021-06-18	
J	Benge, JF; Pastorek, NJ; Thornton, GM				Benge, Jared F.; Pastorek, Nicholas J.; Thornton, G. Matthew			Postconcussive Symptoms in OEF-OIF Veterans: Factor Structure and Impact of Posttraumatic Stress	REHABILITATION PSYCHOLOGY			English	Article; Proceedings Paper	37th Annual Meeting of the International-Neuropsychological-Society	FEB, 2009	Atlanta, GA	Int Neuropsychol Soc		factor analysis; measurement; mild traumatic brain injury; postconcussive symptoms; posttraumatic stress; veterans	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYNDROME; CONSTRUCT-VALIDITY; CHRONIC PAIN; HEAD-INJURY; QUESTIONNAIRE; IRAQ; RELIABILITY; COMPLAINTS	Purpose: Veterans with a history of mild traumatic brain injury (mTBI) are reporting postconcussive symptoms (PCSx) in addition to experiencing postdeployment physical and emotional comorbidities. The Veterans Health Administration has mandated specialized evaluation and treatment for veterans with a history of mTBI and has suggested widespread use of the Neurobehavioral Symptom Inventory (NSI) as a measure of PCSx. This study evaluated the NSI's factor structure and assessed the impact of posttraumatic stress (PTS) on the scale at the item and factor levels. Research Method. Five hundred twenty-nine charts of returning veterans who screened positive for traumatic brain injury were reviewed, and 345 who met criteria for mTBI were included in the study. Results: Results of factor analysis on the NSI revealed a difficult-to-interpret factor structure that was inconsistent with the results of civilian studies. PTS explained 5%-38% of the variance in individual PCSx, and after controlling for this variance, the factor structure more closely paralleled findings from the civilian literature. Conclusion: PTS is an important variable to account for when evaluating PCSx in veterans. Research and clinical implications for the measurement and interpretation of self-reported PCSx are discussed.	[Benge, Jared F.; Pastorek, Nicholas J.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Benge, Jared F.] Baylor Coll Med, Menninger Dept Psychiat, Houston, TX 77030 USA; [Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Thornton, G. Matthew] Univ Houston, Dept Psychol, Houston, TX 77004 USA	Benge, JF (corresponding author), Michael E DeBakey VA Med Ctr, 116 MHCL,2002 Holcombe Blvd, Houston, TX 77030 USA.	Jared.Benge@va.gov		Benge, Jared/0000-0001-6201-3278			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Centers for Disease Control and Prevention, 2008, BLAST INJ EAR BLAST; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; *DEF VET BRAIN INJ, 2006, CLIN PRACT GUID REC; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Herman D., 1993, ANN CONV INT SOC TRA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mendes T, 2008, AGING MENT HEALTH, V12, P177, DOI 10.1080/13607860701797281; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Piland SG, 2003, J ATHL TRAINING, V38, P104; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; SPSS Inc, 2007, SPSS 16 0 COMP SOFTW; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thompson B., 2004, EXPLORATORY CONFIRMA; US Government Accountability Office, 2008, VA HLTH CAR MILD TRA; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	33	61	61	0	1	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2009	54	3					270	278		10.1037/a0016736			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	488SW	WOS:000269371100004	19702425				2021-06-18	
J	Pandya, JD; Pauly, JR; Sullivan, PG				Pandya, Jignesh D.; Pauly, James R.; Sullivan, Patrick G.			The optimal dosage and window of opportunity to maintain mitochondrial homeostasis following traumatic brain injury using the uncoupler FCCP	EXPERIMENTAL NEUROLOGY			English	Article						Neuronal injury; Mitochondrial bioenergetics; Mitochondrial uncoupling; Neuroprotection; Mitochondrial Ca2+	NEURONAL DEATH; CELL-DEATH; PERMEABILITY TRANSITION; THERAPEUTIC TARGET; PROTEIN-2 PROTECTS; FOREBRAIN NEURONS; NMDA RECEPTOR; GLUTAMATE; CALCIUM; OXYGEN	Experimental traumatic brain injury (TBI) leads to a rapid and extensive necrosis at the primary site of injury that appears to be driven in part by significant mitochondrial dysfunction. The present Study is based oil the hypothesis that TBI-induced, aberrant glutamate release increases mitochondriai Ca2+ cycling/overload Ultimately leading to mitochondrial damage. Previous work from Our laboratory demonstrates that mitochondrial uncoupling during the acute phases of TBI-induced excitotoxicity can reduce mitochondrial Ca2+ uptake (cycling), ROS production and mitochondrial damage resulting in neuroprotection and improved behavioral outcome. The current study was designed to determine the optimal dosage and therapeutic window of opportunity for the potent mitochondrial uncoupler FCCP following moderate TBI. For this study, we used Young adult male Sprague-Dawley rats (300-350 g): either sham-operated or moderately (1.5 mm) injured using the controlled cortical impactor (CCI) model of TBI. In the first set of studies animals were injected with either vehicle (100% DMSO) or different Concentrations of FCCP (0.5, 1, 2.5 and 5 mg/kg in 100% DMSO) intraperitoneally at 5 min post-injury; tested behaviorally at 10 days and cortical sparing assessed at 18 days post-injury. The results demonstrate that of all the dosages tested, 2.5 mg/kg tendered the maximum improvement in behavioral outcomes and tissue spared. Using this optimal dose (2.5 mg/kg) and time point for intervention (5 min post-injury). we assessed mitochondrial bioenergetics and mitochondrial structural integrity 24 h post-injury. Furthermore,, using this dosage we assessed mitochondrial bioenergetics and Ca2+ loading at 3 and 6 h post-injury to further verify our target mechanism and establish these assessments as a valid endpoint to use as a means to determine the therapeutic window of FCCP. To begin to address the window of opportunity for maintaining mitochondrial homeostasis, the optimal dose of FCCP was then administered at 5 min, 3, 6, or 24 h post-injury and several parameters of mitochondrial function were used as outcome measures. The results demonstrate that a prolonged window of opportunity exists for targeting mitochondrial dysfunction using uncouplers following TBI and give insight into the cellular pathology associated with TBI. (C) 2009 Elseviei Inc. All rights reserved.	[Sullivan, Patrick G.] Univ Kentucky, Chandler Coll Med, SCoBIRC, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA	Sullivan, PG (corresponding author), Univ Kentucky, Chandler Coll Med, SCoBIRC, 375 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	patsull@uky.edu			National Institute of Health, U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health Service [NS 48191, NS 42196]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191, R01NS042196] Funding Source: NIH RePORTER	The research was supported by funding from the National Institute of Health, U.S. Public Health Service grant NS 48191 (to P.G.S.) and NS 42196 (to J.R.P.). The authors also thank Andrea H. Sebastian, Kristen M. Day, and Mary E. Jennes for expert technical assistance.	ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CHOI DW, 1987, J NEUROSCI, V7, P357; Conti B, 2005, J NEUROCHEM, V93, P493, DOI 10.1111/j.1471-4159.2005.03052.x; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313; HEYTLER PG, 1962, BIOCHEM BIOPH RES CO, V7, P272, DOI 10.1016/0006-291X(62)90189-4; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; LARDY H, 1954, NATURE, V174, P231, DOI 10.1038/174231b0; Liu SS, 1997, BIOSCIENCE REP, V17, P259, DOI 10.1023/A:1027328510931; LOOMIS WF, 1949, J BIOL CHEM, V179, P503; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; Mattiasson G, 2006, ANTIOXID REDOX SIGN, V8, P1, DOI 10.1089/ars.2006.8.1; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MITCHELL P, 1967, NATURE, V213, P137, DOI 10.1038/213137a0; Nicholls DG, 1999, ANN NY ACAD SCI, V893, P1, DOI 10.1111/j.1749-6632.1999.tb07813.x; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rothman Steven M., 1995, Trends in Neurosciences, V18, P57, DOI 10.1016/0166-2236(95)93869-Y; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Starkov AA, 1997, BIOSCIENCE REP, V17, P273, DOI 10.1023/A:1027380527769; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Stelmasiak Z, 2000, Med Sci Monit, V6, P426; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Wallace KB, 2000, ANNU REV PHARMACOL, V40, P353, DOI 10.1146/annurev.pharmtox.40.1.353; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	51	61	62	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2009	218	2			SI		381	389		10.1016/j.expneurol.2009.05.023			9	Neurosciences	Neurosciences & Neurology	472GE	WOS:000268117400025	19477175				2021-06-18	
J	Bruce, JM; Echemendia, RJ				Bruce, Jared M.; Echemendia, Ruben J.			HISTORY OF MULTIPLE SELF-REPORTED CONCUSSIONS IS NOT ASSOCIATED WITH REDUCED COGNITIVE ABILITIES	NEUROSURGERY			English	Article						Cognition; Concussion; Mild traumatic brain injury; Neuropsychology	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; HIGH-SCHOOL; PERFORMANCE; RECOVERY; PLAYERS; IMPACT	OBJECTIVE: The long-term impact of sports-related concussion is uncertain. Several studies using traditional neuropsychological measures have found a relationship between a previous history of concussion and reduced cognitive abilities. In contrast, studies using computerized neuropsychological measures have typically found no relationship between concussion history and cognition. In the present study, we examined the association between a self-reported concussion history and cognition using traditional and computer-based neuropsychological tests. METHODS: A computerized neuropsychological battery was administered to a sample of 858 collegiate male athletes. Of this sample, 298 athletes reported a history of concussion. A traditional neuropsychological battery was administered to a separate sample of 479 male collegiate athletes, 187 of whom reported a history of concussion. Finally, both a computerized and a traditional neuropsychological battery were administered to a third distinct sample of 175 male collegiate athletes, 57 of whom reported a history of concussion. Concussion history was assessed via self-report. None of the athletes had been concussed in the 6 months before testing. RESULTS: No significant association was found between self-reported concussion history and performance on either computerized or traditional neuropsychological tests. CONCLUSION: Findings suggest that athletes who report a distant history of concussion have minimal enduring neurocognitive deficits. Given conflicting findings in the literature, prospective studies that attempt to identify moderating factors are necessary to help determine who is at risk for long-term cognitive difficulties after concussion.	[Bruce, Jared M.] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA	Bruce, JM (corresponding author), Univ Missouri, Dept Psychol, 4825 Troost Bldg,Suite 111-G,5100 Rockhill Rd, Kansas City, MO 64110 USA.	brucejm@umkc.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BENTON AL, 1994, MULTILINGUAL APHASIA, P4409; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Bruce JM, 2004, NEUROLOGY, V63, P1516; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; REITAN R, 1985, HALSTEAD REITAN NEUR, P4409; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; SMITH A, 1973, SYMBOL DIGIT MODALIT, P4409; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; TRENERRY M, 1989, STROOP NEUROLOGICAL, P4409; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044	26	61	62	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2009	64	1					100	106		10.1227/01.NEU.0000336310.47513.C8			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	393MO	WOS:000262377600022	19145158				2021-06-18	
J	Lew, HL; Garvert, DW; Pogoda, TK; Hsu, PT; Devine, JM; White, DK; Myers, PJ; Goodrich, GL				Lew, Henry L.; Garvert, Donn W.; Pogoda, Terri K.; Hsu, Pei-Te; Devine, Jennifer M.; White, Daniel K.; Myers, Paula J.; Goodrich, Gregory L.			Auditory and visual impairments in patients with blast-related traumatic brain injury: Effect of dual sensory impairment on Functional Independence Measure	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast-related; brain injuries; dual sensory impairment; Functional Independence Measure; hearing; outcomes assessment; polytrauma; rehabilitation; sensory disorders; vision	HEARING; SOLDIERS; POPULATION; DEPRESSION; VISION; IRAQ	The frequencies of hearing impairment (HI), vision impairment (VI), or dual (hearing and vision) sensory impairment (DSI) in patients with blast-related traumatic brain injury (TBI) and their effects on functional recovery are not well documented. In this preliminary study of 175 patients admitted to a Polytrauma Rehabilitation Center, we completed hearing and vision examinations and obtained Functional Independence Measure (FIM) scores at admission and discharge for 62 patients with blast-related TBI. We diagnosed HI only, VI only, and DSI in 19%, 34%, and 32% of patients, respectively. Only 15% of the patients had no sensory impairment in either auditory or visual modality. An analysis of variance showed a group difference for the total and motor FIM scores at discharge (p < 0.04). Regression model analyses demonstrated that DSI significantly contributed to reduced gain in total (t = -2.25) and motor (t = -2.50) FIM scores (p < 0.05). Understanding the long-term consequences of sensory impairments in the functional recovery of patients with blast-related TBI requires further research.	[Lew, Henry L.; Hsu, Pei-Te; Devine, Jennifer M.] VA Boston Healthcare Syst, Dept Vet Affairs, Phys Med & Rehabil Serv, Boston, MA USA; [Lew, Henry L.; Hsu, Pei-Te] Harvard Univ, Sch Med, Boston, MA USA; [Lew, Henry L.] VA Boston Healthcare Syst, Def & Vet Brain Injury Ctr, Boston, MA USA; [Lew, Henry L.; Pogoda, Terri K.; Hsu, Pei-Te] VA Boston Healthcare Syst, Traumat Brain Injury Ctr Excellence, Boston, MA USA; [Pogoda, Terri K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA; [White, Daniel K.] Boston Univ, Med Ctr, Boston, MA USA; [Myers, Paula J.] James A Haley Vet Hosp, Audiol Sect, Tampa, FL 33612 USA	Goodrich, GL (corresponding author), VA Palo Alto Hlth Care Syst, Psychol Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	gregory.goodrich@va.gov	Goodrich, Gregory L./AAF-7184-2019; White, Daniel Kenta/AAE-8449-2021; Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780	VA Merit ReviewUS Department of Veterans Affairs [BR5008]; Quality Enhancement Research Initiative [RRP 07-339]	This material was based on work supported in part by a VA Merit Review grant (BR5008) to Dr. Lew and a Quality Enhancement Research Initiative grant (RRP 07-339) to Dr. Goodrich.	Capella-McDonnall NE, 2005, INT J GERIATR PSYCH, V20, P855, DOI 10.1002/gps.1368; CARHART R, 1959, J SPEECH HEAR DISORD, V24, P330, DOI 10.1044/jshd.2404.330; Centers for Disease Control and Prevention, INT CLASS DIS; Chia EM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1465, DOI 10.1001/archopht.124.10.1465; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lupsakko T, 2002, INT J GERIATR PSYCH, V17, P808, DOI 10.1002/gps.689; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Martin F, 1986, INTRO AUDIOLOGY; Myers Paula J., 2009, Seminars in Hearing, V30, P5, DOI 10.1055/s-0028-1111103; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Smith SL, 2008, J REHABIL RES DEV, V45, P597, DOI 10.1682/JRRD.2007.02.0023; Wong TY, 1997, SURV OPHTHALMOL, V41, P433, DOI 10.1016/S0039-6257(97)00022-2	22	61	64	0	11	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					819	826		10.1682/JRRD.2008.09.0129			8	Rehabilitation	Rehabilitation	531BQ	WOS:000272638100013	20104405	Bronze			2021-06-18	
J	Jin, W; Wang, HD; Ji, Y; Hu, QG; Yan, W; Chen, G; Yin, HX				Jin, Wei; Wang, Handong; Ji, Yan; Hu, Qingang; Yan, Wei; Chen, Gang; Yin, Hongxia			Increased intestinal inflammatory response and gut barrier dysfunction in Nrf2-deficient mice after traumatic brain injury	CYTOKINE			English	Article						Nuclear factor E2-related factor 2; Traumatic brain injury; Intestine; Inflammation	NF-KAPPA-B; NRF2 ENHANCES SUSCEPTIBILITY; MULTIPLE ORGAN FAILURE; TRANSCRIPTION FACTOR; MUCOSA STRUCTURE; HEAD-INJURY; RATS; PERMEABILITY; EXPRESSION; INDUCTION	Aim: To explore the role of nuclear factor erythroid 2-related factor 2 (Nrf2) in traumatic brain injury (TBI)-induced intestinal inflammatory response and gut barrier dysfunction in the mice. Methods: Wild-type Nrf2 (+/+) and Nrf2 (-/-)-deficient mice were subjected to a moderately severe weight-drop impact-acceleration head injury. We measured nuclear factor kappa B (NF-kappa B) by electrophoretic mobility shift assay (EMSA); tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay (ELISA); intercellular adhesion molecule-1 (ICAM-1) by immunohistochernistry; intestinal permeability by lactulose/mannitol (L/M) test; plasma endotoxin by chromogenic limulus amebocyte lysate test. Results: Intestinal levels of NF-kappa B, pro-inflammatory cytokines and ICAM-1 in Nrf2 (-/-)-deficient mice were significantly higher compared with Nrf2 (+/+) mice at 24 h after TBI. Furthermore, higher intestinal permeability and plasma level of endotoxin were observed in the Nrf2 (-/-) mice compared with Nrf2 (+/+) mice. Conclusion: Nrf2 plays an important protective role in limiting intestinal inflammatory response and gut barrier dysfunction after TBI. (C) 2008 Elsevier Ltd. All rights reserved.	[Jin, Wei; Wang, Handong; Yan, Wei; Chen, Gang; Yin, Hongxia] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Hu, Qingang; Yan, Wei] Nanjing Univ, Sch Med, Affiliated Stomatol Hosp, Dept Oral & Maxillofacial Surg, Nanjing 210008, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hdwang_nj@yahoo.com.cn	Yin, Hong/AAC-5784-2020	Yan, Wei/0000-0002-1123-0835	Jinling Hospital of China	This work was supported by grants from Jinling Hospital of China. The authors thank Dr. Bo Wu and Dr. Geng-bao Feng for technical assistance.	Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chen F, 1999, CLIN CHEM, V45, P7; Chen G, 2008, J SURG RES, V147, P92, DOI 10.1016/j.jss.2007.05.029; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; Gomes A, 2005, J BIOCHEM BIOPH METH, V65, P45, DOI 10.1016/j.jbbm.2005.10.003; Gong JP, 2002, WORLD J GASTROENTERO, V8, P923, DOI 10.3748/wjg.v8.i5.923; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Guo RF, 2007, ANTIOXID REDOX SIGN, V9, P1991, DOI 10.1089/ars.2007.1785; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Moore FA, 1999, AM J SURG, V178, P449, DOI 10.1016/S0002-9610(99)00231-7; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Shanahan F, 1999, Semin Gastrointest Dis, V10, P8; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Sun J, 2007, CYTOKINE, V40, P151, DOI 10.1016/j.cyto.2007.09.003; Surh YJ, 2005, J NUTR, V135, p2993S, DOI 10.1093/jn/135.12.2993S; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Wang P, 1998, J SURG RES, V74, P141, DOI 10.1006/jsre.1997.5246	32	61	63	0	14	ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-4666			CYTOKINE	Cytokine	OCT	2008	44	1					135	140		10.1016/j.cyto.2008.07.005			6	Biochemistry & Molecular Biology; Cell Biology; Immunology	Biochemistry & Molecular Biology; Cell Biology; Immunology	369NG	WOS:000260700600021	18722136				2021-06-18	
J	Enzinger, C; Ropele, S; Fazekas, F; Loitfelder, M; Gorani, F; Seifert, T; Reiter, G; Neuper, C; Pfurtscheller, G; Muller-Putz, G				Enzinger, Christian; Ropele, Stefan; Fazekas, Franz; Loitfelder, Marisa; Gorani, Faton; Seifert, Thomas; Reiter, Gudrun; Neuper, Christa; Pfurtscheller, Gert; Mueller-Putz, Gernot			Brain motor system function in a patient with complete spinal cord injury following extensive brain-computer interface training	EXPERIMENTAL BRAIN RESEARCH			English	Article						functional MRI; motor recovery; brain-computer interface; spinal cord injury; motor imagery	EEG-BASED CONTROL; PARAPLEGIC PATIENTS; HAND MOVEMENTS; FOOT MOVEMENTS; IMAGERY; ACTIVATION; STROKE; REHABILITATION; COMMUNICATION; STIMULATION	Although several features of brain motor function appear to be preserved even in chronic complete SCI, previous functional MRI (fMRI) studies have also identified significant derangements such as a strongly reduced volume of activation, a poor modulation of function and abnormal activation patterns. It might be speculated that extensive motor imagery training may serve to prevent such abnormalities. We here report on a unique patient with a complete traumatic SCI below C5 who learned to elicit electroencephalographic signals beta-bursts in the midline region upon imagination of foot movements. This enabled him to use a neuroprosthesis and to "walk from thought" in a virtual environment via a brain-computer interface (BCI). We here used fMRI at 3T during imagined hand and foot movements to investigate the effects of motor imagery via persistent BCI training over 8 years on brain motor function and compared these findings to a group of five untrained healthy age-matched volunteers during executed and imagined movements. We observed robust primary sensorimotor cortex (SMC) activity in expected somatotopy in the tetraplegic patient upon movement imagination while such activation was absent in healthy untrained controls. Sensorimotor network activation with motor imagery in the patient (including SMC contralateral to and the cerebellum ipsilateral to the imagined side of movement as well as supplementary motor areas) was very similar to the pattern observed with actual movement in the controls. We interpret our findings as evidence that BCI training as a conduit of motor imagery training may assist in maintaining access to SMC in largely preserved somatopy despite complete deafferentation.	[Enzinger, Christian; Ropele, Stefan; Fazekas, Franz; Loitfelder, Marisa; Seifert, Thomas; Reiter, Gudrun] Med Univ, Dept Neurol, A-8036 Graz, Austria; [Enzinger, Christian] Med Univ, Div Neuroradiol, Dept Radiol, A-8036 Graz, Austria; [Loitfelder, Marisa; Neuper, Christa] Karl Franzens Univ Graz, Inst Psychol, Graz, Austria; [Gorani, Faton] Univ Erlangen Nurnberg, Dept Neurosurg, Erlangen, Germany; [Neuper, Christa; Pfurtscheller, Gert; Mueller-Putz, Gernot] Graz Univ Technol, Lab Brain Comp Interfaces, Inst Knowledge Discovery, A-8010 Graz, Austria	Enzinger, C (corresponding author), Med Univ, Dept Neurol, Auenbruggerpl 22, A-8036 Graz, Austria.	chris.enzinger@meduni-graz.at		Muller-Putz, Gernot/0000-0002-0087-3720	FWF Austrian Science FundAustrian Science Fund (FWF) [P15158]	This work has been supported by the FWF Austrian Science Fund (SR, grant number P15158), "Lorenz Bohler Gesellschaft" and "Allgemeine Unfallversicherung AUVA" (GP, G-M P). We thank the patient for his enthusiasm with the BCI training and this project and Karin Brodtrager for technical assistance.	Alkadhi H, 2005, CEREB CORTEX, V15, P131, DOI 10.1093/cercor/bhh116; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Binkofski F, 2004, NEUROLOGY, V63, P1223, DOI 10.1212/01.WNL.0000140468.92212.BE; Birbaumer N, 2007, J PHYSIOL-LONDON, V579, P621, DOI 10.1113/jphysiol.2006.125633; Cramer SC, 2005, BRAIN, V128, P2941, DOI 10.1093/brain/awh648; Cramer SC, 2007, EXP BRAIN RES, V177, P233, DOI 10.1007/s00221-006-0662-9; de Vries S, 2007, J REHABIL MED, V39, P5, DOI 10.2340/16501977-0020; Ehrsson HH, 2003, J NEUROPHYSIOL, V90, P3304, DOI 10.1152/jn.01113.2002; Floyer-Lea A, 2005, J NEUROPHYSIOL, V94, P512, DOI 10.1152/jn.00717.2004; Friehs GM, 2004, STROKE, V35, P2702, DOI 10.1161/01.STR.0000143235.93497.03; Gerardin E, 2000, CEREB CORTEX, V10, P1093, DOI 10.1093/cercor/10.11.1093; Hanakawa T, 2003, J NEUROPHYSIOL, V89, P989, DOI 10.1152/jn.00132.2002; Hotz-Boenden-Naker S, 2008, NEUROIMAGE, V39, P383, DOI 10.1016/j.neuroimage.2007.07.065; Jackson PL, 2003, NEUROIMAGE, V20, P1171, DOI 10.1016/S1053-8119(03)00369-0; Johnson-Frey SH, 2004, BRAIN COGNITION, V55, P328, DOI 10.1016/j.bandc.2004.02.032; Kalb RG, 2003, ARCH NEUROL-CHICAGO, V60, P805, DOI 10.1001/archneur.60.6.805; Kasess CH, 2008, NEUROIMAGE, V40, P828, DOI 10.1016/j.neuroimage.2007.11.040; Kirshblum SC, 2007, ARCH PHYS MED REHAB, V88, pS62, DOI 10.1016/j.apmr.2006.12.003; Lacourse MG, 2005, NEUROIMAGE, V27, P505, DOI 10.1016/j.neuroimage.2005.04.025; Lauer RT, 1999, NEUROREPORT, V10, P1767, DOI 10.1097/00001756-199906030-00026; Leeb R, 2007, COMPUT INTEL NEUROSC, V2007, DOI [10.1155/2007/79642., DOI 10.1155/2007/79642]; Muller-Putz GR, 2007, BRAIN RES, V1137, P84, DOI 10.1016/j.brainres.2006.12.052; Neuper C, 2006, PROG BRAIN RES, V159, P393, DOI 10.1016/S0079-6123(06)59025-9; Pfurtscheller G, 2000, NEUROSCI LETT, V292, P211, DOI 10.1016/S0304-3940(00)01471-3; Pfurtscheller G, 2006, BRAIN RES, V1071, P145, DOI 10.1016/j.brainres.2005.11.083; Pfurtscheller G, 2005, EURASIP J APPL SIG P, V2005, P3152, DOI 10.1155/ASP.2005.3152; Pfurtscheller G, 2003, NEUROSCI LETT, V351, P33, DOI 10.1016/S0304-3940(03)00947-9; Sabbah P, 2002, J NEUROTRAUM, V19, P53, DOI 10.1089/089771502753460231; Schmahmann J.D., 2000, MRI ATLAS HUMAN CERE; Sharma N, 2006, STROKE, V37, P1941, DOI 10.1161/01.STR.0000226902.43357.fc; Suga R, 1999, J NEUROL SCI, V167, P102, DOI 10.1016/S0022-510X(99)00148-3; Tobimatsu S, 1998, J NEUROL, V245, P256, DOI 10.1007/s004150050215; Weiller C, 1996, NEUROIMAGE, V4, P105, DOI 10.1006/nimg.1996.0034; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3; Woolrich MW, 2004, NEUROIMAGE, V21, P1732, DOI 10.1016/j.neuroimage.2003.12.023; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127	37	61	64	1	27	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	SEP	2008	190	2					215	223		10.1007/s00221-008-1465-y			9	Neurosciences	Neurosciences & Neurology	337RP	WOS:000258453500010	18592230				2021-06-18	
J	McHale, S; Hunt, N				McHale, Sue; Hunt, Nigel			Executive function deficits in short-term abstinent cannabis users	HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL			English	Article						cannabis; marijuana; prospective memory; executive function; visual memory; verbal fluency	TRAUMATIC BRAIN-INJURY; PROSPECTIVE MEMORY; MARIJUANA USERS; DECISION-MAKING; WORKING-MEMORY; VERBAL FLUENCY; PERFORMANCE; EVERYDAY; RECEPTOR; ECSTASY	Objectives Few cognitive tasks are adequately sensitive to show the small decrements in performance in abstinent chronic cannabis users. In this series of three experiments we set out to demonstrate a variety of tasks that are sufficiently sensitive to show differences in visual memory, verbal memory, everyday memory and executive function between controls and cannabis users. Methods A series of three studies explored cognitive function deficits in cannabis users (phonemic verbal fluency, visual recognition and immediate and delayed recall, and prospective memory) in short-term abstinent cannabis users. Participants were selected using snowball sampling, with cannabis users being compared to a standard control group and a tobacco-use control group. Results The cannabis users, compared to both control groups, had deficits on verbal fluency, visual recognition, delayed visual recall, and short- and long-interval prospective memory. There were no differences for immediate visual recall. Conclusions These findings suggest that cannabis use leads to impaired executive function. Further research needs to explore the longer term impact of cannabis use. Copyright (c) 2008 John Wiley & Sons, Ltd.	[McHale, Sue] Sheffield Hallam Univ, Fac Dev & Soc, Brain Behav & Cognit Grp, Sheffield S10 2BP, S Yorkshire, England; [Hunt, Nigel] Univ Nottingham, Inst Work Hlth & Org, Nottingham NG7 2RD, England	McHale, S (corresponding author), Sheffield Hallam Univ, Fac Dev & Soc, Brain Behav & Cognit Grp, Sheffield S10 2BP, S Yorkshire, England.	s.l.mchale@shu.ac.uk	mchale, sue l/B-8743-2009; Hunt, Nigel C/B-8755-2009	Hunt, Nigel C/0000-0002-8492-6577			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baddeley A., 1994, DOORS PEOPLE TEST; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Benton AL, 1967, CORTEX, V3, P32, DOI [10.1016/S0010-9452(67)80005-4, DOI 10.1016/S0010-9452(67)80005-4]; Bolla KI, 2002, NEUROLOGY, V59, P1337, DOI 10.1212/01.WNL.0000031422.66442.49; Bolla KI, 2005, NEUROIMAGE, V26, P480, DOI 10.1016/j.neuroimage.2005.02.012; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; Eldreth DA, 2004, NEUROIMAGE, V23, P914, DOI 10.1016/j.neuroimage.2004.07.032; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GoldmanRakic P. S., 1987, HDB PHYSL NERVOUS SY; Grant I, 2003, J INT NEUROPSYCH SOC, V9, P679, DOI 10.1017/S1355617703950016; Grant S, 2000, NEUROPSYCHOLOGIA, V38, P1180, DOI 10.1016/S0028-3932(99)00158-X; Heffernan TM, 2005, DRUG ALCOHOL DEPEN, V78, P235, DOI 10.1016/j.drugalcdep.2004.11.008; Heffernan TM, 2001, HUM PSYCHOPHARM CLIN, V16, P607, DOI 10.1002/hup.349; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Kanayama G, 2004, PSYCHOPHARMACOLOGY, V176, P239, DOI 10.1007/s00213-004-1885-8; KOPP UA, 2000, 1 INT C PROSP MEM U; LOGIE RH, 1995, CAMBRIDGE HDB VISUOS; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; OWEN AM, 1995, NEUROPSYCHOLOGIA, V33, P1, DOI 10.1016/0028-3932(94)00098-A; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P521, DOI 10.1001/jama.275.7.521; Pope HG, 2001, ARCH GEN PSYCHIAT, V58, P909, DOI 10.1001/archpsyc.58.10.909; Rabbitt P., 1997, METHODOLOGY FRONTAL; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; Rodgers J, 2001, HUM PSYCHOPHARM CLIN, V16, P619, DOI 10.1002/hup.345; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; SCHWARTZ RH, 1989, AM J DIS CHILD, V143, P1214, DOI 10.1001/archpedi.1989.02150220110030; SINNOTT J, 1989, EVERYDAY COGNITION A; SMITH SS, 1991, ADDICTIVE DRUG SURVE; SMYTH MM, 1994, MEM COGNITION, V22, P1, DOI 10.3758/BF03202756; SMYTH MM, 1989, Q J EXP PSYCHOL-A, V41, P235, DOI 10.1080/14640748908402363; Solowij N, 2002, JAMA-J AM MED ASSOC, V287, P1123, DOI 10.1001/jama.287.9.1123; Solowij N., 1998, CANNABIS COGNITIVE F; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Whitlow CT, 2004, DRUG ALCOHOL DEPEN, V76, P107, DOI 10.1016/j.drugalcdep.2004.04.009; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO	38	61	62	1	15	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	0885-6222			HUM PSYCHOPHARM CLIN	Hum. Psychopharmacol.-Clin. Exp.	JUL	2008	23	5					409	415		10.1002/hup.941			7	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology	328WP	WOS:000257829200005	18421794				2021-06-18	
J	Ayaz, D; Leyssen, M; Koch, M; Yan, JK; Srahna, M; Sheeba, V; Fogle, KJ; Holmes, TC; Hassan, BA				Ayaz, Derya; Leyssen, Maarten; Koch, Marta; Yan, Jiekun; Srahna, Mohammed; Sheeba, Vasu; Fogle, Keri J.; Holmes, Todd C.; Hassan, Bassem A.			Axonal injury and regeneration in the adult brain of Drosophila	JOURNAL OF NEUROSCIENCE			English	Article						Drosophila; explant; injury; regeneration; signal transduction	CIRCADIAN PACEMAKER NEURONS; PROTEIN-KINASE-A; SPINAL-CORD; NEURODEGENERATIVE DISEASE; NEURITE ARBORIZATION; SIGNAL-TRANSDUCTION; BEHAVIORAL RHYTHMS; CYCLIC-AMP; C-JUN; TIMELESS	Drosophila melanogaster is a leading genetic model system in nervous system development and disease research. Using the power of fly genetics in traumatic axonal injury research will significantly speed up the characterization of molecular processes that control axonal regeneration in the CNS. We developed a versatile and physiologically robust preparation for the long-term culture of the whole Drosophila brain. We use this method to develop a novel Drosophila model for CNS axonal injury and regeneration. We first show that, similar to mammalian CNS axons, injured adult wild-type fly CNS axons fail to regenerate, whereas adult-specific enhancement of protein kinase A activity increases the regenerative capacity of lesioned neurons. Combined, these observations suggest conservation of neuronal regeneration mechanisms after injury. We next exploit this model to explore pathways that induce robust regeneration and find that adult-specific activation of c-Jun N-terminal protein kinase signaling is sufficient for de novo CNS axonal regeneration injury, including the growth of new axons past the lesion site and into the normal target area.	[Ayaz, Derya; Leyssen, Maarten; Koch, Marta; Yan, Jiekun; Srahna, Mohammed; Hassan, Bassem A.] Flanders Inst Biotechnol VIB, Dept Mol & Dev Genet, Lab Neurogenet, B-3000 Louvain, Belgium; [Ayaz, Derya; Leyssen, Maarten; Koch, Marta; Yan, Jiekun; Srahna, Mohammed; Holmes, Todd C.; Hassan, Bassem A.] Katholieke Univ Leuven, Sch Med, Dept Human Genet, B-3000 Louvain, Belgium; [Ayaz, Derya; Hassan, Bassem A.] Katholieke Univ Leuven, Grp Biomed, Program Mol & Dev Genet, B-3000 Louvain, Belgium; [Hassan, Bassem A.] Katholieke Univ Leuven, Grp Biomed, Program Mol & Cognit Neurosci, B-3000 Louvain, Belgium; [Sheeba, Vasu; Fogle, Keri J.; Holmes, Todd C.] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	Hassan, BA (corresponding author), Flanders Inst Biotechnol VIB, Dept Mol & Dev Genet, Lab Neurogenet, B-3000 Louvain, Belgium.	bassem.hassan@med.kuleuven.be	Hassan, Bassem A/D-5221-2012	Hassan, Bassem A/0000-0001-9533-4908; Holmes, Todd/0000-0001-8152-8832; Vasu, Sheeba/0000-0003-2924-7130	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS046750-03, R01 NS046750-04, R01 NS046750-02, R01-NS046750, R01 NS046750, R01 NS046750-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046750] Funding Source: NIH RePORTER		Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Belenky M, 1996, NEUROSCIENCE, V70, P127, DOI 10.1016/0306-4522(95)00327-F; Berdnik D, 2006, J NEUROSCI, V26, P3367, DOI 10.1523/JNEUROSCI.4941-05.2006; Bier E, 2005, NAT REV GENET, V6, P9, DOI 10.1038/nrg1503; Bilen J, 2005, ANNU REV GENET, V39, P153, DOI 10.1146/annurev.genet.39.110304.095804; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown HLD, 2006, DEVELOPMENT, V133, P275, DOI 10.1242/dev.02191; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Collin C, 1997, J NEUROPHYSIOL, V77, P1614; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; Gu HY, 2006, J NEUROSCI, V26, P265, DOI 10.1523/JNEUROSCI.4109-05.2006; Hallem EA, 2004, TRENDS GENET, V20, P453, DOI 10.1016/j.tig.2004.06.015; Hardin PE, 2005, CURR BIOL, V15, pR714, DOI 10.1016/j.cub.2005.08.019; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Hassan BA, 2000, NEURON, V25, P549, DOI 10.1016/S0896-6273(00)81059-4; Hoopfer ED, 2006, NEURON, V50, P883, DOI 10.1016/j.neuron.2006.05.013; Kaneko M, 2000, J COMP NEUROL, V422, P66, DOI 10.1002/(SICI)1096-9861(20000619)422:1<66::AID-CNE5>3.0.CO;2-2; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kiger JA, 2001, GENETICS, V158, P1157; Kiger JA, 1999, GENETICS, V152, P281; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leyssen M, 2005, EMBO J, V24, P2944, DOI 10.1038/sj.emboj.7600757; Leyssen M, 2007, EMBO REP, V8, P46, DOI 10.1038/sj.embor.7400869; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MacDonald JM, 2006, NEURON, V50, P869, DOI 10.1016/j.neuron.2006.04.028; Margulies C, 2005, CURR BIOL, V15, pR700, DOI 10.1016/j.cub.2005.08.024; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; Miesenbock G, 2005, ANNU REV NEUROSCI, V28, P533, DOI 10.1146/annurev.neuro.28.051804.101610; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Nitabach MN, 2002, CELL, V109, P485, DOI 10.1016/S0092-8674(02)00737-7; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Raivich G, 2007, BRAIN RES REV, V53, P287, DOI 10.1016/j.brainresrev.2006.09.005; Reed BH, 2001, CURR BIOL, V11, P1098, DOI 10.1016/S0960-9822(01)00318-9; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Shafer OT, 2002, J NEUROSCI, V22, P5946; Sheeba V, 2008, J NEUROPHYSIOL, V99, P976, DOI 10.1152/jn.00930.2007; Sheeba V, 2008, J NEUROSCI, V28, P217, DOI 10.1523/JNEUROSCI.4087-07.2008; Shulman JM, 2003, CURR OPIN NEUROL, V16, P443, DOI 10.1097/01.wco.0000084220.82329.60; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Srahna M, 2006, PLOS BIOL, V4, P2076, DOI 10.1371/journal.pbio.0040348; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Weissman TA, 2004, NEURON, V43, P647, DOI 10.1016/j.neuron.2004.08.015; Yanik MF, 2004, NATURE, V432, P822, DOI 10.1038/432822a; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956	49	61	61	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 4	2008	28	23					6010	6021		10.1523/JNEUROSCI.0101-08.2008			12	Neurosciences	Neurosciences & Neurology	308QF	WOS:000256404400016	18524906	Green Accepted, Bronze, Green Published			2021-06-18	
J	Lyons, KE; Pahwa, R				Lyons, Kelly E.; Pahwa, Rajesh			Deep brain stimulation and tremor	NEUROTHERAPEUTICS			English	Article						deep brain stimulation; tremor; essential tremor; primary writing tremor; multiple sclerosis tremor; post-traumatic tremor	CHRONIC THALAMIC-STIMULATION; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; ELECTRICAL-STIMULATION; SUBTHALAMIC AREA; THALAMOTOMY; NUCLEUS; EFFICACY; MANAGEMENT	Deep brain stimulation (DBS) has been used to treat various tremor disorders for several decades. Medication-resistant, disabling essential tremor (ET) is the most common tremor disorder treated with DBS. The treatment has been consistently reported to result in significant benefit in upper extremity, as well as head and voice tremor, all of which were improved more dramatically with bilateral procedures. These benefits have been demonstrated to be sustained for up to 7 years. DBS has also been shown to be beneficial for the tremor associated with multiple sclerosis and post-traumatic tremor; however, fewer cases have been reported and the benefit is less consistent, less dramatic, and more transient than that seen with ET. The ventral intermediate nucleus of the thalamus is the most common DBS target for tremor disorders, but more recent studies have demonstrated benefits in tremor front DBS of the subthalamic area, primarily the zona incerta, Surgical complications are relatively uncommon and are generally less frequent than those seen with thalamotomy. Stimulation-related effects are usually mild and resolve with adjustment of stimulation parameters. DBS is thus a relatively safe and effective treatment for tremor disorders, particularly for medication-resistant, disabling ET, but may also have some role in medication-resistant, disabling tremor associated with multiple sclerosis and traumatic head injury.	[Lyons, Kelly E.; Pahwa, Rajesh] Univ Kansas, Med Ctr, Dept Neurol, Parkinsons Dis & Movement Disorder Ctr, Kansas City, KS 66160 USA	Lyons, KE (corresponding author), Univ Kansas, Med Ctr, Dept Neurol, Parkinsons Dis & Movement Disorder Ctr, 3599 Rainbow Blvd,Mailstop 2012, Kansas City, KS 66160 USA.	lyons.kelly@att.net					ALESCH F, 1995, ACTA NEUROCHIR, V136, P75, DOI 10.1007/BF01411439; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; Berk C, 2002, J NEUROSURG, V96, P615, DOI 10.3171/jns.2002.96.3.0615; Berk C, 2002, J NEUROSURG, V97, P815, DOI 10.3171/jns.2002.97.4.0815; BLOND S, 2001, ACTA NEUROCHIR S, V52, P109; BROGGI G, 1993, MOVEMENT DISORD, V8, P206, DOI 10.1002/mds.870080217; Deuschl G, 2002, MOVEMENT DISORD, V17, pS102, DOI 10.1002/mds.10150; Deuschl G, 1998, MOVEMENT DISORD, V13, P2, DOI 10.1002/mds.870131303; Foote KD, 2005, NEUROSURGERY, V56, P415, DOI 10.1227/01.NEU.0000147978.67424.42; Geny C, 1996, MOVEMENT DISORD, V11, P489, DOI 10.1002/mds.870110503; Hariz GM, 1998, MOVEMENT DISORD, V13, P78, DOI 10.1002/mds.870130117; HASSLER R, 1960, BRAIN, V83, P337, DOI 10.1093/brain/83.2.337; Kitagawa M, 2000, NEUROLOGY, V55, P114, DOI 10.1212/WNL.55.1.114; Koller W, 1997, ANN NEUROL, V42, P292, DOI 10.1002/ana.410420304; Koller WC, 1999, MOVEMENT DISORD, V14, P847, DOI 10.1002/1531-8257(199909)14:5<847::AID-MDS1021>3.0.CO;2-G; Koller WC, 2001, MOVEMENT DISORD, V16, P464, DOI 10.1002/mds.1089; Krauss JK, 2002, NEUROSURGERY, V50, P927, DOI 10.1097/00006123-200205000-00003; Krauss JK, 2001, NEUROSURGERY, V48, P535, DOI 10.1097/00006123-200103000-00015; Kumar K, 1999, STEREOT FUNCT NEUROS, V72, P47, DOI 10.1159/000029671; Limousin P, 1999, J NEUROL NEUROSUR PS, V66, P289, DOI 10.1136/jnnp.66.3.289; Lyons KE, 2003, DRUG SAFETY, V26, P461, DOI 10.2165/00002018-200326070-00003; Minguez-Castellanos A, 1999, MOVEMENT DISORD, V14, P1030, DOI 10.1002/1531-8257(199911)14:6<1030::AID-MDS1021>3.0.CO;2-O; Montgomery EB, 1999, NEUROLOGY, V53, P625, DOI 10.1212/WNL.53.3.625; Murata J, 2003, J NEUROSURG, V99, P708, DOI 10.3171/jns.2003.99.4.0708; Nandi D, 2004, J CLIN NEUROPHYSIOL, V21, P31, DOI 10.1097/00004691-200401000-00005; Olanow CW, 2001, NEUROLOGY, V56, pS1, DOI 10.1212/WNL.56.suppl_5.S1; Ondo W, 1998, NEUROLOGY, V51, P1063, DOI 10.1212/WNL.51.4.1063; Pahwa R, 2006, J NEUROSURG, V104, P506, DOI 10.3171/jns.2006.104.4.506; Pahwa R, 2003, AM J MED, V115, P134, DOI 10.1016/S0002-9343(03)00259-6; Pahwa R, 2001, MOVEMENT DISORD, V16, P140, DOI 10.1002/1531-8257(200101)16:1<140::AID-MDS1025>3.0.CO;2-T; Plaha P, 2004, J NEUROSURG, V101, P48, DOI 10.3171/jns.2004.101.1.0048; Putzke JD, 2005, J NEUROL NEUROSUR PS, V76, P684, DOI 10.1136/jnnp.2004.041434; Putzke JD, 2004, CAN J NEUROL SCI, V31, P333, DOI 10.1017/S0317167100003413; Putzke JD, 2003, PARKINSONISM RELAT D, V10, P81, DOI 10.1016/j.parkreldis.2003.09.002; Racette BA, 2001, J NEUROL, V248, P380, DOI 10.1007/s004150170177; Rehncrona S, 2003, MOVEMENT DISORD, V18, P163, DOI 10.1002/mds.10309; Schulder M, 2003, STEREOT FUNCT NEUROS, V80, P48, DOI 10.1159/000075160; Schulder M, 1999, STEREOT FUNCT NEUROS, V72, P196, DOI 10.1159/000029726; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; Sydow O, 2003, J NEUROL NEUROSUR PS, V74, P1387, DOI 10.1136/jnnp.74.10.1387; Tasker RR, 1998, SURG NEUROL, V49, P145, DOI 10.1016/S0090-3019(97)00459-X; Umemura A, 2004, CLIN NEUROL NEUROSUR, V106, P280, DOI 10.1016/j.clineuro.2003.12.004; Wishart HA, 2003, J NEUROL NEUROSUR PS, V74, P1392, DOI 10.1136/jnnp.74.10.1392; Yap L, 2007, BRIT J NEUROSURG, V21, P349, DOI 10.1080/02688690701544002	44	61	62	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	APR	2008	5	2					331	338		10.1016/j.nurt.2008.01.004			8	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	288SC	WOS:000255005100015	18394574	Green Published, Bronze			2021-06-18	
J	Nadler, Y; Alexandrovich, A; Grigorladis, N; Hartmann, T; Rao, KSJ; Shohami, E; Stein, R				Nadler, Yasmine; Alexandrovich, Alexander; Grigorladis, Nikolaos; Hartmann, Tobias; Rao, Kosagi S. Jagannatha; Shohami, Esther; Stein, Reuven			Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury	GLIA			English	Article						closed head injury; brain-stabbing; presenilin; nicastrin; astrocytes; microglia	CLOSED-HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; BETA-SECRETASE; MOUSE-BRAIN; REACTIVE ASTROCYTES; GLIAL SCAR; IMMUNOHISTOCHEMICAL ANALYSIS; MISSENSE MUTATIONS; ERBB-4 RECEPTOR	gamma-Secretase is an aspartyl protease composed of four proteins: presenilin (PS), nicastrin (Net), APH1, and PEN2. These proteins assemble into a membrane complex that cleaves a variety of substrates within the transmembrane domain. The gamma-secretase cleavage products play an important role in various biological processes such as embryonic development and Alzheimer's disease (AD). The major role of gamma-secretase in brain pathology has been linked to AD and to the production of the amyloid P-peptide. However, little is known about the possible role of gamma-secretase following acute brain insult. Here we examined by immunostaining the expression patterns of two gamma-secretase components, PSI and Net, in three paradigms of brain insult in mice: closed head injury, intracerebroventricular injection of LPS, and brain stabbing. Our results show that in naive and sham-injured brains expression of PS1 and Net is restricted mainly to neurons. However, following insult, the expression of both proteins is also observed in nonneuronal cells, consisting of activated astrocytes and microglia. Furthermore, the proteins are coexpressed within the same astrocytes and microglia, implying that these cells exhibit an enhanced gamma-secretase activity following brain damage. In view of the important role played by astrocytes and microglia in brain disorders, our findings suggest that gamma-secretase may participate in brain damage and repair processes by regulating astrocyte and microglia activation and/or function. (C) 2008 Wiley-Liss, Inc.	[Nadler, Yasmine; Stein, Reuven] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; [Alexandrovich, Alexander; Shohami, Esther] Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Grigorladis, Nikolaos] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurol B, GR-54636 Thessaloniki, Greece; [Grigorladis, Nikolaos] Aristotle Univ Thessaloniki, Lab Expt Neurol, GR-54636 Thessaloniki, Greece; [Hartmann, Tobias] Univ Saarland, Uniklinikum Homburg, D-6600 Saarbrucken, Germany; [Rao, Kosagi S. Jagannatha] Cent Food Technol Res Inst, Dept Biochem & Nutr, Mysore 570013, Karnataka, India	Stein, R (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	reuvens@post.tau.ac.il	Kosagisharaf, Jagannatha Rao/N-6788-2014	Kosagisharaf, Jagannatha Rao/0000-0003-4290-7666; Hartmann, Tobias/0000-0001-7481-6430			Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Berezovska O, 1998, J NEUROPATH EXP NEUR, V57, P738, DOI 10.1097/00005072-199808000-00003; Blanchard V, 1997, BRAIN RES, V758, P209, DOI 10.1016/S0006-8993(97)00231-X; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brunkan AL, 2005, J NEUROCHEM, V93, P769, DOI 10.1111/j.1471-4159.2005.03099.x; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cribbs DH, 1996, NEUROREPORT, V7, P1773, DOI 10.1097/00001756-199607290-00016; De Strooper B, 2005, CELL, V122, P318, DOI 10.1016/j.cell.2005.07.021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Dewji NN, 2004, P NATL ACAD SCI USA, V101, P1057, DOI 10.1073/pnas.0307290101; Diehlmann A, 1999, J NEUROSCI RES, V56, P405; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; Givogri MI, 2006, DEV NEUROSCI-BASEL, V28, P81, DOI 10.1159/000090755; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Grandbarbe L, 2003, DEVELOPMENT, V130, P1391, DOI 10.1242/dev.00374; Grandbarbe L, 2007, GLIA, V55, P1519, DOI 10.1002/glia.20553; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hartlage-Rubsamen M, 2003, GLIA, V41, P169, DOI 10.1002/glia.10178; Heales SJR, 2004, NEUROCHEM RES, V29, P513, DOI 10.1023/B:NERE.0000014822.69384.0f; Hebert SS, 2004, NEUROBIOL DIS, V17, P260, DOI 10.1016/j.nbd.2004.08.002; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P1009, DOI 10.1097/00005072-199709000-00006; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Kim KS, 1997, BRAIN RES, V757, P159, DOI 10.1016/S0006-8993(97)00243-6; KODAM A, IN PRESS NEUROBIOL A; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Laudon H, 2004, J NEUROCHEM, V89, P44, DOI 10.1046/j.1471-4159.2003.02298.x; Lee J, 2002, NEUROMOL MED, V2, P29; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lesne S, 2003, J BIOL CHEM, V278, P18408, DOI 10.1074/jbc.M300819200; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lin CH, 2006, EXP NEUROL, V201, P225, DOI 10.1016/j.expneurol.2006.04.014; Logan A, 2002, ADV EXP MED BIOL, V513, P115; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Magnus T, 2007, J NEUROSCI RES, V85, P2126, DOI 10.1002/jnr.21368; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marchetti B, 2005, TRENDS PHARMACOL SCI, V26, P517, DOI 10.1016/j.tips.2005.08.007; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; Miake H, 1999, ACTA NEUROPATHOL, V98, P337, DOI 10.1007/s004010051090; Moussaoui S, 1996, FEBS LETT, V383, P219, DOI 10.1016/0014-5793(96)00250-5; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pennypacker KR, 1999, BRAIN RES BULL, V48, P539, DOI 10.1016/S0361-9230(99)00031-3; Pitsi D, 2004, J BIOL CHEM, V279, P25333, DOI 10.1074/jbc.M312710200; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramirez MJ, 2001, BRAIN RES, V907, P222, DOI 10.1016/S0006-8993(01)02580-X; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rossner S, 2005, J NEUROCHEM, V92, P226, DOI 10.1111/j.1471-4159.2004.02857.x; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Siman R, 2004, NEUROSCIENCE, V129, P615, DOI 10.1016/j.neuroscience.2004.08.028; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Tanimukai H, 1998, MOL BRAIN RES, V54, P212, DOI 10.1016/S0169-328X(97)00337-9; Toninelli GF, 2003, NEUROREPORT, V14, P917, DOI 10.1097/01.wnr.0000069962.11849.e6; Uchihara T, 2006, NEUROBIOL AGING, V27, P88, DOI 10.1016/j.neurobiolaging.2004.12.011; Uchihara T, 1996, ACTA NEUROPATHOL, V92, P325, DOI 10.1007/s004010050526; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Weggen S, 1998, NEUROREPORT, V9, P3279; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yamada T, 1997, EXP NEUROL, V148, P10, DOI 10.1006/exnr.1997.6661; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	86	61	62	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR	2008	56	5					552	567		10.1002/glia.20638			16	Neurosciences	Neurosciences & Neurology	275KM	WOS:000254070300007	18240300				2021-06-18	
J	Seifman, MA; Adamides, AA; Nguyen, PN; Vallance, SA; Cooper, DJ; Kossmann, T; Rosenfeld, JV; Morganti-Kossmann, MC				Seifman, Marc A.; Adamides, Alexios A.; Nguyen, Phuong N.; Vallance, Shirley A.; Cooper, David James; Kossmann, Thomas; Rosenfeld, Jeffrey V.; Morganti-Kossmann, M. Cristina			Endogenous melatonin increases in cerebrospinal fluid of patients after severe traumatic brain injury and correlates with oxidative stress and metabolic disarray	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebrospinal fluid; lipid peroxidation; melatonin; metabolism; oxidative stress; traumatic brain injury	HEAD-INJURY; OXYGEN RADICALS; DAMAGE; PHASE; ANTIOXIDANTS; SEIZURES; DISEASE; SERUM	Oxidative stress plays a significant role in secondary damage after severe traumatic brain injury (TBI); and melatonin exhibits both direct and indirect antioxidant effects. Melatonin deficiency is deleterious in TBI animal models, and its administration confers neuroprotection, reducing cerebral oedema, and improving neurobehavioural outcome. This study aimed to measure the endogenous cerebrospinal fluid (CSF) and serum melatonin levels post-TBI in humans and to identify relationships with markers of oxidative stress via 8-isoprostaglandin-F-2 alpha (isoprostane), brain metabolism and neurologic outcome. Cerebrospinal fluid and serum samples of 39 TBI patients were assessed for melatonin, isoprostane, and various metabolites. Cerebrospinal fluid but not serum melatonin levels were markedly elevated (7.28 +/- 0.92 versus 1.47 +/- 0.35 pg/mL, P<0.0005). Isoprostane levels also increased in both CSF (127.62 +/- 16.85 versus 18.28 +/- 4.88 pg/mL, P<0.0005) and serum (562.46 +/- 50.78 versus 126.15 +/- 40.08 pg/mL (P<0.0005). A strong correlation between CSF melatonin and CSF isoprostane on day 1 after injury (r = 0.563, P = 0.002) suggests that melatonin production increases in conjunction with lipid peroxidation in TBI. Relationships between CSF melatonin and pyruvate (r = 0.369, P = 0.049) and glutamate (r = 0.373, P = 0.046) indicate that melatonin production increases with metabolic disarray. In conclusion, endogenous CSF melatonin levels increase after TBI, whereas serum levels do not. This elevation is likely to represent a response to oxidative stress and metabolic disarray, although further studies are required to elucidate these relationships.	[Seifman, Marc A.; Adamides, Alexios A.; Nguyen, Phuong N.; Vallance, Shirley A.; Cooper, David James; Kossmann, Thomas; Rosenfeld, Jeffrey V.; Morganti-Kossmann, M. Cristina] Natl Trauma Res Ctr, Melbourne, Vic 3004, Australia; [Seifman, Marc A.; Adamides, Alexios A.; Rosenfeld, Jeffrey V.] Dept Neurosurg, Melbourne, Vic, Australia; [Seifman, Marc A.; Kossmann, Thomas] Dept Trauma Surg, Melbourne, Vic, Australia; [Seifman, Marc A.; Kossmann, Thomas; Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Adamides, Alexios A.; Nguyen, Phuong N.; Morganti-Kossmann, M. Cristina] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Vallance, Shirley A.; Cooper, David James] Dept Intens Care, Melbourne, Vic 3004, Australia	Morganti-Kossmann, MC (corresponding author), Natl Trauma Res Ctr, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@med.monash.edu	Rosenfeld, Jeffrey V/B-7249-2011; Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051; Morganti-Kossmann, Cristina/0000-0002-0807-2063			Antolin I, 2002, BRAIN RES, V943, P163, DOI 10.1016/S0006-8993(02)02551-9; Ates O, 2006, INT J DEV NEUROSCI, V24, P357, DOI 10.1016/j.ijdevneu.2006.08.003; BAYIR H, 2001, MO CL BI CC, V2, P115; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Easton AS, 1998, J PHYSIOL-LONDON, V507, P541, DOI 10.1111/j.1469-7793.1998.541bt.x; Gorgulu AK, 2001, NEUROSURGERY, V49, P1434; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Jimenez-Caliani AJ, 2005, J PINEAL RES, V38, P93, DOI 10.1111/j.1600-079X.2004.00175.x; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; KONTOS HA, 1983, ADV EXP MED BIOL, V161, P365; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Krauchi K, 1997, AM J PHYSIOL-REG I, V272, pR1178, DOI 10.1152/ajpregu.1997.272.4.R1178; Lapin IP, 1998, J PINEAL RES, V24, P215; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Lissoni P, 1997, J BIOL REG HOMEOS AG, V11, P157; Liu RY, 1999, J CLIN ENDOCR METAB, V84, P323, DOI 10.1210/jc.84.1.323; Longatti P, 2007, J PINEAL RES, V42, P113, DOI 10.1111/j.1600-079X.2006.00391.x; Longoni B, 1998, LIFE SCI, V62, P853, DOI 10.1016/S0024-3205(98)00002-2; Manev H, 1996, FASEB J, V10, P1546; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; Rizzo V, 2002, J CHROMATOGR B, V774, P17, DOI 10.1016/S1570-0232(02)00168-X; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rousseau A, 1999, J NEURAL TRANSM, V106, P883, DOI 10.1007/s007020050208; Sano K, 1980, Neurol Res, V2, P253; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tricoire H, 2002, ENDOCRINOLOGY, V143, P84, DOI 10.1210/en.143.1.84; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu YH, 2003, J CLIN ENDOCR METAB, V88, P5898, DOI 10.1210/jc.2003-030833; Zhou JN, 2003, J PINEAL RES, V35, P125, DOI 10.1034/j.1600-079X.2003.00065.x	42	61	61	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2008	28	4					684	696		10.1038/sj.jcbfm.9600603			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	280GS	WOS:000254414500003	18183032	Bronze			2021-06-18	
J	McAllister, TW; Flashman, LA; Rhodes, CH; Tyler, AL; Moore, JH; Saykin, AJ; McDonald, BC; Tosteson, TD; Tsongalis, GJ				McAllister, Thomas W.; Flashman, Laura A.; Rhodes, C. Harker; Tyler, Anna L.; Moore, Jason H.; Saykin, Andrew J.; McDonald, Brenna C.; Tosteson, Tor D.; Tsongalis, Gregory J.			Single nucleotide polymorphisms in ANKK1 and the dopamine D2 receptor gene affect cognitive outcome shortly after traumatic brain injury: A replication and extension study	BRAIN INJURY			English	Article						traumatic brain injury; polymorphisms; dopamine receptor; cognition	HEALTHY-VOLUNTEERS; A1 ALLELE; ASSOCIATION; BINDING; DRD2; POPULATION; HAPLOTYPES	Objective: The two objectives of this study were (1) to replicate the previous finding that a single nucleotide polymorphism (SNP) in the ANKK1 gene (SNP rs1800497 formerly known as the DRD2 TAQ1 A allele) is associated with measures of learning and response latency after traumatic brain injury (TBI) and (2) to further characterize the genetic basis of the effect by testing the strength of association and degree of linkage disequilibrium between the cognitive outcome measures and a selected ensemble of 31 polymorphisms from three adjacent genes in the region of rs1800497. Method: A cohort of 54 patients with TBI and 21 comparison subjects were genotyped for the DRD2 TAQ1 A polymorphism (rs1800497). Ninety-three patients with TBI and 48 comparison subjects (the current cohort and an earlier independent cohort) were also genotyped for 31 additional neighbouring polymorphisms in NCAM, ANKK1 and DRD2. TBI patients were studied 1 month after injury. All subjects completed memory and attention tests, including the California Verbal Learning Test (CVLT) recognition task and the Gordon Continuous Performance Test (CPT). Results: As in a previous study the T allele of TAQ1 A (rs1800497) was associated with poorer performance on the CVLT recognition trial in both TBI and control subjects. There was also a significant diagnosis-by-allele interaction on CPT measures of response latency, largely driven by slower performance in the TBI participants with the T allele. Analysis of 31 additional neighbouring polymorphisms from NCAM, ANKK1 and DRD2 in the TBI patients showed four haploblocks. A haploblock of three SNPs in ANKK1 (rs11604671, rs4938016 and rs1800497 (TAQ1A)) showed the greatest association with cognitive outcome measures. Conclusions: The results confirm a previously published association between the TAQ1 A (rs1800497) T allele and cognitive outcome measures 1 month after TBI and suggest that a haploblock of polymorphisms in ANKK1, rather than the adjacent DRD2 gene, has the highest association with these measures after TBI.	[McAllister, Thomas W.] Dartmouth Med Sch, Sect Neuropsychiat, Dartmouth Hitchcock Med Ctr, Dept Psychiat, Lebanon, NH 03756 USA; [Rhodes, C. Harker; Tsongalis, Gregory J.] Dartmouth Med Sch, Sect Mol Pathol, Lebanon, NH 03756 USA; [Tyler, Anna L.; Moore, Jason H.] Dartmouth Med Sch, Computat Genet Lab, Lebanon, NH 03756 USA; [Saykin, Andrew J.; McDonald, Brenna C.] Indiana Univ, Sch Med, Dept Radiol, Indianapolis, IN 46202 USA; [Saykin, Andrew J.; McDonald, Brenna C.] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; [Tosteson, Tor D.] Dartmouth Med Sch, Epidemiol & Biostat Sect, Dept Community & Family Med, Lebanon, NH 03756 USA	McAllister, TW (corresponding author), Dartmouth Med Sch, Sect Neuropsychiat, Dartmouth Hitchcock Med Ctr, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu	; Saykin, Andrew/A-1318-2007	Tyler, Anna/0000-0001-8371-2377; Saykin, Andrew/0000-0002-1376-8532; Moore, Jason/0000-0002-5015-1099	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA023108] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176-03, R01 HD048176, R01 HD048176-01, R01 HD048176-02, R01 HD048176-05, R01 HD048176-04] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055020, R01 NS040472-02, R01 NS040472-01, R01 NS040472-03, R01 NS040472-04, R01 NS040472] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020, R01NS040472] Funding Source: NIH RePORTER		Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 2000, CALIFORNIA VERBAL LE; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; First MB., 1997, STRUCTURED CLIN INTE; Gemignani F, 2005, CANCER EPIDEM BIOMAR, V14, P1633, DOI 10.1158/1055-9965.EPI-05-0057; Gordon N, 1996, EUR J DISORDER COMM, V31, P359; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hryniewicz-Jankowska A, 2002, FOLIA HISTOCHEM CYTO, V40, P239; Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532; Laruelle M, 1998, MOL PSYCHIATR, V3, P261, DOI 10.1038/sj.mp.4000343; Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282; LONG JC, 1995, AM J HUM GENET, V56, P799; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Pohjalainen T, 1998, MOL PSYCHIATR, V3, P256, DOI 10.1038/sj.mp.4000350; Pritchard JK, 2000, GENETICS, V155, P945; Ritchie T, 2003, NEUROCHEM RES, V28, P73, DOI 10.1023/A:1021648128758; SAVILLE DJ, 1990, AM STAT, V44, P174, DOI 10.2307/2684163; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; TUKEY JW, 1949, BIOMETRICS, V5, P99, DOI 10.2307/3001913; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Wong AHC, 2000, EUR J PHARMACOL, V410, P183; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986	29	61	63	0	7	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	9					705	714		10.1080/02699050802263019			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	336NS	WOS:000258371600008	18698520	Green Accepted			2021-06-18	
J	Staudenmayer, KL; Diaz-Arrastia, R; de Oliveira, A; Gentilello, LM; Shafi, S				Staudenmayer, Kristan L.; Diaz-Arrastia, Ramon; de Oliveira, Ana; Gentilello, Larry M.; Shafi, Shahid			Ethnic disparities in long-term function outcomes after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		traumatic brain injury; ethnic disparities	ACUTE MYOCARDIAL-INFARCTION; IMPACT; TRANSPLANTATION; RACE	Objective: Ethnic disparities in access to acute rehabilitation and in long-term global neurologic outcomes after traumatic brain injury (TBI) have been previously documented. The current study was undertaken to determine whether there are specific types of functional deficits that disproportionately affect ethnic minorities after TBI. Methods: The TBI Clinical Trials Network is a National Institutes of Health-funded multicenter prospective study. Local data from trauma centers in a single ethnically diverse major metropolitan study site were analyzed. Functional outcomes were measured in 211 patients with blunt TBI (head Abbreviated Injury Scale score 3-5) who were alive !,6 months after discharge using the Functional Status Examination (FSE), which measures outcome in 10 functional domains and compares current functional status to preinjury status. For each domain, patients were classified as functionally independent (FSE score 1, 2) or dependent upon others (FSE score 3, 4). Ethnic minorities (n = 66) were compared with non-Hispanic whites (n = 145), with p < 0.05 considered significant. Results: The two groups had similar injury severity (head Abbreviated Injury Scale score, initial Glasgow Coma Scale score, Injury Severity Score) and were equally likely to be placed in rehabilitation after trauma center discharge (minorities 51%, whites 46%, p = 0.28). Minority patients experienced worse long-term functional outcomes in all domains, which reached statistical significance in post-TBI standard of living, engagement in leisure activities, and return to work or school. Conclusions: Ethnic minorities with TBI suffer worse long-term deficits in three specific functional domains. TBI rehabilitation programs should target these specific areas to reduce disparities in functional outcomes in ethnic minorities.	[Gentilello, Larry M.; Shafi, Shahid] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burns Trauma & Crit Care, Dallas, TX 75390 USA; [Staudenmayer, Kristan L.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; [Diaz-Arrastia, Ramon; de Oliveira, Ana] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA	Shafi, S (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burns Trauma & Crit Care, 5323 Harry Hines Blvd,Mail Stop 9158, Dallas, TX 75390 USA.	shahid.shafi@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD42652, R01 HD48179] Funding Source: Medline		Barnato AE, 2005, MED CARE, V43, P308, DOI 10.1097/01.mlr.0000156848.62086.06; Barnhart JM, 2003, ARCH INTERN MED, V163, P461, DOI 10.1001/archinte.163.4.461; Bertoni AG, 2005, J NATL MED ASSOC, V97, P317; Collins KS, 1999, US MINORITY HLTH CHA; Delano BG, 1997, ASAIO J, V43, pM861; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Flattery Maureen P, 2004, J Cult Divers, V11, P25; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Mochari Heidi, 2006, Prev Cardiol, V9, P8, DOI 10.1111/j.1520-037X.2005.3703.x; Reid AE, 2004, LIVER TRANSPLANT, V10, P834, DOI 10.1002/lt.20174; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Syed M, 2000, AM HEART J, V140, P643, DOI 10.1067/mhj.2000.109644; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; *US DHHS, 2000, HLTH PEOPL 2010; *US DHHS, 2005, NAT HEALTHC DISP REP; Venkat A, 2003, ACAD EMERG MED, V10, P1199, DOI 10.1197/S1069-6563(03)00490-1; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Werner RM, 2005, CIRCULATION, V111, P1257, DOI 10.1161/01.CIR.0000157729.59754.09	24	61	61	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2007	63	6					1364	1369		10.1097/TA.0b013e31815b897b			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	243AU	WOS:000251768100031	18212662				2021-06-18	
J	Berrocal, Y; Pearse, DD; Singh, A; Andrade, CM; McBroom, JS; Puentes, R; Eaton, MJ				Berrocal, Yerko; Pearse, Damien D.; Singh, Amanpreet; Andrade, Christian M.; McBroom, Jordan S.; Puentes, Rocio; Eaton, Mary J.			Social and environmental enrichment improves sensory and motor recovery after severe contusive spinal cord injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						growth factors; locomotor function; sensory function; therapeutic approaches for the treatment of CNS; traumatic spinal cord injury	NEUROTROPHIC FACTOR BDNF; FUNCTIONAL RECOVERY; NEUROPATHIC PAIN; NERVE INJURY; EXERCISE; NEURONS; HEMISECTION; COMPLEXITY; EXPRESSION; THRESHOLD	Neuropathic pain and motor dysfunction are difficult problems following spinal cord injury (SCI). Social and environmental enrichment (SEE), which models much of the clinical rehabilitation environment for post-SCI persons, is the focus of the current investigation which examines the effects of multiple-housing and the addition of climbing spaces, improved bedding and crawl toys on the sensory and motor recovery following a severe contusive SCI. Efficacy was determined with sensory testing, open-field motor behavioral testing, lesion volume analysis and quantification of brain-derived neurotrophic factor (BDNF) in the lumbar spinal cord with and without SEE provided during the recovery period. Sensory and motor testing were performed weekly for 12 weeks following SCI. SEE significantly and permanently reversed cutaneous allodynia, but not thermal hyperalgesia, to near normal levels. The gross locomotor performance (BBB [Basso, Beattie, and Bresnahan] motor scores) significantly improved about two points. In addition, the BBB subscale scores were significantly improved nearly seven points by the end of the study. SEE also significantly improved foot rotation to normal levels and reduced gridwalk footfall errors nearly 50%, but had no effect on stride length or base of support dysfunctions. SEE significantly increased the total volume of a thoracic segment of cord encompassing the injury site at 12 weeks, by reducing cavitation and increasing both the volume of grey and white matter spared, compared to SCI alone. When BDNF levels were examined in the injured lumbar spinal cord, SEE significantly returned BDNF levels to near-normal. These data suggest that immediate use of SEE after contusive SCI is able to improve overall spinal cell survival and prevent much of the sensory and motor dysfunction that accompanies contusive SCI.	Miami VA Med Ctr, Miami, FL 33125 USA; Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL USA; Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL USA	Eaton, MJ (corresponding author), Miami VA Med Ctr, D806C 1201 NW 16th St, Miami, FL 33125 USA.	meaton@miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X; Andrade, Christian/0000-0001-6470-0776; Berrocal, Yerko/0000-0002-1089-6563			BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Behrman AL, 2005, PHYS THER, V85, P1356, DOI 10.1093/ptj/85.12.1356; Cao QL, 2005, EXP NEUROL, V191, pS3, DOI 10.1016/j.expneurol.2004.08.026; CELAS P, 2000, PAIN, V86, P95; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Conner JM, 1997, J NEUROSCI, V17, P2295; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; DIAMOND MC, 1972, J NEUROBIOL, V3, P47, DOI 10.1002/neu.480030105; Drew GM, 2004, PAIN, V109, P379, DOI 10.1016/j.pain.2004.02.007; Eaton MJ, 2002, GENE THER, V9, P1387, DOI 10.1038/sj.gt.3301814; Engesser-Cesar C, 2005, J NEUROTRAUM, V22, P157, DOI 10.1089/neu.2005.22.157; Erschbamer MK, 2006, EXP NEUROL, V201, P154, DOI 10.1016/j.expneurol.2006.04.003; GARDNER EB, 1975, PHYSIOL BEHAV, V14, P321, DOI 10.1016/0031-9384(75)90040-2; Ginis KAM, 2003, REHABIL PSYCHOL, V48, P157, DOI 10.1037/0090-5550.48.3.157; Gomez-Pinilla F, 2002, J NEUROPHYSIOL, V88, P2187, DOI 10.1152/jn.00152.2002; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hains BC, 2003, BRAIN RES, V970, P238, DOI 10.1016/S0006-8993(03)02347-3; Hains BC, 2002, NEUROSCI LETT, V320, P125, DOI 10.1016/S0304-3940(02)00026-5; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HUNTLEY MJ, 1972, PHYSIOL BEHAV, V8, P725, DOI 10.1016/0031-9384(72)90103-5; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; Ikeda O, 2002, J NEUROPATH EXP NEUR, V61, P142, DOI 10.1093/jnen/61.2.142; KATZ HB, 1984, EXP NEUROL, V83, P274, DOI 10.1016/0014-4886(84)90098-0; Kerr BJ, 1999, J NEUROSCI, V19, P5138; Koda M, 2002, J NEUROTRAUM, V19, P777, DOI 10.1089/08977150260139147; Lankhorst AJ, 2001, J NEUROTRAUM, V18, P203, DOI 10.1089/08977150150502622; Lindsey AE, 2000, NEUROREHAB NEURAL RE, V14, P287, DOI 10.1177/154596830001400405; Merighi A, 2004, PROG BRAIN RES, V146, P291, DOI 10.1016/S0079-6123(03)46019-6; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Miki K, 2000, NEUROSCI LETT, V278, P85, DOI 10.1016/S0304-3940(99)00908-8; Mills CD, 2001, J NEUROTRAUM, V18, P743, DOI 10.1089/089771501316919111; Moon LDF, 2006, RESTOR NEUROL NEUROS, V24, P147; Pearse DD, 2007, GLIA, V55, P976, DOI 10.1002/glia.20490; Pearse DD, 2005, J NEUROTRAUM, V22, P680, DOI 10.1089/neu.2005.22.680; PERREAU VM, 2005, GENE EXPRESSION, P107; PUGLISIALLEGRA S, 1983, PHARMACOL BIOCHEM BE, V19, P679, DOI 10.1016/0091-3057(83)90344-1; Schwab JM, 2006, PROG NEUROBIOL, V78, P91, DOI 10.1016/j.pneurobio.2005.12.004; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Smith RR, 2006, J NEUROTRAUM, V23, P908, DOI 10.1089/neu.2006.23.908; Van Meeteren NLU, 2003, J NEUROTRAUM, V20, P1029, DOI 10.1089/089771503770195876; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; VIERCK CJ, 2000, NERVOUS SYSTEM PLAST, P411; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004; Woerly S, 2001, J NEUROSCI RES, V66, P1187; Yajima Y, 2002, BRAIN RES, V958, P338, DOI 10.1016/S0006-8993(02)03666-1; Yezierski R P, 2000, Prog Brain Res, V129, P429; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015; Ying Z, 2003, BRAIN RES, V987, P93, DOI 10.1016/S0006-8993(03)03258-X	50	61	63	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1761	1772		10.1089/neu.2007.0327			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500007	18001204				2021-06-18	
J	Moro, N; Katayama, Y; Igarashi, T; Mori, T; Kawamata, T; Kojima, J				Moro, Nobuhiro; Katayama, Yoichi; Igarashi, Takahlro; Mori, Tatsuro; Kawamata, Tatsuro; Kojima, Jun			Hyponatremia in patients with traumatic brain injury: incidence, mechanism, and response to sodium supplementation or retention therapy with hydrocortisone	SURGICAL NEUROLOGY			English	Article						cerebral salt wasting syndrome; hydrocortisone; hyponatremia; hypopituitarism; syndrome of inappropriate secretion of antidiuretic hormone; traumatic brain injury	SALT WASTING SYNDROME; ANTERIOR-PITUITARY DYSFUNCTION; CEREBRAL-BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; HEAD-INJURY; INAPPROPRIATE SECRETION; TRANSCRANIAL DOPPLER; ANTIDIURETIC-HORMONE; HYPERVOLEMIC THERAPY; MANAGEMENT	Background: Hyponatremia is a frequently observed electrolyte abnormality in patients with central nervous system disease. Several mechanisms, such as SIADH, hypopituitarism, and CSWS, have been proposed with varied incidences among several studies. We attempted to clarify the incidence and mechanism of hyponatremia for each type of TBI. We also assessed the efficacy of sodium supplementation and retention therapy. For sodium retention therapy, hydrocortisone was administered, expecting its mineralocorticoid effect, when the hyponatremia was associated with excess natriuresis. Methods: Retrospective analysis of 298 patients with TBI between January 2003 and December 2004 was performed. The incidence, background, clinical data, and outcome were evaluated. Results: Of the 298 patients, 50 (16.8%) presented hyponatremia during the time course. Hyponatremia was associated with longer hospital stay (P <.001) and bad outcome (P =.02). Among these 50 patients, 37 recovered from the hyponatremia with simple sodium supplementation. The remaining 13 patients presented massive natriuresis and required additional sodium retention therapy. Hydrocortisone statistically reduced the amount of sodium excretion (P =.002) and returned the serum sodium level to a normal value. Conclusions: A high rate of hyponatremia after TBI was observed. Further studies are required to establish the precise mechanism of hyponatremia after TBI. Clear definition of CSWS is required to avoid confusion of the pathophysiology that causes hyponatremia. Hydrocortisone was useful to prevent excess natriuresis. (C) 2007 Elsevier Inc. All rights reserved.	Nihon Univ, Sch Med, Dept Neurol Surg, Itabashi Ku, Tokyo 1738610, Japan	Moro, N (corresponding author), Nihon Univ, Sch Med, Dept Neurol Surg, Itabashi Ku, Tokyo 1738610, Japan.	moro@med.nihon-u.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18591615] Funding Source: KAKEN		Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Albanese A, 2001, ARCH DIS CHILD, V85, P246, DOI 10.1136/adc.85.3.246; Berger TM, 2002, CRIT CARE MED, V30, P792, DOI 10.1097/00003246-200204000-00012; Berkenbosch JW, 2002, PEDIATR NEUROSURG, V36, P75, DOI 10.1159/000048356; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Brookes MJ, 2003, J NEUROL NEUROSUR PS, V74, P277, DOI 10.1136/jnnp.74.2.277; Bussmann C, 2001, CHILD NERV SYST, V17, P58; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cole Chad D, 2004, Neurosurg Focus, V16, pE9; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; CORT JH, 1954, LANCET, V1, P752; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Diringer MN, 2006, NEUROLOGIST, V12, P117, DOI 10.1097/01.nrl.0000215741.01699.77; Donati-Genet PCM, 2001, J PEDIATR SURG, V36, P1094, DOI 10.1053/jpsu.2001.24770; ISHIKAWA SE, 1987, ANN INTERN MED, V106, P187, DOI 10.7326/0003-4819-106-2-187; Karovitaki N, 2006, J NEUROL NEUROSUR PS, V77, P276, DOI 10.1136/jnnp.2005.070482; Kinik ST, 2001, PEDIATR NEUROSURG, V35, P216, DOI 10.1159/000050424; Kojima J, 2005, LIFE SCI, V76, P2361, DOI 10.1016/j.lfs.2004.11.010; Kurokawa Y, 1996, SURG NEUROL, V46, P500, DOI 10.1016/S0090-3019(96)00034-1; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; Levine JP, 2001, PLAST RECONSTR SURG, V108, P1501, DOI 10.1097/00006534-200111000-00009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; Miyasaka K, 2004, METHOD FIND EXP CLIN, V26, P287; Mori T, 1999, J NEUROSURG, V91, P947, DOI 10.3171/jns.1999.91.6.0947; Moro N, 2003, STROKE, V34, P2807, DOI 10.1161/01.STR.0000103744.05430.99; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; Oruckaptan HH, 2000, PEDIATR NEUROSURG, V33, P16, DOI 10.1159/000028969; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; Rabinstein AA, 2003, NEUROLOGIST, V9, P290, DOI 10.1097/01.nrl.0000095258.07720.89; SCHWARTZ WB, 1957, AM J MED, V23, P529, DOI 10.1016/0002-9343(57)90224-3; SOLOMON RA, 1984, NEUROSURGERY, V15, P354, DOI 10.1227/00006123-198409000-00010; Sviri GE, 2006, ACTA NEUROCHIR, V148, P529, DOI 10.1007/s00701-005-0666-4; VINGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50, DOI 10.1007/BF01400528; von Bismarck P, 2006, CHILD NERV SYST, V22, P1275, DOI 10.1007/s00381-006-0091-x	47	61	68	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	OCT	2007	68	4					387	393		10.1016/j.surneu.2006.11.052			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	220LO	WOS:000250158400005	17905062				2021-06-18	
J	Holloway, R; Zhou, Z; Harvey, HB; Levasseur, JE; Rice, AC; Sun, D; Hamm, RJ; Bullock, MR				Holloway, R.; Zhou, Z.; Harvey, H. B.; Levasseur, J. E.; Rice, A. C.; Sun, D.; Hamm, R. J.; Bullock, M. R.			Effect of lactate therapy upon cognitive deficits after traumatic brain injury in the rat	ACTA NEUROCHIRURGICA			English	Article						L-lactate; cognitive deficits; ATP; TBI	CELL-DEATH; CREATINE-PHOSPHATE; OXYGEN-CONSUMPTION; N-ACETYLASPARTATE; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; CARDIAC-MUSCLE; UNITED-STATES; METABOLISM; GLUCOSE	Background. In previous studies, it has been shown that intravenous lactate therapy can improve brain neurochemistry, adenosine triphosphate (ATP) generation and outcome after traumatic brain injury (TBI) in rats. In this study, we examined: (1) four L-lactate concentrations to determine the optimal therapeutic dose post TBI in terms of cognitive function; (2) ATP production after TBI for the L-lactate concentration found to be the optimal dose; (3) the possible production of lactic acidosis with the highest L-lactate concentration tested. Methods. Thirty minutes following a fluid percussion injury (FPI) over the left cerebral hemisphere, the animals received an intravenous infusion of 10, 28, 100, or 280mM L-lactate (n = 10 for each group) for 3h at a rate of 0.65ml/h. Shams and control injured animals received a saline infusion. At 11-15 days post injury, cognitive deficits were examined using the Morris Water Maze (MWM) test. Three groups of rats were used for ATP analysis: shams, injured + saline infusion, and injury + the optimal lactate dose as determined by the MWM (n = 4/group). Additionally, a group receiving 280mM L-lactate (n = 5) and one receiving a saline infusion (n = 3) were monitored for arterial blood variables and blood pressures. Findings. In the MWM test, only the 100mM L-lactate-treated injured animals showed a significant reduction in cognitive deficits when compared to saline-treated injured animals (p n 0.05). In the ATP study, injured animals without treatment had a 53% reduction in ATP level in the ipsilateral cortex, while animals with 100mM lactate treatment had a 28% reduction. (p n 0.05). No lactic acidosis was induced by the intravenous infusion of 280mM L-lactate. Conclusions. This study indicates that the intravenous infusion of 100mM L-lactate provided the optimal concentration of the substrate to ameliorate cognitive impairment, probably via the regeneration of ATP following TBI in rats.	Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Neurol, Richmond, VA USA; Virginia Commonwealth Univ, Dept Psychol, Richmond, VA USA; Second Shanghai Med Univ, Renji Hosp, Dept Neurosurg, Shanghai, Peoples R China	Holloway, R (corresponding author), Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Neurosurg, POB 980631,1200 E Broad St, Richmond, VA 23298 USA.	mbullock@mcvh-vcu.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01 12587-27] Funding Source: Medline		Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; BESSHO M, 1991, ANAL BIOCHEM, V192, P117, DOI 10.1016/0003-2697(91)90195-Y; Buck CR, 2003, EXP NEUROL, V181, P149, DOI 10.1016/S0014-4886(03)00043-8; Buczek M, 2002, METAB BRAIN DIS, V17, P153, DOI 10.1023/A:1019973921217; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; DENNIS SC, 1978, BIOCHEM J, V172, P155, DOI 10.1042/bj1720155; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; HULLRYDE EA, 1986, J CHROMATOGR, V377, P165, DOI 10.1016/S0378-4347(00)80771-9; Hutchinson PJA, 2000, ZBL NEUROCHIR, V61, P88, DOI 10.1055/s-2000-8265; IDSTROM JP, 1990, SCAND J CLIN LAB INV, V50, P541, DOI 10.3109/00365519009089169; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Keele CA, 1961, SAMSON WRIGHTS APPL; LEVASSEUR J, 1999, J NEUROTRAUM, V16, P991; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lopez JM, 2003, BIOCHEM J, V370, P1027, DOI 10.1042/BJ20021053; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Mahgoub MA, 1999, ANN THORAC SURG, V68, P22, DOI 10.1016/S0003-4975(99)00277-5; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nordstrom Carl-Henrik, 2003, Neurosurg Focus, V15, pE5; OHSUZU F, 1994, J MOL CELL CARDIOL, V26, P203, DOI 10.1006/jmcc.1994.1023; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Reinert M, 2002, NEUROL RES, V24, P601, DOI 10.1179/016164102101200438; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Schurr A, 1998, DEV NEUROSCI-BASEL, V20, P348, DOI 10.1159/000017330; Schurr A, 2001, BRAIN RES, V895, P268, DOI 10.1016/S0006-8993(01)02082-0; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Thrivikraman KV, 2002, BRAIN RES PROTOC, V10, P84, DOI 10.1016/S1385-299X(02)00185-X; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Zeng JY, 2007, J CEREBR BLOOD F MET, V27, P304, DOI 10.1038/sj.jcbfm.9600335; Zhan C, 2006, PHARMACOL RES, V53, P303, DOI 10.1016/j.phrs.2005.12.008	52	61	63	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	SEP	2007	149	9					919	927		10.1007/s00701-007-1241-y			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	204AT	WOS:000249015900019	17660938				2021-06-18	
J	Clausen, F; Lorant, T; Lewen, A; Hillered, L				Clausen, Fredrik; Lorant, Tomas; Lewen, Anders; Hillered, Lars			T lymphocyte trafficking: A novel target for neuroprotection in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; neuroprotection; reactive oxygen species; S-PBN; T lymphocytes; traumatic brain injury	S-PBN; CELLS; ACTIVATION; EXPRESSION; ADHESION; STROKE; RECRUITMENT; NXY-059; EDEMA; RAT	Infiltration of T lymphocytes is a key feature in transplant rejection and in several autoimmune disorders, but the role of T lymphocytes in traumatic brain injury (TBI) is largely unknown. Here we studied trafficking of immune cells in the brain after experimental TBI. We found that scavenging of reactive oxygen species (ROS) at the endothelial level dramatically reduced the infiltration of activated T lymphocytes. Immune cell infiltration was studied 12 h to 7 days after controlled cortical contusion in rats by ex vivo propagation of T lymphocytes (TcR+, CD8(+)), neutrophils (MPO+), and macrophages/microglia (ED-1(+)) from biopsies taken from injured cortex and analyzed by flow cytometry, as well as by quantitative immunohistochemistry. T lymphocyte and neutrophil infiltration peaked at 24 h and macrophages/ microglia at 7 days post-injury. Pretreatment with 2-sulfophenylN-tert-butylnitrone( S-PBN) produced a dramatic reduction of TcR+T lymphocytes and a significantly smaller attenuation of neutrophil infiltration at 24 h post-injury, but did not affect CD8(+) T lymphocytes or macrophages/microglia. S-PBN significantly reduced the expression of the endothelial adhesion molecules ICAM-1 and VCAM at 24 h for following TBI. We conclude that ROS inhibition at the endothelial level influenced T lymphocyte and neutrophil infiltration following TBI. We submit that the reduction of T lymphocyte infiltration is a key feature in improving TBI outcome after S-PBN treatment. Our data suggest that targeting T lymphocyte trafficking to the injured brain at the microvascular level is a novel concept of neuroprotection in TBI and warrants further exploration.	Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, Uppsala, Sweden; Univ Uppsala Hosp, Sect Transplantat Surg, Dept Surg Sci, Uppsala, Sweden	Hillered, L (corresponding author), Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, Entrance 85,2nd floor, Uppsala, Sweden.	Lars.Hillered@neurokir.uu.se	Lewen, Anders/A-5156-2013; Lorant, Tomas/AAU-2490-2020	Lewen, Anders/0000-0003-4925-1348; Lorant, Tomas/0000-0002-2466-6259; Hillered, Lars/0000-0002-2808-9292; Clausen, Fredrik/0000-0003-3592-4417			Arumugam TV, 2005, NEUROMOL MED, V7, P229, DOI 10.1385/NMM:7:3:229; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chaudhary P, 2006, J NEUROIMMUNOL, V175, P87, DOI 10.1016/j.jneuroim.2006.03.007; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; CLAUSEN F, 2003, NAT NEUR S; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Harris AK, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-49; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Isaksson J, 2001, ACTA NEUROPATHOL, V102, P246; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lorant T, 2002, XENOTRANSPLANTATION, V9, P209, DOI 10.1034/j.1399-3089.2002.01060.x; Maples KR, 2001, FREE RADICAL RES, V34, P417, DOI 10.1080/10715760100300351; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Marshall JWB, 2003, STROKE, V34, P2228, DOI 10.1161/01.STR.0000087790.79851.A8; MAYER TG, 1985, J IMMUNOL, V134, P258; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Potts Mathew B, 2006, NeuroRx, V3, P143; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Soares HD, 1995, J NEUROSCI, V15, P8223; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Wolf SA, 2002, J NEUROIMMUNOL, V133, P72, DOI 10.1016/S0165-5728(02)00367-3; Wong D, 1999, J NEUROPATH EXP NEUR, V58, P138, DOI 10.1097/00005072-199902000-00004	34	61	64	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1295	1307		10.1089/neu.2006.0258			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500001	17711391				2021-06-18	
J	Tian, DS; Dong, Q; Pan, DJ; He, Y; Yu, ZY; Xie, MJ; Wang, W				Tian, Dai-shi; Dong, Qianq; Pan, Deng-ji; He, Yi; Yu, Zhi-yuan; Xie, Min-jie; Wang, Wei			Attenuation of astrogliosis by suppressing of microglial proliferation with the cell cycle inhibitor olomoucine in rat spinal cord injury model	BRAIN RESEARCH			English	Article						cell cycle; spinal cord injury; microglial proliferation; glial interaction; astrogliosis	NECROSIS-FACTOR-ALPHA; TNF-ALPHA; INFLAMMATORY RESPONSE; MESSENGER-RNA; EXPRESSION; CYTOKINES; ACTIVATION; BRAIN; REGENERATION; DEATH	Microglial activation/proliferation and reactive astrogliosis are commonly observed and have been considered to be closely relevant pathological processes during spinal cord injury (SCI). However, the molecular mechanisms underlying this micro glial-astroglial interaction are still poorly understood. We showed recently that the continuous injection of the cell cycle inhibitor olomoucine not only markedly suppressed microglial proliferation and associated release of pro-inflammatory cytokines, but also attenuated astroglial scar formation and the lesion cavity and mitigated the functional deficits in rat SCI animal model. in this study, we asked whether microglial activation/proliferation plays an initial role and also necessary in maintaining astrogliosis in SCI model. Our results showed that traumatic induced microglial activation/proliferation precedes astrogliosis, and the up-regulated GFAP expression at both mRNA and protein levels was temporally posterior to the microglial activation. Furthermore, when the cell cycle inhibitor olomoucine was administered only once 1 h post-SCI that should selectively suppress microglial proliferation, the subsequent SCI induced increase in GFAP expression at 1, 2 and 4 weeks was significantly attenuated, suggesting that microglial activation/proliferation played an important role for the later onset astrogliosis after SCI. Consistent with the results that microglial proliferation always precedes astroglial proliferation and there is at present no evidence of other astroglial precursors, which as always does not mean that they will not be uncovered by further searching, and in view of the fact that micro glial- derived pro-inflammatory cytokines promote astrogliosis as we reported recently, these findings together suggest that by release of cytokines and other soluble products, the early onset microglial activation/proliferation can significantly influence the subsequent development of reactive astrogliosis and glial scar formation in SCI animal model. (C) 2007 Elsevier B.V. All rights reserved.	Huazhong Univ Sci & Technol, Dept Neurol, Affiliated Tongji hosp, Tongji Med Coll, Wuhan 430030, Peoples R China; Fudan Univ, Dept Neurol, Huashan Hosp, Coll Med, Shanghai 200040, Peoples R China; Huazhong Univ Sci & Technol, Dept Med Record, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China	Wang, W (corresponding author), Huazhong Univ Sci & Technol, Dept Neurol, Affiliated Tongji hosp, Tongji Med Coll, Wuhan 430030, Peoples R China.	wwang_tjh@yahoo.com.cn	TIAN, DAISHI/A-8744-2018				Balasingam V, 1996, GLIA, V18, P11, DOI 10.1002/(SICI)1098-1136(199609)18:1<11::AID-GLIA2>3.3.CO;2-C; Balasingam V, 1996, J NEUROSCI, V16, P2945; BALASINGAM V, 1994, J NEUROSCI, V14, P846; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bethea JR, 2000, PROG BRAIN RES, V128, P33; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Cai ZW, 2003, BRAIN RES, V975, P37, DOI 10.1016/S0006-8993(03)02545-9; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Davies SJA, 1997, NATURE, V390, P680; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Fernandes A, 2006, J NEUROCHEM, V96, P1667, DOI 10.1111/j.1471-4159.2006.03680.x; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; GUILLAUD P, 1991, CELL PROLIFERAT, V24, P481, DOI 10.1111/j.1365-2184.1991.tb01176.x; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Herber DL, 2006, GLIA, V53, P382, DOI 10.1002/glia.20272; Hwang SY, 2006, NEUROBIOL DIS, V21, P457, DOI 10.1016/j.nbd.2005.08.006; Iravani MM, 2005, EUR J NEUROSCI, V22, P317, DOI 10.1111/j.1460-9568.2005.04220.x; Ito T, 1997, ACTA NEUROPATHOL, V93, P13; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Kordek R, 1996, P NATL ACAD SCI USA, V93, P9754, DOI 10.1073/pnas.93.18.9754; Kuno R, 2006, BRAIN RES, V1116, P12, DOI 10.1016/j.brainres.2006.07.120; Little AR, 2001, NEUROTOXICOLOGY, V22, P607, DOI 10.1016/S0161-813X(01)00032-8; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Moynagh PN, 2005, J ANAT, V207, P265, DOI 10.1111/j.1469-7580.2005.00445.x; Penkowa M, 2002, EXP NEUROL, V176, P308, DOI 10.1006/exnr.2002.7968; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Rohl C, 2007, BRAIN RES, V1129, P43, DOI 10.1016/j.brainres.2006.10.057; Ruemmele FM, 1999, BIOCHEM BIOPH RES CO, V260, P159, DOI 10.1006/bbrc.1999.0734; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Schultz J, 2004, AM J PATHOL, V165, P671, DOI 10.1016/S0002-9440(10)63331-7; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Woiciechowsky C, 2004, MED SCI MONITOR, V10, pBR325; Xu M, 2005, BRAIN RES, V1055, P137, DOI 10.1016/j.brainres.2005.07.003; Zai LJ, 2005, BRAIN RES, V1052, P147, DOI 10.1016/j.brainres.2005.05.071	45	61	62	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 18	2007	1154						206	214		10.1016/j.brainres.2007.04.005			9	Neurosciences	Neurosciences & Neurology	187OK	WOS:000247857400023	17482149				2021-06-18	
J	Hendricks, HT; Geurts, ACH; van Ginneken, BC; Heeren, AJ; Vos, PE				Hendricks, Henk T.; Geurts, A. C. H.; van Ginneken, Bart C.; Heeren, Anita J.; Vos, Pieter E.			Brain injury severity and autonomic dysregulation accurately predict heterotopic ossification in patients with traumatic brain injury	CLINICAL REHABILITATION			English	Article							CHILDREN	Objective: To assess brain injury severity, autonomic dysregulation and systemic infection as risk factors for the occurrence of heterotopic ossification in patients with severe traumatic brain injury. Design: Historic cohort study. Setting: Radboud University Medical Centre. Subjects: All consecutively admitted patients with severe traumatic brain injury (admission Glasgow Coma Scale score 8 or less) during the years 2002-2003. Main measures: The development of clinically relevant heterotopic ossification, defined as painful swelling of joints with redness and decreased range of motion, confirmed radiographically. Results: Seventy-six (64%) of the 119 patients survived and were eligible for further follow-up. Nine patients (12%) developed 20 symptomatic heterotopic ossifications, in one or more joints. Patients with heterotopic ossification had sustained more severe brain injuries, compared to the group without heterotopic ossification. The mean coma duration in the heterotopic ossification group was 28.11 days (SD 20.20) versus 7.54 days (SD 7.47) in the patients without heterotopic ossification (P < 0.001). The occurrence of autonomic dysregulation (relative risk (RR) 59.55, 95% confidence interval (Cl) 8.39-422.36), diffuse axonal injury (RR 20.68, 95% Cl 4.92-86.91), spasticity (RR 16.96, 95% Cl 3.96-72.57) and systemic infection (RR 13.12, 95% Cl 3.01-57.17) were all associated with an increased risk of developing symptomatic heterotopic ossification. However, only autonomic dysregulation had a high positive (88.9%, 95% Cl 51.7-99.7) and negative (98.5%, 95% Cl 91.9-99.9) predictive value with regard to heterotopic ossification. Conclusions: The occurrence of autonomic dysregulation may predict the chance of developing heterotopic ossification in patients with severe head injury.	Radboud Univ Nijmegen Med Ctr, Dept Rehabil Med, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Inst Neurol, Nijmegen, Netherlands	Hendricks, HT (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Rehabil Med, POB 9011, NL-6500 HB Nijmegen, Netherlands.	h.hendricks@reval.umcn.nl	Vos, Pieter/A-6043-2012; Geurts, Alexander/H-8032-2014	Geurts, Alexander/0000-0001-7478-1119			Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; Flin C., 2002, Annales de Readaptation et de Medecine Physique, V45, P517, DOI 10.1016/S0168-6054(02)00305-7; Fransen M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001160.PUB2; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Goodman TA, 1997, ARTHRITIS RHEUM, V40, P1619, DOI 10.1002/art.1780400911; Guo Y, 2002, ARCH PHYS MED REHAB, V83, P855, DOI 10.1053/apmr.2002.32440; HURVITZ EA, 1992, ARCH PHYS MED REHAB, V73, P459; Jacobs JWG, 1999, RHEUMATOLOGY, V38, P1145, DOI 10.1093/rheumatology/38.11.1145; Lane JE, 2002, POSTGRAD MED J, V78, P494, DOI 10.1136/pmj.78.922.494; LIND M, 1995, CYTOKINE, V7, P78, DOI 10.1006/cyto.1995.1010; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; Sebastiani GD, 2002, CLIN RHEUMATOL, V21, P173, DOI 10.1007/PL00011219; SOBUS KML, 1993, ARCH PHYS MED REHAB, V74, P902; TOW APE, 1995, PARAPLEGIA, V33, P170, DOI 10.1038/sc.1995.38; Zeilig G, 2006, ARCH PHYS MED REHAB, V87, P92, DOI 10.1016/j.apmr.2005.07.308	21	61	68	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JUN	2007	21	6					545	553		10.1177/0269215507075260			9	Rehabilitation	Rehabilitation	193BE	WOS:000248247500006	17613585				2021-06-18	
J	Chen, SY; Atkins, CM; Liu, CLL; Alonso, OF; Dietrich, WD; Hu, BR				Chen, Shaoyi; Atkins, Coleen M.; Liu, Chunli L.; Alonso, Ofelia F.; Dietrich, W. Dalton; Hu, Bingren R.			Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						mTOR; protein synthesis; ribosomal protein S6; synaptic plasticity; translation factor; traumatic brain injury	TRANSIENT CEREBRAL-ISCHEMIA; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; PROTEIN-SYNTHESIS; S6 KINASE; NEUROTROPHIC FACTOR; MESSENGER-RNAS; CELL-SIZE; PHOSPHORYLATION; TRANSLATION	In response to traumatic brain injury ( TBI), neurons initiate neuroplastic processes through the activation of intracellular signaling pathways. However, the molecular mechanisms underlying neuroplasticity after TBI are poorly understood. To study this, we utilized the fluid-percussion brain injury ( FPI) model to investigate alterations in the mammalian target of rapamycin ( mTOR) signaling pathways in response to TBI. Mammalian target of rapamycin stimulates mRNA translation through phosphorylation of eukaryotic initiation factor 4E binding protein-1 (4E-BP1), p70 ribosomal S6 kinase (p70S6K), and ribosomal protein S6 (rpS6). These pathways coordinate cell growth and neuroplasticity via dendritic protein synthesis. Rats received sham surgery or moderate parasagittal FPI on the right side of the parietal cortex, followed by 15 mins, 30 mins, 4 h, 24 h, or 72 h of recovery. Using Western blot analysis, we found that mTOR, p70S6K, rpS6, and 4E-BP1 phosphorylation levels were significantly increased in the ipsilateral parietal cortex and hippocampus from 30 mins to 24 h after TBI, whereas total protein levels were unchanged. Using confocal microscopy to localize these changes, we found that rpS6 phosphorylation was increased in the parietal cortex and all subregions of the hippocampus. In accordance with these results, eIF4E, a key, rate- limiting mRNA translation factor, was also phosphorylated by mitogen-activated protein kinase-interacting kinase 1 (Mnk1) 15 mins after TBI. Together, these results suggest that changes in mRNA translation may be one mechanism that neurons use to respond to trauma and may contribute to the neuroplastic changes observed after TBI.	Univ Miami, Miller Sch Med, Dept Neurol, Neurochem Lab Brain Injury, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Neurol Surg, Neurochem Lab Brain Injury, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA	Hu, BR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Neurochem Lab Brain Injury, POB 16960, Miami, FL 33136 USA.	bhu@med.miami.edu		Atkins, Coleen/0000-0003-4718-7493	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40407, NS30291, NS36810] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS036810, R01NS036810, P50NS030291, R29NS036810, R01NS040407] Funding Source: NIH RePORTER		ATKINS CM, 2006, IN PRESS J CEREB BLO; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cheli V, 2006, J NEUROCHEM, V97, P68, DOI 10.1111/j.1471-4159.2005.03592.x; Duncan RF, 2003, BIOCHEM J, V369, P213, DOI 10.1042/BJ20020435; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FERRARI S, 1991, J BIOL CHEM, V266, P22770; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Golarai G, 2001, J NEUROSCI, V21, P8523; Gong R, 2006, J BIOL CHEM, V281, P18802, DOI 10.1074/jbc.M512524200; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Hu BR, 1999, NEUROSCIENCE, V89, P437, DOI 10.1016/S0306-4522(98)00352-2; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005; Kumar V, 2005, J NEUROSCI, V25, P11288, DOI 10.1523/JNEUROSCI.2284-05.2005; LANGLOIS JA, 2004, TRAUMATIC BRAIN INJU, P1; Liu CL, 2005, NEUROSCIENCE, V134, P1273, DOI 10.1016/j.neuroscience.2005.05.015; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Phillis John W., 2003, Critical Reviews in Neurobiology, V15, P61, DOI 10.1615/CritRevNeurobiol.v15.i1.30; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schratt GM, 2004, J NEUROSCI, V24, P7366, DOI 10.1523/JNEUROSCI.1739-04.2004; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Takei N, 2004, J NEUROSCI, V24, P9760, DOI 10.1523/JNEUROSCI.1427-04.2004; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tsokas P, 2005, J NEUROSCI, V25, P5833, DOI 10.1523/JNEUROSCI.0599-05.2005	42	61	65	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2007	27	5					939	949		10.1038/sj.jcbfm.9600393			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	161FG	WOS:000245999300006	16955078	Bronze			2021-06-18	
J	Marino, S; Zei, E; Battaglini, M; Vittori, C; Buscalferri, A; Bramanti, P; Federico, A; De Stefano, N				Marino, Silvia; Zei, Ettore; Battaglini, Marco; Vittori, Cesare; Buscalferri, Antonella; Bramanti, Placido; Federico, Antonio; De Stefano, Nicola			Acute metabolic brain changes following traumatic brain injury and their relevance to clinical severity and outcome	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; CLOSED-HEAD INJURY; N-ACETYLASPARTATE; AXONAL INJURY; WHITE-MATTER; IN-VIVO; PRACTICAL SCALE; H-1 MRS; DAMAGE; DISABILITY	Background: Conventional MRI can provide critical information for care of patients with traumatic brain injury (TBI), but MRI abnormalities rarely correlate to clinical severity and outcome. Previous magnetic resonance spectroscopy studies have reported clinically relevant brain metabolic changes in patients with TBI. However, these changes were often assessed a few to several days after the trauma, with a consequent variation of the metabolic pattern due to temporal changes. Methods: Proton magnetic resonance spectroscopic imaging (H-1-MRSI) examinations were performed in 10 patients with TBI 48-72 h after the trauma, to obtain early measurements of central brain levels of N-acetylaspartate (NAA), choline (Cho), creatine (Cr) and lactate (La). Metabolite values were expressed as ratios to (1) a metabolic pattern, given by the sum of the resonance intensities of all metabolites detected in the same voxel and (2) intravoxel Cr. Results: NAA ratios were found to be significantly lower in patients with TBI than in normal controls. In contrast, Cho ratios were significantly higher in patients with TBI than in normal controls. Increased La levels were found in 5 of 10 patients with TBI. Both NAA and La values correlated closely with those of the Glasgow Coma Scale at presentation (r = 0.73 and 20.62, respectively; p<0.01 for both) and the Glasgow Outcome Scale at 3 months (r = 20.79 and 0.79, respectively; p<0.01 for both). Conclusion: Spectroscopic measures of neuro-axonal damage occurring soon after a brain trauma are clinically relevant. Significant increases in cerebral La level also may be detected when H-1-MRSI is performed early after the trauma and, at this stage, can represent a reliable index of injury severity and disease outcome in patients with TBI.	Univ Siena, Dept Neurol & Behav Sci, Neurol & Neurometab Unit, I-53100 Siena, Italy; IRCCS, Ctr Neurol Bonino Pulejo, Messina, Italy; Univ Siena, Dept Anesthesia & Intens Care, I-53100 Siena, Italy	De Stefano, N (corresponding author), Univ Siena, Dept Neurol & Behav Sci, Neurol & Neurometab Unit, Viale Bracci 2, I-53100 Siena, Italy.	destefano@unisi.it	Bramanti, Placido/K-5117-2016	de stefano, nicola/0000-0003-4930-7639; federico, antonio/0000-0002-5246-1621			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arnold DL, 1996, MR SPECTROSCOPY CLIN, P139; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Barantin L, 1997, MAGN RESON MED, V38, P179, DOI 10.1002/mrm.1910380203; Bjartmar C, 2002, ANN NEUROL, V51, P51, DOI 10.1002/ana.10052; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; De Stefano N, 2001, ARCH NEUROL-CHICAGO, V58, P65, DOI 10.1001/archneur.58.1.65; DESALLES AAF, 1987, NEUROSURGERY, V20, P297, DOI 10.1227/00006123-198702000-00017; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DeStefano N, 1995, ANN NEUROL, V38, P901, DOI 10.1002/ana.410380610; Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GENTRY LR, 1994, RADIOLOGY, V191, P1; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; JENNETT B, 1975, LANCET, V1, P480; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; McLean MA, 2000, MAGNET RESON MED, V44, P401, DOI 10.1002/1522-2594(200009)44:3<401::AID-MRM10>3.0.CO;2-W; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; Pelletier D, 2002, MAGN RESON IMAGING, V20, P599, DOI 10.1016/S0730-725X(02)00533-7; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; PRICHARD JW, 1991, NMR BIOMED, V4, P99, DOI 10.1002/nbm.1940040212; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2002, ACT NEUR S, V81, P373; SIMMONS ML, 1991, NEUROSCIENCE, V45, P37, DOI 10.1016/0306-4522(91)90101-S; TEASDALE G, 1974, LANCET, V2, P81; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	41	61	66	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2007	78	5					501	507		10.1136/jnnp.2006.099796			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	156YO	WOS:000245686000016	17088335	Green Published			2021-06-18	
J	de la Plata, CM; Ardelean, A; Koovakkattu, D; Srinivasan, P; Miller, A; Phuong, V; Harper, C; Moore, C; Whittemore, A; Madden, C; Diaz-Arrastia, R; Devous, M				de la Plata, Carlos Marquez; Ardelean, Andreea; Della Koovakkattu; Srinivasan, Priya; Miller, Anna; Phuong, Viet; Harper, Caryn; Moore, Carol; Whittemore, Anthony; Madden, Christopher; Diaz-Arrastia, Ramon; Devous, Michael, Sr.			Magnetic resonance imaging of diffuse axonal injury: Quantitative assessment of white matter lesion volume	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury (DAI); FLAIR MRI; functional outcome; TBI	TRAUMATIC BRAIN-INJURY; GLASGOW OUTCOME SCALE; CORPUS-CALLOSUM; HEAD-INJURY; MRI FINDINGS; MORPHOLOGY; ATROPHY; CHILDREN; SEQUELAE; FEATURES	Diffuse axonal injury (DAI) is a common mechanism of traumatic brain injury (TBI) for which there is no well-accepted anatomic measures of injury severity. The present study aims to quantitatively assess DAI by measuring white matter lesion volume visible in fluid-attenuated inversion recovery (FLAIR) weighted images and to determine whether higher lesion volumes are associated with unfavorable functional outcome 6 months after injury. Twenty-four patients who experienced moderate to severe TBI without extra-axial or major cortical contusions were included in this study. Lesion volume was assessed by quantifying areas of hyperintensities in the white matter utilizing digitized FLAIR images. Two independent raters processed the magnetic resonance (MR) images and determined the total DAI volume. Functional outcome was assessed at 6 months after injury using the Glasgow Outcome Scale-Extended (GOSE). Interclass correlation analyses showed very high interrater reliability for each measure between the two raters (Interclass Correlation Coefficient = 0.95,p <= 0.001). Total DAI volume was significantly, although modestly, correlated to GOSE (r = -0.453, p = 0.034). White matter lesion volume resulting from DAI can be quantitatively and reliably assessed from standard FLAIR-weighted MRIs. Patients with greater DAI volume have poorer functional outcomes. These methods may be useful in stratifying injury severity and for the assessment of DAI-directed therapies.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurol Surg, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Radiol, Dallas, TX 75235 USA; Univ Texas, Dept Brain & Behav Sci, Dallas, TX USA	de la Plata, CM (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Carlos.MarquezdelaPlata@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD42652, R01 HD48179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bigler E D, 1999, Appl Neuropsychol, V6, P217, DOI 10.1207/s15324826an0604_4; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; COTRAN R, 1999, ROBBINS PATHOLOGIC B, P1301; Fu JH, 2005, J NEUROL NEUROSUR PS, V76, P793, DOI 10.1136/jnnp.2003.032771; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 2001, MAGNETIC RESONANCE I, P1069; Gootjes L, 2004, DEMENT GERIATR COGN, V18, P180, DOI 10.1159/000079199; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; LEVIDOW L, 1992, MICROBIAL RELEASES, V1, P55; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; Ouhlous M, 2005, AM J NEURORADIOL, V26, P1044; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Randolph JJ, 2005, J INT NEUROPSYCH SOC, V11, P205, DOI 10.1017/S1355617705050253; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; SANFILIPO M, 2006, NEUROLOGY, V3, P12; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	37	61	62	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					591	598		10.1089/neu.2006.0214			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000002	17439343				2021-06-18	
J	Watson, NF; Dikmen, S; Machamer, J; Doherty, M; Temkin, N				Watson, Nathaniel F.; Dikmen, Sureyya; Machamer, Joan; Doherty, Michael; Temkin, Nancy			Hypersomnia Following Traumatic Brain Injury	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						Brain; injury; trauma; sleepiness; hypersomnia		Study Objectives: To evaluate the prevalence and natural history of sleepiness following traumatic brain injury. Methods: This prospective cohort study used the Sickness Impact Profile to evaluate sleepiness in 514 consecutive subjects with traumatic brain injury (TBI), 132 non-cranial trauma controls, and 102 trauma-free controls 1 month and 1 year after injury. Results: Fifty-five percent of TBI subjects, 41% of non-cranial trauma controls, and 3% of trauma-free controls endorsed 1 or more sleepiness items 1 month following injury (p < .001). One year following injury, 27% of TBI subjects, 23% of non-cranial trauma controls, and 1% of trauma-free controls endorsed 1 or more sleepiness items (p < .001). Patients with TBI were sleepier than non-cranial trauma controls at 1 month (p < .02) but not 1 year after injury. Brain-injured subjects were divided into injury-severity groups based on time to follow commands (TFC). At 1 month, the non-cranial trauma controls were less sleepy than the 1- to 6-day (p < .05), 7- to 13-day (p < .01), and 14-day or longer (p < .01) TFC groups. In addition, the <= 24-hour group was less sleepy then the 7- to 13-day and 14-day or longer groups (each p < .05). At 1 year, the non-cranial trauma control group (p < .05) and the <= 24-hour TFC group (p < .01) were less sleepy than the 14-day or longer TFC group. Sleepiness improved in 84% to 100% of subjects in the TBI TFC groups, as compared with 78% of the non-cranial trauma control group (p < .01). Conclusions: Sleepiness is common following traumatic injury, particularly TBI, with more severe injuries resulting in greater sleepiness. Sleepiness improves in many patients, particularly those with TBI. However, about a quarter of TBI subjects and non-cranial trauma control subjects remained sleepy 1 year after injury.	[Watson, Nathaniel F.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Dikmen, Sureyya; Machamer, Joan; Temkin, Nancy] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Doherty, Michael] Swedish Neurosci Inst, Seattle, WA USA; [Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Watson, NF (corresponding author), Univ Washington, Sleep Disorders Ctr, Box 359803,325 Ninth Ave, Seattle, WA 98104 USA.	nwatson@u.washington.edu			NIN-NINDS [R01 NS19463]; AHCPR [HS04146, HS05304]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019463] Funding Source: NIH RePORTER	Grant support: Supported by grants R01 NS19463 from NIN-NINDS, and HS04146 and HS05304 from AHCPR.	[Anonymous], 2005, INT CLASSLEEP DIS; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chervin RD, 1999, NEUROLOGY, V52, P125, DOI 10.1212/WNL.52.1.125; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Evans BM, 2002, J ROY SOC MED, V95, P591, DOI 10.1258/jrsm.95.12.591; FAHY TJ, 1967, LANCET, V2, P475; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Jameison K., 1971, P INT S HEAD INJ, P12; Jennett B., 1971, CLIN NEUROSURG, P200; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; Olson LG, 1998, J SLEEP RES, V7, P248, DOI 10.1046/j.1365-2869.1998.00123.x; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	32	61	62	0	2	AMER ACAD SLEEP MEDICINE	WESTCHESTER	ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA	1550-9389	1550-9397		J CLIN SLEEP MED	J. Clin. Sleep Med.		2007	3	4					363	368					6	Clinical Neurology	Neurosciences & Neurology	V44VK	WOS:000209776300005	17694724				2021-06-18	
J	Prigatano, GP; Gupta, S				Prigatano, George P.; Gupta, Saurabh			Friends after traumatic brain injury in children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						academic performance; affect; children; cognition; friends; TBI	HEAD-INJURY; ACADEMIC-PERFORMANCE; REHABILITATION; ADOLESCENTS; COMPETENCE; BEHAVIOR; DAMAGE	Objective: To determine whether a dose-response relation exists between the number of reported close friends and traumatic brain injury (TBI) severity in the postacute phase in school-age children. Design: A retrospective relational study. Setting and Participants: Primary care hospital/medical center-based study on parental perspectives of recovery following TBI in school-age children (14 with severe TBI; 10 with moderate TBI; 36 with mild TBI; and 16 trauma controls). Main Outcome Measures: Parental ratings on the Child Behavior Checklist and selected neuropsychological test findings and ratings of academic performance. Results: Seventy-five percent of trauma controls but only 38.9% of children with mild and 20% of children with moderate TBI reportedly had 4 or more friends. Only 14.3% of children with severe TBI reportedly had 4 or more friends. Glasgow Coma Scale score at admission correlated with the number of friends postacutely (by parental reports) (r = +0.307, N = 76, P = .007). Conclusion: More severe brain injury is associated with fewer friends in the postacute phase following TBI. The relation, however, was not purely linear and the hypothesis was supported only partially. Broadening the social network of children with moderate and severe TBI should be a major goal of neuropsychological rehabilitation.	St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA	Prigatano, GP (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	gprigat@cbw.edu					Achenbach T., 2001, CHILD BEHAV CHECKLIS; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRANZEN EA, 1973, NEUROPSYCHOLOGIA, V11, P141, DOI 10.1016/0028-3932(73)90002-X; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1975, LANCET, V1, P480; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano GP, 2006, Minimally Invasive Neurosurgery and Multidisciplinary Neurotraumatology, P225, DOI 10.1007/4-431-28576-8_36; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 2004, BARROW Q, V20, P27; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; SCARR S, 1986, UNDERSTANDING DEV; TEASDALE G, 1974, LANCET, V2, P81; Webster-Stratton C, 2004, INFANT YOUNG CHILD, V17, P96, DOI 10.1097/00001163-200404000-00002; Wechsler D., 1991, WECHSLER INTELLIGENC; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	31	61	61	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					505	513		10.1097/00001199-200611000-00005			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400005	17122681				2021-06-18	
J	Louin, G; Marchand-Verrecchia, C; Palmier, B; Plotkine, M; Jafarian-Tehrani, M				Louin, G; Marchand-Verrecchia, C; Palmier, B; Plotkine, M; Jafarian-Tehrani, M			Selective inhibition of inducible nitric oxide synthase reduces neurological deficit but not cerebral edema following traumatic brain injury	NEUROPHARMACOLOGY			English	Article						nitric oxide synthase; fluid percussion brain injury; aminoguanidine; L-NIL; 1400W; cerebral edema; neurological score; rat	ACUTE LUNG INJURY; BARRIER BREAKDOWN; DETRIMENTAL ROLE; NOS ACTIVITY; COLD INJURY; IN-VIVO; RATS; AMINOGUANIDINE; EXPRESSION; INFLAMMATION	The role of inducible nitric oxide synthase (iNOS) in cerebral edema and neurological deficit following traumatic brain injury (TBI) is not yet clear-cut. Therefore, the aim of this study was to investigate the effect of three different iNOS inhibitors on cerebral edema and functional outcome after TBI. First, the time courses of blood-brain barrier (BBB) breakdown, cerebral edema, and neurological deficit were studied in a rat model of fluid percussion-induced TBI. The permeability of BBB to Evans blue was increased from I It to 24 h after TBI. Consistently, a significant increase in brain water content (BWC) was observed at 6 and 24 h post-TBI. A deficit in sensorimotor neurological functions was also observed from 6 It to 7 days with a maximum 24 h after TBI. Second, a single dose of aminoguanidine (AG; 100 mg/kg, i.p.), L-N-iminoethyl-lysine (L-NIL; 20 mg/kg, i.p.), or N-[3-(aminomethyl)benzyl]acetamide (1400W; 20 mg/kg, s.c.) was administered at 6 It post-TBI. Treatment with AG reduced by 71% the increase in BWC evaluated at 24 h, while L-NIL and 1400W had no effect. In contrast, the three iNOS inhibitors reduced the neurological deficit from 30% to 40%. Third, 1400W (20 mg/kg, s.c.) was administered at 5 min, 8 and 16 h post-TBI. Although this treatment paradigm had no effect on cerebral edema evaluated at 24 h, it significantly reduced the neurological deficit and iNOS activity. In conclusion, iNOS contributes to post-TBI neurological deficit but not to cerebral edema. The beneficial effect of iNOS inhibitors is not due to their anti-edematous effect, and the reduction of cerebral edema by AG is unlikely related to iNOS inhibition. The 6 h therapeutic window of iNOS inhibitors could allow their use in the treatment of functional deficit at the acute phase of TBI. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Paris 05, Fac Pharm, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, F-75270 Paris 06, France	Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Fac Pharm, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, 4 Ave Observ, F-75270 Paris 06, France.	mehrnaz.jafarian@univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856			Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Arkovitz MS, 1996, J PEDIATR SURG, V31, P1009, DOI 10.1016/S0022-3468(96)90075-5; Arnbrosini A, 2005, J NEUROSCI METH, V144, P183, DOI 10.1016/j.jbeumeth.2004.11.002; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bucci M, 2005, P NATL ACAD SCI USA, V102, P904, DOI 10.1073/pnas.0408906102; Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Evans SM, 2003, EUR J PHARMACOL, V461, P63, DOI 10.1016/S0014-2999(02)02959-X; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; Handy RLC, 1998, BRIT J PHARMACOL, V123, P1119, DOI 10.1038/sj.bjp.0701735; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Harkin DW, 2004, J SURG RES, V120, P230, DOI 10.1016/j.jss.2004.03.011; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; Kankuri E, 2001, J PHARMACOL EXP THER, V298, P1128; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mikawa K, 2003, ANESTH ANALG, V97, P1751, DOI 10.1213/01.ANE.0000086896.90343.13; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Nag S, 2000, ACT NEUR S, V76, P65; Naka M, 2000, BIOCHEM BIOPH RES CO, V270, P663, DOI 10.1006/bbrc.2000.2474; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Okamoto H, 1998, STROKE, V29, P1209, DOI 10.1161/01.STR.29.6.1209; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Yildiz G, 1998, BRIT J PHARMACOL, V124, P905, DOI 10.1038/sj.bjp.0701924; Young RJ, 2000, BIOORG MED CHEM LETT, V10, P597, DOI 10.1016/S0960-894X(00)00055-X; Zhang L, 2003, J APPL PHYSIOL, V94, P1473, DOI 10.1152/japplphysiol.00789.2002	46	61	63	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB	2006	50	2					182	190		10.1016/j.neuropharm.2005.08.020			9	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	014RP	WOS:000235497900006	16242164				2021-06-18	
J	Nelson, NW; Sweet, JJ; Demakis, GJ				Nelson, NW; Sweet, JJ; Demakis, GJ			Meta-analysis of the MMPI-2 fake bad scale: Utility in forensic practice	CLINICAL NEUROPSYCHOLOGIST			English	Article							VALIDITY SCALES; LEES-HALEY; CONSTRUCT-VALIDITY; MCMI-II; LITIGANTS; SYMPTOMATOLOGY; PROFILES; SYMPTOMS; DISORDER; STANDARD	Some clinical researchers disagree regarding the clinical utility of the MMPI-2 Fake Bad scale (FBS) within forensic and clinical settings. The present meta-analysis summarizes weighted effect size differences among the FBS and other commonly used validity scales (L, F, K, Fb, Fp, F-K, O-S, Ds2, Dsr2) in symptom overreporting and comparison groups. Forty studies that included FBS were identified through exploration of online databases, perusal of published references, and communication with primary authors. Nineteen of the 40 studies met restrictive inclusion criteria, resulting in a pooled sample size of 3664 (1615 overreporting participants and 2049 comparison participants). The largest grand effect sizes were observed for FBS (.96), followed by O-S (.88), Dsr2 (.79), F- K (.69), and the F- scale (.63). Significant within-scale variability was observed for seven validity scales, including FBS (Q = 119.11, p < .001). Several subsequent FBS moderator analyses yielded moderate to large effect sizes and were statistically significant for level of cognitive effort, type of overreporting comparison group, and condition associated with overreporting (e.g., traumatic brain injury, posttraumatic stress, chronic pain). Findings suggest that the FBS performs as well as, if not superior to, other validity scales in discriminating overreporting and comparison groups; the preponderance of the present literature supports the scale's use within forensic settings.	Evanston NW Healthcare Med Grp, Dept Psychiat & Behav Sci, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Evanston, IL USA; Univ N Carolina, Charlotte, NC 28223 USA	Sweet, JJ (corresponding author), Evanston NW Healthcare Med Grp, Dept Psychiat & Behav Sci, 909 Davis St,Suite 160, Evanston, IL 60201 USA.	j-sweet@northwestern.edu					Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Arbisi PA, 2004, ARCH CLIN NEUROPSYCH, V19, P341, DOI 10.1016/j.acn.2003.12.003; ARNOLD G, 2005, 33 ANN M INT NEUR PS; Bagby RM, 2000, ASSESSMENT, V7, P55, DOI 10.1177/107319110000700104; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Bury AS, 2002, PSYCHOL ASSESSMENT, V14, P472, DOI 10.1037//1040-3590.14.4.472; Butcher JN, 2003, ARCH CLIN NEUROPSYCH, V18, P473, DOI 10.1016/S0887-6177(02)00142-7; Butcher JN, 1989, MANUAL ADM SCORING M; CHARLES T, 1999, DISS ABSTR INT, V60, P5221; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cramer KM, 1995, J CLIN PSYCHOL, V51, P831, DOI 10.1002/1097-4679(199511)51:6<831::AID-JCLP2270510616>3.0.CO;2-O; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; Elhai JD, 2000, J PERS ASSESS, V75, P449, DOI 10.1207/S15327752JPA7503_06; Elhai JD, 2001, ASSESSMENT, V8, P221, DOI 10.1177/107319110100800210; FOX DD, 1995, J CLIN PSYCHOL, V51, P42, DOI 10.1002/1097-4679(199501)51:1<42::AID-JCLP2270510108>3.0.CO;2-Z; GOUGH H, 1957, CALIFORNIA PSYCHOL I; Gough H.G, 1950, J CONSULT PSYCHOL, V14, P408; GOUGH HG, 1954, J CONSULT PSYCHOL, V18, P287; GREENE RL, 1991, MMPI 2 MMPI INTERPRE; Greiffenstein MF, 2004, CLIN NEUROPSYCHOL, V18, P573, DOI 10.1080/13854040490888512; Greiffenstein MF, 1996, ARCH CLIN NEUROPSYCH, V11, P283, DOI 10.1016/0887-6177(95)00038-0; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; GREIFFENSTEIN MF, IN PRESS DETECTION N; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P337, DOI 10.1016/j.acn.2003.12.005; GREVE KW, CLIN NEUROPSYCHOLOGI; GRILLO J, 1994, J CLIN PSYCHOL, V50, P651, DOI 10.1002/1097-4679(199407)50:4<651::AID-JCLP2270500424>3.0.CO;2-C; Guez M, 2005, J CLIN EXP NEUROPSYC, V27, P151, DOI 10.1080/13803390490515487; Hedges L. V., 1981, J EDUC STAT, V6, P107; HINOJOSA L, 1993, DISS ABSTR INT, V54, P2203; Iverson GL, 2002, PSYCHOL REP, V90, P131, DOI 10.2466/PR0.90.1.131-136; IVERSON GL, 1995, PSYCHOL ASSESSMENT, V7, P118, DOI 10.1037/1040-3590.7.1.118; Lanyon RI, 2002, J AM ACAD PSYCHIATRY, V30, P400; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Lees-Haley PR, 2004, ARCH CLIN NEUROPSYCH, V19, P333, DOI 10.1016/j.acn.2003.12.004; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; LEESHALEY PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Lipsey MW, 2001, PRACTICAL META ANAL; MCCARTHY J, 2005, 33 ANN M INT NEUR PS; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; MILLIS SR, 1995, 30 ANN S REC DEV US; Nelson NW, 2005, CLIN NEUROPSYCHOL, V19, P154; NELSON NW, IN PRESS J CLIN NEUR; Posthuma AB, 1998, PROF PSYCHOL-RES PR, V29, P437; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rogers R., 1995, ASSESSMENT, V2, P81; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Salekin R. T., 1994, ASSESSMENT, V1, P227, DOI DOI 10.1177/107319119400100302; SCHMIDT FL, 2003, HDB PSYCHOL RES METH, V12; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; Van Gaasbeek JK, 2001, ARCH CLIN NEUROPSYCH, V16, P813; WEGMAN TJ, 2005, 33 ANN M INT NEUR SO; WIENER DN, 1948, J CONSULT PSYCHOL, V12, P164, DOI 10.1037/h0055594	63	61	61	0	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	2006	20	1					39	58		10.1080/13854040500459322			20	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	999OL	WOS:000234399000004	16393920				2021-06-18	
J	Piland, SG; Motl, RW; Guskiewicz, KM; McCrea, M; Ferrara, MS				Piland, SG; Motl, RW; Guskiewicz, KM; McCrea, M; Ferrara, MS			Structural validity of a self-report concussion-related symptom scale	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						confirmatory factor analysis; factorial validity; self-report symptoms (SRS); measurement	COLLEGIATE FOOTBALL PLAYERS; VALIDATION; RECOVERY; RETURN; FIT	Purpose: This Study evaluated the factorial validity of a self-report measure of concussion-related symptom severity among a large sample of male, high-school athletes. Methods: Participants (N = 1089) were nonconcussed, male, high-school football players. All participants completed a single baseline self-report measure of concussion-related symptom severity, namely the graded symptom checklist (GSC). We tested the factorial validity of the, measure with confirmatory factor analysis using LISREL 8.50. Results: The, analysis indicated that a theoretically derived, three-factor model provided a good, but not excellent, fit for the 16-item GSC. Excellent model-data fit was demonstrated for the three-factor model for a 9-item version of the GSC. In both instances, the three factors were best described by a single second-order factor, namely concussion symptomatology. Conclusions: This Study provides additional evidence for the factorial validity of a summative self-reported measure of concussion-related symptoms. The factor structure represents a cohesive group of nine symptoms that can be explained by three underlying latent variables, namely somatic symptoms, neurobehavioral symptoms, and "cognitive" symptoms, subsumed under a single higher-order factor, namely concussion symptoms.	Univ So Mississippi, Sch Human Performance & Recreat, Hattiesburg, MS 39406 USA; Univ Illinois, Dept Kinesiol, Champaign, IL USA; Univ Carolina, Dept Excercise & Sport Sci, Chapel Hill, NC USA; Waukesha Mem Hosp, Neurosci Ctr, Waukesha, WI USA; Univ Georgia, St Marys Athlet Training Educ & Res Lab, Dept Exercise Sci, Athens, GA USA	Piland, SG (corresponding author), Univ So Mississippi, Sch Human Performance & Recreat, 118 Coll Dr 5142, Hattiesburg, MS 39406 USA.	scott.piland@usm.edu		Guskiewicz, Kevin/0000-0002-8682-2130			Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037/0033-2909.103.3.411; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BENTLER H, 2003, PSYCHOL BULL, V88, P588; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; BOLLEN KA, 1993, TESTING STRUCTURAL E, P10; BROWNE MW, 2002, TESTING STRUCTURAL E, P136; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CUDECK R, 1983, MULTIVAR BEHAV RES, V18, P147, DOI 10.1207/s15327906mbr1802_2; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUSKIEWICZ KM, 2001, J ATHL TRAINING, V36, P198; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; JORESKOG K, 1996, LISREL 8 USERS REFER, P271; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MESSICK S, 1995, AM PSYCHOL, V50, P741, DOI 10.1037/0003-066X.50.9.741; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104	26	61	61	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JAN	2006	38	1					27	32		10.1249/01.mss.0000183186.98212.d5			6	Sport Sciences	Sport Sciences	000LS	WOS:000234464100006	16394950				2021-06-18	
J	McAvinue, L; O'Keeffe, F; McMackin, D; Robertson, IH				McAvinue, L; O'Keeffe, F; McMackin, D; Robertson, IH			Impaired sustained attention and error awareness in traumatic brain injury: Implications for insight	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SELF-AWARENESS; QUESTIONNAIRE; CINGULATE; FAILURES; DEFICITS; LESIONS; SYSTEM; TASK	The processes of error awareness and sustained attention were investigated in 18 traumatic brain injury (TBI) individuals and 16 matched control participants. In Experiment 1, we found that: (1) in comparison to controls, TBI participants displayed reduced sustained attention and awareness of error during the Sustained Attention to Response Task; (2) degree of error awareness was strongly correlated with sustained attention capacity, even with severity of injury partialed out; and (3) that error feedback significantly reduced errors. We replicated the finding of a correlation between error awareness and sustained attention capacity in Experiment 2 with a separate sample of 19 TBI participants and 20 controls. We conclude that TBI leads to impaired sustained attention and error awareness. The finding of a significant relationship between these two deficits in TBI suggests there may be a link between these two processes. Feedback on error improves sustained attention performance of control and TBI participants.	Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland; Beaumont Hosp, Dublin 9, Ireland	Robertson, IH (corresponding author), Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland.	Ian.Robertson@tcd.ie		Robertson, Ian H/0000-0001-8637-561X			BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Kiehl KA, 2000, PSYCHOPHYSIOLOGY, V37, P216, DOI 10.1017/S0048577200990231; Lamme VAF, 2003, TRENDS COGN SCI, V7, P12, DOI 10.1016/S1364-6613(02)00013-X; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; Nelson HE, 1982, NATL ADULT READING T; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1999, COGNITIVE NEUROREHAB, P240; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	32	61	63	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	DEC	2005	15	5					569	587		10.1080/09602010443000119			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	994ZM	WOS:000234069700001	16381141				2021-06-18	
J	Ozdemir, D; Tugyan, K; Uysal, N; Sonmez, U; Sonmez, A; Acikgoz, O; Ozdemir, N; Duman, M; Ozkan, H				Ozdemir, D; Tugyan, K; Uysal, N; Sonmez, U; Sonmez, A; Acikgoz, O; Ozdemir, N; Duman, M; Ozkan, H			Protective effect of melatonin against head trauma-induced hippocampal damage and spatial memory deficits in immature rats	NEUROSCIENCE LETTERS			English	Article						traumatic brain injury; immature rat; spatial memory deficits; hippocampal neuron death; melatonin	BRAIN-INJURY; OXIDATIVE STRESS; CHILDREN; DYSFUNCTION; NEURODEGENERATION; VULNERABILITY; ADOLESCENTS; REDUCTION; APOPTOSIS; SYSTEM	It is well known that head trauma induces the cognitive dysfunction resulted from hippocampal damage. In the present study, we aimed to demonstrate the effect of melatonin on hippocampal damage and spatial memory deficits in 7-day-old rat pups subjected to contusion injury. Melatonin was injected intraperitoneally at the doses of 5 or 20 mg/kg of body weight immediately after induction of traumatic injury. Hippocampal damage was examined by cresyl violet staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. Spatial memory performance was assessed in the Morris water maze. Melatonin significantly attenuated trauma-induced neuronal death in hippocampal CA1, CA3 regions and dentate gyrus, and improved spatial memory deficits, which was equally effective at doses of 5-20 mg/kg. The present results suggest that melatonin is a highly promising agent for preventing the unfavorable outcomes of traumatic brain injury in young children. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Dokuz Eylul Univ, Sch Med, Dept Pediat, TR-35340 Izmir, Turkey; Dokuz Eylul Univ, Sch Med, Dept Histol & Embryol, TR-35340 Izmir, Turkey; Dokuz Eylul Univ, Sch Med, Dept Physiol, TR-35340 Izmir, Turkey; Ataturk Training & Res Hosp, Dept Neurosurg, Izmir, Turkey	Ozkan, H (corresponding author), Dokuz Eylul Univ, Sch Med, Dept Pediat, TR-35340 Izmir, Turkey.	hasan.ozkan@deu.edu.tr	Ozkan, Hasan/P-6128-2019; Duman, Murat/Q-2708-2019; Tugyan, Kazim/AAB-3849-2020; acikgoz, osman/C-8046-2012	Ozkan, Hasan/0000-0003-2542-7441; ACIKGOZ, OSMAN/0000-0003-1444-5847; Uysal, Nazan/0000-0002-2348-7427; Duman, Murat/0000-0001-6767-5748			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Amaral David G., 1995, P443; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Chung SY, 2003, J PINEAL RES, V34, P95, DOI 10.1034/j.1600-079X.2003.00010.x; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Felderhoff-Mueser Ursula, 2000, Current Opinion in Neurology, V13, P141, DOI 10.1097/00019052-200004000-00005; Feng Z, 2004, J PINEAL RES, V37, P129, DOI 10.1111/j.1600-079X.2004.00144.x; Guthrie E, 1999, CHILD ADOL PSYCH CL, V8, P807; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ, 2000, BIOL SIGNAL RECEPT, V9, P160; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Shen YX, 2002, J PINEAL RES, V32, P173, DOI 10.1034/j.1600-079x.2002.1o850.x; Shen YX, 2001, ACTA PHARMACOL SIN, V22, P797; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941	34	61	64	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 16	2005	385	3					234	239		10.1016/j.neulet.2005.05.055			6	Neurosciences	Neurosciences & Neurology	952AE	WOS:000230972700012	15970378				2021-06-18	
J	Maier, B; Laurer, HL; Rose, S; Buurman, WA; Marzi, I				Maier, B; Laurer, HL; Rose, S; Buurman, WA; Marzi, I			Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: A normative study	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; interleukin; plasma; reference value; soluble receptors	TRAUMATIC BRAIN INJURY; INTERCELLULAR-ADHESION MOLECULE-1; SOLUBLE E-SELECTIN; INFLAMMATORY RESPONSE; IMMUNE-RESPONSE; TNF RECEPTOR; INTERLEUKIN-8; CYTOKINES; SERUM; RELEASE	Numerous recent studies have reported a significant inflammatory reaction in the brain and the systemic circulation following traumatic brain injury (TBI), infection, or neoplasm of the brain with a sequential release of pro- and anti-inflammatory mediators. Although there is growing knowledge and understanding of the mechanisms leading to the often poor outcome of these patients, only a limited database exists on the physiological expression of pro- and anti-inflammatory cytokines and molecules in plasma and particularly in cerebrospinal fluid (CSF). Therefore, we analyzed paired plasma/CSF samples of healthy human volunteers for the physiological concentrations of Interleukin (IL)-6, IL-8, IL-10, soluble TNF-receptors (sTNF-R) p55 and p75, soluble ICAM (sICAM), and soluble E-selectin (sE-selectin). A physiological release of IL-6, IL-8, IL-10, and sTNF-R p55 and p75 was detected in plasma and CSF. In contrast, sICAM and sE-selectin were only detectable in plasma. Pro- and anti-inflammatory mediators exhibited different concentration patterns in plasma and CSF, suggesting a pro-inflammatory predisposition in the central nervous system.	Goethe Univ Frankfurt, Univ Hosp, Sch Med, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany; Univ Maastricht, Dept Surg, Maastricht, Netherlands	Marzi, I (corresponding author), Goethe Univ Frankfurt, Klin Unfall Hand & Wiederherstellungschirurg, D-69590 Frankfurt, Germany.	marzi@trauma.uni-frankfurt.de					ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; AYALA A, 1991, AM J PHYSIOL, V260, pR167; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bouma M, 1997, IMMUNOCHEMISTRY PRAC, P181; Brockhaus M, 1997, INTENS CARE MED, V23, P808, DOI 10.1007/s001340050416; CINAT M, 1995, J TRAUMA, V39, P112, DOI 10.1097/00005373-199507000-00015; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; ENGELBERTS I, 1992, CLIN IMMUNOL IMMUNOP, V65, P330, DOI 10.1016/0090-1229(92)90165-K; Ertel W, 1998, UNFALLCHIRURG, V101, P520, DOI 10.1007/s001130050304; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; Froon AHM, 1996, EUR J SURG, V162, P287; Handa Shoichi, 1992, Kurume Medical Journal, V39, P257; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kleine TO, 2003, BRAIN RES BULL, V61, P287, DOI 10.1016/S0361-9230(03)00092-3; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Laan MP, 1998, ALLERGY, V53, P51, DOI 10.1111/j.1398-9995.1998.tb03773.x; LAW MM, 1994, J TRAUMA, V37, P100, DOI 10.1097/00005373-199407000-00017; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MAIER B, 1999, UNFALLCHIRURGIE, V25, P100; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Muller M, 2001, Eur J Ultrasound, V12, P203, DOI 10.1016/S0929-8266(00)00118-X; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Polin RS, 1998, J NEUROSURG, V89, P559, DOI 10.3171/jns.1998.89.4.0559; Seekamp A, 1998, J TRAUMA, V44, P874, DOI 10.1097/00005373-199805000-00022; Spuler S, 1996, J NEUROIMMUNOL, V66, P57; TADA M, 1993, J NEURO-ONCOL, V16, P25, DOI 10.1007/BF01324831; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vinante F, 1998, BRIT J HAEMATOL, V102, P1025, DOI 10.1046/j.1365-2141.1998.00872.x; Woiciechowsky C, 1997, ACTA NEUROCHIR, V139, P619, DOI 10.1007/BF01411996	35	61	66	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2005	22	7					822	835		10.1089/neu.2005.22.822			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	945VQ	WOS:000230530800009	16004584				2021-06-18	
J	Vagnozzi, R; Signoretti, S; Tavazzi, B; Cimatti, M; Amorini, AM; Donzelli, S; Delfini, R; Lazzarino, G				Vagnozzi, R; Signoretti, S; Tavazzi, B; Cimatti, M; Amorini, AM; Donzelli, S; Delfini, R; Lazzarino, G			Hypothesis of the postconcussive vulnerable brain: Experimental evidence of its metabolic occurrence	NEUROSURGERY			English	Article						brain concussion; energetic metabolism; high-performance liquid chromatography; N-acetylaspartate; second impact; sports-related injury	MAGNETIC-RESONANCE-SPECTROSCOPY; N-ACETYL ASPARTATE; MITOCHONDRIAL DYSFUNCTION; CEREBRAL CONCUSSION; HEAD-INJURY; CYCLOSPORINE-A; AXONAL INJURY; NEURONAL LOSS; 2ND IMPACT; ACETYLASPARTATE	OBJECTIVE: We evaluated the effects of two consecutive concussive injuries on brain energy metabolism and N-acetylaspartate (NAA) to investigate how the temporal interval between traumatic events influences overall injury severity. METHODS: Rats were injured to induce diffuse traumatic brain injury (TBI) (mild, 450 g/1 m; severe, 450 g/2 m). In two groups, two mild TBIs were delivered in 3- or 5-day intervals. Three additional animal groups were used: single mild TBI, single severe TBI, and sham. All animals were killed 48 hours postinjury. Adenosine 5'-triphosphate (ATP), adenosine diphosphate, and NAA concentrations were analyzed with high-performance liquid chromatography on deproteinized whole brain extracts. RESULTS: In control animals, the NAA concentration was 9.17 +/- 0.38 mu mol/g wet weight, the ATP concentration was 2.25 +/- 0.21 mu mol/g wet weight, and the ATP-to-adenosine diphosphate ratio was 9.38 +/- 1.23. These concentrations decreased to 6.68 +/- 1.12 mu mol/g wet weight, 1.68 +/- 0.24 mu mol/g wet weight, and 6.10 +/- 1.21 mu mol/g wet weight, respectively, in rats that received two mild TBIs at a 5-day interval (P < 0.01; not different from results in rats with single mild TBI). When a second TBI was delivered after 3 days, the NAA concentration was 3.86 +/- 0.53 mu mol/g wet weight, the ATP concentration was 1.11 +/- 0.18 mu mol/g wet weight, and the ATP-to-adenosine diphosphate ratio was 2.64 +/- 0.43 (P < 0.001 versus both controls and 3-day interval; not different from rats receiving a single severe TBI). CONCLUSION: The biochemical modification severity in double TBI is dependent on the interval between traumatic events, which demonstrates the metabolic state of the vulnerable brain after mild TBI. These data support the hypothesis of the application of proton magnetic resonance spectroscopy to measure NAA as a possible tool to monitor the full recovery of brain metabolic functions in the clinical setting, particularly in sports medicine.	Univ Catania, Dept Chem Sci, Biochem Lab, I-95125 Catania, Italy; Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; San Camillo Hosp, Div Neurosurg, Rome, Italy; Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; Univ Roma La Sapienza, Dept Neurol Sci Neurosurg, Rome, Italy; Univ Catania, Dept Chem Sci, Biochem Lab, Catania, Italy	Lazzarino, G (corresponding author), Univ Catania, Dept Chem Sci, Biochem Lab, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@mbox.unict.it	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BAILES JE, 2001, NEUROLOGICAL SPORTS, P1; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2004, NEUROSURGERY, V54, P1078; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; EBISU T, 1994, J CEREBR BLOOD F MET, V14, P373, DOI 10.1038/jcbfm.1994.48; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GERBERDING JL, 2003, C MILD TRAUM BRAIN I, P31; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V7, P469; Jenkins BG, 1996, J CEREBR BLOOD F MET, V16, P450, DOI 10.1097/00004647-199605000-00011; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MOFFETT JR, 1993, J HISTOCHEM CYTOCHEM, V41, P559, DOI 10.1177/41.4.8450195; MOFFETT JR, 1991, NEUROREPORT, V2, P131, DOI 10.1097/00001756-199103000-00005; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Powell JW, 2001, J ATHL TRAINING, V36, P307; Putukian M, 1996, PHYSICIAN SPORTSMED, V24, P25, DOI 10.3810/psm.1996.11.1283; Rooney WD, 1998, NEUROLOGY, V50, P1800, DOI 10.1212/WNL.50.6.1800; Sager TN, 1999, J CEREBR BLOOD F MET, V19, P164; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2002, ACT NEUR S, V81, P373; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Tasch E, 1999, ANN NEUROL, V45, P568, DOI 10.1002/1531-8249(199905)45:5<568::AID-ANA4>3.0.CO;2-P; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; 1997, MMWR MORB MORTAL WKL, V46, P224	63	61	62	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2005	57	1					164	171		10.1227/01.NEU.0000163413.90259.85			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	942ZQ	WOS:000230321800044	15987552				2021-06-18	
J	McKee, JA; Brewer, RP; Macy, GE; Phillips-Bute, B; Campbell, KA; Borel, CO; Reynolds, JD; Warner, DS				McKee, JA; Brewer, RP; Macy, GE; Phillips-Bute, B; Campbell, KA; Borel, CO; Reynolds, JD; Warner, DS			Analysis of the brain bioavailability of peripherally administered magnesium sulfate: A study in humans with acute brain injury undergoing prolonged induced hypermagnesemia	CRITICAL CARE MEDICINE			English	Article						magnesium sulfate; neuroprotective agents; cerebrospinal fluid; subarachnoid hemorrhage; brain ischemia; traumatic brain injury	ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBROSPINAL-FLUID; IONIZED MAGNESIUM; CEREBRAL-ISCHEMIA; ACUTE STROKE; BLOOD-FLOW; IN-VITRO; RAT; PREECLAMPSIA; DEFICIENCY	Objective: Based on preclinical investigations, magnesium sulfate (MgSO4) has gained interest as a neuroprotective agent. However, the ability of peripherally administered MgSO4 to penetrate the blood-brain barrier is limited in normal brain. The current study measured the passage of intravenously administered Mg2+ into cerebrospinal fluid in patients with brain injury requiring ventricular drainage. Design: A prospective evaluation of the cerebrospinal fluid total and ionized magnesium concentration, [Mg2+], during sustained hypermagnesemia was performed. Setting: Neurosciences intensive care unit at a major teaching institution. Patients: Thirty patients with acute brain injury secondary to subarachnoid hemorrhage, traumatic brain injury, primary intracerebral hemorrhage, subdural hematoma, brain tumor, central nervous system infection, or ischemic stroke were studied. Interventions. Patients underwent 24 hrs of induced hypermagnesemia during which total and ionized cerebrospinal fluid [Mg2+] was measured. Serum [Mg2+] was adjusted to 2.1-2.5 mmol/L. Cerebrospinal fluid [Mg2+] was measured at baseline, at 12 and 24 hrs after onset of infusion, and at 12 hrs following infusion termination. Measurements and Main Results. At baseline, total (1.25 +/- 0.14 mmol/L) and ionized (0.80 +/- 0.10 mmol/L) cerebrospinal fluid [Mg2+] was greater than serum total (0.92 +/- 0.18 mmol/L) and ionized (0.63 +/- 0.07 mmol/L) [Mg2+] (p < .05). Total (1.43 +/- 0.13 mmol/L) and ionized (0.89 +/- 0.12 mmol/L) cerebrospinal fluid [Mg2+] was maximally increased by 15% and 11% relative to baseline, respectively, during induced hypermagnesemia (p < .05). Conclusions: Hypermagnesemia produced only marginal increases in total and ionized cerebrospinal fluid [Mg2+]. Regulation of cerebrospinal fluid [Mg2+] is largely maintained following acute brain injury and limits the brain bioavailability of MgSO4.	Duke Univ, Med Ctr, Neurosci Intens Care Unit, Durham, NC 27706 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27706 USA; Duke Univ, Sch Med, Med Ctr, Durham, NC 27706 USA	McKee, JA (corresponding author), Duke Univ, Med Ctr, Neurosci Intens Care Unit, Durham, NC 27706 USA.						Altura BT, 1997, NEUROSCI LETT, V230, P37, DOI 10.1016/S0304-3940(97)00471-0; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P21, DOI 10.3109/00365519409095208; BELFORT MA, 1992, AM J OBSTET GYNECOL, V167, P661, DOI 10.1016/S0002-9378(11)91567-1; Belfort MA, 2003, NEW ENGL J MED, V348, P304, DOI 10.1056/NEJMoa021180; Boet R, 2000, NEUROSURGERY, V47, P602, DOI 10.1097/00006123-200009000-00014; Bradford Andrew, 2000, Curr Control Trials Cardiovasc Med, V1, P184, DOI 10.1186/CVM-1-3-184; Brewer RP, 2001, CLIN NEUROPHARMACOL, V24, P341, DOI 10.1097/00002826-200111000-00005; CHI OZ, 1990, ARCH INT PHARMACOD T, V304, P196; CHOI WW, 1991, AM J OBSTET GYNECOL, V164, P693, DOI 10.1016/S0002-9378(11)80048-7; CHUTKOW JG, 1974, NEUROLOGY, V24, P780, DOI 10.1212/WNL.24.8.780; FuchsBuder T, 1997, J NEUROSURG ANESTH, V9, P324, DOI 10.1097/00008506-199710000-00006; Gee JB, 2004, PEDIATR RES, V55, P93, DOI 10.1203/01.PDR.0000099771.39629.E5; Gee JB, 1999, PEDIATR RES, V46, P281, DOI 10.1203/00006450-199909000-00006; GHRIBI O, 1995, FUNDAM CLIN PHARM, V9, P141, DOI 10.1111/j.1472-8206.1995.tb00273.x; GOLDMAN RS, 1988, NEW ENGL J MED, V319, P1224; HALLAK M, 1992, AM J OBSTET GYNECOL, V167, P1605, DOI 10.1016/0002-9378(92)91749-Z; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; HOFFMAN DJ, 1994, BRAIN RES, V644, P144, DOI 10.1016/0006-8993(94)90357-3; HUANG QF, 1994, AM J PHYSIOL, V266, pR158; KEMP PA, 1993, CLIN SCI, V85, P175, DOI 10.1042/cs0850175; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Lampl Y, 2001, CLIN NEUROPHARMACOL, V24, P11, DOI 10.1097/00002826-200101000-00003; Lampl Y, 1998, J NEUROL, V245, P584, DOI 10.1007/s004150050249; Lees KR, 2004, LANCET, V363, P439; Marinov MB, 1996, J NEUROSURG, V85, P117, DOI 10.3171/jns.1996.85.1.0117; MIURA K, 1988, Neurological Surgery, V16, P1251; Morris M E, 1992, Magnes Res, V5, P303; Muir KW, 1998, MAGNESIUM RES, V11, P43; Nelson RM, 2003, BRAIN RES, V964, P1, DOI 10.1016/S0006-8993(02)03691-0; OPPELT WW, 1963, AM J PHYSIOL, V205, P959; Saver JL, 2002, STROKE, V33, P353; SCHANNE FAX, 1993, BIOCHIM BIOPHYS ACTA, V1158, P257, DOI 10.1016/0304-4165(93)90023-2; Sirin BH, 1998, EUR J CARDIO-THORAC, V14, P82, DOI 10.1016/S1010-7940(98)00140-7; SOMJEN G, 1966, J PHARMACOL EXP THER, V154, P652; Standley CA, 1996, OBSTET GYNECOL, V88, P184, DOI 10.1016/0029-7844(96)00144-5; THURNAU GR, 1987, AM J OBSTET GYNECOL, V157, P1435, DOI 10.1016/S0002-9378(87)80239-9; TORREGROSA G, 1994, J CARDIOVASC PHARM, V23, P1004, DOI 10.1097/00005344-199406000-00020; van den Bergh WM, 2003, ACTA NEUROCHIR, V145, P195, DOI 10.1007/s00701-002-1064-9; VANLINDE AM, 1991, METAB BRAIN DIS, V6, P199; Veyna RS, 2002, J NEUROSURG, V96, P510, DOI 10.3171/jns.2002.96.3.0510; ZOFKOVA I, 1993, HORM METAB RES, V25, P29, DOI 10.1055/s-2007-1002040; Zofkova I, 1995, Magnes Res, V8, P77	42	61	67	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2005	33	3					661	666		10.1097/01.ccm.0000156293.35868.b2			6	Critical Care Medicine	General & Internal Medicine	907CD	WOS:000227691800026	15753761				2021-06-18	
J	Goverover, Y; Chiaravalloti, N; DeLuca, J				Goverover, Y; Chiaravalloti, N; DeLuca, J			The relationship between self-awareness of neurobehavioral symptoms, cognitive functioning, and emotional symptoms in multiple sclerosis	MULTIPLE SCLEROSIS JOURNAL			English	Article						affect measures; concordance; multiple sclerosis; neuropsychological measures; neurobehavioral symptoms; rehabilitation; self-awareness	TRAUMATIC BRAIN-INJURY; IMPAIRED AWARENESS; REHABILITATION; METAMEMORY; DEPRESSION; INVENTORY; DEFICITS; BEHAVIOR; PATIENT; CORTEX	Objective: To examine self-awareness of neurobehavioral symptoms in multiple sclerosis (MS) across three domains of function (apathy, disinhibition, and executive control), and examine the relationship between self-awareness and cognitive functioning. Methods: Twenty-six individuals with MS completed neuropsychological testing, measures of emotional functioning, and self-ratings of neurobehavioral symptoms using the Frontal Systems Behavior Scale (FrSBe), a 46-item questionnaire with subscales assessing frequency of symptoms in executive dysfunction, disinhibition, and apathy. Informants' ratings of the FrSBe were also obtained. Decreasing differences between patient and informant reports on each subscale of the FrSBe (concordance) indicate higher levels of self-awareness. Results: Results showed significant positive correlations between cognitive abilities and self-awareness of executive dysfunction and disinhibition. In contrast, affect symptomatology (measures of anxiety and depression) were negatively correlated with self-awareness of executive dysfunction. Conclusions: Level of self-awareness of neurobehavioral symptoms in MS is related to level of cognitive impairment. In addition, symptoms of depression and anxiety reduced the accuracy of self-reporting. Thus, a clinician who relies on self-reports in creating an evaluation and treatment plan should consider the patient's cognitive and emotional states.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA	Chiaravalloti, N (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	nchiaravalloti@kmrrec.org		Chiaravalloti, Nancy/0000-0003-2943-7567			Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Barnes LLB, 2002, EDUC PSYCHOL MEAS, V62, P603, DOI 10.1177/0013164402062004005; BEATTY WW, 1991, J CLIN EXP NEUROPSYC, V13, P309, DOI 10.1080/01688639108401046; Beck A.T., 1987, BECK DEPRESSION INVE; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Benedict RHB, 2002, J NEUROPSYCH CLIN N, V14, P44, DOI 10.1176/appi.neuropsych.14.1.44; Benedict RHB, 2001, J NEUROPSYCH CLIN N, V13, P70, DOI 10.1176/appi.neuropsych.13.1.70; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; BROWNELL B, 1962, J NEUROL NEUROSUR PS, V25, P315, DOI 10.1136/jnnp.25.4.315; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; EGAN V, 1988, PERS INDIV DIFFER, V9, P179, DOI 10.1016/0191-8869(88)90046-3; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; FONG J, 1997, BRAIN, V120, P15; Goverover Y, 2004, J CLIN EXP NEUROPSYC, V26, P737, DOI 10.1080/13803390490509321; Groth-Marnat G., 1990, HDB PSYCHOL ASSESSME, V2nd ed.; Halper June, 2003, J Neurosci Nurs, V35, P70; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Heaton R., 1993, WISCONSIN CARD SORTI; HEINZE L, 2004, 32 ANN CONV INT NEUR; Hoogervorst ELJ, 2001, NEUROLOGY, V56, P934, DOI 10.1212/WNL.56.7.934; JARMAN RF, 1995, GENET SOC GEN PSYCH, V121, P153; Johnson SK, 2001, J CHRONIC FATIGUE SY, V8, P41, DOI DOI 10.1300/J092V08N03_05; Kaplan E., 1983, BOSTON NAMING TEST; Katz N, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P323; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Maor Y, 2001, MULT SCLER, V7, P131, DOI 10.1177/135245850100700209; McDonnell GV, 2003, MULT SCLER J, V9, P204, DOI 10.1191/1352458503ms890cr; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Nelson T. O., 1992, METACOGNITION CORE R; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Prigatano GP, 1999, REHABIL PSYCHOL, V44, P145, DOI 10.1037/0090-5550.44.2.145; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; PRIGATANO GP, 1991, AWARENESS DEFICIT TR; Randolph JJ, 2004, ARCH CLIN NEUROPSYCH, V19, P259, DOI 10.1016/S0887-6177(03)00026-X; Randolph JJ, 2001, CLIN NEUROPSYCHOL, V15, P357, DOI 10.1076/clin.15.3.357.10278; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; Schacter DL., 1991, AWARENESS DEFICIT BR, P17; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Shimamura AP, 1995, ANN NY ACAD SCI, V769, P151, DOI 10.1111/j.1749-6632.1995.tb38136.x; Souchay C, 2002, NEUROPSYCHOLOGIA, V40, P2386, DOI 10.1016/S0028-3932(02)00075-1; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Spreen O., 1998, COMPENDIUM NEUROPSYC; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Wechsler D., 1987, WECHSLER ADULT INTEL; Wilson BA, 1996, BEHAV ASSESSMENT DYS	59	61	61	0	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1352-4585			MULT SCLER J	Mult. Scler. J.		2005	11	2					203	212		10.1191/1352458505ms1153oa			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	907KW	WOS:000227717400014	15794396				2021-06-18	
J	McFadyen, BJ; Swaine, B; Dumas, D; Durand, A				McFadyen, BJ; Swaine, B; Dumas, D; Durand, A			Residual effects of a traumatic brain injury on locomotor capacity - A first study of spatiotemporal patterns during unobstructed and obstructed walking	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						biomechanics; brain injury; gait; locomotion; kinematics; rehabilitation	BALANCE DEFICITS; OBSTACLES; GAIT; REHABILITATION; ADJUSTMENTS; STROKE; PERFORMANCE; DISORDERS; RECOVERY; HEALTHY	Objectives: To understand the residual locomotor effects of a traumatic brain injury (TBI) on unobstructed and obstructed walking. Participants: Eight young, high-functioning adults with TBI and 4 healthy subjects. Main outcome measures: Spatiotemporal gait parameters and their relation to specific clinical measures of severity and locomotor and balance abilities. Results: Subjects with TBI walked slower and showed a tendency for greater foot clearances in all conditions. Slower walking was due to decreased stride lengths and not cadence, while higher foot clearances were due to placing the trailing foot farther from the obstacle and increasing hip flexion angles during avoidance. Conclusions: The results suggest that this highly functional TBI population used increased caution. Measures of injury severity did not provide simple predictions of locomotor ability, but the one-legged stance test with eyes closed correlated to walking capacity.	Ctr Interdisciplinary Res Rehabil & Social Integr, Quebec City, PQ G1M 1S8, Canada; Univ Laval, Dept Rehabil, Quebec City, PQ, Canada; Inst Readaptat Montreal, Ctr Rech Interdisciplinaire Readaptat, Montreal, PQ, Canada; Univ Montreal, Sch Rehabil, Montreal, PQ, Canada; Quebec Rehabil Inst, Quebec City, PQ, Canada	McFadyen, BJ (corresponding author), Ctr Interdisciplinary Res Rehabil & Social Integr, 525 Hamel, Quebec City, PQ G1M 1S8, Canada.			McFadyen, Bradford/0000-0003-1992-4927			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Begg RK, 1998, GAIT POSTURE, V7, P99, DOI 10.1016/S0966-6362(97)00039-8; Bent LR, 2002, EXP BRAIN RES, V146, P490, DOI 10.1007/s00221-002-1204-8; BERG K, 1989, Physiotherapy Canada, V41, P304; BRIGGS RC, 1989, PHYS THER, V69, P748, DOI 10.1093/ptj/69.9.748; CHEN HC, 1991, J GERONTOL, V46, pM196, DOI 10.1093/geronj/46.6.M196; DREW T, 1993, J NEUROPHYSIOL, V70, P179; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Goldie PA, 1996, ARCH PHYS MED REHAB, V77, P1074, DOI 10.1016/S0003-9993(96)90072-6; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; Kalaska JF, 1997, CURR OPIN NEUROBIOL, V7, P849, DOI 10.1016/S0959-4388(97)80146-8; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; McFadyen BJ, 1997, EXP BRAIN RES, V114, P500, DOI 10.1007/PL00005659; MCFADYEN BJ, 1993, HUM MOVEMENT SCI, V12, P259, DOI 10.1016/0167-9457(93)90019-L; MCFADYEN BJ, 1991, NEUROSCI RES COMMUN, V9, P37; McFayden BJ, 2002, J GERONTOL A-BIOL, V57, pB166, DOI 10.1093/gerona/57.4.B166; McIntosh L, 1999, J REHABIL OUTCOMES M, V3, P1; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Patla AE, 1996, J MOTOR BEHAV, V28, P35, DOI 10.1080/00222895.1996.9941731; PATLA AE, 1995, EXP BRAIN RES, V106, P499; PATLA AE, 1993, GAIT POSTURE, V1, P45, DOI 10.1016/0966-6362(93)90042-Y; PREFACE EA, 1999, J HEAD TRAUMA REHAB, V14, pR5; Said CM, 1999, ARCH PHYS MED REHAB, V80, P1054, DOI 10.1016/S0003-9993(99)90060-6; Said CM, 2001, ARCH PHYS MED REHAB, V82, P1712, DOI 10.1053/apmr.2001.26247; Schall JD, 2002, NEURON, V36, P309, DOI 10.1016/S0896-6273(02)00964-9; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; ShumwayCook A, 1997, PHYS THER, V77, P812, DOI 10.1093/ptj/77.8.812; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Warren WH, 2001, NAT NEUROSCI, V4, P213, DOI 10.1038/84054; Whitney SL, 2000, J VESTIBUL RES-EQUIL, V10, P99; Winter DA., 1991, BIOMECHANICS MOTOR C; Yardley L, 2001, J ANXIETY DISORD, V15, P107, DOI 10.1016/S0887-6185(00)00045-1	35	61	62	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2003	18	6					512	525		10.1097/00001199-200311000-00005			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	747MX	WOS:000186809200005	14707881				2021-06-18	
J	Pardo, R; Andreolotti, AG; Ramos, B; Picatoste, F; Claro, E				Pardo, R; Andreolotti, AG; Ramos, B; Picatoste, F; Claro, E			Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; cell cycle arrest; ERK; GSK-3; lithium; MEK	CEREBELLAR GRANULE CELLS; GLYCOGEN-SYNTHASE KINASE-3; SUBGENUAL PREFRONTAL CORTEX; CEREBRAL-CORTICAL SLICES; CULTURED BRAIN NEURONS; AP-1 DNA-BINDING; INOSITOL MONOPHOSPHATASE; PROTEIN-KINASE; MOOD DISORDERS; GROWTH-FACTORS	Lithium is widely used in the treatment of bipolar disorder, but despite its proven therapeutic efficacy, the molecular mechanisms of action are not fully understood. The present study was undertaken to explore lithium effects of the MEK/ERK cascade of protein kinases in astrocytes and neurons. In asynchronously proliferating rat cortical astrocytes, lithium decreased time- and dose-dependently the phosphorylation of MEK and ERK, with 1 mM concentrations achieving 60 and 50% inhibition of ERK and MEK, respectively, after a 7-day exposure. Lithium also inhibited [H-3] thymidine incorporation into DNA and induced a G2/M cell cycle arrest. In serum-deprived, quiescent astrocytes, pre-exposure to lithium resulted in the inhibition of cell cycle re-entry as stimulated by the mitogen endothelin-1: under this experimental setting, lithium did not affect the rapid, peak phosphorylation of MEK taking place after 3-5 min, but was effective in inhibiting the long-term, sustained phosphorylation of MEK. Lithium inhibition of the astrocyte MEK/ERK pathway was independent of inositol depletion. Further, compound SB216763 inhibited Tau phosphorylation at Ser396 and stabilized cytosolic beta-catenin, consistent with the inhibition of glycogen synthase kinase-3beta (GSK-3beta), but failed to reproduce lithium effects on MEK and ERK phosphorylation and cell cycle arrest. In cerebellar granule neurons, millimolar concentrations of lithium enhanced MEK and ERK phosphorylation in a concentration-dependent manner, again through an inositol and GSK-3beta independent mechanism. These opposing effects in astrocytes and neurons make lithium treatment a promising strategy to favour neural repair and reduce reactive gliosis after traumatic injury.	Univ Autonoma Barcelona, Inst Neurociencies, E-08193 Bellaterra, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Bellaterra, Spain; Univ Extremadura, Dept Fisiol, E-06071 Badajoz, Spain	Claro, E (corresponding author), Univ Autonoma Barcelona, Inst Neurociencies, Edifici M, E-08193 Bellaterra, Spain.		Claro, Enrique/D-5612-2009; Ramos, Belen/K-8067-2015	Claro, Enrique/0000-0002-7592-7906; Ramos, Belen/0000-0002-4577-2106			Alvarez G, 1999, FEBS LETT, V453, P260, DOI 10.1016/S0014-5793(99)00685-7; Asghari V, 1998, MOL BRAIN RES, V58, P95, DOI 10.1016/S0169-328X(98)00107-7; Atack JR, 1996, BRAIN RES REV, V22, P183; ATACK JR, 1993, J NEUROCHEM, V60, P652, DOI 10.1111/j.1471-4159.1993.tb03197.x; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; Centeno F, 1998, NEUROREPORT, V9, P4199, DOI 10.1097/00001756-199812210-00036; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chen G, 1999, MOL BRAIN RES, V64, P52, DOI 10.1016/S0169-328X(98)00303-9; Chen RW, 2003, J NEUROCHEM, V84, P566, DOI 10.1046/j.1471-4159.2003.01548.x; CLARO E, 1993, J NEUROCHEM, V60, P2078, DOI 10.1111/j.1471-4159.1993.tb03492.x; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GODFREY PP, 1989, BIOCHEM J, V258, P621, DOI 10.1042/bj2580621; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hall AC, 2002, MOL CELL NEUROSCI, V20, P257, DOI 10.1006/mcne.2002.1117; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hashimoto R, 2003, NEUROSCIENCE, V117, P55, DOI 10.1016/S0306-4522(02)00577-8; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; KAHAN C, 1992, J BIOL CHEM, V267, P13369; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kopnisky KL, 2003, NEUROSCIENCE, V116, P425, DOI 10.1016/S0306-4522(02)00573-0; Levine S, 2000, CELL PROLIFERAT, V33, P203, DOI 10.1046/j.1365-2184.2000.00170.x; Mao CD, 2001, J BIOL CHEM, V276, P26180, DOI 10.1074/jbc.M101188200; Masgrau R, 2000, J NEUROCHEM, V74, P818, DOI 10.1046/j.1471-4159.2000.740818.x; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nemeth ZH, 2002, J BIOL CHEM, V277, P7713, DOI 10.1074/jbc.M109711200; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Nonaka S, 1998, J PHARMACOL EXP THER, V286, P539; Ongur D, 1998, P NATL ACAD SCI USA, V95, P13290, DOI 10.1073/pnas.95.22.13290; Ozaki N, 1997, J NEUROCHEM, V69, P2336; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Ren M, 2003, P NATL ACAD SCI USA, V100, P6210, DOI 10.1073/pnas.0937423100; Servitja JM, 2000, J NEUROCHEM, V75, P788, DOI 10.1046/j.1471-4159.2000.0750788.x; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; STANIMIROVIC DB, 1995, GLIA, V15, P119, DOI 10.1002/glia.440150204; Torreilles F, 2000, MOL BRAIN RES, V78, P181, DOI 10.1016/S0169-328X(00)00073-5; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200	52	61	62	0	9	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	OCT	2003	87	2					417	426		10.1046/j.1471-4159.2003.02015.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	726JN	WOS:000185596100015	14511119	Bronze			2021-06-18	
J	Wennersten, A; Holmin, S; Mathiesen, T				Wennersten, A; Holmin, S; Mathiesen, T			Characterization of Bax and Bcl-2 in apoptosis after experimental traumatic brain injury in the rat	ACTA NEUROPATHOLOGICA			English	Article						Bax; Bcl-2; apoptosis; brain injury; trauma	INTRACEREBRAL INFLAMMATORY RESPONSE; CORTICAL IMPACT INJURY; PROGRAMMED CELL-DEATH; TRANSGENIC MICE; HEAD-INJURY; IN-VIVO; NEURONS; ISCHEMIA; OVEREXPRESSION; CONTUSIONS	This study was undertaken to fulfill the need for additional data on the dynamics of Bax and Bcl-2 expression in conjunction to the cell death that ensues following experimental brain contusion. Adult Sprague-Dawley rats were subjected to a unilateral experimental controlled cortical contusion and killed at 1, 2, 4, 6 and 10 days post injury (dpi). Cell death was examined by the terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) method together with immunohistochemistry for cellular markers. Expression of Bax and Bcl-2 were analyzed by immunohistochemistry and in situ hybridization. The number of TUNEL-positive cells was highest at 1 dpi and decreased with time. At all time points, 10-16% of the TUNEL-positive cells showed an apoptotic nuclear morphology. The apoptotic features were restricted to neurons and some inflammatory cells. Immunohistochemistry for Bax revealed a translocation of Bax from a diffuse to a granular distribution in neurons. An up-regulation of Bax mRNA at 6 dpi was discernible. This increase was associated with a statistically significant increase in number of cells with up-regulated and translocated Bax protein. Moreover, a statistically significant increase of Bcl-2 mRNA was detected at 10dpi. The potential window for antiapoptotic treatment to salvage neurons is wide. The susceptibility of neurons to necrosis and apoptosis through different pathways during a prolonged post-traumatic period indicate that different pharmacological strategies may be required at different time points after trauma.	Karolinska Inst, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden	Mathiesen, T (corresponding author), Karolinska Inst, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden.			Holmin, Staffan/0000-0002-1628-1615; Mathiesen, Tiit/0000-0001-9463-1919			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1996, J NEUROCHEM, V67, P64; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Fadeel B, 1999, FASEB J, V13, P1647; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; Gahm C, 2000, NEUROSURGERY, V46, P169; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070	46	61	71	0	5	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2003	105	3					281	288		10.1007/s00401-002-0649-y			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	652BN	WOS:000181359800013	12557016				2021-06-18	
J	Amorini, AM; Lazzarino, G; Galvano, F; Fazzina, G; Tavazzi, B; Galvano, G				Amorini, AM; Lazzarino, G; Galvano, F; Fazzina, G; Tavazzi, B; Galvano, G			Cyanidin-3-O-beta-glucopyranoside protects myocardium and erythrocytes from oxygen radical-mediated damages	FREE RADICAL RESEARCH			English	Article						anthocyanin; cyanidin-3-O-beta-glucopyranoside; nutritional antioxidants; reactive oxygen species; oxidative stress; myocardial ischemia and reperfusion	BLOOD ORANGE JUICES; PERFORMANCE LIQUID-CHROMATOGRAPHY; TRAUMATIC BRAIN INJURY; LIPID-PEROXIDATION; OXIDATIVE STRESS; DNA-DAMAGE; REPERFUSION INJURY; ANTHOCYANINS; ANTIOXIDANT; ISCHEMIA	The cyanidin-3-O-beta-glucopyranoside (C-3-G) antioxidant capacity towards reactive oxygen species (ROS)-mediated damages was assessed in tissue and cells submitted to increased oxidative stress. In the isolated ischemic and reperfused rat heart, 10 or 30 muM C-3-G protected from both lipid peroxidation (66.7 and 94% inhibition of malondialdehyde (MDA) generation in 10 and 30 muM C-3-G-reperfused hearts, respectively, in comparison with control reperfused hearts) and energy metabolism impairment (higher ATP concentration in 10 and 30 muM C-3-G-reperfused hearts than in control reperfused hearts). These effects were associated to C-3-G permeation within myocardial cells, as indicated by results obtained in the isolated rat heart perfused for 30 min in the recirculating Langendorff mode under normoxia with 10 and 30 muM C-3-G. Protective effects were exerted, in a dose-dependent manner, by C-3-G also in 2 mM hydrogen peroxide-treated human erythrocytes. With respect to MDA formation, an apparent IC50 of 5.12 muM was calculated for C-3-G (the polyphenol resveratrol used for comparison showed an apparent IC50 of 38.43 muM). The general indications are that C-3-G (largely diffused in dietary plants and fruits, such as pigmented oranges very common in the Mediterranean diet) represents a powerful natural antioxidant with beneficial effects in case of increased oxidative stress, and at pharmacological concentrations it is able to decrease tissue damages occurring in myocardial ischemia and reperfusion.	Univ Catania, Dept Chem Sci, Biochem Lab, Catania, Italy; Univ Reggio Calabria, Dept Agroforestry & Environm Sci & Technol, I-89061 Reggio Di Calabria, Italy; Catholic Univ Rome Sacro Cuore, Inst Biochem & Clin Biochem, I-00167 Rome, Italy; Univ Catania, Dept Agron Agrochem & Anim Prod Sci, I-95125 Catania, Italy	Lazzarino, G (corresponding author), Univ Catania, Dept Chem Sci, Biochem Lab, Viale A Doria 6, Catania, Italy.		Galvano, Fabio/F-8122-2010; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Galvano, Fabio/0000-0003-0644-0755; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955			AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Amorini AM, 2001, FREE RADICAL RES, V35, P953, DOI 10.1080/10715760100301451; Berenshtein E, 1997, J MOL CELL CARDIOL, V29, P3025, DOI 10.1006/jmcc.1997.0535; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Comporti M, 2002, FREE RADICAL BIO MED, V32, P568, DOI 10.1016/S0891-5849(02)00759-1; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Dhalla NS, 2000, CARDIOVASC RES, V47, P446, DOI 10.1016/S0008-6363(00)00078-X; ESTERBAUER H, 1984, METHOD ENZYMOL, V105, P319; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FRANCIS FJ, 1989, CRIT REV FOOD SCI, V28, P273, DOI 10.1080/10408398909527503; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Iqbal K, 2002, AM J CARDIOL, V89, P334, DOI 10.1016/S0002-9149(01)02237-8; ISLAM N, 1995, NEUROSCI LETT, V188, P159, DOI 10.1016/0304-3940(95)11419-W; Landrault N, 2001, J AGR FOOD CHEM, V49, P3341, DOI 10.1021/jf010128f; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; Leighton F, 1999, DRUG EXP CLIN RES, V25, P133; Meiers S, 2001, J AGR FOOD CHEM, V49, P958, DOI 10.1021/jf0009100; Milbury PE, 2002, MECH AGEING DEV, V123, P997, DOI 10.1016/S0047-6374(01)00383-9; Miyazawa T, 1999, J AGR FOOD CHEM, V47, P1083, DOI 10.1021/jf9809582; Mondello L, 2000, J PHARMACEUT BIOMED, V23, P191, DOI 10.1016/S0731-7085(00)00269-7; Ramirez-Tortosa C, 2001, FREE RADICAL BIO MED, V31, P1033, DOI 10.1016/S0891-5849(01)00618-9; RAPISARDA P, 1994, AGROCHIMICA, V38, P157; Rapisarda P, 1998, J AGR FOOD CHEM, V46, P464, DOI 10.1021/jf9603700; RAPISARDA P, 1992, P INT SOC CITRIC, V3, P1130; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; SatueGracia MT, 1997, J AGR FOOD CHEM, V45, P3362, DOI 10.1021/jf970234a; Tavazzi B, 2000, EUR J BIOCHEM, V267, P684, DOI 10.1046/j.1432-1327.2000.01042.x; Tavazzi B, 2001, J BIOL CHEM, V276, P48083, DOI 10.1074/jbc.M101715200; TERAHARA N, 1994, BIOSCI BIOTECH BIOCH, V58, P1324, DOI 10.1271/bbb.58.1324; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; Treitinger A, 2000, EUR J CLIN INVEST, V30, P454; Tsuda T, 1999, FEBS LETT, V449, P179, DOI 10.1016/S0014-5793(99)00407-X; Uesugi N, 2001, AM J KIDNEY DIS, V38, P1016, DOI 10.1053/ajkd.2001.28591; Wang HB, 1999, J NAT PROD, V62, P294, DOI 10.1021/np980501m; WHITEHEAD TP, 1995, CLIN CHEM, V41, P32	38	61	63	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1071-5762			FREE RADICAL RES	Free Radic. Res.		2003	37	4					453	460		10.1080/1071576021000055253			8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	643AD	WOS:000180839000013	12747740				2021-06-18	
S	Skaper, SD		Slikker, W; Andrews, RJ; Trembly, B		Skaper, SD			Poly(ADP-ribose) polymerase-1 in acute neuronal death and inflammation - A strategy for neuroprotection	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	6th International Conference on Neuroprotective Agents	SEP 15-19, 2002	HILTON HEAD ISL, SC			poly(ADP-ribose) polymerase; DNA repair; neurotoxicity; cerebral ischemia; neurodegeneration; neuroinflammation; neuroprotection	ADP-RIBOSE SYNTHETASE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; DNA STRAND BREAKS; POTENT INHIBITOR; GLUTAMATE NEUROTOXICITY; REPERFUSION INJURY; GENE DISRUPTION; MICE DEFICIENT	Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nuclear enzyme that is activated primarily by DNA damage. Upon activation, the enzyme hydrolyzes NAD(+) to nicotinamide and transfers ADP ribose units to a variety of nuclear proteins, including histories and PARP-1 itself. This process is important in facilitating DNA repair. However, excessive activation of PARP-1 can lead to significant decrements in NAD(+), and ATP depletion, and cell death (suicide hypothesis). In response to cellular damage by oxygen radicals or excitotoxicity, a rapid and strong activation of PARP-1 occurs in neurons. Excessive PARP-1 activation is implicated in a variety of insults, including cerebral and cardiac ischemia, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism, traumatic spinal cord injury, and streptozotocin-induced diabetes. The use of PARP inhibitors has, therefore, been proposed as a protective therapy in decreasing excitotoxic neuronal cell death, as,well as ischemic and other tissue damage. Excitotoxic brain lesions initially result in the primary destruction of brain parenchyma and subsequently in secondary damage of neighboring neurons hours after the insult. This secondary damage of initially surviving neurons accounts for most of the volume of the infarcted area and the loss of brain function after a stroke. One major component of secondary neuronal damage is the migration of macrophages and microglial cells toward the sites of injury, where they produce large quantities of toxic cytokines and oxygen radicals. Recent evidence indicates that this microglial migration is strongly controlled in living brain tissue by expression of the integrin CD11a, which is regulated in turn by PARP-1, proposing that PARP-1 downregulation may, therefore, be a promising strategy in protecting neurons from this secondary damage, as well. Studies demonstrating an important role for PARP-1 in the regulation of gene transcription have further increased the intricacy of poly(ADP-ribosyl)ation in the control of cell homeostasis and challenge the notion that energy collapse is the sole mechanism by which poly(ADP-ribose) formation contributes to cell death. The hypothesis that PARI's might regulate cell fate as essential modulators of death and survival transcriptional programs is discussed with relation to nuclear factor kappaB and p53.	GlaxoSmithKline Res & Dev Ltd, Dept Neurophysiol & Cell Sci, Neurol & GI Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	Skaper, SD (corresponding author), GlaxoSmithKline Res & Dev Ltd, Dept Neurophysiol & Cell Sci, Neurol & GI Ctr Excellence Drug Discovery, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Stephen_Skaper-1@gsk.com					Abdelkarim GE, 2001, INT J MOL MED, V7, P255; ALVAREZGONZALEZ R, 1994, MOL CELL BIOCHEM, V138, P33, DOI 10.1007/BF00928440; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cosi C, 1996, BRAIN RES, V729, P264, DOI 10.1016/S0006-8993(96)00571-9; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Dawson Ted M., 1997, P319; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J NEUROSCI, V16, P2479; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Drazen DL, 2001, MOL MED, V7, P761, DOI 10.1007/BF03401966; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Faro R, 2002, ANN THORAC SURG, V73, P575, DOI 10.1016/S0003-4975(01)03329-X; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; Goldfarb RD, 2002, CRIT CARE MED, V30, P974, DOI 10.1097/00003246-200205000-00004; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Koedel U, 2002, J CEREBR BLOOD F MET, V22, P39, DOI 10.1097/00004647-200201000-00005; Lam TT, 1997, RES COMMUN MOL PATH, V95, P241; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Liaudet L, 2000, SHOCK, V14, P134, DOI 10.1097/00024382-200014020-00010; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Love S, 2000, NEUROPATH APPL NEURO, V26, P55, DOI 10.1046/j.1365-2990.2000.00218.x; Love S, 1998, NEUROREPORT, V9, P955, DOI 10.1097/00001756-199804200-00001; Lu X., 2001, Society for Neuroscience Abstracts, V27, P2025; Mabley JG, 2001, INFLAMM RES, V50, P561, DOI 10.1007/PL00000234; Mabley JG, 2001, BRIT J PHARMACOL, V133, P909, DOI 10.1038/sj.bjp.0704156; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Mandir AS, 2000, J NEUROSCI, V20, P8005; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MIWA M, 1971, J BIOL CHEM, V246, P6362; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; Pieper AA, 2000, MOL MED, V6, P271, DOI 10.1007/BF03401936; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Shall S, 2001, MUTAT RES, V460, P1; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo G, 2002, CIRC RES, V90, P100, DOI 10.1161/hh0102.102657; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Williams L., 1999, Society for Neuroscience Abstracts, V25, P1061; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; Yang ZQ, 2000, SHOCK, V13, P60, DOI 10.1097/00024382-200013010-00011; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang J, 2000, BIOCHEM BIOPH RES CO, V278, P590, DOI 10.1006/bbrc.2000.3816	76	61	64	0	5	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-469-2; 1-57331-468-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2003	993						217	228		10.1111/j.1749-6632.2003.tb07532.x			12	Multidisciplinary Sciences; Neurosciences	Science & Technology - Other Topics; Neurosciences & Neurology	BX10T	WOS:000184303000027	12853316				2021-06-18	
J	Andersson, S; Bergedalen, AM				Andersson, S; Bergedalen, AM			Cognitive correlates of apathy in traumatic brain injury	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						apathy; cognitive function; frontal lobe dysfunction; traumatic brain injury	ANTERIOR CINGULATE CORTEX; FRONTAL-SUBCORTICAL CIRCUITS; ALZHEIMERS-DISEASE; HIV-1 INFECTION; DEPRESSION; PERFORMANCE; RELIABILITY; INTERFACE; DEFICITS; VALIDITY	Objective: To investigate the relation between apathy and cognitive deficits in patients with severe traumatic brain injury (TBI). Background: Apathy defined as reduced goal-directed behavior due to lack of motivation constitutes a major neuropsychiatric symptom following TBI. According to definition, apathy should not be associated with global cognitive reduction, but rather with specific areas of cognitive dysfunction. Methods: Results from the Apathy Evaluation Scale (AES) and a comprehensive neuropsychologic assessment were collected in up to 53 patients With severe TBI. Neuropsychologic tests were organized in the following seven areas of cognitive function: acquisition and memory, attention span, executive function, psychomotor speed, verbal skills, nonverbal skills, and motor speed. Results: Apathy score was significantly correlated with reduced performance on acquisition and memory, psychomotor speed, and executive functions. A principal component analysis showed that these specific areas of cognitive functions clustered together with the cognitive dimension of apathy, not with behavioral or emotional aspects of apathy, Conclusions: Apathy is associated with specific cognitive deficits related to frontal lobe dysfunction. The results are in accordance with the definition of apathy and confirm apathy-cognitive function relationships reported in other neurologic populations.	Sunnaas Rehabil Hosp, Oslo, Norway	Andersson, S (corresponding author), Sunnaas Rehab Hosp, Neuropsychol Lab, N-1450 Nesoddtangen, Norway.						Allman JM, 2001, ANN NY ACAD SCI, V935, P107, DOI 10.1111/j.1749-6632.2001.tb03476.x; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Andersson S., 1992, J NORWEGIAN MED ASS, V112, P2070; Andreasen N. C., 1990, SCHIZOPHRENIA POSITI; Arthur G., 1947, POINT SCALE PERFORMA; Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999; Carter CS, 2001, AM J PSYCHIAT, V158, P1423, DOI 10.1176/appi.ajp.158.9.1423; Carter CS, 1999, REV NEUROSCIENCE, V10, P49; Castellon SA, 1998, J NEUROPSYCH CLIN N, V10, P320, DOI 10.1176/jnp.10.3.320; Castellon SA, 2000, J INT NEUROPSYCH SOC, V6, P336, DOI 10.1017/S1355617700633088; Cummings JL, 1995, ANN NY ACAD SCI, V769, P1, DOI 10.1111/j.1749-6632.1995.tb38127.x; DELIS D, 1987, CALIFORNIA VERBAL LE; Finset A, 2000, BRAIN INJURY, V14, P887; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Galynker I, 1997, J NERV MENT DIS, V185, P616, DOI 10.1097/00005053-199710000-00004; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEATON RK, 1993, WISCONSIN CARD SORTI, V2; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; Knutson B, 2000, NEUROIMAGE, V12, P20, DOI 10.1006/nimg.2000.0593; Kuzis G, 1999, NEUROLOGY, V52, P1403, DOI 10.1212/WNL.52.7.1403; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; Litvan I, 1996, NEUROLOGY, V47, P1184, DOI 10.1212/WNL.47.5.1184; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1997, REV PSYCHIAT, V15, P205; Masterman DL, 1997, J PSYCHOPHARMACOL, V11, P107, DOI 10.1177/026988119701100203; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Mega MS, 1996, NEUROLOGY, V46, P130, DOI 10.1212/WNL.46.1.130; Migneco O, 2001, NEUROIMAGE, V13, P896, DOI 10.1006/nimg.2000.0741; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Rabkin JG, 2000, J NEUROPSYCH CLIN N, V12, P451, DOI 10.1176/appi.neuropsych.12.4.451; Spreen O., 1991, COMPENDIUM NEUROPSYC; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Tekin S, 2001, ANN NEUROL, V49, P355, DOI 10.1002/ana.72.abs; WATANABE MD, 1995, J NEUROPSYCH CLIN N, V7, P502; Wechsler D, 1955, WAIS MANUAL WECHSLER; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; Wolfson D., 1993, HALSTEAD REITAN NEUR	44	61	62	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	SEP	2002	15	3					184	191		10.1097/01.WNN.0000026596.88167.8E			8	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	592CL	WOS:000177919100003	12218711				2021-06-18	
J	Huynh, T; Messer, M; Sing, RF; Miles, W; Jacobs, DG; Thomason, MH				Huynh, T; Messer, M; Sing, RF; Miles, W; Jacobs, DG; Thomason, MH			Positive end-expiratory pressure alters intracranial and cerebral perfusion pressure in severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	59th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 16-18, 1999	BOSTON, MA	Amer Assoc Surg Trauma		intracranial; cerebral; airway; positive end-expiratory pressure (PEEP); oxygen transport	RESPIRATORY-DISTRESS-SYNDROME; OXYGEN DELIVERY; CLINICAL-TRIAL; PEEP; RESUSCITATION; MANAGEMENT; MORTALITY; VALUES; INDEX	Background. Optimizing intracranial pressure (ICP) and cerebral perfusion pressure (CPP) is important in the management of severe traumatic brain injury (TBI). In trauma patients with TBI and respiratory dysfunction, positive end-expiratory pressure (PEEP) is often required to support oxygenation. Increases in PEEP may lead to reduced CPP. We hypothesized that increases in PEEP are associated with compromised hemodynamics and altered cerebral perfusion. Methods: Twenty patients (mean Injury Severity Score of 28) with TBI (Glasgow Coma Scale score < 8) were examined. All required simultaneous ICP and hemodynamic monitoring. Data were categorized on the basis of PEEP levels. Variables included central venous pressure, pulmonary artery occlusion pressure, cardiac index, oxygen delivery, and oxygen consumption indices. Differences were assessed using Kruskal-Wallis analysis of variance. Results: Data were expressed as mean +/- SE. As PEEP increased from 0 to 5, to 6 to 10 and 11 to 15 cm H2O, ICP decreased from 14.7 +/- 0.2 to 13.6 +/- 0.2 and 13.1 +/- 0.3 mm Hg, respectively. Concurrently, CPP improved from 77.5 +/- 0.3 to 80.1 +/- 0.5 and 78.9 +/- 0.7 mm Hg. As central venous pressure (5.9 +/- 0.1, 8.3 +/- 0.2, and 12.0 +/- 0.3 min Hg) and pulmonary artery occlusion pressure (8.3 +/- 0.2, 11.6 +/- 0.4, and 15.6 +/- 0.4 mm Hg) increased with rising levels of PEEP, cardiac index, oxygen delivery, and oxygen consumption indices remained unaffected. Overall mortality was 30%. Conclusion: In trauma patients with severe TBI, the strategy of increasing PEEP to optimize oxygenation is not associated with reduced cerebral perfusion or compromised oxygen transport.	Carolinas Med Ctr, Dept Surg, Div Trauma Surg Crit Care, Charlotte, NC 28232 USA	Huynh, T (corresponding author), Carolinas Med Ctr, FH Sammy Ross Jr Trauma Ctr, Trauma Crit Care Serv, Dept Gen Surg, Charlotte, NC 28232 USA.	toan.huynh@carolinashealthcare.org					AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; APUZZO MLJ, 1977, J NEUROSURG, V46, P227, DOI 10.3171/jns.1977.46.2.0227; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BISHOP MH, 1995, J TRAUMA, V38, P780, DOI 10.1097/00005373-199505000-00018; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; Chang MC, 1999, NEW HORIZ-SCI PRACT, V7, P35; Cheatham ML, 1998, CRIT CARE MED, V26, P1801, DOI 10.1097/00003246-199811000-00017; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Clarke JP, 1997, INTENS CARE MED, V23, P106, DOI 10.1007/s001340050298; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COOPER KR, 1985, J NEUROSURG, V63, P552, DOI 10.3171/jns.1985.63.4.0552; Diebel LN, 1997, J TRAUMA, V42, P585, DOI 10.1097/00005373-199704000-00002; DIRUSSO SM, 1995, CRIT CARE MED, V23, P1485, DOI 10.1097/00003246-199509000-00008; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Marini JJ, 1996, CLIN CHEST MED, V17, P555, DOI 10.1016/S0272-5231(05)70331-2; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McGuire G, 1997, CRIT CARE MED, V25, P1059, DOI 10.1097/00003246-199706000-00025; ROPPER AH, 1982, NEUROLOGY, V32, P1288, DOI 10.1212/WNL.32.11.1288; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHAPIRO HM, 1978, J TRAUMA, V18, P254, DOI 10.1097/00005373-197804000-00005; YU M, 1999, NEW HORIZ, V7, P45; Yu MH, 1998, CRIT CARE MED, V26, P1011, DOI 10.1097/00003246-199806000-00018	26	61	70	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2002	53	3					488	492		10.1097/00005373-200209000-00016			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	599GA	WOS:000178324700021	12352486				2021-06-18	
J	Sandstrom, NJ; Loy, R; Williams, CL				Sandstrom, NJ; Loy, R; Williams, CL			Prenatal choline supplementation increases NGF levels in the hippocampus and frontal cortex of young and adult rats	BRAIN RESEARCH			English	Article						nutrition; development; aging; learning; memory	NERVE GROWTH-FACTOR; BASAL FOREBRAIN NEURONS; ENHANCED VISUOSPATIAL MEMORY; FIMBRIA-FORNIX TRANSECTION; P75 NEUROTROPHIN RECEPTOR; RADIAL MAZE PERFORMANCE; IMPROVES SPATIAL MEMORY; LONG-TERM POTENTIATION; TRAUMATIC BRAIN INJURY; AGED RATS	Female Sprague-Dawley rats received similar to300 mg/kg per day of choline chloride through their drinking water on days 11 of pregnancy through birth and the level of nerve growth factor (NGF) in the hippocampus and frontal cortex of their male offspring was measured at 20 and 90 days of age. Prenatal choline supplementation caused significant increases in hippocampal NGF levels at 20 and 90 days of age, while levels of NGF in the frontal cortex were elevated in choline-supplemented rats at 20 days of age, but not 90 days of age. These results suggest that increases in NGF levels during development or adulthood may be one mechanism underlying improvements in spatial and temporal memory of adult rats exposed to elevated levels of choline chloride perinatally. (C) 2002 Elsevier Science B.V. All rights reserved.	Williams Coll, Bronfman Sci Ctr, Dept Psychol, Williamstown, MA 01267 USA; Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14620 USA; Duke Univ, Dept Psychol & Brain Sci, Durham, NC 27708 USA	Sandstrom, NJ (corresponding author), Williams Coll, Bronfman Sci Ctr, Dept Psychol, 18 Hoxsey St, Williamstown, MA 01267 USA.	noah.sandstrom@williams.edu			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG09525] Funding Source: Medline		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Bergado JA, 1997, BRAIN RES, V770, P1, DOI 10.1016/S0006-8993(97)00610-0; Bergado JA, 1998, EUR J PHARMACOL, V345, P181, DOI 10.1016/S0014-2999(98)00092-2; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; Brandner C, 2000, NEUROBIOL LEARN MEM, V73, P49, DOI 10.1006/nlme.1999.3917; Brandner C, 2000, BEHAV BRAIN RES, V111, P165, DOI 10.1016/S0166-4328(00)00153-4; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; Brooks AI, 1999, NEUROREPORT, V10, P337, DOI 10.1097/00001756-199902050-00024; Brooks AI, 2000, P NATL ACAD SCI USA, V97, P13378, DOI 10.1073/pnas.230169397; Brooks AI, 2000, HUM GENE THER, V11, P2341, DOI 10.1089/104303400750038453; Casaccia-Bonnefil P, 1999, MICROSC RES TECHNIQ, V45, P217, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<217::AID-JEMT5>3.0.CO;2-5; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; Cassel JC, 1998, NEUROBIOL LEARN MEM, V69, P22, DOI 10.1006/nlme.1997.3807; CASSEL JC, 1989, PHYSIOL BEHAV, V46, P347, DOI 10.1016/0031-9384(89)90002-4; CAVICCHIOLI L, 1991, MOL BRAIN RES, V9, P319, DOI 10.1016/0169-328X(91)90079-D; Cermak JM, 1999, DEV NEUROSCI-BASEL, V21, P94, DOI 10.1159/000017371; Cermak JM, 1998, FASEB J, V12, P349; Chen KS, 1997, J NEUROSCI, V17, P7288; CRUTCHER KA, 1993, J NEUROSCI, V13, P2540; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Eagle KS, 1995, J COMP NEUROL, V363, P377, DOI 10.1002/cne.903630304; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; FISCHER W, 1991, EXP NEUROL, V113, P93, DOI 10.1016/0014-4886(91)90167-B; FISCHER W, 1992, NEUROBIOL AGING, V13, P9, DOI 10.1016/0197-4580(92)90003-G; FISCHER W, 1991, J NEUROSCI, V11, P1889; FISCHER W, 1994, P NATL ACAD SCI USA, V91, P8607, DOI 10.1073/pnas.91.18.8607; FUSCO M, 1989, NEUROSCIENCE, V33, P47, DOI 10.1016/0306-4522(89)90309-6; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; GNAHN H, 1983, DEV BRAIN RES, V9, P45, DOI 10.1016/0165-3806(83)90107-4; Gustilo MC, 1999, J COMP NEUROL, V405, P491, DOI 10.1002/(SICI)1096-9861(19990322)405:4<491::AID-CNE4>3.0.CO;2-N; HEFTI F, 1986, J NEUROSCI, V6, P2155; HELLWEG R, 1990, BRAIN RES, V537, P123, DOI 10.1016/0006-8993(90)90348-F; Holler T, 1996, FASEB J, V10, P1653; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; Janis LS, 1997, PHYSIOL BEHAV, V62, P69, DOI 10.1016/S0031-9384(97)00143-1; JURASKA JM, 1984, DEV PSYCHOBIOL, V17, P209, DOI 10.1002/dev.420170302; Kelly A, 1998, NEUROPHARMACOLOGY, V37, P561, DOI 10.1016/S0028-3908(98)00048-3; KOH S, 1989, BRAIN RES, V498, P397, DOI 10.1016/0006-8993(89)91125-6; KOH SY, 1989, J NEUROSCI, V9, P2999; KOH SY, 1988, BRAIN RES, V440, P396, DOI 10.1016/0006-8993(88)91015-3; KORNACK DR, 1991, BRAIN RES, V542, P171, DOI 10.1016/0006-8993(91)91015-S; LARGE TH, 1986, SCIENCE, V234, P352, DOI 10.1126/science.3764415; LARKFORS L, 1988, PROG BRAIN RES, V78, P27; LARKFORS L, 1987, J NEUROSCI RES, V18, P525, DOI 10.1002/jnr.490180404; LI YW, 1995, J NEUROSCI, V15, P2888; LOY R, 1991, ADV EXP MED BIOL, V295, P373; LOY R, 1987, DEV BRAIN RES, V34, P156, DOI 10.1016/0165-3806(87)90205-7; MARKOWSKA AL, 1994, J NEUROSCI, V14, P4815; Markowska AL, 1996, J NEUROSCI, V16, P3541; MartinezSerrano A, 1996, P NATL ACAD SCI USA, V93, P6355, DOI 10.1073/pnas.93.13.6355; MARTINEZSERRANO A, 1995, NEURON, V15, P473, DOI 10.1016/0896-6273(95)90051-9; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; MOBLEY WC, 1986, MOL BRAIN RES, V1, P53, DOI 10.1016/0169-328X(86)90020-3; MOBLEY WC, 1989, NEURON, V3, P655, DOI 10.1016/0896-6273(89)90276-6; Montoya DAC, 2000, DEV BRAIN RES, V123, P25, DOI 10.1016/S0165-3806(00)00075-4; Pham TM, 1999, BEHAV BRAIN RES, V103, P63, DOI 10.1016/S0166-4328(99)00019-4; Schenk F, 1995, PSYCHOBIOLOGY, V23, P302; SENUT MC, 1990, INT J DEV NEUROSCI, V8, P65, DOI 10.1016/0736-5748(90)90024-V; SHELTON DL, 1986, P NATL ACAD SCI USA, V83, P2714, DOI 10.1073/pnas.83.8.2714; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SKJEI K, 1995, SOC NEUR ABSTR, V25, P161; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; Tees RC, 1999, DEV PSYCHOBIOL, V35, P328, DOI 10.1002/(SICI)1098-2302(199912)35:4&lt;328::AID-DEV7&gt;3.0.CO;2-4; Tees RC, 1999, DEV PSYCHOBIOL, V35, P226, DOI 10.1002/(SICI)1098-2302(199911)35:3&lt;226::AID-DEV7&gt;3.0.CO;2-H; Tees RC, 1999, BEHAV BRAIN RES, V105, P173, DOI 10.1016/S0166-4328(99)00074-1; Thomas JD, 2000, NEUROTOXICOL TERATOL, V22, P703, DOI 10.1016/S0892-0362(00)00097-0; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; VANTINI G, 1989, NEURON, V3, P267, DOI 10.1016/0896-6273(89)90251-1; WESKAMP G, 1987, J NEUROCHEM, V48, P1779, DOI 10.1111/j.1471-4159.1987.tb05736.x; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WILL B, 1985, BEHAV BRAIN RES, V17, P17, DOI 10.1016/0166-4328(85)90004-X; Williams CL, 1998, BRAIN RES, V794, P225, DOI 10.1016/S0006-8993(98)00229-7; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; WOOLF NJ, 1986, NEUROSCI LETT, V66, P281, DOI 10.1016/0304-3940(86)90032-7; WOOLF NJ, 1983, NEUROSCI LETT, V40, P93, DOI 10.1016/0304-3940(83)90285-9; WOOLF NJ, 1984, BRAIN RES BULL, V13, P751, DOI 10.1016/0361-9230(84)90236-3; Yang YL, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0006.2000; Yen CLE, 1999, FASEB J, V13, P135; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413	91	61	61	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 23	2002	947	1					9	16	PII S0006-8993(02)02900-1	10.1016/S0006-8993(02)02900-1			8	Neurosciences	Neurosciences & Neurology	589PR	WOS:000177769400002	12144847				2021-06-18	
J	Tyor, WR; Avgeropoulos, N; Ohlandt, G; Hogan, EL				Tyor, WR; Avgeropoulos, N; Ohlandt, G; Hogan, EL			Treatment of spinal cord impact injury in the rat with transforming growth factor-beta	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						spinal cord injury; rats; mononuclear phagocytes; cytokines; transforming growth factor-beta	TUMOR-NECROSIS-FACTOR; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TRAUMATIC INJURY; FACTOR-ALPHA; TNF-ALPHA; TGF-BETA; BRAIN; EXPRESSION; GROWTH-FACTOR-BETA-1; CYTOKINES	To investigate the contribution of cytokines, proinflammatory TNF-alpha and inhibitory TGF-beta, to spinal cord injury (SCI) in a rat model, two studies were performed using adult Sprague-Dawley rats which were injured at T9/T10. In the first study, rats were sacrificed at 1, 6, 24, 96 and 168 h after SCI for immunocytochemistry of coronal sections for the presence of mononuclear phagocytes, astrocytes, TNF-alpha and TGF-beta, among other markers. From intervening frozen sections, RNA was extracted for semiquantitative polymerase chain reaction (RTPCR) analysis of TNF-alpha and TGF-beta. In the second experiment, rats were treated with intravenous TGF-beta 30 min after injury and sacrificed at 6 and 48 h after injury. Spinal cord sections were immunocytochemically stained and RNA extracted for semiquantitative PCR as mentioned above, as well as quantitation of lesion volume. There were increases in mononuclear phagocytes and astrocytes, as early as 1 h after SCI, with steady progression over 168 h after injury. TNF-alpha and TGF-beta was produced locally by mononuclear phagocytes and astrocytes. There was an 18-h delay in peak mRNA production of TGF-beta compared to TNF-alpha. The treatment of SCI rats with TGF-beta reduced lesion volume by 50% at 48 h and this was associated with decreased accumulation of mononuclear phagocytes in and around the injury site. This reduction of mononuclear phagocyte numbers around the site of trauma would reduce their contribution to secondary injury. Published by Elsevier Science B.V.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA	Tyor, WR (corresponding author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031767] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 31767] Funding Source: Medline		Aloisi F, 1999, J NEUROSCI RES, V56, P571; Balabanov R, 1998, J NEUROSCI RES, V53, P637, DOI 10.1002/(SICI)1097-4547(19980915)53:6<637::AID-JNR1>3.0.CO;2-6; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; DACUNHA A, 1993, BRAIN RES, V631, P39, DOI 10.1016/0006-8993(93)91183-S; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Grande JP, 1997, P SOC EXP BIOL MED, V214, P27; Hamada Y, 1996, NEUROSCI LETT, V203, P97, DOI 10.1016/0304-3940(95)12271-0; Kitamura M, 1997, J IMMUNOL, V159, P1404; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; POPOVICH PG, 1994, BRAIN RES, V633, P348, DOI 10.1016/0006-8993(94)91560-1; RACKE MK, 1991, J IMMUNOL, V146, P3012; Ransohoff RM, 1997, J LEUKOCYTE BIOL, V62, P645; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SOLIVEN B, 1992, J NEUROSCI, V12, P2665; Takeuchi M, 1998, J IMMUNOL, V160, P1589; Tator C H, 1996, J Spinal Cord Med, V19, P206; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; TYOR WR, 1997, NEUROIMMUNOLOGY CLIN, P3; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; WARWICKDAVIES J, 1995, J IMMUNOL, V155, P3186; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410	28	61	71	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	AUG 15	2002	200	1-2					33	41	PII S0022-510X(02)00113-2	10.1016/S0022-510X(02)00113-2			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	584FY	WOS:000177457600005	12127673				2021-06-18	
J	Hanson, JA; Deliganis, AV; Baxter, AB; Cohen, WA; Linnau, KF; Wilson, AJ; Mann, FA				Hanson, JA; Deliganis, AV; Baxter, AB; Cohen, WA; Linnau, KF; Wilson, AJ; Mann, FA			Radiologic and clinical spectrum of occipital condyle fractures: Retrospective review of 107 consecutive fractures in 95 patients	AMERICAN JOURNAL OF ROENTGENOLOGY			English	Article							TRAUMATIC OCCIPITOVERTEBRAL DISSOCIATION; ATLANTOOCCIPITAL DISLOCATION; LATERAL RADIOGRAPHS; AVULSION FRACTURE; SUPINE SUBJECTS; CT; DIAGNOSIS; CLIVUS	OBJECTIVE. We proposed to characterize the radiologic spectrum of occipital condyle fractures in a large series of patients and to correlate fracture pathology with neurosurgical treatment and patient outcome. MATERIALS AND METHODS. We conducted a retrospective review of the findings on conventional radiography. CT, and MR imaging in 95 patients with 107 occipital condyle fractures. We described fracture patterns according to two previously published classification systems. Clinical findings, neurosurgical management, and patient outcome were obtained.. from the medical records. RESULTS. Inferomedial avulsions (Anderson and Montesano type III) were the most common type of occipital condyle fracture, constituting 80 (75%) of 107 overall fractures. Unilateral occipital condyle fractures were found in 73 (77%) of 95 patients, and 58 patients were treated nonoperatively; occipitocervical fusion was required in nine patients for complex C1-C2 injuries, and six patients died. Bilateral occipital condyle fractures or occipitoatlantoaxial joint injuries were seen in 22 (23%) of 95 patients. Occipitocervical fusion or halo traction for the craniocervical junction was required in 12 patients, all of whom had CT evidence of bilateral occipitoatlantoaxial joint disruption and six of whom showed normal craniocervical relationships on conventional radiographs. Six patients with nondisplaced fractures were treated nonoperatively, and four patients died. Thirty (32%) of 95 patients showed continued disability, whereas 55 (57.5%) of 95 patients had good outcomes at 1 month. Associated cervical spine injuries were present in 29 (31%) of 95 patients. CONCLUSION. Given their associated traumatic brain and cervical spine injuries, occipital condyle fractures are markers of high-energy traumas. That conventional radiographs alone may miss up to half of the patients with acute craniocervical instability has not been well established. Avulsion fracture type and fracture displacement are associated with both injury mechanism and the need for surgical stabilization. In this series. most unilateral occipital condyle fractures were treated nonoperatively, whereas bilateral occipitoatlantoaxial joint injuries with findings of instability usually required surgical stabilization.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Radiol, Seattle, WA 98104 USA	Mann, FA (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Radiol, 325 9th Ave,Box 359728, Seattle, WA 98104 USA.						ADAMS VI, 1992, J FORENSIC SCI, V37, P556; AHUJA A, 1994, SURG NEUROL, V41, P112, DOI 10.1016/0090-3019(94)90107-4; ANDERSON PA, 1988, SPINE, V13, P731, DOI 10.1097/00007632-198807000-00004; BELL C, 1817, MIDDLESEX HOSP J, V4, P469; BETTINI N, 1993, SKELETAL RADIOL, V22, P187; BLACKSIN MF, 1995, AM J ROENTGENOL, V165, P1201, DOI 10.2214/ajr.165.5.7572503; Bloom AI, 1997, CLIN RADIOL, V52, P198, DOI 10.1016/S0009-9260(97)80273-5; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; BUNDSCHUH CV, 1992, SPINE, V17, P245, DOI 10.1097/00007632-199202000-00024; CLAYMAN DA, 1994, AM J NEURORADIOL, V15, P1309; Deliganis AV, 2000, RADIOGRAPHICS, V20, pS237, DOI 10.1148/radiographics.20.suppl_1.g00oc23s237; GOLDBERG AL, 1991, J COMPUT ASSIST TOMO, V15, P174, DOI 10.1097/00004728-199101000-00034; HARRIS JH, 1994, AM J ROENTGENOL, V162, P881, DOI 10.2214/ajr.162.4.8141012; HARRIS JH, 1994, AM J ROENTGENOL, V162, P887, DOI 10.2214/ajr.162.4.8141013; JONES DN, 1990, AM J NEURORADIOL, V11, P1181; Leone A, 2000, RADIOLOGY, V216, P635, DOI 10.1148/radiology.216.3.r00se23635; LINK TM, 1995, RADIOLOGY, V196, P741, DOI 10.1148/radiology.196.3.7644638; MIRVIS SE, 1988, RADIOLOGY, V166, P807, DOI 10.1148/radiology.166.3.3277249; Noble ER, 1996, AM J NEURORADIOL, V17, P507; SATERNUS KS, 1987, Z RECHTSMED, V99, P95; Tanabe M, 1999, NEUROL MED-CHIR, V39, P358, DOI 10.2176/nmc.39.358; Tuli S, 1997, NEUROSURGERY, V41, P368, DOI 10.1097/00006123-199708000-00006; Vishteh AG, 1999, J NEUROSURG, V90, P91, DOI 10.3171/spi.1999.90.1.0091; VOIGT GE, 1974, J TRAUMA, V14, P494, DOI 10.1097/00005373-197406000-00006; VONAHLGREN P, 1964, ROFO FORTSCHR RONTG, V101, P202; WASSERBERG J, 1995, NEURORADIOLOGY, V37, P370; WERNE S, 1957, ACTA ORTHOP SCAND S, V23, pS1; WHITE AA, 1990, CLIN BIOMECHANICS SP, P192; WILLAUSCHUS WG, 1995, SPINE, V20, P2493, DOI 10.1097/00007632-199512000-00006	29	61	62	0	4	AMER ROENTGEN RAY SOC	RESTON	1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA	0361-803X			AM J ROENTGENOL	Am. J. Roentgenol.	MAY	2002	178	5					1261	1268		10.2214/ajr.178.5.1781261			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	543AA	WOS:000175077200040	11959743				2021-06-18	
J	Marklund, N; Clausen, F; Lewander, T; Hillered, L				Marklund, N; Clausen, F; Lewander, T; Hillered, L			Monitoring of reactive oxygen species production after traumatic brain injury in rats with microdialysis and the 4-hydroxybenzoic acid trapping method	JOURNAL OF NEUROTRAUMA			English	Article						free radicals; 2-hydroxybenzoic acid (salicylate : 2-HBA); 4-hydroxybenzoic acid (4-HBA); microdialysis; reactive oxygen species; traumatic brain injury (TBI)	COMPRESSION CONTUSION TRAUMA; HYDROXYL RADICAL GENERATION; EXPERIMENTAL HEAD-INJURY; LIPID-PEROXIDATION; CAUTIONARY NOTE; SODIUM-SALICYLATE; OXIDATIVE STRESS; CELL-DEATH; ISCHEMIA; RELEASE	The detection of reactive oxygen species (ROS) after traumatic brain injury (TBI) is based on indirect methods due to the high reactivity and short half-life of ROS in biological tissue. The commonly used salicylate trapping method has several disadvantages making it unsuitable for human use. We have evaluated 4-hydroxybenzoic acid (4-HBA) together with microdialysis (MD) in the rat as an alternative method. 4-HBA forms one stable adduct, 3,4-dihydroxybenzoic acid (3,4-DHBA), when reacting with ROS and has not previously been used together with MD after TBI. Twenty-seven rats were used for the assessment of 3,4-DHBA production as an indicator of ROS formation in a controlled contusion injury model using intracerebral MD with 3 mM 4-HBA in the perfusate. For comparison, salicylate trapping was used in eight rats. TBI caused a 250 % increase of 3,4-DHBA that peaked at 30 min after injury in severely injured rats and remained significantly elevated as compared to baseline for 90 min after trauma. The mild injury level caused a 100% increase in 3,4-DHBA formation at 30 min after the injury. When the MD probe was placed in the perimeter of the injury site, no significant increase in ROS formation occurred. Salicylate trapping showed a similar increase in adduct formation after severe injury. In addition, high cortical concentrations of 4-HBA and salicylate were found. It is concluded that microdialysis with 4-HBA as a trapping agent appears to be a useful method for ROS detection in the rat with a potential clinical utility.	Univ Uppsala Hosp, Dept Neurosci & Neurosurg, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Psychiat, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Med Sci, SE-75185 Uppsala, Sweden	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosci & Neurosurg, SE-75185 Uppsala, Sweden.	Niklas.Marklund@neurokir.uu.se		Marklund, Niklas/0000-0002-9797-5626; Clausen, Fredrik/0000-0003-3592-4417			ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926; Bogdanov MB, 1999, NEUROSCI LETT, V262, P33, DOI 10.1016/S0304-3940(99)00047-6; CASADEBAIG F, 1991, THROMB RES, V64, P631, DOI 10.1016/0049-3848(91)90063-3; DEJANA E, 1983, THROMB RES, P153; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fernandez MA, 1998, J PHARM PHARMACOL, V50, P1183, DOI 10.1111/j.2042-7158.1998.tb03332.x; FLOYD R A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P13, DOI 10.1016/0748-5514(86)90118-2; Gido G, 2000, ACTA PHYSIOL SCAND, V168, P277; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Groothuis DR, 1998, BRAIN RES, V803, P218, DOI 10.1016/S0006-8993(98)00572-1; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hall ED, 1997, NEUROSURG CLIN N AM, V8, P195; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1991, FREE RADICAL BIO MED, V10, P439, DOI 10.1016/0891-5849(91)90052-5; Halliwell B, 1997, FREE RADICAL RES, V27, P239, DOI 10.3109/10715769709065762; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Love S, 1999, BRAIN PATHOL, V9, P119; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MONTGOMERY J, 1995, FREE RADICAL BIO MED, V19, P927, DOI 10.1016/0891-5849(95)02004-T; Najbauer J, 2000, NEUROSCIENCE, V99, P107, DOI 10.1016/S0306-4522(00)00158-5; Nakagawa Y, 1999, BIOCHEM PHARMACOL, V58, P811, DOI 10.1016/S0006-2952(99)00147-1; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nishio S, 1997, ACT NEUR S, V70, P84; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; STAHLE L, 1991, MICRODIALYSIS NEUROS, P155; Ste-Marie L, 1999, FREE RADICAL BIO MED, V27, P997, DOI 10.1016/S0891-5849(99)00170-7; SteMarie L, 1996, ANAL BIOCHEM, V241, P67, DOI 10.1006/abio.1996.0379; TANAKA T, 1995, CANCER-AM CANCER SOC, V75, P1433, DOI 10.1002/1097-0142(19950315)75:6+<1433::AID-CNCR2820751507>3.0.CO;2-4; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; WATSON BD, 1993, PROG BRAIN RES, V96, P69; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WESTERGREN I, 1995, J NEUROCHEM, V64, P229; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	52	61	67	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2001	18	11					1217	1227		10.1089/089771501317095250			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	491KC	WOS:000172106700003	11721740				2021-06-18	
J	Meythaler, JA; Guin-Renfroe, S; Johnson, A; Brunner, RM				Meythaler, JA; Guin-Renfroe, S; Johnson, A; Brunner, RM			Prospective assessment of tizanidine for spasticity due to acquired brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						baclofen; brain injuries; cerebral palsy; cerebrovascular accident; dystonia; muscle hypertonia; muscle spasticity; rehabilitation	INTRATHECAL BACLOFEN INFUSION; LONG-TERM; SPINAL SPASTICITY; DRUG-THERAPY; DOUBLE-BLIND; DYSTONIA; HEMIPLEGIA; HYPERTONIA; ORIGIN	Objective: To determine if orally delivered tizanidine will control spastic hypertonia due to acquired brain injury. Design: Randomized, double-blind, placebo-controlled, crossover design, with 2 8-week treatment arms separated by a 1-week washout period at baseline. Patients were randomly assigned to receive tizanidine or a matching placebo. Setting: Tertiary care outpatient and inpatient rehabilitation center attached to a university hospital. Participants: Seventeen persons recruited in a consecutive manner, 9 of whom had suffered a stroke and 8 a traumatic brain injury, and had more than 6 months of intractable spastic hypertonia. Intervention: Over a 6-week period, subjects were slowly titrated up to their maximum tolerated dose (up to 36mg/d). Following a 1-week drug taper and 1-week period in which no study drug was administered, patients were then crossed over to the other study medication following an identical titration regime. Main Outcome Measures: Subjects were evaluated for dose and effect throughout the trial as well as for side effects. Data for Ashworth rigidity scores, spasm scores, deep tendon reflex scores, and motor strength were collected on the affected upper extremity (UE) and lower extremity (LE). Differences over time were assessed via descriptive statistics, Friedman's analysis, and Wilcoxon's signed-rank. Data are reported as the mean +/- 1 standard deviation. Results: Following 4 weeks of treatment when subjects reached their maximal tolerated dosage, the average LE Ashworth score on the affected side decreased from 2.3 +/- 1.4 to 1.7 +/- 1.1 (p < .0001). The spasm score decreased from 1.0 +/- 0.9 to 0.5 +/- 0.8 (p = .0464), while the reflex score was not statistically significant decreasing from 2.2 +/- 1.0 to 2.0 +/- 1.1 (p = .0883). The average UE Ashworth score on the affected side decreased from 1.9 +/- 1.1 to 1.5 +/- 0.9 (p < .0001). There was no significant change in the UE spasm and reflex scores. While there were positive placebo effects on motor tone, the active drug was still significantly better than placebo for decreasing LE tone (p = .0006) and UE tone (p = .0007). With a reduction in motor tone, there was an increase in motor strength (p = .0089). The average dosage at 4 weeks was 25.2mg/d. Conclusion: Tizanidine is effective in decreasing the spastic hypertonia associated with acquired brain injury, which is dose-dependent. There are limitations on its use due to side effects related to drowsiness.	Univ Alabama Birmingham, Sch Med, Spain Rehabil Ctr R157, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA	Meythaler, JA (corresponding author), Univ Alabama Birmingham, Sch Med, Spain Rehabil Ctr R157, Dept Phys Med & Rehabil, 619 19th St S, Birmingham, AL 35249 USA.	JMeythal@uab.edu					ADAMS RD, 1993, PRINCIPLES NEUROLOGY, P68; Albright AL, 1996, NEUROSURGERY, V38, P934, DOI 10.1097/00006123-199605000-00015; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; ASHBY P, 1974, J NEUROL NEUROSUR PS, V37, P1352, DOI 10.1136/jnnp.37.12.1352; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BES A, 1988, CURR MED RES OPIN, V10, P709, DOI 10.1185/03007998809111122; BodineFowler SC, 1996, MUSCLE NERVE, V19, P497, DOI 10.1002/mus.880190404; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Coward D M, 1994, Neurology, V44, pS6; DAVIES J, 1984, BRIT J PHARMACOL, V82, P409, DOI 10.1111/j.1476-5381.1984.tb10776.x; DELWAIDE PJ, 1994, NEUROLOGY, V44, P21; Delwaide PJ, 1994, NEUROLOGY S9, pS27; DONOVAN WH, 1988, ARCH PHYS MED REHAB, V69, P193; Ford B, 1996, ARCH NEUROL-CHICAGO, V53, P1241, DOI 10.1001/archneur.1996.00550120049016; Gekht AB, 1998, ZH NEVROPATOL PSIKH, V98, P22; GOLDSTEIN LB, 1991, J NEUROL REHABIL, V5, P129; Gracies JM, 1997, MUSCLE NERVE, pS92; GRANGER CV, 1993, GUIDE USE UNIFORM DA; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; KAMEYAMA T, 1986, EUR J PHARMACOL, V125, P257, DOI 10.1016/0014-2999(86)90035-X; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; LANG AE, 1992, CLIN NEUROPHARMACOL, V15, P142, DOI 10.1097/00002826-199204000-00008; LATASTE X, 1994, NEUROLOGY, V44, P53; Lee K.-C., 1989, J NEUROL REHABIL, V3, P205, DOI DOI 10.1177/136140968900300406; Mann NH, 1991, J NEUROL REHABIL, V5, P51; *MED EC, 1999, PHYS DES REF, P617; MEDICI M, 1989, CURR MED RES OPIN, V11, P398, DOI 10.1185/03007998909110141; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; Meythaler JM, 1997, J HEAD TRAUMA REHAB, V12, P87, DOI 10.1097/00001199-199702000-00012; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; MILANOV I, 1994, ACTA NEUROL SCAND, V89, P274; Milanov I G, 1992, Electromyogr Clin Neurophysiol, V32, P621; NANCE PW, 1994, NEUROLOGY, V44, P44; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; ROBERTS RC, 1994, NEUROLOGY, V44, P29; SAYERS AC, 1980, ARZNEIMITTEL-FORSCH, V30-1, P793; SMITH C, 1994, NEUROLOGY, V44, P34; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whyte J, 1993, REHABILITATION MED P, P825; YARKONY GM, 1987, CLIN ORTHOP RELAT R, P93; YOUNG RR, 1981, NEW ENGL J MED, V304, P28; YOUNG RR, 1981, NEW ENGL J MED, V304, P96	43	61	66	1	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2001	82	9					1155	1163		10.1053/apmr.2001.25141			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	470LR	WOS:000170873900002	11552184				2021-06-18	
J	Cheney, JA; Weisser, JD; Bareyre, FM; Laurer, HL; Saatman, KE; Raghupathi, R; Gribkoff, V; Starrett, JE; McIntosh, TK				Cheney, JA; Weisser, JD; Bareyre, FM; Laurer, HL; Saatman, KE; Raghupathi, R; Gribkoff, V; Starrett, JE; McIntosh, TK			The maxi-K channel opener EMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						BMS-204352; potassium channels; head injury; cerebral edema; neuromotor function; cognition	ACTIVATED POTASSIUM CHANNELS; CEREBELLAR GRANULE CELLS; NEUROBEHAVIORAL FUNCTION; AMINO-ACIDS; HEAD-INJURY; RAT-BRAIN; RILUZOLE; IMPROVES; RELEASE; CONSEQUENCES	Large-conductance, calcium-activated potassium (maxi-K) channels regulate neurotransmitter release and neuronal excitability, and openers of these channels have been shown to be neuroprotective in models of cerebral ischemia. The authors evaluated the effects of postinjury systemic administration of the maxi-K channel opener, BMS-204352, on behavioral and histologic outcome after lateral fluid percussion (PP) traumatic brain injury (TBI) in the rat. Anesthetized Sprague Dawley rats (n = 142) were subjected to moderate FP brain injury (n = 88) or surgery without injury(n = 54) and were randomized to receive a bolus of 0.1 mg/kg BMS-204352 (n = 26, injured; n = 18, sham), 0.03 mg/kg BMS-201352 (n = 25, injured; n = 18, sham), or 2% dimethyl sulfoxide (DMSO) in polyethylene glycol (vehicle, n = 27, injured; n = 18. sham) at IO minutes postinjury. One group of rats was tested for memory retention (Morris water maze) at 42 hours postinjury, then killed for evaluation of regional cerebral edema. A second group of injured/sham rats was assessed for neurologic motor function from 48 hours to 2 weeks postinjury and cortical lesion area. Administration of 0.1 mg/kg BMS-204352 improved neurologic motor function at 1 and 2 weeks postinjury (P < 0.05) and reduced the extent of cerebral edema in the ipsilateral hippocampus, thalamus, and adjacent cortex (P < 0.05). Administration of 0.03 mg/kg EMS-204352 significantly reduced cerebral edema in the ipsilateral thalamus (P < 0.05). No effects on cognitive function or cortical tissue loss were observed with either dose. These results suggest that the novel maxi-a channel opener BMS-204352 may be selectively beneficial in the treatment of experimental TBI.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Bristol Myers Squibb Pharmaceut Res Inst, Wallingford, CT USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NSO8803] Funding Source: Medline		ADAMS PR, 1982, NATURE, V296, P746, DOI 10.1038/296746a0; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BODIE H, 1993, J NEUROTRAUM, V10, pS161; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bullock Ross, 1993, Journal of Emergency Medicine, V11, P23; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAGNI L, 1994, PFLUG ARCH EUR J PHY, V429, P176, DOI 10.1007/BF00374310; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GRIBKOFF VK, 1997, ADV PHARMACOL, V37, P348; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; JALONEN T, 1990, BRAIN RES, V535, P33, DOI 10.1016/0006-8993(90)91820-7; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Knaus HG, 1996, J NEUROSCI, V16, P955; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LIU GL, 1994, INT J TURBO JET ENG, V11, P53; Maas AIR, 2000, CNS DRUGS, V13, P139, DOI 10.2165/00023210-200013020-00007; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MCKAY MC, 1994, J NEUROPHYSIOL, V71, P1873; MUIR JK, 1995, J NEUROTRAUM, V12, P87, DOI 10.1089/neu.1995.12.87; National Research Council, 1996, GUIDE CARE USE LAB A, P1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; PAXINOS G, 1990, STEREOTACTIC ATLAS R; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POSTMUNSON DJ, 2000, P KEYST S POT CHANN, P57; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stark J, 2000, INT SYMP MICROARCH, P57, DOI 10.1109/MICRO.2000.898058; Starrett JE, 1996, CURR PHARM DESIGN, V2, P413; Strobaek D, 1996, NEUROPHARMACOLOGY, V35, P903, DOI 10.1016/0028-3908(96)00096-2; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; YOSHIDA A, 1991, JPN J PHYSIOL, V41, P297, DOI 10.2170/jjphysiol.41.297; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	60	61	62	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2001	21	4					396	403		10.1097/00004647-200104000-00008			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	421PT	WOS:000168073300008	11323525	Bronze			2021-06-18	
J	Segalowitz, SJ; Bernstein, DM; Lawson, S				Segalowitz, SJ; Bernstein, DM; Lawson, S			P300 event-related potential decrements in well-functioning university students with mild head injury	BRAIN AND COGNITION			English	Article							AUDITORY-STIMULI; TASK-DIFFICULTY; REACTION-TIME; CONCUSSION; SYMPTOMS; LATENCY; ATTENTION; DISABILITIES; DETERMINANTS; RECOGNITION	We compared the performance of 10 well-functioning university students who had experienced a mild head injury (MHI) an average of 6.4 years previously and IZ controls on a series of standard psychometric tests of attention, memory, and thinking and on a series of auditory oddball vigilance tasks to which we also took event-related potentials (ERPs). The MHI and Control groups performed equivalently on all the psychometric tasks and on self-report questionnaires of everyday memory and attention difficulties. The MHI group performed more slowly and with lower accuracy on only the most difficult of the oddball tasks, yet they showed substantially and significantly reduced P300 amplitudes and subsequent attentuation on all the oddball tasks. both easy and difficult. There were no alterations of N1. P2. and N2 components. These data suggest that despite excellent behavioral recovery, subtle information processing deficits involving attention nevertheless may persist long after the original injury and may not he apparent on a variety of standard psychometric measures. (C) 2001 Academic Press.	Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada	Segalowitz, SJ (corresponding author), Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada.						BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BRAUN C, 1990, PSYCHOPHYSIOLOGY, V27, pS19; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V23, P1; CAMPBELL K, 1990, EEG S, V41; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; DYWAN J, 1994, PSYCHOL AGING, V9, P568, DOI 10.1037/0882-7974.9.4.568; FORD JM, 1994, BIOL PSYCHIAT, V35, P96, DOI 10.1016/0006-3223(94)91198-3; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; GAILLARD AWK, 1977, PSYCHOPHYSIOLOGY, V14, P563, DOI 10.1111/j.1469-8986.1977.tb01200.x; Granovsky Y, 1998, EVOKED POTENTIAL, V108, P554, DOI 10.1016/S0168-5597(98)00036-7; GRONWALL D, 1975, LANCET, V2, P995; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Houlihan M, 1998, INTELLIGENCE, V26, P9, DOI 10.1016/S0160-2896(99)80049-X; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Knight R. T., 1990, EVENT RELATED BRAIN, P3; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVINE MJ, 1988, COGNITIVE REHABI MAR, P14; Marshall LF, 1989, MILD HEAD INJURY, P276; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PARASURAMAN R, 1982, PERCEPT PSYCHOPHYS, V31, P1, DOI 10.3758/BF03206196; Picton T.W., 1988, HUMAN EVENT RELATED, VVolume 1, P361; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; POLICH J, 1987, ELECTROEN CLIN NEURO, V68, P311, DOI 10.1016/0168-5597(87)90052-9; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RITTER W, 1982, SCIENCE, V218, P909, DOI 10.1126/science.7134983; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SEGALOWITZ S, 1992, J CLIN EXPT NEUROPSY, V14, P73; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TECCE JJ, 1976, ELECTROEN CLIN NEURO, V41, P277, DOI 10.1016/0013-4694(76)90120-6; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WOODCOCK RW, 1977, WOODCOCKJOHNSON PSYC	48	61	65	0	7	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	APR	2001	45	3					342	356		10.1006/brcg.2000.1263			15	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	427PQ	WOS:000168415100003	11305878				2021-06-18	
J	Max, JE; Robertson, BAM; Lansing, AE				Max, JE; Robertson, BAM; Lansing, AE			The phenomenology of personality change due to traumatic brain injury in children and adolescents	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							FRONTAL-LOBE DAMAGE; PSYCHIATRIC-DISORDERS; CHILDHOOD; IMPACT; SCALE	The authors aimed to contribute a clinically rich description of personality change due to traumatic brain injury (PC) in children. The sample consisted of consecutively injured children. Ninety-four subjects ages 5 to 14 years were assessed at the time of hospitalization after a traumatic brain injury (TBI). A standardized psychiatric interview, the Neuropsychiatric Rating Schedule, tons used to elicit symptoms of PC. PC occurred in 59% of severe (22/37) and 5% of mild/moderate (3/57) TBI subjects. Among the 37 severe TBI subjects, the labile subtype of PC was the most common (49%), followed by the aggressive and disinhibited subtypes (38% each), apathy (14%), and paranoia (5%). Also frequent in severe TBI was perseveration (35%). A detailed case example, numerous clinical vignettes of PC symptoms, and a tabulation of their frequencies provide clinicians a broader frame of reference for eliciting symptoms of PC.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA	Max, JE (corresponding author), Univ Calif San Diego, Childrens Hosp, 3665 Kearny Villa Rd,Suite 101, San Diego, CA 92123 USA.				NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1 K08 MH01800-01] Funding Source: Medline		ACKERLY S, 1947, P ASS RES NERVOUS ME, V27, P479; Ackerly SS, 1964, FRONTAL GRANULAR COR, P192; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Blau A, 1936, ARCH NEURO PSYCHIATR, V35, P723, DOI 10.1001/archneurpsyc.1936.02260040031003; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Hoover H.D., 1986, MANUAL SCH ADM IOWA; LEMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; LISHMAN WA, 1978, ORGANIC PSYCHIAT; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P854; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, NEUROCASE, V3, P119; MILLS RAR, 1994, J CAN PETROL TECHNOL, V33, P5; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; RUSSELL WR, 1959, BRAIN MEMORY LEARNIN; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X	27	61	66	0	8	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2001	13	2					161	170		10.1176/appi.neuropsych.13.2.161			10	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	432JE	WOS:000168687800002	11449023				2021-06-18	
J	Sohlberg, MM; Mateer, CA				Sohlberg, MM; Mateer, CA			Improving attention and managing attentional problems - Adapting rehabilitation techniques to adults with ADD	ADULT ATTENTION DEFICIT DISORDER	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article						attention training; compensatory strategies; self-regulation; neuroplasticity; rehabilitation	TRAUMATIC BRAIN INJURY; TRAINING-PROGRAM; HEAD-INJURY; CHILDREN; INTERVENTION; DEFICITS; DAMAGE	Research and clinical experience in the field of brain injury rehabilitation have focused quite extensively on the need and potential to retrain attentional skills that are commonly affected by acquired brain injury. Four approaches to managing attention impairments that have emerged from this literature include attention process training, training use of strategies and environmental support, training use of external aids, and the provision of psychosocial support. Most often, several of these will be used in combination. For example, a therapy regimen might include attention process training emphasizing specific components of attention (e.g., sustained attention), in conjunction with training in pacing techniques, and psychosocial support, where the client keeps behavioral logs and discusses insights gained from tracking attention successes and attention lapses. Although there are as yet little data with regard to the effectiveness of these approaches in adults with developmental disorders of attention, there is a growing literature suggesting they may be effective in children and adolescents with ADHD. Further investigation of the application of such techniques in adults with a wide variety of attention disorders, including developmental disorders, would be valuable.	Univ Victoria, Dept Psychol, Victoria, BC, Canada; Univ Oregon, Eugene, OR 97403 USA	Mateer, CA (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC, Canada.						ADAMS A, 1982, READ RES QUART, V18, P27, DOI 10.2307/747537; ANDREWS J R, 1986, Seminars in Speech and Language, V7, P359, DOI 10.1055/s-0028-1085234; Baddeley A. D., 1986, WORKING MEMORY; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R; DILLER L, 1974, REHABILITATION MONOG, V50; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; GRONWALL D, 1987, NEUROBEHAVIORAL RECO; GRONWALL D, 1991, NEUROPSYCHOLOGY, V5, P235; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kerns KA, 1999, DEV NEUROPSYCHOL, V16, P273, DOI 10.1207/S15326942DN1602_9; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Long CJ., 1996, ECOLOGICAL VALIDITY; MAPOU R, 1995, COGNITIVE FRAMEWORK; Mateer C.A., 1990, COGNITIVE REHABILITA; Mateer C.A., 1992, REHABILITATION POSTC; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Mateer C. A., 1997, NEUROPSYCHOLOGICAL R; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Mateer CA, 2000, BRAIN COGNITION, V42, P106, DOI 10.1006/brcg.1999.1175; Mateer CA, 1988, NEUROPSYCHOLOGICAL S, P202; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; NEIMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Semrud-Clikeman M, 1999, J LEARN DISABIL-US, V32, P581, DOI 10.1177/002221949903200609; SEMRUDCLIKEMAN M, 26 ANN INT NEUR SOC; SIVAK M, 1984, INT J REHABIL RES, V7, P389, DOI 10.1097/00004356-198412000-00002; SIVAK M, 1984, ARCH PHYS MED REHAB, V65, P163; Sohlberg M. M, 1989, COGNITIVE REHABILITA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 1998, BRAIN INJURY, V12, P333; Sohlberg MM., 2000, NEUROPSYCHOLOGICAL M, P137; SOHLBERG MM, 2000, EVALUATION ATTENTION; SOHLBERG MM, 1994, THESIS ASS NEUROPSYC; STURM W, 1993, DEV ASSESSMENT REHAB; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; THOMSON JB, 2000, NEUROPSYCHOLOGICAL M, P233; THOMSON JB, 1995, 23 ANN M INT NEUR SO; Williams D.J., 1989, THESIS U WASHINGTON; WINOGRAD P, 1988, LEARNING STUDY STRAT; Wood R L, 1987, Int Disabil Stud, V9, P149	46	61	64	0	69	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923			ANN NY ACAD SCI	Ann.NY Acad.Sci.		2001	931						359	375					17	Multidisciplinary Sciences	Science & Technology - Other Topics	BT11H	WOS:000172009700021	11462753				2021-06-18	
J	Dennis, M				Dennis, M			Developmental plasticity in children: The role of biological risk development, time, and reserve	JOURNAL OF COMMUNICATION DISORDERS			English	Article						plasticity; biological risk; neurobehavioral outcome; development; reserve	CLOSED-HEAD-INJURY; BRAIN-TUMORS; HYDROCEPHALUS; DISEASE; AGE; ADOLESCENTS; MENINGITIS; CHILDHOOD; SEQUELAE	Older views of the functional developmental plasticity of the developing central nervous system (CNS) focused on the protective effect of a young age at the time of insult. In these views, a younger rather than an older age at onset was thought to produce fewer and/or less severe symptoms and a more rapid recovery. More recently, neurobehavioral outcome has been studied in a variety of medical conditions that affect the developing CNS; at the same time, new investigative techniques, such as brain imaging, have elucidated the biological basis of structural and functional brain plasticity. In consequence of a better understanding of the structural and functional consequences of developmental CNS insults, a body of research has emerged that is shaping a new view of functional developmental plasticity, in which neurobehavioral outcome is set by the biological risk associated with a medical condition and moderated by age and development, the time since onset of the condition, and the reserve available within the child, family, school, and community. (C) 2000 by Elsevier Science Inc.	Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada	Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mdennis@sickkids.on.ca			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD035946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD35946] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS21889-16] Funding Source: Medline		ALLEN JC, 1982, J NEUROSURG, V57, P446, DOI 10.3171/jns.1982.57.4.0446; ANDEREGG F, 1995, AIP CONF PROC, P1; Anderson RH, 1997, CARDIOL YOUNG, V7, P2, DOI 10.1017/S1047951100005795; ANDERSON V, 1994, ARCH DIS CHILD, V70, P476, DOI 10.1136/adc.70.6.476; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BARNES MA, 1999, J INT NEUROPSYCH SOC, V5, P149; BASSER LS, 1962, BRAIN, V85, P427, DOI 10.1093/brain/85.3.427; BROOME CV, 1987, PEDIATR INFECT DIS J, V6, P779, DOI 10.1097/00006454-198708000-00036; BROWN RT, 1993, J CLIN CHILD PSYCHOL, V22, P207, DOI 10.1207/s15374424jccp2202_7; Bruce D. A., 1995, TRAUMATIC HEAD INJUR, P40; CARLSONGREEN B, 1995, J PEDIATR PSYCHOL, V20, P769, DOI 10.1093/jpepsy/20.6.769; DENNIS M, 1994, J DEV BEHAV PEDIATR, V15, P124; Dennis M, 1999, CHANGING NERVOUS SYSTEM, P172; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; Dennis M, 1999, DEV COGN NEUROSCI, P505; DENNIS M, 1998, J INT NEUROPSYCHOLOI, V4, P3; DENNIS M, 1980, LANGUAGE DEV APHASIA, P45; DENNIS M, 1994, HDB PERCEPTION COGNI, V15, P219; Dennis M., 1988, MASTER LECT SERIES, V7, P85; DENNIS M, 1996, BEHAV NEUROLOGY NEUR, P737; DUFFNER PK, 1983, CANCER, V51, P233, DOI 10.1002/1097-0142(19830115)51:2<233::AID-CNCR2820510211>3.0.CO;2-8; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fletcher JM, 2000, SCI PRACT NEUROPSYCH, P25; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; GREENOUGH WT, 1993, AT-RISK INFANTS, P173; Hetherington R, 1999, DEV NEUROPSYCHOL, V15, P25, DOI 10.1080/87565649909540738; HOLMES CS, 1985, J DEV BEHAV PEDIATR, V6, P323; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; KUN LE, 1983, J NEUROSURG, V58, P1, DOI 10.3171/jns.1983.58.1.0001; Maria BL, 1997, J CHILD NEUROL, V12, P423, DOI 10.1177/088307389701200703; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; RAIMONDI AJ, 1981, J NEUROSURG, V55, P174, DOI 10.3171/jns.1981.55.2.0174; Rodier PM, 1996, J COMP NEUROL, V370, P247, DOI 10.1002/(SICI)1096-9861(19960624)370:2<247::AID-CNE8>3.0.CO;2-2; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SHAPIRO EG, 1995, J INHERIT METAB DIS, V18, P413, DOI 10.1007/BF00710053; STOVRING J, 1980, J PEDIATR-US, V96, P820, DOI 10.1016/S0022-3476(80)80549-X; TAKEUCHI T, 1968, MINAMATA DIS, P144; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TAYLOR HG, 1990, NEW ENGL J MED, V323, P1657, DOI 10.1056/NEJM199012133232403; TAYLOR HG, 1999, UNPUB LONGITUDINAL O; TEYLER TJ, 1995, BRAIN SLICES BASIC C, P1; WEBSTER MJ, 1991, J NEUROSCI, V11, P1095; Whitton C. W., 1993, PROGR ANESTHESIOLOGY, V7, P46; WRIGHT M, 1994, ARCH DIS CHILD, V71, P64, DOI 10.1136/adc.71.1.64; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92	47	61	61	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	JUL-AUG	2000	33	4					321	332		10.1016/S0021-9924(00)00028-9			12	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	354AQ	WOS:000089308000005	11001159				2021-06-18	
J	Verger, K; Junque, C; Jurado, MA; Tresserras, P; Bartumeus, F; Nogues, P; Poch, JM				Verger, K; Junque, C; Jurado, MA; Tresserras, P; Bartumeus, F; Nogues, P; Poch, JM			Age effects on long-term neuropsychological outcome in paediatric traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; CHILDREN; ADOLESCENTS; CHILDHOOD; MEMORY; PERFORMANCE; SEVERITY; RECOVERY	In order to investigate the relationship between age at injury and long-term neuropsychological impairment, 29 children and adolescents who sustained traumatic brain injury (TBI) were studied at least 6 years post-trauma. Tests of intellectual, memory, visuospatial and frontal lobe functions were administered to patients and 29 normal matched control subjects. Correlations between performance on neuropsychological tests and age showed the following direction: the younger the child when TBI was sustained, the worse the cognitive outcome. After controlling for injury severity, visuospatial functions remained related to age. Patients' performance differed significantly from chat of controls in half of the neuropsychological variables analysed. To further investigate the effects of age at injury, the sample was divided in two groups (TBI before and after age of 8) and then compared with their respective controls. Patients damaged earlier presented impaired intellectual and visuospatial functions. The results suggest that neuropsychological sequelae remain after at lease 6 years of evolution, and that there is an age at injury effect.	Univ Barcelona, Dept Psiquiatria & Psicobiol Clin, Barcelona 08035, Spain; Hosp Santa Creu & Sant Pau, E-08025 Barcelona, Spain; Hosp Gen Valle Hebron, Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, Dept Psiquiatria & Psicobiol Clin, Passeig Vall dHebron 171, Barcelona 08035, Spain.	cjunque@psi.ub.es	Junque, Carme/B-4400-2011; JURADO, MARIA ANGELES/E-1745-2011	Junque, Carme/0000-0002-6381-3063; JURADO, MARIA ANGELES/0000-0002-9403-1670			ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; BASSER LS, 1962, BRAIN, V85, P427, DOI 10.1093/brain/85.3.427; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; DANTA G, 1975, NEUROLOGY, V25, P43, DOI 10.1212/WNL.25.1.43; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Finger S., 1988, BRAIN INJURY RECOVER, P117; Golden C. J., 1994, STROOP TEST COLORES; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Jordan FM, 1996, BRAIN INJURY, V10, P729, DOI 10.1080/026990596123990; Jordan FM, 1996, BRAIN INJURY, V10, P91, DOI 10.1080/026990596124575; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINGMA A, 1993, AM J PEDIAT HEMATOL, V15, P231; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; MILLER EA, 1973, SCIENCE, V182, P304, DOI 10.1126/science.182.4109.304; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; REY A, 1987, THESIS TEA MADRID; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SMITH A, 1975, NEUROLOGY, V25, P813, DOI 10.1212/WNL.25.9.813; Webb C, 1996, BRAIN INJURY, V10, P303, DOI 10.1080/026990596124476; WECHSLER D, 1976, ESCALA INTELIGENCIA; Wechsler D., 1993, ESCALA INTELIGENCIA	43	61	62	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2000	14	6					495	503					9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	325WN	WOS:000087699600001	10887884				2021-06-18	
J	Kogler, A; Lindfors, J; Odkvist, LM; Ledin, T				Kogler, A; Lindfors, J; Odkvist, LM; Ledin, T			Postural stability using different neck positions in normal subjects and patients with neck trauma	ACTA OTO-LARYNGOLOGICA			English	Article; Proceedings Paper	Meeting of the Collegium Oto-Rhino-Laryngologicum Amicitae Sacrum (CORLAS)	AUG 22-25, 1999	LYON, FRANCE			neck position; neck proprioceptors; postural control; whiplash injury	HEAD EXTENSION; POSTUROGRAPHY	Subjects with neck problems, such as whiplash injuries, often complain of disturbed equilibrium and, in some instances, provocation of the neck position can elicit such problems. The importance of neck proprioceptors for maintaining balance is gaining increased interest, moreover the function or malfunction of the otoliths may disturb equilibrium in certain head positions. The aim of the study was to create a reference material for postural control and its dependence on head position in healthy subjects and to compare this with a set of patients with known neck problems and associated vertiginous problems. A total of 32 healthy subjects (16 men, 16 women; age range 21-58 years) as well as 10 patients age range 27-62 years (mean 44 years) with neck problems and associated balance problems since a whiplash injury were tested For postural control using the EquiTest dynamic posturographic model. The normal subjects were initially split into four age groups in order to estimate the effects of age on performance. The postural stability was evaluated for dependence of support sur face conditions (stable or sway-referenced), visual input (eyes open or closed) and head position (neutral, left rotated, right rotated, extended backwards or flexed forward) using analysis of variance (ANOVA) with Tukey's post hoc test in case of a significant factor effect. As expected, visual cues as well as stable support surface improve postural stability (p < 0.001). Postural stability is statistically different in the head extended backwards condition compared with the other foul head positions (p < 0.001 in all cases) in both patients and controls. Eliminating this test condition from the analysis, only a slight (p < 0.05) difference between head forwards and head turned left remained. This pattern of results remained if the normal subjects were only split into two age groups instead of Four. Finally, the patient group exhibited significantly lower postural performance than all the groups of normal subjects (p < 0.01), but none of the normal groups differed significantly from each other. It is concluded that the postural control system is significantly challenged in the head extended backwards condition in both normal subjects and patients with previous whiplash injury and persistent neck problems. The patient group differed statistically from all groups of normal subjects, This suggests that neck problems impair postural control, and that the head extended position is a more challenging task for the postural system to adapt to. Whether this is due to utricular malpositioning, central integrative functions or cervical proprioceptive afferents is not within the scope of this study to answer.	Linkoping Univ Hosp, Dept ENT, SE-58185 Linkoping, Sweden	Ledin, T (corresponding author), Linkoping Univ Hosp, Dept ENT, SE-58185 Linkoping, Sweden.						Alund M, 1993, J Vestib Res, V3, P383; BARIN K, 1992, OTOLARYNG HEAD NECK, V106, P355, DOI 10.1177/019459989210600407; Barre J-A., 1926, REV NEUROL, V33, P1246; BRANDT T, 1981, ANN NY ACAD SCI, V374, P636, DOI 10.1111/j.1749-6632.1981.tb30907.x; DEJONG JMB, 1986, DISORDERS POSTURE GA, P185; ENBOM H, 1990, THESIS U HOSP LUND; Guez C, 1991, PRINCIPLES NEURAL SC, P596; HAMID MA, 1994, J VESTIB RES, V6, P481; JACKSON RT, 1991, ANN OTO RHINOL LARYN, V100, P63, DOI 10.1177/000348949110000110; Karlberg M, 1995, THESIS U HOSP LUND; OOSTERVELD WJ, 1991, ACTA OTO-LARYNGOL, V111, P201, DOI 10.3109/00016489109137375; PFALTZ CR, 1984, VERTIGO, P179; RYAN GMS, 1955, LANCET, V31, P1355; SHEEHAN S, 1960, NEUROLOGY, V10, P968, DOI 10.1212/WNL.10.11.968; Spitzer W, 1995, SPINE, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; WILLIS WD, 1992, PHYSIOLOGY, P166	16	61	65	0	8	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0001-6489			ACTA OTO-LARYNGOL	Acta Oto-Laryngol.		2000	120	2					151	155					5	Otorhinolaryngology	Otorhinolaryngology	313JJ	WOS:000086996300009	11603761				2021-06-18	
J	Ewing-Cobbs, L; Prasad, M; Kramer, L; Landry, S				Ewing-Cobbs, L; Prasad, M; Kramer, L; Landry, S			Inflicted traumatic brain injury: Relationship of developmental outcome to severity of injury	PEDIATRIC NEUROSURGERY			English	Article						brain injury; cerebral infarction; child abuse; cognition; outcome; infants; children; shaken baby syndrome	HEAD-INJURY; YOUNG-CHILDREN; FOLLOW-UP; IMPACT SYNDROME; ABUSE; INFANTS; ADOLESCENTS; MECHANISMS; SEQUELAE; COMA	Inflicted traumatic brain injury (TBI) is a frequent consequence of physical child abuse in infants and children. Twenty-eight children who were 2-42 months of age when hospitalized for moderate to severe TBI were enrolled in a prospective, longitudinal study of neurobehavioral outcome following acquired brain injury. Relative to a comparison group, the children with inflicted TBI had significant deficits in cognitive, motor and behavioral domains when assessed with the Bayley Scales of Infant Development-II 1 and 3 months after the injury. Nearly half of the injured children showed persisting deficits in attention/arousal, emotional regulation and motor coordination. Greater injury severity, as indicated by lower coma scale scores, longer periods of unconsciousness and the presence of edema/cerebral infarctions was associated with poorer outcomes in all domains. Copyright (C) 2000 S. Karger AG, Basel.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX 77030 USA	Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,Suite 2431, Houston, TX 77030 USA.	lewing@ped1.med.uth.tmc.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR-02558] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29462] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; APPELBAUM AS, 1977, J ABNORM CHILD PSYCH, V5, P417, DOI 10.1007/BF00915089; Bayley N., 2006, BAYLEY SCALES INFANT; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUNST CJ, 1987, CHILD CARE HLTH DEV, V13, P111, DOI 10.1111/j.1365-2214.1987.tb00528.x; ELMER E, 1977, PEDIATRICS, V59, P273; ELMER E, 1967, PEDIATRICS, V40, P596; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; EWINGCOBBS L, IN PRESS CHILDS NERV; FAMULARO R, 1992, CLIN PEDIATR, V31, P536, DOI 10.1177/000992289203100904; FISCHER H, 1994, CLIN PEDIATR, V33, P696, DOI 10.1177/000992289403301113; FITCH MJ, 1976, J PEDIATR PSYCHOL, V1, P32; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; GOLDSON E, 1978, AM J DIS CHILD, V132, P790, DOI 10.1001/archpedi.1978.02120330062016; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Greer A L, 1981, J Med Syst, V5, P129, DOI 10.1007/BF02222066; HAHN YS, 1983, CHILD BRAIN, V10, P229; HOFFMANPLOTKIN D, 1984, CHILD DEV, V55, P794, DOI 10.1111/j.1467-8624.1984.tb03816.x; HOLLINGSHEAD AB, 1975, UNPUB 4 FACTOR INDEX; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; MORSE CW, 1970, AM J DIS CHILD, V120, P439, DOI 10.1001/archpedi.1970.02100100103011; OKUN A, 1994, DEV PSYCHOPATHOL, V6, P77, DOI 10.1017/S0954579400005897; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; TRICKETT PK, 1991, DEV PSYCHOL, V27, P148, DOI 10.1037/0012-1649.27.1.148	40	61	62	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	NOV	1999	31	5					251	258		10.1159/000028872			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	288RC	WOS:000085576200006	10681680				2021-06-18	
J	Ciresi, DL; Cali, RF; Senagore, AJ				Ciresi, DL; Cali, RF; Senagore, AJ			Abdominal closure using nonabsorbable mesh after massive resuscitation prevents abdominal compartment syndrome and gastrointestinal fistula	AMERICAN SURGEON			English	Article; Proceedings Paper	Midwest Surgical Association Meeting	AUG 16-18, 1998	MACKINAC ISL, MICHIGAN	Midwest Surg Assoc			CRITICALLY ILL PATIENTS; VACUUM PACK; EXPERIENCE; MANAGEMENT; PRESSURE; TRAUMA	Patients who receive high-volume resuscitation after massive abdominopelvic trauma, or emergent repair of a ruptured abdominal aortic aneurysm (RAAA), are at a significant risk for postoperative abdominal compartment syndrome (ACS). Absorbable prosthetic closure of the abdominal wall has been recommended as a means of managing ACS. However, use of absorbable prosthetic has been associated with very high rates of intestinal fistula formation and ventral hernia formation. The purpose of this study was to retrospectively review our experience with the use of nonabsorbable prosthetic abdominal closures in patients with documented ACS or at high risk for ACS. All patients managed by this technique from July 1995 through July 1997 after repair of ruptured abdominal aortic aneurysm or massive abdominopelvic trauma were evaluated. A total of 18 patients were identified: 15 primary prosthetic placements (Gore-Tex (TM) patch, 12; Marlex (TM) mesh, 2; and silastic mesh, 1) and 3 delayed prosthetic placements for ACS (Gore-Tex (TM), 1 and Marlex (TM), 2). The mortality rate was 22 per cent (4 of 18) and resulted from multisystem organ failure (2 patients), cardiac arrest 1 hour postoperatively (1 patient), and severe closed head injury (1 patient). Secondary closure and prosthetic removal was possible in 16 of 18 patients, including the 2 patients who died of multisystem organ failure within the same hospitalization. Delayed abdominal closure at a subsequent admission was performed in two cases. This same patient developed an enterocutaneous fistula 2 months after discharge. Importantly, only 1 of 18 closed in this manner developed ACS requiring reoperation. The results indicate that use of a nonabsorbable prosthetic, particularly with Gore-Tex (TM), is efficacious in the prevention of postoperative ACS in high-risk patients, while it enhances the possibility for delayed abdominal closure and minimizes the risk of gastrointestinal fistulization associated with other techniques.	Michigan State Univ, Ctr Surg Educ, Grand Rapids, MI 49503 USA; Michigan State Univ, Div Trauma, Grand Rapids, MI 49503 USA; Michigan State Univ, Div Vasc Surg, Grand Rapids, MI 49503 USA	Senagore, AJ (corresponding author), Michigan State Univ, Ctr Surg Educ, 221 Michigan St NE,Suite 200, Grand Rapids, MI 49503 USA.						BROCK WB, 1995, AM SURGEON, V61, P30; CULLEN DJ, 1989, CRIT CARE MED, V17, P118, DOI 10.1097/00003246-198902000-00002; Eddy V, 1997, SURG CLIN N AM, V77, P801, DOI 10.1016/S0039-6109(05)70585-5; FIETSAM R, 1989, AM SURGEON, V55, P396; HIRSHBERG A, 1995, ANN SURG, V222, P3, DOI 10.1097/00000658-199507000-00002; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; Mayberry JC, 1997, ARCH SURG-CHICAGO, V132, P957; Meldrum DR, 1997, AM J SURG, V174, P667, DOI 10.1016/S0002-9610(97)00201-8; MORRIS JA, 1993, ANN SURG, V217, P576, DOI 10.1097/00000658-199305010-00019; Nagy KK, 1996, AM SURGEON, V62, P331; Oelschlager BK, 1997, AM J SURG, V173, P411, DOI 10.1016/S0002-9610(97)00081-0; SCHEIN M, 1995, J AM COLL SURGEONS, V180, P745; Smith LA, 1997, AM SURGEON, V63, P1102; Williams M, 1997, AM SURGEON, V63, P555	14	61	66	0	1	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	AUG	1999	65	8					720	724					5	Surgery	Surgery	220MR	WOS:000081670200009	10432080				2021-06-18	
J	Yamamoto, M; Marmarou, CR; Stiefel, MF; Beaumont, A; Marmarou, A				Yamamoto, M; Marmarou, CR; Stiefel, MF; Beaumont, A; Marmarou, A			Neuroprotective effect of hypothermia on neuronal injury in diffuse traumatic brain injury coupled with hypoxia and hypotension	JOURNAL OF NEUROTRAUMA			English	Article						neuronal damage; rat; secondary insult; selective vulnerability; traumatic brain injury	ENERGY PHOSPHATE-METABOLISM; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; CLOSED-HEAD INJURY; COMA DATA-BANK; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; FOREBRAIN ISCHEMIA; FLUID-PERCUSSION; RAT-BRAIN	It is well established in mechanical head trauma that posttraumatic secondary insults, such as hypoxia and hypotension exacerbate neuronal injury and lead to worse outcome. In this study, the neuroprotective effect of hypothermia on the reduction of supraventricular subcortical neuronal damage was evaluated using an impact-acceleration model of diffuse traumatic brain injury coupled with both moderate and severe periods of hypoxia and hypotension. A total of 135 adult male Sprague-Dawley rats (340-375 g) were divided into three experimental studies: (I) physiological evaluation (n = 36); (II) quantitative analysis of the effect of trauma coupled with moderate and severe hypotension on neuronal damage assessed at 4 (n = 39) and 24 h (n = 24); and (III) the neuroprotective effect of hypothermia following moderate secondary insult (n = 36). Induction of hypothermia occurred at 15 min postinjury, to a level of 30 degrees C for 60 min. At the designated time points (4 and 24 h), the animals were sacrificed via standard transcardial perfusion techniques for histological processing. Quantitative assessment of neuronal damage using routine H&E staining at 4 hours showed neuronal damage which correlated with the severity of secondary insult. Animals exposed to trauma alone had a mean number of damaged neurons of 7.61 +/- 3.08/high powered field (hpf) compared with a mean of 1.21 +/- 0.30/hpf in the sham operated group (p = 0.015). Animals exposed to trauma,vith 10 min of hypoxia and hypotension (THH-10) showed a statistically significant number of damaged neurons compared to the sham-operated animals (7.50 +/- 2.15 damaged neurons/hpf, p = 0.013), whereas, neuronal damage in animals undergoing trauma with a 30-min secondary insult of hypoxia and hypotension (THH-30) was markedly increased (100 +/- 30.20/hpf, p = 0.002). Statistical analysis showed no significant difference in neuronal damage in animals subjected to secondary insult alone. At 24 h, the evolution of neuronal damage in the trauma alone group (5.08 +/- 1.63/hpf) was relatively static; however, there was a remarkable increase in the neuronal damage of the THH-10 group (29.88 50 +/- 8.20/hpf). However, hypothermia provided nearly complete protection against secondary insults, and neuronal damage was equal to that of the trauma alone group (p = 0.42). The results of this study confirm that hypothermia provides remarkable protection against the adverse effects of neuronal damage exacerbated by secondary injury. This study also presents a new model of secondary insult, which can be used experimentally to further define the mechanism of increased vulnerability of the injured brain.	Virginia Commonwealth Univ Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Marmarou, A (corresponding author), Virginia Commonwealth Univ Med Coll Virginia, Div Neurosurg, POB 508,MCV Stn,Sanger Hall,Rm 8004,1101 E Marsha, Richmond, VA 23298 USA.	marmarou@abic.vcu.edu	Beaumont, Andrew/AAJ-7457-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, R01NS019235] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19235, P01 NS12587] Funding Source: Medline		ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRIERLEY JB, 1973, ARCH NEUROL-CHICAGO, V29, P367, DOI 10.1001/archneur.1973.00490300029003; BROWN AW, 1973, ACTA NEUROPATHOL, V23, P9, DOI 10.1007/BF00689000; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Chappell JE, 1996, J TRAUMA, V41, P781, DOI 10.1097/00005373-199611000-00003; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GARCIA JH, 1978, ACTA NEUROPATHOL, V43, P85; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HEISS WD, 1983, ANN NEUROL, V14, P294, DOI 10.1002/ana.410140307; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; ITO U, 1975, ACTA NEUROPATHOL, V34, P1; ITO U, 1975, ACTA NEUROPATHOL, V32, P209, DOI 10.1007/BF00696570; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1981, ACTA NEUROPATHOL, V55, P205, DOI 10.1007/BF00691320; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; KATAYAMA Y, 1989, NEUROTRAUMA SOC, V6, P200; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KITA H, 1994, ACTA NEUROCHIR, P452; KLEMPT M, 1993, MOL BRAIN RES, V17, P347, DOI 10.1016/0169-328X(93)90021-G; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; MARCOUX FW, 1982, STROKE, V13, P339, DOI 10.1161/01.STR.13.3.339; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; NIDA TY, 1995, J NEUROTRAUM, V12, P77, DOI 10.1089/neu.1995.12.77; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; Yamamoto T, 1997, ACT NEUR S, V70, P71; ZIVIN JA, 1991, SCI AM, V265, P56, DOI 10.1038/scientificamerican0791-56	69	61	69	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1999	16	6					487	500		10.1089/neu.1999.16.487			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	206LD	WOS:000080879800005	10391365				2021-06-18	
J	Wiegner, S; Donders, J				Wiegner, S; Donders, J			Performance on the California Verbal Learning Test after traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CONFIRMATORY FACTOR-ANALYSIS; SEVERE HEAD-INJURY; STANDARDIZATION SAMPLE; MEMORY; SCALE; MODERATE; PATTERNS; CHILDREN; 1-YEAR; COMA	The California Verbal Learning Test (CVLT; Delis, Kramer, Kaplan, & Ober, 1987) data of 150 patients with traumatic brain injury (TBI) were evaluated to determine the latent underlying constructs as well as the possibility of performance subtypes with criterion validity. Confirmatory factor analysis of eight competing latent variable models suggested that a four-factor model (composed of Attention Span, Learning Efficiency, Delayed Recall, and Inaccurate Recall) fit the data relatively well. Two-stage cluster analysis of marker variables of each of these four factors suggested the presence of four reliable subtypes. Level of performance differences between these clusters were related to injury severity parameters. It is concluded that the CVLT is a sensitive and mulitfactorial measure of learning and memory after TBI. Specific recommendations for interpretation of clinically obtained CVLT profiles are provided.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jdonders@mfbrc.com					AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; Belsey DA., 1980, REGRESSION DIAGNOSTI; Bentler PM., 1989, EQS STRUCTURAL EQUAT; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; BURTON DB, 1993, ARCH CLIN NEUROPSYCH, V8, P467, DOI 10.1016/0887-6177(93)90047-5; Burton DB, 1996, CHILD NEUROPSYCHOL, V2, P39, DOI 10.1080/09297049608401349; CERNY BA, 1977, MULTIVAR BEHAV RES, V12, P43, DOI 10.1207/s15327906mbr1201_3; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; Delis DC, 1987, CALIFORNIA VERBAL LE; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; DONDERS J, IN PRESS DEV NEUROPS; Gardner SD, 1998, BRAIN COGNITION, V37, P10; Gorsuch R. L., 1983, FACTOR ANAL; Hatcher L., 1994, STEP BY STEP APPROAC; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; MARTIN JA, 1987, CHILD DEV, V58, P33, DOI 10.1111/j.1467-8624.1987.tb03488.x; MILLIS SR, 1995, PERCEPT MOTOR SKILL, V80, P219, DOI 10.2466/pms.1995.80.1.219; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; NETEMEYER RG, 1990, J APPL PSYCHOL, V75, P148, DOI 10.1037/0021-9010.75.2.148; Rawlings J.O., 1988, APPL REGRESSION ANAL; ROTH DL, 1990, J CLIN EXP NEUROPSYC, V12, P834; *SAS, 1989, SAS STAT US GUID VER, V1; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; TEASDALE G, 1974, LANCET, V2, P81; VANDERPLOEG RD, 1994, J CLIN EXP NEUROPSYC, V16, P243, DOI 10.1080/01688639408402635; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wolfson D., 1993, HALSTEAD REITAN NEUR; WOODARD JL, 1993, J CLIN EXP NEUROPSYC, V15, P968, DOI 10.1080/01688639308402611	34	61	61	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1999	21	2					159	170		10.1076/jcen.21.2.159.925			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	226CL	WOS:000082002700002	10425514				2021-06-18	
J	Kennan, HT; Brundage, SI; Thompson, DC; Maier, RV; Rivara, FP				Kennan, HT; Brundage, SI; Thompson, DC; Maier, RV; Rivara, FP			Does the Face Protect the Brain? A case-control study of traumatic brain injury and facial fractures	ARCHIVES OF SURGERY			English	Article							HEAD-INJURIES	Background: The relationship between facial fractures and traumatic brain injury is controversial. Some studies show an increased risk of brain injury with the presence of facial fractures while others claim that facial fractures protect against brain injury. Objective: To examine the association between facial fractures and traumatic brain injuries. Design: Case-control study. Setting: Subjects were recruited from the emergency departments of 7 hospitals in the Seattle, Wash, area. Patients: Three thousand eight hundred forty-nine injured bicyclists and 5 scene deaths were identified from March 1, 1992, to August 31, 1994, with complete data available on 3388 bicyclists. Interventions: None. Results: The study group was composed of 1602 cases with injuries to the head, face, or brain and 1540 control subjects. There were 203 bicyclists with traumatic brain injuries, of whom 62 had an identifiable intracranial injury and 141 suffered a concussion. A total of 81 patients sustained facial fractures. The odds ratio for the risk of intracranial injury associated with facial fractures after adjustment for significant confounders was 9.9 (95% confidence interval, 5.1-19.3). The effect was less strong but still present when all traumatic brain injuries including concussions were considered (odds ratio, 2;95% confidence interval, 1.1-3.7). No association was found for concussion only. Conclusions: This study demonstrates no evidence that facial fractures help prevent traumatic brain injury. Data indicate that facial fractures are markers for increased risk of brain injury.	Univ Washington, Harborview Injury Prevent & Res Ctr, Dept Pediat & Epidemiol, Seattle, WA 98104 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC USA	Rivara, FP (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Dept Pediat & Epidemiol, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@u.washington.edu					BRESLOW NE, 1980, STATISTICAL METHODS, V1, P32; CANNELL H, 1982, BRIT J ORAL SURG, V20, P183, DOI 10.1016/S0007-117X(82)80036-X; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; TURVEY TA, 1977, J ORAL SURG, V35, P887	6	61	63	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0004-0010	1538-3644		ARCH SURG-CHICAGO	Arch. Surg.	JAN	1999	134	1					14	17		10.1001/archsurg.134.1.14			4	Surgery	Surgery	157GR	WOS:000078053500003	9927123	Bronze			2021-06-18	
J	Youssef, RM; Attia, MSED; Kamel, MI				Youssef, RM; Attia, MSED; Kamel, MI			Children experiencing violence II: Prevalence and determinants of corporal punishment in schools	CHILD ABUSE & NEGLECT			English	Article						corporal punishment; school; prevalence; behavior; Egypt	PEDIATRICIAN	Objective: This study was undertaken to reveal the prevalence and determinants of corporal punishment in preparatory (middle) and secondary (high) schools in Alexandria. Methods: A cross sectional survey targeting preparatory and secondary school students enrolled in main stream public schools was conducted. The multistage random sample technique was adopted to select a priori estimated sample of this population. They were requested to fill a self administered questionnaire to collect relevant information. Data were analyzed using the univariate and multivariate analyses. Results: A substantial proportion of boys (79.96%) and girls (61.53%) incurred physical punishment at the hand of their teachers. Teachers were using their hands, sticks, straps, shoes, and kicks to inflict such punishment without sparing a part of their students' body. Physical injuries were reported by a significantly higher percentage of boys (chi(1)(2) = 12.26, p = .00046) the most common being bumps and contusions followed by wounds and fractures. Moreover, it was only among boys that serious injuries such as loss of consciousness and concussion were encountered. Both univariate and multivariate analyses revealed that corporal punishment was more likely to be used in preparatory schools and on boys. Such means of punishment were also predicted by students' undesirable behavior as well as their poor achievement in academic tasks. Conclusion: This study indicates that corporal punishment in school is used extensively to discipline students whose behavior doesn't conform with the desired standard of educational institutions. However, since it is no longer perceived as a method of discipline, other alternatives can be used providing that teachers are equipped with the necessary skills for its application. (C) 1998 Elsevier Science Ltd.	Fac Med, Dept Publ Hlth, Alexandria, Egypt; High Inst Publ Hlth, Dept Family Hlth, Alexandria, Egypt	Youssef, RM (corresponding author), Fac Med, Dept Publ Hlth, Alexandria, Egypt.						Bergman B., 1990, Journal of the European Ceramic Society, V6, P3, DOI 10.1016/0955-2219(90)90028-E; CLARKE JR, 1982, CHILD YOUTH SERVICES, V4, P47; *COMM PSYCH ASP CH, 1983, PEDIATRICS, V72, P373; *COMM SCH HLTH, 1984, PEDIATRICS, V73, P258; DOLINS JC, 1994, PEDIATRICS, V94, P638; Dubanoski R A, 1983, Child Abuse Negl, V7, P271; EICHELBERGER SP, 1991, PEDIATRICS, V87, P570; FARLEY AC, 1978, INEQUALITY ED, V23, P57; HOSSNY MN, 1981, INTERPRETATION CRIMI; HYMAN IA, 1982, CHILDREN TODAY, V11, P10; KAMEL MI, UNPUB PATTERN SCH IN; Kaplan H.I., 1988, SYNOPSIS PSYCHIAT; Kish Leslie, 1965, SAMPLING SURVEY; MCCORMICK KF, 1992, JAMA-J AM MED ASSOC, V267, P3161, DOI 10.1001/jama.267.23.3161; *OFF GEN COUNS, 1992, JAMA-J AM MED ASSOC, V267, P3205; POOLE SR, 1991, PEDIATRICS, V88, P162; RUTTER M, 1980, PEDIATRICS, V65, P208, DOI 10.1542/peds.65.2.208; SCHULTZ EW, 1987, J SCHOOL HEALTH, V57, P432, DOI 10.1111/j.1746-1561.1987.tb03189.x; SIKORSKI JB, 1996, ISSUES CLIN CHILD PS, P393; USHKOW MC, 1991, PEDIATRICS, V88, P173; WESSEL MA, 1980, PEDIATRICS, V66, P639; Wilson F C, 1982, Child Abuse Negl, V6, P155; WISSOW LS, 1994, PEDIATRICS, V94, P587; Wolkind S, 1990, CHILD ADOLESCENT PSY, P83	24	61	63	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	OCT	1998	22	10					975	985		10.1016/S0145-2134(98)00084-2			11	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	118FC	WOS:000075826900005	9793720				2021-06-18	
J	Machulda, MM; Bergquist, TF; Ito, V; Chew, S				Machulda, MM; Bergquist, TF; Ito, V; Chew, S			Relationship between stress, coping, and postconcussion symptoms in a healthy adult population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							MILD HEAD-INJURY; POST-CONCUSSIVE SYMPTOMS; BASE RATES; IMPAIRMENT; SEQUELAE	Study 1 examined the association between intensity of postconcussive symptoms (PCS), impact of daily stress, and level of perceived stress order the past month in a group of healthy young adults. There was a significant relationship between intensity of PCS and impact of daily sl,ess, as well as level of perceived stress over the past month, independent of the frequency of stressful events experienced. Study 2 assessed the stability of the relationship between PCS nan stress. Subjects rated intensity of PCS, impact of daily stress, and level of perceived stress on two separate occasions approximately 1 month apart. The Perceived Stress Scale demonstrated high test-retest reliability. Significant relationships were again found between intensity of PCS wild level of perceived slr ess at both lime points, independent of the frequency of stressful events. These results suggest that persistent symptoms in some individuals with postconcussive syndrome may be doe, at least in parr, to individual differences in the perceived stress of incurring a mild traumatic brain injury. (C) 1998 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Rehabil Inst Chicago, Chicago, IL 60611 USA; Samford Univ, Birmingham, AL USA	Machulda, MM (corresponding author), Rehabil Inst Chicago, Chicago, IL 60611 USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BRANTLEY PJ, 1988, J PSYCHOPATHOL BEHAV, V10, P75, DOI 10.1007/BF00962987; BRANTLEY PJ, 1987, J BEHAV MED, V10, P61, DOI 10.1007/BF00845128; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; DIKMEN SS, 1989, MILD HEAD INJURY, P229; DOERING S, 1993, ARCH NEUROL-CHICAGO, V50, P617, DOI 10.1001/archneur.1993.00540060055018; EVANS RW, 1992, NEUROL CLIN, V10, P815; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Holroyd K.A., 1982, HDB STRESS THEORETIC, P21; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KRAUS JF, 1989, MILD HEAD INJURY, P8; KURTZKE JF, 1993, CLIN NEUROLOGY, V4, P1; Lazarus R.S., 1984, STRESS APPRAISAL COP; LAZARUS RS, 1990, PERSONALITY DIS, P97; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; SINYOR D, 1986, STROKE, V17, P1102, DOI 10.1161/01.STR.17.6.1102	23	61	61	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	1998	13	5					415	424		10.1016/S0887-6177(97)00031-0			10	Psychology, Clinical; Psychology	Psychology	ZU448	WOS:000074198000001	14590606	Bronze			2021-06-18	
J	Hutchins, JB; Barger, SW				Hutchins, JB; Barger, SW			Why neurons die: Cell death in the nervous system	ANATOMICAL RECORD			English	Article						Alzheimer disease; apoptosis; calcium; free radicals; glutamate; Huntington disease; necrosis; Parkinson disease; stroke	NEUROTOXICITY; DEPRIVATION; DISEASE	It is likely that humans are born with all of the nerve cells (neurons) that will serve them throughout life, For all practical purposes, when our neurons die, they are lost forever. During nervous system development, about one-and-a-half times the adult number of neurons are created. These "extra" neurons are then destroyed or commit suicide. This process of programmed cell death occurs through a series of events termed apoptosis and is an appropriate and essential event during brain development. Later in life, inappropriate neuronal cell death may result from pathological causes such as traumatic injury, environmental toxins, cardiovascular disorders, infectious agents, or genetic diseases, In some cases, the death occurs through apoptosis, In other cases, cell death is random, irreversible, and uncontrollable; to distinguish it from the controlled, planned cell death of apoptosis, we call this necrotic cell death, Understanding the difference between apoptotic and necrotic cell death is essential for designing therapies which will prevent or limit inappropriate cell death in the nervous system. Anat. Rec, (NewAnat.): 253:79-90 1998. (C) 1998 Wiley-Liss, Inc.	Univ Mississippi, Med Ctr, Dept Neurol Res, University, MS 38677 USA; Univ Mississippi, Med Ctr, Dept Ophthalmol, University, MS 38677 USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA	Hutchins, JB (corresponding author), Univ Mississippi, Med Ctr, Dept Neurol Res, University, MS 38677 USA.			Barger, Steven/0000-0001-6049-6480			Barger S. W., 1995, CNS NEUROTRANSMITTER, V2, P273; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; CHALMERSREDMAN RME, 1997, INT REV NEUROBIOL, V40, P1; CHENG B, 1995, J NEUROSCI, V15, P7095; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Clarke Donald D., 1994, P645; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Hill SM, 1998, ANAT REC, V253, P42, DOI 10.1002/(SICI)1097-0185(199804)253:2<42::AID-AR7>3.0.CO;2-G; HOLLAND A, 1994, ENVIRON VALUE, V3, P1; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; OLNEY JW, 1994, PSYCHOPHARMACOL BULL, V30, P533; OLNEY JW, 1971, SCIENCE, V172, P294, DOI 10.1126/science.172.3980.294; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Rosse T, 1998, NATURE, V391, P496; Schwartz LM, 1996, TRENDS NEUROSCI, V19, P555, DOI 10.1016/S0166-2236(96)10067-9; Tymianski M, 1996, ADV NEUROL, V71, P85; WARDMAN P, 1996, FREE RADICALS NATURE; Wyllie AH, 1997, BRIT MED BULL, V53, P451; ZHANG H, 1998, ANAT REC NEW ANAT, V253, P58	24	61	65	0	5	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0003-276X			ANAT REC	Anat. Rec.	JUN	1998	253	3					79	90		10.1002/(SICI)1097-0185(199806)253:3<79::AID-AR4>3.0.CO;2-9			12	Anatomy & Morphology	Anatomy & Morphology	106JD	WOS:000075125400004	9700393				2021-06-18	
J	Ewing-Cobbs, L; Brookshire, B; Scott, MA; Fletcher, JM				Ewing-Cobbs, L; Brookshire, B; Scott, MA; Fletcher, JM			Children's narratives following traumatic brain injury: Linguistic structure, cohesion, and thematic recall	BRAIN AND LANGUAGE			English	Article							CLOSED-HEAD-INJURY; ADOLESCENTS; DISCOURSE; PERFORMANCE; CHILDHOOD; SEQUELAE; ADULTS	Narrative discourse and intellectual functioning were examined 3 years following traumatic brain injury (TBI) in children 1 to 8 years of age at the time of injury. The language-impaired TBI group (n = 9) had language deficits during the subacute stage of recovery; their performance was contrasted with that of a TBI comparison group equated on neurologic and demographic variables that did not show subacute language impairment (n = 8) and a sibling comparison group (n = 9). The language-impaired TBI group had lower Verbal and Full-Scale IQ scores and produced fewer words and utterances than the sibling group on a story retelling task; their stories were characterized by fewer complete referential and lexical ties and more referential errors, indicating difficulty conjoining meaning across sentences. The language impaired TBI group recalled approximately one-third of the propositions needed to maintain the story theme and made more errors sequencing the propositions than either the TBI or the sibling comparison groups. Group differences were not obtained on the Performance IQ scores or on measures of rate or fluency of speech production, mazes, use of conjunctives, or naming errors. The discourse deficiencies of children with TBI and acute language impairment were most pronounced at the level of cognitive organization of the text reflecting text macrostructure and were least apparent at the level of lexical and sentential organization reflecting text microstructure. Results are discussed in terms of the vulnerability of developing language abilities to disruption by brain injury. (C) 1998 Academic Press.	Univ Texas, Hlth Sci Ctr, Dept Pediat MSB 3 222, Div Dev Pediat, Houston, TX 77030 USA	Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat MSB 3 222, Div Dev Pediat, 6431 Fannin, Houston, TX 77030 USA.		fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27597, NS 29462] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER		BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Benson DF, 1979, STUDIES NEUROLINGUIS, P293; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DENNIS M, 1909, DISCOURSE ABILITY BR, P199; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GOLDBERG E, 1981, BRAIN LANG, V14, P144, DOI 10.1016/0093-934X(81)90072-9; Halliday Michael A. K., 1976, COHESION ENGLISH; HEDRICK DL, 1974, SEQUENCED INVENTORY; Hollingshead A. B., 1958, SOCIAL CLASS MENTAL; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; JORDAN FM, 1988, BRAIN INJURY, V2, P175; JORDAN FM, 1909, BRIN INJURY, V4, P147; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Lee L.L., 1974, DEV SENTENCE ANAL GR; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; LOVETT MW, 1986, BRAIN LANG, V29, P224, DOI 10.1016/0093-934X(86)90046-5; McCarthy D., 1972, MCCARTHY SCALES CHIL; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MILLER J, 1992, SALT SYSTEMATIC ANAL; Miller J. F., 1981, ASSESSING LANGUAGE P; Opie I. A., 1974, CLASSIC FAIRY TALES; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Reilly JS, 1998, BRAIN LANG, V61, P335, DOI 10.1006/brln.1997.1882; SPREEN O, 1966, NEUROSENSORY CTR COM; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Ulatowska H.K., 1990, DISCOURSE ABILITY BR, P180, DOI [10.1007/978-1-4612-3262-9_8, DOI 10.1007/978-1-4612-3262-9_8]; Van Dijk T. A., 1985, HDB DISCOURSE ANAL; Wechsler D., 1974, MANUAL WECHSLER INTE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WOOD BS, 1976, CHILDREN COMMUNICATI; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447	47	61	61	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	FEB 15	1998	61	3					395	419		10.1006/brln.1997.1884			25	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	ZK818	WOS:000073366800005	9570871				2021-06-18	
J	Mazda, K; Khairouni, A; Pennecot, GF; Bensahel, H				Mazda, K; Khairouni, A; Pennecot, GF; Bensahel, H			Closed flexible intramedullary nailing of the femoral shaft fractures in children	JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B			English	Article						femoral fracture; intramedullary nailing; children's fracture	AVASCULAR NECROSIS; FEMUR FRACTURES; ADOLESCENT; HEAD	We treated 34 femoral shaft fractures in 32 children with elastic intramedullary nailing using titanium rods. The 24 boys and 8 girls ranged from 6-17 years. All fractures united. The weight bearing was authorized at an average of 67 days and was complete at average of 89 days. All children returned to school before the end of the second postoperative month. At an average 2.5 years, not rotational malalignment was present. Neither anteroposterior nor frontal malalignment of more than 2 degrees was noticed. A leg length discrepancy of more than 10 mm was present in 3 patients (8%). No injury of femoral head vascularization or of the proximal or distal growth plate was noticed. In our experience, this technique seems to be safe for the surgical treatment of the immature femoral shaft fractures. The elastic properties of titanium provide a very good stability of the montage, when the technique is correctly performed.		Mazda, K (corresponding author), UNIV PARIS 07,HOP ROBERT DEBRE,SERV CHIRURG ORTHOPED,FAC MED XAVIER BICHAT,DEPT ORTHOPAED SURG,F-75019 PARIS,FRANCE.						ARONSON J, 1992, J PEDIATR ORTHOPED, V12, P157, DOI 10.1097/01241398-199203000-00003; GALPIN RD, 1994, J PEDIATR ORTHOPED, V14, P184, DOI 10.1097/01241398-199403000-00010; HERZOG B, 1976, Z KINDERCHIR, V19, P74; KIRBY RM, 1981, J PEDIATR ORTHOPED, V1, P193, DOI 10.1097/01241398-198110000-00010; LIGIER JN, 1988, J BONE JOINT SURG BR, V70, P74; METAIZEAU JP, 1984, J CHIR-PARIS, V121, P527; MILESKI RA, 1995, J PEDIATR ORTHOPED, V15, P24, DOI 10.1097/01241398-199501000-00006; OMALLEY DE, 1995, J PEDIATR ORTHOPED, V15, P21, DOI 10.1097/01241398-199501000-00005; RANEY EM, 1993, J PEDIATR ORTHOPED, V13, P16; REEVES RB, 1991, J PEDIATR ORTHOPED, V10, P591; WARD WT, 1992, J PEDIATR ORTHOPED, V12, P626; ZIV I, 1984, J TRAUMA, V24, P432, DOI 10.1097/00005373-198405000-00011	12	61	63	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	1060-152X			J PEDIATR ORTHOP B	J. Pediatr. Orthop.-Part B	JUL	1997	6	3	B				198	202		10.1097/01202412-199707000-00008			5	Orthopedics; Pediatrics	Orthopedics; Pediatrics	XP645	WOS:A1997XP64500008	9260649				2021-06-18	
J	Vilkki, J; Virtanen, S; SurmaAho, O; Servo, A				Vilkki, J; Virtanen, S; SurmaAho, O; Servo, A			Dual task performance after focal cerebral lesions and closed head injuries	NEUROPSYCHOLOGIA			English	Article						attention; diffuse brain injury; executive function; frontal lobe; supervisory control	DIGIT SPAN; ATTENTION; NEGLECT; MEMORY	The aim of this study was to demonstrate that focal frontal lobe lesions and closed head injuries cause a deficit in the deliberate minimizing of dual task decrements that follow when two separate tasks should be done concurrently. In single tasks, subjects counted backwards and cancelled visual targets as quickly and accurately as possible on separate 1 min trials. In the dual task, they were required to do both tasks simultaneously, taking care that performance on neither task would be notably more impaired than on the other, as only the performance showing a larger percentage decrement from the corresponding single task performance was taken into account as the result of the test. Patients with acute closed head injury displayed more pronounced dual task decrement than the controls. This deficit was not secondary to inefficiency on the single tasks but was related to the depth of coma at admission, the acuteness of injury and age. Contrary to expectation, patients with focal frontal lobe lesions or patients with subacute closed head injury did not demonstrate abnormal dual task decrement. Copyright (C) 1996 Elsevier Science Ltd.		Vilkki, J (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT NEUROSURG,TOPELIUKSENKATU 5,FIN-00260 HELSINKI,FINLAND.						BADDELEY A, 1986, Q J EXP PSYCHOL-A, V38, P603, DOI 10.1080/14640748608401616; Baddeley A. D., 1986, WORKING MEMORY; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; HARTMAN A, 1992, CLIN REHABIL, V6, P133; Mayes A., 1988, HUMAN ORGANIC MEMORY; NORMAN DA, 1980, 99 CHIP U CAL SAN DI; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; RAPPORT LJ, 1994, NEUROPSYCHOLOGIA, V32, P517, DOI 10.1016/0028-3932(94)90141-4; ROBERTSON IH, 1990, NEUROPSYCHOLOGIA, V28, P217, DOI 10.1016/0028-3932(90)90103-U; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; Shallice T., 1988, NEUROPSYCHOLOGY MENT; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STUSS DT, 1982, J COMP PHYSIOL PSYCH, V96, P913, DOI 10.1037/0735-7036.96.6.913; TEASDALE G, 1974, LANCET, V2, P81; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMMEREN AH, 1994, CLIN NEUROPSYCHOLOGY; VELTMAN JC, IN PRESS J CLIN EXPT; Wechsler D., 2008, WECHSLER ADULT INTEL; WEINBERG J, 1972, J CLIN PSYCHOL, V28, P361, DOI 10.1002/1097-4679(197207)28:3+<361::AID-JCLP2270280315>3.0.CO;2-5	19	61	61	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	NOV	1996	34	11					1051	1056		10.1016/0028-3932(96)00028-0			6	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	VP114	WOS:A1996VP11400002	8904742				2021-06-18	
J	Bigler, ED; Johnson, SC; Anderson, CV; Blatter, DD; Gale, SD; Russo, AA; Ryser, DK; Macnamara, SE; Bailey, BJ; Hopkins, RO; Abildskov, TJ				Bigler, ED; Johnson, SC; Anderson, CV; Blatter, DD; Gale, SD; Russo, AA; Ryser, DK; Macnamara, SE; Bailey, BJ; Hopkins, RO; Abildskov, TJ			Traumatic brain injury and memory: The role of hippocampal atrophy	NEUROPSYCHOLOGY			English	Article							RECOGNITION MEMORY; TEMPORAL LOBECTOMY; AMNESIC PATIENTS; HEAD-INJURY; SEGMENTATION; HUMANS; MRI	In traumatically brain-injured (TBI) patients (N = 83), memory performance was examined on the Warrington Recognition Memory Test, Rey-Osterrieth Complex Figure, and the Logical Memory and Visual Reproduction subtests of the Wechsler Memory Scale-Revised in relationship to time postinjury and structural changes based on MRI volumetry, including hippocampus volume. Significant trauma-induced changes were observed, including hippocampal atrophy. Structure-function relationships generally became significant only after 90 days postinjury. Memory tended to relate more to the degree of hippocampal atrophy, particularly left hippocampus, than to nonspecific indicators such as the temporal horns or the ventricle-to-brain ratio. A stronger relationship with left versus right hippocampus was evident for measures of verbal and supposedly nonverbal memory. These results are discussed with regard to the role the hippocampus may play in a neural system of memory.	LDS HOSP,SALT LAKE CITY,UT	Bigler, ED (corresponding author), BRIGHAM YOUNG UNIV,DEPT PSYCHOL,POB 25543,PROVO,UT 84602, USA.			Johnson, Sterling/0000-0002-8501-545X			ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; BERMAN KF, 1995, NEUROPSYCHOLOGIA, V33, P1027, DOI 10.1016/0028-3932(95)00035-2; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; BIGLER ED, IN PRESS AM J NEUROR; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; BIGLER ED, 1996, M INT NEUR SOC CHIC; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BLATTER DD, IN PRESS AM J NEUROR; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; CLARKE LP, 1993, MAGN RESON IMAGING, V11, P95, DOI 10.1016/0730-725X(93)90417-C; CLINE HE, 1990, J COMPUT ASSIST TOMO, V14, P1037, DOI 10.1097/00004728-199011000-00041; COMPTON JM, 1992, ARCH CLIN NEUROPSYCH, V7, P165, DOI 10.1016/0887-6177(92)90010-K; FREE SL, 1995, AM J NEURORADIOL, V16, P637; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Gean A, 1994, IMAGING HEAD TRAUMA; GOLDBERG E, 1995, J CLIN EXP NEUROPSYC, V17, P193, DOI 10.1080/01688639508405118; HARTER SB, 1995, AM J NEURORADIOL, V16, P700; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; HUNT WA, 1993, ALCOHOL CLIN EXP RES, V17, P1055, DOI 10.1111/j.1530-0277.1993.tb05664.x; HUPPERT FA, 1976, CORTEX, V12, P3, DOI 10.1016/S0010-9452(76)80024-X; ISAACSON RL, 1986, HIPPOCAMPUS; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KAPUR N, 1987, BRIT J CLIN PSYCHOL, V26, P144, DOI 10.1111/j.2044-8260.1987.tb00741.x; KESNER RP, 1992, NEUROPSYCHOLOGY MEMO, P106; KIM JH, 1995, AM J NEURORADIOL, V16, P627; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LORING DW, 1993, NEUROLOGY, V43, P1789, DOI 10.1212/WNL.43.9.1789; Osborn AG, 1994, DIAGNOSTIC NEURORADI; Osterrieth P. A, 1944, ARCH PSYCHOL, V30, P286; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; RAUSCH R, 1993, ARCH NEUROL-CHICAGO, V50, P812, DOI 10.1001/archneur.1993.00540080023008; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; ROBB RA, 1995, 3 DIMENSIONAL BIOMED; ROLAND PE, 1991, MEMORY ORG LOCUS CHA, P95; ROSEN DL, 1987, CEREBRAL CORTEX, V6; ROSENTHAL M, 1993, TRAUMATIC BRAIN INJU; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SQUIRE LR, 1992, NEUROPSYCHOLOGY MEMO; SQUIRE LR, 1987, MEMORY BRAIN; TRENERRY MR, 1993, NEUROLOGY, V43, P1800, DOI 10.1212/WNL.43.9.1800; WARRINGTON EK, 1984, WARRINGTON RECOGNITI; Wechsler D., 1987, WECHSLER MEMORY SCAL; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WOOD DMG, 1995, BRAIN RES BULL, V38, P545, DOI 10.1016/0361-9230(95)02026-0	56	61	61	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	1996	10	3					333	342		10.1037/0894-4105.10.3.333			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	UY062	WOS:A1996UY06200003					2021-06-18	
J	KINSELLA, G; PRIOR, M; SAWYER, M; MURTAGH, D; EISENMAJER, R; ANDERSON, V; BRYAN, D; KLUG, G				KINSELLA, G; PRIOR, M; SAWYER, M; MURTAGH, D; EISENMAJER, R; ANDERSON, V; BRYAN, D; KLUG, G			NEUROPSYCHOLOGICAL DEFICIT AND ACADEMIC-PERFORMANCE IN CHILDREN AND ADOLESCENTS FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL TESTING; NEUROPSYCHOLOGICAL DEFICIT; NEUROPSYCHOLOGICAL ASSESSMENT; SPECIAL EDUCATION; FOLLOW-UP; ACADEMIC PERFORMANCE	CLOSED-HEAD-INJURY; SEQUELAE; MEMORY; SEVERITY; RECOVERY; COMA	Evaluated the utility of neuropsychological testing in predicting academic outcome in children 1 year following traumatic brain injury (TBI). Fifty-one schoolage children who were admitted to hospital after TBI were assessed with a battery of neuropsychological measures at 3 months postinjury, Academic achievement was assessed at 3 and 12 months postinjury, The neuropsychological battery included intelligence resting and measures of memory, learning, and speed of information processing. Academic outcome was assessed in terms of post-TBI changes in reading, spelling, and arithmetic; changes in teacher ratings of school performance; and change in school placement. According to logistic regression analysis, change in placement from regular to special education at 1-year post-TBI was predicted by injury severity and by neuropsychological performance cat 3 months post-TBI. Findings suggest that neuropsychological resting is useful in identifying children with special educational needs subsequent to TBI.	ROYAL CHILDRENS HOSP,MELBOURNE,VIC,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,ADELAIDE,SA 5006,AUSTRALIA	KINSELLA, G (corresponding author), LA TROBE UNIV,DEPT PSYCHOL,BUNDOORA,VIC 3083,AUSTRALIA.		Kinsella, Glynda/O-6347-2017; Murtagh, Donal/F-8694-2011	Kinsella, Glynda/0000-0002-5859-0934; Murtagh, Donal/0000-0003-1539-3559			Achenbach TM, 1986, MANUAL TEACHERS REPO; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BENTON AL, 1978, MANUAL MULTILINGUAL; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CLARREN SB, 1993, DEV NEUROPSYCHOL, V9, P161, DOI 10.1080/87565649309540550; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DANIEL A, 1983, POWER PRIVILEDGE PRE; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1985, INJURED CHILD, P30; Forrester G., 1991, CLIN NEUROPSYCHOL, V5, P345, DOI DOI 10.1080/13854049108404102; GEFFEN GM, 1994, ARCH CLIN NEUROPSYCH, V9, P303, DOI 10.1016/0887-6177(94)90018-3; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jastak S, 1984, WIDE RANGE ACHIEVEME; JOHNSON DA, 1988, J CHILD PSYCHOL PSYC, V29, P1996; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, NEUROBEHAVIOURAL REC; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; Rey A, 1964, EXAMEN CLIN PSYCHOL; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; Shurtleff H. A., 1988, J PSYCHOEDUCATIONAL, V6, P298, DOI 10.1177/073428298800600313; Smith A., 1973, SYMBOL DIGIT MODALIT; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; TUCKER A, 1987, AUST PSYCHOL, V22, P353, DOI 10.1080/00050068708259536; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wechsler D., 1974, MANUAL WECHSLER INTE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	44	61	61	0	5	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	DEC	1995	20	6					753	767		10.1093/jpepsy/20.6.753			15	Psychology, Developmental	Psychology	TK236	WOS:A1995TK23600005	8558376				2021-06-18	
J	SUN, FY; FADEN, AI				SUN, FY; FADEN, AI			NEUROPROTECTIVE EFFECTS OF 619C89, A USE-DEPENDENT SODIUM-CHANNEL BLOCKER, IN RAT TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article						TRAUMATIC BRAIN INJURY; SODIUM CHANNEL BLOCKER; GLUTAMATE RELEASE INHIBITOR; EXCITOTOXICITY; NEURONAL DAMAGE; MOTOR DEFICIT	EXCITATORY AMINO-ACIDS; TRANSIENT GLOBAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; CORTICAL CELL-CULTURE; SPINAL-CORD INJURY; CEREBRAL-ISCHEMIA; GLUTAMATE RELEASE; NMDA ANTAGONISTS; TRANSPORT SITES; MESSENGER-RNA	Release of the excitatory amino acid (EAA) neurotransmitter glutamate has been implicated in secondary tissue damage following central nervous system (CNS) trauma and ischemia. The present study evaluated the neuroprotective actions of 619C89, a sodium channel blocker that inhibits ischemia-induced glutamate release, on traumatic brain injury (TBI) in rats using a lateral fluid percussion model. Various motor-related behavioral outcomes were used to evaluate neurologic function. Glial fibrillary acidic protein (GFAP) immunostaining and Cresyl violet staining were used to assess the histological changes. Treatment with 619C89, at a dose of 30 mg/kg administered intravenously 15 min before brain injury, significantly attenuated behavioral deficits at 24 h and 1 week. At 2 weeks, neuronal loss in the CA1 and CA3 pyramidal cell layers of the hippocampus was significantly decreased by 619C89 administration. Treatment with this compound also significantly attenuated increases in GFAP-immunoreactivity in both ipsilateral and contralateral CA1 regions. The present results suggest a potential therapeutic role for sodium channel blockade and/or glutamate release inhibition in the treatment of TBI.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline		ALBERS GW, 1990, CLIN NEUROPHARMACOL, V13, P177, DOI 10.1097/00002826-199006000-00001; ANDERSON KJ, 1991, BRAIN RES, V562, P285, DOI 10.1016/0006-8993(91)90633-7; ANDERSON KJ, 1993, BRAIN RES, V622, P93, DOI 10.1016/0006-8993(93)90806-X; BUCHAN AM, 1990, CEREBROVAS BRAIN MET, V2, P1; BUCHAN AM, 1994, NEUROSCI LETT, V132, P255; BULLOCK R, 1994, J CEREBR BLOOD F MET, V14, P466, DOI 10.1038/jcbfm.1994.57; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P357; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; FADDIS BT, 1988, AM J ANAT, V183, P316, DOI 10.1002/aja.1001830405; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GASS P, 1993, J CEREBR BLOOD F MET, V13, P337, DOI 10.1038/jcbfm.1993.42; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; LIPTON SA, 1994, NEW ENGL J MED, V33, P613; LUSTIG HS, 1992, NEUROSCI LETT, V143, P229, DOI 10.1016/0304-3940(92)90271-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM B, 1990, BRAIN METAB REV, V2, P25; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; ORDY JM, 1993, EXP NEUROL, V119, P128, DOI 10.1006/exnr.1993.1014; Panter S. S., 1992, PRINCIPLES PRACTICE, P32; Paxinos G, 1986, RAT BRAIN STEREOTAXI; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; SHANK RP, 1981, LIFE SCI, V28, P837, DOI 10.1016/0024-3205(81)90044-8; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SHARPIRA Y, 1990, J NEUROTRAUM, V7, P131; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SIMON RP, 1992, EXCITAOTRY AMINO ACI, P241; SMITH SE, 1993, NEUROREPORT, V4, P1339, DOI 10.1097/00001756-199309150-00013; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P779, DOI 10.1016/0306-4522(89)90298-4; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q	46	61	62	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 27	1995	673	1					133	140		10.1016/0006-8993(94)01413-C			8	Neurosciences	Neurosciences & Neurology	QJ682	WOS:A1995QJ68200017	7757466				2021-06-18	
J	EVANS, RW; EVANS, RI; SHARP, MJ				EVANS, RW; EVANS, RI; SHARP, MJ			THE PHYSICIAN SURVEY ON THE POST-CONCUSSION AND WHIPLASH SYNDROMES	HEADACHE			English	Article						MILD HEAD INJURY; POST-CONCUSSION SYNDROME; WHIPLASH INJURIES	MINOR HEAD-INJURY; CAR ACCIDENTS; MILD; MANAGEMENT; SYMPTOMS	Background: The post-concussion syndrome (PCS) and whiplash syndrome (WS) have been controversial topics among physicians for many decades. There is little information available on the opinions and practices of physicians. Methods: In June of 1992, we performed a national survey by mail of the four physician groups most commonly treating these problems. The number of respondents and response rates were as follows: family physicians, 118, 16%; neurologists, 100, 21%; neurosurgeons, 97, 23%; orthopedists, 82, 13%. The survey instrument contained items on demographics, definitions, causation, prognosis, medico-legal aspects, testing, and treatment. Results: Only a minority of respondents believe that PCS and WS are clearly defined syndromes. A substantial minority report that psychogenic and litigation factors are most responsible for the conditions. Most of the physicians believe that PCS and WS have a 3-6 month recovery time. A significant minority concur that symptoms of the two syndromes resolve when litigation is settled. Most of the physicians order tests to rule out pathology although a minority order tests to reassure patients or because of litigation concerns. Only a minority of respondents believe that effective treatments are available. Not surprisingly, a multitude of conventional and unconventional treatments are sometimes recommended. Conclusions: Many aspects of PCS and WS are controversial among treating physicians. This controversy can have a profound impact on the quality and cost of patient care. Ongoing research is required to discover more effective treatments for mild brain injury and chronic pain.	UNIV TEXAS,SCH MED,DEPT NEUROL,HOUSTON,TX 77025; BAYLOR COLL MED,HOUSTON,TX 77030							[Anonymous], 1989, Neurology, V39, P1100; AUERBACH AH, 1967, DIS NERV SYST, V28, P110; BALLA JI, 1980, AUST NZ J SURG, V50, P610, DOI 10.1111/j.1445-2197.1980.tb04207.x; CARTLIDGE NEF, 1978, SCOT MED J, V23, P103, DOI 10.1177/003693307802300146; CROWE H, 1964, Calif Med, V100, P12; DACEY RG, 1989, MILD HEAD INJURY, P83; DEANS GT, 1987, INJURY, V18, P10, DOI 10.1016/0020-1383(87)90375-5; DEANS GT, 1986, BRIT MED J, V292, P94, DOI 10.1136/bmj.292.6513.94-a; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; EVANS RW, 1992, NEUROL CLIN, V10, P975; EVANS RW, 1992, NEUROL CLIN, V10, P815; EVANS RW, 1994, IN PRESS SEMIN NEURO, V14; Evans RW., 1992, PROGNOSIS NEUROLOGIC, P97; EVANS RW, 1992, PROGNOSIS NEUROLOGIC, P621; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; HILDINGSSON C, 1990, ACTA ORTHOP SCAND, V61, P357, DOI 10.3109/17453679008993536; Jennett B, 1990, HDB CLIN NEUROLOGY, V13, P1; JENNETT B, 1992, PROGNOSIS NEUROLOGIC, P85; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kraus JF, 1993, HEAD INJURY, P1; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; MCKINNEY LA, 1989, ARCH EMERG MED, V6, P27; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MEALY K, 1986, BRIT MED J, V292, P656, DOI 10.1136/bmj.292.6521.656; MENDELSON G, 1982, MED J AUSTRALIA, V2, P132, DOI 10.5694/j.1326-5377.1982.tb124267.x; ONEIL B, 1972, AM J PUBLIC HEALTH, V62, P403; PENNIE BH, 1990, J BONE JOINT SURG BR, V72, P277; PRIGATANO GP, 1993, NEUROL CLIN, V11, P219; RUTHERFORD WH, 1978, INJURY, V10, P225; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; 1992, ACCIDENT FACTS ITASA, P63	37	61	61	0	5	AMER ASSOC STUDY HEADACHE	WOODBURY	875 KINGS HIGHWAY, STE 200, WOODBURY, NJ 08096	0017-8748			HEADACHE	Headache	MAY	1994	34	5					268	274		10.1111/j.1526-4610.1994.hed3405268.x			7	Clinical Neurology	Neurosciences & Neurology	NM276	WOS:A1994NM27600006	8026944				2021-06-18	
J	HARIRI, RJ; FIRLICK, AD; SHEPARD, SR; COHEN, DS; BARIE, PS; EMERY, JM; GHAJAR, JBG				HARIRI, RJ; FIRLICK, AD; SHEPARD, SR; COHEN, DS; BARIE, PS; EMERY, JM; GHAJAR, JBG			TRAUMATIC BRAIN INJURY, HEMORRHAGIC-SHOCK, AND FLUID RESUSCITATION - EFFECTS ON INTRACRANIAL-PRESSURE AND BRAIN COMPLIANCE	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; HYPOTENSION; INTRACRANIAL HYPERTENSION; RESUSCITATION; BRAIN COMPLIANCE; INTRACRANIAL PRESSURE	HEAD-INJURY; HYPERTONIC SALINE; SYSTEM; EPIDEMIOLOGY; DEATHS; MODEL	Intracranial hypertension following traumatic brain injury is associated with considerable morbidity and mortality. Hemorrhagic hypovolemia commonly coexists with head injury in this population of patients. Therapy directed at correcting hypovolemic shock includes vigorous volume expansion with crystalloid' solutions. It is hypothesized that, following traumatic brain injury, cerebrovascular dysfunction results in rapid loss of brain compliance, resulting in increased sensitivity to cerebrovascular venous pressure. Increased central venous pressure (CVP) occurring with vigorous crystalloid resuscitation may therefore contribute to the loss of brain compliance and the development of intracranial hypertension. The authors tested this hypothesis in miniature swine subjected to traumatic brain injury, hemorrhage, and resuscitation. Elevated CVP following resuscitation from hemorrhage to a high CVP significantly worsened intracranial hypertension in animals with concurrent traumatic brain injury, as compared to animals subjected to traumatic brain injury alone (mean +/- standard error of the mean: 33.0 +/- 2.0 vs. 20.0 +/- 2.0 mm Hg, p < 0.05) or to animals subjected to the combination of traumatic brain injury, hemorrhage, and resuscitation to a low CVP (33.0 +/- 2.0 vs. 24.0 +/- 2.0 mm Hg, p < 0.05). These data support the hypothesis that reduction in brain compliance can occur secondary to elevation of CVP following resuscitation from hemorrhagic shock. This may worsen intracranial hypertension in patients with traumatic brain injury and hemorrhagic shock.		HARIRI, RJ (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT SURG,DIV NEUROSURG,AITKEN NEUROSURG LAB,1300 YORK AVE,NEW YORK,NY 10021, USA.		Barie, Philip/AAN-8811-2020				ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; CRENSHAW C A, 1962, Surg Forum, V13, P6; CROCKARD A, 1979, NEURAL TRAUMA, P19; EISENBERG HM, 1985, CENTRAL NERVOUS SYST, P271; FUJITA K, 1984, BRAIN EDEMA, P228; GHAJAR JBG, 1985, J NEUROSURG, V63, P985, DOI 10.3171/jns.1985.63.6.0985; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; GUNNAR W, 1988, SURGERY, V103, P398; HARIRI RJ, 1989, ANESTH ANALG, V68, pS115; Huizenga KA, 1943, J PHARMACOL EXP THER, V78, P139; JOHNSTON I, 1975, INTRACRANIAL PRESSUR, V2, P50; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KING AS, 1989, JAMA-J AM MED ASSOC, V262, P2195, DOI 10.1001/jama.262.16.2195; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MARSHALL LF, 1982, CLIN NEUR, V29, P312; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; SATO S, 1984, BRAIN EDEMA, P235; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHIRES GT, 1972, ANN SURG, V176, P288, DOI 10.1097/00000658-197209000-00004; SHIRES T, 1964, ARCH SURG-CHICAGO, V88, P688; SMITH D R, 1969, Journal of Neurosurgery, V30, P664, DOI 10.3171/jns.1969.30.6.0664; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TODD MM, 1984, ANESTSIOLOGY, V61, P122; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	34	61	62	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1993	79	3					421	427		10.3171/jns.1993.79.3.0421			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	LU690	WOS:A1993LU69000017	8360740				2021-06-18	
J	YOSHINO, A; HOVDA, DA; KATAYAMA, Y; KAWAMATA, T; BECKER, DP				YOSHINO, A; HOVDA, DA; KATAYAMA, Y; KAWAMATA, T; BECKER, DP			HIPPOCAMPAL CA3 LESION PREVENTS POSTCONCUSSIVE METABOLIC DYSFUNCTION IN CA1	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						CEREBRAL CONCUSSION; 2-DEOXY-DEUTERIUM-GLUCOSE AUTORADIOGRAPHY; EXCITATORY AMINO ACIDS; GLUCOSE METABOLISM; GLUTAMATE; HIPPOCAMPUS	CEREBRAL GLUCOSE-UTILIZATION; TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; RAT-BRAIN; BLOOD-FLOW; EXTRACELLULAR POTASSIUM; PYRAMIDAL CELLS; AMINO-ACIDS; HEAD-INJURY; ISCHEMIA	Immediately following fluid-percussion (F-P) brain injury, the hippocampus exhibits a marked increase in its local CMR(glc) (LCMR(glc); mumol/100 g/min) as determined using [C-14]2-deoxy-D-glucose autoradiography This injury-induced increase in metabolism is followed in 6 h by a subsequent decrease in LCMR(glc). These two postinjury metabolic states may be the result of ionic disruptions following trauma via stimulation of glutamategated ion channels. To determine if endogenous glutamate innervation to the CA, region of the hippocampus can provide an anatomical basis for this proposed mechanism, it was removed by kainic-acid-induced destruction of CA3, and the effect on CA, metabolism following concussive injury was studied. Five days before a lateral F-P injury (3.5-4.5 atm), kainic acid (0.5 mug) or vehicle was stereotaxically injected into the left ventricle of 65 rats. Histological inspection indicated that kainic acid produced severe cell loss primarily in the CA1 region of the hippocampus ipsilateral to the injection. The metabolic results indicated that immediately following injury, animals with an intact hippocampus exhibited an increase in LCMR(glc) to 84.6 +/- 5 within the CA1 region, representing a 81.5% increase over controls. However, in the CA3-lesioned animals, CA1 showed no evidence of an injury-induced hypermetabolism, with LCMR(glc) remaining at control levels (51.4 +/- 3.9). At 6 h postinjury, the intact hippocampus exhibited a reduction of LCMR(glc) to rates of 40.7 +/- 4.7 within the CA1 region, representing a 17.9% reduction compared with controls. In contrast, CA3-lesioned animals exhibited less of an injury-induced decrease in LCMR(glc) within the CA1 region, exhibiting a mean rate of 43.4 +/- 4.5, representing only a 12.5% reduction compared with controls. These results indicate that the removal of the CA3 projection to CA1 protects the CA1 cells from the metabolic dysfunction typically seen following injury. This supports our previous work indicating the important role glutamate plays in the ionic flux and subsequent metabolic changes that follow traumatic brain injury.	UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROSURG, 74-140 CHS, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST BRAIN RES, LOS ANGELES, CA 90024 USA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27544, NS30308] Funding Source: Medline		ANDERSEN BJ, 1989, J CEREB BLOOD FLOW M, V9, pS386; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; GINSBERG M D, 1979, Acta Neurologica Scandinavica Supplementum, V60, P226; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1991, J CEREB BLOOD FLO S2, V11, pS315; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JORGENSEN MB, 1990, J CEREBR BLOOD F MET, V10, P243, DOI 10.1038/jcbfm.1990.41; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KUSHNER M, 1984, ANN NEUROL, V15, P425, DOI 10.1002/ana.410150505; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; NADLER JV, 1976, NATURE, V260, P538, DOI 10.1038/260538a0; NAKAI H, 1988, NEUROL MED CHIR TOKY, V528, P11; NEDERGAARD M, 1988, J CEREBR BLOOD F MET, V8, P100, DOI 10.1038/jcbfm.1988.13; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; ONODERA H, 1988, NEUROSCI LETT, V89, P90, DOI 10.1016/0304-3940(88)90486-7; ONODERA H, 1986, NEUROSCI LETT, V68, P169, DOI 10.1016/0304-3940(86)90136-9; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PAPPIUS HM, 1983, J CEREBR BLOOD F MET, V3, P448, DOI 10.1038/jcbfm.1983.71; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PAPPIUS HM, 1988, METAB BRAIN DIS, V3, P303, DOI 10.1007/BF00999542; PAPPIUS HM, 1982, ANN NEUROL, V12, P157, DOI 10.1002/ana.410120205; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SHIRAISHI K, 1989, J CEREBR BLOOD F MET, V9, P765, DOI 10.1038/jcbfm.1989.110; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STEVENS MK, 1990, J CEREBR BLOOD F MET, V10, P77, DOI 10.1038/jcbfm.1990.10; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; THOMAS M J, 1990, Society for Neuroscience Abstracts, V16, P777; THOMAS S, 1991, Society for Neuroscience Abstracts, V17, P166; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	49	61	61	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	1992	12	6					996	1006		10.1038/jcbfm.1992.137			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	JT803	WOS:A1992JT80300012	1356995	Bronze			2021-06-18	
J	BROUWER, WH; PONDS, RWHM; VANWOLFFELAAR, PC; VANZOMEREN, AH				BROUWER, WH; PONDS, RWHM; VANWOLFFELAAR, PC; VANZOMEREN, AH			DIVIDED ATTENTION 5 TO 10 YEARS AFTER SEVERE CLOSED HEAD-INJURY	CORTEX			English	Article									STATE UNIV LIMBURG,DEPT NEUROPSYCHOL & PSYCHOBIOL,6200 MD MAASTRICHT,NETHERLANDS; TRAFF RES CTR,HAREN,NETHERLANDS	BROUWER, WH (corresponding author), ACAD HOSP,NEUROPSYCHOL UNIT,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.						BROUWER WH, 1985, THESIS U GRONINGEN; DENCKER SJ, 1958, ACTA PSYCHIATRI S122, V33; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P335; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HOPEWELL CA, 1985, J CLIN EXP NEUROPSYC, V7, P148; Luteijn F., 1983, Handleiding Groninger Intelligentie Test [Manual Groningen Intelligence Test]; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; Miller E, 1970, Cortex, V6, P121; Ponds R. W. H. M., 1988, J GERONTOL, V43, P151; REITAN RM, 1958, PERCEPT MOTOR SKILL, V8, P272; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SOMBERG BL, 1982, J EXP PSYCHOL HUMAN, V8, P651, DOI 10.1037/0096-1523.8.5.651; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANWOLFFELAAR P, 1988, ROAD USER BEHAVIOUR, P302; VANWOLFFELAAR PC, 1988, TRACKING TASK DRIVIN; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Wickens C.D., 1984, VARIETIES ATTENTION, P63, DOI 10.1038/s41598-020-80452-5	24	61	61	0	6	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	JUN	1989	25	2					219	230		10.1016/S0010-9452(89)80038-3			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	AD216	WOS:A1989AD21600004	2758848				2021-06-18	
J	CULLUM, CM; BIGLER, ED				CULLUM, CM; BIGLER, ED			VENTRICLE SIZE, CORTICAL ATROPHY AND THE RELATIONSHIP WITH NEUROPSYCHOLOGICAL STATUS IN CLOSED HEAD-INJURY - A QUANTITATIVE-ANALYSIS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									AUSTIN NEUROLOG CLIN,CTR MED SCI,BLDG F,711 W 38TH ST,AUSTIN,TX 78705; UNIV TEXAS,AUSTIN,TX 78712			Cullum, C. Munro/AAC-2496-2019	Cullum, C. Munro/0000-0001-9706-5465			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BIGLER ED, 1985, J NERV MENT DIS, V173, P347, DOI 10.1097/00005053-198506000-00004; BIGLER ED, 1984, INT J NEUROSCI, V24, P295, DOI 10.3109/00207458409089820; BIRD JM, 1982, PROG NEUROBIOL, V19, P91, DOI 10.1016/0301-0082(82)90022-3; Blinkov S. M., 1968, HUMAN BRAIN FIGURES; BOLLER FC, 1972, J NEUROL NEUROSUR PS, V35, P463, DOI 10.1136/jnnp.35.4.463; BRASSOW F, 1978, NEURORADIOLOGY, V16, P187, DOI 10.1007/BF00395246; BRINKMAN SD, 1981, RADIOLOGY, V138, P89, DOI 10.1148/radiology.138.1.7455102; BULL JW, 1961, NEUROLOGY, V11, P1; CULLUM CM, 1985, INT J NEUROSCI, V28, P279, DOI 10.3109/00207458508985395; DAMASIO H, 1983, ARCH NEUROL-CHICAGO, V40, P715, DOI 10.1001/archneur.1983.04050110033004; DELEON MJ, 1983, DEMENTIAS, P103; EARNEST MP, 1979, NEUROLOGY, V29, P1138, DOI 10.1212/WNL.29.8.1138; Evans WA, 1942, ARCH NEURO PSYCHIATR, V47, P931, DOI 10.1001/archneurpsyc.1942.02290060069004; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; HUCKMAN MS, 1975, NEURORADIOLOGY, V166, P85; JACOBY RJ, 1980, BRIT J PSYCHIAT, V136, P249, DOI 10.1192/bjp.136.3.249; Jennett B, 1981, MANAGEMENT HEAD INJU; JERNIGAN TL, 1979, RADIOLOGY, V132, P463, DOI 10.1148/132.2.463; KASZNIAK AW, 1979, NEUROLOGY, V29, P1273, DOI 10.1212/WNL.29.9_Part_1.1273; Kertesz A., 1983, LOCALIZATION NEUROPS; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; KOHLMEYER K, 1981, NEURORADIOLOGY, V20, P271; LAST RJ, 1953, BRIT J SURG, V40, P525, DOI 10.1002/bjs.18004016403; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LITTMAN EB, 1984, 12TH ANN M INT NEUR; MEESE W, 1980, NEURORADIOLOGY, V19, P131, DOI 10.1007/BF00342387; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; ROBERTS MA, 1976, J NEUROL NEUROSUR PS, V39, P986, DOI 10.1136/jnnp.39.10.986; Rosenzweig M. R., 1982, PHYSL PSYCHOL; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; SNOEK J, 1979, J NEUROL NEUROSUR PS, V42, P215, DOI 10.1136/jnnp.42.3.215; SYNEK V, 1976, BRIT J RADIOL, V49, P233, DOI 10.1259/0007-1285-49-579-233; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; TURKHEIMER E, 1984, J NEUROL NEUROSUR PS, V47, P1314, DOI 10.1136/jnnp.47.12.1314; TURKHEIMER E, 1983, BEHAV RES METH INSTR, V15, P471, DOI 10.3758/BF03203689; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; Wechsler D., 2008, WECHSLER ADULT INTEL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WU S, 1981, NEUROLOGY, V31, P1180, DOI 10.1212/WNL.31.9.1180; YEO RA, 1984, INT J NEUROSCI, V24, P299, DOI 10.3109/00207458409089821; YEO RA, 1983, CLIN NEUROPSYCHOLOGY, V5, P45	45	61	61	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1986	8	4					437	452		10.1080/01688638608401333			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	D6021	WOS:A1986D602100010	3745416				2021-06-18	
J	LEVIN, HS; HIGH, WM; EISENBERG, HM				LEVIN, HS; HIGH, WM; EISENBERG, HM			IMPAIRMENT OF OLFACTORY RECOGNITION AFTER CLOSED HEAD-INJURY	BRAIN			English	Article										LEVIN, HS (corresponding author), UNIV TEXAS, MED BRANCH, DIV NEUROSURG E-17, GALVESTON, TX 77550 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889, NS 07377] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ABRAHAM A, 1983, NEUROPSYCHOLOGIA, V21, P277, DOI 10.1016/0028-3932(83)90045-3; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; [Anonymous], 1942, Proc R Soc Med, V35, P601; Benton AL, 1978, MULTILINGUAL APHASIA; Brodal A, 1981, NEUROLOGICAL ANATOMY; Cain W S, 1979, Neurol Res, V1, P1; CAIN WS, 1979, SCIENCE, V203, P467, DOI 10.1126/science.760202; EICHENBAUM H, 1983, BRAIN, V106, P459, DOI 10.1093/brain/106.2.459; ESKENAZI B, 1983, NEUROPSYCHOLOGIA, V21, P365, DOI 10.1016/0028-3932(83)90023-4; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; Holbourn AHS, 1943, LANCET, V2, P438; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JONES BP, 1978, NEUROPSYCHOLOGIA, V16, P323, DOI 10.1016/0028-3932(78)90026-X; Leigh AD, 1943, LANCET, V1, P38; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; PINCHING AJ, 1977, BRAIN, V100, P377, DOI 10.1093/brain/100.2.377; POTTER H, 1979, NEUROSCIENCE, V4, P361, DOI 10.1016/0306-4522(79)90099-X; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; RAUSCH R, 1977, CORTEX, V13, P445, DOI 10.1016/S0010-9452(77)80024-5; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1960, INJURIES BRAIN SPINA, P118; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; SUMNER D, 1962, LANCET, V2, P895; TANABE T, 1975, J NEUROPHYSIOL, V38, P1284; TEASDALE G, 1974, LANCET, V2, P81; VENSTROM D, 1968, J FOOD SCI, V33, P264, DOI 10.1111/j.1365-2621.1968.tb01364.x	28	61	62	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain		1985	108	SEP					579	591		10.1093/brain/108.3.579			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AQV77	WOS:A1985AQV7700002	4041775				2021-06-18	
J	GROAT, RA; WINDLE, WF; MAGOUN, HW				GROAT, RA; WINDLE, WF; MAGOUN, HW			FUNCTIONAL AND STRUCTURAL CHANGES IN THE MONKEYS BRAIN DURING AND AFTER CONCUSSION	JOURNAL OF NEUROSURGERY			English	Article																Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Groat RA, 1944, AM J PHYSIOL, V141, P0117; JAKOB A, 1913, HISTOLOGISCHE HISTOP, V5, P182; Shelden CH, 1944, J NEUROSURG, V1, P67, DOI 10.3171/jns.1944.1.1.0067; SHELDEN CH, 1944, 70TH PROGR AM NEUR A, P40; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561	7	61	61	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1945	2	1					26	35		10.3171/jns.1945.2.1.0026			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	UN052	WOS:A1945UN05200004					2021-06-18	
J	Iglesias, J; Morales, L; Barreto, GE				Iglesias, Jose; Morales, Ludis; Barreto, George E.			Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs	MOLECULAR NEUROBIOLOGY			English	Article						Astrogliosis; PPAR; Glycolysis; Fatty acid oxidation; Ketone bodies; Glutamate; Neuroprotection	ACTIVATED-RECEPTOR-GAMMA; CENTRAL-NERVOUS-SYSTEM; PENTOSE-PHOSPHATE PATHWAY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CHONDROITIN SULFATE PROTEOGLYCANS; FIBRILLARY ACIDIC PROTEIN; FOCAL CEREBRAL-ISCHEMIA; RAT-BRAIN ASTROCYTES; GLUCOSE-UPTAKE; PYRUVATE CARBOXYLATION	Astrocyte-mediated inflammation is associated with degenerative pathologies such as Alzheimer's and Parkinson's diseases and multiple sclerosis. The acute inflammation and morphological and metabolic changes that astrocytes develop after the insult are known as reactive astroglia or astrogliosis that is an important response to protect and repair the lesion. Astrocytes optimize their metabolism to produce lactate, glutamate, and ketone bodies in order to provide energy to the neurons that are deprived of nutrients upon insult. Firstly, we review the basis of inflammation and morphological changes of the different cell population implicated in reactive gliosis. Next, we discuss the more active metabolic pathways in healthy astrocytes and explain the metabolic response of astrocytes to the insult in different pathologies and which metabolic alterations generate complications in these diseases. We emphasize the role of peroxisome proliferator-activated receptors isotypes in the inflammatory and metabolic adaptation of astrogliosis developed in ischemia or neurodegenerative diseases. Based on results reported in astrocytes and other cells, we resume and hypothesize the effect of peroxisome proliferator-activated receptor (PPAR) activation with ligands on different metabolic pathways in order to supply energy to the neurons. The activation of selective PPAR isotype activity may serve as an input to better understand the role played by these receptors on the metabolic and inflammatory compensation of astrogliosis and might represent an opportunity to develop new therapeutic strategies against traumatic brain injuries and neurodegenerative diseases.	[Iglesias, Jose; Morales, Ludis; Barreto, George E.] Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, DC, Colombia; [Barreto, George E.] Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile; [Barreto, George E.] Univ Cient Sur, Lima, Peru	Iglesias, J (corresponding author), Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, DC, Colombia.	joseiglesias@javeriana.edu.co	Barreto, George E./B-5747-2014; Morales, Ludis/AAZ-7053-2020; Barreto, George E./AAD-7420-2020	Barreto, George E./0000-0002-6644-1971; Barreto, George E./0000-0002-6644-1971	Pontificia Universidad Javeriana	JE and GEB' work is supported by Pontificia Universidad Javeriana.	Aguirre-Rueda D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122843; Aguirre-Rueda D, 2015, INT J MED SCI, V12, P48, DOI 10.7150/ijms.10035; Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aleshin S, 2014, MOL CELL NEUROSCI, V59, P127, DOI 10.1016/j.mcn.2014.01.008; Allaman I, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00023; Allaman I, 2010, J NEUROSCI, V30, P3326, DOI 10.1523/JNEUROSCI.5098-09.2010; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Amaral AI, 2013, J INHERIT METAB DIS, V36, P621, DOI 10.1007/s10545-012-9553-3; Amaral Ana I, 2011, Front Neuroenergetics, V3, P5, DOI 10.3389/fnene.2011.00005; Amaral AI, 2010, J NEUROCHEM, V113, P735, DOI 10.1111/j.1471-4159.2010.06636.x; Anbalagan Muralidharan, 2012, Nucl Recept Signal, V10, pe001, DOI 10.1621/nrs.10001; Anderson MA, 2014, NEUROSCI LETT, V565, P23, DOI 10.1016/j.neulet.2013.12.030; Posada-Duque RA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00231; ASHWELL K, 1990, DEV BRAIN RES, V55, P219, DOI 10.1016/0165-3806(90)90203-B; Atsumi T, 2005, DIABETES, V54, P3349, DOI 10.2337/diabetes.54.12.3349; AUESTAD N, 1991, J NEUROCHEM, V56, P1376, DOI 10.1111/j.1471-4159.1991.tb11435.x; Rodriguez MA, 2014, J STEROID BIOCHEM, V144, P294, DOI 10.1016/j.jsbmb.2014.07.009; Bachoo RM, 2004, P NATL ACAD SCI USA, V101, P8384, DOI 10.1073/pnas.0402140101; Badeau RM, 2014, ANN MED, V46, P18, DOI 10.3109/07853890.2013.853369; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Barish GD, 2008, P NATL ACAD SCI USA, V105, P4271, DOI 10.1073/pnas.0711875105; Barreto G, 2007, EUR J NEUROSCI, V25, P3039, DOI 10.1111/j.1460-9568.2007.05563.x; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Barreto G, 2009, ENDOCRINOLOGY, V150, P5010, DOI 10.1210/en.2009-0352; Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132; Barreto GE, 2014, NEUROSCI LETT, V565, P1, DOI 10.1016/j.neulet.2014.01.052; Barreto GE, 2012, EXP NEUROL, V238, P284, DOI 10.1016/j.expneurol.2012.08.015; Barreto GE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027881; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Barros LF, 2010, BRAIN RES REV, V63, P149, DOI 10.1016/j.brainresrev.2009.10.002; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Becher B, 2000, GLIA, V29, P293; Benarroch EE, 2014, NEUROLOGY, V82, P1374, DOI 10.1212/WNL.0000000000000328; Benito C, 2012, BRIT J PHARMACOL, V166, P1474, DOI 10.1111/j.1476-5381.2012.01889.x; Berkich DA, 2007, J NEUROSCI RES, V85, P3367, DOI 10.1002/jnr.21500; Beurrier C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008550; Bezzi P, 2011, CELL, V144, P644, DOI 10.1016/j.cell.2011.02.027; Bigl M, 1999, J NEURAL TRANSM, V106, P499, DOI 10.1007/s007020050174; Bigl M, 2003, J NEURAL TRANSM, V110, P77, DOI 10.1007/s00702-002-0772-x; Blazquez C, 1999, J NEUROCHEM, V73, P1674, DOI 10.1046/j.1471-4159.1999.731674.x; Boneva NB, 2011, HIPPOCAMPUS, V21, P162, DOI 10.1002/hipo.20732; Bouzier-Sore AK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00179; Bramanti Vincenzo, 2010, Front Biosci (Schol Ed), V2, P558; Brekke EMF, 2014, J CEREBR BLOOD F MET, V34, P724, DOI 10.1038/jcbfm.2014.8; Brown AM, 2007, GLIA, V55, P1263, DOI 10.1002/glia.20557; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Cabezas R, 2015, MED CHEM; Cabezas R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00211; Cabezas R, 2012, NEUROSCI RES, V74, P80, DOI 10.1016/j.neures.2012.07.008; Cabodevilla AG, 2013, J BIOL CHEM, V288, P27777, DOI 10.1074/jbc.M113.466656; CADELLI DS, 1992, EXP NEUROL, V115, P189, DOI 10.1016/0014-4886(92)90246-M; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; CHAMAK B, 1994, J NEUROSCI RES, V38, P221, DOI 10.1002/jnr.490380213; Chen RQ, 2012, CELL REP, V2, P1329, DOI 10.1016/j.celrep.2012.09.030; Chen SH, 2015, GLIA, V63, P118, DOI 10.1002/glia.22738; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Cheong SJ, 2015, NUCL MED BIOL, V42, P85, DOI 10.1016/j.nucmedbio.2014.08.013; Ching J, 2015, J CLIN NEUROSCI, V22, P21, DOI 10.1016/j.jocn.2014.09.001; Chistyakov DV, 2015, J NEUROCHEM, V134, P113, DOI 10.1111/jnc.13101; Choi JW, 2004, J NEUROSCI RES, V75, P722, DOI 10.1002/jnr.20009; Chuquet J, 2010, J NEUROSCI, V30, P15298, DOI 10.1523/JNEUROSCI.0762-10.2010; Cimini A, 2005, NEUROSCIENCE, V130, P325, DOI 10.1016/j.neuroscience.2004.09.043; Cimini A, 2008, STEM CELL REV, V4, P293, DOI 10.1007/s12015-008-9024-2; Correa F, 2011, NEUROBIOL DIS, V44, P142, DOI 10.1016/j.nbd.2011.06.016; Cristiano L, 2005, NEUROSCIENCE, V131, P577, DOI 10.1016/j.neuroscience.2004.11.008; Cristiano L, 2001, J NEUROCYTOL, V30, P671, DOI 10.1023/A:1016525716209; Cullingford TE, 2004, PROSTAG LEUKOTR ESS, V70, P253, DOI 10.1016/j.plefa.2003.09.008; Cullingford TE, 2002, NEUROPHARMACOLOGY, V42, P724, DOI 10.1016/S0028-3908(02)00014-X; Cunnane S, 2011, NUTRITION, V27, P3, DOI 10.1016/j.nut.2010.07.021; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Defaux A, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-15; Deitmer JW, 2000, BIOESSAYS, V22, P747, DOI 10.1002/1521-1878(200008)22:8<747::AID-BIES8>3.0.CO;2-0; del Rio-Hortega P, 1919, B SOC ESP BIOL, V9, P69; Del Rio-Hortega P., 1920, TRAB LAB INVEST BIOL, V18, P37; Dello Russo C, 2003, J BIOL CHEM, V278, P5828, DOI 10.1074/jbc.M208132200; Deng YY, 2010, BRAIN PATHOL, V20, P909, DOI 10.1111/j.1750-3639.2010.00387.x; Di Cesare ML, 2014, BIOMED RES INT, V2014, DOI [10.1155/2014/546453, DOI 10.1155/2014/546453]; Dienel GA, 2013, NEUROCHEM INT, V63, P244, DOI 10.1016/j.neuint.2013.06.015; Dill J, 2010, J NEUROSCI, V30, P963, DOI 10.1523/JNEUROSCI.5045-09.2010; Ding F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079977; Ding S, 2014, NEURAL REGEN RES, V9, P2048, DOI 10.4103/1673-5374.147929; Ding YS, 2014, PROG MOL BIOL TRANSL, V121, P451, DOI 10.1016/B978-0-12-800101-1.00014-4; DiNuzzo M, 2013, NEUROCHEM INT, V63, P458, DOI 10.1016/j.neuint.2013.08.004; DiNuzzo M, 2011, BIOESSAYS, V33, P319, DOI 10.1002/bies.201000151; Diradourian C, 2005, BIOCHIMIE, V87, P33, DOI 10.1016/j.biochi.2004.11.010; Drew PD, 2006, NEUROCHEM INT, V49, P183, DOI 10.1016/j.neuint.2006.04.003; Ebert D, 2003, J NEUROSCI, V23, P5928; El Kadmiri N, 2014, PATHOL BIOL, V62, P333, DOI 10.1016/j.patbio.2014.08.002; ELLISON JA, 1995, GLIA, V14, P123, DOI 10.1002/glia.440140207; Escartin C, 2006, J NEUROSCI, V26, P5978, DOI 10.1523/JNEUROSCI.0302-06.2006; Esposito E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041880; Fandel D, 2013, BRAIN RES, V1535, P89, DOI 10.1016/j.brainres.2013.08.022; Barros LF, 2013, TRENDS NEUROSCI, V36, P396, DOI 10.1016/j.tins.2013.04.002; Festuccia WT, 2009, J LIPID RES, V50, P1185, DOI 10.1194/jlr.M800620-JLR200; FINSEN BR, 1993, GLIA, V7, P41, DOI 10.1002/glia.440070109; Floyd ZE, 2012, BBA-MOL BASIS DIS, V1822, P1090, DOI 10.1016/j.bbadis.2012.03.014; Franke H, 2014, NEUROSCI LETT, V565, P14, DOI 10.1016/j.neulet.2013.09.056; Frigerio F, 2012, J NEUROCHEM, V123, P342, DOI 10.1111/j.1471-4159.2012.07933.x; FRISEN J, 1994, EXP NEUROL, V129, P183, DOI 10.1006/exnr.1994.1160; Fu W, 2015, J BIOL CHEM, V290, P12504, DOI 10.1074/jbc.M114.618157; Fu W, 2014, BIOGERONTOLOGY, V15, P579, DOI 10.1007/s10522-014-9525-0; Gao C, 2015, NEUROSCI LETT, V594, P99, DOI 10.1016/j.neulet.2015.03.062; Garcia MD, 2003, J NEUROCHEM, V86, P709, DOI 10.1046/j.1471-4159.2003.01892.x; Garcia-Bueno B, 2007, NEUROPSYCHOPHARMACOL, V32, P1251, DOI 10.1038/sj.npp.1301252; Gibbs ME, 2009, J NEUROCHEM, V109, P230, DOI 10.1111/j.1471-4159.2009.05800.x; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; Grygiel-Gorniak B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-17; Gubern A, 2009, J BIOL CHEM, V284, P32359, DOI 10.1074/jbc.M109.061515; Guo X, 2010, J BIOL CHEM, V285, P23711, DOI 10.1074/jbc.M110.123174; Gupta M, 2015, ARCH DERMATOL RES, V307, P767, DOI 10.1007/s00403-015-1571-1; Guzman M, 2001, TRENDS ENDOCRIN MET, V12, P169, DOI 10.1016/S1043-2760(00)00370-2; Haemmerle G, 2011, NAT MED, V17, P1076, DOI 10.1038/nm.2439; Halim ND, 2010, GLIA, V58, P1168, DOI 10.1002/glia.20996; Hamby ME, 2012, J NEUROSCI, V32, P14489, DOI 10.1523/JNEUROSCI.1256-12.2012; Hertz L, 2007, J CEREBR BLOOD F MET, V27, P219, DOI 10.1038/sj.jcbfm.9600343; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Hihi AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/s00018-002-8467-x; Hoft S, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0602; Hol EM, 2015, CURR OPIN CELL BIOL, V32, P121, DOI 10.1016/j.ceb.2015.02.004; Iglesias J, 2012, J CLIN INVEST, V122, P4105, DOI 10.1172/JCI42127; INNOCENTI GM, 1983, DEV BRAIN RES, V11, P55, DOI 10.1016/0165-3806(83)90201-8; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Itoh Y, 2003, P NATL ACAD SCI USA, V100, P4879, DOI 10.1073/pnas.0831078100; Izawa Y, 2009, BRAIN RES, V1305, P64, DOI 10.1016/j.brainres.2009.09.098; Januszewicz E, 2009, INT J BIOCHEM CELL B, V41, P2599, DOI 10.1016/j.biocel.2009.08.020; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; Jha MK, 2013, BBA-PROTEINS PROTEOM, V1834, P2418, DOI 10.1016/j.bbapap.2012.12.006; Joiner TE, 2002, J PERS ASSESS, V79, P472, DOI 10.1207/S15327752JPA7903_05; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Juliet PAR, 2008, BRAIN RES, V1210, P230, DOI 10.1016/j.brainres.2008.02.099; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796; Khatchadourian A, 2012, BBA-MOL CELL BIOL L, V1821, P607, DOI 10.1016/j.bbalip.2012.01.007; Kim TH, 2013, YONSEI MED J, V54, P545, DOI 10.3349/ymj.2013.54.3.545; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Konig B, 2008, BBA-GEN SUBJECTS, V1780, P899, DOI 10.1016/j.bbagen.2008.03.002; Korenic A, 2015, NEUROSCI LETT, V595, P128, DOI 10.1016/j.neulet.2015.04.020; Kostadinova R, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-34; Koyama Y, 2014, NEUROCHEM INT, V78, P35, DOI 10.1016/j.neuint.2014.08.005; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kumari R, 2010, J CEREBR BLOOD F MET, V30, P352, DOI 10.1038/jcbfm.2009.221; Kwok JCF, 2014, METHODS MOL BIOL, V1162, P127, DOI 10.1007/978-1-4939-0777-9_10; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lee CH, 2011, J NEUROL SCI, V300, P120, DOI 10.1016/j.jns.2010.09.005; Lee YM, 2010, ARCH PHARM RES, V33, P231, DOI 10.1007/s12272-010-0207-4; Li CY, 2015, NEUROCHEM INT, V83-84, P9, DOI 10.1016/j.neuint.2015.03.001; Li HL, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-58; Liao SL, 2013, J NEUROCHEM, V127, P271, DOI 10.1111/jnc.12291; Lleo A, 2007, CELL MOL LIFE SCI, V64, P1403, DOI 10.1007/s00018-007-6516-1; LOTAN M, 1994, EXP NEUROL, V126, P284, DOI 10.1006/exnr.1994.1066; Lovett-Racke AE, 2004, J IMMUNOL, V172, P5790, DOI 10.4049/jimmunol.172.9.5790; Mandrekar-Colucci S, 2012, J NEUROSCI, V32, P10117, DOI 10.1523/JNEUROSCI.5268-11.2012; Martin HL, 2013, NEUROSCIENCE, V240, P191, DOI 10.1016/j.neuroscience.2013.02.058; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; Mazzola JL, 2001, J NEUROCHEM, V76, P442, DOI 10.1046/j.1471-4159.2001.00033.x; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; McKenna MC, 1996, J NEUROCHEM, V66, P386; Michalik L, 2007, BBA-MOL CELL BIOL L, V1771, P991, DOI 10.1016/j.bbalip.2007.02.004; Michalik L, 2011, PROSTAG LEUKOTR ESS, V85, P235, DOI 10.1016/j.plefa.2011.04.016; Michalik L, 2008, PPAR RES, V2008, DOI 10.1155/2008/134059; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Moller T, 1997, J NEUROSCI, V17, P615; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Montagner Alexandra, 2013, Biomol Concepts, V4, P53, DOI 10.1515/bmc-2012-0035; Morken TS, 2014, NEUROCHEM RES, V39, P556, DOI 10.1007/s11064-013-1014-3; Murin R, 2008, NEUROCHEM RES, V33, P279, DOI 10.1007/s11064-007-9444-4; Murin R, 2009, NEUROCHEM RES, V34, P1195, DOI 10.1007/s11064-008-9895-2; Murin R, 2009, NEUROCHEM RES, V34, P194, DOI 10.1007/s11064-008-9840-4; Nadra K, 2006, MOL CELL BIOL, V26, P3266, DOI 10.1128/MCB.26.8.3266-3281.2006; Nagele RG, 2003, BRAIN RES, V971, P197, DOI 10.1016/S0006-8993(03)02361-8; Nakagawa Takayuki, 2013, Curr Mol Pharmacol, V6, P66; Nakajima K, 2007, NEUROCHEM INT, V50, P807, DOI 10.1016/j.neuint.2007.02.006; Nalecz Katarzyna A., 2004, Molecular Aspects of Medicine, V25, P551; Navarrete M, 2011, CELL, V146, P675, DOI 10.1016/j.cell.2011.08.006; Nehlig A, 2004, J CEREBR BLOOD F MET, V24, P1004, DOI 10.1097/01.WCB.0000128533.84196.D8; Nielsen R, 2008, GENE DEV, V22, P2953, DOI 10.1101/gad.501108; Paintlia MK, 2013, J BIOL CHEM, V288, P3831, DOI 10.1074/jbc.M112.405654; Pardo Beatriz, 2013, Front Endocrinol (Lausanne), V4, P149, DOI 10.3389/fendo.2013.00149; Pardo B, 2011, J CEREBR BLOOD F MET, V31, P90, DOI 10.1038/jcbfm.2010.146; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Pelton P, 2006, CURR OPIN INVEST DR, V7, P360; Perea G, 2014, FRONT CELL NEUROSCI, V8, DOI [10.3389/1ncel.2014.00378, 10.3389/fncel.2014.00378]; Perea G, 2009, TRENDS NEUROSCI, V32, P421, DOI 10.1016/j.tins.2009.05.001; Perez-Alvarez A, 2013, CURR DRUG TARGETS, V14, P1220; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Phatnani H, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020628; Polak PE, 2005, J NEUROIMMUNOL, V168, P65, DOI 10.1016/j.jneuroim.2005.07.006; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; Polazzi E, 2001, GLIA, V36, P271, DOI 10.1002/glia.1115; Porta N, 2009, EPILEPSIA, V50, P943, DOI 10.1111/j.1528-1167.2008.01901.x; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Properzi F, 2005, EUR J NEUROSCI, V21, P378, DOI 10.1111/j.1460-9568.2005.03876.x; Raso GM, 2011, J NEUROENDOCRINOL, V23, P591, DOI 10.1111/j.1365-2826.2011.02152.x; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Romero J, 2014, NEUROSCI LETT, V565, P42, DOI 10.1016/j.neulet.2013.10.046; Saez PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071361; Sahebkar A, 2014, EXPERT OPIN PHARMACO, V15, P493, DOI 10.1517/14656566.2014.876992; Sartoris D J, 1990, J Foot Surg, V29, P292; Sastre M, 2003, J NEUROSCI, V23, P9796; Sastre M, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-25; Sato T, 2011, NEUROBIOL AGING, V32, P1626, DOI 10.1016/j.neurobiolaging.2009.10.009; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; Sayan-Ozacmak H, 2011, CURR NEUROVASC RES, V8, P190, DOI 10.2174/156720211796558087; Schitine C, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00076; Schnegg CI, 2013, FREE RADICAL BIO MED, V61, P1, DOI 10.1016/j.freeradbiomed.2013.03.002; Sergeeva MG, 2010, J NEUROCHEM, V115, P399, DOI 10.1111/j.1471-4159.2010.06931.x; SHANK RP, 1985, BRAIN RES, V329, P364, DOI 10.1016/0006-8993(85)90552-9; Shen Y, 2014, REGUL PEPTIDES, V192, P45, DOI 10.1016/j.regpep.2014.08.005; Simard AR, 2007, J COMP NEUROL, V504, P716, DOI 10.1002/cne.21469; Simonini MV, 2010, ASN NEURO, V2, DOI 10.1042/AN20090033; Skripuletz T, 2013, BRAIN, V136, P147, DOI 10.1093/brain/aws262; Spagnolo A, 2007, NEUROSCI LETT, V417, P72, DOI 10.1016/j.neulet.2007.02.036; Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200; Sun H, 2012, NEUROL SCI, V33, P559, DOI 10.1007/s10072-011-0774-2; Sun XY, 2015, J NEUROSCI RES, V93, P1703, DOI 10.1002/jnr.23615; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Tabernero A, 2006, J NEUROCHEM, V99, P1049, DOI 10.1111/j.1471-4159.2006.04088.x; Taib B, 2013, J BIOL CHEM, V288, P37216, DOI 10.1074/jbc.M113.506238; Targett-Adams P, 2005, BBA-GENE STRUCT EXPR, V1728, P95, DOI 10.1016/j.bbaexp.2005.01.017; Tekkok SB, 2005, J NEUROSCI RES, V81, P644, DOI 10.1002/jnr.20573; Thoren AE, 2006, J NEUROCHEM, V97, P968, DOI 10.1111/j.1471-4159.2006.03778.x; Thorens B, 2015, DIABETOLOGIA, V58, P221, DOI 10.1007/s00125-014-3451-1; Tian GX, 2013, INT J IMMUNOPATH PH, V26, P757, DOI 10.1177/039463201302600320; Torrente D, 2014, HUM EXP TOXICOL, V33, P673, DOI 10.1177/0960327113509659; Tourino C, 2010, INT J OBESITY, V34, P557, DOI 10.1038/ijo.2009.262; TSACOPOULOS M, 1994, J NEUROSCI, V14, P1339; Tsukahara T, 2013, BIOCHEM BIOPH RES CO, V433, P281, DOI 10.1016/j.bbrc.2013.02.101; Vannucci SJ, 1998, DEV BRAIN RES, V107, P255, DOI 10.1016/S0165-3806(98)00021-2; Varnat F, 2006, GASTROENTEROLOGY, V131, P538, DOI 10.1053/j.gastro.2006.05.004; Verkhratsky A, 2013, GLIAL PHYSL PATHOPHY, P453; Verma R, 2011, J NEUROSCI RES, V89, P1849, DOI 10.1002/jnr.22710; Vorobyov V, 2013, J NEUROSCI, V33, P234, DOI 10.1523/JNEUROSCI.2283-12.2013; Waagepetersen HS, 2001, J NEUROSCI RES, V66, P763, DOI 10.1002/jnr.10061; Wadosky KM, 2012, AM J PHYSIOL-HEART C, V302, pH515, DOI 10.1152/ajpheart.00703.2011; Wahli W, 2012, TRENDS ENDOCRIN MET, V23, P351, DOI 10.1016/j.tem.2012.05.001; WALZ W, 1988, GLIA, V1, P366, DOI 10.1002/glia.440010603; Wang GM, 2011, NEUROSCI RES, V70, P230, DOI 10.1016/j.neures.2011.02.001; Wang HM, 2010, J ALZHEIMERS DIS, V20, P1189, DOI 10.3233/JAD-2010-091336; Wang P, 2008, BRAIN RES, V1236, P1, DOI 10.1016/j.brainres.2008.08.001; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Woods JW, 2003, BRAIN RES, V975, P10, DOI 10.1016/S0006-8993(03)02515-0; Xiong XX, 2015, STROKE, V46, P2271, DOI 10.1161/STROKEAHA.115.008897; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Xu JH, 2005, J NEUROSCI RES, V81, P403, DOI 10.1002/jnr.20518; Xu JH, 2007, J NEUROCHEM, V103, P1801, DOI 10.1111/j.1471-4159.2007.04875.x; Xu JH, 2007, J IMMUNOL, V178, P1904, DOI 10.4049/jimmunol.178.3.1904; Yao J, 2011, MOL ASPECTS MED, V32, P247, DOI 10.1016/j.mam.2011.10.005; Yawata I, 2008, LIFE SCI, V82, P1111, DOI 10.1016/j.lfs.2008.03.010; Yessoufou A, 2010, SWISS MED WKLY, V140, P4, DOI 10.4414/smw.2010.13071; Yudkoff M, 1997, GLIA, V21, P92, DOI 10.1002/(SICI)1098-1136(199709)21:1<92::AID-GLIA10>3.0.CO;2-W; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhao S, 2016, CELL REP; Zhao WH, 2006, J NEUROCHEM, V99, P1176, DOI 10.1111/j.1471-4159.2006.04172.x	267	60	61	4	57	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAY	2017	54	4					2518	2538		10.1007/s12035-016-9833-2			21	Neurosciences	Neurosciences & Neurology	ES1QY	WOS:000399303300015	26984740				2021-06-18	
J	Gu, S; Betzel, RF; Mattar, MG; Cieslak, M; Delio, PR; Grafton, ST; Pasqualetti, F; Bassett, DS				Gu, Shi; Betzel, Richard F.; Mattar, Marcelo G.; Cieslak, Matthew; Delio, Philip R.; Grafton, Scott T.; Pasqualetti, Fabio; Bassett, Danielle S.			Optimal trajectories of brain state transitions	NEUROIMAGE			English	Article						Network neuroscience; Control theory; Traumatic brain injury; Cognitive control; Diffusion imaging	INTERHEMISPHERIC FUNCTIONAL CONNECTIVITY; RESTING-STATE; DEFAULT-MODE; COGNITIVE IMPAIRMENT; DYNAMICAL-SYSTEMS; HUMAN CONNECTOME; MATTER; ORGANIZATION; NETWORKS; DISCONNECTION	The complexity of neural dynamics stems in part from the complexity of the underlying anatomy. Yet how white matter structure constrains how the brain transitions from one cognitive state to another remains unknown. Here we address this question by drawing on recent advances in network control theory to model the underlying mechanisms of brain state transitions as elicited by the collective control of region sets. We find that previously identified attention and executive control systems are poised to affect a broad array of state transitions that cannot easily be classified by traditional engineering-based notions of control. This theoretical versatility comes with a vulnerability to injury. In patients with mild traumatic brain injury, we observe a loss of specificity in putative control processes, suggesting greater susceptibility to neurophysiological noise. These results offer fundamental insights into the mechanisms driving brain state transitions in healthy cognition and their alteration following injury.	[Gu, Shi] Univ Penn, Appl Math & Computat Sci, Philadelphia, PA 19104 USA; [Gu, Shi; Betzel, Richard F.; Bassett, Danielle S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Mattar, Marcelo G.] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA; [Cieslak, Matthew; Delio, Philip R.; Grafton, Scott T.] Univ Calif Santa Barbara, Dept Psychol & Brain Sci, Santa Barbara, CA 93106 USA; [Delio, Philip R.] Neurol Associates Santa Barbara, Santa Barbara, CA 93105 USA; [Pasqualetti, Fabio] Univ Calif Riverside, Dept Mech Engn, Riverside, CA 92521 USA; [Bassett, Danielle S.] Univ Penn, Dept Elect & Syst Engn, Philadelphia, PA 19104 USA	Bassett, DS (corresponding author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.	dsb@seas.upenn.com	Pasqualetti, Fabio/H-5807-2013	Pasqualetti, Fabio/0000-0002-8457-8656; Mattar, Marcelo G/0000-0003-3303-2490	John D. and Catherine T. MacArthur Foundation; Alfred P. Sloan FoundationAlfred P. Sloan Foundation; Army Research LaboratoryUnited States Department of DefenseUS Army Research Laboratory (ARL); Army Research Office [W911NF-10-2-0022, W911NF-14-1-0679]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [2-R01-DC-009209-11]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R01HD086888-01]; Office of Naval ResearchOffice of Naval Research; National Science FoundationNational Science Foundation (NSF) [BCS-1441502, BCS-1430087, PHY-1554488, BCS 1430280]; Head Health Challenge grant from General Electric; National Football League [SB140165]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD086888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH106799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS099348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC009209] Funding Source: NIH RePORTER	D.S.B., S.G., and R.F.B. acknowledge support from the John D. and Catherine T. MacArthur Foundation, the Alfred P. Sloan Foundation, the Army Research Laboratory and the Army Research Office through Contract numbers W911NF-10-2-0022 and W911NF-14-1-0679, the National Institute of Mental Health (2-R01-DC-009209-11), the National Institute of Child Health and Human Development (1R01HD086888-01), the Office of Naval Research, and the National Science Foundation (BCS-1441502, BCS-1430087, and CAREER PHY-1554488). S.T.G. and P.R.D. acknowledge support from a Head Health Challenge grant from General Electric and the National Football League (SB140165). F.P. acknowledges support from the National Science Foundation award #BCS 1430280. The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding agencies.	Abdelnour F, 2014, NEUROIMAGE, V90, P335, DOI 10.1016/j.neuroimage.2013.12.039; Adachi Y., 2011, CEREBRAL CORTEX; Alavash M, 2015, HUM BRAIN MAPP, V36, P3542, DOI 10.1002/hbm.22861; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Bassett DS, 2015, NAT NEUROSCI, V18, P744, DOI 10.1038/nn.3993; Bassett DS, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003171; Bassett DS, 2011, P NATL ACAD SCI USA, V108, P7641, DOI 10.1073/pnas.1018985108; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Bassett DS, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000748; Betzel R.F., 2016, ARXIV160305261; Boltyanskii V.G.E., 1960, THEORY OPTIMAL PROCE; Braun U, 2015, HUMAN BRAIN NETWORKS; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Bzdok D, 2013, NEUROIMAGE, V81, P381, DOI 10.1016/j.neuroimage.2013.05.046; Cammoun L, 2012, J NEUROSCI METH, V203, P386, DOI 10.1016/j.jneumeth.2011.09.031; Carter AR, 2012, NEUROREHAB NEURAL RE, V26, P7, DOI 10.1177/1545968311411054; Ching SN, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.021920; Cieslak M, 2014, BRAIN IMAGING BEHAV, V8, P292, DOI 10.1007/s11682-013-9254-z; Cima RFF, 2014, J AM ACAD AUDIOL, V25, P29, DOI 10.3766/jaaa.25.1.4; Cocchi L, 2013, TRENDS COGN SCI, V17, P493, DOI 10.1016/j.tics.2013.08.006; Collin G, 2016, SCHIZOPHR RES, V173, P166, DOI 10.1016/j.schres.2015.03.012; Collin G, 2013, NEUROSCIENTIST, V19, P616, DOI 10.1177/1073858413503712; Cools R, 2011, BIOL PSYCHIAT, V69, pE113, DOI 10.1016/j.biopsych.2011.03.028; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Crofts JJ, 2009, J R SOC INTERFACE, V6, P411, DOI 10.1098/rsif.2008.0484; Daducci A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048121; Deco G, 2011, NAT REV NEUROSCI, V12, P43, DOI 10.1038/nrn2961; Di Martino A, 2014, NEURON, V83, P1335, DOI 10.1016/j.neuron.2014.08.050; Durstewitz D, 2008, EUR J NEUROSCI, V27, P217, DOI 10.1111/j.1460-9568.2007.05976.x; Eisenreich B., 2016, CONTROL CONTROLLERS; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Fiete IR, 2010, NEURON, V65, P563, DOI 10.1016/j.neuron.2010.02.003; Freeman Walter J., 1994, Integrative Physiological and Behavioral Science, V29, P294, DOI 10.1007/BF02691333; Galan RF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002148; Garrett DD, 2013, NEUROSCI BIOBEHAV R, V37, P610, DOI 10.1016/j.neubiorev.2013.02.015; Gazzaniga M. S., 2013, COGNITIVE NEUROSCIEN; Goni J, 2014, P NATL ACAD SCI USA, V111, P833, DOI 10.1073/pnas.1315529111; Gu S., 2016, ENERGY LANDSCA UNPUB; Gu S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9414; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hansen ECA, 2015, NEUROIMAGE, V105, P525, DOI 10.1016/j.neuroimage.2014.11.001; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Hermundstad AM, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003591; Hermundstad AM, 2013, P NATL ACAD SCI USA, V110, P6169, DOI 10.1073/pnas.1219562110; Hermundstad AM, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002063; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Honey CJ, 2007, P NATL ACAD SCI USA, V104, P10240, DOI 10.1073/pnas.0701519104; Jbabdi S, 2013, CURR OPIN NEUROBIOL, V23, P207, DOI 10.1016/j.conb.2012.12.004; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnston JM, 2008, J NEUROSCI, V28, P6453, DOI 10.1523/JNEUROSCI.0573-08.2008; Kalpinski RJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/102570; Kandel ER, 2000, PRINCIPLES NEURAL SC; Khambhati A., 2016, VIRTUAL CORTIC UNPUB; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klimm F, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003491; Laughlin SB, 2001, NOVART FDN SYMP, V239, P177; Laughlin SB, 1998, NAT NEUROSCI, V1, P36, DOI 10.1038/236; Lee S, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.16; Lett TA, 2014, BIOL PSYCHIAT, V75, P361, DOI 10.1016/j.biopsych.2013.07.026; Levy N, 2001, NEURAL NETWORKS, V14, P815, DOI 10.1016/S0893-6080(01)00044-2; Liu YY, 2011, NATURE, V473, P167, DOI 10.1038/nature10011; Luenberger D.G., 1979, INTRO DYNAMIC SYSTEM; Medaglia JD, 2015, J COGNITIVE NEUROSCI, V27, P1471, DOI 10.1162/jocn_a_00810; Meunier D, 2009, NEUROIMAGE, V44, P715, DOI 10.1016/j.neuroimage.2008.09.062; Misic B, 2015, NEURON, V86, P1518, DOI 10.1016/j.neuron.2015.05.035; Muller FJ, 2011, NATURE, V478, pE4, DOI 10.1038/nature10543; Muldoon S. F., 2016, ARXIV160100987; Muldoon SF, 2016, SCI REP-UK, V6, DOI 10.1038/srep22057; Nenadovic V, 2008, J NEUROTRAUM, V25, P615, DOI 10.1089/neu.2007.0474; Niven JE, 2008, J EXP BIOL, V211, P1792, DOI 10.1242/jeb.017574; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; O'Reilly JX, 2013, P NATL ACAD SCI USA, V110, P13982, DOI 10.1073/pnas.1305062110; Pasqualetti F, 2014, IEEE T CONTROL NETW, V1, P40, DOI 10.1109/TCNS.2014.2310254; Pestilli F, 2014, NAT METHODS, V11, P1058, DOI 10.1038/nmeth.3098; Peterson, 1989, ATTENTION SYSTEM HUM; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Radhu N, 2012, BRAIN STIMUL, V5, P44, DOI 10.1016/j.brs.2011.01.006; Raichle ME, 2015, ANNU REV NEUROSCI, V38, P433, DOI 10.1146/annurev-neuro-071013-014030; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Raja Beharelle A, 2012, NEUROIMAGE, V60, P1528, DOI 10.1016/j.neuroimage.2012.01.037; Rajan K, 2016, NEURON, V90, P128, DOI 10.1016/j.neuron.2016.02.009; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Reveley C, 2015, P NATL ACAD SCI USA, V112, pE2820, DOI 10.1073/pnas.1418198112; Rusconi E, 2009, ANN NEUROL, V66, P654, DOI 10.1002/ana.21776; Rushworth MFS, 2006, CEREB CORTEX, V16, P1418, DOI 10.1093/cercor/bhj079; Salvador R, 2005, PHILOS T R SOC B, V360, P937, DOI 10.1098/rstb.2005.1645; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shenoy KV, 2011, PROG BRAIN RES, V192, P33, DOI 10.1016/B978-0-444-53355-5.00003-8; Sidaros A., 2008, DIFFUSION TENSOR IMA; Sizemore Ann, 2015, ARXIV151206457; Sommer IEC, 2012, SCHIZOPHRENIA BULL, V38, P704, DOI 10.1093/schbul/sbs034; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Stam CJ, 2014, NAT REV NEUROSCI, V15, P683, DOI 10.1038/nrn3801; Stephan KE, 2009, SCHIZOPHRENIA BULL, V35, P509, DOI 10.1093/schbul/sbn176; Szameitat AJ, 2011, NEUROIMAGE, V54, P1765, DOI 10.1016/j.neuroimage.2010.07.069; Thomas C, 2014, P NATL ACAD SCI USA, V111, P16574, DOI 10.1073/pnas.1405672111; Tortella G, 2014, CNS NEUROL DISORD-DR, V13, P1759; Weiss SA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00081; Yan G, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.218703; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011	100	60	61	2	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAR 1	2017	148						305	317		10.1016/j.neuroimage.2017.01.003			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EO6LD	WOS:000396803100030	28088484	Green Accepted, Other Gold			2021-06-18	
J	Kerr, ZY; Zuckerman, SL; Wasserman, EB; Covassin, T; Djoko, A; Dompier, TP				Kerr, Zachary Y.; Zuckerman, Scott L.; Wasserman, Erin B.; Covassin, Tracey; Djoko, Aristarque; Dompier, Thomas P.			Concussion Symptoms and Return to Play Time in Youth, High School, and College American Football Athletes	JAMA PEDIATRICS			English	Article							SPORTS-RELATED CONCUSSION; STATES HIGH-SCHOOL; EPIDEMIOLOGY; RECOVERY; INJURY; AGE; METAANALYSIS; MANAGEMENT; SEVERITY; OUTCOMES	IMPORTANCE To our knowledge, little research has examined concussion across the youth/adolescent spectrum and even less has examined concussion-related outcomes (ie, symptoms and return to play). OBJECTIVE To examine and compare sport-related concussion outcomes (symptoms and return to play) in youth, high school, and collegiate football athletes. DESIGN, SETTING, AND PARTICIPANTS Athletic trainers attended each practice and game during the 2012 to 2014 seasons and reported injuries. For this descriptive, epidemiological study, data were collected from youth, high school, and collegiate football teams, and the analysis of the data was conducted between July 2015 and September 2015. The Youth Football Surveillance System included more than 3000 youth football athletes aged 5 to 14 years from 118 teams, providing 310 team seasons (ie, 1 team providing 1 season of data). The National Athletic Treatment, Injury, and Outcomes Network Program included 96 secondary school football programs, providing 184 team seasons. The National Collegiate Athletic Association Injury Surveillance Program included 34 college football programs, providing 71 team seasons. MAIN OUTCOMES AND MEASURES We calculated the mean number of symptoms, prevalence of each symptom, and the proportion of patients with concussions that had long return-to-play time (ie, required participation restriction of at least 30 days). Generalized linear models were used to assess differences among competition levels in the mean number of reported symptoms. Logistic regression models estimated the odds of return to play at less than 24 hours and at least 30 days. RESULTS Overall, 1429 sports-related concussions were reported among youth, high school, and college-level football athletes with a mean (SD) of 5.48 (3.06) symptoms. Across all levels, 15.3% resulted return to play at least 30 days after the concussion and 3.1% resulted in return to play less than 24 hours after the concussion. Compared with youth, a higher number of concussion symptoms were reported in high school athletes (beta = 1.39; 95% CI, 0.55-2.24). Compared with college athletes, the odds of return to play at least 30 days after injury were larger in youth athletes (odds ratio, 2.75; 95% CI, 1.10-6.85) and high school athletes (odds ratio, 2.89; 95% CI, 1.61-5.19). The odds of return to play less than 24 hours after injury were larger in youth athletes than high school athletes (odds ratio, 6.23; 95% CI, 1.02-37.98). CONCLUSIONS AND RELEVANCE Differences in concussion-related outcomes existed by level of competition and may be attributable to genetic, biologic, and/or developmental differences or level-specific variations in concussion-related policies and protocols, athlete training management, and athlete disclosure. Given the many organizational, social environmental, and policy-related differences at each level of competition that were not measured in this study, further study is warranted to validate our findings.	[Kerr, Zachary Y.; Djoko, Aristarque; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent Inc, 401 W Michigan St,Ste 500, Indianapolis, IN 46202 USA; [Zuckerman, Scott L.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37212 USA; [Wasserman, Erin B.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA	Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 W Michigan St,Ste 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org		Wasserman, Erin/0000-0001-5957-5878; Kerr, Zachary/0000-0003-1423-1259	USA Football; National Athletic Trainers' Association Research and Education Foundation; Central Indiana Corporate Partnership Foundation; National Collegiate Athletic Association; BioCrossroads	Funding for this study was provided by USA Football; the National Athletic Trainers' Association Research and Education Foundation; BioCrossroads in partnership with the Central Indiana Corporate Partnership Foundation; and the National Collegiate Athletic Association.	[Anonymous], 2014, STUD ATHL PART 1981; Bailey R, 2006, J SCHOOL HEALTH, V76, P397, DOI 10.1111/j.1746-1561.2006.00132.x; Blakemore SJ, 2010, HUM BRAIN MAPP, V31, P926, DOI 10.1002/hbm.21052; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Foley C, 2014, CURR SPORT MED REP, V13, P390, DOI 10.1249/JSR.0000000000000104; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Institute of Medicine, 2013, SPORTS RELATED CONCU; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lee YM, 2013, J NEUROSURG-PEDIATR, V12, P537, DOI 10.3171/2013.7.PEDS12572; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; Murphy J., 2014, NAT ATHL TRAIN ASS 6; National Council of Youth Sports, 2008, REP TRENDS PART ORG; National Federation of State High School Associations, 2014, PART STAT; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Piland SG, 2003, J ATHL TRAINING, V38, P104; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	35	60	60	0	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	JUL	2016	170	7					647	653		10.1001/jamapediatrics.2016.0073			7	Pediatrics	Pediatrics	DQ2OK	WOS:000379041800010	27135397	Green Published, Bronze			2021-06-18	
J	Whiteneck, GG; Cuthbert, JP; Corrigan, JD; Bogner, JA				Whiteneck, Gale G.; Cuthbert, Jeffrey P.; Corrigan, John D.; Bogner, Jennifer A.			Prevalence of Self-Reported Lifetime History of Traumatic Brain Injury and Associated Disability: A Statewide Population-Based Survey	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						activities of daily living; epidemiology; mild traumatic brain injury; quality of life; surveys; traumatic brain injury	UNITED-STATES; MILD; RELIABILITY; VALIDITY; HEALTH	Objective: To investigate the prevalence of all severities of traumatic brain injury (TBI), regardless of treatment setting, and their associated negative outcomes. Participants: A total of 2701 adult Coloradoans. Design: A statewide, population-based, random digit-dialed telephone survey. Main Measures: The lifetime history of TBI was assessed by a modification of the Ohio State University TBI Identification Method; activity limitation and life satisfaction were also assessed. Results: The distribution of self-reported lifetime injury was as follows: 19.8%, no injury; 37.7%, injury but no TBI; 36.4%, mild TBI; and 6.0%, moderate-severe TBI. Of those reporting a TBI, 23.1% were hospitalized, 38.5% were treated in an emergency department, 9.8% were treated in a physician's office, and 27.5% did not seek medical care. A clear gradient of activity limitations and low life satisfaction was seen, with the highest proportions of these negative outcomes occurring in people reporting more severe TBI and the lowest proportions in those not reporting a TBI. Approximately twice as many people reported activity limitations and low life satisfaction after nonhospitalized TBI compared with hospitalized TBI. Conclusions: This investigation highlights the seriousness of TBI as a public health problem and the importance of including all severities of TBI, no matter where, or if treated, in estimating the prevalence of disability co-occurring with TBI.	[Whiteneck, Gale G.; Cuthbert, Jeffrey P.] Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA; [Corrigan, John D.; Bogner, Jennifer A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Whiteneck, GG (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	gale@craig-hospital.org			Colorado Injury Control Research Center through Centers for Disease Control and Prevention [R49 CE001168]; National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education, TBI Model System Centers [H133A070029]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001168] Funding Source: NIH RePORTER	This study was supported by the Colorado Injury Control Research Center through grant no. R49 CE001168 from the Centers for Disease Control and Prevention and the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education, TBI Model System Centers, to Ohio State University (H133A070029). The authors thank Cynthia A. Brooks, MSHA, at Craig Hospital for coordinating the survey subcontract with the University of Colorado Cancer Center Survey Research Shared Resource under the direction of Dr Alfred C. Marcus.	ADAMS PF, 1991, VITAL HLTH STAT, V10, P1; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Battaglia MP, 2004, ABT ASS, P4740; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bureau of Health Statistics and Data Management, 1998, NEW HAMPSH BEH RISK; Caplan B, 1996, J HEAD TRAUMA REHAB, P1; Center for Disease Control and Prevention, 2008, OV BRFSS 2008; Centers for Disease Control and Prevention , 2008, BEH RISK FACT SURV S; Centers for Disease Control and Prevention, BEH RISK FACT SURV S; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; Coronado V. G., 2012, BRAIN INJURY MED, P45; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Cuthbert JP, 2016, J HEAD TRAUMA REHAB, V31, pE36, DOI 10.1097/HTR.0000000000000075; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diener E, 2014, UNDERSTANDING SCORES; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Harrison-Felix C, 1996, ARCH PHYS MED REHAB, V39, DOI [10.1097/00001199-199610000-00002, DOI 10.1097/00001199-199610000-00002]; Health Statistics Section, 2001, COL BEH RISK FACT SU; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Rosenthal M., 1999, REHABILITATION ADULT; Rosenthal M, 1993, J HEAD TRAUMA REHAB, P1; Selassie A, 2003, S CAROLINA TRAUMATIC; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; U.S. Census Bureau, 2012, CPH 2 34; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	30	60	60	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2016	31	1					E55	E62		10.1097/HTR.0000000000000140			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DK9CN	WOS:000375228000006	25931187				2021-06-18	
J	Miller, JP; Sweet, JA; Bailey, CM; Munyon, CN; Luders, HO; Fastenau, PS				Miller, Jonathan P.; Sweet, Jennifer A.; Bailey, Christopher M.; Munyon, Charles N.; Luders, Hans O.; Fastenau, Philip S.			Visual-spatial memory may be enhanced with theta burst deep brain stimulation of the fornix: a preliminary investigation with four cases	BRAIN			English	Article						deep brain stimulation; memory; theta burst stimulation	GEORGIA COMPLEX FIGURES; BOSTON NAMING TEST; 5 ALTERNATE FORMS; ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL TESTS; MEDICAL-COLLEGE; HIPPOCAMPUS; RAT; POTENTIATION; VALIDITY	Memory loss after brain injury can be a source of considerable morbidity, but there are presently few therapeutic options for restoring memory function. We have previously demonstrated that burst stimulation of the fornix is able to significantly improve memory in a rodent model of traumatic brain injury. The present study is a preliminary investigation with a small group of cases to explore whether theta burst stimulation of the fornix might improve memory in humans. Four individuals undergoing stereo-electroencephalography evaluation for drug-resistant epilepsy were enrolled. All participants were implanted with an electrode into the proximal fornix and dorsal hippocampal commissure on the language dominant (n = 3) or language non-dominant (n = 1) side, and stimulation of this electrode reliably produced a diffuse evoked potential in the head and body of the ipsilateral hippocampus. Each participant underwent testing of verbal memory (Rey Auditory-Verbal Learning Test), visual-spatial memory (Medical College of Georgia Complex Figure Test), and visual confrontational naming (Boston Naming Test Short Form) once per day over at least two consecutive days using novel test forms each day. For 50% of the trials, the fornix electrode was continuously stimulated using a burst pattern (200 Hz in 100 ms trains, five trains per second, 100 mu s, 7 mA) and was compared with sham stimulation. Participants and examiners were blinded to whether stimulation was active or not, and the order of stimulation was randomized. The small sample size precluded use of inferential statistics; therefore, data were analysed using descriptive statistics and graphic analysis. Burst stimulation of the fornix was not perceived by any of the participants but was associated with a robust reversible improvement in immediate and delayed performance on the Medical College of Georgia Complex Figure Test. There were no apparent differences on either Rey Auditory-Verbal Learning Test or Boston Naming Test. There was no apparent relationship between performance and side of stimulation (language dominant or non-dominant). There were no complications. Preliminary evidence in this small sample of patients with drug-resistant epilepsy suggests that theta burst stimulation of the fornix may be associated with improvement in visual-spatial memory.	[Miller, Jonathan P.; Sweet, Jennifer A.; Bailey, Christopher M.; Munyon, Charles N.; Luders, Hans O.; Fastenau, Philip S.] Univ Hosp Case Med Ctr, Neurol Inst, Cleveland, OH 44106 USA; [Miller, Jonathan P.; Sweet, Jennifer A.; Munyon, Charles N.] Case Western Reserve Univ, Sch Med, Dept Neurol Surg, Cleveland, OH USA; [Bailey, Christopher M.; Luders, Hans O.; Fastenau, Philip S.] Case Western Reserve Univ, Sch Med, Dept Neurol, Cleveland, OH 44106 USA	Miller, JP (corresponding author), Univ Hosp Case Med Ctr, 11100 Euclid Ave, Cleveland, OH 44106 USA.	Jonathan.Miller@UHHospitals.org		Miller, Jonathan/0000-0001-5441-1751	George R. and Constance P. Lincoln family	This project was supported in part by philanthropic support from the George R. and Constance P. Lincoln family.	Beglinger LJ, 2005, ARCH CLIN NEUROPSYCH, V20, P517, DOI 10.1016/j.acn.2004.12.003; Beglinger LJ, 2003, SCHIZOPHR RES, V62, P191, DOI 10.1016/S0920-9964(02)00425-5; De Ridder D, 2010, NEUROSURGERY, V66, P986, DOI 10.1227/01.NEU.0000368153.44883.B3; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; Fastenau PS, 2002, ARCH CLIN NEUROPSYCH, V17, P834; Fastenau PS, 2001, ARCH CLIN NEUROPSYCH, V16, P824; Fastenau PS, 1998, J CLIN EXP NEUROPSYC, V20, P828, DOI 10.1076/jcen.20.6.828.1105; Fastenau PS, 1996, J CLIN EXP NEUROPSYC, V18, P462, DOI 10.1080/01688639608409003; Fastenau PS, 2002, J INT NEUROPSYCH SOC, V8, P151; Fontaine D, 2013, J ALZHEIMERS DIS, V34, P315, DOI 10.3233/JAD-121579; Hamani C, 2008, ANN NEUROL, V63, P119, DOI 10.1002/ana.21295; Hescham S, 2013, BRAIN STIMUL, V6, P72, DOI 10.1016/j.brs.2012.01.008; Kaplan E., 1983, BOSTON NAMING TEST; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; Laxton AW, 2010, ANN NEUROL, V68, P521, DOI 10.1002/ana.22089; Lee DJ, 2013, J NEUROTRAUM, V30, P131, DOI 10.1089/neu.2012.2646; Loring D.W., 2003, HDB REY OSTERRIETH C; Loring DW, 2008, J INT NEUROPSYCH SOC, V14, P394, DOI 10.1017/S1355617708080582; MACK WJ, 1992, J GERONTOL, V47, pP154, DOI 10.1093/geronj/47.3.P154; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; Nadel L, 2013, J COGNITIVE NEUROSCI, V25, P22, DOI 10.1162/jocn_a_00313; Rey A, 1964, EXAMEN CLIN PSYCHOL; Shirvalkar PR, 2010, P NATL ACAD SCI USA, V107, P7054, DOI 10.1073/pnas.0911184107; Smith GS, 2012, ARCH NEUROL-CHICAGO, V69, P1141, DOI 10.1001/archneurol.2012.590; Soriano-Mas C, 2005, BEHAV BRAIN RES, V160, P141, DOI 10.1016/j.bbr.2004.11.025; Stone SSD, 2011, J NEUROSCI, V31, P13469, DOI 10.1523/JNEUROSCI.3100-11.2011; Suthana N, 2012, NEW ENGL J MED, V366, P502, DOI 10.1056/NEJMoa1107212; Sweet JA, 2014, HIPPOCAMPUS, V24, P1592, DOI 10.1002/hipo.22338; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646; Yamashita H, 2008, PERCEPT MOTOR SKILL, V107, P45, DOI 10.2466/PMS.107.1.45-50; Yasugi M, 2010, PERCEPT MOTOR SKILL, V110, P181, DOI 10.2466/PMS.110.1.181-184	34	60	61	2	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL 1	2015	138		7				1833	1842		10.1093/brain/awv095			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CN6HY	WOS:000358536600017	26106097	Bronze			2021-06-18	
J	Haagsma, JA; Scholten, AC; Andriessen, TMJC; Vos, PE; Van Beeck, EF; Polinder, S				Haagsma, Juanita A.; Scholten, Annemieke C.; Andriessen, Teuntje M. J. C.; Vos, Pieter E.; Van Beeck, Ed F.; Polinder, Suzanne			Impact of Depression and Post-Traumatic Stress Disorder on Functional Outcome and Health-Related Quality of Life of Patients with Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; depression; follow-up study; post-traumatic stress disorder; quality of life; trauma	MENTAL-HEALTH; MAJOR DEPRESSION; RISK-FACTORS; HEAD-INJURY; SYMPTOMS; NETHERLANDS; PREVALENCE; MODERATE; SCALE; EPIDEMIOLOGY	The impact of disability following traumatic brain injury (TBI), assessed by functional measurement scales for TBI or by health-related quality of life (HRQoL), may vary because of a number of factors, including presence of depression or post-traumatic stress disorder (PTSD). The aim of this study was to assess prevalence and impact of depression and PTSD on functional outcome and HRQoL six and 12 months following mild TBI. We selected a sample of 1919 TBI patients who presented to the emergency department (ED) followed by either hospital admission or discharge to the home environment. The sample received postal questionnaires six and 12 months after treatment at the ED. The questionnaires included items regarding socio-demographics, the 36-item Short-Form Health Survey (SF-36), the Perceived Quality of Life Scale (PQoL), the Beck Depression Inventory, and the Impact of Event Scale. A total of 797 (42%) TBI patients completed the six-month follow-up survey. Depression and PTSD prevalence rates at both the six- and 12-month follow-up were 7% and 9%, respectively. Living alone was an independent predictor of depression and/or PTSD at six- and 12-month follow-up. Depression and PTSD were associated with a significantly decreased functional outcome (measured with Glasgow Outcome Scale Extended) and HRQoL (measured using the SF-36 and the PQoL). We conclude that depression and/or PTSD are relatively common in our sample of TBI patients and associated with a considerable decrease in functional outcome and HRQoL.	[Haagsma, Juanita A.; Scholten, Annemieke C.; Van Beeck, Ed F.; Polinder, Suzanne] Erasmus Univ, Med Ctr, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; [Andriessen, Teuntje M. J. C.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6525 ED Nijmegen, Netherlands; [Vos, Pieter E.] Slingeland Hosp, Dept Neurol, Doetinchem, Netherlands	Haagsma, JA (corresponding author), Erasmus Univ, Erasmus Med Ctr, POB 1738, NL-3000 DR Rotterdam, Netherlands.	j.haagsma@erasmusmc.nl					[Anonymous], 1998, ABBR INJ SCAL AIS 19; Bijl RV, 1998, SOC PSYCH PSYCH EPID, V33, P587, DOI 10.1007/s001270050098; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bronner MB, 2009, J TRAUMA STRESS, V22, P74, DOI 10.1002/jts.20379; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; de Graaf R, 2010, INT J METH PSYCH RES, V19, P125, DOI 10.1002/mpr.317; de Vries GJ, 2009, J TRAUMA STRESS, V22, P259, DOI 10.1002/jts.20429; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Feise Ronald J, 2002, BMC Med Res Methodol, V2, P8, DOI 10.1186/1471-2288-2-8; Gil S, 2006, CNS SPECTRUMS, V11, P603, DOI 10.1017/S1092852900013651; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Haagsma JA, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-1; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440-1681.1998.tb02179.x; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; O'Donnell ML, 2013, J CLIN PSYCHIAT, V74, pE137, DOI 10.4088/JCP.12m08011; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Parker SG, 2006, AGE AGEING, V35, P376, DOI 10.1093/ageing/afl003; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Patrick DL, 2000, J CLIN EPIDEMIOL, V53, P779, DOI 10.1016/S0895-4356(00)00205-5; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Seattle Quality of Life Group, 2008, INF SHEET PERC QUAL; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Ware JE., 1993, SF 36 HLTH SURVEY MA; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Weiss D., 1997, ASSESSING PSYCHOL TR; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wittmann L, 2008, COMPR PSYCHIAT, V49, P430, DOI 10.1016/j.comppsych.2008.02.004; Wohlfarth TD, 2003, PSYCHOL ASSESSMENT, V15, P101, DOI 10.1037/1040-3590.15.1.101; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690, DOI 10.1176/ajp.154.12.1690; Zatzick Douglas, 2003, Semin Clin Neuropsychiatry, V8, P149, DOI 10.1016/S1084-3612(03)00017-0; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	63	60	61	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2015	32	11					853	862		10.1089/neu.2013.3283			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0YU	WOS:000363980700011	25320845				2021-06-18	
J	Gibson, TB; Herring, SA; Kutcher, JS; Broglio, SP				Gibson, Teresa B.; Herring, Stanley A.; Kutcher, Jeffrey S.; Broglio, Steven P.			Analyzing the Effect of State Legislation on Health Care Utilization for Children With Concussion	JAMA PEDIATRICS			English	Article							COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; NCAA CONCUSSION; SPORT; EPIDEMIOLOGY; RECOVERY	IMPORTANCE In 2009, Washington State enacted legislation outlining the medical care of children and adolescents with concussion (ie, the Lystedt Law), with all other states and Washington, DC passing legislation by January 2014. OBJECTIVE To evaluate the effect of concussion laws on health care utilization rates from January 1, 2006, through June 30, 2012, in states with and without legislation. DESIGN, SETTING, AND PARTICIPANTS For commercially insured children aged 12 to 18 years from all 50 states and DC from January 1, 2006, through June 30, 2009, we examined the following: (1) prelegislation trends in concussion-related health care utilization from January 1, 2006, through June 30, 2009, (2) postlegislation trends in states without concussion legislation, and (3) the effect of state concussion laws on trends in states with concussion legislation in effect by means of negative binomial multivariable estimation with state and time fixed effects. EXPOSURES Concussion diagnosis. MAIN OUTCOMES AND MEASURES Emergency department and related health care utilization rates for concussion. RESULTS Between academic school years 2008-2009 and 2011-2012, states with legislation experienced a 92% increase in concussion-related health care utilization, while states without legislation had a 75% overall increase in concussion-related health care utilization during the same period. In the multivariable fixed-effects models, controlling for differences across states, rates of treated concussion in states without legislation were 7% higher in the 2009-2010 school year, 20% higher in the 2010-2011 school year, and 34% higher in the 2011-2012 school year compared with the prelegislation trends (2005-2009) (all P < .01). During the same period, states with concussion laws demonstrated a 10% higher concussion-related health care utilization rate compared with states without laws (P < .01). CONCLUSIONS AND RELEVANCE Increased health care utilization rates among children with concussion in the United States are both directly and indirectly related to concussion legislation. A portion of the increased rates (60%) in states without legislation is attributable to an ongoing upward trend demonstrated before enactment of the first state law in 2009. The remaining 40% increase in these states is thought to have resulted from elevated awareness brought about by heightened local and national media attention. Concussion legislation has had a seemingly positive effect on health care utilization, but the overall increase can also be attributed to increased injury awareness.	[Gibson, Teresa B.] Harvard Univ, Sch Med, Ann Arbor, MI USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Michigan NeuroSport, Ann Arbor, MI USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Michigan NeuroSport, Michigan Injury Ctr, Ann Arbor, MI 48109 USA	Broglio, SP (corresponding author), Univ Michigan, Sch Kinesiol, Michigan NeuroSport, Michigan Injury Ctr, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Meijer, Anna/K-5118-2016		Truven Health from the National Institute of Child Health and Human Development	This investigation was supported in part by Truven Health from the National Institute of Child Health and Human Development (Dr Gibson).	Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Bompadre V, 2014, J ATHL TRAINING, V49, P486, DOI 10.4085/1062-6050-49.3.30; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hilbe J.M., 2011, NEGATIVE BINOMIAL RE; Institute of Medicine, 2013, SPORTS REL CONC YOUT; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Truven Health Analytics, MARKETSCAN COMM CLAI	17	60	60	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	FEB	2015	169	2					163	168		10.1001/jamapediatrics.2014.2320			6	Pediatrics	Pediatrics	CA8DV	WOS:000349147700014	25531065	Bronze			2021-06-18	
J	Miller, DM; Singh, IN; Wang, JA; Hall, ED				Miller, Darren M.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.			Nrf2-ARE activator carnosic acid decreases mitochondrial dysfunction, oxidative damage and neuronal cytoskeletal degradation following traumatic brain injury in mice	EXPERIMENTAL NEUROLOGY			English	Article						Lipid peroxidation; Mitochondria; Nrf2; Oxidative damage; Traumatic brain injury; 4-Hydroxy-2-nonenal	IN-VITRO; PROTECTS; SULFORAPHANE; EXPRESSION; CALPAIN; STRESS; KEAP1; VIVO; NEURODEGENERATION; TRANSCRIPTION	The importance of free radical-induced oxidative damage after traumatic brain injury (TBI) has been well documented. Despite multiple clinical trials with radical-scavenging antioxidants that are neuroprotective in TBI models, none is approved for acute TBI patients. As an alternative antioxidant target, Nrf2 is a transcription factor that activates expression of antioxidant and cytoprotective genes by binding to antioxidant response elements (AREs) within DNA. Previous research has shown that neuronal mitochondria are susceptible to oxidative damage post-TBI, and thus the current study investigates whether Nrf2-ARE activation protects mitochondrial function when activated post-TBI. It was hypothesized that administration of carnosic acid (CA) would reduce oxidative damage biomarlcers in the brain tissue and also preserve cortical mitochondrial respiratory function post-TBI. A mouse controlled cortical impact (CCI) model was employed with a 1.0 mm cortical deformation injury. Administration of CA at 15 min post-TBI reduced cortical lipid peroxidation, protein nitration, and cytoskeletal breakdown markers in a dose-dependent manner at 48 h post-injury. Moreover, CA preserved mitochondrial respiratory function compared to vehicle animals. This was accompanied by decreased oxidative damage to mitochondrial proteins, suggesting the mechanistic connection of the two effects. Lastly, delaying the initial administration of CA up to 8 h post-TBI was still capable of reducing cytoskeletal breakdown, thereby demonstrating a clinically relevant therapeutic window for this approach. This study demonstrates that pharmacological Nrf2-ARE induction is capable of neuroprotective efficacy when administered after TBI. (C) 2014 Elsevier Inc All rights reserved.	[Miller, Darren M.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Miller, Darren M.; Singh, Indrapal N.; Hall, Edward D.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Dept Anat & Neurobiol, 741 S Limestone St,BBSRB Room B477, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NIH-NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1T32 DA022738]; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1T32 NS077889, 2P30 NS051220-01]; Kentucky Spinal Cord & Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, T32NS077889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by grants NIH-NIDA 1T32 DA022738, NIH-NINDS 1T32 NS077889, and NIH-NINDS 2P30 NS051220-01, and funds from the Kentucky Spinal Cord & Head Injury Research Trust.	Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Greco T, 2010, J BIOENERG BIOMEMBR, V42, P491, DOI 10.1007/s10863-010-9312-9; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Johnson JA, 2008, ANN NY ACAD SCI, V1147, P61, DOI 10.1196/annals.1427.036; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Li J, 2005, TOXICOL SCI, V83, P313, DOI 10.1093/toxsci/kfi027; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; Miller DM, 2013, FREE RADICAL BIO MED, V57, P1, DOI 10.1016/j.freeradbiomed.2012.12.011; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947; Satoh T, 2008, J NEUROCHEM, V104, P1116, DOI 10.1111/j.1471-4159.2007.05039.x; Son TG, 2010, J NEUROCHEM, V112, P1316, DOI 10.1111/j.1471-4159.2009.06552.x; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	26	60	63	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2015	264						103	110		10.1016/j.expneurol.2014.11.008			8	Neurosciences	Neurosciences & Neurology	CB4IC	WOS:000349590400011	25432068	Green Accepted			2021-06-18	
J	Edelmann, MN; Krull, KR; Liu, W; Glass, JO; Ji, Q; Ogg, RJ; Sabin, ND; Srivastava, DK; Robison, LL; Hudson, MM; Reddick, WE				Edelmann, Michelle N.; Krull, Kevin R.; Liu, Wei; Glass, John O.; Ji, Qing; Ogg, Robert J.; Sabin, Noah D.; Srivastava, Deo Kumar; Robison, Leslie L.; Hudson, Melissa M.; Reddick, Wilburn E.			Diffusion tensor imaging and neurocognition in survivors of childhood acute lymphoblastic leukaemia	BRAIN			English	Article						brain fraction; neuropsychology; neuroimaging; anisotropy; cancer	LONG-TERM SURVIVORS; TRAUMATIC BRAIN-INJURY; WHITE-MATTER; FRACTIONAL ANISOTROPY; MEMORY; LEUKOENCEPHALOPATHY; IMPAIRMENT; ATTENTION; OUTCOMES; THERAPY	Survivors of childhood acute lymphoblastic leukaemia are at risk for neurocognitive impairment, though little information is available on its association with brain integrity, particularly for survivors treated without cranial radiation therapy. This study compares neurocognitive function and brain morphology in long-term adult survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy alone (n = 36) to those treated with cranial radiation therapy (n = 39) and to healthy control subjects (n = 23). Mean (standard deviation) age at evaluation was 24.9 (3.6) years for the chemotherapy group and 26.7 (3.4) years for the cranial radiation therapy group, while time since diagnosis was 15.0 (1.7) and 23.9 (3.1) years, respectively. Brain grey and white matter volume and diffusion tensor imaging was compared between survivor groups and to 23 healthy controls with a mean (standard deviation) age of 23.1 (2.6) years. Survivors treated with chemotherapy alone had higher fractional anisotropy in fibre tracts within the left (P < 0.05), but not in the right, hemisphere when compared to controls. Survivors of acute lymphoblastic leukaemia, regardless of treatment, had a lower ratio of white matter to intracranial volume in frontal and temporal lobes (P < 0.05) compared with control subjects. Survivors of acute lymphoblastic leukaemia treated with chemotherapy alone performed worse in processing speed (P < 0.001), verbal selective reminding (P = 0.01), and academics (P < 0.05) compared to population norms and performed better than survivors treated with cranial radiation therapy on verbal selective reminding (P = 0.02), processing speed (P = 0.05) and memory span (P = 0.009). There were significant associations between neurocognitive performance and brain imaging, particularly for frontal and temporal white and grey matter volume. Survivors of acute lymphoblastic leukaemia treated with chemotherapy alone demonstrated significant long-term differences in neurocognitive function and altered neuroanatomical integrity. These results suggest substantial region-specific white matter alterations in survivors of acute lymphoblastic leukaemia possibly resulting in restricted radial diffusion due to the compaction of neuronal fibres.	[Edelmann, Michelle N.; Krull, Kevin R.; Robison, Leslie L.; Hudson, Melissa M.] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA; [Liu, Wei; Srivastava, Deo Kumar] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Glass, John O.; Ji, Qing; Ogg, Robert J.; Sabin, Noah D.; Reddick, Wilburn E.] St Jude Childrens Res Hosp, Dept Radiol Sci, Memphis, TN 38105 USA; [Hudson, Melissa M.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA	Krull, KR (corresponding author), St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, 262 Danny Thomas Pl,MS 735, Memphis, TN 38105 USA.	kevin.krull@stjude.org	Reddick, Wilburn E/G-8763-2018; Srivastava, Deo Kumar/P-2435-2017; Krull, Kevin R/N-3882-2018; Robison, Leslie/N-8122-2018; Sabin, Noah/N-8144-2018; Hudson, Melissa M/N-4441-2018	Reddick, Wilburn E/0000-0002-1054-1201; Srivastava, Deo Kumar/0000-0001-6693-8120; Krull, Kevin R/0000-0002-0476-7001; Sabin, Noah/0000-0002-7584-2574; Hudson, Melissa M/0000-0001-6984-2407; Glass, John/0000-0001-9679-2054	Cancer Centre Support (CORE) grant from the National Cancer Institute [CA21765]; National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD049888]; National Centre for Research Resources [RR029005]; ALSACAmerican Lebanese Syrian Associated Charities (ALSAC); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD049888] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA021765, R01CA090246] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR029005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007507] Funding Source: NIH RePORTER	This work was supported by the Cancer Centre Support (CORE) grant CA21765 from the National Cancer Institute, grant HD049888 from the National Institute for Child Health and Human Development, grant RR029005 from the National Centre for Research Resources, and by ALSAC.	Armstrong GT, 2013, JNCI-J NATL CANCER I, V105, P899, DOI 10.1093/jnci/djt089; Assaf Y, 2006, AM J NEURORADIOL, V27, P1717; Benton A, 1983, MULTILINGUAL APHASI; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Carey ME, 2008, AM J NEURORADIOL, V29, P792, DOI 10.3174/ajnr.A0904; Conners CK, 2001, CONNERS CONTINUOUS P; Delis DC, 2000, CALIFORNIA VERBAL LE; Dellani PR, 2008, J MAGN RESON IMAGING, V27, P1250, DOI 10.1002/jmri.21364; Genschaft M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078599; Glass JO, 2006, MAGN RESON IMAGING, V24, P785, DOI 10.1016/j.mri.2006.02.001; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hertzberg H, 1997, MED PEDIATR ONCOL, V28, P387, DOI 10.1002/(SICI)1096-911X(199706)28:6<387::AID-MPO1>3.0.CO;2-C; Howlander N, 2011, SEER CANC STAT REV 1; Hudson MM, 2013, JAMA-J AM MED ASSOC, V309, P2371, DOI 10.1001/jama.2013.6296; Hudson MM, 2011, PEDIATR BLOOD CANCER, V56, P825, DOI 10.1002/pbc.22875; Huppi PS, 2006, SEMIN FETAL NEONAT M, V11, P489, DOI 10.1016/j.siny.2006.07.006; Khong PL, 2006, J CLIN ONCOL, V24, P884, DOI 10.1200/JCO.2005.02.4505; Kochunov P, 2007, NEUROIMAGE, V35, P478, DOI 10.1016/j.neuroimage.2006.12.021; Krull KR, 2013, J CLIN ONCOL, V31, P4407, DOI 10.1200/JCO.2012.48.2315; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Mariotto AB, 2009, CANCER EPIDEM BIOMAR, V18, P1033, DOI 10.1158/1055-9965.EPI-08-0988; Metzler-Baddeley C, 2011, J NEUROSCI, V31, P13236, DOI 10.1523/JNEUROSCI.2317-11.2011; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Peterson CC, 2008, PEDIATR BLOOD CANCER, V51, P99, DOI 10.1002/pbc.21544; Peterson DJ, 2011, J CHILD NEUROL, V26, P1296, DOI 10.1177/0883073811405662; Porto L, 2008, EUR RADIOL, V18, P2691, DOI 10.1007/s00330-008-1038-2; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Reddick WE, 2005, AM J NEURORADIOL, V26, P1263; Reynolds C. R., 2007, TEST MEMORY LEARNING; Schuitema I, 2013, J CLIN ONCOL, V31, P3378, DOI 10.1200/JCO.2012.46.7050; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Styner Martin, 2006, Insight J, P242; Trites R, 1977, NEUROPSYCHOLOGICAL T; Vestergaard M, 2011, J COGNITIVE NEUROSCI, V23, P2135, DOI 10.1162/jocn.2010.21592; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wolfson D., 1993, HALSTEAD REITAN NEUR; Woodcock R.W., 2001, WOODCOCKJOHNSON 3 TE; Yu HJ, 2012, NEUROIMAGE, V59, P3713, DOI 10.1016/j.neuroimage.2011.10.053; Zeller B, 2013, J CLIN ONCOL, V31, P2078, DOI 10.1200/JCO.2012.47.4031	44	60	62	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2014	137		11				2973	2983		10.1093/brain/awu230			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AX2GG	WOS:000346760900020	25125614	Green Published, Bronze			2021-06-18	
J	Shany-Ur, T; Lin, N; Rosen, HJ; Sollberger, M; Miller, BL; Rankin, KP				Shany-Ur, Tal; Lin, Nancy; Rosen, Howard J.; Sollberger, Marc; Miller, Bruce L.; Rankin, Katherine P.			Self-awareness in neurodegenerative disease relies on neural structures mediating reward-driven attention	BRAIN			English	Article						ageing; awareness; neurodegenerative diseases; attention; voxel based morphometry	VARIANT FRONTOTEMPORAL DEMENTIA; TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; BEHAVIORAL VARIANT; PREFRONTAL CORTEX; ORBITOFRONTAL CORTEX; ANOSOGNOSIA; DEFICITS; MEMORY	Patients with neurodegenerative diseases often overestimate their functional capacities. Using structural MRI, Shany-Ur et al. examine the neuroanatomical correlates of impaired self-awareness. Overestimation of functioning correlates with degeneration of dorsal frontal regions involved in attention, as well as orbitofrontal and subcortical regions that may assign reward value to self-related knowledge.Accurate self-awareness is essential for adapting one's tasks and goals to one's actual abilities. Patients with neurodegenerative diseases, particularly those with right frontal involvement, often present with poor self-awareness of their functional limitations that may exacerbate their already jeopardized decision-making and behaviour. We studied the structural neuroanatomical basis for impaired self-awareness among patients with neurodegenerative disease and healthy older adults. One hundred and twenty-four participants (78 patients with neurodegenerative diseases including Alzheimer's disease, behavioural variant frontotemporal dementia, right-temporal frontotemporal dementia, semantic variant and non-fluent variant primary progressive aphasia, and 46 healthy controls) described themselves on the Patient Competency Rating Scale, rating observable functioning across four domains (daily living activities, cognitive, emotional control, interpersonal). All participants underwent structural magnetic resonance imaging. Informants also described subjects' functioning on the same scale. Self-awareness was measured by comparing self and informant ratings. Group differences in discrepancy scores were analysed using general linear models, controlling for age, sex and disease severity. Compared with controls, patients with behavioural variant frontotemporal dementia overestimated their functioning in all domains, patients with Alzheimer's disease overestimated cognitive and emotional functioning, patients with right-temporal frontotemporal dementia overestimated interpersonal functioning, and patients with non-fluent aphasia overestimated emotional and interpersonal functioning. Patients with semantic variant aphasia did not overestimate functioning on any domain. To examine the neuroanatomic correlates of impaired self-awareness, discrepancy scores were correlated with brain volume using voxel-based morphometry. To identify the unique neural correlates of overlooking versus exaggerating deficits, overestimation and underestimation scores were analysed separately, controlling for age, sex, total intracranial volume and extent of actual functional decline. Atrophy related to overestimating one's functioning included bilateral, right greater than left frontal and subcortical regions, including dorsal superior and middle frontal gyri, lateral and medial orbitofrontal gyri, right anterior insula, putamen, thalamus, and caudate, and midbrain and pons. Thus, our patients' tendency to under-represent their functional decline was related to degeneration of domain-general dorsal frontal regions involved in attention, as well as orbitofrontal and subcortical regions likely involved in assigning a reward value to self-related processing and maintaining accurate self-knowledge. The anatomic correlates of underestimation (right rostral anterior cingulate cortex, uncorrected significance level) were distinct from overestimation and had a substantially smaller effect size. This suggests that underestimation or 'tarnishing' may be influenced by non-structural neurobiological and sociocultural factors, and should not be considered to be on a continuum with overestimation or 'polishing' of functional capacity, which appears to be more directly mediated by neural circuit dysfunction.	[Shany-Ur, Tal; Lin, Nancy; Rosen, Howard J.; Sollberger, Marc; Miller, Bruce L.; Rankin, Katherine P.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94158 USA; [Shany-Ur, Tal] Natl Inst Rehabil Brain Injured, Tel Aviv, Israel; [Sollberger, Marc] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland	Rankin, KP (corresponding author), Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, 675 Nelson Rising Lane,Suite 190, San Francisco, CA 94158 USA.	krankin@memory.ucsf.edu		Shany-Ur, Tal/0000-0003-0319-5969	National Institute on Aging (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [5-R01 AG029577, 5-P01 AG019724, P50 AG02350]; State of California Alzheimer's Disease Research Center of California (ARCC) [03-75271]; NIH/UCSF-CTSI [UL1 RR024131]; Larry L. Hillblom Foundation [R01 AG030688]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000004] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG032306, P50AG023501, R01AG029577, R01AG030688, P01AG019724, P01AG017586] Funding Source: NIH RePORTER	This research was supported in part by the National Institute on Aging (NIA) grants 5-R01 AG029577, 5-P01 AG019724 and P50 AG02350; the State of California Alzheimer's Disease Research Center of California (ARCC) grant 03-75271; NIH/UCSF-CTSI grant UL1 RR024131 and the Larry L. Hillblom Foundation 2007/2I grant R01 AG030688.	Aalten P, 2005, AGING MENT HEALTH, V9, P414, DOI 10.1080/13607860500143075; Abdulkadir A, 2011, NEUROIMAGE, V58, P785, DOI 10.1016/j.neuroimage.2011.06.029; ADAIR JC, 1995, NEUROLOGY, V45, P241, DOI 10.1212/WNL.45.2.241; Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Anton G., 1898, WIEN KLIN WOCHENSCHR, V11, P227; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Babinski MJ., 1914, REV NEUROL, V27, P845; Banks S, 2008, BRAIN COGNITION, V67, P58, DOI 10.1016/j.bandc.2007.11.004; Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; BELYI BI, 1987, INT J NEUROSCI, V32, P799, DOI 10.3109/00207458709043334; Berti A, 2005, SCIENCE, V309, P488, DOI 10.1126/science.1110625; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Delgado MR, 2007, ANN NY ACAD SCI, V1104, P70, DOI 10.1196/annals.1390.002; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Eslinger PJ, 2005, J NEUROL NEUROSUR PS, V76, P1630, DOI 10.1136/jnnp.2004.053157; Flashman LA, 2001, J NEUROPSYCH CLIN N, V13, P255, DOI 10.1176/appi.neuropsych.13.2.255; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fossati P, 2003, AM J PSYCHIAT, V160, P1938, DOI 10.1176/appi.ajp.160.11.1938; Gilleen J, 2011, SCHIZOPHRENIA BULL, V37, P61, DOI 10.1093/schbul/sbq100; Gorno-Tempini ML, 2011, NEUROLOGY, V76, P1006, DOI 10.1212/WNL.0b013e31821103e6; Hayasaka S, 2004, NEUROIMAGE, V23, P54, DOI 10.1016/j.neuroimage.2004.04.035; Hornberger M, 2014, HUM BRAIN MAPP, V35, P616, DOI 10.1002/hbm.22200; Jenkins AC, 2011, SOC NEUROSCI-UK, V6, P211, DOI 10.1080/17470919.2010.507948; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Josephs KA, 2009, NEUROLOGY, V73, P1443, DOI 10.1212/WNL.0b013e3181bf9945; Kanwisher N, 2006, PHILOS T R SOC B, V361, P2109, DOI 10.1098/rstb.2006.1934; Kloppel S, 2008, BRAIN, V131, P681, DOI 10.1093/brain/awm319; Krebs RM, 2012, CEREB CORTEX, V22, P607, DOI 10.1093/cercor/bhr134; Leung KK, 2009, PSYCHOL MED, V39, P1097, DOI 10.1017/S0033291708004546; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mendez MF, 2011, CONSCIOUS COGN, V20, P1690, DOI 10.1016/j.concog.2011.09.005; Mendez ME, 2005, J NEUROPSYCH CLIN N, V17, P413, DOI 10.1176/appi.neuropsych.17.3.413; Miller BL, 2001, NEUROLOGY, V57, P817, DOI 10.1212/WNL.57.5.817; Mograbi DC, 2009, CONSCIOUS COGN, V18, P989, DOI 10.1016/j.concog.2009.07.005; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Northoff G, 2006, NEUROIMAGE, V31, P440, DOI 10.1016/j.neuroimage.2005.12.002; O'Doherty JP, 2004, CURR OPIN NEUROBIOL, V14, P769, DOI 10.1016/j.conb.2004.10.016; O'Keeffe FM, 2007, BRAIN, V130, P753, DOI 10.1093/brain/awl367; Phan KL, 2004, NEUROIMAGE, V21, P768, DOI 10.1016/j.neuroimage.2003.09.072; Possin KL, 2012, J INT NEUROPSYCH SOC, V18, P834, DOI 10.1017/S1355617712000604; Possin KL, 2009, J INT NEUROPSYCH SOC, V15, P354, DOI 10.1017/S135561770909050X; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2009, CURR OPIN NEUROL, V22, P606, DOI 10.1097/WCO.0b013e328332a1e7; Rankin KP, 2009, NEUROIMAGE, V47, P2005, DOI 10.1016/j.neuroimage.2009.05.077; Rankin KP, 2005, J NEUROL NEUROSUR PS, V76, P632, DOI 10.1136/jnnp.2004.042879; REED BR, 1993, J CLIN EXP NEUROPSYC, V15, P231, DOI 10.1080/01688639308402560; Renoult L, 2012, TRENDS COGN SCI, V16, P550, DOI 10.1016/j.tics.2012.09.003; Ries ML, 2007, J INT NEUROPSYCH SOC, V13, P450, DOI 10.1017/S1355617707070488; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Rosen HJ, 2011, NEUROCASE, V17, P231, DOI 10.1080/13554794.2010.522588; Rosen HJ, 2010, NEUROIMAGE, V49, P3358, DOI 10.1016/j.neuroimage.2009.11.041; Rothkirch M, 2012, NEUROIMAGE, V62, P1717, DOI 10.1016/j.neuroimage.2012.06.016; Ruby P, 2007, J COGNITIVE NEUROSCI, V19, P671, DOI 10.1162/jocn.2007.19.4.671; Salmon E, 2006, HUM BRAIN MAPP, V27, P588, DOI 10.1002/hbm.20203; Sara SJ, 2012, NEURON, V76, P130, DOI 10.1016/j.neuron.2012.09.011; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Schmitz TW, 2007, NEUROSCI BIOBEHAV R, V31, P585, DOI 10.1016/j.neubiorev.2006.12.003; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Schmitz TW, 2004, NEUROIMAGE, V22, P941, DOI 10.1016/j.neuroimage.2004.02.018; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharot T, 2009, J NEUROSCI, V29, P3760, DOI 10.1523/JNEUROSCI.4972-08.2009; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Shibata K, 2008, NEUROSCI LETT, V435, P7, DOI 10.1016/j.neulet.2008.01.065; Sitek EJ, 2011, J INT NEUROPSYCH SOC, V17, P788, DOI 10.1017/S1355617711000725; Sollberger M, 2014, BRAIN BEHAV, V4, P201, DOI 10.1002/brb3.211; Sperduti M, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00041; Sturm VE, 2013, P NATL ACAD SCI USA, V110, P9944, DOI 10.1073/pnas.1301119110; Sturm VE, 2013, SOC COGN AFFECT NEUR, V8, P468, DOI 10.1093/scan/nss023; Whitwell JL, 2009, BRAIN, V132, P2932, DOI 10.1093/brain/awp232; Williamson C, 2010, J NEUROL NEUROSUR PS, V81, P140, DOI 10.1136/jnnp.2008.166041; Zamboni G, 2011, INT J GERIATR PSYCH, V26, P783, DOI 10.1002/gps.2620; Zamboni G, 2010, DEMENT GERIATR COGN, V29, P88, DOI 10.1159/000255141	76	60	60	2	32	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG	2014	137		8				2368	2381		10.1093/brain/awu161			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AM7MI	WOS:000340051100026	24951639	Green Published, Bronze			2021-06-18	
J	Ponsford, J; Bayley, M; Wiseman-Hakes, C; Togher, L; Velikonja, D; McIntyre, A; Janzen, S; Tate, R				Ponsford, Jennie; Bayley, Mark; Wiseman-Hakes, Catherine; Togher, Leanne; Velikonja, Diana; McIntyre, Amanda; Janzen, Shannon; Tate, Robyn		INCOG Expert Panel	INCOG Recommendations for Management of Cognition Following Traumatic Brain Injury, Part II: Attention and Information Processing Speed	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						attention; cognitive rehabilitation; information processing; traumatic brain injury	TIME PRESSURE MANAGEMENT; CLOSED-HEAD INJURY; OF-THE-LITERATURE; DOUBLE-BLIND; WORKING-MEMORY; EXECUTIVE FUNCTION; METHYLPHENIDATE TREATMENT; CONSTRUCT-VALIDITY; REHABILITATION; DEFICITS	Introduction: Traumatic brain injury, due to its diffuse nature and high frequency of injury to frontotemporal and midbrain reticular activating systems, may cause disruption in many aspects of attention: arousal, selective attention, speed of information processing, and strategic control of attention, including sustained attention, shifting and dividing of attention, and working memory. An international team of researchers and clinicians (known as INCOG) convened to develop recommendations for the management of attentional problems. Methods: The experts selected recommendations from published guidelines and then reviewed literature to ensure that recommendations were current. Decision algorithms incorporating the recommendations based on inclusion and exclusion criteria of published trials were developed. The team then prioritized recommendations for implementation and developed audit criteria to evaluate adherence to these best practices. Results: The recommendations and discussion highlight that metacognitive strategy training focused on functional everyday activities is appropriate. Appropriate use of dual task training, environmental modifications, and cognitive behavioral therapy is also discussed. There is insufficient evidence to support mindfulness meditation and practice on de-contextualized computer-based tasks for attention. Administration of the medication methylphenidate should be considered to improve information-processing speed. Conclusion: The INCOG recommendations for rehabilitation of attention provide up-to-date guidance for clinicians treating people with traumatic brain injury.	[Ponsford, Jennie; Togher, Leanne; Tate, Robyn] NHMRC Ctr Res Excellence Traumat Brain Injury Psy, Canberra, ACT, Australia; [Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Melbourne, Vic, Australia; [Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Alfred Hosp, Melbourne, Vic, Australia; [Bayley, Mark] Univ Toronto, Toronto Rehabil Inst, Neuro Rehabil Program, Toronto, ON, Canada; [Wiseman-Hakes, Catherine] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [Togher, Leanne] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [Velikonja, Diana] Hamilton Hlth Sci, Acquired Brain Injury Program, Neuropsychol, Hamilton, ON, Canada; [Velikonja, Diana] McMaster Univ, DeGroote Sch Med, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [McIntyre, Amanda; Janzen, Shannon] Lawson Hlth Res Inst, London, ON, Canada; [Tate, Robyn] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia; [Tate, Robyn] Univ Sydney, Sydney Med Sch Northern, Kolling Inst, Rehabil Res Ctr, Sydney, NSW 2006, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Togher, Leanne/AAC-7083-2019; Wiseman-Hakes, Catherine/AAC-8303-2021	Wiseman-Hakes, Catherine/0000-0001-8441-884X; Togher, Leanne/0000-0002-4518-6748; Bayley, Mark/0000-0001-7860-9463	Victorian Transport Accident Commission (TAC) through its Victorian Neurotrauma Initiative (VNI), Monash University; Ontario Neurotrauma Foundation (ONF)	The authors gratefully acknowledge the support of the Victorian Transport Accident Commission (TAC) through its Victorian Neurotrauma Initiative (VNI), Monash University, and the Ontario Neurotrauma Foundation (ONF) for their support of this project.	ADAPTE Collaboration, 2009, ADAPTE PROC RES TOOL; [Anonymous], AGREE ADV SCI PRACT; Arnsten AFT, 2002, PRINCIPLES FRONTAL L, P51, DOI [DOI 10.1093/ACPROF:OSO/9780195134971.003.0004, 10.1093/acprof:oso/9780195134971.003.0004]; Arnsten AFT, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-2; Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Baddeley A. D., 1986, WORKING MEMORY; Banks S, 2007, J CLIN SLEEP MED, V3, P519; Bayley M., 2007, ABIKUS EVIDENCE BASE; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; BENYISHAY Y, 1987, NEUROPSYCHOL REHABIL, P165; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Carroll LJ, 2004, J REHABIL MED S, V43, P84; Chen AJW, 2011, BRAIN, V134, P1541, DOI 10.1093/brain/awr067; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; Couillet J, 2010, NEUROPSYCHOL REHABIL, V20, P321, DOI 10.1080/09602010903467746; Dirette DK, 1999, OCCUP THER J RES, V19, P223, DOI 10.1177/153944929901900401; Evans JJ, 2009, J INT NEUROPSYCH SOC, V15, P112, DOI 10.1017/S1355617708090152; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Gansler D A, 1991, Arch Clin Neuropsychol, V6, P335, DOI 10.1016/0887-6177(91)90010-7; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, J CLIN EXP IN PRESS; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Hart T, 2009, NEUROPSYCHOLOGY, V23, P729, DOI 10.1037/a0016153; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; James W., 1890, PRINCIPLES PSYCHOL; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; Lindsay P, 2008, CAN MED ASSOC J, V179, pS1, DOI 10.1503/cmaj.081148.R2; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; Murray LL, 2006, J COMMUN DISORD, V39, P37, DOI 10.1016/j.jcomdis.2005.06.001; NEISTADT ME, 1994, AM J OCCUP THER, V48, P421, DOI 10.5014/ajot.48.5.421; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Novakovic-Agopian T, 2011, J HEAD TRAUMA REHAB, V26, P325, DOI 10.1097/HTR.0b013e3181f1ead2; Palmese CA, 2000, BRAIN INJURY, V14, P535; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; Pavlovskaya M, 2007, BRAIN INJURY, V21, P489, DOI 10.1080/02699050701311117; Penkam I, 2004, J COG REHABIL, V2, P13; Pero S, 2006, BRAIN INJURY, V20, P1207, DOI 10.1080/02699050600983271; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Posner M. I., 1992, NEUROPSYCHOLOGY CONS, P91, DOI DOI 10.1016/B978-0-12-498045-7.50010-4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rees L, 2007, BRAIN INJURY, V21, P161, DOI 10.1080/02699050701201813; Renison B, 2012, J INT NEUROPSYCH SOC, V18, P440, DOI 10.1017/S1355617711001883; Robertson I, 1988, Brain Inj, V2, P151, DOI 10.3109/02699058809150939; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Schmitter-Edgecombe M, 2001, J INT NEUROPSYCH SOC, V7, P615, DOI 10.1017/S1355617701755099; Schneider WN, 1999, BRAIN INJURY, V13, P863; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Sloan S., 2012, TRAUMATIC BRAIN INJU, P99; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199604000-00007; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Stuss D.T., 1986, FRONTAL LOBES; Sweeney S, 2010, NEUROPSYCHOL REHABIL, V20, P239, DOI 10.1080/09602010903080531; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Tate R, 2014, J HEAD TRAUMA REHAB, V29, P338, DOI 10.1097/HTR.0000000000000068; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Vallat-Azouvi C, 2009, BRAIN INJURY, V23, P585, DOI 10.1080/02699050902970711; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WEBSTER JS, 1983, INT J CLIN NEUROPSYC, V5, P69; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; Whyte J, 2010, DELISAS PHYS MED REH, P575; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; WILSON C, 1992, NEUROPSYCHOL REHABIL, V2, P193; Winkens I, 2009, CLIN REHABIL, V23, P79, DOI 10.1177/0269215508097855; Winkens I, 2009, ARCH PHYS MED REHAB, V90, P1672, DOI 10.1016/j.apmr.2009.04.016; Wiseman-Hakes C, 2013, BRAIN INJURY, V27, P1364, DOI 10.3109/02699052.2013.823663; Wood R L, 1987, Int Disabil Stud, V9, P149; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; WOOD RL, 1986, J HEAD TRAUMA REHAB, V1, P43, DOI DOI 10.1097/00001199-198609000-00008; Zickefoose S, 2013, BRAIN INJURY, V27, P707, DOI 10.3109/02699052.2013.775484; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	124	60	61	2	54	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					321	337		10.1097/HTR.0000000000000072			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300009	24984095				2021-06-18	
J	McEwen, D; Taillon-Hobson, A; Bilodeau, M; Sveistrup, H; Finestone, H				McEwen, Daniel; Taillon-Hobson, Anne; Bilodeau, Martin; Sveistrup, Heidi; Finestone, Hillel			Virtual Reality Exercise Improves Mobility After Stroke An Inpatient Randomized Controlled Trial	STROKE			English	Article						exercise movement techniques; gait; rehabilitation; virtual reality therapy	FUNCTIONAL BALANCE; ADULTS	Background and Purpose-Exercise using virtual reality (VR) has improved balance in adults with traumatic brain injury and community-dwelling older adults. Rigorous randomized studies regarding its efficacy, safety, and applicability with individuals after stroke are lacking. The purpose of this study was to determine whether an adjunct VR therapy improves balance, mobility, and gait in stroke rehabilitation inpatients. Methods-A blinded randomized controlled trial studying 59 stroke survivors on an inpatient stroke rehabilitation unit was performed. The treatment group (n=30) received standard stroke rehabilitation therapy plus a program of VR exercises that challenged balance (eg, soccer goaltending, snowboarding) performed while standing. The control group (n=29) received standard stroke rehabilitation therapy plus exposure to identical VR environments but whose games did not challenge balance (performed in sitting). VR training consisted of 10 to 12 thirty-minute daily sessions for a 3-week period. Objective outcome measures of balance and mobility were assessed before, immediately after, and 1 month after training. Results-Confidence intervals and effect sizes favored the treatment group on the Timed Up and Go and the Two-Minute Walk Test, with both groups meeting minimal clinical important differences after training. More individuals in the treatment group than in the control group showed reduced impairment in the lower extremity as measured by the Chedoke McMaster Leg domain (P=0.04) immediately after training. Conclusions-This VR exercise intervention for inpatient stroke rehabilitation improved mobility-related outcomes. Future studies could include nonambulatory participants as well as the implementation strategies for the clinical use of VR.	[McEwen, Daniel; Taillon-Hobson, Anne; Bilodeau, Martin; Finestone, Hillel] Bruyere Res Inst, Ottawa, ON K1N 5C8, Canada; [McEwen, Daniel; Bilodeau, Martin; Sveistrup, Heidi] Univ Ottawa, Sch Rehabil Sci, Ottawa, ON, Canada; [Bilodeau, Martin; Sveistrup, Heidi; Finestone, Hillel] Univ Ottawa, Sch Human Kinet, Ottawa, ON, Canada; [Finestone, Hillel] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Finestone, Hillel] Elisabeth Bruyere Hosp, Dept Phys Med & Rehabil, Ottawa, ON, Canada	Finestone, H (corresponding author), Bruyere Res Inst, 43 Bruyere St, Ottawa, ON K1N 5C8, Canada.	hfinestone@bruyere.org			Dr Tony Hakim Innovative Stroke Research Award; Heart and Stroke Foundation Centre for Stroke RecoveryHeart & Stroke Foundation of Canada; Queen Elizabeth II Graduate Scholarship in Science and Technology; University of Ottawa Excellence Scholarship	This study was supported by the Dr Tony Hakim Innovative Stroke Research Award, Heart and Stroke Foundation Centre for Stroke Recovery, and a personal donation from Tony and Elizabeth Graham. D. McEwen holds a Queen Elizabeth II Graduate Scholarship in Science and Technology and a University of Ottawa Excellence Scholarship.	Bisson E, 2007, CYBERPSYCHOL BEHAV, V10, P16, DOI 10.1089/cpb.2006.9997; Brien M, 2011, PEDIATR PHYS THER, V23, P258, DOI 10.1097/PEP.0b013e318227ca0f; Glegg SMN, 2014, DISABIL REHABIL-ASSI, V9, P89, DOI 10.3109/17483107.2013.799236; Hackett ML, 2005, STROKE, V36, P2296, DOI 10.1161/01.STR.0000183622.75135.a4; Hiengkaew V, 2012, ARCH PHYS MED REHAB, V93, P1201, DOI 10.1016/j.apmr.2012.01.014; Laver KE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008349.pub2; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944	7	60	64	0	51	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JUN	2014	45	6					1853	+		10.1161/STROKEAHA.114.005362			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	AI7QR	WOS:000337090700053	24763929	Bronze			2021-06-18	
J	Grieb, P				Grieb, Pawel			Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues	CNS DRUGS			English	Article							ACUTE ISCHEMIC-STROKE; CYTIDINE DIPHOSPHATE CHOLINE; TRAUMATIC BRAIN-INJURY; VASCULAR COGNITIVE IMPAIRMENT; CDP-CHOLINE; ORAL CITICOLINE; OLDER SUBJECTS; METABOLISM; NEURONS; CANCER	Citicoline is the generic name of the pharmaceutical substance that chemically is cytidine-5 '-diphosphocholine (CDP-choline), which is identical to the natural intracellular precursor of phospholipid phosphatidylcholine. Following injection or ingestion, citicoline is believed to undergo quick hydrolysis and dephosphorylation to yield cytidine and choline, which then enter the brain separately and are used to resynthesize CDP-choline inside brain cells. Neuroprotective activity of citicoline has been repeatedly shown in preclinical models of brain ischaemia and trauma, but two recent, large, pivotal clinical trials have revealed no benefits in ischaemic stroke and traumatic brain injury. However, the substance seems to be beneficial in some slowly advancing neurodegenerative disorders such as glaucoma and mild vascular cognitive impairment. This paper critically discusses issues related to the clinical pharmacology of citicoline, including its pharmacokinetics/biotransformation and pharmacodynamics/mode of action. It is concluded that at present, there is no adequate description of the mechanism(s) of the pharmacological actions of this substance. The possibility should be considered and tested that, in spite of apparently fast catabolism, the intact citicoline molecule or the phosphorylated intermediate products of its hydrolysis, cytidine monophosphate and phosphocholine, are pharmacologically active.	Polish Acad Sci, Mossakowski Med Res Ctr, Dept Expt Pharmacol, PL-02106 Warsaw, Poland	Grieb, P (corresponding author), Polish Acad Sci, Mossakowski Med Res Ctr, Dept Expt Pharmacol, 5 Pawinskiego Str, PL-02106 Warsaw, Poland.	pgrieb@imdik.pan.pl		Grieb, Pawel/0000-0002-6983-7947			Adamczyk M, 2006, CLIN CHEM, V52, P2123, DOI 10.1373/clinchem.2006.074369; Adibhatla R, 2005, NEUROCHEM RES, V30, P15, DOI 10.1007/s11064-004-9681-8; Adibhatla RM, 2005, BRAIN RES, V1058, P193, DOI 10.1016/j.brainres.2005.07.067; Adibhatla RM, 2003, J NEUROSCI RES, V73, P308, DOI 10.1002/jnr.10672; AGUT J, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1016; Alvarez XA, 1999, METHOD FIND EXP CLIN, V21, P535, DOI 10.1358/mf.1999.21.8.794835; Alvarez-Sabin J, 2011, STROKE, V42, pS40, DOI 10.1161/STROKEAHA.110.606509; ANSELL GB, 1961, BIOCHEM J, V78, P209, DOI 10.1042/bj0780209; Aquilina G, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2353; Arenth PM, 2011, PM&R, V3, pS123, DOI 10.1016/j.pmrj.2011.03.012; Babb SM, 2002, PSYCHOPHARMACOLOGY, V161, P248, DOI 10.1007/s00213-002-1045-y; Babb SM, 1996, PSYCHOPHARMACOLOGY, V127, P88, DOI 10.1007/BF02805979; Bligh J., 1951, J PHYSL, V117, P234; Bustamante A, 2012, J NEUROCHEM, V123, P217, DOI 10.1111/j.1471-4159.2012.07891.x; Cho HJ, 2009, METHOD FIND EXP CLIN, V31, P171, DOI 10.1358/mf.2009.31.3.1364241; Clark WM, 2012, NAT REV NEUROL, V8, P484, DOI 10.1038/nrneurol.2012.166; Cotroneo AM, 2013, CLIN INTERV AGING, V8, P131, DOI 10.2147/CIA.S38420; Cui FL, 2007, BIOPOLYMERS, V87, P174, DOI 10.1002/bip.20815; Danne O, 2010, EXPERT REV MOL DIAGN, V10, P159, DOI 10.1586/ERM.10.2; Davalos A, 2002, STROKE, V33, P2850, DOI 10.1161/01.STR.0000038691.03334.71; Davalos A, 2012, LANCET, V380, P349, DOI 10.1016/S0140-6736(12)60813-7; DORLANDO KJ, 1995, NEUROL RES, V17, P281, DOI 10.1080/01616412.1995.11740327; Eyigor O, 2012, BRAIN RES BULL, V87, P286, DOI 10.1016/j.brainresbull.2011.11.013; Food Safety Authority of Ireland, 2012, SAF ASS CIT; Fresta M, 1997, LIFE SCI, V61, P1227, DOI 10.1016/S0024-3205(97)00667-X; GALLETTI P, 1991, J NEUROL SCI, V103, pS19; GALLETTI P, 1985, BIOCHEM PHARMACOL, V34, P4121, DOI 10.1016/0006-2952(85)90204-7; Garcia-Cobos R, 2010, J NEUROL SCI, V299, P188, DOI 10.1016/j.jns.2010.08.027; Gibellini F, 2010, IUBMB LIFE, V62, P414, DOI 10.1002/iub.337; Gimenez R, 1998, EUR J PHARMACOL, V344, P149, DOI 10.1016/S0014-2999(98)00035-1; Glunde K, 2006, PHARMACOGENOMICS, V7, P1109, DOI 10.2217/14622416.7.7.1109; Gutierrez-Fernandez M, 2012, NEUROL RES, V34, P649, DOI 10.1179/1743132812Y.0000000058; Han M, 2007, PROSTAG OTH LIPID M, V84, P174, DOI 10.1016/j.prostaglandins.2007.08.003; Hankey GJ, 2012, LANCET, V380, P318, DOI 10.1016/S0140-6736(12)60912-X; HORROCKS L A, 1981, Progress in Lipid Research, V20, P531; Horrocks LA, 1981, United States Patent, Patent No. [4,386,078, 4386078]; Hunt AN, 2001, J BIOL CHEM, V276, P8492, DOI 10.1074/jbc.M009878200; Hurtado O, 2013, J NEUROCHEM, V126, P819, DOI 10.1111/jnc.12269; Hurtado O, 2011, STROKE, V42, pS33, DOI 10.1161/STROKEAHA.110.597435; Jochem J, 2010, J PHYSIOL PHARMACOL, V61, P37; Johansson M, 2009, CANCER EPIDEM BIOMAR, V18, P1538, DOI 10.1158/1055-9965.EPI-08-1193; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Krupinski J, 2005, NEUROCHEM RES, V30, P1067, DOI 10.1007/s11064-005-7201-0; Krupinski J, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-20; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; Lee JE, 2010, CANCER EPIDEM BIOMAR, V19, P884, DOI 10.1158/1055-9965.EPI-09-1295; LIEBERMAN I, 1956, SCIENCE, V124, P81, DOI 10.1126/science.124.3211.81; LOPEZCOVIELLA I, 1995, J NEUROCHEM, V65, P889; MANAKA S, 1974, EXPERIENTIA, V30, P179, DOI 10.1007/BF01927720; Matyja E, 2008, FOLIA NEUROPATHOL, V46, P139; Mir C, 2003, J MOL NEUROSCI, V20, P53, DOI 10.1385/JMN:20:1:53; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; MYKITA S, 1986, J NEUROCHEM, V47, P223; Oshitari T, 2002, NEUROREPORT, V13, P2109, DOI 10.1097/00001756-200211150-00023; Ottobelli L, 2013, OPHTHALMOLOGICA, V229, P219, DOI 10.1159/000350496; Parisi V, 2008, PROG BRAIN RES, V173, P541, DOI 10.1016/S0079-6123(08)01137-0; Park CH, 2006, BRAIN RES, V1081, P203, DOI 10.1016/j.brainres.2005.12.128; Putignano S, 2012, CLIN INTERV AGING, V7, P113, DOI 10.2147/CIA.S29366; Ramos-Cabrer P, 2011, INT J PHARMACEUT, V405, P228, DOI 10.1016/j.ijpharm.2010.12.014; Rejdak R, 2002, OPHTHALMIC RES, V34, P146, DOI 10.1159/000063658; Ruff RL, 2012, JAMA-J AM MED ASSOC, V308, P2032, DOI 10.1001/jama.2012.14008; Sarkar AK, 2012, J PHARMACEUT BIOMED, V71, P144, DOI 10.1016/j.jpba.2012.07.003; Savci V, 2003, EUR J PHARMACOL, V468, P129, DOI 10.1016/S0014-2999(03)01602-9; Schauss AG, 2009, INT J TOXICOL, V28, P479, DOI 10.1177/1091581809349452; SECADES JJ, 1995, METHOD FIND EXP CLIN, V17, P1; Secades JJ, 2012, REV NEUROLOGIA, V54, P173, DOI 10.33588/rn.5403.2011490; Tolvanen T, 2010, EUR J NUCL MED MOL I, V37, P874, DOI 10.1007/s00259-009-1346-z; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; WEISS GB, 1995, LIFE SCI, V56, P637, DOI 10.1016/0024-3205(94)00427-T; WEISS SB, 1958, J BIOL CHEM, V231, P53; Wurtman RJ, 2000, BIOCHEM PHARMACOL, V60, P989, DOI 10.1016/S0006-2952(00)00436-6; Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279; YASHIMA K, 1975, J NUTR SCI VITAMINOL, V21, P49, DOI 10.3177/jnsv.21.49; Yucel N, 2006, NEUROCHEM RES, V31, P767, DOI 10.1007/s11064-006-9075-1; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	75	60	62	2	17	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs	MAR	2014	28	3					185	193		10.1007/s40263-014-0144-8			9	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	AD6EP	WOS:000333348300001	24504829	Green Published, Other Gold			2021-06-18	
J	Jorge, RE; Arciniegas, DB				Jorge, Ricardo E.; Arciniegas, David B.			Mood Disorders After TBI	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Mood disorders; Depressive disorders	TRAUMATIC BRAIN-INJURY; SEROTONIN TRANSPORTER POLYMORPHISMS; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; AGGRESSIVE-BEHAVIOR; BIPOLAR DISORDER; AXIS-I; MANIA; ASSOCIATION; SYMPTOMS	In this article, we examine the epidemiology and risk factors for the development of the most common mood disorders observed in the aftermath of TBI: depressive disorders and bipolar spectrum disorders. We describe the classification approach and diagnostic criteria proposed in the fifth edition of the Diagnostic and Statistical Manual for Mental Disorders. We also examine the differential diagnosis of post-TBI mood disorders and describe the mainstay of the evaluation process. Finally, we place a special emphasis on the analysis of the different therapeutic options and provide guidelines for the appropriate management of these conditions.	[Jorge, Ricardo E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Mental Hlth Care Line, Houston, TX 77030 USA; [Jorge, Ricardo E.; Arciniegas, David B.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Beth K & Stuart C Yudofsky Div Neuropsychiat, Houston, TX 77030 USA; [Arciniegas, David B.] TIRR Mem Hermann, Brain Injury Res Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA	Jorge, RE (corresponding author), One Baylor Plaza, Houston, TX 77030 USA.	jorge@bcm.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH65134 01, R01 MH065134, R01MH53592] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055827] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH053592, R01MH065134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055827] Funding Source: NIH RePORTER		Alper K, 2007, BIOL PSYCHIAT, V62, P345, DOI 10.1016/j.biopsych.2006.09.023; *AM PSYCH ASS, 1995, AM J PSYCHIAT S, V152, P63; American Psychiatric Association, 2010, TREATM PAT MAJ DEPR; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Arango V, 2003, J PSYCHIATR RES, V37, P375, DOI 10.1016/S0022-3956(03)00048-7; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bell KR, 2004, J HEAD TRAUMA REHAB, V19, P502, DOI 10.1097/00001199-200411000-00007; Binder EB, 2004, NAT GENET, V36, P1319, DOI 10.1038/ng1479; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Daniels JP, 2008, J CLIN PSYCHIAT, V69, P497, DOI 10.4088/JCP.v69n0324a; Dealberto MJ, 2008, BIPOLAR DISORD, V10, P111, DOI 10.1111/j.1399-5618.2008.00523.x; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Demakis GJ, 2010, APPL NEUROPSYCHOL, V17, P183, DOI 10.1080/09084282.2010.499752; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hegel MT, 2000, BEHAV MODIF, V24, P94, DOI 10.1177/0145445500241005; Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592; Heim C, 2001, AM J PSYCHIAT, V158, P575, DOI 10.1176/appi.ajp.158.4.575; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hirschfeld R., 2002, GUIDELINE WATCH PRAC; Hornstein A, 1989, J Neuropsychiatry Clin Neurosci, V1, P446; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; Kane JM, 2002, AM J PSYCHIAT, V159, P1, DOI 10.1176/appi.ajp.159.1.1; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kant R, 1998, BRAIN INJURY, V12, P661, DOI 10.1080/026990598122223; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Lanctot KL, 2010, BRAIN INJURY, V24, P959, DOI 10.3109/02699051003789229; Larson MJ, 2009, NEUROPSYCHOLOGY, V23, P433, DOI 10.1037/a0015723; Lasky-Su JA, 2005, AM J MED GENET B, V133B, P110, DOI 10.1016/j.ajmg.b.30104; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Lotrich FE, 2004, PSYCHIAT GENET, V14, P121, DOI 10.1097/00041444-200409000-00001; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Oster TJ, 2007, CNS SPECTRUMS, V12, P764, DOI 10.1017/S1092852900015455; Patkar AA, 2002, PSYCHIAT RES, V110, P103, DOI 10.1016/S0165-1781(02)00098-7; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Reza MF, 2007, NEUROPSYCHOL REHABIL, V17, P723, DOI 10.1080/09602010601082441; Rothman MS, 2007, J NEUROPSYCH CLIN N, V19, P363, DOI 10.1176/appi.neuropsych.19.4.363; Schmitt JAJ, 2001, J PSYCHOPHARMACOL, V15, P173, DOI 10.1177/026988110101500304; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Sen S, 2004, BIOL PSYCHIAT, V55, P244, DOI 10.1016/j.biopsych.2003.08.006; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Smith GS, 2004, NEUROPSYCHOPHARMACOL, V29, P2226, DOI 10.1038/sj.npp.1300552; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; Sun HS, 2004, GENES BRAIN BEHAV, V3, P328, DOI 10.1111/j.1601-183X.2004.00085.x; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tunbridge E, 2004, SYNAPSE, V51, P112, DOI 10.1002/syn.10286; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429; Zubenko GS, 2003, AM J MED GENET B, V123B, P1, DOI 10.1002/ajmg.b.20073	88	60	62	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	MAR	2014	37	1					13	+		10.1016/j.psc.2013.11.005			18	Psychiatry	Psychiatry	AD8UM	WOS:000333541200003	24529421	Green Accepted			2021-06-18	
J	Wilcox, BJ; Beckwith, JG; Greenwald, RM; Chu, JJ; McAllister, TW; Flashman, LA; Maerlender, AC; Duhaime, AC; Crisco, JJ				Wilcox, Bethany J.; Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.; McAllister, Thomas W.; Flashman, Laura A.; Maerlender, Arthur C.; Duhaime, Ann-Christine; Crisco, Joseph J.			Head impact exposure in male and female collegiate ice hockey players	JOURNAL OF BIOMECHANICS			English	Article						Impact biomechanics; Hockey; Gender; Concussion	PHYSICIAN-OBSERVED CONCUSSION; INJURY SURVEILLANCE SYSTEM; WHITE-MATTER INTEGRITY; TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; DESCRIPTIVE EPIDEMIOLOGY; ACCELERATION; MAGNITUDE; SEVERITY; LOCATION	The purpose of this study was to quantify head impact exposure (frequency, location and magnitude of head impacts) for individual male and female collegiate ice hockey players and to investigate differences in exposure by sex, player position, session type, and team. Ninety-nine (41 male, 58 female) players were enrolled and 37,411 impacts were recorded over three seasons. Frequency of impacts varied significantly by sex (males: 287 per season, females: 170, p < 0.001) and helmet impact location (p < 0.001), but not by player position (p=0.088). Head impact frequency also varied by session type; both male and female players sustained more impacts in games than in practices (p < 0.001), however the magnitude of impacts did not differ between session types. There was no difference in 95th percentile peak linear acceleration between sexes (males: 41.6 g, females: 40.8 g), but 95th percentile peak rotational acceleration and HITsp (a composite severity measure) were greater for males than females (4424, 3409 rad/s(2), and 25.6, 22.3, respectively). Impacts to the back of the helmet resulted in the greatest 95th percentile peak linear accelerations for males (45.2 g) and females (50.4 g), while impacts to the side and back of the head were associated with the greatest 95th percentile peak rotational accelerations (males: 4719, 4256 rad/sec(2), females: 3567, 3784 rad/sec(2) respectively). It has been proposed that reducing an individual's head impact exposure is a practical approach for reducing the risk of brain injuries. Strategies to decrease an individual athlete's exposure need to be sport and gender specific, with considerations for team and session type. (C) 2013 Elsevier Ltd. All rights reserved.	[Wilcox, Bethany J.; Crisco, Joseph J.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02903 USA; [Wilcox, Bethany J.; Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI 02903 USA; [Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.] Simbex, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [McAllister, Thomas W.; Flashman, Laura A.] Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA; [Maerlender, Arthur C.] Dartmouth Med Sch, Pediat Neuropsychol Serv, Lebanon, NH USA; [Duhaime, Ann-Christine] Childrens Hosp Dartmouth, Dartmouth Hitchcock Med Ctr, Hanover, NH USA	Wilcox, BJ (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02903 USA.	Bethany_Wilcox@brown.edu			National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of General Medical Sciences at the National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01HD048638, R25GM0 83270, R25GM083270-S1]; National Operating Committee on Standards for Athletic Equipment; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR024484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM083270, P20GM104937] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute of Child Health and Human Development and the National Institute of General Medical Sciences at the National Institute of Health under Award nos. R01HD048638, R25GM0 83270 and R25GM083270-S1 and the National Operating Committee on Standards for Athletic Equipment. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We gratefully acknowledge and thank the engineering team at Simbex for all of their technical support. We would like to thank Lindley Brainard and Wendy Chamberlin at Simbex for their role in data collection and clinical coordination. We would also like to thank Russell Fiore, M.Ed., A.T.C, Emily Burmeister M.S., A.T.C, and Brian Daigneault, M.S., A.T.C at Brown University; as well as Jeff Frechette, A.T.C., and Tracey Poro, A.T.C., Dartmouth College Sports Medicine and Mary Hynes, R.N., M.P.H. Dartmouth Medical School for their support on this project.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gwin J., 2006, J BIOMECH, V39, pS153; Gwin J.T., 2009, J ASTM INT, V6; Hutchison M, 2011, THESIS U TORONTO TOR; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McKnight Cynthia M., 1992, Journal of Athletic Training, V27, P342; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Odelgard B., 1989, SAFETY ICE HOCKEY, P164; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wilcox B.J., 2013, J ATHLETIC IN PRESS	32	60	60	0	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JAN 3	2014	47	1					109	114		10.1016/j.jbiomech.2013.10.004			6	Biophysics; Engineering, Biomedical	Biophysics; Engineering	AA3QU	WOS:000331008200016	24210478	Green Published, Green Accepted			2021-06-18	
J	Spencer, RJ; Axelrod, BN; Drag, LL; Waldron-Perrine, B; Pangilinan, PH; Bieliauskas, LA				Spencer, Robert J.; Axelrod, Bradley N.; Drag, Lauren L.; Waldron-Perrine, Brigid; Pangilinan, Percival H.; Bieliauskas, Linas A.			WAIS-IV Reliable Digit Span is no More Accurate Than Age Corrected Scaled Score as an Indicator of Invalid Performance in a Veteran Sample Undergoing Evaluation for mTBI	CLINICAL NEUROPSYCHOLOGIST			English	Article						Cognition; Effort; Neuropsychological assessment; Traumatic brain injury; Veterans	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; POOR EFFORT; INDEXES	Reliable Digit Span (RDS) is a measure of effort derived from the Digit Span subtest of the Wechsler intelligence scales. Some authors have suggested that the age-corrected scaled score provides a more accurate measure of effort than RDS. This study examined the relative diagnostic accuracy of the traditional RDS, an extended RDS including the new Sequencing task from the Wechsler Adult Intelligence Scale-IV, and the age-corrected scaled score, relative to performance validity as determined by the Test of Memory Malingering. Data were collected from 138 Veterans seen in a traumatic brain injury clinic. The traditional RDS ( 7), revised RDS ( 11), and Digit Span age-corrected scaled score ( 6) had respective sensitivities of 39%, 39%, and 33%, and respective specificities of 82%, 89%, and 91%. Of these indices, revised RDS and the Digit Span age-corrected scaled score provide the most accurate measure of performance validity among the three measures.	[Spencer, Robert J.; Waldron-Perrine, Brigid; Bieliauskas, Linas A.] VA Ann Arbor Healthcare Syst, Dept Mental Hlth Serv, Ann Arbor, MI USA; [Axelrod, Bradley N.] John D Dingell Dept Vet Affairs Med Ctr, Psychol Sect, Detroit, MI USA; [Drag, Lauren L.] Stanford Univ Med Ctr, Palo Alto, CA USA; [Pangilinan, Percival H.] Univ Michigan Hlth Syst, Dept Phys Med & Rehabil, Ann Arbor, MI USA; [Bieliauskas, Linas A.] Univ Michigan Hlth Syst, Dept Psychiat, Ann Arbor, MI USA	Bieliauskas, LA (corresponding author), 2101 Commonwealth Blvd,Ste C, Ann Arbor, MI 48105 USA.	linas@umich.edu					Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Boone K., 2002, B TEST MANUAL; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Green P, 1997, WORD MEMORY TEST USE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schutte C, 2012, MILD TRAUMATIC BRAIN, P159; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Suhr J. A., 2007, ASSESSMENT MALINGERE; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler, 1981, WAIS R MANUAL; Wechsler D, 2008, WAIS 4 ADM SCORING M; Wechsler D., 1997, WAIS 3 ADM SCORING M; Whitney KA, 2013, APPL NEUROPSYCH-ADUL, V20, P83, DOI 10.1080/09084282.2012.670167; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083	23	60	60	0	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 1	2013	27	8					1362	1372		10.1080/13854046.2013.845248			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	273KW	WOS:000328534700010	24099142				2021-06-18	
J	Anstey, KJ; Cherbuin, N; Herath, PM				Anstey, Kaarin J.; Cherbuin, Nicolas; Herath, Pushpani M.			Development of a New Method for Assessing Global Risk of Alzheimer's Disease for Use in Population Health Approaches to Prevention	PREVENTION SCIENCE			English	Article						Risk assessment; Alzheimer's disease; Systematic review; Risk index	MILD COGNITIVE IMPAIRMENT; BODY-MASS INDEX; PHYSICAL-ACTIVITY; DEPRESSIVE SYMPTOMS; DEMENTIA RISK; HEAD-INJURY; INCIDENT DEMENTIA; MOUSE MODEL; LATE-LIFE; METAANALYSIS	Alzheimer's disease (AD) affects approximately 35 million people worldwide. Increasing evidence suggests that many risk factors for AD are modifiable. AD pathology develops over decades. Hence risk reduction interventions require very long follow-ups to show effects on AD incidence. Focussing on AD risk, instead of diagnosis, provides a more realistic target for prevention strategies. We developed a novel methodology that yields a global approach to risk assessment for AD for use in population-based settings and interventions. The methodology was used to develop a risk assessment tool that can be updated as more evidence becomes available. First, a systematic search strategy identified risk and protective factors for AD. Eleven risk factors and four protective factors for AD were identified for which odds ratios were published or could be calculated (age, sex, education, body mass index, diabetes, depression, serum cholesterol, traumatic brain injury, smoking, alcohol intake, social engagement, physical activity, cognitive activity, fish intake, and pesticide exposure). An algorithm was developed to combine the odds ratios into an AD risk score. The approach allows for interactions among risk factors which provides for their varying impact over the life-course as current evidence suggests midlife is a critical period for some risk factors. Finally, a questionnaire was developed to assess the risk and protective factors by self-report. Compared with developing risk indices on single cohort studies, this approach allows for more risk factors to be included, greater generalizeability of results, and incorporation of interactions based on findings from different stages of the lifecourse.	[Anstey, Kaarin J.; Cherbuin, Nicolas; Herath, Pushpani M.] Australian Natl Univ, Ctr Res Ageing Hlth & Wellbeing, Canberra, ACT 0200, Australia	Anstey, KJ (corresponding author), Australian Natl Univ, Ctr Res Ageing Hlth & Wellbeing, Bldg 63, Canberra, ACT 0200, Australia.	kaarin.anstey@anu.edu.au	Cherbuin, Nicolas/A-8515-2008; Anstey, Kaarin J/A-3852-2008; Anstey, Kaarin/AAB-4870-2020	Cherbuin, Nicolas/0000-0001-6481-0748; Anstey, Kaarin/0000-0002-9706-9316			Access Economics Pty Limited, 2009, KEEP DEM FRONT MIND; Akbaraly TN, 2009, NEUROLOGY, V73, P854, DOI 10.1212/WNL.0b013e3181b7849b; Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x; Anstey KJ, 2008, AM J GERIAT PSYCHIAT, V16, P343, DOI 10.1097/JGP.0b013e31816b72d4; Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116; Anstey KJ, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-62; Anstey KJ, 2009, AM J GERIAT PSYCHIAT, V17, P542, DOI 10.1097/JGP.0b013e3181a2fd07; Baldi I, 2003, AM J EPIDEMIOL, V157, P409, DOI 10.1093/aje/kwf216; Barberger-Gateau P, 2007, NEUROLOGY, V69, P1921, DOI 10.1212/01.wnl.0000278116.37320.52; Barnes DE, 2009, NEUROLOGY, V73, P173, DOI 10.1212/WNL.0b013e3181a81636; Barnes DE, 2010, ALZHEIMERS DEMENT, V6, P138, DOI 10.1016/j.jalz.2010.01.005; Bassuk SS, 1999, ANN INTERN MED, V131, P165, DOI 10.7326/0003-4819-131-3-199908030-00002; Benjamin S., 2010, PREVENTING ALZHEIMER; Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2; Caamano-Isorna F, 2006, NEUROEPIDEMIOLOGY, V26, P226, DOI 10.1159/000093378; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Dal Forno G, 2005, ANN NEUROL, V57, P381, DOI 10.1002/ana.20405; DAVIDOFF F, 1995, BRIT MED J, V310, P1085, DOI 10.1136/bmj.310.6987.1085; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fotuhi M, 2009, NAT CLIN PRACT NEURO, V5, P140, DOI 10.1038/ncpneuro1044; Fratiglioni L, 2000, LANCET, V355, P1315, DOI 10.1016/S0140-6736(00)02113-9; Gatz JL, 2005, J GERONTOL A-BIOL, V60, P744, DOI 10.1093/gerona/60.6.744; Geerlings MI, 2008, NEUROLOGY, V70, P1258, DOI 10.1212/01.wnl.0000308937.30473.d1; Hamer M, 2009, PSYCHOL MED, V39, P3, DOI 10.1017/S0033291708003681; Hayden KM, 2010, NEUROLOGY, V74, P1524, DOI 10.1212/WNL.0b013e3181dd4423; Helmer C, 1999, NEUROLOGY, V53, P1953, DOI 10.1212/WNL.53.9.1953; Huang TL, 2005, NEUROLOGY, V65, P1409, DOI 10.1212/01.wnl.0000183148.34197.2e; Jessen F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016852; Jorm AF, 2005, AUST NZ J PSYCHIAT, V39, P959, DOI 10.1111/j.1440-1614.2005.01713.x; Karp A, 2004, AM J EPIDEMIOL, V159, P175, DOI 10.1093/aje/kwh018; Kidd PM, 2008, ALTERN MED REV, V13, P85; Kivipelto M, 2006, LANCET NEUROL, V5, P735, DOI 10.1016/S1474-4422(06)70537-3; Knopman DS, 2007, NEUROLOGY, V69, P739, DOI 10.1212/01.wnl.0000267661.65586.33; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Lenoir H, 2011, J ALZHEIMERS DIS, V26, P27, DOI 10.3233/JAD-2011-101614; Li YS, 2001, INT J GERIATR PSYCH, V16, P718, DOI 10.1002/gps.423; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lobo A, 2000, NEUROLOGY, V54, pS4; Lopez OL, 2007, ARCH NEUROL-CHICAGO, V64, P416, DOI 10.1001/archneur.64.3.416; Lu FP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004144; Lyman Gary H, 2005, BMC Med Res Methodol, V5, P14, DOI 10.1186/1471-2288-5-14; Mielke MM, 2010, NEUROLOGY, V75, P1888, DOI 10.1212/WNL.0b013e3181feb2bf; National Institutes of Health, 2002, NAT CHOL ED PROGR EX; Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Power MC, 2011, EPIDEMIOLOGY, V22, P646, DOI 10.1097/EDE.0b013e31822708b5; Presecki P, 2011, COLLEGIUM ANTROPOL, V35, P115; Redolat Rosa, 2012, Curr Top Behav Neurosci, V10, P293, DOI 10.1007/7854_2011_134; Reitz C, 2010, ARCH NEUROL-CHICAGO, V67, P835, DOI 10.1001/archneurol.2010.136; RITCHIE K, 1995, LANCET, V346, P931, DOI 10.1016/S0140-6736(95)91556-7; Rodriguez JJ, 2011, CURR ALZHEIMER RES, V8, P707; Sabia S, 2009, AM J CLIN NUTR, V89, P601, DOI 10.3945/ajcn.2008.26482; Saczynski JS, 2010, NEUROLOGY, V75, P35, DOI 10.1212/WNL.0b013e3181e62138; Saczynski JS, 2006, AM J EPIDEMIOL, V163, P433, DOI 10.1093/aje/kwj061; Sandroff BM, 2012, ACTA NEUROL SCAND, V126, P256, DOI 10.1111/j.1600-0404.2011.01634.x; Scarmeas N, 2009, JAMA-J AM MED ASSOC, V302, P627, DOI 10.1001/jama.2009.1144; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Solomon A, 2009, DEMENT GERIATR COGN, V28, P75, DOI 10.1159/000231980; Tyas SL, 2001, INT J EPIDEMIOL, V30, P590, DOI 10.1093/ije/30.3.590; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS13, DOI 10.1093/ije/20.Supplement_2.S13; Wang J, 2006, FASEB J, V20, P2313, DOI 10.1096/fj.06-6281com; Weikert M, 2012, MED ENG PHYS, V34, P590, DOI 10.1016/j.medengphy.2011.09.005; Wilson RS, 2007, NEUROLOGY, V69, P1911, DOI 10.1212/01.wnl.0000271087.67782.cb; Zammit S, 2010, BRIT J PSYCHIAT, V197, P207, DOI 10.1192/bjp.bp.109.070904	65	60	68	2	27	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1389-4986	1573-6695		PREV SCI	Prev. Sci.	AUG	2013	14	4					411	421		10.1007/s11121-012-0313-2			11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	173GB	WOS:000321065300007	23319292	Green Published, Other Gold			2021-06-18	
J	Perez-Polo, JR; Rea, HC; Johnson, KM; Parsley, MA; Unabia, GC; Xu, GJ; Infante, SK; DeWitt, DS; Hulsebosch, CE				Perez-Polo, J. Regino; Rea, Harriet C.; Johnson, Kathia M.; Parsley, Margaret A.; Unabia, Geda C.; Xu, GuoJing; Infante, Smitha K.; DeWitt, Douglas S.; Hulsebosch, Claire E.			Inflammatory Consequences in a Rodent Model of Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; blood-brain barrier; cytokines; inflammation; mild traumatic brain injury	SPINAL-CORD-INJURY; NECROSIS-FACTOR-ALPHA; CENTRAL NEUROPATHIC PAIN; INTERLEUKIN-1 RECEPTOR ANTAGONIST; FIBRILLARY ACIDIC PROTEIN; NATIONAL-FOOTBALL-LEAGUE; RAT-BRAIN; CYTOKINE PRODUCTION; MESSENGER-RNA; HEAD-INJURY	Mild traumatic brain injury (mTBI), particularly mild "blast type'' injuries resulting from improvised exploding devices and many sport-caused injuries to the brain, result in long-term impairment of cognition and behavior. Our central hypothesis is that there are inflammatory consequences to mTBI that persist over time and, in part, are responsible for resultant pathogenesis and clinical outcomes. We used an adaptation (1 atmosphere pressure) of a well-characterized moderate-to-severe brain lateral fluid percussion (LFP) brain injury rat model. Our mild LFP injury resulted in acute increases in interleukin-1 alpha/beta and tumor necrosis factor alpha levels, macrophage/microglial and astrocytic activation, evidence of heightened cellular stress, and blood-brain barrier (BBB) dysfunction that were evident as early as 3-6 h postinjury. Both glial activation and BBB dysfunction persisted for 18 days postinjury.	[Perez-Polo, J. Regino; Rea, Harriet C.; Johnson, Kathia M.; Parsley, Margaret A.; Unabia, Geda C.; Xu, GuoJing; Infante, Smitha K.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Parsley, Margaret A.; DeWitt, Douglas S.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Hulsebosch, Claire E.] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	Perez-Polo, JR (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	regino.perez-polo@utmb.edu					Akuzawa S, 2008, J VASC SURG, V48, P694, DOI 10.1016/j.jvs.2008.04.011; Alkire MT, 2007, ANESTHESIOLOGY, V107, P264, DOI 10.1097/01.anes.0000270741.33766.24; Banwell V, 2009, J STROKE CEREBROVASC, V18, P269, DOI 10.1016/j.jstrokecerebrovasdis.2008.11.009; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Brambilla R, 2009, J NEUROCHEM, V110, P765, DOI 10.1111/j.1471-4159.2009.06190.x; Brochu ME, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-55; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crown ED, 2008, EXP NEUROL, V213, P257, DOI 10.1016/j.expneurol.2008.05.025; de Leo JA, 2006, PAIN, V122, P17, DOI 10.1016/j.pain.2006.02.034; Department of Veterans Affairs, 2009, CLIN PRACT GUID MAN; Detloff MR, 2008, EXP NEUROL, V212, P337, DOI 10.1016/j.expneurol.2008.04.009; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dinarello CA, 2011, EUR J IMMUNOL, V41, P1203, DOI 10.1002/eji.201141550; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doll H, 2009, J NEUROTRAUM, V26, P235, DOI 10.1089/neu.2008.0741; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Ekmark-Lewen S, 2010, J NEUROTRAUM, V27, P1643, DOI 10.1089/neu.2009.0953; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Fabian RH, 2004, INT J DEV NEUROSCI, V22, P225, DOI 10.1016/j.ijdevneu.2004.03.006; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Genovese T, 2009, J NEUROCHEM, V108, P1360, DOI 10.1111/j.1471-4159.2009.05899.x; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Gwak YS, 2008, PAIN, V138, P410, DOI 10.1016/j.pain.2008.01.021; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hu XM, 2005, J NEUROCHEM, V93, P26, DOI 10.1111/j.1471-4159.2004.02968.x; Hulsebosch CE, 2005, CURR PHARM DESIGN, V11, P1411, DOI 10.2174/1381612053507864; Hulsebosch CE, 2008, EXP NEUROL, V214, P6, DOI 10.1016/j.expneurol.2008.07.016; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; LASEK RJ, 1974, P NATL ACAD SCI USA, V71, P1188, DOI 10.1073/pnas.71.4.1188; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lee SI, 2010, J NEUROSCI RES, V88, P2409, DOI 10.1002/jnr.22411; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Lu HB, 2010, NEUROIMAGE, V50, P7, DOI 10.1016/j.neuroimage.2009.12.053; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; McAdoo DJ, 1999, EXP NEUROL, V159, P538, DOI 10.1006/exnr.1999.7166; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Nesic O, 2005, J NEUROCHEM, V95, P998, DOI 10.1111/j.1471-4159.2005.03462.x; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Nguyen HT, 2009, ANESTHESIOLOGY, V110, P326, DOI 10.1097/ALN.0b013e3181942b5b; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Shafer RA, 1997, GLIA, V21, P370, DOI 10.1002/(SICI)1098-1136(199712)21:4<370::AID-GLIA4>3.0.CO;2-7; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Tai PA, 2010, J NEUROTRAUM, V27, P1121, DOI 10.1089/neu.2009.1162; TANAKA M, 1994, J NEUROCHEM, V63, P266; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3574, DOI 10.2174/138161208786848739; VILLEGAS J, 1972, J PHYSIOL-LONDON, V225, P275, DOI 10.1113/jphysiol.1972.sp009940; Ward JL, 2011, J TRAUMA, V70, P1471, DOI 10.1097/TA.0b013e31821c38bd; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xiong Ye, 2004, J Stroke Cerebrovasc Dis, V13, P129, DOI 10.1016/j.jstrokecerebrovasdis.2004.05.001; Xu GY, 2008, NEUROSCIENCE, V153, P1034, DOI 10.1016/j.neuroscience.2008.02.065; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhou ZG, 2009, EXP NEUROL, V220, P183, DOI 10.1016/j.expneurol.2009.08.018	79	60	62	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		727	740		10.1089/neu.2012.2650			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600005	23360201	Green Published			2021-06-18	
J	Virji-Babul, N; Borich, MR; Makan, N; Moore, T; Frew, K; Emery, CA; Boyd, LA				Virji-Babul, Naznin; Borich, Michael R.; Makan, Nadia; Moore, Tiffany; Frew, Kira; Emery, Carolyn A.; Boyd, Lara A.			Diffusion Tensor Imaging of Sports-Related Concussion in Adolescents	PEDIATRIC NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURY; ANISOTROPY; CHILDREN; LESIONS; STROKE	Concussion is among the least understood neurologic injuries. The impact of concussion on the adolescent brain remains largely unknown. This study sought to establish short-term changes in white-matter integrity after sports-related concussion in adolescents, and examine the association between changes in white-matter integrity and a clinical measure of concussion. Twelve adolescents, aged 14-17 years with a sports-related concussion within 2 months, and 10 age-matched adolescents with no history of concussion were evaluated with the Sports Concussion Assessment Tool 2 and diffusion tensor imaging. Two measures compared the two groups: fractional anisotropy and mean diffusivity. Whole-brain fractional anisotropy values significantly increased (F(1,40) = 6.29, P = 0.010), and mean diffusivity values decreased (F(1,40) = 4.75, P = 0.036), in concussed athletes compared with control participants. Total scores on the Sports Concussion Assessment Tool 2 were associated with whole-brain fractional anisotropy. Mean diffusivity values with lower scores were associated with higher fractional anisotropy (R-2 = 0.25, P = 0.017) and lower mean diffusivity (R-2 = 0.20, P = 0.038). We provide evidence of structural changes in the integrity of white matter in adolescent athletes after sports-related concussion. (C) 2013 Elsevier Inc. All rights reserved.	[Virji-Babul, Naznin; Borich, Michael R.; Makan, Nadia; Moore, Tiffany; Frew, Kira; Boyd, Lara A.] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V6T 1Z3, Canada; [Virji-Babul, Naznin] Child & Family Res Inst, Vancouver, BC, Canada; [Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Emery, Carolyn A.] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst Child & Maternal, Calgary, AB, Canada	Virji-Babul, N (corresponding author), Univ British Columbia, Dept Phys Therapy, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	nvb31@mail.ubc.ca	Borich, Michael Robert/E-1683-2011; Emery, Carolyn/AAI-2761-2020	Borich, Michael Robert/0000-0002-0469-6282; Virji-Babul, Naznin/0000-0002-8984-5848	Martha Piper Research Fund; Brain Research Centre at the University of British Columbia; University of British Columbia; British Columbia Hockey; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Canada Research ChairsCanada Research ChairsCGIAR; Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research	This research was supported by the Martha Piper Research Fund, the Brain Research Centre at the University of British Columbia, and the University of British Columbia. The authors thank British Columbia Hockey for their support and all the participants, trainers, and coaches who contributed to this study. M.R.B. received salary support from the Heart and Stroke Foundation of Canada. The Canada Research Chairs and Michael Smith Foundation for Health Research support L.A.B. The authors also thank Alex Rauscher, PhD for his assistance with the magnetic resonance imaging protocol, and Shelina Babul-Wellar, PhD for help with participant recruitment.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Bhagat YA, 2006, J CEREBR BLOOD F MET, V26, P1442, DOI 10.1038/sj.jcbfm.9600294; Billette J- M, INJURIES CANADA INSI; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Green HAL, 2002, STROKE, V33, P1517, DOI 10.1161/01.STR.0000016973.80180.7B; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mori S., 2005, MRI ATLAS HUMAN WHIT; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Talairach J., 1988, COPLANAR STEREOTAXIC; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	31	60	64	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	JAN	2013	48	1					24	29		10.1016/j.pediatrneurol.2012.09.005			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	079VC	WOS:000314199300005	23290016				2021-06-18	
J	Zhao, ZR; Loane, DJ; Murray, MG; Stoica, BA; Faden, AI				Zhao, Zaorui; Loane, David J.; Murray, Michael G., II; Stoica, Bogdan A.; Faden, Alan I.			Comparing the Predictive Value of Multiple Cognitive, Affective, and Motor Tasks after Rodent Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; composite score; controlled cortical impact; correlation; traumatic brain injury	CONTROLLED CORTICAL IMPACT; RECOGNITION MEMORY; SEARCH STRATEGIES; SPATIAL MEMORY; HEAD-INJURY; RATS; RECOVERY; DEFICITS; MODEL; IMPAIRMENT	Controlled cortical impact injury (CCI) is a widely-used, clinically-relevant model of traumatic brain injury (TBI). Although functional outcomes have been used for years in this model, little work has been done to compare the predictive value of various cognitive and sensorimotor assessment tests, singly or in combination. Such information would be particularly useful for assessing mechanisms of injury or therapeutic interventions. Following isoflurane anesthesia, C57BL/6 mice were subjected to sham, mild (5.0 m/sec), moderate (6.0 m/sec), or severe (7.5 m/sec) CCI. A battery of behavioral tests were evaluated and compared, including the standard Morris water maze (sMWM), reversal Morris water maze (rMWM), novel object recognition (NOR), passive avoidance (PA), tail-suspension (TS), beam walk (BW), and open-field locomotor activity. The BW task, performed at post-injury days (PID) 0, 1, 3, 7, 14, 21, and 28, showed good discrimination as a function of injury severity. The sMWM and rMWM tests (PID 14-23), as well as NOR (PID 24 and 25), effectively discriminated spatial and novel object learning and memory across injury severity levels. Notably, the rMWM showed the greatest separation between mild and moderate/severe injury. PA (PID 27 and 28) and TS (PID 24) also reflected differences across injury levels, but to a lesser degree. We also compared individual functional measures with histological outcomes such as lesion volume and neuronal cell loss across anatomical regions. In addition, we created a novel composite behavioral score index from individual complementary behavioral scores, and it provided superior discrimination across injury severities compared to individual tests. In summary, this study demonstrates the feasibility of using a larger number of complementary functional outcome behavioral tests than those traditionally employed to follow post-traumatic recovery after TBI, and suggests that the composite score may be a helpful tool for screening new neuroprotective agents or for addressing injury mechanisms.	[Zhao, Zaorui] Univ Maryland, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Hlth Sci Facil HSFI 1, Baltimore, MD 21201 USA; Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA	Zhao, ZR (corresponding author), Univ Maryland, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Hlth Sci Facil HSFI 1, 685 W Baltimore St,Room 263, Baltimore, MD 21201 USA.	zzhao@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 (NS052568), R01 (NS061839)]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839, R01NS052568] Funding Source: NIH RePORTER	We thank Rainier Cabatbat for expert technical support and Dr. Shruti Kabadi and Dr. Ming Tan for helpful discussion. This work was supported by NIH grants R01 (NS052568) and R01 (NS061839) to A.I.F.	BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Best P. J., 1979, PHYSIOL BEHAV, V10, P193; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; BOUTON ME, 1993, PSYCHOL BULL, V114, P80, DOI 10.1037/0033-2909.114.1.80; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Byrnes KR, 2009, ANN NEUROL, V66, P63, DOI 10.1002/ana.21673; Clark RE, 2000, J NEUROSCI, V20, P8853; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donkin JJ, 2011, J NEUROTRAUM, V28, P217, DOI 10.1089/neu.2010.1632; Duffy S, 2008, NEUROPSYCHOPHARMACOL, V33, P1004, DOI 10.1038/sj.npp.1301486; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; Gresack JE, 2007, NEUROBIOL LEARN MEM, V88, P393, DOI 10.1016/j.nlm.2007.07.015; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Janus C, 2004, LEARN MEMORY, V11, P337, DOI 10.1101/lm.70104; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Labrie V, 2009, LEARN MEMORY, V16, P28, DOI 10.1101/lm.1112209; Lattal KM, 2001, J NEUROSCI, V21, P5773; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MOSER E, 1993, J NEUROSCI, V13, P3916; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; O'Leary TP, 2011, BEHAV BRAIN RES, V216, P531, DOI 10.1016/j.bbr.2010.08.030; Pajoohesh-Ganji A, 2010, NEUROSCI RES, V67, P117, DOI 10.1016/j.neures.2010.02.009; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Rossato JI, 2006, LEARN MEMORY, V13, P431, DOI 10.1101/lm.315206; RUSSO NJ, 1976, PHYSIOL BEHAV, V16, P191, DOI 10.1016/0031-9384(76)90304-8; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; Varvel SA, 2005, PSYCHOPHARMACOLOGY, V179, P863, DOI 10.1007/s00213-004-2121-2; Wan HM, 1999, J NEUROSCI, V19, P1142; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whiting M. D., 2006, ANIMAL MODELS COGNIT; Xu J, 2009, J NEUROSCI, V29, P3676, DOI 10.1523/JNEUROSCI.5716-08.2009; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang HT, 2008, NEUROPSYCHOPHARMACOL, V33, P1611, DOI 10.1038/sj.npp.1301537; Zhao ZR, 2010, P NATL ACAD SCI USA, V107, P5605, DOI 10.1073/pnas.0910578107	74	60	62	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2012	29	15					2475	2489		10.1089/neu.2012.2511			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	022NY	WOS:000309967300005	22924665	Green Published			2021-06-18	
J	King, D; Clark, T; Gissane, C				King, Doug; Clark, Trevor; Gissane, Conor			Use of a rapid visual screening tool for the assessment of concussion in amateur rugby league: A pilot study	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Vision; Eye movements; Sports-related concussion; King-Devick test	SPORTS-RELATED CONCUSSION; RELIABILITY; SYMPTOMS; TESTS	Aim: This study undertook to use the K-D sideline test with the SCAT2 to see if concussions could be identified in amateur rugby league players over a representative competition period. Method: A prospective cohort study was conducted on two teams participating in an amateur rugby league. All players were tested for signs of concussion utilising the K-D test and players with longer times than their baseline scores undertook a further concussion assessment with the SCAT2. Results: Five athletes with suspected concussion were evaluated by K-D testing. Three concussions were associated with witnessed events during the matches and two athletes were identified by the team medic as having longer K-D time scores incidentally post-match compared to baseline. Post-match K-D scores for all concussed athletes were worse than baseline for those with reported or witnessed concussion events (7 s; 5.0-7.1; p = 0.025) and for those identified incidentally (>5 s; 8.9-9.1 s). Both groups also reported more symptoms on the PCSS (a part of the SCAT2) post-match. Discussion: In this rugby cohort, the K-D test was not only useful in identifying changes in players with witnessed head trauma, but in identifying changes in players with an un-witnessed suspected concussion. (c) 2012 Elsevier B.V. All rights reserved.	[King, Doug] Auckland Univ Technol, Fac Hlth & Environm Sci, Sch Sport & Recreat, Sports Performance Res Inst New Zealand, Auckland, New Zealand; [Clark, Trevor] Massey Univ, Res Ctr Maori Hlth & Dev, Te Pumanawa Hauora, Wellington, New Zealand; [Gissane, Conor] St Marys Univ Coll, Sch Sport Hlth & Appl Sci, Twickenham, Middx, England	King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	dking@autac.nz	Gissane, Conor/I-3661-2019	Gissane, Conor/0000-0003-4677-3853; Clark, Dr Trevor/0000-0002-2853-0068			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Heitger M., 2008, C P IEEE ENG MED BIO; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; King DA, 2009, J SCI MED SPORT, V12, P12, DOI 10.1016/j.jsams.2007.12.001; King DA, 2009, NZ J SPORTS MED, V36, P6; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020	20	60	61	0	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	SEP 15	2012	320	1-2					16	21		10.1016/j.jns.2012.05.049			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	000JC	WOS:000308381600004	22694977				2021-06-18	
J	Menditto, VG; Lucci, M; Polonara, S; Pomponio, G; Gabrielli, A				Menditto, Vincenzo G.; Lucci, Moira; Polonara, Stefano; Pomponio, Giovanni; Gabrielli, Armando			Management of Minor Head Injury in Patients Receiving Oral Anticoagulant Therapy: A Prospective Study of a 24-Hour Observation Protocol	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; PREINJURY WARFARIN USE; COMPUTED-TOMOGRAPHY; CT; RISK	Study objective: Patients receiving warfarin who experience minor head injury are at risk of intracranial hemorrhage, and optimal management after a single head computed tomography (CT) scan is unclear. We evaluate a protocol of 24-hour observation followed by a second head CT scan. Methods: In this prospective case series, we enrolled consecutive patients receiving warfarin and showing no intracranial lesions on a first CT scan after minor head injury treated at a Level II trauma center. We implemented a structured clinical pathway, including 24-hour observation and a CT scan performed before discharge. We then evaluated the frequency of death, admission, neurosurgery, and delayed intracranial hemorrhage. Results: We enrolled and observed 97 consecutive patients. Ten refused the second CT scan and were well during 30-day follow-up. Repeated CT scanning in the remaining 87 patients revealed a new hemorrhage lesion in 5 (6%), with 3 subsequently hospitalized and 1 receiving craniotomy. Two patients discharged after completing the study protocol with 2 negative CT scan results were admitted 2 and 8 days later with symptomatic subdural hematomas; neither received surgery. Two of the 5 patients with delayed bleeding at 24 hours had an initial international normalized ratio greater than 3.0, as did both patients with delayed bleeding beyond 24 hours. The relative risk of delayed hemorrhage with an initial international normalized ratio greater than 3.0 was 14 (95% confidence interval 4 to 49). Conclusion: For patients receiving warfarin who experience minor head injury and have a negative initial head CT scan result, a protocol of 24-hour observation followed by a second CT scan will identify most occurrences of delayed bleeding. An initial international normalized ratio greater than 3 suggests higher risk. [Ann Emerg Med. 2012;59:451-455.]	[Menditto, Vincenzo G.; Polonara, Stefano] Osped Riuniti Ancona, Emergency Dept, Ancona, Italy; [Lucci, Moira; Pomponio, Giovanni; Gabrielli, Armando] Univ Politecn Marche, Dept Internal Med, Ancona, Italy	Menditto, VG (corresponding author), Osped Riuniti Ancona, Emergency Dept, Ancona, Italy.	vincenzomenditto74@yahoo.it	Gabrielli, Armando/AAC-3173-2019; menditto, vincenzo g/ABF-1651-2020	menditto, vincenzo g/0000-0001-6231-2251			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Kaen A, 2010, J TRAUMA, V68, P895, DOI 10.1097/TA.0b013e3181b28a76; Karni A, 2001, AM SURGEON, V67, P1098; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Leiblich A, 2011, EMERG MED J, V28, P115, DOI 10.1136/emj.2009.079442; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Mascarenhas Lino, 2006, Neurosurgery, V59, pE1152; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; Saab M, 1996, J ACCID EMERG MED, V13, P208; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Turedi S, 2008, J EMERG MED, V34, P253, DOI 10.1016/j.jemermed.2007.05.055; Volans AP, 1998, J ACCID EMERG MED, V15, P159; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	25	60	63	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JUN	2012	59	6					451	455		10.1016/j.annemergmed.2011.12.003			5	Emergency Medicine	Emergency Medicine	959HA	WOS:000305302300002	22244878				2021-06-18	
J	Lu, J; Ng, KC; Ling, G; Wu, J; Poon, DJF; Kan, EM; Tan, MH; Wu, YJ; Li, P; Moochhala, S; Yap, E; Lee, LKH; Teo, M; Yeh, IB; Sergio, DMB; Chua, F; Kumar, SD; Ling, EA				Lu, Jia; Ng, Kian Chye; Ling, Geoffrey; Wu, Jian; Poon, David Jia Fei; Kan, Enci Mary; Tan, Mui Hong; Wu, Ya Jun; Li, Ping; Moochhala, Shabbir; Yap, Eric; Lee, Lionel Kim Hock; Teo, Melissa; Yeh, Ing Berne; Sergio, Darvi Michell Bufete; Chua, Frederic; Kumar, Srinivasan Dinesh; Ling, Eng-Ang			Effect of Blast Exposure on the Brain Structure and Cognition in Macaca fascicularis	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; immunohistochemistry; magnetic resonance imaging; models of injury; traumatic brain injury	DIFFUSE AXONAL INJURY; PROINFLAMMATORY CYTOKINES; MICROGLIA; CELL; PRESSURE; NEURONS; PROTEIN; TRAUMA; DAMAGE; EXPRESSION	Blast injury to the brain is one of the major causes of death and can also significantly affect cognition and physical and psychological skills in survivors of blast. The complex mechanisms via which blast injury causes impairment of cognition and other symptoms are poorly understood. In this study, we investigated the effects of varying degrees of primary blast overpressure (BOP; 80 and 200 kPa) on the pathophysiological and magnetic resonance imaging (MRI) changes and neurocognitive performance as assessed by the monkey Cambridge Neuropsychological Test Automated Battery (mCANTAB) in non-human primates (NHP). The study aimed to examine the effects of neurobehavioral and histopathological changes in NHP. MRI and histopathology revealed ultrastructural changes in the brain, notably in the Purkinje neurons in the cerebellum and pyramidal neurons in the hippocampus, which were most vulnerable to the blast. The results correlated well with the behavioral changes and changes in motor coordination and working memory of the affected monkeys. In addition, there was white matter damage affecting myelinated axons, astrocytic hypertrophy, and increased aquaporin-4 (AQP-4) expression in astrocytes, suggesting cerebral edema. Increased apoptosis appeared to involve astrocytes and oligodendrocytes in the animals following blast exposure. The small sample size could have contributed to the non-significant outcome in cognitive performance post-blast and limited quantitative analyses. Nevertheless, the study has provided initial descriptive changes for establishing a primary BOP threshold for brain injury to serve as a useful platform for future investigations that aim to estimate brain injury potential and set safe limits of exposure.	[Lu, Jia] DSO Natl Labs, Def Med & Environm Res Inst, Combat Care Lab, Singapore 117510, Singapore; [Ling, Geoffrey] DARPA, Arlington, VA USA; [Lu, Jia; Wu, Ya Jun; Li, Ping; Kumar, Srinivasan Dinesh; Ling, Eng-Ang] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117595, Singapore; [Yeh, Ing Berne] Alexandra Hosp, Dept Radiol, Singapore, Singapore; [Sergio, Darvi Michell Bufete] Singapore Gen Hosp, Singhlth Expt Med Ctr, Singapore 0316, Singapore	Lu, J (corresponding author), DSO Natl Labs, Def Med & Environm Res Inst, Combat Care Lab, 27 Med Dr, Singapore 117510, Singapore.	ljia@dso.org.sg	Lee, Lionel/F-3394-2015; Srinivasan, Dinesh Kumar/A-9872-2008; Srinivasan, Dinesh Kumar/P-6528-2019; Srinivasan, Dinesh Kumar/E-6383-2017	Srinivasan, Dinesh Kumar/0000-0001-6535-5441; Srinivasan, Dinesh Kumar/0000-0001-6535-5441; Sergio, Darvi Michell/0000-0002-5480-8094; Wu, Yajun/0000-0001-9598-4433; MOOCHHALA, SHABBIR/0000-0003-4521-3192	Defense Advanced Research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)	This study was supported by a research grant from Phase I of the PREVENT blast research program from the Defense Advanced Research Projects Agency (DARPA).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Avidan V, 2005, AM J SURG, V190, P927, DOI 10.1016/j.amjsurg.2005.08.022; Barenberg P, 2001, NEUROSCI RES, V40, P245, DOI 10.1016/S0168-0102(01)00234-6; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Born CT, 2005, SCAND J SURG, V94, P279, DOI 10.1177/145749690509400406; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Cemak I., 1997, INT REV ARMED FORCES, V70, P114; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chang MC, 2010, NEUROREHABILITATION, V26, P347, DOI 10.3233/NRE-2010-0572; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Deng YY, 2008, BRAIN PATHOL, V18, P387, DOI 10.1111/j.1750-3639.2008.00138.x; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Dobbie C.B., 1963, PREBANSHEE CALIBRATI, P62; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; Elsayed NM, 1997, TOXICOLOGY, V121, P81, DOI 10.1016/S0300-483X(97)03657-3; FIFKOVA E, 1985, CELL MOL NEUROBIOL, V5, P47, DOI 10.1007/BF00711085; Fray PJ, 1996, NEUROTOXICOL TERATOL, V18, P499, DOI 10.1016/0892-0362(96)00027-X; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Hausmann R, 2007, INT J LEGAL MED, V121, P175, DOI 10.1007/s00414-006-0122-x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Johnson D.L., 1998, BLAST OVERPRESSURE S; Johnson D.L., 1993, BLAST OVERPRESSURE S; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kaur C, 2005, NEUROSCIENCE, V135, P1217, DOI 10.1016/j.neuroscience.2005.06.023; Kaur C, 1999, HISTOL HISTOPATHOL, V14, P417, DOI 10.14670/HH-14.417; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; LLINAS R, 1989, EUR J NEUROSCI, V1, P587, DOI 10.1111/j.1460-9568.1989.tb00365.x; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Lu J, 2001, BRAIN RES, V889, P344, DOI 10.1016/S0006-8993(00)03235-2; Lukoyanov NV, 2006, BEHAV BRAIN RES, V173, P229, DOI 10.1016/j.bbr.2006.06.026; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Meme W, 2006, FASEB J, V20, P494, DOI 10.1096/fj.05-4297fje; Molteni E, 2008, ANN BIOMED ENG, V36, P1216, DOI 10.1007/s10439-008-9506-z; Nag Sukriti, 2003, Methods Mol Med, V89, P133; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Obhi SS, 2002, MOTOR CONTROL, V6, P319, DOI 10.1123/mcj.6.4.319; Olney JW, 2004, ANESTHESIOLOGY, V101, P273, DOI 10.1097/00000542-200408000-00004; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Risling M, 2002, FOIR0757SE SWED DEF, P1; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; Soriano SG, 2005, ANESTHESIOLOGY, V102, P866, DOI 10.1097/00000542-200504000-00030; Thompson JM, 2008, CAN FAM PHYSICIAN, V54, P1549; Willoughby KA, 2004, J NEUROCHEM, V91, P1284, DOI 10.1111/j.1471-4159.2004.02812.x; Wu J, 2008, ACTA NEUROCHIR SUPPL, V105, P59; Zhou JP, 2008, NEUROREPORT, V19, P1, DOI 10.1097/WNR.0b013e3282f2b4eb	61	60	61	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1434	1454		10.1089/neu.2010.1591			21	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600017	21639720				2021-06-18	
J	Shi, W; Nie, DK; Jin, GH; Chen, WW; Xia, L; Wu, XJ; Su, X; Xu, XD; Ni, LC; Zhang, XA; Zhang, XH; Chen, J				Shi, Wei; Nie, Dekang; Jin, Guohua; Chen, Weiwei; Xia, Liang; Wu, Xiujie; Su, Xing; Xu, Xide; Ni, Lanchun; Zhang, Xianan; Zhang, Xinhua; Chen, Jian			BDNF blended chitosan scaffolds for human umbilical cord MSC transplants in traumatic brain injury therapy	BIOMATERIALS			English	Article						Human umbilical cord mesenchymal stem cells; Chitosan scaffold; Co-culture; Brain-derived neurotrophic factor; Genipin; Neural stem cell	MESENCHYMAL STEM-CELLS; JELLY-DERIVED CELLS; IN-VITRO; NERVE REGENERATION; CEREBRAL-CORTEX; RAT; BLOOD; EXPRESSION; DEFICIT; TUBE	This study tested the cytotoxicity of a BDNF blended chitosan scaffold with human umbilical cord mesenchymal stem cells (hUC-MSCs), and the in vitro effect of BDNF blended chitosan scaffolds on neural stem cell differentiation with the aim of contributing alternative methods in tissue engineering for the treatment of traumatic brain injury (TBI). The chitosan scaffold based on immobilization of BDNF by genipin (GP) as a crosslinking agent referred to hereafter as a CGB scaffold was prepared by freezing-drying technique. hUC-MSCs were co-cultured with the CGB scaffold. Fluorescent nuclear staining (Hoechst 33342) was employed to determine the attachment of the hUC-MSCs to CGB scaffolds on the 1st, 3rd, 7th and 10th day of co-culture. The viability of hUC-MSCs adhered to the CGB scaffold was determined by digesting with 0.25% trypsin and evaluating with the cell counting kit-8 (CCK-8). Prior to this, the diameter and porosity of CGB scaffolds were measured. The amount of BDNF released from CGB over a 30 day period was determined by ELISA Finally, we investigated whether the released BDNF can induce NSC to differentiate into neurons. There were no significant differences in diameter and porosity of individual CGB scaffolds (P > 0.05). There were on average more cells on the CGB scaffold on the first day than on any other day sampled (P < 0.05). The CGB scaffolds released BDNF in a uniform profile, whereas the CB scaffolds only released BDNF during the first 3 days. BDNF released from CGB scaffold promoted neuronal differentiation of NSCs and led to significant differences in differentiation rate and average neuron perimeter compared with the control group. The results of this study demonstrate that CGB scaffolds are biocompatible with hUC-MSCs and that granular CGB scaffolds covered with hUC-MSCs are expected to generate new advances for future treatment of traumatic brain injury. Crown Copyright (c) 2012 Published by Elsevier Ltd. All rights reserved.	[Shi, Wei; Nie, Dekang; Xia, Liang; Wu, Xiujie; Su, Xing; Xu, Xide; Ni, Lanchun; Chen, Jian] Nantong Univ, Affiliated Hosp, Surg Comprehens Lab, Dept Neurosurg, Nantong 226001, Peoples R China; [Nie, Dekang; Jin, Guohua; Chen, Weiwei; Zhang, Xianan; Zhang, Xinhua] Nantong Univ, Dept Anat & Neurobiol, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Peoples R China; [Chen, Weiwei] Ningxia Med Univ, Dept Anat, Yinchuan 750004, Peoples R China	Chen, J (corresponding author), Nantong Univ, Affiliated Hosp, Surg Comprehens Lab, Dept Neurosurg, Nantong 226001, Peoples R China.	zhangxinhua@ntu.edu.cn; chenjian9079@126.com	Zhang, Xinhua/A-3225-2011	Zhang, Xin-hua/0000-0002-5702-6733	National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171130]; Priority Academic Program Development of Jiangsu Higher Education institutions; Application Research Project of Nantong City [K2010040]; Nantong University for Innovation Talent	We thank Department of Human Anatomy of Medical College in Nantong University and Surgical Comprehensive Laboratory in Affiliated Hospital of Nantong University for technical assistance and equipment support. This work was supported by National Nature Science Foundation of China (Grant No. 81171130); A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education institutions; Application Research Project of Nantong City (Grant No. K2010040); The Grant of Nantong University for Innovation Talent.	Cheng MY, 2003, J BIOMAT SCI-POLYM E, V14, P1155, DOI 10.1163/156856203769231628; Dokmeci MR, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3594781; Fukuda J, 2006, BIOMATERIALS, V27, P5259, DOI 10.1016/j.biomaterials.2006.05.044; Hsu YY, 1997, J BIOMED MATER RES, V35, P107, DOI 10.1002/(SICI)1097-4636(199704)35:1<107::AID-JBM11>3.0.CO;2-G; Itoh S, 2003, ARTIF ORGANS, V27, P1079, DOI 10.1111/j.1525-1594.2003.07208.x; Itoh S, 2003, BRAIN RES, V993, P111, DOI 10.1016/j.brainres.2003.09.003; Jiang QS, 2011, CHINESE MED J-PEKING, V124, P1540, DOI 10.3760/cma.j.issn.0366-6999.2011.10.019; Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006-0286; Keilhoff G, 2006, CELL MOL NEUROBIOL, V26, P1235, DOI 10.1007/s10571-006-9029-9; Kim Ju-Yeon, 2010, World J Stem Cells, V2, P34, DOI 10.4252/wjsc.v2.i2.34; Lee JH, 2011, J NEUROL SCI, V300, P86, DOI 10.1016/j.jns.2010.09.025; Lenas P, 2009, TISSUE ENG PART B-RE, V15, P381, DOI [10.1089/ten.teb.2008.0575, 10.1089/ten.TEB.2008.0575]; Li HM, 2011, HISTOCHEM CELL BIOL, V136, P515, DOI 10.1007/s00418-011-0864-5; Li XG, 2009, BIOMATERIALS, V30, P1121, DOI 10.1016/j.biomaterials.2008.10.063; Li ZS, 2005, BIOMATERIALS, V26, P3919, DOI 10.1016/j.biomaterials.2004.09.062; Lim JY, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt79; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mi FL, 2002, BIOMATERIALS, V23, P181, DOI 10.1016/S0142-9612(01)00094-1; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Sanchez-Ramos JR, 2001, EXP NEUROL, V171, P109, DOI 10.1006/exnr.2001.7748; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Sung HW, 1999, J BIOMAT SCI-POLYM E, V10, P63, DOI 10.1163/156856299X00289; Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007-0439; Vindigni V, 2009, INT J MOL SCI, V10, P2972, DOI 10.3390/ijms10072972; Wang G, 2010, ACTA BIOMATER, V6, P3630, DOI 10.1016/j.actbio.2010.03.039; Wang HW, 2011, CHINESE MED J-PEKING, V124, P1534, DOI 10.3760/cma.j.issn.0366-6999.2011.10.018; Weiss ML, 2008, STEM CELLS, V26, P2865, DOI 10.1634/stemcells.2007-1028; Yan Xiao-hua, 2006, Zhonghua Er Ke Za Zhi, V44, P214; Yang YM, 2011, EUR J PHARM BIOPHARM, V79, P519, DOI 10.1016/j.ejpb.2011.06.008; Zhang HT, 2011, NEUROSCI LETT, V487, P118, DOI 10.1016/j.neulet.2010.10.008; Zhang S, 2009, CHIN J TRAUMATOL, V12, P195, DOI 10.3760/cma.j.issn.1008-1275.2009.04.001; Zhao ZQ, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-37	34	60	62	2	60	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	APR	2012	33	11					3119	3126		10.1016/j.biomaterials.2012.01.009			8	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	909JR	WOS:000301561300005	22264526				2021-06-18	
J	Dusick, JR; Wang, CT; Cohan, P; Swerdloff, R; Kelly, DF				Dusick, Joshua R.; Wang, Christina; Cohan, Pejman; Swerdloff, Ronald; Kelly, Daniel F.			Chapter 1: pathophysiology of hypopituitarism in the setting of brain injury	PITUITARY			English	Article						Traumatic brain injury; Pituitary; Hypopituitarism; Pathophysiology	CRITICALLY-ILL PATIENTS; SEVERE HEAD-INJURY; ANTERIOR-PITUITARY FUNCTION; GROWTH-HORMONE; POSTTRAUMATIC HYPOPITUITARISM; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; ADRENAL INSUFFICIENCY; DIABETES-INSIPIDUS; ACUTE-PHASE	The complex pathophysiology of traumatic brain injury (TBI) involves not only the primary mechanical event but also secondary insults such as hypotension, hypoxia, raised intracranial pressure and changes in cerebral blood flow and metabolism. It is increasingly evident that these initial insults as well as transient events and treatments during the early injury phase can impact hypothalamic-pituitary function both acutely and chronically after injury. In turn, untreated pituitary hormonal dysfunction itself can further hinder recovery from brain injury. Secondary adrenal insufficiency, although typically reversible, occurs in up to 50% of intubated TBI victims and is associated with lower systemic blood pressure. Chronic anterior hypopituitarism, although reversible in some patients, persists in 25-40% of moderate and severe TBI survivors and likely contributes to long-term neurobehavioral and quality of life impairment. While the rates and risk factors of acute and chronic pituitary dysfunction have been documented for moderate and severe TBI victims in numerous recent studies, the pathophysiology remains ill-defined. Herein we discuss the hypotheses and available data concerning hypothalamic-pituitary vulnerability in the setting of head injury. Four possible pathophysiological mechanisms are considered: (1) the primary brain injury event, (2) secondary brain insults, (3) the stress of critical illness and (4) medication effects. Although each of these factors appears to be important in determining which hormonal axes are affected, the severity of dysfunction, their time course and possible reversibility, this process remains incompletely understood.	[Kelly, Daniel F.] St Johns Hlth Ctr, John Wayne Canc Inst, Neuroendocrine Tumor Ctr, Santa Monica, CA 90404 USA; [Dusick, Joshua R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; [Wang, Christina; Swerdloff, Ronald] Harbor UCLA Med Ctr, Dept Med, Div Endocrinol, Torrance, CA 90509 USA; [Wang, Christina; Swerdloff, Ronald] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [Cohan, Pejman] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Los Angeles, CA 90095 USA; [Cohan, Pejman] Univ Calif Los Angeles, David Geffen Sch Med, Gonda Diabet Ctr, Los Angeles, CA 90095 USA	Kelly, DF (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, Neuroendocrine Tumor Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	kellyd@jwci.org			NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000124] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000124] Funding Source: NIH RePORTER		Absalom A, 1999, ANAESTHESIA, V54, P861; ADAMS JH, 1966, ACTA ENDOCRINOL-COP, V51, P377, DOI 10.1530/acta.0.0510377; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; [Anonymous], 1999, JAMA, V282, P974; Asa Sylvia L., 1995, P3; Bavisetty S, 2008, NEUROSURGER IN PRESS, V62; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BISTRITZER T, 1981, AM J DIS CHILD, V135, P966, DOI 10.1001/archpedi.1981.02130340070022; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; BROOKS SM, 1972, NEW ENGL J MED, V286, P1125, DOI 10.1056/NEJM197205252862103; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Choileain NN, 2006, SURG-J R COLL SURG E, V4, P23, DOI 10.1016/S1479-666X(06)80018-1; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CROZIER TA, 1987, ANESTHESIOLOGY, V66, P628, DOI 10.1097/00000542-198705000-00006; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DANIEL P M, 1963, Sci Basis Med Annu Rev, P83; DANIEL PM, 1959, LANCET, V2, P927; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dimopoulou I, 2005, NEUROCRIT CARE, V3, P224, DOI 10.1385/NCC:3:3:224; Dimopoulou I, 2005, INTENS CARE MED, V31, P1020, DOI 10.1007/s00134-005-2689-y; EDWARDS OM, 1986, MEDICINE, V65, P281; Estes Susie M, 2005, Pituitary, V8, P267, DOI 10.1007/s11102-006-6053-1; FELLOWS IW, 1983, BRIT MED J, V287, P1835, DOI 10.1136/bmj.287.6408.1835; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; GIRARD J, 1977, J PEDIATR-US, V90, P241, DOI 10.1016/S0022-3476(77)80637-9; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GORCZYCA W, 1987, NEUROSURGERY, V20, P369, DOI 10.1227/00006123-198703000-00003; HALIMI P, 1988, J COMPUT ASSIST TOMO, V12, P135, DOI 10.1097/00004728-198801000-00026; Hana V, 2002, EUR J ENDOCRINOL, V147, P333, DOI 10.1530/eje.0.1470333; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Ho HC, 2004, ARCH SURG-CHICAGO, V139, P1199, DOI 10.1001/archsurg.139.11.1199; Hoen S, 2002, ANESTHESIOLOGY, V97, P807, DOI 10.1097/00000542-200210000-00010; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KLINGBEIL GEG, 1985, ARCH PHYS MED REHAB, V66, P44; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Maas AIR, 2004, ACT NEUR S, V89, P113; Maiya B, 2008, INTENS CARE MED, V34, P468, DOI 10.1007/s00134-007-0902-x; Malerba G, 2005, INTENS CARE MED, V31, P388, DOI 10.1007/s00134-004-2550-8; MASSOL J, 1987, NEURORADIOLOGY, V29, P299, DOI 10.1007/BF00451773; MILLER WL, 1980, NEW ENGL J MED, V302, P724, DOI 10.1056/NEJM198003273021305; Napoli R, 2003, J CLIN ENDOCR METAB, V88, P2817, DOI 10.1210/jc.2003-030144; NEWMAN LH, 1987, ANAESTHESIA, V42, P929, DOI 10.1111/j.1365-2044.1987.tb05362.x; Nierman DM, 1999, CRIT CARE MED, V27, P2418, DOI 10.1097/00003246-199911000-00016; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Rhoton AL, 2002, NEUROSURGERY, V51, pS335, DOI 10.1227/01.NEU.0000028680.51299.00; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Salehi F, 2007, BRAIN INJURY, V21, P651, DOI 10.1080/02699050701426956; Scheepens A, 2000, J PEDIATR ENDOCR MET, V13, P1483; Scheepens A, 2001, NEUROSCIENCE, V104, P677, DOI 10.1016/S0306-4522(01)00109-9; Schenarts CL, 2001, ACAD EMERG MED, V8, P1, DOI 10.1111/j.1553-2712.2001.tb00537.x; Schneider HJ, 2007, J ENDOCRINOL INVEST, V30, pRC9, DOI 10.1007/BF03346291; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; SHEEHAN HL, 1971, AM J OBSTET GYNECOL, V111, P852, DOI 10.1016/0002-9378(71)90500-X; Silha JV, 2005, CLIN ENDOCRINOL, V63, P79, DOI 10.1111/j.1365-2265.2005.02303.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; Van den Berghe G., 2002, VERH K ACAD GENEESKD, V64, P187; Van den Berghe Greet, 2002, Verh K Acad Geneeskd Belg, V64, P167; Vanhorebeek I, 2006, NAT CLIN PRACT ENDOC, V2, P20, DOI 10.1038/ncpendmet0071; WAGNER RL, 1984, NEW ENGL J MED, V310, P1415, DOI 10.1056/NEJM198405313102202; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; Ye P, 1999, ENDOCRINOLOGY, V140, P3063, DOI 10.1210/en.140.7.3063; Ye P, 2002, J NEUROSCI, V22, P6041; Zhong J, 2005, J NEUROSCI RES, V80, P481, DOI 10.1002/jnr.20490	94	60	61	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-341X	1573-7403		PITUITARY	Pituitary	MAR	2012	15	1					2	9		10.1007/s11102-008-0130-6			8	Endocrinology & Metabolism	Endocrinology & Metabolism	904IG	WOS:000301187500001	18481181	Green Accepted			2021-06-18	
J	Peter, SJ; Mofrad, MRK				Peter, Stephen J.; Mofrad, Mohammad R. K.			Computational Modeling of Axonal Microtubule Bundles under Tension	BIOPHYSICAL JOURNAL			English	Article							BRAIN-INJURY; TAU-PROTEIN; MECHANICS; TRANSPORT; NETWORKS; CELLS; DEGENERATION; DENDRITES; FILAMENTS; NEURONS	Microtubule bundles cross-linked by tau protein serve a variety of neurological functions including maintaining mechanical integrity of the axon, promoting axonal growth, and facilitating cargo transport. It has been observed that axonal damage in traumatic brain injury leads to bundle disorientation, loss of axonal viability, and cognitive impairment. This study investigates the initial mechanical response of axonal microtubule bundles under uniaxial tension using a discrete bead-spring representation. Mechanisms of failure due to traumatic stretch loading and their impact on the mechanical response and stability are also characterized. This study indicates that cross-linked axonal microtubule bundles in tension display stiffening behavior similar to a power-law relationship from nonaffine network deformations. Stretching of cross-links and microtubule bending were the primary deformation modes at low stresses. Microtubule stretch was negligible up to tensile stresses of similar to 1 MPa. Bundle failure occurred by failure of cross-links leading to pull-out of microtubules and loss of bundle integrity. This may explain the elongation, undulation, and delayed elasticity of axons following traumatic stretch loading. More extensively cross-linked bundles withstood higher tensile stresses before failing. The bundle mechanical behavior uncovered by these computational techniques should guide future experiments on stretch-injured axons.	[Peter, Stephen J.; Mofrad, Mohammad R. K.] Univ Calif Berkeley, Mol Cell Biomech Lab, Dept Bioengn, Berkeley, CA 94720 USA; [Peter, Stephen J.] Univ Calif Berkeley, Mol Cell Biomech Lab, Dept Mech Engn, Berkeley, CA 94720 USA	Mofrad, MRK (corresponding author), Univ Calif Berkeley, Mol Cell Biomech Lab, Dept Bioengn, Berkeley, CA 94720 USA.	mofrad@berkeley.edu	/R-6010-2019	/0000-0001-7004-4859	Div Of Chem, Bioeng, Env, & Transp SysNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [0829205] Funding Source: National Science Foundation		[Anonymous], 2010, TRAUM BRAIN INJ US; Baas PW, 2006, TRAFFIC, V7, P490, DOI 10.1111/j.1600-0854.2006.00392.x; Bathe M, 2008, BIOPHYS J, V94, P2955, DOI 10.1529/biophysj.107.119743; Becker JS, 2007, J ANAL ATOM SPECTROM, V22, P761, DOI 10.1039/b701440f; Bertaud J, 2010, ACTA BIOMATER, V6, P2457, DOI 10.1016/j.actbio.2010.01.028; Blundell JR, 2009, MACROMOLECULES, V42, P5388, DOI 10.1021/ma9004633; Brangwynne CP, 2006, J CELL BIOL, V173, P733, DOI 10.1083/jcb.200601060; Chandran PL, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.011906; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Claessens MMAE, 2006, NAT MATER, V5, P748, DOI 10.1038/nmat1718; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; Erturk A, 2007, J NEUROSCI, V27, P9169, DOI 10.1523/JNEUROSCI.0612-07.2007; FADIC R, 1985, J COMP NEUROL, V236, P258, DOI 10.1002/cne.902360209; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Guzik BW, 2004, CURR OPIN CELL BIOL, V16, P443, DOI 10.1016/j.ceb.2004.06.002; Head DA, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.108102; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Kim T, 2009, EXP MECH, V49, P91, DOI 10.1007/s11340-007-9091-3; Lele TP, 2007, CELL BIOCHEM BIOPHYS, V47, P348, DOI 10.1007/s12013-007-0013-x; MANDELKOW E, 1995, NEUROBIOL AGING, V16, P347, DOI 10.1016/0197-4580(95)00026-B; Mehrbod M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025627; Mofrad MRK, 2009, ANNU REV FLUID MECH, V41, P433, DOI 10.1146/annurev.fluid.010908.165236; Onck PR, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.178102; Pampaloni F, 2006, P NATL ACAD SCI USA, V103, P10248, DOI 10.1073/pnas.0603931103; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Rodney D, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.108004; Rosenberg KJ, 2008, P NATL ACAD SCI USA, V105, P7445, DOI 10.1073/pnas.0802036105; Sandersius SA, 2008, PHYS BIOL, V5, DOI 10.1088/1478-3975/5/1/015002; Silber J, 2004, HEARING RES, V197, P112, DOI 10.1016/j.heares.2004.06.006; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tolomeo JA, 1997, BIOPHYS J, V73, P2241, DOI 10.1016/S0006-3495(97)78255-9; YU WQ, 1994, J NEUROSCI, V14, P2818	34	60	61	2	22	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0006-3495			BIOPHYS J	Biophys. J.	FEB 22	2012	102	4					749	757		10.1016/j.bpj.2011.11.4024			9	Biophysics	Biophysics	900WE	WOS:000300921600005	22385845	Green Published, Bronze			2021-06-18	
J	Li, ZY; Wang, B; Kan, ZS; Zhang, BL; Yang, Z; Chen, JL; Wang, D; Wei, HJ; Zhang, JN; Jiang, RC				Li, Zhanying; Wang, Bin; Kan, Zhisheng; Zhang, Baoliang; Yang, Zhuo; Chen, Jieli; Wang, Dong; Wei, Huijie; Zhang, Jian-ning; Jiang, Rongcai			Progesterone Increases Circulating Endothelial Progenitor Cells and Induces Neural Regeneration after Traumatic Brain Injury in Aged Rats	JOURNAL OF NEUROTRAUMA			English	Article						aged rats; EPCs; neurological function; progesterone; TBI; vascular remodeling	CD34(+) CELLS; BEHAVIORAL ABNORMALITIES; THERAPEUTIC ANGIOGENESIS; INFLAMMATORY RESPONSE; CEREBRAL EDEMA; BLOOD-VESSELS; NEUROGENESIS; TRANSPLANTATION; VASCULOGENESIS; MOBILIZATION	Vascular remodeling plays a key role in neural regeneration in the injured brain. Circulating endothelial progenitor cells (EPCs) are a mediator of the vascular remodeling process. Previous studies have found that progesterone treatment of traumatic brain injury (TBI) decreases cerebral edema and cellular apoptosis and inhibits inflammation, which in concert promote neuroprotective effects in young adult rats. However, whether progesterone treatment regulates circulating EPC level and fosters vascular remodeling after TBI have not been investigated. In this study, we hypothesize that progesterone treatment following TBI increases circulating EPC levels and promotes vascular remodeling in the injured brain in aged rats. Male Wistar 20-month-old rats were subjected to a moderate unilateral parietal cortical contusion injury and were treated with or without progesterone (n =54/group). Progesterone was administered intraperitoneally at a dose of 16mg/kg at 1 h post-TBI and was subsequently injected subcutaneously daily for 14 days. Neurological functional tests and immnunostaining were performed. Circulating EPCs were measured by flow cytometry. Progesterone treatment significantly improved neurological outcome after TBI measured by the modified neurological severity score, Morris Water Maze and the long term potentiation in the hippocampus as well as increased the circulating EPC levels compared to TBI controls (p<0.05). Progesterone treatment also significantly increased CD34 and CD31 positive cell number and vessel density in the injured brain compared to TBI controls (p<0.05). These data indicate that progesterone treatment of TBI improves multiple neurological functional outcomes, increases the circulating EPC level, and facilitates vascular remodeling in the injured brain after TBI in aged rats.	[Li, Zhanying; Wang, Bin; Zhang, Baoliang; Wang, Dong; Wei, Huijie; Zhang, Jian-ning; Jiang, Rongcai] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Li, Zhanying; Wang, Bin; Zhang, Baoliang; Wang, Dong; Wei, Huijie; Zhang, Jian-ning; Jiang, Rongcai] Tianjin Neurol Inst, Tianjin, Peoples R China; [Li, Zhanying; Wang, Bin; Zhang, Baoliang; Wang, Dong; Wei, Huijie; Zhang, Jian-ning; Jiang, Rongcai] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [Li, Zhanying; Wang, Bin; Zhang, Baoliang; Wang, Dong; Wei, Huijie; Zhang, Jian-ning; Jiang, Rongcai] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin, Peoples R China; [Li, Zhanying; Kan, Zhisheng] Hebei United Univ, Kailuan Hosp, Dept Neurosurg, Tangshan, Peoples R China; [Yang, Zhuo] Nankai Univ, Coll Life Sci, Minist Educ, Sch Med,Key Lab Bioact Mat, Tianjin 300071, Peoples R China; [Chen, Jieli] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA	Jiang, RC (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com; jianghope@gmail.com			National 973 Projects of ChinaNational Basic Research Program of China [2005CB522605]; Application Foundation and Advanced Technology [11JCZDJC18100]	We acknowledge Li Liu and Fanglian Chen in our laboratory for their excellent technical support. We also acknowledge Michael Chopp from Henry Ford Hospital and Jing-fei Dong from Baylor College of Medicine for their suggestions and editing on this manuscript. This work is supported by the National 973 Projects of China (grant 2005CB522605) and Tianjin Research Program of Application Foundation and Advanced Technology (grant 11JCZDJC18100).	Al-Jarrah M, 2010, NEUROREHABILITATION, V26, P369, DOI 10.3233/NRE-2010-0574; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Blann AD, 2006, THROMB HAEMOSTASIS, V95, P49, DOI 10.1160/TH05-07-0527; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Bulut D, 2007, CLIN RES CARDIOL, V96, P258, DOI 10.1007/s00392-007-0494-z; Camara CC, 2010, BRAZ J MED BIOL RES, V43, P657, DOI 10.1590/S0100-879X2010007500050; Campagnolo P, 2010, CIRCULATION, V121, P1735, DOI 10.1161/CIRCULATIONAHA.109.899252; Carr BR, 1998, CONTRACEPTION, V58, p23S, DOI 10.1016/S0010-7824(98)00079-1; Chang EI, 2007, CIRCULATION, V116, P2818, DOI 10.1161/CIRCULATIONAHA.107.715847; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Edelberg JM, 2003, FRONT BIOSCI-LANDMRK, V8, pS1199, DOI 10.2741/1166; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Friedrich EB, 2006, CIRC RES, V98, pE20, DOI 10.1161/01.RES.0000205765.28940.93; Frontczak-Baniewicz M, 2003, ACTA NEUROBIOL EXP, V63, P65; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Ishigami S, 2010, ANTICANCER RES, V30, P2453; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Jin XY, 2008, J ETHNOPHARMACOL, V117, P473, DOI 10.1016/j.jep.2008.02.033; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Kawamoto A, 2006, CIRCULATION, V114, P2163, DOI 10.1161/CIRCULATIONAHA.106.644518; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kiernan TJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-66; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Krupinski J, 2003, NEUROREPORT, V14, P1171, DOI 10.1097/00001756-200306110-00014; Ladhoff J, 2010, CARDIOVASC RES, V88, P121, DOI 10.1093/cvr/cvq109; Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58; Lam CF, 2008, ANESTH ANALG, V107, P686, DOI 10.1213/ane.0b013e31817e6719; Lapergue B, 2007, PROG NEUROBIOL, V83, P349, DOI 10.1016/j.pneurobio.2007.08.001; Lara-Hernandez R, 2010, ANN VASC SURG, V24, P287, DOI 10.1016/j.avsg.2009.10.012; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Maeng YS, 2009, BLOOD, V113, P233, DOI 10.1182/blood-2008-06-162891; Mahooti S, 2000, AM J PATHOL, V157, P75, DOI 10.1016/S0002-9440(10)64519-1; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morris CL, 2003, BRIT J HAEMATOL, V120, P413, DOI 10.1046/j.1365-2141.2003.04107.x; Murasawa S, 2005, PHYSIOLOGY, V20, P36, DOI 10.1152/physiol.00033.2004; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Okada S, 2008, DIABETES CARE, V31, P157, DOI 10.2337/dc07-1125; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rufaihah AJ, 2010, REGEN MED, V5, P231, DOI 10.2217/RME.09.83; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Senegaglia AC, 2010, EXP BIOL MED, V235, P119, DOI 10.1258/ebm.2009.009194; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stellos K, 2010, ARTERIOSCL THROM VAS, V30, P1127, DOI 10.1161/ATVBAHA.110.204370; Su ZJ, 2009, J NEUROTRAUM, V26, P1695, DOI 10.1089/neu.2008.0519; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tian F, 2009, BLOOD, V113, P5352, DOI 10.1182/blood-2008-08-173773; VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Wang JX, 2010, CIRC RES, V106, P1904, DOI 10.1161/CIRCRESAHA.110.221762; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xing CH, 2009, J NEUROSCI RES, V87, P2571, DOI 10.1002/jnr.22076; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Xue S, 2010, NEUROSCI LETT, V473, P186, DOI 10.1016/j.neulet.2010.02.035; Yu H, 2008, CELL ADHES MIGR, V2, P254, DOI 10.4161/cam.2.4.6818; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	83	60	65	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					343	353		10.1089/neu.2011.1807			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300013	21534727	Green Published			2021-06-18	
J	Wang, YF; Song, JH; Denisova, JV; Park, WM; Fontes, JD; Belousov, AB				Wang, Yongfu; Song, Ji-Hoon; Denisova, Janna V.; Park, Won-Mee; Fontes, Joseph D.; Belousov, Andrei B.			Neuronal Gap Junction Coupling Is Regulated by Glutamate and Plays Critical Role in Cell Death during Neuronal Injury	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM; IN-VIVO; EPILEPTIFORM ACTIVITY; ELECTRICAL SYNAPSES; RECEPTOR AGONIST; GLOBAL-ISCHEMIA; RAT NEOCORTEX; EXPRESSION; ACTIVATION	In the mammalian CNS, excessive release of glutamate and overactivation of glutamate receptors are responsible for the secondary (delayed) neuronal death following neuronal injury, including ischemia, traumatic brain injury (TBI), and epilepsy. The coupling of neurons by gap junctions (electrical synapses) increases during neuronal injury. We report here that the ischemic increase in neuronal gap junction coupling is regulated by glutamate via group II metabotropic glutamate receptors (mGluRs). Specifically, using electrotonic coupling, Western blots, and siRNA in the mouse somatosensory cortex in vivo and in vitro, we demonstrate that activation of group II mGluRs increases background levels of neuronal gap junction coupling and expression of connexin 36 (Cx36) (neuronal gap junction protein), and inactivation of group II mGluRs prevents the ischemia-mediated increases in the coupling and Cx36 expression. We also show that the regulation is via cAMP/PKA (cAMP-dependent protein kinase)-dependent signaling and posttranscriptional control of Cx36 expression and that other glutamate receptors are not involved in these regulatory mechanisms. Furthermore, using the analysis of neuronal death, we show that inactivation of group II mGluRs or genetic elimination of Cx36 both dramatically reduce ischemia-mediated neuronal death in vitro and in vivo. Similar results are obtained using in vitro models of TBI and epilepsy. Our results indicate that neuronal gap junction coupling is a critical component of glutamate-dependent neuronal death. They also suggest that causal link among group II mGluR function, neuronal gap junction coupling, and neuronal death has a universal character and operates in different types of neuronal injuries.	[Wang, Yongfu; Song, Ji-Hoon; Denisova, Janna V.; Park, Won-Mee; Belousov, Andrei B.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Fontes, Joseph D.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	Belousov, AB (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 2146 W 39th Ave, Kansas City, KS 66160 USA.	abelousov@kumc.edu		Fontes, Joseph/0000-0003-4796-343X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS064256, HD002528]; University of Kansas Medical Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064256] Funding Source: NIH RePORTER	This work was supported by NIH Grant R01 NS064256 and the University of Kansas Medical Center funds (A.B.B.). Core support was provided by NIH Grant HD002528. We are grateful to Drs. D. Paul and M. Feller for providing us with the Cx36 knock-out mice and Dr. R. Nudo for help with establishing ischemic models.	[Anonymous], STROKE, V25, P2085; [Anonymous], STROKE, V25, P2089; Arumugam H, 2005, NAT NEUROSCI, V8, P1720, DOI 10.1038/nn1588; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bani-Yaghoub M, 1999, DEV GENET, V24, P69, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<69::AID-DVG8>3.0.CO;2-M; Belluardo N, 2000, BRAIN RES, V865, P121, DOI 10.1016/S0006-8993(00)02300-3; Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1; Beraudi A, 2007, EXP EYE RES, V84, P544, DOI 10.1016/j.exer.2006.11.008; Bond A, 2000, J PHARMACOL EXP THER, V294, P800; Chang QA, 2000, J NEUROSCI, V20, P674, DOI 10.1523/JNEUROSCI.20-02-00674.2000; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Conn PJ, 2005, NAT REV NEUROSCI, V6, P787, DOI 10.1038/nrn1763; CONNORS BW, 1983, J NEUROSCI, V3, P773; Cusato K, 2006, CELL DEATH DIFFER, V13, P1707, DOI 10.1038/sj.cdd.4401876; Cusato K, 2003, J NEUROSCI, V23, P6413; Danesh-Meyer HV, 2008, J CLIN NEUROSCI, V15, P1253, DOI 10.1016/j.jocn.2008.08.002; De Cristobal J, 2001, J NEUROCHEM, V79, P456, DOI 10.1046/j.1471-4159.2001.00600.x; de Pina-Benabou MH, 2005, STROKE, V36, P2232, DOI 10.1161/01.STR.0000182239.75969.d8; Deans MR, 2001, NEURON, V31, P477, DOI 10.1016/S0896-6273(01)00373-7; Decrock E, 2009, CELL DEATH DIFFER, V16, P524, DOI 10.1038/cdd.2008.196; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Gajda Z, 2003, EPILEPSIA, V44, P1596, DOI 10.1111/j.0013-9580.2003.25803.x; Garrett FG, 2008, NEURON GLIA BIOL, V4, P295, DOI 10.1017/S1740925X09990093; Hatton GI, 1998, CELL BIOL INT, V22, P765, DOI 10.1006/cbir.1998.0386; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Hormuzdi SG, 2001, NEURON, V31, P487, DOI 10.1016/S0896-6273(01)00387-7; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kandler Karl, 1995, Current Opinion in Neurobiology, V5, P98, DOI 10.1016/0959-4388(95)80093-X; Lobner D, 1994, DIPYRIDAMOLE INCREAS, V390, P38; LOTURCO JJ, 1991, SCIENCE, V252, P563, DOI 10.1126/science.1850552; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Movsesyan VA, 2006, J NEUROTRAUM, V23, P117, DOI 10.1089/neu.2006.23.117; Oguro K, 2001, J NEUROSCI, V21, P7534; Park WM, 2011, J NEUROSCI, V31, P5909, DOI 10.1523/JNEUROSCI.6787-10.2011; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; Peixoto PM, 2009, BIOCH BIOPHYS RES CO; PEREZVELAZQUEZ JL, 1994, J NEUROSCI, V14, P4308; Personius K, 2001, CELL COMMUN ADHES, V8, P329, DOI 10.3109/15419060109080748; Rash JE, 2000, P NATL ACAD SCI USA, V97, P7573, DOI 10.1073/pnas.97.13.7573; Samoilova M, 2003, J NEUROCHEM, V86, P687, DOI 10.1046/j.1471-4159.2003.01893.x; Sohl G, 2005, NAT REV NEUROSCI, V6, P191, DOI 10.1038/nrn1627; Thompson RJ, 2008, SCIENCE, V322, P1555, DOI 10.1126/science.1165209; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vaccari JCDR, 2007, J NEUROPHYSIOL, V98, P2878, DOI 10.1152/jn.00362.2007; Velazquez JLP, 2003, NEUROSCIENTIST, V9, P5, DOI 10.1177/1073858402239586; Wang YF, 2010, J NEUROPHYSIOL, V104, P3551, DOI 10.1152/jn.00656.2010; Wong M, 2001, DEV BRAIN RES, V128, P113, DOI 10.1016/S0165-3806(01)00149-3; Yoshioka H, 2009, NEUROSCI LETT, V461, P266, DOI 10.1016/j.neulet.2009.06.056	48	60	64	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 11	2012	32	2					713	725		10.1523/JNEUROSCI.3872-11.2012			13	Neurosciences	Neurosciences & Neurology	876QE	WOS:000299121800033	22238107	Bronze, Green Accepted, Green Published			2021-06-18	
J	Andelic, N; Anke, A; Skandsen, T; Sigurdardottir, S; Sandhaug, M; Ader, T; Roe, C				Andelic, N.; Anke, A.; Skandsen, T.; Sigurdardottir, S.; Sandhaug, M.; Ader, T.; Roe, C.			Incidence of Hospital-Admitted Severe Traumatic Brain Injury and In-Hospital Fatality in Norway: A National Cohort Study	NEUROEPIDEMIOLOGY			English	Article						Severe traumatic brain injury; Hospital admissions; Adults; epidemiology; Incidence National cohort study; Case-fatality rate	HEAD-INJURY; NORDIC COUNTRIES; EPIDEMIOLOGY; POPULATION; MORTALITY; MANAGEMENT; OUTCOMES; IMPACT; CLASSIFICATION; EUROPE	Aims: The aims of this study were to assess the incidence of hospital-admitted severe traumatic brain injury (TBI) in the adult population in Norway, and to determine whether there were differences in the epidemiological characteristics of severe TBI between rural and urban regions. Methods: A prospective population-based study on adults with severe TBI admitted to the Norwegian Trauma Referral Centres during the 2-year period (2009-2010). The electronic patient register was searched weekly for ICD-10 diagnoses of intracranial injuries (S06.0-S06.9) to identify patients. Severe TBI was defined as lowest unsedated Glasgow Coma Scale Score <= 8 during the first 24 h after injury. Results: The annual age-adjusted incidence was estimated at 5.2/100,000 in 2009 and 4.1/100,000 in 2010. The highest frequency of hospitalized patients was found among the youngest and the oldest age groups. The most common causes of injury were falls and transport accidents. The highest in-hospital case-fatality rate was found among the oldest patients. There were consistent epidemiological characteristics of severe TBI from both rural and urban regions. Conclusions:The incidence of hospital-admitted patients with severe TBI in this national study supports the declining incidence of TBI reported internationally. No major differences were found in epidemiological characteristics between the urban and rural parts of Norway. Copyright (C) 2012 S. Karger AG, Basel	[Andelic, N.; Roe, C.] Oslo Univ Hosp, Dept Phys Med & Rehabil, NO-0424 Oslo, Norway; [Anke, A.] Univ Hosp N Norway, Div Rehabil, Tromso, Norway; [Anke, A.] Univ Tromso, Inst Clin Med, Fac Hlth Sci, Tromso, Norway; [Skandsen, T.] St Olavs Univ Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Skandsen, T.] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway; [Sigurdardottir, S.] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway; [Sandhaug, M.] Sorlandet Hosp, Res Unit, Dept Phys Med & Rehabil, Kristiansand, Norway; [Ader, T.] Haukeland Hosp, Dept Phys Med & Rehabil, N-5021 Bergen, Norway; [Roe, C.] Univ Oslo, Fac Med, Oslo, Norway	Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, NO-0424 Oslo, Norway.	nadand@ous-hf.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Anke, Audny/0000-0002-2491-2560; Andelic, Nada/0000-0002-3719-4406	Norwegian Research CouncilResearch Council of NorwayEuropean Commission	The authors would like to thank the Neurosurgical Department of Stavanger University Hospital for all their help with registrations from their patient registers. Thanks to Unn Manskow, Beate Holmquist Karlsen and Stine Borgen Lund for valuable help with data collection. Special thanks are extended to the Norwegian Patient Registry for personal communication/overview of the ICD-10 diagnoses for patients admitted to the Norwegian hospitals in 2009. This study was supported by grants from the Norwegian Research Council.	Andelic N, 2010, J TRAUMA MANAG OUTCO, V26, P4; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Annoni J M, 1992, Disabil Rehabil, V14, P23; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Falk Ann-Charlotte, 2007, Dev Neurorehabil, V10, P49, DOI 10.1080/13638490600864066; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gerber Linda M, 2009, J Trauma Manag Outcomes, V3, P9, DOI 10.1186/1752-2897-3-9; Heskestad B, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-6; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kelly DF, 2001, WORLD J SURG, V25, P1179; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Norwegian Institute for Alcohol and Drug Research, 2006, ALC DRUGS NORW, P28; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Skandsen T, 2010, MODERATE SEVERE TRAU; Sollid S, 2009, EMERG MED J, V26, P769, DOI 10.1136/emj.2008.061630; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Strand Bjorn Heine, 2003, Tidsskr Nor Laegeforen, V123, P2849; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x	40	60	61	0	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350	1423-0208		NEUROEPIDEMIOLOGY	Neuroepidemiology		2012	38	4					259	267		10.1159/000338032			9	Public, Environmental & Occupational Health; Clinical Neurology	Public, Environmental & Occupational Health; Neurosciences & Neurology	963XV	WOS:000305659200011	22678449	Bronze			2021-06-18	
J	Griffin, JM; Friedemann-Sanchez, G; Jensen, AC; Taylor, BC; Gravely, A; Clothier, B; Simon, AB; Bangerter, A; Pickett, T; Thors, C; Ceperich, S; Poole, J; van Ryn, M				Griffin, Joan M.; Friedemann-Sanchez, Greta; Jensen, Agnes C.; Taylor, Brent C.; Gravely, Amy; Clothier, Barbara; Simon, Alisha Baines; Bangerter, Ann; Pickett, Treven; Thors, Christina; Ceperich, Sherry; Poole, John; van Ryn, Michelle			The Invisible Side of War: Families Caring for US Service Members With Traumatic Brain Injuries and Polytrauma	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						polytrauma; caregiving; families; traumatic brain injury; veterans	CAREGIVER; REHABILITATION; QUALITY; PREDICTORS; DEPRESSION; DEMENTIA; BURDEN; CARE	Objectives: To (1) identify informal caregivers to injured US service members following acute rehabilitation for polytraumatic injuries, principally traumatic brain injury (TBI), and (2) describe the prevalence and variation of care recipient and caregiver experiences. Design: Cross-sectional survey of caregivers. Participants: Caregivers (N = 564) of service members with TBI who received inpatient rehabilitation care in a Veterans Affairs' Polytrauma Rehabilitation Center between 2001 and 2009. Main Outcome Measures: Questions about caregiver and patient characteristics, type, and quantity of care currently being provided. Results: Caregiving responsibilities fall primarily on women (79%), typically a parent (62%) or spouse (32%). After a median 4 years since injury, 22% of patients still required assistance with activities of daily living and instrumental activities of daily living. An additional 48% required assistance with only instrumental activities of daily living. Nearly 25% of caregivers reported more than 40 h/wk of care and another 20% reported 5 to 40 h/wk of care. Of caregivers providing assistance with activities of daily living, 49% provided care >= 80 h/wk. Nearly 60% of caregivers were solely responsible for the caregiving. Most caregivers also reported providing other help, including managing emotions and navigating health and legal systems. Conclusions: Caregivers who provide assistance with either activities of daily living or instrumental activities of daily living may need additional resources to meet the long-term needs of their injured family member.	[Griffin, Joan M.; Jensen, Agnes C.; Taylor, Brent C.; Gravely, Amy; Clothier, Barbara; Simon, Alisha Baines; Bangerter, Ann] Dept Vet Affairs Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Griffin, Joan M.; Taylor, Brent C.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; [Friedemann-Sanchez, Greta] Univ Minnesota, Humphrey Sch Publ Affairs, Minneapolis, MN USA; [Taylor, Brent C.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Pickett, Treven; Ceperich, Sherry] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Pickett, Treven] Virginia Commonwealth Univ, Dept Psychiat, Sch Med, Richmond, VA 23284 USA; [Pickett, Treven] Virginia Commonwealth Univ, Dept PM&R, Sch Med, Richmond, VA 23284 USA; [Pickett, Treven] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Thors, Christina] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Poole, John] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; [van Ryn, Michelle] Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, Minneapolis, MN 55455 USA	Griffin, JM (corresponding author), VA Med Ctr, Ctr Chron Dis Outcomes Res, 1 Vet Dr,Mailstop 110, Minneapolis, MN 55417 USA.	joan.griffin2@va.gov	Taylor, Brent C/A-8069-2009	Taylor, Brent C/0000-0002-2140-8377; Friedemann-Sanchez, Greta/0000-0002-0493-7218	Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs; Health Services Research and Development (HSRD) service [SDR-07-044]	This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and a grant from the Health Services Research and Development (HSR&D) service (SDR-07-044). The findings and conclusions presented in this manuscript are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or HSR&D. The sponsor was not involved in any aspect of the study's design and conduct; data collection, management, analysis, or interpretation of data; or the preparation, review, or approval of the manuscript.	American Association for Public Opinion Research, 2009, STAND DEF FIN DISP C; Badr H, 2010, RISK RESILIENCE US M; Bakas T, 2001, Oncol Nurs Forum, V28, P847; Belle SH, 2006, ANN INTERN MED, V145, P727, DOI 10.7326/0003-4819-145-10-200611210-00005; Burg MM, 1994, ANN BEHAV MED, V16, P115; CARNWATH TCM, 1987, BRIT MED J, V294, P409, DOI 10.1136/bmj.294.6569.409; Chandra A, 2011, RISK AND RESILIENCE IN U S MILITARY FAMILIES, P175, DOI 10.1007/978-1-4419-7064-0_9; Covinsky KE, 2003, J GEN INTERN MED, V18, P1006, DOI 10.1111/j.1525-1497.2003.30103.x; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Griffin JM, 2009, J REHABIL RES DEV, V46, P879, DOI 10.1682/JRRD.2008.08.0104; Hart T, 2007, J HEAD TRAUMA REHAB, V22, P122, DOI 10.1097/01.HTR.0000265100.37059.44; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kreutzer JS, 2010, J HEAD TRAUMA REHAB, V25, P113, DOI 10.1097/HTR.0b013e3181cf0712; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lilly MB, 2007, MILBANK Q, V85, P641, DOI 10.1111/j.1468-0009.2007.00504.x; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; National Alliance for Caregiving AARP, 2010, CAR US 2009; Naumann RB, 2010, TRAFFIC INJ PREV, V11, P353, DOI 10.1080/15389588.2010.486429; Navaie-Waliser M, 2002, AM J PUBLIC HEALTH, V92, P409, DOI 10.2105/AJPH.92.3.409; Navaie-Waliser M, 2002, MED CARE, V40, P1249, DOI 10.1097/00005650-200212000-00012; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Ory MG, 1999, GERONTOLOGIST, V39, P177, DOI 10.1093/geront/39.2.177; Pruchno RA, 2008, GERONTOLOGIST, V48, P820, DOI 10.1093/geront/48.6.820; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Tooth L, 2005, BRAIN INJURY, V19, P963, DOI 10.1080/02699050500110785; van Ryn M, 2011, PSYCHO-ONCOLOGY, V20, P44, DOI 10.1002/pon.1703; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Williamson GM, 2002, HEALTH PSYCHOL, V21, P405, DOI 10.1037//0278-6133.21.4.405; Williamson GM, 2001, PSYCHOL AGING, V16, P217, DOI 10.1037//0882-7974.16.2.217	36	60	60	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					3	13		10.1097/HTR.0b013e3182274260			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400001	21873883				2021-06-18	
J	Hoffmann, M; Lefering, R; Rueger, JM; Kolb, JP; Izbicki, JR; Ruecker, AH; Rupprecht, M; Lehmann, W				Hoffmann, M.; Lefering, R.; Rueger, J. M.; Kolb, J. P.; Izbicki, J. R.; Ruecker, A. H.; Rupprecht, M.; Lehmann, W.		German Soc Trauma Surg	Pupil evaluation in addition to Glasgow Coma Scale components in prediction of traumatic brain injury and mortality	BRITISH JOURNAL OF SURGERY			English	Article							SEVERE HEAD-INJURY; SCORE; MODELS	Background: Early diagnosis and prediction of traumatic brain injury (TBI) is essential for determining treatment strategies and allocating resources. This study evaluated the predictive accuracy of Glasgow Coma Scale (GCS) verbal, motor and eye components alone, or in addition to pupil size and reactivity, for TBI. Methods: A retrospective cohort analysis of data from 51 425 severely injured patients registered in the Trauma Registry of the German Society for Trauma Surgery from 1993 to 2009 was undertaken. Only directly admitted patients alive on admission and with complete data on GCS, pupil size and pupil reactivity were included. The unadjusted predictive roles of GCS components and pupil parameters, alone or in combination, were modelled using area under the receiver operating characteristic (AUROC) curve analyses and multivariable logistic regression regarding presence of TBI and death. Results: Some 24 115 patients fulfilled the study inclusion criteria. Best accuracy for outcome prediction was found for pupil reactivity (AUROC 0.770, 95 per cent confidence interval 0.761 to 0.779) and GCS motor component (AUROC 0.797, 0.788 to 0.805), with less accuracy for GCS eye and verbal components. The combination of pupil reactivity and GCS motor component (AUROC 0.822, 0.814 to 0.830) outmatched the predictive accuracy of GCS alone (AUROC 0.808, 0.800 to 0.815). Pupil reactivity and size were significantly correlated (r(s) = 0.56, P < 0.001). Patients displaying both unequal pupils and fixed pupils were most likely to have TBI (95.1 per cent of 283 patients). Good outcome (Glasgow Outcome Scale score 4 or more) was documented for only 1929 patients (8.0 per cent) showing fixed and bilateral dilated pupils. Conclusion: The best predictive accuracy for presence of TBI was obtained using the GCS components. Pupil reactivity together with the GCS motor component performed best in predicting death.	[Hoffmann, M.; Rueger, J. M.; Kolb, J. P.; Ruecker, A. H.; Rupprecht, M.; Lehmann, W.] Univ Hosp Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Univ Med Ctr Hamburg, D-20246 Hamburg, Germany; [Izbicki, J. R.] Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Hamburg, Germany; [Lefering, R.] Univ Witten Herdecke, Cologne Merheim Med Ctr, Inst Res Operat Med, Cologne, Germany	Hoffmann, M (corresponding author), Univ Hosp Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Univ Med Ctr Hamburg, Martinistr 52, D-20246 Hamburg, Germany.	mi.hoffmann@uke.de	Lehmann, Wolfgang/H-3555-2012				Alkhoury F, 2011, AM SURGEON, V77, P277; Chieregato A, 2010, ACTA ANAESTH SCAND, V54, P696, DOI 10.1111/j.1399-6576.2010.02234.x; Crossman J, 1998, INJURY, V29, P435, DOI 10.1016/S0020-1383(98)00079-5; de Jongh MAC, 2011, BRIT J SURG, V98, P790, DOI 10.1002/bjs.7436; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; Duncan R, 2009, J EMERG MED, V37, P451, DOI 10.1016/j.jemermed.2008.11.026; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Huber-Wagner S, 2009, LANCET, V373, P1455, DOI 10.1016/S0140-6736(09)60232-4; Jain S, 2008, INJURY, V39, P598, DOI 10.1016/j.injury.2007.06.003; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Juarez V J, 1995, J Neurosci Nurs, V27, P283; Klein KU, 2010, BEST PRACT RES-CLIN, V24, P535, DOI 10.1016/j.bpa.2010.10.008; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; Namiki J, 2011, CLIN NEUROL NEUROSUR, V113, P393, DOI 10.1016/j.clineuro.2011.01.001; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Rehn M, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-17; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Soreide K, 2007, WORLD J SURG, V31, P2092, DOI 10.1007/s00268-007-9226-9; TEASDALE G, 1974, LANCET, V2, P81; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Varon J, 2011, AM J EMERG MED	24	60	61	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0007-1323			BRIT J SURG	Br. J. Surg.	JAN	2012	99			1			122	130		10.1002/bjs.7707			9	Surgery	Surgery	930PG	WOS:000303151000020	22441866				2021-06-18	
J	Rona, RJ; Jones, M; Fear, NT; Hull, L; Murphy, D; Machell, L; Coker, B; Iversen, AC; Jones, N; David, AS; Greenberg, N; Hotopf, M; Wessely, S				Rona, Roberto J.; Jones, Margaret; Fear, Nicola T.; Hull, Lisa; Murphy, Dominic; Machell, Louise; Coker, Bolaji; Iversen, Amy C.; Jones, Norman; David, Anthony S.; Greenberg, Neil; Hotopf, Matthew; Wessely, Simon			Mild Traumatic Brain Injury in UK Military Personnel Returning From Afghanistan and Iraq: Cohort and Cross-sectional Analyses	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; postconcussion symptoms; posttraumatic stress disorder; prevalence	POSTTRAUMATIC-STRESS-DISORDER; ENDURING FREEDOM; WAR; VETERANS; HEALTH; DEPLOYMENT; SYMPTOMS	Objectives: To assess (a) the prevalence of mild traumatic brain injury (mTBI) in UK military personnel deployed to Iraq and/or Afghanistan, (b) the risk factors associated with mTBI, and (c) the association between mTBI and subsequent postconcussion symptoms (PCS). Participants: A total of 4620 personnel deployed to Iraq and/or Afghanistan who completed a questionnaire between 2007 and 2009, of whom 2333 were also studied in 2005, participated in the study. Main Outcome Measures: Mild traumatic brain injury during deployment, as identified using a modified version of the Brief Traumatic Brain Injury Screen questionnaire; symptoms associated with PCS in the month before questionnaire completion. Results: The prevalence of mTBI was 4.4%, and the prevalence in those with a combat role was 9.5%. Having an mTBI was associated with current symptoms of posttraumatic stress disorder (adjusted odds ratio (AOR), 5.2; 95% confidence interval [CI], 2.3-11.4), alcohol misuse (AOR, 2.3; 95% CI, 1.4-3.7), and multiple physical symptoms (AOR, 2.6; 95% CI, 1.3-5.2). Only 3 of 9 symptoms remained associated with mTBI after adjustment. Psychological distress and alcohol misuse recorded before deployment were associated with subsequent mTBI. Conclusions: The prevalence of mTBI in UK military is lower than that in the US military. Symptoms of current posttraumatic stress disorder and alcohol misuse are associated with mTBI. Symptoms of mental disorder predated occurrence of mTBI. The majority PCS were not associated with mTBI.	[Rona, Roberto J.] Kings Coll London, Weston Educ Ctr, Kings Ctr Mil Hlth Res, London SE5 9RJ, England; [Fear, Nicola T.; Jones, Norman; Greenberg, Neil] Kings Coll London, Acad Ctr Def Mental Hlth, London SE5 9RJ, England; [David, Anthony S.] Kings Coll London, Inst Psychiat, Sect Cognit Neuropsychiat, London SE5 9RJ, England	Rona, RJ (corresponding author), Kings Coll London, Weston Educ Ctr, Kings Ctr Mil Hlth Res, 10 Cutcombe Rd, London SE5 9RJ, England.	Roberto.rona@kcl.ac.uk	David, Anthony/O-1750-2019; Fear, Nicola/A-1917-2012; David, Anthony S/C-1315-2011; Wessely, Simon C/A-8713-2008; Hotopf, Matthew/E-4971-2010	David, Anthony/0000-0003-0967-774X; Fear, Nicola/0000-0002-5792-2925; David, Anthony S/0000-0003-0967-774X; Wessely, Simon Charles/0000-0002-6743-9929; Hotopf, Matthew/0000-0002-3980-4466; Rona, Roberto/0000-0003-3739-5571; greenberg, neil/0000-0003-4550-2971	UK Ministry of Defence	The UK Ministry of Defence funded this project.	Babor TF, 2001, AU DIT ALCOHOL USE D; Belasco A, 2009, C RES SERV TROOP LEV; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Carlson KF, 2010, J HEAD TRAUMA REHABI, DOI 1097/HTR.0b013e3181e50ef1; Evans RW, 2008, HEADACHE, V48, P1216, DOI 10.1111/j.1526-4610.2008.01216.x; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Fear NT, 2010, LANCET, V375, P1783, DOI 10.1016/S0140-6736(10)60672-1; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Goldberg D, 1988, USERS GUIDE GEN HLTH; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, LANCET, V368, P837, DOI 10.1016/S0140-6736(06)69315-X; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Horn O, 2010, EUR J EPIDEMIOL, V25, P87, DOI 10.1007/s10654-009-9414-z; Hotopf M, 2006, LANCET, V368, P837, DOI 10.1016/S0140-6736(06)69316-1; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Lange RL, J CLIN EXPT NEUROPSY, DOI [10.1080/13803391003645757, DOI 10.1080/13803391003645757]; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shephard Ben, 2000, WAR NERVES SOLDIERS; Tanielian T., 2008, PSYCHOL COGNITIVE IN; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilson J, 2008, J TRAUMA STRESS, V21, P385, DOI 10.1002/jts.20352; IRAQ COALITION CASUA	34	60	61	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					33	44		10.1097/HTR.0b013e318212f814			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400004	22241066				2021-06-18	
J	Simpkins, JW; Singh, M; Brock, C; Etgen, AM				Simpkins, James W.; Singh, Meharvan; Brock, Courtney; Etgen, Anne M.			Neuroprotection and Estrogen Receptors	NEUROENDOCRINOLOGY			English	Article						Estradiol; Estrogens; Nonfeminizing estrogens; Estrogen receptor alpha; Estrogen receptor beta; Traumatic brain injury; Neuroprotection; Cerebral ischemia; Stroke; Spinal cord injury	ACTIVATED PROTEIN-KINASE; CONJUGATED EQUINE ESTROGENS; METABOTROPIC GLUTAMATE RECEPTORS; HORMONE REPLACEMENT THERAPY; MILD COGNITIVE IMPAIRMENT; CEREBRAL-ARTERY OCCLUSION; HEALTH INITIATIVE MEMORY; BETA-ESTRADIOL PROTECTS; GROWTH-FACTOR-I; POSTMENOPAUSAL WOMEN	This review is intended to assess the state of current knowledge on the role of estrogen receptors (ERs) in the neuroprotective effects of estrogens in models for acute neuronal injury and death. We evaluate the overall evidence that estrogens are neuroprotective in acute injury and critically assess the role of ER alpha, ER beta, GPR 30, and nonreceptor-mediated mechanisms in these robust neuroprotective effects of this ovarian steroid hormone. We conclude that all three receptors, as well as nonreceptor-mediated mechanisms can be involved in neuroprotection, depending on the model used, the level of estrogen administrated, and the mode of administration of the steroid. Also, the signaling pathways used by both ER-dependent and ER-independent mechanisms to exert neuroprotection are considered. Finally, further studies that are needed to parse out the relative contribution of receptor versus nonreceptor-mediated signaling are discussed. Copyright (C) 2012 S. Karger AG, Basel	[Simpkins, James W.; Singh, Meharvan; Brock, Courtney] Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Inst Aging & Alzheimers Dis Res, Ft Worth, TX 76107 USA; [Etgen, Anne M.] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10467 USA	Simpkins, JW (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Inst Aging & Alzheimers Dis Res, 3500 Camp Bowie Bvld, Ft Worth, TX 76107 USA.	james.simpkins@unthsc.edu		Singh, Meharvan/0000-0002-8072-1769	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG022550, T32AG020494] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG027956, T32 AG020494, P01 AG022550] Funding Source: Medline		Abdelhamid R, 2011, ACS CHEM NEUROSCI, V2, P256, DOI 10.1021/cn100106a; Aguirre C, 2010, J NEUROCHEM, V115, P1277, DOI 10.1111/j.1471-4159.2010.07038.x; Akama KT, 2003, J NEUROSCI, V23, P2333; Al Sweidi S, 2012, J NEUROENDOCRINOL, V24, P48, DOI 10.1111/j.1365-2826.2011.02193.x; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Amantea D, 2007, FEBS J, V274, P4464, DOI 10.1111/j.1742-4658.2007.05975.x; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; Azcoitia I, 1999, GLIA, V26, P260; Azcoitia I, 2010, EUR J NEUROSCI, V32, P1995, DOI 10.1111/j.1460-9568.2010.07516.x; Bains M, 2007, EXP NEUROL, V204, P767, DOI 10.1016/j.expneurol.2007.01.020; Bao YJ, 2011, MOL CELL NEUROSCI, V48, P185, DOI 10.1016/j.mcn.2011.07.004; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Behl C, 1997, MOL PHARMACOL, V51, P535; Bi RF, 2000, P NATL ACAD SCI USA, V97, P3602, DOI 10.1073/pnas.060034497; BISHOP J, 1994, MOL CELL NEUROSCI, V5, P303, DOI 10.1006/mcne.1994.1036; Bondar G, 2009, J NEUROSCI, V29, P15323, DOI 10.1523/JNEUROSCI.2107-09.2009; Bourque M, 2009, FRONT NEUROENDOCRIN, V30, P142, DOI 10.1016/j.yfrne.2009.04.014; Brann DW, 2007, STEROIDS, V72, P381, DOI 10.1016/j.steroids.2007.02.003; Bryant DN, 2010, NEUROSCIENCE, V170, P1261, DOI 10.1016/j.neuroscience.2010.08.019; Carswell HVO, 2004, AM J PHYSIOL-HEART C, V287, pH1501, DOI 10.1152/ajpheart.00227.2004; Carswell HVO, 2000, AM J PHYSIOL-HEART C, V278, pH290; Chen JF, 2001, ANESTH ANALG, V92, P1520, DOI 10.1097/00000539-200106000-00033; Choi YC, 2004, FUND CLIN PHARMACOL, V18, P547, DOI 10.1111/j.1472-8206.2004.00284.x; Cimarosti H, 2006, NEUROCHEM RES, V31, P483, DOI 10.1007/s11064-006-9043-9; Clark RA, 1997, J ACQ IMMUN DEF SYND, V15, P341, DOI 10.1097/00042560-199708150-00003; Connell BJ, 2011, ADV PHARMACOL SCI, V2011, DOI 10.1155/2011/976951; Cordey M, 2005, BRAIN RES, V1045, P217, DOI 10.1016/j.brainres.2005.03.032; Crawford DK, 2010, BRAIN, V133, P2999, DOI 10.1093/brain/awq237; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; D'Astous M, 2006, MOL PHARMACOL, V69, P1492, DOI 10.1124/mol.105.018671; D'Astous M, 2004, NEUROPHARMACOLOGY, V47, P1180, DOI 10.1016/j.neuropharm.2004.08.020; Dai XN, 2007, NEUROPHARMACOLOGY, V52, P1124, DOI 10.1016/j.neuropharm.2006.11.012; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Dhandapani KM, 2007, EXP GERONTOL, V42, P70, DOI 10.1016/j.exger.2006.06.032; Dominguez R, 2010, J NEUROSCI, V30, P12589, DOI 10.1523/JNEUROSCI.1038-10.2010; Donzelli A, 2010, J PHARMACOL SCI, V114, P158, DOI 10.1254/jphs.10164FP; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Elzer JG, 2010, J CEREBR BLOOD F MET, V30, P935, DOI 10.1038/jcbfm.2009.258; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; Farr TD, 2007, BRAIN RES, V1185, P275, DOI 10.1016/j.brainres.2007.09.009; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; Fitzpatrick JL, 2002, J NEUROCHEM, V82, P674, DOI 10.1046/j.1471-4159.2002.01000.x; Fugger HN, 2001, NEUROSCI LETT, V309, P207, DOI 10.1016/S0304-3940(01)02083-3; Fukuda K, 2000, STROKE, V31, P155, DOI 10.1161/01.STR.31.1.155; Gamerdinger M, 2006, J NEUROCHEM, V97, P57, DOI 10.1111/j.1471-4159.2006.03675.x; Gingerich S, 2010, NEUROSCIENCE, V170, P54, DOI 10.1016/j.neuroscience.2010.06.076; Gorosito SV, 2008, NEUROSCIENCE, V154, P1173, DOI 10.1016/j.neuroscience.2008.05.001; Green PS, 1997, J NEUROSCI, V17, P511; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Grove-Strawser D, 2010, NEUROSCIENCE, V170, P1045, DOI 10.1016/j.neuroscience.2010.08.012; Gu Q, 1999, ENDOCRINOLOGY, V140, P660, DOI 10.1210/en.140.2.660; Guo JB, 2010, J CEREBR BLOOD F MET, V30, P545, DOI 10.1038/jcbfm.2009.226; Hammond R, 2011, BRAIN RES, V1379, P53, DOI 10.1016/j.brainres.2010.11.098; Handa RJ, 2012, NEUROENDOCRINOLOGY, V96, P111, DOI 10.1159/000338397; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Henderson VW, 2010, PROG BRAIN RES, V182, P77, DOI 10.1016/S0079-6123(10)82003-5; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; Horstink MWIM, 2003, ADV NEUROL, V91, P107; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Jover-Mengual T, 2007, ENDOCRINOLOGY, V148, P1131, DOI 10.1210/en.2006-1137; Jover-Mengual T, 2010, BRAIN RES, V1321, P1, DOI 10.1016/j.brainres.2010.01.046; Jung-Testas I, 1998, J STEROID BIOCHEM, V65, P243, DOI 10.1016/S0960-0760(97)00191-X; Kelly MJ, 2009, MOL CELL ENDOCRINOL, V308, P17, DOI 10.1016/j.mce.2009.03.008; Kramar EA, 2009, J NEUROSCI, V29, P12982, DOI 10.1523/JNEUROSCI.3059-09.2009; Kuo J, 2010, J NEUROSCI, V30, P12950, DOI 10.1523/JNEUROSCI.1158-10.2010; Lebesgue D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008642; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Lewis DK, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.007; Liu R, 2007, NEUROSCI LETT, V415, P237, DOI 10.1016/j.neulet.2007.01.074; Liu SB, 2011, CLIN EXP PHARMACOL P, V38, P577, DOI 10.1111/j.1440-1681.2011.05549.x; Liu X, 2005, J NEUROSCI RES, V81, P653, DOI 10.1002/jnr.20583; Luciani P, 2008, ENDOCRINOLOGY, V149, P4256, DOI 10.1210/en.2007-1795; Maki PM, 2001, AM J PSYCHIAT, V158, P227, DOI 10.1176/appi.ajp.158.2.227; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Marder K, 1998, NEUROLOGY, V50, P1141, DOI 10.1212/WNL.50.4.1141; Marin R, 2003, ANN NY ACAD SCI, V1007, P108, DOI 10.1196/annals.1286.011; Marin R, 2008, STEROIDS, V73, P992, DOI 10.1016/j.steroids.2007.12.007; Marin R, 2009, J STEROID BIOCHEM, V114, P2, DOI 10.1016/j.jsbmb.2008.12.014; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; McDowell ML, 2011, NEUROCHEM INT, V59, P175, DOI 10.1016/j.neuint.2011.04.011; Meltser I, 2008, J CLIN INVEST, V118, P1563, DOI 10.1172/JCI32796; Mendelowitsch A, 1901, BRAIN RES, V200, P230; Mendez P, 2005, J ENDOCRINOL, V185, P11, DOI 10.1677/joe.1.06058; Merchenthaler I, 2003, ANN NY ACAD SCI, V1007, P89, DOI 10.1196/annals.1286.009; Micevych PE, 2012, NEUROENDOCRINOLOGY, V96, P103, DOI 10.1159/000338400; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Milner TA, 2001, J COMP NEUROL, V429, P355; Mirshams N, 2011, NEUR M PLANN WASH SO; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Mong JA, 2006, NEUROSCIENCE, V138, P967, DOI 10.1016/j.neuroscience.2005.10.017; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Morissette M, 2008, J STEROID BIOCHEM, V108, P327, DOI 10.1016/j.jsbmb.2007.09.011; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Nishio M, 2004, NEUROSCI LETT, V355, P109, DOI 10.1016/j.neulet.2003.10.064; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; Perez E, 2005, DRUG DEVELOP RES, V66, P78, DOI 10.1002/ddr.20047; Perez E, 2005, BRAIN RES, V1038, P216, DOI 10.1016/j.brainres.2005.01.026; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Picciarelli-Lima P, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-51; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Raz L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027039; Resnick SM, 1998, HORM BEHAV, V34, P171, DOI 10.1006/hbeh.1998.1476; Resnick SM, 2001, ANN NY ACAD SCI, V949, P203; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Richardson TE, 2011, ENDOCRINOLOGY, V152, P2742, DOI 10.1210/en.2011-0184; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Russo R, 2008, PROG BRAIN RES, V173, P583, DOI 10.1016/S0079-6123(08)01144-8; Sampei K, 2000, STROKE, V31, P738, DOI 10.1161/01.STR.31.3.738; Sawada M, 2000, J CEREBR BLOOD F MET, V20, P112, DOI 10.1097/00004647-200001000-00015; Scott E, 2012, FRONT NEUROENDOCRIN, V33, P85, DOI 10.1016/j.yfrne.2011.10.001; Selvamani A, 2010, J NEUROSCI, V30, P6852, DOI 10.1523/JNEUROSCI.0761-10.2010; Sherwin BB, 1997, NEUROLOGY, V48, pS21, DOI 10.1212/WNL.48.5_Suppl_7.21S; Sherwin BB, 1998, P SOC EXP BIOL MED, V217, P17; Shimada K, 2011, HYPERTENSION, V57, P1161, DOI 10.1161/HYPERTENSIONAHA.110.167650; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Singer CA, 1999, J NEUROSCI, V19, P2455; Singh M, 2006, EXP BIOL MED, V231, P514; Singh M, 1999, J NEUROSCI, V19, P1179; Singh M, 2000, J NEUROSCI, V20, P1694; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Spampinato SF, 2012, MOL PHARMACOL, V81, P12, DOI 10.1124/mol.111.074021; Spence RD, 2011, P NATL ACAD SCI USA, V108, P8867, DOI 10.1073/pnas.1103833108; Sribnick EA, 2006, NEUROSCIENCE, V137, P197, DOI 10.1016/j.neuroscience.2005.08.074; Srivastava DP, 2011, J NEUROSCI, V31, P16056, DOI 10.1523/JNEUROSCI.4097-11.2011; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Toran-Allerand CD, 2005, ENDOCRINOLOGY, V146, P3843, DOI 10.1210/en.2004-1616; Toran-Allerand CD, 2002, J NEUROSCI, V22, P8391; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Toung TK, 2000, STROKE, V31, P2701, DOI 10.1161/01.STR.31.11.2701; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wang L, 2008, J CEREBR BLOOD F MET, V28, P1824, DOI 10.1038/jcbfm.2008.70; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Wigginton JG, 2010, CRIT CARE MED, V38, pS620, DOI 10.1097/CCM.0b013e3181f243a9; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Xia Y, 2009, NEUROSCIENCE, V162, P292, DOI 10.1016/j.neuroscience.2009.04.068; Yang LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009851; Yang SH, 2003, ANN NY ACAD SCI, V1007, P101, DOI 10.1196/annals.1286.010; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yang SH, 2001, J CEREBR BLOOD F MET, V21, P174, DOI 10.1097/00004647-200102000-00009; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zhang QG, 2011, P NATL ACAD SCI USA, V108, pE617, DOI 10.1073/pnas.1104391108; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhao LZ, 2007, BRAIN RES, V1172, P48, DOI 10.1016/j.brainres.2007.06.092; Zhao LQ, 2004, BRAIN RES, V1010, P22, DOI 10.1016/j.brainres.2004.02.066; Zhou XH, 2007, DEV NEUROBIOL, V67, P603, DOI 10.1002/dneu.20373	159	60	62	0	21	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0028-3835	1423-0194		NEUROENDOCRINOLOGY	Neuroendocrinology		2012	96	2					119	130		10.1159/000338409			12	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	008SK	WOS:000308976700004	22538356	Green Accepted			2021-06-18	
J	Weir, J; Steyerberg, EW; Butcher, I; Lu, J; Lingsma, HF; McHugh, GS; Roozenbeek, B; Maas, AIR; Murray, GD				Weir, James; Steyerberg, Ewout W.; Butcher, Isabella; Lu, Juan; Lingsma, Hester F.; McHugh, Gillian S.; Roozenbeek, Bob; Maas, Andrew I. R.; Murray, Gordon D.			Does the Extended Glasgow Outcome Scale Add Value to the Conventional Glasgow Outcome Scale?	JOURNAL OF NEUROTRAUMA			English	Article						clinical trial; Glasgow Outcome Scale-Extended; Glasgow Outcome Scale; ordinal analysis; outcome; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; REGRESSION-MODELS; CLINICAL-TRIALS; IMPACT; RELIABILITY; ADJUSTMENT; DISABILITY; VALIDITY; MODERATE	The Glasgow Outcome Scale (GOS) is firmly established as the primary outcome measure for use in Phase III trials of interventions in traumatic brain injury (TBI). However, the GOS has been criticized for its lack of sensitivity to detect small but clinically relevant changes in outcome. The Glasgow Outcome Scale-Extended (GOSE) potentially addresses this criticism, and in this study we estimate the efficiency gain associated with using the GOSE in place of the GOS in ordinal analysis of 6-month outcome. The study uses both simulation and the reanalysis of existing data from two completed TBI studies, one an observational cohort study and the other a randomized controlled trial. As expected, the results show that using an ordinal technique to analyze the GOS gives a substantial gain in efficiency relative to the conventional analysis, which collapses the GOS onto a binary scale (favorable versus unfavorable outcome). We also found that using the GOSE gave a modest but consistent increase in efficiency relative to the GOS in both studies, corresponding to a reduction in the required sample size of the order of 3-5%. We recommend that the GOSE be used in place of the GOS as the primary outcome measure in trials of TBI, with an appropriate ordinal approach being taken to the statistical analysis.	[Murray, Gordon D.] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [Steyerberg, Ewout W.; Lingsma, Hester F.; Roozenbeek, Bob] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Lu, Juan] Virginia Commonwealth Univ, Dept Neurosurg, Med Ctr, Richmond, VA USA; [Roozenbeek, Bob; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium	Murray, GD (corresponding author), Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	Gordon.Murray@ed.ac.uk	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734; Lu, Juan/0000-0002-5389-7603	U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS-042691]; U.K. Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish	This work was supported by the U.S. National Institutes of Health (Clinical Trial Design and Analysis in TBI Project: R01 NS-042691), and the U.K. Medical Research Council (Edinburgh Hub for Trials Methodology Research: G0800803).	Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; Bolland K, 1998, STAT MED, V17, P2835, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2835::AID-SIM933>3.3.CO;2-#; Ford I, 2002, STAT MED, V21, P2899, DOI 10.1002/sim.1294; GOUVIER WD, 1986, INT J CLIN NEUROPSYC, V8, P1; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; HORNE G, 1989, AUST NZ J SURG, V59, P465, DOI 10.1111/j.1445-2197.1989.tb01612.x; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1975, LANCET, V7905, P480; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Livingston M G, 1985, Int Rehabil Med, V7, P145; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Sandset EC, 2011, LANCET, V377, P741, DOI 10.1016/S0140-6736(11)60104-9; SMITH RM, 1979, CLIN NEUROPSYCHOL, V1, P48; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	27	60	63	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					53	58		10.1089/neu.2011.2137			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300005	22026476	Green Published			2021-06-18	
J	Max, JE; Keatley, E; Wilde, EA; Bigler, ED; Levin, HS; Schachar, RJ; Saunders, A; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Yang, TT				Max, Jeffrey E.; Keatley, Eva; Wilde, Elisabeth A.; Bigler, Erin D.; Levin, Harvey S.; Schachar, Russell J.; Saunders, Ann; Ewing-Cobbs, Linda; Chapman, Sandra B.; Dennis, Maureen; Yang, Tony T.			Anxiety Disorders in Children and Adolescents in the First Six Months After Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CLOSED-HEAD INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSONALITY-CHANGE; RELIABILITY; VALIDITY; MOOD; NEUROBIOLOGY; PREDICTORS; DEPRESSION; SCHEDULE	The study's objective was to assess the nature, rate, predictive factors, and neuroimaging correlates of novel (new-onset) definite anxiety disorders and novel definite/subclinical anxiety disorders (in a broader group of children with at least subclinical anxiety disorders) after traumatic brain injury (TBI). Children with TBI from consecutive admissions to five trauma centers were enrolled and studied with psychiatric interviews soon after injury (baseline) and again 6 months post-injury. Novel definite anxiety disorder and novel definite/subclinical anxiety disorders were heterogeneous and occurred in 8.5% (N = 12) and 17% (N = 24) of participants, respectively, in the first 6 months after injury. Novel definite anxiety disorder was significantly associated with younger age at injury and tended to be associated with novel depressive disorder, as well as lesions of the superior frontal gyrus. Novel definite/subclinical anxiety disorder was significantly associated with concurrent psychiatric problems of personality change due to TBI and novel definite/subclinical depressive disorder, as well as with lesions of the superior frontal gyrus and a trend-association with frontal lobe white-matter lesions. These findings suggest that anxiety after childhood TBI may be part of a broader problem of affective dysregulation related to damaged dorsal frontal lobe and frontal white-matter systems, with younger children being at greatest risk for developing novel anxiety disorder after TBI. (The Journal of Neuropsychiatry and Clinical Neurosciences 2011; 23:29-39)	[Max, Jeffrey E.; Keatley, Eva; Yang, Tony T.] Univ Calif San Diego, Dept Psychiat, Childrens Hosp & Hlth Ctr, San Diego, CA 92103 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Schachar, Russell J.] Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr, Dept Pediat, Houston, TX USA; [Saunders, Ann] Univ Texas Hlth Sci Ctr, Dept Psychiat, Houston, TX USA; [Chapman, Sandra B.] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75230 USA	Max, JE (corresponding author), Rady Childrens Hosp, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	National Institute of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800, R01MH085734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This study was supported by National Institute of Mental Health (NIMH) Grant K-08 MH01800 (Dr. Max) and National Institute of Neurological Disorders and Stroke (NINDS) Grant NS-21889 (Dr. Levin).	ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kendler KS, 2008, PSYCHOL MED, V38, P1001, DOI 10.1017/S0033291707001821; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Last CG, 1996, J AM ACAD CHILD PSY, V35, P1502, DOI 10.1097/00004583-199611000-00019; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Mathew SJ, 2008, AM J MED GENET C, V148C, P89, DOI 10.1002/ajmg.c.30172; Max J. E., 2005, J AM ACAD CHILD ADOL, V44, P435; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Ressler KJ, 2007, NAT NEUROSCI, V10, P1116, DOI 10.1038/nn1944; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	34	60	60	0	17	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2011	23	1					29	39		10.1176/appi.neuropsych.23.1.29			11	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	717VY	WOS:000287076700029	21304136				2021-06-18	
J	Hilz, MJ; DeFina, PA; Anders, S; Koehn, J; Lang, CJ; Pauli, E; Flanagan, SR; Schwab, S; Marthol, H				Hilz, Max J.; DeFina, Philip A.; Anders, Stefan; Koehn, Julia; Lang, Christoph J.; Pauli, Elisabeth; Flanagan, Steven R.; Schwab, Stefan; Marthol, Harald			Frequency Analysis Unveils Cardiac Autonomic Dysfunction after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						autonomic dysfunction; baroreflex; cardiovascular modulation; head trauma; TBI	HEART-RATE-VARIABILITY; BAROREFLEX EFFECTIVENESS INDEX; HYPERTENSIVE PATIENTS; PROGNOSTIC VALUE; BLOOD-PRESSURE; SUDDEN-DEATH; SENSITIVITY; ARRHYTHMIAS; MORTALITY; MODULATION	Long-term mortality is increased after mild traumatic brain injury (mTBI). Central cardiovascular-autonomic dysregulation resulting from subtle, trauma-induced brain lesions might contribute to cardiovascular events and fatalities. We investigated whether there is cardiovascular-autonomic dysregulation after mTBI. In 20 mTBI patients (37 +/- 13 years, 5-43 months post-injury) and 20 healthy persons (26 +/- 9 years), we monitored respiration, RR intervals (RRI), blood pressures (BP), while supine and upon standing. We calculated the root mean square successive RRI differences (RMSSD) reflecting cardiovagal modulation, the ratio of maximal and minimal RRIs around the 30th and 15th RRI upon standing (30:15 ratio) reflecting baroreflex sensitivity (BRS), spectral powers of parasympathetic high-frequency (HF: 0.15-0.5 Hz) RRI oscillations, of mainly sympathetic low-frequency (LF: 0.04-0.15 Hz) RRI oscillations, of sympathetic LF-BP oscillations, RRI-LF/HF-ratios reflecting sympathovagal balance, and the gain between BP and RRI oscillations as additional BRS index (BRSgain). We compared supine and standing parameters of patients and controls (repeated measures analysis of variance; significance: p < 0.05). While supine, patients had lower RRIs (874.2 +/- 157.8 vs. 1024.3 +/- 165.4 ms), RMSSDs (30.1 +/- 23.6 vs. 56.3 +/- 31.4 ms), RRI-HF powers (298.1 +/- 309.8 vs. 1507.2 +/- 1591.4 ms(2)), and BRSgain (8.1 +/- 4.4 vs. 12.5 +/- 8.1 ms.mmHg(-1)), but higher RRI-LF/HF-ratios (3.0 +/- 1.9 vs. 1.2 +/- 0.7) than controls. Upon standing, RMSSDs and RRI-HF-powers decreased significantly in controls, but not in patients; patients had lower RRI-30:15-ratios (1.3 +/- 0.3 vs. 1.6 +/- 0.3) and RRI-LF-powers (2450.0 +/- 2110.3 vs. 4805.9 +/- 3453.5 ms(2)) than controls. While supine, mTBI patients had reduced cardiovagal modulation and BRS. Upon standing, their BRS was still reduced, and patients did not withdraw parasympathetic or augment sympathetic modulation adequately. Impaired autonomic modulation probably contributes to cardiovascular irregularities post-mTBI.	[Hilz, Max J.] NYU, Sch Med, Dept Neurol, New York, NY 10016 USA; [Hilz, Max J.] NYU, Dept Med, New York, NY 10016 USA; [Hilz, Max J.] NYU, Dept Psychiat, New York, NY 10016 USA; [Hilz, Max J.; Anders, Stefan; Koehn, Julia; Lang, Christoph J.; Pauli, Elisabeth; Schwab, Stefan; Marthol, Harald] Univ Erlangen Nurnberg, Dept Neurol, D-8520 Erlangen, Germany; [DeFina, Philip A.] Int Brain Res Fdn, Edison, NJ USA; [Flanagan, Steven R.] NYU, Sch Med, Dept Rehabil Med, New York, NY 10016 USA	Hilz, MJ (corresponding author), NYU, Sch Med, Dept Neurol, 550 1st Ave,Suite NB 7W11, New York, NY 10016 USA.	max.hilz@nyumc.org		Flanagan, Steven/0000-0001-9005-5897	International Brain Research Foundation Inc.; Genzyme Corporation, Cambridge, MASanofi-AventisGenzyme Corporation; IBRF, Edison, NJ	The study was partially funded by the International Brain Research Foundation Inc., IBRF, Edison, NJ.; Dr. Hilz received compensation for lectures and consulting services, and received research support from Genzyme Corporation, Cambridge, MA and IBRF, Edison, NJ.	ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Barbic F, 2007, HYPERTENSION, V49, P120, DOI 10.1161/01.HYP.0000250939.71343.7c; Barron HV, 1998, LANCET, V351, P461, DOI 10.1016/S0140-6736(05)78676-1; BENARROCH EE, 1997, CENTRAL AUTONOMIC NE; Black M, 2002, J CLIN PATHOL, V55, P44, DOI 10.1136/jcp.55.1.44; Brown AW, 2004, NEUROREHABILITATION, V19, P37; CDC, 2003, REP C MILD TRAUM BRA; Cencetti S, 1999, HEART, V82, P365, DOI 10.1136/hrt.82.3.365; Chan CT, 2008, J HYPERTENS, V26, P1795, DOI 10.1097/HJH.0b013e328308b7c8; Chan CT, 2005, KIDNEY INT, V68, P338, DOI 10.1111/j.1523-1755.2005.00411.x; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; DREIFUS LS, 1993, J AM COLL CARDIOL, V22, P948, DOI 10.1016/0735-1097(93)90217-O; Dutsch M, 2007, NEUROLOGY, V69, P2249, DOI 10.1212/01.wnl.0000286946.06639.a7; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Hilz MJ, 2008, STROKE, V39, P2421, DOI 10.1161/STROKEAHA.108.518613; Hilz MJ, 2010, J HYPERTENS, V28, P1438, DOI 10.1097/HJH.0b013e328336a077; Hilz MJ, 2002, BRAIN, V125, P985, DOI 10.1093/brain/awf092; Hilz MJ, 2001, ANN NEUROL, V49, P575, DOI 10.1002/ana.1006; Hilz MJ, 2002, NEUROMUSCULAR FUNCTI, P1899; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Honzikova N, 2000, PHYSIOL RES, V49, P643; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huikuri HV, 1999, J AM COLL CARDIOL, V34, P1878, DOI 10.1016/S0735-1097(99)00468-4; Johansson M, 2007, J HYPERTENS, V25, P163, DOI 10.1097/01.hjh.0000254377.18983.eb; Krause M, 2009, PEDIATR DIABETES, V10, P255, DOI 10.1111/j.1399-5448.2008.00447.x; La Rovere MT, 2001, CIRCULATION, V103, P2072; La Rovere MT, 1998, LANCET, V351, P478; Lanfranchi PA, 2002, AM J PHYSIOL-REG I, V283, pR815, DOI 10.1152/ajpregu.00051.2002; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; MCMILLAN TM, 2011, J NEUROL NEUROS 0131; NATELSON BH, 1993, NEUROL CLIN, V11, P293; National Institute of Neurological Disorders and Stroke, 2002, NIH PUBL; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; NOVAK V, 1997, CLIN AUTONOMIC DISOR, P323; Oppenheimer S, 2006, CLIN AUTON RES, V16, P6, DOI 10.1007/s10286-006-0276-0; OPPENHEIMER SM, 1991, BRAIN RES, V550, P115, DOI 10.1016/0006-8993(91)90412-O; OPPENHEIMER SM, 1990, ARCH NEUROL-CHICAGO, V47, P513, DOI 10.1001/archneur.1990.00530050029008; Orlandi G, 2000, ACTA NEUROL SCAND, V102, P317, DOI 10.1034/j.1600-0404.2000.102005317.x; Ormezzano O, 2008, J HYPERTENS, V26, P1373, DOI 10.1097/HJH.0b013e3283015e5a; PAGANI M, 1988, HYPERTENSION, V12, P600, DOI 10.1161/01.HYP.12.6.600; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; Parati G, 2001, ANN NY ACAD SCI, V940, P469; Rosengard-Barlund M, 2009, DIABETOLOGIA, V52, P1164, DOI 10.1007/s00125-009-1340-9; Rudiger H, 2001, AUTON NEUROSCI-BASIC, V93, P71, DOI 10.1016/S1566-0702(01)00326-5; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schwartz PJ, 1998, EUR HEART J, V19, P1593, DOI 10.1053/euhj.1998.1292; Singer DH, 1995, HEART RATE VARIABILI, P429; Sykora M, 2008, CRIT CARE MED, V36, P3074, DOI 10.1097/CCM.0b013e31818b306d; Sykora M, 2009, STROKE, V40, P737, DOI 10.1161/STROKEAHA.108.519967; Tokgozoglu SL, 1999, STROKE, V30, P1307, DOI 10.1161/01.STR.30.7.1307; Tsuji H, 1996, CIRCULATION, V94, P2850, DOI 10.1161/01.CIR.94.11.2850; Wieling W, 1997, CLIN AUTONOMIC DISOR, P73; WIELING W, 1999, AUTONOMIC FAILURE, P197	55	60	60	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1727	1738		10.1089/neu.2010.1497			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000006	21355816				2021-06-18	
J	Ponsford, J; McLaren, A; Schonberger, M; Burke, R; Rudzki, D; Olver, J; Ponsford, M				Ponsford, Jennie; McLaren, Anna; Schoenberger, Michael; Burke, Richard; Rudzki, Dion; Olver, John; Ponsford, Michael			The Association between Apolipoprotein E and Traumatic Brain Injury Severity and Functional Outcome in a Rehabilitation Sample	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; outcome; traumatic brain injury	AMYLOID BETA-PROTEIN; HEAD-INJURY; APOE GENOTYPE; ALZHEIMERS-DISEASE; E EPSILON-4; E POLYMORPHISM; POSTTRAUMATIC SEIZURES; APOE-EPSILON-4 ALLELE; INFLAMMATORY RESPONSE; EARLY-STAGE	Traumatic brain injury (TBI) can result in significant disability, but outcome is variable. The impact of known predictors accounts for a limited proportion of the variance in outcomes. Apolipoprotein E (ApoE) genotype has been investigated as an additional source of variability in injury severity and outcome, with mixed findings reflecting variable methodology and generally limited sample sizes. This study aimed to examine whether possession of the ApoE epsilon 4 allele was associated with greater acute injury severity and poorer long-term outcome in patients referred for rehabilitation following TBI. ApoE genotype was determined for 648 patients with TBI, who were prospectively followed up a mean of 1.9 years post-injury. Hypotheses that epsilon 4 carriers would have lower Glasgow Coma Scale (GCS) scores and longer post-traumatic amnesia (PTA) duration were not supported. Prediction of worse Glasgow Outcome Scale-Extended (GOSE) scores for epsilon 4 carriers was supported with greater susceptibility seen in females. These results indicate the ApoE epsilon 4 allele may be associated with poorer long-term outcome, but not acute injury severity. Possible mechanisms include differential effects of the epsilon 4 allele on inflammatory and cellular repair processes, and/or amyloid deposition.	[Ponsford, Jennie; McLaren, Anna; Rudzki, Dion] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie; Olver, John; Ponsford, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol, Freiburg, Germany; [Burke, Richard] Monash Univ, Sch Biol Sci, Melbourne, Vic 3004, Australia; [Olver, John] Monash Univ, Fac Med, Melbourne, Vic 3004, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton Campus,Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au		Burke, Richard/0000-0003-0086-0767; Olver, John/0000-0001-7069-1191	Victorian Neurotrauma Initiative; Transport Accident Commission	This study was supported by the Victorian Neurotrauma Initiative and the Transport Accident Commission.	ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Anderson GD, 2009, EPILEPSY BEHAV, V16, P501, DOI 10.1016/j.yebeh.2009.08.025; Aoki K, 2003, STROKE, V34, P875, DOI 10.1161/01.STR.0000064320.73388.C6; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brichtova E, 2008, CHILD NERV SYST, V24, P349, DOI 10.1007/s00381-007-0459-6; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Hiekikanen H, 2007, BRAIN INJURY, V21, P1307, DOI 10.1080/02699050701739549; Hoe HS, 2006, J BIOL CHEM, V281, P3425, DOI 10.1074/jbc.M509380200; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Jiang Y, 2008, ACTA NEUROCHIR SUPPL, V105, P233; Jiang Y, 2007, J NEUROTRAUM, V24, P1802, DOI 10.1089/neu.2007.0299; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kraus J. F., 1999, REHABILITATION ADULT, P3; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Macfarlane DP, 1999, NEUROREPORT, V10, P3945, DOI 10.1097/00001756-199912160-00040; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Maysinger D, 2008, J NEUROSCI, V28, P7891, DOI 10.1523/JNEUROSCI.1461-08.2008; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Michikawa M, 1999, MECH AGEING DEV, V107, P233, DOI 10.1016/S0047-6374(98)00134-1; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Ost M, 2008, ACTA ANAESTH SCAND, V52, P1364, DOI 10.1111/j.1399-6576.2008.01675.x; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Shea TB, 2002, FREE RADICAL BIO MED, V33, P1115, DOI 10.1016/S0891-5849(02)01001-8; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	78	60	62	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1683	1692		10.1089/neu.2010.1623			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000001	21651315				2021-06-18	
J	Salinsky, M; Spencer, D; Boudreau, E; Ferguson, F				Salinsky, Martin; Spencer, David; Boudreau, Eilis; Ferguson, Felicia			Psychogenic nonepileptic seizures in US veterans	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; EPILEPSY; DIAGNOSIS; DISORDER	Objectives: Psychogenic nonepileptic seizures (PNES) are frequently encountered in epilepsy monitoring units (EMU) and can result in significant long-term disability. We reviewed our experience with veterans undergoing seizure evaluation in the EMU to determine the time delay to diagnosis of PNES, the frequency of PNES, and cumulative antiepileptic drug (AED) treatment. We compared veterans with PNES to civilians with PNES studied in the same EMU. Methods: We reviewed records of all patients admitted to one Veterans Affairs Medical Center (VAMC) EMU over a 10-year interval. These patients included 203 veterans and 726 civilians from the university affiliate. The percentage of patients with PNES was calculated for the veteran and civilian groups. Fifty veterans with only PNES were identified. Each veteran with PNES was matched to the next civilian patient with PNES. The 2 groups were compared for interval from onset of the habitual spells to EMU diagnosis, cumulative AED treatment, and other measures. Results: PNES were identified in 25% of veterans and 26% of civilians admitted to the EMU. The delay from onset of spells to EMU diagnosis averaged 60.5 months for veterans and 12.5 months for civilians (p < 0.001). Cumulative AED treatment was 4 times greater for veterans with PNES as compared to civilians (p < 0.01). Fifty-eight percent of veterans with PNES were thought to have seizures related to traumatic brain injury. Conclusions: The results indicate a substantial delay in the diagnosis of PNES in veterans as compared to civilians. The delay is associated with greater cumulative AED treatment. Neurology (R) 2011;77:945-950	Portland VA Med Ctr, Portland, OR USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Salinsky, M (corresponding author), 3181 SW Sam Jackson Pk Rd,CR-120, Portland, OR 97239 USA.	Salinsky@ohsu.edu			NIH (NIDA, NIAAA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Dr. Salinsky serves on speakers' bureaus for UCB and Pfizer Inc and has served on scientific advisory boards for and received honoraria from Medtronic, Inc., Cyberonics Inc., and Lundbeck Inc. Dr. Spencer has served on the speakers' bureau of and received honoraria from UCB; serves as Patient Page Editor for Neurology (R), Chief Editor for EMedicine, Associate Editor for the Journal of Behavior and Brain Science, and on the Professional Advisory Board for Neurology Now; has received research support from NeuroPace, Inc.; and holds stock in StemCells, Inc. Dr. Boudreau serves on the editorial board of Aviation, Space, and Environmental Medicine; and has received research support from the NIH (NIDA, NIAAA). Dr. Ferguson reports no disclosures.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Barry E, 1998, EPILEPSIA, V39, P427, DOI 10.1111/j.1528-1157.1998.tb01395.x; Benbadis SR, 1999, EUR NEUROL, V41, P114, DOI 10.1159/000008015; Benbadis SR, 2004, EPILEPSIA, V45, P1150, DOI 10.1111/j.0013-9580.2004.14504.x; Bowman ES, 1996, AM J PSYCHIAT, V153, P57; Buchanan N, 1993, Seizure, V2, P141, DOI 10.1016/S1059-1311(05)80119-0; *COMM GULF WAR HLT, 2009, GULF WAR HLTH, V7, P7; D'Alessio L, 2006, SEIZURE-EUR J EPILEP, V15, P333, DOI 10.1016/j.seizure.2006.04.003; Dworetzky BA, 2005, EPILEPSIA, V46, P1418, DOI 10.1111/j.1528-1167.2005.13004.x; Ettinger AB, 1999, EPILEPSIA, V40, P1292, DOI 10.1111/j.1528-1157.1999.tb00860.x; Goldstein LH, 2010, NEUROLOGY, V74, P1986, DOI 10.1212/WNL.0b013e3181e39658; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Kanner AM, 1999, NEUROLOGY, V53, P933, DOI 10.1212/WNL.53.5.933; LaFrance WC, 2006, EPILEPSY BEHAV, V8, P451, DOI 10.1016/j.yebeh.2006.02.004; LEMPERT T, 1990, J NEUROL, V237, P35, DOI 10.1007/BF00319665; Martin R, 2003, NEUROLOGY, V61, P1791, DOI 10.1212/01.WNL.0000098890.13946.F5; Martin RC, 1998, SEIZURE-EUR J EPILEP, V7, P385, DOI 10.1016/S1059-1311(05)80007-X; McKenzie P, 2010, NEUROLOGY, V74, P64, DOI 10.1212/WNL.0b013e3181c7da6a; PIERELLI F, 1989, EPILEPSIA, V30, P513, DOI 10.1111/j.1528-1157.1989.tb05465.x; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Reuber M, 2003, ANN NEUROL, V53, P305, DOI 10.1002/ana.3000; Rosenberg HJ, 2000, EPILEPSIA, V41, P447, DOI 10.1111/j.1528-1157.2000.tb00187.x; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Selwa LM, 2000, EPILEPSIA, V41, P1330, DOI 10.1111/j.1528-1157.2000.tb04613.x; vanMerode T, 1997, SEIZURE, V6, P311; WALCZAK TS, 1995, EPILEPSIA, V36, P1131, DOI 10.1111/j.1528-1157.1995.tb00472.x; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x	28	60	60	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP	2011	77	10					945	950		10.1212/WNL.0b013e31822cfc46			6	Clinical Neurology	Neurosciences & Neurology	815PR	WOS:000294538100011	21893668				2021-06-18	
J	Erlandsson, A; Lin, CHA; Yu, FG; Morshead, CM				Erlandsson, Anna; Lin, Chia-Hsun Anthony; Yu, Fenggang; Morshead, Cindi M.			Immunosuppression promotes endogenous neural stem and progenitor cell migration and tissue regeneration after ischemic injury	EXPERIMENTAL NEUROLOGY			English	Article						Neural stem cells; Immunosuppression; Stroke; Neurogenesis; Migration; Neurosphere; NOD/SCID; Cyclosporine; Functional recovery; Regeneration	TRAUMATIC BRAIN-INJURY; ADULT MAMMALIAN FOREBRAIN; SUBVENTRICULAR ZONE; CYCLOSPORINE-A; GROWTH-FACTOR; INDUCED NEUROGENESIS; DIRECTED MIGRATION; MOUSE BRAIN; CNS INJURY; STROKE	Recent work has demonstrated that self-repair in the adult brain can be augmented by the infusion of growth factors to activate endogenous neural precursor cells that contribute to new tissue formation and functional recovery in a model of stroke. Using both a genetic model and drug treatment, we demonstrate that immunosuppression mimics the effects of growth factor activation, including tissue regeneration, neural precursor cell migration and functional recovery following ischemic injury. In the absence of growth factor treatment, mice with a functional immune system develop a prominent cavity in the cortex underlying the ischemic injury. In untreated immunodeficient NOD/SCID mice, however, the cortical cavity forms but is then filled with regenerated cortical tissue containing glial cells and subependyma derived neural stem and progenitor cells that migrate from their niche lining the lateral ventricles. The daily administration of Cyclosporine A also results in endogenous neural precursor cell migration and regenerated cortical tissue at the site of the cortical injury. Different from growth factor-treated animals is the finding that the regenerated cortical tissue in immunosuppressed animals is devoid of new neurons. Interestingly, both the growth factor and immunosuppressed (NOD/SCID and Cyclosporine A) treated animals displayed functional behavioural recovery despite the lack of neurogenesis within the regenerated cortical tissue. This article is part of a Special Issue entitled "Interaction between repair, disease, & inflammation." (C) 2010 Elsevier Inc. All rights reserved.	[Erlandsson, Anna; Morshead, Cindi M.] Univ Toronto, Dept Surg, Div Anat, Donnelly Ctr, Toronto, ON M5S 3E1, Canada; [Lin, Chia-Hsun Anthony; Yu, Fenggang] Uppsala Univ, Dept Neurosci, Uppsala, Sweden	Morshead, CM (corresponding author), Univ Toronto, Dept Surg, Div Anat, Donnelly Ctr, 160 Coll St,1006, Toronto, ON M5S 3E1, Canada.	cindi.morshead@utoronto.ca			Stem Cell Network; Canadian Stroke Network; Heart and Stroke FoundationHeart & Stroke Foundation of Canada	The authors thank Amy Hoyles, Angela Kam and Vince Cheng for their technical expertise and contributions to the manuscript. AE is supported by the Stem Cell Network, CMM is supported by the Stem Cell Network, Canadian Stroke Network and the Heart and Stroke Foundation.	Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P63, DOI 10.1016/S0162-3109(00)00186-7; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Craig CG, 1996, J NEUROSCI, V16, P2649; Cui X, 2009, J NEUROSCI RES, V87, P86, DOI 10.1002/jnr.21836; Ekdahl C.T., 2008, NEUROSCIENCE; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Gonzalez CLR, 2003, EUR J NEUROSCI, V18, P1950, DOI 10.1046/j.1460-9568.2003.02928.x; Guo JS, 2007, NEUROREPORT, V18, P863, DOI 10.1097/WNR.0b013e32811d6d36; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Hunt J, 2010, J NEUROSCI, V30, P2888, DOI 10.1523/JNEUROSCI.5991-09.2010; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Iosif RE, 2008, J CEREBR BLOOD F MET, V28, P1574, DOI 10.1038/jcbfm.2008.47; Jakubs K, 2008, J NEUROSCI, V28, P12477, DOI 10.1523/JNEUROSCI.3240-08.2008; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; KERSCHENSTEINER M, 2008, NEUROSCIENCE; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Lorke DE, 2008, HISTOCHEM CELL BIOL, V130, P693, DOI 10.1007/s00418-008-0463-2; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Maysami S, 2008, J CEREBR BLOOD F MET, V28, P1104, DOI 10.1038/jcbfm.2008.4; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Mitchell BS, 1997, BRIT J BIOMED SCI, V54, P278; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morshead CM, 1998, DEVELOPMENT, V125, P2251; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; Nonoyama S, 1996, Int Rev Immunol, V13, P289, DOI 10.3109/08830189609061753; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sohur US, 2006, PHILOS T R SOC B, V361, P1477, DOI 10.1098/rstb.2006.1887; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tran PB, 2004, J NEUROSCI RES, V76, P20, DOI 10.1002/jnr.20001; Yuan RR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001924; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	45	60	61	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUL	2011	230	1			SI		48	57		10.1016/j.expneurol.2010.05.018			10	Neurosciences	Neurosciences & Neurology	781BT	WOS:000291906300006	20685361				2021-06-18	
J	Li, YG; Lein, PJ; Liu, CM; Bruun, DA; Tewolde, T; Ford, G; Ford, BD				Li, Yonggang; Lein, Pamela J.; Liu, Cuimei; Bruun, Donald A.; Tewolde, Teclemichael; Ford, Gregory; Ford, Byron D.			Spatiotemporal pattern of neuronal injury induced by DFP in rats: A model for delayed neuronal cell death following acute OP intoxication	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Acute intoxication; Delayed neurotoxicity; DFP; Neuronal injury; Organophosphate; Rat model	CENTRAL-NERVOUS-SYSTEM; CHRONIC NEUROLOGICAL SEQUELAE; TRAUMATIC BRAIN INJURY; FLUORO-JADE-B; BEHAVIORAL DEFICITS; INDUCED SEIZURES; FOCAL ISCHEMIA; SOMAN; DEGENERATION; ORGANOPHOSPHATE	Organophosphate (OP) neurotoxins cause acute cholinergic toxicity and seizures resulting in delayed brain damage and persistent neurological symptoms. Testing novel strategies for protecting against delayed effects of acute OP intoxication has been hampered by the lack of appropriate animal models. In this study, we characterize the spatiotemporal pattern of cellular injury after acute intoxication with the OP diisopropylfluorophosphate (DFP). Adult male Sprague-Dawley rats received pyridostigmine (0.1 mg/kg, im) and atropine methylnitrate (20 mg/kg, im) prior to DFP (9 mg/kg, ip) administration. All DFP-treated animals exhibited moderate to severe seizures within minutes after DFP injection but survived up to 72 h. AChE activity was significantly depressed in the cortex, hippocampus, subcortical brain tissue and cerebellum at 1 h post-DFP injection and this inhibition persisted for up to 72 h. Analysis of neuronal injury by Fluoro-Jade B (FJB) labeling revealed delayed neuronal cell death in the hippocampus, cortex, amygdala and thalamus, but not the cerebellum, starting at 4 h and persisting until 72 h after DFP treatment, although temporal profiles varied between brain regions. At 24 h post-DFP injection, the pattern of FJB labeling corresponded to TUNEL staining in most brain regions, and FJB-positive cells displayed reduced NeuN immunoreactivity but were not immunopositive for astrocytic (GFAP), oligodendroglial (O4) or macrophage/microglial (ED1) markers, demonstrating that DFP causes a region-specific delayed neuronal injury mediated in part by apoptosis. These findings indicate the feasibility of this model for testing neuroprotective strategies, and provide insight regarding therapeutic windows for effective pharmacological intervention following acute OP intoxication. (C) 2011 Elsevier Inc. All rights reserved.	[Li, Yonggang; Liu, Cuimei; Tewolde, Teclemichael; Ford, Gregory; Ford, Byron D.] Morehouse Sch Med, Inst Neurosci, Dept Neurobiol, Atlanta, GA 30310 USA; [Lein, Pamela J.; Bruun, Donald A.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; [Ford, Gregory] Morehouse Coll, Dept Biol, Atlanta, GA 30310 USA	Ford, BD (corresponding author), Morehouse Sch Med, Inst Neurosci, Dept Neurobiol, 720 Westview Dr SW, Atlanta, GA 30310 USA.	bford@msm.edu		Lein, Pamela/0000-0001-7665-7584	National Institutes of Health Office of the DirectorUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS 057993]; National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12-RR03034]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12RR003034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS057993] Funding Source: NIH RePORTER	The research is supported by the CounterACT Program, National Institutes of Health Office of the Director, and the National Institute of Neurological Diseases and Stroke Grant Number U01 NS 057993 and Grants Number G12-RR03034 and G12-RR03034 from the National Center for Research Resources (NCRR) (BDF). The sponsor was involved in the study design but not in the collection, analysis, and interpretation of data, in the writing of the report or in the decision to submit the paper for publication.	Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Anderson KJ, 2003, J NEUROTRAUM, V20, P1223, DOI 10.1089/089771503770802899; Auta J, 2004, NEUROPHARMACOLOGY, V46, P397, DOI 10.1016/j.neuropharm.2003.09.010; Baille V, 2005, TOXICOLOGY, V215, P1, DOI 10.1016/j.tox.2005.05.028; Baille V, 2001, PHARMACOL BIOCHEM BE, V69, P561, DOI 10.1016/S0091-3057(01)00549-4; Butler TL, 2002, BRAIN RES, V929, P252, DOI 10.1016/S0006-8993(01)03371-6; Collombet JM, 2007, NEUROTOXICOLOGY, V28, P38, DOI 10.1016/j.neuro.2006.07.011; Collombet JM, 2006, NEUROSCI LETT, V398, P337, DOI 10.1016/j.neulet.2006.01.029; Collombet JM, 2006, NEUROTOXICOLOGY, V27, P201, DOI 10.1016/j.neuro.2005.10.002; Damjanac M, 2007, BRAIN RES, V1128, P40, DOI 10.1016/j.brainres.2006.05.050; Deshpande LS, 2010, TOXICOL SCI, V116, P623, DOI 10.1093/toxsci/kfq157; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Duckworth EAM, 2005, BRAIN RES, V1042, P29, DOI 10.1016/j.brainres.2005.02.021; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gunnell D, 2003, INT J EPIDEMIOL, V32, P902, DOI 10.1093/ije/dyg307; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1; Hoffman A, 2007, MIL MED, V172, P607, DOI 10.7205/MILMED.172.6.607; Jett DA, 2007, ANN NEUROL, V61, P9, DOI 10.1002/ana.21072; Kadriu B, 2009, TOXICOLOGY, V256, P164, DOI 10.1016/j.tox.2008.11.021; Kim YB, 1999, ENVIRON TOXICOL PHAR, V7, P147, DOI 10.1016/S1382-6689(99)00006-X; Kokaia Z, 1998, EXP NEUROL, V154, P289, DOI 10.1006/exnr.1998.6888; Kwong TC, 2002, THER DRUG MONIT, V24, P144, DOI 10.1097/00007691-200202000-00022; Leikin JB, 2002, CRIT CARE MED, V30, P2346, DOI 10.1097/00003246-200210000-00026; LEMERCIER G, 1983, ACTA NEUROPATHOL, V61, P123, DOI 10.1007/BF00697391; Luttjohann A, 2009, PHYSIOL BEHAV, V98, P579, DOI 10.1016/j.physbeh.2009.09.005; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MAZZONE A, 1995, HAEMATOLOGICA, V80, P161; MCDONOUGH JH, 1987, BRAIN RES, V435, P123, DOI 10.1016/0006-8993(87)91593-9; MCDONOUGH JH, 1995, NEUROTOXICOLOGY, V16, P123; McDonough JH, 1997, NEUROSCI BIOBEHAV R, V21, P559, DOI 10.1016/S0149-7634(96)00050-4; MCLEOD CG, 1985, FUND APPL TOXICOL, V5, pS10, DOI 10.1016/0272-0590(85)90110-1; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; PETRAS JM, 1994, J EXP ANAL BEHAV, V61, P319, DOI 10.1901/jeab.1994.61-319; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SAVAGE EP, 1988, ARCH ENVIRON HEALTH, V43, P38, DOI 10.1080/00039896.1988.9934372; Schmued LC, 2003, BRAIN RES, V974, P127, DOI 10.1016/S0006-8993(03)02563-0; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SCHREIBER SS, 1995, TRENDS NEUROSCI, V18, P446, DOI 10.1016/0166-2236(95)94495-Q; SHIH TM, 1991, NEUROSCI BIOBEHAV R, V15, P349; Shih TM, 2003, TOXICOL APPL PHARM, V188, P69, DOI 10.1016/S0041-008X(03)00019-X; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; STEENLAND K, 1994, AM J PUBLIC HEALTH, V84, P731, DOI 10.2105/AJPH.84.5.731; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; WATSON N, 1992, BRIT J PHARMACOL, V105, P107, DOI 10.1111/j.1476-5381.1992.tb14219.x; Wesseling C, 2002, INT J OCCUP ENV HEAL, V8, P27, DOI 10.1179/oeh.2002.8.1.27; Wright LKM, 2010, NEUROTOXICOL TERATOL, V32, P329, DOI 10.1016/j.ntt.2009.12.006; Xu ZF, 2004, BIOCHEM BIOPH RES CO, V322, P440, DOI 10.1016/j.bbrc.2004.07.149	54	60	60	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	JUN 15	2011	253	3					261	269		10.1016/j.taap.2011.03.026			9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	774FZ	WOS:000291372000010	21513723	Green Accepted			2021-06-18	
J	Hillary, FG; Medaglia, JD; Gates, K; Molenaar, PC; Slocomb, J; Peechatka, A; Good, DC				Hillary, Frank G.; Medaglia, John D.; Gates, Kathleen; Molenaar, Peter C.; Slocomb, Julia; Peechatka, Alyssa; Good, David C.			Examining working memory task acquisition in a disrupted neural network	BRAIN			English	Article						brain injury; brain plasticity; connectivity; structural equation model; working memory	TRAUMATIC BRAIN-INJURY; COGNITIVE-CONTROL; FMRI; ACTIVATION; ATTENTION; DEFICITS; REORGANIZATION; PERFORMANCE; PLASTICITY; MODERATE	There is mounting literature that examines brain activation during tasks of working memory in individuals with neurological disorders such as traumatic brain injury. These studies represent a foundation for understanding the functional brain changes that occur after moderate and severe traumatic brain injury, but the focus on topographical brain-'activation' differences ignores potential alterations in how nodes communicate within a distributed neural network. The present study makes use of the most recently developed connectivity modelling (extended-unified structural equation model) to examine performance during a well-established working-memory task (the n-back) in individuals sustaining moderate and severe traumatic brain injury. The goal is to use the findings observed in topographical activation analysis as the basis for second-level effective connectivity modelling. Findings reveal important between-group differences in within-hemisphere connectivity during task acquisition, with the control sample demonstrating rapid within-left hemisphere connectivity increases and the traumatic brain injury sample demonstrating consistently elevated within-right hemisphere connectivity. These findings also point to important maturational effects from 'early' to 'late' during task performance, including diminished right prefrontal cortex involvement and an anterior to posterior shift in connectivity with increased task exposure. We anticipate that this approach to functional imaging data analysis represents an important future direction for understanding how neural plasticity is expressed in brain disorders.	[Hillary, Frank G.; Medaglia, John D.; Peechatka, Alyssa] Penn State Univ, Dept Psychol, University Pk, PA 16801 USA; [Hillary, Frank G.; Slocomb, Julia; Good, David C.] Hershey Med Ctr, Dept Neurol, Hershey, PA 16801 USA; [Gates, Kathleen; Molenaar, Peter C.] Dept Human Dev & Family Sci, University Pk, PA 17033 USA	Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, 223 Bruce V Moore Bldg, University Pk, PA 16802 USA.	fhillary@psu.edu	Hillary, Frank/AAN-8622-2021		New Jersey Commission on Brain Injury Research [0120090178]; Pennsylvania Tobacco Settlement Funds; Social Sciences Research Institute, PSU, University Park	New Jersey Commission on Brain Injury Research, Grant #: 0120090178; Pennsylvania Tobacco Settlement Funds; Social Sciences Research Institute, PSU, University Park.	Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Brett M, 2010, MNI BRAIN TALAIRACH; Brown T.A, 2006, CONFIRMATORY FACTOR, V3rd; Chang L, 2001, NEUROLOGY, V57, P1001, DOI 10.1212/WNL.57.6.1001; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Frith CD, 1995, HUM BRAIN MAPP, V3, P153, DOI 10.1002/hbm.460030209; Gates KM, 2010, NEUROIMAGE, V50, P1118, DOI 10.1016/j.neuroimage.2009.12.117; Gates KM, 2010, NEUROIMAGE, V54, P1151; Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hillary F, 2001, ARCH CLIN NEUROPSYCH, V16, P171, DOI 10.1016/S0887-6177(00)00050-0; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Kelly C, 2006, ARCH PHYS MED REHAB, V87, pS20, DOI 10.1016/j.apmr.2006.08.333; Kim J, 2007, HUM BRAIN MAPP, V28, P85, DOI 10.1002/hbm.20259; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Maguire EA, 2001, BRAIN, V124, P1156, DOI 10.1093/brain/124.6.1156; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mclntosh AR, 1994, HUM BRAIN MAPP, V2, P2, DOI DOI 10.1002/HBM.460020104; Medaglia JD, HUM BRAIN M IN PRESS; Molenaar P.C.M., 2004, MEAS INTERDISCIP RES, V2, P201, DOI [10.1207/s15366359mea0204_1., DOI 10.1207/S15366359MEA0204_1]; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Oikonomou VP, 2010, IEEE T INF TECHNOL B, V14, P664, DOI 10.1109/TITB.2009.2039712; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Price CJ, 2006, J MAGN RESON IMAGING, V23, P816, DOI 10.1002/jmri.20580; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Sarty GE, 2006, COMPUTING BRAIN ACTI; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Speck O, 2000, NEUROREPORT, V11, P2581, DOI 10.1097/00001756-200008030-00046; Strangman GE, 2009, NEUROREHAB NEURAL RE, V23, P226, DOI 10.1177/1545968308324225; TEASDALE G, 1974, LANCET, V2, P81; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Wechlser D, 1997, DIGIT SPAN SUBTEST W; Wechlser D, 1997, INFORM SUBTEST WAIS; WORSLEY KJ, 1995, NEUROIMAGE, V2, P183, DOI 10.1006/nimg.1995.1024	47	60	61	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY	2011	134		5				1555	1570		10.1093/brain/awr043			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	766WZ	WOS:000290818600032	21571783				2021-06-18	
J	Moore, FO; Goslar, PW; Coimbra, R; Velmahos, G; Brown, CVR; Coopwood, TB; Lottenberg, L; Phelan, HA; Bruns, BR; Sherck, JP; Norwood, SH; Barnes, SL; Matthews, MR; Hoff, WS; de Moya, MA; Bansal, V; Hu, CKC; Karmy-Jones, RC; Vinces, F; Pembaur, K; Notrica, DM; Haan, JM				Moore, Forrest O.; Goslar, Pamela W.; Coimbra, Raul; Velmahos, George; Brown, Carlos V. R.; Coopwood, Thomas B., Jr.; Lottenberg, Lawrence; Phelan, Herb A.; Bruns, Brandon R.; Sherck, John P.; Norwood, Scott H.; Barnes, Stephen L.; Matthews, Marc R.; Hoff, William S.; de Moya, Marc A.; Bansal, Vishal; Hu, Charles K. C.; Karmy-Jones, Riyad C.; Vinces, Fausto; Pembaur, Karl; Notrica, David M.; Haan, James M.			Blunt Traumatic Occult Pneumothorax: Is Observation Safe?-Results of a Prospective, AAST Multicenter Study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Occult pneumothorax; Tube thoracostomy; Computed tomography	TUBE THORACOSTOMY; COMPUTED-TOMOGRAPHY; CRITICAL-CARE; CHEST TRAUMA; MANAGEMENT; CT; COMPLICATIONS; PATIENT	Background: An occult pneumothorax (OPTX) is found incidentally in 2% to 10% of all blunt trauma patients. Indications for intervention remain controversial. We sought to determine which factors predicted failed observation in blunt trauma patients. Methods: A prospective, observational, multicenter study was undertaken to identify patients with OPTX. Successfully observed patients and patients who failed observation were compared. Multivariate logistic regression was used to identify predictors of failure of observation. OPTX size was calculated by measuring the largest air collection along a line perpendicular from the chest wall to the lung or mediastinum. Results: Sixteen trauma centers identified 588 OPTXs in 569 blunt trauma patients. One hundred twenty-one patients (21%) underwent immediate tube thoracostomy and 448 (79%) were observed. Twenty-seven patients (6%) failed observation and required tube thoracostomy for OPTX progression, respiratory distress, or subsequent hemothorax. Fourteen percent (10 of 73) failed observation during positive pressure ventilation. Hospital and intensive care unit lengths of stay, and ventilator days were longer in the failed observation group. OPTX progression and respiratory distress were significant predictors of failed observation. Most patient deaths were from traumatic brain injury. Fifteen percentage of patients in the failed observation group developed complications. No patient who failed observation developed a tension PTX, or experienced adverse events by delaying tube thoracostomy. Conclusion: Most blunt trauma patients with OPTX can be carefully monitored without tube thoracostomy; however, OPTX progression and respiratory distress are independently associated with observation failure.	[Moore, Forrest O.; Goslar, Pamela W.] St Josephs Hosp, Phoenix, AZ 85013 USA; [Moore, Forrest O.; Goslar, Pamela W.] Med Ctr, Phoenix, AZ 85013 USA; [Coimbra, Raul; Bansal, Vishal] Univ Calif San Diego, Med Ctr, San Diego, CA USA; [Velmahos, George; de Moya, Marc A.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Brown, Carlos V. R.; Coopwood, Thomas B., Jr.] Univ Med Ctr Brackenridge, Austin, TX USA; [Lottenberg, Lawrence] Univ Florida, Hlth Sci Ctr, Gainesville, FL USA; [Phelan, Herb A.] UT Southwestern, Med Ctr, Dallas, TX USA; [Bruns, Brandon R.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA; [Sherck, John P.] Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; [Norwood, Scott H.] E Texas Med Ctr, Tyler, TX USA; [Barnes, Stephen L.] Univ Missouri, Columbia, MO USA; [Matthews, Marc R.] Maricopa Cty Gen Hosp, Phoenix, AZ USA; [Hoff, William S.] St Lukes Hosp, Bethlehem, PA USA; [Hoff, William S.] Med Ctr, Bethlehem, PA USA; [Hu, Charles K. C.] Scottsdale Osborne Med Ctr, Scottsdale, AZ USA; [Karmy-Jones, Riyad C.] Southwest Washington Med Ctr, Vancouver, WA USA; [Vinces, Fausto; Pembaur, Karl] Lutheran Med Ctr, Brooklyn, NY USA; [Notrica, David M.] Phoenix Childrens Hosp, Phoenix, AZ USA; [Haan, James M.] Via Christi Reg Med Ctr, Wichita, KS USA	Moore, FO (corresponding author), St Josephs Hosp, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	moore677@aol.com	Coimbra, Raul/AAP-3019-2020; Notrica, David/D-4616-2014	Coimbra, Raul/0000-0002-3759-6851; Barnes, Stephen/0000-0001-6186-1435; Notrica, David/0000-0002-2939-1119			Bailey RC, 2000, J ACCID EMERG MED, V17, P111; Ball CG, 2005, J TRAUMA, V59, P917, DOI 10.1097/01.ta.0000174663.46453.86; Ball CG, 2003, CAN J SURG, V46, P373; Barrios C, 2008, AM SURGEON, V74, P958; Brasel KJ, 1999, J TRAUMA, V46, P987, DOI 10.1097/00005373-199906000-00001; COLLINS JC, 1992, AM SURGEON, V58, P743; de Moya MA, 2007, J TRAUMA, V63, P13, DOI 10.1097/TA.0b013e31806864fc; ENDERSON BL, 1993, J TRAUMA, V35, P726, DOI 10.1097/00005373-199311000-00013; ETOCH SW, 1995, ARCH SURG-CHICAGO, V130, P521; GARRAMONE RR, 1991, SURG GYNECOL OBSTET, V173, P257; Guerrero-Lopez F, 2000, CRIT CARE MED, V28, P1370, DOI 10.1097/00003246-200005000-00018; Hill SL, 1999, AM SURGEON, V65, P254; Lamb ADG, 2007, EUR J EMERG MED, V14, P65, DOI 10.1097/01.mej.0000228439.87286.ed; Lee KL, 2010, INJURY, V41, P492, DOI 10.1016/j.injury.2009.12.017; Misthos P, 2004, EUR J CARDIO-THORAC, V25, P859, DOI 10.1016/j.ejcts.2004.01.044; Ouellet JF, 2009, AM J SURG, V197, P581, DOI 10.1016/j.amjsurg.2008.12.007; Plurad D, 2007, J TRAUMA, V62, P631, DOI 10.1097/TA.0b013e31802bf009; RHEA JT, 1989, J TRAUMA, V29, P502, DOI 10.1097/00005373-198904000-00015; TOCINO IM, 1984, AM J ROENTGENOL, V143, P987, DOI 10.2214/ajr.143.5.987; Wilson H, 2009, INJURY, V40, P928, DOI 10.1016/j.injury.2009.04.005; WOLFMAN NT, 1993, J COMPUT ASSIST TOMO, V17, P56, DOI 10.1097/00004728-199301000-00009	21	60	64	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2011	70	5					1019	1023		10.1097/TA.0b013e318213f727			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	762LQ	WOS:000290480300009	21610419				2021-06-18	
J	Nakase-Richardson, R; Sherer, M; Seel, RT; Hart, T; Hanks, R; Arango-Lasprilla, JC; Yablon, SA; Sander, AM; Barnett, SD; Walker, WC; Hammond, F				Nakase-Richardson, R.; Sherer, M.; Seel, R. T.; Hart, T.; Hanks, R.; Arango-Lasprilla, J. C.; Yablon, S. A.; Sander, A. M.; Barnett, S. D.; Walker, W. C.; Hammond, F.			Utility of post-traumatic amnesia in predicting 1-year productivity following traumatic brain injury: comparison of the Russell and Mississippi PTA classification intervals	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; GALVESTON ORIENTATION; SEVERITY; MULTICENTER; DISABILITY; MODERATE; RETURN; SCALE; REHABILITATION; RECOVERY	Background Duration of post-traumatic amnesia (PTA) correlates with global outcomes and functional disability. Russell proposed the use of PTA duration intervals as an index for classification of traumatic brain injury (TBI) severity. Alternative duration-based schemata have been recently proposed as better predictors of outcome to the commonly cited Russell intervals. Objective Validate a TBI severity classification model (Mississippi intervals) of PTA duration anchored to late productivity outcome, and compare sensitivity against the Russell intervals. Methods Prospective observational data on TBI Model System participants (n=3846) with known or imputed PTA duration during acute hospitalisation. Productivity status at 1-year postinjury was used to compare predicted outcomes using the Mississippi and Russell classification intervals. Logistic regression model-generated curves were used to compare the performance of the classification intervals by assessing the area under the curve (AUC); the highest AUC represented the best-performing model. Results All severity variables evaluated were individually associated with return to productivity at 1 year (RTP1). Age was significantly associated with RTP1; however, younger patients had a different association than older patients. After adjustment for individually significant variables, the odds of RTP1 decrease by 14% with every additional week of PTA duration (95% CI 12% to 17%; p<0.0001). The AUC for the Russell intervals was significantly smaller than the Mississippi intervals. Conclusions PTA duration is an important predictor of late productivity outcome after TBI. The Mississippi PTA interval classification model is a valid predictor of productivity at 1 year postinjury and provides a more sensitive categorisation of PTA values than the Russell intervals.	[Nakase-Richardson, R.] James A Haley Vet Hosp, MHBS Polytrauma 116B, Tampa, FL 33612 USA; [Nakase-Richardson, R.; Barnett, S. D.] James A Haley Vet Hosp, Res Ctr Excellence, Tampa, FL 33612 USA; [Nakase-Richardson, R.] TBIMS Natl Data & Stat Ctr, Denver, CO USA; [Sherer, M.] TIRR Mem Hermann, Houston, TX USA; [Sherer, M.; Sander, A. M.] Baylor Coll Med, Houston, TX 77030 USA; [Seel, R. T.] Shepherd Ctr, Atlanta, GA USA; [Hart, T.] Moss Rehabil Res Inst, Philadelphia, PA USA; [Hanks, R.] Wayne State Univ, Sch Med, Detroit, MI USA; [Arango-Lasprilla, J. C.; Walker, W. C.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA; [Yablon, S. A.] Baylor Inst Rehabil, Dallas, TX USA; [Hammond, F.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, F.] Indiana Univ, Dept Phys Med & Rehabil, Indianapolis, IN 46204 USA	Nakase-Richardson, R (corresponding author), James A Haley Vet Hosp, MHBS Polytrauma 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	risa.richardson@va.gov	Walker, William C/N-3162-2014		National Institute on Disability and Rehabilitation Research, Department of Education [H133A060038, H133B090023, H133A070043, H133A070040, H133A-080044, H133A070036, H133A070027, H133A070042]	The contents of this manuscript were developed under grants from the National Institute on Disability and Rehabilitation Research, Department of Education (H133A060038 (TBI Model System National Data and Statistical Center), H133B090023 (Rehabilitation Research and Training Center on Developing Stategies to Foster Community Integration and Participation for Individuals With Traumatic Brain Injury), H133A070043 (Texas TBI Model System of TIRR), H133A070040 (Moss TBI Model System), H133A-080044 (Southeastern Michigan TBI System), H133A070036 (Virginia Commonwealth TBI Model System), H133A070027 (North Texas TBI Model System), H133A070042 (Carolinas Traumatic Brain Injury Rehabilitation and Research System)).	BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kalmar K, 2008, ARCH PHYS MED REHAB, V89, P942, DOI 10.1016/j.apmr.2008.01.008; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Nakase-Richardson R, 2009, ARCH PHYS MED REHAB, V90, P17, DOI 10.1016/j.apmr.2008.06.030; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; STEIN SC, 1996, NEUROTRAUMA; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	34	60	60	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2011	82	5					494	499		10.1136/jnnp.2010.222489			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	746HL	WOS:000289234500006	21242285				2021-06-18	
J	Reimunde, P; Quintana, A; Castanon, B; Casteleiro, N; Vilarnovo, Z; Otero, A; Devesa, A; Otero-Cepeda, XL; Devesa, J				Reimunde, P.; Quintana, A.; Castanon, B.; Casteleiro, N.; Vilarnovo, Z.; Otero, A.; Devesa, A.; Otero-Cepeda, X. L.; Devesa, J.			Effects of growth hormone (GH) replacement and cognitive rehabilitation in patients with cognitive disorders after traumatic brain injury	BRAIN INJURY			English	Article						Cognitive rehabilitation; frontal lobe; memory; intelligence; traumatic brain injury	POSITRON-EMISSION-TOMOGRAPHY; MOTOR CORTEX PLASTICITY; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; FACTOR-I; RAT-BRAIN; STROKE PATIENTS; IGF-I; INSITU HYBRIDIZATION; DEFICIENT PATIENTS	Objective: To assess the effects of growth hormone (GH) treatment combined with cognitive rehabilitation in patients with adult growth hormone deficiency (GHD) and cognitive disorders occurring after traumatic brain injury (TBI). Participants: Nineteen adult patients with TBI: GHD was found in 11 of them. Intervention: Patients were treated with GH (GHD; sc; 1 mg/day) or vehicle (controls; sc; 1 mg/day); daily cognitive rehabilitation therapy was performed in both groups for 3 months. Main outcome measures: The GHRH arginine test established GHD. The neuropsychological test WAIS was performed before commencing the treatment and 3 months after commencing it. Results: Controls achieved significant improvements in digits and in manipulative intelligence quotient (IQ) (p < 0.05 vs. baseline). GHD achieved significant improvements in more cognitive parameters: understanding, digits, numbers and incomplete figures (p < 0.05 vs. baseline) and similarities, vocabulary, verbal IQ, manipulative IQ and total IQ (p < 0.01). GHD reached significantly greater improvements than controls in similarities (p < 0.01) and in vocabulary, verbal IQ and total IQ (p < 0.05). Conclusion: GH administration significantly improved cognitive rehabilitation in GHD patients. Since at the end of treatment period plasma IGF-I levels were similar in both groups it is likely that exogenous GH administration is responsible for the significant differences found.	[Reimunde, P.; Quintana, A.; Castanon, B.; Casteleiro, N.; Vilarnovo, Z.; Otero, A.; Devesa, A.; Devesa, J.] Med Ctr Proyecto Foltra, La Coruna 15886, Spain; [Reimunde, P.; Devesa, J.] Univ Santiago de Compostela, Dept Physiol, Santiago De Compostela, Spain; [Otero-Cepeda, X. L.] Univ Santiago de Compostela, Dept Biostat, Sch Med, Santiago De Compostela, Spain	Devesa, J (corresponding author), Med Ctr Proyecto Foltra, Cacheiras 64 Teo, La Coruna 15886, Spain.	jesus.devesa@usc.es	Devesa, J./C-4910-2018	Devesa, J./0000-0002-4153-2543; Reimunde, Pedro/0000-0002-9190-2469	Fundacion Foltra (Teo, Spain)	This study was supported by Fundacion Foltra (Teo, Spain).	Aberg MAI, 2003, MOL CELL NEUROSCI, V24, P23, DOI 10.1016/S1044-7431(03)00082-4; Aberg MAI, 2000, J NEUROSCI, V20, P2896; Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Aberg ND, 2009, J ENDOCRINOL, V201, P141, DOI 10.1677/JOE-08-0495; AGUADO F, 1993, J MOL ENDOCRINOL, V11, P231, DOI 10.1677/jme.0.0110231; ARAUJO DM, 1989, BRAIN RES, V484, P130, DOI 10.1016/0006-8993(89)90355-7; Arwert LI, 2006, NEUROENDOCRINOLOGY, V83, P12, DOI 10.1159/000093337; Arwert LI, 2005, NEUROENDOCRINOLOGY, V81, P31, DOI 10.1159/000084872; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P47, DOI 10.1016/j.ghir.2004.11.004; Azcoitia I, 2005, NEUROBIOL AGING, V26, P697, DOI 10.1016/j.neurobiolaging.2004.06.007; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; Behrman AL, 2006, PHYS THER, V86, P1406, DOI 10.2522/ptj.20050212; Beilharz EJ, 1998, MOL BRAIN RES, V59, P119, DOI 10.1016/S0169-328X(98)00122-3; Bhagia V, 2010, BRAIN INJURY, V24, P560, DOI 10.3109/02699051003601705; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Bulow B, 2002, CLIN ENDOCRINOL, V56, P183, DOI 10.1046/j.0300-0664.2001.01461.x; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; Christophidis LJ, 2009, GROWTH HORM IGF RES, V19, P497, DOI 10.1016/j.ghir.2009.05.001; Chung YH, 2002, BRAIN RES, V946, P307, DOI 10.1016/S0006-8993(02)03041-X; Costoya JA, 1999, ENDOCRINOLOGY, V140, P5937, DOI 10.1210/en.140.12.5937; Daly JJ, 2007, THESCIENTIFICWORLDJO, V7, P2031, DOI 10.1100/tsw.2007.299; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; DEVESA J, 2009, MED CLIN BARC; Drago F, 1996, PSYCHONEUROENDOCRINO, V21, P401, DOI 10.1016/0306-4530(96)00003-0; Dunlop SA, 2008, TRENDS NEUROSCI, V31, P410, DOI 10.1016/j.tins.2008.05.004; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; GOSSARD F, 1987, NEUROSCI LETT, V79, P251, DOI 10.1016/0304-3940(87)90438-1; GUAN J, 1993, J CEREBR BLOOD F MET, V13, P609, DOI 10.1038/jcbfm.1993.79; Guan J, 2001, J CEREBR BLOOD F MET, V21, P493, DOI 10.1097/00004647-200105000-00003; Gustafson K, 1999, PEDIATR RES, V45, P318, DOI 10.1203/00006450-199903000-00005; High WM, 2010, J NEUROTRAUMA; Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282; Jones TA, 1999, J NEUROSCI, V19, P10153; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kleim JA, 1996, J NEUROSCI, V16, P4529; LAI ZN, 1991, BRAIN RES, V546, P222, DOI 10.1016/0006-8993(91)91485-J; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Liepert J, 2001, J NEUROL, V248, P315, DOI 10.1007/s004150170207; LOBIE PE, 1993, DEV BRAIN RES, V74, P225, DOI 10.1016/0165-3806(93)90008-X; Markowska AL, 1998, NEUROSCIENCE, V87, P559, DOI 10.1016/S0306-4522(98)00143-2; Marshall RS, 2000, STROKE, V31, P656, DOI 10.1161/01.STR.31.3.656; Maruff P, 2005, HORM RES, V64, P100, DOI 10.1159/000089325; Morrison JH, 2002, PROG BRAIN RES, V136, P467; Nelles G, 2001, NEUROIMAGE, V13, P1146, DOI 10.1006/nimg.2001.0757; Nieves-Martinez E, 2010, J ENDOCRINOL, V204, P31, DOI 10.1677/JOE-09-0323; Nudo RJ, 1996, J NEUROSCI, V16, P785; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; PAVLOVIC D, 2009, EUROPEAN J NEUROLOGY; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Rensink M, 2009, J ADV NURS, V65, P737, DOI 10.1111/j.1365-2648.2008.04925.x; Rosa A, 2010, 12 EUR C END PRAG 24, V22; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; Sathiavageeswaran M, 2007, EUR J ENDOCRINOL, V156, P439, DOI 10.1530/eje.1.02346; Scheepens A, 2000, J PEDIATR ENDOCR MET, V13, P1483; Scheepens A, 2001, NEUROSCIENCE, V104, P677, DOI 10.1016/S0306-4522(01)00109-9; SCHNEIDERRIVAS S, 1995, LIFE SCI, V56, pPL433, DOI 10.1016/0024-3205(95)00171-2; Shetty AK, 1999, EXP NEUROL, V158, P491, DOI 10.1006/exnr.1999.7107; Shin DH, 2004, NEUROSCI LETT, V354, P64, DOI 10.1016/j.neulet.2003.09.070; van Dam P Sylze, 2006, Treat Endocrinol, V5, P159; van Dam PS, 2005, HORM RES, V64, P109, DOI 10.1159/000089326; van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1; van Nieuwpoort IC, 2008, EUR J ENDOCRINOL, V159, pS53, DOI 10.1530/EJE-08-0279; Vitali P, 2007, NEUROREHAB NEURAL RE, V21, P152, DOI 10.1177/1545968306294735; Vogenthaler D R, 1987, Brain Inj, V1, P113; WECHSLER D, 1990, MANUAL WECHSLER ADUL; WERTHER GA, 1990, MOL ENDOCRINOL, V4, P773, DOI 10.1210/mend-4-5-773; ZIMMERMAN IL, 1989, CLIN INTERPRETATION	74	60	66	2	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2011	25	1					65	73		10.3109/02699052.2010.536196			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700008	21117918				2021-06-18	
J	Gean, AD; Fischbein, NJ				Gean, Alisa D.; Fischbein, Nancy J.			Head Trauma	NEUROIMAGING CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Scalp; Skull; Vascular; Hemorrhage	DIFFUSE AXONAL INJURY; PROTON MR SPECTROSCOPY; PHOTON EMISSION CT; BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; COMPUTED-TOMOGRAPHY; PERFUSION-CT; DECOMPRESSIVE CRANIECTOMY; CORPUS-CALLOSUM; MIXED-DENSITY	Worldwide, an estimated 10 million people are affected annually by traumatic brain injury (TBI). More than 5 million Americans currently live with long-term disability as a result of TBI and more than 1.5 million individuals sustain a new TBI each year. It has been predicted that TBI will become the third leading cause of death and disability in the world by the year 2020. This article outlines the classification of TBI, details the types of lesions encountered, and discusses the various imaging modalities available for the evaluation of TBI.	[Gean, Alisa D.] Univ Calif San Francisco, Dept Radiol, San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Fischbein, Nancy J.] Stanford Univ, Sch Med, Dept Radiol NF, Stanford, CA 94305 USA	Gean, AD (corresponding author), Univ Calif San Francisco, Dept Radiol, San Francisco Gen Hosp, 1001 Potrero Ave, San Francisco, CA 94110 USA.	agean@sfghrad.ucsf.edu					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Chang MC, 2010, NEUROREHABILITATION, V26, P339, DOI 10.3233/NRE-2010-0571; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; Davis PC, 2007, AM J NEURORADIOL, V28, P1619; Enterline DS, 2006, TECH VASC INTERV RAD, V9, P192, DOI 10.1053/j.tvir.2007.03.003; Field AS, 2005, AM J NEURORADIOL, V26, P2168; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; GEAN AD, RADIOLOGY IN PRESS; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Given CA, 2003, AM J NEURORADIOL, V24, P254; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Guerra WKW, 1999, INTENS CARE MED, V25, P1327; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2005, JAMA-J AM MED ASSOC, V294, P1551, DOI 10.1001/jama.294.12.1551; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kinuya K, 2004, NUCL MED COMMUN, V25, P333, DOI 10.1097/00006231-200404000-00004; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Krings T, 2008, EUR RADIOL, V18, P1531, DOI 10.1007/s00330-008-0915-z; Kunze E, 1998, ACT NEUR S, V71, P16; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEROUX PD, 1992, NEUROSURGERY, V31, P678, DOI 10.1227/00006123-199210000-00010; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; Little SC, 2006, ARCH OTOLARYNGOL, V132, P1300, DOI 10.1001/archotol.132.12.1300; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Marion Donald W, 2006, Prog Neurol Surg, V19, P171, DOI 10.1159/000095191; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; NANASSIS K, 1989, Neurosurgical Review, V12, P243, DOI 10.1007/BF01790657; Newberg AB, 2003, SEMIN NUCL MED, V33, P136, DOI 10.1053/snuc.2003.127299; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Provenzale J, 2007, EMERG RADIOL, V14, P1, DOI 10.1007/s10140-007-0587-z; PROVENZALE JM, 1995, AM J ROENTGENOL, V165, P1099, DOI 10.2214/ajr.165.5.7572483; Pruthi N, 2009, SURG NEUROL, V71, P202, DOI 10.1016/j.surneu.2007.10.032; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmiedeskamp H, 2010, MAGN RESON MED, V63, P959, DOI 10.1002/mrm.22222; Shimony JS, 1999, RADIOLOGY, V212, P770, DOI 10.1148/radiology.212.3.r99au51770; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Soustiel JF, 2008, NEURORADIOLOGY, V50, P189, DOI 10.1007/s00234-007-0337-7; Stamatakis EA, 2002, J NUCL MED, V43, P476; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Stiver SI, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E5; Su TM, 2008, J TRAUMA, V65, P1298, DOI 10.1097/TA.0b013e31815885d9; Subramanian SK, 2002, NEUROL RES, V24, P125, DOI 10.1179/016164102101199657; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Woodcock RJ, 2001, AM J NEURORADIOL, V22, P1698; WU Z, J MAGN RESON IMAGING; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; York G, 2005, AM J ROENTGENOL, V184, P1672, DOI 10.2214/ajr.184.5.01841672; Young RJ, 2002, NEUROIMAG CLIN N AM, V12, P189, DOI 10.1016/S1052-5149(02)00003-5; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	95	60	60	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1052-5149	1557-9867		NEUROIMAG CLIN N AM	Neuroimaging Clin. N. Am.	NOV	2010	20	4					527	+		10.1016/j.nic.2010.08.001			32	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	683VE	WOS:000284504300007	20974375				2021-06-18	
J	Laskowitz, DT; Song, PP; Wang, HC; Mace, B; Sullivan, PM; Vitek, MP; Dawson, HN				Laskowitz, Daniel T.; Song, Pingping; Wang, Haichen; Mace, Brian; Sullivan, Patrick M.; Vitek, Michael P.; Dawson, Hana N.			Traumatic Brain Injury Exacerbates Neurodegenerative Pathology: Improvement with an Apolipoprotein E-Based Therapeutic	JOURNAL OF NEUROTRAUMA			English	Article						Alzheimer's disease; amyloid; apolipoprotein E; microglia; pharmacogenomics; tau	AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; E-BASED PEPTIDE; ALZHEIMERS-DISEASE; MOUSE MODEL; MURINE MODEL; SUBARACHNOID HEMORRHAGE; MICROGLIAL ACTIVATION; TARGETED REPLACEMENT; BETA-PEPTIDE	Cognitive impairment is common following traumatic brain injury (TBI), and neuroinflammatory mechanisms may predispose to the development of neurodegenerative disease. Apolipoprotein E (apoE) polymorphisms modify neuroinflammatory responses, and influence both outcome from acute brain injury and the risk of developing neurodegenerative disease. We demonstrate that TBI accelerates neurodegenerative pathology in double-transgenic animals expressing the common human apoE alleles and mutated amyloid precursor protein, and that pathology is exacerbated in the presence of the apoE4 allele. The administration of an apoE-mimetic peptide markedly reduced the development of neurodegenerative pathology in mice homozygous for apoE3 as well as apoE3/E4 heterozygotes. These results demonstrate that TBI accelerates the cardinal neuropathological features of neurodegenerative disease, and establishes the potential for apoE mimetic therapies in reducing pathology associated with neurodegeneration.	[Laskowitz, Daniel T.; Song, Pingping; Wang, Haichen; Vitek, Michael P.; Dawson, Hana N.] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; [Laskowitz, Daniel T.; Vitek, Michael P.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; [Mace, Brian; Sullivan, Patrick M.] Duke Univ, Med Ctr, Dept Geriatr Med, Durham, NC 27710 USA; [Vitek, Michael P.] Cognosci Inc, Res Triangle Pk, NC USA	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu		Vitek, Michael/0000-0001-8140-8048	Institute for the Study of Aging; Alzheimer's AssociationAlzheimer's Association	This work was supported by a grant from the Institute for the Study of Aging (to D.T.L.) and the Alzheimer's Association (to M.P.V.). The mice were generously provided by Eli Lilly & Company. COG1410 was provided by Cognosci, Inc.	Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BRUGG B, 1995, P NATL ACAD SCI USA, V92, P3032, DOI 10.1073/pnas.92.7.3032; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Dawson HN, 2007, J NEUROSCI, V27, P9155, DOI 10.1523/JNEUROSCI.5492-06.2007; DAWSON HN, 2010, NEUROSCIENC IN PRESS; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; GALLO G, 1994, AM J PATHOL, V145, P526; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gomez-Ramos P, 2007, J ALZHEIMERS DIS, V11, P53; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoe HS, 2005, J NEUROCHEM, V93, P145, DOI 10.1111/j.1471-4159.2004.03007.x; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hoofien D, 2001, BRAIN INJURY, V15, P189; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Kaufman NA, 2010, BEHAV BRAIN RES, V214, P395, DOI 10.1016/j.bbr.2010.06.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mesis Rachel G, 2006, Neurosurg Focus, V21, pE4; Misra V, 2001, Indian J Pathol Microbiol, V44, P271; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Ophir G, 2005, NEUROBIOL DIS, V20, P709, DOI 10.1016/j.nbd.2005.05.002; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Sadowski MJ, 2006, P NATL ACAD SCI USA, V103, P18787, DOI 10.1073/pnas.0604011103; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sullivan PM, 2004, NEUROSCIENCE, V124, P725, DOI 10.1016/j.neuroscience.2003.10.011; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Szekely CA, 2008, NEUROLOGY, V70, P17, DOI 10.1212/01.wnl.0000284596.95156.48; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Wilcock DM, 2006, NAT PROTOC, V1, P1591, DOI 10.1038/nprot.2006.277; Wirths O, 2004, J NEUROCHEM, V91, P513, DOI 10.1111/j.1471-4159.2004.02737.x; Wirths O, 2008, NEUROBIOL AGING, V29, P891, DOI 10.1016/j.neurobiolaging.2006.12.004; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	57	60	61	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1983	1995		10.1089/neu.2010.1396			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500006	20812776				2021-06-18	
J	Tin, ST; Woodward, A; Ameratunga, S				Tin, Sandar Tin; Woodward, Alistair; Ameratunga, Shanthi			Injuries to pedal cyclists on New Zealand roads, 1988-2007	BMC PUBLIC HEALTH			English	Article							PUBLIC HOSPITAL DISCHARGES; BICYCLISTS; TRAUMA; WALKING; SCHOOL; ENVIRONMENT; FATALITIES; SEVERITY; ACCURACY; CHILDREN	Background: The risk of injury is one of the major barriers to engaging in cycling. We investigated exposure-based rates and profiles of traffic injuries sustained by pedal cyclists that resulted in death or hospital inpatient treatment in New Zealand, one of the most car dependent countries. Methods: Pedal cyclist traffic injuries were identified from the Mortality Collection and the National Minimum Dataset. Total time spent cycling was used as the measure of exposure and computed from National Household Travel Surveys. Analyses were undertaken for the periods 1988-91, 1996-99 and 2003-07 in relation to other major road users and by age, gender and body region affected. A modified Barell matrix was used to characterise the profiles of pedal cyclist injuries by body region affected and nature of injury. Results: Cyclists had the second highest rate of traffic injuries compared to other major road user categories and the rate increased from 1996-99 to 2003-07. During 2003-07, 31 injuries occurred per million hours spent cycling. Non-collision crashes (40%) and collisions with a car, pick-up truck or van (26%) accounted for two thirds of the cycling injuries. Children and adolescents aged under 15 years were at the highest risk, particularly of non-collision crashes. The rate of traumatic brain injuries fell from 1988-91 to 1996-99; however, injuries to other body parts increased steadily. Traumatic brain injuries were most common in collision cases whereas upper extremity fractures were most common in other crashes. Conclusions: The burden of fatal and hospitalised injuries among pedal cyclists is considerable and has been increasing over the last decade. This underscores the development of road safety and injury prevention programmes for cyclists alongside the cycling promotion strategies.	[Tin, Sandar Tin; Ameratunga, Shanthi] Univ Auckland, Sch Populat Hlth, Epidemiol & Biostat Sect, Auckland 1, New Zealand	Tin, ST (corresponding author), Univ Auckland, Sch Populat Hlth, Epidemiol & Biostat Sect, Auckland 1, New Zealand.	s.tintin@auckland.ac.nz	Tin, Sandar Tin/I-6392-2019	Tin, Sandar Tin/0000-0002-7303-061X; Woodward, Alistair/0000-0001-5425-6018; Ameratunga, Shanthi/0000-0001-8042-2251			Aharonson-Daniel L, 2005, INJURY PREV, V11, P197, DOI 10.1136/ip.2005.008227; Aharonson-Daniel L, 2003, INJURY PREV, V9, P156, DOI 10.1136/ip.9.2.156; AHARONSONDANIEL L, 2003, P INT COLL EFF INJ S, V4, P1026; Ahlbom A., 1993, BIOSTATISTICS EPIDEM; [Anonymous], INT CLASSIFICATION D, V3rd; *ASS ADV AUT MED, 1998, ABBR INJ SCAL 1990 R; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bostrom L, 2001, J TRAUMA, V50, P900, DOI 10.1097/00005373-200105000-00021; Cavill N, 2007, CYCLING HLTH WHATS E; Civil I, 2003, INJURY, V34, P740, DOI 10.1016/j.injury.2003.08.013; Clark DE, 2006, INJURY PREV, V12, P111, DOI 10.1136/ip.2005.010058; *COMM MED ASP AUT, 1971, JAMA-J AM MED ASSOC, V215, P277; Cryer C, 2006, INJURY PREV, V12, P67, DOI 10.1136/ip.2006.011668; Cryer C, 2008, DEV INDICATORS INJUR; *CTC, 1997, BARR CYCL PERSP EX P; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Davie G, 2008, INJURY PREV, V14, P319, DOI 10.1136/ip.2007.017954; Davison Kirsten K, 2008, Prev Chronic Dis, V5, pA100; DOW N, 2001, TRENDS CYCLIST INJUR; GILBERT K, 1994, BRIT MED J, V308, P1534, DOI 10.1136/bmj.308.6943.1534; HAWLEY DA, 1995, J FORENSIC SCI, V40, P205; Jacobsen PL, 2003, INJURY PREV, V9, P205, DOI 10.1136/ip.9.3.205; Jacobson GA, 1998, AUST NZ J PUBL HEAL, V22, P451, DOI 10.1111/j.1467-842X.1998.tb01413.x; Johansson LA, 2002, J EPIDEMIOL COMMUN H, V56, P301, DOI 10.1136/jech.56.4.301; Kearns RA, 2003, AREA, V35, P285, DOI 10.1111/1475-4762.00177; Kerr J, 2006, MED SCI SPORT EXER, V38, P787, DOI 10.1249/01.mss.0000210208.63565.73; Langley J, 2006, INJURY PREV, V12, P58, DOI 10.1136/ip.2005.010173; Langley J, 2002, INJ PREV, V8, P332, DOI 10.1136/ip.8.4.332; Langley JD, 2003, INJURY PREV, V9, P376, DOI 10.1136/ip.9.4.376; LANGLEY JD, 1995, METHOD INFORM MED, V34, P340; LANGLOIS JA, 1995, INT J EPIDEMIOL, V24, P136, DOI 10.1093/ije/24.1.136; Meuleners LB, 2007, ACCIDENT ANAL PREV, V39, P1222, DOI 10.1016/j.aap.2007.03.006; *MIN TRANSP, 2010, COMP TRAV MOD HOUS T; *MIN TRANSP, 1999, DUTCH BIC MAST PLAN; *MIN TRANSP, 2010, DRIV TRAV CARS VANS; *MIN TRANSP, 2007, SUST SAF LAND TRANSP; *MIN TRANSP, 2009, CYCL CRASH FACT SHEE; Ministry of Transport, 2009, NZ TRAV TRENDS NZ HO; Ministry of Transport, 2010, SAF JOURN NZ ROAD SA, P3; Missoni E, 2003, CROAT MED J, V44, P610; *NZ TRANSP AG, 2008, CYCL SKILLS TRAIN GU; OFALLEN C, 2007, 338 LAND TRANSP NZ; OFALLEN C, 2001, WALKING SCH BUS NETW; OSTROM M, 1993, INT J EPIDEMIOL, V22, P483, DOI 10.1093/ije/22.3.483; PEARCE L, 1998, CYCLING HLTH NATION; Richter M, 2007, J TRAUMA, V62, P1118, DOI 10.1097/01.ta.0000221060.78894.cb; ROWE BH, 1995, CAN MED ASSOC J, V152, P45; SCOTT D, 2005, INJURY B, V86; Sport and Recreation New Zealand. SportNZ.org, 2008, SPORT RECR PHYS ACT; *SPORT RECR NZ, 2007, SPARC FACTS 97 01; Stutts JC, 1999, ACCIDENT ANAL PREV, V31, P505, DOI 10.1016/S0001-4575(99)00007-X; Timperio A, 2004, PREV MED, V38, P39, DOI 10.1016/j.ypmed.2003.09.026; Tin ST, 2009, INT J BEHAV NUTR PHY, V6, DOI 10.1186/1479-5868-6-64; Wardlaw M, 2002, TRAFFIC ENG CONTROL, V43, P420; Wen LM, 2008, HEALTH EDUC RES, V23, P325, DOI 10.1093/her/cym043; Zavoski R, 1995, Conn Med, V59, P3; NZ MOTOR VEHICLE REG; NZ BICYCLE IMPORT ST; NZ HOUSEHOLD TRAVEL	59	60	60	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2458			BMC PUBLIC HEALTH	BMC Public Health	OCT 30	2010	10								655	10.1186/1471-2458-10-655			10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	683FT	WOS:000284458200001	21034490	DOAJ Gold, Green Published			2021-06-18	
J	Ji, XT; Liu, WB; Xie, KL; Liu, WP; Qu, Y; Chao, XD; Chen, T; Zhou, J; Fei, Z				Ji, Xituan; Liu, Wenbo; Xie, Keliang; Liu, Weiping; Qu, Yan; Chao, Xiaodong; Chen, Tao; Zhou, Jun; Fei, Zhou			Beneficial effects of hydrogen gas in a rat model of traumatic brain injury via reducing oxidative stress	BRAIN RESEARCH			English	Article						Traumatic brain injury (TBI); Reactive oxygen species (ROS); Oxidative stress; Hydrogen gas	INTESTINAL ISCHEMIA/REPERFUSION; REPERFUSION INJURY; MICE; ISCHEMIA; IMPACT; INHALATION; BIOMARKERS; MARKERS; ACID	Traumatic brain injury (TBI) is a leading cause of mortality and disability among the young population. It has been shown that hydrogen gas (H(2)) exerts a therapeutic antioxidant activity by selectively reducing hydroxyl radical (center dot OH, the most cytotoxic ROS). Recently, we have found that H(2) inhalation significantly improved the survival rate and organ damage of septic mice. In the present study, we investigated the effectiveness of H(2) therapy on brain edema, blood brain barrier (BBB) breakdown, neurological dysfunction and injury volume in TBI-challenged rats. In addition, we investigated the effects of H(2) treatment on the changes of oxidative products and antioxidant enzymes in brain tissue of TBI-challenged rats. Hydrogen treatment was given by exposure to 2% H(2) from 5 min to 5 h after sham or TBI operation, respectively. Here, we found that TBI-challenged rats showed significant brain injuries characterized by the increase of BBB permeability, brain edema and lesion volume as well as neurological dysfunction, which was significantly attenuated by 2% H(2) treatment. In addition, we found that the decrease of oxidative products and the increase of endogenous antioxidant enzymatic activities in the brain tissue may be associated with the protective effects of H(2) treatment in TBI-challenged rats. The present study supports that H(2) inhalation may be a more effective therapeutic strategy for patients with TBI. (C) 2010 Elsevier B.V. All rights reserved.	[Ji, Xituan; Liu, Wenbo; Liu, Weiping; Qu, Yan; Chao, Xiaodong; Chen, Tao; Fei, Zhou] Fourth Mil Med Univ, Xiing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi Prov, Peoples R China; [Xie, Keliang] Tianjin Med Univ, Gen Hosp, Dept Anesthesiol, Tianjin 300052, Peoples R China; [Zhou, Jun] Urumqi Gen Hosp PLA, Dept Pharm, Urumqi 830000, Peoples R China	Fei, Z (corresponding author), Fourth Mil Med Univ, Xiing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi Prov, Peoples R China.	feizhou@fmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930093/H0906]	This work was supported by research grants from the National Natural Science Foundation of China (no. 30930093/H0906).	Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Cai JM, 2008, NEUROSCI LETT, V441, P167, DOI 10.1016/j.neulet.2008.05.077; Cai JM, 2009, BRAIN RES, V1256, P129, DOI 10.1016/j.brainres.2008.11.048; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; Elliott MB, 2009, BRAIN RES, V1305, P183, DOI 10.1016/j.brainres.2009.09.104; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Fukuda KI, 2007, BIOCHEM BIOPH RES CO, V361, P670, DOI 10.1016/j.bbrc.2007.07.088; George JF, 2010, KIDNEY INT, V77, P85, DOI 10.1038/ki.2009.432; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hayashida K, 2008, BIOCHEM BIOPH RES CO, V373, P30, DOI 10.1016/j.bbrc.2008.05.165; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Kumar A, 2008, NEONATOLOGY, V94, P96, DOI 10.1159/000116633; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu DD, 2008, CRIT CARE MED, V36, P565, DOI 10.1097/01.CCM.0000299737.24338.5C; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Mao YF, 2009, BIOCHEM BIOPH RES CO, V381, P602, DOI 10.1016/j.bbrc.2009.02.105; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Matchett GA, 2009, BRAIN RES, V1259, P90, DOI 10.1016/j.brainres.2008.12.066; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Ohta Shigeo, 2008, Nihon Ronen Igakkai Zasshi, V45, P355; Sakamoto M, 2002, NEUROL RES, V24, P301, DOI 10.1179/016164102101199783; Sato Y, 2008, BIOCHEM BIOPH RES CO, V375, P346, DOI 10.1016/j.bbrc.2008.08.020; Satpute RM, 2009, FOOD CHEM TOXICOL, V47, P2689, DOI 10.1016/j.fct.2009.06.007; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Winterbourn CC, 2002, TOXICOLOGY, V181, P223, DOI 10.1016/S0300-483X(02)00286-X; XIE K, 2010, SHOCK           0323; Xie KL, 2010, SHOCK, V34, P90, DOI 10.1097/SHK.0b013e3181cdc4ae; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zheng XF, 2009, FREE RADICAL RES, V43, P478, DOI 10.1080/10715760902870603	39	60	65	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 1	2010	1354						196	205		10.1016/j.brainres.2010.07.038			10	Neurosciences	Neurosciences & Neurology	654IT	WOS:000282162400021	20654594				2021-06-18	
J	Pietrzak, RH; Goldstein, MB; Malley, JC; Rivers, AJ; Johnson, DC; Morgan, CA; Southwick, SM				Pietrzak, Robert H.; Goldstein, Marc B.; Malley, James C.; Rivers, Alison J.; Johnson, Douglas C.; Morgan, Charles A., III; Southwick, Steven M.			Posttraumatic growth in Veterans of Operations Enduring Freedom and Iraqi Freedom	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Posttraumatic stress disorder; Trauma; Posttraumatic growth; Veterans; Social support; Psychosocial; Resilience	TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; STRESS-DISORDER; SOCIAL SUPPORT; RESILIENCE INVENTORY; DEPLOYMENT RISK; POSITIVE CHANGE; WAR; SYMPTOMS; SOLDIERS	Objective: A growing body of research has examined the prevalence and correlates of psychopathology, mild traumatic brain injury, and related problems in Veterans of Operations Enduring Freedom and Iraqi Freedom (OEF-OIF). While these studies help characterize the deleterious effects of combat, no known study has examined factors that may enhance posttraumatic growth or positive changes experienced as a result of combat in this population. Method: A total of 272 predominantly older Reservist/National Guard OEF-OIF Veterans completed an anonymous mail survey that assessed combat exposure, psychopathology, psychosocial functioning, social support, and posttraumatic growth. Results: Seventy-two percent of the sample endorsed a significant degree of posttraumatic growth in at least one of the areas assessed, the most common of which were changing priorities about what is important in life (52.2%), being able to better appreciate each day (51.1%), and being better able to handle difficulties (48.5%). Hierarchical regression analysis revealed that younger age, greater posttraumatic stress disorder (PTSD) symptoms, and increased perceptions of unit member support and effort/perseverance were significantly associated with posttraumatic growth. Respondents with PTSD scored higher on an overall measure of posttraumatic growth and on items reflecting appreciation of life and personal strength. Limitations: This study is limited by a relatively low survey return rate and employment of an abbreviated measure of posttraumatic growth. Conclusions: Results of this study suggest that interventions to bolster unit member support and to enhance perceptions of effort and perseverance may help promote posttraumatic growth in OEF-OIF Veterans. (C) 2010 Elsevier B.V. All rights reserved.	[Pietrzak, Robert H.; Rivers, Alison J.; Morgan, Charles A., III; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA; [Pietrzak, Robert H.; Rivers, Alison J.; Morgan, Charles A., III; Southwick, Steven M.] VA Connecticut Healthcare Syst, Resilience Lab, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA; [Goldstein, Marc B.] Cent Connecticut State Univ, Dept Psychol, New Britain, CT 06050 USA; [Malley, James C.] Cent Connecticut State Univ, Dept Counseling & Family Therapy, New Britain, CT 06050 USA; [Johnson, Douglas C.] Univ Calif San Diego, Sch Med, Naval Hlth Res Ctr, San Diego, CA 92103 USA; [Johnson, Douglas C.] Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92103 USA	Pietrzak, RH (corresponding author), Yale Univ, Sch Med, Dept Psychiat, 950 Campbell Ave 151E, West Haven, CT 06516 USA.	robert.pietrzak@yale.edu			State of Connecticut; Department of Mental Health and Addiction Services; National Center for PTSD	We thank the veterans who participated in this survey. We appreciate the assistance of the Center for Public Policy and Social Research at Central Connecticut State University and the Connecticut Department of Veterans' Affairs in conducting this research. This work was supported by grants from the State of Connecticut, the Department of Mental Health and Addiction Services, the National Center for PTSD, and a private gift.	ALDWIN CM, 1994, PSYCHOL AGING, V9, P34, DOI 10.1037/0882-7974.9.1.34; Bellizzi KM, 2006, HEALTH PSYCHOL, V25, P47, DOI 10.1037/0278-6133.25.1.47; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Cadell S, 2003, AM J ORTHOPSYCHIAT, V73, P281, DOI 10.1037/0002-9432.73.3.279; Calhoun LG, 2000, J TRAUMA STRESS, V13, P521, DOI 10.1023/A:1007745627077; Cieslak R, 2009, ANXIETY STRESS COPIN, V22, P449, DOI 10.1080/10615800802403815; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Dekel R, 2009, HEALTH SOC WORK, V34, P87, DOI 10.1093/hsw/34.2.87; Dirik G, 2008, J CLIN PSYCHOL MED S, V15, P193, DOI 10.1007/s10880-008-9115-x; Duckworth AL, 2005, ANNU REV CLIN PSYCHO, V1, P629, DOI 10.1146/annurev.clinpsy.1.102803.144154; ELDER GH, 1989, J PERS, V57, P311, DOI 10.1111/j.1467-6494.1989.tb00485.x; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fava GA, 2005, PSYCHOTHER PSYCHOSOM, V74, P26, DOI 10.1159/000082023; Feder A, 2008, PSYCHIATRY, V71, P359, DOI 10.1521/psyc.2008.71.4.359; Fontana A, 1998, J TRAUMA STRESS, V11, P485, DOI 10.1023/A:1024452612412; Forstmeier S, 2009, AM J GERIAT PSYCHIAT, V17, P1030, DOI 10.1097/JGP.0b013e3181ab8b36; Gangstad B, 2009, REHABIL PSYCHOL, V54, P69, DOI 10.1037/a0014639; Helgeson VS, 2006, J CONSULT CLIN PSYCH, V74, P797, DOI 10.1037/0022-006X.74.5.797; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Levine SZ, 2009, J TRAUMA STRESS, V22, P282, DOI 10.1002/jts.20409; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; McCaslin SE, 2009, J TRAUMA STRESS, V22, P334, DOI 10.1002/jts.20426; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Park CL, 1996, J PERS, V64, P71, DOI 10.1111/j.1467-6494.1996.tb00815.x; Park CL, 2008, AM J ORTHOPSYCHIAT, V78, P300, DOI 10.1037/a0014054; Peterson C, 2008, J TRAUMA STRESS, V21, P214, DOI 10.1002/jts.20332; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558; Powell S, 2003, J CLIN PSYCHOL, V59, P71, DOI 10.1002/jclp.10117; Rosenbach C, 2008, J BURN CARE RES, V29, P638, DOI 10.1097/BCR.0b013e31817de275; Schorr Y.H., 2002, ANN M INT SOC TRAUM; Schroevers MJ, 2010, PSYCHO-ONCOLOGY, V19, P46, DOI 10.1002/pon.1501; SNAPE MC, 1997, PSYCHOL HEALTH MED, V2, P237, DOI DOI 10.1080/13548509708400581; Solomon Z, 2007, J TRAUMA STRESS, V20, P303, DOI 10.1002/jts.20216; Swickert R, 2009, J HEALTH PSYCHOL, V14, P387, DOI 10.1177/1359105308101677; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1007/BF02103658; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weathers F., 1991, PTSD CHECKLIST MILIT; Widows MR, 2005, HEALTH PSYCHOL, V24, P266, DOI 10.1037/0278-6133.24.3.266; Zoellner T, 2006, CLIN PSYCHOL REV, V26, P626, DOI 10.1016/j.cpr.2006.01.008	45	60	62	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	OCT	2010	126	1-2					230	235		10.1016/j.jad.2010.03.021			6	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	658KD	WOS:000282488000029	20399504				2021-06-18	
J	Coldren, RL; Kelly, MP; Parish, RV; Dretsch, M; Russell, ML				Coldren, Rodney L.; Kelly, Mark P.; Parish, Robert V.; Dretsch, Michael; Russell, Michael L.			Evaluation of the Military Acute Concussion Evaluation for Use in Combat Operations More Than 12 Hours After Injury	MILITARY MEDICINE			English	Article							RECOVERY	The diagnosis and management of concussion can be difficult in a combat environment, especially in the absence of loss of consciousness or post-traumatic amnesia. As no validated test exists to diagnose or grade neurocognitive impairment from a concussion, the military currently employs the Military Acute Concussion Evaluation (MACE) in Iraq. This is a two-part test, which incorporates the standardized assessment of concussion (SAC) as its objective score, although it has not been shown to be valid unless administered shortly after injury. A research team deployed to Iraq between January and April 2009 to examine the validity of several tests of neurocognitive function following a concussion, including the MACE. When administered more than 12 hours after the concussive injury, the MACE lacked sufficient sensitivity and specificity to be clinically useful.	[Coldren, Rodney L.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; [Kelly, Mark P.; Parish, Robert V.] Walter Reed Army Med Ctr, Dept Psychol, Washington, DC 20003 USA; [Dretsch, Michael] USA, Aeromed Res Lab, Ft Rucker, AL 36362 USA; [Russell, Michael L.] Lincoln Ctr, San Antonio, TX 78230 USA	Coldren, RL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.						Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; *DEP DEF, 2007, 07030 DEP DEF HLTH A; Giza CC, 2001, J ATHL TRAINING, V36, P228; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Nassiri JD, 2002, MIL MED, V167, P873; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; *OFF US ARM SURG G, 2009, 09068 OTSGMEDCOM OFF; Tanielian T, 2008, INVISIBLE WOUNDS WAR	15	60	60	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	JUL	2010	175	7					477	481		10.7205/MILMED-D-09-00258			5	Medicine, General & Internal	General & Internal Medicine	624EN	WOS:000279799200005	20684450	Bronze			2021-06-18	
J	Lewis, SB; Wolper, R; Chi, YY; Miralia, L; Wang, Y; Yang, C; Shaw, G				Lewis, Stephen B.; Wolper, Regina; Chi, Yueh-Yun; Miralia, Lynn; Wang, Yong; Yang, Cui; Shaw, Gerry			Identification and Preliminary Characterization of Ubiquitin C Terminal Hydrolase 1 (UCHL1) as a Biomarker of Neuronal Loss in Aneurysmal Subarachnoid Hemorrhage	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neurofilaments; NF-H; pNF-H; ubiquitin C-terminal hydrolase 1; UCHL1; S100 beta; biomarker; aneurysmal subarachnoid hemorrhage; vasospasm	NEUROFILAMENT HEAVY-CHAIN; TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; S-100 PROTEIN; AXONAL INJURY; NF-H; SERUM S100B; PNF-H; MARKERS; DAMAGE	By using two different approaches, ubiquitin C-terminal hydrolase 1 (UCHL1) was identified as a potential cerebrospinal fluid (CSF) biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage (ASAH) and presumably other CNS damage and disease states. Appropriate antibodies and a sensitive ELISA were generated, and the release of UCHL1 into CSF was compared with that of pNF-H and S100 beta in a cohort of 30 ASAH patients. Both UCHL1 and pNF-H showed persistent release into CSF in almost all patients in the second week postaneurysmal rupture (AR), and S100 beta levels rapidly declined to baseline levels in 23 of 30 patients. Seven of thirty patients showed persistently elevated S100 beta levels over the first 5 days post-AR and also had relatively higher levels of pNF-H and UCHL1 higher compared with the rest. These patients proved to have very poor outcomes, with 6 of 7 expiring. Patients who did reduce S100 beta levels tended to have a better outcome if pNF-H and UCHL1 levels were also lower, and elevated UCHL1 levels in the second week post-AR were particularly predictive of poor outcome. Acute coordinated releases of large amounts of UCHL1, pNF-H, and S100 beta in 16 of 30 patients were observed, suggesting sudden loss of brain tissues associated with secondary events. We conclude that measurement of the CSF levels of these proteins reveals details of ASAH progression and recovery and predicts patient outcome. (C) 2010 Wiley-Liss, Inc.	[Yang, Cui; Shaw, Gerry] Univ Florida, Coll Med, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA; [Lewis, Stephen B.; Wolper, Regina; Miralia, Lynn] Univ Florida, Coll Med, McKnight Brain Inst, Dept Neurol Surg, Gainesville, FL 32610 USA; [Wang, Yong; Shaw, Gerry] EnCor Biotechnol Inc, Gainesville, FL USA	Shaw, G (corresponding author), Univ Florida, Coll Med, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA.	shaw@mbi.ufl.edu	, Gerry/X-2377-2019; Chi, Yueh-Yun/AAL-6234-2020		General Clinical Research CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO1-RR00082]; Departments of Neurosurgery and Neuroscience, McKnight Brain Institute, University of Florida College of Medicine; EnCor Biotechnology Inc.; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000082] Funding Source: NIH RePORTER	Contract grant sponsor: General Clinical Research Center; Contract grant number: MO1-RR00082 (to S.B.L.); Contract grant sponsor: Departments of Neurosurgery and Neuroscience, McKnight Brain Institute, University of Florida College of Medicine; Contract grant sponsor: EnCor Biotechnology Inc.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Berger RP, 2004, CHILD ABUSE NEGLECT, V28, P739, DOI 10.1016/j.chiabu.2004.01.007; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; Deisenhammer F, 2009, EUR J NEUROL, V16, P760, DOI 10.1111/j.1468-1331.2009.02595.x; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; Gresle MM, 2008, J NEUROSCI RES, V86, P3548, DOI 10.1002/jnr.21803; Guy J, 2008, MOL VIS, V14, P2443; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2005, J NEUROTRAUM, V22, P407, DOI 10.1089/neu.2005.22.407; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Petzold A, 2009, MUSCLE NERVE, V40, P42, DOI 10.1002/mus.21239; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; Sanchez-Pena P, 2008, CRIT CARE MED, V36, P2267, DOI 10.1097/CCM.0b013e3181809750; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; TAKAYASU M, 1985, J NEUROSURG, V63, P417, DOI 10.3171/jns.1985.63.3.0417; THOMPSON RJ, 1983, BRAIN RES, V278, P294; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630	23	60	62	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 15	2010	88	7					1475	1484		10.1002/jnr.22323			10	Neurosciences	Neurosciences & Neurology	585VP	WOS:000276858600008	20077430				2021-06-18	
J	McNamara, KCS; Lisembee, AM; Lifshitz, J				McNamara, Katelyn C. S.; Lisembee, Amanda M.; Lifshitz, Jonathan			The Whisker Nuisance Task Identifies a Late-Onset, Persistent Sensory Sensitivity in Diffuse Brain-Injured Rats	JOURNAL OF NEUROTRAUMA			English	Article						corticosterone; physical therapy; plasticity; rehabilitation	COGNITIVE FUNCTION; ENVIRONMENTAL ENRICHMENT; PLASTICITY; CORTEX; STIMULATION; EXPRESSION; RECOVERY; MOTOR; PAIN; ORGANIZATION	Post-traumatic morbidity reduces the quality of life for traumatic brain injury (TBI) survivors by altering neuropsychological function. After midline fluid percussion injury (FPI), diffuse pathology in the ventral posterior thalamus suggests that somatosensory whisker function may be impaired post-injury. The goals of the present study were to design and validate a task to detect injury-induced somatosensory morbidity (Experiment 1), and to evaluate preliminary applications of the task (Experiment 2). In Experiment 1, male Sprague-Dawley rats were subjected to moderate FPI (similar to 1.9 atm) or sham injury. Over an 8-week time course, the whiskers on both mystacial pads were stimulated manually with an applicator stick in an open field for three 5-min periods. Behavioral responses in this whisker nuisance task were recorded using objective criteria (max score = 16). Sham animals were ambivalent or soothed by whisker stimulation (4.0 +/- 0.8), whereas brain-injured rats showed aggravated responses at 1 week (6.7 +/- 0.9), which became significant at 4 weeks (9.5 +/- 0.5) and 8 weeks (8.4 +/- 1.1) compared to sham injury, indicating chronic injury-induced sensory sensitivity. Total free serum corticosterone levels indicated a significant stress response in brain-injured (125.0 +/- 17.7 ng/mL), but not uninjured animals (74.2 +/- 12.2 ng/mL) in response to whisker stimulation. In Experiment 2, to evaluate applications of the whisker nuisance task, four additional uninjured and brain-injured groups were subjected to mild brain injury only, shaved whiskers after moderate brain injury, repeated whisker nuisance task stimulation after moderate brain injury, or regular opportunities for tactile exploration of an enriched environment after moderate brain injury over 4 weeks post-injury. The whisker nuisance task has the sensitivity to detect mild brain injury (7.7 +/- 1.0), but morbidity was not mitigated by any of the neurorehabilitative interventions. Following diffuse brain injury, the whisker nuisance task is a promising tool to detect post-traumatic morbidity and the efficacy of therapeutic interventions that may restore discrete circuit function in brain-injured patients.	[Lifshitz, Jonathan] Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Coll Med,Off B463, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Dept Phys Med & Rehabil, Coll Med, Lexington, KY 40536 USA	Lifshitz, J (corresponding author), Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Coll Med,Off B463, Biomed & Biol Sci Res Bldg,741 S Limestone St, Lexington, KY 40536 USA.	JLifshitz@uky.edu			University of Kentucky; Experience Based Career Education (EBCE); University of Kentucky College of Medicine; NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065052, p30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS065052] Funding Source: NIH RePORTER	We are grateful to Dr. Mark A. Prendergast and his laboratory for assistance with the corticosterone assays. We thank Dr. Karin Westlund High and Dr. Fei Ma for their assistance in evaluating pressure sensitivity in the whisker pad. We are grateful to Dr. Michael T. Bardo and Ms. Emily D. Denehy for conducting the open-field behavioral analysis. Also, we wish to thank Experiences in Undergraduate Research and Kreative Activities (eUreka!), Students Promoting Undergraduate Research (SPUR), Kentucky Yang Researchers Program (KYRP), and National Conference for Undergraduate Research (NCUR) at the University of Kentucky as well as Experience Based Career Education (EBCE) for their continued support of undergraduate research. Supported, in part, by University of Kentucky College of Medicine, NIH NINDS R01 NS065052 and NIH NINDS p30 NS051220.	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BERNARDO KL, 1987, J COMP NEUROL, V258, P542, DOI 10.1002/cne.902580406; Bisler S, 2002, J CHEM NEUROANAT, V23, P187, DOI 10.1016/S0891-0618(01)00155-7; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Bothwell S, 2001, J NEUROSCI, V21, P4789, DOI 10.1523/JNEUROSCI.21-13-04789.2001; Brecht M, 1997, BEHAV BRAIN RES, V84, P81, DOI 10.1016/S0166-4328(97)83328-1; Carmichael ST, 2001, NEUROBIOL DIS, V8, P910, DOI 10.1006/nbdi.2001.0425; CARVELL GE, 1990, J NEUROSCI, V10, P2638; Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012; CHMIELOWSKA J, 1989, J COMP NEUROL, V285, P325, DOI 10.1002/cne.902850304; CHOI Y, 1994, PAIN, V59, P369, DOI 10.1016/0304-3959(94)90023-X; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Cromwell HC, 2008, CLIN EEG NEUROSCI, V39, P69, DOI 10.1177/155005940803900209; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; DYCK RH, 2004, BEHAV LAB RAT; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Faisal AA, 2008, NAT REV NEUROSCI, V9, P292, DOI 10.1038/nrn2258; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feldman DE, 2005, SCIENCE, V310, P810, DOI 10.1126/science.1115807; Franklin JL, 1998, J CELL BIOL, V142, P1313, DOI 10.1083/jcb.142.5.1313; Frostig RD, 2006, CURR OPIN NEUROBIOL, V16, P445, DOI 10.1016/j.conb.2006.06.001; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GOLD BG, 1991, J NEUROSCI, V11, P943; GONZALEZ MF, 1985, J COMP NEUROL, V231, P457, DOI 10.1002/cne.902310405; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; GUICROBLES E, 1989, BEHAV BRAIN RES, V31, P285, DOI 10.1016/0166-4328(89)90011-9; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Henderson T. A., 1995, CEREBRAL CORTEX BARR, P123; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Iarocci G, 2006, J AUTISM DEV DISORD, V36, P77, DOI 10.1007/s10803-005-0044-3; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; ISAAC WL, 1989, BEHAV NEUROSCI, V103, P345, DOI 10.1037/0735-7044.103.2.345; Jones EG, 2000, ANNU REV NEUROSCI, V23, P1, DOI 10.1146/annurev.neuro.23.1.1; JOURDAN D, 1995, PAIN, V63, P237, DOI 10.1016/0304-3959(95)00049-X; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kleindienst A, 2009, J NEUROTRAUM, V26, P1435, DOI 10.1089/neu.2008.0601; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; Krupa DJ, 2004, SCIENCE, V304, P1989, DOI 10.1126/science.1093318; LAND PW, 1995, J COMP NEUROL, V355, P573, DOI 10.1002/cne.903550407; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELZER P, 1985, BRAIN RES, V348, P229, DOI 10.1016/0006-8993(85)90441-X; Nesic O, 2005, J NEUROCHEM, V95, P998, DOI 10.1111/j.1471-4159.2005.03462.x; Ordyan N E, 1998, Neurosci Behav Physiol, V28, P22, DOI 10.1007/BF02461907; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Povlishock JT, 2001, HEAD TRAUMA, P281; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ren K, 1999, PHYSIOL BEHAV, V67, P711, DOI 10.1016/S0031-9384(99)00136-5; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Skouras E, 2009, RESTOR NEUROL NEUROS, V27, P237, DOI 10.3233/RNN-2009-0474; Vierck C J Jr, 2000, Prog Brain Res, V129, P411, DOI 10.1016/S0079-6123(00)29032-8; VOS BP, 1994, J NEUROSCI, V14, P2708; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wang GX, 2008, J NEUROSCI, V28, P11959, DOI 10.1523/JNEUROSCI.3296-08.2008; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; Wooters TE, 2009, PSYCHOPHARMACOLOGY, V204, P551, DOI 10.1007/s00213-009-1487-6	80	60	60	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2010	27	4					695	706		10.1089/neu.2009.1237			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	584CG	WOS:000276727000004	20067394	Green Published			2021-06-18	
J	Inamasu, J; Kuramae, T; Nakatsukasa, M				Inamasu, Joji; Kuramae, Takumi; Nakatsukasa, Masashi			Does Difference in the Storage Method of Bone Flaps After Decompressive Craniectomy Affect the Incidence of Surgical Site Infection After Cranioplasty? Comparison Between Subcutaneous Pocket and Cryopreservation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Bone flap; Cranioplasty; Cryopreservation; Decompressive craniectomy; Subcutaneous pocket; Surgical site infection; Traumatic brain injury	DELAYED CRANIOPLASTY; GRAFT INFECTION; FROZEN; PRESERVATION	Background: After decompressive craniectomy for brain swelling, bone flaps need to be stored in a sterile fashion until cranioplasty. Temporary placement in a subcutaneous pocket (SP) and cryopreservation (CP) are the two commonly used methods for preserving bone flaps. Surgical site infection (SSI) is a serious complication of cranioplasty, and the storage method associated with a lower SSI incidence is favored. It is unclear, however, whether one storage method is superior to the other in terms of SSI prevention. Methods: During a 9-year period, 70 patients underwent decompressive craniectomy and subsequent cranioplasty. Bone flaps from 39 patients were stored using SP and those from the other 31 were stored using CP. Demographic data and SSI incidence was compared. Results: There were no significant demographic differences between the groups. SSI occurred in seven patients: 2 (5.1%) in the SP group and 5 (16.1%) in the CP group. The difference was not statistically significant (p = 0.23). When each group was further divided into two categories based oil etiology (traumatic brain injury [TBI] versus non-TBI), CP showed a significantly higher SSI incidence compared with SP (28.6% versus 0%, p = 0.02.) in the TBI category. However, the difference in incidence was not significant in the non-TBI category. Conclusions: SP and CP may be equally efficacious for storage of bone flails of non-TBI etiology; however, SP may be the storage method of choice for TBI. It remains to be verified in a prospective fashion whether SP is truly the better method of storing bone flaps in TBI.	[Inamasu, Joji; Kuramae, Takumi; Nakatsukasa, Masashi] Saiseikai Utsunomiya Hosp, Dept Neurosurg, Utsunomiya, Tochigi 3210974, Japan	Inamasu, J (corresponding author), Saiseikai Utsunomiya Hosp, Dept Neurosurg, 911-1 Takebayashi, Utsunomiya, Tochigi 3210974, Japan.	ginamasu@aol.com	Inamasu, Joji/R-7314-2019				ACIKGOZ B, 1986, SURG NEUROL, V26, P557, DOI 10.1016/0090-3019(86)90339-3; Asano Y, 1993, No To Shinkei, V45, P1145; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Crotti F M, 1979, J Neurosurg Sci, V23, P289; Flannery T, 2001, BRIT J NEUROSURG, V15, P518, DOI 10.1080/02688690120097732; Grossman N., 2007, Cell and Tissue Banking, V8, P243, DOI 10.1007/s10561-006-9032-x; HAUPTLI J, 1980, HELV CHIR ACTA, V47, P121; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Ichinose T, 2007, NEUROL SURG TOKYO, V35, P151; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Missori P, 2003, ACTA NEUROCHIR, V145, P899, DOI 10.1007/s00701-003-0118-y; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Nagayama K, 2002, NEUROL SURG TOKYO, V30, P165; Nakajima T, 1977, No Shinkei Geka, V5, P1329; OSAWA M, 1990, ACTA NEUROCHIR, V102, P38, DOI 10.1007/BF01402184; PACSAOGLU A, 1996, NEUROSURG REV, V19, P153; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; Shimizu S, 2002, NEUROL SURG TOKYO, V30, P479; Tybor K, 2005, NEUROL NEUROCHIR POL, V39, P225; Tybor Krzysztof, 2005, Neurol Neurochir Pol, V39, P220; Yano H, 2006, J CRANIOFAC SURG, V17, P1076, DOI 10.1097/01.scs.0000244916.84511.b6; Zingale A, 2003, J Neurosurg Sci, V47, P137	23	60	62	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2010	68	1					183	187		10.1097/TA.0b013e3181c45384			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	543NR	WOS:000273585800035	20065773				2021-06-18	
J	Madathil, SK; Evans, HN; Saatman, KE				Madathil, Sindhu Kizhakke; Evans, Heather N.; Saatman, Kathryn E.			Temporal and Regional Changes in IGF-1/IGF-1R Signaling in the Mouse Brain after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						Akt; axonal injury; blood vessels; controlled cortical impact; neurotrophic factor	GROWTH-FACTOR-I; CENTRAL-NERVOUS-SYSTEM; HYPOXIC-ISCHEMIC INJURY; CORTICAL IMPACT INJURY; PROTEIN-KINASE-B; IGF-I; MESSENGER-RNA; RAT-BRAIN; GERBIL HIPPOCAMPUS; NEURONAL SURVIVAL	Although neurotrophic factors such as nerve growth factor, basic fibroblast growth factor, brain-derived neurotrophic factor, and neurotrophin 4/5 are elevated after traumatic brain injury (TBI), little is known about the endogenous response of insulin-like growth factor-1 (IGF-1). We evaluated IGF-1, IGF-1 receptor (IGF-1R), and total and phosphorylated Akt (p-Akt), a known downstream mediator of IGF-1 signaling, using ELISA, Western blotting, and immunohistochemistry at 1, 6, 24, 48, and 72 h following 0.5-mm controlled cortical impact brain injury in adult mice. IGF-1 was transiently upregulated in homogenates of injured cortex at 1 h, and cells with increased IGF-1 immunoreactivity were observed in and around the cortical contusion site up to 48 h. IGF-1R and total Akt levels in cortical homogenates were unchanged, although immunohistochemistry revealed regional changes. In contrast, serine p-Akt levels increased significantly in homogenates at 6 h post-injury. Interestingly, delayed increases in vascular IGF-1R, total Akt, and p-Akt immunostaining were observed in and around the cortical contusion. IGF-1 and its downstream mediators were also upregulated in the subcortical white matter. Our findings indicate that moderate TBI results in a brief induction of IGF-1 and its signaling components in the acute post-traumatic period. This may reflect an attempt at endogenous neuroprotection or repair.	[Madathil, Sindhu Kizhakke; Evans, Heather N.; Saatman, Kathryn E.] Univ Kentucky, Dept Physiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Saatman, KE (corresponding author), Univ Kentucky, Dept Physiol, Spinal Cord & Brain Injury Res Ctr, B473 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.	k.saatman@uky.edu	Madathil, Sindhu K/E-9407-2012		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045131, NS051220, NS058484]; Kentucky Spinal Cord and Brain Injury Research Trust;  [KSCHIRT 7-20]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058484, P30NS051220, R01NS045131] Funding Source: NIH RePORTER	We greatly appreciate the technical assistance with photo-microscopy and surgery/brain injury provided by Mary Jennes and Nathan Surles, respectively. This work was supported by National Institutes of Health grants NS045131, NS051220, and NS058484, KSCHIRT 7-20, and a Kentucky Spinal Cord and Brain Injury Research Trust fellowship to S. K. M.	Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Anderson MF, 2002, DEV BRAIN RES, V134, P115; ANDERSSON IK, 1988, ACTA PHYSIOL SCAND, V132, P167, DOI 10.1111/j.1748-1716.1988.tb08314.x; BARTLETT WP, 1991, DEV BIOL, V147, P239, DOI 10.1016/S0012-1606(05)80021-1; Beilharz EJ, 1998, MOL BRAIN RES, V59, P119, DOI 10.1016/S0169-328X(98)00122-3; BERGSTEDT K, 1993, J CEREBR BLOOD F MET, V13, P895, DOI 10.1038/jcbfm.1993.112; BONDY C, 1992, NEUROSCIENCE, V46, P909, DOI 10.1016/0306-4522(92)90193-6; Brywe KG, 2005, EUR J NEUROSCI, V21, P1489, DOI 10.1111/j.1460-9568.2005.03982.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cao Y, 2003, J CEREBR BLOOD F MET, V23, P739, DOI 10.1097/01.WCB.0000067720.12805.6F; Chisalita SI, 2004, AM J PHYSIOL-ENDOC M, V286, pE896, DOI 10.1152/ajpendo.00327.2003; Clawson TF, 1999, BIOL SIGNAL RECEPT, V8, P281; Conte V., 2003, EUR J TRAUMA, V29, P335; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GARCIAESTRADA J, 1992, BRAIN RES, V592, P343, DOI 10.1016/0006-8993(92)91695-B; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Guan J, 1996, NEUROREPORT, V7, P632, DOI 10.1097/00001756-199601310-00061; Guan J, 2000, BRAIN RES, V853, P163, DOI 10.1016/S0006-8993(99)02030-2; Guan J, 2001, NEUROSCIENCE, V105, P299, DOI 10.1016/S0306-4522(01)00145-2; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hollis ER, 2009, EXP NEUROL, V215, P53, DOI 10.1016/j.expneurol.2008.09.014; Hung KS, 2007, J NEUROSURG-SPINE, V6, P35, DOI 10.3171/spi.2007.6.1.7; Hwang IK, 2004, NEUROCHEM INT, V45, P149, DOI 10.1016/j.neuint.2003.10.006; Janelidze S, 2001, NEUROBIOL DIS, V8, P147, DOI 10.1006/nbdi.2000.0325; Kawano T, 2001, J CEREBR BLOOD F MET, V21, P1268, DOI 10.1097/00004647-200111000-00003; Kazanis I, 2004, EXP NEUROL, V186, P221, DOI 10.1016/j.expneurol.2003.12.004; Leinninger GM, 2004, FASEB J, V18, P1544, DOI 10.1096/fj.04-1581fje; Liu XF, 2001, NEUROSCI LETT, V308, P91, DOI 10.1016/S0304-3940(01)01982-6; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Nakao Y, 2001, J THORAC CARDIOV SUR, V122, P136, DOI 10.1067/mtc.2001.114101; Namura S, 2000, J CEREBR BLOOD F MET, V20, P1301, DOI 10.1097/00004647-200009000-00004; Niblock MM, 2000, J NEUROSCI, V20, P4165; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NORDQVIST ACS, 1996, BRAIN RES MOL BRAIN, V38, P285; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Reynolds AJ, 2000, BRAIN RES REV, V33, P169, DOI 10.1016/S0165-0173(00)00028-X; Romanelli RJ, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M704309200; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Trejo JL, 2001, J NEUROSCI, V21, P1628; Vincent AM, 2004, NEUROBIOL DIS, V16, P407, DOI 10.1016/j.nbd.2004.03.001; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; WERTHER GA, 1990, MOL ENDOCRINOL, V4, P773, DOI 10.1210/mend-4-5-773; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Zeger M, 2007, GLIA, V55, P400, DOI 10.1002/glia.20469; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhao H, 2006, MOL NEUROBIOL, V34, P249, DOI 10.1385/MN:34:3:249; Zheng WH, 2000, ADV RES NEURODEGENER, V8, P261	63	60	64	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					95	107		10.1089/neu.2009.1002			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200008	19751099	Green Published			2021-06-18	
J	Meierhans, R; Bechir, M; Ludwig, S; Sommerfeld, J; Brandi, G; Haberthur, C; Stocker, R; Stover, JF				Meierhans, Roman; Bechir, Markus; Ludwig, Silke; Sommerfeld, Jutta; Brandi, Giovanna; Haberthuer, Christoph; Stocker, Reto; Stover, John F.			Brain metabolism is significantly impaired at blood glucose below 6 mM and brain glucose below 1 mM in patients with severe traumatic brain injury	CRITICAL CARE			English	Article							INTENSIVE INSULIN THERAPY; CEREBRAL ENERGY-METABOLISM; GLYCEMIC CONTROL; MICRODIALYSIS; HYPERGLYCEMIA; GLUTAMATE; LACTATE; IMPACT; ACCUMULATION; HOMEOSTASIS	Introduction: The optimal blood glucose target following severe traumatic brain injury (TBI) must be defined. Cerebral microdialysis was used to investigate the influence of arterial blood and brain glucose on cerebral glucose, lactate, pyruvate, glutamate, and calculated indices of downstream metabolism. Methods: In twenty TBI patients, microdialysis catheters inserted in the edematous frontal lobe were dialyzed at 1 mu l/min, collecting samples at 60 minute intervals. Occult metabolic alterations were determined by calculating the lactate-pyruvate (L/P), lactate-glucose (L/Glc), and lactate-glutamate (L/Glu) ratios. Results: Brain glucose was influenced by arterial blood glucose. Elevated L/P and L/Glc were significantly reduced at brain glucose above 1 mM, reaching lowest values at blood and brain glucose levels between 6-9 mM (P < 0.001). Lowest cerebral glutamate was measured at brain glucose 3-5 mM with a significant increase at brain glucose below 3 mM and above 6 mM. While L/Glu was significantly increased at low brain glucose levels, it was significantly decreased at brain glucose above 5 mM (P < 0.001). Insulin administration increased brain glutamate at low brain glucose, but prevented increase in L/Glu. Conclusions: Arterial blood glucose levels appear to be optimal at 6-9 mM. While low brain glucose levels below 1 mM are detrimental, elevated brain glucose are to be targeted despite increased brain glutamate at brain glucose > 5 mM. Pathogenity of elevated glutamate appears to be relativized by L/Glu and suggests to exclude insulin-induced brain injury.	[Meierhans, Roman; Bechir, Markus; Ludwig, Silke; Sommerfeld, Jutta; Brandi, Giovanna; Stocker, Reto; Stover, John F.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Brandi, Giovanna] Osped Maggiore Policlin Milano, I-20122 Milan, Italy; [Haberthuer, Christoph] Luzerner Kantonsspital, CH-6000 Luzern 16, Switzerland	Stover, JF (corresponding author), Univ Zurich Hosp, Ramistr 100, CH-8091 Zurich, Switzerland.	john.stover@access.unizh.ch			Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF); SUVA Fonds	The help of the nursing staff in collecting and analyzing subcutaneous and cerebral microdialysis samples is gratefully acknowledged. The study was supported by grants from the Swiss National Science Foundation (SNF) and the SUVA Fonds to JFS and RS.	Alessandri B, 1999, ACT NEUR S, V75, P25; Alm-Kruse K, 2008, BMC NURS, V7, DOI 10.1186/1472-6955-7-1; Aronson D, 2008, ADV CARDIOL, V45, P1, DOI 10.1159/000115118; Bak LK, 2007, NEUROCHEM RES, V32, P671, DOI 10.1007/s11064-006-9161-4; Bak LK, 2006, J CEREBR BLOOD F MET, V26, P1285, DOI 10.1038/sj.jcbfm.9600281; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bingham EM, 2002, DIABETES, V51, P3384, DOI 10.2337/diabetes.51.12.3384; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Duarte AI, 2003, BRAIN RES, V977, P23, DOI 10.1016/S0006-8993(03)02679-9; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Guyot LL, 2000, NEUROSCI LETT, V288, P61, DOI 10.1016/S0304-3940(00)01168-X; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hattori N, 2004, J NUCL MED, V45, P775; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Li PA, 1999, FREE RADICAL BIO MED, V27, P1033, DOI 10.1016/S0891-5849(99)00152-5; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Meier R, 2008, CRIT CARE, V12, DOI 10.1186/cc6974; Nagel A, 2009, J NEUROSURG, V111, P94, DOI 10.3171/2009.1.JNS08587; Occhipinti R, 2009, J NEUROPHYSIOL, V101, P2528, DOI 10.1152/jn.90377.2008; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Pellerin L, 2008, CURR OPIN CLIN NUTR, V11, P701, DOI 10.1097/MCO.0b013e328312c368; Poblete-Naredo I, 2009, NEUROSCI LETT, V451, P134, DOI 10.1016/j.neulet.2008.12.049; Ringel F, 2006, NEUROSCI LETT, V398, P306, DOI 10.1016/j.neulet.2006.01.012; Ronald Zielke H, 2009, J NEUROCHEM, V109, P24, DOI 10.1111/j.1471-4159.2009.05941.x; Samuelsson C, 2009, J NEUROSURG, V111, P910, DOI 10.3171/2008.8.JNS0889; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Sperry JL, 2007, J TRAUMA, V63, P487, DOI 10.1097/TA.0b013e31812e51fc; Strong AJ, 2007, CURR OPIN CRIT CARE, V13, P126, DOI 10.1097/MCC.0b013e32807faffb; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	56	60	65	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2010	14	1							R13	10.1186/cc8869			13	Critical Care Medicine	General & Internal Medicine	587KD	WOS:000276989800047	20141631	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Brenner, LA; Homaifar, BY; Adler, LE; Wolfman, JH; Kemp, J				Brenner, Lisa A.; Homaifar, Beeta Y.; Adler, Lawrence E.; Wolfman, Jessica H.; Kemp, Jan			Suicidality and Veterans With a History of Traumatic Brain Injury: Precipitating Events, Protective Factors, and Prevention Strategies	REHABILITATION PSYCHOLOGY			English	Article						suicide; traumatic brain injury; Veterans; qualitative	PEOPLE; REHABILITATION; POPULATION; HEALTH; IRAQ	Objectives: To increase understanding regarding precipitating and preventative factors of suicidal behavior and to highlight past experiences and recommendations regarding services aimed at suicide prevention among Veterans with a history of traumatic brain injury (TBI). Study Design: Qualitative. Participants: Sample of 13 Veterans with a history of TBI, and a history of clinically significant suicidal ideation or behavior. Method: In-person interviews were conducted and data were analyzed using a hermeneutic approach. Results: Shared precipitants noted included loss-of-self post-TBI, cognitive sequelae, and psychiatric and emotional disturbances. Common protective factors noted included social supports, a sense of purpose regarding the future, religion and spirituality, and mental health care. Means of improving care were also identified (e.g., increasing the availability of services and mental health professionals' knowledge regarding TBI, providing more structured treatment). Conclusions: Findings highlight potential areas of importance in the assessment and treatment of suicidal Veterans with a history of TBI. Recommendations regarding means of improving care are also presented.	[Brenner, Lisa A.] VA Eastern Colorado Hlth Care Syst, MIRECC, VISN 19, Denver, CO 80220 USA; [Homaifar, Beeta Y.; Adler, Lawrence E.] Univ Colorado, Sch Med, Dept Psychiat, MIRECC,VISN 19, Denver, CO 80262 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [Wolfman, Jessica H.] Drexel Univ, MIRECC, VISN 19, Philadelphia, PA 19104 USA; [Kemp, Jan] VA Off Mental Hlth Serv, VISN Ctr Excellence 2, Canandaigua, NY USA	Brenner, LA (corresponding author), VA Eastern Colorado Hlth Care Syst, MIRECC, VISN 19, 1055 Clermont St, Denver, CO 80220 USA.	lisa.brenner@va.gov	Brenner, Lisa A./AAG-2442-2019				Brenner L.A., 2008, J MENT HLTH COUNS, V30, P211; BRENNER LA, WAR SUICIDE IN PRESS; BRENNER LA, 2008, BRAIN INJURY PROFESS, V5, P26; Chwalisz K, 2008, REHABIL PSYCHOL, V53, P387, DOI 10.1037/a0012998; Crabtree B.F., 1999, DOING QUALITATIVE RE; Crisp R., 1993, DISABILITY HANDICAP, V8, P393, DOI [DOI 10.1080/02674649366780371, 10.1080/02674649366780371]; Crist JD, 2003, NURS RES, V52, P202, DOI 10.1097/00006199-200305000-00011; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; *DEP VET AFF, 2004, VETEESA138 SP DEP VE; Haynes SN, 1995, PSYCHOL ASSESSMENT, V7, P238, DOI 10.1037/1040-3590.7.3.238; Hesse-Biber S., 2003, APPROACHES QUALITATI; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; KINSELLA EA, 2006, FQS FORUM QUALITATIV, V7; Kuipers P, 2000, J HEAD TRAUMA REHAB, V15, P1275, DOI 10.1097/00001199-200012000-00007; Lakeman R, 2008, J ADV NURS, V64, P114, DOI 10.1111/j.1365-2648.2008.04773.x; Lorge E, 2008, ARMY RESPONDS RISING; Malone KM, 2000, AM J PSYCHIAT, V157, P1084, DOI 10.1176/appi.ajp.157.7.1084; Maris RW, 2000, COMPREHENSIVE TXB SU; Miklowitz D.J., 1997, BIPOLAR DISORDER FAM; MOSCICKI EK, 1999, HARVARD MED SCH GUID, P40; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Paterson M, 2005, QUAL REP, V10, P339; Patterson M.E., 2002, COLLECTING ANAL QUAL; PEAKE JB, 2008, STATEMENT PRESENTATI; Peterson DB, 2005, REHABIL PSYCHOL, V50, P105, DOI 10.1037/0090-5550.50.2.105; Rubin IS., 1995, QUALITATIVE INTERVIE; Rudd MD, 2006, SUICIDE LIFE-THREAT, V36, P255, DOI 10.1521/suli.2006.36.3.255; Shotton L, 2007, BRAIN INJURY, V21, P857, DOI 10.1080/02699050701481621; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; STANLEY B, 2008, SAFETY PLAN TR UNPUB; Strauss A., 1990, BASICS QUALITATIVE R; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman DJ., 1995, GUIDELINES SURVEILLA; White M., 1990, NARRATIVE MEANS THER; World Health Organization, 2001, INT CLASS FUNCT DIS	42	60	60	1	11	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2009	54	4					390	397		10.1037/a0017802			8	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	526YF	WOS:000272331600005	19929120				2021-06-18	
J	von Reyn, CR; Spaethling, JM; Mesfin, MN; Ma, M; Neumar, RW; Smith, DH; Siman, R; Meaney, DF				von Reyn, Catherine R.; Spaethling, Jennifer M.; Mesfin, Mahlet N.; Ma, Marek; Neumar, Robert W.; Smith, Douglas H.; Siman, Robert; Meaney, David F.			Calpain Mediates Proteolysis of the Voltage-Gated Sodium Channel alpha-Subunit	JOURNAL OF NEUROSCIENCE			English	Article							NA+ CHANNELS; INJURY; MECHANISMS; NEURONS; CLEAVAGE	Alterations in the expression, molecular composition, and localization of voltage-gated sodium channels play major roles in a broad range of neurological disorders. Recent evidence identifies sodium channel proteolysis as a key early event after ischemia and traumatic brain injury, further expanding the role of the sodium channel in neurological diseases. In this study, we investigate the protease responsible for proteolytic cleavage of voltage-gated sodium channels (NaChs). NaCh proteolysis occurs after protease activation in rat brain homogenates, pharmacological disruption of ionic homeostasis in cortical cultures, and mechanical injury using an in vitro model of traumatic brain injury. Proteolysis requires Ca2+ and calpain activation but is not influenced by caspase-3 or cathepsin inhibition. Proteolysis results in loss of the full-length alpha-subunits, and the creation of fragments comprising all domains of the channel that retain interaction even after proteolysis. Cell surface biotinylation after mechanical injury indicates that proteolyzed NaChs remain in the membrane before noticeable evidence of neuronal death, providing a mechanism for altered action potential initiation, propagation, and downstream signaling events after Ca2+ elevation.	[von Reyn, Catherine R.; Mesfin, Mahlet N.; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Spaethling, Jennifer M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Smith, Douglas H.; Siman, Robert; Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Ma, Marek; Neumar, Robert W.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Ma, Marek] Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	smith, douglas/A-1321-2007	von Reyn, Catherine/0000-0002-5753-2134; Meaney, David/0000-0002-0954-4122	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 35712, NS PPG P01 NS 056202, U24NS050606]; NHBLI Gene Therapy Resource Program; University of Pennsylvania Preclinical Vector Core facility; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048234, P01NS056202, U24NS050606, R01NS035712] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) Grants NS 35712 and NS PPG P01 NS 056202. The monoclonal antibodies Na<INF>v</INF>1.1 and Na<INF>v</INF>1.2 were developed by and/or obtained from the University of California, Davis/NIH NeuroMab Facility, supported by NIH Grant U24NS050606, and maintained by the Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis. Support for vector production was provided by the NHBLI Gene Therapy Resource Program and the University of Pennsylvania Preclinical Vector Core facility.	Agrawal SK, 1996, J NEUROSCI, V16, P545; Beacham D, 2007, J NEUROSCI, V27, P11543, DOI 10.1523/JNEUROSCI.1743-07.2007; Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595; Bevers MB, 2009, J NEUROCHEM, V108, P1237, DOI 10.1111/j.1471-4159.2008.05860.x; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cantrell AR, 2001, NAT REV NEUROSCI, V2, P397, DOI 10.1038/35077553; Fache MP, 2004, J CELL BIOL, V166, P571, DOI 10.1083/jcb.200312155; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Jette N, 2006, J CEREBR BLOOD F MET, V26, P777, DOI 10.1038/sj.jcbfm.9600226; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Paillart C, 1996, J CELL BIOL, V134, P499, DOI 10.1083/jcb.134.2.499; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Siman R, 1996, ADV NEUROL, V71, P167; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; STYS PK, 1992, J NEUROSCI, V12, P430; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Waxman SG, 2007, NAT NEUROSCI, V10, P405, DOI 10.1038/nn1857; Wu HY, 2007, J BIOL CHEM, V282, P20075, DOI 10.1074/jbc.M700624200	26	60	61	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	AUG 19	2009	29	33					10350	10356		10.1523/JNEUROSCI.2339-09.2009			7	Neurosciences	Neurosciences & Neurology	484YQ	WOS:000269087300018	19692609	Green Accepted, Green Published, Bronze			2021-06-18	
J	Sharma, S; Zhuang, Y; Ying, Z; Wu, A; Gomez-Pinilla, F				Sharma, S.; Zhuang, Y.; Ying, Z.; Wu, A.; Gomez-Pinilla, F.			DIETARY CURCUMIN SUPPLEMENTATION COUNTERACTS REDUCTION IN LEVELS OF MOLECULES INVOLVED IN ENERGY HOMEOSTASIS AFTER BRAIN TRAUMA	NEUROSCIENCE			English	Article						curcumin; energy homeostasis; traumatic brain injury	ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL CREATINE-KINASE; CYTOCHROME-C-OXIDASE; FOCAL CEREBRAL-ISCHEMIA; FLUID-PERCUSSION INJURY; CENTRAL-NERVOUS-SYSTEM; UNCOUPLING PROTEIN-2; SYNAPTIC PLASTICITY; CALORIE RESTRICTION; NEUROTROPHIC FACTOR	Traumatic brain injury (TBI) is followed by an energy crisis that compromises the capacity of the brain to cope with challenges, and often reduces cognitive ability. New research indicates that events that regulate energy homeostasis crucially impact synaptic function and this can compromise the capacity of the brain to respond to challenges during the acute and chronic phases of TBI. The goal of the present study is to determine the influence of the phenolic yellow curry pigment curcumin on molecular systems involved with the monitoring, balance, and transduction of cellular energy, in the hippocampus of animals exposed to mild fluid percussion injury (FPI). Young adult rats were exposed to a regular diet (RD) without or with 500 ppm curcumin (Cur) for four weeks, before an FPI was performed. The rats were assigned to four groups: RD/Sham, Cur/Sham, RD/FPI, and Cur/FPI. We found that FPI decreased the levels of AMP-activated protein kinase (AMPK), ubiquitous mitochondrial creatine kinase (uMtCK) and cytochrome c oxidase II (COX-II) in RD/FPI rats as compared to the RD/sham rats. The curcumin diet counteracted the effects of FPI and elevated the levels of AMPK, uMtCK, COX-II in Cur/FPI rats as compared to RD/sham rats. In addition, in the Cur/sham rats, AMPK and uMtCK increased compared to the RD/sham. Results show the potential of curcumin to regulate molecules involved in energy homeostasis following TBI. These studies may foster a new line of therapeutic treatments for TBI patients by endogenous upregulation of molecules important for functional recovery. (C) 2009 Published by Elsevier Ltd on behalf of IBRO.	[Gomez-Pinilla, F.] Univ Calif Los Angeles, Dept Physiol Sci, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Gomez-Pinilla, F.] Univ Calif Los Angeles, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, Brain Injury Res Ctr, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	Fgomezpi@ucla.edu	Sharma, Sandeep/A-9248-2011	Sharma, Sandeep/0000-0002-9680-7460	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS50465]	Studies were supported by funds related to awards covered under National Institutes of Health, NS50465. We are also thankful to the Brain Injury Research Center, UCLA for their cooperation.	Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Arsenijevic D, 2007, J NEUROIMMUNOL, V186, P121, DOI 10.1016/j.jneuroim.2007.03.013; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Begum AN, 2008, J PHARMACOL EXP THER, V326, P196, DOI 10.1124/jpet.108.137455; Biegon A, 2004, CURR PHARM DESIGN, V10, P2177, DOI 10.2174/1381612043384196; Boero J, 2003, MOL CELL BIOCHEM, V244, P69, DOI 10.1023/A:1022409101641; BRAND MD, 1994, BBA-BIOENERGETICS, V1187, P132, DOI 10.1016/0005-2728(94)90099-X; Bronner M, 2004, BIOCHEM J, V384, P295, DOI 10.1042/BJ20040955; Chen LL, 1995, J COMP NEUROL, V363, P389, DOI 10.1002/cne.903630305; Cheng G, 2003, BIOCHEM BIOPH RES CO, V308, P573, DOI 10.1016/S0006-291X(03)01409-8; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dagon Y, 2005, J BIOL CHEM, V280, P42142, DOI 10.1074/jbc.M507607200; Dai W, 2009, BRAIN RES, V1251, P287, DOI 10.1016/j.brainres.2008.11.034; de Lange P, 2006, FASEB J, V20, DOI 10.1096/fj.06-6025fje; EPPENBERGER ME, 1967, NATURE, V214, P239, DOI 10.1038/214239a0; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; FRIEDMAN DL, 1994, J COMP NEUROL, V343, P500, DOI 10.1002/cne.903430311; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Ganguli M, 2000, ARCH NEUROL-CHICAGO, V57, P824, DOI 10.1001/archneur.57.6.824; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Gomez-Pinilla F, 2008, EUR J NEUROSCI, V28, P2278, DOI 10.1111/j.1460-9568.2008.06524.x; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hisahara S, 2005, J PHARMACOL SCI, V98, P200, DOI 10.1254/jphs.FMJ05001X2; Horvath TL, 1999, J NEUROSCI, V19, P10417; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Huttemann M, 2008, NEUROSCIENCE, V151, P148, DOI 10.1016/j.neuroscience.2007.09.029; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kim SJ, 2008, J BIOL CHEM, V283, P14497, DOI 10.1074/jbc.M708373200; Kim-Han JS, 2005, ANTIOXID REDOX SIGN, V7, P1173, DOI 10.1089/ars.2005.7.1173; Kleman AM, 2008, J NEUROSCI METH, V167, P292, DOI 10.1016/j.jneumeth.2007.08.028; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lim GP, 2001, J NEUROSCI, V21, P8370; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; NegreSalvayre A, 1997, FASEB J, V11, P809; NELSON C, 1994, PEDIATR RES, V36, P12, DOI 10.1203/00006450-199407001-00003; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nisoli E, 2006, J CELL SCI, V119, P2855, DOI 10.1242/jcs.03062; North RA, 2006, PFLUG ARCH EUR J PHY, V452, P479, DOI 10.1007/s00424-006-0060-y; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Richard D, 1999, INT J OBESITY, V23, pS53, DOI 10.1038/sj.ijo.0800947; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; ROJO M, 1991, J BIOL CHEM, V266, P20290; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sumanont Y, 2006, LIFE SCI, V78, P1884, DOI 10.1016/j.lfs.2005.08.028; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman S, 2006, NEUROSCIENCE, V139, P1221, DOI 10.1016/j.neuroscience.2006.01.062; WHITTINGHAM TS, 1981, J NEUROCHEM, V37, P1618, DOI 10.1111/j.1471-4159.1981.tb06337.x; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Zhao J, 2008, BRAIN RES, V1229, P224, DOI 10.1016/j.brainres.2008.06.117	63	60	62	1	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUL 21	2009	161	4					1037	1044		10.1016/j.neuroscience.2009.04.042			8	Neurosciences	Neurosciences & Neurology	458EU	WOS:000266998600008	19393301	Green Accepted			2021-06-18	
J	Echemendia, RJ; Herring, S; Bailes, J				Echemendia, R. J.; Herring, S.; Bailes, J.			Who should conduct and interpret the neuropsychological assessment in sports-related concussion?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				HIGH-SCHOOL; FOOTBALL PLAYERS; TESTING USEFUL; RECOVERY; PERFORMANCE; RETURN; IMPAIRMENT; MANAGEMENT; INJURY; IMPACT	Objective: This paper seeks to (i) describe the education and training of clinical neuropsychologists, (ii) discuss the significant differences between test administration and clinical assessment, (iii) outline the complex factors involved in psychometric test theory and test interpretation, and (iv) provide a framework for the role of clinical neuropsychologists in the interpretation and administration of neuropsychological instruments within the sports context. Design: Review of pertinent professional practice, empirical and theoretical literature. Intervention: Pubmed, Medline and Psych Info databases were reviewed. In total, 35 articles and 2 books were reviewed. Results: The decision to return an athlete to play following sports-related brain injury is complex and requires the analysis of several sources of data. The decision is determined by a team physician; ideally within the context of a multidisciplinary team that employs comprehensive concussion surveillance and management, including baseline and post-injury neuropsychological assessment. Neuropsychologists possess the training and skill sets necessary to provide unique expertise in the assessment of cognitive functioning and post-injury neurocognitive and psychological assessment. Conclusions: Baseline neuropsychological testing is a technical procedure that can be conducted by technicians under the supervision/guidance of a neuropsychologist. Post-injury assessment requires advanced neuropsychological expertise that is best provided by a clinical neuropsychologist. Significant international differences exist with respect to the training and availability of clinical neuropsychologists, which require modification of these views on a country by country basis.	[Echemendia, R. J.] Psychol & Neurobehav Associates Inc, State Coll, PA 16801 USA; [Herring, S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, S.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA USA; [Herring, S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Bailes, J.] W Virginia Univ, Sch Med, Dept Neurol Surg, Morgantown, WV 26506 USA	Echemendia, RJ (corresponding author), Psychol & Neurobehav Associates Inc, 204 E Calder Way,St 205, State Coll, PA 16801 USA.	rechemendia@comcast.net	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Axelrod B, 2000, ARCH CLIN NEUROPSYCH, V15, P379, DOI 10.1093/arclin/15.5.379; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barth JT., 1989, MILD HEAD INJURY, P257; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; *DIV 40 TASK FORC, 1989, CLIN NEUROPSYCHOL, V3, P23; ECHEMENDIA R, 2008, CONC SPORT CLIN S NE; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2006, SPORTS NEUROPSYCHOLO; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hannay HJ, 1998, ARCH CLIN NEUROPSYCH, V13, P157, DOI 10.1016/S0887-6177(98)00003-1; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; IVERSON G, 2004, TRAUMATIC BRAIN INJU; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 2005, J ATHL TRAINING, V40, P152; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; *NAT AC NEUR, 2001, ARCH CLIN NEUROPSYCH, V15, P379; Randolph C, 2005, J ATHL TRAINING, V40, P139	36	60	60	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I32	I35		10.1136/bjsm.2009.058164			4	Sport Sciences	Sport Sciences	450YO	WOS:000266438100006	19433423				2021-06-18	
J	Riggio, S; Wong, M				Riggio, Silvana; Wong, Meredith			Neurobehavioral Sequelae of Traumatic Brain Injury	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						frontal lobe seizures; neuropsychiatric disorders; postconcussive syndrome; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; PSYCHIATRIC-DISORDERS; CHRONIC PAIN; FATIGUE; ASSOCIATION; DISABILITY; COMPLAINTS; SYMPTOMS; RISK	The neurobehavioral sequelae of traumatic brain injury consist of a spectrum of somatic and neuropsychiatric symptoms. The neuropsychiatric symptoms are divided into cognitive and behavioral presentations. In the literature, these neurobehavioral sequelae have been called postconcussive symptoms, postconcussive syndrome, and postconcussive disorder; however, the authors of this review do not use this terminology because the symptoms are not restricted to patients with concussion but instead can be found in all traumatic brain injury patients of all injury severities. The development of neurobehavioral sequelae after traumatic brain injury is a multifactorial process. The patient evaluation requires a multidisciplinary approach in order to delineate psysiologic dysfunction and place deficits in the context of the patient's preinjury and postinjury psychiatric status. Consequently, the evaluation of the posttraumatic brain injury patient with neurobehavioral sequelae requires a carefully structured history and physical examination with an emphasis on neurological and psychiatric function. Adjunctive evaluations must be trailored to the patient with neuroimaging, neurophysiological, and neuropsychiatric testing. Maximized outcomes may be achieved by the performance of a careful and detailed assessment that places compliants with the context of the individual. Mt Sinai J Med 76:163-172, 2009 (C) 2009 Mount Sinai School of Medicine	[Riggio, Silvana; Wong, Meredith] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA; [Riggio, Silvana] Mt Sinai Sch Med, Dept Neurol, New York, NY USA	Riggio, S (corresponding author), Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.	silvana.riggio@mssm.edu					Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; *DIV INJ DIS OUTC, 2004, TRAUM BRAIN INJ US E; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Greve KW, 2001, BRAIN INJURY, V15, P255; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Quesney LF, 1986, RECENT ADV EPILEPSY, V3, P81; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; RIGGIO S, 1995, ADV NEUROL, V66, P153; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Ruff RM, 1996, BRAIN INJURY, V8, P61; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	58	60	62	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					163	172		10.1002/msj.20097			10	Medicine, General & Internal	General & Internal Medicine	427OE	WOS:000264787800009	19306386	Bronze			2021-06-18	
J	Kennedy, MRT; Wozniak, JR; Muetzel, RL; Mueller, BA; Chiou, HH; Pantekoek, K; Lim, KO				Kennedy, Mary R. T.; Wozniak, Jeffrey R.; Muetzel, Ryan L.; Mueller, Bryon A.; Chiou, Hsin-Huei; Pantekoek, Kari; Lim, Kelvin O.			White matter and neurocognitive changes in adults with chronic traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Diffusion tensor imaging; Anisotropy; Brain injury; Executive functions; Cognition	DIFFUSE AXONAL INJURY; HEAD-INJURY; PERFORMANCE; IMPAIRMENT	Diffusion tensor imaging was used to investigate white matter (WM) integrity in adults with traumatic brain injury (TBI) and healthy adults as controls. Adults with TBI had sustained severe vehicular injuries on the average of 7 years earlier. A multivariate analysis of covariance with verbal IQ as the covariate revealed that adults with TBI had lower fractional anisotropy and higher mean diffusivity than controls, specifically in the three regions of interest (ROIs), the centrum semiovale (CS), the superior frontal (SPF), and the inferior frontal (INF). Adults with TBI averaged in the normal range in motor speed and two of three executive functions and were below average in delayed verbal recall and inhibition, whereas controls were above average. Time since injury, but not age, was associated with WM changes in the SPF ROI, whereas age, but not time since injury, was associated with WM changes in the INF ROI, suggesting that the effects of WM on time since injury may interact with age. To understand the utility of WM changes in chronic recovery, larger sample sizes are needed to investigate associations between cognition and WM integrity of severely injured individuals who have substantial cognitive impairment compared to severely injured individuals with little cognitive impairment. (JINS, 2009, 15, 130-136.)	[Kennedy, Mary R. T.; Chiou, Hsin-Huei; Pantekoek, Kari] Univ Minnesota, Dept Speech Language Hearing Sci, Minneapolis, MN 55455 USA; [Wozniak, Jeffrey R.; Muetzel, Ryan L.; Mueller, Bryon A.; Pantekoek, Kari; Lim, Kelvin O.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA	Kennedy, MRT (corresponding author), Univ Minnesota, Dept Speech Language Hearing Sci, 115 Shevlin Hall,164 Pillsbury Dr SE, Minneapolis, MN 55455 USA.	kenneG47@umn.edu	Lim, Kelvin/AAF-6833-2020	Lim, Kelvin/0000-0002-2390-7268; Wozniak, Jeffrey/0000-0002-7132-8519	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR008079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS057091] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41 RR008079-13, P41 RR008079] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS057091-01, P30 NS057091-03, P30 NS057091, P30 NS057091-04, P30 NS057091-02, P30 NS057091-05] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Braver TS, 2001, CEREB CORTEX, V11, P825, DOI 10.1093/cercor/11.9.825; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2001, DELISKAPLAN EXECUTIV; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Kertesz A., 1982, W APHASIA BATTERY; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Le Bihan D, 1995, DIFFUSION PERFUSION; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Skoglund TS, 2008, ACTA RADIOL, V49, P98, DOI 10.1080/02841850701561372; STRICH SJ, 1961, LANCET, V2, P443; TEASDALE G, 1974, LANCET, V2, P81; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilson, 1991, NATL ADULT READING T; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	36	60	63	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2009	15	1					130	136		10.1017/S1355617708090024			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	398NR	WOS:000262739300014	19128536	Green Accepted			2021-06-18	
J	Lefering, R; Paffrath, T; Linker, R; Bouillon, B; Neugebauer, EAM				Lefering, Rolf; Paffrath, Thomas; Linker, Ralph; Bouillon, Bertil; Neugebauer, Edmund A. M.		Deutsch Gesellsch Unfallchirurg	Head Injury and Outcome-What Influence do Concomitant Injuries Have?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Trauma Registry Meeting	2006	Munich, GERMANY			Wounds and injuries; Head injury; Score systems; Outcome; Mortality	MULTIPLE-ORGAN FAILURE; TRAUMATIC BRAIN-INJURY; SEVERITY SCORE; MORTALITY; CARE	Background. Severe head injury (HI) is known to be a major determinant of mortality in patients with multiple injuries but additional injuries also contribute to the clinical outcome. The Trauma Registry of the German Society for Trauma Surgery offers sufficient data for comparative outcome analysis in relation to the injury pattern. Methods: A total of 21,356 cases from Trauma Registry of the German Society for Trauma Surgery with complete data for pattern of injury (Abbreviated Injury Scale [AIS], Injury Severity Score), the incidence of hospital mortality, organ failure, sepsis, duration of hospital stay, and intubation-free days. Maximum AIS severity of HI, including brain, skull, face, and cervical spine, and injuries to the torso and/or extremities (TEI) were used for comparative subgroup analysis. Results: Overall mortality rate was 13.7% (mean age, 41.3 years; 72.6% men; mean Injury Severity Score, 24.4). Patients with relevant HI (AIS(HI) >= 3) were found to have a higher mortality rate (22.1 %) than patients with relevant TEI (12.9%). In all HI severity subgroups mortality increased consistently by about 5% with TEI of grade 4, and by 15% with TEI of grade 5, but no increase is observed for lower severity grades. The incidence of organ failure (overall 31.4%), multiple organ failure (15.0%), and sepsis (9.9%) are mainly influenced by the severity of TEI. Intubation-free days are equally influenced by both types of injuries of grade 3 or higher. Conclusions: Mortality in patients with severe trauma is mainly determined by the severity of HI, while TEI contribute consistently only from AIS grade 4 or higher.	[Lefering, Rolf; Neugebauer, Edmund A. M.] Univ Witten Herdecke, IFOM Inst Res Operat Med, D-51109 Cologne, Germany; [Paffrath, Thomas; Bouillon, Bertil] Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, D-51109 Cologne, Germany; [Linker, Ralph] Orthoped Med Practice Ctr, Zell Mosel, Germany	Lefering, R (corresponding author), Univ Witten Herdecke, IFOM Inst Res Operat Med, Campus Cologne Merheim,Bldg 38,Ostmerheimer St 20, D-51109 Cologne, Germany.	rolf.lefering@ifom-uni-wh.de					[Anonymous], 1990, ABBR INJ SCAL AIS 19; *ASS ADV AUT MED, 1998, ABBR INJ SCAL 1990 R; Baethmann A, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P169; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baltas I, 1998, J Neurosurg Sci, V42, P85; BONE RC, 1991, CRIT CARE MED, V19, P973, DOI 10.1097/00003246-199107000-00024; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1990, J TRAUMA, V30, P539, DOI 10.1097/00005373-199005000-00003; Champion HR, 1996, J TRAUMA, V40, P42, DOI 10.1097/00005373-199601000-00009; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Dutton RP, 2006, J TRAUMA, V60, pS70, DOI 10.1097/01.ta.0000200856.47545.64; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; Lefering R, 2002, LANGENBECK ARCH SURG, V387, P14, DOI 10.1007/s00423-001-0269-3; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; PAPE HC, 2000, EUR J TRAUMA, V1, P233; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; RAUM MR, 2001, EUR J TRAUMA, V27, P110; Rixen D, 2001, SHOCK, V15, P83, DOI 10.1097/00024382-200115020-00001; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016	26	60	61	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2008	65	5					1036	1044		10.1097/TA.0b013e318184ee48			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	372DD	WOS:000260881000012	19001971				2021-06-18	
J	Talvik, I; Alexander, RC; Talvik, T				Talvik, Inga; Alexander, Randell C.; Talvik, Tiina			Shaken baby syndrome and a baby's cry	ACTA PAEDIATRICA			English	Article						crying; inflicted traumatic brain injury; trigger for child abuse	TRAUMATIC BRAIN-INJURY; AGE-RELATED INCIDENCE; YOUNG-CHILDREN; IMPACT SYNDROME; HEAD TRAUMA; 1ST YEAR; ABUSE; OUTCOMES; INFANTS; TOMOGRAPHY	The aim of this study was to investigate the relationship between crying of an infant and inflicted head injury by shaking and/or impact. During the period between January 1, 1997 and December 31, 2003, 26 cases of shaken baby syndrome (SBS) were identified in Estonia. The incidence of SBS was 28.7 per 100 000 children under 1 year of age during the whole study period. In this group there were four children from twin pairs: two twin boys and a girl from a twin pair and a boy from another twin pair. This represents 15.4% of the 26 cases. Twins in Estonia represent 2.12% of infant births. The mean age on admission was 3.9 months. According to outpatient records almost all parents (88.5%) in the study group (23/26) had contacted their family physicians and other specialists because of excessive crying or irritability of the baby prior to the admission to the hospital with SBS or death. We found that the time curve of crying was similar to the curve of highest incidence of cases of SBS except the crying curve began earlier. Conclusion. Our data confirm that the families with twins are at additional risk for SBS and parent's complaints of excessive crying of their infants should be taken as signal that parents need to be carefully counselled.	[Talvik, Inga; Talvik, Tiina] Tartu Univ Hosp, Childrens Clin, Tartu, Estonia; [Talvik, Tiina] Univ Tartu, Dept Paediat, EE-50090 Tartu, Estonia; [Alexander, Randell C.] Univ Florida Jacksonville, Jacksonville, FL USA; [Alexander, Randell C.] Florida Childrens Med Serv, Jacksonville, FL USA; [Alexander, Randell C.] Morehouse Sch Med, Atlanta, GA 30310 USA	Talvik, I (corresponding author), Tartu Univ Hosp, Childrens Clin, 6 Lunini St, Tartu, Estonia.	inga.talvik@kliinikum.ee					Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; Alexander RC, 1996, ARCH PEDIAT ADOL MED, V150, P444; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Barr RG, 2005, J DEV BEHAV PEDIATR, V26, P14; BARR RG, 1989, PEDIATRICS, V84, P514; Barr RG, 1998, CHILD CARE HLTH DEV, V24, P425; BARR RG, 1990, DEV MED CHILD NEUROL, V32, P356; Bonnier C, 2003, PEDIATRICS, V112, P808, DOI 10.1542/peds.112.4.808; BOWLBY J, 1958, INT J PSYCHOANAL, V39, P350; BRAZELTON TB, 1962, PEDIATRICS, V29, P579; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DYKES LJ, 1986, CHILD ABUSE NEGLECT, V10, P211, DOI 10.1016/0145-2134(86)90082-7; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Hiscock H, 2004, MED J AUSTRALIA, V181, P507, DOI 10.5694/j.1326-5377.2004.tb06414.x; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Kairys SW, 2001, PEDIATRICS, V108, P206; Karandikar S., 2004, CHILD ABUSE REV, V13, P178, DOI DOI 10.1002/CAR.850; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kochanek PM, 2007, J NEUROTRAUM, V24, P1, DOI 10.1089/neu.2006.0209; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; LEVITT C, 1994, CHILD ABUSE MED DIAG; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; McMahon C, 2001, AUST NZ J PSYCHIAT, V35, P581, DOI 10.1080/0004867010060505; Mierisch RF, 2004, PEDIATR EMERG CARE, V20, P118, DOI 10.1097/01.pec.0000113883.10140.c2; Pounder DJ, 1997, AM J FOREN MED PATH, V18, P321, DOI 10.1097/00000433-199712000-00001; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; Reijneveld SA, 2001, PEDIATRICS, V108, P893, DOI 10.1542/peds.108.4.893; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; STJAMESROBERTS I, 1991, J CHILD PSYCHOL PSYC, V32, P951; Talvik I, 2007, ACTA PAEDIATR, V96, P1164, DOI 10.1111/j.1651-2227.2007.00362.x; Talvik I, 2006, ACTA PAEDIATR, V95, P799, DOI 10.1080/08035250500464923; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	39	60	62	1	11	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0803-5253			ACTA PAEDIATR	Acta Paediatr.	JUN	2008	97	6					782	785		10.1111/j.1651-2227.2008.00778.x			4	Pediatrics	Pediatrics	296FJ	WOS:000255528600022	18397351				2021-06-18	
J	Jayakumar, AR; Rao, KVR; Panickar, KS; Moriyama, M; Reddy, PVB; Norenberg, MD				Jayakumar, Arumugam R.; Rao, K. V. Rama; Panickar, Kiran S.; Moriyama, M.; Reddy, P. V. B.; Norenberg, Michael D.			Trauma-induced cell swelling in cultured astrocytes	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						astrocytes; cell cultures; cell swelling; cytotoxic edema; mitochondrial permeability transition; mitogen-activated protein kinases; nitric oxide; oxidative stress; traumatic brain injury	MITOCHONDRIAL PERMEABILITY TRANSITION; STRETCH-INDUCED INJURY; BRAIN-INJURY; OXIDATIVE STRESS; CYCLOSPORINE-A; NITRIC-OXIDE; IN-VITRO; CORTICAL CONTUSION; EDEMA FORMATION; FREE-RADICALS	Brain edema and associated increased intracranial pressure are major consequences of traumatic brain injury that account for most early deaths after traumatic brain injury. An important component of brain edema after traumatic brain injury is astrocyte swelling (cytotoxic edema). To examine the pathophysiologic mechanisms of trauma-induced astrocyte swelling, we used an in vitro fluid percussion trauma model. Exposure of cultured rat astrocytes to 5 atm of pressure resulted in significant cell swelling at I to 24 hours posttrauma that was maximal at 3 hours. Because oxidative/nitrosative stress, mitochondrial permeability transition (mPT), and mitogen-activated protein kinases (MAPKs) have been implicated in astrocyte swelling in other neurologic conditions, we examined their potential roles in this model. We previously showed increased free radical generation after in vitro trauma and show here that trauma to astrocytes increased the production of nitric oxide. Trauma also induced mPT and increased phosphorylation (activation) of MAPKs (extracellular signal-regulated kinase 1/2, c-Jun-N-terminal kinase, and p38-MAPK); these changes were diminished by antioxidants and the nitric oxide synthase inhibitor N-nitro-L-arginine methyl ester. Antioxidants, N-nitro-L-arginine methyl ester, the mPT inhibitor cyclosporin A, and inhibitors of MAPKs all significantly diminished trauma-induced astrocyte swelling. These findings demonstrate that direct mechanical injury to cultured astrocytes brings about cell swelling, and that blockade of oxidative/nitrosative stress, mPT, and MAPKs significantly reduce such swelling.	[Jayakumar, Arumugam R.; Rao, K. V. Rama; Reddy, P. V. B.; Norenberg, Michael D.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Norenberg, Michael D.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [Norenberg, Michael D.] Vet Affairs Med Ctr, Miami, FL 33125 USA; [Panickar, Kiran S.] USDA, Beltsville Human Nutr Res Ctr, Diet Genom & Immunol Lab, Beltsville, MD 20705 USA; [Moriyama, M.] Osaka Prefecture Univ, Lab Integrat Physiol Vet Sci, Osaka, Japan	Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu		Moriyama, Mitsuaki/0000-0001-8123-8835			Adams H., 1963, METHOD ENZYMAT AN, P539; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Aplin AE, 1999, J CELL SCI, V112, P695; Bai G, 2001, J NEUROSCI RES, V66, P981, DOI 10.1002/jnr.10056; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Blanc A, 2004, ANTIOXID REDOX SIGN, V6, P353, DOI 10.1089/152308604322899422; Brahma B, 2000, J NEUROCHEM, V74, P1263; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; BULLOCK MR, 1999, NEUROSURGERY, V45, P17; Cai S, 1998, AM J PHYSIOL-CELL PH, V275, pC1349; CHAN PH, 1989, ANN NY ACAD SCI, V559, P237; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; Chen CJ, 2000, J NEUROCHEM, V75, P1557, DOI 10.1046/j.1471-4159.2000.0751557.x; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Fukui S, 2003, ACT NEUR S, V86, P301; Gaitanaki C, 2003, J EXP BIOL, V206, P2759, DOI 10.1242/jeb.00483; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Haskew RE, 2002, J NEUROCHEM, V82, P903, DOI 10.1046/j.1471-4159.2002.01037.x; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUANG JA, 1995, BRAIN RES, V680, P16, DOI 10.1016/0006-8993(95)00209-9; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Jacques-Fricke BT, 2006, J NEUROSCI, V26, P5656, DOI 10.1523/JNEUROSCI.0675-06.2006; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Kawamata T, 1997, ACT NEUR S, V70, P191; Kerr PM, 1999, AM J PHYSIOL-HEART C, V276, pH496; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KIMELBERG HK, 1987, J PHYSIOL-PARIS, V82, P294; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mongin A. A., 2005, NEUROGLIA, P550; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nicholls DG, 2005, CELL CALCIUM, V38, P311, DOI 10.1016/j.ceca.2005.06.011; Norenberg MD, 2007, NEUROCHEM INT, V50, P983, DOI 10.1016/j.neuint.2007.02.008; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; OLSON JE, 1992, CAN J PHYSIOL PHARM, V70, pS350, DOI 10.1139/y92-282; OLSON JE, 1992, METAB BRAIN DIS, V7, P183, DOI 10.1007/BF01000245; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Panickar K.S., 2006, SOC NEUR ABSTR, V180, P14; Panickar KS, 2002, NEUROCHEM RES, V27, P161, DOI 10.1023/A:1014875210852; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rao KVR, 2007, NEUROTOXICOLOGY, V28, P807, DOI 10.1016/j.neuro.2007.03.001; Rao KVR, 2004, J BIOL CHEM, V279, P32333, DOI 10.1074/jbc.M402096200; Rao KVR, 2003, J NEUROSCI RES, V74, P891, DOI 10.1002/jnr.10755; Rao KVR, 2003, METAB BRAIN DIS, V18, P113, DOI 10.1023/A:1023858902184; Reichert SA, 2001, J NEUROSCI, V21, P6608; Reinehr R, 2007, GLIA, V55, P758, DOI 10.1002/glia.20504; SACHS F, 1992, SOC GEN PHY, V47, P241; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schliess F, 2004, GLIA, V47, P21, DOI 10.1002/glia.20019; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SHEPHERD D, 1969, BIOCHEM J, V114, P597, DOI 10.1042/bj1140597; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Staub F, 1996, ACT NEUR S, V66, P56; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Zhang DX, 2007, AM J PHYSIOL-HEART C, V292, pH2023, DOI 10.1152/ajpheart.01283.2006; Zielinska M, 2002, NEUROCHEM RES, V27, P37, DOI 10.1023/A:1014894320421; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	81	60	62	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2008	67	5					417	427		10.1097/NEN.0b013e31816fc9d4			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	294YN	WOS:000255442300004	18431255	Other Gold			2021-06-18	
J	Chevignard, MP; Taillefer, C; Picq, C; Poncet, F; Noulhiane, M; Pradat-Diehl, P				Chevignard, M. P.; Taillefer, C.; Picq, C.; Poncet, F.; Noulhiane, M.; Pradat-Diehl, P.			Ecological assessment of the dysexecutive syndrome using execution of a cooking task	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						ecological assessment; executive functions; multi-tasking; rehabilitation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PROSPECTIVE MEMORY; PERFORMING ACTIVITIES; COGNITIVE STRUCTURE; HEAD-INJURY; DEFICITS; DYSFUNCTION; TESTS; EVENT; REHABILITATION	Patients with a dysexecutive syndrome often have severe disabilities in daily life activities. The aims of this study were to use a naturalistic experimental task to assess patients' disabilities, and to study the nature of the cognitive disorders underlying them. Execution of a cooking task involving multi-tasking (Chevignard et al., 2000) was studied in 45 patients with a dysexecutive syndrome following acquired brain injury. Patients made significantly more errors and were slower than controls; more than half of the patients did not achieve the goal and demonstrated dangerous behaviours. Those results were significantly correlated to the results of the Six Elements Task and to a behavioural questionnaire. They were also correlated to brain injury severity and to patients' cooking habits. This naturalistic assessment is clinically relevant to better assess patients' dysexecutive impairments in complex activities of daily living. Correlations of the results in the cooking task with the neuropsychological assessment highlighted the role of the dysexecutive syndrome in patients' disabilities, indicating control alterations rather than planning disorders, difficulty in dealing with the environment, and inhibiting inappropriate actions. The role of attention and prospective memory was also underlined, whereas other cognitive functions did not influence task performance.	[Chevignard, M. P.] Hop Natl St Maurice, INR A, Dept Rehabil Children Acquired Brain Injury, F-94410 St Maurice, France; [Taillefer, C.; Picq, C.; Poncet, F.; Pradat-Diehl, P.] Grp Hosp Pitie Salpetriere, AP HP, Serv Med Phys & Readaptat, F-75634 Paris, France; [Chevignard, M. P.; Taillefer, C.; Picq, C.; Pradat-Diehl, P.] INSERM, U731, Paris, France; [Chevignard, M. P.; Taillefer, C.; Picq, C.; Pradat-Diehl, P.] Univ Paris 06, UMR S731, Paris, France; [Noulhiane, M.] Univ Paris 05, CNRS, F-75270 Paris, France; [Noulhiane, M.] Lab Psychol & Neurosci Cognit, FRE 2987, Paris, France	Chevignard, MP (corresponding author), Hop Natl St Maurice, INR A, Dept Rehabil Children Acquired Brain Injury, 14 Rue Val Osne, F-94410 St Maurice, France.	m.chevignard@hopital-saint-maurice.fr		Noulhiane, Marion/0000-0003-2832-0332			Allain P, 2004, REV NEUROPSYCHOL, V14, P285; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BRICKENKAMP R, 1966, ADAPTATION FRANCAISE; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Burgess P. W., 1997, COGNITIVE MODELS MEM, P247; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; BURGESS PW, 1994, REV NEUROPSYCHOL, V4, P345; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Cazalis F, 2001, J INT NEUROPSYCH SOC, V7, P795, DOI 10.1017/S1355617701777028; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; CRIPE LI, 1998, ECOLOGICAL VALIDITY, P171; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; DUTIL E, 2003, PROFIL AVQ VERSION 3; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Fuster J, 1989, PREFRONTAL CORTEX; Garnier C, 1998, REV NEUROPSYCHOL, V8, P385; Godbout L, 2005, BRAIN INJURY, V19, P337, DOI 10.1080/02699050400005093; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Kozlowski O., 2002, Annales de Readaptation et de Medecine Physique, V45, P466, DOI 10.1016/S0168-6054(02)00297-0; Le Thiec F., 1999, Annales de Readaptation et de Medecine Physique, V42, P1, DOI 10.1016/S0168-6054(99)80030-0; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LHERMITTE F, 1986, ANN NEUROL, V19, P326, DOI 10.1002/ana.410190404; Luria A. R., 1966, HIGHER CORTICAL FUNC; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P336, DOI 10.1037/0278-7393.24.2.336; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Mazaux JM, 2002, ACT NEUR S, V79, P49; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; MEACHAM JA, 1977, J PSYCHOL, V97, P191, DOI 10.1080/00223980.1977.9923962; Miotto EC, 1998, CORTEX, V34, P639, DOI 10.1016/S0010-9452(08)70770-6; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NORMAN DA, 1980, 99 CTR HUM INF PROC; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pandya DN, 1996, RES PER NEUROSCI, P13; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Quintard B., 2002, Annales de Readaptation et de Medecine Physique, V45, P456, DOI 10.1016/S0168-6054(02)00296-9; Rabbitt P., 1997, METHODOLOGY FRONTAL, P1; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; Rey A., 1959, TEST COPIE REPROD ME; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Semkovska M, 2004, SCHIZOPHR RES, V69, P289, DOI 10.1016/j.schres.2003.07.005; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, ALLOCATION PROCESSIN, P328; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Sohlberg M. M., 2001, COGNITIVE REHABILITA; TEASDALE G, 1974, LANCET, V2, P81; Teuber H. L., 1964, FRONTAL GRANULAR COR; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wechsler D., 2000, ECHELLE INTELLIGENCE; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zalla T, 2001, NEUROPSYCHOLOGIA, V39, P759, DOI 10.1016/S0028-3932(01)00019-7; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X; ZIMMERMANN P, 1992, BATTERIE TESTS NEURO	81	60	60	0	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	4					461	485		10.1080/09602010701643472			25	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	318SO	WOS:000257113000004	18576272				2021-06-18	
J	Klose, M; Watt, T; Brennum, J; Feldt-Rasmussen, U				Klose, M.; Watt, T.; Brennum, J.; Feldt-Rasmussen, U.			Posttraumatic hypopituitarism is associated with an unfavorable body composition and lipid profile, and decreased quality of life 12 months after injury	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							TRAUMATIC BRAIN-INJURY; GROWTH-HORMONE DEFICIENCY; BASE-LINE; QOL-AGHDA; FACTOR-I; ADULTS; REPLACEMENT; HEALTH; GH	Objective: Our objective was to describe body composition, lipid profile, and health-related quality of life (HRQL) in patients with traumatic brain injury (TBI) in relation to the development of post-traumatic hypopituitarism. Design: This is a cross-sectional evaluation with a nested prospective substudy. Patients: The cross-sectional cohort included 104 hospitalized patients with TBI [26 females/78 males; median age 41 yr (range 18 64); body mass index (BMI) 25 kg/m(2) (range 17 -39); and severity, mild (Glasgow Coma Scale score (GCS) 13 -15) n = 44, moderate (GCS 9 -12) n = 20, and severe (GCS < 9) n = 40)]. A nested cohort of 46 patients was followed prospectively. Measurements: BMI, waist circumference, lipid profile, total-and regional-fat mass were assessed 3 and 12 months (prospective) or only 12 months (cross-sectional) posttraumatically. HRQL questionnaires (Nottingham Health Profile, EuroQoL-5D, and the GH deficiency (GHD) specific instrument, Quality of Life Assessment of GHD in Adults) were completed "pre-traumatically," 3 and 12 months (prospective), or only 12 months (cross-sectional) posttraumatically. Results: Patients with posttraumatic hypopituitarism had higher age-, gender-, and BMI-adjusted 12-month low-density lipoprotein-cholesterol, waist circumference, and total fat mass (P < 0.05 in all cases), and a higher increase in total cholesterol (P = 0.01) during follow-up compared with sufficient patients. These findings were unrelated to 12-month IGF-I and IGF-I SD scores. Hypopituitary patients also had worse age, BMI, and TBI severity adjusted overall EuroQoL-5D visual analog scale (P = 0.03) and Quality of Life Assessment of GHD in Adults (P = 0.01) scores, and worse Nottingham Health Profile dimension scores of sleep (P = 0.03), energy (P = 0.02), and social isolation (P = 0.04), compared with patients with an intact pituitary function. Conclusion: Posttraumatic hypopituitarism was an independent predictor of the classical phenotypical features of hypopituitarism, including an unfavorable lipid and body composition profile, as well as worsened HRQL.	Univ Copenhagen Hosp, Rigshosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Glostrup Hosp, Dept Neurosurg, DK-2600 Glostrup, Denmark	Klose, M (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Med Endocrinol, PE2131,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	mcklose@hotmail.com	Watt, Torquil/ABC-3252-2020	Watt, Torquil/0000-0002-6001-7440; Brennum, Jannick/0000-0002-7961-0156			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Carroll PV, 1997, EUR J ENDOCRINOL, V137, P146, DOI 10.1530/eje.0.1370146; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Coons SJ, 2000, PHARMACOECONOMICS, V17, P13, DOI 10.2165/00019053-200017010-00002; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Feldt-Rasmussen U, 2004, GROWTH HORM IGF RES, V14, pS51, DOI 10.1016/j.ghir.2004.03.013; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; *GROWTH RES SOC WO, 1998, J CLIN ENDOCR METAB, V87, P379; HAMMOND FM, 2006, J HEAD TRAUMA REHAB, V64, P481; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; KANE R, 2006, UNDERSTANDING HLTH C, P377; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Maiter D, 2006, EUR J ENDOCRINOL, V155, P253, DOI 10.1530/eje.1.02209; Mard G, 1994, ENDOCRINOLOGY MET SA, VI, P43; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; McMillan CV, 2003, CLIN ENDOCRINOL, V59, P467, DOI 10.1046/j.1365-2265.2003.01870.x; Montazeri Ali, 2003, Health Qual Life Outcomes, V1, P19, DOI 10.1186/1477-7525-1-19; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; RASMUSSEN MH, 1995, J CLIN ENDOCR METAB, V80, P1407, DOI 10.1210/jc.80.4.1407; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Stahl Elisabeth, 2005, Health Qual Life Outcomes, V3, P56, DOI 10.1186/1477-7525-3-56; Stewart PM, 2001, HORM RES, V56, P1, DOI 10.1159/000048126; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; THORSEN H, 1995, DAN MED BULL, V42, P105; Thorsen Hanne, 1993, Scandinavian Journal of Primary Health Care, V11, P124, DOI 10.3109/02813439308994914; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wiren L, 2000, CLIN ENDOCRINOL, V52, P143, DOI 10.1046/j.1365-2265.2000.00899.x	38	60	62	0	4	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	OCT	2007	92	10					3861	3868		10.1210/jc.2007-0901			8	Endocrinology & Metabolism	Endocrinology & Metabolism	220HS	WOS:000250148400017	17652217	Bronze			2021-06-18	
J	Pan, DS; Liu, WG; Yang, XF; Cao, F				Pan, De-Sheng; Liu, Wei-Guo; Yang, Xiao-Feng; Cao, Fei			Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury	BIOMEDICAL AND ENVIRONMENTAL SCIENCES			English	Article						traumatic brain injury; progesterone; inflammation	NF-KAPPA-B; EXPRESSION	Objective Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality in young people. Inflammatory cytokines play an important part in the pathophysiology of TBI. Recent studies demonstrate that progesterone significantly reduces cerebral edema and enhances functional recovery from TBI and stroke in several animal models. This study was designed to investigate the inhibitory effect of progesterone on inflammatory response after traumatic brain injury. Methods Progesterone was injected intraperitoneally using rats as a model of traumatic brain injury, and Western blot technique was applied to detect the expression of three inflammation-related factors: nuclear factor kappa B p65 (NF kappa B p65), glial fibrillary acidic protein (GFAP), and tumor necrosis factor-alpha (TNF-alpha). The water content of injured brain was also examined. A neurological severity score was recorded to evaluate the effect of progesterone on neurodeficit recovery. Results NF kappa B p65, GFAP, and TNF-alpha were increased in all injured animals. In rats treated with progesterone, the expression level of NF kappa B p65 and TNF-alpha were reduced significantly in comparison with vehicle-treated rats. However, progesterone did not alter the expression of GFAP in the injured rats. Progesterone also reduced the water content of injured brain and the lesion volume. In addition, progesterone-treated injured rats showed significant improvements in the Neurological Severity Score test, compared with vehicle-treated ones. Conclusions Progesterone inhibits the inflammatory response after experimental traumatic brain injury and mitigates the severity of brain damage.	Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China; Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Peoples R China	Yang, XF (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China.	zjcswk@126.com					Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gu ZZ, 2000, INT J DEV NEUROSCI, V18, P185, DOI 10.1016/S0736-5748(99)00087-8; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; STAMATOVIC SM, 2006, ACTA NEUROCHIR SUPPL, P444; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	17	60	62	0	12	CHINESE CENTER DISEASE CONTROL & PREVENTION	BEIJING	155 CHANGBAI RD, CHANGPING DISTRICT, BEIJING, 102206, PEOPLES R CHINA	0895-3988			BIOMED ENVIRON SCI	Biomed. Environ. Sci.	OCT	2007	20	5					432	438					7	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	226UC	WOS:000250613000015	18188998				2021-06-18	
J	Morgan, R; Kreipke, CW; Roberts, G; Bagchi, M; Rafols, JA				Morgan, Randy; Kreipke, Christian W.; Roberts, George; Bagchi, Mihir; Rafols, Jose A.			Neovascularization following traumatic brain injury: possible evidence for both angiogenesis and vasculogenesis	NEUROLOGICAL RESEARCH			English	Article						brain trauma; VEGF; capillary density	ENDOTHELIAL GROWTH-FACTOR; CEREBRAL-ISCHEMIA; UP-REGULATION; RAT-BRAIN; EXPRESSION; MODEL; VEGF; BARRIER	Objective: Our goal was to characterize the angiogenic response following traumatic brain injury (TBI). Methods: Western analysis for vascular endothelial growth factor (VEGF) expression, double immunofluorescence labeling of endothelium and vascular endothelial growth factor receptor 2 (VEGFR2), bromodioxyuridine (BrdU) incorporation and measurement of capillary density, were all used to determine the temporal angiogenic response following TBI. Results: The angiogenic factors, VEGF and VEGFR2, increase following trauma. Capillary density increases and BrdU incorporation confirm the presence of newly formed vessels up to 48 hours post-injury. Discussion: Our results indicated that following TBI, there is a substantial increase in angiogenesis and based on morphologic characterization of BrdU-positive nuclei within the endothelium, we provide evidence for vasculogenesis following injury.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Rafols, JA (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield, Detroit, MI 48201 USA.	jrafols@med.wayne.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS039860] Funding Source: Medline		Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Folkman J, 2006, EXP CELL RES, V312, P594, DOI 10.1016/j.yexcr.2005.11.015; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Gu WG, 2001, ACTA NEUROPATHOL, V102, P216; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Hayashi T, 2006, CURR NEUROVASC RES, V3, P119, DOI 10.2174/156720206776875902; Hurtado Olivia, 2006, Cerebrovasc Dis, V21 Suppl 2, P54, DOI 10.1159/000091704; *I LAB AN RES COMM, 1996, NIH PUBL; Jiang SG, 2004, P NATL ACAD SCI USA, V101, P16891, DOI 10.1073/pnas.0404398101; Kreipke CW, 2007, NEUROL RES, V29, P369, DOI 10.1179/016164107X204684; Lafuente JV, 2006, J NEURAL TRANSM, V113, P487, DOI 10.1007/s00702-005-0407-0; Lambrechts D, 2006, TRENDS MOL MED, V12, P345, DOI 10.1016/j.molmed.2006.06.008; Li B, 2006, FASEB J, V20, P1495, DOI 10.1096/fj.05-5137fje; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martinez A, 2006, CANCER LETT, V236, P157, DOI 10.1016/j.canlet.2005.04.008; Meixensberger J, 1998, LANGENBECK ARCH SURG, V383, P214, DOI 10.1007/s004230050121; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; PING FC, 1978, CAN ANAESTH SOC J, V25, P468, DOI 10.1007/BF03007408; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P654, DOI 10.1097/00005072-199906000-00010; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Tomanek Robert J., 2005, Angiogenesis, V8, P273, DOI 10.1007/s10456-005-9014-9; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	28	60	62	0	8	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	JUN	2007	29	4					375	381		10.1179/016164107X204693			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	192PM	WOS:000248214200007	17626733				2021-06-18	
J	Denson, K; Morgan, D; Cunningham, R; Nigliazzo, A; Brackett, D; Lane, M; Smith, B; Albrecht, R				Denson, Kent; Morgan, Daniel; Cunningham, Rob; Nigliazzo, Anthony; Brackett, Daniel; Lane, Mary; Smith, Brenda; Albrecht, Roxie			Incidence of venous thromboembolism in patients with traumatic brain injury	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	49th Annual Meeting of the Midwest-Surgical-Association	AUG 06-09, 2006	Mackinac Isl, MI	Midwest Surg Assoc		venous thromboembolism; intraparenchymal hemorrhage; trauma; prophylaxis	PROPHYLAXIS; ENOXAPARIN; HEAD; SURVEILLANCE; THROMBOSIS; HEPARIN; SAFETY; RISK	Background: Traumatic brain injury (TBI) may be a risk factor for venous thromboembolism (VTE). This study was designed to review the incidence of VTE in critically injured patients with an isolated TBI using a standardized venous duplex color-flow Doppler imaging program and to compare it with the overall and high-risk trauma populations. Methods: Trauma patients who underwent lower-extremity surveillance color-flow Doppler imaging for VTE were identified. Analyses included patient demographics, characteristics of TBI, VTE risk factors, prophylaxis, incidence, location, and patient outcome. Results: A total of 5,787 patients were admitted during the study period. Of these, 539 (9%) were deemed high risk for VTE. The incidence of VTE in patients with isolated TBI (88, 16%) was 25%. All patients and the high-risk population had incidences of 2% and 17%, respectively. Conclusions: The incidence of VTE in isolated TBI is greatest in patients with intraparenchymal hemorrhage. Early VTE prophylaxis is warranted in TBI patients. (c) 2007 Excerpta Medica Inc. All rights reserved.	Univ Oklahoma, Hlth Sci Ctr, Dept Gen Surg, Oklahoma City, OK 73190 USA	Denson, K (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Gen Surg, POB 26901,1122 NE 13th 3rd Floor, Oklahoma City, OK 73190 USA.	kent-denson@cox.net					Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; Cipolle MD, 2002, J TRAUMA, V52, P453, DOI 10.1097/00005373-200203000-00007; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P191, DOI 10.1097/01.PHM.0000113401.47681.A6; KAUFMAN HH, 1983, ANGIOLOGY, V34, P627, DOI 10.1177/000331978303401001; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Merrer J, 2001, JAMA-J AM MED ASSOC, V286, P700, DOI 10.1001/jama.286.6.700; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Proctor MC, 2006, J TRAUMA, V60, P147, DOI 10.1097/01.ta.0000197180.79965.bc; Skaf E, 2005, AM J CARDIOL, V96, P1731, DOI 10.1016/j.amjcard.2005.07.097; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160	14	60	64	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010 USA	0002-9610			AM J SURG	Am. J. Surg.	MAR	2007	193	3					380	383		10.1016/j.amjsurg.2006.12.004			4	Surgery	Surgery	146MS	WOS:000244939200034	17320539				2021-06-18	
J	Douglas, JM; Bracy, CA; Snow, PC				Douglas, Jacinta M.; Bracy, Christine A.; Snow, Pamela C.			Measuring perceived communicative ability after traumatic brain injury: Reliability and validity of the La Trobe Communication Questionnaire	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; communication disorders; language tests; outcome assessment; rehabilitation; reliability and validity	CLOSED HEAD-INJURY; DISCOURSE ASSESSMENT; AWARENESS; ADULTS; DEFICITS	Objective: Further psychometric evaluation of a measure designed to assess communication ability after traumatic brain injury (TBI). Design: Internal consistency, test-retest reliability, and validity for self-report and close-other versions of the tool were evaluated. Participants: Eighty-eight adults with severe TBI (mean posttraumatic amnesia 53.12 days) and 71 close others (relatives or friends). Measure: The La Trobe Communication Questionnaire (LCQ), a 30-item questionnaire that measures cognitive-communication ability from multiple perspectives. Results: Internal consistency coefficients were above 0.9 and test-retest reliability exceeded 0.80. The questionnaire was sensitive to the effect of severity of injury. Conclusion: The La Trobe Communication Questionnaire is a promising tool for measuring perceived communication ability in adults with severe TBI.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia; La Trobe Univ, Sch Publ Hlth, Bundoora, Vic 3086, Australia	Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	J.Douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Snow, Pamela/0000-0002-2426-8349; Douglas, Jacinta/0000-0003-0940-6624			Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Damico JS, 1985, COMMUNICATION SKILLS, P165; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Fleming JM, 1996, BRAIN INJURY, V10, P1; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GILLIES S, 1990, PERCEPTIONS COMMUNIC; Godfrey H.P.D., 1993, J CLIN EXP PSYCHOL, V15, P530; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [DOI 10.1007/BF02214959, 10.1007/BF02214959]; Grice P, 1975, SYNTAX SEMANTICS, VIII, P41; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hagen C, 1984, LANGUAGE DISORDERS A, P245; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; KREUTZER J, 1999, NEUROBEHAV FUNCTIONI; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1986, NEUROPSYCHOL REHAB B; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Selltiz C., 1976, RES METHODS SOCIAL R; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 2000, BRAIN INJURY, V14, P397; STRAHAN R, 1972, J CLIN PSYCHOL, V28, P191, DOI 10.1002/1097-4679(197204)28:2<191::AID-JCLP2270280220>3.0.CO;2-G; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Ylvisaker M., 2001, LANGUAGE INTERVENTIO	34	60	60	0	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2007	22	1					31	38		10.1097/00001199-200701000-00004			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	130SX	WOS:000243820400004	17235229				2021-06-18	
J	Lee, KH; Suh-Kim, H; Choi, JS; Jeun, SS; Kim, EJ; Kim, SS; Yoon, DH; Lee, BH				Lee, Kyung Hee; Suh-Kim, Haeyoung; Choi, Ji Soo; Jeun, Sin-Soo; Kim, Eun Jin; Kim, Sung-Soo; Yoon, Do Heum; Lee, Bae Hwan			Human mesenchymal stem cell transplantation promotes functional recovery following acute spinal cord injury in rats	ACTA NEUROBIOLOGIAE EXPERIMENTALIS			English	Article						spinal cord injury; human mesenchymal stem cell; transplantation; behavioral test; electrophysiology	MARROW STROMAL CELLS; TRAUMATIC BRAIN INJURY; CONTUSION MODEL; SENSORY AXONS; ADULT-RAT; IN-VITRO; DIFFERENTIATE; REGENERATION; GROWTH; ALLODYNIA	Many attempts have been made in animals to produce cellular regeneration in the spinal cord using a variety of transplanted cell types. The present study was to investigate whether transplantation of human mesenchymal stem cells (hMSCs) into the spinal cord after contusion injury promotes a functional outcome. Spinal cord injury (SCI) was induced using an NYU impactor and hMSCs were transplanted I week after SCI. Behavioral testing was performed weekly for 2 months. Somatosensory (SSEPs) and motor evoked potentials (MEPs) were recorded to determine functional recovery. Hindlimb performance was modestly improved in the transplanted group based on BBB scaling and pain tests. SSEP latencies in the transplanted group were significantly shorter than in the media-treated group. Pathologically, LacZ and hTau positive cells were located at the injury and adjacent sites. The data indicate improvement in functional outcome in animals treated with hMSC transplantation compared to media-treated animals.	Yonsei Univ, Coll Med, Dept Physiol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Res Inst, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Ajou Univ, Sch Med, Dept Anat, Suwon 443721, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 443721, South Korea; Catholic Univ Korea, Coll Med, Dept Neurosurg, Seoul 137701, South Korea; Yonsei Univ, Coll Med, Dept Neurosurg, Seoul 120752, South Korea	Lee, BH (corresponding author), Yonsei Univ, Coll Med, Dept Physiol, Seoul 120752, South Korea.	bhlee@yumc.yonsei.ac.kr		Lee, Bae H./0000-0003-4719-9021; Suh-Kim, Haeyoung/0000-0001-8175-1209; Kim, Sung-Soo/0000-0003-3591-5932			Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Blesch A, 2003, J COMP NEUROL, V467, P403, DOI 10.1002/cne.10934; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; Falci S, 1997, J NEUROTRAUM, V14, P875, DOI 10.1089/neu.1997.14.875; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Jones LL, 2003, J NEUROSCI, V23, P9276; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Lee BH, 2004, BRAIN RES, V1020, P37, DOI 10.1016/j.brainres.2004.05.113; Lee KH, 2005, J NEUROTRAUM, V22, P575, DOI 10.1089/neu.2005.22.575; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lindsey AE, 2000, NEUROREHAB NEURAL RE, V14, P287, DOI 10.1177/154596830001400405; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Qiu J, 2002, PROG BRAIN RES, V137, P381; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Schwab ME, 1996, PHYSIOL REV, V76, P319; Tuszynski MH, 1999, CNS REGENERATION BAS; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Yoon YW, 2004, SOMATOSENS MOT RES, V21, P25, DOI 10.1080/0899022042000201272; Zurita M, 2004, NEUROREPORT, V15, P1105, DOI 10.1097/00001756-200405190-00004; Zurita M, 2006, NEUROSCI LETT, V402, P51, DOI 10.1016/j.neulet.2006.03.069	36	60	80	0	4	NENCKI INST EXPERIMENTAL BIOLOGY	WARSAW	UL PASTEURA 3, 02-093 WARSAW, POLAND	0065-1400			ACTA NEUROBIOL EXP	Acta Neurobiol. Exp.		2007	67	1					13	22					10	Neurosciences	Neurosciences & Neurology	159YO	WOS:000245904000002	17474317				2021-06-18	
J	Bombardier, CH; Fann, JR; Temkin, N; Esselman, PC; Pelzer, E; Keough, M; Dikmen, S				Bombardier, Charles H.; Fann, Jesse R.; Temkin, Nancy; Esselman, Peter C.; Pelzer, Erika; Keough, Meghan; Dikmen, Sureyya			Posttraumatic stress disorder symptoms during the first six months after traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	51st Annual Meeting of the Academy-of-Psychosomatic-Medicine	NOV, 2004	Ft Myers, FL	Acad Psychosomat Med			PSYCHOMETRIC PROPERTIES; PSYCHIATRIC-DISORDERS; PTSD CHECKLIST; HEAD-INJURY; PRIME-MD; DEPRESSION; VALIDITY; CLASSIFICATION; AMNESIA; COCAINE	Controversy exists regarding the rate and risk factors for posttraumatic stress disorder (PTSD) following traumatic brain injury (TBI) The authors determined the rate and phenomenology of PTSD symptoms in the 6 months after TBI by conducting a prospective cohort study of 124 subjects who completed the PTSD Checklist-Civilian Version. The cumulative incidence of meeting PTSD symptom criteria at 6 months was 11% and full criteria 5.6%. Prevalence peaked at I month (10%). Eighty-six percent had another psychiatric disorder and 29% a history of PTSD. Symptoms were associated with not completing high school, assault, recalling being terrified or helpless, and positive toxicology. PTSD after TBI is rare and the relation to risk factors and comorbidities must be examined.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Behav Sci, Seattle, WA 98195 USA	Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA.	chb@u.washington.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R0-1 HD39415] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039415] Funding Source: NIH RePORTER		Acierno R, 1999, J ANXIETY DISORD, V13, P541, DOI 10.1016/S0887-6185(99)00030-4; APA, 2000, DIAGN STAT MAN MENT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BOROWSKI TB, 1994, PHARMACOL BIOCHEM BE, V49, P935, DOI 10.1016/0091-3057(94)90246-1; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Epstein RS, 1998, AM J PSYCHIAT, V155, P934, DOI 10.1176/ajp.155.7.934; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Katon W, 2002, J PSYCHOSOM RES, V53, P859, DOI 10.1016/S0022-3999(02)00313-6; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; KORNBLITH AB, 2003, CANCER, V98, P697; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Post R M, 1999, Semin Clin Neuropsychiatry, V4, P282; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Semple WE, 2000, PSYCHIATRY, V63, P65, DOI 10.1080/00332747.2000.11024895; Silver RC, 2002, JAMA-J AM MED ASSOC, V288, P1235, DOI 10.1001/jama.288.10.1235; Solomon SD, 2002, J CLIN PSYCHOL, V58, P947, DOI 10.1002/jclp.10069; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2000, AM J OBSTET GYNECOL, V183, P759, DOI 10.1067/mob.2000.106580; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weather FW, 1991, PTSD CHECKLIST CIVIL; Weathers F. W., 1993, INT SOC TRAUM STRESS; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams JW, 2002, JAMA-J AM MED ASSOC, V287, P1160, DOI 10.1001/jama.287.9.1160; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941	45	60	61	1	7	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2006	18	4					501	508		10.1176/appi.neuropsych.18.4.501			8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	103BX	WOS:000241861800005	17135375				2021-06-18	
J	Cullen, DK; LaPlaca, MC				Cullen, D. Kacy; LaPlaca, Michelle C.			Neuronal response to high rate shear deformation depends on heterogeneity of the local strain field	JOURNAL OF NEUROTRAUMA			English	Article						cell mechanics; neuron; shear strain; strain rate; traumatic brain injury	IN-VITRO MODEL; TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; STRETCH-INDUCED INJURY; CENTRAL-NERVOUS-SYSTEM; MECHANICAL STRETCH; MEMBRANE-PERMEABILITY; NEURAL TRAUMA; TISSUE; CULTURES	Many cellular models of traumatic brain injury (TBI) deform cells in a planar (2-D) configuration, a contrast from the three-dimensional (3-D) architecture of the brain, resulting in strain fields that may fail to represent the complex deformation patterns seen in vivo. Cells cultured in 3-D may more accurately represent in vivo cellular behavior than planar models due to differences in cytostructure, cell-cell/cell-matrix interactions and access to trophic factors; however, the effects of culture configuration on the response to high rate deformation have not been evaluated. We examined cell viability following a defined mechanical insult to primary cortical neurons distributed throughout a bioactive matrix (3-D) or in a monolayer sandwiched between layers of a bioactive matrix (2-D). After high rate loading (20 or 30 sec(-1); 0.50 strain), there was a significant decrease in neuron viability for both configurations versus unloaded control cultures; however, neurons in 3-D presented greater cell death based on matched bulk loading parameters. Computer simulations of bulk loading predicted local cellular strains, revealing that neurons in 3-D were subjected to a heterogeneous strain field simultaneously consisting of tensile, compressive and shear strains; conversely, neurons in 2-D experienced a less complex deformation regime varying mainly based on shear strains. These results show differential susceptibility to mechanical loading between neurons cultured in 2-D and 3-D that may be due to differences in cellular strain manifestation. Models of TBI that accurately represent the related cellular biomechanics and pathophysiology are important for the elucidation of cellular tolerances and the development of mechanistically driven intervention strategies.	Emory Univ, Wallace H Coulter Dept Biomed Engn, Parker H Petit Inst Bioengn & Biosci, Georgia Inst Technol,Lab Neuroengn, Atlanta, GA 30332 USA	LaPlaca, MC (corresponding author), Emory Univ, Wallace H Coulter Dept Biomed Engn, Parker H Petit Inst Bioengn & Biosci, Georgia Inst Technol,Lab Neuroengn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001014] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB001014] Funding Source: Medline		Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Cullen DK, 2005, J NEUROTRAUM, V22, P1250; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; Grinnell F, 2003, TRENDS CELL BIOL, V13, P264, DOI 10.1016/S0962-8924(03)00057-6; Holbourn AHS, 1943, LANCET, V2, P438; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MIGHELI A, 1988, J NEUROSCI, V8, P1846; MILLER BE, 1985, CANCER RES, V45, P4200; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Nakayama Y, 2001, J NEUROTRAUM, V18, P545, DOI 10.1089/089771501300227341; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; SAHAY KB, 1992, J BIOMECH, V25, P319, DOI 10.1016/0021-9290(92)90029-Z; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Sieg F, 1999, J NEUROTRAUM, V16, P1197, DOI 10.1089/neu.1999.16.1197; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 1999, J NEUROSCI, V19, P4263; THIBAULT LE, 1989, 10 INT TECH C EXPT S; WINSTON FK, 1989, J APPL PHYSIOL, V67, P397; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001	52	60	62	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2006	23	9					1304	1319		10.1089/neu.2006.23.1304			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	085LP	WOS:000240605900003	16958583				2021-06-18	
J	Chapman, SB; Gamino, JF; Cook, LG; Hanten, G; Li, XQ; Levin, HS				Chapman, SB; Gamino, JF; Cook, LG; Hanten, G; Li, XQ; Levin, HS			Impaired discourse gist and working memory in children after brain injury	BRAIN AND LANGUAGE			English	Article						discourse; language; brain injury; children; gist; cognition; summary; top down processing; working memory; memory	CLOSED-HEAD-INJURY; COMPREHENSION; RETRIEVAL; RECALL	Emerging evidence suggests that a traumatic brain injury (TBI) in childhood may disrupt the ability to abstract the central meaning or gist-based memory from connected language (discourse). The current study adopts a novel approach to elucidate the role of immediate and working memory processes in producing a cohesive and coherent gist-based text in the form of a summary in children with mild and severe TBI as compared to typically developing children, ages 8-14 years at test. Both TBI groups showed decreased performance on a summary production task as well as retrieval of specific content from a long narrative. Working memory on n-back tasks was also impaired in children with severe TBI, whereas immediate memory performance for recall of a simple word list in both TBI groups was comparable to controls. Interestingly, working memory, but not simple immediate memory for a word list, was significantly correlated with summarization ability and ability to recall discourse content. (c) 2005 Elsevier Inc. All rights reserved.	Univ Texas, Inst Biomed Sci & Technol, Ctr BrainHlth, Dallas, TX 75230 USA; Baylor Coll Med, Houston, TX 77030 USA	Chapman, SB (corresponding author), Univ Texas, Inst Biomed Sci & Technol, Ctr BrainHlth, Dallas, TX 75230 USA.	schapman@utdallas.edu					Adams C, 1997, J GERONTOL B-PSYCHOL, V52, pP187, DOI 10.1093/geronb/52B.4.P187; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; BARTLETT R, 1936, REMEMBERING; Brainerd CJ, 1998, DEV PSYCHOL, V34, P342, DOI 10.1037/0012-1649.34.2.342; BROWN AL, 1983, J VERB LEARN VERB BE, V22, P1, DOI 10.1016/S0022-5371(83)80002-4; Caspari I, 2000, J NEUROLINGUIST, V13, P15, DOI 10.1016/S0911-6044(99)00009-3; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DELIS D, 1986, CALIFORNIA VERBAL LE; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Engle RW, 2004, PSYCHOL LEARN MOTIV, V44, P145; Ferstl EC, 1999, BRAIN LANG, V70, P385, DOI 10.1006/brln.1999.2151; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Graesser AC, 1997, ANNU REV PSYCHOL, V48, P163, DOI 10.1146/annurev.psych.48.1.163; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; JOHNSON NS, 1983, CHILDRENS LANGUAGE, P314; Laughlin SB, 2003, SCIENCE, V301, P1870, DOI 10.1126/science.1089662; Lehman S, 2002, J EDUC PSYCHOL, V94, P738, DOI 10.1037//0022-0663.94.4.738; LEVIN HS, 1979, CHILD BRAIN, V5, P281; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; LYTTINEN S, 1998, ED PSYCHOL, V18, P157; MALONE LD, 1992, EXCEPT CHILDREN, V58, P270; Radvansky GA, 1999, J EXP PSYCHOL GEN, V128, P563, DOI 10.1037/0096-3445.128.4.563; Ramos BP, 2003, NEURON, V40, P835, DOI 10.1016/S0896-6273(03)00694-9; Reilly JS, 1998, BRAIN LANG, V61, P335, DOI 10.1006/brln.1997.1882; Schacter D.L, 2002, 7 SINS MEMORY MIND F; Singer M, 1996, MEM COGNITION, V24, P733, DOI 10.3758/BF03201098; Singer M, 2001, DISCOURSE PROCESS, V31, P27, DOI 10.1207/S15326950dp3101_2; St George M, 1999, BRAIN, V122, P1317, DOI 10.1093/brain/122.7.1317; STEIN BL, 1992, J READING BEHAV, V24, P217, DOI 10.1080/10862969209547773; TANNOCK R, 1995, J ABNORM CHILD PSYCH, V23, P235, DOI 10.1007/BF01447091; TEASDALE G, 1974, LANCET, V2, P81; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; VANDIJK TA, 1995, DISCOURSE COMPREHENSION, P383; WITTROCK MC, 1990, AM EDUC RES J, V27, P489, DOI 10.2307/1162933	44	60	61	1	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	MAY	2006	97	2					178	188		10.1016/j.bandl.2005.10.002			11	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	040EG	WOS:000237361200005	16288805				2021-06-18	
J	Browne, GJ; Lam, LT				Browne, GJ; Lam, LT			Concussive head injury in children and adolescents related to sports and other leisure physical activities	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; INTRACRANIAL INJURY; MANAGEMENT; OUTCOMES; SCHOOL	Objective: To compare the characteristics of children and adolescents with concussive head injury (CHI) sustained during organised sports or other leisure physical activity. Methods: This was a case series study reviewing the medical records retrospectively over a four year period of children 6 - 16 years presenting to the emergency department with a CHI after participating in sport and/or recreation activity. Results: There were 592 cases of sport and recreation related concussion over the study period ( 2000 2003). Most of the patients (n = 424, 71.6%) were male, with half ( n = 304, 51.4%) being older than 10 years of age. A total of 152 ( 25.7%) cases of CHI were related to playing sports. Most cases (71.2%) were mild concussion. The cause of injury was a fall ( n = 322, 54.4%) or a collision. Nearly a quarter of the children ( n = 143, 24.2%) were admitted to hospital, with imaging performed in 134 ( 22.7%). Most children were treated appropriately and no adverse events were reported. Conclusions: A severe CHI in a child is six times more likely to have resulted from organised sport than from other leisure physical activities. Outcomes for CHI in children is excellent, although their management places a considerable burden on emergency services. The need for activity restriction and the benefits of this in reducing long term cognitive effects of CHI are uncertain.	Childrens Hosp Westmead, CHISM, Sydney, NSW 2145, Australia; Royal Alexandra Hosp Children, Sydney, NSW, Australia	Browne, GJ (corresponding author), Childrens Hosp Westmead, CHISM, Sydney, NSW 2145, Australia.	garyb@chw.edu.au		Lam, Lawrence T./0000-0001-6183-6854			Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Bergman DA, 1999, PEDIATRICS, V104, P1407; BIJUR PE, 1995, ARCH PEDIAT ADOL MED, V149, P1009, DOI 10.1001/archpedi.1995.02170220075010; BIJUR PE, 1990, PEDIATRICS, V86, P337; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; CANTU RC, 1995, CLIN SPORT MED, V14, P517; Cassell EP, 2003, BRIT J SPORT MED, V37, P405, DOI 10.1136/bjsm.37.5.405; CEDILLA RK, 2002, ANN EMERG MED, V40, P446; DUNNING J, 2004, EMERG MED AUSTRAL S1, V16, pA93; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gotsch K, 2002, JAMA-J AM MED ASSOC, V288, P1977; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Kamerling SN, 2003, PEDIATR EMERG CARE, V19, P431, DOI 10.1097/01.pec.0000092590.40174.1f; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LECHER S, 2001, SPORTS MED, V31, P629; Ni H, 2002, INJURY PREV, V8, P60, DOI 10.1136/ip.8.1.60; O' Rourke KP, 2004, MED SCI SPORT EXER, V36, pS312; OSMOND MH, 2004, ACAD EMERG MED, V11, P449; Poirier MP, 2000, PEDIATR EMERG CARE, V16, P278, DOI 10.1097/00006565-200008000-00018; POIRIER MP, 2003, CLIN PEDIAT EMERG ME, V4, P179, DOI DOI 10.1016/S1522-8401(03)00061-2; Posner Jill C, 2004, Pediatr Crit Care Med, V5, P293, DOI 10.1097/01.PCC.0000124018.18536.0B; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; SWAINE B, 2000, ARCH PHYS MED REHAB, V81, P1617; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; 1999, P 3 WRLD C BRAIN INJ, P230	34	60	61	1	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	FEB	2006	40	2					163	168		10.1136/bjsm.2005.021220			6	Sport Sciences	Sport Sciences	005NP	WOS:000234831400016	16432005	Green Published			2021-06-18	
J	Labombarda, F; Gonzalez, S; Deniselle, MCG; Garay, L; Guennoun, R; Schumacher, M; De Nicola, AF				Labombarda, F; Gonzalez, S; Deniselle, MCG; Garay, L; Guennoun, R; Schumacher, M; De Nicola, AF			Progesterone increases the expression of myelin basic protein and the number of cells showing NG(2) immunostairling in the lesioned spinal cord	JOURNAL OF NEUROTRAUMA			English	Article						myelin basic protein; neuroprotection; NG(2)+ cells; oligodendrocytes; progesterone; spinal cord injury	OLIGODENDROCYTE PROGENITOR CELLS; PERIPHERAL NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; SCHWANN-CELLS; SLICE CULTURES; MESSENGER-RNA; GLIAL-CELLS; RAT-BRAIN; PROLIFERATION	It is now widely accepted that progesterone (PROG) brings neuroprotection in lesions of the peripheral and central nervous system. Spinal cord trauma leads to neuronal degeneration, astrogliosis, demyelination, and proliferation of oligodendrocyte-precursor cells (OPCs). In this work, we studied the effects of PROG on myelin-related parameters in rats with complete spinal cord transection (TRX). To this end, sham-operated controls and rats with TRX at thoracic level T10 received vehicle or PROG (4 mg/kg/day) during 3 days. Three variables were measured in the lumbar L4 region below the lesion: (1) expression of myelin basic protein (MBP) at the protein and mRNA levels; (2) density of NG(2)-immunopositive cells as markers for OPCs; and (3) number of cells immunopositive for RIP, an antibody staining mature oligodendrocytes. TRX decreased MBP immunostaining in the corticospinal tract (CST) and dorsal ascending tract (DAT) but not the ventral funiculus'(VF). NG(2)(+) cells, which were detected in low number in controls, increased after TRX in the gray and white matter. RIP-positive cell number, however, remained unchanged. PROG treatment of rats with TRX enhanced the expression of MBP protein and mRNA in CST and DAT, but not VF and highly stimulated the number of cells showing NG(2) immunostaining over untreated lesioned rats. Instead, density of RIP positive cells was similar in the PROG-treated and untreated lesioned groups. We propose that PROG effects on expression of MBP and the number of NG2 immunopositive cells may contribute to neuroprotection, as they go in parallel with previous results showing enhanced biochemical and morphological parameters of motoneurons of animals with TRX receiving PROG treatment.	Univ Buenos Aires, Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Dept Human Biochem, RA-1428 Buenos Aires, DF, Argentina; Hop Bicetre, INSERM, U488, Le Kremlin Bicetre, France	De Nicola, AF (corresponding author), Univ Buenos Aires, Inst Biol & Med Expt, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar	Schumacher, Michael/G-3581-2013; Messier, Claude/A-2322-2008; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Messier, Claude/0000-0002-4791-1763; Guennoun, Rachida/0000-0002-9219-7300			Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BUNGE RP, 1993, ADV NEUROL, V59, P75; Carroll WM, 1998, BRAIN, V121, P293, DOI 10.1093/brain/121.2.293; Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; Chan JR, 2001, P NATL ACAD SCI USA, V98, P14661, DOI 10.1073/pnas.251543398; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Du YZ, 2003, DEV NEUROSCI-BASEL, V25, P116, DOI 10.1159/000072261; FERRINI M, 1995, LIFE SCI, V57, P2403, DOI 10.1016/0024-3205(95)02236-3; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Gago N, 2004, J NEUROSCI RES, V78, P770, DOI 10.1002/jnr.20348; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Greenwood K, 2003, MOL CELL NEUROSCI, V23, P544, DOI 10.1016/S1044-7431(03)00176-3; Guennoun R, 2001, MOL BRAIN RES, V90, P75, DOI 10.1016/S0169-328X(01)00094-8; HUBBARD P, 2003, SPINAL RES, V1, P100; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Ishii K, 2001, J NEUROSCI RES, V65, P500, DOI 10.1002/jnr.1180; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Jung-Testas I, 1999, J STEROID BIOCHEM, V69, P97, DOI 10.1016/S0960-0760(98)00149-6; JungTestas I, 1996, CELL MOL NEUROBIOL, V16, P439, DOI 10.1007/BF02088110; Keirstead HS, 1997, J NEUROPATH EXP NEUR, V56, P1191, DOI 10.1097/00005072-199711000-00003; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li G, 2004, J NEUROTRAUM, V21, P1044, DOI 10.1089/0897715041651015; McTigue DM, 1998, J NEUROSCI, V18, P5354; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Melcangi RC, 2000, PROG NEUROBIOL, V60, P291, DOI 10.1016/S0301-0082(99)00028-3; Nguyen KB, 1999, ACTA NEUROPATHOL, V98, P39, DOI 10.1007/s004010051049; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; PAXINOS G, 1983, RAT BRAIN STEREOTAXI; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Sim FJ, 2000, NEUROSCIENCE, V100, P131, DOI 10.1016/S0306-4522(00)00252-9; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tolwani RJ, 2004, J NEUROSCI RES, V77, P662, DOI 10.1002/jnr.20181; VERDI JM, 1990, J BIOL CHEM, V265, P20314; Ye P, 2003, J NEUROSCI, V23, P4401	50	60	61	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					181	192		10.1089/neu.2006.23.181			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600007	16503802				2021-06-18	
J	Kim, YH; Ko, MH; Na, SY; Park, SH; Kim, KW				Kim, YH; Ko, MH; Na, SY; Park, SH; Kim, KW			Effects of single-dose methylphenidate on cognitive performance in patients with traumatic brain injury: a double-blind placebo-controlled study	CLINICAL REHABILITATION			English	Article							WORKING-MEMORY; ATTENTION; DEPRESSION; ADULT	Objectives: To determine the effect of a single dose of methylphenidate on the cognitive performance of patients with traumatic brain injury (TBI), and particularly on working memory and visuospatial attention. Design: A double-blind placebo-controlled study. The subjects were randomly divided into an experimental group taking methylphenidate and a control group taking a placebo. Setting: The Department of Rehabilitation Medicine of a university hospital. Subjects: Eighteen subjects with TBI (16 male and two female) were enrolled. Interventions: The patients were given 20 mg methylphenidate or a placebo. Cognitive assessments were performed at three times: before the medication as a baseline, 2 h after medication and at follow-up (48 h later). Main measures: Cognitive assessments consisted of working memory tasks and endogenous visuospatial attention tasks designed using SuperLabPro 2.0 software. Response accuracy and reaction time were measured. Results: There were significant improvements in response accuracy in the methylphenidate group compared with the placebo group for both the working memory and visuospatial attention tasks. A significant decrease in the reaction time was also observed in the methylphenidate group only for the working memory task. Conclusions: The administration of single-dose methylphenidate has an effect in improving cognitive functioning following a TBI. The effects were most prominent regarding the reaction time of the working memory.	Sungkyunkwan Univ, Sch Med, Dept Phys Med & Rehabil, Samsung Med Ctr,Stroke & Cerebrovasc Ctr, Seoul 135710, South Korea; Chonbuk Natl Univ, Dept Rehabil Med, Coll Med, Jeonju, South Korea; Chonbuk Natl Univ, Dept Pharmacol, Coll Med, Jeonju, South Korea	Kim, YH (corresponding author), Sungkyunkwan Univ, Sch Med, Dept Phys Med & Rehabil, Samsung Med Ctr,Stroke & Cerebrovasc Ctr, 50 Ilwon Dong, Seoul 135710, South Korea.	yunkim@smc.samsung.co.kr	Kim, Yun Hee/F-4600-2014	Ko, Myoung-Hwan/0000-0002-0566-3677			BONTKE CF, 1996, PHYS MED REHABILITAT, P1027; Burke DT, 2003, AM J PHYS MED REHAB, V82, P493, DOI 10.1097/00002060-200307000-00001; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; Galynker I, 1997, J NEUROPSYCH CLIN N, V9, P231; GILMAN AG, 1985, PHARMACOL BASIS THER, P236; GOLDSTEIN LB, 2003, PHYS MED REH CLIN N, V14, P125; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; Ilic TV, 2003, NEUROREPORT, V14, P773, DOI 10.1097/01.wnr.0000063251.41814.70; JOHNSON ML, 1992, AM J PHYS MED REHAB, V71, P239, DOI 10.1097/00002060-199208000-00008; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KEVIN SL, 1999, NEUROIMAGE, V10, P695; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; LAZARUS LW, 1992, J CLIN PSYCHIAT, V53, P447; McFayden MP, 2002, DEV PSYCHOBIOL, V41, P123, DOI 10.1002/dev.10059; Mehta MA, 2000, J NEUROSCI, V20; Meyers CA, 1998, J CLIN ONCOL, V16, P2522, DOI 10.1200/JCO.1998.16.7.2522; Moore JL, 2002, EPILEPSY BEHAV, V3, P92, DOI 10.1006/ebeh.2001.0313; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; SAWAGUCHI T, 1994, J NEUROPHYSIOL, V71, P515; Sekine Y, 2000, J CLIN PSYCHOPHARM, V20, P584, DOI 10.1097/00004714-200010000-00019; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Szobot CM, 2003, EUR J NUCL MED MOL I, V30, P423, DOI 10.1007/s00259-002-1082-0; Wax PM, 1997, J TOXICOL-CLIN TOXIC, V35, P203, DOI 10.3109/15563659709001195; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86	30	60	60	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JAN	2006	20	1					24	30		10.1191/0269215506cr927oa			7	Rehabilitation	Rehabilitation	015CY	WOS:000235530700004	16502746				2021-06-18	
J	Perlstein, WM; Larson, MJ; Dotson, VM; Kelly, KG				Perlstein, WM; Larson, MJ; Dotson, VM; Kelly, KG			Temporal dissociation of components of cognitive control dysfunction in severe TBI: ERPs and the cued-Stroop task	NEUROPSYCHOLOGIA			English	Article; Proceedings Paper	32nd Annual Meeting of the International-Neuropsychological-Society	FEB 04-07, 2004	Baltimore, MD	Int Neuropsychol Soc		traumatic brain injury; cognitive control; event-related potentials; Stroop task; working memory capacity	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY LOAD; ANTERIOR CINGULATE; PREFRONTAL CORTEX; HEAD-INJURY; CONFLICT; DEFICITS; ATTENTION; CONTEXT; SCHIZOPHRENIA	Cognitive control comprises two essential interactive component processes: a regulative component supporting the activation and implementation of control and an evaluative component that monitors the need for regulative control and signals when adjustments in control are necessary. Survivors of severe traumatic brain injury (TBI) experience cognitive control impairments, but the specific nature of these impairments is poorly characterized. Using event-related potentials (ERPs) acquired in the context of a trial-by-trial task-switching version of the Stroop task we temporally dissociated the regulative and evaluative processes in order to shed light on the potential roles of these components in TBI-related cognitive control impairment. Behaviorally, TBI patients showed a specific performance deficit suggestive of a failure to implement cognitive control in the service of processing conflict information. ERP findings showed that TBI patients were impaired in both the implementation of control and subsequent detection and processing of conflict. TBI patients were also impaired on a measure of, working memory capacity, a measure that correlated with the ability to implement regulative control and overcome conflict. These findings suggest that patients with predominantly chronic severe TBI patients are impaired on both regulative and evaluative components of cognitive control, and may have implications for the design and evaluation of behavioral and pharmacological remediation strategies. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA	Perlstein, WM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HSC Box 100165, Gainesville, FL 32610 USA.	wmp@grove.ufl.edu	Larson, Michael J/C-8543-2012; Dotson, Vonetta/K-6090-2015	Larson, Michael J/0000-0002-8199-8065; Dotson, Vonetta/0000-0002-3043-3320	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH001857, R21MH073076] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01 MH01857, R21 MH073076] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; Arnsten AFT, 1998, TRENDS COGN SCI, V2, P436, DOI 10.1016/S1364-6613(98)01240-6; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Barch DM, 1999, SCHIZOPHRENIA BULL, V25, P749, DOI 10.1093/oxfordjournals.schbul.a033416; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BERG P, 1994, ELECTROEN CLIN NEURO, V90, P229, DOI 10.1016/0013-4694(94)90094-9; BERTRAND O, 1985, ELECTROEN CLIN NEURO, V62, P462, DOI 10.1016/0168-5597(85)90058-9; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Braver TS, 2002, NEUROSCI BIOBEHAV R, V26, P809, DOI 10.1016/S0149-7634(02)00067-2; Braver TS, 1999, BIOL PSYCHIAT, V46, P312, DOI 10.1016/S0006-3223(99)00116-X; BRAVER TS, 1999, PDPCNS991 CARN MELL; Burgess P. W., 2002, PRINCIPLES FRONTAL L, P557, DOI 10.1093/acprof:oso/9780195134971.003.0033; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Clark H. J., 1924, AM J PHYSL OPTICS, V5, P269; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Cohen JD, 1999, J ABNORM PSYCHOL, V108, P120, DOI 10.1037/0021-843X.108.1.120; Curtin JJ, 2003, J ABNORM PSYCHOL, V112, P424, DOI 10.1037/0021-843X.112.3.424; DANEMAN M, 1980, J CLIN EXP NEUROPSYC, V21, P200; Dias EC, 2003, CEREB CORTEX, V13, P701, DOI 10.1093/cercor/13.7.701; ERSKINE A, 1990, PAIN, V41, P255, DOI 10.1016/0304-3959(90)90002-U; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; Gerstenbrand F, 2001, BRAIN INJURY, V15, P95; Golden C., 1978, STROOP COLOR WORD TE; Ille N, 2002, J CLIN NEUROPHYSIOL, V19, P113, DOI 10.1097/00004691-200203000-00002; ILLE N, 1997, BIOMED TECH S, V42, P80; JONIDES J, 1984, PSYCHOL BULL, V96, P29, DOI 10.1037/0033-2909.96.1.29; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; LARSON MJ, 2004, 32 ANN M INT NEUR SO; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Liotti M, 2000, NEUROPSYCHOLOGIA, V38, P701, DOI 10.1016/S0028-3932(99)00106-2; MacDonald AW, 2003, J ABNORM PSYCHOL, V112, P689, DOI 10.1037/0021-843X.112.4.689; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McNeely HE, 2003, J ABNORM PSYCHOL, V112, P679, DOI 10.1037/0021-843X.112.4.679; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; MENG XL, 1992, PSYCHOL BULL, V111, P172, DOI 10.1037/0033-2909.111.1.172; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miltner WHR, 1997, J COGNITIVE NEUROSCI, V9, P788, DOI 10.1162/jocn.1997.9.6.788; Neter J., 1985, APPL LINEAR STAT MOD; Perlstein WM, 1998, NEUROPSYCHOLOGY, V12, P414, DOI 10.1037/0894-4105.12.3.414; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Polo MD, 2002, NEUROPSYCHOLOGIA, V40, P2350, DOI 10.1016/S0028-3932(02)00127-6; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; Rebai M, 1997, INT J NEUROSCI, V91, P85, DOI 10.3109/00207459708986367; Ridderinkhof KR, 2004, BRAIN COGNITION, V56, P129, DOI 10.1016/j.bandc.2004.09.016; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; ROCKSTROH B, 1985, SLOW CORTICAL POTENT; Rosnow RL, 1996, PSYCHOL METHODS, V1, P331, DOI 10.1037/1082-989X.1.4.331; Schwarz N, 1999, AM PSYCHOL, V54, P93, DOI 10.1037/0003-066X.54.2.93; SEIGNOUREL PJ, IN PRESS NEUROPSYCHO; Speilberger C. D., 1983, MANUAL STATE TRAIT A; Stone AA, 2002, ANN BEHAV MED, V24, P236, DOI 10.1207/S15324796ABM2403_09; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; West R, 1999, J GERONTOL B-PSYCHOL, V54, pP34, DOI 10.1093/geronb/54B.1.P34; West R, 1999, COGNITIVE BRAIN RES, V8, P157, DOI 10.1016/S0926-6410(99)00017-8; West R, 2000, BRAIN RES, V873, P102, DOI 10.1016/S0006-8993(00)02530-0; West R, 2004, J COGNITIVE NEUROSCI, V16, P103, DOI 10.1162/089892904322755593; West R, 2000, PSYCHOPHYSIOLOGY, V37, P179, DOI 10.1017/S0048577200981460; West R, 2003, NEUROPSYCHOLOGIA, V41, P1122, DOI 10.1016/S0028-3932(02)00297-X; West R, 2000, CEREB CORTEX, V10, P748, DOI 10.1093/cercor/10.8.748; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0	90	60	62	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	2					260	274		10.1016/j.neuropsychologia.2005.05.009			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	011HS	WOS:000235259500011	15979655				2021-06-18	
J	Machamer, J; Temkin, N; Fraser, R; Doctor, JN; Dikmen, S				Machamer, J; Temkin, N; Fraser, R; Doctor, JN; Dikmen, S			Stability of employment after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						head injuries; work; neuropsychology; risk factors; prognosis; outcome assessment (health care)	COMMUNITY INTEGRATION; RANDOMIZED-TRIAL; HEAD-INJURY; WORK; RETURN; PREDICTION; TBI; VALPROATE; MODERATE; MODEL	Although substantial information exists about factors related to who returns to work and time taken to return to work after traumatic brain injury (TBI), less is known about the stability of the work experience after the injury. One hundred sixty-five workers with complicated mild to severe traumatic brain injury were followed for 3 to 5 years postinjury. Work stability definitions included amount of time worked (amount of time worked divided by time observed postinjury) and maintenance of uninterrupted employment once a person returned to work. Amount of time worked was significantly and systematically related to brain injury severity, neuropsychological functioning at 1-month postinjury, and preinjury characteristics such as prior work stability and earnings. However, once persons returned to work, the ability to maintain uninterrupted employment was largely related to premorbid characteristics such as being older, higher income before the injury, or a preinjury job with benefits. It was also related to higher neuropsychological functioning at 1-month postinjury (reflecting the combined effects of premorbid functioning and traumatic brain injury severity), but not related to neurologic indices of severity.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA USA; Univ Washington, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Machamer, J (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	machamer@u.washington.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01INS19643] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER		*ASS ADV AUT MED, 1990, ABBR INJ SCAL; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Fleming J, 1999, BRAIN INJURY, V13, P417; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; McLeod A, 2004, OCCUP ENVIRON MED, V61, P414, DOI 10.1136/oem.2003.007336; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Reitan R.M., 1993, HALSTEADREITAN NEURO; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SELZER ML, 1975, J STUD ALCOHOL, V36, P127; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; *US DEP LAB, 2005, LOC AR UN STAT; Wechsler D., 1955, MANUAL WECHSLER ADUL; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27	29	60	60	0	2	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2005	11	7					807	816		10.1017/S135561770505099X			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	000JT	WOS:000234458500002	16519260				2021-06-18	
J	Marmarou, CR; Walker, SA; Davis, CL; Povlishock, JT				Marmarou, CR; Walker, SA; Davis, CL; Povlishock, JT			Quantitative analysis of the relationship between intra-axonal neurofilament compaction and impaired axonal transport following diffuse traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						amyloid pre-cursor protein (APP); neurofilament compaction (NFC); traumatic axonal injury (TAI); traumatic brain injury (TBI)	AMYLOID PRECURSOR PROTEIN; CYCLOSPORINE-A; BETA-APP; POSTTRAUMATIC HYPOTHERMIA; RETROGRADE CONVERSION; SPECTRIN PROTEOLYSIS; CORTICAL IMPACT; CALCIUM INFLUX; WHITE MATTER; NERVE-FIBERS	Traumatic axonal injury (TAI) following traumatic brain injury (TBI) contributes to morbidity and mortality. TAI involves intra-axonal changes assumed to progress to impaired axonal transport (IAT), disconnection, and axonal bulb formation. Immunocytochemical studies employing antibodies to amyloid precursor protein (APP), a marker of IAT and RMO14, a marker of neurofilament compaction (NFC), have shown that TAI involves both NFC and IAT, with the suggestion that NFC leads to IAT. Recently, new data has suggested that NFC may occur independently of IAT. The objective of this study was to determine quantitatively the precise relationship between NFC and IAT. Following TBI, rats were studied at 30 min, 3 h, and 24 h. Using single-label immunocytochemistry employing the antibodies RMO14, APP, or a combined labeling strategy targeting APP/RMO14 in aggregate, the immunoreactive (IR) profiles were counted in the corticospinal tract (CSpT) and medial lemniscus (ML). In the CSpT, the number of axons demonstrating RMO14-IR approximated the number of axons showing APP-IR, with the APP-IR population showing a significant increase over 24 h (p < 0.05). The sum of both single-label counts equaled the aggregate APP/RMO14 numbers, demonstrating little relationship between NFC and IAT. In the ML, 75% of fibers demonstrated a separation of APP-IR and NFC-IR; however, 25% of the ML fibers showed co-localization of APP-IR and RMO14. The results of these studies indicate that, in the majority of damaged axons, NFC is not associated with IAT. Our findings argue for the use of multiple markers when evaluating the extent of TAI or the efficacy of therapies targeting the treatment of TAI.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Ctr Hlth, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Ctr Hlth, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, T32NS007288] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, NS20193] Funding Source: Medline		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FRAPPIER T, 1992, EUR J BIOCHEM, V205, P85, DOI 10.1111/j.1432-1033.1992.tb16754.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; He Xiaosheng, 1999, Chin J Traumatol, V2, P25; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Leclercq PD, 2002, J NEUROTRAUM, V19, P1183, DOI 10.1089/08977150260337985; MALBOUISSON AMB, 1985, ANAT EMBRYOL, V171, P339, DOI 10.1007/BF00347022; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Niess C, 2002, ACTA NEUROPATHOL, V104, P79, DOI 10.1007/s00401-002-0525-9; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PANNESE E, 1984, ACTA ANAT, V118, P193; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 2001, HEAD TRAUMA, P281; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; PRICE RL, 1988, J NEUROCYTOL, V17, P55, DOI 10.1007/BF01735377; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGEMATSU K, 1992, BRAIN RES, V592, P353, DOI 10.1016/0006-8993(92)91697-D; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; UEDA Y, 2001, J NEUROTRAUM, V18, P1179; WATSON D, 1991, J NEUROSCI RES, V30, P226, DOI 10.1002/jnr.490300123; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAZAKI T, 1993, VIRCHOWS ARCH B, V63, P173, DOI 10.1007/BF02899258	70	60	65	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1066	1080		10.1089/neu.2005.22.1066			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600004	16238484				2021-06-18	
J	Esposito, TJ; Reed, RL; Gamelli, RL; Luchette, FA				Esposito, TJ; Reed, RL; Gamelli, RL; Luchette, FA			Neurosurgical coverage - Essential, desired, or irrelevant for good patient care and trauma center status	ANNALS OF SURGERY			English	Article							MINIMAL HEAD-INJURY; ASSOCIATION; MANAGEMENT; SURGEONS; UTILITY; SCANS; RISK	Summ. and Background Data: As a result of many factors, the availability of neurosurgeons (NS) to care for trauma patients (TP) is increasingly sparse. This has precipitated a crisis in access to neurosurgical support in many trauma systems, often placing undue burden on level I centers. This study examines the profile of head-injured (HI) trauma patients and their actual need for the specific expertise of a neurosurgeon. Methods: The National Trauma Data Bank (NTDB) was queried for specific information relating to the volume, nature, timeliness, and outcome of HI TP. Study patients were identified by reported International Classification of Diseases, 9th Edition (ICD-9) codes denoting open (OHI) or closed head injury (CHI) in isolation or in combination with other injuries. Results: Total number of NTDB patients studied was 731,823, of which 213,357 (29%) had a reported HI. CHI represented 22% of all TP and 74% of HI. OHI was reported in 8% of all TP and was 26% of HI. Craniotomy (crani) was performed in 3.6% of all HI (1% of all TP). This was in 2.8% of OHI and 2.6% of CHI. Mean Glasgow Coma Scale score (GCS) of crani patients was 9, and 13 for the noncrani group. Subdural hematoma occurred in 18% of HI (5% of TP), with 13% undergoing crani. Epidural hematoma occurred in 10% of HI (3% of all TP), with 17% undergoing crani. Median time to OR for all cranis was 195 minutes (195 for CHI; 183 for OHI). Of all crams, 6.5% were performed within 1 hour of hospital admission. intracranial pressure (ICP) monitoring was reportedly used in 0.7% of TP and 2.2% of HI. Conclusions: Care of TP with HI rarely requires the explicit expertise and immediate presence of a neurosurgeon due to volume and nature of care. HI was diagnosed in < 30% of TP reported to the NTDB. Over 95% required nonoperative management alone, with only 1% of all TP and 2%- 4% of HI TP requiring cram and/or ICP monitoring. Immediate availability of NS is not essential if a properly trained and credentialed trauma surgeon or other health care provider can appropriately monitor patients for neurologic demise and effect early transfer to a center capable of, and committed to, operative and postoperative neurosurgical care. A subgroup of patients known to have a high propensity for the specific expertise of a neurosurgeon may be able to be identified for direct transport to these committed centers.	Loyola Univ, Med Ctr, Dept Surg, Div Truma Surg Crit Care & Burns, Maywood, IL 60153 USA; Burn Shock Trauma Inst, Maywood, IL USA	Esposito, TJ (corresponding author), Loyola Univ, Med Ctr, Dept Surg, Div Truma Surg Crit Care & Burns, 2160 S 1st Ave,Bldg 110,Room 4235, Maywood, IL 60153 USA.	tesposi@lumc.edu	Luchette, Fred/ABF-1710-2020; Reed, Robert/AAJ-2575-2020	Luchette, Fred/0000-0002-8857-9111			*AM ASS SURG TRAUM, 1992, J TRAUMA, V33, P491; BIRKMEYER JD, 2003, LEAPFROG GROUPS PATI; BISHOFBERGER TE, 2004, J TRAUMA, V57, P457; Chesnut RM, 1997, J TRAUMA, V42, pS19, DOI 10.1097/00005373-199705001-00004; *COMM TRAUM AM COL, 1999, RES OPT CAR INJ PAT; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Esposito T, 1993, NATL SURVEY SURG TRA; ESPOSITO TJ, 1994, J TRAUMA, V37, P996, DOI 10.1097/00005373-199412000-00022; ESPOSITO TJ, 1991, ARCH SURG-CHICAGO, V126, P292; Ko K, 2003, J TRAUMA, V55, P480, DOI 10.1097/01.TA.0000074111.04885.28; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; National Center for Injury Prevention and Control, 2001, INJ FACT BOOK 2001 2; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Rotondo MF, 2005, J TRAUMA, V59, P77, DOI 10.1097/01.TA.0000171848.22633.C0; SANTANIELLO JM, 2003, SURGERY, V134, P4; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEILL IG, 1997, ANN EMERG MED, V30, P14; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Stephan PJ, 2002, J TRAUMA, V53, P895, DOI 10.1097/00005373-200211000-00014; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TRUNKEY DD, 2003, B AM COLL SURG, V88, P9; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004	26	60	61	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	SEP	2005	242	3					364	374		10.1097/01.sla.0000179624.50455.db			11	Surgery	Surgery	962QV	WOS:000231748200007	16135922	Green Published			2021-06-18	
J	McCauley, SR; Boake, C; Pedroza, C; Brown, SA; Levin, HS; Goodman, HS; Merritt, SG				McCauley, SR; Boake, C; Pedroza, C; Brown, SA; Levin, HS; Goodman, HS; Merritt, SG			Postconcussional disorder - Are the DSM-IV criteria an improvement over the ICD-10?	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						postconcussional syndrome; head injuries; closed; outcome	NEUROBEHAVIORAL RATING-SCALE; TRAUMATIC BRAIN INJURY; HEAD-INJURY; SOCIAL SUPPORT; SYMPTOMS; VALIDITY; SEQUELAE; MODERATE; SENSITIVITY; PREDICTORS	Little is known about the characteristics and outcomes of patients diagnosed with postconcussional disorder (PCD) under the provisionally proposed criteria in the DSM-IV and how they differ from patients diagnosed with postconcussional syndrome (PCS) under the International Classification of Diseases, 10th edition clinical (ICD-10) criteria. This study investigated differences in outcome based on a diagnosis of PCD (DSM-IV) versus PCS (ICD-10 clinical criteria) as to which criteria set might be preferred for clinical practice. A consecutive series of adult patients with mild (N = 3 19) to moderate (N = 2 1) traumatic brain injury was assessed at 3 months postinjury with a brief neuropsychological battery and measures of specific outcome domains. In two separate series of analyses, patients with PCD were compared with those without PCD, and those with PCS were compared with those without PCS. Although the two criteria sets resulted in markedly different incidence rates, there was no substantial pattern of differences between the DSM-IV and ICD-10 in the outcome domains of psychiatric symptoms and disorders, social and community integration, health-related quality of life, or global outcome as measured by the Glasgow Outcome Scale-Extended. In spite of significant differences between the two diagnostic criteria sets and different incidence rates for PCD/PCS, outcome in all measured domains was very similar at 3 months postinjury. There is no compelling evidence, based on these outcome domains, to suggest which of the two diagnostic criteria sets should be clinically preferred.	Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; Univ Texas, Sch Med, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA	McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, 6560 Fannin St,Ste 1144, Houston, TX 77030 USA.			Pedroza, Claudia/0000-0003-4235-1282	ODCDC CDC HHS [R49/CCR612707] Funding Source: Medline		AITKEN RCB, 1969, P ROY SOC MED, V62, P989, DOI 10.1177/003591576906201005; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BOAKE C, IN PRESS J NEUROPSYC; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; *COMM INJ SCAL, 1990, ABBR INJ SCAL; DIKMEN SS, 1989, MILD HEAD INJURY, P229; EVANS RW, 1992, NEUROL CLIN, V10, P815; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; FIRST MB, 1995, USERS GUIDE STRUCTUR; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; IVERSON GL, 2001, J COGNIT REHABIL, V19, P18; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LETSCH EA, 2003, DISS ABSTR INT B, V63, P3925; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MEYERS JE, 1995, REY COMPLEX FITURE T; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RUSSELL RW, 1971, TRAUMATIC AMNESIAS; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; *SAS, 2001, STAT AN SOFTW WIND; Smith A., 1982, SYMBOL DIGIT MODALIT; STOGNER BL, 2000, DISS ABSTR INT B, V61, P550; TEASDALE G, 1974, LANCET, V2, P81; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; Ware JE., 1993, SF 36 HLTH SURVEY MA; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; World Health Organization, 1992, ICD 10 CLASS MENT BE	48	60	61	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-3018	1539-736X		J NERV MENT DIS	J. Nerv. Ment. Dis.	AUG	2005	193	8					540	550		10.1097/01.nmd.0000172592.05801.71			11	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	954TK	WOS:000231177600007	16082299				2021-06-18	
J	Withnall, C; Shewchenko, N; Gittens, R; Dvorak, J				Withnall, C; Shewchenko, N; Gittens, R; Dvorak, J			Biomechanical investigation of head impacts in football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SOCCER PLAYERS; BRAIN-INJURY; PROFESSIONAL FOOTBALL; CONCUSSION	Objectives: This study sought to measure the head accelerations induced from upper extremity to head and head to head impact during the game of football and relate this to the risk of mild traumatic brain injury using the Head Impact Power (HIP) index. Furthermore, measurement of upper neck forces and torques will indicate the potential for serious neck injury. More stringent rules or punitive sanctions may be warranted for intentional impact by the upper extremity or head during game play. Methods: Game video of 62 cases of head impact (38% caused by the upper extremity and 30% by the head of the opposing player) was provided by F-MARC. Video analysis revealed the typical impact configurations and representative impact speeds. Upper extremity impacts of elbow strike and lateral hand strike were re-enacted in the laboratory by five volunteer football players striking an instrumented Hybrid III pedestrian model crash test manikin. Head to head impacts were re-enacted using two instrumented test manikins. Results: Elbow to head impacts (1.7-4.6 m/s) and lateral hand strikes (5.2-9.3 m/s) resulted in low risk of concussion (<5%) and severe neck injury (<5%). Head to head impacts (1.5-3.0 m/s) resulted in high concussion risk (up to 67%) but low risk of severe neck injury (<5%). Conclusion: The laboratory simulations suggest little risk of concussion based on head accelerations and maximum HIP. There is no biomechanical justification for harsher penalties in this regard. However,. deliberate use of the head to impact another player's head poses a high risk of concussion, and justifies a harsher position by regulatory bodies. In either case the risk of serious neck injury is very low.	FIFA Med Assessment & Res Ctr, Zurich, Switzerland		withnall@biokinetics.com					Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; ANDERSEN TE, 2003, BRIT J SPORT MED, V37, P326; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; DiMasi FP, 1995, TRANSFORMATION 9 ACC; FULLER C, 2005, BR J SPORTS MED S10, V20, pR30; Fuller CW, 2004, AM J SPORT MED, V32, p17S, DOI 10.1177/0363546503261249; Fuller CW, 2004, AM J SPORT MED, V32, p43S, DOI 10.1177/0363546503261248; Fuller CW, 2004, AM J SPORT MED, V32, p28S, DOI 10.1177/0363546503261247; Fuller CW, 1997, SAFETY SCI, V27, P115; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hawkins RD, 1998, BRIT J SPORT MED, V32, P326, DOI 10.1136/bjsm.32.4.326; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; MATSER E, 2001, BRIT J SPORT MED, V35, P373; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Nahum AM, 2002, ACCIDENTAL INJURY BI; Newman J, 2000, NEW BIOMECHANICAL 2; NEWMAN J, 2005, IN PRESS J BIOMECH; NEWMAN J, 1999, NEW BIOMECHANICAL 1; Newman J, 2000, 44 STAPP CAR CRASH C; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rahnama N, 2002, BRIT J SPORT MED, V36, P354, DOI 10.1136/bjsm.36.5.354; *SAE, 1995, SAE HDB; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	29	60	60	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I49	I57		10.1136/bjsm.2005.019182			9	Sport Sciences	Sport Sciences	954KI	WOS:000231153600007	16046356	Green Published, Bronze			2021-06-18	
J	Hall, ED; Gibson, TR; Pavel, KM				Hall, ED; Gibson, TR; Pavel, KM			Lack of a gender difference in post-traumatic neurodegeneration in the mouse controlled cortical impact injury model	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; gender; mouse; neurodegeneration; traumatic brain injury	TRAUMATIC BRAIN-INJURY; LIPID PEROXYL RADICALS; NITRIC-OXIDE; MITOCHONDRIAL DYSFUNCTION; SEXUAL-DIMORPHISM; ALPHA-TOCOPHEROL; BCL-2 EXPRESSION; SMOOTH-MUSCLE; HEAD-INJURY; ESTROGEN	Recent studies using a mouse model of weight-drop-induced "diffuse" traumatic brain injury (TBI) have demonstrated a substantial gender difference in the time course and magnitude of post-traumatic neurodegeneration following a severe level of injury. The time of maximal damage, as assessed by the de Olmos aminocupric silver staining method, occurred at 72 h in male mice, whereas the peak of neurodegeneration was not observed until 14 days in females and was less in magnitude compared to males. This difference, favoring females, has been postulated to relate to the neuroprotective actions of estrogen and progesterone. In the presently reported experiments, we compared the time course and peak of neurodegeneration in male and female mice after a severe level of "focal" controlled cortical impact (CCI; I mm, 3.5 m/sec) TBI using the same strain (CF-1) and weight (29-31 g) as employed in the "diffuse" TBI study. The volume of silver staining was measured using image analysis methods at 24, 48, and 72 h, and 1, 2 and 4 weeks. In male and female mice, a significant increase in neurodegeneration was observed at 24 h, and the volume was not significantly different between the two genders. In both gender groups, the maximal neurodegeneration was seen at 48 h after injury. Although the female mice exhibited a trend toward higher mean volumes of silver staining, this difference was not significantly different compared to males. Furthermore, the rate of resolution of staining between 48 h and 4 weeks was similar. However, injured females still exhibited a significantly higher volume of staining compared to sham, non-injured females at 4 weeks, whereas the difference in staining volume between sham and injured males was no longer significant at that time point. These results show that, following a "focal" CCI, there is no gender difference that favors females, in contrast to that seen with the "diffuse" injury paradigm. The disparity between the effects of gender in the two models may be due to the fact that, in the "focal" CCI model, the timing of post-traumatic neurodegeneration is significantly more rapid than that seen in the "diffuse" model, which may overwhelm the neuroprotective effects of estrogen and progesterone and obscure the appearance of a gender difference.	Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,B383 BBSRB, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013				Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V620, P472; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; GRAFE MR, 1980, J NEUROPATH EXP NEUR, V39, P555, DOI 10.1097/00005072-198009000-00005; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HALL ED, 1995, NEUROSURGERY, V96, P505; HAYASHI T, 1995, BIOCHEM BIOPH RES CO, V214, P847, DOI 10.1006/bbrc.1995.2364; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; MADDOX YT, 1987, J PHARMACOL EXP THER, V240, P392; McIntosh TK, 1996, LAB INVEST, V74, P315; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MIKKOLA T, 1995, J CLIN ENDOCR METAB, V80, P1832, DOI 10.1210/jc.80.6.1832; Murphy AN, 1999, ANN NY ACAD SCI, V893, P19, DOI 10.1111/j.1749-6632.1999.tb07815.x; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; O'Donnell VB, 2001, CIRC RES, V88, P12, DOI 10.1161/01.RES.88.1.12; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; Pelligrino DA, 2001, JPN J PHARMACOL, V86, P137, DOI 10.1254/jjp.86.137; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rubbo H, 2000, J BIOL CHEM, V275, P10812, DOI 10.1074/jbc.275.15.10812; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; YAMAMOTO T, 1986, BRAIN RES, V374, P419, DOI 10.1016/0006-8993(86)90442-7; ZHANG A, 1992, BRIT J PHARMACOL, V105, P305, DOI 10.1111/j.1476-5381.1992.tb14250.x; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267	48	60	62	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2005	22	6					669	679		10.1089/neu.2005.22.669			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	936EN	WOS:000229838400006	15941376				2021-06-18	
J	Mitrasinovic, OM; Grattan, A; Robinson, CC; Lapustea, NB; Poon, C; Ryan, H; Phong, C; Murphy, GM				Mitrasinovic, OM; Grattan, A; Robinson, CC; Lapustea, NB; Poon, C; Ryan, H; Phong, C; Murphy, GM			Microglia overexpressing the macrophage colony-stimulating factor receptor are neuroprotective in a microglial-hippocampal organotypic coculture system	JOURNAL OF NEUROSCIENCE			English	Article						microglia; hippocampus; organotypic; M-CSF; excitotoxicity; neuroprotection; ribozyme; laser capture microdissection	METHYL-D-ASPARTATE; M-CSF RECEPTOR; IN-VITRO MODEL; NEUROTROPHIC FACTOR; NEURONAL SURVIVAL; MESSENGER-RNA; EXPRESSION; CELLS; ACTIVATION; NEUROTOXICITY	Microglia with increased expression of the macrophage colony-stimulating factor receptor (M-CSFR; c-fms) are found surrounding plaques in Alzheimer's disease ( AD) and in mouse models for AD and after ischemic or traumatic brain injury. Increased expression of M-CSFR causes microglia to adopt an activated state that results in proliferation, release of cytokines, and enhanced phagocytosis. To determine whether M-CSFR-induced microglial activation affects neuronal survival, we assembled a coculture system consisting of BV-2 microglia transfected to overexpress the M-CSFR and hippocampal organotypic slices treated with NMDA. Twenty-four hours after assembly of the coculture, microglia overexpressing M-CSFR proliferated at a higher rate than nontransfected control cells and exhibited enhanced migration toward NMDA-injured hippocampal cultures. Surprisingly, coculture with c-fms-transfected microglia resulted in a dramatic reduction in NMDA-induced neurotoxicity. Similar results were observed when cocultures were treated with the teratogen cyclophosphamide. Biolistic overexpression of M-CSFR on microglia endogenous to the organotypic culture also rescued neurons from excitotoxicity. Furthermore, c-fms-transfected microglia increased neuronal expression of macrophage colony-stimulating factor (M-CSF), the M-CSFR, and neurotrophin receptors in the NMDA-treated slices, as determined with laser capture microdissection. In the coculture system, direct contact between the exogenous microglia and the slice was necessary for neuroprotection. Finally, blocking expression of the M-CSF ligand by exogenous c-fms-transfected microglia with a hammerhead ribozyme compromised their neuroprotective properties. These results demonstrate a protective role for microglia overexpressing M-CSFR in our coculture system and suggest under certain circumstances, activated microglia can help rather than harm neurons subjected to excitotoxic and teratogen-induced injury.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Stanford, CA 94305 USA	Murphy, GM (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Med Sch Lab Surge Bldg,Room P-104, Stanford, CA 94305 USA.	gmurphy@leland.stanford.edu	Poon, Chi Sun/H-4152-2015		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH057833] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH057833, MH 57833] Funding Source: Medline		Aschner M, 1999, ANNU REV PHARMACOL, V39, P151, DOI 10.1146/annurev.pharmtox.39.1.151; Bamberger ME, 2002, NEUROSCIENTIST, V8, P276, DOI 10.1177/1073858402008003013; BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7; Berezovskaya O, 1996, ACTA NEUROPATHOL, V92, P479, DOI 10.1007/s004010050550; Bruccoleri A, 2000, J NEUROSCI RES, V62, P146, DOI 10.1002/1097-4547(20001001)62:1<146::AID-JNR15>3.0.CO;2-L; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Fedoroff S, 1997, NEUROSCI BIOBEHAV R, V21, P187, DOI 10.1016/S0149-7634(96)00009-7; Fixe P, 1997, EUR CYTOKINE NETW, V8, P125; Francis K, 1997, P NATL ACAD SCI USA, V94, P12258, DOI 10.1073/pnas.94.23.12258; Garden GA, 2002, GLIA, V40, P240, DOI 10.1002/glia.10155; Glass JD, 2001, MICROSC RES TECHNIQ, V54, P95, DOI 10.1002/jemt.1124; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; Haapasalo A, 2002, J BIOL CHEM, V277, P43160, DOI 10.1074/jbc.M205202200; Hailer NP, 2001, EUR J NEUROSCI, V14, P315, DOI 10.1046/j.0953-816x.2001.01649.x; Hao AJ, 2002, NEUROSCIENCE, V112, P889, DOI 10.1016/S0306-4522(02)00144-6; Hao AJ, 2001, J NEUROSCI RES, V64, P79, DOI 10.1002/jnr.1056; Hartmann M, 2004, J CELL SCI, V117, P5803, DOI 10.1242/jcs.01511; Jiang XY, 2003, ANN NY ACAD SCI, V993, P134, DOI 10.1111/j.1749-6632.2003.tb07522.x; Kim WK, 1998, J NEUROSCI RES, V54, P17, DOI 10.1002/(SICI)1097-4547(19981001)54:1<17::AID-JNR3>3.0.CO;2-K; KONDO K, 1995, NEUROSCI LETT, V188, P140, DOI 10.1016/0304-3940(95)11408-O; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; Luder CGK, 1999, EXP PARASITOL, V93, P23, DOI 10.1006/expr.1999.4421; McGeer PL, 1998, J NEURAL TRANSM-SUPP, P159; McGeer PL, 2002, J NEUROVIROL, V8, P529, DOI 10.1080/13550280290100969; Mitrasinovic OM, 2004, J NEUROSCI RES, V77, P420, DOI 10.1002/jnr.20168; Mitrasinovic OM, 2003, NEUROBIOL AGING, V24, P807, DOI 10.1016/S0197-4580(02)00237-3; Mitrasinovic OM, 2002, J BIOL CHEM, V277, P29889, DOI 10.1074/jbc.M200868200; Mitrasinovic OM, 2001, J BIOL CHEM, V276, P30142, DOI 10.1074/jbc.M104265200; Murase S, 1998, J NEUROSCI, V18, P10481; MURPHY GM, 1995, J NEUROSCI RES, V40, P755, DOI 10.1002/jnr.490400607; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Nelson PT, 2002, ANN MED, V34, P491, DOI 10.1080/078538902321117698; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; Rossler OG, 2004, J NEUROCHEM, V88, P1240, DOI 10.1046/j.1471-4159.2003.02255.x; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schwartz M, 2004, TRENDS PHARMACOL SCI, V25, P407, DOI 10.1016/j.tips.2004.06.010; Schwartz M, 2003, TRENDS NEUROSCI, V26, P297, DOI 10.1016/S0166-2236(03)00126-7; Shaked I, 2004, J NEUROIMMUNOL, V146, P84, DOI 10.1016/j.jneuroim.2003.10.049; Smits HA, 2001, J IMMUNOL, V166, P6869, DOI 10.4049/jimmunol.166.11.6869; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Suzuki T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004; Tong N, 2000, J IMMUNOL, V164, P1333, DOI 10.4049/jimmunol.164.3.1333; UEMURA N, 1993, BLOOD, V82, P2634; Vincent VAM, 2002, J NEUROSCI RES, V69, P578, DOI 10.1002/jnr.10329; Vincent VAM, 2002, J NEUROCHEM, V82, P1388, DOI 10.1046/j.1471-4159.2002.01087.x; Wang MJ, 2002, EUR J NEUROSCI, V16, P2103, DOI 10.1046/j.1460-9568.2002.02290.x; Wang YQ, 1999, J NEUROSCI RES, V57, P616, DOI 10.1002/(SICI)1097-4547(19990901)57:5<616::AID-JNR4>3.0.CO;2-E; Watanabe H, 2000, NEUROSCI LETT, V289, P53, DOI 10.1016/S0304-3940(00)01252-0; Xie Z, 2004, GLIA, V45, P170, DOI 10.1002/glia.10314; Yacoubian TA, 2000, NAT NEUROSCI, V3, P342; Yao GQ, 2003, ENDOCRINOLOGY, V144, P3677, DOI 10.1210/en.2002-221071; Zietlow R, 1999, EUR J NEUROSCI, V11, P1657, DOI 10.1046/j.1460-9568.1999.00583.x; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	60	60	64	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	APR 27	2005	25	17					4442	4451		10.1523/JNEUROSCI.0514-05.2005			10	Neurosciences	Neurosciences & Neurology	920PP	WOS:000228702900025	15858070	Green Published, Bronze			2021-06-18	
J	Parizel, PM; Van Goethem, JW; Ozsarlak, O; Maes, M; Phillips, CD				Parizel, PM; Van Goethem, JW; Ozsarlak, O; Maes, M; Phillips, CD			New developments in the neuroradiological diagnosis of craniocerebral trauma	EUROPEAN RADIOLOGY			English	Article						head trauma; diffusion-weighted imaging; multi-detector CT	DIFFUSE AXONAL INJURY; CHRONIC SUBDURAL-HEMATOMA; HEAD-INJURY; WEIGHTED MRI; BRAIN-INJURY; INTRACRANIAL HEMORRHAGE; IMAGING FINDINGS; CT; FEATURES	Accurate radiographic diagnosis is a cornerstone of the clinical management and outcome prediction of the head-injured patient. New technological advances, such as multi-detector computed tomography (MDCT) scanning and diffusion-weighted magnetic resonance imaging (MRI) have influenced imaging strategy. In this article we review the impact of these developments on the neuroradiological diagnosis of acute head injury. In the acute phase, multi-detector CT has supplanted plain X-ray films of the skull as the initial imaging study of choice. MRI, including fluid-attenuated inversion recovery, gradient echo T2* and diffusion-weighted sequences, is useful in determining the severity of acute brain tissue injury and may help to predict outcome. The role of MRI in showing diffuse axonal injuries is emphasized. We review the different patterns of primary and secondary extra-axial and intra-axial traumatic brain lesions and integrate new insights. Assessment of intracranial hypertension and cerebral herniation are of major clinical importance in patient management. We discuss the issue of pediatric brain trauma and stress the importance of MRI in non-accidental injury. In summary, new developments in imaging technology have advanced our understanding of the pathophysiology of brain trauma and contribute to improving the survival of patients with craniocerebral injuries.	Univ Antwerp, Dept Radiol, B-2020 Antwerp, Belgium; Univ Virginia Hlth Syst, Dept Radiol, Charlottesville, VA USA	Parizel, PM (corresponding author), Univ Antwerp, Dept Radiol, B-2020 Antwerp, Belgium.	paul.parizel@uza.be		Van Goethem, Johan/0000-0003-3993-4583; Parizel, Paul M./0000-0002-0221-2854			Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Bakshi R, 1999, AM J NEURORADIOL, V20, P629; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Blumenthal I, 2002, POSTGRAD MED J, V78, P732, DOI 10.1136/pmj.78.926.732; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Campbell B G, 1998, Top Magn Reson Imaging, V9, P208; Demaerel P, 2002, EUR RADIOL, V12, P849, DOI 10.1007/s00330-001-1145-9; Gean A, 1994, IMAGING HEAD TRAUMA; Gean A D, 1995, New Horiz, V3, P549; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 2002, MAGNETIC RESONANCE I, P1059; HAN BK, 1990, AM J ROENTGENOL, V154, P361, DOI 10.2214/ajr.154.2.2105031; HASHIMOTO N, 1992, J NEUROSURG, V77, P310, DOI 10.3171/jns.1992.77.2.0310; Heidemann RM, 2003, EUR RADIOL, V13, P2323, DOI 10.1007/s00330-003-1992-7; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; IPLIKCIOGLU AC, 1991, J TRAUMA, V31, P272; Lin DDM, 2001, AM J NEURORADIOL, V22, P1275; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Mirvis S E, 1994, J Intensive Care Med, V9, P305; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murray JG, 1996, SEMIN ULTRASOUND CT, V17, P185, DOI 10.1016/S0887-2171(96)90035-9; PARIZEL G, 1973, ANGIOLOGY, V24, P17, DOI 10.1177/000331977302400103; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Parizel PM, 2004, DISEASES OF THE BRAIN, HEAD AND NECK, SPINE, P60; Parizel PM, 2003, PEDIATR RADIOL, V33, P868, DOI 10.1007/s00247-003-1025-3; Parizel PM, 2002, INTENS CARE MED, V28, P85, DOI 10.1007/s00134-001-1160-y; Parizel PM, 2001, EUR RADIOL, V11, P1770, DOI 10.1007/s003300000800; Parizel PM, 2001, STROKE, V32, P2942, DOI 10.1161/str.32.12.2942; Poussaint TY, 2002, NEUROIMAG CLIN N AM, V12, P271, DOI 10.1016/S1052-5149(02)00005-9; Schaefer PW, 2001, J NEUROL SCI, V186, pS25, DOI 10.1016/S0022-510X(01)00488-9; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Server A, 2001, ACTA RADIOL, V42, P254; Sklar EM, 2000, AM J NEURORADIOL, V21, P808; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; WILMS G, 1992, NEURORADIOLOGY, V34, P497, DOI 10.1007/BF00598959; YORK JE, 1999, CURR PRACT MED, V2, P773; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	45	60	64	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	MAR	2005	15	3					569	581		10.1007/s00330-004-2558-z			13	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	912OT	WOS:000228089500018	15696294				2021-06-18	
J	Mateer, CA; Sira, CS; O'Connell, ME				Mateer, CA; Sira, CS; O'Connell, ME			Putting humpty dumpty together again - The importance of integrating cognitive and emotional interventions	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognitive rehabilitation; mood and anxiety disorders; multimodal interventions; psychotherapy	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; POSTCONCUSSION SYMPTOMS; MEMORY PERFORMANCE; METAMEMORY; DEPRESSION; SUICIDE; STRESS	Acquired brain injury commonly results in both cognitive and emotional sequela, and it is increasingly recognized that these domains of functioning interact. Consequently, interventions directed at only or primarily one domain may be confounded by this interaction. To maximize treatment potential, we believe cognitive rehabilitation must integrate both cognitive and emotional interventions, and attend to belief systems about, and affective responses to, cognitive challenges. We review the scant literature addressing the impact of combined interventions for clients with acquired brain injury. Integrated with these reviews are 2 case studies that appear to break treatment "myths." Specifically, we address the notion that emotion-focused treatments are appropriate only for clients with awareness or insight and the notion that cognitive interventions arc ineffective, and potentially even contraindicated, for clients whose profile suggests emotional distress and functional, as opposed to neurological, impairments. In each of these cases, we demonstrate that combining cognitive and emotional interventions was not only effective but also even more valuable than previous treatment approaches aimed exclusively at one domain. We conclude by emphasizing the importance of understanding emotional response to, and beliefs about, cognitive difficulties in developing effective interventions.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada	Mateer, CA (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	cmateer@uvic.ca	O'Connell, Megan/A-4691-2012				BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; CAVANAUGH JC, 1989, PSYCHOL AGING, V4, P365, DOI 10.1037/0882-7974.4.3.365; Dobson KS, 2001, HDB COGNITIVE BEHAV; ELLIOTT E, 1989, ADV PSYCHOL PSYCHOL; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Hayes JS, 1998, ARCH CLIN NEUROPSYCH, V13, P27; HERTZOG C, 1990, PSYCHOL AGING, V5, P215, DOI 10.1037/0882-7974.5.2.215; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; HOBSON P, 2002, CRADLE THOUGHT EXPLO, V13; Jonker C, 1997, EDUC GERONTOL, V23, P115, DOI 10.1080/0360127970230203; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LACHMAN ME, 1992, J GERONTOL, V47, pP293, DOI 10.1093/geronj/47.5.P293; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; O'Connell ME, 2003, NEUROREHABILITATION, V18, P9; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PRIGATANO GP, 1999, COGNITIVE NEUROREHAB; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; ROSENTHAL M, 1990, REHABILIATION ADULT; SAWCHYN JM, IN PRESS J HEAD TRAU; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SIRA CS, 2004, 6 ANN REH PSYCH DIV; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; SYMONDS CP, 1937, P ROY SOC MED, V30, P1092; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Teasdale TW, 2001, J EPIDEMIOL COMMUN H, V55, P863, DOI 10.1136/jech.55.12.863; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; WEBMAN P, 1988, J HEAD TRAUMA REHAB, V3, P82; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284	35	60	60	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2005	20	1					62	75		10.1097/00001199-200501000-00007			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	894AT	WOS:000226762900006	15668571				2021-06-18	
J	Asplund, CA; McKeag, DB; Olsen, CH				Asplund, CA; McKeag, DB; Olsen, CH			Sport-related concussion - Factors associated with prolonged return to play	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; sports; symptoms; outcomes	BRAIN-INJURY; HIGH-SCHOOL; CONTACT-SPORTS; 2ND IMPACT; PERFORMANCE; COLLEGIATE; SEVERITY; DURATION; SYMPTOMS; MILD	Objective: To assess predictive value of concussion signs and symptoms based on return-to-play timelines. Design: Physician practice study without diagnosis that includes presentation, initial and subsequent treatment, and management of concussion. Setting: National multisite primary care sports medicine provider locations. Participants: Twenty-two providers at 18 sites; 101 athletes (91 men, 10 women in the following sports: 73 football, 8 basketball, 8 soccer, 3 wrestling, 2 lacrosse, 2 skiing, 5 others; 51 college, 44 high school, 4 professional, and 2 recreational). Main Outcome Measurements: Duration of symptoms, presence of clinical signs, and time to return to play following concussion. Results: One hundred one concussions were analyzed. Pearson chi(2) analysis of common early and late concussion symptoms revealed statistical significance (P < 0.05) of headache > 3 hours, difficulty concentrating > 3 hours, any retrograde amnesia or loss of consciousness, and return to play > 7 days. There appeared to be a trend in patients with posttraumatic amnesia toward poor outcome, but this was not statistically significant. Conclusions: When evaluating concussion, symptoms of headache > 3 hours, difficulty concentrating > 3 hours, retrograde amnesia, or loss of consciousness may indicate a more severe injury or prolonged recovery; great caution should be exercised before returning these athletes to play.	DeWitt Army Community Hosp, Dept Family Practice, Ft Belvoir, VA 22060 USA; Indiana Univ, Ctr Sports Med, Sch Med, Indianapolis, IN 47405 USA; Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA	Asplund, CA (corresponding author), 5663 Marshall Rd, Ft Belvoir, VA 22060 USA.	chad.asplund@us.army.mil					CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kelly JP, 1997, NEUROLOGY, V48, P581; Long C J, 1983, Psychiatr Med, V1, P35; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrory P, 1997, PHYSICIAN SPORTSMED, V25, P33, DOI 10.3810/psm.1997.02.1133; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sosin DM, 1996, BRAIN INJURY, V10, P47; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	31	60	60	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2004	14	6					339	343		10.1097/00042752-200411000-00003			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	943BZ	WOS:000230328100003	15523205				2021-06-18	
J	Holmin, S; Hojeberg, B				Holmin, S; Hojeberg, B			In situ detection of intracerebral cytokine expression after human brain contusion	NEUROSCIENCE LETTERS			English	Article						brain injury; cytokine; human; inflammation; trauma	TUMOR-NECROSIS-FACTOR; SEVERE HEAD-INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; RAT-BRAIN; CEREBROSPINAL-FLUID; INTERLEUKIN-1; BARRIER; MECHANISMS; INCREASE; TRAUMA	The study was undertaken to analyze intracerebral expression of pro- and anti-inflammatory cytokines after traumatic brain injury (TBI) in man in order to compare the findings with previous experimental data regarding the pathogenesis of secondary brain injury. Contused brain tissue biopsies were obtained from 12 consecutive patients undergoing surgery for brain contusions 3 h to 5 days after trauma. Cytokine expression was analyzed by in situ hybridization and immunohistochemistry. In patients undergoing surgery less than 24 h after trauma, strong expression of both the pro-inflammatory cytokines interleukin (IL)-1-beta, IL-6 and interferon (IFN)-gamma and the anti-inflammatory cytokine IL-4 was detected. In patients undergoing surgery between 3 and 5 days after trauma, IL-4 expression was significantly lower (P < 0.05) compared to the patients operated early. IL-1-beta and IFN-gamma expression remained strong in comparison to IL-6 and IL-4 expression (P < 0.05). Immunohistochemistry for IL-1-beta confirmed that the protein was produced with a temporal and regional pattern that corresponded to in situ hybridization results. The study provides in situ data on intracerebral cytokine expression after contusion in the clinical setting. Strong intracerebral cytokine expression occurs in the perilesional zone both in the early and the delayed phase after traumatic brain injury in humans. The temporal regulation of pro- and anti-inflammatory cytokines differs which reveals different therapeutic windows for pharmacological intervention. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Karolinska Univ Hosp Solna, Neurosurg Sect, Dept Clin Neurosci, Karolinska Inst, S-17176 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Neurol Sect, Dept Clin Neurosci, Stockholm, Sweden	Holmin, S (corresponding author), Karolinska Univ Hosp Solna, Neurosurg Sect, Dept Clin Neurosci, Karolinska Inst, S-17176 Stockholm, Sweden.	staffan.holmin@kus.se		Holmin, Staffan/0000-0002-1628-1615			Allan SM, 2000, P NATL ACAD SCI USA, V97, P5580, DOI 10.1073/pnas.090464197; Allan SM, 2000, ANN NY ACAD SCI, V917, P84; Barone FC, 2000, EXPERT OPIN INV DRUG, V9, P2281, DOI 10.1517/13543784.9.10.2281; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BULLOCK R, 1989, P 7 INT S INTR PRESS, P637; Campbell IL, 1998, ANN NY ACAD SCI, V840, P83, DOI 10.1111/j.1749-6632.1998.tb09552.x; CLAUDIO L, 1994, LAB INVEST, V70, P850; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Falcone M, 1998, J IMMUNOL, V160, P4822; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GORDON CR, 1990, ACT NEUR S, V51, P268; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Holmin, 1996, ACTA NEUROCHIR, V138, P418, DOI 10.1007/BF01420304; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MCLAURIN RL, 1965, J NEUROSURG, V23, P296, DOI 10.3171/jns.1965.23.3.0296; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; OLSSON T, 1995, IMMUNOL REV, V144, P245, DOI 10.1111/j.1600-065X.1995.tb00072.x; Patel HC, 2003, ANN NY ACAD SCI, V992, P39, DOI 10.1111/j.1749-6632.2003.tb03136.x; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	40	60	62	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 14	2004	369	2					108	114		10.1016/j.neulet.2004.07.044			7	Neurosciences	Neurosciences & Neurology	861SE	WOS:000224438100005	15450678				2021-06-18	
J	Boake, C; McCauley, SR; Levin, HS; Contant, CE; Song, JX; Brown, SA; Goodman, HS; Brundage, SI; Diaz-Marchan, PJ; Merritt, SG				Boake, C; McCauley, SR; Levin, HS; Contant, CE; Song, JX; Brown, SA; Goodman, HS; Brundage, SI; Diaz-Marchan, PJ; Merritt, SG			Limited agreement between criteria-based diagnoses of postconcussional syndrome	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD-INJURY; DISORDER; CONSCIOUSNESS; DEPRESSION; SCALE	The objectives of this study were to compare diagnoses of postconcussional syndrome between the International Classification of Diseases, 10th revision (ICD-10) and Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). The patient sample was comprised of 178 adults with mild-moderate traumatic brain injury (TBI). The study design was inception cohort, and the main outcome measure was a structured interview 3 months after injury. The results were that, despite concordance of DSM-IV and ICD-10 symptom criteria (kappa = 0.73), agreement between overall DAM-IV and ICD-10 diagnoses was slight (kappa = 0.13) because fewer patients met the DSM-IV cognitive deficit and clinical significance criteria. Agreement between DSM-IV postconcussional disorder and ICD-10 postconcussional syndrome appears limited by different prevalences and thresholds.	Univ Texas, Baylor Coll Med, Sch Med, Dept Phys Med & Rehabil, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA	Boake, C (corresponding author), TIRR, 133 Moursund, Houston, TX 77030 USA.	corwin.boake@uth.tmc.edu			ODCDC CDC HHS [R49/CCR612707-01] Funding Source: Medline		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson SD, 1996, B AM ACAD PSYCH LAW, V24, P493; BROWN S, 1994, DSM 4 SOURCEBOOK, V1, P319; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; First M.B., 1998, STRUCTURED CLIN INTE; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus Jess F., 1994, P3; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; McAllister Thomas W., 1994, P357; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; NEWCOMBE F, 1982, INJURY, V14, P111, DOI 10.1016/0020-1383(82)90046-8; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SAS Institute, 1999, SAS SYST WIND REL 8; Smith A., 1973, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; TEASDALE G, 1974, LANCET, V2, P81; World Health Organization, 1992, ICD 10 CLASS MENT BE; World Health Organization (WHO), 1978, MENT DIS GLOSS GUID	27	60	61	0	1	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2004	16	4					493	499		10.1176/appi.neuropsych.16.4.493			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	881VN	WOS:000225897600013	15616177				2021-06-18	
J	Ehrlich, PF; Seidman, PS; Atallah, O; Haque, A; Helmkamp, J				Ehrlich, PF; Seidman, PS; Atallah, O; Haque, A; Helmkamp, J			Endotracheal intubations in rural pediatric trauma patients	JOURNAL OF PEDIATRIC SURGERY			English	Article						endotracheal intubation; prehospital intubation; pediatric trauma	ADVANCED LIFE-SUPPORT; PREHOSPITAL CARE; CHILDREN; EPIDEMIOLOGY; STATE; SYSTEM; INJURY; SCOOP; TRIAL; DEATH	Background/Purpose: Evidence from urban trauma centers questions the efficacy of pediatric field endotracheal intubations (ETIs). It is recognized that in the rural environment, discovery, transport delays, and a paucity of pediatric expertise contribute to higher pediatric trauma mortality rates compared with urban environments. The purpose of our study was to determine the effectiveness of field ETI in rural pediatric trauma patients. Methods: ETI attempts (field, referring hospital, trauma center [TC]) in trauma patients less than 19 years old were included. Prehospital and TC charts, including demographics, injury mechanism, indication, location, person performing, number of attempts, Glascow Coma Scale (GCS), complications from ETI, and outcome, were assessed. losing airway control (37%), closed head injury (36.1%), respiratory rate less than 10 or greater than 40 (11.2%), cardiopulmonary arrest (6.5%), respiratory arrest (4.6%), and airway obstruction 4.6%. Only 9.3% of children could not be oxygenated or ventilated by bag valve mask (BVM) before ETI. Twenty-three percent had complications directly related to ETI leg, aspiration). The relative risk of an airway complication was 2.5x higher with more then one ETI attempt (P<.05). Four percent of the airway complications occurred in TC, 29% (transferring hospital) and 66% (field, P<.05), respectively. Airway complications and multiple ETIs were associated with transport delay, lower GCS, longer hospital stay, and lower discharge GCS (P<.001) but independent of injury severity score, sex, age, and survival (P>.05). Results: Between 1991 and 2000, 105 of 2,907 patients met study criteria. Paramedics, trauma flight nurses (field ETIs), emergency physicians, surgeons, and anesthesiologists performed the ETI. One hundred fiftyfive ETIs (1 to 6 per patient) were attempted in 105 children. Fifty-seven percent of the ETIs were attempted in the field, 22% in transferring hospital, and 21% at the TC. Successful intubation on first attempt was 67% (field), 69% (referring hospital), and 95% (TC). Subsequent ETI attempts had failure rates of 50% (field) and 0% (referring hospital, TC). Indication for ETI included fear of. Conclusions: Multiple ETI attempts are associated with significant complications and may offer limited advantage over BVM and possibly may affect outcome. Indications for field intubations may require review especially in rural pediatric trauma. (C) 2004 Elsevier Inc. All rights reserved.	W Virginia Univ, Sch Med, Dept Pediat Surg, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Dept Anesthesia, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Ctr Rural Emergency Med, Morgantown, WV 26506 USA	Ehrlich, PF (corresponding author), Univ Michigan, CS Mott Childrens Hosp, F-3970,1500 E Med Ctr Dr,POB 0245, Ann Arbor, MI 48109 USA.						*AM COLL RHEUM, 1998, RHEUM PRINC CAR PHYS, P1; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP S; CAYTEN CG, 1993, J TRAUMA, V35, P460, DOI 10.1097/00005373-199309000-00021; Cooper A, 2001, Semin Pediatr Surg, V10, P3, DOI 10.1053/spsu.2001.19379; DAVIS DP, 2002, ANN M AM ASS SURG TR, V61, P104; Demetriades D, 1996, ARCH SURG-CHICAGO, V131, P133; Ehrlich P F, 2002, W V Med J, V98, P66; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Glaeser P, 2000, JAMA-J AM MED ASSOC, V283, P797, DOI 10.1001/jama.283.6.797; GOLD CR, 1987, ANN EMERG MED, V16, P797, DOI 10.1016/S0196-0644(87)80578-4; Grossman DC, 1997, J TRAUMA, V42, P723, DOI 10.1097/00005373-199704000-00024; GROSSMAN DC, 1995, J TRAUMA, V38, P14, DOI 10.1097/00005373-199501000-00006; Hapgood R, 2001, Inj Prev, V7, P14, DOI 10.1136/ip.7.1.14; Hoyt DB, 2003, ANN SURG, V237, P161, DOI 10.1097/00000658-200302000-00002; Hulka F, 1997, J TRAUMA, V42, P514, DOI 10.1097/00005373-199703000-00020; Institute of Medicine (U.S.) . Committee on Pediatric Emergency Medical Services, 1993, EM MED SERV CHILDR; KATZ SH, 1998, ACAD EMERG MED, V5, P429; KRAUSZ MM, 1992, J TRAUMA, V33, P6, DOI 10.1097/00005373-199207000-00002; Liberman M, 2003, ANN SURG, V237, P153, DOI 10.1097/00000658-200302000-00001; LOSEK J D, 1989, Pediatric Emergency Care, V5, P1, DOI 10.1097/00006565-198903000-00001; MATTOX KL, 1986, J TRAUMA, V26, P779, DOI 10.1097/00005373-198609000-00002; NAKAYAMA D, 1992, ANN SURG, V216, P201; NAKAYAMA DK, 1990, ANN SURG, V211, P218, DOI 10.1097/00000658-199002000-00015; Parada MA, 2001, ACCIDENT ANAL PREV, V33, P139, DOI 10.1016/S0001-4575(00)00012-9; POTTER D, 1988, ANN EMERG MED, V17, P582, DOI 10.1016/S0196-0644(88)80397-4; RASHKIN MC, 1986, CHEST, V89, P165, DOI 10.1378/chest.89.2.165; RODGERS FB, 1999, J TRAUMA, V47, P802; Rogers FB, 2001, J TRAUMA, V50, P409, DOI 10.1097/00005373-200103000-00003; Sampalis JS, 1997, J TRAUMA, V43, P608, DOI 10.1097/00005373-199710000-00008; SANAKARAN K, 1985, ANN ROYAL COLL PHYS, V18, P135; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Smith GA, 1997, ANN EMERG MED, V29, P504, DOI 10.1016/S0196-0644(97)70224-5; STEWART RD, 1984, ANN EMERG MED, V13, P1032, DOI 10.1016/S0196-0644(84)80064-5; STRATTON SJ, 1991, ANN EMERG MED, V20, P1314, DOI 10.1016/S0196-0644(05)81073-X; Svenson JE, 1996, ANN EMERG MED, V27, P625, DOI 10.1016/S0196-0644(96)70167-1; Svenson JE, 1996, PEDIATR EMERG CARE, V12, P173, DOI 10.1097/00006565-199606000-00007; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28; VANE DW, 1995, J TRAUMA, V38, P867, DOI 10.1097/00005373-199506000-00006; VANE DW, 1993, J PEDIATR SURG, V28, P1295, DOI 10.1016/S0022-3468(05)80316-1	39	60	62	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	SEP	2004	39	9					1376	1380		10.1016/j.jpedsurg.2004.05.010			5	Pediatrics; Surgery	Pediatrics; Surgery	855HF	WOS:000223963300013	15359393				2021-06-18	
J	Brewer-Smyth, K; Burgess, AW; Shults, J				Brewer-Smyth, K; Burgess, AW; Shults, J			Physical and sexual abuse, salivary cortisol, and neurologic correlates of violent criminal behavior in female prison inmates	BIOLOGICAL PSYCHIATRY			English	Article; Proceedings Paper	2002 State of the Science Meeting	SEP 26-28, 2002	WASHINGTON, D.C.	Amer Assoc Coll Nursing, Natl Inst Nursing Res		violent female prison inmates; traumatic brain injury; neuroendocrine; childhood abuse; suicide attempts; limbic system	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; INCARCERATED WOMEN; CHILDHOOD ABUSE; DEVELOPMENTAL TRAUMATOLOGY; PSYCHIATRIC-DISORDERS; AGGRESSIVE-BEHAVIOR; MENTAL-ILLNESS; BATTERED WOMEN; UNITED-STATES	Background: Both physical and emotional traumas have been related to neurologic and neuroendocrine abnormalities that may be associated with violent behavior. Methods: A modified case-control design was used for blinded comparison of 113 female inmates convicted of violent and nonviolent crimes. History of having been physically or sexually abused, neurologic history and physical examination, basal salivary cortisol levels, and associated variables were investigated to identify possible risk factors for violent compared to nonviolent criminal convictions. Results: Of all inmates studied, 95% had neurologic histories predating the current crime and/or neurologic examination abnormalities. Logistic regression revealed morning cortisol levels, number of years since last abuse, number of prior suicide attempts, and traumatic brain injuries with loss of consciousness to be significantly associated with current violent convictions, with a mean of two brain injuries with loss of consciousness per subject in the violent group. Conclusions: A greater number of traumatic brain injuries with loss of consciousness and suicide attempts, more recent abuse, and low morning basal salivary cortisol levels could be associated with dangerous violent criminal behavior, including murder, in female prison inmates. Future research should investigate neuroendocrine challenges, more psychiatric and violence measures, and different populations with longitudinal designs. (C) 2004 Society of Biological Psychiatry.	Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	Brewer-Smyth, K (corresponding author), Univ Delaware, Coll Hlth & Nursing Sci, 313 McDowell Hall, Newark, DE 19716 USA.				NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32 NR07036] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR007036] Funding Source: NIH RePORTER		ADNA RF, 1999, JAMA-J AM MED ASSOC, V282, P1652; BATES B, 1995, GUIDE PHYSICAL EXAMI; Beck A. T., 1996, BECK DEPRESSION INVE; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; BREWERSMYTH K, 2001, THESIS UMI ANN ARBOR; Browne A, 1999, INT J LAW PSYCHIAT, V22, P301, DOI 10.1016/S0160-2527(99)00011-4; BURGESS AW, 1987, AM J PSYCHIAT, V144, P1431; BUYDENSBRANCHEY L, 1992, PSYCHONEUROENDOCRINO, V17, P45, DOI 10.1016/0306-4530(92)90075-I; Centers for Disease Control and Prevention, 1999, BRAIN INJ US REP C; Clerici M, 2000, ANN NY ACAD SCI, V917, P956; Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591; De Bellis MD, 1999, BIOL PSYCHIAT, V45, P1259, DOI 10.1016/S0006-3223(99)00044-X; De Bellis MD, 2001, DEV PSYCHOPATHOL, V13, P539, DOI 10.1017/S0954579401003078; DEBELLIS MD, 1999, BIOL PSYCHIAT, V45, P1235; Dube SR, 2001, JAMA-J AM MED ASSOC, V286, P3089, DOI 10.1001/jama.286.24.3089; FISHBEIN DH, 1990, CRIMINOLOGY, V28, P27, DOI 10.1111/j.1745-9125.1990.tb01317.x; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLDIER J, 1998, DEV PSYCHOPATHOL, V10, P857; Gur RC, 2002, CEREB CORTEX, V12, P998, DOI 10.1093/cercor/12.9.998; Halasz J, 2002, NEUROREPORT, V13, P1267; Hegel MT, 2000, BEHAV MODIF, V24, P94, DOI 10.1177/0145445500241005; Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; Heim Christine, 2002, Semin Clin Neuropsychiatry, V7, P147, DOI 10.1053/scnp.2002.33127; Hennekens CH, 1987, EPIDEMIOLOGY MED; Herzog AG, 2001, ARCH GEN PSYCHIAT, V58, P513, DOI 10.1001/archpsyc.58.5.513; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; Jacobs AR, 1999, BIOL PSYCHIAT, V46, P856, DOI 10.1016/S0006-3223(99)00081-5; Jordan BK, 1996, ARCH GEN PSYCHIAT, V53, P513; Kalin NH, 1999, J CLIN PSYCHIAT, V60, P29; Kendall-Tackett KA, 2000, CHILD ABUSE NEGLECT, V24, P799, DOI 10.1016/S0145-2134(00)00136-8; King JA, 2001, PSYCHIAT CLIN NEUROS, V55, P71, DOI 10.1046/j.1440-1819.2001.00787.x; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; KIRSCHBAUM C, 1992, LIFE SCI, V50, P435, DOI 10.1016/0024-3205(92)90378-3; Krakowski M, 1988, NEUROPSY NEUROPSY BE, V1, P21; Krishnan KR, 1999, J CLIN PSYCHIAT, V60, P50; LEWIS DO, 1979, J AM ACAD CHILD PSY, V18, P307, DOI 10.1016/S0002-7138(09)61045-1; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; McBurnett K, 2000, ARCH GEN PSYCHIAT, V57, P38, DOI 10.1001/archpsyc.57.1.38; MCEWEN B, 1988, NEW ENGL J MED, V238, P171; Meyer IH, 1996, CHILD ABUSE NEGLECT, V20, P213, DOI 10.1016/S0145-2134(95)00137-9; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; MUENZENMAIER K, 1993, HOSP COMMUNITY PSYCH, V44, P666; NETTER FH, 1972, CIBA COLLECTION MED, V1; New AS, 2002, ARCH GEN PSYCHIAT, V59, P621, DOI 10.1001/archpsyc.59.7.621; *NIH, 1996, PROT HUM SUBJ 46; O'Keefe M, 1998, J TRAUMA STRESS, V11, P71, DOI 10.1023/A:1024457116085; Pajer K, 2001, ARCH GEN PSYCHIAT, V58, P297, DOI 10.1001/archpsyc.58.3.297; Pastore AL, 2000, SOURCEBOOK CRIMINAL; PINCUS JH, 1991, SEMIN NEUROL, V11, P146, DOI 10.1055/s-2008-1041216; Rasmussen K, 2001, J AM ACAD PSYCHIATRY, V29, P186; REEVES AG, 1969, ARCH NEUROL-CHICAGO, V20, P616, DOI 10.1001/archneur.1969.00480120062005; RESNICK HS, 1995, AM J PSYCHIAT, V152, P1675; Schwartz EB, 1998, CHILD DEV, V69, P1503, DOI 10.1111/j.1467-8624.1998.tb06173.x; *SPSS, 1997, SPSS PROF STAT 10 0; *STAT, 1999, STAT STAT SOFTW REL; Steer RA, 1997, PSYCHOL REP, V80, P443, DOI 10.2466/pr0.1997.80.2.443; STEIN M, 1996, SOC BIOL PSYCHIAT, V42, P680; Teplin LA, 1996, ARCH GEN PSYCHIAT, V53, P505; Treiman D M, 1991, Adv Neurol, V55, P341; *US DEP JUST BUR J, 1994, NCJ145321; *US DEP JUST FED B, 1998, PROF FEM OFF; VOLAVKA J, 1995, NEUROBIOLOGY VIOLENC; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; Weiss EL, 1999, AM J PSYCHIAT, V156, P816, DOI 10.1176/ajp.156.6.816; WIDOM CS, 1989, PSYCHOL BULL, V106, P3, DOI 10.1037/0033-2909.106.1.3; WIDOM CS, 1989, SCIENCE, V244, P160, DOI 10.1126/science.2704995; Yehuda R, 1999, J CLIN PSYCHIAT, V60, P33; Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006; Zlotnick C, 1997, J NERV MENT DIS, V185, P761, DOI 10.1097/00005053-199712000-00007	75	60	60	2	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	JAN 1	2004	55	1					21	31		10.1016/S0006-3223(03)00705-4			11	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	759NH	WOS:000187743400003	14706421				2021-06-18	
J	Currier, BL; Todd, LT; Maus, TP; Fisher, DR; Yaszemski, MJ				Currier, BL; Todd, LT; Maus, TP; Fisher, DR; Yaszemski, MJ			Anatomic relationship of the internal carotid artery to the C1 vertebra: A case report of cervical reconstruction for chordoma and pilot study to assess the risk of screw fixation of the atlas	SPINE			English	Article; Proceedings Paper	Meeting of the European Section of the Cervical-Spine-Research-Society	JUN, 2002	PARIS, FRANCE	Cerv Spine Res Soc, European Sect		internal carotid artery injury; atlantoaxial transarticular screws; C1 lateral mass screws; atlantoaxial fusion; preoperative computed tomography	ATLANTOAXIAL ARTHRODESIS; TRANSARTICULAR SCREWS; C1-C2 FUSION; SPINE; PLACEMENT; ACCURACY; INJURY	Study Design. A case of internal carotid artery impingement by the tip of a well- positioned C1 - C2 transarticular screw is presented along with a pilot study involving radiologic and anatomic evaluation of human cadaveric specimens. Objective. To raise awareness that the internal carotid artery may be in close proximity to the anterior aspect of the atlas and at risk of injury during placement of C1 - C2 transarticular screws or C1 lateral mass screws. Summary of Background Data. To our knowledge, no cases of internal carotid artery injury or impingement have been reported with screw fixation of the atlas. Methods. A case of internal carotid artery impingement by a C1 - C2 transarticular screw is presented. The C1 - C2 rotation appeared to place the internal carotid artery in the path of the screw, prompting a pilot study. Three fresh- frozen human cadaveric head and neck specimens were fixed in different degrees of rotation. Thinsection computed tomography of the specimens was obtained in the plane of the atlas. The frozen specimens were sectioned in the same plane as the computed tomography images. Measurements were taken to assess the location of the internal carotid artery relative to the anterior aspect of the atlas. Results. Cervical rotation does not have a predictable effect on the location of the internal carotid artery. Medial angulation of a screw placed in the lateral mass of C1 appears to increase the margin of safety for the internal carotid artery. The internal carotid artery varies in location and may be within 1 mm of the ideal exit point of a bicortical transarticular screw or a C1 lateral mass screw. Conclusions. The internal carotid artery is at risk during bicortical screw fixation of the atlas. We recommend a contrast- enhanced computed tomography to assess the location of the internal carotid artery before screw fixation of the atlas.	Mayo Clin & Mayo Fdn, Dept Orthoped Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Radiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Anat, Rochester, MN 55905 USA	Currier, BL (corresponding author), Mayo Clin & Mayo Fdn, Dept Orthoped Surg, 200 1st St SW, Rochester, MN 55905 USA.						ABOU MA, 1997, J BONE JOINT SURG BR, V79, P820; Apfelbaum Ronald I., 1994, Contemporary Neurosurgery, V16, P1; Bloch O, 2001, J NEUROSURG, V95, P74, DOI 10.3171/spi.2001.95.1.0074; Casey ATH, 1997, BRIT J NEUROSURG, V11, P508; CHRISTENSEN DM, 2000, 28 ANN M CERV SPIN R; Coric D, 1996, J NEUROSURG, V85, P340, DOI 10.3171/jns.1996.85.2.0340; DICKMAN CA, 1995, J NEUROSURG, V83, P248, DOI 10.3171/jns.1995.83.2.0248; Dickman CA, 1998, NEUROSURGERY, V43, P275, DOI 10.1097/00006123-199808000-00056; DULL ST, 1995, NEUROSURGERY, V37, P150, DOI 10.1227/00006123-199507000-00026; Ebraheim NA, 2000, SURG NEUROL, V53, P208, DOI 10.1016/S0090-3019(00)00160-9; Eleraky MA, 1998, J NEUROSURG, V89, P8, DOI 10.3171/jns.1998.89.1.0008; Farey ID, 1999, CLIN ORTHOP RELAT R, P126, DOI 10.1097/00003086-199902000-00013; Gebhard JS, 1998, SPINE, V23, P2185, DOI 10.1097/00007632-199810150-00008; Goel A, 1999, J NEUROSURG, V90, P376; Grant JCB, 1972, GRANTS ATLAS ANATOMY; GROB D, 1992, SPINE, V17, P480, DOI 10.1097/00007632-199205000-00003; GROB D, 1991, J BONE JOINT SURG BR, V73, P972; Haid RW, 2001, NEUROSURGERY, V49, P65, DOI 10.1097/00006123-200107000-00010; Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014; Henriques T, 2000, SPINE, V25, P2877, DOI 10.1097/00007632-200011150-00007; JEANNERET B, 1992, J SPINAL DISORD, V5, P464, DOI 10.1097/00002517-199212000-00012; Jun BY, 1998, SPINE, V23, P1703, DOI 10.1097/00007632-199808010-00018; Kawaguchi Yoshiharu, 2002, J Orthop Sci, V7, P131, DOI 10.1007/s776-002-8434-y; Kazan S, 2000, CLIN ANAT, V13, P237, DOI 10.1002/1098-2353(2000)13:4<237::AID-CA2>3.0.CO;2-K; Madawi AA, 1997, J NEUROSURG, V86, P961, DOI 10.3171/jns.1997.86.6.0961; Magerl F., 1985, CERVICAL SPINE, P322; Mandel IM, 2000, SPINE, V25, P1542, DOI 10.1097/00007632-200006150-00014; McGraw R W, 1973, J Bone Joint Surg Br, V55, P482; Mitchell TC, 1999, J ORTHOP TRAUMA, V13, P483, DOI 10.1097/00005131-199909000-00004; Naderi S, 1998, SPINE, V23, P1946, DOI 10.1097/00007632-199809150-00005; Nishimura K, 1996, AM J ROENTGENOL, V166, P219, DOI 10.2214/ajr.166.1.8571894; OSGUTHORPE JD, 1981, OTOLARYNG HEAD NECK, V89, P758, DOI 10.1177/019459988108900513; Paramore CG, 1996, J NEUROSURG, V85, P221, DOI 10.3171/jns.1996.85.2.0221; PICCIARDELLI E, 1989, ARCH OTOLARYNGOL, V115, P519; Prabhu VC, 2001, SURG NEUROL, V55, P29, DOI 10.1016/S0090-3019(00)00338-4; SASSO RC, 1994, SPINE, V19, P2364, DOI 10.1097/00007632-199410150-00021; Song GS, 1997, J NEUROSURG, V87, P851, DOI 10.3171/jns.1997.87.6.0851; Welch WC, 1997, NEUROSURGERY, V40, P958, DOI 10.1097/00006123-199705000-00016; Wright NM, 1998, J NEUROSURG, V88, P634, DOI 10.3171/jns.1998.88.4.0634	39	60	67	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	NOV 15	2003	28	22					E461	E467		10.1097/01.BRS.0000092385.19307.9E			7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	744QD	WOS:000186642800013	14624095				2021-06-18	
J	Erten, SF; Kocak, A; Ozdemir, I; Aydemir, S; Colak, A; Reeder, BS				Erten, SF; Kocak, A; Ozdemir, I; Aydemir, S; Colak, A; Reeder, BS			Protective effect of melatonin on experimental spinal cord ischemia	SPINAL CORD			English	Article						catalase; glutathione peroxidase; lipid peroxidation; melatonin; superoxide dismutase; spinal cord ischemia	IMPROVES NEUROLOGIC RECOVERY; CENTRAL-NERVOUS-SYSTEM; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; REPERFUSION INJURY; TRAUMATIC BRAIN; THORACIC AORTA; DOSE-RESPONSE; BLOOD-FLOW; MECHANISMS	Study design: Experimental animal model to assess ischemic spinal cord injury following occlusion of the thoraco-abdominal aorta. Objectives: To measure whether melatonin administered to rabbits before and after occlusion exerts an effect on the repair of ischemia-reperfusion (IR) injury. Setting: Medical Biology Laboratory, Inonu University, Malatya, Turkey. Methods: Rabbits were divided into three IR treatment groups and one sham-operated (ShOp) control group. The three treatment groups had their infrarenal aorta temporarily occluded for 25 min, while the ShOp group had laparotomy without aortic occlusion. Melatonin was administered either 10 min before aortic occlusion or 10 min after the clamp was removed. Physiologic saline was administered to the control animals. After treatment, the animals were euthanized and lumbosacral spinal cord tissue was removed for the determination of relevant enzyme activities. Results: Malondialdehyde levels, indicating the extent of lipid peroxidation, were found to be significantly increased in the nonmelatonin treated (IR) group when compared to the ShOp group. Melatonin, whether given to pre- or post occlusion groups, suppressed malondialdehyde levels below that of the ShOp group. Catalase (CAT) and glutathione peroxidase (GSH-Px) enzyme activities were increased in the IR group compared to the ShOp group. Melatonin given preocclusion resulted in a significant decrease in both CAT and GSH-Px enzyme levels. The superoxide dismutase ( SOD) enzyme activity was decreased in the ischemia-reperfusion treatment group. However, the melatonin treatment increased SOD enzyme activity to levels approximating that of the ShOp group. Conclusion: To our knowledge, this is the first study that shows the effects of melatonin administered both pre- and postischemia on induced oxidative damage to injured spinal cords. Our data also expands on reports that melatonin administration may significantly reduce the incidence of spinal cord injury following temporary aortic occlusion.	Stanford Univ, Fac Med, Dept Radiat Oncol, Div Radiat & Canc Biol, Stanford, CA 94305 USA; Inonu Univ, Fac Med, Dept Neurosurg, Malatya, Turkey; Inonu Univ, Fac Sci, Dept Biochem, Malatya, Turkey; Inonu Univ, Fac Sci, Dept Mol Biol, Malatya, Turkey; Taksim First Aid Hosp, Dept Neurosurg, Istanbul, Turkey; Inonu Univ, Fac Med, Dept Med Biol & Genet, Malatya, Turkey	Reeder, BS (corresponding author), Stanford Univ, Fac Med, Dept Radiat Oncol, Div Radiat & Canc Biol, CCSR S 269 Campus Dr,Room 1255, Stanford, CA 94305 USA.		aydemir, songul/AAA-4291-2021	aydemir, songul/0000-0002-7921-0662			ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; CHEN LD, 1994, AM J PHYSIOL, V267, P57; CONNOLLY JE, 1986, J CARDIOVASC SURG, V27, P410; CRAWFORD ES, 1986, J VASC SURG, V3, P389, DOI 10.1067/mva.1986.avs0030389; CUEVAS P, 1990, ACTA ANAT, V137, P303; CUEVAS P, 1989, ANAT EMBRYOL, V179, P251, DOI 10.1007/BF00326590; DELABAUME S, 1981, NEUROSCIENCE, V6, P315, DOI 10.1016/0306-4522(81)90125-1; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Fujimoto T, 2000, SPINE, V25, P769, DOI 10.1097/00007632-200004010-00003; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; JOHNSON SH, 1993, STROKE, V24, P1547, DOI 10.1161/01.STR.24.10.1547; KASAI H, 1984, JPN J CANCER RES, V75, P841; KATIRCIOGLU SF, 1993, SURGERY, V114, P36; KAYNAR MY, 1988, TOKUSHIMA J EXP MED, V41, P133; KOCHHAR A, 1988, ARCH NEUROL-CHICAGO, V45, P148, DOI 10.1001/archneur.1988.00520260034016; Kouchoukos N T, 1993, Semin Thorac Cardiovasc Surg, V5, P47; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LIM KH, 1986, ANN THORAC SURG, V42, P282, DOI 10.1016/S0003-4975(10)62735-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luck H, 1963, METHOD ENZYMAT AN, P885; Marini C P, 1993, Adv Card Surg, V4, P89; Marshall KA, 1996, FREE RADICAL BIO MED, V21, P307, DOI 10.1016/0891-5849(96)00046-9; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1983, NEW ENGL J MED, V312, P59; NISHIBE M, 1989, Hokkaido Journal of Medical Science, V64, P301; OLDFIELD EH, 1982, J NEUROSURG, V56, P511, DOI 10.3171/jns.1982.56.4.0511; Reiter RJ, 2001, ANN NY ACAD SCI, V939, P200; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; SCOTT MD, 1991, J LAB CLIN MED, V118, P7; SLATER TF, 1984, BIOCHEM J, V222, P1; SVENSSON LG, 1986, ANN SURG, V204, P38, DOI 10.1097/00000658-198607000-00005; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; TAN DX, 1993, CANCER LETT, V70, P65, DOI 10.1016/0304-3835(93)90076-L; TAOKA Y, 1995, PARAPLEGIA, V33, P450, DOI 10.1038/sc.1995.98; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; VERDANT A, 1988, ANN THORAC SURG, V46, P147, DOI 10.1016/S0003-4975(10)65887-0; WALDEN LRB, 1995, NEUROCHEM INT, V26, P497; ZIVIN JA, 1980, STROKE, V11, P200, DOI 10.1161/01.STR.11.2.200	43	60	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393			SPINAL CORD	Spinal Cord	OCT	2003	41	10					533	538		10.1038/sj.sc.3101508			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	725GL	WOS:000185535400002	14504608	Bronze			2021-06-18	
J	Sohlberg, MM; Avery, J; Kennedy, M; Ylvisaker, M; Coelho, C; Turkstra, L; Yorkston, K				Sohlberg, MM; Avery, J; Kennedy, M; Ylvisaker, M; Coelho, C; Turkstra, L; Yorkston, K			Practice guidelines for direct attention training	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							DEFICITS; REHABILITATION; REMEDIATION	This article is part of a series of reports from a committee charged with developing evidence-based practice (EBP) guidelines for rehabilitation of cognitive-communication deficits following traumatic brain injury (TBI). We examine the literature for evidence of the effectiveness of direct attention training to treat attention impairments following TBI. Evidence is gleaned from the outcomes of nine Class I and Class II studies that span intervention from acute to outpatient rehabilitation. Results and discussion are organized using five key questions as a mechanism to review the research to determine if the approach, outcomes, and associated recommendations warrant a change in clinical practice. The key questions are: Who are the participants who received the intervention? What comprises the attention training? What are the outcomes of the intervention? Are there methodological concerns? Are there clinically applicable trends across different attention remediation studies? The complexities and difficulties inherent in implementing clinical trials with the heterogeneous TBI population are discussed. The article concludes with treatment guidelines and options supported by the research review. Future research needs are highlighted.	Univ Oregon, Eugene, OR 97403 USA; Univ Minnesota, Dept Commun Disorders, Minneapolis, MN 55455 USA; Coll St Rose, Dept Commun Disorders, Albany, NY USA; Univ Connecticut, Dept Commun Sci, Storrs, CT USA; Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	Sohlberg, MM (corresponding author), Univ Oregon, 5281, Eugene, OR 97403 USA.	mckay@oregon.uoregon.edu					Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; GODFREY HPD, 1985, J CONSULT CLIN PSYCH, V53, P555, DOI 10.1037/0022-006X.53.4.555; GOLPER LC, 2001, EVIDENCE BASED PRACT; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; KENNEDY MR, 2002, J MED SPEECH-LANG PA, V10, P9; KEWMAN DG, 1985, REHABIL PSYCHOL, V30, P11; Lucyshyn JM, 1997, J CONSULT CLIN PSYCH, V65, P241, DOI 10.1037/0022-006X.65.2.241; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; MOFFAT N, 1992, CLIN MANAGEMENT MEMO, P83; Montgomery EB, 2003, J MED SPEECH-LANG PA, V11, pIX; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; ROBEY R, 2001, ASHA SPECIAL INTERES, V11, P10; SimmonsMackie NN, 1996, DISABIL REHABIL, V18, P540, DOI 10.3109/09638289609166315; Sohlberg M. M., 2001, COGNITIVE REHABILITA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; STRACHE W, 1987, INT J REHABIL RES S5, V10, pS141; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; Ylvisaker M., 1998, COLLABORATIVE BRAIN	28	60	61	0	15	DELMAR CENGAGE LEARNING	FLORENCE	PO BOX 6904, FLORENCE, KY 41022-6904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	SEP	2003	11	3					XIX	XLII					21	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	722PH	WOS:000185384900003					2021-06-18	
J	Mayberry, JC; Welker, KJ; Goldman, RK; Mullins, RJ				Mayberry, JC; Welker, KJ; Goldman, RK; Mullins, RJ			Mechanism of acute ascites formation after trauma resuscitation	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	30th International Educational and Scientific Symposium of the Society-for-Critical-Care-Medicine	FEB 11-14, 2001	SAN FRANCISCO, CALIFORNIA	Soc Crit Care Med			ABDOMINAL COMPARTMENT SYNDROME; ISOLATED EXTRAPERITONEAL INJURIES; INTRAPERITONEAL PRESSURE; SECONDARY; PREVENTION; CATS	Background: Severely injured patients have been observed to acutely develop ascites; however, the pathogenesis of this rare phenomenon is poorly understood. Objectives: To report the factors common among severely injured patients developing ascites and to formulate a hypothesis regarding its origin. Methods: Retrospective review of case series Results: We identified 9 injured patients between January 1, 1993, and December 31, 1998, who acutely developed significant amounts of ascites. The mean+/-SD estimated ascites volume was 2.0+/-0.8 L. All 9 patients had severe shock and were mechanically ventilated before abdominal decompression for the abdominal compartment syndrome. The mean+/-SD peak inspiratory pressure was 39.0+/-5.8 cm H2O. The mean+/-SD volumes of crystalloid and blood product infusion before decompression were 16.1+/-10.2 L and 5.2+/-4.8 L, respectively, in a mean+/-SD of 17+/-15 hours. In comparison, the mean+/-SD volumes of crystalloid and blood product trans-fusion among 100 contemporary, randomly selected patients undergoing trauma laparotomy were 5.1+/-5.5 L and 1.1+/-2.5 L, respectively (P<.001). Eight patients had only extra-abdominal injuries, while 1 patient had a combination of extra- and intra-abdominal injuries. Two patients were found to be cirrhotic by liver biopsy, but the other 7 patients had no known preexisting hepatic disease. Eight patients had absorbable mesh temporary abdominal closure, and 1 patient had primary fascial closure. There was persistent ascitic drainage in 5 patients; however, in all but 1 patient with cirrhosis, the drainage did not persist beyond 3 days. Two patients died, 1 of sepsis and the other of a closed head injury. Conclusions: Common denominators of posttraumatic ascites include shock, massive fluid resuscitation, and elevated intrathoracic pressure. The rapid onset of ascites in the setting of elevated intrathoracic pressure suggests that the patient's ability to clear ascitic fluid is overwhelmed.	Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97239 USA	Mayberry, JC (corresponding author), Oregon Hlth Sci Univ, Dept Surg, 3181 SW Sam Jackson Pk Rd,Mail Stop L223A, Portland, OR 97239 USA.			Mayberry, John/0000-0001-6978-9079			ADAIR T, 1982, LYMPHATIC IMAGING LY, V1; Biffl WL, 2001, AM J SURG, V182, P645, DOI 10.1016/S0002-9610(01)00814-5; BORLASE BC, 1990, J TRAUMA, V30, P1340, DOI 10.1097/00005373-199011000-00006; ELDOR J, 1991, RESUSCITATION, V21, P289, DOI 10.1016/0300-9572(91)90054-3; Garcia-Tsao G, 1995, Gastroenterologist, V3, P41; Hirvela E, 2000, J TRAUMA, V49, P747; Kopelman T, 2000, J TRAUMA, V49, P744, DOI 10.1097/00005373-200010000-00025; Latenser BA, 2002, J BURN CARE REHABIL, V23, P190, DOI 10.1097/00004630-200205000-00008; Lucas CE, 2001, J AM COLL SURGEONS, V192, P86, DOI 10.1016/S1072-7515(00)00761-4; Macalino Joel U, 2002, Asian J Surg, V25, P244, DOI 10.1016/S1015-9584(09)60184-6; Markert DJ, 1997, CLIN RADIOL, V52, P384, DOI 10.1016/S0009-9260(97)80135-3; Maxwell RA, 1999, J TRAUMA, V47, P995, DOI 10.1097/00005373-199912000-00001; Mayberry JC, 1999, LANCET, V354, P1749, DOI 10.1016/S0140-6736(99)00407-9; Mayberry JC, 1997, ARCH SURG-CHICAGO, V132, P957; Michielsen PP, 1996, ACTA GASTRO-ENT BELG, V59, P191; SCHILLING JA, 1952, J CLIN INVEST, V31, P602; VOLWILER W, 1950, GASTROENTEROLOGY, V14, P40, DOI 10.1016/S0016-5085(50)80111-7; ZARINS CK, 1978, CIRC RES, V43, P925, DOI 10.1161/01.RES.43.6.925; ZINK J, 1977, AM J PHYSIOL, V233, pH185; ZINK J, 1977, GASTROENTEROLOGY, V73, P1119	20	60	69	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	JUL	2003	138	7					773	776		10.1001/archsurg.138.7.773			4	Surgery	Surgery	697RH	WOS:000183956700020	12860760	Bronze			2021-06-18	
J	Chiaravalloti, ND; Christodoulou, C; Demaree, HA; DeLuca, J				Chiaravalloti, ND; Christodoulou, C; Demaree, HA; DeLuca, J			Differentiating simple versus complex processing speed: Influence on new learning and memory performance	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CHRONIC-FATIGUE-SYNDROME; CLOSED-HEAD-INJURY; TRAUMATIC BRAIN INJURY; SERIAL ADDITION TEST; MULTIPLE-SCLEROSIS; WORKING-MEMORY; RHEUMATOID-ARTHRITIS; CONSTRUCT-VALIDITY; REVISED CRITERIA; NORMAL EGYPTIANS	The current study was designed to examine how the construct of human information processing speed is conceptualized and measured, while also examining the influence of information processing speed on higher cognitive processes (i.e., learning). A mixed medical sample of 92 subjects participated in this study. Subjects underwent a broad-based neuropsychological evaluation, including measures of verbal and visuospatial new learning, spatial and verbal working memory, simple reaction time, choice reaction time, and information processing speed. Principal components factor analysis with varimax rotation resulted in a three-factor solution, comprised of: (1) simple speed/reaction time, (2) complex information processing and new learning, and (3) working memory. Notably, this factor solution identified 2 distinct forms of processing speed-simple and complex information processing speeds. In contrast to the abundance of literature grouping these two constructs together under one term (i.e., processing speed), these results indicate simple and complex speed to be distinct constructs assessed with different neuropsychological instruments. While the expected relationship between complex information processing capacities and working memory abilities was evident in this study, information processing speed also showed a significant relationship with new learning ability. The implications of this intriguing relationship are discussed.	Kessler Med Rehabil Res & Educ Corp, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA; Case Western Reserve Univ, Dept Psychol, Cleveland, OH 44106 USA	DeLuca, J (corresponding author), Kessler Med Rehabil Res & Educ Corp, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.			Demaree, Heath/0000-0001-9655-8882	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH052810] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH 52810-01A1] Funding Source: Medline		ANDERSON BO, 1989, SURGERY, V106, P347; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A. D., 1994, Neuropsychology, V8, P485, DOI [10.1037/0894-4105.8.4.485., 10.1037/0894-4105.8.4.485]; BAKER LA, 1991, BEHAV GENET, V21, P351, DOI 10.1007/BF01065972; BARBIZET J, 1968, INT J NEUROL, V7, P44; BARRETT P, 1986, INTELLIGENCE, V10, P9, DOI 10.1016/0160-2896(86)90025-5; BARTLE EJ, 1988, SURGERY, V104, P311; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Bryan J, 1996, PSYCHOL AGING, V11, P3, DOI 10.1037/0882-7974.11.1.3; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CHANNON S, 1993, PSYCHOL MED, V23, P87, DOI 10.1017/S0033291700038873; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P255, DOI 10.1080/713755575; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DELUCA J, 1993, ARCH NEUROL-CHICAGO, V50, P301, DOI 10.1001/archneur.1993.00540030065016; DELUCA J, 1995, J NEUROL NEUROSUR PS, V58, P38, DOI 10.1136/jnnp.58.1.38; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; Elwan O, 1996, J NEUROL SCI, V136, P73, DOI 10.1016/0022-510X(95)00292-A; Elwan O, 1997, J NEUROL SCI, V148, P79, DOI 10.1016/S0022-510X(96)05336-1; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GOLD AE, 1995, PSYCHOPHARMACOLOGY, V119, P325, DOI 10.1007/BF02246299; GOLD AE, 1995, PHYSIOL BEHAV, V58, P501, DOI 10.1016/0031-9384(95)00085-W; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502; Johnson SK, 1996, PERCEPT MOTOR SKILL, V83, P51, DOI 10.2466/pms.1996.83.1.51; Kail R, 1998, J CLIN EXP NEUROPSYC, V20, P98, DOI 10.1076/jcen.20.1.98.1483; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; Kessels RPC, 1998, ACTA NEUROL SCAND, V97, P188; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KLOVE H, 1987, J CLIN EXP NEUROPSYC, V9, P297, DOI 10.1080/01688638708402792; KRUPP LB, 1994, ARCH NEUROL-CHICAGO, V51, P705, DOI 10.1001/archneur.1994.00540190089021; LAIDLAW TM, 1993, INT J CLIN EXP HYP, V41, P97, DOI 10.1080/00207149308414541; LARRABEE GJ, 1995, J CLIN EXP NEUROPSYC, V17, P536, DOI 10.1080/01688639508405144; Levander MB, 1998, BRAIN INJURY, V12, P165, DOI 10.1080/026990598122791; LEVINE G, 1987, PERS INDIV DIFFER, V8, P599, DOI 10.1016/0191-8869(87)90057-2; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LITIVAN I, 1985, ARCH NEUROL-CHICAGO, V45, P281; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Marshall PS, 1997, PSYCHOSOM MED, V59, P58, DOI 10.1097/00006842-199701000-00008; Martin SE, 1996, AM J RESP CRIT CARE, V153, P1328, DOI 10.1164/ajrccm.153.4.8616562; Michiels V, 1996, J CLIN EXP NEUROPSYC, V18, P666, DOI 10.1080/01688639608408290; Michiels V, 1999, J CLIN EXP NEUROPSYC, V21, P709, DOI 10.1076/jcen.21.5.709.875; ODONNELL JP, 1994, J CLIN PSYCHOL, V50, P596, DOI 10.1002/1097-4679(199407)50:4<596::AID-JCLP2270500416>3.0.CO;2-S; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Prevey ML, 1998, EPILEPSY RES, V30, P1, DOI 10.1016/S0920-1211(97)00091-0; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; RASMUSSEN K, 1993, AM J IND MED, V24, P553, DOI 10.1002/ajim.4700240506; ROEDIGER HL, 1980, MEM COGNITION, V8, P231, DOI 10.3758/BF03197611; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; RUCHKIN DS, 1994, BRAIN, V117, P289, DOI 10.1093/brain/117.2.289; Salthouse T. A., 1985, THEORY COGNITIVE AGI; Salthouse T. A., 1993, J GERONTOL B-PSYCHOL, V48, P245; SALTHOUSE TA, 1994, J EXP PSYCHOL LEARN, V20, P1486, DOI 10.1037/0278-7393.20.6.1486; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; SLIWINSKI M, 1997, J GERONTOL B-PSYCHOL, V52, P308; STUSS D. T., 1988, CLIN NEUROPSYCHOL, V2, P246, DOI DOI 10.1080/13854048808520107; Thomas L, 1996, SEIZURE, V5, P205, DOI 10.1016/S1059-1311(96)80037-9; Thornton AE, 1997, NEUROPSYCHOLOGY, V11, P357, DOI 10.1037/0894-4105.11.3.357; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; TIERSKY LA, 1998, CLIN NEUROPSYCHOL, V12, P1; UZZELL BP, 1986, J CLIN EXP NEUROPSYC, V8, P581, DOI 10.1080/01688638608405177; Valley V, 1981, Rev Electroencephalogr Neurophysiol Clin, V11, P133, DOI 10.1016/S0370-4475(81)80044-5; Weersink EJM, 1997, AM J RESP CRIT CARE, V156, P1144, DOI 10.1164/ajrccm.156.4.9701001; Wiens AN, 1997, J CLIN EXP NEUROPSYC, V19, P473, DOI 10.1080/01688639708403737	69	60	60	2	9	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	2003	25	4					489	501		10.1076/jcen.25.4.489.13878			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	683GY	WOS:000183141300005	12911103				2021-06-18	
J	Kunz, T; Marklund, N; Hillered, L; Oliw, EH				Kunz, T; Marklund, N; Hillered, L; Oliw, EH			Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H-2 metabolism in traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical contusion injury; cyclopentenone prostaglandins; fluid percussion injury; nonenzymatic transformation; prostaglandin metabolism; TUNEL staining	ACTIVATED RECEPTOR-GAMMA; MOLECULAR-BIOLOGY; FEBRILE RESPONSE; CELL-DEATH; MICE; IDENTIFICATION; EXPRESSION; NEURONS; ACIDS; LEUKOTRIENES	Inflammatory mediators are important in traumatic brain injury (TBI). The objective of the present study was to investigate the expression of cyclooxygenase-2 (COX-2), prostaglandin E (PGE) and PGD synthases, and PGH(2) metabolism in two rat models of TBI. Fluid percussion injury (FPI) resulted in bilateral induction of COX-2 mRNA in the dentate gyri and the cortex, whereas controlled cortical contusion injury (CCC) induced COX-2 mRNA in the ipsilateral dentate gyrus and intensely in the cortex as judged by in situ hybridization. The induction subsided within 24 h. COX-2 immunoreactivity was detectable in these areas and persisted in the ipsilateral cortex for at least 72 h after CCC. Regions with COX-2 induction co-localized with TUNEL staining, suggesting a link between COX-2 expression and cell damage. COX-2 forms PGH(2), which can be isomerized to PGD(2), PGE(2), and PGF(2alpha) by enzymatic and non-enzymatic mechanisms. In situ hybridization showed that mRNA of PGD synthase and microsomal PGE synthase were present in the choroid plexus. The microsomal PGE synthase was induced bilaterally after FPI and unilaterally after CCC. Liquid chromatography-mass spectrometry showed that low speed supernatant of normal and traumatized cortex and hippocampus transformed PGH(2) to PGD(2) as main product. PGD(2) was dehydrated in brain homogenates to biological active compounds, for example, 15-deoxy-Delta(12,14)-PGJ(2). Thus COX-2 increases in certain neurons following TBI without neuronal induction of PGD and microsomal PGE synthases, suggesting that PGH(2) may decompose to PGD(2) and its dehydration products by nonenzymatic mechanisms or to PGD(2) by low constitutive levels of PGD synthase.	Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, SE-75124 Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosci Neurosurg, Uppsala, Sweden	Kunz, T (corresponding author), Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, POB 591, SE-75124 Uppsala, Sweden.	Tina.Kunz@farmbio.uu.se		Oliw, Ernst/0000-0002-7986-8130; Marklund, Niklas/0000-0002-9797-5626			ABDELHALIM MS, 1977, PROSTAGLANDINS, V14, P633, DOI 10.1016/0090-6980(77)90190-3; Andreasson KI, 2001, J NEUROSCI, V21, P8198; Bernoud-Hubac N, 2001, J BIOL CHEM, V276, P30964, DOI 10.1074/jbc.M103768200; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMBERG M, 1976, BIOCHIM BIOPHYS ACTA, V431, P189, DOI 10.1016/0005-2760(76)90273-3; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li LY, 2001, J BIOL CHEM, V276, P38152; Li S, 1999, BRAIN RES, V825, P86, DOI 10.1016/S0006-8993(99)01225-1; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Maxey KM, 2000, PROSTAG OTH LIPID M, V62, P15, DOI 10.1016/S0090-6980(00)00072-1; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Medhora M, 2001, TRENDS CARDIOVAS MED, V11, P38, DOI 10.1016/S1050-1738(01)00082-2; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Oliw EH, 2001, BIOCHEM PHARMACOL, V62, P407, DOI 10.1016/S0006-2952(01)00683-9; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PAXINOS G, 1996, RAT BRAIN STEREOTAXI; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; URADE Y, 1993, P NATL ACAD SCI USA, V90, P9070, DOI 10.1073/pnas.90.19.9070; Ushikubi F, 1998, NATURE, V395, P281; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001	48	60	62	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2002	19	9					1051	1064		10.1089/089771502760341965			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	598KW	WOS:000178275900006	12482118				2021-06-18	
J	Borgens, RB; Bohnert, D				Borgens, RB; Bohnert, D			Rapid recovery from spinal cord injury after subcutaneously administered polyethylene glycol	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						nerve sealing; neurotrauma; PEG; polyethylene glycol; spinal cord injury; spinal recovery	APPLIED ELECTRIC-FIELDS; METHYLPREDNISOLONE; RECONNECTION; HEMISECTION; MEMBRANES; AXONS	Arguably a seminal event in most trauma and disease is the breakdown of the cell membrane. In most cells, this is first observed as a collapse of the axolemmas barrier properties allowing a derangement of ions to occur, leading to a progressive dissolution of the cell or its process. We have shown that an artificial sealing of mechanically damaged membranes by topical application of hydrophilic polymers such as polyethylene glycol (PEG) immediately restores variable levels of nerve impulse conduction through the lesion. This was documented by a rapid recovery of somatosensory evoked potential (SSEP) conduction, and by recovery of the cutaneous trunchi muscle (CTM) reflex in PEG-treated animals. The CTM reflex is a sensorimotor behavior dependent on an intact (and identified) white matter tract within the ventrolateral funiculus of the spinal cord, and is thus an excellent index of white matter integrity. We show that PEG can be safely introduced into the bloodstream by several routes of administration. Using a fluorescein decorated PEG, we demonstrate that the polymer specifically targets the hemorrhagic contusion of the adult guinea pig spinal cord when administered through the vasculature, but not intact regions of the spinal cord. A single subcutaneous injection (30% weight by weight in sterile saline) made 6 hr after a standardized spinal cord contusion in adult guinea pigs was sufficient to produce a rapid recovery of SSEP propagation through the lesion in only PEG-treated animals, accompanied by a statistically significant recovery of the CTM reflex. These data suggest that parenterally administered PEG may be a novel treatment for not only spinal injury, but head injury and stroke as well. (C) 2001 Wiley-Liss, Inc.	Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Inst Appl Neurol, W Lafayette, IN 47907 USA	Borgens, RB (corresponding author), Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Inst Appl Neurol, 1244 VCPR, W Lafayette, IN 47907 USA.	cpr@vet.purdue.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 39288-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039288] Funding Source: NIH RePORTER		Alberstone CD, 1999, SPINE SURG TECHNIQUE, P1; BITTNER GD, 1986, BRAIN RES, V367, P351, DOI 10.1016/0006-8993(86)91617-3; Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; BLIGHT AR, 1993, ADV NEUROL, V59, P91; Borgens R B, 1988, Adv Neurol, V47, P51; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DUERSTOCK BS, 2001, IN PRESS J EXPT BIO; EPSTEIN N, 1999, SPINE SURG, P1249; JOHNSON AJ, 1971, BRIT J HAEMATOL, V21, P21, DOI 10.1111/j.1365-2141.1971.tb03414.x; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; MALGREM L, 1977, J HISTOCHEM CYTOCHEM, V25, P1280; MARKS JD, 2000, FASEB J, V15, P1107; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; POINTILLART V, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Working PK, 1997, ACS SYM SER, V680, P45; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	34	60	60	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 15	2001	66	6					1179	1186					8	Neurosciences	Neurosciences & Neurology	499GH	WOS:000172562500017	11746451				2021-06-18	
J	Jellinger, KA; Paulus, W; Wrocklage, C; Litvan, I				Jellinger, KA; Paulus, W; Wrocklage, C; Litvan, I			Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						Alzheimer's disease; ApoE allele frequency; closed traumatic brain injury	HEAD-INJURY; SENILE DEMENTIA; RISK; PREVALENCE; AD	In order to assess the impact of traumatic brain injury (TBI) and Apolipoprotein E (ApoE) allele frequency on the development of Alzheimer's disease (AD), we examined: (i) the incidence of AD pathology in 55 consecutive autopsy cases (mean age +/- SD 77.6 +/- 7.3 years) with residual closed TBI lesions and (ii) the frequency of TBI residuals in 53 age-matched autopsy proven AD cases. In both series, ApoE was evaluated from archival paraffin-em bedded brain material. The results were as follows: (i) In the TBI series, 12.7% showed Consortium to Establish a Registry for Alzheimer's disease (CERAD) definite and 9.1% probable AD, only one with ApoE epsilon4. From the remaining 43 non-AD cases, three had ApoE epsilon4. The prevalence of 21.8% AD in this small autopsy cohort was significantly higher than 3.3% in a recent large clinical series and 14% in the general population over the age of 70. (ii) In the AD cohort with ApoE epsilon4 allele frequency of 30% similar to other AD series, residuals of TBI were seen in 4 brains (7.5%), all lacking the ApoE epsilon4 allele. TBI incidence was slightly higher than 8.5% in the clinical MIRAGE study. The results of this first retrospective autopsy study of TBI, ApoE allele frequency, and AD confirms clinical studies suggesting severe TBI to be a risk factor for the development of AD particularly in subjects lacking ApoE epsilon4.	L Boltzmann Inst Clin Neurobiol, Vienna, Austria; Univ Munster, Sch Med, Inst Neuropathol, D-4400 Munster, Germany; HM Jackson Fdn, Cognit Neuropharmacol Unit, Bethesda, MD USA	Jellinger, KA (corresponding author), Otto Wagner Hosp, L Boltzmann Inst Clin Neurobiol, B Bldg,1 Baumgartner Hohe, A-1140 Vienna, Austria.		Litvan, Irene/X-9319-2018	Litvan, Irene/0000-0002-3485-3445			Bancher C, 1997, ACTA NEUROPATHOL, V94, P403, DOI 10.1007/s004010050726; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Corder EH, 1998, CELL MOL LIFE SCI, V54, P928, DOI 10.1007/s000180050223; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geldmacher DS, 1996, NEW ENGL J MED, V335, P330, DOI 10.1056/NEJM199608013350507; Gottlieb S, 2000, BRIT MED J, V321, P1100; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HARRINGTON CR, 1994, AM J PATHOL, V145, P1472; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Hy LX, 2000, NEUROLOGY, V55, P198, DOI 10.1212/WNL.55.2.198; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; REICHIES FM, 1997, NERVENARZT, V68, P719; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SMITH C, 2001, NEUROPATHOL APPL NEU, V27, P151; WROCKLAGE C, 1999, ACTA NEUROPATHOL, V99, P557	22	60	61	0	4	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	NOV	2001	8	6					707	710		10.1046/j.1468-1331.2001.00322.x			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	503NB	WOS:000172803600023	11784357				2021-06-18	
J	Clausen, T; Zauner, A; Levasseur, JE; Rice, AC; Bullock, R				Clausen, T; Zauner, A; Levasseur, JE; Rice, AC; Bullock, R			Induced mitochondrial failure in the feline brain: implications for understanding acute post-traumatic metabolic events	BRAIN RESEARCH			English	Article						mitochondrial failure; cerebral metabolism; traumatic brain injury; microdialysis; cyanide	EXCITATORY AMINO-ACIDS; HUMAN HEAD-INJURY; SUBARACHNOID HEMORRHAGE; MULTIPARAMETER SENSORS; ENDOPLASMIC-RETICULUM; SUBSTRATE DELIVERY; CYANIDE PERFUSION; RELEASE; MICRODIALYSIS; CALCIUM	Objective: Recently, evidence has become available implicating mitochondrial failure as a crucial factor in the pathogenesis of acute brain damage following severe traumatic brain injury (TBI). However, it remains unclear how mitochondrial dysfunction affects cerebral metabolism. Therefore the aim of the study was to evaluate the impact of `isolated' mitochondrial failure on local cerebral metabolism. Methods: Cerebral mitochondrial metabolism was blocked by local microdialysis perfusion with cyanide in seven cats. Local brain tissue oxygen tension (p(tiO2)), carbon dioxide tension (p(tiCO2)) and pH, as well as extracellular cerebral fluid, glucose, lactate, pyruvate and glutamate were monitored, using a Neurotrend sensor-and microdialysis, respectively. Tissue oxygen consumption was measured in a microrespirometric system, and ultrastructural changes evaluated via electron microscopy. Results: Brain tissue oxygen tension increased from a baseline of 31 +/-9 mmHg to 84 +/- 30 mmHg after 60 min of cyanide perfusion (P <0.05), concomitant a decrease in oxygen consumption from 14.45 +/-3.91 mul/h/mg to 10.83 +/-1.74 mul/h/mg (P <0.05). Brain tissue pH was decreased after 60 min of cyanide perfusion (6.83 +/-0.16) compared to baseline (7.07 +/-0.39) (P <0.05), whereas p(tiCO2), did not show significant changes. Lactate massively increased from a baseline of 599 +/- 270 mu mol/l to 2609 +/- 1188 mu mol/l immediately after cyanide perfusion (P <0.05). The lactate:glucose ratio increased from 0.79 +/-0.15 before cyanide perfusion to 6.40 +/-1.44 at 40 min after cyanide perfusion (P <0.05), while no significant changes in the lactate:pyruvate ratio could be observed. Glutamate increased from a baseline of 11.6 +/-7.2 mu mol/l to 61.4 +/- 44.7 mu mol/l after cyanide perfusion (P <0.05). Conclusion: The results of this study show that `isolated' cerebral mitochondrial failure initiates changes in cerebral substrates and biochemistry, which are very similar to most of the changes seen after severe human head injury, except for the early fall in p(tiO2), further indicating a crucial involvement of mitochondrial impairment in the development of brain damage after TBI. (C) 2001 Elsevier Science B.V. All rights reserved.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Univ Halle Wittenberg, Dept Anesthesiol & Intens Care Med, Halle, Germany	Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.	robullock@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		ALBAUM HG, 1946, J BIOL CHEM, V164, P45; Alessandri B, 1999, ACT NEUR S, V75, P21; ALIUKHIN S, 1974, FIZIOL ZH SSSR IM IM, V60, P1376; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; BOROWITZ JL, 1994, TOXICOL APPL PHARM, V129, P80, DOI 10.1006/taap.1994.1230; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CAMERINO PW, 1966, J BIOL CHEM, V241, P970; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755; HALLANTYNE B, 1972, BRIT J PHARMACOL, V44, pP382; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hutchinson PJ, 1999, NEUROL RES, V21, P352, DOI 10.1080/01616412.1999.11740943; Hutchinson PJA, 2000, ZBL NEUROCHIR, V61, P88, DOI 10.1055/s-2000-8265; JOHNSON JD, 1986, TOXICOL APPL PHARM, V84, P464, DOI 10.1016/0041-008X(86)90251-6; JOHNSON JD, 1987, TOXICOL APPL PHARM, V88, P217, DOI 10.1016/0041-008X(87)90007-X; Kanchukh A A, 1971, Nauchnye Doki Vyss Shkoly Biol Nauki, V12, P37; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KIUCHI Y, 1992, NEUROSCI LETT, V147, P193, DOI 10.1016/0304-3940(92)90593-V; Koester J., 1991, PRINCIPLES NEURAL SC, V3, P81; KOOLMAN J, 1998, TASCHENATLAS BIOCH, P140; Koura SS, 1998, ACT NEUR S, V71, P244; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; LISZCZAK TM, 1984, ACTA NEUROPATHOL, V65, P150, DOI 10.1007/BF00690469; MACMILLAN VH, 1989, J CEREBR BLOOD F MET, V9, P156, DOI 10.1038/jcbfm.1989.23; MATSUMOTO M, 1993, NEUROPHARMACOLOGY, V32, P681, DOI 10.1016/0028-3908(93)90081-D; Miller RJ, 1998, TRENDS NEUROSCI, V21, P95, DOI 10.1016/S0166-2236(97)01206-X; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS P, 1972, BIOCHIM BIOPHYS ACTA, V275, P279, DOI 10.1016/0005-2728(72)90208-3; NIEMI M, 1965, HISTOCHEMISTRY, V4, P451, DOI 10.1007/BF00306255; PATEL MN, 1991, NEUROSCI LETT, V131, P42, DOI 10.1016/0304-3940(91)90332-N; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PIANTADOSI CA, 1983, J CLIN INVEST, V72, P1224, DOI 10.1172/JCI111078; PIANTADOSI CA, 1984, TOXICOLOGY, V33, P67, DOI 10.1016/0300-483X(84)90017-9; PITT BR, 1979, ARCH ENVIRON HEALTH, V34, P354, DOI 10.1080/00039896.1979.10667431; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; SANCHEZPRIETO J, 1988, J NEUROCHEM, V50, P1322, DOI 10.1111/j.1471-4159.1988.tb10611.x; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Sarrafzadeh AS, 1998, ZBL NEUROCHIR, V59, P269; Siesjo BK, 1999, J CEREBR BLOOD F MET, V19, P19, DOI 10.1097/00004647-199901000-00002; Siesjo BK, 1999, ACTA NEUROCHIR SUPPL, V73, P7; Solomonson LP, 1981, CYANIDE BIOL, P11; THOMAS RC, 1972, PHYSIOL REV, V52, P563; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; ZAUNER A, 2000, UNPUB CEREBRAL METAB	54	60	60	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 20	2001	908	1					35	48		10.1016/S0006-8993(01)02566-5			14	Neurosciences	Neurosciences & Neurology	456RB	WOS:000170095100004	11457429				2021-06-18	
J	Jackson, RGM; Samra, GS; Radcliffe, J; Clark, GH; Price, CP				Jackson, RGM; Samra, GS; Radcliffe, J; Clark, GH; Price, CP			The early fall in levels of S-100 beta in traumatic brain injury	CLINICAL CHEMISTRY AND LABORATORY MEDICINE			English	Article; Proceedings Paper	European Meeting on Biomarkers of Organ Damage and Dysfunction	APR 03-07, 2000	CAMBRIDGE, ENGLAND			S-100 protein; outcome; head injury; blood	SEVERE HEAD-INJURY; PROTEIN S-100; BARRIER CHANGES; SERUM LEVELS; BLOOD	Protein S-100 beta has been suggested as a prognostic marker in traumatic brain injury, However, little is known of its behaviour in the immediate post-injury period. With Ethics Committee approval, we recruited 30 patients with a history of head injury presenting to our Accident and Emergency Department. Blood was taken on arrival and at four hours post-injury. Serum S-100 beta was estimated using an immunoluminometric assay. Levels of S-100 beta were seen to fall rapidly with time. Half-time was distributed non-parametrically with a median of 198 minutes. Using the Mann-Whitney U test we found a statistically significant difference between non-desirable (Glasgow Outcome Score 1-3) and desirable (Glasgow Outcome Score 4-5) outcome on admission (p = 0.0155) but not at four hours (p = 0.1336). Levels of S-100 beta fell rapidly after its release following traumatic brain injury. Time after injury is therefore critical in assessing the significance of levels of S-100 beta, and sampling should be as early as possible to gain maximum information. If S-100 beta is to be assessed as a monitor of ongoing brain injury in the intensive therapy unit sampling must be frequent (e.g. every 4 hours) to be able to detect rises in serum levels before they have decayed to baseline.	Royal London Hosp, Acad Dept Anaesthesia & Intens Care, Anaesthet Unit, London E1 1BB, England; Royal London Hosp, Dept Clin Biochem, London E1 1BB, England	Samra, GS (corresponding author), Royal London Hosp, Acad Dept Anaesthesia & Intens Care, Anaesthet Unit, London E1 1BB, England.						Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, ACT NEUR S, V70, P243; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; McKeating EG, 1998, ACT NEUR S, V71, P117; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; USUI A, 1989, CLIN CHEM, V35, P1942; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	14	60	62	0	0	WALTER DE GRUYTER & CO	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1434-6621			CLIN CHEM LAB MED	Clin. Chem. Lab. Med.	NOV	2000	38	11					1165	1167		10.1515/CCLM.2000.179			3	Medical Laboratory Technology	Medical Laboratory Technology	395TD	WOS:000166596600020	11156351				2021-06-18	
J	Sandhu, RS; Pasquale, MD; Miller, K; Wasser, TE				Sandhu, RS; Pasquale, MD; Miller, K; Wasser, TE			Measurement of endotracheal tube cuff leak to predict postextubation stridor and need for reintubation	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							TRACHEAL EXTUBATION; LARYNGEAL EDEMA; DOUBLE-BLIND; RISK-FACTORS; PREVENTION; DEXAMETHASONE; COMPLICATIONS; INTUBATION; ADULTS	Background: The purpose of this study was to determine the predictive value of an endotracheal tube cuff leak for the development of postextubation strider and the need for reintubation. Study Design: Consecutive trauma patients who required intubation at a level I trauma center from July 1997 to July 1998 were studied prospectively. Pediatric patients and those who did not meet the standard weaning protocol criteria established by the Division of Trauma and Surgical Critical Care were excluded. Injury Severity Score, endotracheal tube size, reason for intubation, and the number of days intubated before the initial extubation attempt were recorded. At the time of extubation, the difference in exhaled tidal volume from before to after endotracheal tube cuff deflation was calculated. This number was then divided by the exhaled tidal volume before cuff deflation and was recorded as the percent cuff leak. Patients were followed for 24 hours after extubation for the development of strider or need for reintubation. Statistical analysis to compare subgroups of patients was performed using ANOVA with Scheffe post hoc analysis. Results: Among the 110 patients analyzed, the most common reason for intubation was closed-head injury. Seven patients (6.4%) developed strider alone and had a mean cuff leak of 58 mL (8.4% of tidal volume before cuff deflation). Six patients (5.5%) experienced strider that required reintubation and had a mean cuff leak of 68 mL (9.2% of tidal volume before cuff deflation). Patients who developed strider or needed reintubation had been intubated for a significantly greater length of time than those not developing strider or requiring reintubation (2.6 versus 3.0 days, p < 0.001). There were no differences in Injury Severity Score, endotracheal tube size, or reason for intubation between these groups. Conclusions: A cuff leak of less than 10% of tidal volume before cuff deflation is useful in identifying patients at risk for strider or reintubation (96% specificity). It appears that the amount of cuff leak decreases after intubation for more than 3 days, increasing the risk of strider and need for reintubation. This information may be helpful in identifying those patients who need treatment for laryngotracheal edema, ie, use of steroids or anesthesia during extubation, the efficacy of which remains to be determined. (J Am Coll Surg 2000;190:682-687, (C) 2000 by the American College of Surgeons).	Lehigh Valley Hosp, Dept Surg, Allentown, PA 18105 USA; Lehigh Valley Hosp, Div Trauma & Surg Crit Care, Allentown, PA 18105 USA; Lehigh Valley Hosp, Dept Resp Care, Allentown, PA 18105 USA; Lehigh Valley Hosp, Dept Hlth Studies, Allentown, PA 18105 USA	Sandhu, RS (corresponding author), Lehigh Valley Hosp, Dept Surg, Cedar Crest & I-78,POB 689, Allentown, PA 18105 USA.						ADDERLEY RJ, 1987, CAN J ANAESTH, V34, P304, DOI 10.1007/BF03015171; Anene O, 1996, CRIT CARE MED, V24, P1666, DOI 10.1097/00003246-199610000-00011; Chevron V, 1998, CRIT CARE MED, V26, P1049, DOI 10.1097/00003246-199806000-00026; COLICE GL, 1989, CHEST, V96, P877, DOI 10.1378/chest.96.4.877; Daley BJ, 1996, CHEST, V110, P1577, DOI 10.1378/chest.110.6.1577; DARMON JY, 1992, ANESTHESIOLOGY, V77, P245, DOI 10.1097/00000542-199208000-00004; DEMLING RH, 1988, CRIT CARE MED, V16, P573, DOI 10.1097/00003246-198806000-00001; Epstein SK, 1998, AM J RESP CRIT CARE, V158, P489, DOI 10.1164/ajrccm.158.2.9711045; FISHER MM, 1992, ANAESTHESIA, V47, P10, DOI 10.1111/j.1365-2044.1992.tb01943.x; Ho LI, 1996, INTENS CARE MED, V22, P933; KASTANOS N, 1983, CRIT CARE MED, V11, P362, DOI 10.1097/00003246-198305000-00009; Marik P., 1996, RESP CARE, V41, P509; Miller RL, 1996, CHEST, V110, P1035, DOI 10.1378/chest.110.4.1035; Mort TC, 1998, ANESTH ANALG, V86, P1171, DOI 10.1097/00000539-199806000-00006; TELLEZ DW, 1991, J PEDIATR-US, V118, P289, DOI 10.1016/S0022-3476(05)80505-0	15	60	65	0	1	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	JUN	2000	190	6					682	687		10.1016/S1072-7515(00)00269-6			6	Surgery	Surgery	321TN	WOS:000087470900010	10873003				2021-06-18	
J	Hofman, PAM; Nelemans, P; Kemerink, GJ; Wilmink, JT				Hofman, PAM; Nelemans, P; Kemerink, GJ; Wilmink, JT			Value of radiological diagnosis of skull fracture in the management of mild head injury: meta-analysis	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; skull fracture; meta-analysis; radiological diognosis	SIGNIFICANT INTRACRANIAL INJURY; COMPUTED-TOMOGRAPHY; BRAIN INJURY; TRAUMA; RISK; PREDICTORS; EMERGENCY; ADMISSION; UTILITY; TESTS	Objectives-Head injury is a common event. Most patients sustain a mild head injury (MHI), and management depends on the risk of an intracranial haemorrhage (ICH). The value of a plain skull radiograph as a screening tool for ICH is controversial. The aim of this metaanalysis was to estimate and explain differences in reported sensitivity and specificity of the finding of a skull fracture for the diagnosis of ICH, in order to assess the value of the plain skull radiograph in the investigation of patients with MHI, and to estimate the prevalence of ICH in these patients. Method-After a systematic literature search 20 studies were selected that reported data on the prevalence of ICH after MHI and/or data on the diagnostic value of skull fracture for the diagnosis of ICH. The mean prevalence of ICH weighted for the sample size was determined. The sensitivity and specificity of different studies were combined using a summary receiver operator characteristic curve. Correlation analysis was used to determine factors that could explain the reported differences between studies. Results-The weighted mean prevalence of ICH after MHI is 0.083. The potential for verification bias and the percentage of patients who had suffered loss of consciousness or post-traumatic amnesia were the most significant factors explaining interstudy differences in sensitivity and specificity. Based on studies wherein at least 50% of patients had a CT study of the brain, the estimated sensitivity of a radiographic finding of skull fracture for the diagnosis of ICH is 0.38 with a corresponding specificity of 0.95. Conclusion-The plain skull radiograph is of little value in the initial assessment of MHI patients.	Univ Hosp Maastricht, Dept Radiol, NL-6200 AZ Maastricht, Netherlands; Univ Maastricht, NL-6200 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Dept Epidemiol, NL-6200 AZ Maastricht, Netherlands	Hofman, PAM (corresponding author), Univ Hosp Maastricht, Dept Radiol, POB 5800, NL-6200 AZ Maastricht, Netherlands.						Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; BEGG CB, 1988, RADIOLOGY, V167, P565, DOI 10.1148/radiology.167.2.3357976; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Bradburn MJ., 1998, STATA TECH B, V44, P4; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; EVANS KT, 1977, BRIT J RADIOL, V50, P299, DOI 10.1259/0007-1285-50-593-299; GALBRAITH S, 1981, LANCET, V2, P1350; GomezGallego F, 1996, FASEB J, V10, P153; GORMAN DF, 1987, ARCH EMERG MED, V4, P141; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Holmes JF, 1997, ACAD EMERG MED, V4, P788, DOI 10.1111/j.1553-2712.1997.tb03786.x; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Hutchinson PJA, 1998, J ACCID EMERG MED, V15, P84; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121403; RAO R, 1991, J TRAUMA, V31, P801; RAO R, 1991, J TRAUMA, V31, P804; ROBERTS CJ, 1981, LANCET, V2, P791; Sackett DL., 1991, CLIN EPIDEMIOLOGY BA; SERVADEI F, 1995, J TRAUMA, V39, P696, DOI 10.1097/00005373-199510000-00015; SERVADEI F, 1988, SURG NEUROL, V30, P364, DOI 10.1016/0090-3019(88)90199-1; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Stein SC, 1996, NEUROSURG QUART, V6, P108, DOI 10.1097/00013414-199606000-00004; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE G, 1974, LANCET, V2, P81; THILLAINAYAGAM K, 1987, INJURY, V18, P319, DOI 10.1016/0020-1383(87)90051-9; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	39	60	63	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2000	68	4					416	422		10.1136/jnnp.68.4.416			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	299AQ	WOS:000086174000005	10727475	Green Published, Bronze			2021-06-18	
J	Allen, GV; Gerami, D; Esser, MJ				Allen, GV; Gerami, D; Esser, MJ			Conditioning effects of repetitive mild neurotrauma on motor function in an animal model of focal brain injury	NEUROSCIENCE			English	Article						cerebral cortex; heat shock protein; GFAP; motor function; beam-walking test	HEAT-SHOCK-PROTEIN; GLUCOSE-REGULATED PROTEINS; RAT-BRAIN; NEURONAL DEGENERATION; MOLECULAR CHAPERONES; SPREADING DEPRESSION; VASCULAR DISRUPTION; CEREBRAL-ISCHEMIA; C-FOS; EXPRESSION	A weight drop model of brain injury was used to determine the effects of repetitive mild brain injury on motor function, heat shock protein and glial fibrillary acidic protein expression in the anesthetized, adult male, Sprague-Dawley rat. Repetitive mild brain injury was produced when animals received a series of three mild injuries spaced three days apart. A separate group of repetitive mild injured animals also received a subsequent severe brain injury between three and five days after the last mild injury. All animals were trained on a beam-walking test prior to surgery. The mild, repetitive mild and repetitive mild plus severe brain injury groups showed no motor deficits in the beam-walking test, whereas the animals with only severe brain injury showed significant motor deficits (increase in number of footslips) in the beam-walking test that recovered within eight days after injury. Both repetitive mild plus severe injury and severe injury only animals had cortical necrotic cavities of similar size in the region of the hindlimb meter cortex. Both the repetitive mild and severe brain-injured animals had marked heat shock protein 27 kDa and glial fibrillary acidic protein staining in the cerebral cortex. Fluoro-Jade, heat shock protein 27 kDa and 72 kDa labeling indicated that there were widespread effects on cortical, subcortical and spinal neurons and glial cells after repetitive mild brain injury. These results suggest that repetitive mild brain injury conditions the brain so that subsequent brain injury at the same site has no effect on motor function. Furthermore, repetitive mild injury-induced activation of processes distant to the primary injury site may have a role in activation of secondary sites involved in recovery of motor function. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Dalhousie Univ, Fac Med, Dept Anat & Neurobiol, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Fac Med, Dept Pharmacol, Halifax, NS B3H 4H7, Canada	Allen, GV (corresponding author), Dalhousie Univ, Fac Med, Dept Anat & Neurobiol, Halifax, NS B3H 4H7, Canada.	gva@is.dal.ca					BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; Chen J, 1996, J CEREBR BLOOD F MET, V16, P566, DOI 10.1097/00004647-199607000-00006; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CURRIE RW, 1981, SCIENCE, V214, P72, DOI 10.1126/science.7280681; CURRIE RW, 1993, CIRCULATION, V87, P963, DOI 10.1161/01.CIR.87.3.963; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DONNELLY TJ, 1992, CIRCULATION, V85, P769, DOI 10.1161/01.CIR.85.2.769; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Freyaldenhoven TE, 1997, BRAIN RES, V759, P9, DOI 10.1016/S0006-8993(97)00045-0; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hermann DM, 1999, NEUROSCIENCE, V88, P599, DOI 10.1016/S0306-4522(98)00249-8; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HUTTER MM, 1994, CIRCULATION, V89, P355, DOI 10.1161/01.CIR.89.1.355; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kanayama G, 1997, PSYCHIAT CLIN NEUROS, V51, P157, DOI 10.1111/j.1440-1819.1997.tb02379.x; KATO H, 1991, BRAIN RES, V553, P238, DOI 10.1016/0006-8993(91)90831-F; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; KITAGAWA K, 1991, J CEREBR BLOOD F MET, V11, P449, DOI 10.1038/jcbfm.1991.86; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; KUBOTA M, 1989, NEUROSURG REV S1, V12, P333; Lewis SE, 1999, J NEUROSCI, V19, P8945, DOI 10.1523/JNEUROSCI.19-20-08945.1999; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; MANTHORPE M, 1986, ASTROCYTES, P315; Matsushima K, 1996, J CEREBR BLOOD F MET, V16, P221, DOI 10.1097/00004647-199603000-00006; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; NEEDELS DL, 1986, NEUROSCIENCE, V18, P517, DOI 10.1016/0306-4522(86)90055-2; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NISHI S, 1993, BRAIN RES, V615, P281, DOI 10.1016/0006-8993(93)90039-P; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; Plumier JCL, 1997, J CEREBR BLOOD F MET, V17, P781; Plumier JCL, 1997, MOL BRAIN RES, V45, P239, DOI 10.1016/S0169-328X(96)00255-0; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Schmued LC, 1997, BRAIN RES, V759, P135, DOI 10.1016/S0006-8993(97)00173-X; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14	56	60	63	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2000	99	1					93	105		10.1016/S0306-4522(00)00185-8			13	Neurosciences	Neurosciences & Neurology	343GA	WOS:000088692300010	10924955				2021-06-18	
S	Emmerling, MR; Morganti-Kossmann, MC; Kossmann, T; Stahel, PF; Watson, MD; Evans, LM; Mehta, PD; Spiegel, K; Kuo, YM; Roher, AE; Raby, CA		Kalaria, RN; Ince, P		Emmerling, MR; Morganti-Kossmann, MC; Kossmann, T; Stahel, PF; Watson, MD; Evans, LM; Mehta, PD; Spiegel, K; Kuo, YM; Roher, AE; Raby, CA			Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta(42) in human CSF - A possible role for nerve cell injury	VASCULAR FACTORS IN ALZHEIMER'S DISEASE	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Conference on Vascular Factors in Alzheimers Disease	MAY 25-28, 1999	NEWCASTLE TYNE, ENGLAND	Bayer AG, Eisai Ltd, GJ Livanos Trust, Alzheimers Report, Hoechst Marrion Roussel, Janssen Pharmaceut, Novartis Pharma AG, Parke Davis, Pfizer Inc, SmithKline Beecham Pharmaceut, Zeneca, Med Res Council, Inst Brain & Blood Vessels, Akita, Inst Hlth Elderly, Univ Newcastle Upon Tyne			CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; PRECURSOR PROTEIN; TAU-PROTEINS; HEAD-INJURY; DISEASE; PROGRESSION; SERUM	The increased risk for Alzheimer's Disease (AD) associated with traumatic brain injury (TBI) suggests that environmental insults may influence the development of this age-related dementia, Recently, we have shown that the levels of the beta-amyloid peptide (A beta(1-42)) increase in the cerebrospinal fluid (CSF) of patients after severe brain injury and remain elevated for some time after the initial event, The relationships of elevated A beta with markers of blood-brain barrier (BBB) disruption, inflammation, and nerve cell or axonal injury were evaluated in CSF samples taken daily from TBI patients, This analysis reveals that the rise in A beta(1-42) is best correlated with possible markers of neuronal or axonal injury, the cytoskeletal protein tan, neuron-specific enolase (NSE), and apolipoprotein E (ApoE), Similar or better correlations were observed between A beta(1-40) and the three aforementioned markers, These results imply that the degree of brain injury may play a decisive role in determining the levels of A beta(1-42) and A beta(1-40) in the CSP of TBI patients, inflammation and alterations in BBB may play lesser, but nonetheless significant, roles In determining the A beta level in CSF after brain injury.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Neurosci Thepeut, Ann Arbor, MI 48106 USA; Univ Zurich Hosp, Div Trauma Surg, Dept Surg, CH-8091 Zurich, Switzerland; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA; Sun Hlth Res Inst, Haldeman Lab Alzheimers Dis Res, Sun City, AZ 85372 USA	Emmerling, MR (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Neurosci Thepeut, 2800 Plymouth Rd, Ann Arbor, MI 48106 USA.		Kuo, Yu-Min/A-9050-2013	Kuo, Yu-Min/0000-0003-4867-2482; Morganti-Kossmann, Cristina/0000-0002-0807-2063			Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; EMMERLING MR, 1999, UNIFYING HYPOTHESIS, P33; Jensen M, 1999, ANN NEUROL, V45, P504, DOI 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; LEHTIMAKI T, 1995, HUM GENET, V95, P39; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; Pirttila T, 1996, BRAIN RES, V722, P71, DOI 10.1016/0006-8993(96)00183-7; PIRTTILA T, 1994, NEUROBIOL AGING, V15, P313, DOI 10.1016/0197-4580(94)90026-4; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Raby CA, 1998, J NEUROCHEM, V71, P2505; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Smith AD, 1996, BRIT MED BULL, V52, P575; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	18	60	60	0	7	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-251-7	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2000	903						118	122		10.1111/j.1749-6632.2000.tb06357.x			5	Multidisciplinary Sciences; Clinical Neurology; Peripheral Vascular Disease	Science & Technology - Other Topics; Neurosciences & Neurology; Cardiovascular System & Cardiology	BQ26Z	WOS:000087756800016	10818496				2021-06-18	
J	Guyot, LL; Michael, DB				Guyot, LL; Michael, DB			Post-traumatic hydrocephalus	NEUROLOGICAL RESEARCH			English	Article						traumatic brain injury; post-traumatic hydrocephalus; neurotrauma	NORMAL-PRESSURE HYDROCEPHALUS; SEVERE HEAD-INJURY; POSTTRAUMATIC HYDROCEPHALUS; COMPUTED-TOMOGRAPHY; DIAGNOSIS; DYNAMICS	The syndrome of post-traumatic hydrocephalus (PTH) has been recognized since Dandy's report in 1914. The incidence of symptomatic PTH ranges from 0.7%-29%. If CT criteria of ventriculomegaly are used the incidence has been reported to be from 30%-86%. Differences in diagnostic criteria and classification have contributed to the variation in reported incidence. The diagnosis of PTH is established using a combination of clinical, imaging and physiologic data. Symptomatic PTH is to be distinguished from post-traumatic ventriculomegaly resulting from atrophy. Symptomatic PTH patients are likely to improve when treated by shunting. Ventriculomegaly secondary to atrophy is less likely to respond to shunting. A series of traumatic brain injury patients at Wayne State University has been followed since 1989. The overall incidence of shunt placement in this group is 3.65%. Future studies of PTH should be aimed at refining diagnostic classification and criteria. Analysis of a large PTH population may then identify alterable risk factors in the early post-traumatic brain injury period. Minimizing these factors will help prevent subsequent PTH and obviate the need for shunting.	Wayne State Univ, Dept Anat & Physiol, Detroit, MI USA; Wayne State Univ, Dept Cell Biol, Detroit, MI USA; Wayne State Univ, Dept Neurol Surg, Detroit, MI USA; Detroit Med Ctr, Detroit, MI USA	Michael, DB (corresponding author), Detroit Receiving Hosp, 6E-UHC,4201 St Antoine, Detroit, MI 48201 USA.						CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Dandy WE, 1914, AM J DIS CHILD, V8, P406; FLEISCHER AS, 1988, ANN EMERG MED, V17, P165, DOI 10.1016/S0196-0644(88)80305-6; FOLTZ EL, 1956, J NEUROSURG, V13, P546, DOI 10.3171/jns.1956.13.6.0546; GARDEUR D, 1979, J RADIOL ELEC MED N, V60, P79; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; GURDJIAN E, 1966, HEAD INJURY C P, P550; Hakim S, 1965, J Neurol Sci, V2, P307, DOI 10.1016/0022-510X(65)90016-X; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; KOSTELJANETZ M, 1985, ACTA NEUROCHIR, V77, P8, DOI 10.1007/BF01402299; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEWIN W, 1965, BIOCH ASPECTS NEUROL, P182; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; OI S, 1987, J PEDIAT NEUROSCI, V3, P133; OJEMANN RG, 1969, J NEUROSURG, V31, P279, DOI 10.3171/jns.1969.31.3.0279; PENDERSON K, 1973, ACTA NEUROL SCAND, V48, P99; Penfield W, 1943, CAN MED ASSOC J, V48, P99; PENN RD, 1978, ANN NEUROL, V3, P216, DOI 10.1002/ana.410030306; PHILIPPON J, 1976, NEUROCHIRURGIE, V22, P111; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; SHEFFLER LR, 1994, ARCH PHYS MED REHAB, V75, P338, DOI 10.1016/0003-9993(94)90039-6; STEIN SC, 1974, J NEUROSURG, V41, P463, DOI 10.3171/jns.1974.41.4.0463; TAGAKI H, 1981, SURG NEUROL, V16, P103; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; WOOD JH, 1974, NEUROLOGY, V24, P517, DOI 10.1212/WNL.24.6.517; ZANDER E, 1976, HDB CLIN NEUROLOGY 2, P231	28	60	68	0	6	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	JAN	2000	22	1					25	28					4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	281HF	WOS:000085152300004	10672577				2021-06-18	
J	Berger, E; Leven, F; Pirente, N; Bouillon, B; Neugebauer, E				Berger, E; Leven, F; Pirente, N; Bouillon, B; Neugebauer, E			Quality of life after traumatic brain injury: A systematic review of the literature	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						brain injuries; quality of life; head injury	SEVERE HEAD-INJURY; OF-LIFE; SOCIAL SUPPORT; FOLLOW-UP; SURGERY; IMPACT; SCALE; REHABILITATION; OUTCOMES; COMA	In modern industrial countries traumatic brain injury (TBI) is a common sequel after different kinds of accidents especially amongst young male adults. Apart from medical and economic consequences Quality of Life (QoL) after TBI becomes increasingly important in outcome assessment, Besides the classical domains of QoL (physical, psychological, social) cognitive impairments are playing an important role especially for TBI patients. In 1991 the Meran conference set important standards and formulated basic guidelines for defining and measuring QoL in surgery, but a special index for TBI patients has not yet been developed. Instead, QoL research concentrates on physical, medical, psychological and social problems only. Based on the existing QoL concept extended by the cognitive aspect it was the aim of this review to give an overview about the recent QoL research in TBI patients since 1991. Sixteen studies in TBI patients mentioning at least 2 domains of QoL (physical, psychological, social, cognitive) were published since 1991. Five of them considered all 4 domains of QoL. All studies except of one dealt with psychological and social problems. Only half of the studies considered cognitive impairments. Four studies tried to define QoL, but none of them included the cognitive component. There was no consensus regarding the definition and the choice of measurement instrument for QoL after TBI. This review of 16 studies considering outcome and QoL after TBI confirms that a homogenous and clinically relevant QoL concept for this group of patients is still missing. Further research in TBI patients should include all 4 domains of QoL.	Univ Cologne, Dept Surg 2, Biochem & Expt Div, D-51109 Cologne, Germany; Neurosurg Clin, Cologne, Germany; Univ Cologne, Dept Surg 2, D-5000 Cologne 41, Germany	Berger, E (corresponding author), Univ Cologne, Dept Surg 2, Biochem & Expt Div, Ostmerheimer Str 200, D-51109 Cologne, Germany.	eva.berger@uni-koeln.de					Aaronson N K, 1988, Oncology (Williston Park), V2, P69; Annoni J M, 1992, Disabil Rehabil, V14, P23; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Bullinger M, 1996, Rehabilitation (Stuttg), V35, pXVII; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; BULLINGER M, 1996, REHABILITATION STUTT, V35, P27; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Emilien G, 1996, ACTA NEUROL BELG, V96, P89; EYPASCH E, 1990, THEOR SURG, V5, P3; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; GAINOTTI G, 1993, REHABILITATION, V3, P259; Haffey W. J., 1990, NEUROPSYCHOLOGY EVER, P99; HAMILTON BB, 1987, REHABILITATION OUTCO, P135; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HELLAWELL J, 1997, INT J REHABIL RES, V20, P345; JENNETT B, 1975, LANCET, V480, P480; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; KAPLAN S, 1991, CLIN NEUROPSYCHOL, V5, P360, DOI DOI 10.1080/13854049108404103; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; KOCH U, 1998, REHABILITATIONSMEDIZ; KOLLER M, 1995, ANHANG, V2; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MAHONEY F I, 1965, Md State Med J, V14, P61; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; NEUGEBAUER E, 1991, THEOR SURG, V6, P123; NEUGEBAUER E, 1991, THEOR SURG, V6, P121; Olver JH, 1995, CURR OPIN NEUROL, V8, P443, DOI 10.1097/00019052-199512000-00008; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SCHAFMAYER A, 1989, CHIRURG, V60, P458; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; SPILKER G, 1991, THEOR SURG, V6, P216; TEASDALE G, 1974, LANCET, V2, P81; TROIDL H, 1989, CHIRURG, V60, P445; VANBALEN HGG, 1996, DISABILITY REHABILIT, V18, P81; WAANDERS R, 1997, ACTA CHIR AUSTRIACA, P221; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Woischneck D, 1997, NEUROL RES, V19, P305, DOI 10.1080/01616412.1997.11740817	43	60	61	0	4	IOS PRESS	AMSTERDAM	VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	2-3					93	102					10	Neurosciences	Neurosciences & Neurology	183XN	WOS:000079579700003	22387504				2021-06-18	
J	Ownsworth, TL; Oei, TPS				Ownsworth, TL; Oei, TPS			Depression after traumatic brain injury: conceptualization and treatment considerations	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; DISORDERS; REHABILITATION; ADJUSTMENT; RELATIVES	The understanding and treatment of depression that develops following traumatic brain injury (TBI) is still unclear and likely to be the result of a complex variety of interacting factors. Past researchers have developed ways to classify important variables related to patients' depression into broad domains such as: Pre-injury assets and liabilities, the nature and severity of brain injury; and reaction to difficulties. However, a better conceptualization of the problem is required in order to guide the assessment and treatment considerations for depressed patients with TBI. This review provides this conceptualization by postulating six theoretical relationships between depression and TBI. The degree of empirical support provided in the literature for there links is indicated. Research findings suggested that an individual with TBI is the most susceptible to depression when any of the following conditions exist: a pre-existing psychiatric disturbance is exacerbated; the injury sustained involved the left anterior region of the brain; and when her individual has poor insight into her deficits, attempts to resume her pre-injury roles and experiences significant failure. For each relationship, a likely outcome is predicted if the recommended treatment plan is not conducted. The present conceptualization and treatment considerations will be of substantial benefit to clinicians working in the area.	Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia	Oei, TPS (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.		Oei, Tian Po/K-4870-2012	Oei, Tian Po/0000-0001-9041-8803; Ownsworth, Tamara/0000-0003-1835-7094			ALEXANDER MP, 1975, PSYCHIAT ASPECTS NEU, P219; Barco P.P., 1991, COGNITIVE REHABILITA, P129; Beck A. T., 1987, J COGN PSYCHOTHER, V1, P5; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BLUMER D, 1975, PSYCHIATRIC ASPECTS, V1, P151; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1989, ASSESSMENT BEHAV CON, P61; EAMES P, 1989, ASSESSMENT BEH CONSE, P195; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fennell M, 1989, COGNITIVE BEHAV THER, P169; FINSET A, 1988, CEREBRAL HEMISPHERE, P51; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; GAULTIERI CT, 1988, BRAIN INJURY, V6, P219; GILES GM, 1993, BRAIN INJURY REHABIL; GLENN MB, 1989, J HEAD TRAUMA REHAB, V4, P85; GODFREY HP, 1995, FAMILY SUPPORT PROGR; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GODFREY HPD, 1996, FACILITATING PSYCHOS; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hartley L. L., 1995, COGNITIVE COMMUNICAT; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAY T, 1989, ASSESSMENT BEHAV CON, P145; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KWON SM, 1994, CLIN PSYCHOL REV, V14, P331, DOI 10.1016/0272-7358(94)90032-9; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Lezak M. D., 1989, ASSESSMENT BEHAV CON, P113; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LIPOWSKI ZJ, 1975, PSYCHIAT ASPECTS NEU, V1, P11; LISHMAN WA, 1978, ORGANIC PSYCHIAT PSY; MAPOU RL, 1993, HDB HEAD TRAUMA ACUT, P76; MATEER CA, 1991, CONITIVE REHABILITAT, P117; MCALLISTER TW, 1992, COMPR PSYCHIAT, V33, P296, DOI 10.1016/0010-440X(92)90036-P; McAllister TW, 1997, COMMUNITY MENT HLT J, V33, P341, DOI 10.1023/A:1025055426260; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; McNair DM, 1981, PROFILE MOOD STATES; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Morse P, 1992, CLIN SYNDROMES ADULT, P85; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NAUGLE RL, TRAUMATIC BRAIN INJU, P69; Pepping M, 1991, NEUROPSYCHOLOGY EVER, P215; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P243; PRIGATANO GP, 1987, NEUROBEHAVIORAL RECO, P216; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; RICKLER KC, 1975, PSYCHIAT ASPECTS NEU, V2; ROBINSON RG, 1983, STROKE, V14, P736, DOI 10.1161/01.STR.14.5.736; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; ROSS LK, 1992, HDB HEAD TRAUMA ACUT, P151; SACKEIM HA, 1991, AM PSYCHOP, P209; SARGENT MM, 1989, NEUROPSYCHOLOGICAL T, P183; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; SOHLBERG MM, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; ZENCIUS AH, 1994, PRACTICAL GUIDE HEAD	67	60	60	0	10	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1998	12	9					735	751		10.1080/026990598122133			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	117ET	WOS:000075768500002	9755365				2021-06-18	
J	Brown, JIM; Baker, AJ; Konasiewicz, SJ; Moulton, RJ				Brown, JIM; Baker, AJ; Konasiewicz, SJ; Moulton, RJ			Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans	JOURNAL OF NEUROTRAUMA			English	Article						cerebral ischemia; clinical outcome; glutamate; temporal pattern; traumatic brain injury	EXCITATORY AMINO-ACIDS; SEVERE HEAD-INJURY; IN-VIVO MICRODIALYSIS; CEREBROSPINAL-FLUID; RELEASE; ISCHEMIA; ASPARTATE; ANTAGONISTS; RECEPTORS; GLYCINE	Glutamate excitotoxicity is a putative mechanism of secondary damage after traumatic brain injury (TBI), No relationship between glutamate release and clinical status has been shown in humans, however, We hypothesize a dose-response relationship between CSF glutamate concentrations and severity of injury, electrophysiological deterioration as measured by somatosensory evoked potential amplitudes, and clinical outcome, From August 1991 to March 1996, intensive monitoring of 55 patients with severe TBI (GCS less than or equal to 8 after resuscitation) included twice daily CSF glutamate levels and hourly somatosensory evoked potentials (SSEPs) for an average of 5 days, Clinical outcomes were survival/nonsurvival and Glasgow outcome score (GOS) at 3 months or more post-injury, Glutamate levels were not associated with severity of injury, electrophysiological deterioration, or clinical outcome. Neither peak nor mean glutamate levels significantly improved a simple logistic regression model which used only age and presence of bilaterally unreactive pupils to predict survival, Using this methodology CSF glutamate concentrations did not display a dose-response relationship to severity of injury, electrophysiological deterioration, or predict clinical outcomes following TBI in a group of 55 patients, An early effect of glutamate, an effect dependent on time of exposure to glutamate or other modulating effects cannot be ruled out.	Univ Toronto, St Michaels Hosp, Dept Anaesthesia, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Dept Surg, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada	Brown, JIM (corresponding author), Univ Toronto, St Michaels Hosp, Dept Anaesthesia, 30 Bond St, Toronto, ON M5B 1W8, Canada.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BAKER CJ, 1995, NEUROSURGERY, V36, P994, DOI 10.1227/00006123-199505000-00016; BONDOLI A, 1981, RESUSCITATION, V9, P119, DOI 10.1016/0300-9572(81)90021-6; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; CHOI DW, 1987, J NEUROSCI, V7, P357; Davson H., 1967, PHYSL CEREBROSPINAL; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERRARESE C, 1993, ANN NEUROL, V33, P316, DOI 10.1002/ana.410330316; GENNARELLI TA, 1993, HEAD INJURY, P1; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1976, LANCET, V1, P1031; Kanthan R, 1996, NEUROSCI LETT, V209, P207, DOI 10.1016/0304-3940(96)12642-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kempski O, 1990, Adv Neurol, V52, P219; KONASIEWICZ SJ, 1994, J TRAUMA, V37, P370, DOI 10.1097/00005373-199409000-00006; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MOULTON R, 1991, J TRAUMA, V31, P676, DOI 10.1097/00005373-199105000-00012; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; REGAN RF, 1994, NEUROBIOLOGY CENTRAL, P173; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; SHEDDEN P M, 1990, Pediatric Neurosurgery, V16, P203, DOI 10.1159/000120527; Shuaib A, 1996, ACT NEUR S, V67, P53; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TSUCHIDA E, 1995, J NEUROTRAUM, V12, P279, DOI 10.1089/neu.1995.12.279; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zauner A, 1996, ACT NEUR S, V67, P40; ZORNOW MH, 1995, J NEUROSURG ANESTH, V7, P148, DOI 10.1097/00008506-199504000-00022	41	60	60	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1998	15	4					253	263		10.1089/neu.1998.15.253			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZF401	WOS:000072893800003	9555971				2021-06-18	
J	Stahel, PF; Kossmann, T; MorgantiKossmann, MC; Hans, VHJ; Barnum, SR				Stahel, PF; Kossmann, T; MorgantiKossmann, MC; Hans, VHJ; Barnum, SR			Experimental diffuse axonal injury induces enhanced neuronal C5a receptor mRNA expression in rats	MOLECULAR BRAIN RESEARCH			English	Article						complement; chemotactic receptor; traumatic brain injury; neuron	TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; HUMAN CEREBROSPINAL-FLUID; CLOSED-HEAD-INJURY; ADULT-RAT; NEUTROPHIL ACCUMULATION; PNEUMOCOCCAL MENINGITIS; ANAPHYLATOXIN RECEPTOR; COMPLEMENT ACTIVATION; HUMAN ASTROCYTES	Several studies suggest the involvement of the complement system in the pathophysiology of traumatic brain injury (TBI). Since the intrathecal generation of anaphylatoxin C5a has been shown to mediate inflammatory effects within the central nervous system, we sought to characterize the cellular expression of the mRNA for the C5a receptor (C5aR, CD88) in brains of rats with experimental diffuse axonal injury (DAI) by in situ hybridization. Infiltrating leukocytes expressing C5aR mRNA were seen in meninges and lateral ventricles as early as 4 h after induction of DAI. The number of infiltrating C5aR-positive cells increased gradually up to 24 h after trauma. Within the brain parenchyma, up-regulation of C5aR mRNA expression was first seen in cerebellar Purkinje cells within 8 h. At 24 h after TBI, expression of C5aR mRNA was widespread bilaterally throughout the cortex and cerebellum, the cellular expression being restricted to pyramidal neurons and Purkinje cells. The intensity of C5aR transcript signals on neurons increased further up to 96 h after trauma. Ligand binding of C5a to its receptor on neurons might mediate previously unknown functions, thus possibly leading to neurotoxicity and secondary neuronal damage after TBI. (C) 1997 Elsevier Science B.V.	UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; UNIV ZURICH HOSP,DEPT SURG,DIV TRAUMA SURG,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH HOSP,DEPT SURG,DIV RES,CH-8091 ZURICH,SWITZERLAND				Morganti-Kossmann, Cristina/0000-0002-0807-2063	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29719] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS029719] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BECKER P, 1987, ANAESTHESIST, V36, P301; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P49; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; DAVIS WD, 1992, CLIN EXP RHEUMATOL, V10, P455; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; ERNST JD, 1984, INFECT IMMUN, V46, P81, DOI 10.1128/IAI.46.1.81-86.1984; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas I., 1996, Neurobiology of Aging, V17, pS183, DOI 10.1016/S0197-4580(96)80738-X; FAUSTUMANN PM, 1995, ACTA NEUROPATHOL, V89, P239; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GASQUE P, 1995, J IMMUNOL, V155, P4882; Gasque P, 1997, AM J PATHOL, V150, P31; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.immunol.12.1.775; GIULIAN D, 1993, J NEUROSCI, V13, P29; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Horuk R, 1997, J IMMUNOL, V158, P2882; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KADURUGAMUWA JL, 1989, J INFECT DIS, V160, P715, DOI 10.1093/infdis/160.4.715; KASUYA H, 1989, J NEUROSURG, V71, P741, DOI 10.3171/jns.1989.71.5.0741; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Kochanek P M, 1993, Crit Care Med, V21, pS333, DOI 10.1097/00003246-199309001-00016; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kossmann T, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P263; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; Lindsberg PJ, 1996, ANN NEUROL, V40, P587, DOI 10.1002/ana.410400408; Luer MS, 1996, PHARMACOTHERAPY, V16, P830; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P158; MullerLadner U, 1996, J NEUROL SCI, V144, P135, DOI 10.1016/S0022-510X(96)00217-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; OPPERMANN M, 1994, IMMUNOLOGY, V82, P516; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; RINK A, 1995, AM J PATHOL, V147, P1575; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; ROTH J, 1992, LAB INVEST, V67, P263; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; SPIEGEL K, IN PRESS INFLAMMATOR; Stahel PF, 1997, J IMMUNOL, V159, P861; Tornqvist E, 1996, NEUROBIOL AGING, V17, P695; TUOMANEN E, 1986, MICROB PATHOGENESIS, V1, P15, DOI 10.1016/0882-4010(86)90028-8; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; XIA M, 1996, J NEUROPATHOL EXP NE, V55, P619; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; ZWAHLEN A, 1982, J INFECT DIS, V145, P635, DOI 10.1093/infdis/145.2.635	62	60	60	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	OCT 15	1997	50	1-2					205	212		10.1016/S0169-328X(97)00189-7			8	Neurosciences	Neurosciences & Neurology	YF868	WOS:A1997YF86800026	9406936				2021-06-18	
J	Hall, ED; Andrus, PK; Smith, SL; Fleck, TJ; Scherch, HM; Lutzke, BS; Sawada, GA; Althaus, JS; Vonvoigtlander, PF; Padbury, GE; Larson, PG; Palmer, JR; Bundy, GL				Hall, ED; Andrus, PK; Smith, SL; Fleck, TJ; Scherch, HM; Lutzke, BS; Sawada, GA; Althaus, JS; Vonvoigtlander, PF; Padbury, GE; Larson, PG; Palmer, JR; Bundy, GL			Pyrrolopyrimidines: Novel brain-penetrating antioxidants with neuroprotective activity in brain injury and ischemia models	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							NERVOUS-SYSTEM TRAUMA; CEREBRAL-ARTERY OCCLUSION; LIPID-PEROXIDATION; FOREBRAIN ISCHEMIA; PARKINSONS-DISEASE; TRANSIENT; U74006F; RATS; 21-AMINOSTEROIDS; PROTECTION	A novel group of antioxidant compounds, the pyrrolopyrimidines, has been discovered recently. Many of these possess significantly improved oral bioavailability (56-70% in rats), increased efficacy and potency in protecting cultured neurons against iron-induced lipid peroxidative injury and as much as a 5-fold increase in brain uptake compared with the 21-aminosteroid antioxidant compound, tirilazad mesylate (U-74006F), described earlier. They appear to quench lipid peroxidation reactions by electron-donating and/or radical-trapping mechanisms. Several compounds in the series, such as U-101033E and U-104067F, demonstrate greater ability than tirilazad to protect the hippocampal CA1 region in the gerbil transient (5-min) forebrain ischemia model. Delaying treatment until 4 hr after the ischemic insult still results in significant CA1 neuronal protection. U-101033E is still effective in salvaging a portion of the CA1 neuronal population when the ischemic duration is extended to 10 min. In addition, U-101033E has been found to be protective in the context of focal cerebral ischemia, reducing infarct size in the mouse permanent middle cerebral artery occlusion model, in contrast to tirilazad which is minimally effective. These results suggest that antioxidant compounds with improved brain parenchymal penetration are better able to limit certain types of ischemic brain damage than those which are localized in the cerebral microvasculature. However, the activity of U-101033E in improving early post-traumatic recovery in mice subjected to severe concussive head injury is similar to that of tirilazad. Last, the oral bioavailability of many pyrrolopyrimidines suggests that they may be useful for certain chronic neurodegenerative disorders in which lipid peroxidation plays a role.	PHARMACIA & UPJOHN INC,DRUG DELIVERY SYST RES,KALAMAZOO,MI 49001; PHARMACIA & UPJOHN INC,DRUG METAB RES,KALAMAZOO,MI 49001; PHARMACIA & UPJOHN INC,MED CHEM RES,KALAMAZOO,MI 49001	Hall, ED (corresponding author), PHARMACIA & UPJOHN INC,CNS DIS RES,KALAMAZOO,MI 49001, USA.		Hall, Edward D/F-8930-2013				AUDUS KL, 1991, FREE RADICAL BIO MED, V11, P361, DOI 10.1016/0891-5849(91)90152-S; BECK T, 1990, BRAIN RES, V532, P336, DOI 10.1016/0006-8993(90)91779-G; BECK T, 1991, BRAIN RES, V560, P159, DOI 10.1016/0006-8993(91)91226-Q; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BUCHAN AM, 1992, J CEREBR BLOOD F MET, V12, P250, DOI 10.1038/jcbfm.1992.35; BUNDY GL, 1995, J MED CHEM, V38, P4161, DOI 10.1021/jm00021a004; BUXSER S, 1981, INFECT IMMUN, V31, P929, DOI 10.1128/IAI.31.3.929-934.1981; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; CLEMENS JA, 1991, STROKE, V22, P1048, DOI 10.1161/01.STR.22.8.1048; COHEN G, 1986, ADV NEUROL, V45, P119; FICI GJ, 1996, FREE RADIC BIOL MED, V22, P223; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; HALL ED, 1993, STROKE, V24, P711, DOI 10.1161/01.STR.24.5.711; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1988, STROKE, V19, P1008, DOI 10.1161/01.STR.19.8.1008; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALL ED, 1995, ACTA NEUROCHIR S, V66, P107; JENNER P, 1992, NEUROLOGY, V42, P2241, DOI 10.1212/WNL.42.12.2241; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; PAHLMARK K, 1993, STROKE, V24, P731, DOI 10.1161/01.STR.24.5.731; PARK CK, 1994, BRAIN RES, V645, P157; PHILLIS JW, 1990, NEUROSCI LETT, V116, P315, DOI 10.1016/0304-3940(90)90093-O; PREHN JHM, 1992, J CEREBR BLOOD F MET, V12, P78, DOI 10.1038/jcbfm.1992.10; Raub TJ, 1993, J DRUG TARGET, V1, P269, DOI 10.3109/10611869308996085; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sawada G. A., 1995, Pharmaceutical Research (New York), V12, pS311; Sawada G. A., 1995, Pharmaceutical Research (New York), V12, pS300; SCHMIDELSAESSER R, 1996, CEREBROVASC DIS, V6, P43; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SMITH MA, 1994, ANN NY ACAD SCI, V738, P447; SUBBARAO KV, 1990, J NEUROCHEM, V55, P342, DOI 10.1111/j.1471-4159.1990.tb08858.x; SUTHERLAND G, 1993, NEUROSCI LETT, V149, P123, DOI 10.1016/0304-3940(93)90751-6; XUE D, 1992, STROKE, V23, P894, DOI 10.1161/01.STR.23.6.894; YOUDIM MBH, 1993, MOVEMENT DISORD, V8, P1, DOI 10.1002/mds.870080102; Zhang JR, 1996, J NEUROCHEM, V66, P355; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	39	60	61	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	MAY	1997	281	2					895	904					10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	WX658	WOS:A1997WX65800037	9152399				2021-06-18	
J	Max, JE; Smith, WL; Sato, Y; Mattheis, PJ; Castillo, CS; Lindgren, SD; Robin, DA; Stierwalt, JAG				Max, JE; Smith, WL; Sato, Y; Mattheis, PJ; Castillo, CS; Lindgren, SD; Robin, DA; Stierwalt, JAG			Traumatic brain injury in children and adolescents: Psychiatric disorders in the first three months	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; children; adolescents; psychiatric disorder	HEAD-INJURY; FAMILY; RELIABILITY; SEVERITY; SCALE	Objective: To assess predictive factors of psychiatric outcome in the first 3 months after traumatic brain injury (TBI) in children and adolescents. Method: Subjects were children aged 6 to 14 years at the time they were hospitalized after TBI. The study used a prospective follow-up design. Assessments of preinjury psychiatric, behavioral, adaptive functioning, family functioning, and family psychiatric history status were conducted. Severity of injury was assessed by standard clinical scales and neuroimaging was analyzed. The outcome measure was the development of a psychiatric disorder, never before present (''novel'') in a subject during the first 3 months after the TBI. Results: Fifty subjects enrolled, and the analyses focused on 37 subjects followed up at 3 months. Increasing severity of injury, presence of a lifetime psychiatric disorder, family psychiatric history, family dysfunction, and lower socioeconomic class/preinjury intellectual function predicted the development of a ''novel'' psychiatric disorder in the first 3 months of follow-up. Conclusions: These data suggest that there are children, identifiable through clinical assessment, at increased risk for development of psychiatric disorders in the first 3 months after TBI.	UNIV MONTANA,MISSOULA,MT 59812; CEDAR CTR,PSYCHIAT GRP,CEDAR RAPIDS,IA; UNIV IOWA,DEPT PSYCHIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT RADIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT SPEECH PATHOL & AUDIOL,IOWA CITY,IA 52242			Robin, Donald/F-2109-2010	Sato, Yutaka/0000-0002-5245-232X			ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; Black P, 1981, BRAIN DYSFUNCTION CH, P171; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Garmezy N., 1994, CHILD ADOLESCENT PSY, P191; GERSON AC, 1993, P ANN M AM AC CHILD; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Hoover H.D., 1986, MANUAL SCH ADM IOWA; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; MARSHALL LD, 1991, J NEUROSURG, V75, P514; Max J. E., 1992, NEUROPSYCHIATRIC RAT; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Sparrow S., 1984, VINELAND ADAPTIVE BE; *SPSS, 1993, SPSS WIND PROF STAT; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81	28	60	60	0	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	JAN	1997	36	1					94	102		10.1097/00004583-199701000-00022			9	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	WA553	WOS:A1997WA55300023	9000786				2021-06-18	
J	Lucius, R; Sievers, J				Lucius, R; Sievers, J			Postnatal retinal ganglion cells in vitro: Protection against reactive oxygen species (ROS)-induced axonal degeneration by cocultured astrocytes	BRAIN RESEARCH			English	Article						retinal ganglion cell; axonal regeneration; astrocyte; reactive oxygen species; neurotoxicity	CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE; ACTIVATED MICROGLIA; SUPPORT SURVIVAL; CULTURED NEURONS; MAMMALIAN BRAIN; FREE-RADICALS; ADULT MICE; RAT-BRAIN; GLUTATHIONE	Reactive oxygen species (ROS) are supposed to be involved in neurodegenerative processes like Parkinson's or Alzheimer's disease. Beside this there are an increasing number of studies indicating an involvement of ROS in traumatic brain injury. We therefore studied the potential role of astrocytes against neurotoxic effects of ROS in cocultures of rat cortical astrocytes with regenerating postnatal retinal ganglion cells (RGC). The sydnonimine SIN-1, which spontaneously decomposes to yield nitric oxide (NO) and superoxide anion radicals, led to axonal degeneration at concentrations between 1 mu M and 10 mu M. Comparable effects were seen after addition of iron salts (Fe2(+)/Fe3(+)), which catalyze the generation of hydroxyl radicals. In contrast, in cocultures of RGC with astrocytes or after addition of free radical scavengers there was no neurotoxic/neurodegenerative effect of ROS as compared with control cultures. Vitamin E (1-10 mu M) and vitamin C (10-100 mu M) abolished the neurotoxic effect of both SIN-1 or iron ions. Beside this, there was an additional effect concerning the number and the length of neurites growing out from the retinal explant: in cocultures both parameters were greatly enhanced. These results suggest that (i) astrocytes are able to protect retinal ganglion cells against ROS-induced oxidative stress, (ii) astrocytes release soluble neurotrophic factors supporting RGC axonal regeneration, and (iii) free radical production after tissue injury may partly contribute to the failure of axonal regeneration in the adult mammalian central nervous system.		Lucius, R (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,INST ANAT,OLSHAUSENSTR 40,D-24118 KIEL,GERMANY.		Lucius, Ralph/B-1614-2010; Sievers, Jobst/A-8672-2010				ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R; ALLCUTT D, 1984, DEV BRAIN RES, V16, P219, DOI 10.1016/0165-3806(84)90027-0; ALLCUTT D, 1984, DEV BRAIN RES, V16, P231, DOI 10.1016/0165-3806(84)90028-2; ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BANKER GA, 1980, SCIENCE, V209, P809, DOI 10.1126/science.7403847; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BUSCIGILO J, 1996, NATURE, V378, P776; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHAO CC, 1993, J IMMUNOL, V151, P1473; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEGROOT H, 1993, FEBS LETT, V315, P139, DOI 10.1016/0014-5793(93)81150-X; Demopoulos H, 1979, NEURAL TRAUMA, P63; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Giulian D., 1992, CURRENT TOPICS NEURO, V12, P23; GREEN SJ, 1991, J LEUKOCYTE BIOL, V50, P93; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUSAIN J, 1995, BRAIN RES, V698, P86, DOI 10.1016/0006-8993(95)00832-B; Kirschner PB, 1996, BRAIN RES, V713, P178, DOI 10.1016/0006-8993(95)01513-2; LANGEVELD CH, 1995, NEUROSCI LETT, V192, P13, DOI 10.1016/0304-3940(95)11596-O; LIESI P, 1983, J CELL BIOL, V96, P920, DOI 10.1083/jcb.96.3.920; LIESI P, 1986, EXP CELL RES, V163, P175, DOI 10.1016/0014-4827(86)90570-7; LINDSAY RM, 1979, NATURE, V282, P80, DOI 10.1038/282080a0; LIU DX, 1994, J NEUROCHEM, V62, P37; LUCIUS R, 1995, J NEUROCHEM, V64, P1841; Lucius R, 1996, INT J DEV NEUROSCI, V14, P387; MAKAR TK, 1994, J NEUROCHEM, V62, P45; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OGAWA N, 1994, BRAIN RES, V657, P207, DOI 10.1016/0006-8993(94)90969-5; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; RATAN RR, 1994, J NEUROCHEM, V62, P376; RICHARDSON A, 1993, GLIA, V7, P25, DOI 10.1002/glia.440070107; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SAGARA J, 1993, J NEUROCHEM, V61, P1672, DOI 10.1111/j.1471-4159.1993.tb09802.x; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; THANOS S, 1989, EUR J NEUROSCI, V1, P19, DOI 10.1111/j.1460-9568.1989.tb00770.x; TIDOW S, 1988, SENSE ORGANS, P347; VARON S, 1984, J NEUROSCI, V4, P654; ZIELASEK J, 1992, CELL IMMUNOL, V141, P114	48	60	60	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	DEC 16	1996	743	1-2					56	62		10.1016/S0006-8993(96)01029-3			7	Neurosciences	Neurosciences & Neurology	WC373	WOS:A1996WC37300008	9017230				2021-06-18	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Traumatic brain axonal injury produces sustained decline in intracellular free magnesium concentration	BRAIN RESEARCH			English	Article						nuclear magnetic resonance; trauma; brain injury	RAT; DEFICIENCY; METABOLISM; MECHANISMS; ISCHEMIA; NEURONS; DAMAGE; MG-2+	Decline in brain intracellular free magnesium concentration following experimental traumatic brain injury has been widely reported in a number of studies. However, to date, these studies have been confined to focal models of brain injury and temporally limited to the immediate 8-h period post-trauma. Recently, a new model of impact-acceleration brain injury has been developed which produces nonfocal diffuse axonal injury more typical of severe clinical trauma. The present study has used phosphorus magnetic resonance spectroscopy and the rotarod motor test to characterise magnesium homeostasis and neurologic outcome over a period of 8 days after induction of severe impact-acceleration injury in rats. Severe impact-acceleration induced injury resulted in a highly significant and sustained decline in intracellular free magnesium concentration that was apparent for 4 days post-trauma with recovery to preinjury levels by day six. There were no significant changes in pH or ATP concentration at any time point post-injury. All animals demonstrated a significant neurologic deficit over the assessment period. The extended period of magnesium decline after severe diffuse brain trauma suggests that repeated administration may be required for pharmacotherapies targeted at restoring magnesium homeostasis.	JAMES COOK UNIV N QUEENSLAND,DEPT PHYSIOL & PHARMACOL,TOWNSVILLE,QLD 4811,AUSTRALIA			Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667			AGUS ZS, 1991, ANNU REV PHYSIOL, V53, P299, DOI 10.1146/annurev.ph.53.030191.001503; ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524; Bara M, 1984, MAGNESIUM, V3, P212; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GARFINKEL L, 1985, Magnesium, V4, P60; GUNTHER T, 1994, MAGNESIUM-B, V16, P38; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALLAK M, 1994, J SOC GYNECOL INVEST, V1, P25, DOI 10.1177/107155769400100106; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; TERASAKI M, 1985, P NATL ACAD SCI USA, V82, P7324, DOI 10.1073/pnas.82.21.7324; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; VINK R, 1988, J BIOL CHEM, V263, P757; WELCH KMA, 1993, NEUROLOGY, V43, P21; WILLIAMS GD, 1995, MAGNET RESON MED, V33, P853, DOI 10.1002/mrm.1910330618	26	60	65	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 28	1996	738	1					150	153		10.1016/0006-8993(96)00957-2			4	Neurosciences	Neurosciences & Neurology	VT492	WOS:A1996VT49200020	8949939				2021-06-18	
J	Soblosky, JS; Matthews, MA; Davidson, JF; Tabor, SL; Carey, ME				Soblosky, JS; Matthews, MA; Davidson, JF; Tabor, SL; Carey, ME			Traumatic brain injury of the forelimb and hindlimb sensorimotor areas in the rat: Physiological, histological and behavioral correlates	BEHAVIOURAL BRAIN RESEARCH			English	Article						behavioral compensation; axonal degeneration; forelimb deficit; hindlimb deficit; cerebellum; sensorimotor cortex; traumatic brain injury; rat	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; MOTOR CORTEX; HEAD-INJURY; FUNCTIONAL RECOVERY; NEOCORTICAL DAMAGE; ORGANIZATION; NOREPINEPHRINE; AMPHETAMINE; CONTUSION	This study characterizes physiological, histological and behavioral effects of traumatic brain injury (TBI) produced by a controlled pneumatic impactor striking the entire right sensorimotor cortex of the anesthetized rat. Damage to both the fore- and hindlimb sensorimotor areas resulted in a hemiparetic animal which allowed us to use four sensitive behavioral/neurological tests to track the recovery sequelae after injury. Initial experiments measured cardiovascular and respiratory effects after cortical impact which depressed the dura to varying depths. Both 0.5 mm and 1 mm cortical depressions produced a momentary decrease (P<0.05) in mean arterial blood pressure (MABP) while cortical impacts to depths of 2 mm or 3 mm produced a momentary increase (P<0.05) in MABP. Normotension was re-established within 30 s after the initial response at all injury levels. Respiratory rate was affected only following 3 mm cortical depressions. A 1 mm cortical depression appeared ideal in terms of minimal cardiorespiratory effects, low mortality and lasting behavioral effects. For behavioral and histologic studies, therefore, additional rats were injured by a 1 mm cortical impact and tested for 8 weeks after TBI using four behavioral tests. Injured rats displayed both fore- and hindlimb deficits up to 56 days while traversing a narrow beam (P<0.001) and up to 28 days when crossing a pegged beam (P<0.05). Forelimb deficits evaluated on a wire grid platform were evident for 28 days (P<0.05). Forepaw preference measured in a non-test setting indicated a bias to use the unaffected::forepaw for 35 days (P<0.05). A biphasic pattern of functional recovery was seen on all tests. A period of rapid functional recovery lasting 7 to 10 days was followed by a slower period of functional recovery lasting many weeks. Possible meanings of this biphasic recovery are discussed as issues of behavioral compensation/adaptation versus true neural recovery. Eight weeks after TBI histological analyses indicated that axonal degeneration was present in the areas adjacent to the ipsilateral cortical injury site. Degenerating fibers also extended across the corpus callosum into the homologous area in the contralateral cortex and were seen in the ipsilateral striatum, somatosensory and motor thalamic nuclei and substantia nigra. Significant axonal degeneration occurred bilaterally around the deep cerebellar nuclei. Degenerating fibers extended into the folia and terminated in the cerebellar granule cell layer. Thus the entire sensorimotor control system appeared to have been affected by a cortical injury.	LOUISIANA STATE UNIV,MED CTR,DEPT ANAT,NEW ORLEANS,LA 70112	Soblosky, JS (corresponding author), LOUISIANA STATE UNIV,MED CTR,DEPT NEUROSURG,NEUROTRAUMA RES LAB,NEW ORLEANS,LA 70112, USA.						BARTH TM, 1990, STROKE, V21, P153; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P901; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BRAILOWSKY S, 1986, BRAIN RES, V362, P322, DOI 10.1016/0006-8993(86)90457-9; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; de Olmos JS, 1981, NEUROANATOMICAL TRAC, P117; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; EBRAHIMI A, 1992, NEUROSCI RES, V14, P39, DOI 10.1016/S0168-0102(05)80005-7; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; GOLDSTEIN LB, 1993, NEUROSCI PROTOCOLS, P1; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Ito, 1984, CEREBELLUM NEURAL CO; IZUMI Y, 1992, NEUROSCI LETT, V144, P121, DOI 10.1016/0304-3940(92)90730-U; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; Kolb B, 1991, CEREB CORTEX, V1, P189, DOI 10.1093/cercor/1.2.189; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; LEVERE TE, 1980, PHYSIOL PSYCHOL, V8, P297, DOI 10.3758/BF03337462; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARSHALL JF, 1985, INT REV NEUROBIOL, V26, P201, DOI 10.1016/S0074-7742(08)60075-6; MARSHALL JF, 1984, ANNU REV PSYCHOL, V35, P277, DOI 10.1146/annurev.psych.35.1.277; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PELLEGRINO I, 1979, STEREOTAXIC ATLAS RA; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; ROSE FD, 1993, BEHAV BRAIN RES, V5, P93; ROUILLER EM, 1991, NEUROSCI LETT, V125, P93, DOI 10.1016/0304-3940(91)90139-K; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SWITZER RC, 1991, NEUROSCI BIOBEHAV R, V15, P89, DOI 10.1016/S0149-7634(05)80097-1; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805	56	60	61	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	SEP	1996	79	1-2					79	92		10.1016/0166-4328(95)00264-2			14	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	VH444	WOS:A1996VH44400009	8883819				2021-06-18	
J	Reilly, JF; Kumari, VG				Reilly, JF; Kumari, VG			Alterations in fibroblast growth factor receptor expression following brain injury	EXPERIMENTAL NEUROLOGY			English	Article							FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; RAT CEREBRAL-CORTEX; MESSENGER-RNA; FGF RECEPTOR; FACTOR BFGF; DIFFERENTIAL EXPRESSION; ASTROCYTE PROLIFERATION; REACTIVE ASTROCYTES; ASTROGLIAL REACTION	Traumatic injuries to the central nervous system result in astrogliosis and the formation of a dense scar at the site of the wound. Basic fibroblast growth factor (bFGF) has mitogenic and morphogenic effects on astrocytes, and an interaction between bFGF and its receptor is likely to play a role in astrogliosis. We examined trauma-induced changes in the spatial and temporal expression of FGF receptor (FGFR) in adult rats over a 28-day period following a stereotaxic lesion through the cortex and hippocampus. Immunohistochemistry and image analysis were used to evaluate the changes. Antibody characterization studies strongly suggested that staining represented FGFR 1, but did not rule out possible cross-reactivity with FGFR 2 or 3. Double immunohistochemistry for FGFR and glial fibrillary acidic protein demonstrated that mature astrocytes expressed FGFR. Expression was increased on astrocytes adjacent to the wound cavity by Day 2 postlesion. Staining increased further through Day 10 and decreased to control values by Day 28, except for a sustained increase in staining of reactive astrocytes immediately adjacent to the wound cavity. Basic FGF was detected in the nuclei of cells staining for FGFR, suggesting that FGFR-expressing astrocytes also contained bFGF. These data demonstrate a time course for astrocyte expression of FGFR that precedes and parallels the time course for astrocyte hypertrophy. Our observations suggest that endogenous bFGF, acting directly on FGFR-expressing astrocytes, may contribute to astrogliosis. (C) 1996 Academic Press, Inc.		Reilly, JF (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT HUMAN ANAT & CELL BIOL,DAVIS,CA 95616, USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 06159] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG006159] Funding Source: NIH RePORTER		ALONSO G, 1993, J NEUROSCI RES, V34, P523, DOI 10.1002/jnr.490340505; ASAI T, 1993, MOL BRAIN RES, V17, P174, DOI 10.1016/0169-328X(93)90088-7; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BAROTTE C, 1989, NEUROSCI LETT, V101, P197, DOI 10.1016/0304-3940(89)90530-2; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ECLANCHER F, 1990, GLIA, V3, P502, DOI 10.1002/glia.440030609; Emoto N, 1989, GROWTH FACTORS, V2, P21, DOI 10.3109/08977198909069078; ENDOH M, 1994, MOL BRAIN RES, V22, P76, DOI 10.1016/0169-328X(94)90034-5; FERRARA N, 1988, BRAIN RES, V462, P223, DOI 10.1016/0006-8993(88)90550-1; FINKLESTEIN SP, 1990, STROKE, V21, P122; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GOMEZPINILLA F, 1992, NEUROSCIENCE, V49, P771, DOI 10.1016/0306-4522(92)90355-6; GOMEZPINILLA F, 1995, J NEUROSCI, V15, P2021; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GUILIAN D, 1989, Journal of Neuroscience, V9, P4416; Hajos F., 1993, Neurobiology (Budapest), V1, P123; HANNEKEN A, 1992, EXP EYE RES, V54, P1011, DOI 10.1016/0014-4835(92)90166-P; HOU YJ, 1995, J NEUROSCI RES, V40, P359, DOI 10.1002/jnr.490400310; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; ITOH N, 1994, MOL BRAIN RES, V21, P344, DOI 10.1016/0169-328X(94)90265-8; JANECZKO K, 1989, BRAIN RES, V485, P236, DOI 10.1016/0006-8993(89)90566-0; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATO T, 1991, NEUROSCI LETT, V122, P33, DOI 10.1016/0304-3940(91)90186-W; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kuchler Karl, 1993, Trends in Cell Biology, V3, P421, DOI 10.1016/0962-8924(93)90030-5; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1988, MOL CELL ENDOCRINOL, V58, P275, DOI 10.1016/0303-7207(88)90164-5; LOGAN A, 1992, J NEUROSCI, V12, P3828; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MENON VK, 1994, EXP NEUROL, V129, P142, DOI 10.1006/exnr.1994.1155; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; MOUMDJIAN RA, 1991, BRAIN RES, V547, P223, DOI 10.1016/0006-8993(91)90965-X; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; SAITO H, 1991, BIOCHEM BIOPH RES CO, V174, P136, DOI 10.1016/0006-291X(91)90496-T; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; TAKAMI K, 1993, EXP BRAIN RES, V97, P185; TETZLAFF W, 1988, GLIA, V1, P90, DOI 10.1002/glia.440010110; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; TORRIGLIA A, 1994, NEUROSCI LETT, V172, P125, DOI 10.1016/0304-3940(94)90678-5; VANDERWAL EA, 1994, NEUROSCIENCE, V60, P311, DOI 10.1016/0306-4522(94)90245-3; VENKATESWARAN S, 1992, HYBRIDOMA, V11, P729, DOI 10.1089/hyb.1992.11.729; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; VIJAYAN VK, 1993, INT J DEV NEUROSCI, V11, P257, DOI 10.1016/0736-5748(93)90084-Q; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403	52	60	61	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	AUG	1996	140	2					139	150		10.1006/exnr.1996.0124			12	Neurosciences	Neurosciences & Neurology	VA089	WOS:A1996VA08900004	8690057				2021-06-18	
J	Veltman, JC; Brouwer, WH; vanZomeren, AH; vanWolffelaar, PC				Veltman, JC; Brouwer, WH; vanZomeren, AH; vanWolffelaar, PC			Central executive aspects of attention in subacute severe and very severe closed head injury patients: Planning, inhibition, flexibility, and divided attention	NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE DAMAGE; WORKING-MEMORY; DEFICITS	Central executive aspects of attention were investigated in a group of 20 closed head injury (CHI) patients with an average posttraumatic amnesia duration of 23.9 days, tested in the first half year after injury. Four aspects were distinguished: planning, inhibition, flexibility, and divided attention. Tasks allowed assessment of these with experimental or statistical control for the individual speed of information processing. This precaution appears necessary because slow information processing is a pervasive effect of CHI and may cause spurious effects on complex cognitive tasks under time pressure. Strong effects of CHI were shown on speed of information processing. Controlling this factor, central executive aspects of attention were normal, on average. A tentative analysis of the results in relation to severity indicated that less severely injured patients are better in this respect than controls, and more severely injured patients are worse. In comparison with the healthy control group, the performance of those with milder injuries appears to be characterized by greater cautiousness and increased mental effort.	UNIV GRONINGEN HOSP, DEPT NEUROPSYCHOL, NL-9700 RB GRONINGEN, NETHERLANDS; UNIV GRONINGEN, TRAFF RES CTR, HAREN, NETHERLANDS							ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ALLPORT A, 1993, ATTENTION PERFORM, V14, P183; AZOUVI P, 1995, J INT NEUROPSYCH SOC, V1, P213; Baddeley A., 1993, ATTENTION SELECTION, P152; Brouwer W.H., 1985, THESIS U GRONINGEN N; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; CANTAGALLO A, 1995, J INT NEUROPSYCH SOC, V1, P198; CLIFTON GL, 1980, J NEUROSURG, V52, P619; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; FASOTTI L, 1995, TRAUMATIC BRAIN INJU, P141; HARTMAN A, 1992, CLIN REHABIL, V6, P133; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Luria A. R., 1966, HIGHER CORTICAL FUNC; Mayer N., 1990, NEUROPSYCHOLOGY EVER, P259; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1989, THEORY FUNCTION BRID, P28; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, NEUROPSYCHOLOGY COGN, P199; SHALLICE T, 1993, ATTENTION PERFORM, V14, P395; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STANKOV L, 1988, PSYCHOL AGING, V3, P59, DOI 10.1037/0882-7974.3.1.59; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TROMP E, 1991, J CLIN EXPT NEUROPSY, V13, P828; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANWOLFFELAAR PC, 1991, COMP PSYCH, V3, P187; VANWOLFFELAAR PC, 1990, DRIVING BEHAV SOCIAL, P564; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; VILKKI J, 1995, J INT NEUROPSYCH SOC, V1, P208; Wickens C.D., 1984, VARIETIES ATTENTION, P63, DOI 10.1038/s41598-020-80452-5; WITTENBORN TR, 1943, PSYCHOMETRIKA, V8, P19	40	60	60	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	1996	10	3					357	367		10.1037/0894-4105.10.3.357			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	UY062	WOS:A1996UY06200006					2021-06-18	
J	Cicerone, KD; Smith, LC; Ellmo, W; Mangel, HR; Nelson, P; Chase, RF; Kalmar, K				Cicerone, KD; Smith, LC; Ellmo, W; Mangel, HR; Nelson, P; Chase, RF; Kalmar, K			Neuropsychological rehabilitation of mild traumatic brain injury	BRAIN INJURY			English	Article							CONCUSSION	A significant minority of patients who have sustained a mild traumatic brain injury (MTBI) may exhibit persistent disability. There have been few attempts to describe and evaluate the effectiveness of neurorehabilitation for these patients. We conducted a retrospective analysis of the results of a neuropsychological rehabilitation programme for 20 patients with MTBI. Based upon the ability to resume productive functioning after treatment, 10 patients were determined to exhibit a good outcome and 10 patients were considered to exhibit a poor outcome. Patients with good outcome exhibited significant pre-post-treatment improvements on both neuropsychological measures of cognitive functioning and self-reported post-concussive symptoms. Patients with poor outcome demonstrated little improvement in either area, and in some cases showed a decline in functioning. The results are consistent with the view that there may be significant variability in recovery and response to treatment after MTBI. There is a continued need to identify which patients may benefit from neurorehabilitation, develop specially tailored interventions, and conduct controlled, prospective studies in this area.	JFK JOHNSON REHABIL INST,EDISON,NJ							Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; AXELROD BN, 1993, CLIN NEUROPSYCHOL, V7, P205, DOI 10.1080/13854049308401523; Cicerone K. D., 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; KEPPEL G, 1983, DESIGN ANAL; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MATEER C, 1992, POSTCONCUSSIVE DISOR, P143; MATEER CA, 1990, COGNITIVE REHABILITA, P68; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Reitan R.M., 1993, HALSTEADREITAN NEURO; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SHUMWAYCOOK A, 1990, NEUROL CLIN, V8, P441, DOI 10.1016/S0733-8619(18)30366-9; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1974, MANUAL WECHSLER INTE	24	60	60	0	9	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	APR	1996	10	4					277	286		10.1080/026990596124458			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UJ541	WOS:A1996UJ54100005	9044693				2021-06-18	
J	Curt, A; Dietz, V				Curt, A; Dietz, V			Traumatic cervical spinal cord injury: Relation between somatosensory evoked potentials, neurological deficit, and hand function	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							NERVE-STIMULATION; QUADRIPLEGIA; RECOVERY; LESIONS; ULNAR; BRAIN; MOTOR; SEP	Objective: Median and ulnar somatosensory evoked potentials (SEP) in the assessment of cervical spinal cord injury (SCI) in relation to the outcome of hand function. Design: Cohort analytical study. Setting: Spinal cord injury center, university hospital. Patients: Consecutively sampled, 23 acute and 46 chronic tetraplegics. Main Outcome Measures: (1) Median and ulnar SEP recordings graded in 5 categories, from normal to absent; (2) clinical examination of algesia/aesthesia in dermatomes C5/6 and C8/Th1 graded in categories of normal, impaired, and loss of sensation; (3) clinical examination of hand function graded in 4 categories, from active to inactive hand function. Results: Pathological median and ulnar SEP were found in 46% and 76% of patients, respectively. A differentiation between upper (C3-C6) and lower (C6/C7-Th1) cervical SCI was possible by comparing the SEP N20 latencies (but not amplitudes) of both nerves (Mann-Whitney U test, p < .01). In follow-up examinations over 6 months the N20 amplitude increased significantly (ANCOVA, p < .001), while the N20 latency did not change. By both ulnar SEP recordings and assessment of the sensory deficit in dermatome C8/Th1 the outcome of hand function, ie, the development of active or inactive hand function, could be predicted (Mann-Whitney U test, p < .01). Conclusion: Median and ulnar SEP are valuable to indicate the level of injury, the degree of sensory impairment and to predict the outcome of hand function even in unconscious patients. They can improve the diagnostic assessment of cervical SCI. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation		Curt, A (corresponding author), UNIV HOSP BALGRIST, SWISS PARAPLEG CTR, FORCHSTR 340, CH-8008 ZURICH, SWITZERLAND.						BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BUCHNER H, 1991, EEG-EMG-Z ELEK ELEKT, V22, P51; CURTIN M, 1994, PARAPLEGIA, V32, P159, DOI 10.1038/sc.1994.29; DEMOL BAJM, 1990, THORAC CARDIOV SURG, V38, P146, DOI 10.1055/s-2007-1014009; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; DITUNNO JF, 1992, ARCH PHYS MED REHAB, V73, P431; DORFMAN LJ, 1980, J NEUROSURG, V52, P654, DOI 10.3171/jns.1980.52.5.0654; HASHIMOTO T, 1991, SPINAL CORD MONITORI, P431; HOULDEN DA, 1992, J TRAUMA, V33, P244, DOI 10.1097/00005373-199208000-00014; IZUMI T, 1991, SPINAL CORD MONITORI, P445; JACOBS SR, 1992, ARCH PHYS MED REHAB, V73, P790; JONES SJ, 1979, J NEUROL NEUROSUR PS, V42, P107, DOI 10.1136/jnnp.42.2.107; KIWERSKI J, 1981, PARAPLEGIA, V19, P31, DOI 10.1038/sc.1981.9; KOVINDHA A, 1992, PARAPLEGIA, V30, P502, DOI 10.1038/sc.1992.105; LARREA LG, 1988, ELECTROEN CLIN NEURO, V71, P180, DOI 10.1016/0168-5597(88)90003-2; LIVINGSTONE EF, 1984, ARCH PHYS MED REHAB, V65, P726; NAGATA S, 1991, SPINAL CORD MONITORI, P526; NUWER MR, 1994, ELECTROEN CLIN NEURO, V91, P6, DOI 10.1016/0013-4694(94)90012-4; RESTUCCIA D, 1992, NEUROLOGY, V42, P1054, DOI 10.1212/WNL.42.5.1054; RESTUCCIA D, 1993, NEUROLOGY, V43, P2269, DOI 10.1212/WNL.43.11.2269; RESTUCCIA D, 1994, J NEUROL NEUROSUR PS, V57, P301, DOI 10.1136/jnnp.57.3.301; ROWED DW, 1978, SURG NEUROL, V9, P203; ROWED DW, 1982, EARLY MANAGEMENT ACU, P167; SEDGWICK EM, 1980, J NEUROL NEUROSUR PS, V43, P823, DOI 10.1136/jnnp.43.9.823; TURANO G, 1991, BRAIN, V114, P663, DOI 10.1093/brain/114.1.663; VEILLEUX M, 1987, ELECTROEN CLIN NEURO, V68, P415, DOI 10.1016/0168-5597(87)90053-0; WATERS RL, 1993, ARCH PHYS MED REHAB, V74, P242; WATERS RL, 1994, ARCH PHYS MED REHAB, V75, P756; YIANNIKAS C, 1986, ARCH NEUROL-CHICAGO, V43, P1264, DOI 10.1001/archneur.1986.00520120046015; YORK DH, 1983, SPINE, V8, P832, DOI 10.1097/00007632-198311000-00004; Young W., 1982, EARLY MANAGEMENT ACU, P153	31	60	62	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1996	77	1					48	53		10.1016/S0003-9993(96)90219-1			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	TN532	WOS:A1996TN53200010	8554473				2021-06-18	
J	ANDERSON, CV; BIGLER, ED				ANDERSON, CV; BIGLER, ED			VENTRICULAR DILATION, CORTICAL ATROPHY, AND NEUROPSYCHOLOGICAL OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CLOSED HEAD-INJURY; DEGENERATIVE CHANGES; SEQUELAE; INDEX	Day-of-injury computed tomographic scans were compared with postinjury magnetic resonance imaging of 38 patients with traumatic brain injury. Ventricles and several white and gray matter structures were measured. Results demonstrated signficant changes in ventricular sizes and all measures of white matter. Changes in gray matter were nonsignficant, except in the putamen/globus pallidus. Patients were grouped according to ventricular change, and neuropsychological outcome was examined. The group with the highest ventricular change had significantly lower memory scores but did not show significant differences on tests of intellectual functioning. A three-dimensional image analysis was performed to enhance visualization of the injured brain.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,1086 SWKT,PROVO,UT 84602							ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Barr ML, 1988, HUMAN NERVOUS SYSTEM; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bigler E D, 1987, Arch Clin Neuropsychol, V2, P293, DOI 10.1016/0887-6177(87)90017-5; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Carpenter M.B., 1985, CORE TEXT NEUROANATO; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVINHS, 1989, J CLIN EXP NEUROPSYC, V12, P129; MACNAMARA SE, 1992, ARCH CLIN NEUROPSYCH, V7, P275, DOI 10.1016/0887-6177(92)90169-N; MARTINEZ PFA, 1985, NEUROANATOMY; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; RUTTER M, 1982, Journal of Clinical Neuropsychology, V4, P91, DOI 10.1080/01688638208401121; SATTLER JM, 1992, ASSESSMENT CHILDRENS; SATZ P, 1992, NEUROLOGY, V7, P273; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29	26	60	61	0	2	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1995	7	1					42	48					7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	QD727	WOS:A1995QD72700007	7711490				2021-06-18	
J	KREUTZER, JS; MARWITZ, JH; WITOL, AD				KREUTZER, JS; MARWITZ, JH; WITOL, AD			INTERRELATIONSHIPS BETWEEN CRIME, SUBSTANCE-ABUSE, AND AGGRESSIVE BEHAVIORS AMONG PERSONS WITH TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							HEAD-INJURY	Professionals have suggested that aggessiveness, substance abuse, and criminality contribute to poor outcomes after brain injury. There is considerable research regarding post-injury aggressive behaviour, but limited information concerning criminal behaviour and alcohol use patterns. With a sample of 327 patients varying in severity of traumatic brain injury, the present investigation examined alcohol use patterns, arrest histories, behavioural characteristics, and psychiatric treatment histories. Relative to the uninjured population, analysis revealed relatively high incidence of heavy drinking, both pre- and post-injury, among patients with a history of arrest. Increases in abstinence rates were found regardless of arrest history. In addition, a history of arrest was associated with a seater likelihood of psychiatric treatment. Findings also indicated relatively high levels of aggressive behaviours. Discussion focuses on implications for evaluation, rehabilitation, and future research.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROL SURG,RICHMOND,VA 23298	KREUTZER, JS (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT REHABIL MED,RICHMOND,VA 23298, USA.						ABRAMS D, 1993, J HEAD TRAUMA REHABI, V4, P59; BAUNACH P, 1988, REPORT NATION CRIME, P30; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; GAILBRAITH S, 1976, BRIT J SURG, V63, P735; GLOW BA, 1989, ALCOHOLISM SUBSTANCE, P65; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HURLEY J, 1990, ALCOHOL HLTH; JOHNSON P, 1977, ADM281760200; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1987, GENERAL HLTH HIST QU; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LEZAK M, 1983, NEUROPSYCHOLOGICAL A, P212; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MILLER JD, 1983, ADM831277; NOBEL EP, 1978, HE2083132 US DHEW RE; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Reilly E L, 1986, Adv Psychosom Med, V16, P17; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; ZAWITZ MW, 1988, NCJ105506 US DEP JUS; 1985, ALCOHOL USE PERSONS	25	60	60	0	9	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	NOV-DEC	1995	9	8					757	768		10.3109/02699059509008232			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TH499	WOS:A1995TH49900001	8605509				2021-06-18	
J	FUKUDA, K; PANTER, SS; SHARP, FR; NOBLE, LJ				FUKUDA, K; PANTER, SS; SHARP, FR; NOBLE, LJ			INDUCTION OF HEME OXYGENASE-1 (HO-1) AFTER TRAUMATIC BRAIN INJURY IN THE RAT	NEUROSCIENCE LETTERS			English	Article						HEME OXYGENASE; HEMORRHAGE; RATS; TRAUMATIC BRAIN INJURY	MESSENGER-RNA; PROTEIN; ANTIOXIDANT; EXPRESSION; BILIRUBIN; HSP32	The induction of heme oxygenase-1 (HO-1), the 32 kDa heat shock protein, was examined in the traumatized rat brain. At 24 h after either mild or severe brain injury or sham surgery, HO-1 was immunolocalized in fixed sections of brain. After mild brain injury, hemorrhage was apparent in the subarachnoid space, external capsule and cerebellum. HO-1 was induced in similar areas in macrophages in the subarachnoid space and in glia in the cortex adjacent to the site of impact, the ipsilateral hippocampus, external capsule and cerebellum. After severe brain injury, extensive hemorrhage occurred in the external capsule, hippocampus and cerebellum. HO-1 was induced in glia in these areas of hemorrhage but was more extensive than that seen after mild injury and included the contralateral external capsule and hippocampus. These findings demonstrate remarkable induction of HO-1 in glia in the injured brain. Since heme is a potent inducer of HO-1, it is likely that the subarachnoid and/or intraparenchymal blood induced HO-1 in the glia where the heme was metabolized to biliverdin, iron, and carbon monoxide.	UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94121					NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL053040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, R01NS028167, P01NS014543] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL53040] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS28167, NS14543] Funding Source: Medline		BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KEYSE SM, 1989, CARCINOGENESIS, V11, P787; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; MAINES MD, 1988, FASEB J, V2, P2557; MATZ P, 1995, UNPUB J CEREB BLOOD; NIMURA T, 1995, UNPUB STROKE; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; PASCHEN W, 1994, NEUROSCI LETT, V180, P5, DOI 10.1016/0304-3940(94)90900-8; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUN Y, 1990, J BIOL CHEM, V265, P8212; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352	18	60	61	0	3	ELSEVIER SCI PUBL IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	OCT 20	1995	199	2					127	130		10.1016/0304-3940(95)12042-3			4	Neurosciences	Neurosciences & Neurology	TE035	WOS:A1995TE03500012	8584240				2021-06-18	
J	MEJIA, RE; POLLACK, MM				MEJIA, RE; POLLACK, MM			VARIABILITY IN BRAIN-DEATH DETERMINATION PRACTICES IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES	Objective.-To investigate variability in practices for determining brain death and organ procurement results in pediatric intensive care units (PICUs). Design.-Prospective cohort study. Setting.-Pediatric ICUs. Patients.-Children undergoing brain death evaluations selected from 5415 consecutive PICU admissions. Main Outcome Measures.-Data from children undergoing brain death evaluations including number of coma examinations, number and duration of apnea tests, Pco(2) measurements at the end of the apnea test, ancillary tests used to confirm brain death, organ procurement, and reasons for nonprocurement. Results.-A total of 93 (37%) of 248 deaths were brain deaths. Compared with the other deaths, children who were classified as brain dead were sicker on admission (mean Pediatric Risk of Mortality [PRISM] score+/-SD: 31+/-11 vs 23+/-12, P<,001; pre-ICU cardiopulmonary resuscitation, 72% vs 40%, P<.001), and had more traumatic injuries (42% vs 12%, P<.001). Variability in apnea testing included lack of apnea testing in 23 patients (25%) and controversial apnea testing practices in 20 patients (22%). Three patients (3%) had brain death evaluations within hours of discontinuing barbiturate infusions, and four of 30 patients younger than 1 year did not have a confirmatory test, Solid organ procurement was successful in 32%, Reasons for nonprocurement included parental refusal (12%), disease state (12%), and medical examiner's case (22%). Conclusions.-Substantial variability exists in the criteria used by clinicians for the diagnosis of brain death. Some practices are contradictory to the Guidelines for the Determination of Brain Death in Children and to recommendations for apnea testing. Organ procurement could be improved by increased medical examiner cooperation.	CHILDRENS NATL MED CTR,DEPT CRIT CARE MED,WASHINGTON,DC 20010; CHILDRENS NATL MED CTR,CHILRENS RES INST,CTR HLTH SERV & CLIN RES,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCH-110584] Funding Source: Medline		ALJUMAH M, 1992, CRIT CARE MED, V20, P1564; ASHWAL S, 1993, J HEART LUNG TRANSPL, V12, pS176; Ashwal S, 1991, Adv Pediatr, V38, P181; DRAKE B, 1986, PEDIATRICS, V78, P107; EDMONDS JF, 1989, PEDIAT BRAIN DEATH O, P89; FACKLER JC, 1988, AM J DIS CHILD, V142, P999, DOI 10.1001/archpedi.1988.02150090097034; FREEMAN JM, 1988, PEDIATRICS, V81, P301; GONNELLA JS, 1986, DISEASE STAGING CLIN; Hauser J E, 1969, J Forensic Sci, V14, P501; KAUFMAN HH, 1989, NEUROSURGERY, V25, P275, DOI 10.1227/00006123-198908000-00019; KOHRMAN MH, 1990, PEDIATR NEUROL, V6, P47, DOI 10.1016/0887-8994(90)90078-F; LEVETOWN M, 1994, JAMA-J AM MED ASSOC, V272, P1271, DOI 10.1001/jama.272.16.1271; NARKEWICZ RM, 1989, PEDIATRICS, V83, P629; POLLACK MM, 1993, CRIT CARE MED, V21, P607, DOI 10.1097/00003246-199304000-00023; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; POWNER DJ, 1976, JAMA-J AM MED ASSOC, V236, P1123, DOI 10.1001/jama.236.10.1123; RIVIELLO JJ, 1988, PEDIATR NEUROL, V4, P213, DOI 10.1016/0887-8994(88)90033-1; SCHAFER JA, 1984, CRIT CARE MED, V12, P357; SHAFER T, 1994, JAMA-J AM MED ASSOC, V272, P1607, DOI 10.1001/jama.272.20.1607; SHERIDAN F, 1993, J HEART LUNG TRANSPL, V12, pS179; SHEWMON DA, 1988, ANN NEUROL, V24, P789; SHEWMON DA, 1988, NEUROLOGY, V38, P1813, DOI 10.1212/WNL.38.11.1813-b; SQUIRES S, 1993, WASHINGTON POST 1118; SQUIRES S, 1994, WASHINGTON POST 0729; STAWORN D, 1994, CRIT CARE MED, V22, P1301, DOI 10.1097/00003246-199408000-00014; 1984, PEDIATRICS, V74, P505; 1981, JAMA-J AM MED ASSOC, V246, P2184	28	60	62	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					550	553		10.1001/jama.274.7.550			4	Medicine, General & Internal	General & Internal Medicine	RN466	WOS:A1995RN46600025	7629983				2021-06-18	
J	LANKFORD, DA; WELLMAN, JJ; OHARA, C				LANKFORD, DA; WELLMAN, JJ; OHARA, C			POSTTRAUMATIC NARCOLEPSY IN MILD-TO-MODERATE CLOSED-HEAD INJURY	SLEEP			English	Article; Proceedings Paper	4th International Conference on Narcolepsy	OCT 17-18, 1993	PARIS, FRANCE			POSTTRAUMATIC NARCOLEPSY; HEAD INJURY; SECONDARY NARCOLEPSY; HLA TYPING; NARCOLEPSY		Scattered reports exist describing secondary narcolepsy that develops following disease or organic insult to the brain. The present study is concerned with one particular type of secondary narcolepsy, posttraumatic narcolepsy, which we define as ''narcolepsy that develops following a head injury in a previously asymptomatic individual''. We obtained data on nine patients who had been previously diagnosed with mild to moderate closed head injury and who had unresolved sleep complaints. All patients presented with complaints of excessive daytime somnolence and/or sleep attacks. Patients also presented with a mix of cataplexy, hypnagogic hallucinations and/ or sleep paralysis. All patients had undergone previous neurological and/or neuropsychological evaluation and testing, with seven of the nine patients having the Halstead-Reitan Neuropsychological Test Battery. Human leucocyte antigen (HLA) tissue typing was obtained in six of the nine cases. The standard protocol was utilized, consisting of overnight polysomnography with a Multiple Sleep Latency Test (MSLT) the following day. All patients' histories were negative for narcolepsy or any other significant sleep disorders prior to the head injury. The results of the neuropsychological testing indicated that all patients fell within the mild to moderate impairment range. The results of overnight polysomnography and MSLT data, along with patient histories, indicated a diagnosis of narcolepsy in all cases. The results of HLA typing indicated that three patients were DR2 positive, two were DR4 positive and one was DQW1 positive. We conclude that narcolepsy may be ''dormant'' and that, in cases genetically at risk, even a minor injury to the central nervous system can cause that person to become symptomatic. In other cases, our data call into question the relationship of HLA type to narcolepsy, then point to the possibility of additional variance in narcolepsy.		LANKFORD, DA (corresponding author), SLEEP DISORDERS CTR GEORGIA,ATLANTA,GA, USA.						BROUGHTON RJ, 1990, HDB SLEEP DISORDERS, P197; GOOD JL, 1989, J NEUROSURG, V71, P765, DOI 10.3171/jns.1989.71.5.0765; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; GUILLEMINAULT C, 1989, PRINCIPLES PRACTICE, P338; Honda Y., 1990, HDB SLEEP DISORDERS, P217; HONDA Y, 1989, 3RD SEL P INT S NARC, P27; MACCARIO M, 1987, MIL MED, V152, P370; PARKES JD, 1985, SLEEP ITS DISORDERS; 1990, INT CLASSIFICATION S	9	60	61	0	4	AMER SLEEP DISORDERS ASSOC	ROCHESTER	1610 14TH STREET NW SUITE 300, ROCHESTER, MN 55806	0161-8105			SLEEP	Sleep	DEC	1994	17	8		S			S25	S28		10.1093/sleep/17.suppl_8.S25			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	QD081	WOS:A1994QD08100007	7701196	Bronze			2021-06-18	
J	AIHARA, N; TANNO, H; HALL, JJ; PITTS, LH; NOBLE, LJ				AIHARA, N; TANNO, H; HALL, JJ; PITTS, LH; NOBLE, LJ			IMMUNOCYTOCHEMICAL LOCALIZATION OF IMMUNOGLOBULINS IN THE RAT-BRAIN - RELATIONSHIP TO THE BLOOD-BRAIN-BARRIER	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						IMMUNOCYTOCHEMISTRY; IMMUNOGLOBULIN G; NEURONAL ACCUMULATION OF PROTEIN	CENTRAL NERVOUS-SYSTEM; RETROGRADE AXONAL-TRANSPORT; PROTEIN EXTRAVASATION; ENDOTHELIAL-CELLS; MOTOR NEURONS; MOUSE; IGG; INJURY; PERMEABILITY; PEROXIDASE	The central nervous system has been traditionally regarded as an immunologically privileged area. This feature has been in part attributed to the blood-brain barrier, which provides a restrictive interface to circulating immunoglobulins (IgG). Recent kinetic studies suggest that the barrier to immune proteins is not absolute, but rather may be regulated by a specific transfer mechanism. In this study, we confirm the presence of IgG in the central nervous system by immunocytochemistry and demonstrate a close anatomical relationship between the distribution of this protein and the blood-brain barrier. IgG was immunolocalized in the normal rat brain by using monoclonal and polyclonal antibodies to IgG and its subclasses. On the basis of an initial evaluation, the most appropriate antibodies and dilutions were selected for subsequent analyses. In the first study, IgG and albumin were immunolocalized in adjacent sections. In the second study, horseradish peroxidase (HRP) was given intravenously prior to sacrifice, in order to examine artifacts related to perfusion fixation. The distribution of HRP and IgG was then examined in adjacent sections. In the third study, IgG was immunolocalized in sections of brain after mild traumatic head injury. A monoclonal antibody to IgG2a and a polyclonal antibody to IgG were selected on the basis of specificity and consistent, mutual localization. Distinct, patchy, perivascular staining, infrequently associated with labeled neurons, was noted throughout the brain. Electron microscopy confirmed the perivascular localization; IgG was localized along the basal lamina of microvasculature and within the adjacent parenchyma. Albumin and HRP did not exhibit a similar pattern of perivascular immunostaining. After head injury, prominent immunostaining for IgG was observed in the injured hemisphere. In summary, these data indicate that the normal rat brain contains IgG, which dramatically increases after head injury. The distinct perivascular distribution in the normal brain suggests local microvascular permeability. This permeability is selective for IgG, since albumin does not share a similar perivascular localization. The neuronal staining which is closely associated with perivascular label may reflect one intracellular route for extravasated IgG. (C) 1994 Wiley-Liss, Inc.*	SAN FRANCISCO GEN HOSP, DEPT NEUROSURG, SAN FRANCISCO, CA 94110 USA; UNIV CALIF SAN FRANCISCO, CNS INJURY & EDEMA RES CTR, SAN FRANCISCO, CA 94110 USA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, R01NS023324, P50NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NINDS RO1 NS23324, NINDS NS14543] Funding Source: Medline		AZZI G, 1990, BIOL CELL, V68, P31, DOI 10.1016/0248-4900(90)90283-9; BALIN BJ, 1986, J COMP NEUROL, V251, P260, DOI 10.1002/cne.902510209; BRIGHTMA.MW, 1970, J NEUROL SCI, V10, P215, DOI 10.1016/0022-510X(70)90151-6; Brightman M W, 1968, Prog Brain Res, V29, P19; BROADWELL RD, 1976, J COMP NEUROL, V166, P257, DOI 10.1002/cne.901660302; BROADWELL RD, 1993, EXP NEUROL, V120, P245, DOI 10.1006/exnr.1993.1059; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; FABIAN RH, 1987, NEUROLOGY, V37, P1780, DOI 10.1212/WNL.37.11.1780; FISHMAN PS, 1989, J NEUROPATH EXP NEUR, V48, P212, DOI 10.1097/00005072-198903000-00008; HANSSON GK, 1984, P NATL ACAD SCI-BIOL, V81, P3103, DOI 10.1073/pnas.81.10.3103; HUGHES CCW, 1986, NEUROSCI LETT, V68, P100, DOI 10.1016/0304-3940(86)90237-5; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KOZLOWSKI GP, 1992, PROG BRAIN RES, V91, P149; KRISTENSSON K, 1971, BRAIN RES, V32, P399, DOI 10.1016/0006-8993(71)90332-5; MOOS T, 1991, NEUROSCI LETT, V127, P1, DOI 10.1016/0304-3940(91)90879-X; NAG S, 1981, J NEUROPATH EXP NEUR, V40, P327, DOI 10.1097/00005072-198105000-00092; NYLAND H, 1982, ACTA PATH MICRO IM C, V90, P217; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; POLLACK IF, 1990, EXP NEUROL, V108, P114, DOI 10.1016/0014-4886(90)90017-M; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; SCHMIDTKASTNER R, 1990, NEUROSCIENCE, V38, P527, DOI 10.1016/0306-4522(90)90048-9; SEITZ RJ, 1985, ACTA NEUROPATHOL, V68, P15, DOI 10.1007/BF00688950; SPARROW JR, 1981, BRAIN RES, V212, P159, DOI 10.1016/0006-8993(81)90044-5; SPARROW JR, 1980, J HISTOCHEM CYTOCHEM, V28, P570, DOI 10.1177/28.6.6993552; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TENGVAR C, 1986, ACTA NEUROPATHOL, V71, P177, DOI 10.1007/BF00688038; TRIGUERO D, 1989, P NATL ACAD SCI USA, V86, P4761, DOI 10.1073/pnas.86.12.4761; Westergaard E, 1980, Adv Neurol, V28, P55; WESTERGAARD E, 1973, J COMP NEUROL, V152, P17, DOI 10.1002/cne.901520103; YAMAMOTO T, 1987, NEUROLOGY, V37, P843, DOI 10.1212/WNL.37.5.843; ZLOKOVIC BV, 1990, EXP NEUROL, V107, P263, DOI 10.1016/0014-4886(90)90144-H	35	60	62	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	APR 22	1994	342	4					481	496		10.1002/cne.903420402			16	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	NF979	WOS:A1994NF97900001	8040362				2021-06-18	
J	ANDREWS, K				ANDREWS, K			RECOVERY OF PATIENTS AFTER 4 MONTHS OR MORE IN THE PERSISTENT VEGETATIVE STATE	BRITISH MEDICAL JOURNAL			English	Article							SEVERE HEAD-INJURY; TRAUMATIC COMA; PROGNOSIS	A retrospective review was made of the case notes of 43 consecutive patients admitted to a unit specialising in the rehabilitation of people in the persistent vegetative state. Eleven of these patients regained awareness four months or more after suffering brain damage. The time to the first reported incidence of eye tracking was between four months and three years, and the time to the first response to command was between four and 12 months. Only one patient was eventually unable to communicate, six could use non-verbal methods of indicating at least a yes or no response, and four were able to speak. Six patients remained totally dependent while two became independent in daily activities. Four patients became independent in feeding, three required help, and four remained on gastrostomy feeding. Thus some patients can regain awareness after more than four months in a vegetative state, and, although few reach full independence, most can achieve an improved quality of life within the limitations of their disabilities. The recovery period is prolonged and may continue for several years. Even patients with profound brain damage should be offered the opportunity of a specialist rehabilitation programme.	ROYAL HOSP & HOME,RES SERV,LONDON SW15 3SW,ENGLAND	ANDREWS, K (corresponding author), ROYAL HOSP & HOME,MED SERV,LONDON SW15 3SW,ENGLAND.						ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERROL S, 1986, J HEAD TRAUMA REHAB, V1, P7; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; CRAIG CW, 1986, J NEUROSURG, V65, P9; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; HEIDEN JS, 1983, PHYS THER, V63, P1946, DOI 10.1093/ptj/63.12.1946; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; JENNETT B, 1991, BMJ-BRIT MED J, V302, P1256, DOI 10.1136/bmj.302.6787.1256; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1992, BRIT MED J, V305, P1305, DOI 10.1136/bmj.305.6865.1305; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Levy D E, 1978, Ann N Y Acad Sci, V315, P293, DOI 10.1111/j.1749-6632.1978.tb50347.x; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MAY PG, 1968, DIS NERV SYST, V29, P837; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; ROSENBERG GA, 1977, ANN NEUROL, V2, P167, DOI 10.1002/ana.410020215; ROSIN AJ, 1978, SCAND J REHABIL MED, V10, P33; SAZBON L, 1992, BRAIN INJURY, V4, P359; STEINBOCK B, 1989, HASTINGS CENT REP, V19, P14, DOI 10.2307/3562294; TANHEHCO J, 1982, ARCH PHYS MED REHAB, V63, P36; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; 1993, BMA NEWS REV, V19, P9	30	60	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1597	1600		10.1136/bmj.306.6892.1597			4	Medicine, General & Internal	General & Internal Medicine	LH128	WOS:A1993LH12800027	8329926	Green Published, Bronze			2021-06-18	
J	MCDONALD, S				MCDONALD, S			DIFFERENTIAL PRAGMATIC LANGUAGE LOSS AFTER CLOSED HEAD-INJURY - ABILITY TO COMPREHEND CONVERSATIONAL IMPLICATURE	APPLIED PSYCHOLINGUISTICS			English	Article							BRAIN-DAMAGED PATIENTS; REQUESTS; APPRECIATION	Two experiments in which 2 closed-head-injured (CHI) subjects and 12 non-brain-damaged control subjects took part investigated the capacity to comprehend indirect speech acts. In the first experiment. the subjects were required to interpret conventional indirect speech acts. One CHI subject, but not the other, had trouble rejecting the literal meaning. In the second experiment, the subjects were required to interpret the meaning behind two literally conflicting sentences. While the control subjects interpreted these as representing a sarcastic exchange, the CHI subjects were unable to provide an adequate explanation. The results were interpreted in terms of common cognitive deficits after closed head injury.		MCDONALD, S (corresponding author), LIDCOMBE HOSP,DEPT NEUROPSYCHOL,JOSEPH ST,LIDCOMBE,NSW 2141,AUSTRALIA.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			CLARK HH, 1979, COGNITIVE PSYCHOL, V11, P430, DOI 10.1016/0010-0285(79)90020-3; CLARK HH, 1975, J VERB LEARN VERB BE, V14, P56, DOI 10.1016/S0022-5371(75)80006-5; CLARK HH, 1980, COGNITION, V8, P111, DOI 10.1016/0010-0277(80)90009-8; Cronbach L.J., 1972, DEPENDABILITY BEHAVI; EDINGTON ES, 1980, RANDOPMISATION TESTS, V31; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; GIBBS R, 1982, TEXT, V2, P9; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; Gordon D., 1975, SYNTAX SEMANTICS, V3, P83; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Hagan C., 1982, COGNITIVE REHABILITA, P131; HIRST W, 1984, BRAIN LANG, V23, P26, DOI 10.1016/0093-934X(84)90003-8; HOLLAND AL, 1984, CLIN APHASIOLOGY, V14, P345; JORGENSON J, 1984, J EXPT PSYCHOL GENER, V13, P112; KERTESZ A, 1981, W APHASIA BATTERY; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVINSONSC, 1983, PRAGMETICS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milton S. B., 1984, CLIN APHASIOLOGY, V14, P114; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Searle John, 1975, SYNTAX SEMANTICS, V3; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Slugoski B. R., 1988, J LANG SOC PSYCHOL, V7, P101, DOI DOI 10.1177/0261927X8800700202; SNOW P, 1987, BRAIN IMPAIRMENT; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SPERBER D, 1984, J EXP PSYCHOL GEN, V113, P130, DOI 10.1037/0096-3445.113.1.130; Sperber D., 1986, RELEVANCE COMMUNICAT; Sperber Dan, 1981, RADICAL PRAGMATICS; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; WALK KW, 1985, UNDERSTANDING BRAIN; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4	33	60	63	1	5	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0142-7164			APPL PSYCHOLINGUIST	Appl. Psycholinguist.	SEP	1992	13	3					295	312		10.1017/S0142716400005658			18	Linguistics; Psychology, Experimental	Linguistics; Psychology	KB875	WOS:A1992KB87500003					2021-06-18	
J	ROPER, SN; MENA, I; KING, WA; SCHWEITZER, J; GARRETT, K; MEHRINGER, CM; MCBRIDE, D				ROPER, SN; MENA, I; KING, WA; SCHWEITZER, J; GARRETT, K; MEHRINGER, CM; MCBRIDE, D			AN ANALYSIS OF CEREBRAL BLOOD-FLOW IN ACUTE CLOSED-HEAD INJURY USING TECHNETIUM-99M-HMPAO SPECT AND COMPUTED-TOMOGRAPHY	JOURNAL OF NUCLEAR MEDICINE			English	Article							FLUID-PERCUSSION INJURY; BRAIN INJURY; ACUTE PHASE; PERFUSION	Technetium-99m-hexamethylpropyleneamine (HMPAO) SPECT and x-ray CT were compared in 15 patients with acute closed-head injury. There were 44 focal lesions in all. Fifteen (34%) lesions were seen on both x-ray and SPECT. Seventeen (39%) lesions were seen only on SPECT. Twelve (27%) of the lesions were seen on x-ray tomography only. Of the lesions seen on x-ray tomography but not on SPECT, two were subarachnoid hemorrhage, two were thin subdural hematomas, and eight were contusions. This study shows that SPECT can detect focal disturbances of cerebral blood flow that are not seen on x-ray tomography. It also suggests that there are two types of contusions: those with a decreased cerebral blood flow (i.e., detectable on SPECT) and those with a cerebral blood flow equal to that of the surrounding brain.	UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DIV NUCL MED,TORRANCE,CA 90509; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DIV NEURORADIOL,TORRANCE,CA 90509	ROPER, SN (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,SCH MED,DIV NEUROSURG,10833 LECONTE AVE,TORRANCE,CA 90509, USA.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; COLD GE, 1980, ACTA ANAESTH SCAND, V24, P245, DOI 10.1111/j.1399-6576.1980.tb01544.x; COLD GE, 1986, ACTA ANAESTH SCAND, V30, P453, DOI 10.1111/j.1399-6576.1986.tb02452.x; DeWitt D S, 1988, Brain Inj, V2, P291, DOI 10.3109/02699058809150899; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUTREVOU MD, 1987, S AFR J SURG, V25, P95; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEONARD JP, 1986, J NUCL MED, V27, P1819; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; NEIRINCKX RD, 1987, J NUCL MED, V28, P191; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OBRIST WD, 1979, NEURAL TRAUMA, P41; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; PODREKA I, 1987, J NUCL MED, V28, P1657; SHARP PF, 1986, J NUCL MED, V27, P171; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	23	60	60	0	2	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 22090-5316	0161-5505			J NUCL MED	J. Nucl. Med.	SEP	1991	32	9					1684	1687					4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	GD043	WOS:A1991GD04300009	1880569				2021-06-18	
J	CLINTON, J; AMBLER, MW; ROBERTS, GW				CLINTON, J; AMBLER, MW; ROBERTS, GW			POSTTRAUMATIC ALZHEIMERS-DISEASE - PREPONDERANCE OF A SINGLE PLAQUE TYPE	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						ALZHEIMERS DISEASE; AMYLOID; BETA-PROTEIN (BETA-PROTEIN); PLAQUES, TRAUMA	DEMENTIA; DEPOSITS; BRAINS; IMMUNOCYTOCHEMISTRY	The cause of Alzheimer's disease is unknown. Several factors have been proposed including head trauma. At present, the link between head injury and a subsequent neurodegenerative process is largely circumstantial, except in the case of dementia pugilistica (punch drunk syndrome) found in boxers. Recent studies have shown that the brains of boxers with this syndrome contain large numbers of 'diffuse' beta-protein immunoreactive plaques. We supposed that this plaque type might be associated with trauma induced Alzheimer-like degeneration. In order to test this hypothesis we have re-investigated a previously reported case of post-traumatic premature Alzheimer's disease. Immunocytochemistry using antibodies to amyloid beta-protein revealed large numbers of 'diffuse' non-Congophilic plaques with little or no neuritic component. A similar preponderance of this plaque type is present in the brains of boxers with dementia pugilistica. Our observations support the idea of a trauma induced Alzheimer-like degenerative process and indicate that such a condition is associated with a marked preponderance of 'diffuse' plaques.	ST MARYS HOSP,SCH MED,DEPT ANAT & CELL BIOL,LONDON W2 1PG,ENGLAND; RHODE ISL HOSP,DEPT PATHOL,PROVIDENCE,RI 02902							CHANDRA V, 1986, NEUROLOGY, V36, P209, DOI 10.1212/WNL.36.2.209; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1959, J MENT SCI, V105, P714; COURVILLE CYRIL B., 1962, BULL LOS ANGELES NEUROL SOC, V27, P160; DAVIES L, 1988, NEUROLOGY, V38, P1688, DOI 10.1212/WNL.38.11.1688; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; GENTLEMAN SM, 1989, HISTOCHEMISTRY, V92, P355, DOI 10.1007/BF00500553; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; IKEDA S, 1989, LAB INVEST, V60, P113; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KITAMOTO T, 1987, LAB INVEST, V57, P230; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MAJOCHA RE, 1988, P NATL ACAD SCI USA, V85, P6182, DOI 10.1073/pnas.85.16.6182; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; PROBST A, 1987, ACTA NEUROPATHOL, V74, P133, DOI 10.1007/BF00692843; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1988, NEUROLOGY, V38, P1534, DOI 10.1212/WNL.38.10.1534; ROBERTS GW, 1988, LANCET, V2, P1456; ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WISNIEWSKI HM, 1973, PROGR NEUROPATHOLOGY, V2, P1; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V76, P541, DOI 10.1007/BF00689591	24	60	61	0	2	BLACKWELL SCIENCE LTD	OXFORD	OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	FEB	1991	17	1					69	74		10.1111/j.1365-2990.1991.tb00695.x			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	FB769	WOS:A1991FB76900009	2057052				2021-06-18	
J	Jenkins, LW; Lyeth, BG; Lewelt, W; Moszynski, K; Dewitt, DS; Balster, RL; Miller, LP; Clifton, GL; Young, HF; Hayes, RL				Jenkins, L. W.; Lyeth, B. G.; Lewelt, W.; Moszynski, K.; Dewitt, D. S.; Balster, R. L.; Miller, L. P.; Clifton, G. L.; Young, H. F.; Hayes, R. L.			Combined Pretrauma Scopolamine and Phencyclidine Attenuate Posttraumatic Increased Sensitivity to Delayed Secondary Ischemia	JOURNAL OF NEUROTRAUMA			English	Article							PROTEIN-KINASE-C; EXCITATORY AMINO-ACIDS; LONG-TERM POTENTIATION; BRAIN-INJURY; GRANULE CELLS; RAT; RECEPTORS; METABOLISM; VULNERABILITY; ANTAGONISTS	Fasted Wistar rats were given a mild level of traumatic brain injury (TBI) and then subjected to 6 min of transient forebrain ischemia 24 h posttrauma. One group was given simultaneous 1 mg/kg scopolamine and 4 mg/kg phencyclidine intraperitoneally (IP) 15 min before trauma and another group an equal volume of plasmalyte A solution. After 7 days of postinjury survival, placebo-treated rats demonstrated increased posttraumatic vulnerability to secondary ischemie CAI neuronal death even 24 h after trauma. This finding confirmed that increased posttraumatic ischemie vulnerability persists for at least 24 h even following mild trauma. Combined muscarinic receptor and N-methyl-Daspartate (NMDA) receptor coupled ion channel blockade given and present during the mild TBI statistically attenuated this enhanced secondary ischemie CAI neuronal death and thus posttraumatic increased ischemie vulnerability. Placebo-treated rats had 335.3 +/- 93.6 CAI neurons/10(6)mu m(2) and drug-treated rats had 844.8 +/- 184.9 CAI neurons/10(6)mu m(2). This result suggests that muscarinic and/or NMDA receptor-mediated events confined to TBI and the early posttraumatic period are in part responsible for the phenomenon of increased posttraumatic ischemie vulnerability.	[Jenkins, L. W.; Lyeth, B. G.; Moszynski, K.; Clifton, G. L.; Young, H. F.; Hayes, R. L.] Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; [Lewelt, W.] Med Coll Virginia, Dept Anesthesiol, Richmond, VA 23298 USA; [Balster, R. L.] Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; [Dewitt, D. S.] Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Winston Salem, NC USA; [Miller, L. P.] Vet Adm Med Ctr, Div Neurosci, Washington, DC 20422 USA	Jenkins, LW (corresponding author), Med Coll Virginia, Div Neurosurg, Box 693,MCV Stn, Richmond, VA 23298 USA.			Lyeth, Bruce/0000-0003-4811-1474	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS19550, NS21458, NS19355]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, R01NS019550, R01NS019355] Funding Source: NIH RePORTER	We gratefully acknowledge the careful editorial contribution of Fay Akers. This work was supported by NIH Grants NS19550 (LWJ), NS21458 (RLH), and NS19355 (DSD).	Akers R.F., 1987, J NEUROSCI, V7, P3876; BARABAN JM, 1987, TRENDS NEUROSCI, V10, P57, DOI 10.1016/0166-2236(87)90022-1; CHOI DW, 1988, J NEUROSCI, V8, P185; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; CONNOR JA, 1988, SCIENCE, V240, P649, DOI 10.1126/science.2452481; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GOSSELIN RE, 1955, J PHARMACOL EXP THER, V115, P217; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; HAYES R L, 1988, Society for Neuroscience Abstracts, V14, P1153; HAYES R L, 1987, Society for Neuroscience Abstracts, V13, P1254; Hayes R.L., 1988, MILD HEAD I IN PRESS; Hayes R.L., 1988, J NEUROSURG UNPUB; Hayes R.L., 1989, J NEUROTRAUM, V5, P287; Jahr C.E., 1987, NATURE, V325, P276; Jenkins L.W., 1989, BRAIN RES UNPUB; Jenkins L.W., 1988, MILD HEAD INJURY CON, V3; Jenkins L.W., 1988, NEUROTRAUMA MONITORI, V4; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KALSER SC, 1957, J PHARMACOL EXP THER, V121, P449; KATAYAMA Y, 1988, Society for Neuroscience Abstracts, V14, P1154; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; LINDEN DJ, 1987, J NEUROSCI, V7, P3783; Lyeth B.G., 1988, NEUROTRAUMA IN PRESS, V4; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MAYER ML, 1987, TRENDS NEUROSCI, V10, P59, DOI 10.1016/0166-2236(87)90023-3; McNamara J O, 1986, Adv Neurol, V44, P303; MISRA AL, 1980, LIFE SCI, V27, P2501, DOI 10.1016/0024-3205(80)90529-9; Miyazaki S., 1989, 7 INT S INT IN PRESS, V7; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; NICOLETTI F, 1987, J NEUROCHEM, V48, P967, DOI 10.1111/j.1471-4159.1987.tb05611.x; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; RASMUSSEN H, 1983, CALCIUM CELL FUNCTIO, V4, P2; SAVAGE DD, 1983, J COMP NEUROL, V221, P106, DOI 10.1002/cne.902210109; SIESJO BK, 1986, ANN NY ACAD SCI, V462, P207, DOI 10.1111/j.1749-6632.1986.tb51255.x; SIESJO BK, 1985, CEREBROVASC DIS, P187; WAHL D, 1985, ARZNEIMITTEL-FORSCH, V35, P255; WORLEY PF, 1988, SCIENCE, V239, P1428, DOI 10.1126/science.2831626	45	60	60	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	4					275	U40		10.1089/neu.1988.5.275			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	V21VO	WOS:000208235300002	2854856				2021-06-18	
J	GRIFFITHS, MV				GRIFFITHS, MV			INCIDENCE OF AUDITORY AND VESTIBULAR CONCUSSION FOLLOWING MINOR HEAD-INJURY	JOURNAL OF LARYNGOLOGY AND OTOLOGY			English	Article																BARBER H O, 1964, Laryngoscope, V74, P891; BARR JB, 1964, LANCET, V2, P519; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HOUGH JVD, 1969, ANN OTO RHINOL LARYN, V78, P210, DOI 10.1177/000348946907800202; JENNETT B, 1975, BRIT MED J, V3, P267, DOI 10.1136/bmj.3.5978.267; KERR TA, 1971, BRIT J PREV SOC MED, V25, P179; LEWIN W, 1968, BMJ-BRIT MED J, V1, P465, DOI 10.1136/bmj.1.5590.465; LEWIN W, 1970, P ROY SOC MED, V63, P8; MAWSON SR, 1967, DISEASES EAR, P431; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; MORRISON AW, 1975, MANAGEMENT SENSORI N, P210; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SCHUKNECHT HF, 1951, ANN OTO RHINOL LARYN, V60, P273, DOI 10.1177/000348945106000201; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109	14	60	63	0	0	HEADLEY BROTHERS LTD	ASHFORD	INVICTA PRESS, ASHFORD, KENT, ENGLAND TN24 8HH	0022-2151			J LARYNGOL OTOL	J. Laryngol. Otol.		1979	93	3					253	265		10.1017/S0022215100086990			13	Otorhinolaryngology	Otorhinolaryngology	GM951	WOS:A1979GM95100003	429902				2021-06-18	
J	Ni, HQ; Yang, S; Siaw-Debrah, F; Hu, JN; Wu, K; He, ZB; Yang, JJ; Pan, SS; Lin, X; Ye, HT; Xu, Z; Wang, F; Jin, KL; Zhuge, QC; Huang, LJ				Ni, Haoqi; Yang, Su; Siaw-Debrah, Felix; Hu, Jiangnan; Wu, Ke; He, Zibin; Yang, Jianjing; Pan, Sishi; Lin, Xiao; Ye, Haotuo; Xu, Zhu; Wang, Fan; Jin, Kunlin; Zhuge, Qichuan; Huang, Lijie			Exosomes Derived From Bone Mesenchymal Stem Cells Ameliorate Early Inflammatory Responses Following Traumatic Brain Injury	FRONTIERS IN NEUROSCIENCE			English	Article						traumatic brain injury; bone mesenchymal stem cells; exosomes; neuroprotection; microglia/macrophage; inflammation	STROMAL CELLS; EXTRACELLULAR VESICLES; FUNCTIONAL RECOVERY; ANIMAL-MODELS; TRANSPLANTATION; REGULATORS; THERAPY	Traumatic brain injury (TBI) is a leading cause of mortality and disability worldwide. Although treatment guidelines have been developed, no best treatment option or medicine for this condition exists. Recently, mesenchymal stem cells (MSCs)-derived exosomes have shown lots of promise for the treatment of brain disorders, with some results highlighting the neuroprotective effects through neurogenesis and angiogenesis after TBI. However, studies focusing on the role of exosomes in the early stages of neuroinflammation post-TBI are not sufficient. In this study, we investigated the role of bone mesenchymal stem cells (BMSCs)-exosomes in attenuating neuroinflammation at an early stage post-TBI and explored the potential regulatory neuroprotective mechanism. We administered 30 vg protein of BMSCsexosomes or an equal volume of phosphate-buffered saline (PBS) via the retro-orbital route into C57BL/6 male mice 15 min after controlled cortical impact (CCI)-induced TBI. The results showed that the administration of BMSCs-exosomes reduced the lesion size and improved the neurobehavioral performance assessed by modified Neurological Severity Score (mNSS) and rotarod test. In addition, BMSCs-exosomes inhibited the expression of proapoptosis protein Bcl-2-associated X protein (BAX) and proinflammation cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1 beta, while enhancing the expression of the anti-apoptosis protein B-cell lymphoma 2 (BCL2). Furthermore, BMSCs-exosomes modulated microglia/macrophage polarization by downregulating the expression of inducible nitric oxide synthase (INOS) and upregulating the expression of clusters of differentiation 206 (CD206) and arginase-1 (Arg1). In summary, our result shows that BMSCs-exosomes serve a neuroprotective function by inhibiting early neuroinflammation in TBI mice through modulating the polarization of microglia/macrophages. Further research into this may serve as a potential therapeutic strategy for the future treatment of TBI.	[Ni, Haoqi; Yang, Su; Siaw-Debrah, Felix; Wu, Ke; He, Zibin; Yang, Jianjing; Pan, Sishi; Lin, Xiao; Ye, Haotuo; Xu, Zhu; Wang, Fan; Jin, Kunlin; Zhuge, Qichuan; Huang, Lijie] Wenzhou Med Univ, Affiliated Hosp 1, Zhejiang Prov Key Lab Aging & Neurol Disorder Res, Wenzhou, Peoples R China; [Ni, Haoqi; Yang, Su; Siaw-Debrah, Felix; Wu, Ke; He, Zibin; Yang, Jianjing; Pan, Sishi; Lin, Xiao; Ye, Haotuo; Xu, Zhu; Wang, Fan; Zhuge, Qichuan; Huang, Lijie] Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Peoples R China; [Hu, Jiangnan; Jin, Kunlin] Univ North Texas, Dept Pharmacol & Neurosci, Hlth Sci Ctr, Ft Worth, TX USA	Zhuge, QC; Huang, LJ (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Zhejiang Prov Key Lab Aging & Neurol Disorder Res, Wenzhou, Peoples R China.; Zhuge, QC; Huang, LJ (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Peoples R China.	zhugeqichuan@vip.163.com; lijiehuangwy@163.com	Hu, John/AAL-6376-2021	Su, Yang/0000-0001-8120-6016	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81771262]; Zhejiang Health Science and Technology Project [2016RCA022]; Zhejiang Key Research and Development Project [2017C03027]	The work has been supported by National Natural Science Foundation of China (81771262), Zhejiang Health Science and Technology Project (2016RCA022), and Zhejiang Key Research and Development Project (2017C03027).	Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; Huang JH, 2017, J NEUROTRAUM, V34, P3388, DOI 10.1089/neu.2017.5063; Jeong JO, 2011, CIRC RES, V108, P1340, DOI 10.1161/CIRCRESAHA.110.239848; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Lai RC, 2011, REGEN MED, V6, P481, DOI [10.2217/RME.11.35, 10.2217/rme.11.35]; Li Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0648-5; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mincheva-Nilsson Lucia, 2016, Curr Protoc Immunol, V115, DOI 10.1002/cpim.17; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Perez EJ, 2017, J CLIN INVEST, V127, P3114, DOI 10.1172/JCI92300; Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wen ZY, 2017, BRAIN RES, V1665, P88, DOI 10.1016/j.brainres.2017.04.001; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wiklander OPB, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26316; Williams AM, 2019, J NEUROTRAUM, V36, P54, DOI 10.1089/neu.2018.5711; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu H, 2018, MOL PHARMACEUT, V15, P1892, DOI 10.1021/acs.molpharmaceut.8b00059; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang JJ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00061; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yardeni T, 2011, LAB ANIMAL, V40, P155, DOI 10.1038/laban0511-155; Zhang H, 2017, BONE MARROW STEM CEL, P81, DOI DOI 10.1007/978-981-10-2929-5_4; Zhang L, 2011, STROKE, V42, P1437, DOI 10.1161/STROKEAHA.110.593129; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061	46	59	60	4	25	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	JAN 24	2019	13								14	10.3389/fnins.2019.00014			10	Neurosciences	Neurosciences & Neurology	HI8ZM	WOS:000456744500001	30733666	DOAJ Gold, Green Published	Y	N	2021-06-18	
J	Li, Y; Yang, YY; Ren, JL; Xu, F; Chen, FM; Li, A				Li, Ye; Yang, Yuan-Yuan; Ren, Jia-Li; Xu, Feng; Chen, Fa-Ming; Li, Ang			Exosomes secreted by stem cells from human exfoliated deciduous teeth contribute to functional recovery after traumatic brain injury by shifting microglia M1/M2 polarization in rats	STEM CELL RESEARCH & THERAPY			English	Article						Traumatic brain injury; Stem cells from human exfoliated deciduous teeth; Exosomes; Microglia; Neuroinflammation	TISSUES; TRANSPLANTATION; REGENERATION; SCAFFOLDS; VESICLES; THERAPY	Background: Traumatic brain injury (TBI) is one of the major causes of mortality and disability for all ages worldwide. Mesenchymal stem cells (MSCs)-originated exosomes have provided therapeutic effects. However, as an indispensable component of MSCs, whether odontogenic stem cell-generated exosomes could benefit TBI is still unclear. Thus we aimed to explore the potential of stem cells from human exfoliated deciduous teeth-originated exosomes (SHED-Ex) for the management of TBI. Methods: First, a transwell system was used to co-culture activated BV-2 microglia cells with SHED. The secretion levels of neuroinflammatory factors and nitrite were evaluated by enzyme-linked immunosorbent assay (ELISA) and Griess assay. Furthermore, purified SHED-Ex were co-cultured with activated BV-2. ELISA, Griess assay, flow cytometry, immunofluorescence, and qRT-PCR were performed to test the levels of inflammatory factors as well as the microglia phenotype. Finally, SHED and SHED-Ex were locally injected into TBI rat models. Basso, Beattie, and Bresnahan (BBB) scores were chosen to evaluate the motor functional recovery. Histopathology and immunofluorescence were performed to measure the lesion volume and neuroinflammation. Results: As a result, SHED-Ex could reduce neuroinflammation by shifting microglia polarization. The administration of SHED-Ex improves rat motor functional recovery and reduces cortical lesion compared with the control group 2 weeks post-injury (P < 0.05). Conclusions: The current study demonstrates for the first time that SHED-Ex contribute a therapeutic benefit to TBI in rats, at least in part by shifting microglia polarization to reduce neuroinflammation. The use of odontogenic stem cells, and indeed their exosomes, may be expanded for the treatment of TBI or other neurological disorders.	[Li, Ye; Li, Ang] Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian, Shaanxi, Peoples R China; [Li, Ye; Yang, Yuan-Yuan; Ren, Jia-Li; Li, Ang] Xi An Jiao Tong Univ, Coll Stomatol, Dept Periodontol, Xi Wu Rd 98, Xian 710004, Shaanxi, Peoples R China; [Xu, Feng] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian, Shaanxi, Peoples R China; [Xu, Feng] Xi An Jiao Tong Univ, BEBC, Xian, Shaanxi, Peoples R China; [Chen, Fa-Ming] Fourth Mil Med Univ, Sch Stomatol, Dept Periodontol, Xian, Shaanxi, Peoples R China	Li, A (corresponding author), Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian, Shaanxi, Peoples R China.; Li, A (corresponding author), Xi An Jiao Tong Univ, Coll Stomatol, Dept Periodontol, Xi Wu Rd 98, Xian 710004, Shaanxi, Peoples R China.	drliang@mail.xjtu.edu.cn	Xu, Feng/H-4468-2011	Xu, Feng/0000-0003-4351-0222	Shaanxi Provincial Science and Technology Innovation Project co-ordination of Resources Oriented Industries of Key Technologies Project [2011KTCL03-24]	The current work was supported by Shaanxi Provincial Science and Technology Innovation Project co-ordination of Resources Oriented Industries of Key Technologies Project No. 2011KTCL03-24.	Annibali S, 2014, EUR REV MED PHARMACO, V18, P2863; Arslan F, 2013, STEM CELL RES, V10, P301, DOI 10.1016/j.scr.2013.01.002; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Brites D, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00476; Daltoe FP, 2014, BRAZ ORAL RES, V28, P413, DOI 10.1590/1807-3107BOR-2014.vol28.0037; Dorronsoro A, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt187; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferguson SW, 2016, J CONTROL RELEASE, V228, P179, DOI 10.1016/j.jconrel.2016.02.037; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gu JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052465; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Harry GJ, 2012, NEUROTOXICOLOGY, V33, P558, DOI 10.1016/j.neuro.2012.03.013; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867; Jose S, 2015, CELL BIOL INT, V39, P1355, DOI 10.1002/cbin.10516; Kanafi MM, 2013, CYTOTHERAPY, V15, P1228, DOI 10.1016/j.jcyt.2013.05.008; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Ma L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051777; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Marote A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00231; Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100; Nakamura Y, 2015, FEBS LETT, V589, P1257, DOI 10.1016/j.febslet.2015.03.031; Nishino Y, 2011, CYTOTHERAPY, V13, P598, DOI 10.3109/14653249.2010.542462; Oh JY, 2008, STEM CELLS, V26, P1047, DOI 10.1634/stemcells.2007-0737; Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44; Rosa V, 2013, J DENT RES, V92, P970, DOI 10.1177/0022034513505772; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tsai CL, 2015, CORNEA, V34, P1471, DOI 10.1097/ICO.0000000000000532; Turturici G, 2014, AM J PHYSIOL-CELL PH, V306, pC621, DOI 10.1152/ajpcell.00228.2013; Ueda M, 2010, J CRANIOFAC SURG, V21, P1861, DOI 10.1097/SCS.0b013e3181f43f0a; Vakhrushev IV, 2012, B EXP BIOL MED+, V153, P143, DOI 10.1007/s10517-012-1663-2; van Buul GM, 2012, OSTEOARTHR CARTILAGE, V20, P1186, DOI 10.1016/j.joca.2012.06.003; Xiong Y, 2015, EXPERT OPIN INV DRUG, V24, P743, DOI 10.1517/13543784.2015.1021919; Yeh YC, 2015, HISTOPATHOLOGY, V66, P922, DOI 10.1111/his.12468; Yin ZH, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0309-0; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339	38	59	63	0	22	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-6512			STEM CELL RES THER	Stem Cell Res. Ther.	SEP 29	2017	8								198	10.1186/s13287-017-0648-5			11	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	FI7RM	WOS:000412195400002	28962585	DOAJ Gold, Green Published			2021-06-18	
J	Matsumura, Y; Yamashita, T; Sasaki, A; Nakata, E; Kohno, K; Masuda, T; Tozaki-Saitoh, H; Imai, T; Kuraishi, Y; Tsuda, M; Inoue, K				Matsumura, Yuta; Yamashita, Tomohiro; Sasaki, Atsushi; Nakata, Eriko; Kohno, Keita; Masuda, Takahiro; Tozaki-Saitoh, Hidetoshi; Imai, Toshiyasu; Kuraishi, Yasushi; Tsuda, Makoto; Inoue, Kazuhide			A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain	SCIENTIFIC REPORTS			English	Article							PROTEIN-KINASE ACTIVATION; PERIPHERAL-NERVE INJURY; NEUROPATHIC PAIN; SPINAL MICROGLIA; NEUROTROPHIC FACTOR; PURINERGIC RECEPTORS; P2X(4) RECEPTORS; POSTHERPETIC NEURALGIA; TRANSCRIPTION FACTOR; UP-REGULATION	Accumulating evidence indicates that purinergic P2X4 receptors (P2X4R: cation channels activated by extracellular ATP) expressed in spinal microglia are crucial for pathological chronic pain caused by nerve damage, suggesting a potential target for drug discovery. We identified NP-1815-PX (5-[3-(5-thioxo-4H-[1,2,4]oxadiazol-3-yl)phenyl]-1H-naphtho[1,2-b][1,4]diazepine-2,4(3H,5H)-dione) as a novel antagonist selective for P2X4R with high potency and selectivity compared with other P2XR subtypes. In in vivo assay for acute and chronic pain, intrathecal administration of NP-1815-PX produced an anti-allodynic effect in mice with traumatic nerve damage without affecting acute nociceptive pain and motor function (although its oral administration did not produce the effect). Furthermore, in a mouse model of herpetic pain, P2X4R upregulation in the spinal cord exclusively occurred in microglia, and intrathecal NP-1815-PX suppressed induction of mechanical allodynia. This model also showed K+/Cl- cotransporter 2 (KCC2) downregulation, which is implicated in dorsal horn neuron hyperexcitability; this downregulation was restored by intrathecal treatment with NP-1815-PX or by interfering with brain-derived neurotrophic factor (BDNF) signaling, a P2X4R-activated microglial factor implicated in KCC2 downregulation. Taken together, the newly developed P2X4R antagonist NP-1815-PX produces anti-allodynic effects in chronic pain models without altering acute pain sensitivity, suggesting that microglial P2X4R could be an attractive target for treating chronic pain.	[Matsumura, Yuta; Kohno, Keita; Masuda, Takahiro; Tozaki-Saitoh, Hidetoshi; Tsuda, Makoto] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Life Innovat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan; [Matsumura, Yuta; Yamashita, Tomohiro; Tsuda, Makoto; Inoue, Kazuhide] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan; [Sasaki, Atsushi; Kuraishi, Yasushi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Appl Pharmacol, Toyama 9300194, Japan; [Nakata, Eriko; Imai, Toshiyasu] Nippon Chemiphar Co Ltd, Discovery Res Labs, Misato, Saitama 3410005, Japan; [Masuda, Takahiro] Univ Freiburg, Inst Neuropathol, Neurozentrum, Breisacherstr 64, D-79106 Freiburg, Germany	Tsuda, M (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Life Innovat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.; Tsuda, M (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	tsuda@phar.kyushu-u.ac.jp	Tsuda, Makoto/AAE-7256-2020	, hidetoshi/0000-0003-0423-2143; Masuda, Takahiro/0000-0003-3687-452X	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15H02522, 25117013]; Japan Science and Technology Agency (JST) through Core Research for Evolutional Science and Technology (CREST) program; Adaptable and Seamless Technology Transfer Program (A-STEP) through Target-driven R&D from Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED); AMEDJapan Agency for Medical Research and Development (AMED); Toray Science FoundationToray Industries, Inc.; Takeda Science FoundationTakeda Science Foundation (TSF); Nakatomi Foundation; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15H02522] Funding Source: KAKEN	This work was supported by JSPS KAKENHI Grant Numbers 15H02522 (MT), 25117013 (KI, HTS), the Japan Science and Technology Agency (JST) through the Core Research for Evolutional Science and Technology (CREST) program (K.I.), the Adaptable and Seamless Technology Transfer Program (A-STEP) through Target-driven R&D (T.I., K.I.) from Japan Agency for Medical Research and Development (AMED), the Research Project on Elucidation of Chronic Pain from AMED (M.T.), Platform for Drug Discovery, Informatics, and Structural Life Science from AMED (K.I.), the Toray Science Foundation (M.T.), Takeda Science Foundation (M.T.), and The Nakatomi Foundation (M.T.).	Alexander K, 1999, J PHARMACOL EXP THER, V291, P1135; Ase AR, 2015, MOL PHARMACOL, V87, P606, DOI 10.1124/mol.114.096222; Balazs B, 2013, CELL PHYSIOL BIOCHEM, V32, P11, DOI 10.1159/000350119; Beggs S, 2012, NAT NEUROSCI, V15, P1068, DOI 10.1038/nn.3155; Binder DK, 1999, J NEUROSCI, V19, P1424; Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Donnelly-Roberts D, 2008, J PHARMACOL EXP THER, V324, P409, DOI 10.1124/jpet.106.105890; Dworkin RH, 1996, PAIN, V67, P241, DOI 10.1016/0304-3959(96)03122-3; Gagnon M, 2013, NAT MED, V19, P1524, DOI 10.1038/nm.3356; GNANN JW, 1994, ANN NEUROL, V35, pS69, DOI 10.1002/ana.410350720; Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531; Hernandez-Olmos V, 2012, J MED CHEM, V55, P9576, DOI 10.1021/jm300845v; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Horvath G, 2014, NEUROBIOL DIS, V70, P162, DOI 10.1016/j.nbd.2014.06.011; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Inoue K, 2006, PHARMACOL THERAPEUT, V109, P210, DOI 10.1016/j.pharmthera.2005.07.001; Jacobson KA, 2016, NEUROPHARMACOLOGY, V104, P31, DOI 10.1016/j.neuropharm.2015.12.001; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Khakh BS, 2012, NEURON, V76, P51, DOI 10.1016/j.neuron.2012.09.024; Khakh BS, 1999, J NEUROSCI, V19, P7289, DOI 10.1523/JNEUROSCI.19-17-07289.1999; Kobayashi K, 2008, J NEUROSCI, V28, P2892, DOI 10.1523/JNEUROSCI.5589-07.2008; Kobayashi K, 2011, NEUROSCI LETT, V504, P57, DOI 10.1016/j.neulet.2011.08.058; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kuraishi Y, 2004, LIFE SCI, V74, P2619, DOI 10.1016/j.lfs.2004.01.005; LANCASTER T, 1995, BRIT J GEN PRACT, V45, P39; LOESER JD, 1986, PAIN, V25, P149, DOI 10.1016/0304-3959(86)90089-8; Masuda T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4771; Masuda T, 2012, CELL REP, V1, P334, DOI 10.1016/j.celrep.2012.02.014; Nagata K, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-20; NAKAJIMA K, 1992, J NEUROCHEM, V58, P1401, DOI 10.1111/j.1471-4159.1992.tb11356.x; Ochi-ishi R, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-53; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Peng JY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12029; Sasaki A, 2008, J PHARMACOL SCI, V108, P266, DOI 10.1254/jphs.08154FP; Sorge RE, 2015, NAT NEUROSCI, V18, P1081, DOI 10.1038/nn.4053; Takasaki I, 2000, JPN J PHARMACOL, V83, P319, DOI 10.1254/jjp.83.319; Takasaki I, 2000, PAIN, V86, P95, DOI 10.1016/S0304-3959(00)00240-2; Takasaki I, 2012, PAIN, V153, P585, DOI 10.1016/j.pain.2011.11.022; Toyomitsu E, 2012, PURINERG SIGNAL, V8, P301, DOI 10.1007/s11302-011-9288-x; Tozaki-Saitoh H, 2008, J NEUROSCI, V28, P4949, DOI 10.1523/JNEUROSCI.0323-08.2008; Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; Tsuda M, 2007, J NEUROCHEM, V102, P1658, DOI 10.1111/j.1471-4159.2007.04796.x; Tsuda M, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-28; Tsuda M, 2009, P NATL ACAD SCI USA, V106, P8032, DOI 10.1073/pnas.0810420106; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Unezaki S, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-59; Yajima Y, 2005, J NEUROCHEM, V93, P584, DOI 10.1111/j.1471-4159.2005.03045.x; Zhao J, 2006, MOL CELL NEUROSCI, V31, P539, DOI 10.1016/j.mcn.2005.11.008	53	59	63	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 31	2016	6								32461	10.1038/srep32461			11	Multidisciplinary Sciences	Science & Technology - Other Topics	DU5IN	WOS:000382245500001	27576299	DOAJ Gold, Green Published			2021-06-18	
J	Kovacs, GG; Lutz, MI; Ricken, G; Strobel, T; Hoftberger, R; Preusser, M; Regelsberger, G; Honigschnabl, S; Reiner, A; Fischer, P; Budka, H; Hainfellner, JA				Kovacs, Gabor G.; Lutz, Mirjam I.; Ricken, Gerda; Stroebel, Thomas; Hoeftberger, Romana; Preusser, Matthias; Regelsberger, Guenther; Hoenigschnabl, Selma; Reiner, Angelika; Fischer, Peter; Budka, Herbert; Hainfellner, Johannes A.			Dura mater is a potential source of A beta seeds	ACTA NEUROPATHOLOGICA			English	Article						Alzheimer disease; Amyloid-beta; Dura mater; Iatrogenic Creutzfeldt-Jakob disease; Prion; Propagon	CEREBRAL AMYLOID ANGIOPATHY; TRAUMATIC BRAIN-INJURY; ALPHA-SYNUCLEIN PATHOLOGY; CREUTZFELDT-JAKOB-DISEASE; ALZHEIMERS-DISEASE; UNRESOLVED QUESTIONS; NEURODEGENERATIVE DISEASES; APOLIPOPROTEIN-E; TAU; PROPAGATION	Deposition of amyloid-beta (A beta) in the brain parenchyma and vessels is one of the hallmarks of Alzheimer disease (AD). Recent observations of A beta deposition in iatrogenic Creutzfeldt-Jakob disease (iCJD) after dural grafting or treatment with pituitary extracts raised concerns whether A beta is capable of transmitting disease as seen in prion diseases by the disease-associated prion protein. To address this issue, we re-sampled and re-evaluated archival material, including the grafted dura mater of two cases with iCJD (28 and 33-years-old) without mutations in the A beta PP, PSEN1 and PSEN2 genes, and carrying epsilon 3/epsilon 3 alleles of the APOE gene. In addition, we evaluated 84 dura mater samples obtained at autopsy (mean age 84.9 +/- A 0.3) in the community-based VITA study for the presence of A beta deposition. We show that the dura mater may harbor A beta deposits (13 %) in the form of cerebral amyloid angiopathy or amorphous aggregates. In both iCJD cases, the grafted dura mater had accumulated A beta. The morphology and distribution pattern of cerebral A beta deposition together with the lack of tau pathology distinguishes the A beta proteinopathy in iCJD from AD, from that seen in young individuals without cognitive decline carrying one or two APOE4 alleles, and from that related to traumatic brain injury. Our novel findings of A beta deposits in the dura mater, including the grafted dura, and the distinct cerebral A beta distribution in iCJD support the seeding properties of A beta. However, in contrast to prion diseases, our study suggests that such A beta seeding is unable to reproduce the full clinicopathological phenotype of AD.	[Kovacs, Gabor G.; Lutz, Mirjam I.; Ricken, Gerda; Stroebel, Thomas; Hoeftberger, Romana; Regelsberger, Guenther; Budka, Herbert; Hainfellner, Johannes A.] Med Univ Vienna, Inst Neurol, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria; [Preusser, Matthias] Med Univ Vienna, Dept Med 1, Vienna, Austria; [Preusser, Matthias] Med Univ Vienna, Ctr Comprehens Canc, CNS Unit, Vienna, Austria; [Hoenigschnabl, Selma; Reiner, Angelika] Danube Hosp Vienna, Inst Pathol, Vienna, Austria; [Fischer, Peter] Danube Hosp, Med Res Soc Vienna, Dept Psychiat, DC, Vienna, Austria; [Budka, Herbert] Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland	Kovacs, GG (corresponding author), Med Univ Vienna, Inst Neurol, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria.	gabor.kovacs@meduniwien.ac.at	Kovacs, Gabor G/A-7468-2013	Kovacs, Gabor G/0000-0003-3841-5511; Preusser, Matthias/0000-0003-3541-2315	Medical University of Vienna; Ludwig Boltzmann Institute of Ageing Research; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [278486]; Federal Ministry of Health, Austria	Open access funding provided by Medical University of Vienna. The Vienna Trans-Danube Ageing (VITA) study was supported and organized by the Ludwig Boltzmann Institute of Ageing Research. The neuropathology study was supported by the European Commission's 7th Framework Programme under GA No 278486, "DEVELAGE". The Austrian Reference Centre for Human Prion Diseases is supported by the Federal Ministry of Health, Austria.	Aho L, 2010, J ALZHEIMERS DIS, V20, P1015, DOI 10.3233/JAD-2010-091681; Alafuzoff I, 2009, ACTA NEUROPATHOL, V117, P309, DOI 10.1007/s00401-009-0485-4; ANDRES KH, 1967, Z ZELLFORSCH MIK ANA, V79, P272, DOI 10.1007/BF00369291; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Attems J, 2011, NEUROPATH APPL NEURO, V37, P75, DOI 10.1111/j.1365-2990.2010.01137.x; Bohl J, 1989, Prog Clin Biol Res, V317, P1007; Braak H, 2015, BRAIN, V138, P2814, DOI 10.1093/brain/awv236; Braak H, 2011, ACTA NEUROPATHOL, V121, P171, DOI 10.1007/s00401-010-0789-4; Brettschneider J, 2015, NAT REV NEUROSCI, V16, P109, DOI 10.1038/nrn3887; Carare RO, 2013, NEUROPATH APPL NEURO, V39, P593, DOI 10.1111/nan.12042; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cupidi C, 2010, J ALZHEIMERS DIS, V19, P57, DOI 10.3233/JAD-2010-1205; DELAERE P, 1991, ACTA NEUROPATHOL, V81, P328, DOI 10.1007/BF00305876; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Eisele YS, 2016, ACTA NEUROPATHOL, V131, P5, DOI 10.1007/s00401-015-1516-y; Fischer P, 2002, J NEURAL TRANSM-SUPP, P105; FOLDI M, 1968, ANGIOLOGICA, V5, P250; Frontzek K, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14287; Ghoshal N, 2009, ARCH NEUROL-CHICAGO, V66, P1240, DOI 10.1001/archneurol.2009.224; Grinberg LT, 2009, NEUROPATH APPL NEURO, V35, P406, DOI [10.1111/j.1365-2990.2008.00997.x, 10.1111/j.1365-2990.2009.00997.x]; Guo JL, 2014, NAT MED, V20, P130, DOI 10.1038/nm.3457; HIXSON JE, 1990, J LIPID RES, V31, P545; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Irwin DJ, 2013, JAMA NEUROL, V70, P462, DOI 10.1001/jamaneurol.2013.1933; Jaunmuktane Z, 2015, NATURE, V525, P247, DOI 10.1038/nature15369; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Keable A, 2016, BBA-MOL BASIS DIS, V1862, P1037, DOI 10.1016/j.bbadis.2015.08.024; KIDA S, 1993, NEUROPATH APPL NEURO, V19, P480, DOI 10.1111/j.1365-2990.1993.tb00476.x; Kovacs GG, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020189; Kovacs GG, 2015, NEUROBIOL AGING, V36, P3100, DOI 10.1016/j.neurobiolaging.2015.07.018; Kovacs GG, 2013, ACTA NEUROPATHOL, V126, P365, DOI 10.1007/s00401-013-1157-y; Kovacs GG, 2011, ACTA NEUROPATHOL, V121, P39, DOI 10.1007/s00401-010-0713-y; Kovacs GG, 2013, PRIONS AND DIS, V2, P103; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Lewis J, 2016, ACTA NEUROPATHOL, V131, P27, DOI 10.1007/s00401-015-1507-z; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Metsaars WP, 2003, NEUROBIOL AGING, V24, P563, DOI 10.1016/S0197-4580(02)00134-3; Murakami T, 2014, VET PATHOL, V51, P363, DOI 10.1177/0300985813511128; Parchi P, 2012, ACTA NEUROPATHOL, V124, P517, DOI 10.1007/s00401-012-1002-8; Pletnikova O, 2015, COGN BEHAV NEUROL, V28, P144, DOI 10.1097/WNN.0000000000000071; Preusser M, 2006, J NEUROL NEUROSUR PS, V77, P413, DOI 10.1136/jnnp.2005.070805; Reiniger L, 2011, ACTA NEUROPATHOL, V121, P5, DOI 10.1007/s00401-010-0691-0; ROLAND J, 1987, SURG RADIOL ANAT, V9, P43, DOI 10.1007/BF02116853; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Stratmann K, 2016, BRAIN PATHOL, V26, P371, DOI 10.1111/bpa.12289; Thal DR, 2008, ACTA NEUROPATHOL, V115, P599, DOI 10.1007/s00401-008-0366-2; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Thal DR, 2002, J NEUROPATH EXP NEUR, V61, P282, DOI 10.1093/jnen/61.3.282; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uchihara T, 2016, ACTA NEUROPATHOL, V131, P1, DOI 10.1007/s00401-015-1517-x; Uchihara T, 2016, ACTA NEUROPATHOL, V131, P49, DOI 10.1007/s00401-015-1485-1; Weller RO, 2008, BRAIN PATHOL, V18, P253, DOI 10.1111/j.1750-3639.2008.00133.x	57	59	59	0	18	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2016	131	6					911	923		10.1007/s00401-016-1565-x			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	DM3WM	WOS:000376277400009	27016065	Green Published, Other Gold			2021-06-18	
J	Lambert, C; Cisternas, P; Inestrosa, NC				Lambert, Catherine; Cisternas, Pedro; Inestrosa, Nibaldo C.			Role of Wnt Signaling in Central Nervous System Injury	MOLECULAR NEUROBIOLOGY			English	Article						Wnt signaling; Stroke; Spinal cord injury; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; SPINAL-CORD-INJURY; BETA-CATENIN; SYNAPTIC DIFFERENTIATION; ISCHEMIC-STROKE; GENE-EXPRESSION; NEURONAL DEATH; IMPACT INJURY; IN-VITRO	The central nervous system (CNS) is highly sensitive to external mechanical damage, presenting a limited capacity for regeneration explained in part by its inability to restore either damaged neurons or the synaptic network. The CNS may suffer different types of external injuries affecting its function and/or structure, including stroke, spinal cord injury, and traumatic brain injury. These pathologies critically affect the quality of life of a large number of patients worldwide and are often fatal because available therapeutics are ineffective and produce limited results. Common effects of the mentioned pathologies involves the triggering of several cellular and metabolic responses against injury, including infiltration of blood cells, inflammation, glial activation, and neuronal death. Although some of the underlying molecular mechanisms of those responses have been elucidated, the mechanisms driving these processes are poorly understood in the context of CNS injury. In the last few years, it has been suggested that the activation of the Wnt signaling pathway could be important in the regenerative response after CNS injury, activating diverse protective mechanisms including the stimulation of neurogenesis, blood brain structure consolidation and the recovery of cognitive brain functions. Because Wnt signaling is involved in several physiological processes, the putative positive role of its activation after injury could be the basis for novel therapeutic approaches to CNS injury.	[Lambert, Catherine; Cisternas, Pedro; Inestrosa, Nibaldo C.] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Ctr Envejecimiento & Regenerac CARE, Alameda 340,POB 114-D, Santiago, Chile; [Inestrosa, Nibaldo C.] Univ New S Wales, Fac Med, Sch Psychiat, Ctr Hlth Brain Ageing, Sydney, NSW, Australia; [Inestrosa, Nibaldo C.] Pontificia Univ Catolica Chile, Ctr UC, Sindrome Down, Santiago, Chile; [Inestrosa, Nibaldo C.] Univ Magallanes, Ctr Excelencia Biomed Magallanes CEBIMA, Punta Arenas, Chile	Inestrosa, NC (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Ctr Envejecimiento & Regenerac CARE, Alameda 340,POB 114-D, Santiago, Chile.	ninestrosa@bio.puc.cl			Basal Center for Excellence in Science and Technology (Conicyt-PFB); FondecytComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT [1120156, 3150291, 3150475]; Sociedad Quimica y Minera de Chile (SQM)	This work was supported by grants from the Basal Center for Excellence in Science and Technology (Conicyt-PFB 12/2007) and from Fondecyt: to NCI (No 1120156) to CL (postdoctoral fellowships No 3150291) and PC (postdoctoral fellowships No 3150475). We also thank the Sociedad Quimica y Minera de Chile (SQM) for special grants to study "The role of potassium in hypertension and cognition" and "The role of lithium in human health". We also thank Felipe G. Serrano for artwork (www.illustrative-science.com).	Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Arrazola MS, 2009, J CELL PHYSIOL, V221, P658, DOI 10.1002/jcp.21902; BelAiba RS, 2006, CIRC RES, V98, P828, DOI 10.1161/01.RES.0000210539.54861.27; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Benbrook DM, 2011, CURR CANCER DRUG TAR, V11, P586; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Cao HQ, 2013, NEUROSCI BULL, V29, P94, DOI 10.1007/s12264-012-1277-8; Cerpa W, 2008, J BIOL CHEM, V283, P5918, DOI 10.1074/jbc.M705943200; Chen YC, 2012, NEUROL RES, V34, P390, DOI 10.1179/1743132812Y.0000000027; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Cisternas P, 2014, MOL NEUROBIOL, V49, P574, DOI 10.1007/s12035-013-8540-5; Clark CEJ, 2014, SCI CHINA LIFE SCI, V57, P366, DOI 10.1007/s11427-014-4640-3; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; David MD, 2010, J NEUROSCI RES, V88, P3011, DOI 10.1002/jnr.22464; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178; Dobkin BH, 1997, CURR OPIN NEUROL, V10, P493, DOI 10.1097/00019052-199712000-00010; Dupont P, 2012, NEUROBIOL DIS, V47, P237, DOI 10.1016/j.nbd.2012.04.007; Edvinsson LIH, 2011, J CEREBR BLOOD F MET, V31, P1554, DOI 10.1038/jcbfm.2011.70; Fancy SPJ, 2011, NAT NEUROSCI, V14, P1009, DOI 10.1038/nn.2855; Farias GG, 2007, J NEUROSCI, V27, P5313, DOI 10.1523/JNEUROSCI.3934-06.2007; Farias GG, 2009, J BIOL CHEM, V284, P15857, DOI 10.1074/jbc.M808986200; Feigenson K, 2011, ASN NEURO, V3, DOI 10.1042/AN20110004; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Gonzalez P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050793; Gonzalez-Fernandez C, 2014, J NEUROTRAUM, V31, P565, DOI 10.1089/neu.2013.3067; Guo SZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052665; Habib SJ, 2013, SCIENCE, V339, P1445, DOI 10.1126/science.1231077; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hall EC, 2014, J TRAUMA ACUTE CARE, V76, P859, DOI 10.1097/TA.0000000000000148; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hodar C, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-348; Inestrosa NC, 2012, J NEUROIMMUNE PHARM, V7, P788, DOI 10.1007/s11481-012-9417-5; Inestrosa NC, 2010, NAT REV NEUROSCI, V11, P77, DOI 10.1038/nrn2755; Jansen O, 2013, NAT REV NEUROL, V9, P645, DOI 10.1038/nrneurol.2013.204; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kalani MYS, 2008, P NATL ACAD SCI USA, V105, P16970, DOI 10.1073/pnas.0808616105; Kang WH, 2015, J NEUROTRAUM, V32, P1011, DOI 10.1089/neu.2014.3667; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Leeds PR, 2014, ACS CHEM NEUROSCI, V5, P422, DOI 10.1021/cn500040g; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; Li XJ, 2013, INT J CLIN EXP PATHO, V6, P1245; Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024; Liu B, 2013, INVEST OPHTH VIS SCI, V54, P444, DOI 10.1167/iovs.12-10774; Liu FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066393; Liu YB, 2008, J NEUROSCI, V28, P8376, DOI 10.1523/JNEUROSCI.1939-08.2008; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marchetti B, 2013, TRENDS MOL MED, V19, P144, DOI 10.1016/j.molmed.2012.12.001; Fernandez-Martos CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027000; Mastroiacovo F, 2009, J CEREBR BLOOD F MET, V29, P264, DOI 10.1038/jcbfm.2008.111; Miyashita T, 2009, J NEUROTRAUM, V26, P955, DOI 10.1089/neu.2008.0776; Mufti RE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103530; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Niu LJ, 2012, NEUROSCIENCE, V213, P19, DOI 10.1016/j.neuroscience.2012.03.057; Nusse R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011163; Nusse R, 2012, EMBO J, V31, P2670, DOI 10.1038/emboj.2012.146; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Pi XC, 2009, P NATL ACAD SCI USA, V106, P5675, DOI 10.1073/pnas.0809568106; Piccin D, 2011, STEM CELLS, V29, P528, DOI 10.1002/stem.589; Pinto C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00239; Planutiene M, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-28; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Reeves MJ, 2008, LANCET NEUROL, V7, P915, DOI 10.1016/S1474-4422(08)70193-5; Rios JA, 2014, PROG NEUROBIOL, V121, P125, DOI 10.1016/j.pneurobio.2014.07.004; Rosso SB, 2005, NAT NEUROSCI, V8, P34, DOI 10.1038/nn1374; Rosso SB, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00103; Salinas PC, 2008, ANNU REV NEUROSCI, V31, P339, DOI 10.1146/annurev.neuro.31.060407.125649; Scott EL, 2013, BRAIN RES, V1514, P63, DOI 10.1016/j.brainres.2012.12.015; Seifert-Held T, 2011, ATHEROSCLEROSIS, V218, P233, DOI 10.1016/j.atherosclerosis.2011.05.015; Serrano FG, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-61; Silva-Alvarez C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00097; Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594; Tapia-Rojas C, 2015, BIOCHEM J, V466, P415, DOI 10.1042/BJ20140207; Tian YF, 2012, J CEREBR BLOOD F MET, V32, P780, DOI 10.1038/jcbfm.2011.179; Toledo EM, 2010, MOL PSYCHIATR, V15, P272, DOI 10.1038/mp.2009.72; Tourette C, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001895; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Umschweif G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076129; Varela-Nallar L, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00100; Varela-Nallar L, 2010, P NATL ACAD SCI USA, V107, P21164, DOI 10.1073/pnas.1010011107; Wang HY, 2006, CELL SIGNAL, V18, P934, DOI 10.1016/j.cellsig.2005.12.008; Wang SS, 2013, BIOTECHNOL LETT, V35, P1199, DOI 10.1007/s10529-013-1199-1; Warlow C, 2003, J THROMB HAEMOST, V1, P1422, DOI 10.1046/j.1538-7836.2003.00328.x; Warlow C, 2003, LANCET, V362, P1211, DOI 10.1016/S0140-6736(03)14544-8; Weinsheimer SM, 2011, TRANSL STROKE RES, V2, P575, DOI 10.1007/s12975-011-0103-3; White BD, 2010, STEM CELLS, V28, P297, DOI 10.1002/stem.268; Whiting M.D., 2006, COGNITIVE IMPAIRMENT; Wu XM, 2013, INT J CLIN EXP PATHO, V6, P1282; Xie R, 2014, STROKE, V45, P2769, DOI 10.1161/STROKEAHA.114.005406; Xiong Ye, 2004, J Stroke Cerebrovasc Dis, V13, P129, DOI 10.1016/j.jstrokecerebrovasdis.2004.05.001; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang XT, 2014, J NEUROSCI RES, V92, P148, DOI 10.1002/jnr.23314; Yin Y, 2013, NEUROBIOL DIS, V59, P165, DOI 10.1016/j.nbd.2013.07.013; Young W, 2009, CELL TRANSPLANT, V18, P951, DOI 10.3727/096368909X471251; Yu FS, 2013, J NEUROSURG, V119, P766, DOI 10.3171/2013.6.JNS13135; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang JC, 2014, NEUROSCIENCE, V274, P419, DOI 10.1016/j.neuroscience.2014.06.001; Zhang L, 2013, INT J MOL MED, V32, P867, DOI 10.3892/ijmm.2013.1456; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang YK, 2013, J CLIN INVEST, V123, P2268, DOI 10.1172/JCI65364; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; Zimmerman ZF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008086; Zou FH, 2013, J MOL NEUROSCI, V49, P395, DOI 10.1007/s12031-012-9906-2	115	59	63	1	26	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAY	2016	53	4					2297	2311		10.1007/s12035-015-9138-x			15	Neurosciences	Neurosciences & Neurology	DI6WS	WOS:000373641500021	25976365				2021-06-18	
J	Veenith, TV; Carter, EL; Geeraerts, T; Grossac, J; Newcombe, VFJ; Outtrim, J; Gee, GS; Lupson, V; Smith, R; Aigbirhio, FI; Fryer, TD; Hong, YT; Menon, DK; Coles, JP				Veenith, Tonny V.; Carter, Eleanor L.; Geeraerts, Thomas; Grossac, Julia; Newcombe, Virginia F. J.; Outtrim, Joanne; Gee, Gloria S.; Lupson, Victoria; Smith, Rob; Aigbirhio, Franklin I.; Fryer, Tim D.; Hong, Young T.; Menon, David K.; Coles, Jonathan P.			Pathophysiologic Mechanisms of Cerebral Ischemia and Diffusion Hypoxia in Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; NORMOBARIC HYPEROXIA; HEAD-INJURY; TISSUE PO2; PET; METABOLISM; STROKE; MICRODIALYSIS; CONTUSION; PRESSURE	IMPORTANCE Combined oxygen 15-labeled positron emission tomography (O-15 PET) and brain tissue oximetry have demonstrated increased oxygen diffusion gradients in hypoxic regions after traumatic brain injury (TBI). These data are consistent with microvascular ischemia and are supported by pathologic studies showing widespread microvascular collapse, perivascular edema, and microthrombosis associated with selective neuronal loss. Fluorine 18-labeled fluoromisonidazole ([F-18]FMISO), a PET tracer that undergoes irreversible selective bioreduction within hypoxic cells, could confirm these findings. OBJECTIVE To combine [F-18]FMISO and O-15 PET to demonstrate the relative burden, distribution, and physiologic signatures of conventional macrovascular and microvascular ischemia in early TBI. DESIGN, SETTING, AND PARTICIPANTS This case-control study included 10 patients who underwent [F-18]FMISO and O-15 PET within 1 to 8 days of severe or moderate TBI. Two cohorts of 10 healthy volunteers underwent [F-18]FMISO or O-15 PET. The study was performed at the Wolfson Brain Imaging Centre of Addenbrooke's Hospital. Cerebral blood flow, cerebral blood volume, cerebral oxygen metabolism (CMRO2), oxygen extraction fraction, and brain tissue oximetry were measured in patients during [F-18]FMISO and O-15 PET imaging. Similar data were obtained from control cohorts. Data were collected from November 23, 2007, to May 22, 2012, and analyzed from December 3, 2012, to January 6, 2016. MAIN OUTCOMES AND MEASURES Estimated ischemic brain volume (IBV) and hypoxic brain volume (HBV) and a comparison of their spatial distribution and physiologic signatures. RESULTS The 10 patients with TBI (9 men and 1 woman) had a median age of 59 (range, 30-68) years; the 2 control cohorts (8 men and 2 women each) had median ages of 53 (range, 41-76) and 45 (range, 29-59) years. Compared with controls, patients with TBI had a higher median IBV (56 [range, 9-281] vs 1 [range, 0-11] mL; P < .001) and a higher median HBV (29 [range, 0-106] vs 9 [range, 1-24] mL; P = .02). Although both pathophysiologic tissue classes were present within injured and normal appearing brains, their spatial distributions were poorly matched. When compared with tissue within the IBV compartment, the HBV compartment showed similar median cerebral blood flow (17 [range, 11-40] vs 14 [range, 6-22] mL/100 mL/min), cerebral blood volume (2.4 [range, 1.6-4.2] vs 3.9 [range, 3.4-4.8] mL/100 mL), and CMRO2 (44 [range, 27-67] vs 71 [range, 34-88] mu mol/100 mL/min) but a lower oxygen extraction fraction (38%[range, 29%-50%] vs 89%[range, 75%-100%]; P < .001), and more frequently showed CMRO2 values consistent with irreversible injury. Comparison with brain tissue oximetry monitoring suggested that the threshold for increased [F-18]FMISO trapping is probably 15 mm Hg or lower. CONCLUSIONS AND RELEVANCE Tissue hypoxia after TBI is not confined to regions with structural abnormality and can occur in the absence of conventional macrovascular ischemia. This physiologic signature is consistent with microvascular ischemia and is a target for novel neuroprotective strategies.	[Veenith, Tonny V.; Carter, Eleanor L.; Geeraerts, Thomas; Grossac, Julia; Newcombe, Virginia F. J.; Outtrim, Joanne; Menon, David K.; Coles, Jonathan P.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Hills Rd,POB 93, Cambridge CB2 0QQ, England; [Veenith, Tonny V.] Univ Hosp Birmingham Natl Hlth Serv Trust, Queen Elizabeth Med Ctr, Dept Crit Care Med, Birmingham, England; [Geeraerts, Thomas; Grossac, Julia] Univ Hosp Toulouse, Dept Anesthesiol & Crit Care, Toulouse, France; [Gee, Gloria S.; Lupson, Victoria; Smith, Rob; Aigbirhio, Franklin I.; Fryer, Tim D.; Hong, Young T.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge CB2 0QQ, England	Coles, JP (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Hills Rd,POB 93, Cambridge CB2 0QQ, England.	jpc44@wbic.cam.ac.uk	Veenith, Tonny/AAI-3067-2020	Veenith, Tonny/0000-0002-4125-8804; Newcombe, Virginia/0000-0001-6044-9035	National Institute of Academic Anaesthesia; Raymond Beverly Sackler studentship; Societe Francaise d'Anesthesie et de Reanimation; Health Foundation/Academy of Medical Sciences; National Institute for Health ResearchNational Institute for Health Research (NIHR); Wellcome TrustWellcome TrustEuropean Commission [WT093267]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390 ID 65883]; UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); UK Department of Health; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1000183B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-14-007] Funding Source: researchfish	This study was supported by a clinical research training fellowship from National Institute of Academic Anaesthesia and Raymond Beverly Sackler studentship (Dr Veenith), a clinical research training fellowship from the Societe Francaise d'Anesthesie et de Reanimation (Dr Geeraerts), a Clinician Scientist Fellowship from the Health Foundation/Academy of Medical Sciences (Dr Newcombe), a Senior Investigator Award from the National Institute for Health Research (Dr Menon), grant WT093267 from the Wellcome Trust Project, program grant G9439390 ID 65883 from the Medical Research Council (Acute Brain Injury: Heterogeneity of Mechanisms, Therapeutic Targets and Outcome Effects), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, and the UK Department of Health (Drs Aigbirhio, Fryer, Menon, and Coles, for the Technology Platform).	Alawneh JA, 2014, EUR J NUCL MED MOL I, V41, P736, DOI 10.1007/s00259-013-2581-x; Alian Aymen A, 2008, J Clin Monit Comput, V22, P169, DOI 10.1007/s10877-008-9118-z; Bartlett RM, 2012, J NUCL MED, V53, P1608, DOI 10.2967/jnumed.112.103523; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2009, J CEREBR BLOOD F MET, V29, P965, DOI 10.1038/jcbfm.2009.22; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Dienel GA, 2014, J CEREBR BLOOD F MET, V34, P1736, DOI 10.1038/jcbfm.2014.153; GROSS MW, 1995, INT J CANCER, V61, P567, DOI 10.1002/ijc.2910610422; Hong YT, 2011, J CEREBR BLOOD F MET, V31, P648, DOI 10.1038/jcbfm.2010.141; Hong YT, 2010, NEUROIMAGE, V51, P164, DOI 10.1016/j.neuroimage.2010.02.013; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Markus R, 2004, BRAIN, V127, P1427, DOI 10.1093/brain/awh162; Markus R, 2003, STROKE, V34, P2646, DOI 10.1161/01.STR.0000094422.74023.FF; Markus R, 2002, NEUROIMAGE, V16, P425, DOI 10.1006/nimg.2002.1056; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Moustafa RR, 2007, CRIT CARE, V11, DOI 10.1186/cc5973; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Peeters SGJA, 2015, INT J RADIAT ONCOL, V91, P351, DOI 10.1016/j.ijrobp.2014.09.045; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Ponce LL, 2012, NEUROSURGERY, V70, P1492, DOI 10.1227/NEU.0b013e31824ce933; Read SJ, 1998, NEUROLOGY, V51, P1617, DOI 10.1212/WNL.51.6.1617; Rockswold SB, 2013, J NEUROSURG, V118, P1317, DOI 10.3171/2013.2.JNS121468; Sarrafzadeh AS, 2010, J CEREBR BLOOD F MET, V30, P36, DOI 10.1038/jcbfm.2009.199; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Smielewski Peter, 2002, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Takasawa M, 2008, STROKE, V39, P1629, DOI 10.1161/STROKEAHA.107.485938; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Veenith TV, 2014, J CEREBR BLOOD F MET, V34, P1622, DOI 10.1038/jcbfm.2014.123; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14, DOI 10.1001/jama.2013.281053; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	49	59	61	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	MAY	2016	73	5					542	550		10.1001/jamaneurol.2016.0091			9	Clinical Neurology	Neurosciences & Neurology	DL2JW	WOS:000375461900016	27019039	Bronze			2021-06-18	
J	Kochanek, PM; Bramlett, HM; Dixon, CE; Shear, DA; Dietrich, WD; Schmid, KE; Mondello, S; Wang, KKW; Hayes, RL; Povlishock, JT; Tortella, FC				Kochanek, Patrick M.; Bramlett, Helen M.; Dixon, C. Edward; Shear, Deborah A.; Dietrich, W. Dalton; Schmid, Kara E.; Mondello, Stefania; Wang, Kevin K. W.; Hayes, Ronald L.; Povlishock, John T.; Tortella, Frank C.			Approach to Modeling, Therapy Evaluation, Drug Selection, and Biomarker Assessments for a Multicenter Pre-Clinical Drug Screening Consortium for Acute Therapies in Severe Traumatic Brain Injury: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						therapy; rat; penetrating ballistic-like brain injury; biomarker; micropig; controlled cortical impact; fluid percussion; neuroprotection	CONTROLLED CORTICAL IMPACT; TIME-DEPENDENT CHANGES; SEVERE HEAD-INJURY; HEMORRHAGIC-SHOCK; RAT MODEL; CEREBROSPINAL-FLUID; DAMAGE; AMANTADINE; CHILDREN; DEFICITS	Traumatic brain injury (TBI) was the signature injury in both the Iraq and Afghan wars and the magnitude of its importance in the civilian setting is finally being recognized. Given the scope of the problem, new therapies are needed across the continuum of care. Few therapies have been shown to be successful. In severe TBI, current guidelines-based acute therapies are focused on the reduction of intracranial hypertension and optimization of cerebral perfusion. One factor considered important to the failure of drug development and translation in TBI relates to the recognition that TBI is extremely heterogeneous and presents with multiple phenotypes even within the category of severe injury. To address this possibility and attempt to bring the most promising therapies to clinical trials, we developed Operation Brain Trauma Therapy (OBTT), a multicenter, pre-clinical drug screening consortium for acute therapies in severe TBI. OBTT was developed to include a spectrum of established TBI models at experienced centers and assess the effect of promising therapies on both conventional outcomes and serum biomarker levels. In this review, we outline the approach to TBI modeling, evaluation of therapies, drug selection, and biomarker assessments for OBTT, and provide a framework for reports in this issue on the first five therapies evaluated by the consortium.	[Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA; [Bramlett, Helen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Shear, Deborah A.] Walter Reed Army Inst Res, Ctr Excellence Psychiat & Neurosci, Brain Trauma Neuroprotect & Neurorestorat Branch, In Vivo Neuroprotect Labs, Silver Spring, MD USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33136 USA; [Schmid, Kara E.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect & Neurorestorat Dept, Silver Spring, MD USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers, Ctr Innovat Res, Alachua, FL USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Combat Casualty Care Res Program Brain Trauma & N, Silver Spring, MD USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Blasiole B, 2013, ANESTHESIOLOGY, V118, P649, DOI 10.1097/ALN.0b013e318280a42d; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Brockman EC, 2013, J CEREBR BLOOD F MET, V33, P1457, DOI 10.1038/jcbfm.2013.104; Browning M, 2016, J NEUROTRAUM, V33, P581, DOI 10.1089/neu.2015.4131; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Foley LM, 2013, J CEREBR BLOOD F MET, V33, P129, DOI 10.1038/jcbfm.2012.145; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00040; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Langham J., 2000, COCHRANE DATABASE SY, V2; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Mondello S, 2012, BRAIN INJURY, V26, P1629, DOI 10.3109/02699052.2012.700083; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mountney A, 2016, J NEUROTRAUM, V33, P567, DOI 10.1089/neu.2015.4130; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams A, 2006, J NEUROTRAUM, V23, P1039; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Winn HR, 2007, LANCET NEUROL, V6, P478, DOI 10.1016/S1474-4422(07)70116-3; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	67	59	59	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					513	522		10.1089/neu.2015.4113			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800002	26439468				2021-06-18	
J	Xing, ZH; Xia, Z; Peng, WJ; Li, J; Zhang, CH; Fu, CY; Tang, T; Luo, JK; Zou, Y; Fan, R; Liu, WP; Xiong, XG; Huang, W; Sheng, CX; Gan, PP; Wang, Y				Xing, Zhihua; Xia, Zian; Peng, Weijun; Li, Jun; Zhang, Chunhu; Fu, Chunyan; Tang, Tao; Luo, Jiekun; Zou, Yong; Fan, Rong; Liu, Weiping; Xiong, Xingui; Huang, Wei; Sheng, Chenxia; Gan, Pingping; Wang, Yang			Xuefu Zhuyu decoction, a traditional Chinese medicine, provides neuroprotection in a rat model of traumatic brain injury via an anti-inflammatory pathway	SCIENTIFIC REPORTS			English	Article							MAMMALIAN TARGET; MACROPHAGE POLARIZATION; INFLAMMATORY RESPONSES; ARACHIDONIC-ACID; TISSUE LOSS; TNF-ALPHA; RAPAMYCIN; MTOR; NEUROINFLAMMATION; DEFICITS	Neuroinflammation is central to the pathology of traumatic brain injury (TBI). Xuefu Zhuyu decoction (XFZY) is an effective traditional Chinese medicine to treat TBI. To elucidate its potential molecular mechanism, this study aimed to demonstrate that XFZY functions as an anti-inflammatory agent by inhibiting the PI3K-AKT-mTOR pathway. Sprague-Dawley rats were exposed to controlled cortical impact to produce a neuroinflammatory response. The treatment groups received XFZY (9 g/kg and 18 g/kg), Vehicle group and Sham group were gavaged with equal volumes of saline. The modified neurologic severity score (mNSS) and the Morris water maze test were used to assess neurological deficits. Arachidonic acid (AA) levels in brain tissue were measured using tandem gas chromatography-mass spectrometry. TNF-alpha and IL-1 beta levels in injured ipsilateral brain tissue were detected by ELISA. AKT and mTOR expression were measured by western blot analysis. The results indicated that XFZY significantly enhanced spatial memory acquisition. XFZY (especially at a dose of 9 g/kg) markedly reduced the mNSS and levels of AA, TNF-alpha and IL-1 beta. Significant downregulation of AKT/mTOR/p70S6K proteins in brain tissues was observed after the administration of XFZY (especially at a dose of 9 g/kg). XFZY may be a promising therapeutic strategy for reducing inflammation in TBI.	[Xing, Zhihua; Xia, Zian; Zhang, Chunhu; Tang, Tao; Luo, Jiekun; Fan, Rong; Liu, Weiping; Xiong, Xingui; Huang, Wei; Wang, Yang] Cent S Univ, Lab Ethnopharmacol, Inst Integrated Tradit Chinese & Western Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Peng, Weijun; Sheng, Chenxia] Cent S Univ, Dept Tradit Chinese Med, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China; [Li, Jun] Cent S Univ, Thyroid Tumour Internal Med Dept, Canc Hosp, Xiangya Sch Med, Changsha 410011, Hunan, Peoples R China; [Fu, Chunyan] Shaoyang Med Coll Level Specialty Sch, Dept Pharm, Shaoyang 422000, Peoples R China; [Zou, Yong] Cent S Univ, Xiangya Hosp, Dept Gerontol & Resp Dis, Changsha 410008, Hunan, Peoples R China; [Gan, Pingping] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China	Wang, Y (corresponding author), Cent S Univ, Lab Ethnopharmacol, Inst Integrated Tradit Chinese & Western Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.	wangyang_xy87@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303074, 81202781, 81403259, 81303098]; Science and Technology Plan Projects of Hunan Province, China [2013SK3280]; People's Livelihood Support of Science and Technology Special Funds of Changsha, China [K1205018-31]	This research was supported by the National Natural Science Foundation of China (Grant Nos. 81303074, 81202781, 81403259 and 81303098), Science and Technology Plan Projects of Hunan Province, China (No. 2013SK3280) and People's Livelihood Support of Science and Technology Special Funds of Changsha, China (No. K1205018-31).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Brough D, 2011, TRENDS PHARMACOL SCI, V32, P617, DOI 10.1016/j.tips.2011.06.002; Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; Cheng T, 2015, CELL MOL NEUROBIOL, V35, P641, DOI 10.1007/s10571-015-0159-9; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Don ASA, 2012, DRUG DISCOV TODAY, V17, P861, DOI 10.1016/j.drudis.2012.04.010; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Hoeffer CA, 2010, TRENDS NEUROSCI, V33, P67, DOI 10.1016/j.tins.2009.11.003; Huang X., 2006, ZHONGGUO ZHONG YI JI, V15, P144; Huang X., 2006, ZHONGGUO ZHONG YI JI, V15, P121; Hwang HJ, 2008, J MICROBIOL BIOTECHN, V18, P1641; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Klann E, 2004, NAT REV NEUROSCI, V5, P931, DOI 10.1038/nrn1557; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kou K, 2014, WORLD J EMERG MED, V5, P245, DOI 10.5847/wjem.j.issn.1920-8642.2014.04.001; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Lin C, 2015, SCI REP-UK, V5, DOI 10.1038/srep13442; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu Q, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-44; Luo L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5407; Ma CH, 2015, J ETHNOPHARMACOL, V168, P349, DOI 10.1016/j.jep.2015.03.068; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Moore AH, 2009, NEUROSCIENCE, V164, P1484, DOI 10.1016/j.neuroscience.2009.08.073; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Paoletti I, 2013, INFLAMMATION, V36, P1316, DOI 10.1007/s10753-013-9670-7; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; PINKEL D, 1958, CANCER RES, V18, P853; Rosi S, 2005, J NEUROSCI, V25, P723, DOI 10.1523/JNEUROSCI.4469-04.2005; Steiner N, 2016, NEUROCHEM INT, V95, P46, DOI 10.1016/j.neuint.2015.10.013; Sucher NJ, 2013, EXPERT OPIN DRUG DIS, V8, P21, DOI 10.1517/17460441.2013.739602; Sun M, 2008, CHIN J INTEGR MED, V14, P137, DOI 10.1007/s11655-008-0137-x; Sun X, 2010, BIOORG MED CHEM LETT, V20, P4120, DOI 10.1016/j.bmcl.2010.05.076; Teng F., 2014, J EVIDENCE BASED COM, V2014; Wang J., 2013, J EVIDENCE BASED COM, V2013; Wang J, 2013, PAIN PHYSICIAN, V16, pE563; Wang N, 2011, NEURAL REGEN RES, V6, P1635, DOI 10.3969/j.issn.1673-5374.2011.21.006; Wang WZ, 2016, MOL NEUROBIOL, V53, P4809, DOI 10.1007/s12035-015-9385-x; Wang Z.W., 2010, SHANXI ZHONG YI, V31, P850; Weichhart T, 2008, ANN RHEUM DIS, V67, P70, DOI 10.1136/ard.2008.098459; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Yang SG, 2012, J NEUROTRAUM, V29, P2696, DOI 10.1089/neu.2012.2442; Yue HF, 2007, J PHARMACEUT BIOMED, V43, P1122, DOI 10.1016/j.jpba.2006.10.009; Zhai PP, 2015, NEUROPHARMACOLOGY, V95, P1, DOI 10.1016/j.neuropharm.2015.02.026; Zhu XX, 2014, J CEREBR BLOOD F MET, V34, P1531, DOI 10.1038/jcbfm.2014.113; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	61	59	61	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 28	2016	6								20040	10.1038/srep20040			14	Multidisciplinary Sciences	Science & Technology - Other Topics	DB8RY	WOS:000368785500001	26818584	DOAJ Gold, Green Published			2021-06-18	
J	Gupta, R; Sen, N				Gupta, Rajaneesh; Sen, Nilkantha			Traumatic brain injury: a risk factor for neurodegenerative diseases	REVIEWS IN THE NEUROSCIENCES			English	Article						Alzheimer disease; amyotrophic lateral sclerosis; chronic traumatic encephalopathy; neurodegeneration; traumatic brain injury	AMYOTROPHIC-LATERAL-SCLEROSIS; UBIQUITIN-PROTEASOME PATHWAY; UP-REGULATION; HEAD-INJURY; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; MOUSE-BRAIN; CELL-DEATH; KAPPA-B; EXPRESSION	Traumatic brain injury (TBI), a major global health and socioeconomic problem, is now established as a chronic disease process with a broad spectrum of pathophysiological symptoms followed by long-term disabilities. It triggers multiple and multidirectional biochemical events that lead to neurodegeneration and cognitive impairment. Recent studies have presented strong evidence that patients with TBI history have a tendency to develop proteinopathy, which is the pathophysiological feature of neurodegenerative disorders such as Alzheimer disease (AD), chronic traumatic encephalopathy (CTE), and amyotrophic lateral sclerosis (ALS). This review mainly focuses on mechanisms related to AD, CTE, and ALS that are induced after TBI and their relevance to the advancement of these neurodegenerative diseases. This review encompasses acute effects and chronic neurodegenerative consequences after TBI for a better understanding of TBI-induced neuronal death and to design therapies that will effectively treat patients in the primary or secondary progressive stages.	[Sen, Nilkantha] Georgia Regents Univ, Augusta, GA 30912 USA; [Gupta, Rajaneesh] Georgia Regents Univ, Neurosci & Regenerat Med, Augusta, GA 30912 USA	Sen, N (corresponding author), Georgia Regents Univ, 1120 15th St CA 2018, Augusta, GA 30912 USA.	nsen@gru.edu	Gupta, Rajaneesh/AAD-5893-2019; Sen, Nilkantha/AAW-9788-2020	Gupta, Rajaneesh/0000-0003-0212-6478; 	NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01 EY025622] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS094516] Funding Source: Medline; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY025622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094516] Funding Source: NIH RePORTER		Achi EY, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/806306; Bettcher BM, 2014, CLIN PHARMACOL THER, V96, P464, DOI 10.1038/clpt.2014.147; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Bolmont T, 2007, AM J PATHOL, V171, P2012, DOI 10.2353/ajpath.2007.070403; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen Y, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00022; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Chow VW, 2010, NEUROMOL MED, V12, P1, DOI 10.1007/s12017-009-8104-z; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gupta RK, 2013, BIOGERONTOLOGY, V14, P531, DOI 10.1007/s10522-013-9459-y; Gupta RK, 2016, MOL NEUROBIOL, V53, P3377, DOI 10.1007/s12035-015-9287-y; Gupta RK, 2014, NEUROCHEM RES, V39, P150, DOI 10.1007/s11064-013-1200-3; Gupta RK, 2013, AGE, V35, P59, DOI 10.1007/s11357-011-9330-5; Haass C, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006270; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Huang RQ, 2010, NEUROSCI LETT, V473, P22, DOI 10.1016/j.neulet.2010.02.011; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jordan Barry D, 2014, Continuum (Minneap Minn), V20, P1588, DOI 10.1212/01.CON.0000458972.94013.e1; Jucker M, 2011, ANN NEUROL, V70, P532, DOI 10.1002/ana.22615; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Lee J, 2014, J TRAUMA ACUTE CARE, V77, P709, DOI 10.1097/TA.0000000000000445; LEIGH PN, 1991, BRAIN, V114, P775, DOI 10.1093/brain/114.2.775; Luo P, 2011, BRAIN RES BULL, V85, P313, DOI 10.1016/j.brainresbull.2011.05.004; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Massaad CA, 2011, ANTIOXID REDOX SIGN, V14, P2013, DOI 10.1089/ars.2010.3208; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nonaka T, 2009, FEBS LETT, V583, P394, DOI 10.1016/j.febslet.2008.12.031; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RIGGS JE, 1993, MIL MED, V158, P55; RIGGS JE, 1985, ARCH NEUROL-CHICAGO, V42, P205, DOI 10.1001/archneur.1985.04060030015004; RIGGS JE, 1995, CLIN NEUROPHARMACOL, V18, P273, DOI 10.1097/00002826-199506000-00008; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Roman GC, 1996, J NEUROL NEUROSUR PS, V61, P131, DOI 10.1136/jnnp.61.2.131; Rosen RF, 2012, J NEUROCHEM, V120, P660, DOI 10.1111/j.1471-4159.2011.07551.x; Rosenbohm A, 2014, J NEUROL, V261, P283, DOI 10.1007/s00415-013-7185-7; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Schwartz AL, 1999, ANNU REV MED, V50, P57; Shi P, 2010, BBA-MOL BASIS DIS, V1802, P707, DOI 10.1016/j.bbadis.2010.05.008; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Staal JA, 2009, J NEUROTRAUM, V26, P781, DOI 10.1089/neu.2008.0669; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang X, 2010, EXP NEUROL, V223, P299, DOI 10.1016/j.expneurol.2009.07.033	75	59	61	0	26	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	JAN	2016	27	1					93	100		10.1515/revneuro-2015-0017			8	Neurosciences	Neurosciences & Neurology	CZ3QR	WOS:000367019600006	26352199				2021-06-18	
J	Ding, K; Xu, JG; Wang, HD; Zhang, L; Wu, Y; Li, T				Ding, Ke; Xu, Jianguo; Wang, Handong; Zhang, Li; Wu, Yong; Li, Tao			Melatonin protects the brain from apoptosis by enhancement of autophagy after traumatic brain injury in mice	NEUROCHEMISTRY INTERNATIONAL			English	Article						Melatonin; Traumatic brain injury; Autophagy; Apoptosis	SUBARACHNOID HEMORRHAGE; CELL-DEATH; PATHWAY; MECHANISM; RAPAMYCIN; STRESS; MODEL; DEGENERATION; INFLAMMATION; INVOLVEMENT	Melatonin has been proven to possess neuroprotection property against various neurological diseases by decreasing cerebral oxidative stress and inhibiting inflammatory process. However, whether administration of inelatonin influences the autophagy pathway, which has recently been reported playing a pivotal role in traumatic brain injury, is yet not fully understood. We supposed that treatment of melatonin enhances the autophagy pathway after traumatic brain injury (TBI) in mice and subsequently inhibited the mitochondrion apoptotic pathway. Firstly, we investigated the neurological severity score, brain water content and neuronal apoptosis in mice cortex to demonstrate the neuroprotection of melatonin. Then we determined the autophagy markers, namely Beclinl and LC3-II, using western blot and immunofluorescence. Next, we evaluated the mitochondrial apoptotic pathway in the presence or absence of melatonin. More significantly, we employed 3-methyladenine (3-MA) to inhibit the autophagy pathway, to further confirm our hypothesis. The results showed that melatonin significantly ameliorated secondary brain injury induced by TBI. In addition, melatonin enhanced autophagy after TBI, which was accompanied by a decrease in both the translocation of Bax to mitochondria and the release of cytochrome C to cytoplasm. Furthermore, simultaneous treatment of 3-MA reversed the beneficial effects of melatonin on mitochondrial apoptotic pathway. Taken together, we conclude that melatonin enhances autophagy, which inhibits mitochondrial apoptotic pathway, thus protecting mice from secondary brain injury after TBI. (C) 2015 Elsevier Ltd. All rights reserved.	[Ding, Ke; Xu, Jianguo; Wang, Handong; Zhang, Li; Wu, Yong; Li, Tao] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357]; Jiangsu Provincial Science and Technology Department [BL2013027]; Medical Science Youth Breeding Project of PLA [14QNP035]	This work was supported by Grants from the National Natural Science Foundation of China (no. 81371357), Jiangsu Provincial Science and Technology Department (no.BL2013027) and Medical Science Youth Breeding Project of PLA (no.14QNP035).	Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Bromme HJ, 2000, J PINEAL RES, V29, P201, DOI 10.1034/j.1600-0633.2002.290402.x; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Cavallucci V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.511; Cervantes M, 2008, J PINEAL RES, V45, P1, DOI 10.1111/j.1600-079X.2007.00551.x; Chang CC, 2012, J PINEAL RES, V53, P188, DOI 10.1111/j.1600-079X.2012.00986.x; Chang CF, 2012, J PINEAL RES, V52, P312, DOI 10.1111/j.1600-079X.2011.00945.x; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Choi SI, 2013, J PINEAL RES, V54, P361, DOI 10.1111/jpi.12039; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMc1303158, 10.1056/NEJMra1205406]; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fernandez A, 2015, J PINEAL RES, V59, P292, DOI 10.1111/jpi.12264; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gooneratne NS, 2012, J PINEAL RES, V52, P437, DOI 10.1111/j.1600-079X.2011.00958.x; Hamacher-Brady A, 2006, J BIOL CHEM, V281, P29776, DOI 10.1074/jbc.M603783200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kongsuphol P, 2009, J PINEAL RES, V46, P199, DOI 10.1111/j.1600-079X.2008.00648.x; Kunz A, 2010, BEST PRACT RES-CLIN, V24, P495, DOI 10.1016/j.bpa.2010.10.001; Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696; Li MM, 2015, APOPTOSIS, V20, P769, DOI 10.1007/s10495-015-1110-8; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo SQ, 2013, AUTOPHAGY, V9, P104, DOI 10.4161/auto.22399; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918; Nopparat C, 2010, J PINEAL RES, V49, P382, DOI 10.1111/j.1600-079X.2010.00805.x; Pandi-Perumal SR, 2013, NEUROTOX RES, V23, P267, DOI 10.1007/s12640-012-9337-4; Radogna F, 2010, BIOCHEM PHARMACOL, V80, P1844, DOI 10.1016/j.bcp.2010.07.041; Seifman MA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00237; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sun M, 2015, J NEUROTRAUM, V32, P66, DOI 10.1089/neu.2012.2432; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152; Xu JG, 2014, BRAIN RES, V1582, P237, DOI 10.1016/j.brainres.2014.07.042; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Zhang XN, 2013, AUTOPHAGY, V9, P1321, DOI 10.4161/auto.25132; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005	46	59	62	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2015	91						46	54		10.1016/j.neuint.2015.10.008			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CZ0FL	WOS:000366780400005	26527380				2021-06-18	
J	Lei, J; Gao, GY; Feng, JF; Jin, YC; Wang, CF; Mao, Q; Jiang, JY				Lei, Jin; Gao, Guoyi; Feng, Junfeng; Jin, Yichao; Wang, Chuanfang; Mao, Qing; Jiang, Jiyao			Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study	CRITICAL CARE			English	Article							THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; CLINICAL-TRIALS; SERUM; MODERATE; BLOOD; GFAP; PREDICTION; MANAGEMENT; PROGNOSIS	Introduction: Glial fibrillary acidic protein (GFAP) may serve as a serum marker of traumatic brain injury (TBI) that can be used to monitor biochemical changes in patients and gauge the response to treatment. However, the temporal profile of serum GFAP in the acute period of brain injury and the associated utility for outcome prediction has not been elucidated. Methods: We conducted a prospective longitudinal cohort study of consecutive severe TBI patients in a local tertiary neurotrauma center in Shanghai, China, between March 2011 and September 2014. All patients were monitored and managed with a standardized protocol with inclusion of hypothermia and other intensive care treatments. Serum specimens were collected on admission and then daily for the first 5 days. GFAP levels were measured using enzyme-linked immunosorbent assay techniques. Patient outcome was assessed at 6 months post injury with the Glasgow Outcome Scale and further grouped into death versus survival and unfavorable versus favorable. Results: A total of 67 patients were enrolled in the study. The mean time from injury to admission was 2.6 hours, and the median admission Glasgow Coma Scale score was 6. Compared with healthy subjects, patients with severe TBI had increased GFAP levels on admission and over the subsequent 5 days post injury. Serum GFAP levels showed a gradual reduction from admission to day 3, and then rebounded on day 4 when hypothermia was discontinued with slow rewarming. GFAP levels were significantly higher in patients who died or had an unfavorable outcome across all time points than in those who were alive or had a favorable outcome. Results of receiver operating characteristic curve analysis indicated that serum GFAP at each time point could predict neurological outcome at 6 months. The areas under the curve for GFAP on admission were 0.761 for death and 0.823 for unfavorable outcome, which were higher than those for clinical variables such as age, Glasgow Coma Scale score, and pupil reactions. Conclusions: Serum GFAP levels on admission and during the first 5 days of injury were increased in patients with severe TBI and were predictive of neurological outcome at 6 months.	[Lei, Jin; Gao, Guoyi; Feng, Junfeng; Jin, Yichao; Wang, Chuanfang; Mao, Qing; Jiang, Jiyao] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Inst Head Trauma,Dept Neurosurg, Shanghai 200127, Peoples R China; [Lei, Jin; Gao, Guoyi; Feng, Junfeng; Jin, Yichao; Wang, Chuanfang; Mao, Qing; Jiang, Jiyao] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Inst Head Trauma,Dept Neurosurg, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.	jiyaojiangrenji@126.com			National Key Basic Research ProjectNational Basic Research Program of China [2012CB518100]; National Natural Scientific FoundationNational Natural Science Foundation of China (NSFC) [81271381]; Program for Outstanding Medical Academic Leader of Shanghai [2014529]	This research was supported by grants from the National Key Basic Research Project (No. 2012CB518100), the National Natural Scientific Foundation (No. 81271381) and the Program for Outstanding Medical Academic Leader of Shanghai (No. 2014529). We thank Dr. Xiao Zhang from Pharmaceutical Product Development, LLC (PPD (R)) for her valuable statistical assistance in our work. We are also grateful to Dr. Justin Dean from University of Auckland for his important assistance in English.	Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Crossley S, 2014, CRIT CARE, V18, DOI 10.1186/cc13835; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dvorak F, 2009, CEREBROVASC DIS, V27, P37, DOI 10.1159/000172632; Fox JL, 2010, CAN J EMERG MED, V12, P355; Gao L, 2015, FRONT BIOSCI-LANDMRK, V20, P763, DOI 10.2741/4335; Hemingway H, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e5595; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Jacobs B, 2013, NEUROCRIT CARE, V19, P79, DOI 10.1007/s12028-012-9795-9; Lei J, 2015, CONTEMP CLIN TRIALS, V40, P9, DOI 10.1016/j.cct.2014.11.008; Lei J, 2013, J NEUROTRAUM, V30, P529, DOI 10.1089/neu.2012.2548; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mouser PE, 2006, AM J PATHOL, V168, P936, DOI 10.2353/ajpath.2006.050798; Mrozek S, 2014, CRIT CARE, V18, DOI 10.1186/cc13841; Nichol AD, 2009, INJURY, V40, P471, DOI 10.1016/j.injury.2009.01.002; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; WARE JH, 1993, EUR RESPIR J, V6, P325; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yang ZH, 2015, TRENDS NEUROSCI, V38, P364, DOI 10.1016/j.tins.2015.04.003; Yokobori S, 2013, J NEUROSURG, V118, P370, DOI 10.3171/2012.10.JNS12725	44	59	60	0	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	OCT 12	2015	19								362	10.1186/s13054-015-1081-8			12	Critical Care Medicine	General & Internal Medicine	CT0IM	WOS:000362478400001	26455520	DOAJ Gold, Green Published			2021-06-18	
J	Veeramuthu, V; Narayanan, V; Kuo, TL; Delano-Wood, L; Chinna, K; Bondi, MW; Waran, V; Ganesan, D; Ramli, N				Veeramuthu, Vigneswaran; Narayanan, Vairavan; Kuo, Tan Li; Delano-Wood, Lisa; Chinna, Karuthan; Bondi, Mark William; Waran, Vicknes; Ganesan, Dharmendra; Ramli, Norlisah			Diffusion Tensor Imaging Parameters in Mild Traumatic Brain Injury and Its Correlation with Early Neuropsychological Impairment: A Longitudinal Study	JOURNAL OF NEUROTRAUMA			English	Article						DTI; imaging biomarker; mTBI; neuropsychology; ROI; TBSS	WHITE-MATTER INTEGRITY; AXONAL INJURY; CORPUS-CALLOSUM; COGNITIVE DYSFUNCTION; SPATIAL STATISTICS; ASTROCYTE ACTIVATION; SPINAL-CORD; NEUROPATHOLOGY; ANISOTROPY; MEMORY	We explored the prognostic value of diffusion tensor imaging (DTI) parameters of selected white matter (WM) tracts in predicting neuropsychological outcome, both at baseline and 6 months later, among well-characterized patients diagnosed with mild traumatic brain injury (mTBI). Sixty-one patients with mTBI (mean age=27.08; standard deviation [SD], 8.55) underwent scanning at an average of 10h (SD, 4.26) post-trauma along with assessment of their neuropsychological performance at an average of 4.35h (SD, 7.08) upon full Glasgow Coma Scale recovery. Results were then compared to 19 healthy control participants (mean age=29.05; SD, 5.84), both in the acute stage and 6 months post-trauma. DTI and neuropsychological measures between acute and chronic phases were compared, and significant differences emerged. Specifically, chronic-phase fractional anisotropy and radial diffusivity values showed significant group differences in the corona radiata, anterior limb of internal capsule, cingulum, superior longitudinal fasciculus, optic radiation, and genu of corpus callosum. Findings also demonstrated associations between DTI indices and neuropsychological outcome across two time points. Our results provide new evidence for the use of DTI as an imaging biomarker and indicator of WM damage occurring in the context of mTBI, and they underscore the dynamic nature of brain injury and possible biological basis of chronic neurocognitive alterations.	[Veeramuthu, Vigneswaran; Narayanan, Vairavan; Waran, Vicknes; Ganesan, Dharmendra] Univ Malaya, Dept Surg, Div Neurosurg, Kuala Lumpur 50603, Wilayah Perseku, Malaysia; [Kuo, Tan Li; Ramli, Norlisah] Univ Malaya, Res Imaging Ctr, Kuala Lumpur 50603, Wilayah Perseku, Malaysia; [Delano-Wood, Lisa; Bondi, Mark William] VA San Diego Healthcare Syst, San Diego, CA USA; [Delano-Wood, Lisa; Bondi, Mark William] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Chinna, Karuthan] Univ Malaya, Dept Social & Prevent Med, Julius Ctr, Kuala Lumpur 50603, Wilayah Perseku, Malaysia	Veeramuthu, V (corresponding author), Univ Malaya, Dept Surg, Div Neurosurg, Kuala Lumpur 50603, Wilayah Perseku, Malaysia.	vicveera@gmail.com	GANESAN, DHARMENDRA/B-8437-2010; chinna, karuthan/E-4495-2014; RAMLI, NORLISAH MOHD/I-6372-2016; Veeramuthu, Vigneswaran/F-2220-2015; Mathaneswaran, Vickneswaran/E-5180-2010; NARAYANAN, VAIRAVAN/B-9191-2010; Ramli, Norlisah M/G-5209-2010; Tan, Li Kuo/B-5494-2010	chinna, karuthan/0000-0002-5449-2341; RAMLI, NORLISAH MOHD/0000-0001-7497-8093; Veeramuthu, Vigneswaran/0000-0003-2052-0858; NARAYANAN, VAIRAVAN/0000-0002-1118-5042; Ramli, Norlisah M/0000-0001-7497-8093; Tan, Li Kuo/0000-0002-6912-172X	University Malaya Research Grant (UMRG) [RG008C-13HTM]; High Impact Research Grant of University of Malaya [HIR-UM.C/625/1/HIR-MOHE/12]	This research is partially funded by a University Malaya Research Grant (UMRG; RG008C-13HTM) and a High Impact Research Grant of University of Malaya (HIR-UM.C/625/1/HIR-MOHE/12).	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Alexander AL, 2011, BRAIN CONNECT, V1, P423, DOI 10.1089/brain.2011.0071; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bach M, 2014, NEUROIMAGE, V100, P358, DOI 10.1016/j.neuroimage.2014.06.021; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bigler ED, 2010, PSYCHOL INJ LAW, V3, P36, DOI 10.1007/s12207-010-9064-1; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bonnier Christine, 2004, Pediatr Rehabil, V7, P165, DOI 10.1080/13638490410001703325; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burzynska AZ, 2010, NEUROIMAGE, V49, P2104, DOI 10.1016/j.neuroimage.2009.09.041; Chan YL, 2003, PEDIATR RADIOL, V33, P574, DOI 10.1007/s00247-003-0949-y; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Faul M., 2010, TBI US EMERGENCY DEP; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Ghonemi MO, 2013, EGYPT J CRIT CARE ME, V1, P139, DOI 10.1016/j.ejccm.2013.03.002; Gold BT, 2010, NEUROIMAGE, V52, P1487, DOI 10.1016/j.neuroimage.2010.05.036; Green Robin, 2010, Neuropsychol Rehabil, V20, P471, DOI 10.1080/09602011003693298; Grossman Elan J, 2010, Top Magn Reson Imaging, V21, P379, DOI 10.1097/RMR.0b013e31823e65b8; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Iffland P, 2014, VASCULAR MECH CNS TR, P29, DOI DOI 10.1007/978-1-4614-8690-9_2; Imperati D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023437; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kubicki M, 2007, J PSYCHIATR RES, V41, P15, DOI 10.1016/j.jpsychires.2005.05.005; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mukherjee P, 2002, AM J NEURORADIOL, V23, P1445; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Patt S, 1999, EXP TOXICOL PATHOL, V51, P119, DOI 10.1016/S0940-2993(99)80084-0; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Perez AM, 2014, J NEUROTRAUM, V31, P1478, DOI 10.1089/neu.2013.3216; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Rovaris M, 2005, NEUROLOGY, V65, P1526, DOI 10.1212/01.wnl.0000184471.83948.e0; Saatman K. E., 2012, TRAUMATIC BRAIN SPIN; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Sen PN, 2005, BIOPHYS J, V89, P2927, DOI 10.1529/biophysj.105.063016; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shiramizu H, 2008, NEUROL MED-CHIR, V48, P1, DOI 10.2176/nmc.48.1; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Strangman GE, 2012, NEUROREHABILITATION, V31, P295, DOI 10.3233/NRE-2012-0797; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Voets NL, 2006, BRAIN, V129, P754, DOI 10.1093/brain/awh679; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	81	59	62	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2015	32	19					1497	1509		10.1089/neu.2014.3750			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CR8NC	WOS:000361609500008	25952562	Bronze, Green Published, Green Accepted			2021-06-18	
J	Cifu, DX; Wares, JR; Hoke, KW; Wetzel, PA; Gitchel, G; Carne, W				Cifu, David X.; Wares, Joanna R.; Hoke, Kathy W.; Wetzel, Paul A.; Gitchel, George; Carne, William			Differential Eye Movements in Mild Traumatic Brain Injury Versus Normal Controls	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						eye tracking; fixations; mild traumatic brain injury; postconcussion syndrome; saccades; smooth pursuit	DEFICITS; CONCUSSION; ACTIVATION; SYMPTOMS; SOLDIERS; TBI; MRI; US	Objectives: Objective measures to diagnose and to monitor improvement of symptoms following mild traumatic brain injury (mTBI) are lacking. Computerized eye tracking has been advocated as a rapid, user friendly, and field-ready technique to meet this need. Design: Eye-tracking data collected via a head-mounted, video-based binocular eye tracker was used to examine saccades, fixations, and smooth pursuit movement in military Service Members with postconcussive syndrome (PCS) and asymptomatic control subjects in an effort to determine if eye movement differences could be found and quantified. Participants: Sixty Military Service Members with PCS and 26 asymptomatic controls. Outcome Measures: The diagnosis of mTBI was confirmed by the study physiatrist's history, physical examination, and a review of any medical records. Various features of saccades, fixation and smooth pursuit eye movements were analyzed. Results: Subjects with symptomatic mTBI had statistically larger position errors, smaller saccadic amplitudes, smaller predicted peak velocities, smaller peak accelerations, and longer durations. Subjects with symptomatic mTBI were also less likely to follow a target movement (less primary saccades). In general, symptomatic mTBI tracked the stepwise moving targets less accurately, revealing possible brain dysfunction. Conclusions: A reliable, standardized protocol that appears to differentiate mTBI from normals was developed for use in future research. This investigation represents a step toward objective identification of those with PCS. Future studies focused on increasing the specificity of eye movement differences in those with PCS are needed.	[Cifu, David X.; Carne, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Wetzel, Paul A.; Gitchel, George] Virginia Commonwealth Univ, Dept Biomed Engn, Richmond, VA 23298 USA; [Cifu, David X.] Dept Vet Affairs, Phys Med & Rehabil Program Off, Richmond, VA USA; [Wares, Joanna R.; Hoke, Kathy W.] Univ Richmond, Dept Math & Comp Sci, Richmond, VA 23173 USA	Carne, W (corresponding author), Virginia Commonwealth Univ, Dept PM&R, 1223 East Marshall St, Richmond, VA 23298 USA.	lasile@aol.com		Cifu, David/0000-0003-1600-9387	Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-09-2-206]; US Navy Bureau of Medicine and Surgery; US Army Medical Materiel Development Activity	Funding was provided for the primary study by a Defense Advanced Research Projects Agency grant (N66001-09-2-206), US Navy Bureau of Medicine and Surgery for contract funding temporary duty requirements, and the US Army Medical Materiel Development Activity for end-of-study contract funding. The funding sources had no role in the study design, analysis, interpretation of the data, the writing of the paper, or the decision to submit the paper for publication.	Arciniegas David B, 2004, Phys Med Rehabil Clin N Am, V15, P177, DOI 10.1016/S1047-9651(03)00104-9; Bast A., VETERANS HEAD INJURI; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Buxton RB, 2004, NEUROIMAGE, V23, pS220, DOI 10.1016/j.neuroimage.2004.07.013; Ceranic BJ, 1998, J NEUROL NEUROSUR PS, V65, P523, DOI 10.1136/jnnp.65.4.523; Cifu DX, 2014, J HEAD TRAUMA REHAB, V29, P11, DOI 10.1097/HTR.0b013e3182a6aaf0; Ciuffreda KJ, 2011, OPTOMETRY, V82, P61, DOI 10.1016/j.optm.2010.11.011; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Deppe M, 2004, NEUROIMAGE, V21, P1124, DOI 10.1016/j.neuroimage.2003.10.016; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Leigh R. J., 2006, NEUROLOGY EYE MOVEME; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Murkin J M, 2009, Br J Anaesth, V103 Suppl 1, pi3, DOI 10.1093/bja/aep299; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Pickett TC, 2007, J REHABIL RES DEV, V44, P983, DOI 10.1682/JRRD.2007.01.0001; Ramat S, 2007, BRAIN, V130, P10, DOI 10.1093/brain/awl309; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; US Department of Veterans Affairs, MAN CONC MILD TRAUM; World Health Organization, ICD 10 INT STAT CLAS; Yang M., HEAD TRAUMA SENSORS; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	26	59	59	0	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					21	28		10.1097/HTR.0000000000000036			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400011	24695263				2021-06-18	
J	Raj, R; Siironen, J; Skrifvars, MB; Hernesniemi, J; Kivisaari, R				Raj, Rahul; Siironen, Jari; Skrifvars, Markus B.; Hernesniemi, Juha; Kivisaari, Riku			Predicting Outcome in Traumatic Brain Injury: Development of a Novel Computerized Tomography Classification System (Helsinki Computerized Tomography Score)	NEUROSURGERY			English	Article						Computerized tomography; Helsinki CT; Marshall CT; Prediction model; Prognosis; Rotterdam CT; Sensitivity and specificity; Traumatic brain injury	GLASGOW COMA SCALE; HEAD-INJURY; ADMISSION CHARACTERISTICS; EXTERNAL VALIDATION; PROGNOSTIC VALUE; PRACTICAL SCALE; IMPACT MODELS; MORTALITY; MODERATE; CUSTOMIZATION	BACKGROUND: Early computerized tomography (CT) abnormalities are important predictors of outcome after traumatic brain injury (TBI). OBJECTIVE: To develop a novel CT scoring system (Helsinki CT score) and to compare it with the Marshall CT classification and the Rotterdam CT score in predicting long-term outcome of patients with TBI. METHODS: Eight hundred sixty-nine consecutive TBI patients were included in this open-cohort, retrospective, single-center study. Logistic regression was used to develop the Helsinki CT score. The scores from the Marshall, Rotterdam, and Helsinki CT scoring methods were added to a clinical model based on age, motor score, and pupils to evaluate their value in predicting outcome. Internal validity was assessed by a bootstrap technique and expressed as area under the curve (AUC). Outcome was 6-month unfavorable neurological outcome and mortality. RESULTS: Variables included in the Helsinki CT score were bleeding type and size, intraventricular hemorrhage, and suprasellar cisterns. In the present data set, the performance of the Helsinki CT score was superior to that of the Marshall CT and Rotterdam CT scores (AUC, 0.74-0.75 vs 0.63-0.70; P < .001). Addition of the Helsinki CT score modestly increased prognostic performance of the clinical model (AUC neurological outcome 10.02 [P =.002]; AUC mortality, 10.01 [P = .21]). In contrast, the Marshall and Rotterdam CT scores were of no additional predictive value to the clinical model (P > .05). CONCLUSION: Use of the novel Helsinki CT score improved outcome prediction accuracy, and the Helsinki CT score is a feasible alternative to the Rotterdam and Marshall CT systems. External validation of the Helsinki CT score is advocated to show generalizability.	[Raj, Rahul; Siironen, Jari; Hernesniemi, Juha; Kivisaari, Riku] Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland; [Skrifvars, Markus B.] Helsinki Univ Hosp, Dept Intens Care, Helsinki, Finland	Raj, R (corresponding author), Helsinki Univ Hosp, Dept Neurosurg, Topeliuksenkatu 5,PB 266, Helsinki 00029, Finland.	rahul.raj@hus.fi	Raj, Rahul/K-7693-2012	Raj, Rahul/0000-0003-4243-9591	Finska Lakaresallskapet; Maire Taponen Foundation; Helsinki University Hospital EVO [TYH2012142]	This study was funded by grants from Finska Lakaresallskapet, the Maire Taponen Foundation, and a Helsinki University Hospital EVO grant (TYH2012142). The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Bakhshi-Raiez F, 2007, CRIT CARE MED, V35, P2553, DOI 10.1097/01.CCM.0000288123.29559.5A; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS91; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; Huang YH, 2012, NEUROSURGERY, V71, P80, DOI 10.1227/NEU.0b013e3182517aa1; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Jacobs B, 2013, NEUROCRIT CARE, V19, P79, DOI 10.1007/s12028-012-9795-9; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; JENNETT B, 1975, LANCET, V1, P480; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; LEE JP, 1991, ACTA NEUROL SCAND, V84, P85, DOI 10.1111/j.1600-0404.1991.tb04913.x; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; Moons KGM, 2002, J CLIN EPIDEMIOL, V55, P1054, DOI 10.1016/S0895-4356(02)00453-5; Moreno R, 1997, CRIT CARE MED, V25, P2001, DOI 10.1097/00003246-199712000-00017; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Raj R, 2014, CRIT CARE, V18, DOI 10.1186/cc13814; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Seshan VE, 2013, STAT MED, V32, P1483, DOI 10.1002/sim.5648; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Steyerberg E., 2010, CLIN PREDICTION MODE; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1974, LANCET, V2, P81; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Zhu BP, 1996, CRIT CARE MED, V24, P57, DOI 10.1097/00003246-199601000-00011	37	59	63	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2014	75	6					632	646		10.1227/NEU.0000000000000533			15	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AU2FK	WOS:000345431600022	25181434				2021-06-18	
J	Asehnoune, K; Seguin, P; Allary, J; Feuillet, F; Lasocki, S; Cook, F; Floch, H; Chabanne, R; Geeraerts, T; Roger, C; Perrigault, PF; Hanouz, JL; Lukaszewicz, AC; Biais, M; Boucheix, P; Dahyot-Fizelier, C; Capdevila, X; Mahe, PJ; Le Maguet, P; Paugam-Burtz, C; Gergaud, S; Plaud, B; Constantin, JM; Malledant, Y; Flet, L; Sebille, V; Roquilly, A				Asehnoune, Karim; Seguin, Philippe; Allary, Jeremy; Feuillet, Fanny; Lasocki, Sigismond; Cook, Fabrice; Floch, Herve; Chabanne, Russell; Geeraerts, Thomas; Roger, Claire; Perrigault, Pierre F.; Hanouz, Jean L.; Lukaszewicz, Anne C.; Biais, Matthieu; Boucheix, Perrine; Dahyot-Fizelier, Claire; Capdevila, Xavier; Mahe, Pierre J.; Le Maguet, Pascale; Paugam-Burtz, Catherine; Gergaud, Soizic; Plaud, Benoit; Constantin, Jean M.; Malledant, Yannick; Flet, Laurent; Sebille, Veronique; Roquilly, Antoine		Corti-TC Study Grp	Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial	LANCET RESPIRATORY MEDICINE			English	Article							LOW-DOSE HYDROCORTISONE; SEPTIC SHOCK; MANAGEMENT; MORTALITY; THERAPY; INSUFFICIENCY; CYTOKINES; GROWTH	Background Hospital-acquired pneumonia is common after traumatic brain injury, and might be partly a result of traumatic brain injury-induced adrenal insufficiency. We tested the efficacy of low-dose hydrocortisone with fludrocortisone for the prevention of hospital-acquired pneumonia. Methods We did this double-blind, phase 3, placebo-controlled trial in 19 intensive care units in France. We enrolled patients aged 15-65 years in the first 24 h after severe traumatic brain injury (Glasgow coma scale score 158 and trauma-associated lesion on brain CT scan). Patients were randomly assigned (1:1; fixed blocks of 12, stratified by centre and mechanism, Glasgow coma scale, age, and arterial pressure [MGAP] score) to receive either hydrocortisone (200 mg per day tapered) and fludrocortisone (50 mu g tablet once per day) or matching placebo for 10 days. Before receiving study drug, adrenal function was assessed with a short corticotropin test. Treatment was stopped if patients had no adrenal insufficiency. The primary outcome was the occurrence of hospital-acquired pneumonia within 28 days after randomisation. We did an intention-to-treat analysis and a modified intention-to-treat analysis including only patients with adrenal insufficiency (adjusted for etomidate use). This study is registered with ClinicalTrials.gov, number NCT01093261. Findings From Sept 1,2010, to Nov 29,2012, we enrolled 336 patients (168 assigned to each group). Eight patients withdrew consent. At day 28,74 of 165 patients (45%) in the steroid group and 87 of 163 (53%) in the placebo group had developed one or more episodes of hospital-acquired pneumonia (hazard ratio [Hit] 0.75; 95% CI 0.55-1-03, p=0-07). In intention-to-treat analysis, we recorded 86 episodes of hospital-acquired pneumonia in the steroid group versus 110 in the placebo group (median 0, IQR 0-1 vs median 1, IQR 0-1 cases per patient, p=0.07). In modified intention-to-treat analyses, the HR for hospital-acquired pneumonia with steroids versus placebo was 0-80 (95% CI 0.56-1-14, p=0.22) in patients with adrenal insufficiency, and, in an exploratory preplanned analysis, 0.48 (0.23-1.01; p=0.05) in patients with normal adrenal function. We recorded no adverse events related to treatment. Interpretation Low-dose hydrocortisone with fludrocortisone did not improve the outcome of patients with traumatic brain injury. However, the study was underpowered because the proportion of patients with hospital-acquired pneumonia in the placebo group was lower than expected. The results were close to statistical significance for efficacy, meaning that further studies are therefore needed.	[Asehnoune, Karim; Mahe, Pierre J.; Roquilly, Antoine] CHU Nantes, Serv Anesthesie Reanimat Chirurg, Pole Anesthesie Reanimat, F-44093 Nantes 1, France; [Seguin, Philippe; Le Maguet, Pascale; Malledant, Yannick] Univ Rennes 1, CHU Rennes, Serv Anesthesie Reanimat 1, Rennes, France; [Allary, Jeremy; Paugam-Burtz, Catherine] Hop Beaujon, AP HP, Serv Anesthesie Reanimat Chirurg, Beaujon, France; [Feuillet, Fanny; Sebille, Veronique] CHU Nantes, Plateforme Biometrie Cellule Promot Rech Clin, F-44093 Nantes 1, France; [Feuillet, Fanny; Sebille, Veronique] Univ Nantes, EA SPHERE Biostat Pharmacoepidemiol & Human Sci 4, UFR Pharm, Nantes, France; [Lasocki, Sigismond; Gergaud, Soizic] CHU Angers, Serv Anesthesie Reanimat, Angers, France; [Cook, Fabrice; Plaud, Benoit] Hop Henri Mondor, AP HP, Serv Anesthesie Reanimat Chirurg, F-94010 Creteil, France; [Floch, Herve] CHU Brest, Serv Anesthesie Reanimat, F-29285 Brest, France; [Chabanne, Russell; Constantin, Jean M.] CHU Clermont Ferrand, Serv Anesthesie Reanimat, Clermont Ferrand, France; [Geeraerts, Thomas] Univ Toulouse 3, Dept Anesthesiol & Intens Care, Univ Hosp Toulouse, Equipe Accueil Modelisat Agress Tissulaire & Noci, F-31062 Toulouse, France; [Roger, Claire] CHU Nimes, Serv Reanimat, Div Anesthesie Reanimat Douleur Urgence, Nimes, France; [Perrigault, Pierre F.] CHU Montpellier, Hop Gui de Chauliac, Serv Anesthesie Reanimat, Montpellier, France; [Hanouz, Jean L.] CHU Caen, Serv Anesthesie Reanimat, F-14000 Caen, France; [Lukaszewicz, Anne C.] Hop Lariboisiere, AP HP, Serv Anesthesie Reanimat chirurg, F-75475 Paris, France; [Biais, Matthieu] CHU Bordeaux, Serv Anesthesie Reanimat, Bordeaux, France; [Boucheix, Perrine] CHU Grenoble, Hop Michallon, Serv Anesthesie Reanimat, F-38043 Grenoble, France; [Dahyot-Fizelier, Claire] CHU Poitiers, Serv Anesthesie Reanimat, Poitiers, France; [Capdevila, Xavier] CHU Montpellier, Hop Lapeyronie, Serv Anesthesie Reanimat, Montpellier, France; [Flet, Laurent] CHU Nantes, Pole Biol Pharm, Serv Pharm, F-44093 Nantes 1, France	Asehnoune, K (corresponding author), CHU Nantes, Serv Anesthesie Reanimat, 1 Pl Alexis Ricordeau, F-44093 Nantes 1, France.	karim.asehnoune@chu-nantes.fr	Sebille, Veronique/L-8761-2015; Didier, Journois/J-3074-2019; Seguin, Philippe/P-9487-2019; FLET, Laurent/X-1192-2019; Roquilly, Antoine/P-9826-2017; Feuillet, Fanny/L-9041-2015; Sebille, Veronique/I-3309-2015; lasocki, sigismond/G-9443-2016	Didier, Journois/0000-0003-1096-7373; Seguin, Philippe/0000-0002-7774-4257; FLET, Laurent/0000-0001-8305-7085; capdevila, xavier/0000-0002-9791-8779; mimoz, olivier/0000-0003-1737-7915; Paugam-Burtz, Catherine/0000-0002-8168-7152; Malledant, yannick/0000-0001-6680-5184; Sebille, Veronique/0000-0002-0780-7742; hanouz, jean-luc/0000-0003-1845-8610; Roquilly, Antoine/0000-0002-1029-6242	Societe Francaise d'Anesthesie Reanimation	Funding Societe Francaise d'Anesthesie Reanimation.	Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Asehnoune K, 2012, INTENS CARE MED, V38, P1673, DOI 10.1007/s00134-012-2619-8; Asehnoune K, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-228; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Boonen E, 2013, NEW ENGL J MED, V368, P1477, DOI 10.1056/NEJMoa1214969; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; HASAN D, 1989, STROKE, V20, P1156, DOI 10.1161/01.STR.20.9.1156; Huh JW, 2011, RESPIROLOGY, V16, P1088, DOI 10.1111/j.1440-1843.2011.02018.x; Kanangat S, 1999, INFECT IMMUN, V67, P2834, DOI 10.1128/IAI.67.6.2834-2840.1999; Kaufmann I, 2008, INTENS CARE MED, V34, P344, DOI 10.1007/s00134-007-0868-8; Keh D, 2003, AM J RESP CRIT CARE, V167, P512, DOI 10.1164/rccm.200205-446OC; Klompas M, 2010, AM J INFECT CONTROL, V38, P237, DOI 10.1016/j.ajic.2009.10.003; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Marik PE, 2008, CRIT CARE MED, V36, P1937, DOI 10.1097/CCM.0b013e31817603ba; Meduri GU, 1999, AM J RESP CRIT CARE, V160, P961, DOI 10.1164/ajrccm.160.3.9807080; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Reynolds SF, 2005, CHEST, V127, P1397, DOI 10.1378/chest.127.4.1397; Roquilly A, 2013, AM J RESP CRIT CARE, V188, P958, DOI 10.1164/rccm.201301-0116OC; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; Roquilly A, 2011, JAMA-J AM MED ASSOC, V305, P1201, DOI 10.1001/jama.2011.360; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Sartorius D, 2010, CRIT CARE MED, V38, P831, DOI 10.1097/CCM.0b013e3181cc4a67; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004	33	59	62	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-2600			LANCET RESP MED	Lancet Resp. Med.	SEP	2014	2	9					706	716		10.1016/S2213-2600(14)70144-4			11	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	AO1IE	WOS:000341065000018	25066331				2021-06-18	
J	Zhou, NN; Tang, Y; Keep, RF; Ma, XX; Xiang, JM				Zhou, Ningna; Tang, Yang; Keep, Richard F.; Ma, Xiaoxia; Xiang, Jianming			Antioxidative effects of Panax notoginseng saponins in brain cells	PHYTOMEDICINE			English	Article						Oxidative stress; Total saponins of Panax notoginseng leaves; Astrocytes; SH-SY5Y cells	OXIDATIVE STRESS; GLUCOSE DEPRIVATION; INDUCED APOPTOSIS; IN-VITRO; INJURY; OXYGEN; ASTROCYTES; MEMBRANE; MODULATION; ISCHEMIA	Oxidative stress resulting from accumulation of reactive oxygen species (ROS) is involved in cell death associated with neurological disorders such as stroke, Alzheimer's disease and traumatic brain injury. Antioxidant compounds that improve endogenous antioxidant defenses have been proposed for neural protection. The purpose of this study was to investigate the potential protective effects of total saponin in leaves of Panax notoginseng (LPNS) on oxidative stress and cell death in brain cells in vitro. Lactate dehydrogenase (LDH) assay indicated that LPNS (5 mu g/ml) reduced H2O2-induced cell death in primary rat cortical astrocytes (23 +/- 8% reduction in LDH release vs. control). Similar protection was found in oxygen and glucose deprivation/reoxygenation induced SH-SY5Y (a human neuroblastoma cell line) cell damage (78 +/- 7% reduction vs. control). The protective effects of LPNS in astrocytes were associated with attenuation of reactive oxygen species (ROS) accumulation. These effects involved activation of Nrf2 (nuclear translocation) and upregulation of downstream antioxidant systems including heme oxygenase-1 (HO-1) and glutathione S-transferase pi 1 (GSTP1). These results demonstrate for the first time that LPNS has antioxidative effects which may be neuroprotective in neurological disorders. (C) 2014 Elsevier GmbH. All rights reserved.	[Zhou, Ningna; Tang, Yang; Keep, Richard F.; Xiang, Jianming] Univ Michigan, Dept Neurosurg, Sch Med, Ann Arbor, MI 48109 USA; [Zhou, Ningna] Yunnan Univ Tradit Chinese Med, Dept Pharmacol, Kunming, Peoples R China; [Keep, Richard F.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Ma, Xiaoxia] Yunnan Univ Tradit Chinese Med, Dept Chinese Med, Kunming, Peoples R China	Xiang, JM (corresponding author), Univ Michigan, Dept Neurosurg, 5014 BSRB, Ann Arbor, MI 48109 USA.	jmxxdrnx@umich.edu		Keep, Richard/0000-0001-6441-5334	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-034709]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81260649]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034709] Funding Source: NIH RePORTER	This study was supported by a grant, NS-034709 (RFK), from the National Institutes of Health (NIH) and 81260649, from the National Natural Science Foundation of China. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and National Natural Science Foundation of China.	Bienert GP, 2006, BBA-BIOMEMBRANES, V1758, P994, DOI 10.1016/j.bbamem.2006.02.015; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Chan P, 2002, ACTA PHARMACOL SIN, V23, P1157; Chen SX, 2011, J ETHNOPHARMACOL, V137, P263, DOI 10.1016/j.jep.2011.05.011; Chen X, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006305.pub2; Choi Roy Chi-Yan, 2010, Chin Med, V5, P38, DOI 10.1186/1749-8546-5-38; COCHRANE CG, 1991, AM J MED, V91, pS23, DOI 10.1016/0002-9343(91)90280-B; Copin JC, 2001, FASEB J, V15, P525, DOI 10.1096/fj.00-0330com; Crack PJ, 2005, FREE RADICAL BIO MED, V38, P1433, DOI 10.1016/j.freeradbiomed.2005.01.019; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Fu Jian-hua, 2006, Zhongguo Zhong Yao Za Zhi, V31, P62; Giffard RG, 2005, GLIA, V50, P299, DOI 10.1002/glia.20167; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Guo SH, 2009, J NEUROCHEM, V108, P1309, DOI 10.1111/j.1471-4159.2009.05877.x; Gyulkhandanyan AV, 2003, J NEUROCHEM, V87, P448, DOI 10.1046/j.1471-4159.2003.02029.x; Hamdi Y, 2011, J NEUROCHEM, V118, P416, DOI 10.1111/j.1471-4159.2011.07315.x; He L, 2011, PHYTOMEDICINE, V18, P437, DOI 10.1016/j.phymed.2010.10.004; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022; Kedar N P, 2003, J Postgrad Med, V49, P236; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; LEI XL, 1986, AM J CHINESE MED, V14, P145, DOI 10.1142/S0192415X86000235; Lotharius J, 2005, J NEUROSCI, V25, P6329, DOI 10.1523/JNEUROSCI.1746-05.2005; Mathers J, 2004, BIOCHEM SOC SYMP, V71, P157, DOI 10.1042/bss0710157; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Ng TB, 2006, J PHARM PHARMACOL, V58, P1007, DOI 10.1211/jpp.58.8.0001; Papadopoulos MC, 1998, NEUROSCIENCE, V82, P915; Park JS, 2011, J NEUROCHEM, V119, P909, DOI 10.1111/j.1471-4159.2011.07395.x; Pedroso N, 2009, FREE RADICAL BIO MED, V46, P289, DOI 10.1016/j.freeradbiomed.2008.10.039; Peuchen S, 1997, PROG NEUROBIOL, V52, P261, DOI 10.1016/S0301-0082(97)00010-5; Resende R, 2008, FREE RADICAL BIO MED, V44, P2051, DOI 10.1016/j.freeradbiomed.2008.03.012; Sabirzhanova IB, 2009, BIOCHEM BIOPH RES CO, V389, P338, DOI 10.1016/j.bbrc.2009.08.146; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; Shen LH, 2008, GLIA, V56, P1747, DOI 10.1002/glia.20722; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Thimmulappa RK, 2002, CANCER RES, V62, P5196; de Almeida LMV, 2008, ARCH BIOCHEM BIOPHYS, V480, P27, DOI 10.1016/j.abb.2008.09.006; Wagner H., 2011, CHROMATOGRAPHIC FING, P843; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; WINTERBOURN CC, 1981, BIOCHEM J, V198, P125, DOI 10.1042/bj1980125; Xiang H, 2011, PHYTOMEDICINE, V18, P731, DOI 10.1016/j.phymed.2010.11.014; Yao Xiao-hao, 2002, Zhongguo Zhongyao Zazhi, V27, P371; Yoo MS, 2003, MOL BRAIN RES, V110, P76, DOI 10.1016/S0169-328X(02)00586-7; Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507; Zhu JR, 2010, ACTA PHARMACOL SIN, V31, P273, DOI 10.1038/aps.2010.9	48	59	68	5	56	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0944-7113	1618-095X		PHYTOMEDICINE	Phytomedicine	SEP	2014	21	10					1189	1195		10.1016/j.phymed.2014.05.004			7	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	AN1IT	WOS:000340336700008	24916704	Green Accepted			2021-06-18	
J	Jamieson, M; Cullen, B; McGee-Lennon, M; Brewster, S; Evans, JJ				Jamieson, Matthew; Cullen, Breda; McGee-Lennon, Marilyn; Brewster, Stephen; Evans, Jonathan J.			The efficacy of cognitive prosthetic technology for people with memory impairments: A systematic review and meta-analysis	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Memory aid; Assistive technology; Memory impairment; Cognitive rehabilitation; Brain injury; Degenerative disease	TRAUMATIC BRAIN-INJURY; ASSISTIVE TECHNOLOGY; ELECTRONIC MEMORY; PAGING SYSTEM; REHABILITATION; AID; INDIVIDUALS; DEFICITS; QUALITY; DESIGN	Technology can compensate for memory impairment. The efficacy of assistive technology for people with memory difficulties and the methodology of selected studies are assessed. A systematic search was performed and all studies that investigated the impact of technology on memory performance for adults with impaired memory resulting from acquired brain injury (ABI) or a degenerative disease were included. Two 10-point scales were used to compare each study to an ideally reported single case experimental design (SCED) study (SCED scale; Tate et al., 2008) or randomised control group study (PEDro-P scale; Maher, Sherrington, Herbert, Moseley, & Elkins, 2003). Thirty-two SCED (mean = 5.9 on the SCED scale) and 11 group studies (mean = 4.45 on the PEDro-P scale) were found. Baseline and intervention performance for each participant in the SCED studies was re-calculated using non-overlap of all pairs (Parker & Vannest, 2009) giving a mean score of 0.85 on a 0 to 1 scale (17 studies, n = 36). A meta-analysis of the efficacy of technology vs. control in seven group studies gave a large effect size (d = 1.27) (n = 147). It was concluded that prosthetic technology can improve performance on everyday tasks requiring memory. There is a specific need for investigations of technology for people with degenerative diseases.	[Jamieson, Matthew; Cullen, Breda; Evans, Jonathan J.] Univ Glasgow, Inst Hlth & Wellbeing, Gartnavel Royal Hosp, Glasgow G12 0XH, Lanark, Scotland; [Jamieson, Matthew; McGee-Lennon, Marilyn; Brewster, Stephen] Univ Glasgow, Glasgow Interact Syst Grp, Sch Comp Sci, Glasgow G12 0XH, Lanark, Scotland	Jamieson, M (corresponding author), Univ Glasgow, Acad Ctr, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	m.jamieson.1@research.gla.ac.uk	Cullen, Breda/C-9154-2012; Cullen, Breda/N-3449-2019; brewster, stephen/J-9003-2017	Cullen, Breda/0000-0002-7259-9505; Cullen, Breda/0000-0002-7259-9505; brewster, stephen/0000-0001-9720-3899; Lennon, Marilyn/0000-0003-3271-2400	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1232093] Funding Source: researchfish	This paper was written during a doctorate studentship which is funded by the Medical Research Council.	Bharucha AJ, 2009, AM J GERIAT PSYCHIAT, V17, P88, DOI 10.1097/JGP.0b013e318187dde5; Boman IL, 2010, DISABIL REHABIL-ASSI, V5, P339, DOI 10.3109/17483100903131777; Burke DT, 2001, J HEAD TRAUMA REHAB, V16, P284, DOI 10.1097/00001199-200106000-00007; BUSSE RT, 1995, J SCHOOL PSYCHOL, V33, P269, DOI 10.1016/0022-4405(95)00014-D; Caprani N, 2006, PSYCHNOLOGY J, V4, P205; Chang Y. J., 2011, PERS UBIQUIT COMPUT, V17, P1; Chang YJ, 2011, RES DEV DISABIL, V32, P2669, DOI 10.1016/j.ridd.2011.06.006; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; De Joode EA, 2013, NEUROPSYCHOL REHABIL, V23, P133, DOI 10.1080/09602011.2012.726632; de Joode E, 2010, CLIN REHABIL, V24, P701, DOI 10.1177/0269215510367551; DEVAUL RW, 2000, CHI 2000 WORKSH SIT; Dowds MM, 2011, J HEAD TRAUMA REHAB, V26, P339, DOI 10.1097/HTR.0b013e3181f2bf1d; Emslie H, 2007, NEUROPSYCHOL REHABIL, V17, P567, DOI 10.1080/09602010701381933; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; Gentry T, 2008, AM J OCCUP THER, V62, P18, DOI 10.5014/ajot.62.1.18; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; Gillespie A, 2012, J INT NEUROPSYCH SOC, V18, P1, DOI 10.1017/S1355617711001548; Hodges S, 2006, LECT NOTES COMPUT SC, V4206, P177; Jin ZX, 2007, PROCEEDINGS OF THE 2007 INTERNATIONAL CONFERENCE ON MANAGEMENT SCIENCE AND ENGINEERING - MANAGEMENT AND ORGANIZATION STUDIES SECTION, P933; Kirsch NL, 2004, REHABIL PSYCHOL, V49, P200, DOI 10.1037/0090-5550.49.3.200; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; KIRSCH NL, 1988, ICAART 88 ANN C ARL; KIRSCH NL, 1992, J HEAD TRAUMA REHAB, V7, P13, DOI DOI 10.1097/00001199-199209000-00004; Klarborg B, 2012, ACCIDENT ANAL PREV, V48, P57, DOI 10.1016/j.aap.2011.05.004; Labelle KL, 2006, AM J OCCUP THER, V60, P442, DOI 10.5014/ajot.60.4.442; Lemoncello R, 2011, NEUROPSYCHOL REHABIL, V21, P825, DOI 10.1080/09602011.2011.618661; Lemoncello R, 2011, DISABIL REHABIL-ASSI, V6, P440, DOI 10.3109/17483107.2010.542571; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; McBurney D. H., 2009, RES METHODS; McDonald A, 2011, NEUROPSYCHOL REHABIL, V21, P784, DOI 10.1080/09602011.2011.598405; Mihailidis A, 2004, IEEE T INF TECHNOL B, V8, P238, DOI 10.1109/TITB.2004.834386; MIHAILIDIS A, 2000, TECHNOLOGY DISABILIT, V13, P23, DOI DOI 10.3233/TAD-2000-13104; Mihailidis Alex, 2008, BMC Geriatr, V8, P28, DOI 10.1186/1471-2318-8-28; O'Neill B., 2013, SOCIAL CARE NEURODIS, V4, P17; O'Neill B, 2010, NEUROPSYCHOL REHABIL, V20, P509, DOI 10.1080/09602010903519652; O'Neill B, 2008, J ASSIST TECHNOL, V2, P22, DOI 10.1108/17549450200800015; Oriani M, 2003, AGING MENT HEALTH, V7, P22, DOI 10.1080/1360786021000045863; Parker RI, 2009, BEHAV THER, V40, P357, DOI 10.1016/j.beth.2008.10.006; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Stapleton S, 2007, BRAIN INJURY, V21, P401, DOI 10.1080/02699050701252030; Svoboda E, 2012, NEUROPSYCHOL REHABIL, V22, P408, DOI 10.1080/09602011.2011.652498; Svoboda E, 2009, J INT NEUROPSYCH SOC, V15, P629, DOI 10.1017/S1355617709090791; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Tellis Winston, 2013, QUALITATIVE REPORT, V3; Thone-Otto AIT, 2003, INT J PSYCHOL, V38, P236, DOI 10.1080/00207590344000169; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Van Hulle A, 2006, BRAIN INJURY, V20, P101, DOI 10.1080/02699050500309684; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Waldron B., 2012, IRISH J PSYCHOL, V33, P37; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	61	59	59	0	31	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUN-AUG	2014	24	3-4					419	444		10.1080/09602011.2013.825632			26	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AJ9LN	WOS:000338032300008	23957379				2021-06-18	
J	Eakin, K; Baratz-Goldstein, R; Pick, CG; Zindel, O; Balaban, CD; Hoffer, ME; Lockwood, M; Miller, J; Hoffer, BJ				Eakin, Katharine; Baratz-Goldstein, Renana; Pick, Chiam G.; Zindel, Ofra; Balaban, Carey D.; Hoffer, Michael E.; Lockwood, Megan; Miller, Jonathan; Hoffer, Barry J.			Efficacy of N-Acetyl Cysteine in Traumatic Brain Injury	PLOS ONE			English	Article							INFLAMMATORY RESPONSE; COGNITIVE DEFICITS; ACETYLCYSTEINE; MODEL; STRESS; ACID	In this study, using two different injury models in two different species, we found that early post-injury treatment with N-Acetyl Cysteine (NAC) reversed the behavioral deficits associated with the TBI. These data suggest generalization of a protocol similar to our recent clinical trial with NAC in blast-induced mTBI in a battlefield setting [1], to mild concussion from blunt trauma. This study used both weight drop in mice and fluid percussion injury in rats. These were chosen to simulate either mild or moderate traumatic brain injury (TBI). For mice, we used novel object recognition and the Y maze. For rats, we used the Morris water maze. NAC was administered beginning 30-60 minutes after injury. Behavioral deficits due to injury in both species were significantly reversed by NAC treatment. We thus conclude NAC produces significant behavioral recovery after injury. Future preclinical studies are needed to define the mechanism of action, perhaps leading to more effective therapies in man.	[Eakin, Katharine; Lockwood, Megan; Miller, Jonathan; Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA; [Baratz-Goldstein, Renana; Pick, Chiam G.; Zindel, Ofra] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Balaban, Carey D.] Univ Pittsburgh, Dept Otolaryngol Neurobiol Commun Sci & Disorders, Pittsburgh, PA 15260 USA; [Hoffer, Michael E.] Naval Med Ctr San Diego, Dept Otolaryngol, Spatial Orientat Ctr, San Diego, CA USA; [Hoffer, Barry J.] Taipei Med Univ, Grad Program Neuroregenerat, Taipei, Taiwan	Hoffer, BJ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA.	barry.hoffer@case.edu	Balaban, Carey/I-3467-2017; Balaban, Carey/O-6586-2019	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	Lincoln Master Clinician in Neurosurgery Award [USPHS] [NS070825]; National Science Council of TaiwanMinistry of Science and Technology, Taiwan [NSC98-2314-B-038-011-MY3, NSC101-2321-B-038-005]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS070825] Funding Source: NIH RePORTER	This work was supported in part by the Lincoln Master Clinician in Neurosurgery Award to JM, [USPHS grant #NS070825]; and the National Science Council of Taiwan [#NSC98-2314-B-038-011-MY3], [NSC101-2321-B-038-005]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bergold P, 2012, J NEUROTRAUM, V29, pA109; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Cuzzocrea S, 2000, BRIT J PHARMACOL, V130, P1219, DOI 10.1038/sj.bjp.0703421; De Vries H, 1996, PHARMACOL REV, V49, P143; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duarte JMD, 2012, BIOL PSYCHIAT, V71, P1006, DOI 10.1016/j.biopsych.2011.07.035; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Franzblau M, 2013, MED HYPOTHESES, V81, P842, DOI 10.1016/j.mehy.2013.09.012; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hart AM, 2004, NEUROSCIENCE, V125, P91, DOI 10.1016/j.neuroscience.2003.12.040; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Lante F, 2008, HIPPOCAMPUS, V18, P602, DOI 10.1002/hipo.20421; Lappas M, 2003, J CLIN ENDOCR METAB, V88, P1723, DOI 10.1210/jc.2002-021677; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Moussawi K, 2009, NAT NEUROSCI, V12, P182, DOI 10.1038/nn.2250; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Prabhu A, 2009, ANN VASC SURG, V23, P645, DOI 10.1016/j.avsg.2008.12.005; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Santangelo F, 2003, CURR MED CHEM, V10, P2599, DOI 10.2174/0929867033456567; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; Stipanuk MH, 2006, J NUTR, V136, p1652S, DOI 10.1093/jn/136.6.1652S; Tang Y, 1997, P NATL ACAD SCI USA, V94, P12667, DOI 10.1073/pnas.94.23.12667; Tsai SY, 2009, P NATL ACAD SCI USA, V106, P22468, DOI 10.1073/pnas.0909089106; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; West CA, 2007, ACTA NEUROCHIR SUPPL, V100, P29; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	40	59	60	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2014	9	4							e90617	10.1371/journal.pone.0090617			7	Multidisciplinary Sciences	Science & Technology - Other Topics	AI4VW	WOS:000336863900004	24740427	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Giordano, C; Cloots, RJH; van Dommelen, JAW; Kleiven, S				Giordano, C.; Cloots, R. J. H.; van Dommelen, J. A. W.; Kleiven, S.			The influence of anisotropy on brain injury prediction	JOURNAL OF BIOMECHANICS			English	Article						Traumatic Brain Injury (TBI); Diffuse Axonal Injury (DAI); Anisotropy; Head model; Finite Element Method (FEM)	HEAD; MODEL; STEM	Traumatic Brain Injury (TBI) occurs when a mechanical insult produces damage to the brain and disrupts its normal function. Numerical head models are often used as tools to analyze TBIs and to measure injury based on mechanical parameters. However, the reliability of such models depends on the incorporation of an appropriate level of structural detail and accurate representation of the material behavior. Since recent studies have shown that several brain regions are characterized by a marked anisotropy, constitutive equations should account for the orientation-dependence within the brain. Nevertheless, in most of the current models brain tissue is considered as completely isotropic. To study the influence of the anisotropy on the mechanical response of the brain, a head model that incorporates the orientation of neural fibers is used and compared with a fully isotropic model. A simulation of a concussive impact based on a sport accident illustrates that significantly lowered strains in the axonal direction as well as increased maximum principal strains are detected for anisotropic regions of the brain. Thus, the orientation-dependence strongly affects the response of the brain tissue. When anisotropy of the whole brain is taken into account, deformation spreads out and white matter is particularly affected. The introduction of local axonal orientations and fiber distribution into the material model is crucial to reliably address the strains occurring during an impact and should be considered in numerical head models for potentially more accurate predictions of brain injury. (C) 2014 Elsevier Ltd. All rights reserved.	[Giordano, C.; Kleiven, S.] Royal Inst Technol, Sch Technol & Hlth, Div Neuron Engn, SE-14152 Huddinge, Sweden; [Cloots, R. J. H.; van Dommelen, J. A. W.] Eindhoven Univ Technol, Mat Technol Inst, NL-5600 MB Eindhoven, Netherlands	Giordano, C (corresponding author), Royal Inst Technol KTH, Sch Technol & Hlth, Div Neuron Engn, Alfred Nobels Alle 10, S-14152 Huddinge, Sweden.	chiara.giordano@sth.kth.se; sveink@kth.se					Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Chatelin S., 2011, J MECH BEHAV BIOMED; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S., 2006, SCANDINAVIAN J FOREN, V2, P73; Kleiven S., 2002, 20029 KUNGL TEKN HOG; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; McCracken PJ, 2005, MAGN RESON MED, V53, P628, DOI 10.1002/mrm.20388; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Newman J, 2000, P 44 STAPP CAR CRASH; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1	24	59	63	0	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	MAR 21	2014	47	5					1052	1059		10.1016/j.jbiomech.2013.12.036			8	Biophysics; Engineering, Biomedical	Biophysics; Engineering	AE6GG	WOS:000334088000017	24462379				2021-06-18	
J	Yoon, EJ; Kim, YK; Kim, HR; Kim, SE; Lee, Y; Shin, HI				Yoon, Eun Jin; Kim, Yu Kyeong; Kim, Hye-Ri; Kim, Sang Eun; Lee, Youngjo; Shin, Hyung Ik			Transcranial Direct Current Stimulation to Lessen Neuropathic Pain After Spinal Cord Injury: A Mechanistic PET Study	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						neuropathic pain; transcranial direct current stimulation; spinal cord injury; FDG-PET	MOTOR CORTEX STIMULATION; ELECTRICAL-STIMULATION; PREFRONTAL CORTEX; VISUAL ILLUSION; BRAIN ACTIVITY; RESTING-STATE; PERCEPTION; MODULATION; PREVALENCE; HUMANS	Background. It is suggested that transcranial direct current stimulation (tDCS) can produce lasting changes in corticospinal excitability and can potentially be used for the treatment of neuropathic pain. However, the detailed mechanisms underlying the effects of tDCS are unknown. Objective. We investigated the underlying neural mechanisms of tDCS for chronic pain relief using [F-18]-fluorodeoxyglucose positron emission tomography ([F-18] FDG-PET). Methods. Sixteen patients with neuropathic pain (mean age 44.1 +/- 8.6 years, 4 females) due to traumatic spinal cord injury received sham or active anodal stimulation of the motor cortex using tDCS for 10 days (20 minutes, 2 mA, twice a day). The effect of tDCS on regional cerebral glucose metabolism was evaluated by [F-18] FDG-PET before and after tDCS sessions. Results. There was a significant decrease in the numeric rating scale scores for pain, from 7.6 +/- 0.5 at baseline to 5.9 +/- 1.8 after active tDCS (P =.016). We found increased metabolism in the medulla and decreased metabolism in the left dorsolateral prefrontal cortex after active tDCS treatment compared with the changes induced by sham tDCS. Additionally, an increase in metabolism after active tDCS was observed in the subgenual anterior cingulate cortex and insula. Conclusion. The results of this study suggest that anodal stimulation of the motor cortex using tDCS can modulate	[Yoon, Eun Jin; Kim, Yu Kyeong] Seoul Natl Univ, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul, South Korea; [Yoon, Eun Jin; Kim, Yu Kyeong; Kim, Sang Eun] Seoul Natl Univ, Coll Med, Seoul, South Korea; [Yoon, Eun Jin; Kim, Yu Kyeong; Kim, Sang Eun] Seoul Natl Univ, Med Res Ctr, Seoul, South Korea; [Kim, Hye-Ri; Kim, Sang Eun; Shin, Hyung Ik] Seoul Natl Univ, Bundang Hosp, Gyeonggi Do, South Korea; [Lee, Youngjo] Seoul Natl Univ, Seoul, South Korea	Shin, HI (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Rehabil Med, 82,Gumi Ro 173 Beon Gil, Songnam, Gyeonggi Do, South Korea.	hyungik1@snu.ac.kr		Shin, Hyungik/0000-0001-8805-3104	National Research Foundation of Korea (NRF)National Research Foundation of Korea; Korea government (MSIP) [2011-0030815]; SNUBH Research Fund [11-2008-010]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2011-0030815), and Grant 11-2008-010 from SNUBH Research Fund.	Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Baliki MN, 2008, J NEUROSCI, V28, P1398, DOI 10.1523/JNEUROSCI.4123-07.2008; Baliki MN, 2010, NEURON, V66, P149, DOI 10.1016/j.neuron.2010.03.002; Boggio PS, 2008, EUR J NEUROL, V15, P1124, DOI 10.1111/j.1468-1331.2008.02270.x; Burgmer M, 2009, NEUROIMAGE, V44, P502, DOI 10.1016/j.neuroimage.2008.09.008; Cauda F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004542; Coghill RC, 1999, J NEUROPHYSIOL, V82, P1934; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Soler MD, 2010, BRAIN, V133, P2565, DOI 10.1093/brain/awq184; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Finnerup NB, 2003, BRAIN, V126, P57, DOI 10.1093/brain/awg007; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2007, LANCET NEUROL, V6, P188, DOI 10.1016/S1474-4422(07)70032-7; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Garcia-Larrea L, 2007, NEUROIMAGE, V37, pS71, DOI 10.1016/j.neuroimage.2007.05.062; GEORGE MS, 1995, AM J PSYCHIAT, V152, P341; Ho PT, 2011, J PSYCHOSOM RES, V70, P541, DOI 10.1016/j.jpsychores.2010.10.006; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3; Kishima H, 2007, J NEUROSURG, V107, P43, DOI 10.3171/JNS-07/07/0043; Kumru H, 2013, EUR J PAIN, V17, P55, DOI 10.1002/j.1532-2149.2012.00167.x; Lefaucheur JP, 2004, J NEUROL NEUROSUR PS, V75, P612, DOI 10.1136/jnnp.2003.022236; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; Mori F, 2010, J PAIN, V11, P436, DOI 10.1016/j.jpain.2009.08.011; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Peyron R, 1999, BRAIN, V122, P1765, DOI 10.1093/brain/122.9.1765; PEYRON R, 1995, PAIN, V62, P275, DOI 10.1016/0304-3959(94)00211-V; Peyron R, 2007, NEUROIMAGE, V34, P310, DOI 10.1016/j.neuroimage.2006.08.037; Phillips ML, 2003, BIOL PSYCHIAT, V54, P515, DOI 10.1016/S0006-3223(03)00171-9; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Quarantelli M, 2004, J NUCL MED, V45, P192; Rocher AB, 2003, NEUROIMAGE, V20, P1894, DOI 10.1016/j.neuroimage.2003.07.002; Siddall PJ, 2003, PAIN, V103, P249, DOI 10.1016/S0304-3959(02)00452-9; Taylor JJ, 2013, NEUROPSYCHOPHARMACOL, V38, P1189, DOI 10.1038/npp.2013.13; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; Vogt BA, 2003, EUR J NEUROSCI, V18, P3134, DOI 10.1111/j.1460-9568.2003.03034.x; Widerstrom-Noga E, 2008, SPINAL CORD, V46, P818, DOI 10.1038/sc.2008.64; Wrigley PJ, 2013, PAIN, V154, P2178, DOI 10.1016/j.pain.2013.06.045	44	59	62	1	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAR	2014	28	3					250	259		10.1177/1545968313507632			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AA3YF	WOS:000331030400006	24213958				2021-06-18	
J	Ferreira, LCB; Regner, A; Miotto, KD; de Moura, S; Ikuta, N; Vargas, AE; Chies, JAB; Simon, D				Brasiliano Ferreira, Luiz Carlos; Regner, Andrea; Miotto, Karen Dal Lago; de Moura, Silvana; Ikuta, Nilo; Vargas, Andreia Escosteguy; Bogo Chies, Jose Artur; Simon, Daniel			Increased levels of interleukin-6,-8 and-10 are associated with fatal outcome following severe traumatic brain injury	BRAIN INJURY			English	Article						Interleukins; IL-6; IL-8; IL-10; traumatic brain injury	CEREBROSPINAL-FLUID; MAJOR TRAUMA; HEAD-INJURY; CYTOKINE; PLASMA; MORTALITY; CHILDREN; MEDIATOR; RELEASE; IL-6	Background: Despite the involvement of cytokine production in neurotrauma, there is still controversy regarding cytokines levels and clinical outcome following severe traumatic brain injury (TBI). Objective: The present study was designed to investigate whether cytokine levels (of IL-1 beta, IL-6, IL-8, IL-10, IL-12p70 and TNF-alpha) are associated with primary outcome (death or survival) after severe TBI. Methods: This prospective study enrolled 24 male patients, victims of severe TBI. Venous blood samples were taken in the Intensive Care Unit (ICU) (study entry), 24 and 48 hours later. Plasma cytokine levels were assayed by flow cytometry. Results: Severe TBI was associated with a 42% mortality rate. TBI patients had a significant increase in the levels of all cytokines measured, except for IL-1 beta, compared to controls. Statistically significant increases in the IL-10, -8 and -6 levels were observed in the non-survivors TBI patients compared to the survivors sub-group measured in the first sample (study entry) and in the subsequent sample (24 hours later). There were no significant differences in IL-1 beta, TNF-alpha and IL-12p70 levels between survivors and non-survivors in any time sampled. Conclusions: The findings indicate that increased IL-10, -8 and -6 levels may constitute an early predictor of unfavourable outcome in severe TBI patients.	[Brasiliano Ferreira, Luiz Carlos; Regner, Andrea; Ikuta, Nilo; Simon, Daniel] Univ Luterana Brasil ULBRA, Programa Posgrad Diagnost Genet & Mol, Canoas, Brazil; [Regner, Andrea; Simon, Daniel] Univ Luterana Brasil, Programa Posgrad Biol Celular & Mol Aplicada Saud, Canoas, Brazil; [Miotto, Karen Dal Lago; de Moura, Silvana] Univ Luterana Brasil, Curso Med, Canoas, Brazil; [Vargas, Andreia Escosteguy] FUC, Porto Alegre, RS, Brazil; [Bogo Chies, Jose Artur] Univ Fed Rio Grande do Sul, Dept Genet, Porto Alegre, RS, Brazil	Simon, D (corresponding author), Univ Luterana Brasil, PPG Biol Celular & Mol Aplicada Saude, Av Farroupilha,8001 Predio 22-5 Andar, BR-92425900 Canoas, RS, Brazil.	daniel.simon@ulbra.br	Chies, Jose Artur Bogo/K-9664-2015; Simon, Daniel/A-9087-2011; Regner, Andrea/M-2596-2014	Chies, Jose Artur Bogo/0000-0001-7025-0660; Simon, Daniel/0000-0003-1122-8468; Regner, Andrea/0000-0002-6657-7991; Vargas-Seymour, Andreia/0000-0003-3275-0829	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [484391/2007-0, 568691/2008-3]; Fundacao de Amparo a Pesquisa do Rio Grande do Sul (FAPERGS)Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [09/0041-5, 1630-25.51/09-0]	The authors report no conflicts of interest. The present study received financial support from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, grant 484391/2007-0 and 568691/2008-3) and from Fundacao de Amparo a Pesquisa do Rio Grande do Sul (FAPERGS, grant 09/0041-5, 1630-25.51/09-0).	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Dalla Libera AL, 2011, BRAIN INJURY, V25, P365, DOI 10.3109/02699052.2011.556107; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Gopcevic A, 2007, TOHOKU J EXP MED, V211, P387, DOI 10.1620/tjem.211.387; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; KRAUS JF, 1996, NEUROTRAUMA, P13; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MALEFYT RD, 1991, J EXP MED, V174, P1209; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; Ng PC, 2004, PEDIATRICS, V113, pE7, DOI 10.1542/peds.113.1.e7; Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Seekamp A, 2002, EUR J TRAUMA, V28, P183; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stensballe J, 2009, ACTA ANAESTH SCAND, V53, P515, DOI 10.1111/j.1399-6576.2008.01801.x; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039	43	59	64	1	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	10					1311	1316		10.3109/02699052.2014.916818			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AN2ZZ	WOS:000340455900012	24830571				2021-06-18	
J	Heldt, SA; Elberger, AJ; Deng, Y; Guley, NH; Del Mar, N; Rogers, J; Choi, GW; Ferrell, J; Rex, TS; Honig, MG; Reiner, A				Heldt, Scott A.; Elberger, Andrea J.; Deng, Yunping; Guley, Natalie H.; Del Mar, Nobel; Rogers, Joshua; Choi, Gy Won; Ferrell, Jessica; Rex, Tonia S.; Honig, Marcia G.; Reiner, Anton			A novel closed-head model of mild traumatic brain injury caused by primary overpressure blast to the cranium produces sustained emotional deficits in mice	FRONTIERS IN NEUROLOGY			English	Article						mild TBI; anxiety; fear; depression; mice		Emotional disorders are a common outcome from mild traumatic brain injury (TBI) in humans, but their pathophysiological basis is poorly understood. We have developed a mouse model of closed-head blast injury using an air pressure wave delivered to a small area on one side of the cranium, to create mild TBI. We found that 20-psi blasts in 3-month-old C57BL/6 male mice yielded no obvious behavioral or histological evidence of brain injury, while 25-40 psi blasts produced transient anxiety in an open field arena but little histological evidence of brain damage. By contrast, 50-60 psi blasts resulted in anxiety-like behavior in an open field arena that became more evident with time after blast. In additional behavioral tests conducted 2-8 weeks after blast, 50-60 psi mice also demonstrated increased acoustic startle, perseverance of learned fear, and enhanced contextual fear, as well as depression-like behavior and diminished prepulse inhibition. We found no evident cerebral pathology, but did observe scattered axonal degeneration in brain sections from 50 to 60 psi mice 3-8 weeks after blast. Thus, the TBI caused by single 50-60 psi blasts in mice exhibits the minimal neuronal loss coupled to "diffuse" axonal injury characteristic of human mild TBI. A reduction in the abundance of a subpopulation of excitatory projection neurons in basolateral amygdala enriched in Thy1 was, however, observed. The reported link of this neuronal population to fear suppression suggests their damage by mild TBI may contribute to the heightened anxiety and fearfulness observed after blast in our mice. Our overpressure air blast model of concussion in mice will enable further studies of the mechanisms underlying the diverse emotional deficits seen after mild TBI.	[Heldt, Scott A.; Elberger, Andrea J.; Deng, Yunping; Guley, Natalie H.; Del Mar, Nobel; Rogers, Joshua; Choi, Gy Won; Ferrell, Jessica; Honig, Marcia G.; Reiner, Anton] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, 855 Monroe Av, Memphis, TN 38163 USA; [Rex, Tonia S.; Reiner, Anton] Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA; [Rex, Tonia S.] Vanderbilt Univ, Dept Ophthalmol & Visual Sci, Nashville, TN 37235 USA	Reiner, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, 855 Monroe Av, Memphis, TN 38163 USA.	areiner@uthsc.edu	Reiner, Anton/AAG-8860-2020	Reiner, Anton/0000-0002-2146-5232	University of Tennessee Neuroscience Institute; Methodist Hospitals Endowed Professorship in Neuroscience; DoDUnited States Department of Defense [W81XWH-10-1-0528]; Research to Prevent Blindness Career Development AwardResearch to Prevent Blindness (RPB); Research to Prevent Blindness Unrestricted Funds; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY022349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS081370] Funding Source: NIH RePORTER	The technical assistance of Drs. Rafiq Islam, Danielle Howell, Marion Joni, and Rhonda Williams is gratefully acknowledged. Supported by The University of Tennessee Neuroscience Institute (Anton Reiner, Andrea J. Elberger), The Methodist Hospitals Endowed Professorship in Neuroscience (Anton Reiner), DoD grant W81XWH-10-1-0528 (Tonia S. Rex), Research to Prevent Blindness Career Development Award (Tonia S. Rex), and Research to Prevent Blindness Unrestricted Funds (Drs. Fleming and Sternberg).	Anagnostaras SG, 1999, J NEUROSCI, V19, P1106; Baisley SK, 2011, PHYSIOL BEHAV, V104, P796, DOI 10.1016/j.physbeh.2011.08.001; Bareyre FM, 2005, NAT MED, V11, P1355, DOI 10.1038/nm1331; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bose P, 2013, J NEUROTRAUM, V30, P1177, DOI 10.1089/neu.2012.2740; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; Dragatsis I, 2009, NEUROBIOL DIS, V33, P315, DOI 10.1016/j.nbd.2008.10.009; Drai D, 2001, NEUROSCI BIOBEHAV R, V25, P409, DOI 10.1016/S0149-7634(01)00022-7; Drai D, 2000, J NEUROSCI METH, V96, P119, DOI 10.1016/S0165-0270(99)00194-6; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Gorski JA, 2002, J NEUROSCI, V22, P6309; Grillon C, 1996, PSYCHIAT RES, V64, P169, DOI 10.1016/S0165-1781(96)02942-3; Heldt S, 2000, BEHAV NEUROSCI, V114, P749, DOI 10.1037//0735-7044.114.4.719; Heldt SA, 2006, BRAIN RES, V1073, P229, DOI 10.1016/j.brainres.2005.12.053; Heldt SA, 2004, NEUROPSYCHOPHARMACOL, V29, P1610, DOI 10.1038/sj.npp.1300468; Hemphill MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022899; Herry C, 2008, NATURE, V454, P600, DOI 10.1038/nature07166; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; HOF PR, 1990, J COMP NEUROL, V301, P44, DOI 10.1002/cne.903010105; Holstein DH, 2010, J AFFECT DISORDERS, V126, P188, DOI 10.1016/j.jad.2010.02.122; Jasnow AM, 2013, J NEUROSCI, V33, P10396, DOI 10.1523/JNEUROSCI.5539-12.2013; Kafkafi N, 2003, BEHAV NEUROSCI, V117, P464, DOI 10.1037/0735-7044.117.3.464; Kafkafi N, 2001, J NEUROSCI METH, V109, P111, DOI 10.1016/S0165-0270(01)00392-2; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kim KK, 2009, J BIOL CHEM, V284, P31052, DOI 10.1074/jbc.M109.052969; King CE, 1997, NEUROREPORT, V8, P1663; Kohl S, 2013, J PSYCHIATR RES, V47, P445, DOI 10.1016/j.jpsychires.2012.11.018; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lipkind D, 2004, J APPL PHYSIOL, V97, P347, DOI 10.1152/japplphysiol.00148.2004; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meade CA, 2002, J COMP NEUROL, V449, P241, DOI 10.1002/cne.10295; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Miller G, 2011, SCIENCE, V333, P517, DOI 10.1126/science.333.6042.517; Miller G, 2011, SCIENCE, V333, P514, DOI 10.1126/science.333.6042.514; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moojen VKM, 2012, BRAIN RES, V1466, P82, DOI 10.1016/j.brainres.2012.05.041; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Phelps EA, 2004, NEURON, V43, P897, DOI 10.1016/j.neuron.2004.08.042; Pollak DD, 2010, ANN MED, V42, P252, DOI 10.3109/07853891003769957; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Reiner A, 2012, BRAIN RES, V1473, P161, DOI 10.1016/j.brainres.2012.07.026; Reiner A, 2012, NEUROBIOL DIS, V47, P75, DOI 10.1016/j.nbd.2012.03.025; Reiner A, 2007, J COMP NEUROL, V505, P603, DOI 10.1002/cne.21515; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Weinberger S, 2011, NATURE, V477, P390, DOI 10.1038/477390a; Yan HC, 2010, NEUROSCI BULL, V26, P327, DOI 10.1007/s12264-010-0323-7	73	59	59	0	6	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								2	10.3389/fneur.2014.00002			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QW	WOS:000209629300002	24478749	DOAJ Gold, Green Published			2021-06-18	
J	Poole, VN; Abbas, K; Shenk, TE; Breedlove, EL; Breedlove, KM; Robinson, ME; Leverenz, LJ; Nauman, EA; Talavage, TM; Dydak, U				Poole, Victoria N.; Abbas, Kausar; Shenk, Trey E.; Breedlove, Evan L.; Breedlove, Katherine M.; Robinson, Meghan E.; Leverenz, Larry J.; Nauman, Eric A.; Talavage, Thomas M.; Dydak, Ulrike			MR Spectroscopic Evidence of Brain Injury in the Non-Diagnosed Collision Sport Athlete	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; METABOLIC-CHANGES; IN-VIVO; CHOLINE METABOLITES; HEAD-INJURY; CONCUSSION; GLUTAMINE; CHILDREN	With growing evidence of long-term neurological damage in individuals enduring repetitive head trauma, it is critical to detect lower-level damage accumulation for the early diagnosis of injury in at-risk populations. Proton magnetic resonance spectroscopic scans of the dorsolateral prefrontal cortex and primary motor cortex were collected from high school American (gridiron) football athletes, prior to and during their competition seasons. Although no concussions were diagnosed, significant metabolic deviations from baseline and non-collision sport controls were revealed. Overall the findings indicate underlying biochemical changes, consequential to repetitive hits, which have previously gone unnoticed due to a lack of traditional neurological symptoms.	[Poole, Victoria N.; Robinson, Meghan E.; Nauman, Eric A.; Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Poole, Victoria N.; Nauman, Eric A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Abbas, Kausar; Shenk, Trey E.; Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Breedlove, Evan L.; Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Breedlove, Evan L.; Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Dydak, Ulrike] Purdue Univ, Sch Hlth Sci, W Lafayette, IN 47907 USA; [Dydak, Ulrike] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA	Talavage, TM (corresponding author), 465 Northwestern Ave, W Lafayette, IN 47907 USA.	tmt@purdue.edu		Poole, Victoria/0000-0003-0974-2564	Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health	This work was supported by the Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health [to TMT, LJL, EAN].	Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Associations N. F. o. S. H. S., 2009, HIGH SCH ATHL PART S; Babb SM, 2004, PSYCHIAT RES-NEUROIM, V130, P1, DOI 10.1016/S0925-4927(03)00104-5; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Buck PW, 2011, HEALTH SOC WORK, V36, P299, DOI 10.1093/hsw/36.4.299; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; Dechent P, 1999, AM J PHYSIOL-REG I, V277, pR698; Erickson KI, 2012, BRAIN BEHAV, V2, P32, DOI 10.1002/brb3.30; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gonzales MM, 2013, BRAIN TOPOGR, V26, P126, DOI 10.1007/s10548-012-0248-8; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Lin Alexander, 2005, NeuroRx, V2, P197, DOI 10.1602/neurorx.2.2.197; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maddock RJ, 2011, NEUROIMAGE, V57, P1324, DOI 10.1016/j.neuroimage.2011.05.048; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mountford C, 2006, J MAGN RESON IMAGING, V24, P459, DOI 10.1002/jmri.20668; Newsholme P, 2003, CELL BIOCHEM FUNCT, V21, P1, DOI 10.1002/cbf.1003; Posse S, 2007, MAGN RESON MED, V58, P236, DOI 10.1002/mrm.21287; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tan J, 1998, MAGN RESON MED, V39, P1005, DOI 10.1002/mrm.1910390619; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van der Graaf M, 2010, EUR BIOPHYS J BIOPHY, V39, P527, DOI 10.1007/s00249-009-0517-y; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	49	59	59	1	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2014	39	6					459	473		10.1080/87565641.2014.940619			15	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	AO0PL	WOS:000341012400003	25144258				2021-06-18	
J	Broglio, SP; Martini, D; Kasper, L; Eckner, JT; Kutcher, JS				Broglio, Steven P.; Martini, Douglas; Kasper, Luke; Eckner, James T.; Kutcher, Jeffery S.			Estimation of Head Impact Exposure in High School Football Implications for Regulating Contact Practices	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries; concussions; impact magnitude; impact frequency; football (American)	CHRONIC TRAUMATIC ENCEPHALOPATHY; PROFESSIONAL FOOTBALL; BRAIN-INJURY; RECURRENT CONCUSSION; COLLEGIATE; SPORT; EPIDEMIOLOGY; IMPAIRMENT; PLAYERS; RISK	Background: Increased attention is being placed on the role of subconcussive impacts to the head during football participation and long-term cognitive health. Some have suggested that mitigating impacts to the head can be achieved by reducing or eliminating contact football practices. The effect that this might have on the number and magnitude of impacts is unknown. Purpose: To estimate the effect of limiting contact practices on the frequency and magnitude of head impacts through the retrospective assessment of in vivo head impact data. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Data on impact magnitude and frequency were collected with the Head Impact Telemetry System during the 2009 football season among 42 varsity high school football athletes (mean age, 16.2 0.6 years; mean height, 180.9 7.2 cm; mean weight, 89.8 +/- 20.1 kg). Head impacts were compared between player positions and session types (noncontact practice, contact practice, and game). These results were used to estimate the frequency and magnitude of head impacts when contact sessions were restricted. Results: The participants collectively sustained 32,510 impacts over the 15-week season. The typical athlete sustained a mean of 774 +/- 502 impacts during the season, with linemen (center, guard, and offensive or defensive tackle positions) sustaining the highest number of impacts per athlete (1076 +/- 541), followed by tight ends, running backs, and linebackers (779 +/- 286); wide receivers, cornerbacks, and safeties (417 +/- 266); and quarterbacks (356 +/- 433). When viewed by session type, noncontact practices (n = 21) accounted for 1998 total impacts (2.4 +/- 1.4 per athlete per session), contact practices (n = 36) accounted for 16,346 impacts (10.5 +/- 7.7 per athlete per session), and games (n = 14) accounted for 14,166 impacts (24.1 +/- 19.1 per athlete per session). Significantly more impacts occurred during games when compared with contact (P = .02) and noncontact practices (P < .001), and contact practices yielded significantly more impacts than noncontact practices (P = .02). Limiting contact practices to once per week would result in a 18% reduction in impacts for the duration of a season, while eliminating all contact practices would further reduce seasonal impacts by 39% across all players. Impact magnitudes were significantly highest during game sessions compared with contact and noncontact practices. Conclusion: Our findings suggest that limiting or eliminating contact football practices may reduce the number of head impacts sustained by athletes over the course of a season, although the effect that such rule changes may have on the magnitude of head impacts during practice sessions is less clear. As such, the potential effect of reductions in contact practices on athletes' long-term cerebral health remains unknown.	[Broglio, Steven P.; Martini, Douglas; Kasper, Luke; Eckner, James T.; Kutcher, Jeffery S.] Univ Michigan, Ann Arbor, MI 48109 USA	Broglio, SP (corresponding author), Univ Michigan, Neurosport Res Lab, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu			Scott Hamilton; Unity Rockets; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	The authors thank Scott Hamilton and the Unity Rockets for their support in this study.	Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Cantu RC, 2012, SPORTS LEGACY I HIT; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Greenwald RM, 2012, CLIN J SPORT MED, V22, P83, DOI 10.1097/JSM.0b013e31824cc5d3; Gurdjian E.S., 1963, 7 STAPP CAR CRASH C, P470; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kim J, 2011, REPORT REGARDING IVY; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512	37	59	59	1	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2013	41	12					2877	2884		10.1177/0363546513502458			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	258QH	WOS:000327473300021	24001576	Green Accepted			2021-06-18	
J	Haber, M; Baki, SGA; Grin'kina, NM; Irizarry, R; Ershova, A; Orsi, S; Grill, RJ; Dash, P; Bergold, PJ				Haber, Margalit; Baki, Samah G. Abdel; Grin'kina, Natalia M.; Irizarry, Rachel; Ershova, Alina; Orsi, Sara; Grill, Raymond J.; Dash, Pramod; Bergold, Peter J.			Minocycline plus N-acetylcysteine synergize to modulate inflammation and prevent cognitive and memory deficits in a rat model of mild traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Animal model; Cognition; Memory; Neuroinflammation; Therapeutics	MICROGLIAL ACTIVATION; SURFACE EXPRESSION; SYSTEM X(C)(-); NEUROINFLAMMATION; HIPPOCAMPUS; MICE; NEUROPROTECTION; MACROSIALIN; MACROPHAGES; IMPAIRMENT	Traumatic brain injury (TBI) differs in severity from severe to mild. This study examined whether a combination of the drugs minocycline (MIND) plus N-acetylcysteine (NAC) produces behavioral and histological improvements in a mild version of the controlled cortical impact model of TBI (mCCI). Following mCCI, rats acquired an active place avoidance task by learning the location of a stationary shock zone on a rotating arena. Rats acquired this task with a training protocol using a 10-minute intertrial interval. Mildly injured rats had an apparent deficit in long-term memory since they did not acquire the task when the intertrial interval was increased to 24 h. Mildly injured rats also had an apparent deficit in set shifting since, after successfully learning one shock zone location they did not learn the location of a second shock zone. MIND plus NAC synergistically limited these behavioral deficits in long-term memory and set shifting. mCCI also produced neuroinflammation at the impact site and at distal white matter tracts including the corpus callosum. At the impact site, MIND plus NAC attenuated CD68-expressing phagocytic microglia without altering neutrophil infiltration or astrocyte activation. The drugs had no effect on astrocyte activation in the corpus callosum or hippocampus. In the corpus callosum, MIND plus NAC decreased CD68 expression yet increased overall microglial activation as measured by Iba-1. MIND plus NAC acted synergistically to increase Iba-1 expression since MIND alone suppressed expression and NAC alone had no effect. Despite the known anti-inflammatory actions of the individual drugs, MINO plus NAC appeared to modulate, rather than suppress neuroinflammation. This modulation of neuroinflammation may underlie the synergistic improvement in memory and set-shifting by the drug combination after mCCI. (C) 2013 Elsevier Inc. All rights reserved.	[Haber, Margalit; Baki, Samah G. Abdel; Grin'kina, Natalia M.; Irizarry, Rachel; Ershova, Alina; Bergold, Peter J.] Robert F Furchgott Ctr Neural & Behav Sci, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; [Haber, Margalit; Baki, Samah G. Abdel; Grin'kina, Natalia M.; Irizarry, Rachel; Ershova, Alina; Bergold, Peter J.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; [Orsi, Sara; Dash, Pramod] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrated Biol & Pharmacol, Houston, TX 77030 USA	Bergold, PJ (corresponding author), Suny Downstate Med Ctr, 450 Clarkson Ave,Box 29, Brooklyn, NY 11203 USA.	Peter.Bergold@downstate.edu		Bergold, Peter/0000-0002-6335-1380; Dash, Pramod/0000-0001-6746-1002	Department of DefenseUnited States Department of Defense [W81XWH-10-2-0171]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076693] Funding Source: NIH RePORTER	This work was supported by an award W81XWH-10-2-0171 from the Department of Defense to P.J.B.	Abdel Bald S.G., 2010, PLOS ONE, V5; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Bridges R, 2012, PHARMACOL REV, V64, P780, DOI 10.1124/pr.110.003889; Brune B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cai ZY, 2010, NEUROSCI BULL, V26, P28, DOI 10.1007/s12264-010-0818-2; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; De Bundel D, 2011, J NEUROSCI, V31, P5792, DOI 10.1523/JNEUROSCI.5465-10.2011; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faul M., 2002, TRAUMATIC BRAIN INJU; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Inman CF, 2005, J IMMUNOL METHODS, V302, P156, DOI 10.1016/j.jim.2005.05.005; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kupchik YM, 2012, BIOL PSYCHIAT, V71, P978, DOI 10.1016/j.biopsych.2011.10.024; Kurushima H, 2000, J LEUKOCYTE BIOL, V67, P104; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Suma T, 2008, NEUROL RES, V30, P420, DOI 10.1179/016164107X251745; Vassar M. J., 2013, J NEUROTRAUMA; Yong VW, 2009, NEURON, V64, P55, DOI 10.1016/j.neuron.2009.09.035; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang LJ, 2012, NEUROCHEM INT, V61, P1220, DOI 10.1016/j.neuint.2012.09.002	35	59	60	0	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2013	249						169	177		10.1016/j.expneurol.2013.09.002			9	Neurosciences	Neurosciences & Neurology	240ZE	WOS:000326135400018	24036416				2021-06-18	
J	Zou, HC; Brayer, SW; Hurwitz, M; Niyonkuru, C; Fowler, LE; Wagner, AK				Zou, Huichao; Brayer, Samuel W.; Hurwitz, Maxwell; Niyonkuru, Christian; Fowler, Lorraine E.; Wagner, Amy K.			Neuroprotective, Neuroplastic, and Neurobehavioral Effects of Daily Treatment With Levetiracetam in Experimental Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; glutamate transporter; levitiracetam; neuroprotection; neuroplasticity; neuroinflammation	GLUTAMATE TRANSPORTER GLT-1; INTRAVENOUS LEVETIRACETAM; WATER MAZE; PHENYTOIN; PROPHYLAXIS; MODEL; PERFORMANCE; EXPRESSION; SEIZURES; SUBTYPES	Background. Prophylactic treatment with antiepileptic drugs (AEDs) has been recommended to prevent early seizure onset in patients with traumatic brain injury (TBI). However, the potential neuroprotective and/or detrimental effects of prophylactic AED treatment on behavioral and cognitive function after TBI are not well studied. Objective. To investigate the effects of a novel AED, levitiracetam (LEV), on behavioral and cognitive function after experimental TBI in rats. Methods. Adult male rats were administered LEV (intraperitoneal 50 mg/kg) or vehicle (saline; SL) daily for 20 days beginning 1 day after controlled cortical impact (CCI; 2.8 mm; 4 m/s) or sham surgery. Beam performance (days 1-6), Y-maze (day 7), and Morris water maze (days 14-19) postinjury testing was assessed. Results. Daily LEV treatment improved motor function, increased novel arm exploration in the Y-maze, elicited greater hippocampal cell sparing, and decreased contusion volumes compared with CCI/SL rats. Daily LEV administration also reversed a TBI-induced decrease in regional glutamate transporter expression and neuroplastic marker proteins present 20 days post-CCI. Also, daily LEV treatment decreased regional IL-1 expression after TBI. Conclusions. These results suggest that daily LEV treatment has beneficial effects on histological, molecular, and behavioral elements of neurological recovery after TBI, in part, via modulation of neuroinflammatory and excitatory pathways.	[Zou, Huichao; Brayer, Samuel W.; Hurwitz, Maxwell; Niyonkuru, Christian; Fowler, Lorraine E.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Zou, Huichao; Brayer, Samuel W.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Wagner, AK (corresponding author), Univ Pittsburgh, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu		Canham, Lorraine/0000-0002-9444-4125	University of Pittsburgh Department of Physical Medicine and Rehabilitation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the University of Pittsburgh Department of Physical Medicine and Rehabilitation.	Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Bell KFS, 2007, J NEUROSCI, V27, P10810, DOI 10.1523/JNEUROSCI.3269-07.2007; Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310; Cain DP, 2006, BEHAV BRAIN RES, V170, P241, DOI 10.1016/j.bbr.2006.02.023; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Cotton BA, 2011, J TRAUMA, V71, P375, DOI 10.1097/TA.0b013e318224d307; Crepeau AZ, 2010, EXPERT REV NEUROTHER, V10, P159, DOI [10.1586/ern.10.5, 10.1586/ERN.10.3]; Da Cunha C, 2003, NEUROBIOL LEARN MEM, V79, P236, DOI 10.1016/S1074-7427(03)00008-X; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Darrah SH, 2011, J NEUROTRAUM, V28, P43, DOI 10.1089/neu.2010.1521; De Smedt T, 2007, CNS DRUG REV, V13, P43, DOI 10.1111/j.1527-3458.2007.00004.x; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165-3806(01)00303-0; Furuta A, 1997, J NEUROSCI, V17, P8363; Gee JR, 2005, INT J BIOCHEM CELL B, V37, P1145, DOI 10.1016/j.biocel.2004.10.004; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Harris J, 2012, J CEREB BLOOD FLOW M, V31, P2122; HAUSER WA, 1990, NEW ENGL J MED, V323, P540, DOI 10.1056/NEJM199008233230809; Hoh TE, 1997, BEHAV NEUROSCI, V111, P1285, DOI 10.1037/0735-7044.111.6.1285; Hurwitz M, 2011, J NEUROTRAUM, V28, pA103; Kazerooni R, 2010, CLINICOECONOMIC OUTC, V2, P15; Li GM, 2013, NEUROL SCI, V34, P963, DOI 10.1007/s10072-012-1173-z; Lyoo IK, 2009, ARCH GEN PSYCHIAT, V66, P878, DOI 10.1001/archgenpsychiatry.2009.86; Miyoshi E, 2002, BRAIN RES BULL, V58, P41, DOI 10.1016/S0361-9230(02)00754-2; Pagni Carlo Alberto, 2006, Expert Rev Neurother, V6, P1223, DOI 10.1586/14737175.6.8.1223; Palmada M., 1998, FRONT, V3, P701, DOI [10.2741/A314, DOI 10.2741/A314]; Pieracci FM, 2012, J TRAUMA ACUTE CARE, V72, P276, DOI 10.1097/TA.0b013e31823df31f; Prow NA, 2008, J NEUROCHEM, V105, P1276, DOI 10.1111/j.1471-4159.2008.05230.x; PULLIAINEN V, 1995, EPILEPSIA, V36, P1195, DOI 10.1111/j.1528-1157.1995.tb01062.x; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, NEUROCHEM RES, V26, P497; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Schluter K, 2002, EUR J NEUROSCI, V16, P836, DOI 10.1046/j.1460-9568.2002.02130.x; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; Steinbaugh LA, 2012, EPILEPSY BEHAV, V23, P280, DOI 10.1016/j.yebeh.2011.12.005; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Takeuchi H, 2008, EXP NEUROL, V214, P144, DOI 10.1016/j.expneurol.2008.08.001; Ueda Y, 2001, J NEUROCHEM, V76, P892, DOI 10.1046/j.1471-4159.2001.00087.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Xing XC, 2011, BIOORG MED CHEM LETT, V21, P5774, DOI 10.1016/j.bmcl.2011.08.009	45	59	61	1	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	NOV	2013	27	9					878	888		10.1177/1545968313491007			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	229IL	WOS:000325256000012	23812605				2021-06-18	
J	Honeybul, S; Janzen, C; Kruger, K; Ho, KM				Honeybul, Stephen; Janzen, Courtney; Kruger, Kate; Ho, Kwok M.			The impact of cranioplasty on neurological function	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; decompressive craniectomy; syndrome of trephined; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DEATH FOLLOWING CRANIOPLASTY; COGNITIVE STATUS EXAMINATION; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; BLOOD-FLOW; HEMICRANIECTOMY; COMPLICATION; IMPROVEMENT	Objectives. To assess changes in neurological function after cranioplasty. Methods. Functional and neurocognitive assessments including activities of daily living assessment, functional independence measure (FIM) and the Cognitive assessment report (COGNISTAT) were conducted on all patients within 72 h before and 7 days after cranioplasty. A change in the total FIM score of 2 points was taken to be clinically significant. Results. Assessments were performed on 25 patients. The functional status was unchanged in eighteen patients (72%), four patients (16%) demonstrated a significant improvement and three patients (12%) deteriorated significantly. Those with deterioration after cranioplasty had some forms of complications including pneumocephalus or seizure. After excluding the three patients who had immediate medical or surgical complications after surgery, there was a mild overall improvement in the mean FIM score (2.1, 95% confidence interval 0.1-4.3, p = 0.049), mainly due to an improvement in their motor function. Conclusions. A small but significant number of patients appear to improve clinically following cranioplasty. The so-called syndrome of the trephined may be more common than had been previously appreciated.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6000, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA, Australia; [Janzen, Courtney; Kruger, Kate] Sir Charles Gairdner Hosp, Dept Occupat Therapy, Perth, WA 6000, Australia; [Ho, Kwok M.] Univ Western Australia, Royal Perth Hosp, Dept Intens Care Med, Nedlands, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6000, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Agrawal D, 2005, EUR J CLIN MICROBIOL, V24, P772, DOI 10.1007/s10096-005-0017-7; Ahmed AI, 2010, NEUROCRIT CARE, V13, P393, DOI 10.1007/s12028-010-9420-8; Baussart B, 2006, ACTA ANAESTH SCAND, V50, P762, DOI 10.1111/j.1399-6576.2006.01038.x; Bijlenga P, 2007, J NEUROL NEUROSUR PS, V78, P430, DOI 10.1136/jnnp.2006.099242; Chalouhi N, 2012, NEUROLOGIST, V18, P423, DOI 10.1097/NRL.0b013e318272f7be; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; Di Rienzo A, 2008, ACTA NEUROCHIR, V150, P1057, DOI 10.1007/s00701-008-0019-1; Di Stefano C, 2012, BRIT J NEUROSURG, V26, P827, DOI 10.3109/02688697.2012.692838; Dickson HG, 1995, SCAND J REHABIL MED, V27, P253; Doninger NA, 2000, J HEAD TRAUMA REHAB, V15, P683, DOI 10.1097/00001199-200002000-00007; Doninger NA, 2006, REHABIL PSYCHOL, V51, P281, DOI 10.1037/0090-5550.51.4.281; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Ferro JM, 2011, STROKE, V42, P2825, DOI 10.1161/STROKEAHA.111.615393; Gottlob Irene, 2002, Strabismus, V10, P271, DOI 10.1076/stra.10.4.271.13830; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Lanterna LA, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0910; Mokri B, 2010, HEADACHE, V50, P1206, DOI 10.1111/j.1526-4610.2010.01715.x; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Voss HU, 2011, CLIN IMAG, V35, P253, DOI 10.1016/j.clinimag.2010.07.008; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166; Zebian B, 2011, BRIT J NEUROSURG, V25, P785, DOI 10.3109/02688697.2011.623801	36	59	60	0	10	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2013	27	5					636	641		10.3109/02688697.2013.817532			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	216FG	WOS:000324266800015	23883370				2021-06-18	
J	McCrory, P; Meeuwisse, WH; Aubry, M; Cantu, B; Dvorak, J; Echemendia, RJ; Engebretsen, L; Johnston, K; Kutcher, JS; Raftery, M; Sills, A; Benson, BW; Davis, GA; Ellenbogan, R; Guskiewicz, K; Herring, SA; Iverson, GL; Jordan, BD; Kissick, J; McCrea, M; McIntosh, AS; Maddocks, D; Makdissi, M; Purcell, L; Putukian, M; Schneider, K; Tator, CH; Turner, M				McCrory, Paul; Meeuwisse, Willem H.; Aubry, Mark; Cantu, Bob; Dvorak, Jiri; Echemendia, Ruben J.; Engebretsen, Lars; Johnston, Karen; Kutcher, Jeffrey S.; Raftery, Martin; Sills, Allen; Benson, Brian W.; Davis, Gavin A.; Ellenbogan, Richard; Guskiewicz, Kevin; Herring, Stanley A.; Iverson, Grant L.; Jordan, Barry D.; Kissick, James; McCrea, Michael; McIntosh, Andrew S.; Maddocks, David; Makdissi, Michael; Purcell, Laura; Putukian, Margot; Schneider, Kathryn; Tator, Charles H.; Turner, Michael			Consensus Statement on Concussion in Sport: The 4th International Conference on Concussion in Sport Held in Zurich, November 2012	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; HEAD-INJURIES; POSTURAL CONTROL; LONG-TERM; POSTCONCUSSION SYNDROME; PROFESSIONAL FOOTBALL; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION		[McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Meeuwisse, Willem H.] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB, Canada; [Meeuwisse, Willem H.] Univ Calgary, Fac Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Aubry, Mark] IOC Med Commiss Games Grp, Ottawa, ON, Canada; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Cantu, Bob] Boston Univ, Dept Neurosurg, Med Ctr, Boston, MA USA; [Cantu, Bob] Boston Univ, Study Traumat Encephalopathy, Med Ctr, Boston, MA USA; [Dvorak, Jiri] Univ Zurich, Dept Neurol, Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin Zurich, F MARC FIFA Med Assessment & Res Ctr, Zurich, Switzerland; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA; [Engebretsen, Lars] Univ Oslo, Oslo Univ Hosp, Dept Orthopaed Surg, N-0316 Oslo, Norway; [Engebretsen, Lars] Univ Oslo, Fac Med, N-0316 Oslo, Norway; [Engebretsen, Lars] Oslo Sports Trauma Res Ctr, Oslo, Norway; [Engebretsen, Lars] IOC, Lausanne, Switzerland; [Johnston, Karen] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Johnston, Karen] Concuss Management Program Athlet Edge Sports Med, Toronto, ON, Canada; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Michigan NeuroSport, Ann Arbor, MI USA; [Raftery, Martin] Int Rugby Board, Dublin, Ireland; [Sills, Allen] Vanderbilt Univ, Med Ctr, Dept Neurosurg Orthopaed Surg & Rehabil, Vanderbilt Sports Concuss Ctr, Nashville, TN USA; [Benson, Brian W.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Benson, Brian W.] Univ Calgary, Dept Family Med, Calgary, AB, Canada; [Benson, Brian W.] Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB, Canada; [Davis, Gavin A.] Austin & Cabrini Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Davis, Gavin A.] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Ellenbogan, Richard] Univ Washington Seattle, Dept Neurol Surg, Seattle, WA USA; [Guskiewicz, Kevin] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Herring, Stanley A.] Seattle Sports Concuss Program, Team Phys Seattle Seahawks & Seattle Mariner, Seattle, WA USA; [Iverson, Grant L.] Univ British Columbia, Neuropsychol Outcome Assessment Lab, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada; [Jordan, Barry D.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Jordan, Barry D.] Burke Rehabil Hosp, White Plains, NY USA; [Jordan, Barry D.] New York State Athlet Commiss, New York, NY USA; [Kissick, James] Univ Ottawa, Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Kissick, James] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McIntosh, Andrew S.] Univ New S Wales, Fac Sci, Monash Univ, Australian Ctr Res Injury Sports & its Prevent,Mo, Sydney, NSW 2052, Australia; [McIntosh, Andrew S.] McIntosh Consultancy & Res Pty Ltd, Sydney, NSW, Australia; [Maddocks, David] Perry Maddocks Trollope Lawyers, Melbourne, Vic, Australia; [Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Makdissi, Michael] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne Physiotherapy Dept, Melbourne, Vic, Australia; [Purcell, Laura] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Purcell, Laura] McMaster Univ, David Braley Sport Med & Rehabil Ctr, Hamilton, ON, Canada; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Putukian, Margot] Univ Med & Dent New Jersey, Newark, NJ 07103 USA; [Schneider, Kathryn] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB, Canada; [Tator, Charles H.] Toronto Western Hosp, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Tator, Charles H.] Krembil Neurosci Ctr, Toronto, ON, Canada; [Turner, Michael] British Horseracing Author, London, England	McCrory, P (corresponding author), Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019; Fahimifar, Sepideh/M-5303-2019; Echemendia, Ruben/R-6939-2019	McCrory, Paul/0000-0003-4850-0568; Guskiewicz, Kevin/0000-0002-8682-2130; Iverson, Grant/0000-0001-7348-9570; Schneider, Kathryn/0000-0002-5951-5899			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JH, 2005, J SOL ENERG-T ASME, V127, P1, DOI 10.1115/1.1854691; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Eckner JT, 2012, PSYCHOL ASSESSMENT, V24, P249, DOI 10.1037/a0025042; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 2000, SPORT HLTH, V18, P35; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2000, STANDARDIZED ASSESSM, P22; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh A, 2005, RUGBY HEADGEAR STUDY; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Peng Rui-yun, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Sandberg Nordqvist AC, 1996, BRAIN RES MOL BRAIN, V38, P285; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Shaw NH, 2004, CMAJ, V170, P8; Shaw NH, 2004, CMAJ, V170, P6; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, pS71, DOI 10.1080/02701367.2005.10599291; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	156	59	60	1	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	MAY	2013	216	5					E55	E71		10.1016/j.jamcollsurg.2013.02.020			17	Surgery	Surgery	140UF	WOS:000318680500004	23582174	Green Accepted			2021-06-18	
J	Zhang, PY; Yu, HX; Zhou, NY; Zhang, J; Wu, Y; Zhang, YL; Bai, YL; Jia, J; Zhang, Q; Tian, S; Wu, JF; Hu, YS				Zhang, Pengyue; Yu, Huixian; Zhou, Naiyun; Zhang, Jie; Wu, Yi; Zhang, Yuling; Bai, Yulong; Jia, Jie; Zhang, Qi; Tian, Shan; Wu, Junfa; Hu, Yongshan			Early exercise improves cerebral blood flow through increased angiogenesis in experimental stroke rat model	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						Early exercise; Cerebral blood flow; Angiogenesis; Laser speckle flowmetry; Cerebral ischemia and reperfusion	LASER SPECKLE FLOWMETRY; TRAUMATIC BRAIN-INJURY; ARTERY OCCLUSION; PROGENITOR CELLS; STEM-CELLS; EXPRESSION; ISCHEMIA; NEOVASCULARIZATION; NEUROGENESIS; RECOVERY	Background: Early exercise after stroke promoted angiogenesis and increased microvessles density. However, whether these newly formatted vessels indeed give rise to functional vascular and improve the cerebral blood flow (CBF) in impaired brain region is still unclear. The present study aimed to determine the effect of early exercise on angiogenesis and CBF in ischemic region. Methods: Adult male Sprague Dawley rats were subjected to 90 min middle cerebral artery occlusion(MCAO) and randomly divided into early exercise and non-exercised control group 24 h later. Two weeks later, CBF in ischemic region was determined by laser speckle flowmetry(LSF). Meantime, micro vessels density, the expression of tie-2, total Akt and phosphorylated Akt (p-Akt), and infarct volume were detected with immunohistochemistry, 2,3,5 triphenyltetrazolium chloride (TTC) staining and western blotting respectively. The function was evaluated by seven point's method. Results: Our results showed that CBF, vessel density and expression of Tie-2, p-Akt in ischemic region were higher in early exercise group compared with those in non-exercise group. Consistent with these results, rats in early exercise group had a significantly reduced infarct volume and better functional outcomes than those in non-exercise group. Conclusions: Our results indicated that early exercise after MCAO improved the CBF in ischemic region, reduced infarct volume and promoted the functional outcomes, the underlying mechanism was correlated with angiogenesis in the ischemic cortex.	[Zhang, Pengyue; Yu, Huixian; Wu, Yi; Zhang, Yuling; Bai, Yulong; Jia, Jie; Zhang, Qi; Tian, Shan; Wu, Junfa; Hu, Yongshan] Fudan Univ, Huashan Hosp, Dept Rehabil, Shanghai 200433, Peoples R China; [Zhou, Naiyun] Shanghai Jiao Tong Univ, Dept Biomed Engn, Shanghai 200030, Peoples R China; [Zhou, Naiyun] SUNY Stony Brook, Dept Biomed Engn, New York, NY USA; [Zhang, Jie] First Peoples Hosp Yunnan Prov, Genet Diag Ctr, Yunnan Prov Key Lab Birth Defects & Genet Dis, Kunming, Peoples R China; [Wu, Yi] Fudan Univ, Huashan Hosp, Yonghe Branch, Shanghai 200032, Peoples R China	Hu, YS (corresponding author), Fudan Univ, Huashan Hosp, Dept Rehabil, Shanghai 200433, Peoples R China.	dr_huys@yahoo.com.cn		pengyue, zhang/0000-0002-7381-9303	Chinese National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81272169, 81201502, 81171856, 81171855]	The present study is supported by Chinese National Natural Science Foundation (81272169, 81201502, 81171856, and 81171855).	Arai K, 2009, FEBS J, V276, P4644, DOI 10.1111/j.1742-4658.2009.07176.x; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P744, DOI 10.1097/01.WCB.0000122745.72175.D5; Bajetto A, 2001, FRONT NEUROENDOCRIN, V22, P147, DOI 10.1006/frne.2001.0214; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Beck H, 2009, ACTA NEUROPATHOL, V117, P481, DOI 10.1007/s00401-009-0483-6; Boas DA, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3285504; BONNER R, 1981, APPL OPTICS, V20, P2097, DOI 10.1364/AO.20.002097; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Bullitt E, 2009, AM J NEURORADIOL, V30, P1857, DOI 10.3174/ajnr.A1695; Chae CH, 2009, NEUROSCIENCE, V164, P1665, DOI 10.1016/j.neuroscience.2009.09.075; Chae CH, 2009, NEUROCHEM INT, V55, P208, DOI 10.1016/j.neuint.2009.02.024; Chen MD, 2011, STROKE, V42, P832, DOI 10.1161/STROKEAHA.110.607747; Cheng XW, 2010, CIRCULATION, V122, P707, DOI 10.1161/CIRCULATIONAHA.109.909218; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Croll SD, 2001, MOL NEUROBIOL, V23, P121, DOI 10.1385/MN:23:2-3:121; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Ding YH, 2006, NEUROL RES, V28, P184, DOI 10.1179/016164106X98053; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Favier J, 2001, THERAPIE, V56, P455; Galvin R, 2011, STROKE, V42, P681, DOI 10.1161/STROKEAHA.110.594689; Gao XW, 2008, J NEUROCHEM, V105, P943, DOI 10.1111/j.1471-4159.2008.05218.x; Gao XW, 2010, TRANSL STROKE RES, V1, P202, DOI 10.1007/s12975-010-0017-5; GARCIA JH, 1971, ACTA NEUROPATHOL, V18, P273, DOI 10.1007/BF00688441; Gavin TP, 2007, ACTA PHYSIOL, V191, P139, DOI 10.1111/j.1748-1716.2007.01723.x; Gertz K, 2006, CIRC RES, V99, P1132, DOI 10.1161/01.RES.0000250175.14861.77; Ginsberg MD, 1997, AM J NEURORADIOL, V18, P1435; Green AR, 2008, BRIT J PHARMACOL, V153, pS325, DOI 10.1038/sj.bjp.0707594; Green DJ, 2011, EXP PHYSIOL, V96, P57, DOI 10.1113/expphysiol.2009.048694; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; Hayashi T, 2006, CURR NEUROVASC RES, V3, P119, DOI 10.2174/156720206776875902; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jiang Q, 2005, NEUROIMAGE, V28, P698, DOI 10.1016/j.neuroimage.2005.06.063; JW G, 1965, SOME EFFECTS TARGET, P1688; Krupinski J, 2003, NEUROREPORT, V14, P1171, DOI 10.1097/00001756-200306110-00014; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Laughlin MH, 2008, J PHYSIOL PHARMACOL, V59, P71; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Lin TN, 2000, J CEREBR BLOOD F MET, V20, P387, DOI 10.1097/00004647-200002000-00021; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Michelini LC, 2009, EXP PHYSIOL, V94, P947, DOI 10.1113/expphysiol.2009.047449; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Patan S, 2004, CANC TREAT, V117, P3; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Rhyu IJ, 2010, NEUROSCIENCE, V167, P1239, DOI 10.1016/j.neuroscience.2010.03.003; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Saxena SK, 2007, ACTA NEUROL SCAND, V115, P339, DOI 10.1111/j.1600-0404.2006.00751.x; Shin HK, 2008, STROKE, V39, P1548, DOI 10.1161/STROKEAHA.107.499483; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Slevin M, 2006, CLIN SCI, V111, P171, DOI 10.1042/CS20060049; Strong AJ, 2006, J CEREBR BLOOD F MET, V26, P645, DOI 10.1038/sj.jcbfm.9600240; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Swain RA, 2003, NEUROSCIENCE, V117, P1037, DOI 10.1016/S0306-4522(02)00664-4; Teng H, 2008, J CEREBR BLOOD F MET, V28, P764, DOI 10.1038/sj.jcbfm.9600573; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Timmons JA, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-19; Wan YQ, 2007, J NEUROSCI RES, V85, P73, DOI 10.1002/jnr.21091; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; Wei L, 2001, STROKE, V32, P2179, DOI 10.1161/hs0901.094282; Weintraub MI, 2006, STROKE, V37, P1917, DOI 10.1161/01.STR.0000226651.04862.da; Woulfe DS, 2010, EXPERT REV HEMATOL, V3, P81, DOI 10.1586/EHM.09.75; Xu XS, 2008, BRAIN RES, V1227, P12, DOI 10.1016/j.brainres.2008.06.018; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Zhang PY, 2013, INT J MOL SCI, V14, P6074, DOI 10.3390/ijms14036074; Zhang Pengyue, 2012, Front Biosci (Elite Ed), V4, P2476; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zheng QP, 2011, TOHOKU J EXP MED, V224, P221, DOI 10.1620/tjem.224.221; Zinn S, 2007, ARCH PHYS MED REHAB, V88, P173, DOI 10.1016/j.apmr.2006.11.015	75	59	64	1	42	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	APR 26	2013	10								43	10.1186/1743-0003-10-43			10	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	141NY	WOS:000318733100001	23622352	DOAJ Gold, Green Published			2021-06-18	
J	Waszkielewicz, AM; Gunia, A; Szkaradek, N; Sloczynska, K; Krupinska, S; Marona, H				Waszkielewicz, A. M.; Gunia, A.; Szkaradek, N.; Sloczynska, K.; Krupinska, S.; Marona, H.			Ion Channels as Drug Targets in Central Nervous System Disorders	CURRENT MEDICINAL CHEMISTRY			English	Article						ASIC; central nervous system; CNS; KCNQ; ion channels; NMDA; P2X; TRP	GATED SODIUM-CHANNELS; D-ASPARTATE RECEPTOR; TARANTULA TOXIN PSALMOTOXIN-1; PERIPHERAL NEUROPATHIC PAIN; GLYCINE ANTAGONIST GV150526; ACID-SENSING ION-CHANNEL-1; SUBTYPE-SELECTIVE AGONIST; TRAUMATIC BRAIN-INJURY; TRANSGENIC MOUSE MODEL; ISCHEMIC CELL-DEATH	Ion channel targeted drugs have always been related with either the central nervous system (CNS), the peripheral nervous system, or the cardiovascular system. Within the CNS, basic indications of drugs are: sleep disorders, anxiety, epilepsy, pain, etc. However, traditional channel blockers have multiple adverse events, mainly due to low specificity of mechanism of action. Lately, novel ion channel subtypes have been discovered, which gives premises to drug discovery process led towards specific channel subtypes. An example is Na+ channels, whose subtypes 1.3 and 1.7-1.9 are responsible for pain, and 1.1 and 1.2 - for epilepsy. Moreover, new drug candidates have been recognized. This review is focusing on ion channels subtypes, which play a significant role in current drug discovery and development process. The knowledge on channel subtypes has developed rapidly, giving new nomenclatures of ion channels. For example, Ca2+ channels are not any more divided to T, L, N, P/Q, and R, but they are described as Ca(v)1.1-Ca(v)3.3, with even newer nomenclature alpha 1A-alpha 1I and alpha 1S. Moreover, new channels such as P2X1-P2X7, as well as TRPA1-TRPV1 have been discovered, giving premises for new types of analgesic drugs.	[Waszkielewicz, A. M.; Gunia, A.; Szkaradek, N.; Sloczynska, K.; Krupinska, S.; Marona, H.] Jagiellonian Univ, Fac Pharm, Coll Med, Dept Bioorgan Chem,Chair Organ Chem, PL-30688 Krakow, Poland	Waszkielewicz, AM (corresponding author), Jagiellonian Univ, Fac Pharm, Coll Med, Dept Bioorgan Chem,Chair Organ Chem, 9 Med St, PL-30688 Krakow, Poland.	awaszkie@cm-uj.krakow.pl		Waszkielewicz, Anna/0000-0002-2871-9418; Sloczynska, Karolina/0000-0002-7366-2676; Marona, Henryk/0000-0002-3815-4174; L Londoner, Kenneth/0000-0001-9085-3813; Gunia-Krzyzak, Agnieszka/0000-0003-4162-4760	European Regional Development Fund through the Innovative Economy Program	This publication is supported by the European Regional Development Fund through the Innovative Economy Program.	Aarsland D, 2009, LANCET NEUROL, V8, P613, DOI 10.1016/S1474-4422(09)70146-2; Abrams J, 2006, NAT REV DRUG DISCOV, V5, P453, DOI 10.1038/nrd2069; Abu-Arafeh I, 2012, DEV MED CHILD NEUROL, V54, P204, DOI 10.1111/j.1469-8749.2011.04152.x; Albers GV, 2001, JAMA-J AM MED ASSOC, V286, P2673, DOI 10.1001/jama.286.21.2673; Almeida L, 2007, NEUROTHERAPEUTICS, V4, P88, DOI 10.1016/j.nurt.2006.10.005; Anand R, 2010, CLIN NEUROPHARMACOL, V33, P297, DOI 10.1097/WNF.0b013e3181f8d501; Anderson SM, 2008, NAT NEUROSCI, V11, P344, DOI 10.1038/nn2054; Andries M, 2007, NEUROBIOL DIS, V25, P8, DOI 10.1016/j.nbd.2006.08.018; Anger T, 2001, J MED CHEM, V44, P115, DOI 10.1021/jm000155h; Arias C, 2002, EXP NEUROL, V177, P284, DOI 10.1006/exnr.2002.7988; Arroyo S, 2007, NEUROTHERAPEUTICS, V4, P155, DOI 10.1016/j.nurt.2006.11.006; Atack JR, 2011, J PSYCHOPHARMACOL, V25, P314, DOI 10.1177/0269881109354927; Atack JR, 2006, J PHARMACOL EXP THER, V316, P410, DOI 10.1124/jpet.105.089920; Ates O, 2007, J CLIN NEUROSCI, V14, P658, DOI 10.1016/j.jocn.2006.03.023; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Barajas RF, 2010, EPILEPSIA, V51, P473, DOI 10.1111/j.1528-1167.2009.02287.x; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Belardetti F., 2012, WIRES MEMBR TRANSP S, V1, P433; Belardetti F, 2010, FUTURE MED CHEM, V2, P791, DOI 10.4155/FMC.10.30; Belforte JE, 2010, NAT NEUROSCI, V13, P76, DOI 10.1038/nn.2447; BENNETT DA, 1990, PROG CLIN BIOL RES, V361, P519; Benson CJ, 1999, CIRC RES, V84, P921; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Berrout J, 2012, BRAIN RES, V1436, P1, DOI 10.1016/j.brainres.2011.11.044; Bezencon C, 2007, CHEM SENSES, V32, P41, DOI 10.1093/chemse/bjl034; Bialer M, 2010, EPILEPSY RES, V92, P89, DOI 10.1016/j.eplepsyres.2010.09.001; Bialer M, 2010, NAT REV DRUG DISCOV, V9, P68, DOI 10.1038/nrd2997; Bialer M, 2009, EPILEPSY RES, V83, P1, DOI 10.1016/j.eplepsyres.2008.09.005; Black JA, 2004, PAIN, V108, P237, DOI 10.1016/j.pain.2003.12.035; Black JA, 2008, J NEUROL SCI, V274, P57, DOI 10.1016/j.jns.2008.04.001; Blackshaw LA, 2010, GUT, V59, P126, DOI 10.1136/gut.2009.179523; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; Blumenfeld H, 2005, EPILEPSIA, V46, P21, DOI 10.1111/j.1528-1167.2005.00311.x; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Bollimuntha S, 2005, J BIOL CHEM, V280, P2132, DOI 10.1074/jbc.M407384200; Bonifacio MJ, 2001, EPILEPSIA, V42, P600, DOI 10.1046/j.1528-1157.2001.43600.x; Bordi F, 1997, EXP NEUROL, V145, P425, DOI 10.1006/exnr.1997.6442; Brown DA, 2009, BRIT J PHARMACOL, V156, P1185, DOI 10.1111/j.1476-5381.2009.00111.x; Brown ML, 1997, J MED CHEM, V40, P602, DOI 10.1021/jm960692v; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; Bullock MR, 1999, ANN NY ACAD SCI, V890, P51, DOI 10.1111/j.1749-6632.1999.tb07980.x; Burnstock G, 2011, ADV PHARMACOL, V61, P333, DOI 10.1016/B978-0-12-385526-8.00011-4; Burnstock G, 2010, ACTA PHYSIOL, V199, P93, DOI 10.1111/j.1748-1716.2010.02114.x; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605; Cain SM, 2010, CHANNELS, V4, P475, DOI 10.4161/chan.4.6.14106; Carnally SM, 2008, BIOCHEM BIOPH RES CO, V372, P752, DOI 10.1016/j.bbrc.2008.05.100; Catterall WA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003947; Cavaliere F, 2001, NEUROCHEM INT, V38, P199, DOI 10.1016/S0197-0186(00)00087-5; Cavaliere F, 2003, NEUROSCIENCE, V120, P85, DOI 10.1016/S0306-4522(03)00228-8; Cavaliere F, 2005, NEUROSCIENCE, V136, P615, DOI 10.1016/j.neuroscience.2005.04.038; Cavaliere F, 2001, NEUROCHEM INT, V38, P189, DOI 10.1016/S0197-0186(00)00088-7; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Chahine M, 2008, CNS NEUROL DISORD-DR, V7, P144, DOI 10.2174/187152708784083830; Chahl LA, 2007, BBA-MOL BASIS DIS, V1772, P968, DOI 10.1016/j.bbadis.2007.05.003; Chahl LA, 2011, ADV EXP MED BIOL, V704, P987, DOI 10.1007/978-94-007-0265-3_51; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chazot PL, 1997, J NEUROCHEM, V69, P2138; Chebib M, 2000, J MED CHEM, V43, P1427, DOI 10.1021/jm9904349; Chebib M, 2009, J PHARMACOL EXP THER, V328, P448, DOI 10.1124/jpet.108.146464; Chen NS, 1999, J NEUROCHEM, V72, P1890, DOI 10.1046/j.1471-4159.1999.0721890.x; Chen XM, 2006, J GEN PHYSIOL, V127, P267, DOI 10.1085/jgp.200509409; Chen XM, 2005, J GEN PHYSIOL, V126, P71, DOI 10.1085/jgp.200509303; Chen XM, 2010, EUR J PHARMACOL, V648, P15, DOI 10.1016/j.ejphar.2010.09.005; Chen XM, 2010, NEUROPHARMACOLOGY, V58, P1045, DOI 10.1016/j.neuropharm.2010.01.011; Cheng W, 2010, PROTEIN CELL, V1, P802, DOI 10.1007/s13238-010-0108-9; Chevalier M, 2006, EUR J NEUROSCI, V23, P2321, DOI 10.1111/j.1460-9568.2006.04761.x; Chizh BA, 2001, TRENDS PHARMACOL SCI, V22, P636, DOI 10.1016/S0165-6147(00)01863-0; Christensen T, 2005, BASIC CLIN PHARMACOL, V96, P316, DOI 10.1111/j.1742-7843.2005.pto960407.x; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Clayton DA, 2002, J NEUROSCI, V22, P3628; Coddou C, 2011, REV NEUROSCIENCE, V22, P335, DOI 10.1515/RNS.2011.014; Conti F, 1997, BRAZ J MED BIOL RES, V30, P555, DOI 10.1590/S0100-879X1997000500001; Cope DW, 2005, J NEUROSCI, V25, P11553, DOI 10.1523/JNEUROSCI.3362-05.2005; Coryell MW, 2009, J NEUROSCI, V29, P5381, DOI 10.1523/JNEUROSCI.0360-09.2009; Cui J, 2001, J BIOL CHEM, V276, P17244, DOI 10.1074/jbc.M010904200; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; de Haas SL, 2008, J PSYCHOPHARMACOL, V22, P24, DOI 10.1177/0269881107082108; de Haas SL, 2009, J PSYCHOPHARMACOL, V23, P625, DOI 10.1177/0269881108092595; de Hass SL, 2007, J PSYCHOPHARMACOL, V21, P374, DOI 10.1177/0269881106072343; Delmas P, 2005, NAT REV NEUROSCI, V6, P850, DOI 10.1038/nrn1785; DeSarro G, 1996, PHARMACOL BIOCHEM BE, V55, P281, DOI 10.1016/S0091-3057(96)00085-8; Deval E, 2011, J NEUROSCI, V31, P6059, DOI 10.1523/JNEUROSCI.5266-10.2011; Deval E, 2010, PHARMACOL THERAPEUT, V128, P549, DOI 10.1016/j.pharmthera.2010.08.006; Devinsky O, 2002, SEIZURE-EUR J EPILEP, V11, P371, DOI 10.1053/seiz.2001.0669; Di X, 1997, STROKE, V28, P2244, DOI 10.1161/01.STR.28.11.2244; Diaz-Hernandez M, 2009, FASEB J, V23, P1893, DOI 10.1096/fj.08-122275; Dib-Hajj SD, 2009, BRAIN RES REV, V60, P65, DOI 10.1016/j.brainresrev.2008.12.005; Dibbens LM, 2004, HUM MOL GENET, V13, P1315, DOI 10.1093/hmg/ddh146; DiFabio R, 1997, J MED CHEM, V40, P841, DOI 10.1021/jm960644a; Dingledine R, 1999, PHARMACOL REV, V51, P7; Diochot S, 2007, TOXICON, V49, P271, DOI 10.1016/j.toxicon.2006.09.026; Diochot S, 2004, EMBO J, V23, P1516, DOI 10.1038/sj.emboj.7600177; Dong XP, 2010, J NEUROCHEM, V113, P313, DOI 10.1111/j.1471-4159.2010.06626.x; Doody RS, 2008, LANCET, V372, P207, DOI 10.1016/S0140-6736(08)61074-0; Doty P, 2007, NEUROTHERAPEUTICS, V4, P145, DOI 10.1016/j.nurt.2006.10.002; Duan B, 2007, J NEUROSCI, V27, P11139, DOI 10.1523/JNEUROSCI.3364-07.2007; Dube GR, 2005, PAIN, V117, P88, DOI 10.1016/j.pain.2005.05.021; DUNN PM, 1988, BRIT J PHARMACOL, V93, P243, DOI 10.1111/j.1476-5381.1988.tb11427.x; Duplantier AJ, 2011, BIOORG MED CHEM LETT, V21, P3708, DOI 10.1016/j.bmcl.2011.04.077; Dyker AG, 1999, STROKE, V30, P986, DOI 10.1161/01.STR.30.5.986; Dyker AG, 1999, STROKE, V30, P2038, DOI 10.1161/01.STR.30.10.2038; Eikermann-Haerter K, 2010, CURR NEUROL NEUROSCI, V10, P167, DOI 10.1007/s11910-010-0099-1; Encabo A, 1996, BRIT J PHARMACOL, V119, P702, DOI 10.1111/j.1476-5381.1996.tb15729.x; Errington AC, 2006, NEUROPHARMACOLOGY, V50, P1016, DOI 10.1016/j.neuropharm.2006.02.002; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Escoubas P, 2003, PROTEIN SCI, V12, P1332, DOI 10.1110/ps.0307003; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Ettaiche M, 2009, INVEST OPHTH VIS SCI, V50, P2417, DOI 10.1167/iovs.08-3028; Fatemi SH, 2009, SCHIZOPHRENIA BULL, V35, P528, DOI 10.1093/schbul/sbn187; Feng HJ, 2010, PHARMACEUTICALS, V3, P3461, DOI 10.3390/ph3113461; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; Fitzgerald PB, 2010, CURR OPIN INVEST DR, V11, P92; Fletcher CF, 2001, FASEB J, V15, P1288; Folkersma H, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-67; Franke H, 2004, J NEUROPATH EXP NEUR, V63, P686, DOI 10.1093/jnen/63.7.686; Friese MA, 2007, NAT MED, V13, P1483, DOI 10.1038/nm1668; Froestl W, 2011, FUTURE MED CHEM, V3, P163, DOI 10.4155/FMC.10.285; Gao XM, 2000, AM J PSYCHIAT, V157, P1141, DOI 10.1176/appi.ajp.157.7.1141; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; Garcia-Sanz N, 2004, J NEUROSCI, V24, P5307, DOI 10.1523/JNEUROSCI.0202-04.2004; Gardoni F, 2002, J NEUROCHEM, V80, P438, DOI 10.1046/j.0022-3042.2001.00713.x; Garza A, 2010, J PHARMACOL EXP THER, V332, P489, DOI 10.1124/jpet.109.152884; Geffen Y, 2009, EUR NEUROPSYCHOPHARM, V19, P1, DOI 10.1016/j.euroneuro.2008.07.002; Gerlach M, 1996, BRAIN RES, V741, P142, DOI 10.1016/S0006-8993(96)00915-8; Ghafari M, 2011, BEHAV BRAIN RES, V221, P142, DOI 10.1016/j.bbr.2011.02.042; Gill R, 2002, J PHARMACOL EXP THER, V302, P940, DOI 10.1124/jpet.102.034322; GOFF DC, 1995, AM J PSYCHIAT, V152, P1213; Goff DC, 2012, SCHIZOPHRENIA BULL, V38, P936, DOI 10.1093/schbul/sbs012; Gottesmann C, 2002, NEUROSCIENCE, V111, P231, DOI 10.1016/S0306-4522(02)00034-9; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; Griebel G, 2003, CNS DRUG REV, V9, P3, DOI 10.1111/j.1527-3458.2003.tb00241.x; Griebel G, 1999, PHARMACOL BIOCHEM BE, V62, P689, DOI 10.1016/S0091-3057(98)00209-3; Grimwood S, 1999, NEUROREPORT, V10, P461, DOI 10.1097/00001756-199902250-00004; GROTTA JC, 1990, ANN NEUROL, V27, P612, DOI 10.1002/ana.410270605; Gu QH, 2010, PHARMACEUTICALS, V3, P1411, DOI 10.3390/ph3051411; Guadalupe A., 2008, PHYSL MINIREV, V3, P25; Guan YZ, 2011, CLIN THER, V33, P159, DOI 10.1016/j.clinthera.2011.02.007; Gutman GA, 2005, PHARMACOL REV, V57, P473, DOI 10.1124/pr.57.4.10; Haines WR, 2001, J NEUROSCI, V21, P5885; Hains BC, 2003, J NEUROSCI, V23, P8881; Haley EC, 2005, STROKE, V36, P1006, DOI 10.1161/01.STR.0000163053.77982.8d; Halonen T, 1999, EPILEPSY RES, V34, P251, DOI 10.1016/S0920-1211(98)00122-3; Hammarstrom AKM, 1998, J PHYSIOL-LONDON, V510, P735, DOI 10.1111/j.1469-7793.1998.735bj.x; Hansen HH, 2006, J PHARMACOL EXP THER, V318, P1006, DOI 10.1124/jpet.106.106757; Harnmarstrom AKM, 2002, EUR BIOPHYS J BIOPHY, V31, P323, DOI 10.1007/s00249-002-0218-2; Harty TP, 2000, EPILEPSY RES, V39, P47, DOI 10.1016/S0920-1211(99)00108-4; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; Heresco-Levy U, 1998, INT J NEUROPSYCHOPH, V1, P131, DOI 10.1017/S1461145798001242; Hernandez CC, 2008, J PHYSIOL-LONDON, V586, P1811, DOI 10.1113/jphysiol.2007.148304; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; Hildebrand MS, 2004, HEARING RES, V190, P149, DOI 10.1016/S0378-5955(04)00015-2; Hogg S, 1998, J NEUROTRAUM, V15, P545, DOI 10.1089/neu.1998.15.545; Howard RJ, 2007, NEURON, V53, P663, DOI 10.1016/j.neuron.2007.02.010; Hracsko Z, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-28; Iftinca M C, 2011, J Med Life, V4, P126; Jacobson KA, 2002, J MED CHEM, V45, P4057, DOI 10.1021/jm020046y; Jacobson Kenneth A, 2006, Novartis Found Symp, V276, P58; Jahr H, 2005, BIOCHEM BIOPH RES CO, V337, P349, DOI 10.1016/j.bbrc.2005.09.054; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jarvis MF, 2009, NEUROPHARMACOLOGY, V56, P208, DOI 10.1016/j.neuropharm.2008.06.067; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Jiang LH, 2003, J NEUROSCI, V23, P8903; Jones-Davis DM, 2003, CURR OPIN PHARMACOL, V3, P12, DOI 10.1016/S1471-4892(02)00015-2; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Kaczmarek-Hajek K, 2012, PURINERG SIGNAL, V8, P375, DOI 10.1007/s11302-012-9314-7; Kahlig KM, 2010, BRIT J PHARMACOL, V161, P1414, DOI 10.1111/j.1476-5381.2010.00976.x; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kemp JA, 2002, NAT NEUROSCI, V5, P1039, DOI 10.1038/nn936; Khakh BS, 2001, PHARMACOL REV, V53, P107; Khan HN, 2012, EPILEPSY RES, V98, P62, DOI 10.1016/j.eplepsyres.2011.08.016; Kharlamov A, 2002, EXP BRAIN RES, V147, P353, DOI 10.1007/s00221-002-1251-1; Khosravani H, 2006, PHYSIOL REV, V86, P941, DOI 10.1152/physrev.00002.2006; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; KIRSCH GE, 1993, J GEN PHYSIOL, V102, P797, DOI 10.1085/jgp.102.5.797; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; KRISHTAL OA, 1981, BRAIN RES, V214, P150, DOI 10.1016/0006-8993(81)90446-7; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Kullmann DM, 2005, PROG BIOPHYS MOL BIO, V87, P33, DOI 10.1016/j.pbiomolbio.2004.06.003; Kuo CC, 1998, MOL PHARMACOL, V54, P712; KUO CC, 1994, MOL PHARMACOL, V46, P716; Kyle DJ, 2007, J MED CHEM, V50, P2583, DOI 10.1021/jm061005v; Laposky AD, 2001, NEUROREPORT, V12, P4143, DOI 10.1097/00001756-200112210-00056; Large CH, 2012, EPILEPSIA, V53, P425, DOI 10.1111/j.1528-1167.2011.03364.x; Large CH, 2009, EPILEPSY RES, V85, P96, DOI 10.1016/j.eplepsyres.2009.02.018; Larsson V, 2010, INT J GERIATR PSYCH, V25, P1030, DOI 10.1002/gps.2506; Le Feuvre RA, 2003, J CEREBR BLOOD F MET, V23, P381, DOI 10.1097/01.WCB.0000048519.34839.97; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lees KR, 2001, CEREBROVASC DIS, V11, P20, DOI 10.1159/000047607; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Lermontova NN, 2000, B EXP BIOL MED+, V129, P544, DOI 10.1007/BF02434871; Lessard CB, 2005, CELL SIGNAL, V17, P437, DOI 10.1016/j.cellsig.2004.09.005; Li MQ, 2012, CELL CALCIUM, V51, P486, DOI 10.1016/j.ceca.2012.04.014; Li MH, 2010, J PHYSIOL-LONDON, V588, P3883, DOI 10.1113/jphysiol.2010.192922; Licata SC, 2005, J PHARMACOL EXP THER, V313, P1118, DOI 10.1124/jpet.104.081612; Licata SC, 2010, NEUROPHARMACOLOGY, V58, P357, DOI 10.1016/j.neuropharm.2009.10.004; Lipkind GM, 2005, MOL PHARMACOL, V68, P1611, DOI 10.1124/mol.105.014803; Lipkind GM, 2010, MOL PHARMACOL, V78, P631, DOI 10.1124/mol.110.064683; Lipton P, 1999, PHYSIOL REV, V79, P1431; Litvinenko I V, 2010, Neurosci Behav Physiol, V40, P149, DOI 10.1007/s11055-009-9244-1; Liu G, 2003, NEUROPHARMACOLOGY, V44, P413, DOI 10.1016/S0028-3908(02)00400-8; Liu Y, 2009, EPILEPSY RES, V83, P66, DOI 10.1016/j.eplepsyres.2008.09.006; Ljungstrom T, 2003, PFLUG ARCH EUR J PHY, V446, P684, DOI 10.1007/s00424-003-1111-2; Loscher W, 2011, SEIZURE-EUR J EPILEP, V20, P359, DOI 10.1016/j.seizure.2011.01.003; Loscher W, 2002, CNS DRUGS, V16, P669; Lu JL, 2001, BIOCHEMISTRY-US, V40, P10934, DOI 10.1021/bi010763e; Lu XY, 2006, P NATL ACAD SCI USA, V103, P1593, DOI 10.1073/pnas.0508901103; Luszczki J, 2009, J NEURAL TRANSM, V116, P57, DOI 10.1007/s00702-008-0152-2; Lv RJ, 2011, EPILEPSY RES, V96, P74, DOI 10.1016/j.eplepsyres.2011.05.002; Lydiard RB, 2006, J CLIN SLEEP MED, V2, P309; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MacDonald JF, 2006, TRENDS NEUROSCI, V29, P75, DOI 10.1016/j.tins.2005.12.001; MADDEN KP, 1993, STROKE, V24, P1068, DOI 10.1161/01.STR.24.7.1068; Main MJ, 2000, MOL PHARMACOL, V58, P253; Majoie HJM, 2006, EPILEPSY RES, V71, P135, DOI 10.1016/j.eplepsyres.2006.06.003; Malek R, 2003, POL J PHARMACOL, V55, P691; Mantegazza M, 2010, LANCET NEUROL, V9, P413, DOI 10.1016/S1474-4422(10)70059-4; Maren S, 2009, CELL, V139, P867, DOI 10.1016/j.cell.2009.11.008; Martin MS, 2007, HUM MOL GENET, V16, P2892, DOI 10.1093/hmg/ddm248; Mathiasen L, 2005, PSYCHOPHARMACOLOGY, V182, P475, DOI 10.1007/s00213-005-0119-z; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; Mazzuca M, 2007, NAT NEUROSCI, V10, P943, DOI 10.1038/nn1940; McDonald S, 2011, AM J HEALTH-SYST PH, V68, P2335, DOI 10.2146/ajhp110134; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; McNamara CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/pnas.0705924104; Mellergard P, 2012, J NEUROTRAUM, V29, P112, DOI 10.1089/neu.2010.1732; Metman LV, 2002, NEUROLOGY, V59, P694; Mitchell IJ, 1997, NEUROSCI BIOBEHAV R, V21, P469, DOI 10.1016/S0149-7634(96)00036-X; Mohammadianinejad SE, 2011, CLIN NEUROPHARMACOL, V34, P174, DOI 10.1097/WNF.0b013e318225140c; Molliver DC, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-35; Moon DE, 2010, CLIN THER, V32, P2370, DOI 10.1016/j.clinthera.2011.01.014; Morales I, 2007, AM J PHYSIOL-CELL PH, V292, pC1934, DOI 10.1152/ajpcell.00593.2006; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Nakayama J, 2009, BRAIN DEV-JPN, V31, P359, DOI 10.1016/j.braindev.2008.11.014; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nehlig A, 2003, EPILEPSY RES, V52, P253, DOI 10.1016/S0920-1211(02)00236-X; Nelson MT, 2006, CURR PHARM DESIGN, V12, P2189, DOI 10.2174/138161206777585184; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Ng CKL, 2011, FUTURE MED CHEM, V3, P197, DOI 10.4155/FMC.10.286; Nicholson E, 2009, J NEUROIMMUNOL, V215, P25, DOI 10.1016/j.jneuroim.2009.07.009; Nicke A, 2003, MOL PHARMACOL, V63, P243, DOI 10.1124/mol.63.1.243; Nicolaidis R, 2005, NEUROCHEM RES, V30, P385, DOI 10.1007/s11064-005-2613-4; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Nilius B, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-218; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Nutt JG, 2008, MOVEMENT DISORD, V23, P1860, DOI 10.1002/mds.22169; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; Omori Y, 2009, J PHARMACOL SCI, V109, P532, DOI 10.1254/jphs.08319FP; Ondo WG, 2011, PARKINSONISM RELAT D, V17, P156, DOI 10.1016/j.parkreldis.2010.12.003; Otto JE, 2004, EPILEPSIA, V45, P1009, DOI 10.1111/j.0013-9580.2004.65703.x; Palfi S, 1997, EXP NEUROL, V146, P135, DOI 10.1006/exnr.1997.6520; Paoletti P, 2007, CURR OPIN PHARMACOL, V7, P39, DOI 10.1016/j.coph.2006.08.011; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Patino GA, 2011, J NEUROSCI, V31, P14577, DOI 10.1523/JNEUROSCI.0361-11.2011; Patino GA, 2010, NEUROSCI LETT, V486, P53, DOI 10.1016/j.neulet.2010.06.050; Payandeh J, 2012, NATURE, V486, P135, DOI 10.1038/nature11077; Payandeh J, 2011, NATURE, V475, P353, DOI 10.1038/nature10238; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Perez-Otano I, 2001, J NEUROSCI, V21, P1228; Perret D, 2009, NEUROTHERAPEUTICS, V6, P679, DOI 10.1016/j.nurt.2009.07.006; Perucca E, 1997, PHARMACOL RES, V35, P241, DOI 10.1006/phrs.1997.0124; Peters HC, 2005, NAT NEUROSCI, V8, P51, DOI 10.1038/nn1375; PIGGOTT MA, 1992, BRAIN RES, V588, P277, DOI 10.1016/0006-8993(92)91586-4; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; Pischalnikova AV, 2009, J NEUROIMMUNE PHARM, V4, P71, DOI 10.1007/s11481-008-9130-6; Pongs O., 2008, V44, P145, DOI 10.1007/400_2007_032; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Qi JS, 2006, J PHYSIOL-LONDON, V577, P579, DOI 10.1113/jphysiol.2006.113134; Ragsdale DS, 1996, P NATL ACAD SCI USA, V93, P9270, DOI 10.1073/pnas.93.17.9270; Rappold PM, 2006, BRAIN RES, V1089, P171, DOI 10.1016/j.brainres.2006.03.040; REDDY NL, 1994, J MED CHEM, V37, P260, DOI 10.1021/jm00028a009; Reggiani A, 2001, EUR J PHARMACOL, V419, P147, DOI 10.1016/S0014-2999(01)00948-7; Richards MC, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.013938; Ritz B, 2010, ANN NEUROL, V67, P600, DOI 10.1002/ana.21937; Roedding AS, 2012, BIPOLAR DISORD, V14, P151, DOI 10.1111/j.1399-5618.2012.01003.x; Roeloffs R, 2008, J PHARMACOL EXP THER, V326, P818, DOI 10.1124/jpet.108.137794; Romagnoli R, 2008, EXPERT OPIN THER TAR, V12, P647, DOI 10.1517/14728222.12.5.647 ; Rosenberg R, 2007, J CLIN SLEEP MED, V3, P374; Rowlett JK, 2005, P NATL ACAD SCI USA, V102, P915, DOI 10.1073/pnas.0405621102; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Rudolph U, 2001, TRENDS PHARMACOL SCI, V22, P188, DOI 10.1016/S0165-6147(00)01646-1; Rush AM, 2005, J PHYSIOL-LONDON, V564, P803, DOI 10.1113/jphysiol.2005.083089; Russo E, 2004, NEUROPHARMACOLOGY, V46, P865, DOI 10.1016/j.neuropharm.2003.11.028; Ryan DP, 2010, NEURON, V68, P282, DOI 10.1016/j.neuron.2010.10.008; Sander JW, 2003, CURR OPIN NEUROL, V16, P165, DOI 10.1097/00019052-200304000-00008; Sawada H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015298; Schabitz WR, 2000, STROKE, V31, P1709, DOI 10.1161/01.STR.31.7.1709; Schaefer M, 2005, PFLUG ARCH EUR J PHY, V451, P35, DOI 10.1007/s00424-005-1467-6; Scharf MB, 2007, SLEEP, V30, P743, DOI 10.1093/sleep/30.6.743; Selvaraj S, 2009, CELL CALCIUM, V46, P209, DOI 10.1016/j.ceca.2009.07.008; Semel D, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-85; Sheets PL, 2008, J PHARMACOL EXP THER, V326, P89, DOI 10.1124/jpet.107.133413; Shibuya I, 1999, J PHYSIOL-LONDON, V514, P351, DOI 10.1111/j.1469-7793.1999.351ae.x; Shimada S, 2006, ARCH HISTOL CYTOL, V69, P227, DOI 10.1679/aohc.69.227; Shoulson I, 2001, NEUROLOGY, V56, P455; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sitnikova E, 2010, EPILEPSY RES, V89, P17, DOI 10.1016/j.eplepsyres.2009.09.005; Smith MR, 1998, J NEUROSCI, V18, P6093; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Sotty F, 2009, J PHARMACOL EXP THER, V328, P951, DOI 10.1124/jpet.108.146944; Steece-Collier K, 2000, EXP NEUROL, V163, P239, DOI 10.1006/exnr.2000.7374; Steinlein OK, 2004, NAT REV NEUROSCI, V5, P400, DOI 10.1038/nrn1388; Stephen LJ, 2011, CNS DRUGS, V25, P89, DOI 10.2165/11584860-000000000-00000; Stock TC, 2012, J RHEUMATOL, V39, P720, DOI 10.3899/jrheum.110874; Strupp M, 2007, NEUROTHERAPEUTICS, V4, P267, DOI 10.1016/j.nurt.2007.01.014; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Subasinghe NL, 2012, BIOORG MED CHEM LETT, V22, P4080, DOI 10.1016/j.bmcl.2012.04.075; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Sun GC, 2007, EPILEPSIA, V48, P774, DOI 10.1111/j.1528-1167.2007.01001.x; Sun Y, 2001, J BIOL CHEM, V276, P24713, DOI 10.1074/jbc.M103501200; TAKIZAWA S, 1991, J CEREBR BLOOD F MET, V11, P786, DOI 10.1038/jcbfm.1991.136; Tan J, 2011, MOL VIS, V17, P3300; Tang YP, 1999, NATURE, V401, P63; Tarnawa Istvan, 2007, Recent Pat CNS Drug Discov, V2, P57, DOI 10.2174/157488907779561754; Taverna S, 1998, EPILEPSY RES, V32, P304, DOI 10.1016/S0920-1211(98)00060-6; Taylor M, 2003, PSYCHOL MED, V33, P387, DOI 10.1017/S0033291702006876; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; Tolino LA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.202366; Tomlinson SE, 2009, CLIN NEUROPHYSIOL, V120, P1768, DOI 10.1016/j.clinph.2009.07.003; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Tottene A, 2009, NEURON, V61, P762, DOI 10.1016/j.neuron.2009.01.027; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; Trudeau MM, 2006, J MED GENET, V43, P527, DOI 10.1136/jmg.2005.035667; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409; Ugawa S, 2007, BIOCHEM BIOPH RES CO, V363, P203, DOI 10.1016/j.bbrc.2007.08.133; Urbani A, 2000, EUR J NEUROSCI, V12, P3567, DOI 10.1046/j.1460-9568.2000.00242.x; Vacher H, 2008, PHYSIOL REV, V88, P1407, DOI 10.1152/physrev.00002.2008; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Vergo S, 2011, BRAIN, V134, P571, DOI 10.1093/brain/awq337; Vila-Carriles WH, 2006, J BIOL CHEM, V281, P19220, DOI 10.1074/jbc.M603100200; Vincent A, 2004, BRAIN, V127, P701, DOI 10.1093/brain/awh077; Voilley N, 2001, J NEUROSCI, V21, P8026; Volonte C, 1996, J NEUROSCI RES, V45, P183; Volonte C, 1999, NEUROPHARMACOLOGY, V38, P1335, DOI 10.1016/S0028-3908(99)00034-9; Vreugdenhil M, 1999, EPILEPSIA, V40, P1512, DOI 10.1111/j.1528-1157.1999.tb02034.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waszkielewicz AM, 2011, CURR MED CHEM, V18, P4344; Watanabe H, 2000, J NEUROCHEM, V75, P28, DOI 10.1046/j.1471-4159.2000.0750028.x; Waxman SG, 1999, MUSCLE NERVE, V22, P1177, DOI 10.1002/(SICI)1097-4598(199909)22:9<1177::AID-MUS3>3.3.CO;2-G; Weiergraber M, 2010, BRAIN RES REV, V62, P245, DOI 10.1016/j.brainresrev.2009.12.005; Weiner MW, 2011, ALZHEIMERS DEMENT, V7, P425, DOI 10.1016/j.jalz.2010.09.003; Weir GA, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-116; Wemmie JA, 2004, P NATL ACAD SCI USA, V101, P3621, DOI 10.1073/pnas.0308753101; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Whitaker WRJ, 2001, NEUROSCIENCE, V106, P275, DOI 10.1016/S0306-4522(01)00212-3; Wickenden AD, 2008, MOL PHARMACOL, V73, P977, DOI 10.1124/mol.107.043216; Wickenden AD, 2000, MOL PHARMACOL, V58, P591; Wimmer VC, 2010, J PHYSIOL-LONDON, V588, P1829, DOI 10.1113/jphysiol.2010.188417; Wolfel M, 2003, J NEUROSCI, V23, P7059, DOI 10.1523/JNEUROSCI.23-18-07059.2003; Wong HK, 2008, HUM MOL GENET, V17, P3223, DOI 10.1093/hmg/ddn218; Wulff H, 2008, CHEM REV, V108, P1744, DOI 10.1021/cr078234p; Wulff H, 2007, CURR OPIN DRUG DISC, V10, P438; Xie XM, 2001, PFLUG ARCH EUR J PHY, V441, P425, DOI 10.1007/s004240000448; Xiong QJ, 2008, TRENDS PHARMACOL SCI, V29, P99, DOI 10.1016/j.tips.2007.11.010; Yamamoto S, 2007, BBA-MOL BASIS DIS, V1772, P958, DOI 10.1016/j.bbadis.2007.03.006; Yan BY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022440; Yang Y, 2003, HUM MOL GENET, V12, P975, DOI 10.1093/hmg/ddg118; YASUMATSU H, 1994, BRIT J PHARMACOL, V111, P1170, DOI 10.1111/j.1476-5381.1994.tb14868.x; Ye Q, 2011, NEUROSCI LETT, V487, P394, DOI 10.1016/j.neulet.2010.10.064; Yiangou YG, 2001, EUR J GASTROEN HEPAT, V13, P891, DOI 10.1097/00042737-200108000-00003; Yokoo H, 1998, N-S ARCH PHARMACOL, V357, P526, DOI 10.1007/PL00005203; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zamponi GW, 2010, PFLUG ARCH EUR J PHY, V460, P395, DOI 10.1007/s00424-009-0772-x; Zamponi GW, 2009, BIOORG MED CHEM LETT, V19, P6467, DOI 10.1016/j.bmcl.2009.09.008; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3; Zhan XJ, 2000, J NEUROSCI, V20, P3909; Ziemann AE, 2008, NAT NEUROSCI, V11, P816, DOI 10.1038/nn.2132; Ziemann AE, 2009, CELL, V139, P1012, DOI 10.1016/j.cell.2009.10.029; Zoladz PR, 2006, PHARMACOL BIOCHEM BE, V85, P298, DOI 10.1016/j.pbb.2006.08.011; ZONA C, 1990, EXP BRAIN RES, V81, P313	378	59	61	1	60	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	0929-8673	1875-533X		CURR MED CHEM	Curr. Med. Chem.	APR	2013	20	10					1241	1285					45	Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	112TN	WOS:000316616600005	23409712				2021-06-18	
J	Lindemer, ER; Salat, DH; Leritz, EC; McGlinchey, RE; Milberg, WP				Lindemer, Emily R.; Salat, David H.; Leritz, Elizabeth C.; McGlinchey, Regina E.; Milberg, William P.			Reduced cortical thickness with increased lifetime burden of PTSD in OEF/OIF Veterans and the impact of comorbid TBI	NEUROIMAGE-CLINICAL			English	Article						Posttraumatic stress disorder; Mild traumatic brain injury; Cortical thickness; Whole-brain analysis; Neuroimaging; Comorbidity	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; SURFACE-BASED ANALYSIS; GRAY-MATTER VOLUME; DEFAULT-MODE; GEOMETRICALLY ACCURATE; COGNITIVE PERFORMANCE; NETWORK CONNECTIVITY; HIPPOCAMPAL VOLUME; CORTEX	Posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) in military personnel is increasing dramatically following the OEF/OIF conflicts and is associated with alterations to brain structure. The present study examined the relationship between PTSD and cortical thickness, and its possible modification by mTBI, in a 104-subject OEF/OIF veteran cohort ranging in age from 20 to 62 years. For each participant, two T1-weighted scans were averaged to create high-resolution images for calculation of regional cortical thickness. PTSD symptoms were assessed using the Clinician Administered PTSD Scale (CAPS) and scores were derived based on the previous month's symptoms ("current") and a Cumulative Lifetime Burden of PTSD (CLB-P) reflecting the integral of CAPS scores across the lifetime. Mild TBI was diagnosed using the Boston Assessment of TBI-Lifetime (BAT-L). Results demonstrated a clear negative relationship between current PTSD severity and thickness in both postcentral gyri and middle temporal gyri. This relationship was stronger and more extensive when considering lifetime burden (CLB-P), demonstrating the importance of looking at trauma in the context of an individual's lifetime, rather than only at their current symptoms. Finally, interactions with current PTSD only and comorbid current PTSD and mTBI were found in several regions, implying an additive effect of lifetime PTSD and mTBI on cortical thickness. (C) 2013 The Authors. Published by Elsevier Inc.	[Lindemer, Emily R.; Salat, David H.; Leritz, Elizabeth C.; McGlinchey, Regina E.; Milberg, William P.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA 02130 USA; [Salat, David H.; Leritz, Elizabeth C.] AA Martinos Ctr Biomed Imaging, Boston, MA USA; [McGlinchey, Regina E.; Milberg, William P.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Leritz, Elizabeth C.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA	Milberg, WP (corresponding author), VA Boston Healthcare Syst, TRACTS GRECC 182,150 S Huntington Ave, Boston, MA 02130 USA.	William_milberg@hms.harvard.edu	McGlinchey, Regina E/R-1971-2016		Translational Research Center for TBI and Stress Disorders (TRACTS); VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; VA Merit Review AwardUS Department of Veterans Affairs	This research was support by the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C) and VA Merit Review Award to Regina McGlinchey.	Ahmed F, 2012, NEUROPSYCHOBIOLOGY, V66, P174, DOI 10.1159/000339558; Apfel BA, 2011, BIOL PSYCHIAT, V69, P541, DOI 10.1016/j.biopsych.2010.09.044; Atkinson M.P., 2009, MANAGE SCI, V55, P13; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bluhm RL, 2009, J PSYCHIATR NEUROSCI, V34, P187; Brands AMA, 2006, DIABETES, V55, P1800, DOI 10.2337/db05-1226; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Breslau N, 2002, CAN J PSYCHIAT, V47, P923; Breslau N, 2010, BEHAV RES THER, V48, P1063, DOI 10.1016/j.brat.2010.07.001; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; Chao LL, 2012, NEUROREPORT, V23, P412, DOI 10.1097/WNR.0b013e328352025e; Cougle JR, 2009, BEHAV RES THER, V47, P1012, DOI 10.1016/j.brat.2009.07.014; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; De Bellis MD, 2006, BIOL PSYCHIAT, V60, P697, DOI 10.1016/j.biopsych.2006.04.035; Dickerson BC, 2008, NEUROIMAGE, V39, P10, DOI 10.1016/j.neuroimage.2007.08.042; Fennema-Notestine C, 2002, BIOL PSYCHIAT, V52, P1089, DOI 10.1016/S0006-3223(02)01413-0; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fortier C.B., 2012, J HEAD TRAUMA; Fortier CB, 2011, ALCOHOL CLIN EXP RES, V35, P2193, DOI 10.1111/j.1530-0277.2011.01576.x; Geuze E, 2008, NEUROIMAGE, V41, P675, DOI 10.1016/j.neuroimage.2008.03.007; Geuze E, 2007, PROG BRAIN RES, V167, P293, DOI 10.1016/S0079-6123(07)67026-5; Glover DA, 2006, PSYCHIATRY, V69, P191, DOI 10.1521/psyc.2006.69.3.191; Green B.L., 1996, MEASUREMENT STRESS T, P366; Gschwind M, 2012, CEREB CORTEX, V22, P1564, DOI 10.1093/cercor/bhr226; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hayes JP, 2011, J PSYCHIATR RES, V45, P660, DOI 10.1016/j.jpsychires.2010.10.007; HERMAN JL, 1989, AM J PSYCHIAT, V146, P490; Herringa R, 2012, PSYCHIAT RES-NEUROIM, V203, P139, DOI 10.1016/j.pscychresns.2012.02.005; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hooper LM, 2011, J LOSS TRAUMA, V16, P258, DOI 10.1080/15325024.2011.572035; Ishibe N, 2009, J HEAD TRAUMA REHAB, V24, P424, DOI 10.1097/HTR.0b013e3181c13426; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Jovicich J, 2009, NEUROIMAGE, V46, P177, DOI 10.1016/j.neuroimage.2009.02.010; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kashdan TB, 2010, BEHAV THER, V41, P350, DOI 10.1016/j.beth.2009.09.003; Kerr KM, 2007, HIPPOCAMPUS, V17, P697, DOI 10.1002/hipo.20315; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kroes MCW, 2011, J PSYCHIATR NEUROSCI, V36, P256, DOI 10.1503/jpn.100077; Lanius RA, 2010, ACTA PSYCHIAT SCAND, V121, P33, DOI 10.1111/j.1600-0447.2009.01391.x; Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039025; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MALLOY PF, 1983, J CONSULT CLIN PSYCH, V51, P488, DOI 10.1037/0022-006X.51.4.488; MASON JW, 1986, J NERV MENT DIS, V174, P145, DOI 10.1097/00005053-198603000-00003; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McEwen BS, 1999, ANN NY ACAD SCI, V896, P30, DOI 10.1111/j.1749-6632.1999.tb08103.x; Morra L., 2011, INT NEUR SOC ANN M F; Nardo D, 2010, J PSYCHIATR RES, V44, P477, DOI 10.1016/j.jpsychires.2009.10.014; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rubin DC, 2008, PSYCHOL REV, V115, P985, DOI 10.1037/a0013397; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shi CJ, 1999, J COMP NEUROL, V406, P299, DOI 10.1002/(SICI)1096-9861(19990412)406:3<299::AID-CNE2>3.0.CO;2-9; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tate DF, 2012, BRAIN IMAGING BEHAV, V6, P103, DOI 10.1007/s11682-012-9185-0; Tavanti M, 2012, NEUROL SCI, V33, P59, DOI 10.1007/s10072-011-0659-4; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Whalley MG, 2013, BRAIN COGNITION, V81, P151, DOI 10.1016/j.bandc.2012.10.002; Woodward SH, 2006, BIOL PSYCHIAT, V59, P582, DOI 10.1016/j.biopsych.2005.07.033; Woodward SH, 2009, ARCH GEN PSYCHIAT, V66, P1373, DOI 10.1001/archgenpsychiatry.2009.160; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Yehuda R, 2007, J PSYCHIATR RES, V41, P435, DOI 10.1016/j.jpsychires.2005.12.002; Zhang J, 2011, PSYCHIAT RES-NEUROIM, V192, P84, DOI 10.1016/j.pscychresns.2010.09.001; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	82	59	59	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2013	2						601	611		10.1016/j.nicl.2013.04.009			11	Neuroimaging	Neurosciences & Neurology	V37LH	WOS:000209276800066	24179811	DOAJ Gold, Green Published			2021-06-18	
J	Macher, H; Egea-Guerrero, JJ; Revuelto-Rey, J; Gordillo-Escobar, E; Enamorado-Enamorado, J; Boza, A; Rodriguez, A; Molinero, P; Guerrero, JM; Dominguez-Roldan, JM; Murillo-Cabezas, F; Rubio, A				Macher, Hada; Egea-Guerrero, Juan J.; Revuelto-Rey, Jaume; Gordillo-Escobar, Elena; Enamorado-Enamorado, Judy; Boza, Antonio; Rodriguez, Ana; Molinero, Patrocinio; Guerrero, Juan M.; Dominguez-Roldan, Jose M.; Murillo-Cabezas, Francisco; Rubio, Amalia			Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury	CLINICA CHIMICA ACTA			English	Article						Cell free-DNA; Prognostic marker; Real-time PCR; Traumatic brain injury	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; PLASMA DNA; S100-BETA PROTEIN; DAMAGE; SERUM; EXCHANGE; ORIGIN; S100B	Introduction: Circulating cell-free DNA levels are increased after trauma injury. This increase is higher since the first hours after trauma and may be related with primary outcome. A sensitive and reliable biomarker for patients at higher risk is needed to identify these patients to initiate early intervention. In this way, circulating DNA may be a possible biological marker after severe TBI. Materials and methods: We investigated DNA plasma concentrations after severe traumatic brain injury and during the next 96 h in the Intensive Care Unit (ICU) by real time PCR. 65 patients suffering severe TBI were included in the study. Results: Cell-free DNA levels were considerably higher in patients samples compared with voluntary control ones. After the following four days we observed a 51% decrease during the first 24 h and a 71% fall from 48 h. TBI population was stratified for the primary outcome (survivors/non-survivor) and DNA levels decrease ratio was calculated for the first 48 h. A higher decrease in the survivors from 0 h to 24 h compared with the non-survivors was found. A cut-off point of 1.95 ratio was established for the detection of the highest proportions of patients after the TBI that will not survive after the injury with a sensitivity of 70% and specificity of 66%. Conclusions: In summary we showed that severe TBI is associated with elevated cf-DNA levels and we propose that cf-DNA decrease during the first 24 h may predict patient outcome. (C) 2012 Elsevier B.V. All rights reserved.	[Macher, Hada; Boza, Antonio; Rodriguez, Ana; Molinero, Patrocinio; Guerrero, Juan M.; Rubio, Amalia] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBiS, Seville, Spain; [Egea-Guerrero, Juan J.; Revuelto-Rey, Jaume; Gordillo-Escobar, Elena; Enamorado-Enamorado, Judy; Dominguez-Roldan, Jose M.; Murillo-Cabezas, Francisco] Hosp Univ Virgen del Rocio Sevilla, Serv Cuidados Criticos, Seville, Spain; [Egea-Guerrero, Juan J.; Revuelto-Rey, Jaume; Gordillo-Escobar, Elena; Enamorado-Enamorado, Judy; Dominguez-Roldan, Jose M.; Murillo-Cabezas, Francisco] Hosp Univ Virgen del Rocio Sevilla, Urgencias Hosp Traumatol, Seville, Spain	Rubio, A (corresponding author), Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBiS, Seville, Spain.	hadamacher@hotmail.com; jjegeaguerrero@gmail.com; drjau@hotmail.com; lenylane@hotmail.com; drajudyenamorado@gmail.com; darkenns@gmail.com; swroder_an@hotmail.com; molinero@us.es; guerrero@us.es; jmdominguez@telefonica.net; murillomunoz@telefonica.net; amaliarubio@us.es	Guerrero, Josep M./Y-2929-2019; IBIS, NEUROCRITICOS/C-1805-2016; Murillo-Cabezas, Francisco/AAO-3348-2021; Rubio, Amalia/L-1992-2017; Rodriguez-Rodriguez, Ana/F-4718-2016; IBIS, NEUROINMUNO/O-9306-2015; Dominguez-Roldan, Jose-Maria/M-1728-2016; Egea-Guerrero, Juan Jose/P-5080-2014	Guerrero, Josep M./0000-0001-5236-4592; Rubio, Amalia/0000-0002-5905-0534; Rodriguez-Rodriguez, Ana/0000-0002-6854-9695; Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478; Revuelto-Rey, Jaume/0000-0001-8350-9555; Egea-Guerrero, Juan Jose/0000-0002-4166-313X; Guerrero, Juan Miguel/0000-0001-7553-0119; Molinero Hueso, Patrocinio/0000-0002-2988-0422	MAPFRE Foundation	This work was supported by a research grant from the MAPFRE Foundation.	Arnalich F, 2010, CRIT CARE, V14, DOI 10.1186/cc8934; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Burns S, 2004, ANN NY ACAD SCI, V1022, P323; Butt AN, 2008, ANN NY ACAD SCI, V1137, P236, DOI 10.1196/annals.1448.002; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Duff D, 2003, AXONE, V23, P18; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Gahan PB, 2008, ANN NY ACAD SCI, V1137, P7, DOI 10.1196/annals.1448.046; Gahan PB, 2010, CELL BIOCHEM FUNCT, V28, P529, DOI 10.1002/cbf.1690; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Holdenrieder S, 2009, CRIT REV CL LAB SCI, V46, P1, DOI [10.1080/10408360802485875 , 10.1080/10408360802485875]; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Lam NYL, 2003, CLIN CHEM, V49, P1286, DOI 10.1373/49.8.1286; LEON SA, 1977, CANCER RES, V37, P646; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; Lo YMD, 2000, CLIN CHEM, V46, P319; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Macher HC, 2012, CLIN CHIM ACTA, V413, P490, DOI 10.1016/j.cca.2011.11.004; MANDEL P, 1948, C R Seances Soc Biol Fil, V142, P241; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Navratil O, 2006, Bratisl Lek Listy, V107, P110; Ohayon S, 2012, J NEUROTRAUM, V29, P261, DOI 10.1089/neu.2011.1938; Palomaki GE, 2011, GENET MED, V13, P913, DOI 10.1097/GIM.0b013e3182368a0e; Papasavva T, 2008, ANN NY ACAD SCI, V1137, P302, DOI 10.1196/annals.1448.029; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rainer TH, 2003, CLIN CHEM, V49, P562, DOI 10.1373/49.4.562; Rainer TH, 2001, CLIN CHIM ACTA, V313, P81, DOI 10.1016/S0009-8981(01)00653-2; Saukkonen K, 2008, CLIN CHEM, V54, P1000, DOI 10.1373/clinchem.2007.101030; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Tong YK, 2006, CLIN CHIM ACTA, V363, P187, DOI 10.1016/j.cccn.2005.05.048; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van der Vaart M, 2008, ANN NY ACAD SCI, V1137, P18, DOI 10.1196/annals.1448.022; Yurgel VC, 2007, J NEUROTRAUM, V24, P1172, DOI 10.1089/neu.2006.0160; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	38	59	65	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	DEC 24	2012	414						12	17		10.1016/j.cca.2012.08.001			6	Medical Laboratory Technology	Medical Laboratory Technology	059DU	WOS:000312685400003	22902808				2021-06-18	
J	Farbota, KDM; Sodhi, A; Bendlin, BB; McLaren, DG; Xu, GF; Rowley, HA; Johnson, SC				Farbota, Kimberly D. M.; Sodhi, Aparna; Bendlin, Barbara B.; McLaren, Donald G.; Xu, Guofan; Rowley, Howard A.; Johnson, Sterling C.			Longitudinal Volumetric Changes following Traumatic Brain Injury: A Tensor-Based Morphometry Study	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Longitudinal studies; Recovery of function; Brain injuries; humans; Neurosciences; Magnetic resonance imaging; Chronic brain injuries; Brain mapping; Apoptosis; Necrosis	INDUCED AXONAL INJURY; WALLERIAN DEGENERATION; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; ATROPHY; MILD; AXOTOMY; PATHOBIOLOGY; AUTOPHAGY; ANIMALS	After traumatic injury, the brain undergoes a prolonged period of degenerative change that is paradoxically accompanied by cognitive recovery. The spatiotemporal pattern of atrophy and the specific relationships of atrophy to cognitive changes are ill understood. The present study used tensor-based morphometry and neuropsychological testing to examine brain volume loss in 17 traumatic brain injury (TBI) patients and 13 controls over a 4-year period. Patients were scanned at 2 months, 1 year, and 4 years post-injury. High-dimensional warping procedures were used to create change maps of each subject's brain for each of the two intervals. TBI patients experienced volume loss in both cortical areas and white matter regions during the first interval. We also observed continuing volume loss in extensive regions of white matter during the second interval. Neuropsychological correlations indicated that cognitive tasks were associated with subsequent volume loss in task-relevant regions. The extensive volume loss in brain white matter observed well beyond the first year post-injury suggests that the injured brain remains malleable for an extended period, and the neuropsychological relationships suggest that this volume loss may be associated with subtle cognitive improvements. (JINS, 2012, 18, 1006-1018)	[Farbota, Kimberly D. M.; Sodhi, Aparna; Bendlin, Barbara B.; McLaren, Donald G.; Xu, Guofan; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53792 USA; [Farbota, Kimberly D. M.; McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA; [Sodhi, Aparna; Bendlin, Barbara B.; Xu, Guofan; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA	Farbota, KDM (corresponding author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, J5M-162 CSC,600 Highland Ave, Madison, WI 53792 USA.	kim.farbota@gmail.com		Johnson, Sterling/0000-0002-8501-545X; Bendlin, Barbara/0000-0002-0580-9875; McLaren, Donald/0000-0002-0566-4610	Department of Veterans AffairsUS Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH65723, AG000213]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD003352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000213] Funding Source: NIH RePORTER	This study was supported by a Merit Review Grant from the Department of Veterans Affairs, the NIH MH65723 (SCJ), NIH AG000213, and by the facilities and resources of the William S. Middleton Memorial Veterans Hospital. The authors declare no conflict of interest. The assistance of Robert Dempsey, MD, Jack Sherman, PhD, Tisha Kawahara, Taylor Schmitz, Lisa Newman, Amy Hawley, and Erik Kastman is greatly appreciated. We also greatly appreciate the support of researchers and staff at the Waisman Center, University of Wisconsin, Madison, where MR imaging took place. Donald McLaren, PhD, is now affiliated with Harvard University Medical School and the Massachusetts General Hospital, Department of Neurology. Finally, we thank all the patients who took part in this study. The contents of this study do not represent the views of the Department of Veterans Affairs or the United States Government.	Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson V, 2012, J NEUROTRAUM, V29, P143, DOI 10.1089/neu.2011.2012; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Cernich AN, 2010, CURR TREAT OPTION NE, V12, P412, DOI 10.1007/s11940-010-0085-6; Chen HC, 2012, SPINE, V37, P470, DOI 10.1097/BRS.0b013e318221e859; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Demir SO, 2006, BRAIN INJURY, V20, P1383, DOI 10.1080/02699050601081844; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Hua X, 2008, NEUROIMAGE, V41, P19, DOI 10.1016/j.neuroimage.2008.02.010; Johanson C, 2011, J NEURAL TRANSM, V118, P115, DOI 10.1007/s00702-010-0498-0; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Keren O, 2001, BRAIN INJURY, V15, P633, DOI 10.1080/02699050010009568; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Leow AD, 2009, NEUROIMAGE, V45, P645, DOI 10.1016/j.neuroimage.2009.01.004; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; STERN B, 1985, SCAND J REHABIL MED, P27; Takeuchi S, 2011, ARCH NEUROL-CHICAGO, V68, P1090, DOI 10.1001/archneurol.2011.205; Tao GZ, 2009, J NEUROL SCI, V282, P39, DOI 10.1016/j.jns.2008.12.035; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0	45	59	60	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2012	18	6					1006	1018		10.1017/S1355617712000835			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	048IT	WOS:000311905300008	22883443	Green Accepted			2021-06-18	
J	Chandra, N; Ganpule, S; Kleinschmit, NN; Feng, R; Holmberg, AD; Sundaramurthy, A; Selvan, V; Alai, A				Chandra, N.; Ganpule, S.; Kleinschmit, N. N.; Feng, R.; Holmberg, A. D.; Sundaramurthy, A.; Selvan, V.; Alai, A.			Evolution of blast wave profiles in simulated air blasts: experiment and computational modeling	SHOCK WAVES			English	Article						Blast wave; Shock tube; Pressure profiles; Expansion; Jet wind; Experiments; Numerical simulations; TBI	SHOCK-WAVES; INDUCED NEUROTRAUMA; BRAIN-INJURY; OPEN-END; MECHANISMS; RAT; PROPAGATION; PRESSURE	Shock tubes have been extensively used in the study of blast traumatic brain injury due to increased incidence of blast-induced neurotrauma in Iraq and Afghanistan conflicts. One of the important aspects in these studies is how to best replicate the field conditions in the laboratory which relies on reproducing blast wave profiles. Evolution of the blast wave profiles along the length of the compression-driven air shock tube is studied using experiments and numerical simulations with emphasis on the shape and magnitude of pressure time profiles. In order to measure dynamic pressures of the blast, a series of sensors are mounted on a cylindrical specimen normal to the flow direction. Our results indicate that the blast wave loading is significantly different for locations inside and outside of the shock tube. Pressure profiles inside the shock tube follow the Friedlander waveform fairly well. Upon approaching exit of the shock tube, an expansion wave released from the shock tube edges significantly degrades the pressure profiles. For tests outside the shock tube, peak pressure and total impulse reduce drastically as we move away from the exit and majority of loading is in the form of subsonic jet wind. In addition, the planarity of the blast wave degrades as blast wave evolves three dimensionally. Numerical results visually and quantitatively confirm the presence of vortices, jet wind and three-dimensional expansion of the planar blast wave near the exit. Pressure profiles at 90A degrees orientation show flow separation. When cylinder is placed inside, this flow separation is not sustained, but when placed outside the shock tube this flow separation is sustained which causes tensile loading on the sides of the cylinder. Friedlander waves formed due to field explosives in the intermediate-to far-field ranges are replicated in a narrow test region located deep inside the shock tube.	[Chandra, N.; Ganpule, S.; Kleinschmit, N. N.; Feng, R.; Holmberg, A. D.; Sundaramurthy, A.; Selvan, V.; Alai, A.] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA	Chandra, N (corresponding author), Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA.	nchandra2@unl.edu	Sundaramurthy, Aravind/O-2047-2019	Sundaramurthy, Aravind/0000-0002-0359-8680	U.S. Army Research Office [W911NF-08-1-0483]	The authors acknowledge the financial support provided by the U.S. Army Research Office for the project on "Army-UNL Center for Trauma Mechanics," Contract No. W911NF-08-1-0483. Project monitor: Larry Russel, PI: Namas Chandra.	Abdul-Wahab R, 2011, NORTHEAST BIOENGIN C; Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Arakeri JH, 2004, PHYS FLUIDS, V16, P1008, DOI 10.1063/1.1649339; Baker WE., 1973, EXPLOSIONS AIR; BLEAKNEY W, 1949, REV MOD PHYS, V21, P584, DOI 10.1103/RevModPhys.21.584; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Chandra N., 2011, U.S. provisional patent application, Patent No. 61542354; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Courtney AC, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3702803; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; DUFF RE, 1966, REV SCI INSTRUM, V37, P579, DOI 10.1063/1.1720256; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Ganpule S, 2012, COMPUT METHOD BIOMEC, V15, P1233, DOI 10.1080/10255842.2011.597353; Honma H, 2003, SHOCK WAVES, V13, P179, DOI 10.1007/s00193-003-0206-1; Jiang Z, 1999, SHOCK WAVES, V9, P1, DOI 10.1007/s001930050133; Jiang Z, 2003, SHOCK WAVES, V13, P103, DOI 10.1007/s00193-003-0197-y; Jiang Z, 1998, PHYS FLUIDS, V10, P277, DOI 10.1063/1.869566; Kashimura H., 2000, J THERM SCI, V9, P30, DOI [DOI 10.1007/S11630-000-0042-X, 10.1007/s11630-000-0042-x]; Kleinschmit N, 2011, SHOCK TUBE TECHNIQUE; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Moss WC, 2011, P NATL ACAD SCI USA, V108, pE82, DOI 10.1073/pnas.1101671108; Onodera O, 1998, JSME INT J B-FLUID T, V41, P408, DOI 10.1299/jsmeb.41.408; Rafaels K., 2010, THESIS U VIRGINIA; Rafaels K.A., 2010, PERS ARM SAF S PASS; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Setoguchi T., 1993, P 1993 ASME WINT M N, V170, P57; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zhu F, 2012, BIOMECH MODEL MECHAN, V11, P341, DOI 10.1007/s10237-011-0314-2	31	59	61	3	51	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-1287	1432-2153		SHOCK WAVES	Shock Waves	SEP	2012	22	5					403	415		10.1007/s00193-012-0399-2			13	Mechanics	Mechanics	996FA	WOS:000308068900002					2021-06-18	
J	Oddo, M; Levine, JM; Kumar, M; Iglesias, K; Frangos, S; Maloney-Wilensky, E; Le Roux, PD				Oddo, Mauro; Levine, Joshua M.; Kumar, Monisha; Iglesias, Katia; Frangos, Suzanne; Maloney-Wilensky, Eileen; Le Roux, Peter D.			Anemia and brain oxygen after severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Hemoglobin; Brain tissue oxygen tension; Anemia; Traumatic brain injury; Cerebral oxygenation; Clinical study; Humans; Outcome; Brain oxygen; Brain injury	BLOOD-CELL TRANSFUSION; TISSUE OXYGEN; HEAD-INJURY; HEMODILUTIONAL ANEMIA; CEREBRAL OXYGENATION; TENSION; CLASSIFICATION; MORTALITY; PERFUSION; DELIVERY	To investigate the relationship between hemoglobin (Hgb) and brain tissue oxygen tension (PbtO(2)) after severe traumatic brain injury (TBI) and to examine its impact on outcome. This was a retrospective analysis of a prospective cohort of severe TBI patients whose PbtO(2) was monitored. The relationship between Hgb-categorized into four quartiles (a parts per thousand currency sign9; 9-10; 10.1-11; > 11 g/dl)-and PbtO(2) was analyzed using mixed-effects models. Anemia with compromised PbtO(2) was defined as episodes of Hgb a parts per thousand currency sign 9 g/dl with simultaneous PbtO(2) < 20 mmHg. Outcome was assessed at 30 days using the Glasgow outcome score (GOS), dichotomized as favorable (GOS 4-5) vs. unfavorable (GOS 1-3). We analyzed 474 simultaneous Hgb and PbtO(2) samples from 80 patients (mean age 44 +/- A 20 years, median GCS 4 (3-7)). Using Hgb > 11 g/dl as the reference level, and controlling for important physiologic covariates (CPP, PaO2, PaCO2), Hgb a parts per thousand currency sign 9 g/dl was the only Hgb level that was associated with lower PbtO(2) (coefficient -6.53 (95 % CI -9.13; -3.94), p < 0.001). Anemia with simultaneous PbtO(2) < 20 mmHg, but not anemia alone, increased the risk of unfavorable outcome (odds ratio 6.24 (95 % CI 1.61; 24.22), p = 0.008), controlling for age, GCS, Marshall CT grade, and APACHE II score. In this cohort of severe TBI patients whose PbtO(2) was monitored, a Hgb level no greater than 9 g/dl was associated with compromised PbtO(2). Anemia with simultaneous compromised PbtO(2), but not anemia alone, was a risk factor for unfavorable outcome, irrespective of injury severity.	[Oddo, Mauro] CHU Vaudois, Dept Intens Care Med, CH-1011 Lausanne, Switzerland; [Oddo, Mauro; Levine, Joshua M.; Kumar, Monisha; Frangos, Suzanne; Maloney-Wilensky, Eileen; Le Roux, Peter D.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.; Kumar, Monisha] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Levine, Joshua M.; Kumar, Monisha] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Iglesias, Katia] Univ Lausanne Hosp, CHUV, Inst Social & Prevent Med, Fac Biol & Med, CH-1011 Lausanne, Switzerland	Oddo, M (corresponding author), CHU Vaudois, Dept Intens Care Med, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [320030_138191]; European Society of Intensive Care Medicine (ECCRN Clinical Research Award); Integra Foundation; Mary Elisabeth Groff Surgical and Medical Research Trust	Supported by grants from the Swiss National Science Foundation (grant no. 320030_138191) and the European Society of Intensive Care Medicine (ECCRN Clinical Research Award 2010) (to M. O.), and the Integra Foundation and the Mary Elisabeth Groff Surgical and Medical Research Trust (to P.D.L.).	Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; BORGSTROM L, 1975, ACTA PHYSIOL SCAND, V93, P505, DOI 10.1111/j.1748-1716.1975.tb05842.x; Dexter F, 1997, BRIT J ANAESTH, V79, P346, DOI 10.1093/bja/79.3.346; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Duane TM, 2008, J SURG RES, V147, P163, DOI 10.1016/j.jss.2008.02.044; George ME, 2008, NEUROCRIT CARE, V8, P337, DOI 10.1007/s12028-008-9066-y; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hare GMT, 2003, J APPL PHYSIOL, V94, P2058, DOI 10.1152/japplphysiol.00931.2002; Hare Gregory M T, 2004, Curr Opin Anaesthesiol, V17, P363, DOI 10.1097/00001503-200410000-00003; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Kramer AH, 2009, CRIT CARE, V13, DOI 10.1186/cc7916; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; McLaren AT, 2007, AM J PHYSIOL-REG I, V292, pR403, DOI 10.1152/ajpregu.00403.2006; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Oddo M, 2010, NEUROSURGERY, V67, P338, DOI 10.1227/01.NEU.0000371979.48809.D9; Pendem S, 2006, NEUROCRIT CARE, V4, P63, DOI 10.1385/NCC:4:1:063; Rigamonti A, 2008, BRIT J ANAESTH, V100, P357, DOI 10.1093/bja/aem401; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, V4, P5103; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Weiskopf RB, 2000, ANESTHESIOLOGY, V92, P1646, DOI 10.1097/00000542-200006000-00023	35	59	62	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2012	38	9					1497	1504		10.1007/s00134-012-2593-1			8	Critical Care Medicine	General & Internal Medicine	992GT	WOS:000307764300011	22584800				2021-06-18	
J	Chen, A; Bushmeneva, K; Zagorski, B; Colantonio, A; Parsons, D; Wodchis, WP				Chen, Amy; Bushmeneva, Ksenia; Zagorski, Brandon; Colantonio, Angela; Parsons, Daria; Wodchis, Walter P.			Direct cost associated with acquired brain injury in Ontario	BMC NEUROLOGY			English	Article							MEDICAL-CARE; EPIDEMIOLOGY; COHORT; HEALTH; OUTCOMES; MILD	Background: Acquired Brain Injury (ABI) from traumatic and non traumatic causes is a leading cause of disability worldwide yet there is limited research summarizing the health system economic burden associated with ABI. The objective of this study was to determine the direct cost of publicly funded health care services from the initial hospitalization to three years post-injury for individuals with traumatic (TBI) and non-traumatic brain injury (nTBI) in Ontario Canada. Methods: A population-based cohort of patients discharged from acute hospital with an ABI code in any diagnosis position in 2004 through 2007 in Ontario was identified from administrative data. Publicly funded health care utilization was obtained from several Ontario administrative healthcare databases. Patients were stratified according to traumatic and non-traumatic causes of brain injury and whether or not they were discharged to an inpatient rehabilitation center. Health system costs were calculated across a continuum of institutional and community settings for up to three years after initial discharge. The continuum of settings included acute care emergency departments inpatient rehabilitation (IR) complex continuing care home care services and physician visits. All costs were calculated retrospectively assuming the government payer's perspective. Results: Direct medical costs in an ABI population are substantial with mean cost in the first year post-injury per TBI and nTBI patient being $32132 and $38018 respectively. Among both TBI and nTBI patients those discharged to IR had significantly higher treatment costs than those not discharged to IR across all institutional and community settings. This tendency remained during the entire three-year follow-up period. Annual medical costs of patients hospitalized with a brain injury in Ontario in the first follow-up year were approximately $120.7 million for TBI and $368.7 million for nTBI. Acute care cost accounted for 46-65% of the total treatment cost in the first year overwhelming all other cost components. Conclusions: The main finding of this study is that direct medical costs in ABI population are substantial and vary considerably by the injury cause. Although most expenses occur in the first follow-up year ABI patients continue to use variety of medical services in the second and third year with emphasis shifting over time from acute care and inpatient rehabilitation towards homecare physician services and long-term institutional care. More research is needed to capture economic costs for ABI patients not admitted to acute care.	[Chen, Amy; Colantonio, Angela; Parsons, Daria; Wodchis, Walter P.] Toronto Rehabil Inst, Toronto, ON, Canada; [Bushmeneva, Ksenia; Wodchis, Walter P.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Zagorski, Brandon; Wodchis, Walter P.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada	Wodchis, WP (corresponding author), Toronto Rehabil Inst, Toronto, ON, Canada.	walter.wodchis@utoronto.ca	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; wodchis, walter/0000-0003-2494-7031; Colantonio, Angela/0000-0003-2094-4765	Ontario Neurotrauma Foundation; Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario; Health System Performance Research Network	This study was supported by funding from the Ontario Neurotrauma Foundation and a grant from the Ministry of Health and Long Term Care to Toronto Rehabilitation Institute as well as funding from the Health System Performance Research Network which is also supported by a grant from the Ontario Ministry of Health and Long-Term Care. We would like to thank the Ministry of Health and Long Term Care in providing us with data and the Canadian Institute for Health Information for advice on data quality and codes. Finally we would like to extend our thanks to Rika Vander Laan for her input in methodology discussions.	ABI Network, 2012, DEF ACQ BRAIN INJ; Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; Berg Jenny, 2004, Eur J Health Econ, V5 Suppl 1, pS84, DOI 10.1007/s10198-005-0293-2; Brener I, 2004, J HEAD TRAUMA REHAB, V19, P405, DOI 10.1097/00001199-200409000-00005; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Canadian Institute for Health Information, 2011, NAT HLTH EXP TRENDS; Canadian Institute for Health Information, 2007, BURD NEUR DIS DIS IN; Canadian Institute of Health Information, NRS LENGTH STAY LENG; Canadian Institute of Health Information, NAT REH REP SYST NRS; Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ US E; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Chen AY, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-16; Colantonio A, 2009, TORONTO ABI DATASET; Collier R, 2009, CAN MED ASSOC J, V181, P668, DOI 10.1503/cmaj.109-3068; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Juurlink D., 2006, Canadian Institute for Health Information Discharge Abstract Database: a validation study; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; Krahn MD, 2010, BJU INT, V105, P338, DOI 10.1111/j.1464-410X.2009.08758.x; Krajden M, 2010, CAN J GASTROENTEROL, V24, P717, DOI 10.1155/2010/569692; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mar J, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-46; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Ontario Joint Policy and Planning Committee, DEV REH PAT GROUPS R; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; SNOW WG, 1988, CAN J SURG, V31, P191; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vangel SJ, 2005, AM J PHYS MED REHAB, V84, P153, DOI 10.1097/01.PHM.0000154896.55045.E7; Wodchis WP, 2008, MED CARE, V46, P882, DOI 10.1097/MLR.0b013e3181789471; Wodchis WP, 2011, TARGETING HLTH SYSTE; Wooder SD., 2011, PRIMARY CARE COMPENS; World Health Organization (WHO), 2006, NEUR DIS	40	59	59	0	19	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	AUG 17	2012	12								76	10.1186/1471-2377-12-76			12	Clinical Neurology	Neurosciences & Neurology	052MJ	WOS:000312201700001	22901094	DOAJ Gold, Green Published			2021-06-18	
J	Huang, MX; Nichols, S; Robb, A; Angeles, A; Drake, A; Holland, M; Asmussen, S; D'Andrea, J; Chun, W; Levy, M; Cui, L; Song, T; Baker, DG; Hammer, P; McLay, R; Theilmann, RJ; Coimbra, R; Diwakar, M; Boyd, C; Neff, J; Liu, TT; Webb-Murphy, J; Farinpour, R; Cheung, C; Harrington, DL; Heister, D; Lee, RR				Huang, Ming-Xiong; Nichols, Sharon; Robb, Ashley; Angeles, Annemarie; Drake, Angela; Holland, Martin; Asmussen, Sarah; D'Andrea, John; Chun, Won; Levy, Michael; Cui, Li; Song, Tao; Baker, Dewleen G.; Hammer, Paul; McLay, Robert; Theilmann, Rebecca J.; Coimbra, Raul; Diwakar, Mithun; Boyd, Cynthia; Neff, John; Liu, Thomas T.; Webb-Murphy, Jennifer; Farinpour, Roxanna; Cheung, Catherine; Harrington, Deborah L.; Heister, David; Lee, Roland R.			An automatic MEG low-frequency source imaging approach for detecting injuries in mild and moderate TBI patients with blast and non-blast causes	NEUROIMAGE			English	Article						Magnetoencephalography; Traumatic brain injury; Slow-wave; Blast; Motor vehicle accident; Sport injury	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; SIGNAL SPACE SEPARATION; WHITE-MATTER INJURY; SLOW-WAVE ACTIVITY; MINOR HEAD-INJURY; DELTA WAVES; POSTCONCUSSIVE SYNDROME; SCHIZOPHRENIC-PATIENTS; CLINICAL MANAGEMENT	Traumatic brain injury (TBI) is a leading cause of sustained impairment in military and civilian populations. However, mild (and some moderate) TBI can be difficult to diagnose because the injuries are often not detectable on conventional MRI or CT. Injured brain tissues in TBI patients generate abnormal low-frequency magnetic activity (ALFMA, peaked at 1-4 Hz) that can be measured and localized by magnetoencephalography (MEG). We developed a new automated MEG low-frequency source imaging method and applied this method in 45 mild TB! (23 from combat-related blasts, and 22 from non-blast causes) and 10 moderate TBI patients (non-blast causes). Seventeen of the patients with mild TBI from blasts had tertiary injuries resulting from the blast. The results show our method detected abnormalities at the rates of 87% for the mild TBI group (blast-induced plus non-blast causes) and 100% for the moderate group. Among the mild TBI patients, the rates of abnormalities were 96% and 77% for the blast and non-blast TBI groups, respectively. The spatial characteristics of abnormal slow-wave generation measured by Z scores in the mild blast TBI group significantly correlated with those in non-blast mild TBI group. Among 96 cortical regions, the likelihood of abnormal slow-wave generation was less in the mild TBI patients with blast than in the mild non-blast TBI patients, suggesting possible protective effects due to the military helmet and armor. Finally, the number of cortical regions that generated abnormal slow-waves correlated significantly with the total post-concussive symptom scores in TBI patients. This study provides a foundation for using MEG low-frequency source imaging to support the clinical diagnosis of TBI. Published by Elsevier Inc.	[Huang, Ming-Xiong] Univ Calif San Diego, Radiol Imaging Lab, Dept Radiol, San Diego, CA 92121 USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Chun, Won; Baker, Dewleen G.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Serv Radiol, San Diego, CA USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Chun, Won; Baker, Dewleen G.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Chun, Won; Baker, Dewleen G.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Rehab Serv, San Diego, CA USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Chun, Won; Baker, Dewleen G.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Nichols, Sharon] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92121 USA; [Drake, Angela; Holland, Martin; Asmussen, Sarah; McLay, Robert; Boyd, Cynthia; Neff, John; Farinpour, Roxanna; Cheung, Catherine] USN, San Diego Med Ctr, San Diego, CA 92152 USA; [Levy, Michael] Univ Calif San Diego, Rady Childrens Hosp San Diego, San Diego, CA 92121 USA; [Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92121 USA; [Hammer, Paul] Def Ctr Excellence Psychol Hlth, Arlington, VA USA; [Hammer, Paul] Def Ctr Traumat Brain Injury, Arlington, VA USA; [Coimbra, Raul] Univ Calif San Diego, Dept Surg, San Diego, CA 92121 USA; [Webb-Murphy, Jennifer] USN, Ctr Combat & Operat Stress Control, San Diego, CA 92152 USA	Huang, MX (corresponding author), Univ Calif San Diego, Radiol Imaging Lab, Dept Radiol, 3510 Dunhill St, San Diego, CA 92121 USA.	mxhuang@ucsd.edu	Levy, Michael/AAL-4647-2020; Baker, Dewleen/O-4957-2019; Coimbra, Raul/AAP-3019-2020	Baker, Dewleen/0000-0002-1736-9838; Coimbra, Raul/0000-0002-3759-6851; Liu, Thomas/0000-0002-1978-7486	Department of Veterans AffairsUS Department of Veterans Affairs; National Football League; McDonnell Foundation via the Brain Trauma Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS082083] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX000146] Funding Source: NIH RePORTER	This work was supported in part by Merit Review Grants from the Department of Veterans Affairs (two for M.X. Huang, one R.R. Lee), National Football League (M.X. Huang and R.R. Lee), and McDonnell Foundation via the Brain Trauma Foundation (PI: J. Ghajar, site PIs: R.R. Lee and M.X. Huang). We would like to thank Angelica Dilay, Susan Yoder, Richard Daugherty, and Terry Curry (RN) for their efforts in recruiting TBI patients, and Dr. J. Chris Edgar for helpful suggestions to the manuscript. We would also like to thank the anonymous reviewers' constructive suggestions that substantially strengthen the present study.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; [Anonymous], 1987, CONTINUOUS OPTIMIZAT; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baayen JC, 2003, BRAIN TOPOGR, V16, P85, DOI 10.1023/B:BRAT.0000006332.71345.b7; BALL GJ, 1977, ELECTROEN CLIN NEURO, V43, P346, DOI 10.1016/0013-4694(77)90258-9; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2004, STUD NEUROPSYCHOL DE, P71; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Brang D, 2010, NEUROIMAGE, V53, P268, DOI 10.1016/j.neuroimage.2010.06.008; Canive JM, 1998, PSYCHOPHARMACOL BULL, V34, P101; Canive JM, 1996, PSYCHOPHARMACOL BULL, V32, P741; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cohen D., 2002, P 13 INT C BIOM, P919; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; de Jongh A, 2003, NEUROIMAGE, V20, P2291, DOI 10.1016/j.neuroimage.2003.07.030; DECKER DA, 1972, ELECTROEN CLIN NEURO, V33, P303, DOI 10.1016/0013-4694(72)90157-5; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fehr T, 2003, SCHIZOPHR RES, V63, P63, DOI 10.1016/S0920-9964(02)00213-X; Fehr T, 2001, BIOL PSYCHIAT, V50, P108, DOI 10.1016/S0006-3223(01)01122-2; Fernandez A, 2002, BIOL PSYCHIAT, V52, P764, DOI 10.1016/S0006-3223(02)01366-5; Fisch B., 1999, FISCH SPEHLMANNS EEG; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Green P., 2005, GREENS WORD MEMORY T; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Huang MX, 2007, NEUROIMAGE, V37, P731, DOI 10.1016/j.neuroimage.2007.06.002; Huang MX, 2010, BRAIN TOPOGR, V23, P82, DOI 10.1007/s10548-009-0122-5; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huang MX, 2000, HUM BRAIN MAPP, V11, P59, DOI 10.1002/1097-0193(200010)11:2<59::AID-HBM10>3.0.CO;2-5; Huang MX, 2006, NEUROIMAGE, V31, P1025, DOI 10.1016/j.neuroimage.2006.01.029; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ioannides A. A., 1993, Brain Topography, V6, P27; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Lewine J D, 1995, Neuroimaging Clin N Am, V5, P575; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Matsuura K, 1997, IEEE T BIO-MED ENG, V44, P720, DOI 10.1109/10.605428; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mosher JC, 1999, IEEE T BIO-MED ENG, V46, P245, DOI 10.1109/10.748978; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; NAGATA K, 1985, NEUROSURGERY, V17, P613, DOI 10.1227/00006123-198510000-00014; Niedermeyer E, 2005, ELECTROENCEPHALOGRAP; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rockstroh BS, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-44; Rowan AJ, 2003, PRIMER EEG MINIATLAS; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song T, 2008, MED BIOL ENG COMPUT, V46, P923, DOI 10.1007/s11517-007-0290-y; Taulu S, 2004, BRAIN TOPOGR, V16, P269, DOI 10.1023/b:brat.0000032864.93890.f9; Taulu S, 2004, Neurol Clin Neurophysiol, V2004, P35; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Uutela K, 1999, NEUROIMAGE, V10, P173, DOI 10.1006/nimg.1999.0454; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Vieth JB, 1996, BRAIN TOPOGR, V8, P215, DOI 10.1007/BF01184772; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	89	59	59	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JUL 16	2012	61	4					1067	1082		10.1016/j.neuroimage.2012.04.029			16	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	967PP	WOS:000305920600034	22542638				2021-06-18	
J	Cocker, PJ; Hosking, JG; Benoit, J; Winstanley, CA				Cocker, Paul J.; Hosking, Jay G.; Benoit, James; Winstanley, Catharine A.			Sensitivity to Cognitive Effort Mediates Psychostimulant Effects on a Novel Rodent Cost/Benefit Decision-Making Task	NEUROPSYCHOPHARMACOLOGY			English	Article						cognitive effort; cost/benefit decision making; individual differences; amphetamine; caffeine; rat	REACTION-TIME-TASK; NUCLEUS-ACCUMBENS DOPAMINE; TRAUMATIC BRAIN-INJURY; D-AMPHETAMINE; PREFRONTAL CORTEX; ATTENTIONAL PERFORMANCE; ACETYLCHOLINE-RELEASE; CARDIOVASCULAR-RESPONSE; CORTICAL ACETYLCHOLINE; SUSTAINED ATTENTION	Amotivational states and insufficient recruitment of mental effort have been observed in a variety of clinical populations, including depression, traumatic brain injury, post-traumatic stress disorder, and attention deficit hyperactivity disorder. Previous rodent models of effort-based decision making have utilized physical costs whereas human studies of effort are primarily cognitive in nature, and it is unclear whether the two types of effortful decision making are underpinned by the same neurobiological processes. We therefore designed a novel rat cognitive effort task (rCET) based on the 5-choice serial reaction time task, a well-validated measure of attention and impulsivity. Within each trial of the rCET, rats are given the choice between an easy or hard visuospatial discrimination, and successful hard trials are rewarded with double the number of sugar pellets. Similar to previous human studies, stable individual variation in choice behavior was observed, with 'workers' choosing hard trials significantly more than their 'slacker' counterparts. Whereas workers 'slacked off in response to administration of amphetamine and caffeine, slackers 'worked harder' under amphetamine, but not caffeine. Conversely, these stimulants increased motor impulsivity in all animals. Ethanol did not affect animals' choice but invigorated behavior. In sum, we have shown for the first time that rats are differentially sensitive to cognitive effort when making decisions, independent of other processes such as impulsivity, and these baseline differences can influence the cognitive response to psychostimulants. Such findings could inform our understanding of impairments in effort-based decision making and contribute to treatment development. Neuropsychopharmacology (2012) 37, 1825-1837; doi:10.1038/npp.2012.30; published online 28 March 2012	[Cocker, Paul J.; Hosking, Jay G.; Benoit, James; Winstanley, Catharine A.] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada	Winstanley, CA (corresponding author), Univ British Columbia, Dept Psychol, 2136 West Mall, Vancouver, BC V6T 1Z4, Canada.	jayhosking@psych.ubc.ca	Winstanley, Catharine/K-5003-2015	Winstanley, Catharine/0000-0001-7032-4471; Cocker, Paul/0000-0002-2957-2884	Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research; CIHRCanadian Institutes of Health Research (CIHR); University of British Columbia's University; Pacific Century Graduate Scholarship	This work was supported by an operating grant awarded to CAW from the Canadian Institutes for Health Research (CIHR). CAW also receives salary support through the Michael Smith Foundation for Health Research and the CIHR New Investigator Award program. JGH was supported by the University of British Columbia's University Graduate Fellowship and the Pacific Century Graduate Scholarship.	ANDERSON KJ, 1994, J PERS SOC PSYCHOL, V67, P334, DOI 10.1037/0022-3514.67.2.334; Bardgett ME, 2009, BEHAV NEUROSCI, V123, P242, DOI 10.1037/a0014625; Barnes A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006626; Bizarro L, 2004, BEHAV PHARMACOL, V15, P195, DOI 10.1097/01.fbp.0000131574.61491.50; Bizarro L, 2003, DRUG ALCOHOL DEPEN, V72, P287, DOI 10.1016/j.drugalcdep.2003.08.004; Botvinick MM, 2009, COGN AFFECT BEHAV NE, V9, P16, DOI 10.3758/CABN.9.1.16; Brunye TT, 2010, BRAIN COGNITION, V72, P181, DOI 10.1016/j.bandc.2009.07.013; Cardinal RN, 2006, ANOVA BEHAV SCI RES, p[xvi, 448]; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chudasama Y, 2006, BIOL PSYCHOL, V73, P19, DOI 10.1016/j.biopsycho.2006.01.005; Chudasama Y, 2004, LEARN MEMORY, V11, P78, DOI 10.1101/lm.70904; COHEN RM, 1982, ARCH GEN PSYCHIAT, V39, P593; COLE BJ, 1987, PSYCHOPHARMACOLOGY, V91, P458, DOI 10.1007/BF00216011; Collins LE, 2012, PHARMACOL BIOCHEM BE, V100, P498, DOI 10.1016/j.pbb.2011.10.015; Cousins MS, 1996, BEHAV BRAIN RES, V74, P189, DOI 10.1016/0166-4328(95)00151-4; COUSINS MS, 1994, PSYCHOPHARMACOLOGY, V116, P529, DOI 10.1007/BF02247489; Croxson PL, 2009, J NEUROSCI, V29, P4531, DOI 10.1523/JNEUROSCI.4515-08.2009; Dalley JW, 2004, CEREB CORTEX, V14, P922, DOI 10.1093/cercor/bhh052; Dalley JW, 2001, J NEUROSCI, V21, P4908, DOI 10.1523/JNEUROSCI.21-13-04908.2001; de Wit H, 2000, BEHAV NEUROSCI, V114, P830, DOI 10.1037//0735-7044.114.4.830; de Wit H, 2002, NEUROPSYCHOPHARMACOL, V27, P813, DOI 10.1016/S0893-133X(02)00343-3; Drummer OH, 2003, FORENSIC SCI INT, V134, P154, DOI 10.1016/S0379-0738(03)00134-8; Egeland J, 2010, J LEARN DISABIL-US, V43, P430, DOI 10.1177/0022219409355473; Field M, 2010, ALCOHOL CLIN EXP RES, V34, P1346, DOI 10.1111/j.1530-0277.2010.01218.x; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; Floresco SB, 2008, NEUROPSYCHOPHARMACOL, V33, P1966, DOI 10.1038/sj.npp.1301565; Floresco SB, 2007, CEREB CORTEX, V17, P251, DOI 10.1093/cercor/bhj143; Floresco SB, 2008, COGN AFFECT BEHAV NE, V8, P375, DOI 10.3758/CABN.8.4.375; Ghods-Sharifi S, 2009, J NEUROSCI, V29, P5251, DOI 10.1523/JNEUROSCI.0315-09.2009; Givens B, 1997, PSYCHOPHARMACOLOGY, V129, P135, DOI 10.1007/s002130050173; Gold JI, 2007, ANNU REV NEUROSCI, V30, P535, DOI 10.1146/annurev.neuro.29.051605.113038; Hammar A, 2003, J INT NEUROPSYCH SOC, V9, P954, DOI 10.1017/S1355617703960152; Hammar A, 2011, NORD J PSYCHIAT, V65, P74, DOI 10.3109/08039488.2010.494311; Herrnstein RJ, 1970, J EXP ANAL BEHAV, V13, P243, DOI 10.1901/jeab.1970.13-243; Higgins GA, 2007, BEHAV BRAIN RES, V185, P32, DOI 10.1016/j.bbr.2007.07.013; Himmelheber AM, 2000, COGNITIVE BRAIN RES, V9, P313, DOI 10.1016/S0926-6410(00)00012-4; Holdstock L, 2000, ALCOHOL CLIN EXP RES, V24, P789, DOI 10.1097/00000374-200006000-00007; Huang ZL, 2005, NAT NEUROSCI, V8, P858, DOI 10.1038/nn1491; Jones-Cage C, 2012, PSYCHOPHARMACOLOGY, V220, P205, DOI 10.1007/s00213-011-2467-1; Kitzbichler MG, 2011, J NEUROSCI, V31, P8259, DOI 10.1523/JNEUROSCI.0440-11.2011; Kool W, 2010, J EXP PSYCHOL GEN, V139, P665, DOI 10.1037/a0020198; Kurniawan IT, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00081; Lawrie SM, 1997, PSYCHOL MED, V27, P995, DOI 10.1017/S0033291797005370; Lazarus M, 2011, J NEUROSCI, V31, P10067, DOI 10.1523/JNEUROSCI.6730-10.2011; McGaughy J, 2002, J NEUROSCI, V22, P1905, DOI 10.1523/JNEUROSCI.22-05-01905.2002; McGuire JT, 2010, P NATL ACAD SCI USA, V107, P7922, DOI 10.1073/pnas.0910662107; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mitchell MR, 2011, PSYCHOPHARMACOLOGY, V218, P703, DOI 10.1007/s00213-011-2363-8; Mukherjee S, 2011, CLIN NEUROPHYSIOL, V122, P2059, DOI 10.1016/j.clinph.2011.02.032; Naccache L, 2005, NEUROPSYCHOLOGIA, V43, P1318, DOI 10.1016/j.neuropsychologia.2004.11.024; Nakamura K, 2001, PHARMACOL BIOCHEM BE, V68, P65, DOI 10.1016/S0091-3057(00)00440-8; Ongini E, 1996, TRENDS PHARMACOL SCI, V17, P364, DOI 10.1016/S0165-6147(96)10045-6; Passetti F, 2000, EUR J NEUROSCI, V12, P3051, DOI 10.1046/j.1460-9568.2000.00183.x; Paterson NE, 2011, NEUROSCI RES, V69, P41, DOI 10.1016/j.neures.2010.10.001; Peeling P, 2007, ADV PHYSIOL EDUC, V31, P332, DOI 10.1152/advan.00003.2007; REVELLE W, 1980, J EXP PSYCHOL GEN, V109, P1, DOI 10.1037//0096-3445.109.1.1; Robbins TW, 2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/s00213-002-1154-7; Rudebeck PH, 2006, NAT NEUROSCI, V9, P1161, DOI 10.1038/nn1756; Rushworth MFS, 2011, NEURON, V70, P1054, DOI 10.1016/j.neuron.2011.05.014; SALAMONE JD, 1994, BEHAV BRAIN RES, V65, P221, DOI 10.1016/0166-4328(94)90108-2; Salamone JD, 2007, PSYCHOPHARMACOLOGY, V191, P389, DOI 10.1007/s00213-006-0623-9; Shah AK, 2008, PSYCHOL BULL, V134, P207, DOI 10.1037/0033-2909.134.2.207; SHALEV A, 1990, PSYCHOSOMATICS, V31, P197, DOI 10.1016/S0033-3182(90)72195-0; Silber BY, 2006, PSYCHOPHARMACOLOGY, V187, P154, DOI 10.1007/s00213-006-0410-7; Smit AS, 2004, ACTA PSYCHOL, V115, P35, DOI 10.1016/j.actpsy.2003.11.001; St Onge JR, 2010, PSYCHOPHARMACOLOGY, V211, P209, DOI 10.1007/s00213-010-1883-y; Stolerman IP, 2009, BEHAV PHARMACOL, V20, P742, DOI 10.1097/FBP.0b013e328333b290; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sun HS, 2012, PSYCHOPHARMACOLOGY, V219, P285, DOI 10.1007/s00213-011-2419-9; Treadway MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006598; Van Dort CJ, 2009, J NEUROSCI, V29, P871, DOI 10.1523/JNEUROSCI.4111-08.2009; Wallman Karen E, 2007, Res Sports Med, V15, P47, DOI 10.1080/15438620601184331; Walton ME, 2003, J NEUROSCI, V23, P6475; White TL, 2007, EXP CLIN PSYCHOPHARM, V15, P599, DOI 10.1037/1064-1297.15.6.599; Winstanley CA, 2003, PSYCHOPHARMACOLOGY, V167, P304, DOI 10.1007/s00213-003-1398-x; Winstanley CA, 2011, BRIT J PHARMACOL, V164, P1301, DOI 10.1111/j.1476-5381.2011.01323.x; Winstanley CA, 2010, BEHAV BRAIN RES, V210, P263, DOI 10.1016/j.bbr.2010.02.044; Wright RA, 2003, PSYCHOPHYSIOLOGY, V40, P98, DOI 10.1111/1469-8986.00010; Wright RA, 2008, INT J PSYCHOPHYSIOL, V69, P127, DOI 10.1016/j.ijpsycho.2008.04.002; Zeeb FD, 2009, NEUROPSYCHOPHARMACOL, V34, P2329, DOI 10.1038/npp.2009.62	81	59	60	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	JUL	2012	37	8					1825	1837		10.1038/npp.2012.30			13	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	960EZ	WOS:000305372100006	22453140	Green Published, Bronze			2021-06-18	
J	Giacino, J; Fins, JJ; Machado, A; Schiff, ND				Giacino, Joseph; Fins, Joseph J.; Machado, Andre; Schiff, Nicholas D.			Central Thalamic Deep Brain Stimulation to Promote Recovery from Chronic Posttraumatic Minimally Conscious State: Challenges and Opportunities	NEUROMODULATION			English	Article						Deep brain stimulation (DBS); minimally conscious state (MCS); neuromodulation; neurostimulation; thalamus	THRESHOLD CALCIUM CURRENTS; INTRATHECAL BACLOFEN; VISUOMOTOR FUNCTIONS; RETICULAR-FORMATION; VEGETATIVE STATE; SPIKE-BURSTS; COMA; ACTIVATION; MECHANISMS; DISORDERS	Background: Central thalamic deep brain stimulation (CT-DBS) may have therapeutic potential to improve behavioral functioning in patients with severe traumatic brain injury (TBI), but its use remains experimental. Current research suggests that the central thalamus plays a critical role in modulating arousal during tasks requiring sustained attention, working memory, and motor function. The aim of the current article is to review the methodology used in the CT-DBS protocol developed by our group, outline the challenges we encountered and offer suggestions for future DBS trials in this population. Rational for CT-DBS in TBI: CT-DBS may therefore be able to stimulate these functions by eliciting action potentials that excite thalamocortical and thalamostriatal pathways. Because patients in chronic minimally conscious state (MCS) have a very low probability of regaining functional independence, yet often have significant sparing of cortical connectivity, they may represent a particularly appropriate target group for CT-DBS. Pilot Study Results: We have conducted a series of single-subject studies of CT-DBS in patients with chronic posttraumatic MCS, with 24-month follow-up. Outcomes were measured using the Coma Recovery Scale-Revised as well as a battery of secondary outcome measures to capture more granular changes. Findings from our index case suggest that CT-DBS can significantly increase functional communication, motor performance, feeding, and object naming in the DBS on state, with performance in some domains remaining above baseline even after DBS was turned off. Conclusions: The use of CT-DBS in patients in MCS, however, presents challenges at almost every step, including during surgical planning, outcome measurement, and postoperative care. Additionally, given the difficulties of obtaining informed consent from patients in MCS and the experimental nature of the treatment, a robust, scientifically rooted ethical framework is resented for pursuing this line of work.	[Giacino, Joseph] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Giacino, Joseph] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Fins, Joseph J.] Weill Cornell Med Coll, Div Med Eth, New York, NY USA; [Machado, Andre] Cleveland Clin Fdn, Neurol Inst, Ctr Neurol Restorat, Cleveland, OH 44195 USA; [Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA	Giacino, J (corresponding author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.	jgiacino@partners.org	Giacino, Joseph/AAF-1952-2021; Machado, Andre GG/B-7572-2014	Giacino, Joseph/0000-0002-7916-9698; Machado, Andre GG/0000-0002-8132-5610			APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Bell E, 2010, J CLIN ETHIC, V21, P101; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Bosk CL, 2003, FORGIVE REMEMBER MAN; Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281; COHADON F, 1985, NEUROSTIMULATION OVE, P247; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Cruse D, 2010, CURR OPIN NEUROL, V23, P656, DOI 10.1097/WCO.0b013e32833fd4e7; DELIAC P, 1993, NEUROCHIRURGIE, V39, P293; Fins J J, 2000, CNS Spectr, V5, P32; Fins JJ, 2003, NEUROSURG CLIN N AM, V14, P303, DOI 10.1016/S1042-3680(02)00118-3; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Fins JJ, 2000, NEUROL RES, V22, P273; Fins JJ, 2011, PRES BIOETH COMM NEW; Fins JJ, 2006, PALLIATIVE ETHIC CAR; Fins JJ, RIGHTS COME MI UNPUB; Fins JJ, 2008, AM J BIOETHICS, V8, P46, DOI 10.1080/15265160802334490; Fins Joseph J, 2006, Palliat Support Care, V4, P169; Fins JJ, 2010, HASTINGS CENT REP, V40, P21, DOI 10.1353/hcr.0.0257; Fins Joseph J, 2008, Cleve Clin J Med, V75 Suppl 6, pS7; Giacino JT, 2007, CURR OPIN NEUROL, V20, P614, DOI 10.1097/WCO.0b013e3282f189ef; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Giacino JT, 2005, REHABILITATION TRAUM, P305; GLENN LL, 1982, J NEUROSCI, V2, P1387; Gold L, 2002, P NATL ACAD SCI USA, V99, P7699, DOI 10.1073/pnas.112012499; Grillner S, 2005, TRENDS NEUROSCI, V28, P364, DOI 10.1016/j.tins.2005.05.004; HASSLER R, 1969, ELECTROEN CLIN NEURO, V27, P306, DOI 10.1016/0013-4694(69)90060-1; Hosobuchi Y, 1993, Adv Neurol, V63, P247; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.ph.58.030196.001553; Isope P, 2005, J PHYSIOL-LONDON, V562, P257, DOI 10.1113/jphysiol.2004.074211; Jeanmonod D, 1996, BRAIN, V119, P363, DOI 10.1093/brain/119.2.363; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jones E.G., 2007, THALAMUS; Jones EG, 2001, TRENDS NEUROSCI, V24, P595, DOI 10.1016/S0166-2236(00)01922-6; Kahneman D., 1973, ATTENTION EFFORT; Kaplan E., 1983, BOSTON NAMING TEST; Kelley AS, 2009, AM HEART J, V157; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S., 2003, European Journal of Neurology, V10, P224; Llinas RR, 2002, P NATL ACAD SCI USA, V99, P449, DOI 10.1073/pnas.012604899; Lujan JL, 2009, STEREOT FUNCT NEUROS, V87, P229, DOI 10.1159/000225976; Machado A, 2006, MOVEMENT DISORD, V21, pS247, DOI 10.1002/mds.20959; Mair RG, 2008, J NEUROSCI, V28, P14293, DOI 10.1523/JNEUROSCI.3301-08.2008; McLardy T, 1968, Trans Am Neurol Assoc, V93, P25; Medtronic, 2010, MRI GUID MEDTR DEEP; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Nagai Y, 2004, NEUROIMAGE, V21, P1232, DOI 10.1016/j.neuroimage.2003.10.036; Nakase-Thompson R, 2005, BRAIN INJURY, V19, P685, DOI 10.1080/02699050400025331; NAT'L BIOETHICS ADVISORY COMM'N, 1998, RES INV PERS MENT DI; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Parasuraman R, 1999, ATTENTIVE BRAIN, P1; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Paus T, 1997, J COGNITIVE NEUROSCI, V9, P392, DOI 10.1162/jocn.1997.9.3.392; Posner MI., 1978, CHRONOMETRIC EXPLORA; Purpura KP, 1997, NEUROSCIENTIST, V3, P8, DOI 10.1177/107385849700300110; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIZZOLATTI G, 1987, NEUROPSYCHOLOGIA, V25, P31, DOI 10.1016/0028-3932(87)90041-8; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff N.D., 1997, Patent No. [#5,938,688, 5938688]; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schiff ND, 2009, ARCH NEUROL-CHICAGO, V66, P697, DOI 10.1001/archneurol.2009.79; Schiff Nicholas D., 2002, Thalamus & Related Systems, V2, P55, DOI 10.1017/S1472928802000286; SCHLAG J, 1984, J NEUROPHYSIOL, V51, P1175; SCHLAGREY M, 1984, J NEUROPHYSIOL, V51, P1149; Shah SA, 2010, EUR J NEUROSCI, V32, P1135, DOI 10.1111/j.1460-9568.2010.07420.x; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Shirvalkar P, 2006, P NATL ACAD SCI USA, V103, P17007, DOI 10.1073/pnas.0604811103; Smith AC, 2009, J NEUROSCI METH, V183, P267, DOI 10.1016/j.jneumeth.2009.06.028; Smith Y, 2009, BRAIN RES BULL, V78, P60, DOI 10.1016/j.brainresbull.2008.08.015; STERIADE M, 1982, J NEUROPHYSIOL, V48, P352; STERIADE M, 1993, NEUROSCIENCE, V56, P1, DOI 10.1016/0306-4522(93)90556-U; STERIADE M, 1997, THALAMUS, V1; STURM V, 1979, ACTA NEUROCHIR, V47, P235, DOI 10.1007/BF01406406; Tsubokawa T, 1990, Brain Inj, V4, P315; Yamamoto T, 2005, NEUROPSYCHOL REHABIL, V15, P406, DOI 10.1080/09602010443000353	86	59	72	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	JUL-AUG	2012	15	4					339	349		10.1111/j.1525-1403.2012.00458.x			11	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	984VG	WOS:000307219900009	22624587				2021-06-18	
J	Hanlon, EM; Bir, CA				Hanlon, Erin M.; Bir, Cynthia A.			Real-Time Head Acceleration Measurement in Girls' Youth Soccer	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; INJURY; ON-FIELD MEASUREMENT; SOCCER HEADING; COLLISION	FOOTBALL; IMPACT; CONCUSSION; INJURIES	HANLON, E. M., and C. A. BIR. Real-Time Head Acceleration Measurement in Girls' Youth Soccer. Med. Sci. Sports Exerc., Vol. 44, No. 6, pp. 1102-1108,2012. Purpose: The purpose of the current study was to collect real-time head acceleration data for soccer impacts during girls' youth (U14) soccer play. Methods: Linear and angular head accelerations were collected during girls' youth soccer scrimmages using a wireless head acceleration measurement device (the Head Impact Telemetry System). After field data collection, each individual impact was analyzed. The type of impact, header or nonheader, was determined, and nonheader impacts were further assessed by the category of impact. The head injury criterion and resultant linear and angular accelerations were analyzed and compared with current injury tolerance values for all impacts. Results: A total of 47 header and 20 nonheader impacts were observed during the study. The front of the head experienced more headers than the other locations (n = 17). Header impacts ranged in peak linear acceleration from 4.5g to 62.9g and in peak angular head acceleration from 444.8 to 8869.1 rad.s(-2). The majority of the nonheader impacts (40%) were player collisions with other players. Only one goalpost collision occurred, but it resulted in the highest peak angular acceleration (5179.5 rad.s(-2)) and was the only nonheader impact to exceed any of the tolerance levels. Conclusions: Head accelerations were found to exceed the majority of previous laboratory studies. None of the impacts exceeded linear acceleration tolerance values for concussion, but angular accelerations did exceed the suggested limits. Three angular acceleration measurements for heading events (4509.8, 5298.3, and 8869.1 rad.s(-2)) exceeded the concussion tolerance values, but no concussions were diagnosed during the study.	[Hanlon, Erin M.; Bir, Cynthia A.] Wayne State Univ, Coll Engn, Dept Biomed Engn, Detroit, MI 48201 USA	Bir, CA (corresponding author), Wayne State Univ, Coll Engn, Dept Biomed Engn, 818 W Hancock, Detroit, MI 48201 USA.	cbir@wayne.edu		Bir, Cynthia/0000-0002-0777-0951	Anthony and Joyce Danielski Kales Scholarship; National Organizing Committee on Standards for Athletic Equipment	This study was also supported in part by the Anthony and Joyce Danielski Kales Scholarship.; The authors thank the National Organizing Committee on Standards for Athletic Equipment for funding this project.	Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Gadd CW., 1966, P 10 STAPP CAR CRASH, P164; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; JANDA DH, 1995, AM J SPORT MED, V23, P340, DOI 10.1177/036354659502300316; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Newman J A, 2000, Stapp Car Crash J, V44, P215; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson Steven, 2009, Biomed Sci Instrum, V45, P113; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Self BP, 2006, ENG SPORT 6, V6, P81; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI26, DOI 10.1136/bjsm.2005.019042; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	27	59	59	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUN	2012	44	6					1102	1108		10.1249/MSS.0b013e3182444d7d			7	Sport Sciences	Sport Sciences	944TQ	WOS:000304227100017	22592278				2021-06-18	
J	Wilde, EA; Merkley, TL; Bigler, ED; Max, JE; Schmidt, AT; Ayoub, KW; McCauley, SR; Hunter, JV; Hanten, G; Li, XQ; Chu, ZLD; Levin, HS				Wilde, Elisabeth A.; Merkley, Tricia L.; Bigler, Erin D.; Max, Jeffrey E.; Schmidt, Adam T.; Ayoub, Kareem W.; McCauley, Stephen R.; Hunter, Jill V.; Hanten, Gerri; Li, Xiaoqi; Chu, Zili D.; Levin, Harvey S.			Longitudinal changes in cortical thickness in children after traumatic brain injury and their relation to behavioral regulation and emotional control	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Traumatic brain injury; Child; Imaging; Volumetrics; Longitudinal; Behavior; Emotion; Frontal lobes; Cortical thickness	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; EXECUTIVE FUNCTION BRIEF; CLOSED-HEAD INJURY; PERSONALITY-CHANGE; CEREBRAL-CORTEX; RATING INVENTORY; NERVOUS-SYSTEM; ADOLESCENTS 6; CELL-DEATH; MODERATE	The purpose of this study was to assess patterns of cortical development over time in children who had sustained traumatic brain injury (TBI) as compared to children with orthopedic injury (OI), and to examine how these patterns related to emotional control and behavioral dysregulation, two common post-TBI symptoms. Cortical thickness was measured at approximately 3 and 18 months post-injury in 20 children aged 8.2-17.5 years who had sustained moderate-to-severe closed head injury and 21 children aged 7.4-16.7 years who had sustained OI. At approximately 3 months post-injury, the TBI group evidenced decreased cortical thickness bilaterally in aspects of the superior frontal, dorsolateral frontal, orbital frontal, and anterior cingulate regions compared to the control cohort, areas of anticipated vulnerability to TBI-induced change. At 18 months post-injury, some of the regions previously evident at 3 months post-injury remained significantly decreased in the TBI group, including bilateral frontal, fusiform, and lingual regions. Additional regions of significant cortical thinning emerged at this time interval (bilateral frontal regions and fusiform gyrus and left parietal regions). However, differences in other regions appeared attenuated (no longer areas of significant cortical thinning) by 18 months post-injury including large bilateral regions of the medial aspects of the frontal lobes and anterior cingulate. Cortical thinning within the OI group was evident over time in dorsolateral frontal and temporal regions bilaterally and aspects of the left medial frontal and precuneus, and right inferior parietal regions. Longitudinal analyses within the TBI group revealed decreases in cortical thickness over time in numerous aspects throughout the right and left cortical surface, but with notable "sparing" of the right and left frontal and temporal poles, the medial aspects of both the frontal lobes, the left fusiform gyrus, and the cingulate bilaterally. An analysis of longitudinal changes in cortical thickness over time (18 months-3 months) in the TBI versus OI group demonstrated regions of relative cortical thinning in the TBI group in bilateral superior parietal and right paracentral regions, but relative cortical thickness increases in aspects of the medial orbital frontal lobes and bilateral cingulate and in the right lateral orbital frontal lobe. Finally, findings from analyses correlating the longitudinal cortical thickness changes in TBI with symptom report on the Emotional Control subscale of the Behavior Rating Inventory of Executive Function (BRIEF) demonstrated a region of significant correlation in the right medial frontal and right anterior cingulate gyrus. A region of significant correlation between the longitudinal cortical thickness changes in the TBI group and symptom report on the Behavioral Regulation Index was also seen in the medial aspect of the left frontal lobe. Longitudinal analyses of cortical thickness highlight an important deviation from the expected pattern of developmental change in children and adolescents with TBI, particularly in the medial frontal lobes, where typical patterns of thinning fail to occur over time. Regions which fail to undergo expected cortical thinning in the medial aspects of the frontal lobes correlate with difficulties in emotional control and behavioral regulation, common problems for youth with TBI. Examination of post-TBI brain development in children may be critical to identification of children that may be at risk for persistent problems with executive functioning deficits and the development of interventions to address these issues. (C) 2012 ISDN. Published by Elsevier Ltd. All rights reserved.	[Wilde, Elisabeth A.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili D.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Utah Brain Inst, Salt Lake City, UT USA; [Max, Jeffrey E.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Max, Jeffrey E.] Rady Childrens Hosp, San Diego, CA USA; [Ayoub, Kareem W.] Rice Univ, Dept Bioengn, Houston, TX USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Hunter, Jill V.; Chu, Zili D.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Wilde, EA (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	National Institute Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was supported by the National Institute Neurological Disorders and Stroke grant R01-NS21889 ("Neurobehavioral outcome of head injury in children," Levin, PI). We also acknowledge the generous contribution of Mission Connect of the TIRR Foundation. We gratefully acknowledge the contribution of Ana C. Vasquez, Deleene Menefee, PhD., Summer Lane, Lori Cook, Sandra B. Chapman, Ph.D., and Gillian Hotz, Ph.D. in data collection, and Joshua Cooper and Ragini Yallampalli in manuscript preparation. We thank the participants and their families for their participation in this research.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Athinoula A., 2005, FREESURFER; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Cole WR, 2008, BRAIN INJURY, V22, P932, DOI 10.1080/02699050802454808; *COMM INJ SCAL, 1990, ABBR INJ SCAL; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Ferriero DM, 2010, J ANAT, V217, P429, DOI 10.1111/j.1469-7580.2010.01226.x; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Giorgio A, 2010, NEUROIMAGE, V49, P94, DOI 10.1016/j.neuroimage.2009.08.003; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; GOODMAN R, 1989, BRIT J PSYCHIAT, V154, P292, DOI 10.1192/bjp.154.3.292; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hauser RM, 1997, SOCIOL METHODOL, V27, P177, DOI 10.1111/1467-9531.271028; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Huttenlocher P.R., 1994, SYNAPTOGENESIS HUMAN, P137; Jernigan TL, 2011, PROG BRAIN RES, V189, P77, DOI 10.1016/B978-0-444-53884-0.00019-1; Kim WR, 2011, DEV GROWTH DIFFER, V53, P225, DOI 10.1111/j.1440-169X.2010.01226.x; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Landing BH, 2002, PEDIATR PATHOL MOL M, V21, P321, DOI 10.1080/02770930290056541; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max . I. E., 2010, J NEUROPSYCHIATRY CL, V22, P30, DOI [10.1176/appi.neuropsych.22.1.30, DOI 10.1176/APPI.NEUROPSYCH.22.1.30]; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Porto L, 2011, EUR J PAEDIATR NEURO, V15, P493, DOI [10. 1016/j.ejpn.2011.06.004, DOI 10.1016/J.EJPN.2011.06.004]; Potter JL, 2011, REHABIL PSYCHOL, V56, P351, DOI 10.1037/a0025445; Powell KB, 2004, J CHILD NEUROL, V19, P785, DOI 10.1177/08830738040190100801; Raznahan A, 2011, J NEUROSCI, V31, P7174, DOI 10.1523/JNEUROSCI.0054-11.2011; Reuter M, 2011, NEUROIMAGE, V57, P19, DOI 10.1016/j.neuroimage.2011.02.076; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rosso IM, 2004, ANN NY ACAD SCI, V1021, P355, DOI 10.1196/annals.1308.045; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Stiles J, 2010, NEUROPSYCHOL REV, V20, P327, DOI 10.1007/s11065-010-9148-4; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; TEASDALE G, 1974, LANCET, V2, P81; Thurman D.J., 2007, BRAIN INJURY MED PRI; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Westlye LT, 2010, NEUROIMAGE, V52, P172, DOI 10.1016/j.neuroimage.2010.03.056; Whitford TJ, 2007, HUM BRAIN MAPP, V28, P228, DOI 10.1002/hbm.20273; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wood JN, 2003, NAT REV NEUROSCI, V4, P139, DOI 10.1038/nrn1033; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	82	59	60	0	42	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748			INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		267	276		10.1016/j.ijdevneu.2012.01.003			10	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800013	22266409	Green Accepted			2021-06-18	
J	Chuang, JY; Lee, CW; Shih, YH; Yang, TT; Yu, L; Kuo, YM				Chuang, Jia-Ying; Lee, Chu-Wan; Shih, Yao-Hsiang; Yang, Tingting; Yu, Lung; Kuo, Yu-Min			Interactions between Amyloid-beta and Hemoglobin: Implications for Amyloid Plaque Formation in Alzheimer's Disease	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SENILE PLAQUES; A-BETA; DIFFERENTIAL EXPRESSION; MICROVASCULAR PATHOLOGY; CEREBROSPINAL-FLUID; PROTEIN-PRECURSOR; APOLIPOPROTEIN-E; MOUSE MODEL; RAT-BRAIN	Accumulation of amyloid-beta (A beta) peptides in the brain is one of the central pathogenic events in Alzheimer's disease (AD). However, why and how A beta aggregates within the brain of AD patients remains elusive. Previously, we demonstrated hemoglobin (Hb) binds to A beta and co-localizes with the plaque and vascular amyloid deposits in post-mortem AD brains. In this study, we further characterize the interactions between Hb and A beta in vitro and in vivo and report the following observations: 1) the binding of Hb to A beta required iron-containing heme; 2) other heme-containing proteins, such as myoglobin and cytochrome C, also bound to A beta; 3) hemin-induced cytotoxicity was reduced in neuroblastoma cells by low levels of A beta; 4) Hb was detected in neurons and glial cells of post-mortem AD brains and was up-regulated in aging and APP/PS1 transgenic mice; 5) microinjection of human Hb into the dorsal hippocampi of the APP/PS1 transgenic mice induced the formation of an envelope-like structure composed of A beta surrounding the Hb droplets. Our results reveal an enhanced endogenous expression of Hb in aging brain cells, probably serving as a compensatory mechanism against hypoxia. In addition, A beta binds to Hb and other hemoproteins via the iron-containing heme moiety, thereby reducing Hb/heme/iron-induced cytotoxicity. As some of the brain Hb could be derived from the peripheral circulation due to a compromised blood-brain barrier frequently observed in aged and AD brains, our work also suggests the genesis of some plaques may be a consequence of sustained amyloid accretion at sites of vascular injury.	[Chuang, Jia-Ying; Lee, Chu-Wan; Shih, Yao-Hsiang; Yu, Lung; Kuo, Yu-Min] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 70101, Taiwan; [Yang, Tingting] I Shou Univ, Sch Chinese Med Postbaccalaureate, Div Neurosci & Neuropathol, Kaohsiung, Taiwan; [Yu, Lung] Natl Cheng Kung Univ, Inst Behav Med, Tainan 70101, Taiwan; [Kuo, Yu-Min] Natl Cheng Kung Univ, Dept Cell Biol & Anat, Tainan 70101, Taiwan	Chuang, JY (corresponding author), Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 70101, Taiwan.	lungyu@mail.ncku.edu.tw; kuoym@mail.ncku.edu.tw	Ting-Ting, YANG/E-6009-2010; Kuo, Yu-Min/A-9050-2013	Ting-Ting, YANG/0000-0001-5975-8359; Kuo, Yu-Min/0000-0003-4867-2482; Shih, Yao-Hsiang/0000-0001-9145-7492	National Science council (NSC) of TaiwanMinistry of Science and Technology, Taiwan [99-2320-B-006-017-MY3, NSC99-2321-B-006-003, NSC97-2410-H-006-074-MY3]	This work was supported by National Science council (NSC 99-2320-B-006-017-MY3, NSC99-2321-B-006-003, NSC97-2410-H-006-074-MY3) of Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ascoli F, 1981, Methods Enzymol, V76, P72; Atamna H, 2006, P NATL ACAD SCI USA, V103, P3381, DOI 10.1073/pnas.0600134103; Atamna H, 2004, P NATL ACAD SCI USA, V101, P11153, DOI 10.1073/pnas.0404349101; Atwood CS, 2003, BRAIN RES REV, V43, P164, DOI 10.1016/S0165-0173(03)00206-6; Biagioli M, 2009, P NATL ACAD SCI USA, V106, P15454, DOI 10.1073/pnas.0813216106; Bishop GM, 2004, BRAIN PATHOL, V14, P448; Bishop GM, 2003, J NEUROSCI RES, V73, P316, DOI 10.1002/jnr.10661; Blalock EM, 2003, J NEUROSCI, V23, P3807; Buee L, 1997, ANN NY ACAD SCI, V826, P7, DOI 10.1111/j.1749-6632.1997.tb48457.x; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Cortes-Canteli M, 2010, NEURON, V66, P695, DOI 10.1016/j.neuron.2010.05.014; Cullen KM, 2006, NEUROBIOL AGING, V27, P1786, DOI 10.1016/j.neurobiolaging.2005.10.016; de la Torre JC, 2004, LANCET NEUROL, V3, P184, DOI 10.1016/S1474-4422(04)00683-0; ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Evin G, 2002, PEPTIDES, V23, P1285, DOI 10.1016/S0196-9781(02)00063-3; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Grammas P, 2002, J ALZHEIMERS DIS, V4, P217, DOI 10.3233/JAD-2002-4311; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HAMAZAKI H, 1995, BIOCHEM BIOPH RES CO, V211, P349, DOI 10.1006/bbrc.1995.1819; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HARDY JA, 1986, NEUROBIOL AGING, V7, P489, DOI 10.1016/0197-4580(86)90086-2; Hardy J, 2006, J ALZHEIMERS DIS, V9, P151; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; He YD, 2009, J CEREBR BLOOD F MET, V29, P596, DOI 10.1038/jcbfm.2008.145; Holcomb LA, 2000, MECH AGEING DEV, V112, P135, DOI 10.1016/S0047-6374(99)00086-X; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Jellinger KA, 2002, J NEURAL TRANSM, V109, P813, DOI 10.1007/s007020200068; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; KARELIN AA, 1994, BIOCHEM BIOPH RES CO, V202, P410, DOI 10.1006/bbrc.1994.1943; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Khan S, 2008, CAN MED ASSOC J, V178, P1687, DOI 10.1503/cmaj.1080038; Kokjohn TA, 2011, IS ALZHEIMERS DIS AM; Kontush A, 2001, FREE RADICAL BIO MED, V30, P119, DOI 10.1016/S0891-5849(00)00458-5; KOO EH, 1990, NEURON, V4, P97, DOI 10.1016/0896-6273(90)90446-M; Kumar-Singh S, 2005, AM J PATHOL, V167, P527, DOI 10.1016/S0002-9440(10)62995-1; Kuo YM, 1999, BIOCHEM BIOPH RES CO, V257, P787, DOI 10.1006/bbrc.1999.0552; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; MASLIAH E, 1994, ACTA NEUROPATHOL, V87, P135; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; Meyer EP, 2008, P NATL ACAD SCI USA, V105, P3587, DOI 10.1073/pnas.0709788105; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; MIYAKAWA T, 1979, ACTA NEUROPATHOL, V48, P153, DOI 10.1007/BF00691158; MIYAKAWA T, 1982, VIRCHOWS ARCH B, V40, P121, DOI 10.1007/BF02932857; ONO T, 1978, P NATL ACAD SCI USA, V75, P4431, DOI 10.1073/pnas.75.9.4431; OYAMA F, 1991, J NEUROPATH EXP NEUR, V50, P560, DOI 10.1097/00005072-199109000-00004; Oyama R, 2000, BBA-PROTEIN STRUCT M, V1479, P91, DOI 10.1016/S0167-4838(00)00057-1; Paris D, 2000, NEUROBIOL AGING, V21, P183, DOI 10.1016/S0197-4580(00)82162-4; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Raby CA, 1998, J NEUROCHEM, V71, P2505; Raymackers J, 2000, ELECTROPHORESIS, V21, P2266, DOI 10.1002/1522-2683(20000601)21:11<2266::AID-ELPS2266>3.0.CO;2-Z; Richter F, 2009, J COMP NEUROL, V515, P538, DOI 10.1002/cne.22062; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; Schelshorn DW, 2009, J CEREBR BLOOD F MET, V29, P585, DOI 10.1038/jcbfm.2008.152; Schonberger SJ, 2001, PROTEOMICS, V1, P1519, DOI 10.1002/1615-9861(200111)1:12<1519::AID-PROT1519>3.0.CO;2-L; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SLEMMON JR, 1994, J NEUROSCI, V14, P2225; Stone J, 2008, MED HYPOTHESES, V71, P347, DOI 10.1016/j.mehy.2008.04.007; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wu CW, 2007, J NEUROCHEM, V103, P2471, DOI 10.1111/j.1471-4159.2007.04987.x; Wu CW, 2004, NEUROBIOL DIS, V17, P367, DOI 10.1016/j.nbd.2004.08.014; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yeh SR, 1998, NAT STRUCT BIOL, V5, P222, DOI 10.1038/nsb0398-222; Zhao XR, 2009, J NEUROSCI, V29, P15819, DOI 10.1523/JNEUROSCI.3776-09.2009; Zlokovic BV, 2005, TRENDS NEUROSCI, V28, P202, DOI 10.1016/j.tins.2005.02.001; Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002	78	59	59	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2012	7	3							e33120	10.1371/journal.pone.0033120			10	Multidisciplinary Sciences	Science & Technology - Other Topics	928XD	WOS:000303021100049	22412990	DOAJ Gold, Green Published			2021-06-18	
J	Gao, TL; Yuan, XT; Yang, D; Dai, HL; Wang, WJ; Peng, X; Shao, HJ; Jin, ZF; Fu, ZJ				Gao, Tie-Lei; Yuan, Xiang-Tian; Yang, Dan; Dai, Hai-Li; Wang, Wen-Jing; Peng, Xue; Shao, Hong-Jiang; Jin, Zhan-Feng; Fu, Zhi-Jun			Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						HMGB1; RAGE; traumatic brain injury; brain	MOBILITY GROUP BOX-1; GENE-EXPRESSION; AMPHOTERIN; PROTEIN; CYTOKINE; ISCHEMIA; PATHWAY; CANCER; CELLS	BACKGROUND: Increasing evidence suggests that an inflammatory reaction contributes to the secondary brain injury that plays a critical role in the clinical outcome of patients with traumatic brain injury (TBI). Recently, high-mobility group box 1 (HMGB1) has been identified as a key cytokine in the inflammatory reaction and may represent a new target for the treatment of TBI. However, the expression of HMGB1 during this injury process has not yet been studied. METHODS: In this study, the levels of both HMGB1 and receptor for advanced glycation end products (RAGE) in the rat brain were analyzed by Western blot at different time points after TBI. Immunohistochemistry was also performed to examine the expression pattern of HMGB1 and RAGE in both the rat and the human brain after TBI. RESULTS: In the rat brain, HMGB1 levels significantly declined below the basal level at 6 hours after TBI and then gradually returned to the basal level 2 days later. RAGE expression increased 6 hours after TBI and reached its peak after 1 day; this level then slowly decreased but remained higher than the sham-injury group until 6 days after TBI. In both rat and human brains, HMGB1 either disappeared or was translocated from the nucleus to the cytoplasm at early stages after TBI and then was localized to the cytoplasm of phagocytic microglia at later stages. RAGE expression increased in the region surrounding the contused area after TBI in both rat and human brains. At later stages, RAGE was mainly expressed in microglia. CONCLUSION: HMGB1 is involved in both early and later stages after TBI. Targeting HMGB1 signaling may be a promising therapeutic approach for the treatment of TBI. (J Trauma. 2012; 72: 643-649. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Gao, Tie-Lei; Yang, Dan; Dai, Hai-Li; Wang, Wen-Jing; Peng, Xue; Shao, Hong-Jiang; Jin, Zhan-Feng] Harbin Med Coll, Dept Forens Med, Harbin 150081, Peoples R China; [Yuan, Xiang-Tian] Hulunbeier Municipal Publ Secur Bur, Res Inst Criminal Technol, Hulunbeier, Peoples R China	Jin, ZF (corresponding author), Harbin Med Coll, Dept Forens Med, 157th Bao Jian Rd, Harbin 150081, Peoples R China.	jinzf2003@yahoo.com.cn			211 Foundation at Harbin Medical University	Supported by a grant from the 211 Foundation at Harbin Medical University.	Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Huttunen HJ, 2004, J INTERN MED, V255, P351, DOI 10.1111/j.1365-2796.2003.01301.x; Karlsson S, 2008, INTENS CARE MED, V34, P1046, DOI 10.1007/s00134-008-1032-9; Kawabata H, 2010, SPINE, V35, P1109, DOI 10.1097/BRS.0b013e3181bd14b6; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Luan ZG, 2010, IMMUNOBIOLOGY, V215, P956, DOI 10.1016/j.imbio.2009.11.001; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Park JS, 2003, AM J PHYSIOL-CELL PH, V284, pC870, DOI 10.1152/ajpcell.00322.2002; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Taguchi A, 2000, NATURE, V405, P354; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Thomas JO, 2001, BIOCHEM SOC T, V29, P395, DOI 10.1042/BST0290395; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Yamada S, 2007, CLIN CHIM ACTA, V375, P36, DOI 10.1016/j.cca.2006.07.019; Yang QW, 2010, J CEREBR BLOOD F MET, V30, P243, DOI 10.1038/jcbfm.2009.202; Zhai DX, 2008, NEUROSCI LETT, V445, P117, DOI 10.1016/j.neulet.2008.08.077	25	59	61	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2012	72	3					643	649		10.1097/TA.0b013e31823c54a6			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	906TR	WOS:000301371100029	22491548				2021-06-18	
J	Oliva, AA; Kang, Y; Sanchez-Molano, J; Furones, C; Atkins, CM				Oliva, Anthony A., Jr.; Kang, Yuan; Sanchez-Molano, Juliana; Furones, Concepcion; Atkins, Coleen M.			STAT3 signaling after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; inflammation; signal transducer and activation of transcription-3; traumatic brain injury	NITRIC-OXIDE SYNTHASE; COLONY-STIMULATING FACTOR; FOCAL CEREBRAL-ISCHEMIA; LEUKEMIA INHIBITORY FACTOR; SPINAL-CORD-INJURY; HUMAN HEAD-INJURY; REACTIVE ASTROCYTES; ONCOSTATIN-M; GROWTH-FACTOR; UP-REGULATION	Astrocytes respond to trauma by stimulating inflammatory signaling. In studies of cerebral ischemia and spinal cord injury, astrocytic signaling is mediated by the cytokine receptor glycoprotein 130 (gp130) and Janus kinase (Jak) which phosphorylates the transcription factor signal transducer and activator of transcription-3 (STAT3). To determine if STAT3 is activated after traumatic brain injury (TBI), adult male SpragueDawley rats received moderate parasagittal fluid-percussion brain injury or sham surgery, and then the ipsilateral cortex and hippocampus were analyzed at various post-traumatic time periods for up to 7 days. Western blot analyses indicated that STAT3 phosphorylation significantly increased at 30 min and lasted for 24 h post-TBI. A significant increase in gp130 and Jak2 phosphorylation was also observed. Confocal microscopy revealed that STAT3 was localized primarily within astrocytic nuclei. At 6 and 24 h post-TBI, there was also an increased expression of STAT3 pathway-related genes: suppressor of cytokine signaling 3, nitric oxide synthase 2, colony stimulating factor 2 receptor beta, oncostatin M, matrix metalloproteinase 3, cyclin-dependent kinase inhibitor 1A, CCAAT/enhancer-binding protein beta, interleukin-2 receptor gamma, interleukin-4 receptor a, and a-2-macroglobulin. These results clarify some of the signaling pathways operative in astrocytes after TBI and demonstrate that the gp130-Jak2-STAT3 signaling pathway is activated after TBI in astrocytes.	[Oliva, Anthony A., Jr.; Kang, Yuan; Sanchez-Molano, Juliana; Furones, Concepcion; Atkins, Coleen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA.	catkins@med.miami.edu		Atkins, Coleen/0000-0003-4718-7493	Miami Project to Cure Paralysis; Buoniconti Fund to Cure Paralysis	This work was supported by The Miami Project to Cure Paralysis and The Buoniconti Fund to Cure Paralysis. The authors declare no conflict of interest. We thank Drs Ina Wanner, Valerie Bracchi-Ricard, W. Dalton Dietrich and Michael Norenberg for critical reading of the manuscript.	Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; Beurel E, 2008, J BIOL CHEM, V283, P21934, DOI 10.1074/jbc.M802481200; Brantley EC, 2008, MOL CANCER RES, V6, P675, DOI 10.1158/1541-7786.MCR-07-2180; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Choi JS, 2003, GLIA, V41, P237, DOI 10.1002/glia.10186; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Dawn B, 2004, CARDIOVASC RES, V64, P61, DOI 10.1016/j.cardiores.2004.05.011; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DiNapoli VA, 2010, NEUROSCIENCE, V170, P633, DOI 10.1016/j.neuroscience.2010.07.011; Dziennis S, 2007, J NEUROSCI, V27, P7268, DOI 10.1523/JNEUROSCI.1558-07.2007; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Fischer P, 2004, BIOCHEM J, V378, P449, DOI 10.1042/BJ20030893; Gahm C, 2000, NEUROSURGERY, V46, P169; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Glezer I, 2010, BRAIN BEHAV IMMUN, V24, P695, DOI 10.1016/j.bbi.2010.01.005; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gurney KJ, 2006, NEUROBIOL DIS, V23, P87, DOI 10.1016/j.nbd.2006.02.006; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Ishikawa K, 1999, J TRAUMA, V46, P999, DOI 10.1097/00005373-199906000-00004; Jung JE, 2009, J NEUROSCI, V29, P7003, DOI 10.1523/JNEUROSCI.1110-09.2009; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Kim EJ, 2008, J CEREBR BLOOD F MET, V28, P1329, DOI 10.1038/jcbfm.2008.26; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kim YS, 2005, J NEUROSCI, V25, P3701, DOI 10.1523/JNEUROSCI.4346-04.2005; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Laird AD, 2003, MOL CANCER THER, V2, P461; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leibinger M, 2009, J NEUROSCI, V29, P14334, DOI 10.1523/JNEUROSCI.2770-09.2009; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Morikawa Yoshihiro, 2005, Anatomical Science International, V80, P53, DOI 10.1111/j.1447-073x.2005.00100.x; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Na YJ, 2007, J NEUROCHEM, V103, P637, DOI 10.1111/j.1471-4159.2007.04769.x; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Planas AM, 1996, EUR J NEUROSCI, V8, P2612, DOI 10.1111/j.1460-9568.1996.tb01556.x; Qin HW, 2008, J IMMUNOL, V181, P3167, DOI 10.4049/jimmunol.181.5.3167; Qiu J, 2005, J NEUROSCI, V25, P1645, DOI 10.1523/JNEUROSCI.3269-04.2005; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Rychli K, 2010, J THROMB HAEMOST, V8, P596, DOI 10.1111/j.1538-7836.2010.03741.x; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; Shyu WC, 2008, J CLIN INVEST, V118, P133, DOI 10.1172/JCI32723; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Suzuki S, 2005, J CEREBR BLOOD F MET, V25, P685, DOI 10.1038/sj.jcbfm.9600061; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Weiss TW, 2006, FASEB J, V20, P2369, DOI 10.1096/fj.06-5850fje; Wen TC, 2001, NEUROSCI LETT, V303, P153, DOI 10.1016/S0304-3940(01)01711-6; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Xia X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018282; Yamashita T, 2005, J NEUROCHEM, V94, P459, DOI 10.1111/j.1471-4159.2005.03227.x; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019; Yu JH, 2006, BIOCHEM PHARMACOL, V72, P1555, DOI 10.1016/j.bcp.2006.07.008; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	78	59	60	1	11	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3042			J NEUROCHEM	J. Neurochem.	MAR	2012	120	5					710	720		10.1111/j.1471-4159.2011.07610.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	895NQ	WOS:000300503400007	22145815	Bronze			2021-06-18	
J	Tran, HT; Sanchez, L; Brody, DL				Tran, Hien T.; Sanchez, Laura; Brody, David L.			Inhibition of JNK by a Peptide Inhibitor Reduces Traumatic Brain Injury-Induced Tauopathy in Transgenic Mice	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						c-Jun N-terminal kinase; Controlled cortical impact; D-JNKil; Kinase; Phosphorylation; Tau; Traumatic brain injury	DEPENDENT PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; PHOSPHORYLATES TAU-PROTEIN; ALZHEIMER-DISEASE BRAIN; REPETITIVE HEAD-INJURY; DIFFUSE AXONAL INJURY; BETA-AMYLOID PROTEIN; IN-VIVO; NEUROFIBRILLARY TANGLES; MOUSE MODEL	Traumatic brain injury (TBI) is a major environmental risk factor for subsequent development of Alzheimer disease (AD). Pathological features that are common to AD and many tauopathies are neurofibrillary tangles (NFTs) and neuropil threads composed of hyperphosphorylated tau. Axonal accumulations of total and phospho-tau have been observed within hours to weeks, and intracytoplasmic NFTs have been documented years after severe TBI in humans. We previously reported that controlled cortical impact TBI accelerated tau pathology in young 3xTg-AD mice. Here, we used this TBI mouse model to investigate mechanisms responsible for increased tau phosphorylation and accumulation after brain trauma. We found that TBI resulted in abnormal axonal accumulation of several kinases that phosphorylate tau. Notably, c-Jun N-terminal kinase (JNK) was markedly activated in injured axons and colocalized with phospho-tau. We found that moderate reduction of JNK activity (40%) by a peptide inhibitor, D-JNKil, was sufficient to reduce total and phospho-tau accumulations in axons of these mice with TBI. Longer-term studies will be required to determine whether reducing acute tau pathology proves beneficial in brain trauma.	[Tran, Hien T.; Sanchez, Laura; Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Brody, David L.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 S Euclid, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065069, K08 NS049237]; Wellcome Career Award in the Biomedical Sciences; Thrasher Research Fund; NIH Neuroscience Blueprint Interdisciplinary Center [P30 NS057105]; Office of Undergraduate Research Award at Washington University; Alafi Neuroimaging facility; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237, P30NS057105, R01NS065069] Funding Source: NIH RePORTER	This work was supported by NIH R01 NS065069 (David L. Brody), NIH K08 NS049237 (Brody), a Burroughs Wellcome Career Award in the Biomedical Sciences (David L. Brody), the Thrasher Research Fund (Brody), the Alafi Neuroimaging facility and the NIH Neuroscience Blueprint Interdisciplinary Center Core Grant P30 NS057105 to Washington University, and the Office of Undergraduate Research Award at Washington University (Laura Sanchez).	ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Anderton BH, 1998, PROG NEUROBIOL, V55, P595, DOI 10.1016/S0301-0082(98)00022-7; Arendt T, 1998, NEUROBIOL AGING, V19, P3, DOI 10.1016/S0197-4580(98)00003-7; Averill S, 2001, MOL CELL NEUROSCI, V18, P183, DOI 10.1006/mcne.2001.1015; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Ballatore C, 2010, J MED CHEM, V53, P3739, DOI 10.1021/jm100138f; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brunden KR, 2010, J NEUROSCI, V30, P13861, DOI 10.1523/JNEUROSCI.3059-10.2010; Brunden KR, 2009, NAT REV DRUG DISCOV, V8, P783, DOI 10.1038/nrd2959; Buee-Scherrer V, 2002, FEBS LETT, V515, P151, DOI 10.1016/S0014-5793(02)02460-2; Cavalli V, 2005, J CELL BIOL, V168, P775, DOI 10.1083/jcb.200410136; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Cohen TJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1255; Colombo A, 2007, CELL DEATH DIFFER, V14, P1845, DOI 10.1038/sj.cdd.4402202; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gerdts J, 2011, J BIOL CHEM, V286, P28011, DOI 10.1074/jbc.M111.250472; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; Goedert M, 2005, BBA-MOL BASIS DIS, V1739, P240, DOI 10.1016/j.bbadis.2004.08.007; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Hernandez F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2011, BRAIN PATHOL, P12; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kanaan NM, 2011, J NEUROSCI, V31, P9858, DOI 10.1523/JNEUROSCI.0560-11.2011; Kim J, 2009, NEURON, V64, P632, DOI 10.1016/j.neuron.2009.11.013; Kins S, 2001, J BIOL CHEM, V276, P38193; Kyriakis JM, 2001, PHYSIOL REV, V81, P807; Leroy K, 2002, ACTA NEUROPATHOL, V103, P91; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Merrick SE, 1997, J NEUROSCI, V17, P5726; Middlemas A, 2003, BRAIN, V126, P1671, DOI 10.1093/brain/awg150; Miller BR, 2009, NAT NEUROSCI, V12, P387, DOI 10.1038/nn.2290; Min SW, 2010, NEURON, V67, P953, DOI 10.1016/j.neuron.2010.08.044; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Reynolds AJ, 2001, NEUROSCIENCE, V105, P761, DOI 10.1016/S0306-4522(01)00235-4; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTSON J, 1993, DEMENTIA, V4, P256, DOI 10.1159/000107331; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Silva RM, 2005, MOVEMENT DISORD, V20, P653, DOI 10.1002/mds.20390; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tseng HC, 2002, FEBS LETT, V523, P58, DOI 10.1016/S0014-5793(02)02934-4; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Virdee K, 2007, FEBS LETT, V581, P2657, DOI 10.1016/j.febslet.2007.05.009; Vogel J, 2009, NEUROPHARMACOLOGY, V57, P539, DOI 10.1016/j.neuropharm.2009.07.021; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; Yoshida H, 2004, J NEUROCHEM, V90, P352, DOI 10.1111/j.1471-4159.2004.02479.x; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	97	59	63	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	FEB	2012	71	2					116	129		10.1097/NEN.0b013e3182456aed			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	879IQ	WOS:000299323300003	22249463	Green Accepted			2021-06-18	
J	Zlotnik, A; Sinelnikov, I; Gruenbaum, BF; Gruenbaum, SE; Dubilet, M; Dubilet, E; Leibowitz, A; Ohayon, S; Regev, A; Boyko, M; Shapira, Y; Teichberg, VI				Zlotnik, Alexander; Sinelnikov, Igor; Gruenbaum, Benjamin F.; Gruenbaum, Shaun E.; Dubilet, Michael; Dubilet, Elena; Leibowitz, Akiva; Ohayon, Sharon; Regev, Adi; Boyko, Matthew; Shapira, Yoram; Teichberg, Vivian I.			Effect of Glutamate and Blood Glutamate Scavengers Oxaloacetate and Pyruvate on Neurological Outcome and Pathohistology of the Hippocampus after Traumatic Brain Injury in Rats	ANESTHESIOLOGY			English	Article							CLOSED-HEAD-INJURY; CORTICAL CONTUSION INJURY; EXCITATORY AMINO-ACIDS; LONG-TERM OUTCOMES; CEREBROSPINAL-FLUID; EXPERIMENTAL-MODELS; COGNITIVE DEFICITS; ISCHEMIC-STROKE; NEURONAL LOSS; RELEASE	Background: Decreasing blood glutamate concentrations after traumatic brain injury accelerates brain-to-blood glutamate efflux, leading to improved neurologic outcomes. The authors hypothesize that treatment with blood glutamate scavengers should reduce neuronal cell loss, whereas administration of glutamate should worsen outcomes. The authors performed histologic studies of neuronal survival in the rat hippocampus after traumatic brain injury and treatment with blood glutamate scavengers. Methods: Traumatic brain injury was induced on anesthetized male Sprague-Dawley rats by a standardized weight drop. Intravenous treatment groups included saline (control), oxaloacetate, pyruvate, and glutamate. Neurologic outcome was assessed using a Neurological Severity Score at 1 h, and 1, 2, 7, 14, 21, 28 days. Blood glutamate was determined at baseline and 90 min. Four weeks after traumatic brain injury, a histologic analysis of surviving neurons was performed. Results: Oxaloacetate and pyruvate treatment groups demonstrated increased neuronal survival (oxaloacetate 2,200 +/- 37, pyruvate 2,108 +/- 137 vs. control 1,978 +/- 46, P < 0.001, mean +/- SD). Glutamate treatment revealed decreased neuronal survival (1,715 +/- 48, P < 0.001). Treatment groups demonstrated favorable neurologic outcomes at 24 and 48 h (Neurological Severity Score at 24 and 48 h: 5.5 (1-8.25), 5 (1.75-7.25), P = 0.02 and 3(1-6.5), 4 (1.75-4.5), P = 0.027, median +/- corresponding interquartile range). Blood glutamate concentrations were decreased in the oxaloacetate and pyruvate treatment groups. Administration of oxaloacetate and pyruvate was not shown to have any adverse effects. Conclusions: The authors demonstrate that the blood glutamate scavengers oxaloacetate and pyruvate provide neuro-protection after traumatic brain injury, expressed both by reduced neuronal loss in the hippocampus and improved neurologic outcomes. The findings of this study may bring about new therapeutic possibilities in a variety of clinical settings.	[Zlotnik, Alexander] Ben Gurion Univ Negev, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; [Zlotnik, Alexander; Gruenbaum, Benjamin F.; Dubilet, Michael; Leibowitz, Akiva; Ohayon, Sharon; Regev, Adi; Boyko, Matthew; Shapira, Yoram] Soroka Univ Med Ctr, Dept Anesthesiol & Crit Care, Beer Sheva, Israel; [Sinelnikov, Igor; Dubilet, Elena] Soroka Univ Med Ctr, Dept Pathol, Beer Sheva, Israel; [Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Gruenbaum, Shaun E.] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA	Zlotnik, A (corresponding author), Ben Gurion Univ Negev, Soroka Med Ctr, IL-84105 Beer Sheva, Israel.	zlotnika@bgu.ac.il	Leibowitz, Akiva/F-1397-2012	Boyko, Matthew/0000-0003-3116-1643; Leibowitz, Akiva/0000-0003-4244-1915	Ben-Gurion University of the Negev, Beer-Sheva, Israel; Nella and Leon Benoziyo Center for Neurological Diseases, Weizmann Institute of Science, Rehovot, Israel; Carl and Micaela Einhorn-Dominic Institute for Brain Research, Weizmann Institute of Science; Irwin Green Alzheimer's Research Fund, Detroit, Michigan; Nursing, Critical Care Unit, Soroka Medical Center, Beer Sheva, Israel	Received from the Department of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel. Submitted for publication August 18, 2010. Accepted for publication September 26, 2011. Supported by Ben-Gurion University of the Negev, Beer-Sheva, Israel; Nella and Leon Benoziyo Center for Neurological Diseases, Weizmann Institute of Science, Rehovot, Israel; Carl and Micaela Einhorn-Dominic Institute for Brain Research, Weizmann Institute of Science; and Irwin Green Alzheimer's Research Fund, Detroit, Michigan. Dr. Teichberg was the incumbent of the Louis and Florence Katz Cohen Professorial Chair of Neuropharmacology, Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel. The data obtained are part of Matthew Boyko's doctoral thesis. Drs. Zlotnik and Sinelnikov contributed equally to the article.; The authors gratefully acknowledge the help of Shira Ovadia, D.V.M., Director of the Animal Resources Unit, Faculty of Health Sciences, Ben-Gurion University, Beer Sheva, Israel. The authors also thank Adina Elir, R.N., M.A., Director of Nursing, Critical Care Unit, Soroka Medical Center, Beer Sheva, Israel, for her support and helpful discussions.	BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; BERL S, 1962, J BIOL CHEM, V237, P2562; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Cosar M, 2009, SURG NEUROL, V71, P54, DOI 10.1016/j.surneu.2007.08.020; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Desagher S, 1997, J NEUROSCI, V17, P9060; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; GRAHAM LT, 1966, ANAL BIOCHEM, V15, P487, DOI 10.1016/0003-2697(66)90110-2; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Klin Y, 2010, BIOCHEM BIOPH RES CO, V399, P694, DOI 10.1016/j.bbrc.2010.07.144; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Koura SS, 1998, ACT NEUR S, V71, P244; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prieto R, 2009, NEUROCIRUGIA, V20, P225; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zlotnik A, 2009, J NEUROSURG ANESTH, V21, P235, DOI 10.1097/ANA.0b013e3181a2bf0b	51	59	60	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JAN	2012	116	1					73	83		10.1097/ALN.0b013e31823d7731			11	Anesthesiology	Anesthesiology	869OU	WOS:000298608400012	22129535	Bronze			2021-06-18	
J	Amen, DG; Newberg, A; Thatcher, R; Jin, Y; Wu, J; Keator, D; Willeumier, K				Amen, Daniel G.; Newberg, Andrew; Thatcher, Robert; Jin, Yi; Wu, Joseph; Keator, David; Willeumier, Kristen			Impact of Playing American Professional Football on Long-Term Brain Function	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; CLOSED-HEAD INJURY; EEG PHASE RESET; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; PERFORMANCE; DEPRESSION; PLAYERS; SPECT; MILD	The authors recruited 100 active and former National Football League players, representing 27 teams and all positions. Players underwent a clinical history, brain SPECT imaging, qEEG, and multiple neuropsychological measures, including MicroCog. Relative to a healthy-comparison group, players showed global decreased perfusion, especially in the prefrontal, temporal, parietal, and occipital lobes, and cerebellar regions. Quantitative EEG findings were consistent, showing elevated slow waves in the frontal and temporal regions. Significant decreases from normal values were found in most neuropsychological tests. This is the first large-scale brain-imaging study to demonstrate significant differences consistent with a chronic brain trauma pattern in professional football players. (The Journal of Neuropsychiatry and Clinical Neurosciences 2011; 23:98-106)	[Amen, Daniel G.; Willeumier, Kristen] Amen Clin Inc, Newport Beach, CA 92660 USA; [Newberg, Andrew] Thomas Jefferson Univ & Hosp, Myrna Brind Ctr Integrat Med, Philadelphia, PA USA; [Wu, Joseph; Keator, David] Univ Calif Irvine, Irvine, CA 92717 USA	Amen, DG (corresponding author), Amen Clin Inc, 4019 Westerly Pl,Suite 100, Newport Beach, CA 92660 USA.	docamen@amenclinic.com		Keator, David/0000-0001-5281-5576; Newberg, Andrew/0000-0001-8230-1752			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ALEXANDER GE, 1995, J NEUROPSYCH CLIN N, V7, P188; Amen DG, 2009, J NEUROPSYCH CLIN N, V21, P430, DOI 10.1176/appi.neuropsych.21.4.430; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; BAVETTA S, 1994, NUCL MED COMMUN, V15, P961, DOI 10.1097/00006231-199412000-00007; BOUTROS N, 2008, AM PSYCHIAT TXB NEUR; *CDCP, 1997, SPORTS REL REC BRAIN; Centers for Disease Control and Prevention, 2010, OB HALT EP MAK HLTH; *CNN, HOUS PAN CONS BRAIN; Conners CK, 2003, J ABNORM CHILD PSYCH, V31, P555, DOI 10.1023/A:1025457300409; Conners K, CONNERS CPT 2 V 5; Dubroff JG, 2008, SEMIN NEUROL, V28, P548, DOI 10.1055/s-0028-1083698; Ferguson G., 1976, STAT ANAL PSYCHOL ED; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; JOHN ER, 1977, FUNCTIONAL NEUROSCIE, V2; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Mayberg HS, 1997, NEUROREPORT, V8, P1057, DOI 10.1097/00001756-199703030-00048; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medical Care Corporation, 2007, MILD COGN IMP SCREEN; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; Nunez P., 1981, ELECT FIELDS BRAIN; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Ommaya AK, 1968, J BIOMECH; Powell D, 2004, MICROCOG ASSESSMENT; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Shankle WR, 2009, ALZHEIMERS DEMENT, V5, P295, DOI 10.1016/j.jalz.2008.11.001; Tana M G, 2010, Comput Intell Neurosci, P329213, DOI 10.1155/2010/329213; Thatcher RW, 2008, NEUROIMAGE, V42, P1639, DOI 10.1016/j.neuroimage.2008.06.009; Thatcher RW, 2005, CLIN EEG NEUROSCI, V36, P116, DOI 10.1177/155005940503600211; Thatcher R. W., 2003, Journal of Neurotherapy, V7, P87, DOI 10.1300/J184v07n03_05; Thatcher RW, 2009, HUM BRAIN MAPP, V30, P553, DOI 10.1002/hbm.20524; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Trenkle DL, 2007, J ALZHEIMERS DIS, V11, P323; Tucker AM, 2009, JAMA-J AM MED ASSOC, V301, P2111, DOI 10.1001/jama.2009.716; Weir D. R., 2009, STUDY RETIRED NFL PL	42	59	59	1	36	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2011	23	1					98	106		10.1176/appi.neuropsych.23.1.98			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	717VY	WOS:000287076700038	21304145				2021-06-18	
J	Wade, SL; Walz, NC; Carey, J; McMullen, KM; Cass, J; Mark, E; Yeates, KO				Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; McMullen, Kendra M.; Cass, Jennifer; Mark, Erin; Yeates, Keith Owen			Effect on Behavior Problems of Teen Online Problem-Solving for Adolescent Traumatic Brain Injury	PEDIATRICS			English	Article						adolescents; traumatic brain injury; telehealth; behavioral interventions	FAMILY; CHILDREN; PREDICTORS; CHILDHOOD; EFFICACY	PURPOSE: To report the results of a randomized clinical trial of teen online problem-solving (TOPS) meant to improve behavioral outcomes of adolescents with traumatic brain injury (TBI). METHODS: A randomized clinical trial was conducted to compare the efficacy of TOPS with access to Internet resources in teenagers with TBI in improving parent and self-reported behavior problems and parentteen conflicts. Participants included 41 adolescents aged 11 to 18 years (range: 11.47-17.90 years) who had sustained a moderate-to-severe TBI between 3 and 19 months earlier. Teens in the TOPS group received 10 to 14 online sessions that provided training in problem-solving, communication skills, and self-regulation. Outcomes were assessed before treatment and at a follow-up assessment an average of 8 months later. Groups were compared on follow-up scores after we controlled for pretreatment levels. Injury severity and socioeconomic status were examined as potential moderators of treatment efficacy. RESULTS: Forty-one participants provided consent and completed baseline assessments, and follow-up assessments were completed for 35 participants (16 TOPS, 19 Internet resource comparison). The TOPS group reported significantly less parent-teen conflict at follow-up than did the Internet-resource-comparison group. Improvements in teen behavior after TOPS were moderated by injury severity; there were greater improvements in the teens' internalizing symptoms after TOPS among adolescents with severe TBI. Family socioeconomic status also moderated the efficacy of TOPS in improving behavior problems reported by both parents and teens, although the nature of the moderation effects varied. CONCLUSION: Our findings suggest that TOPS contributes to improvements in parent-teen conflict generally and parent and self-reported teen behavior problems for certain subsets of participants. Pediatrics 2011; 128: e947-e953	[Wade, Shari L.] Univ Cincinnati, Cincinnati Childrens Hosp, Dept Pediat, Med Ctr,Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Cass, Jennifer; Mark, Erin; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Cass, Jennifer; Mark, Erin; Yeates, Keith Owen] Nationwide Childrens Hosp, Ctr Biobehav Hlth, Res Inst, Columbus, OH USA; [Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; McMullen, Kendra M.] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA	Wade, SL (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Dept Pediat, Med Ctr,Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Disability and Rehabilitation Research [H133G050239]; US Department of Education and Emergency Medical Services from the Ohio Department of Safety [10503]	This work was supported by National Institute of Disability and Rehabilitation Research grant H133G050239 (to Dr Wade) and US Department of Education and Emergency Medical Services grant 10503 from the Ohio Department of Safety.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V., 2010, PEDIAT TRAUMATIC BRA, P179; Foster SL., 1989, NEGOTIATING PARENT A; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007	15	59	59	0	12	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	OCT	2011	128	4					E947	E953		10.1542/peds.2010-3721			7	Pediatrics	Pediatrics	827DH	WOS:000295406800021	21890828	Green Published			2021-06-18	
J	Yang, R; Fredman, G; Krishnamoorthy, S; Agrawal, N; Irimia, D; Piomelli, D; Serhan, CN				Yang, Rong; Fredman, Gabrielle; Krishnamoorthy, Sriram; Agrawal, Nitin; Irimia, Daniel; Piomelli, Daniele; Serhan, Charles N.			Decoding Functional Metabolomics with Docosahexaenoyl Ethanolamide (DHEA) Identifies Novel Bioactive Signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANNABINOID RECEPTOR; WHOLE-BLOOD; FATTY-ACIDS; ANANDAMIDE; ENDOCANNABINOIDS; PLATELETS; INJURY; BINDS; D1; INFLAMMATION	Neuroinflammation and traumatic brain injury involve activation of inflammatory cells and production of local pro-inflammatory mediators that can amplify tissue damage. Using LC-UV-MS-MS-based lipidomics in tandem with functional screening at the single-cell level in microfluidic chambers, we identified a series of novel bioactive oxygenated docosahexaenoyl ethanolamide( DHEA) derived products that regulated leukocyte motility. These included 10,17-dihydroxydocosahexaenoyl ethanolamide (10,17-diHDHEA) and 15-hydroxy-16(17)-epoxy-docosapentaenoyl ethanolamide (15-HEDPEA), each of which was an agonist of recombinant CB2 receptors with EC50 3.9 X 10(-10) and 1.0 X 10(-10)M. In human whole blood, 10,17-diHDHEA and 15-HEDPEA at concentrations as low as 10 pM each prevented formation of platelet-leukocyte aggregates involving either platelet-monocyte or platelet-polymorphonuclear leukocyte. In vivo, 15-HEDPEA was organ-protective in mouse reperfusion second organ injury. Together these results indicate that DHEA oxidative metabolism produces potent novel molecules with anti-inflammatory and organ-protective properties.	[Yang, Rong; Fredman, Gabrielle; Krishnamoorthy, Sriram; Serhan, Charles N.] Brigham & Womens Hosp, Harvard Inst Med, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Yang, Rong; Fredman, Gabrielle; Krishnamoorthy, Sriram; Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Agrawal, Nitin; Irimia, Daniel] Shriners Hosp Children, Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02129 USA; [Agrawal, Nitin; Irimia, Daniel] Harvard Univ, Sch Med, Boston, MA 02129 USA; [Piomelli, Daniele] Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92617 USA; [Piomelli, Daniele] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92617 USA; [Piomelli, Daniele] Italian Inst Technol, I-16163 Genoa, Italy	Serhan, CN (corresponding author), Brigham & Womens Hosp, Harvard Inst Med, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 829,77 Ave Louis Pasteur, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Irimia, Daniel/S-5404-2019; Irimia, Daniel/A-4095-2008	Irimia, Daniel/0000-0001-7347-2082; Irimia, Daniel/0000-0001-7347-2082	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS067686, RC2AT005909, R01DE019938]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine [RC2AT005909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE019938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM092804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067686] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grants R01NS067686 (to C. N. S.), RC2AT005909 (to C. N. S.), and R01DE019938 (to C. N. S. and D. I.).	Arnason BG, 2010, NEUROIMMUNE, V9, P1; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131; Berger A, 2001, P NATL ACAD SCI USA, V98, P6402, DOI 10.1073/pnas.101119098; Calder PC, 2010, P NUTR SOC, V69, P565, DOI 10.1017/S0029665110000157; De Petrocellis L, 2000, CHEM PHYS LIPIDS, V108, P191, DOI 10.1016/S0009-3084(00)00196-1; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Dona M, 2008, BLOOD, V112, P848, DOI 10.1182/blood-2007-11-122598; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; Franklin A, 2003, J NEUROSCI, V23, P7767; Furman MI, 2001, J AM COLL CARDIOL, V38, P1002, DOI 10.1016/S0735-1097(01)01485-1; Hassan IR, 2009, J IMMUNOL, V182, P3223, DOI 10.4049/jimmunol.0802064; Irimia D, 2006, LAB CHIP, V6, P191, DOI 10.1039/b511877h; Kasuga K, 2008, J IMMUNOL, V181, P8677, DOI 10.4049/jimmunol.181.12.8677; KILGORE KS, 1999, REPERFUSION INJURY; Kim HY, 2011, BIOCHEM J, V435, P327, DOI 10.1042/BJ20102118; Kozak KR, 2002, PROSTAG LEUKOTR ESS, V66, P211, DOI 10.1054/plef.2001.0359; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; KUMAR V, 2004, ROBBINS COTRAN PATHO; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Nishiura H, 1996, J BIOL CHEM, V271, P878, DOI 10.1074/jbc.271.2.878; Olson KR, 2007, ASSAY DRUG DEV TECHN, V5, P137, DOI 10.1089/adt.2006.052; Pace-Asciak CR, 1999, ADV EXP MED BIOL, V447, P123; Pavlopoulos S, 2006, CURR PHARM DESIGN, V12, P1751, DOI 10.2174/138161206776873743; PREISSNER WC, 1983, BRIT J DERMATOL, V109, P1, DOI 10.1111/j.1365-2133.1983.tb03984.x; Qiu FH, 2000, P NATL ACAD SCI USA, V97, P4267, DOI 10.1073/pnas.97.8.4267; RINDER HM, 1991, BLOOD, V78, P1730; ROWLEY FA, 1998, EICOSANOIDS; Sarma J, 2002, CIRCULATION, V105, P2166, DOI 10.1161/01.CIR.0000015700.27754.6F; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Sheskin T, 1997, J MED CHEM, V40, P659, DOI 10.1021/jm960752x; Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541; Tjonahen E, 2006, CHEM BIOL, V13, P1193, DOI 10.1016/j.chembiol.2006.09.011; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; van Gils JM, 2009, J LEUKOCYTE BIOL, V85, P195, DOI 10.1189/jlb.0708400; Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003; Xu ZZ, 2010, NAT MED, V16, P592, DOI 10.1038/nm.2123; Yanes O, 2010, NAT CHEM BIOL, V6, P411, DOI 10.1038/nchembio.364; YANG R, 2011, CURR PR S94 IN PRESS; Zygmunt PM, 1999, NATURE, V400, P452	42	59	60	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2011	286	36					31532	31541		10.1074/jbc.M111.237990			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	814WI	WOS:000294487500048	21757729	Green Published, Other Gold			2021-06-18	
J	Mihalik, JP; Guskiewicz, KM; Marshall, SW; Greenwald, RM; Blackburn, JT; Cantu, RC				Mihalik, Jason P.; Guskiewicz, Kevin M.; Marshall, Stephen W.; Greenwald, Richard M.; Blackburn, J. Troy; Cantu, Robert C.			Does Cervical Muscle Strength in Youth Ice Hockey Players Affect Head Impact Biomechanics?	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						youth athlete; biomechanics; concussion; helmets; traumatic brain injury	SEGMENT DYNAMIC STABILIZATION; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; SPORTS; CONCUSSION; SEVERITY; FOOTBALL; RISK	Objective: To evaluate the effect of cervical muscle strength on head impact biomechanics. Design: Prospective cohort. Setting: Field setting. Participants: Thirty-seven volunteer ice hockey players (age = 15.0 +/- 1.0 years, height = 173.5 +/- 6.2 cm, mass = 66.6 +/- 9.0 kg, playing experience = 2.9 +/- 3.7 years). Interventions: Participants were equipped with accelerometer-instrumented helmets to collect head impact biomechanics (linear and rotational acceleration) throughout an entire playing season. Before the season, isometric cervical muscle strength was measured for the anterior neck flexors, anterolateral neck flexors, cervical rotators, posterolateral neck extensors, and upper trapezius. Data were analyzed using random intercept general mixed linear models, with each individual player as a repeating factor/cluster. Main Outcome Measures: Dependent variables included linear and rotational head accelerations. Cervical strength data were categorized into tertiles, creating groups with high, moderate, and low strength. Strength measures were averaged and normalized to body mass. Results: Significant differences in cervical muscle strength existed across our strength groups (P < 0.05). No differences were observed in linear or rotational acceleration across strength groups for the anterior neck flexors (P-Lin = 0.399; P-Rot = 0.060), anterolateral neck flexors (P-Lin = 0.987; PRot = 0.579), cervical rotators (P-Lin = 0.136; P-Rot = 0.238), posterolateral neck extensors (P-Lin = 0.883; P-Rot = 0.101), or upper trapezius (P-Lin = 0.892; P-Rot = 0.689). Conclusions: Our hypothesis that players with greater static neck strength would experience lower resultant head accelerations was not supported. This contradicts the notion that cervical muscle strength mitigates head impact acceleration. Because we evaluated cervical strength isometrically, future studies should consider dynamic (ie, isokinetic) methods in the context of head impact biomechanics.	[Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Guskiewicz, Kevin M.; Blackburn, J. Troy] Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Blackburn, J. Troy] Univ N Carolina, Dept Exercise & Sport Sci, Neuromuscular Res Lab, Chapel Hill, NC 27599 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Sport Med, Concord, MA USA	Mihalik, JP (corresponding author), Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, 313 Woollen Gymnasium,Campus Box 8605, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233	Ontario Neurotrauma Foundation (Toronto, Ontario, Canada); USA Hockey Foundation (Colorado Springs, Colorado); National Operating Committee on Standards for Athletic Equipment (Overland Park, Kansas)	Supported by the Ontario Neurotrauma Foundation (Toronto, Ontario, Canada), the USA Hockey Foundation (Colorado Springs, Colorado), and the National Operating Committee on Standards for Athletic Equipment (Overland Park, Kansas).	Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hislop HJ, 1986, DANIELS WORTHINGHAMS; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kendall FM, 1993, MUSCLES TESTING FUNC; Mansell J, 2005, J ATHL TRAINING, V40, P310; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Ono K, 1996, ACCIDENT ANAL PREV, V28, P493, DOI 10.1016/0001-4575(96)00019-X; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Seng KY, 2003, AVIAT SPACE ENVIR MD, V74, P164; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA	18	59	59	1	36	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2011	21	5					416	421		10.1097/JSM.0B013E31822C8A5C			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	814VJ	WOS:000294485000006	21892015				2021-06-18	
J	Matsushita, M; Hosoda, K; Naitoh, Y; Yamashita, H; Kohmura, E				Matsushita, Makoto; Hosoda, Kohkichi; Naitoh, Yasuo; Yamashita, Haruo; Kohmura, Eiji			Utility of diffusion tensor imaging in the acute stage of mild to moderate traumatic brain injury for detecting white matter lesions and predicting long-term cognitive function in adults Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cognitive dysfunction; diffuse brain injury; diffusion tensor imaging; magnetic resonance imaging; traumatic brain injury	AXONAL INJURY; CORPUS-CALLOSUM; HEAD-INJURY; CLASSIFICATION; PERFORMANCE; P300	Object. Traumatic brain injury (TBI) often impairs cognitive function. Diffusion tensor (DT) imaging, a novel modality, permits evaluation of the effects of head trauma on white matter nerve fibers. The objectives of the current study were to investigate where the white matter injury following mild to moderate TBI is specifically located on DT imaging in the acute disease stage and to examine the relationship between the severity of the white matter lesion on DT imaging in the acute stage of TBI and future cognitive function in the chronic disease stage. Methods. Twenty adult patients with mild to moderate TBI (Glasgow Coma Scale score between 9 and 15) underwent conventional MR and DT imaging a median of 3.5 days after injury, and 27 matched healthy controls also underwent both imaging modalities. The patients with TBI were further subdivided into 2 groups, that is, mild and more severe TBI groups, based on clinical (mild or moderate TBI), CT (diffuse brain injury [DBI] I or II), or MR imaging (normal or pathological appearance) classification. Fractional anisotropies (FAs) were compared between patients and controls using the region of interest method. Regions of interest were located in 8 different areas including the genu, stem, and splenium of the corpus callosum and the corona radiata (CR), anterior limb of the internal capsule (ALIC), posterior limb of the internal capsule (PLIC), frontal white matter (FWM), and occipital white matter (OWM) of the periventricular white matter. Eleven patients with TBI also underwent neuropsychological testing, which included the Trail Making Test, Wisconsin Card Sorting Test, Wechsler Adult Intelligence Scale-Revised, and P300 testing in the chronic disease stage (median 364 days). Results. Region of interest analysis demonstrated significantly lower FA values in the genu, stem, and splenium of the corpus callosum in more severe TBI groups (moderate TBI on clinical classification; DBI 11 on CT classification, and pathological appearance on MR imaging classification) than in controls. A significant difference was also observed in the FA of the splenium between controls and the mild TBI group of the clinical classification. No significant difference was observed in the FA of the CR, ALIC, PLIC, FWM, and OWM between controls and any of the TBI groups of clinical or imaging classifications. No significant difference was observed in the FA of any regions between mild and more severe TBI groups of the clinical or imaging classifications. Multiple regression analysis showed a statistically significant positive linear relationship between FA in the splenium and total IQ (r = 0.79, p = 0.004). A significant negative linear relationship between FA in the FWM and P300 latency was also observed (r = 0.62, p = 0.04). Conclusions. Fractional anisotropy reductions in the splenium and FWM in the acute stage of mild to moderate TBI may be a useful prognostic factor for long-term cognitive dysfunction. (DOI: 10.3171/2011.2.JNS101547)	[Hosoda, Kohkichi] Kobe Univ, Grad Sch Med, Dept Neurosurg, Chou Ku, Kobe, Hyogo 6500017, Japan; [Matsushita, Makoto; Yamashita, Haruo] Kobe Red Cross Hosp, Hyogo Emergency Med Ctr, Dept Neurosurg, Kobe, Hyogo, Japan; [Naitoh, Yasuo] Osaka Prefecture Univ, Sch Comprehens Rehabil, Osaka, Japan	Hosoda, K (corresponding author), Kobe Univ, Grad Sch Med, Dept Neurosurg, Chou Ku, 7-5-1 Kusunoki Chou, Kobe, Hyogo 6500017, Japan.	khosoda@med.kobe-u.ac.jp	Hosoda, Kohkichi/AAF-1949-2020		General Insurance Association of Japan [19591674]	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. This study was supported in part by a Grant-in-Aid for Scientific Research (KAKENHI) (19591674) and a medical research grant on traffic accidents from the General Insurance Association of Japan.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BROWN EC, 1958, J CONSULT PSYCHOL, V22, P469, DOI 10.1037/h0039980; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fujita K, 2006, JAPANESE VERSION WAI; GIL R, 1993, ELECTROEN CLIN NEURO, V88, P182, DOI 10.1016/0168-5597(93)90003-8; Hawkins KA, 2002, ARCH CLIN NEUROPSYCH, V17, P49, DOI 10.1016/S0887-6177(00)00099-8; Hayes JP, 2009, PSYCHIAT RES-NEUROIM, V172, P7, DOI 10.1016/j.pscychresns.2008.05.005; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kato M., 1988, KEIO IGAKU, V65, P861; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lee CEC, 2009, NEURORADIOLOGY, V51, P3, DOI 10.1007/s00234-008-0441-3; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu F, 2010, BRAIN RES, V1343, P37, DOI 10.1016/j.brainres.2010.04.064; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Naito Yasuo, 2005, Kobe Journal of Medical Sciences, V51, P95; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Shiramizu H, 2008, NEUROL MED-CHIR, V48, P1, DOI 10.2176/nmc.48.1; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	31	59	61	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2011	115	1					130	139		10.3171/2011.2.JNS101547			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	782JO	WOS:000292004700027	21417709				2021-06-18	
J	Scudday, T; Brasel, K; Webb, T; Codner, P; Somberg, L; Weigelt, J; Herrmann, D; Peppard, W				Scudday, Travis; Brasel, Karen; Webb, Travis; Codner, Panna; Somberg, Lewis; Weigelt, John; Herrmann, David; Peppard, William			Safety and Efficacy of Prophylactic Anticoagulation in Patients with Traumatic Brain Injury	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article; Proceedings Paper	118th Scientific Session of the Western-Surgical-Association	NOV 07-10, 2010	Chicago, IL	Western Surg Assoc			MOLECULAR-WEIGHT HEPARIN; INTRACRANIAL HEMORRHAGIC INJURIES; VENOUS THROMBOEMBOLISM; ENOXAPARIN PROPHYLAXIS; 1602 EPISODES; DATA-BANK; THROMBOSIS	BACKGROUND: Patients with traumatic brain injury (TBI) are at high risk for venous thromboembolism (VTE), but physicians are cautious with chemical prophylaxis in these patients because of concern about exacerbating intracranial hemorrhage. We hypothesized that early use of chemical thromboprophylaxis would reduce VTE incidence without increasing intracranial hemorrhage. STUDY DESIGN: Records of all patients admitted with a TBI to a Level I trauma center from 2006 to 2008 were reviewed. TBI was defined as intracranial hemorrhage, hematoma, contusion, or diffuse axonal injury with a head Abbreviated Injury Scale score >2. Patients were excluded if they were discharged or died within 72 hours of admission. Chemical prophylaxis was defined as subcutaneous or intravenous unfractionated heparin or low molecular weight heparin before any VTE diagnosis. Progression of TBI was defined by worsening CT findings. VTE was defined as deep venous thrombosis or pulmonary embolus confirmed by radiology reports. Primary outcomes were progression of hemorrhage and VTE events. RESULTS: Eight hundred and twelve of the 1,258 patients admitted to the trauma center with a TBI met study criteria. Chemical thromboprophylaxis was given to 49.5% (n = 402). Mean head Abbreviated Injury Scale score was 3.4 in both groups. One hundred and sixty-nine patients started prophylaxis within 48 hours and 242 patients began within 72 hours. Patients receiving chemical prophylaxis had a lower incidence of VTE (1% versus 3%; p = 0.019). Although not statistically significant, they also had a lower rate of injury progression, 3% versus 6% (p = 0.055). CONCLUSIONS: Use of chemical thromboprophylaxis in TBI patients with a stable or improved head CT after 24 hours substantially reduces the incidence of VTE and does not increase the risk of progression of intracranial hemorrhage. (J Am Coll Surg 2011; 213: 148-154. (C) 2011 by the American College of Surgeons)	[Scudday, Travis; Brasel, Karen; Webb, Travis; Codner, Panna; Somberg, Lewis; Weigelt, John] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Herrmann, David; Peppard, William] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Dept Pharm, Milwaukee, WI 53226 USA	Brasel, K (corresponding author), Med Coll Wisconsin, Dept Surg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	kbrasel@mcw.edu		Scudday, Travis/0000-0001-8865-492X			BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; *BRAIN TRAUM FDN A, 2007, J NEUROTRAUMA S1, V24, pS32, DOI DOI 10.1089/NEU.2007.9991; Brandt MM, 2007, AM J SURG, V193, P383; Cohn SM, 1999, VASCULAR SURG, V33, P219, DOI 10.1177/153857449903300219; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Depew AJ, 2008, AM SURGEON, V74, P906; Fowkes FJI, 2003, EUR J VASC ENDOVASC, V25, P1, DOI 10.1053/ejvs.2002.1778; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Hirsh J, 2001, CHEST, V119, p64S, DOI 10.1378/chest.119.1_suppl.64S; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Martinelli I, 2001, THROMB HAEMOSTASIS, V86, P395; Meissner MH, 2003, J TRAUMA, V54, P224, DOI 10.1097/01.TA.0000046253.33495.70; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Shackford SR, 2004, ANN SURG, V240, P496; Tominaga GT, 2002, ARCH SURG-CHICAGO, V137, P701; Tooher R, 2005, ANN SURG, V241, P397, DOI 10.1097/01.sla.0000154120.96169.99	20	59	63	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	JUL	2011	213	1					148	153		10.1016/j.jamcollsurg.2011.02.027			6	Surgery	Surgery	794SU	WOS:000292922400033	21459632				2021-06-18	
J	Chen, JL; Yeh, DP; Lee, JP; Chen, CY; Huang, CY; Lee, SD; Chen, CC; Kuo, TBJ; Kao, CL; Kuo, CH				Chen, Jui-Lien; Yeh, Ding-Peng; Lee, Jo-Ping; Chen, Chung-Yu; Huang, Chih-Yang; Lee, Shin-Da; Chen, Chiu-Chou; Kuo, Terry B. J.; Kao, Chung-Lan; Kuo, Chia-Hua			PARASYMPATHETIC NERVOUS ACTIVITY MIRRORS RECOVERY STATUS IN WEIGHTLIFTING PERFORMANCE AFTER TRAINING	JOURNAL OF STRENGTH AND CONDITIONING RESEARCH			English	Article						fatigue; weightlifter; strength performance; frequency-domain analysis; muscle power; vagal	HEART-RATE-VARIABILITY; TRAUMATIC BRAIN-INJURY; VAGAL-CARDIAC CONTROL; RESISTANCE EXERCISE; FUNCTIONAL RECOVERY; BLOOD-PRESSURE; DEHYDROEPIANDROSTERONE; HEALTH; MOOD; DHEA	Chen, J-L, Yeh, D-P, Lee, J-P, Chen, C-Y, Huang, C-Y, Lee, S-D, Chen, C-C, Kuo, TBJ, Kao, C-L, and Kuo, C-H. Parasympathetic nervous activity mirrors recovery status in weightlifting performance after training. J Strength Cond Res 25(6): 1546-1552, 2011-Heart rate variability (HRV) and parasympathetic power are closely related to the well-being and health status in humans. The main goal of the study was to determine whether these measures can reflect recovery status after weight training. After a 10-day detraining period, 7 weightlifters were challenged with a 2-hour weight training which elicited approximately fourfold increases in circulating muscle creatine kinase level and protracted pain feeling (p < 0.05). Weightlifting performance was then evaluated 3, 24, 48, and 72 hours after training to determine the degree of recovery from fatigue. Heart rate variability, circulating dehydroepiandrostendione sulfate (DHEA-S), and muscle damage markers were measured before each performance test. An electrocardiogram was recorded for 5 minutes continuously at rest in seated positions. After training, weightlifting performance of the subjects decreased below baseline in paralleled with suppressed parasympathetic power (high-frequency [HF] HRV), whereas sympathetic power (normalized low-frequency HRV) was slightly elevated at 3 hours of recovery (p < 0.05). Both weightlifting performances and parasympathetic power returned to baseline values in 24 hours and further increased above baseline during 48-72 hours of recovery in a similar fashion (p < 0.05). Circulating DHEA-S level dropped at 24 hours (p < 0.05) and returned to normal values by 48 hours. Muscle pain increased at 3 hours after training and remained higher than baseline values for the 72-hour recovery period (p < 0.05). Our data suggest that parasympathetic power, indicated by HF HRV, is able to reflect the recovery status of weightlifters after training.	[Chen, Jui-Lien; Yeh, Ding-Peng; Lee, Jo-Ping; Chen, Chung-Yu; Chen, Chiu-Chou; Kuo, Chia-Hua] Taipei Phys Educ Coll, Lab Exercise Biochem, Taipei, Taiwan; [Huang, Chih-Yang] China Med Univ, Grad Inst Chinese Med Sci, Grad Inst Basic Med Sci, Taichung, Taiwan; [Huang, Chih-Yang] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan; [Lee, Shin-Da; Kuo, Chia-Hua] China Med Univ, Grad Inst Rehabil Sci, Dept Phys Therapy, Taichung, Taiwan; [Lee, Shin-Da] Asia Univ, Dept Healthcare Adm, Taichung, Taiwan; [Kuo, Terry B. J.; Kao, Chung-Lan] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Kao, Chung-Lan] Taipei Vet Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan	Kuo, CH (corresponding author), Taipei Phys Educ Coll, Lab Exercise Biochem, Taipei, Taiwan.	clkao@vghtpe.gov.tw; kuochiahua@gmail.com	Yuang, Chih-Yang/O-5111-2015; Lee, Shin-Da/Q-2798-2015	Lee, Shin-Da/0000-0002-8393-8349; Kuo, Chia-Hua/0000-0002-1731-4984	National Science Council, Taipei, TaiwanMinistry of Science and Technology, Taiwan [NSC 96-2413-H-154-003-MY3]	This work was partly sponsored by a grant from the National Science Council (grant number: NSC 96-2413-H-154-003-MY3), Taipei, Taiwan. Conflict of interest: N/A.	AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Buchheit M, 2007, AM J PHYSIOL-HEART C, V293, pH133, DOI 10.1152/ajpheart.00062.2007; Burton AR, 2009, J PHYSIOL-LONDON, V587, P183, DOI 10.1113/jphysiol.2008.162230; Camm AJ, 1996, EUR HEART J, V17, P354; Carter JR, 2003, J APPL PHYSIOL, V94, P2212, DOI 10.1152/japplphysiol.01109.2002; Collier SR, 2009, ACTA PHYSIOL, V195, P339, DOI 10.1111/j.1748-1716.2008.01897.x; Cooke WH, 2005, EUR J APPL PHYSIOL, V93, P719, DOI 10.1007/s00421-004-1243-x; Figueroa A, 2008, CLIN PHYSIOL FUNCT I, V28, P49, DOI 10.1111/j.1475-097X.2007.00776.x; Garet M, 2004, MED SCI SPORT EXER, V36, P2112, DOI 10.1249/01.MSS.0000147588.28955.48; Gudemez E, 2002, MICROSURG, V22, P234, DOI 10.1002/micr.10039; Hanson EKS, 2001, BIOL PSYCHOL, V56, P23, DOI 10.1016/S0301-0511(01)00066-7; Hedelin R, 2001, MED SCI SPORT EXER, V33, P1394, DOI 10.1097/00005768-200108000-00023; Herbert J, 1998, EXP GERONTOL, V33, P713, DOI 10.1016/S0531-5565(98)00039-4; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Iellamo F, 2004, MED SCI SPORT EXER, V36, P1342, DOI 10.1249/01.MSS.0000135796.75091.8A; Karemaker JM, 2000, EUR HEART J, V21, P435, DOI 10.1053/euhj.1999.1969; KRISTALBONEH E, 1995, SCAND J WORK ENV HEA, V21, P85, DOI 10.5271/sjweh.15; Lee WC, 2006, HIGH ALT MED BIOL, V7, P228, DOI 10.1089/ham.2006.7.228; Liu T, 2009, ADAPT MED, V1, P24; Malik AS, 2003, J NEUROTRAUM, V20, P463, DOI 10.1089/089771503765355531; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; McCraty R, 1998, INTEGR PHYS BEH SCI, V33, P151, DOI 10.1007/BF02688660; Melo RC, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.035246; Montano N, 2000, HYPERTENSION, V36, P1029, DOI 10.1161/01.HYP.36.6.1029; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; SAYERS BM, 1973, ERGONOMICS, V16, P17; Straub RH, 2002, EUR J ENDOCRINOL, V146, P365, DOI 10.1530/eje.0.1460365; Taylor AC, 2003, MED SCI SPORT EXER, V35, P251, DOI 10.1249/01.MSS.0000048725.15026.B5; Tsai YM, 2006, LIFE SCI, V79, P1281, DOI 10.1016/j.lfs.2006.04.001; Wang HT, 2009, J SPORT SCI, V27, P291, DOI 10.1080/02640410802520810; Wang JS, 2009, STEROIDS, V74, P945, DOI 10.1016/j.steroids.2009.06.011	31	59	64	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1064-8011	1533-4287		J STRENGTH COND RES	J. Strength Cond. Res.	JUN	2011	25	6					1546	1552		10.1519/JSC.0b013e3181da7858			7	Sport Sciences	Sport Sciences	766OD	WOS:000290792600007	21273908				2021-06-18	
J	Guresir, E; Vatter, H; Schuss, P; Oszvald, A; Raabe, A; Seifert, V; Beck, J				Gueresir, Erdem; Vatter, Hartmut; Schuss, Patrick; Oszvald, Agi; Raabe, Andreas; Seifert, Volker; Beck, Juergen			Rapid closure technique in decompressive craniectomy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; duraplasty; subarachnoid hemorrhage; intracerebral hemorrhage; cerebral infarction; brain swelling	MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; INTRACRANIAL HYPERTENSION; SUBARACHNOID HEMORRHAGE; MALIGNANT INFARCTION; DURAL CLOSURE; HEAD-INJURY; HEMICRANIECTOMY; MULTICENTER; SURGERY	Object. The object of this study was to describe the rapid closure technique in decompressive craniectomy without duraplasty and its use in a large cohort of consecutive patients. Methods. Between 1999 and 2008, supratentorial rapid closure decompressive craniectomy (RCDC) was performed 341 times in 318 patients at the authors' institution. Cases were stratified as 1) traumatic brain injury, 2) subarachnoid hemorrhage, 3) intracerebral hemorrhage, 4) cerebral infarction, and 5) other. A large bone flap was removed and the dura mater was opened in a stellate fashion. Duraplasty was not performed that is, the dura was not sutured, and a dural substitute was neither sutured in nor layed on. The dura and exposed brain tissue were covered with hemostyptic material (Surgicel). Surgical time and complications of this procedure including follow-up (> 6 months) were recorded. After 3-6 months cranioplasty was performed, and, again, surgical time and any complications were recorded. Results. Rapid closure decompressive craniectomy was feasible in all cases. Complications included superficial wound healing disturbance (3.5% of procedures), abscess (2.6%) and CSF fistula (0.6%); the mean surgical time (+/- SD) was 69 +/- 20 minutes. Cranioplasty was performed in 196 cases; the mean interval (+/- SD) from craniectomy to cranioplasty was 118 +/- 40 days. Complications of cranioplasty included epidural hematoma (4.1%), abscess (2.6%), wound healing disturbance (6.1%), and CSF fistula (1%). Compared with the results reported in the literature for decompressive craniectomy with duraplasty followed by cranioplasty, there were no significant differences in the frequency of complications. However, surgical time for RCDC was significantly shorter (69 +/- 20 vs 129 +/- 43 minutes, p < 0.0001). Conclusions. The present analysis of the largest series reported to date reveals that the rapid closure technique is feasible and safe in decompressive craniectomy. The surgical time is significantly shorter without increased complication rates or additional complications. Cranioplasty after a RCDC procedure was also feasible, fast, safe and not impaired by the RCDC technique. (DOI: 10.3171/2009.12.JNS091065)	[Gueresir, Erdem; Vatter, Hartmut; Schuss, Patrick; Oszvald, Agi; Raabe, Andreas; Seifert, Volker; Beck, Juergen] Goethe Univ Frankfurt, Dept Neurosurg, D-60528 Frankfurt, Germany	Guresir, E (corresponding author), Goethe Univ Frankfurt, Dept Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	Gueresir@em.uni-frankfurt.de	Schuss, Patrick/ABC-6469-2020; guresir, erdem/AAL-4484-2020	Schuss, Patrick/0000-0002-5806-2576; guresir, erdem/0000-0002-6624-6885; Guresir, Erdem/0000-0001-8319-0847; Beck, Jurgen/0000-0002-7687-6098			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Barth M, 2008, NEUROSURGERY, V63, P352, DOI 10.1227/01.NEU.0000310696.52302.99; Beck J, 2006, J NEUROSURG, V105, P220, DOI 10.3171/jns.2006.105.2.220; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Guresir E, 2008, NEUROSURGERY, V63, P1088, DOI 10.1227/01.NEU.0000335170.76722.B9; Horaczek JA, 2008, NEUROSURGERY, V63, P176, DOI 10.1227/01.NEU.0000312707.25073.CB; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Ko K, 2007, NEUROSURGERY, V60, P255, DOI 10.1227/01.NEU.0000255380.64969.81; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Malliti M, 2004, NEUROSURGERY, V54, P599, DOI 10.1227/01.NEU.0000108640.45371.1A; Marion DW, 2006, NEUROSURGERY, V58, P655; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	19	59	61	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2011	114	4					954	960		10.3171/2009.12.JNS091065			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	739NW	WOS:000288725900014	20113157				2021-06-18	
J	Newcombe, VFJ; Outtrim, JG; Chatfield, DA; Manktelow, A; Hutchinson, PJ; Coles, JP; Williams, GB; Sahakian, BJ; Menon, DK				Newcombe, Virginia F. J.; Outtrim, Joanne G.; Chatfield, Doris A.; Manktelow, Anne; Hutchinson, Peter J.; Coles, Jonathan P.; Williams, Guy B.; Sahakian, Barbara J.; Menon, David K.			Parcellating the neuroanatomical basis of impaired decision-making in traumatic brain injury	BRAIN			English	Article						traumatic brain injury; diffusion tensor imaging; decision-making	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PREFRONTAL CORTEX LESIONS; DIFFUSE AXONAL INJURY; HEAD-INJURY; PERSONALITY-CHANGE; NORMAL VOLUNTEERS; DAMAGE; AMANTADINE; SURVIVORS; COGNITION	Cognitive dysfunction is a devastating consequence of traumatic brain injury that affects the majority of those who survive with moderate-to-severe injury, and many patients with mild head injury. Disruption of key monoaminergic neurotransmitter systems, such as the dopaminergic system, may play a key role in the widespread cognitive dysfunction seen after traumatic axonal injury. Manifestations of injury to this system may include impaired decision-making and impulsivity. We used the Cambridge Gambling Task to characterize decision-making and risk-taking behaviour, outside of a learning context, in a cohort of 44 patients at least six months post-traumatic brain injury. These patients were found to have broadly intact processing of risk adjustment and probability judgement, and to bet similar amounts to controls. However, a patient preference for consistently early bets indicated a higher level of impulsiveness. These behavioural measures were compared with imaging findings on diffusion tensor magnetic resonance imaging. Performance in specific domains of the Cambridge Gambling Task correlated inversely and specifically with the severity of diffusion tensor imaging abnormalities in regions that have been implicated in these cognitive processes. Thus, impulsivity was associated with increased apparent diffusion coefficient bilaterally in the orbitofrontal gyrus, insula and caudate; abnormal risk adjustment with increased apparent diffusion coefficient in the right thalamus and dorsal striatum and left caudate; and impaired performance on rational choice with increased apparent diffusion coefficient in the bilateral dorsolateral prefrontal cortices, and the superior frontal gyri, right ventrolateral prefrontal cortex, the dorsal and ventral striatum, and left hippocampus. Importantly, performance in specific cognitive domains of the task did not correlate with diffusion tensor imaging abnormalities in areas not implicated in their performance. The ability to dissociate the location and extent of damage with performance on the various task components using diffusion tensor imaging allows important insights into the neuroanatomical basis of impulsivity following traumatic brain injury. The ability to detect such damage in vivo may have important implications for patient management, patient selection for trials, and to help understand complex neurocognitive pathways.	[Newcombe, Virginia F. J.; Outtrim, Joanne G.; Chatfield, Doris A.; Manktelow, Anne; Coles, Jonathan P.; Williams, Guy B.; Menon, David K.] Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge CB2 2QQ, England; [Newcombe, Virginia F. J.; Outtrim, Joanne G.; Chatfield, Doris A.; Manktelow, Anne; Hutchinson, Peter J.; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; [Sahakian, Barbara J.] Univ Cambridge, Sch Clin Med, Dept Psychiat, Cambridge CB2 2QQ, England; [Sahakian, Barbara J.] Univ Cambridge, MRC Wellcome Trust Behav, Cambridge CB2 3EB, England; [Sahakian, Barbara J.] Univ Cambridge, Clin Neurosci Inst, Cambridge CB2 3EB, England	Newcombe, VFJ (corresponding author), Addenbrookes Hosp, Univ Div Anaesthesia, Hills Rd,Box 93, Cambridge CB2 2QQ, England.	vfjn2@cam.ac.uk	Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745; Outtrim, Joanne/0000-0001-8118-6430; Newcombe, Virginia/0000-0001-6044-9035	Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390 ID 65883]; UK National Institutes of Health Research Biomedical Research Centre at Cambridge; UK Department of Health, Technology; Gates Cambridge Trust; Overseas Research Studentship; National Institute for Health ResearchNational Institute for Health Research (NIHR); Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Academy of Medical Sciences/Health Foundation; Clinician Scientist Award; Wellcome TrustWellcome TrustEuropean Commission [089589/Z/09/Z]; BOC Professorship of the Royal College of Anaesthetists; Evelyn Trust; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G1000183B, G0001354, G0001354B, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-14-007, NF-SI-0508-10327] Funding Source: researchfish	Medical Research Council (UK) Program Grant [Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects (G9439390 ID 65883)]; UK National Institutes of Health Research Biomedical Research Centre at Cambridge; UK Department of Health, Technology Platform funding. Gates Cambridge Trust (to V.F.J.N.); Overseas Research Studentship (to V.F.J.N.); National Institute for Health Research Academic Clinical Fellow (to V.F.J.N.); Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship (to P.J.H.); Academy of Medical Sciences/Health Foundation, Clinician Scientist Award (to J.P.C.); Wellcome Trust Programme Grant (No 089589/Z/09/Z to B.J.S.); BOC Professorship of the Royal College of Anaesthetists (to D.K.M.); Evelyn Trust (to D.K.M.).	Bazanis E, 2002, PSYCHOL MED, V32, P1395, DOI 10.1017/S0033291702006657; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bonatti E, 2008, COGN BEHAV NEUROL, V21, P164, DOI 10.1097/WNN.0b013e318184e688; Brennan AR, 2008, ANN NY ACAD SCI, V1129, P236, DOI 10.1196/annals.1417.007; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Clark L, 2008, BRAIN, V131, P1311, DOI 10.1093/brain/awn066; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Correia MM, 2009, MAGN RESON IMAGING, V27, P163, DOI 10.1016/j.mri.2008.06.011; Deakin J, 2004, J INT NEUROPSYCH SOC, V10, P590, DOI 10.1017/S1355617704104104; Debette S, 2002, J NEUROL, V249, P1678, DOI 10.1007/s00415-002-0903-1; DeVito EE, 2008, BIOL PSYCHIAT, V64, P636, DOI 10.1016/j.biopsych.2008.04.017; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Ersche KD, 2005, PSYCHOPHARMACOLOGY, V180, P612, DOI 10.1007/s00213-005-2205-7; Franzen M D, 2000, Crit Care Nurs Q, V23, P58; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Garcia-Molina A, 2007, NEUROLOGIA, V22, P206; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Hanten G, 2006, NEUROCASE, V12, P247, DOI 10.1080/13554790600910490; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Hughes S, 2005, BRAIN INJURY, V19, P1197, DOI 10.1080/02699050500309296; Johansen-Berg H, 2007, CURR BIOL, V17, pR141, DOI 10.1016/j.cub.2006.12.022; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langevin R, 2006, BRAIN COGNITION, V60, P206; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Lew HL, 2009, AM J PHYS MED REHAB, V88, P1, DOI 10.1097/PHM.0b013e3181911102; MacPherson SE, 2009, CLIN NEUROPSYCHOL, V23, P510, DOI 10.1080/13854040802396586; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MULLER U, 1994, PROG NEURO-PSYCHOPH, V18, P1103, DOI 10.1016/0278-5846(94)90114-7; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Pavlovskaya M, 2007, BRAIN INJURY, V21, P489, DOI 10.1080/02699050701311117; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Rubinsztein JS, 2001, BRAIN, V124, P2550, DOI 10.1093/brain/124.12.2550; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Shiga T, 2006, EUR J NUCL MED MOL I, V33, P817, DOI 10.1007/s00259-005-0033-y; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; Volkow ND, 2007, ARCH GEN PSYCHIAT, V64, P932, DOI 10.1001/archpsyc.64.8.932; Watkins LHA, 2000, NEUROPSYCHOLOGIA, V38, P1112, DOI 10.1016/S0028-3932(00)00028-2; Weddell RA, 2006, BRAIN INJURY, V20, P1221, DOI 10.1080/02699050601049783; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Xue G, 2010, NEUROIMAGE, V50, P709, DOI 10.1016/j.neuroimage.2009.12.097; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073	60	59	61	0	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2011	134		3				759	768		10.1093/brain/awq388			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	726RZ	WOS:000287745100012	21310727	Bronze, Green Published			2021-06-18	
J	Han, XG; Yang, N; Xu, YS; Zhu, JL; Chen, ZQ; Liu, ZJ; Dang, GT; Song, CL				Han, Xiaoguang; Yang, Ning; Xu, Yingsheng; Zhu, Jinglin; Chen, Zhongqiang; Liu, Zhongjun; Dang, Gengting; Song, Chunli			Simvastatin treatment improves functional recovery after experimental spinal cord injury by upregulating the expression of BDNF and GDNF	NEUROSCIENCE LETTERS			English	Article						Spinal cord injury; Simvastatin; Electrophysiology; Neurotrophin	TRAUMATIC BRAIN-INJURY; NEUROGENESIS; ATORVASTATIN; INCREASE; CELLS; RATS; TRANSPLANTATION; OVEREXPRESSION; ACTIVATION; SURVIVAL	The aim of this study was to determine the therapeutic efficacy of simvastatin treatment starting 1 day after spinal cord injury (SCI) in rat and to investigate the underlying mechanism. Spinal cord injury was induced in adult female Sprague-Dawley rats after laminectomy at T9-T10. Then additionally with sham group (laminectomy only) the SCI animals were randomly divided into 3 groups: vehicle-treated group; 5-mg/kg simvastatin-treated group; and 10-mg/kg simvastatin-treated group. Simvastatin or vehicle was administered orally at 1 day after SCI and then daily for 5 weeks. Locomotor functional recovery was assessed during 8 weeks postoperation by performing open-field locomotor test and inclined-plane test. At the end of study, motor evoked potentials (MEPs) and somatosensory evoked potentials (SEPs) were assessed to evaluate the integrity of spinal cord pathways. Then, the animals were killed, and 1-cm segments of spinal cord encompassing the injury site were removed for histopathological analysis. Immunohistochemistry was performed to observe the expression of brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF) in the spinal cord. Results show that the simvastatin-treated animals showed significantly better locomotor function recovery, better electrophysiological outcome, less myelin loss, and higher expression of BDNF and GDNF. These findings suggest that simvastatin treatment starting 1 day after SCI can significantly improve locomotor recovery, and this neuro protective effect may be related to the upregulation of BDNF and GDNF. Therefore, simvastatin may be useful as a promising therapeutic agent for SCI. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Xu, Yingsheng] Peking Univ, Hosp 3, Dept Neurol, Beijing 100191, Peoples R China; [Han, Xiaoguang; Yang, Ning; Zhu, Jinglin; Chen, Zhongqiang; Liu, Zhongjun; Dang, Gengting; Song, Chunli] Peking Univ, Hosp 3, Dept Orthoped, Beijing 100191, Peoples R China	Xu, YS (corresponding author), Peking Univ, Hosp 3, Dept Neurol, Beijing 100191, Peoples R China.	xys@bjmu.edu.cn; schl@bjmu.edu.cn		Han, Xiaoguang/0000-0001-7477-3274	National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30300352, 30772200]	This work was supported by the National Nature Science Foundation of China (30300352, 30772200).	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Dery MA, 2009, NEUROSCI LETT, V453, P73, DOI 10.1016/j.neulet.2009.01.062; Garcia-Alias G, 2004, J NEUROSCI RES, V75, P632, DOI 10.1002/jnr.20029; Kao CH, 2008, RESUSCITATION, V77, P395, DOI 10.1016/j.resuscitation.2008.01.023; Karki K, 2009, STROKE, V40, P3384, DOI 10.1161/STROKEAHA.108.544395; Lee SI, 2009, J NEUROSCI RES, V87, P3186, DOI 10.1002/jnr.22149; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Mann CM, 2010, EXP NEUROL, V221, P285, DOI 10.1016/j.expneurol.2009.11.006; Paintlia AS, 2005, FASEB J, V19, P1407, DOI 10.1096/fj.05-3861com; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Pereira JE, 2009, EXP NEUROL, V220, P71, DOI 10.1016/j.expneurol.2009.07.030; Perot P L Jr, 1987, Cent Nerv Syst Trauma, V4, P149; Shunmugavel A, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-17; Tolwani RJ, 2004, J NEUROSCI RES, V77, P662, DOI 10.1002/jnr.20181; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yaguchi M, 2008, J NEUROSCI RES, V86, P1972, DOI 10.1002/jnr.21658; Zhang LQ, 2009, GLIA, V57, P1178, DOI 10.1002/glia.20840	21	59	68	0	22	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 10	2011	487	3					255	259		10.1016/j.neulet.2010.09.007			5	Neurosciences	Neurosciences & Neurology	712WQ	WOS:000286697400001	20851742				2021-06-18	
J	Covassin, T; Elbin, RJ				Covassin, Tracey; Elbin, R. J.			The Female Athlete: The Role of Gender in the Assessment and Management of Sport-Related Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Gender differences; Females; Symptoms	TRAUMATIC BRAIN-INJURY; SEGMENT DYNAMIC STABILIZATION; SEX-DIFFERENCES; HIGH-SCHOOL; NEUROPSYCHOLOGICAL FUNCTION; AGREEMENT STATEMENT; SYMPTOMS; MIGRAINE	Concussions remain a serious public health concern, with approximately 1.6 million to 3 million sport and recreational traumatic and brain injuries occurring every year in the United States. Most research on concussions has been conducted on male athletes, specifically, football players. However, female sport participation has steadily increased over the past decade. Recent studies suggest that the incidence of and recovery from sport-related concussion varies between male and female athletes, with women having a higher risk of sustaining a concussion and taking a longer time to recover than men. As a result, this article addresses the role of gender in the assessment and management of sport-related concussion.	[Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Elbin, R. J.] E Tennessee State Univ, Dept Kinesiol Leisure & Sport Sci, Johnson City, TN 37614 USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 105 Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT, 2001, J ATHL TRAINING, V36, P253; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; de Courten-Myers GM, 1999, J NEUROPATH EXP NEUR, V58, P217; DEHAAS DM, 2009, 198182200708 NCAA; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Esposito G, 1996, J NUCL MED, V37, P559; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRANITO VJ, 2000, DISS ABSTR INT B, V61, P530; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hootman JM, 2007, J ATHL TRAINING, V42, P311; KREIGHBAUM E., 1996, BIOMECHANICS QUALITA; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Launer LJ, 1999, NEUROLOGY, V53, P537, DOI 10.1212/WNL.53.3.537; Lipton RB, 2001, HEADACHE, V41, P638, DOI 10.1046/j.1526-4610.2001.041007638.x; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Mansell J, 2005, J ATHL TRAINING, V40, P310; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; *NFHSA, 2008, PART HIGH SCH SPORTS; PLAGENHOEF S, 1983, RES Q EXERCISE SPORT, V54, P169, DOI 10.1080/02701367.1983.10605290; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; SILBERSTEIN SD, 2007, TXB CLIN NEUROLOGY, P1247; SMITH SS, 1989, BRAIN RES, V503, P354, DOI 10.1016/0006-8993(89)91691-0; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X	43	59	59	0	32	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					125	+		10.1016/j.csm.2010.08.001			8	Sport Sciences	Sport Sciences	691XR	WOS:000285114800012	21074087				2021-06-18	
J	Phillips, LH; Henry, JD; Scott, C; Summers, F; Whyte, M; Cook, M				Phillips, Louise H.; Henry, Julie D.; Scott, Clare; Summers, Fiona; Whyte, Maggie; Cook, Moira			Specific Impairments of Emotion Perception in Multiple Sclerosis	NEUROPSYCHOLOGY			English	Article						multiple sclerosis; emotion perception; quality of life	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; FACIAL EXPRESSIONS; RECOGNITION; DEFICITS; DISABILITY; ATROPHY; MATTER; MEMORY	Objective: Multiple sclerosis (MS) often results in demyelination of a network of frontal-subcortical tracts involved in processing emotional information. We investigated the effect of MS on the ability to identify emotional and nonemotional information from static and dynamic stimuli and determined whether difficulties in emotion perception related to quality of life. Method: 32 MS and 33 control participants, matched for age and education, identified emotions and nonemotional information from static images of faces and dynamic videos of people interacting. They also completed cognitive assessment and quality of life ratings. Results: On the static face perception tasks, participants with MS performed more poorly than healthy controls on emotion perception, t(63) = 3.30, p < .01, d = .83, but not identity perception, t(63) = 1.18, d = .30. For the dynamic tasks, the MS group were impaired on emotion perception, t(63) = 3.41, p = .001, d = .86, but not age/gender perception, t(63) = 0.15, d = .04. Ratings of social and psychological aspects of quality of life in MS were related to emotion perception scores controlling for disease severity and duration, age, depression, and cognitive function, with r(2) ranging from .17 to .24. Conclusions: These results indicate a specific deficit in decoding static and dynamic information about emotion in MS, as compared to nonemotional information. There were specific relationships between emotion perception problems and poor social and psychological quality of life, indicating that emotional skills should be considered when evaluating functioning in MS.	[Phillips, Louise H.] Univ Aberdeen, Sch Psychol, Coll Life Sci & Med, Aberdeen AB24 2UB, Scotland; [Henry, Julie D.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Summers, Fiona; Whyte, Maggie] Aberdeen Royal Infirm, Aberdeen, Scotland	Phillips, LH (corresponding author), Univ Aberdeen, Sch Psychol, Coll Life Sci & Med, Aberdeen AB24 2UB, Scotland.	louise.phillips@abdn.ac.uk	Phillips, Louise H/A-7952-2008	Phillips, Louise H/0000-0003-1005-8567; Henry, Julie/0000-0002-2081-3717; Phillips, Louise/0000-0002-0988-3028	Tenovus, Scotland	This research was funded by Tenovus, Scotland.	Adolphs R, 2000, J NEUROSCI, V20, P2683; Ambadar Z, 2005, PSYCHOL SCI, V16, P403, DOI 10.1111/j.0956-7976.2005.01548.x; BEATTY WW, 1995, NEUROLOGY, V45, P718, DOI 10.1212/WNL.45.4.718; BEATTY WW, 1989, B PSYCHONOMIC SOC, V27, P361; Beatty WW, 2003, MULT SCLER, V9, P148, DOI 10.1191/1352458503ms897oa; Benedict RHB, 2009, J NEUROL NEUROSUR PS, V80, P201, DOI 10.1136/jnnp.2008.148403; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bobholz JA, 2006, NEUROLOGY, V67, P1640, DOI 10.1212/01.wnl.0000242885.71725.76; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Chopra P, 2008, INT J REHABIL RES, V31, P141, DOI 10.1097/MRR.0b013e32830150e6; Clark US, 2008, NEUROPSYCHOLOGIA, V46, P2300, DOI 10.1016/j.neuropsychologia.2008.03.014; Filley CM, 2005, ANN NY ACAD SCI, V1064, P162, DOI 10.1196/annals.1340.028; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1166, DOI 10.1016/j.neuropsychologia.2005.10.006; Henry JD, 2009, J INT NEUROPSYCH SOC, V15, P277, DOI 10.1017/S1355617709090195; HOHOL MJ, 1995, NEUROLOGY, V45, P251, DOI 10.1212/WNL.45.2.251; Kalmar JH, 2008, NEUROPSYCHOLOGY, V22, P442, DOI 10.1037/0894-4105.22.4.442; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Phillips LH, 2010, PSYCHOL AGING, V25, P38, DOI 10.1037/a0017369; Phillips LH, 2009, BRIT J CLIN PSYCHOL, V48, P101, DOI 10.1348/014466508X379566; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Ruffman T, 2008, NEUROSCI BIOBEHAV R, V32, P863, DOI 10.1016/j.neubiorev.2008.01.001; Skevington SM, 2004, QUAL LIFE RES, V13, P299, DOI 10.1023/B:QURE.0000018486.91360.00; Slessor G, 2007, PSYCHOL AGING, V22, P639, DOI 10.1037/0882-7974.22.3.639; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Sullivan S, 2004, BRIT J PSYCHOL, V95, P1, DOI 10.1348/000712604322779424; Tedeschi G, 2005, NEUROLOGY, V65, P280, DOI 10.1212/01.wnl.0000168837.87351.1f; Young A., 2002, FACIAL EXPRESSIONS E; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	29	59	59	0	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JAN	2011	25	1					131	136		10.1037/a0020752			6	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	711AQ	WOS:000286558500014	21090898				2021-06-18	
J	Fanconi, M; Lips, U				Fanconi, Manuela; Lips, Ulrich			Shaken baby syndrome in Switzerland: results of a prospective follow-up study, 2002-2007	EUROPEAN JOURNAL OF PEDIATRICS			English	Article						Shaken baby syndrome; Non-accidental head injury; Traumatic brain hemorrhage; Incidence; Outcome	TRAUMATIC BRAIN-INJURY; AGE-RELATED INCIDENCE; YOUNG-CHILDREN; HEAD TRAUMA; RETINAL HEMORRHAGES; SUBDURAL HAEMATOMA; WHIPLASH INJURY; INFANTS; SHAKING; TRIGGER	Since the incidence of shaken baby syndrome in Switzerland was not known, we conducted a nationwide prospective follow-up study for a 5-year period (from 2002 to 2007). The data were collected through the Swiss Pediatric Surveillance Unit. Inclusion criteria were the presence, in a child a parts per thousand currency sign6 years of age, of 1) more than or equal to two clinical symptoms (altered consciousness, convulsions, respiratory irregularities, and bulging fontanel), 2) one eye finding (retinal hemorrhages, vitreous hemorrhages), 3) one MRI/CT finding (subdural hematoma, subarachnoid hematoma, and parenchymatous lesions), or 4) history of shaking. Exclusion criteria were age > 6 years or documented accident/disease explaining symptoms/findings. To describe outcome, we used the King's Outcome Scale for Childhood Head Injury (KOSCHI). 56 cases were reported from 13 of 26 Swiss cantons, representing 80% of the Swiss population; 49 cases met the inclusion criteria. Preponderance of male infants was high (31 male and 18 female); median age at admission was 4 months (1-58). Clinical symptoms were present in 42 infants, retinal/vitreous hemorrhages in 39 infants, and pathological brain/head imaging in 46 infants. In 13 cases, the caregivers admitted shaking the child. Outcomes (KOSCHI 1-5; n = 47 patients) were death (KOSCHI 1) 8 (17.7%), vegetative state (KOSCHI 2) 0, severe disability (KOSCHI 3) 11 (22.2%), moderate disability (KOSCHI 4) 14 (31.1%), and good recovery (KOSCHI 5) 14 (28.8%). Based on these data, the incidence of shaken baby syndrome in Switzerland is 14 per 100 000 live births, which corresponds to the incidence in other Western countries. Demographic characteristics and outcomes of Swiss patients were comparable to published studies.	[Fanconi, Manuela; Lips, Ulrich] Univ Childrens Hosp Zurich, Child Protect Grp, CH-8032 Zurich, Switzerland	Lips, U (corresponding author), Univ Childrens Hosp Zurich, Child Protect Grp, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	ulrich.lips@kispi.uzh.ch					Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Karandikar S., 2004, CHILD ABUSE REV, V13, P178, DOI DOI 10.1002/CAR.850; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Kochanek PM, 2007, J NEUROTRAUM, V24, P1, DOI 10.1089/neu.2006.0209; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Mungan NK, 2007, CURR OPIN OPHTHALMOL, V18, P392, DOI 10.1097/ICU.0b013e3282a167f0; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1969, LANCET, V2, P237; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; Talvik I, 2006, ACTA PAEDIATR, V95, P799, DOI 10.1080/08035250500464923	30	59	61	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-6199			EUR J PEDIATR	Eur. J. Pediatr.	AUG	2010	169	8					1023	1028		10.1007/s00431-010-1175-x			6	Pediatrics	Pediatrics	614SU	WOS:000279080800017	20213304	Green Accepted			2021-06-18	
J	Bailey, CM; Samples, HL; Broshek, DK; Freeman, JR; Barth, JT				Bailey, Christopher M.; Samples, Hillary L.; Broshek, Donna K.; Freeman, Jason R.; Barth, Jeffrey T.			The Relationship Between Psychological Distress and Baseline Sports-Related Concussion Testing	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						head injury; mild traumatic brain injury; neuropsychology; athlete; personality	HIGH-SCHOOL; NEUROPSYCHOLOGICAL DEFICITS; SEX-DIFFERENCES; SYMPTOMS; PERFORMANCE; RECOVERY; DEPRESSION; IMPAIRMENT; ANXIETY; IMPACT	Objective: This study examined the effect of psychological distress on neurocognitive performance measured during baseline concussion testing. Design: Archival data were utilized to examine correlations between personality testing and computerized baseline concussion testing. Significantly correlated personality measures were entered into linear regression analyses, predicting baseline concussion testing performance. Suicidal ideation was examined categorically. Setting: Athletes underwent testing and screening at a university athletic training facility. Participants: Participants included 47 collegiate football players 17 to 19 years old, the majority of whom were in their first year of college. Interventions: Participants were administered the Concussion Resolution Index (CRI), an internet-based neurocognitive test designed to monitor and manage both at-risk and concussed athletes. Participants took the Personality Assessment Inventory (PAI), a self-administered inventory designed to measure clinical syndromes, treatment considerations, and interpersonal style. Main Outcome Measures: Scales and subscales from the PAI were utilized to determine the influence psychological distress had on the CRI indices: simple reaction time, complex reaction time, and processing speed. Results: Analyses revealed several significant correlations among aspects of somatic concern, depression, anxiety, substance abuse, and suicidal ideation and CRI performance, each with at least a moderate effect. When entered into a linear regression, the block of combined psychological symptoms accounted for a significant amount of baseline CRI performance, with moderate to large effects (r(2) = 0.23-0.30). When examined categorically, participants with suicidal ideation showed significantly slower simple reaction time and complex reaction time, with a similar trend on processing speed. Conclusions: Given the possibility of obscured concussion deficits after injury, implications for premature return to play, and the need to target psychological distress outright, these findings heighten the clinical importance of screening for psychological distress during baseline and post-injury concussion evaluations.	[Bailey, Christopher M.] Case Western Reserve Univ, Sch Med, Dept Neurol, Cleveland, OH 44106 USA; [Samples, Hillary L.; Broshek, Donna K.; Freeman, Jason R.; Barth, Jeffrey T.] Univ Virginia Hlth Syst, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA	Bailey, CM (corresponding author), 11100 Euclid Ave,Mail Stop HAN 5040, Cleveland, OH 44106 USA.	christopher.bailey3@uhhospitals.org					Austin MP, 2001, BRIT J PSYCHIAT, V178, P200, DOI 10.1192/bjp.178.3.200; Bailes JE, 2009, J INT NEUROPSYCH SOC, V15, P509, DOI 10.1017/S1355617709090936; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BARTH JT, 2002, ENCY HUMAN BRAIN, V3, P81; Barth JT., 1989, MILD HEAD INJURY, P257; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BREWER BW, 2001, COPING SPORT INJURIE, P1; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Butters MA, 2004, ARCH GEN PSYCHIAT, V61, P587, DOI 10.1001/archpsyc.61.6.587; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Eysenck MW, 2007, EMOTION, V7, P336, DOI 10.1037/1528-3542.7.2.336; EYSENCK MW, 1992, COGNITION EMOTION, V6, P409, DOI 10.1080/02699939208409696; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FURTADO JL, 2006, SPORTS NEUROPSYCHOLO, P287; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HARTLAGE S, 1993, PSYCHOL BULL, V113, P247, DOI 10.1037/0033-2909.113.2.247; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Morey L. C., 1991, PERSONALITY ASSESSME; Nebes RD, 2000, PSYCHOL MED, V30, P679, DOI 10.1017/S0033291799001968; Porter RJ, 2003, BRIT J PSYCHIAT, V182, P214, DOI 10.1192/bjp.182.3.214; PUTUKIAN M, 2006, SPORTS NEUROPSYCHOLO, P297; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214	42	59	59	2	34	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2010	20	4					272	277		10.1097/JSM.0b013e3181e8f8d8			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	622EA	WOS:000279641800005	20606512				2021-06-18	
J	Kahraman, S; Dutton, RP; Hu, P; Xiao, Y; Aarabi, B; Stein, DM; Scalea, TM				Kahraman, Sibel; Dutton, Richard P.; Hu, Peter; Xiao, Yan; Aarabi, Bizhan; Stein, Deborah M.; Scalea, Thomas M.			Automated Measurement of "Pressure Times Time Dose" of Intracranial Hypertension Best Predicts Outcome After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST)	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma (AAST)		Intracranial pressure; Cerebral perfusion pressure; Traumatic brain injury; Outcome; Automated recording; Pressure time dose; ICP; CPP; TBI; PTD	CEREBRAL PERFUSION-PRESSURE; THRESHOLDS; REACTIVITY; AGREEMENT; INSULTS; IMPACT	Background: Earlier, more accurate assessment of secondary brain injury is essential in management of patients with traumatic brain injury (TBI). We assessed the accuracy and utility of high-resolution automated intracranial pressure (ICP) and cerebral perfusion pressure (CPP) recording and their analysis in patients with severe TBI. Methods: ICP and CPP data for 30 severe TBI patients were collected automatically at 6-second intervals. The degree and duration of ICP and CPP above and below treatment thresholds were calculated as "pressure times time dose" (PTD; mm Hg . h) using automated recordings (PTDa) or manual recordings (PTDm) for early stage (trauma resuscitation unit [TRU]) and total monitoring time (TRU and intensive care unit). Results: Bland-Altman plots showed lack of agreement between PTDa and PTDm. For ICP >20 mm Hg and CPP <60 mm Hg, PTDa, but not PTD m, was significantly higher in patients with unfavorable outcome (Extended Glasgow Outcome Scale score <= 4) than in patients with favorable outcome (Extended Glasgow Outcome Scale score >4). Total PTD a for ICP >20 mm Hg and CPP <60 mm Hg had high predictive power for functional outcome (area under the receiver operating characteristics curve: 0.92 +/- 0.05 and 0.82 +/- 0.08, respectively) and inhospital mortality (0.76 +/- 0.15 and 0.79 +/- 0.14, respectively) and were strongly correlated with length of intensive care unit stay (p = 0.009 and 0.007), length of hospital stay (p = 0.009 and 0.005), and discharge Glasgow Coma Scale scores (p = 0.008 and p = 0.038). PTD a of CPP > 100 mm Hg during TRU monitoring and during the first 24 hours showed highest predictive power for mortality (area under the receiver operating characteristics curve: 0.72 +/- 0.18 and 0.85 +/- 0.13, respectively). PTD a was better than PTD m and the duration of episodes alone in predicting outcome. Conclusions: PTD calculation of high resolution ICP and CPP recording is a reliable and feasible way of monitoring severe TBI patients.	[Kahraman, Sibel; Dutton, Richard P.; Hu, Peter; Xiao, Yan] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Dutton, Richard P.] Univ Maryland Med Syst, Div Trauma Anesthesiol, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA	Dutton, RP (corresponding author), Univ Maryland Med Syst, Div Trauma Anesthesiol, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	RDutton@umaryland.edu	Xiao, Yan/A-7506-2009	Xiao, Yan/0000-0003-2805-0619; Stein, Deborah/0000-0003-3683-3963			[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; O'Sullivan Cormac T, 2007, AANA J, V75, P43; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	22	59	59	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2010	69	1					110	118		10.1097/TA.0b013e3181c99853			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	627AQ	WOS:000280010600017	20038855				2021-06-18	
J	Vaishnav, RA; Singh, IN; Miller, DM; Hall, ED				Vaishnav, Radhika A.; Singh, Indrapal N.; Miller, Darren M.; Hall, Edward D.			Lipid Peroxidation-Derived Reactive Aldehydes Directly and Differentially Impair Spinal Cord and Brain Mitochondrial Function	JOURNAL OF NEUROTRAUMA			English	Article						acrolein; 4-hydroxy 2-nonenal; oxidative stress; spinal cord injury; traumatic brain injury	INDUCED OXIDATIVE DAMAGE; HYDROGEN-PEROXIDE; ALZHEIMERS-DISEASE; FREE-RADICALS; PEROXYNITRITE SCAVENGERS; MOUSE MODEL; CELL-DEATH; INJURY; ACROLEIN; STRESS	Mitochondrial bioenergetic dysfunction in traumatic spinal cord and brain injury is associated with post-traumatic free radical-mediated oxidative damage to proteins and lipids. Lipid peroxidation by-products, such as 4-hydroxy-2-nonenal and acrolein, can form adducts with proteins and exacerbate the effects of direct free radical-induced protein oxidation. The aim of the present investigation was to determine and compare the direct contribution of 4-hydroxy-2-nonenal and acrolein to spinal cord and brain mitochondrial dysfunction. Ficoll gradient-isolated mitochondria from normal rat spinal cords and brains were treated with carefully selected doses of 4-hydroxy-2-nonenal or acrolein, followed by measurement of complex I- and complex II-driven respiratory rates. Both compounds were potent inhibitors of mitochondrial respiration in a dose-dependent manner. 4-Hydroxy-2-nonenal significantly compromised spinal cord mitochondrial respiration at a 0.1-mu M concentration, whereas 10-fold greater concentrations produced a similar effect in brain. Acrolein was more potent than 4-hydroxy-2-nonenal, significantly decreasing spinal cord and brain mitochondrial respiration at 0.01 mu M and 0.1 mu M concentrations, respectively. The results of this study show that 4-hydroxy-2-nonenal and acrolein can directly and differentially impair spinal cord and brain mitochondrial function, and that the targets for the toxic effects of aldehydes appear to include pyruvate dehydrogenase and complex I-associated proteins. Furthermore, they suggest that protein modification by these lipid peroxidation products may directly contribute to post-traumatic mitochondrial damage, with spinal cord mitochondria showing a greater sensitivity than those in brain.	[Vaishnav, Radhika A.; Singh, Indrapal N.; Miller, Darren M.; Hall, Edward D.] Univ Kentucky, Coll Med, SCoBIRC, Lexington, KY 40536 USA; [Singh, Indrapal N.; Miller, Darren M.; Hall, Edward D.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, SCoBIRC, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013; Vaishnav, Radhika/AAN-4556-2021		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH-NINDS 1F32NS063744-01, NIH-NIDA 1T32DA022738-01, NIH-NINDS 1P30NS051220-01]; Kentucky Spinal Cord and Head Injury Research Trust [6-5]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS063744, P30NS051220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by funding from the National Institutes of Health: NIH-NINDS 1F32NS063744-01 (R.A.V.); NIH-NIDA 1T32DA022738-01 (E.D.H.); NIH-NINDS 1P30NS051220-01 (E.D.H.); and the Kentucky Spinal Cord and Head Injury Research Trust Grant #6-5 (E.D.H.). We thank Dr. Malhar Jhaveri and Dr. Manan Jhaveri for assistance with the statistical analyses. Also we thank Drs. Bradford Hill and Daniel Conklin for sharing their valuable suggestions on storage and handling of acrolein.	Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Burcham PC, 2002, TOXICOLOGY, V181, P229, DOI 10.1016/S0300-483X(02)00287-1; Butterfield DA, 2001, MECH AGEING DEV, V122, P945, DOI 10.1016/S0047-6374(01)00249-4; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI [10.1089/neu.2008.0870, 10.1089/neu.2008-0870]; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Ellis EM, 2007, PHARMACOL THERAPEUT, V115, P13, DOI 10.1016/j.pharmthera.2007.03.015; Galvani S, 2008, FREE RADICAL BIO MED, V45, P1457, DOI 10.1016/j.freeradbiomed.2008.08.026; Hall E D, 2001, J Spinal Cord Med, V24, P142; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2008, J NEUROCHEM, V104, P708, DOI 10.1111/j.1471-4159.2007.05002.x; Hill BG, 2009, BIOCHEM J, V417, P513, DOI 10.1042/BJ20081615; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Jenner P, 2006, NEUROLOGY, V66, pS24, DOI 10.1212/WNL.66.10_suppl_4.S24; Jia ZQ, 2009, NEUROCHEM RES, V34, P1924, DOI 10.1007/s11064-009-9978-8; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Kruman I, 1997, J NEUROSCI, V17, P5089; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Lovell MA, 2001, NEUROBIOL AGING, V22, P187, DOI 10.1016/S0197-4580(00)00235-9; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; McLennan HR, 2000, J BIOENERG BIOMEMBR, V32, P153, DOI 10.1023/A:1005507913372; Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006; Nunomura A., 2007, CNS & Neurological Disorders-Drug Targets, V6, P411, DOI 10.2174/187152707783399201; PARKER WD, 1984, NEUROLOGY, V34, P1477, DOI 10.1212/WNL.34.11.1477; Perez-Pinzon MA, 2005, ANTIOXID REDOX SIGN, V7, P1150, DOI 10.1089/ars.2005.7.1150; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Picklo MJ, 2001, BBA-MOL BASIS DIS, V1535, P145, DOI 10.1016/S0925-4439(00)00093-4; Picklo MJ, 1999, J NEUROCHEM, V72, P1617, DOI 10.1046/j.1471-4159.1999.721617.x; Sayre LM, 2008, CHEM RES TOXICOL, V21, P172, DOI 10.1021/tx700210j; Sims NR, 2000, MOL BRAIN RES, V77, P176, DOI 10.1016/S0169-328X(00)00049-8; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2005, PROG NEURO-PSYCHOPH, V29, P407, DOI 10.1016/j.pnpbp.2004.12.007; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xiong YQ, 2009, FREE RADICAL RES, V43, P604, DOI 10.1080/10715760902977432; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025	60	59	59	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1311	1320		10.1089/neu.2009.1172			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100015	20392143	Green Published			2021-06-18	
J	Kharatishvili, I; Pitkanen, A				Kharatishvili, Irina; Pitkanen, Asla			Association of the severity of cortical damage with the occurrence of spontaneous seizures and hyperexcitability in an animal model of posttraumatic epilepsy	EPILEPSY RESEARCH			English	Article						Cortical damage; Epilepsy; Fluid percussion brain injury; Histopathology; Hyperexcitability	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; LITHIUM-PILOCARPINE MODEL; GUINEA-PIG BRAIN; HIPPOCAMPAL-ENTORHINAL LOOP; PREFERENTIAL NEURONAL LOSS; SYSTEM IN-VITRO; HEAD-INJURY; PARAHIPPOCAMPAL REGION; EPILEPTIFORM ACTIVITY	Posttraumatic epilepsy is a common consequence of traumatic brain injury in humans. Major predictors for the development of posttraumatic epilepsy include the severity of injury and occurrence of cortical contusions. The effect of the size or location of the cortical lesion on the risk of epileptogenesis, however, is poorly understood. Here, we investigated the extent and location of cortical damage and its association with a lowered seizure threshold and the occurrence of spontaneous seizures in rats (n=77) that had experienced moderate or severe lateral fluid-percussion brain injury (FPBI) 12 months earlier. Spontaneous seizures were detected with video-electroencephalography monitoring and a lowered seizure threshold was determined based on a pentylenetetrazol (PTZ) test. Cortical atrophy was evaluated from thionin-stained sections using the Cavalieri estimation in four different experiments in which rats developed either spontaneous recurrent seizures (i.e., epilepsy) or a lowered seizure threshold. Our data show that damage to the cortex ipsilateral to the injury was more severe and extended more caudally in epileptic animals than in those without epilepsy (p<0.05 and p<0.001 for 2 independent experiments). Further, the extent of the cortical damage correlated positively with chronically increased hyperexcitability (number of spikes in PTZ test) in animals with traumatic brain injury (r=-0.54, p<0.05; r=-0.72, p<0.01 for 2 independent experiments). Specifically, cortical lesions located at the level of the perirhinal, entorhinal, and postrhinal cortices were associated with a lowered seizure threshold and seizures. The severity of the cortical injury did not correlate with the severity of hippocampal damage. These findings indicate that, like in humans, the severity of cortical injury correlates with epileptogenesis and epilepsy in an experimental model of posttraumatic epilepsy. (C) 2010 Elsevier B.V. All rights reserved.	[Kharatishvili, Irina; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Epilepsy Res Lab, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland.	Asla.Pitkanen@uef.fi			Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; Finnish Epilepsy Foundation; Finnish Cultural FoundationFinnish Cultural Foundation	This study was supported by the Academy of Finland (A.P.), the Sigrid Juselius Foundation (A.P.), the Finnish Epilepsy Foundation (I.K.), and the Northern Savo Regional Fund of the Finnish Cultural Foundation (I.K.)	Aarabi B, 2000, Neurosurg Focus, V8, pe1; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Andre V, 2007, EPILEPSIA, V48, P41, DOI 10.1111/j.1528-1167.2007.01288.x; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1996, MAYO CLIN PROC, V71, P570, DOI 10.4065/71.6.570; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Avants B, 2008, ACAD RADIOL, V15, P1360, DOI 10.1016/j.acra.2008.07.007; Avoli M, 2002, PROG NEUROBIOL, V68, P167, DOI 10.1016/S0301-0082(02)00077-1; Avoli M, 1996, J NEUROSCI, V16, P3912; Barbarosie M, 2000, J NEUROPHYSIOL, V83, P1115; Barbarosie M, 1997, J NEUROSCI, V17, P9308; Bartolomei F, 2005, EPILEPSIA, V46, P677, DOI 10.1111/j.1528-1167.2005.43804.x; BEAR J, 1993, EPILEPSY RES, V14, P183, DOI 10.1016/0920-1211(93)90043-7; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Bernasconi N, 1999, NEUROLOGY, V52, P1870, DOI 10.1212/WNL.52.9.1870; Bernasconi N, 2003, BRAIN, V126, P462, DOI 10.1093/brain/awg034; Bernasconi N, 2001, NEUROLOGY, V56, P1335, DOI 10.1212/WNL.56.10.1335; Bernasconi N, 2000, ANN NY ACAD SCI, V911, P495; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bonilha L, 2003, J NEUROL NEUROSUR PS, V74, P1627, DOI 10.1136/jnnp.74.12.1627; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BULLOCK MR, 2005, HEAD INJURY PATHOPHY, P113; Burwell RD, 1995, HIPPOCAMPUS, V5, P390, DOI 10.1002/hipo.450050503; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566; DASILVA AM, 1990, ACT NEUR S, V50, P48; de Curtis M, 1998, BRAIN RES PROTOC, V3, P221, DOI 10.1016/S1385-299X(98)00044-0; De Guzman P, 2004, NEUROSCIENCE, V123, P875, DOI 10.1016/j.neuroscience.2003.11.013; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DU F, 1993, EPILEPSY RES, V16, P223, DOI 10.1016/0920-1211(93)90083-J; DU F, 1995, J NEUROSCI, V15, P6301; Eftekhar B, 2009, J NEUROSURG, V110, P319, DOI 10.3171/2008.4.17519; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gean A, 1994, IMAGING HEAD TRAUMA; Gnatkovsky V, 2008, ANN NEUROL, V64, P674, DOI 10.1002/ana.21519; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Guyot LL, 2000, NEUROL RES, V22, P25; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hauser WA, 1996, MAYO CLIN PROC, V71, P576, DOI 10.4065/71.6.576; HEIKKINEN ER, 1990, STEREOT FUNCT NEUROS, V54-5, P25, DOI 10.1159/000100186; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Insausti R, 1997, HIPPOCAMPUS, V7, P146, DOI 10.1002/(SICI)1098-1063(1997)7:2<146::AID-HIPO4>3.0.CO;2-L; Jutila L, 2001, AM J NEURORADIOL, V22, P1490; Kazemi M, 2004, MAGN RESON IMAGING, V22, P653, DOI 10.1016/j.mri.2004.01.043; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharatishvili I, 2009, EXP NEUROL, V217, P154, DOI 10.1016/j.expneurol.2009.01.026; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mikkonen M, 1998, ANN NEUROL, V44, P923, DOI 10.1002/ana.410440611; Nagao T, 1996, NEUROSCIENCE, V72, P399, DOI 10.1016/0306-4522(95)00534-X; Nairismagi J, 2006, EPILEPSIA, V47, P479, DOI 10.1111/j.1528-1167.2006.00455.x; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Noulhiane A, 2006, J NEUROSCI METH, V156, P293, DOI 10.1016/j.jneumeth.2006.02.021; PARE D, 1992, J NEUROSCI, V12, P1867; Paxinos G, 1998, RAT BRAIN STEREOTACT; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2006, MODELS OF SEIZURES AND EPILEPSY, P465, DOI 10.1016/B978-012088554-1/50039-6; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; Roch C, 2002, EPILEPSIA, V43, P1129, DOI 10.1046/j.1528-1157.2002.17802.x; Roch C, 2002, EPILEPSIA, V43, P325, DOI 10.1046/j.1528-1157.2002.11301.x; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salmenpera T, 2000, SEIZURE-EUR J EPILEP, V9, P208, DOI 10.1053/seiz.1999.0373; Salmenpera T, 2000, EPILEPSY RES, V40, P155, DOI 10.1016/S0920-1211(00)00121-2; Schierhout G, 2000, COCHRANE DB SYST REV, V2; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SPENCER SS, 1994, EPILEPSIA, V35, P721, DOI 10.1111/j.1528-1157.1994.tb02502.x; Sudbury JR, 2007, EUR J NEUROSCI, V26, P3571, DOI 10.1111/j.1460-9568.2007.05962.x; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Uva L, 2005, EPILEPSIA, V46, P1914, DOI 10.1111/j.1528-1167.2005.00342.x; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wozny C, 2005, NEUROBIOL DIS, V19, P451, DOI 10.1016/j.nbd.2005.01.016; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983	92	59	60	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	JUN	2010	90	1-2					47	59		10.1016/j.eplepsyres.2010.03.007			13	Clinical Neurology	Neurosciences & Neurology	621FK	WOS:000279560700008	20435440				2021-06-18	
J	Granger, CV; Markello, SJ; Graham, JE; Deutsch, A; Reistetter, TA; Ottenbacher, KJ				Granger, Carl V.; Markello, Samuel J.; Graham, James E.; Deutsch, Anne; Reistetter, Timothy A.; Ottenbacher, Kenneth J.			The Uniform Data System for Medical Rehabilitation Report of Patients with Traumatic Brain Injury Discharged from Rehabilitation Programs in 2000-2007	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Rehabilitation Outcomes; Benchmark; Quality Improvement; Traumatic Brain Injury	FUNCTIONAL INDEPENDENCE MEASURE; 1ST ADMISSIONS; STROKE; PAYMENT	Granger CV, Markello SJ, Graham JE, Deutsch A, Reistetter TA, Ottenbacher KJ: The Uniform Data System for Medical Rehabilitation: Report of patients with traumatic brain injury discharged from rehabilitation programs in 2000-2007. Am J Phys Med Rehabil 2010;89:265-278. Objective: To provide benchmarking information for a large national sample of patients receiving inpatient rehabilitation after traumatic brain injury. Design: Secondary data analysis from 893 medical rehabilitation facilities located in the United States that contributed information to the Uniform Data System for Medical Rehabilitation from January 2000 through December 2007. Variables analyzed included demographic information (age, sex, marital status, race or ethnicity, prehospital living setting, and discharge setting), hospitalization information (length of stay, program interruptions, payer, onset date, rehabilitation impairment group, Internation Classification of Diseases-9th revision codes for admitting diagnosis, and co-morbidities), and functional status information (FIM instrument [FIM] ratings at admission and discharge, FIM efficiency, FIM gain). Results: Descriptive statistics from 101,188 patients showed length of stay decreasing from a mean of 22.7 (+/-20.5) days to 16.6 (+/-14.8) days during the 8-yr study period. FIM total admission and discharge ratings also decreased. Mean admission ratings decreased from 58.6 (+/-24.7) to 54.8 (+/-21.2). Mean discharge ratings decreased from 92.4 (+/-24.2) to 85.0 (+/-24.0). Accordingly, mean functional independence measure change decreased from 33.8 (+/-20.5) to 30.2 (+/-18.4). The percentage of patients discharged to the community settings ranged from 81.3% in 2000 to 74.1% in 2007. All results are likely influenced by various policy changes affecting classification or documentation processes or both. Conclusions: National rehabilitation data from persons with traumatic brain injury in 2000-2007 indicate that patients are spending less time in an inpatient care setting than in the previous years and are experiencing improvements in functional independence during their stay. In addition, a majority of patients are discharged to community settings after inpatient rehabilitation.	[Graham, James E.; Ottenbacher, Kenneth J.] Univ Texas Galveston, Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Granger, Carl V.; Markello, Samuel J.] Uniform Data Syst Med Rehabil, Buffalo, NY USA; Northwestern Univ, Feinberg Sch Med, Rehabil Inst Chicago, Chicago, IL 60611 USA; [Deutsch, Anne] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA; [Reistetter, Timothy A.] E Carolina Univ, Dept Occupat Therapy, Greenville, NC USA	Ottenbacher, KJ (corresponding author), Univ Texas Galveston, Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.			Deutsch, Anne/0000-0003-2290-7757; Ottenbacher, Kenneth/0000-0001-5990-3982	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133G080163, H133F090030]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD055929] Funding Source: NIH RePORTER	This work was funded in part by grants H133G080163 (to KJO) and H133F090030 (to JEG) from the National Institute on Disability and Rehabilitation Research, U.S. Department of Education. The FIM instrument is a registered trademark of the Uniform Data System for Medical Rehabilitation, a division of UB Foundation Activities, Inc. Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article.	Carter GM, 2003, HEALTH CARE FINANC R, V24, P25; CARTER GM, 2002, EXECUTIVE SUMMARY AN; Deutsch A, 2002, AM J PHYS MED REHAB, V81, P133, DOI 10.1097/00002060-200202000-00010; Deutsch A, 2008, ARCH PHYS MED REHAB, V89, P2274, DOI 10.1016/j.apmr.2008.06.014; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P444, DOI 10.1097/00002060-199809000-00019; Fiedler RC, 1997, AM J PHYS MED REHAB, V76, P76, DOI 10.1097/00002060-199701000-00017; Fiedler RC, 1996, AM J PHYS MED REHAB, V75, P125, DOI 10.1097/00002060-199603000-00010; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P69, DOI 10.1097/00002060-199801000-00013; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P87, DOI 10.1097/00002060-200001000-00017; Granger CV, 2007, AM J PHYS MED REHAB, V86, P883, DOI 10.1097/PHM.0b013e318152058a; Granger CV, 2009, AM J PHYS MED REHAB, V88, P961, DOI [10.1097/PHM.0b013e3181c1ec38, 10.1097/PHM.0b013e3181clec38]; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P62, DOI 10.1097/00002060-199501000-00011; GRANGER CV, 1994, AM J PHYS MED REHAB, V73, P51, DOI 10.1097/00002060-199473010-00012; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; GRANGER CV, 1992, AM J PHYS MED REHAB, V71, P108, DOI 10.1097/00002060-199204000-00009; *IRF PAI, 2001, TRAIN MAN; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Segal ME, 1996, AM J PHYS MED REHAB, V75, P208, DOI 10.1097/00002060-199605000-00013; Stineman MG, 1997, STROKE, V28, P550, DOI 10.1161/01.STR.28.3.550; UB Foundation Activities, 2004, INP REH FAC PAT ASS; 2003, FED REG, V68, P45674	23	59	59	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	APR	2010	89	4					265	278		10.1097/PHM.0b013e3181d3eb20			14	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	584CA	WOS:000276726400001	20299850	Green Accepted			2021-06-18	
J	Varma, A; Hill, EG; Nicholas, J; Selassie, A				Varma, Abhay; Hill, Elizabeth G.; Nicholas, Joyce; Selassie, Anbesaw			Predictors of Early Mortality After Traumatic Spinal Cord Injury A Population-Based Study	SPINE			English	Article						spinal cord injury; mortality; comorbidities; ISS; TBI; Frankel grade	LONG-TERM SURVIVAL; SEVERITY SCORE; MULTIPLE INJURIES; IMPROVES ACCURACY; OLMSTED COUNTY; UNITED-STATES; PREVALENCE; OBESITY; TRENDS; DEATH	Study Design. Retrospective cohort study. Objective. To identify predictors of early mortality following traumatic spinal cord injury (TSCI). Summary of Background Data. Limited information is available on factors associated with early mortality following TSCI. Ability to identify high risk individuals can help to appropriately treat them, and reduce mortality. Methods. Early mortality was defined as death occurring during the initial hospital admission. Retrospective analysis of 1995 patients with TSCI, admitted to various hospitals of South Carolina from 1993 to 2003, was performed. There were 251 patients with early mortality. Multivariable logistic regression was used in modeling of early death following TSCI with gender, race, age, Frankel grade, trauma center, level of injury, injury severity score (ISS), traumatic brain injury (TBI), and medical comorbidities as covariates. Results. Increasing age after 20 years (OR: 1.2, P = <0.0001), male gender (OR: 1.6, P = 0.016), severe (ISS >= 15) systemic injuries (OR: 1.9, P = 0.012), TBI (OR: 3.7, P < 0.0001), 1 or more comorbidities (P < 0.0001), poor neurologic status (P = 0.015), and level 1 trauma center (OR: 1.4, P = 0.026) were significantly associated with early mortality, after adjusting for other covariates. Conclusion. Early mortality following TSCI is influenced by multiple factors. Timely recognition of these factors is crucial for improving survival in the acute care setting. Severe systemic injuries, medical comorbidities, and TBI continue to be the main limiting factors affecting the outcome. These findings also suggest the need to allocate resources for trauma prevention, and promote research towards improving the care of acutely injured patients.	[Varma, Abhay] Med Univ S Carolina, Div Neurosurg, Dept Neurosci, Charleston, SC 29425 USA; [Hill, Elizabeth G.; Nicholas, Joyce; Selassie, Anbesaw] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA	Varma, A (corresponding author), Med Univ S Carolina, Div Neurosurg, Dept Neurosci, 96 Jonathan Lucas St,Suite 428-CSB, Charleston, SC 29425 USA.	varma@musc.edu					[Anonymous], 1996, INT CLASS DIS 9 REV; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bilello JF, 2003, ARCH SURG-CHICAGO, V138, P1127, DOI 10.1001/archsurg.138.10.1127; Damadi AA, 2008, J TRAUMA, V64, P745, DOI 10.1097/TA.0b013e3180341fc6; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Frankel H L, 1969, Paraplegia, V7, P179; Frankel HL, 1998, SPINAL CORD, V36, P266, DOI 10.1038/sj.sc.3100638; Garshick E, 2005, SPINAL CORD, V43, P408, DOI 10.1038/sj.sc.3101729; Gregg EW, 2004, DIABETES CARE, V27, P2806, DOI 10.2337/diacare.27.12.2806; GRIFFIN MR, 1985, AM J EPIDEMIOL, V121, P884, DOI 10.1093/oxfordjournals.aje.a114058; GRIFFIN MR, 1985, J CHRON DIS, V38, P643, DOI 10.1016/0021-9681(85)90018-9; Harsha DW, 2008, HYPERTENSION, V51, P1420, DOI 10.1161/HYPERTENSIONAHA.107.094011; Hosalkar HS, 2005, J BONE JOINT SURG AM, V87A, P2480, DOI 10.2106/JBJS.D.01897; KRAUS JF, 1980, J NEUROSURG, V53, pS3; Krause JS, 1997, ARCH PHYS MED REHAB, V78, P815, DOI 10.1016/S0003-9993(97)90193-3; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; Lavoie A, 2004, J TRAUMA, V56, P1312, DOI 10.1097/01.TA.0000075342.36072.EF; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacLeod JBA, 2004, AM SURGEON, V70, P805; McGwin G, 2004, J TRAUMA, V56, P1291, DOI 10.1097/01.TA.0000089354.02065.D0; National Spinal Cord Injury Statistical Center, 2005, J SPINAL CORD MED, V28, P379; Nijboer JMM, 2007, J TRAUMA, V63, P670, DOI 10.1097/01.ta.0000228890.65522.53; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ong KL, 2007, HYPERTENSION, V49, P69, DOI 10.1161/01.HYP.0000252676.46043.18; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; SAMSA GP, 1993, ARCH NEUROL-CHICAGO, V50, P909, DOI 10.1001/archneur.1993.00540090018005; Saunders LL, 2009, J TRAUMA, V66, P184, DOI 10.1097/TA.0b013e31815644e5; Seeman Teresa E., 1997, Archives of Internal Medicine, V157, P2259, DOI 10.1001/archinte.157.19.2259; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Soderstrom CA, 1997, J TRAUMA, V43, P925; Surkin J, 2000, SPINE, V25, P716, DOI 10.1097/00007632-200003150-00011; Thurman DJ., 1995, GUIDELINES SURVEILLA; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; Yeo JD, 1998, SPINAL CORD, V36, P329, DOI 10.1038/sj.sc.3100628	39	59	60	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	APR 1	2010	35	7					778	783		10.1097/BRS.0b013e3181ba1359			6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	585NV	WOS:000276833500010	20228715				2021-06-18	
J	Kim, MS; Boone, KB; Victor, T; Marion, SD; Amano, S; Cottingham, ME; Ziegler, EA; Zeller, MA				Kim, Michelle S.; Boone, Kyle B.; Victor, Tara; Marion, Sarah D.; Amano, Stacy; Cottingham, Maria E.; Ziegler, Elizabeth A.; Zeller, Michelle A.			The Warrington Recognition Memory Test for Words as a Measure of Response Bias: Total Score and Response Time Cutoffs Developed on "Real World" Credible and Noncredible Subjects	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Malingering; symptom validity testing; Forensic neuropsychology; Head injury; Traumatic brain injury	SENSITIVITY; SPECIFICITY; PERFORMANCE; DYSFUNCTION; IMPAIRMENT; DEFICITS; INJURY; TRIAL	Several studies have examined the usefulness of the Warrington Recognition Memory Test-Words as a measure to detect suspect effort, although samples have generally been small and/or comprised of simulators rather than "real world" credible and noncredible patients. The current study examined the Warrington Recognition Memory Test-Words total score and response time of "real world" noncredible patients (as determined by motive to feign, failure on >= 2 independent measures of response bias, low cognitive scores inconsistent with normal ADLs; n = 190) versus credible patients (as determined by no motive to feign, failure of < 1 measure of response bias; n = 124) derived from an archival database of individuals from the Harbor-UCLA Medical Center, Department of Psychiatry, Outpatient Neuropsychology Service, and the private practice of the second author. Noncredible patients obtained significantly lower total scores and longer times to complete the task. A total correct cutoff of < 42 was found to have excellent specificity (91.9%) and sensitivity (88.9%), whereas a time cutoff of >= 207 ' was associated with 65.5% sensitivity at 90.7% specificity, and when the time cut-score was used in combination with the total score cutoff, an additional 5% of the noncredible participants were captured, raising overall sensitivity to 93.7% (at 87.1% specificity). Thus, the Warrington Recognition Memory Test-Words, although not originally created for the purposes of measuring suspect effort, appears to be an excellent measure for detecting response bias on neuropsychological testing.	[Kim, Michelle S.; Marion, Sarah D.; Amano, Stacy] Fuller Grad Sch Psychol, Pasadena, CA USA; [Boone, Kyle B.] Alliant Int Univ, Calif Sch Forens Studies, Ctr Forens Studies, Los Angeles, CA USA; [Victor, Tara] Calif State Univ Dominguez Hills, Dept Psychol, Carson, CA USA; [Cottingham, Maria E.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA; [Ziegler, Elizabeth A.] Spokane VA Med Ctr, Spokane, WA USA; [Zeller, Michelle A.] W Los Angeles VA Med Ctr, Dept Psychol, Los Angeles, CA USA	Boone, KB (corresponding author), 24564 Hawthorne Blvd,Suite 208, Torrance, CA 90505 USA.	kboone@labiomed.org	Victor, Tara/K-6581-2019				Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Baker R, 2000, Appl Neuropsychol, V7, P111, DOI 10.1207/S15324826AN0702_8; Boone K., 2002, DOT COUNTING TEST; Boone K. B., 2002, B TEST; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; BOONE KB, 2009, CLIN NEUROPSYCHOLOGI; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Egeland J, 2003, J CLIN EXP NEUROPSYC, V25, P79, DOI 10.1076/jcen.25.1.79.13630; GOLDBERG HB, 2007, ASSESSMENT FEIGNED C; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; O'Bryant SE, 2003, ARCH CLIN NEUROPSYCH, V18, P135, DOI 10.1016/S0887-6177(01)00189-5; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Ross SR, 2006, J CLIN EXP NEUROPSYC, V28, P111, DOI 10.1080/13803390590929270; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Tardif HP, 2000, INT J PSYCHOPHYSIOL, V36, P1, DOI 10.1016/S0167-8760(00)00083-0; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Warrington EK., 1984, RECOGNITION MEMORY T; Wogar MA, 1998, BRIT J CLIN PSYCHOL, V37, P327, DOI 10.1111/j.2044-8260.1998.tb01389.x	35	59	59	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2010	25	1					60	70		10.1093/arclin/acp088			11	Psychology, Clinical; Psychology	Psychology	547DI	WOS:000273865400007	19906738	Bronze			2021-06-18	
J	Riley, RD; Steyerberg, EW				Riley, Richard D.; Steyerberg, Ewout W.			Meta-analysis of a binary outcome using individual participant data and aggregate data	RESEARCH SYNTHESIS METHODS			English	Article						meta-analysis; evidence synthesis; individual participant data (IPD); binary data; participant-level covariate	PATIENT DATA; META-REGRESSION; ECOLOGICAL BIAS; LEVEL; MODELS; ASSOCIATIONS; FRAMEWORK	In this paper, we develop meta-analysis models that synthesize a binary outcome from health-care studies while accounting for participant-level covariates. In particular, we show how to synthesize the observed event-risk across studies while accounting for the within-study association between participant-level covariates and individual event probability. The models are adapted for situations where studies provide individual participant data (IPD), or a mixture of IPD and aggregate data. We show that the availability of IPD is crucial in at least some studies; this allows one to model potentially complex within-study associations and separate them from across-study associations, so as to account for potential ecological bias and study-level confounding. The models can produce pertinent population-level and individual-level results, such as the pooled event-risk and the covariate-specific event probability for an individual. Application is made to 14 studies of traumatic brain injury, where IPD are available for four studies and the six-month mortality risk is synthesized in relation to individual age. The results show that as individual age increases the probability of six-month mortality also increases; further, the models reveal clear evidence of ecological bias, with the mean age in each study additionally influencing an individual's mortality probability. Copyright (C) 2010 John Wiley & Sons, Ltd.	[Riley, Richard D.] Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Med Stat, Birmingham B15 2TT, W Midlands, England; [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Med Decis Making, NL-3000 CA Rotterdam, Netherlands	Riley, RD (corresponding author), Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Publ Hlth Bldg, Birmingham B15 2TT, W Midlands, England.	r.d.riley@bham.ac.uk	Riley, Richard David/ABE-5877-2020	Riley, Richard David/0000-0001-8699-0735	U.S. National Institutes of Health (Clinical Trial Design and Analysis in TBI Project)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS-042691]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800808] Funding Source: researchfish	The work by E. W. Steyerberg on TBI is supported by the U.S. National Institutes of Health (Clinical Trial Design and Analysis in TBI Project: R01 NS-042691). We thank the Editors, an Associate Editor, and two Reviewers for their constructive comments that have greatly improved the content of this paper.	Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643; Barr DR, 1999, AM STAT, V53, P357, DOI 10.2307/2686057; Begg MD, 2003, STAT MED, V22, P2591, DOI 10.1002/sim.1524; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; Berlin JA, 2002, STAT MED, V21, P371, DOI 10.1002/sim.1023; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Dwyer T, 2005, PAEDIATR PERINAT EP, V19, P48, DOI 10.1111/j.1365-3016.2005.00615.x; Goldstein H, 2000, J ROY STAT SOC C-APP, V49, P399, DOI 10.1111/1467-9876.00200; Greenland S, 2002, STAT MED, V21, P389, DOI 10.1002/sim.1024; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; GREENLAND S, 1989, INT J EPIDEMIOL, V18, P269, DOI 10.1093/ije/18.1.269; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jackson C, 2006, STAT MED, V25, P2136, DOI 10.1002/sim.2370; Lambert PC, 2002, J CLIN EPIDEMIOL, V55, P86, DOI 10.1016/S0895-4356(01)00414-0; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Lee KJ, 2008, STAT MED, V27, P418, DOI 10.1002/sim.2897; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Mancl LA, 2000, J DENT RES, V79, P1778, DOI 10.1177/00220345000790100801; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; NEUHAUS JM, 1991, INT STAT REV, V59, P25, DOI 10.2307/1403572; Pinheiro J.C., 1995, J COMPUT GRAPH STAT, V4, P12, DOI [10.2307/1390625, DOI 10.2307/1390625, 10.1080/10618600.1995.10474663]; RICHARDSON S, 1987, INT J EPIDEMIOL, V16, P111, DOI 10.1093/ije/16.1.111; Riley RD, 2008, STAT MED, V27, P1870, DOI 10.1002/sim.3165; Riley RD, 2007, J CLIN EPIDEMIOL, V60, P431, DOI 10.1016/j.jclinepi.2006.09.009; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Riley RD, 2008, STAT MED, V27, P6111, DOI 10.1002/sim.3441; Schmid CH, 2004, J CLIN EPIDEMIOL, V57, P683, DOI 10.1016/j.jclinepi.2003.12.001; Simmonds MC, 2007, STAT MED, V26, P2982, DOI 10.1002/sim.2768; Simmonds MC, 2005, THESIS U CAMBRIDGE; Spiegelhalter DJ, 2003, BAYESIAN APPROACHES; Steyerberg EW, 2000, STAT MED, V19, P141, DOI 10.1002/(SICI)1097-0258(20000130)19:2<141::AID-SIM334>3.0.CO;2-O; Sutton AJ, 2008, STAT MED, V27, P651, DOI 10.1002/sim.2916; Thompson SG, 2005, LANCET, V365, P341, DOI 10.1016/S0140-6736(05)17790-3; Turner RM, 2000, STAT MED, V19, P3417, DOI 10.1002/1097-0258(20001230)19:24<3417::AID-SIM614>3.3.CO;2-C; VACH W, 1991, AM J EPIDEMIOL, V134, P895, DOI 10.1093/oxfordjournals.aje.a116164; White IR, 2005, STAT MED, V24, P993, DOI 10.1002/sim.1981; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; Zhou XH, 1999, STAT MED, V18, P557, DOI 10.1002/(SICI)1097-0258(19990315)18:5<557::AID-SIM53>3.0.CO;2-F	39	59	59	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1759-2879	1759-2887		RES SYNTH METHODS	Res. Synth. Methods	JAN-MAR	2010	1	1					2	19		10.1002/jrsm.4			18	Mathematical & Computational Biology; Multidisciplinary Sciences	Mathematical & Computational Biology; Science & Technology - Other Topics	V38ZC	WOS:000209380300002	26056090				2021-06-18	
S	Sharma, HS; Zimmermann-Meinzingen, S; Johanson, CE		Andrews, RJ; Slikker, W; Trembly, B; Patterson, TA		Sharma, Hari Shanker; Zimmermann-Meinzingen, Sibilla; Johanson, Conrad E.			Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	9th International Conference on Neuroprotective Agents	SEP 07-11, 2008	Marine Biol Lab, Woods Hole, MA		Marine Biol Lab	traumatic brain injury; brain edema; blood-brain barrier; blood-CSF barrier; choroid plexus; neuronal injury; cell death; Cerebrolysin; intracerebroventricular administration; sensory-motor function	SPINAL-CORD-INJURY; ANTIOXIDANT COMPOUND H-290/51; WHOLE-BODY HYPERTHERMIA; EDEMA FORMATION; HEAT-STRESS; NEUROTROPHIC FACTORS; CELL INJURY; 5-HT LEVEL; PATHOPHYSIOLOGY; DISRUPTION	Traumatic brain injuries (TBIs) induce profound breakdown of the blood-brain and blood-cerebrospinal fluid barriers (BCSFB), brain pathology/edema, and sensory-motor disturbances. Because neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1), and glial cell-derived neurotrophic factor (GDNF), are neuroprotective in models of brain and spinal cord injuries, we hypothesized that a combination of neurotrophic factors would enhance neuroprotective efficacy. In the present investigation, we examined the effects of Cerebrolysin, a mixture of different neurotrophic factors (Ebewe Neuro Pharma, Austria) on the brain pathology and functional outcome in a rat model of TBI. TBI was produced under Equithesin (3 mL/kg, i.p.) anesthesia by making a longitudinal incision into the right parietal cerebral cortex. Untreated injured rats developed profound disruption of the blood-brain barrier (BBB) to proteins, edema/cell injury, and marked sensory-motor dysfunctions on rota-rod and grid-walking tests at 5 h TBI. Intracerebroventricular administration of Cerebrolysin (10 or 30 mu L) either 5 min or 1 h after TBI significantly reduced leakage of Evans blue and radioiodine tracers across the BBB and BCSFB, and attenuated brain edema formation/neuronal damage in the cortex as well as underlying subcortical regions. Cerebrolysin-treated animals also had improved sensory-motor functions. However, administration of Cerebrolysin 2 h after TBI did not affect these parameters significantly. These observations in TBI demonstrate that early intervention with Cerebrolysin reduces BBB and BCSFB permeability changes, attenuates brain pathology and brain edema, and mitigates functional deficits. Taken together, our observations suggest that Cerebrolysin has potential therapeutic value in TBI.	[Sharma, Hari Shanker] Uppsala Univ, Univ Hosp, Dept Anaesthesiol & Intens Care, Lab Cerebrovasc Res,Inst Surg Sci, Uppsala, Sweden; [Zimmermann-Meinzingen, Sibilla] EVER Neuro Pharma, Unterach, Austria; [Johanson, Conrad E.] Rhode Isl Hosp, Brown Med Sch, Dept Clin Neurosci, Providence, RI USA	Sharma, HS (corresponding author), Frodingsgatan 12 28, SE-75421 Uppsala, Sweden.	Sharma@surgsci.uu.se		Johanson, Conrad/0000-0002-1297-5484	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [2710]; Astra-Zeneca, Molndal, SwedenAstraZeneca; National Institute of Health, USAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS27601]; Alexander von Humboldt Foundation, GermanyAlexander von Humboldt Foundation; Ebewe Neuro-Pharma, Austria Sweden; The University Grants Commission, New Delhi, IndiaUniversity Grants Commission, India; Indian Council of Medical Research, New Delhi, IndiaIndian Council of Medical Research (ICMR); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027601] Funding Source: NIH RePORTER	The authors' research is supported by grants from Swedish Medical Research Council (2710, HSS); Astra-Zeneca, Molndal (HSS), Sweden; National Institute of Health (NS27601, CEJ), USA; Alexander von Humboldt Foundation (HSS), Germany; Ebewe Neuro-Pharma, Austria Sweden (HSS); The University Grants Commission (HSS), New Delhi, India; and The Indian Council of Medical Research (HSS), New Delhi, India. The expert technical assistance of Karstin Flink, Kerstin Rystedt, Franziska Drum, and Katherin Kern, the secretarial assistance of Aruna Sharma, and the graphical and editing contributions of Nancy and Julie Johanson are all greatly appreciated.	Abdolvahabi RM, 2001, NEUROL RES, V23, P210, DOI 10.1179/016164101101198361; ANDREWS RJ, 1991, STROKE, V22, P943, DOI 10.1161/01.STR.22.7.943; Batchelor PE, 2008, J NEUROTRAUM, V25, P1217, DOI 10.1089/neu.2007.0308; Guzman DC, 2009, BIOMED PHARMACOTHER, V63, P517, DOI 10.1016/j.biopha.2008.09.013; Chan W W, 2008, Ir Med J, V101, P255; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; DEY PK, 1983, INDIAN J MED RES, V77, P554; Johanson CE, 2005, PHARM RES-DORDR, V22, P1011, DOI 10.1007/s11095-005-6039-0; Johanson CE, 2000, CELL MOL NEUROBIOL, V20, P197, DOI 10.1023/A:1007097622590; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; Muresanu DF, 2007, ANN NY ACAD SCI, V1122, P1, DOI 10.1196/annals.1403.001; Ren J, 2007, RESTOR NEUROL NEUROS, V25, P25; Rossignol S, 2007, J NEUROSCI, V27, P11782, DOI 10.1523/JNEUROSCI.3444-07.2007; Sharma, 2004, BLOOD SPINAL CORD BR, P437; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P295, DOI 10.1196/annals.1403.022; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P426; Sharma HS, 2008, EXPERT OPIN PHARMACO, V9, P2773, DOI [10.1517/14656566.9.16.2773, 10.1517/14656566.9.16.2773 ]; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P95, DOI 10.1196/annals.1403.007; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P112, DOI 10.1196/annals.1403.008; Sharma HS, 2007, PROG BRAIN RES, V162, P459, DOI 10.1016/S0079-6123(06)62023-2; Sharma HS, 2007, PROG BRAIN RES, V162, P245, DOI 10.1016/S0079-6123(06)62013-X; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1841; Sharma HS, 2008, ANN NY ACAD SCI, V1139, P242, DOI 10.1196/annals.1432.052; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Sharma HS, 2006, J NEURAL TRANSM, V113, P521, DOI 10.1007/s00702-005-0405-2; Sharma HS, 1998, PROG BRAIN RES, V115, P351; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; SHARMA HS, 1986, NEUROPHARMACOLOGY, V25, P161, DOI 10.1016/0028-3908(86)90037-7; Sharma HS, 2002, AMINO ACIDS, V23, P261, DOI 10.1007/s00726-001-0137-z; Sharma HS, 2000, ACT NEUR S, V76, P91; Sharma HS, 2000, AMINO ACIDS, V19, P351, DOI 10.1007/s007260070066; SHARMA HS, 1990, ACT NEUR S, V51, P383; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SHARMA HS, 1987, BRAIN RES, V424, P153, DOI 10.1016/0006-8993(87)91205-4; SHARMA HS, 2009, ANN NEW YOR IN PRESS; Sharma HS, 2004, BLOOD SPINAL CORD BR, P159; Ubhi K, 2009, ACTA NEUROPATHOL, V117, P699, DOI 10.1007/s00401-009-0505-4; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Windisch M, 1998, J NEURAL TRANSM-SUPP, P289; Wong GKC, 2005, ACTA NEUROCHIR SUPPL, V95, P59	41	59	61	0	15	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-777-1	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1199						125	137		10.1111/j.1749-6632.2009.05329.x			13	Multidisciplinary Sciences; Neurosciences	Science & Technology - Other Topics; Neurosciences & Neurology	BRJ59	WOS:000282838900015	20633118				2021-06-18	
J	Salim, A; Teixeira, P; Ley, EJ; DuBose, J; Inaba, K; Margulies, DR				Salim, Ali; Teixeira, Pedro; Ley, Eric J.; DuBose, Joseph; Inaba, Kenji; Margulies, Daniel R.			Serum Ethanol Levels: Predictor of Survival After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Alcohol; Traumatic brain injury; Outcome; Intoxication	753 CONSECUTIVE DEATHS; GLASGOW COMA SCALE; HEAD-INJURY; ALCOHOL-INTOXICATION; SUBSTANCE-ABUSE; HOSPITAL COURSE; SCORE; ASSOCIATION; PREVALENCE; PREVENTION	Background: Recent studies have suggested that moderate doses of ethanol (ETOH) before traumatic brain injury (TBI) may have a neuroprotective role. Objective: The objective of this study is to investigate the effects of serum ETOH levels on outcomes after TBI. Our hypothesis was that ETOH exposure is associated with improved survival in severe TBI patients and that the serum ETOH levels on admission correlate with survival. Methods: All patients sustaining severe TBI (head abbreviated injury score >= 3) admitted to the Surgical Intensive Care Unit at the Los Angeles County + University of Southern California Medical Center from January 2000 to December 2005 who had a serum ETOH level measured on admission were analyzed. Patients were classified into ETOH-positive and ETOH-negative groups, according to the serum ETOH levels and compared for differences in outcomes using logistic regression to adjust for clinically and statistically relevant confounding factors. Results: During the 5-year study period, 482 severe TBI patients admitted to the Surgical Intensive Care Unit at Los Angeles County + University of Southern California Medical Center had a serum ETOH level measured on admission. A total of 47% of severe TBI patients were tested for ETOH. ETOH levels were positive in 37% (179) and negative in 63% (303) of the TBI patients. The ETOH-positive group had a higher percentage of males (91% vs. 79%, p = 0.001), lower percentage of penetrating injuries (9% vs. 20%, p = 0.002), and lower injury severity score (25.7 +/- 11.5 vs. 28.4 +/- 14.1, p = 0.05). Overall mortality was significantly lower in the ETOH-positive group at 27% versus 40% (odds ratio = 0.55, 95% confidence interval: 0.37-0.82; p = 0.004). This survival benefit remained significant after multivariable analysis (adjusted odds ratio = 0.54, 95% confidence interval: 0.31-0.92; adjusted p = 0.02). The mean serum ETOH level was significantly higher for survivors than for nonsurvivors (0.11 +/- 0.21 vs. 0.05 +/- 0.10, p < 0.001). The serum ETOH levels significantly correlated with the probability of survival (r = 0.21, p < 0.001), but this correlation was not strong as shown by the low r value. Conclusion: The results of this study suggest that elevated ETOH serum levels are independently associated with higher survival in patients with severe traumatic brain injuries. Additional research is required to further investigate the mechanism and potential therapeutic implications of this association.	[Salim, Ali; Ley, Eric J.; Margulies, Daniel R.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Teixeira, Pedro; DuBose, Joseph; Inaba, Kenji] Univ So Calif, Med Ctr, Div Trauma, Los Angeles, CA USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	INABA, KENJI/AAC-8532-2020; Teixeira, Pedro/H-2239-2011	Teixeira, Pedro/0000-0002-7258-7977			Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Association for the Advancement of Automotive Medicine, 2005, ABBR INJ SCAL; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; Christensen M A, 2001, J Neurosci Nurs, V33, P184; Cornwell EE, 1998, AM SURGEON, V64, P461; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Flaherty S, 2003, J TRAUMA, V54, P70; Golan JD, 2007, J TRAUMA, V63, P365, DOI 10.1097/TA.0b013e31811ec178; Guidot DM, 2005, J INVEST MED, V53, P235, DOI 10.2310/6650.2005.53506; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HERVE C, 1986, J TRAUMA, V26, P1123, DOI 10.1097/00005373-198612000-00013; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Masse J, 2000, J NEUROTRAUM, V17, P421, DOI 10.1089/neu.2000.17.421; MILLER TR, 1994, ACCIDENT ANAL PREV, V26, P583, DOI 10.1016/0001-4575(94)90020-5; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; NHTSA, 2000, EC IMP MOT VEH CRASH; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rootman DB, 2007, J TRAUMA, V62, P755, DOI 10.1097/TA.0b013e318031aa7f; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sperry JL, 2006, J TRAUMA, V61, P1305, DOI 10.1097/01.ta.0000240113.13552.96; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TEASDALE G, 1974, LANCET, V2, P81; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; WOOLF PD, 1991, J TRAUMA, V31, P1271, DOI 10.1097/00005373-199109000-00012; Woolf PD, 1991, J TRAUMA, V31, P1275	51	59	62	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2009	67	4					697	703		10.1097/TA.0b013e3181b5dcf2			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	506BE	WOS:000270747000004	19820573				2021-06-18	
J	Kaneko, T; Kasaoka, S; Miyauchi, T; Fujita, M; Oda, Y; Tsuruta, R; Maekawa, T				Kaneko, Tadashi; Kasaoka, Shunji; Miyauchi, Takashi; Fujita, Motoki; Oda, Yasutaka; Tsuruta, Ryosuke; Maekawa, Tsuyoshi			Serum glial fibrillary acidic protein as a predictive biomarker of neurological outcome after cardiac arrest	RESUSCITATION			English	Article						Cardiac arrest; Therapeutic hypothermia; Brain ischemia	NEURON-SPECIFIC-ENOLASE; TRAUMATIC BRAIN-INJURY; REGAINING CONSCIOUSNESS; CEREBRAL-ISCHEMIA; HYPOTHERMIA; S-100; DAMAGE; ENCEPHALOPATHY; S100B; GFAP	Aim of the study: Serum glial fibrillary acidic protein (GFAP) has recently been identified as a specific predictor of brain damage and neurological outcome in patients with head trauma. In this study, serum GFAP was assessed as a predictor of neurological outcome in post-cardiac-arrest (PCA) patients. Methods: This study was a retrospective, single-medical-center analysis, conducted in the intensive care unit of a university hospital. Forty-four sequential PCA patients with cardiogenic or non-cardiogenic arrest were included. The patients were treated with or without therapeutic hypothermia (TH). Serum samples were collected from the patients at 12, 24, and 48 h after the return of spontaneous circulation (ROSC). Serum GFAP concentrations were measured by enzyme-linked immunosorbent assay and compared in patients with good and poor neurological outcomes, evaluated over a period of 6 months using Glasgow Outcome Scale. Results: Serum GFAP was significantly higher in patients with a poor outcome at 12 and 24 h without TH and at 48 h with TH (P<0.05). GFAP (>0.1 ng dL(-1)) was a specific predictor of poor neurological outcome at 6 months with or without TH treatment. Conclusions: Although this study is preliminary, serum GFAP after ROSC reflected a poor neurological outcome in PCA patients. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Kaneko, Tadashi; Kasaoka, Shunji; Miyauchi, Takashi; Fujita, Motoki; Oda, Yasutaka; Tsuruta, Ryosuke; Maekawa, Tsuyoshi] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr AMEC3, Yamaguchi, Japan	Kaneko, T (corresponding author), Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr AMEC3, 1-1-1 Minamikogushi, Yamaguchi, Japan.	kaneyui-ygc@umin.ac.jp			Japanese Ministry of Health, Labor, and WelfareMinistry of Health, Labour and Welfare, Japan [19791329]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [19791329] Funding Source: KAKEN	This clinical study was supported by a research project grant from the Japanese Ministry of Health, Labor, and Welfare (number 19791329).; We are very grateful to Hitomi Ikemoto for her valuable technical assistance in all measurements. We also express our thanks to Masako Ueda for assistance in the grant related paper work.	Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bottiger BW, 2001, CIRCULATION, V103, P2694; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Hachimi-Idrissi S, 2005, RESUSCITATION, V64, P187, DOI 10.1016/j.resuscitation.2004.08.008; Hachimi-Idrissi S, 2002, RESUSCITATION, V53, P251, DOI 10.1016/S0300-9572(02)00027-8; Hara A, 2005, CIRCULATION, V112, P84, DOI 10.1161/CIRCULATIONAHA.104.527077; Holzer M, 2002, NEW ENGL J MED, V346, P549; Kaneko T, 2005, CRIT CARE MED, V33, pA18, DOI 10.1097/00003246-200512002-00071; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Strbian D, 2008, NEUROSCIENCE, V153, P175, DOI 10.1016/j.neuroscience.2008.02.012	22	59	61	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUL	2009	80	7					790	794		10.1016/j.resuscitation.2009.04.003			5	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	468RH	WOS:000267837100019	19411130				2021-06-18	
J	Povlishock, JT; Wei, EP				Povlishock, John T.; Wei, Enoch P.			Posthypothermic Rewarming Considerations following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			axonal damage; contusion; microvascular damage and dysfunction; posthypothermic rewarming; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; POSTTRAUMATIC HYPOTHERMIA; CYCLOSPORINE-A; AXONAL INJURY; CEREBRAL MICROCIRCULATION; THERAPEUTIC HYPOTHERMIA; PROLONGED HYPOTHERMIA; MODERATE HYPOTHERMIA; OXYGEN RADICALS; DAMAGE	To date, considerable attention has been focused upon the use of hypothermia as a therapeutic strategy for attenuating many of the damaging consequences of traumatic brain injury (TBI). Despite the promise of hypothermic intervention following TBI, many questions remain regarding the optimal use of hypothermic intervention, including, but not limited to, the rewarming rates needed to assure optimal brain protection. In this review, we revisit the relatively limited literature examining the issue of hypothermia and differing rewarming rates following TBI. Considering both experimental and clinical literature, evidence is presented that the rate of posthypothermic rewarming is an important variable for influencing the protective effects of hypothermic intervention following TBI. In the experimental setting, posttraumatic hypothermia followed by slow rewarming appears to provide maximal protection in terms of traumatically induced axonal damage, microvascular damage and dysfunction, and contusional expansion. In contrast, hypothermia followed by rapid rewarming not only reverses the protective effects associated with hypothermic intervention, but in many cases, exacerbates the traumatically induced pathology and its functional consequences. While similar evaluations have not been conducted in the clinical setting, multiple lines of clinical evidence suggest the benefits of posttraumatic hypothermia are optimized through the use of slow rewarming, with the suggestion that such a strategy reduces the potential for rebound vasodilation, elevated intracranial pressure (ICP), and impaired neurocognitive recovery. Collectively, this review highlights not only the benefits of hypothermic intervention, but also the rate of posthypothermic rewarming as an important variable in assuring maximal efficacy following the use of hypothermic intervention.	[Povlishock, John T.; Wei, Enoch P.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045824, R21NS057175] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD055813, R01 HD055813-24, R01HD055813] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045824, R01 NS045824-01A1, R01NS045824, R21 NS057175-01A2, R21NS057175-01, R21 NS057175] Funding Source: Medline		Alzaga AG, 2006, RESUSCITATION, V70, P369, DOI 10.1016/j.resuscitation.2006.01.017; Berger C, 2007, EXP NEUROL, V204, P131, DOI 10.1016/j.expneurol.2006.10.002; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; BLOCH M, 1967, BRAIN, V90, P769, DOI 10.1093/brain/90.4.769; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Grigore AM, 2002, ANESTH ANALG, V94, P4, DOI 10.1097/00000539-200201000-00002; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kontos H A, 1980, Adv Exp Med Biol, V131, P243; Kontos H A, 1983, Physiologist, V26, P165; Kontos H A, 1981, Trans Am Clin Climatol Assoc, V92, P111; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1981, FED PROC, V40, P2326; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Vigue B, 2006, ANN FR ANESTH, V25, P838, DOI 10.1016/j.annfar.2006.03.017; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; WEI EP, 1985, AM J PHYSIOL, V248, pH157; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	39	59	60	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					333	340		10.1089/neu.2008.0604			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900006	19292695	Green Accepted, Green Published			2021-06-18	
J	Galbiati, S; Recla, M; Pastore, V; Liscio, M; Bardoni, A; Castelli, E; Strazzer, S				Galbiati, Susanna; Recla, Monica; Pastore, Valentina; Liscio, Mariarosaria; Bardoni, Alessandra; Castelli, Enrico; Strazzer, Sandra			Attention Remediation Following Traumatic Brain Injury in Childhood and Adolescence	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; attention components; cognitive deficit; neuropsychological treatment; ecological context	COGNITIVE REHABILITATION; SUSTAINED ATTENTION; WORKING-MEMORY; CHILDREN; DEFICITS; MANAGEMENT; SEVERITY	Traumatic brain injury (TBI) frequently affects both the basic and the superordinate components of attention; deficits vary according to patient age. This study evaluated the efficacy of a specific remediation intervention for attention. Sixty-five TBI patients (aged 6-18 years) with attention deficit were assessed at baseline and at I-year follow-up: 40 patients received attention-specific neuropsychological training for 6 months, and the control group comprised 25 patients. Cognitive assessment included a Wechsler Intelligence Scale (e.g., A. Orsini, 1993) and the Continuous Performance Test II (CPT II; C. K. Conners, 2000). The Vineland Adaptive Behavior Scales (VABS; S. Sparrow, D. Balla & D. V. Cicchetti, 1984) was administered to assess the treatment's ecological validity. At baseline, all patients presented with a mild intellectual disability and pathological scores on the CPT II. At follow-up, significant differences were found between the 2 groups on the CPT 11 and VABS: The clinical group improved more than the control group. Specific remediation training for attention, including a combination of a process-specific approach and metacognitive strategies, significantly improved attention performance. Improvement in attention skills also affected adaptive skills positively.	[Galbiati, Susanna; Recla, Monica; Pastore, Valentina; Liscio, Mariarosaria; Bardoni, Alessandra; Strazzer, Sandra] IRCCS E Medea, I-23842 Bosisio Parini, Lecco, Italy; [Castelli, Enrico] Osped Pediat Bambin Gesu, Rome, Italy	Strazzer, S (corresponding author), IRCCS E Medea, Via Don Luigi Monza 20, I-23842 Bosisio Parini, Lecco, Italy.	sandrastrazzer@yahoo.it	BARDONI, ALESSANDRA/AAH-7233-2019; Recla, Monica/ABG-1905-2020; Galbiati, Susanna/AAH-6883-2019; Pastore, Valentina/AAH-6831-2019; Strazzer, Sandra/AAH-5712-2019; Castelli, Enrico/J-1887-2012	BARDONI, ALESSANDRA/0000-0001-8404-3857; Recla, Monica/0000-0002-3001-8872; Galbiati, Susanna/0000-0001-7209-4251; Pastore, Valentina/0000-0002-3170-3070; Strazzer, Sandra/0000-0001-8414-6565; 			Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Conners C., 2000, CONNERS CONTINUOUS P; Conners C. K., 1995, CONNERS CONTINUOUS P; DINUOVO S, 1992, ATTENZIONE CONCENTRA; ESLINGER PJ, 2002, NEUROPSYCHOLOGICAL I; Fernandez-Guinea S, 2001, REV NEUROLOGIA, V33, P373, DOI 10.33588/rn.3304.2000193; HANNEY M, 1994, 22 ANN M INT NEU SOC; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Jha AP, 2002, COGNITIVE BRAIN RES, V15, P61, DOI 10.1016/S0926-6410(02)00216-1; Klingberg T, 2006, NEUROPSYCHOLOGIA, V44, P2171, DOI 10.1016/j.neuropsychologia.2005.11.019; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; Limond J, 2005, J CHILD PSYCHOL PSYC, V46, P339, DOI 10.1111/j.1469-7610.2004.00397.x; LISCIO M, 2003, DAL COMA REINSERIMEN; MACKWORTH NH, 1957, ADVANCEMENT SCIENCE, V53, P389; MARZOCCHI GM, 2000, ATTENZIONE METACOGNI; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Michaud L. J., 1995, TRAUMATIC HEAD INJUR, P247; Michel J A, 2006, Eura Medicophys, V42, P59; Mulligan Shelley, 2001, Physical and Occupational Therapy in Pediatrics, V20, P25, DOI 10.1300/J006v20n04_03; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Nag S, 1999, NEUROL INDIA, V47, P32; Oberg L, 1998, J HEAD TRAUMA REHAB, V13, P44, DOI 10.1097/00001199-199806000-00005; Oh Hyun Soo, 2005, Taehan Kanho Hakhoe Chi, V35, P270; Olesen PJ, 2007, CEREB CORTEX, V17, P1047, DOI 10.1093/cercor/bhl0l4; Orsini A., 1997, WISC R CONTRIBUTO TA; Orsini A, 1993, WISC R CONTRIBUTO TA; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Pavawalla SP, 2006, J INT NEUROPSYCH SOC, V12, P802, DOI 10.1017/S135561770606098X; Penkman Louise, 2004, Pediatr Rehabil, V7, P111, DOI 10.1080/13638490310001649417; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PRATHER P, 1991, ATTENZIONE SUOI DIST; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SCHUHFRIED, 1996, REHACOM; Shalev L, 2007, CHILD NEUROPSYCHOL, V13, P382, DOI 10.1080/09297040600770787; Shapiro ES, 1998, J LEARN DISABIL, V31, P545, DOI 10.1177/002221949803100604; Sohlberg M. M., 2001, COGNITIVE REHABILITA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Thomson J. B., 1995, J INT NEUROPSYCH SOC, V1, P149; THOMSON JB, 2000, NEUROPSYCHOLOGICAL M, P233; TROMP E, 1991, J CLIN EXPT NEUROPSY, V13, P167; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Van't Hooft I, 2005, BRAIN INJURY, V19, P511, DOI 10.1080/02699050400025224; van't Hooft I, 2003, ACTA PAEDIATR, V92, P935, DOI 10.1080/08035250310004586; vant Hooft I, 2007, NEUROREHABILITATION, V22, P109; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	60	59	60	1	21	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2009	23	1					40	49		10.1037/a0013409			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	391CA	WOS:000262209300004	19210031				2021-06-18	
J	Toklu, HZ; Hakan, T; Biber, N; Solakolu, S; Ogunc, AV; Sener, G				Toklu, Hale Z.; Hakan, Tayfun; Biber, Necat; Solakolu, Seyhun; Oeguenc, Ayliz Velioglu; Sener, Goeksel			The protective effect of alpha lipoic acid against traumatic brain injury in rats	FREE RADICAL RESEARCH			English	Article						Alpha lipoic acid; brain injury; closed head; trauma; blood-brain barrier; oedema	ISCHEMIA-REPERFUSION INJURY; CLOSED-HEAD INJURY; OXIDATIVE STRESS; REACTIVE OXYGEN; NA+,K+-ATPASE ACTIVITY; METABOLIC ANTIOXIDANT; MELATONIN; MODEL; PATHOPHYSIOLOGY; NEUROPROTECTION	Traumatic brain injury (TBI) was induced by a weight-drop device using 300 g-1 m weight-height impact. The study groups were: control, alpha-lipoic acid (LA) (100 mg/kg, po), TBI, and TBI + LA (100 mg/kg, po). Forty-eight hours after the injury, neurological scores were measured and brain samples were taken for histological examination or determination of thiobarbituric acid reactive substances (TBARS) and glutathione (GSH) levels, myeloperoxidase (MPO) and Na+-K+ ATPase activities, whereas cytokines (TNF-, IL-1) were determined in blood. Brain oedema was evaluated by wet-dry weight method and blood-brain barrier (BBB) permeability was evaluated by Evans Blue (EB) extravasation. As a result, neurological scores mildly increased in trauma groups. Moreover, TBI caused a significant decrease in brain GSH and Na+-K+ ATPase activity, which was accompanied with significant increases in TBARS level, MPO activity and plasma proinflammatory cytokines. LA treatment reversed all these biochemical indices as well as histopathological alterations. TBI also caused a significant increase in brain water content and EB extravasation which were partially reversed by LA treatment. These findings suggest that LA exerts neuroprotection by preserving BBB permeability and by reducing brain oedema probably by its anti-inflammatory and antioxidant properties in the TBI model.	[Toklu, Hale Z.; Sener, Goeksel] Marmara Univ, Sch Pharm, Dept Pharmacol, TR-34668 Istanbul, Turkey; [Hakan, Tayfun; Biber, Necat] Haydarpasa Numune Teaching & Res Hosp, Dept Neurosurg, Istanbul, Turkey; [Solakolu, Seyhun] Istanbul Univ, Sch Med, Dept Histol & Embriyol, Istanbul, Turkey; [Oeguenc, Ayliz Velioglu] Marmara Univ, Vocat Sch Hlth Related Sci, TR-34668 Istanbul, Turkey	Sener, G (corresponding author), Marmara Univ, Sch Pharm, Dept Pharmacol, TR-34668 Istanbul, Turkey.	gsener@marmara.edu.tr	Hakan, Tayfun/P-8626-2015; Toklu, Hale/AAR-2330-2020; Hakan, Tayfun/O-9979-2019	Hakan, Tayfun/0000-0003-1444-7076; Toklu, Hale/0000-0002-9797-3591; Hakan, Tayfun/0000-0003-1444-7076; solakoglu, seyhun/0000-0002-1389-9639	Mikrogen Pharmaceuticals	The authors are grateful to Mikrogen Pharmaceuticals for supplying alpha lipoic acid.	Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Arivazhagan P, 2002, EXP GERONTOL, V37, P803, DOI 10.1016/S0531-5565(02)00015-3; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Biewenga GP, 1997, GEN PHARMACOL, V29, P315, DOI 10.1016/S0306-3623(96)00474-0; Buege J A, 1978, Methods Enzymol, V52, P302; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Chng HT, 2009, BRAIN RES, V1251, P80, DOI 10.1016/j.brainres.2008.11.025; Darakchiev BJ, 1997, ACT NEUR S, V70, P98; DAVIES GR, 1992, GUT, V33, P1467, DOI 10.1136/gut.33.11.1467; Dulundu E, 2007, PHARMACOLOGY, V79, P163, DOI 10.1159/000098953; Durmaz R, 2003, J NEUROL SCI, V215, P87, DOI 10.1016/S0022-510X(03)00207-7; ERECINSKA M, 1994, PROG NEUROBIOL, V43, P37, DOI 10.1016/0301-0082(94)90015-9; Erecinska M, 2004, PROG NEUROBIOL, V73, P397, DOI 10.1016/j.pneurobio.2004.06.003; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feng Dong-fu, 2004, Chin J Traumatol, V7, P148; Fiske CH, 1925, J BIOL CHEM, V66, P375; GRISAR T, 1984, ANN NEUROL, V16, pS128, DOI 10.1002/ana.410160719; Hagen TM, 1999, FASEB J, V13, P411, DOI 10.1096/fasebj.13.2.411; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; KIM YK, 1986, TOXICOL APPL PHARM, V86, P411, DOI 10.1016/0041-008X(86)90368-6; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kurella E, 1997, ANN NY ACAD SCI, V834, P661, DOI 10.1111/j.1749-6632.1997.tb52344.x; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makeeva AV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P76, DOI 10.1134/S0006297908010112; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Moini H, 2002, TOXICOL APPL PHARM, V182, P84, DOI 10.1006/taap.2002.9437; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Packer L, 1997, Adv Pharmacol, V38, P79; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; Prahalathan C, 2006, TOXICOLOGY, V222, P225, DOI 10.1016/j.tox.2006.02.015; READING HW, 1980, Q J EXP PHYSIOL CMS, V65, P105, DOI 10.1113/expphysiol.1980.sp002495; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Rossol M, 1998, J AM INST CONSERV, V37, P231, DOI 10.2307/3179807; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Sehirli O, 2008, CLIN EXP PHARMACOL P, V35, P249, DOI 10.1111/j.1440-1681.2007.04810.x; Selvakumar E, 2006, CLIN CHIM ACTA, V367, P114, DOI 10.1016/j.cca.2005.11.034; Sener G, 2005, SURG TODAY, V35, P52, DOI 10.1007/s00595-004-2879-1; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Shay KP, 2008, IUBMB LIFE, V60, P362, DOI 10.1002/iub.40; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Smrcka M, 2007, BRATISL MED J, V108, P144; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Toklu HZ, 2008, J SURG RES, V145, P214, DOI 10.1016/j.jss.2007.03.072; Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; Yang YB, 2003, ACTA PHARMACOL SIN, V24, P703; Yu SP, 2003, BIOCHEM PHARMACOL, V66, P1601, DOI 10.1016/S0006-2952(03)00531-8	62	59	60	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-5762	1029-2470		FREE RADICAL RES	Free Radic. Res.		2009	43	7					658	667	PII 911687855	10.1080/10715760902988843			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	457ZS	WOS:000266979200003	19468925				2021-06-18	
J	DuBose, JJ; Browder, T; Inaba, K; Teixeira, PGR; Chan, LS; Demetriades, D				DuBose, Joseph J.; Browder, Timothy; Inaba, Kenji; Teixeira, Pedro G. R.; Chan, Linda S.; Demetriades, Demetrios			Effect of Trauma Center Designation on Outcome in Patients With Severe Traumatic Brain Injury	ARCHIVES OF SURGERY			English	Article							AMERICAN-COLLEGE; LEVEL-I; SYSTEM; SURGEONS; MORTALITY; VOLUME; VERIFICATION; IMPACT; CARE	Objective: To determine the association of the American College of Surgeons ( ACS) designation with outcomes in patients, specifically those with severe traumatic brain injuries. Design: A retrospective review. Logistic regression was performed for mortality, complications, and progression of initial neurologic insult. Setting: Data from the National Trauma Data Bank. Patients: A total of 16 037 patients with isolated severe head injury ( head acute injury score, >= 3 and other body region abbreviated injury score, < 3) classified into 2 groups ( level 1 and level 2) according to ACS designation. Results: Patients admitted to a level 2 center had higher mortality rates ( 13.9% vs 9.6%; P < .001), higher rates of complication ( 15.5% vs 10.6%; P < .001), and higher rates of progression of initial neurologic insult ( 2.0% vs 1.1%; P < .001). After adjustment for the factors that were different between the 2 groups, admission to a level 2 facility remained an independent predictor of mortality ( adjusted odds ratio [ OR], 1.57; 95% confidence interval [ CI], 1.41-1.75; P < .001), complications ( adjusted OR, 1.55; 95% CI, 1.40-1.71; P < .001), and progression of neurologic insult ( adjusted OR, 1.78; 95% CI, 1.37-2.31; P < .001). Other independent risk factors for mortality were penetrating mechanism, age of 55 years or older, Injury Severity Score of 20 or higher, Glasgow Coma Scale score of 8 or lower, and hypotension ( systolic blood pressure, < 90 mm Hg). Conclusion: Patients with severe traumatic brain injury treated in ACS-designated level 1 trauma centers have better survival rates and outcomes than those treated in ACS-designated level 2 centers.	[DuBose, Joseph J.; Browder, Timothy; Inaba, Kenji; Teixeira, Pedro G. R.; Chan, Linda S.; Demetriades, Demetrios] Univ So Calif, Los Angeles Cty Hosp, Sch Med, Los Angeles, CA 90033 USA	DuBose, JJ (corresponding author), Univ So Calif, 1200 N State St,Room 10-750, Los Angeles, CA 90033 USA.	jjd3c@yahoo.com	Teixeira, Pedro/H-2239-2011; INABA, KENJI/AAC-8532-2020	Teixeira, Pedro/0000-0002-7258-7977; 			Biffl WL, 2005, J AM COLL SURGEONS, V200, P922, DOI 10.1016/j.jamcollsurg.2005.01.014; Clancy TV, 2001, J TRAUMA, V51, P346, DOI 10.1097/00005373-200108000-00021; Committee on Trauma of the American College of Surgeons, 2000, RES OPT CAR INJ PAT; Cooper A, 2000, J TRAUMA, V48, P16, DOI 10.1097/00005373-200001000-00004; Cornwell EE, 2003, ARCH SURG-CHICAGO, V138, P838, DOI 10.1001/archsurg.138.8.838; Demetriades D, 2006, J AM COLL SURGEONS, V202, P212, DOI 10.1016/j.jamcollsurg.2005.09.027; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Demetriades D, 1998, BRIT J SURG, V85, P379; DiRusso S, 2001, J TRAUMA, V51, P294, DOI 10.1097/00005373-200108000-00011; Ehrlich PF, 2002, J TRAUMA, V53, P811, DOI 10.1097/00005373-200211000-00001; Harbrecht BG, 2005, AM SURGEON, V71, P942; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Helling TS, 1997, J TRAUMA, V42, P1091, DOI 10.1097/00005373-199706000-00018; Mullins RJ, 1998, J TRAUMA, V44, P609, DOI 10.1097/00005373-199804000-00009; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; NORWOOD S, 1995, J TRAUMA, V39, P240, DOI 10.1097/00005373-199508000-00009; Pasquale MD, 2001, J TRAUMA, V50, P465, DOI 10.1097/00005373-200103000-00010; Piontek FA, 2003, J TRAUMA, V54, P1041, DOI 10.1097/01.TA.0000061107.55798.31; SAMPALIS JS, 1995, J TRAUMA, V39, P232, DOI 10.1097/00005373-199508000-00008; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; SMITH RF, 1990, J TRAUMA, V30, P1066, DOI 10.1097/00005373-199009000-00002; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778	22	59	63	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0004-0010	1538-3644		ARCH SURG-CHICAGO	Arch. Surg.	DEC	2008	143	12					1213	1217		10.1001/archsurg.143.12.1213			5	Surgery	Surgery	384JO	WOS:000261741300015	19075174	Bronze			2021-06-18	
J	Tapia-Perez, JH; Sanchez-Aguilar, M; Torres-Corzo, JG; Gordillo-Moscoso, A; Martinez-Perez, P; Madeville, P; de la Cruz-Mendoza, E; Chalita-Williams, J				Tapia-Perez, J. Humberto; Sanchez-Aguilar, Martin; Torres-Corzo, Jaime G.; Gordillo-Moscoso, Antonio; Martinez-Perez, Patricia; Madeville, Peter; de la Cruz-Mendoza, Esperanza; Chalita-Williams, Juan			Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758)	JOURNAL OF NEUROTRAUMA			English	Article						amnesia; inflammation; rosuvastatin	ANEURYSMAL SUBARACHNOID HEMORRHAGE; ATORVASTATIN REDUCTION; GALVESTON ORIENTATION; NEURONAL SURVIVAL; RATS; INFLAMMATION; SIMVASTATIN; THROMBOSIS; INCREASE; OBJECT	Amnesia is a common sequela following traumatic brain injury (TBI), for which there is no current treatment. Pleiotropic effects of statins have demonstrated faster recovery of spatial memory after TBI in animals. We conducted a double-blind randomized clinical trial add-on of patients with TBI (16-50 years of age), with Glasgow Coma Scale (GCS) scores of 9-13, and intracranial lesions as demonstrated by computed tomography (CT) scan. We excluded those patients with recent head injury or severe disability; administration of known drugs as modifiers of statin metabolism; multisystemic trauma; prior use of mannitol, barbiturate, corticosteroids, indomethacin or calcium antagonists; surgical or isolated lesion in brainstem; allergy to statins; previous hepatopathy or myopathy; previous management in another clinic; or pregnancy. Each patient received the same treatment and was randomly allocated to receive either rosuvastatin (RVS) or placebo over a period of 10 days. The primary outcome measures assessed were amnesia and disorientation times using Galveston Orientation Amnesia Test. Additionally, we evaluated plasma levels of interleukin (IL) 1 beta, tumor necrosis factor (TNF) alpha, and IL-6, as well as disability at 3 months. We analyzed eight patients with RVS and 13 controls with similar basal characteristics. Using Cox regression analysis, administration of RVS showed a reduction of amnesia time with a hazard ratio of 53.76 (95% confidence interval [CI], 1.58-1824.64). This was adjusted for early intubation, basal leukocytes, basal Marshall and Fisher score, change of IL-1 beta levels, and lesion side. IL-6 values at day 3 were increased in the RVS group (p = 0.04). No difference was detected in disability at 3 months. While statins may reduce amnesia time after TBI, possibly by immunomodulation, further trials are needed in order to confirm this positive association.	[Tapia-Perez, J. Humberto; de la Cruz-Mendoza, Esperanza] Univ Autonoma San Luis Potosi, Fac Med, Nucl Med Lab, San Luis Potosi 78210, SLP, Mexico; [Tapia-Perez, J. Humberto; Torres-Corzo, Jaime G.; Chalita-Williams, Juan] Hosp Cent Dr Ignacio Morones Prieto, San Luis Potosi, SLP, Mexico	Tapia-Perez, JH (corresponding author), Univ Autonoma San Luis Potosi, Fac Med, Nucl Med Lab, Av Venustiano Carranza 2405, San Luis Potosi 78210, SLP, Mexico.	lehwand@hotmail.com		TORRES-CORZO, JAIME G./0000-0002-3981-0831			Amarenco P, 2006, NEW ENGL J MED, V355, P549; BLESSING R, 2005, STROKE, V36, P2024; BROWNE RH, 1995, STAT MED, V14, P1933, DOI 10.1002/sim.4780141709; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; *COMBI, 2008, DIS RAT SCAL; Curtis CE, 2000, NEUROPSYCHOLOGIA, V38, P1503, DOI 10.1016/S0028-3932(00)00062-2; Curtis CE, 2000, NEUROREPORT, V11, P2203, DOI 10.1097/00001756-200007140-00028; Fletcher B, 2005, CIRCULATION, V112, P3184, DOI 10.1161/CIRCULATIONAHA.105.169180; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Heegaard W, 2007, EMERG MED CLIN N AM, V25, P655, DOI 10.1016/j.emc.2007.07.001; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lu DY, 2004, J NEUROSURG, V101, P822, DOI 10.3171/jns.2004.101.5.0822; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; Maguire EA, 2001, NEUROIMAGE, V13, P743, DOI 10.1006/nimg.2000.0712; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Nariai T, 2001, J NEUROTRAUM, V18, P1323, DOI 10.1089/08977150152725623; Naval NS, 2008, NEUROCRIT CARE, V8, P6, DOI 10.1007/s12028-007-0080-2; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Silva SCFE, 2007, REV LAT-AM ENFERM, V15, P651, DOI 10.1590/S0104-11692007000400020; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Tseng MY, 2007, J NEUROSURG, V107, P1092, DOI 10.3171/JNS-07/12/1092; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031	28	59	59	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2008	25	8					1011	1017		10.1089/neu.2008.0554			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	343ZT	WOS:000258895700007	18690806				2021-06-18	
J	Thal, SC; Wyschkon, S; Pieter, D; Engelhard, K; Werner, C				Thal, Serge C.; Wyschkon, Sebastian; Pieter, Dana; Engelhard, Kristin; Werner, Christian			Selection of endogenous control genes for normalization of gene expression analysis after experimental brain trauma in mice	JOURNAL OF NEUROTRAUMA			English	Article						control gene; housekeeping gene; PCR; real-time; traumatic brain injury	POLYMERASE CHAIN-REACTION; REAL-TIME; HOUSEKEEPING GENES; RIBOSOMAL-RNA; BETA-ACTIN; RT-PCR; VALIDATION; STANDARDS; TISSUE; ASSAYS	Quantitative measurements of gene expression require correction for tissue sample size, RNA quantity, and reverse transcription efficiency. This can be achieved by normalization with control genes. The study was designed to identify candidates not altered after brain trauma. Male C57Bl/6 mice were anesthetized with isoflurane, and a pneumatic brain trauma was induced by controlled cortical impact (CCI) on the right parietal cortex. Brains were removed at 15 min, and 3, 6, 12 and 24 h after CCI and from naive animals (n = 6 each). Absolute copies of six control genes (beta-2-microglobin [B2M], cyclophilin A, beta-actin, hypoxanthine ribosyltransferase [HPRT], porphobilinogen deaminase [PBGD], and glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) and one example target gene (iNOS) were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR; Lightcycler(R)) in the traumatic focus and contralateral tissue. Control gene expression was stable until 12 h after CCI. At 24 h after CCI expression of B2M, cyclophilin A and HPRT remained stable in the contusion, while expression of beta-actin, GAPDH, and PBGD increased. Due to variations between animals (+/- 85%), increases in beta-actin (+/- 64%) and GAPDH (+59%) did not reach the level of significance. In non-contused tissue, expression of all genes dropped 24 h after CCI (range, -17% to -61%). Due to low variations between animals and stable expression after CCI, B2M and cyclophilin A seem to be suitable to serve as single normalizer. Normalization of the example target gene iNOS resulted in varying relative expression extending from onefold (PBDG) to 10-fold (HPRT). The results suggest that the knowledge of the temporal profile of control genes is essential to properly interpret results of mRNA quantification.	[Thal, Serge C.; Wyschkon, Sebastian; Pieter, Dana; Engelhard, Kristin; Werner, Christian] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, D-55131 Mainz, Germany	Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729			Bas A, 2004, SCAND J IMMUNOL, V59, P566, DOI 10.1111/j.0300-9475.2004.01440.x; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Bustin Stephen A, 2004, J Biomol Tech, V15, P155; Cronin Maureen, 2004, Clin Chem, V50, P1464, DOI 10.1373/clinchem.2004.035675; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Goidin D, 2001, ANAL BIOCHEM, V295, P17, DOI 10.1006/abio.2001.5171; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Nishida Y, 2006, J PHARMACOL SCI, V101, P52, DOI 10.1254/jphs.FP0050881; Ohl F, 2005, J MOL MED, V83, P1014, DOI 10.1007/s00109-005-0703-z; Peters IR, 2007, VET IMMUNOL IMMUNOP, V117, P55, DOI 10.1016/j.vetimm.2007.01.011; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; SPANAKIS E, 1993, NUCLEIC ACIDS RES, V21, P3809, DOI 10.1093/nar/21.16.3809; Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02; Talaat AM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf103; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003-2697(02)00311-1; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang CM, 2004, BIOTECHNIQUES, V36, P508, DOI 10.2144/04363RN06; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	20	59	60	1	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					785	794		10.1089/neu.2007.0497			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000006	18627256				2021-06-18	
J	Fabbri, A; Servadei, F; Marchesini, G; Stein, SC; Vandelli, A				Fabbri, A.; Servadei, F.; Marchesini, G.; Stein, S. C.; Vandelli, A.			Early predictors of unfavourable outcome in subjects with moderate head injury in the emergency department	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC SUBARACHNOID HEMORRHAGE; COMPUTED TOMOGRAPHIC SCAN; BRAIN-INJURY; PROGNOSTIC-FACTORS; MANAGEMENT; CT; ANTICOAGULATION; CARE; PROGRESSION; DIAGNOSIS	Background: Subjects with moderate head injury are a particular challenge for the emergency physician. They represent a heterogeneous population of subjects with large variability in injury severity, clinical course and outcome. We aimed to determine the early predictors of outcome of subjects with moderate head injury admitted to an Emergency Department (ED) of a general hospital linked via telemedicine to the Regional Neurosurgical Centre. Patients and methods: We reviewed, prospectively, 12 675 subjects attending the ED of a General Hospital between 1999 and 2005 for head injury. A total of 309 cases (2.4%) with an admission Glasgow Coma Scale (GCS) 9-13 were identified as having moderate head injury. The main outcome measure was an unfavourable outcome at 6 months after injury. The predictive value of a model based on main entry variables was evaluated by logistic regression analysis. Findings: 64.7% of subjects had a computed tomographic scan that was positive for intracranial injury, 16.5% needed a neurosurgical intervention, 14.6% had an unfavourable outcome at 6 months (death, permanent vegetative state, permanent severe disability). Six variables (basal skull fracture, subarachnoid haemorrhage, coagulopathy, subdural haematoma, modified Marshall category and GCS) predicted an unfavourable outcome at 6 months. This combination of variables predicts the 6-month outcome with high sensitivity (95.6%) and specificity (86.0%). Interpretation: A group of selected variables proves highly accurate in the prediction of unfavourable outcome at 6 months, when applied to subjects admitted to an ED of a General Hospital with moderate head injury.	[Fabbri, A.; Vandelli, A.] Presidio Ospedaliero Morgagni Pierantoni, Dipartimento Emergenza, I-47100 Forli, Italy; [Servadei, F.] Ospedale M Bufalini, Div Neurochirurg Traumatol, Cesena, Italy; [Marchesini, G.] Univ Bologna, Alma Mater Studiorum, Bologna, Italy; [Stein, S. C.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Fabbri, A (corresponding author), Presidio Ospedaliero Morgagni Pierantoni, Dipartimento Emergenza, Azienda USL Forli,Via Forlanini 34, I-47100 Forli, Italy.	andrea.fabbri@formulatre.it		Fabbri, Andrea/0000-0002-9837-4638; Servadei, Franco/0000-0002-3595-3464; Marchesini, Giulio/0000-0003-2407-9860			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Karni A, 2001, AM SURGEON, V67, P1098; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; NORUSIS MJ, 1992, SPSS PC BASE SYSTEM; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROBERSON FC, 1979, SURG NEUROL, V12, P161; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2002, ACT NEUR S, V81, P81; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Servadei F, 2000, NEUROSURGERY, V46, P70; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; STEIN SC, 1996, NEUROTRAUMA, P755; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; ZWEIG MH, 1993, CLIN CHEM, V39, P561	40	59	59	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2008	79	5					567	573		10.1136/jnnp.2007.120162			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	287LK	WOS:000254918400017	17766433	Bronze			2021-06-18	
J	Hanten, G; Wilde, EA; Menefee, DS; Li, XQ; Lane, S; Vasquez, C; Chu, ZL; Ramos, MA; Yallampalli, R; Swank, P; Chapman, SB; Gamino, J; Hunter, JV; Levin, HS				Hanten, Gerri; Wilde, Elisabeth A.; Menefee, Deleene S.; Li, Xiaoqi; Lane, Summer; Vasquez, Carmen; Chu, Zili; Ramos, Marco A.; Yallampalli, Ragini; Swank, Paul; Chapman, Sandra B.; Gamino, Jacque; Hunter, Jill V.; Levin, Harvey S.			Correlates of social problem solving during the first year after traumatic brain injury in children	NEUROPSYCHOLOGY			English	Article						social problem solving; childhood TBI; Interpersonal Negotiations Strategies; MRI; diffusion tensor imaging; neuroimaging; cognition	CLOSED-HEAD INJURY; INTERPERSONAL NEGOTIATION STRATEGIES; PREFRONTAL CORTEX; CHILDHOOD; OUTCOMES; INTEGRATION; INHIBITION; DISORDER; BEHAVIOR; MEMORY	Effects of pediatric traumatic brain injury (TBI) on social problem-solving were examined in a longitudinal study of 103 children with moderate-to-severe TBI (n = 52) or orthopedic injury (01; n = 5 1) using the Interpersonal Negotiation Strategies task (INS). Children solved age-appropriate hypothetical social conflicts, with responses for four problem-solving steps scored by developmental level. The 01 group performed better than the TBI group, but rate of change in performance over time did not differ between groups, suggesting improvement in children with TBI was not due to recovery from injury. Strong relations between INS performance and memory and language skills emerged, but emotional processing was only weakly related to INS performance. Frontal focal lesions influenced INS performance in younger (but not older) children with TBI. Diffusion tensor imaging (DTI), revealed strong relationships between the INS and increased apparent diffusion coefficient (ADC) measures indexing connectivity in the dorsolateral and cingulate regions in both TBI and OI groups, and in the temporal and parietal regions in the TBI group. These findings inform studies of social problem-solving skills during the first year post TBI.	[Hanten, Gerri; Wilde, Elisabeth A.; Menefee, Deleene S.; Li, Xiaoqi; Vasquez, Carmen; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Lane, Summer; Chapman, Sandra B.; Gamino, Jacque] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75230 USA; [Chu, Zili; Ramos, Marco A.; Yallampalli, Ragini; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Swank, Paul] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA; [Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Hanten, G (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu		Ramos, Marco/0000-0002-1649-7547	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P396, DOI 10.1037//0894-4105.15.3.396; Anderson P., 2000, CLIN NEUROPSYCHOL AS, V1, P247, DOI DOI 10.1076/chin.8.4.231.13509; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; CHAPMAN SB, 1999, BRAIN DAM B, P235; COPES WS, 1988, J TRAUMA, V28, P78, DOI 10.1097/00005373-198801000-00011; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Friederici AD, 2006, NEURON, V52, P941, DOI 10.1016/j.neuron.2006.12.002; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Hanten G, 2004, DEV NEUROPSYCHOL, V25, P85, DOI 10.1207/s15326942dn2501&2_6; Hanten G, 2007, DEV NEUROPSYCHOL, V32, P585, DOI 10.1080/87565640701361112; Harnishfeger KK, 1996, J EXP CHILD PSYCHOL, V62, P292, DOI 10.1006/jecp.1996.0032; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; SCHMITHORST VJ, IN PRESS HUMAN BRAIN; Schultz L.H., 1988, INTERPERSONAL NEGOTI; Secord, 1989, TEST LANGUAGE COMPET; SELMAN RL, 1986, DEV PSYCHOL, V22, P450, DOI 10.1037/0012-1649.22.4.450; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sparrow S., 1984, VINELAND ADAPTIVE BE; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; TEASDALE G, 1974, LANCET, V2, P81; Wilke M, 2003, NEUROIMAGE, V20, P202, DOI 10.1016/S1053-8119(03)00199-X; Woodcock R.W., 1989, WOODCOCK JOHNSON TES; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; YEATES KO, 1991, MERRILL PALMER QUART, V37, P369; YEATES KO, 1990, CLIN PSYCHOL REV, V10, P567, DOI 10.1016/0272-7358(90)90097-T	50	59	59	0	23	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2008	22	3					357	370		10.1037/0894-4105.22.3.357			14	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	294AX	WOS:000255377600009	18444714				2021-06-18	
J	Kashluba, S; Paniak, C; Casey, JE				Kashluba, Shauna; Paniak, Chris; Casey, Joseph E.			Persistent symptoms associated with factors identified by the who task force on mild traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						adults; functional outcome; premorbid factors; symptom persistence; TBI.	EMOTIONAL RISK-FACTORS; CLOSED-HEAD-INJURY; MISERABLE MINORITY; PATIENT COMPLAINTS; RANDOMIZED-TRIAL	The current study examined the role offactors identified by the World Health Organization's Task Force on Mild Traumatic Brain Injury as being associated with poor outcome after mild traumatic brain injury. Employing symptom severity ratings at 3 months post-injury greater than "mild, " subgroups of Higher-Severity (20%) and Lower-Severity (80%) participants were identified. Findings revealed that individuals who report greatersymptom complaints at 3 months post-MTBI may be identifiable soon after injury on the basis of the magnitude and severity of early self-reported symptoms, pre-morbidpsychological issues, and involvement in compensation-seeking. Injury severity factors did not differ between the groups.	[Kashluba, Shauna; Casey, Joseph E.] Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; [Paniak, Chris] Glenrose Rehabil Hosp, Edmonton, AB, Canada; [Paniak, Chris] Univ Alberta, Edmonton, AB, Canada	Casey, JE (corresponding author), Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada.	jecasey@uwindsor.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; CARROLL LJ, 2004, J REHABIL MED S, V43, pS84; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2006, LEGAL CRIMINOL PSYCH, V11, P131, DOI 10.1348/135532505X49828; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Paniak C, 2000, BRAIN INJURY, V14, P219; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	29	59	59	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAR	2008	22	2					195	208		10.1080/13854040701263655			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	279ZA	WOS:000254393500002	17853135				2021-06-18	
J	Rabinstein, AA; Sandhu, K				Rabinstein, Alejandro A.; Sandhu, Kirsten			Non-infectious fever in the neurological intensive care unit: incidence, causes and predictors	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SUBARACHNOID HEMORRHAGE; BODY-TEMPERATURE; BRAIN-INJURY; HYPERTHERMIA; DAMAGE; FEASIBILITY; VASOSPASM; TRIAL; RISK	Background and objective: Non-infectious causes of fever are often considered in critical neurological patients but their true significance has not been formally studied. The aim of this study was to evaluate the incidence, causes and predictors of fever in patients with acute neurological/neurosurgical disease and no documented infection. Methods: Prospective data collection of consecutive patients admitted to the neurological intensive care unit (NICU) of an academic medical centre for more than 48 h was carried out. Fever was defined as body temperature >= 101 degrees F (38.3 degrees C) documented on at least one measurement for 2 consecutive days. Patients were enrolled only if a diagnostic workup, including cultures of >= 2 body samples, was performed before antibiotic use. Febrile patients with no proven evidence of infection were considered to have non-infectious fever. Results: 93 patients were included in the final analysis. Fever was non-infectious in 31 patients (33%). There were no differences between the infectious and non-infectious fever groups in terms of age, use and duration of invasive catheters, daily duration of fever and number of days with fever. Documented infections tended to be more common among febrile patients with traumatic brain injury (52% vs 36%; p = 0.06). Non-infectious fever was more frequent among patients with subarachnoid haemorrhage (48% vs 18%; p = 0.01) in whom it was associated with vasospasm ( p = 0.03) and symptomatic vasospasm ( p = 0.05). Non-infectious fever started earlier ( mean 2.6 vs 4 days; p = 0.007) and onset of fever within the first 72 h of admission predicted negative evaluation for infection ( p = 0.01). Subarachnoid haemorrhage and fever onset within the first 72 h were independent predictors of non-infectious fever on multivariable analysis. Conclusions: Fever in the absence of documented infections occurs commonly in the NICU, especially among patients with subarachnoid haemorrhage and vasospasm. Early onset of fever predicts a non-infectious cause.	Univ Miami, Jackson Mem Hosp, Sch Med, Neurosci Intens Care Unit, Miami, FL 33136 USA	Rabinstein, AA (corresponding author), Mayo Clin, Dept Neurol, W8b,200 1st St SW, Rochester, MN 55905 USA.	rabinstein.alejandro@mayo.edu					Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Badjatia N, 2004, NEUROCRIT CARE, V1, P145, DOI 10.1385/NCC:1:2:145; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Frosini M, 1999, EXP BRAIN RES, V126, P252, DOI 10.1007/s002210050734; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Marik PE, 2000, CHEST, V117, P855, DOI 10.1378/chest.117.3.855; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; O'Grady NP, 1998, CRIT CARE MED, V26, P392, DOI 10.1097/00003246-199802000-00046; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; ROUSSEAUX P, 1980, SURG NEUROL, V14, P459; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Shibata M, 1998, MED HYPOTHESES, V50, P185, DOI 10.1016/S0306-9877(98)90016-0; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Thompson HJ, 2003, NEUROBIOL DIS, V12, P163, DOI 10.1016/S0969-9961(02)00030-X	20	59	63	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2007	78	11					1278	1280		10.1136/jnnp.2006.112730			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	225LE	WOS:000250518600030	17940175	Green Published			2021-06-18	
J	McMillan, TM; Teasdale, GM				McMillan, T. M.; Teasdale, G. M.			Death rate is increased for at least 7 years after head injury: a prospective study	BRAIN			English	Article						head; brain; injury mortality; outcome	TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVAL; LIFE EXPECTANCY; YOUNG-PEOPLE; MORTALITY; DISABILITY; AGE; EPIDEMIOLOGY; DEPRIVATION; VARIABLES	Although a high mortality rate among patients recently admitted to hospital with severe head injury is well recognized, less is known about their later mortality and very little about the ensuing lifestyle and less-severe injuries that lead to death. The aims of this study were to determine the rate of death in the first and six subsequent years after head injury, in a prospectively identified cohort admitted to hospital, and investigate the factors associated with death comparing these with general death rates in Scottish populations. A structured sample of 767 patients aged 14 years and over was identified at the time of admission to hospital after a head injury and followed up 7 years later. A trace exercise was conducted to identify those deceased. The General Register of Scotland confirmed death and provided information about cause of death. Seven years after head injury, 206/767 (27%) people had died. Compared to the Glasgow population, risk of death was high after head injury in months 1-2 (23 times), 3-12 (3 times) and 13-84 (2 times), and overall was especially raised in younger people, even late (13-84 months) after injury (7 times). Mortality was only associated with greater severity of head injury during year 1. Pre-injury medical history was associated both with earlier and later deaths, but risk of death remained higher in those with no such history. Later deaths were often associated with lifestyle post-injury. The primary causes of death after head injury were the same as those in the general population. Compared to the general population, the death rate after admission to hospital with head injury remains high for at least 7 years, and is particularly high for those aged under 55 years. Interventions aimed at change in lifestyle may reduce this continuing excess mortality.	Univ Glasgow, Gartnavel Royal Hosp, Glasgow G12 OXH, Lanark, Scotland; NHS Qual Improvement Scotland, Glasgow GI 2NP, Lanark, Scotland; Univ Glasgow, Div Clin Neurosci, Glasgow, Lanark, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, 1055 Great Westerm Rd, Glasgow G12 OXH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					ACHTE KA, 1971, ACTA PSYCHIAT SCAND, P1; Baguley I, 2000, BRAIN INJURY, V14, P505; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gujral IB, 2006, BRAIN INJURY, V20, P283, DOI 10.1080/02699050500488058; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KRAUS J, 2000, NEUROSURG FOCUS, P8; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Ritchie MA, 2000, ONLINE J KNOWL SYN N, V7; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	39	59	59	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2007	130		10				2520	2527		10.1093/brain/awm185			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	218UC	WOS:000250039500006	17686808	Green Published, Bronze			2021-06-18	
J	Fernandez-Ortega, JF; Prieto-Palomino, MA; Munoz-Lopez, A; Lebron-Gallardo, M; Cabrera-Ortiz, H; Quesada-Garcia, G				Francisco Fernandez-Ortega, Juan; Angel Prieto-Palomino, Miguel; Munoz-Lopez, Alfonso; Lebron-Gallardo, Miguel; Cabrera-Ortiz, Hector; Quesada-Garcia, Guillermo			Prognostic influence and computed tomography findings in dysautonomic crises after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						brain injury; computed tomography; dysautonomia; autonomic dysfunction	SEVERE HEAD-INJURY; DIENCEPHALIC SEIZURES; BROMOCRIPTINE; DYSFUNCTION; SYSTEM	Background: Dysautonomic crises represent a relatively unknown complication in patients with severe traumatic brain injury (TBI). Few studies have been undertaken of their pathophysiology and prognostic repercussions. We studied the prevalence of dysautonomic crises after TBI, their radiologic substrate, influence on the clinical course in the intensive care unit (ICU), and effect on neurologic recovery. Methods: A case-control study involving 11 patients with dysautonomic crises admitted with TBI during a span of 1 year and 26 patients admitted with TBI but no crises during the first 3 months of the same year. The initial severity was assessed from Apache 11, Glasgow Coma Scale (GCS) scores, and computed tomography (CT) during the first 24 hours. Complications were assessed by the duration of ICU stay, days on mechanical ventilation, need for tracheotomy, and number of infectious complications. Neurologic recovery was assessed with the GCS at discharge from the ICU and with the Glasgow Outcome Scale 12 months later. Results: Both groups were similar at admission. The prevalence of dysautonomic crises was 9.3%. Patients with dysautonomic crises had more focal lesions on cranial CT than patients without crises, a significantly longer ICU stay, and a tendency to have a worse level of consciousness at discharge from the ICU but not 12 months later. Conclusions: Almost 10% of patients with severe TBI have dysautonomic crises during their ICU stay. Patients with dysautonomia were more likely to have focal intraparenchymal lesions, and crises were associated with greater morbidity and a longer ICU stay. Dysautonomic crises determined a worse short-term neurologic recovery.	Carlos Haya Reg Univ Hosp, Intens Care Unit, Malaga, Spain; Carlos Haya Reg Univ Hosp, Neurosurg Serv, Malaga, Spain	Fernandez-Ortega, JF (corresponding author), C Mirador Candado 1, Malaga 29018, Spain.	patferon@eresmas.com		Fernandez Ortega, Juan F/0000-0003-2130-1331			Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; BHIGJEE AI, 1985, J NEUROL SCI, V71, P79; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CARMEL PW, 1985, ACTA NEUROCHIR, V75, P113, DOI 10.1007/BF01406331; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; DARNELL RB, 1993, NEUROLOGY, V43, P579, DOI 10.1212/WNL.43.3_Part_1.579; Fernandez-Ortega JF, 2004, REV NEUROLOGIA, V39, P715, DOI 10.33588/rn.3908.2004034; FERNANDEZORTEGA JF, 2004, MED INTENSIVA, V28, P376; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; JENNETT B, 1975, LANCET, V1, P480; KLUG N, 1984, ACTA NEUROCHIR, V72, P219, DOI 10.1007/BF01406872; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MAZEY RM, 1974, JAMA-J AM MED ASSOC, V230, P575, DOI 10.1001/jama.230.4.575; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; ROVNE R N, 1962, Trans Am Neurol Assoc, V87, P232; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SALOMON GH, 1973, J PEDIAT CHILD HLTH, V83, P277; SILVER JK, 1994, ARCH PHYS MED REHAB, V75, P885, DOI 10.1016/0003-9993(94)90113-9; TADAHIKO S, 1993, J NEUROSURG, V78, P501	24	59	61	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2006	61	5					1129	1133		10.1097/01.ta.0000197634.83217.80			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	105TB	WOS:000242054100017	17099518				2021-06-18	
J	Winstanley, J; Simpson, G; Tate, R; Myles, B				Winstanley, Julie; Simpson, Grahame; Tate, Robyn; Myles, Bridget			Early indicators and contributors to psychological distress in relatives during rehabilitation following severe traumatic brain injury - Findings from the brain injury outcomes study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						family; psychological distress; traumatic brain injury	BLUNT HEAD-INJURY; PRIMARY CAREGIVERS; SOCIAL SUPPORT; FAMILY; PREDICTORS; BURDEN; HEALTH	Objectives: To develop a multivariate model of the dynamic interactions among key variables associated with relative distress and disrupted family functioning after traumatic brain injury (TBI). Participants: A relative sample (parents, spouses, close others; n = 134) derived from a statewide cohort of people with TBI recruited to the multicenter Brain Injury Outcomes Study. Setting: A consecutive series of referrals over a 2-year period to the 11 adult units of the Brain Injury Rehabilitation Program in New South Wales, Australia. Main Outcome Measures: Relative measures included General Health Questionnaire-28 (psychological distress), Family Assessment Device (family functioning), and BIOS Family Needs Questionnaire (perceived adequacy of support). The degree of impairment and level of participation of the person with TBI were assessed by the Mayo-Portland Adaptability Inventory and Sydney Psychosocial Reintegration Scale, respectively. Analysis: Path analysis examined the varying contribution of impairment, participation, and support variables to both relative distress and disturbances in family functioning. Results: The overall model accounted for substantial proportions of the variance in psychological distress and family functioning. Importantly, the distress experienced by relatives was not due to the direct impact of the neurobehavioral impairments, but the effect of these impairments was mediated by the degree of community participation achieved by the person with TBI. Conclusions: The model highlights the impact on families when the person with TBI experiences restrictions in participation. Clinically, a greater focus on the provision of respite or case management services may assist in reducing relative distress.	Univ Sunshine Coast, Fac Sci Hlth & Educ, Maroochydore, Qld 4558, Australia; Univ Sydney, Fac Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Winstanley, J (corresponding author), Univ Sunshine Coast, Fac Sci Hlth & Educ, Maroochydore, Qld 4558, Australia.	JWinstan@usc.edu.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Winstanley, Julie/0000-0002-9353-6757			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Arbuckle J.L., 1999, AMOS 4 0 USERS GUIDE; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GREY JM, 1994, CLIN REHABIL, V8, P188; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Holmes-Smith P, 2002, STRUCTURAL EQUATION; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Leathem J, 1996, BRAIN INJURY, V10, P27; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McDonald RP, 1996, MULTIVAR BEHAV RES, V31, P239, DOI 10.1207/s15327906mbr3102_5; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; NORUSIS M, 1986, STAT PACKAGE SOCIAL; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Panting A., 1972, REHABILITATION, V38, P33; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; Siegel S., 1956, NONPARAMETRIC STAT B; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE R, BRAIN INJURY OUTCOME; Tate R.L., 2006, BRAIN IMPAIR, V7, P1, DOI DOI 10.1375/brim.7.1.1; Tate RL, 2003, STUD NEUROPSYCHOL DE, P137; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; World Health Organization, 2001, INT CLASS FUNCT DIS; Ylvisaker M., 1998, COLLABORATIVE BRAIN	38	59	60	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					453	466		10.1097/00001199-200611000-00001			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400001	17122677				2021-06-18	
J	Josan, VA; Sgouros, S				Josan, V. A.; Sgouros, S.			Early decompressive craniectomy may be effective in the treatment of refractory intracranial hypertension after traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article; Proceedings Paper	31st Annual Meeting of the International-Society-for-Pediatric-Neurosurgery	SEP 14-18, 2003	MONACO	Int Soc Pediatr Neurosurg		decompressive craniectomy; head injury; refractory intracranial hypertension	SEVERE HEAD-INJURIES; SURGICAL DECOMPRESSION; CHILDREN; MANAGEMENT; PRESSURE; EDEMA; AGE	Introduction: We compared the effect of early decompressive craniectomy (< 24 h) vs non-operative treatment on the outcome of children with refractory intracranial hypertension after severe traumatic brain injury. Material and methods: We retrospectively reviewed 12 consecutive patients treated between 1999 and 2001 for refractory intracranial hypertension after isolated severe head injury without any intracranial haematomas. In all patients, treatment included sedation, paralysis and IV mannitol under intracranial pressure monitoring. Early decompressive craniectomy was carried out in six patients (mean age: 13 years) at mean time from injury of 7 h (range: 2-18 h), whereas six patients (mean age: 11.5 years) were managed with non-operative treatment. The Marshall Grading system was used to score the severity of radiological abnormalities in CT scans. The Glasgow Outcome Scale (GOS) at 1-year follow-up was used as outcome measure. Results:The mean Marshall grade was 3 in the craniectomy group and 2 in the non-operative group. All patients in the craniectomy group survived: four patients scored 5 and two patients scored 4 on the GOS. In the non-operative group, two patients (33%) died, one of whom received late decompressive craniectomy at 9 days, while three patients scored 5 and one patient scored 3 on the GOS. Conclusion: In children who suffered severe head injury with refractory intracranial hypertension without intracranial haematoma, early decompressive craniectomy employed in the first few hours after injury before the onset of irreversible ischaemic changes may be an effective method to treat the secondary deterioration that commonly leads to death or severe neurological deficit.	Birmingham Childrens Hosp, Dept Paediat Neurosurg, Birmingham B4 6NH, W Midlands, England	Sgouros, S (corresponding author), Birmingham Childrens Hosp, Dept Paediat Neurosurg, Steelhouse Lane, Birmingham B4 6NH, W Midlands, England.	S.Sgouros@bham.ac.uk	Sgouros, Spyridon/AAH-1361-2020	Sgouros, Spyridon/0000-0003-4615-0808			ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Hieu PD, 1996, CHILD NERV SYST, V12, P270; JENNETT B, 1975, LANCET, V1, P480; KIRKHAM FJ, 1986, DEV MED CHILD NEUROL, V28, P506; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LD, 1991, J NEUROSURG, V75, P514; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Munch E, 2000, NEUROSURGERY, V47, P315; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Rekate Harold L., 2001, Child's Nervous System, V17, P632, DOI 10.1007/s003810100487; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Zimmerman R, 1994, NEUROIMAG CLIN N AM, P349	26	59	62	0	3	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	OCT	2006	22	10					1268	1274		10.1007/s00381-006-0064-0			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	087CY	WOS:000240721300012	16496158				2021-06-18	
J	Levine, B; Fujiwara, E; O'Connor, C; Richard, N; Kovacevic, N; Mandic, M; Restagno, A; Easdon, C; Robertson, IH; Graham, SJ; Cheung, G; Gao, FQ; Schwartz, ML; Black, SE				Levine, Brian; Fujiwara, Esther; O'Connor, Charlene; Richard, Nadine; Kovacevic, Natasa; Mandic, Marina; Restagno, Adriana; Easdon, Craig; Robertson, Ian H.; Graham, Simon J.; Cheung, Gordon; Gao, Fuqiang; Schwartz, Michael L.; Black, Sandra E.			In vivo characterization of traumatic brain injury neuropathology with structural and functional neuroimaging	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	14th Annual Conference on Traumatic Brain Injury - From Molecule to Family Systems	2004	Rotman Res Inst, Toronto, CANADA		Rotman Res Inst	diffuse axonal injury; magnetic resonance imaging; neuroplasticity; neuropsychology	CLOSED-HEAD-INJURY; DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; EVENT-RELATED FMRI; POSITRON-EMISSION-TOMOGRAPHY; WORKING-MEMORY LOAD; TECHNETIUM-99M-HMPAO SPECT; COMPUTERIZED-TOMOGRAPHY; MORPHOMETRIC-ANALYSIS; DEGENERATIVE CHANGES	Quantitative neuroimaging is increasingly used to study the effects of traumatic brain injury (TBI) on brain structure and function. This paper reviews quantitative structural and functional neuroimaging studies of patients with TBI, with an emphasis on the effects of diffuse axonal injury (DAI), the primary neuropathology in TBI. Quantitative structural neuroimaging has evolved from simple planometric measurements through targeted region-of-interest analyses to whole-brain analysis of quantified tissue compartments. Recent studies converge to indicate widespread volume loss of both gray and white matter in patients with moderate-to-severe TBI. These changes can be documented even when patients with focal lesions are excluded. Broadly speaking, performance on standard neuropsychological tests of speeded information processing are related to these changes, but demonstration of specific brain-behavior relationships requires more refined experimental behavioral measures. The functional consequences of these structural changes can be imaged with activation functional neuroimaging. Although this line of research is at an early stage, results indicate that TBI causes a more widely dispersed activation in frontal and posterior cortices. Further progress in analysis of the consequences of TBI on neural structure and function will require control of variability in neuropathology and behavior.	Rotman Res Inst, Baycrest Ctr Geriatr Care, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Surg Neurosurg, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada; Trinity Coll Dublin, Dept Psychol, Dublin, Ireland; Trinity Coll Dublin, Inst Neurosci, Dublin, Ireland; Sunnybrook Hlth Sci Ctr, Dept Surg Neurosurg, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Dept Diagnost Imaging & Radiol, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Dept Imaging Res, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Heart & Stroke Fdn Ctr Stroke Recovery, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, LC Campbell Cognit Neurol Res Unit, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Dept Med Neurol, Toronto, ON M4N 3M5, Canada	Levine, B (corresponding author), Rotman Res Inst, Baycrest Ctr Geriatr Care, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	levine@psych.utoronto.ca	Levine, Brian/G-4328-2010; Levine, Brian/O-2725-2019; Black, Sandra E./C-7294-2011; Fujiwara, Esther/F-8233-2011	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Fujiwara, Esther/0000-0003-4154-0145; Robertson, Ian H/0000-0001-8637-561X; Black, Sandra/0000-0001-7093-8289	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042385, R01 HD042385-03, HD42385-01] Funding Source: Medline		Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alavi A, 1997, J NUCL MED, V38, P1717; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Army Individual Test Battery, 1944, MAN DIR SCOR; ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Backman L, 1999, NEUROLOGY, V52, P1861, DOI 10.1212/WNL.52.9.1861; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cabeza R, 1997, J NEUROSCI, V17, P391; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; COURVILLE CB, 1937, PAHTOLOGY CTR NERV 4; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dade LA, 2004, NEUROIMAGE, V22, P1492, DOI 10.1016/j.neuroimage.2004.03.023; Davatzikos C, 2004, NEUROIMAGE, V23, P17, DOI 10.1016/j.neuroimage.2004.05.010; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Easdon C, 2004, BRAIN COGNITION, V54, P136; Engelien A, 1995, BRAIN, V118, P1395, DOI 10.1093/brain/118.6.1395; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Freedman M, 1998, CEREB CORTEX, V8, P18, DOI 10.1093/cercor/8.1.18; Friston KJ, 2004, NEUROIMAGE, V23, P21, DOI 10.1016/j.neuroimage.2004.04.021; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Gilboa A, 2005, HIPPOCAMPUS, V15, P535, DOI 10.1002/hipo.20090; Goldstone BP, 2001, READ TEACH, V55, P362; GRADY CL, 1994, J NEUROSCI, V14, P1450; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRAY BG, 1992, J NUCL MED, V33, P52; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Halstead WC., 1947, BRAIN INTELLIGENCE Q; ICHISE M, 1994, J NUCL MED, V35, P217; Jacobs A, 1996, J NUCL MED, V37, P1605; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kelly JP, 1997, NEUROLOGY, V48, P581; Kovacevic N, 2002, NEUROIMAGE, V17, P1087, DOI 10.1006/nimg.2002.1221; LANGFITT TW, 1977, ANN SURG, V186, P411, DOI 10.1097/00000658-197710000-00002; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Liddle PF, 2001, HUM BRAIN MAPP, V12, P100, DOI 10.1002/1097-0193(200102)12:2<100::AID-HBM1007>3.0.CO;2-6; Logan Gordon D., 1994, P189; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Mattay VS, 1997, NEUROREPORT, V8, P2977, DOI 10.1097/00001756-199709080-00034; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McIntosh AR, 1996, NEUROIMAGE, V3, P143, DOI 10.1006/nimg.1996.0016; McIntosh AR, 2004, NEUROIMAGE, V23, P764, DOI 10.1016/j.neuroimage.2004.05.018; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; O'Connor C, 2004, BRAIN COGNITION, V54, P133, DOI 10.1016/S0278-2626(03)00268-9; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Price CJ, 2002, TRENDS COGN SCI, V6, P416, DOI 10.1016/S1364-6613(02)01976-9; Price CJ, 2001, J COGNITIVE NEUROSCI, V13, P419, DOI 10.1162/08989290152001853; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2004, BRAIN INJURY, V18, P661, DOI 10.1080/02699050310001646170; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Smith A., 1978, SYMBOL DIGIT MODALIT; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Spence SA, 2000, BRIT J PSYCHIAT, V176, P52, DOI 10.1192/bjp.176.1.52; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Tisserand DJ, 2002, NEUROIMAGE, V17, P657, DOI 10.1006/nimg.2002.1173; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Verger K, 2001, BRAIN INJURY, V15, P211; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Woodard JL, 1998, NEUROPSYCHOLOGY, V12, P491, DOI 10.1037/0894-4105.12.4.491; Yamaki T, 1996, J NUCL MED, V37, P1166; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zarahn E, 1999, COGNITIVE BRAIN RES, V7, P255, DOI 10.1016/S0926-6410(98)00029-9	123	59	64	1	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1396	1411		10.1089/neu.2006.23.1396			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500003	17020478	Green Accepted			2021-06-18	
J	Bahloul, M; Chaari, AN; Kallel, H; Khabir, A; Ayadi, A; Charfeddine, H; Hergafi, L; Chaari, AD; Chelly, HE; Ben Hamida, C; Rekik, N; Bouaziz, M				Bahloul, Mabrouk; Chaari, Anis N.; Kallel, Hatem; Khabir, Abdelmajid; Ayadi, Adnene; Charfeddine, Hanene; Hergafi, Leila; Chaari, Adel D.; Chelly, Hedi E.; Ben Hamida, Chokri; Rekik, Noureddine; Bouaziz, Mounir			Neurogenic pulmonary edema due to traumatic brain injury: Evidence of cardiac dysfunction	AMERICAN JOURNAL OF CRITICAL CARE			English	Article								BACKGROUND Acute neurogenic pulmonary edema, a common and underdiagnosed clinical entity, can occur after virtually any form of injury of the central nervous system and is a potential early contributor to pulmonary dysfunction inpatients with head injuries. OBJECTIVE To explore myocardial function inpatients with evident neurogenic pulmonary edema after traumatic head injury. METHODS During a 1-year period in a university hospital in Sfax, Tunisia, information was collected prospectively on patients admitted to the 22-bed intensive care unit because of isolated traumatic head injury who had neurogenic pulmonary edema. Data included demographic information, vital signs, neurological status, physiological status, and laboratory findings. All of the patients had computed tomography and plain radiography of the neck and determination of cardiac function. RESULTS All 7 patients in the sample had cardiac dysfunction. Evidence of myocardial damage was confirmed by echocardiography in 3 patients, pulmonary artery catheterization in 3 patients, and/or postmortem myocardial biopsy in 4 patients. Echocardiography studies, repeated 7 days after the initial study in one patient and 90 days afterward in another, showed complete improvement in wall motion, with a left ventricular ejection fraction of 0.65. CONCLUSION All patients who had neurogenic pulmonary edema due to traumatic head injury had myocardial dysfunction. The mechanisms of the dysfunction were multiple. The great improvement in wall motion seen in 2 patients indicated the presence of a stunned myocardium. Further studies are needed to understand the mechanisms of this cardiac dysfunction.	Ctr Hosp Univ Habib Bourguiba, Serv Reanimat Med, Sfax, Tunisia; Ctr Hosp Univ Habib Bourguiba, Serv Anatomopathol, Sfax, Tunisia; Ctr Hosp Univ Habib Bourguiba, Serv Med Legale, Sfax, Tunisia; Ctr Hosp Univ Hedi Chaker, Serv Cardiol, Sfax, Tunisia	Bahloul, M (corresponding author), Hop Habib Bourguiba, Serv Reanimat Med, Route El Ain Km 1, Sfax 3029, Tunisia.	bahloulmab@yahoo.fr		Bahloul, Mabrouk/0000-0002-6488-8294			Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; BACHOFEN H, 1993, AM REV RESPIR DIS, V147, P997, DOI 10.1164/ajrccm/147.4.997; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Cariou A, 1998, J CRIT CARE, V13, P198, DOI 10.1016/S0883-9441(98)90006-5; CARLSON RW, 1979, CHEST, V75, P731, DOI 10.1378/chest.75.6.731; COLICE GL, 1984, AM REV RESPIR DIS, V130, P941; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; de Chazal I, 2005, ANESTH ANALG, V100, P1147, DOI 10.1213/01.ANE.0000147704.90285.2A; Deehan SC, 1996, INTENS CARE MED, V22, P672, DOI 10.1007/BF01709745; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; FRASER RG, 1970, DIAGNOSIS DIS CHEST, P854; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; JOHNSTON SC, 1995, ANN NEUROL, V37, P531, DOI 10.1002/ana.410370416; KOWALSKI ML, 1989, AM REV RESPIR DIS, V140, P101, DOI 10.1164/ajrccm/140.1.101; Macmillan CSA, 2002, INTENS CARE MED, V28, P1012, DOI 10.1007/s00134-002-1382-7; MARON MB, 1987, J APPL PHYSIOL, V62, P470; MAYER SA, 1994, NEUROLOGY, V44, P815, DOI 10.1212/WNL.44.5.815; Parr MJA, 1996, BRIT MED J, V313, P681; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; Samuels MA, 1987, AM J CARDIOL, V60, P15, DOI [10.1016/0002-9149(87)90678-3, DOI 10.1016/0002-9149(87)90678-3]; SIMMONS RL, 1969, ANN SURG, V170, P39, DOI 10.1097/00000658-196907000-00005; SIMON RP, 1993, NEUROL CLIN, V11, P309; Smith WS, 1997, CHEST, V111, P1326, DOI 10.1378/chest.111.5.1326; THEODORE J, 1976, AM REV RESPIR DIS, V113, P405; Wasowska-Krolikowska K, 2000, Med Sci Monit, V6, P1003; WEST JB, 1992, LANCET, V340, P762, DOI 10.1016/0140-6736(92)92301-U; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046; WRAY NP, 1978, AM REV RESPIR DIS, V118, P783, DOI 10.1164/arrd.1978.118.4.783; YABUMOTO M, 1986, NEUROSURGERY, V19, P300, DOI 10.1227/00006123-198608000-00025; Yildirim E, 2004, EUR J CARDIO-THORAC, V25, P523, DOI 10.1016/j.ejcts.2003.12.021	31	59	71	0	1	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1062-3264			AM J CRIT CARE	Am. J. Crit. Care	SEP	2006	15	5					462	470					9	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	V44BT	WOS:000202978900005	16926367				2021-06-18	
J	Ghaffar, O; McCullagh, S; Ouchterlony, D; Feinstein, A				Ghaffar, Omar; McCullagh, Scott; Ouchterlony, Donna; Feinstein, Anthony			Randomized treatment trial in mild traumatic brain injury	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						traumatic brain injury (TBI); closed head injury; depression; neuropsychiatry; neuropsychological testing; treatment	MINOR HEAD-INJURY; ROUTINE FOLLOW-UP; BEHAVIORAL TOXICITY; MAJOR DEPRESSION; CONCUSSION; RECOVERY; QUESTIONNAIRE; IMPROVEMENT; POPULATION; MANAGEMENT	Objective: To determine whether multidisciplinary treatment of mild traumatic brain injury (MTBI) improves neurobehavioral outcome at 6 months postinjury. Methods: Subjects with MTBI were randomly assigned to treatment (n=97) or non-treatment (control, n=94) groups. Treated patients were assessed within 1 week of injury and thereafter managed by a multidisciplinary team according to clinical need for a further 6 months. Control subjects were not offered treatment. Six-month outcome measures included: severity of postconcussive symptoms (Rivermead Post-Concussion Disorder Questionnaire), psychosocial functioning (Rivermead Follow-up Questionnaire), psychological distress (General Health Questionnaire), and cognition (neurocognitive battery). Results: Treatment and control subjects were well-matched for demographic and MTBI severity data. In addition, the two groups did not differ on any outcome measure. However, in individuals with preinjury psychiatric difficulties (22.9% of the entire sample), subjects in the treatment group had significantly fewer depressive symptoms 6 months postinjury compared with untreated controls (P=.01). Conclusions: These findings suggest that routine treatment of all MTBI patients offers little benefit; rather, targeting individuals with preinjury psychiatric problems may prove a more rational and cost-effective approach. (c) 2006 Elsevier Inc. All rights reserved.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; Univ Toronto, St Michaels Hosp, Dept Rehabil Med, Toronto, ON M5B 1W8, Canada	Feinstein, A (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Psychiat, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	ant.feinstein@utoronto.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; AUSTIN MP, 1992, J AFFECT DISORDERS, V25, P21, DOI 10.1016/0165-0327(92)90089-O; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; FEINSTEIN A, 1992, BRAIN, V115, P1402; FEINSTEIN A, 2000, CAN J PUBLIC HLTH, V91, P5; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1989, MILD HEAD INJURY; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hindmarch I, 1998, INT CLIN PSYCHOPHARM, V13, pS5, DOI 10.1097/00004850-199807006-00002; HINDMARCH I, 1995, INT CLIN PSYCHOPHARM, V9, P13, DOI 10.1097/00004850-199501004-00002; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KURTZKE JF, 1993, CLIN NEUROLOGY; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Mahon D, 1989, J Neurosci Nurs, V21, P382; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Ridout F, 2003, HUM PSYCHOPHARM CLIN, V18, P261, DOI 10.1002/hup.494; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Smith A., 1968, LEARNING DISORDERS, P83; STOUDEMIRE A, 1995, J NEUROPSYCH CLIN N, V7, P31; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; VEIEL HOF, 1997, J CLIN EXP NEUROPSYC, V19, P541; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wechsler D, 1997, WAIS 3 ADM SCORING M; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42	52	59	59	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999			J PSYCHOSOM RES	J. Psychosomat. Res.	AUG	2006	61	2					153	160		10.1016/j.jpsychores.2005.07.018			8	Psychiatry	Psychiatry	074GJ	WOS:000239800400002	16880017				2021-06-18	
J	Curtis, KL; Greve, KW; Bianchini, KJ; Brennan, A				Curtis, KL; Greve, KW; Bianchini, KJ; Brennan, A			California verbal learning test indicators of malingered neurocognitive dysfunction - Sensitivity and specificity in traumatic brain injury	ASSESSMENT			English	Article; Proceedings Paper	24th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 17-20, 2004	Seattle, WA	Natl Acad Neuropsychol		malingering; memory; neuropsychological assessment; traumatic brain injury; diagnostic accuracy	ADULT INTELLIGENCE SCALE; CARD SORTING TEST; HEAD-INJURY; RESPONSE BIAS; BASE RATES; IDENTIFICATION; PERFORMANCE; VALIDATION	The present study used well-defined traumatic brain injury (TBI) and mixed neurological (other than TBI) and psychiatric samples to examine the specificity and sensitivity to Malingered Neurocognitive Dysfunction (MND) of four individual California Verbal Learning Test (CVLT) variables and eight composite CVLT malingering indicators. Participants were 275 traumatic brain injury and 352 general clinical patients seen for neuropsychological evaluation. The TBI patients were assigned to one of five groups using the Slick, Sherman, and Iverson (1999) criteria: no incentive, incentive only, suspect, and malingering (both Probable MND and Definite MND). Within TBI, persons with the strongest evidence for malingering (Probable and Definite) had the most extreme scores. Good sensitivity (approximately 50%) in the context of excellent specificity (> 95%) was found in the TBI samples. Issues related to the appropriate clinical application of these data are discussed.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Univ New Orleans, Jefferson Neurobehav Grp, New Orleans, LA 70148 USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAND DIGIT RECOG; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Gouvier WD, 1998, CRIT ISS NE, P55; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Hennekens CH, 1987, EPIDEMIOLOGY MED; KAGEHIRO DK, 1990, PSYCHOL SCI, V1, P194, DOI 10.1111/j.1467-9280.1990.tb00197.x; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LEZAK MD, 2004, NEURO PSYCHOL ASSESS; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; MILLIS SR, 1997, M INT NEUR SOC BERG; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671	34	59	59	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	MAR	2006	13	1					46	61		10.1177/1073191105285210			16	Psychology, Clinical	Psychology	014LV	WOS:000235482600004	16443718				2021-06-18	
J	Burns, TL; Ineck, JR				Burns, TL; Ineck, JR			Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain	ANNALS OF PHARMACOTHERAPY			English	Article						analgesia; cannabinoids; chronic pain	CLOSED-HEAD INJURY; RAT-BRAIN; DEXANABINOL HU-211; NEUROPATHIC PAIN; ORAL DELTA-9-TETRAHYDROCANNABINOL; INTRAMUSCULAR LEVONANTRADOL; MEDICINAL EXTRACTS; NMDA ANTAGONIST; ANANDAMIDE; RECEPTOR	OBJECTIVE: To review the literature concerning the physiology of the endocannabinoid system, current drug development of cannabinoid agonists, and current clinical research on the use of cannabinoid agonists for analgesia. DATA SOURCES: Articles were identified through a search of MEDLINE (1966-August 2005) using the key words cannabis, cannabinoid, cannabi*, cannabidiol, nabilone, THC, pain, and analgesia. No search limits were included. Additional references were located through review of the bibliographies of the articles identified. STUDY SELECTION AND DATA EXTRACTION: Studies of cannabinoid agonists for treatment of pain were selected and were not limited by pain type or etiology. Studies or reviews using animal models of pain were also included. Articles that related to the physiology and pharmacology of the endocannabinoid system were evaluated. DATA SYNTHESIS: The discovery of cannabinoid receptors and endogenous ligands for these receptors has led to increased drug development of cannabinoid agonists. New cannabimimetic agents have been associated with fewer systemic adverse effects than delta-9-tetrahydrocannabinol, including recent development of cannabis medicinal extracts for sublingual use (approved in Canada), and have had promising results for analgesia in initial human trials. Several synthetic cannabinoids have also been studied in humans, including 2 cannabinoid agonists available on the international market, CONCLUSIONS: Cannabinoids provide a potential approach to pain management with a novel therapeutic target and mechanism. Chronic pain often requires a polypharmaceutical approach to management, and cannabinoids are a potential addition to the arsenal of treatment options.	Creighton Univ, Dept Pharm Practice, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA; Creighton Univ, Med Ctr, Omaha, NE 68178 USA	Ineck, JR (corresponding author), Creighton Univ, Dept Pharm Practice, Sch Pharm & Hlth Profess, 2500 Calif Plaza, Omaha, NE 68178 USA.	jineck@creighton.edu	Cote, Mathieu/A-6735-2008	Burns, Tammy/0000-0002-1278-8515			[Anonymous], 2003, Drugs R D, V4, P306; BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; BEAL JE, 1995, J PAIN SYMPTOM MANAG, V10, P89, DOI 10.1016/0885-3924(94)00117-4; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Berman JS, 2004, PAIN, V112, P299, DOI 10.1016/j.pain.2004.09.013; Breivogel CS, 1998, NEUROBIOL DIS, V5, P417, DOI 10.1006/nbdi.1998.0229; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; Buggy DJ, 2003, PAIN, V106, P169, DOI 10.1016/S0304-3959(03)00331-2; Burstein SH, 2004, LIFE SCI, V75, P1513, DOI 10.1016/j.lfs.2004.04.010; Burstein SH, 1999, PHARMACOL THERAPEUT, V82, P87, DOI 10.1016/S0163-7258(98)00069-2; CABRAL GA, 1991, ADV BIOSCI, V80, P93; CAMPBELL JA, 2001, BRIT MED J, V323, P1; Childers SR, 1998, DRUG ALCOHOL DEPEN, V51, P173, DOI 10.1016/S0376-8716(98)00075-1; Compton DR, 1997, J PHARMACOL EXP THER, V283, P1138; Costa B, 2004, BRIT J PHARMACOL, V141, P4, DOI 10.1038/sj.bjp.0705587; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; CRONIN CM, 1981, J CLIN PHARMACOL, V21, pS43, DOI 10.1002/j.1552-4604.1981.tb02572.x; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; Deutsch DG, 1997, BIOCHEM PHARMACOL, V53, P255, DOI 10.1016/S0006-2952(96)00830-1; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1999, CURR MED CHEM, V6, P721; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Dogrul A, 2004, NEUROSCI LETT, V368, P82, DOI 10.1016/j.neulet.2004.06.060; Dogrul A, 2003, PAIN, V105, P11, DOI 10.1016/S0304-3959(03)00068-X; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; Gallily R, 1997, J PHARMACOL EXP THER, V283, P918; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; Gebremedhin D, 1999, AM J PHYSIOL-HEART C, V276, pH2085, DOI 10.1152/ajpheart.1999.276.6.H2085; Goutopoulos A, 2002, PHARMACOL THERAPEUT, V95, P103, DOI 10.1016/S0163-7258(02)00250-4; Grotenhermen F, 2002, CANNABIS CANNABINOID; Hamann W, 1999, LANCET, V353, P560, DOI 10.1016/S0140-6736(98)05429-4; HANUS L, 1993, J MED CHEM, V36, P3032, DOI 10.1021/jm00072a026; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; Holdcroft A, 1997, ANAESTHESIA, V52, P483, DOI 10.1111/j.1365-2044.1997.139-az0132.x; Ibrahim MM, 2003, P NATL ACAD SCI USA, V100, P10529, DOI 10.1073/pnas.1834309100; JAIN AK, 1981, J CLIN PHARMACOL, V21, pS320, DOI 10.1002/j.1552-4604.1981.tb02610.x; Joy JE, 1999, MARIJUANA MED ASSESS; Karst M, 2003, JAMA-J AM MED ASSOC, V290, P1757, DOI 10.1001/jama.290.13.1757; Killestein J, 2002, NEUROLOGY, V58, P1404, DOI 10.1212/WNL.58.9.1404; KNOLLER N, 1998, C NEUR SURG SEATTL O; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; Lichtman AH, 1996, J PHARMACOL EXP THER, V276, P585; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MACKIE K, 1995, J NEUROSCI, V15, P6552; MAILLEUX P, 1992, NEUROSCIENCE, V48, P655, DOI 10.1016/0306-4522(92)90409-U; Malan TP, 2003, CURR OPIN PHARMACOL, V3, P62, DOI 10.1016/S1471-4892(02)00004-8; Malan TP, 2001, PAIN, V93, P239, DOI 10.1016/S0304-3959(01)00321-9; Martin BR, 1999, LIFE SCI, V65, P573, DOI 10.1016/S0024-3205(99)00281-7; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; McPartland J. M., 2001, Journal of Cannabis Therapeutics, V1, P103, DOI 10.1300/J175v01n03_08; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Meng ID, 1998, NATURE, V395, P381, DOI 10.1038/26481; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Naef M, 2003, PAIN, V105, P79, DOI 10.1016/S0304-3959(03)00163-5; Notcutt W, 2004, ANAESTHESIA, V59, P440, DOI 10.1111/j.1365-2044.2004.03674.x; NOYES R, 1975, CLIN PHARMACOL THER, V18, P84; PATON WDM, 1975, ANNU REV PHARMACOL, V15, P191, DOI 10.1146/annurev.pa.15.040175.001203; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Rhee MH, 1997, J MED CHEM, V40, P3228, DOI 10.1021/jm970126f; Rice ASC, 2003, PROG PAIN RES MANAG, V24, P437; Romero J, 2002, PHARMACOL THERAPEUT, V95, P137, DOI 10.1016/S0163-7258(02)00253-X; Rosenberg RN, 2003, ARCH NEUROL-CHICAGO, V60, P1520, DOI 10.1001/archneur.60.11.1520; Schweitzer P, 2000, J NEUROSCI, V20, P51, DOI 10.1523/JNEUROSCI.20-01-00051.2000; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; STEELE N, 1980, CANCER TREAT REP, V64, P219; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; THOMPSON GR, 1973, TOXICOL APPL PHARM, V25, P363, DOI 10.1016/0041-008X(73)90310-4; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Wade DT, 2003, CLIN REHABIL, V17, P21, DOI 10.1191/0269215503cr581oa; Walker JM, 1999, LIFE SCI, V65, P665, DOI 10.1016/S0024-3205(99)00289-1; Walker JM, 2002, PHARMACOL THERAPEUT, V95, P127, DOI 10.1016/S0163-7258(02)00252-8; YAKSH TL, 1981, J CLIN PHARMACOL, V21, pS334, DOI 10.1002/j.1552-4604.1981.tb02612.x; Zurier RB, 1998, ARTHRITIS RHEUM-US, V41, P163, DOI 10.1002/1529-0131(199801)41:1<163::AID-ART20>3.3.CO;2-0	75	59	62	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	FEB	2006	40	2					251	260		10.1345/aph.1G217			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	015QA	WOS:000235564700011	16449552				2021-06-18	
J	Padayachee, L; Cooper, DJ; Irons, S; Ackland, HM; Thoinson, K; Rosenfeld, J; Kossmann, T				Padayachee, L; Cooper, DJ; Irons, S; Ackland, HM; Thoinson, K; Rosenfeld, J; Kossmann, T			Cervical spine clearance in unconscious traumatic brain injury patients: Dynamic flexion-extension fluoroscopy versus computed tomography with three-dimensional reconstruction	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Scientific Meeting of the Australian-and-New Zealand-Intensive-Care-Society	SEP 13, 2003	Perth, AUSTRALIA	Australia & New Zealand Intens Care Soc		cervical spine; traumatic brain injury; flexion-extension fluoroscopy	BLUNT TRAUMA; PROTOCOL; VIEWS	Background: An optimal protocol for clearing the cervical spine in unconscious patients with traumatic brain injury remains controversial. Protocols include plain radiographs and computed tomography (CT), and ligamentous injury may be identified with flexion-extension radiographs. We questioned whether cervical CT with three-dimensional (3D) reconstructions may obviate the need for flexion-extension radiology in the detection of occult ligamentous injury. Methods: Between July 1999 and November 2001, 276 unconscious traumatic brain injured patients admitted to The Alfred Hospital received cervical spine plain radiographs, CT with 3D reconstructions, and dynamic flexion-extension X-ray studies with fluoroscopy as part of a routine protocol. These patients were identified from a prospective intensive care unit database and all radiology reports were reviewed. Results: Dynamic flexion-extension X-ray studies with fluoroscopy identified no new fractures or instability; there were no instances of true-positive results. Dynamic flexion-extension was true-negative in 260 of 276 (94%) patients, falsely positive in six patients (2.2%) and falsely negative in one (0.4%) patient. In nine patients, dynamic flexion-extension was inadequate. Conclusion: Dynamic flexion-extension X-ray studies with fluoroscopy delayed cervical spine clearance and were almost always reported as normal. In a cervical spine clearance protocol for unconscious traumatic brain injury patients, dynamic flexion-extension Xray studies with fluoroscopy did not identify any patients with cervical fracture or instability not already identified by plain radiographs and fine-cut CT (CO to T2) with 3D reconstructions.	Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia; Alfred Hosp, Dept Intens Care, Melbourne, Vic 3181, Australia; Alfred Hosp, Dept Radiol, Melbourne, Vic 3181, Australia; Alfred Hosp, Dept Neurosurg, Melbourne, Vic 3181, Australia; Alfred Hosp, Dept Trauma Surg, Melbourne, Vic 3181, Australia	Cooper, DJ (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3181, Australia.	j.cooper@alfred.org.au	Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051			Ajani AE, 1998, ANAESTH INTENS CARE, V26, P487, DOI 10.1177/0310057X9802600502; Albrecht RM, 2003, AM SURGEON, V69, P261; Anglen J, 2002, J TRAUMA, V52, P54, DOI 10.1097/00005373-200201000-00011; Bolinger B, 2004, J TRAUMA, V56, P132, DOI 10.1097/01.TA.0000044629.69247.0A; Brooks RA, 2001, J TRAUMA, V50, P862; Chiu WC, 2001, J TRAUMA, V50, P457, DOI 10.1097/00005373-200103000-00009; DAVIS JW, 1995, J TRAUMA, V39, P435; Davis JW, 2001, J TRAUMA, V50, P1044, DOI 10.1097/00005373-200106000-00011; EYPASCH E, 1995, BRIT MED J, V311, P619, DOI 10.1136/bmj.311.7005.619; Freedman I, 2005, J TRAUMA, V58, P1183, DOI 10.1097/01.TA.0000169807.96533.F2; Griffiths HJ, 2002, SKELETAL RADIOL, V31, P587, DOI 10.1007/s00256-002-0545-5; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Sees DW, 1998, J TRAUMA, V45, P768, DOI 10.1097/00005373-199810000-00026	15	59	63	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2006	60	2					341	345		10.1097/01.ta.0000195716.73126.12			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	018MF	WOS:000235767700018	16508493				2021-06-18	
J	Wen, TC; Rogido, M; Peng, H; Genetta, T; Moore, J; Sola, A				Wen, T. C.; Rogido, M.; Peng, H.; Genetta, T.; Moore, J.; Sola, A.			Gender differences in long-term beneficial effects of erythropoietin given after neonatal stroke in postnatal day-7 rats	NEUROSCIENCE			English	Article						erythropoletin; neonatal focal stroke; neuroprotection; gender differences	TRAUMATIC BRAIN-INJURY; CEREBRAL HYPOXIA-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL-MODEL; PROTECTS NEURONS; PERINATAL STROKE; DAMAGE; MEMORY; MICE; MECHANISMS	Recently, we reported that erythropoletin attenuates neonatal brain injury caused by focal cerebral ischemia. The long-term effects of erythropoietin on focal cerebral ischemia-induced injury to the developing brain and the potential gender differences in these long-term effects have not been studied in detail. The current study demonstrated a similarity in the mean infarct volume in both the vehicle-treated male and female rats at 6 and 12 weeks after focal cerebral Schema. On the other hand, erythropoietin treatment (1000 U/kg x three doses after focal cerebral ischemia) caused a significant reduction in the mean infarct volume in both males and females at 6 weeks after focal cerebral ischemia when compared with the corresponding vehicle-treated animals (males: 141.4 +/- 48.2 mm(3) vs. 194.0 +/- 59.2 mm(3), P < 0.05; females: 85.4 +/- 31.6 mm(3) VS. 183.4 +/- 46.3 mm(3), P < 0.05). Interestingly, the reduction in the mean infarct volume in the erythropoletin-treated males was significantly less than that in the erythropoietin-treated females at 6 weeks after focal cerebral ischemia (141.4 +/- 48.2 mm(3) VS. 85.4 +/- 31.6 mm(3), P < 0.05). At 12 weeks after focal cerebral Ischernia, the mean infarct volume in the erythropoletintreated males significantly increased to 181.0 +/- 50.4 mm(3) (P < 0.05). In contrast, the mean infarct volume in the erythropoietin-treated females remained stable (87.0 +/- 41.7 mm(3)). Additionally, erythropoietin treatment significantly improved sensorimotor function recovery with a misstep number similar to the sham-operation group at 6 and 12 weeks after focal cerebral ischernia. Moreover, the mean number of missteps in the erythropoietin-treated females was less than that in males at 6 (13.5 +/- 2.0 vs. 24.5 +/- 2.5, P < 0.05) and 12 (12.5 +/- 2.0 vs. 20.0 +/- 2.0 P < 0.05) weeks after focal cerebral ischemia. These results indicate that erythropoietin administration after focal cerebral ischernia produces a significant long-term neuroprotective benefit on the developing brain, and that this effect is more beneficial in the female rats. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Emory Univ, Sch Med, Dept Pediat, Div Neonatal Perinatal Med, Atlanta, GA 30322 USA	Wen, TC (corresponding author), Emory Univ, Sch Med, Dept Pediat, Div Neonatal Perinatal Med, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	Tong_wen@oz.ped.emory.edu		Moore, James/0000-0003-0399-6432			Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Aydin A, 2003, BRAIN DEV-JPN, V25, P494, DOI 10.1016/S0387-7604(03)00039-1; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2003, J NEUROPATH EXP NEUR, V62, P228, DOI 10.1093/jnen/62.3.228; Carruth LL, 2002, NAT NEUROSCI, V5, P933, DOI 10.1038/nn922; Carswell HVO, 1999, HYPERTENSION, V33, P681, DOI 10.1161/01.HYP.33.2.681; Chang YS, 2005, PEDIATR RES, V58, P106, DOI 10.1203/01.PDR.0000163616.89767.69; Dame C, 2001, BIOL NEONATE, V79, P228; deVeber G, 2000, Semin Pediatr Neurol, V7, P309, DOI 10.1053/spen.2000.20074; Dewing P, 2003, MOL BRAIN RES, V118, P82, DOI 10.1016/S0169-328X(03)00339-5; Donders J, 2003, J HEAD TRAUMA REHAB, V18, P106, DOI 10.1097/00001199-200303000-00002; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Driscoll MC, 2003, BLOOD, V101, P2401, DOI 10.1182/blood.V101.6.2401; Edwards AD, 2000, PEDIATR RES, V47, P431, DOI 10.1203/00006450-200004000-00003; Edwards D, 2004, J PEDIATR-US, V145, P723, DOI 10.1016/j.jpeds.2004.08.062; Fisher JW, 2003, EXP BIOL MED, V228, P1; Hack M, 2005, JAMA-J AM MED ASSOC, V294, P318, DOI 10.1001/jama.294.3.318; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hurn PD, 2005, STROKE, V36, P193, DOI 10.1161/01.STR.0000153064.41332.f6; Ifudu O, 2001, AM J KIDNEY DIS, V38, P518, DOI 10.1053/ajkd.2001.26842; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Kumral A, 2003, BIOL NEONATE, V83, P224, DOI 10.1159/000068926; Lynch JK, 2002, PEDIATRICS, V109, P116, DOI 10.1542/peds.109.1.116; Lynch JK, 2001, CURR OPIN PEDIATR, V13, P499, DOI 10.1097/00008480-200112000-00002; Matsushita H, 2003, NEUROREPORT, V14, P1757, DOI 10.1097/00001756-200309150-00020; Ment LR, 2004, J PEDIATR-US, V145, P832, DOI 10.1016/j.jpeds.2004.07.035; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Nelson KB, 2004, LANCET NEUROL, V3, P150, DOI 10.1016/S1474-4422(04)00679-9; Partridge JC, 2005, PEDIATRICS, V116, pE263, DOI 10.1542/peds.2004-2274; Pritchett K, 2003, CONTEMP TOP LAB ANIM, V42, P53; Ramaswamy V, 2004, NEUROLOGY, V62, P2088, DOI 10.1212/01.WNL.0000129909.77753.C4; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Sola A, 2005, PEDIATR RES, V57, P481, DOI 10.1203/01.PDR.0000155760.88664.06; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Spandou E, 2005, BRAIN RES, V1045, P22, DOI 10.1016/j.brainres.2005.03.013; Spandou E, 2004, NEUROSCI LETT, V366, P24, DOI 10.1016/j.neulet.2004.05.032; Stillger Adrienne, 1999, Indian Journal of Pediatrics, V66, P141, DOI 10.1007/BF02752373; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; Sun Y, 2004, J CEREBR BLOOD F MET, V24, P259, DOI 10.1097/01.WCB.0000110049.43905.AC; Vannucci RC, 1997, BIOL NEONATE, V72, P187; Vannucci SJ, 1996, J CEREBR BLOOD F MET, V16, P77, DOI 10.1097/00004647-199601000-00009; Wang CH, 2004, BIOCHEM BIOPH RES CO, V314, P1064, DOI 10.1016/j.bbrc.2004.01.005; Wen TC, 2004, BRAIN RES PROTOC, V13, P76, DOI 10.1016/j.brainresprot.2004.02.003; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601; Zeng S M, 2001, J Gend Specif Med, V4, P35; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	52	59	60	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2006	139	3					803	811		10.1016/j.neuroscience.2006.02.057			9	Neurosciences	Neurosciences & Neurology	044RP	WOS:000237690400003	16581190				2021-06-18	
J	Max, JE; Schachar, RJ; Levin, HS; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Saunders, A; Landis, J				Max, JE; Schachar, RJ; Levin, HS; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Saunders, A; Landis, J			Predictors of attention-deficit/hyperactivity disorder within 6 months after pediatric traumatic brain injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; secondary attention-deficit/hyperactivity disorder; orbitofrontal gyrus	DEFICIT HYPERACTIVITY DISORDER; CLOSED-HEAD INJURY; CHILDREN; RELIABILITY; VALIDITY; LESIONS; SYMPTOMATOLOGY; ADOLESCENTS; SCHEDULE; ADHD	Objective: To assess the phenomenology and predictive factors of attention-deficit/hyperactivity disorder (ADHD) after traumatic brain injury (TBI), also called secondary ADHD (SADHD). Method: Children without preinjury ADHD 5-14 years old with TBI from consecutive admissions (n = 143) to five trauma centers were observed prospectively for 6 months (baseline and 6 months), with semistructured psychiatric interviews. Injury severity, lesion characteristics, and preinjury variables including psychiatric disorder, family psychiatric history, family psychiatric history of ADHD, family function, socioeconomic status, psychosocial adversity, and adaptive function were assessed with standardized instruments. Results: SADHD in the first 6 months after injury occurred in 18 of 115 (16%) of returning participants. All subtypes of ADHD occurred. Socioeconomic status (p = .041) and orbitofrontal gyrus lesions (p = .005) independently significantly predicted SADHD. Conclusions: These findings are consistent with research on developmental ADHD that implicate psychosocial factors and prefrontal structural and functional differences between those with and without the disorder.	Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Hosp Sick Children, Dept Psychiat, Res Inst, Brain & Behav Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Psychol, Res Inst, Brain & Behav Program, Toronto, ON M5G 1X8, Canada; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Psychiat, Houston, TX 77225 USA; Univ Texas, Ctr Brain Hlth, Dallas, TX 75230 USA; Univ Houston, Dept Educ Psychol, Houston, TX 77004 USA	Max, JE (corresponding author), Childrens Hosp & Hlth Ctr, 3020 Childrens Way,MC 5033, San Diego, CA 92123 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Boyle MH, 1996, J AM ACAD CHILD PSY, V35, P1440, DOI 10.1097/00004583-199611000-00012; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Castellanos FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/nrn896; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Damasio H., 1989, LESION ANAL NEUROPSY; FARAONE SV, 1995, J AM ACAD CHILD PSY, V34, P1001, DOI 10.1097/00004583-199508000-00009; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hesslinger B, 2002, NEUROSCI LETT, V328, P319, DOI 10.1016/S0304-3940(02)00554-2; HOLLINGSHEAD A, 1975, 4 FACOR INDEX SOCIAL; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Konrad K, 2003, COGNITIVE BRAIN RES, V16, P425, DOI 10.1016/S0926-6410(03)00057-0; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; Lee JS, 2005, HUM BRAIN MAPP, V24, P157, DOI 10.1002/hbm.20067; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2002, J AM ACAD CHILD PSY, V41, P563, DOI 10.1097/00004583-200205000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P443, DOI 10.1097/01.chi.0000156661.38576.0f; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8	29	59	59	1	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	OCT	2005	44	10					1032	1040		10.1097/01.chi.0000173293.05817.b1			9	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	967GD	WOS:000232078600014	16175108				2021-06-18	
J	Wagner, AK; Chen, XB; Kline, AE; Li, YM; Zafonte, RD; Dixon, CE				Wagner, AK; Chen, XB; Kline, AE; Li, YM; Zafonte, RD; Dixon, CE			Gender and environmental enrichment impact dopamine transporter expression after experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; environmental enrichment; gender; dopamine transporter	CONTROLLED CORTICAL IMPACT; MEDIAL PREFRONTAL CORTEX; STRIATAL DOPAMINE; COGNITIVE FUNCTION; FRONTAL-CORTEX; BLOOD-FLOW; ESTROGEN; PROGESTERONE; AMPHETAMINE; NEUROTROPHIN	Dopamine (DA) systems are implicated in cognitive deficits following traumatic brain injury (TBI). Rodent studies have demonstrated that both environmental enrichment (EE) and sex hormones can influence DA systems. The dopamine transporter (DAT) plays a crucial role in regulating DA transmission, and previous work shows that DAT is decreased after TBI in mates. Therefore, the purpose of this study was to examine the effects of gender and EE on frontal cortex and striatal DAT expression after TBI. Sprague -Dawley male (n = 24) and cycling female rats (n = 24) were placed into EE or standard housing after controlled cortical impact (2.7 nun, 4.0 m/s) injury or sham surgery (eight groups, n = 6/group). Four weeks post-surgery, bilateral frontal cortex and striatal DAT expression was examined via Western blot. Results demonstrated that there was a significant effect of injury, EE, and region on DAT expression (P < 0.05 all comparisons) on female groups. There were no significant DAT decreases in any region as a result of injury, however, EE did promote significant post-injury DAT decreases in the striatum and ipsilateral frontal cortex (P < 0.05 all comparisons) compared to female shams housed in the standard environment. For males, there was a significant effect of injury, EE, and region for male groups (P < 0.05 all comparisons). There were decreases in DAT expression in three regions studied for injured males housed in the standard environment compared to sham males in the standard environment (P < 0.05 all comparisons), however, EE did not add significantly to post-injury DAT decreases in these regions. These results suggest that CCI causes larger relative decreases in DAT expression for males compared to females and that treatment with EE has larger effects on post-injury DAT expression for females than males. These findings may have some relevance to treatment paradigms using dopaminergic neurostimulants after TBI. (c) 2005 Elsevier Inc. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	wagnera@msx.upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833, R03HD41399] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS40125] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833, R03HD041399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040125] Funding Source: NIH RePORTER		Bardo MT, 2001, PSYCHOPHARMACOLOGY, V155, P278; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P803, DOI 10.1016/S0091-3057(99)00168-9; Becker JB, 2001, ANN NY ACAD SCI, V937, P172, DOI 10.1111/j.1749-6632.2001.tb03564.x; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P53, DOI 10.1016/S0091-3057(99)00091-X; Bezard E, 2003, J NEUROSCI, V23, P10999; Blurton-Jones M, 2004, J COMP NEUROL, V468, P347, DOI 10.1002/cne.10989; Borland LM, 2004, J NEUROCHEM, V91, P220, DOI 10.1111/j.1471-4159.2004.02708.x; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Crosson B, 2003, J INT NEUROPSYCH SOC, V9, P1027, DOI 10.1017/S1355617703970068; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; ELOVIC E, 1996, MED REHABILITATION T, P1; GARRIS PA, 1994, J NEUROSCI, V14, P442; Gazzaley A, 2002, NEUROSCIENCE, V111, P853, DOI 10.1016/S0306-4522(02)00021-0; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Kelly SJ, 1999, PHARMACOL BIOCHEM BE, V64, P655, DOI 10.1016/S0091-3057(99)00167-7; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; KLINE AE, 2001, MO CL BI CC, V2, P267; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; KOLB B, 1995, BEHAV NEUROSCI, V109, P285, DOI 10.1037/0735-7044.109.2.285; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Kuppers E, 2000, J NEUROCYTOL, V29, P375, DOI 10.1023/A:1007165307652; Lavalaye J, 2000, EUR J NUCL MED, V27, P867, DOI 10.1007/s002590000279; Lee I, 2003, J NEUROSCI, V23, P1517; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; MORISSETTE M, 1993, NEUROENDOCRINOLOGY, V58, P16, DOI 10.1159/000126507; Moron JA, 2002, J NEUROSCI, V22, P389, DOI 10.1523/JNEUROSCI.22-02-00389.2002; Mundorf ML, 2001, J NEUROCHEM, V79, P130, DOI 10.1046/j.1471-4159.2001.00554.x; Neugebauer NM, 2004, DEV BRAIN RES, V153, P213, DOI 10.1016/j.devbrainres.2004.09.001; ODONNELL P, 1995, J NEUROSCI, V15, P3622; PARENT A, 1995, BRAIN RES REV, V20, P91, DOI 10.1016/0165-0173(94)00007-C; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; PERIS J, 1991, BRAIN RES, V566, P255, DOI 10.1016/0006-8993(91)91706-7; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.0.CO;2-K; RIVEST R, 1995, BRAIN RES, V692, P269, DOI 10.1016/0006-8993(95)00611-S; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vafaei AA, 2004, BEHAV BRAIN RES, V149, P61, DOI 10.1016/S0166-4328(03)00209-2; Valentini V, 2004, J NEUROCHEM, V88, P917, DOI 10.1046/j.1471-4159.2003.02238.x; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; WAGNER AK, IN PRESS J NEUROCHEM; WELINGTON R, 2003, PSYCHOPHARMACOLOGY, V170, P51; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Winterfeld KT, 1998, J NEUROSCI RES, V52, P201, DOI 10.1002/(SICI)1097-4547(19980415)52:2<201::AID-JNR8>3.0.CO;2-E; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zhu J, 2004, BEHAV BRAIN RES, V148, P107, DOI 10.1016/S0166-4328(03)00190-6; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	62	59	62	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2005	195	2					475	483		10.1016/j.expneurol.2005.06.009			9	Neurosciences	Neurosciences & Neurology	968VI	WOS:000232190600021	16023635				2021-06-18	
J	Wilson, BA; Emslie, H; Quirk, K; Evans, J; Watson, P				Wilson, BA; Emslie, H; Quirk, K; Evans, J; Watson, P			A randomized control trial to evaluate a paging system for people with traumatic brain injury	BRAIN INJURY			English	Article							MEMORY; NEUROPAGE	Although memory problems following acquired brain damage are common, some people are able to compensate for these problems through external aids. It was recently demonstrated that a paging system could reduce the everyday memory and planning problems for people with non-progressive brain injury. The 143 patients who participated in the study comprised several diagnostic groups. This paper reports on the sub-group of people with TBI (n = 63). This sub-group was part of the larger sample of 143 already published in the 2001 study. A randomized control cross-over design randomly allocated people to group A (pager first) or group B (waiting list first). Each participant chose their own tasks for which they needed reminders. During a 2 week baseline, successful task achievement was documented. Group A achieved 47.14% of tasks and group B 47.88%. People in group A then received a pager for 7 weeks. During the last 2 weeks of this 7 week period, task achievement was documented again. Group A now achieved 71.80% of tasks and group B (on the waiting list) achieved 49.05% (no different from baseline). Group A then returned their pagers and group B received pagers. During the last 2 weeks of this stage participants were monitored once more. At this point, people in group A had dropped back slightly but were still statistically significantly better than during the baseline (67.23%). Group B, meanwhile, were now achieving 73.62% of tasks. This was statistically significantly better than baseline and significantly better than group A, now in the post-pager phase. It is concluded that this paging system significantly reduces the everyday memory and planning problems of people with TBI.	Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Cambridge, England	Wilson, BA (corresponding author), Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Box 58, Cambridge, England.	Barbara.wilson@mrc-cbu.cam.ac.uk		Watson, Peter/0000-0002-9436-0693			Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; EVERITT BS, 1995, CAMBRIDGE DICT STAT; Inglis EA, 2004, NEUROPSYCHOL REHABIL, V14, P77, DOI 10.1080/09602010343000129; Wilson BA, 2003, NEUROREHABILITATION, V18, P3; Wilson BA, 2003, NEURO S B C, P329; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477	8	59	61	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2005	19	11					891	894		10.1080/02699050400002363			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983YY	WOS:000233269500003	16296571				2021-06-18	
J	Zai, LJ; Yoo, S; Wrathall, JR				Zai, LJ; Yoo, S; Wrathall, JR			Increased growth factor expression and cell proliferation after contusive spinal cord injury	BRAIN RESEARCH			English	Article						GGF2; FGF2; CNTF; oligodendrocyte; astrocyte; glia; precursor; progenitor; BrdU; NG2	OLIGODENDROCYTE PRECURSOR CELLS; ROOT GANGLION NEURONS; FACTOR MESSENGER-RNA; ADULT-RAT BRAIN; NEUROTROPHIC FACTOR; GENE-EXPRESSION; MATURE OLIGODENDROCYTES; PROGENITOR CELLS; WHITE-MATTER; IN-VIVO	The damage caused by traumatic central nervous system (CNS) injury can be divided into two phases: primary and secondary. The initial injury destroys many of the local neurons and glia and triggers secondary mechanisms that result in further cell loss. Approximately 50 % of the astrocytes and oligodendrocytes in the spared white matter of the epicenter die by 24 h after spinal cord injury (SCI) but their densities return to normal levels by 6 weeks. This repopulation is largely due to the proliferation of local progenitors that divide in response of CNS injury. Previous studies indicate that the secondary events that cause cell death after SCI also increase the local levels of several growth factors that stimulate the proliferation of these endogenous progenitors. We compared the spatial pattern of the post-injury up-regulation of the pro-mitotic growth factors with that of 5-bromodeoxyuridine (BrdU) incorporation to determine if each could play a role in proliferation. Three days after a standard contusive SO or laminectomy, animals received intraperitoneal BrdU injections to label dividing cells and were perfused 2 h after the last injection. Immunohistochemistry for BrdU and basic fibroblast growth factor (FGF2) and in situ hybridization for ciliary neurotrophic factor (CNTF) and glial growth factor (GGF2) mRNA were used to compare the number of dividing cells with growth factor levels in sections 2 and 4 turn from the epicenter. All three growth factors are significantly up-regulated 3 days after SCI, when cell proliferation is maximal. The increase in GGF2 and FGF2 levels is highest in sections 2 mm rostral to the epicenter, mimicking BrdU incorporation. Addition of rhGGF2 to cultured cells isolated from the spinal cord 3 days after SCI increased the number of NG2+ glial progenitors. These data suggest that FGF2 and GGF2 may contribute to the spontaneous recovery observed after SO by stimulating the proliferation of local progenitors that help repopulate the injured cord. (c) 2005 Elsevier B.V. All rights reserved.	Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA	Wrathall, JR (corresponding author), Georgetown Univ, Dept Neurosci, 3970 Reservoir Rd NW,NRB-EG31, Washington, DC 20057 USA.	wrathalj@georgetown.edu		Yoo, Soonmoon/0000-0002-1645-6809	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035647, F31NS043019] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31 NS43019, R01 NS035647] Funding Source: Medline		Albrecht PJ, 2003, NEUROBIOL DIS, V13, P89, DOI 10.1016/S0969-9961(03)00019-6; Albrecht PJ, 2002, EXP NEUROL, V173, P46, DOI 10.1006/exnr.2001.7834; Bambakidis Nicholas C, 2004, Spine J, V4, P16, DOI 10.1016/j.spinee.2003.07.004; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Cannella B, 1999, J NEUROIMMUNOL, V100, P233, DOI 10.1016/S0165-5728(99)00201-5; Cannella B, 1998, P NATL ACAD SCI USA, V95, P10100, DOI 10.1073/pnas.95.17.10100; Canoll PD, 1999, MOL CELL NEUROSCI, V13, P79, DOI 10.1006/mcne.1998.0733; Canoll PD, 1996, NEURON, V17, P229, DOI 10.1016/S0896-6273(00)80155-5; Cook JL, 1998, MOL BRAIN RES, V55, P9, DOI 10.1016/S0169-328X(97)00350-1; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; FRESSINAUD C, 1993, DEV BIOL, V158, P317, DOI 10.1006/dbio.1993.1191; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; GRINSPAN JB, 1993, J NEUROSCI RES, V36, P672, DOI 10.1002/jnr.490360608; Grossman SD, 1999, J NEUROSCI, V19, P5711, DOI 10.1523/JNEUROSCI.19-14-05711.1999; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hinks GL, 1999, MOL CELL NEUROSCI, V14, P153, DOI 10.1006/mcne.1999.0771; Horner PJ, 2000, J NEUROSCI, V20, P2218; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; Jiang FJ, 1999, J NEUROSCI RES, V57, P447, DOI 10.1002/(SICI)1097-4547(19990815)57:4<447::AID-JNR4>3.0.CO;2-B; Kojima A, 2000, J NEUROPATH EXP NEUR, V59, P687, DOI 10.1093/jnen/59.8.687; Kojima A, 2002, J NEUROTRAUM, V19, P223, DOI 10.1089/08977150252806974; Lee MY, 1998, NEUROSCI LETT, V255, P79, DOI 10.1016/S0304-3940(98)00710-1; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Mocchetti I, 1996, EXP NEUROL, V141, P154, DOI 10.1006/exnr.1996.0149; Murakami Y, 2002, J NEUROL SCI, V198, P63, DOI 10.1016/S0022-510X(02)00080-1; NEUBERGER TJ, 1993, J NEUROCYTOL, V22, P449, DOI 10.1007/BF01181565; Ohta K, 2001, CELLS TISSUES ORGANS, V169, P410, DOI 10.1159/000047909; Oyesiku NM, 1997, J NEUROBIOL, V32, P251, DOI 10.1002/(SICI)1097-4695(199703)32:3<251::AID-NEU1>3.3.CO;2-D; RABEHEVSKY AG, 2000, EXP NEUROL, V164, P280; Redwine JM, 1998, J NEUROBIOL, V37, P413, DOI 10.1002/(SICI)1097-4695(19981115)37:3<413::AID-NEU7>3.0.CO;2-8; Rosano C, 1999, GLIA, V27, P189, DOI 10.1002/(SICI)1098-1136(199909)27:3<189::AID-GLIA1>3.0.CO;2-I; Rosenberg LJ, 2005, GLIA, V49, P107, DOI 10.1002/glia.20096; Shi JY, 1998, J NEUROSCI, V18, P4627; Shihabuddin LS, 1997, EXP NEUROL, V148, P577, DOI 10.1006/exnr.1997.6697; SMITH GM, 1987, ANN NY ACAD SCI, V495, P185, DOI 10.1111/j.1749-6632.1987.tb23675.x; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999; Tokita Y, 2001, J NEUROSCI, V21, P1257; WATANABE H, 1975, ARCH NEUROL-CHICAGO, V32, P181, DOI 10.1001/archneur.1975.00490450061008; Wrathall JR, 1998, J NEUROSCI, V18, P8780; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176	46	59	59	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 9	2005	1052	2					147	155		10.1016/j.brainres.2005.05.071			9	Neurosciences	Neurosciences & Neurology	959BX	WOS:000231493000004	16005441				2021-06-18	
J	Straume-Naesheim, TM; Andersen, TE; Dvorak, J; Bahr, R				Straume-Naesheim, TM; Andersen, TE; Dvorak, J; Bahr, R			Effects of heading exposure and previous concussions on neuropsychological performance among Norwegian elite footballers	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							COMPUTERIZED COGNITIVE ASSESSMENT; BRAIN-INJURY; SOCCER; IMPAIRMENT; FREQUENCY; RECOVERY; IMPACT	Background: Cross-sectional studies have indicated that neurocognitive performance may be impaired among football players. Heading the ball has been suggested as the cause, but recent reviews state that the reported deficits are more likely to be the result of head injuries. Objective: To examine the association between previous concussions and heading exposure with performance on computer based neuropsychological tests among professional Norwegian football players. Methods: Players in the Norwegian professional football league (Tippeligaen) performed two consecutive baseline neuropsychological tests (Cogsport) before the 2004 season (90.3% participation, n = 271) and completed a questionnaire assessing previous concussions, match heading exposure (self-reported number of heading actions per match), player career, etc. Heading actions for 18 players observed in two to four matches were counted and correlated with their self-reported values. Results: Neither match nor lifetime heading exposure was associated with neuropsychological test performance. Nineteen players scored below the 95% confidence interval for one or more subtasks, but they did not differ from the rest regarding the number of previous concussions or lifetime or match heading exposure. The number of previous concussions was positively associated with lifetime heading exposure (exponent (B) = 1.97(1.03-3.75), p =0.039), but there was no relation between previous concussions and test performance. Self-reported number of headings correlated well with the observed values (Spearman's rho = 0.77, p<0.001). Conclusion: Computerised neuropsyckological testing revealed no evidence of neuropsychological impairment due to heading exposure or previous concussions in a cohort of Norwegian professional football players.	Oslo Sports Trauma & Res Ctr, Oslo, Norway; FIFA Med Assessment & Res Ctr, Zurich, Switzerland; Norwegian Univ Sport & Phys Educ, Oslo, Norway	Straume-Naesheim, TM (corresponding author), Oslo Sports Trauma & Res Ctr, Oslo, Norway.	truls.straume-nesheim@nih.no	Bahr, Roald/B-6964-2014	Andersen, Thor Einar/0000-0003-4172-4518; Bahr, Roald/0000-0001-5725-4237			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BANGSBO J, 1991, CAN J SPORT SCI, V16, P110; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; COLLIE A, 2005, SPORTS NEUROPSYCHOLO; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Darby D, 2002, NEUROLOGY, V59, P1042, DOI 10.1212/WNL.59.7.1042; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; MCSWEENY AJ, 1993, CLIN NEUROPSYCHOL, V7, P460; Mollica CM, 2004, HUM PSYCHOPHARM CLIN, V19, P445, DOI 10.1002/hup.624; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; Silbert BS, 2004, BRIT J ANAESTH, V92, P814, DOI 10.1093/bja/aeh157; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Westerman R, 2001, ADF HLTH, V2, P29; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	44	59	60	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I70	I77		10.1136/bjsm.2005.019646			8	Sport Sciences	Sport Sciences	954KI	WOS:000231153600010	16046359	Bronze, Green Published			2021-06-18	
J	Boake, C; McCauley, SR; Pedroza, C; Levin, HS; Brown, SA; Brundage, SI				Boake, C; McCauley, SR; Pedroza, C; Levin, HS; Brown, SA; Brundage, SI			Lost productive work time after mild to moderate traumatic brain injury with and without hospitalization	NEUROSURGERY			English	Article						craniocerebral trauma; economic costs; employment; head injuries; minor head injury; prognosis; traumatic brain injury	HEAD-INJURY; MODEL SYSTEMS; RETURN; DISABILITY; METAANALYSIS	OBJECTIVE: Lost productivity after mild traumatic brain injury (TBI) is a large component of the economic costs of brain trauma in the United States. This is the first prospective study of employment after mild TBI to include patients not admitted to a hospital. METHODS: Concurrent inception cohorts of 210 working-age adults with mild to moderate TBI and 122 patients who sustained general trauma not involving the brain were recruited at a trauma center and followed up to 6 months later. Outcomes were time from injury until first day worked and problems reported after resuming work. RESULTS: Most patients who worked after their injury remained employed 6 months later in a similar capacity as before the injury. No consistent differences were demonstrated between employment outcomes of patients with mild TBI and those with general trauma. The majority of nonhospitalized patients with mild TBI did not work for at least 1 month and did not begin working until 1 to 3 months after injury. Most patients with moderate TBI remained unemployed at 6 months postinjury. Patients with lower preinjury occupational status tended to have longer work absences. CONCLUSION: Lost productive work time after nonhospitalized TBI may cause significant economic costs because these injuries are frequent. Contrary to the theory that brain injury is more disabling to patients in cognitively demanding occupations, patients with higher job status tended to begin work earlier. A technique is needed to screen patients with mild TBI for risk of employment problems. Rehabilitation after moderate TBI may help to minimize lost productivity.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Stanford Univ, Dept Surg, Med Ctr, Stanford, CA 94305 USA	Boake, C (corresponding author), TIRR,1333 Moursund, Houston, TX 77030 USA.	corwin.boake@uth.tmc.edu		Pedroza, Claudia/0000-0003-4235-1282	ODCDC CDC HHS [R49/CCR612707-01, R49/CCR612707] Funding Source: Medline		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Centers for Disease Control and Prevention, REP C MILD TRAUM BRA; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; COX DR, 1972, J R STAT SOC B, V34, P187; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 2001, HEAD TRAUMA, P327; *US CENS BUR, 2000, QTP3; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006	29	59	61	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	2005	56	5					994	1002		10.1227/01.NEU.0000158319.38230.C3			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	925LJ	WOS:000229054300039	15854247				2021-06-18	
J	Ewert, T; Grill, E; Bartholomeyczik, S; Finger, M; Mokrusch, T; Kostanjsek, N; Stucki, G				Ewert, T; Grill, E; Bartholomeyczik, S; Finger, M; Mokrusch, T; Kostanjsek, N; Stucki, G			ICF Core Set for patients with neurological conditions in the acute hospital	DISABILITY AND REHABILITATION			English	Article						rehabilitation; consensus development conference; nervous system diseases; acute rehabilitation; ICF; ICF core set	TRAUMATIC BRAIN-INJURY; STROKE UNIT; REHABILITATION; DEPRESSION; IDENTIFICATION; IMPAIRMENT; DISABILITY; CATEGORIES; PRINCIPLES; MANAGEMENT	Purpose: The aim of this consensus process was to decide on a first version of the ICF Core Set for patients with neurological conditions in the acute hospital. Methods: The ICF Core Set development involved a formal decision-making and consensus process, integrating evidence gathered from preliminary studies including focus groups of health professionals, a systematic review of the literature and empiric data collection from patients. Results: Twenty-one experts selected a total of 85 second-level categories. The largest number of categories was selected from the ICF component Body Functions ( 41 categories or 48%). Five (6%) of the categories were selected from the component Body Structures, 18 (21%) from Activities and Participation and 21 (25%) from Environmental Factors. Conclusions: The Acute ICF Core Set for patients with neurological conditions provides all professionals with a clinical framework to comprehensively assess patients in the acute hospital. This first ICF Core Set will be further tested through empiric studies in German-speaking countries and internationally.	Univ Munich, Dept Phys Med & Rehabil, D-81377 Munich, Germany; Univ Munich, IMBK, WHO FIC Collaborating Ctr, ICF Res Branch, Munich, Germany; Univ Witten Herdecke, Inst Nursing Sci, Witten, Germany; Rehabil Clin Bellikon, Bellikon, Switzerland; Hedon Clin, Lingen, Germany; WHO, Classificat Assessment Surveys & Terminol Team, CH-1211 Geneva, Switzerland	Stucki, G (corresponding author), Univ Munich, Dept Phys Med & Rehabil, Marchioninistr 15, D-81377 Munich, Germany.	gerold.stucki@med.uni-muenchen.de	Grill, Eva/AAF-8104-2020; Grill, Eva/D-1875-2010	Grill, Eva/0000-0002-0273-7984; Grill, Eva/0000-0002-0273-7984			Adams HP, 1997, DRUGS, V54, P60, DOI 10.2165/00003495-199700543-00010; Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Barnes MP, 2003, J NEUROL NEUROSUR PS, V74, P3; Brosseau L, 1996, AM J PHYS MED REHAB, V75, P422, DOI 10.1097/00002060-199611000-00005; *DEP HLTH, HOSP EP STAT ENGL FI, P7; Dombovy ML, 1998, BRAIN INJURY, V12, P443, DOI 10.1080/026990598122412; Donchin Yoel, 2002, Curr Opin Crit Care, V8, P316, DOI 10.1097/00075198-200208000-00008; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; Grill E, 2005, DISABIL REHABIL, V27, P447, DOI 10.1080/09638280400014048; Grill E, 2005, DISABIL REHABIL, V27, P437, DOI 10.1080/09638280400014030; Grill E, 2005, DISABIL REHABIL, V27, P361, DOI 10.1080/09638280400013974; Ham C, 2003, BRIT MED J, V327, P1257, DOI 10.1136/bmj.327.7426.1257; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Howard RS, 2003, J NEUROL NEUROSUR PS, V74, pIII10, DOI 10.1136/jnnp.74.suppl_3.iii10; Howard RS, 2003, J NEUROL NEUROSUR PS, V74, piii2; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Kase CS, 1998, STROKE, V29, P805, DOI 10.1161/01.STR.29.4.805; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Langhorne P, 2002, AGE AGEING, V31, P365, DOI 10.1093/ageing/31.5.365; Launois R, 2004, STROKE, V35, P770, DOI 10.1161/01.STR.0000117574.19517.80; MAHONEY F I, 1965, Md State Med J, V14, P61; McKinney Aidin A, 2002, Intensive Crit Care Nurs, V18, P320, DOI 10.1016/S0964-3397(02)00069-1; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x; Payne KA, 2002, PHARMACOECONOMICS, V20, P813, DOI 10.2165/00019053-200220120-00002; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Robinson RG, 1997, ANNU REV MED, V48, P217; Scheuringer M, 2005, DISABIL REHABIL, V27, P419, DOI 10.1080/09638280400014089; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Srikanth VK, 2003, STROKE, V34, P1136, DOI 10.1161/01.STR.0000069161.35736.39; Stier-Jarmer M, 2005, DISABIL REHABIL, V27, P389, DOI 10.1080/09638280400014022; Stucki G, 2005, DISABIL REHABIL, V27, P353, DOI 10.1080/09638280400014105; Stucki G, 2002, DISABIL REHABIL, V24, P932, DOI 10.1080/09638280210148594; TEASDALE G, 1974, LANCET, V2, P81; WADE DT, 1993, CURR OPIN NEUROL NEU, V6, P78; Wade DT, 2003, AM J PHYS MED REHAB, V82, pS26, DOI 10.1097/01.PHM.0000086996.89383.A1; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; Weir CJ, 2003, QJM-INT J MED, V96, P67, DOI 10.1093/qjmed/hcg008; Whyte EM, 2002, BIOL PSYCHIAT, V52, P253, DOI 10.1016/S0006-3223(02)01424-5; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; World Health Organization, 2001, INT CLASS FUNCT DIS	43	59	73	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	APR	2005	27	7-8					367	373		10.1080/09638280400014014			7	Rehabilitation	Rehabilitation	920CN	WOS:000228666600004	16040538				2021-06-18	
J	Serra-Grabulosa, JM; Junque, C; Verger, K; Salgado-Pineda, P; Maneru, C; Mercader, JM				Serra-Grabulosa, JM; Junque, C; Verger, K; Salgado-Pineda, P; Maneru, C; Mercader, JM			Cerebral correlates of declarative memory dysfunctions in early traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; HIPPOCAMPAL-FORMATION; CHILDREN; MR; NEUROGENESIS; ADOLESCENTS; STRIATUM; ATROPHY; VOLUME	We investigated residual brain damage in subjects who suffered severe traumatic brain injury (TBI) in childhood, and its relationship with declarative memory impairment. Magnetic resonance imaging (MRI) volumetric data and memory performance were compared between 16 adolescents with antecedents of severe TBI and 16 matched normal controls. Volumes of grey matter, white matter, cerebrospinal fluid (CSF), hippocampus, and caudate nuclei were measured. Verbal memory was assessed by the Rey's Auditory Verbal Learning test and visual memory by the Rey's Complex Figure. TBI patients performed significantly worse than controls in both verbal and visual memory. Patients presented decreased white matter volume and increased CSF. The hippocampus was reduced, but not the caudate nuclei. Memory performance correlated with CSF. Plasticity is incomplete for structural and functional deficits in children with TBI. Hippocampal atrophy, white matter loss, and memory impairment remain until adolescence. Memory sequelae are related more to diffuse brain injury, as reflected by MRI findings of increased CSF, than to hippocampal injury.	Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona 08035, Spain; Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; Hosp Clin Barcelona, Ctr Diagnost Imatge, Barcelona, Spain	Serra-Grabulosa, JM (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Pg Vall Hebron 171, Barcelona 08035, Spain.	jmserra@ub.edu	Serra-Grabulosa, Josep M/S-8371-2019; Serra-Grabulosa, Josep M/B-4655-2011; Junque, Carme/B-4400-2011	Serra-Grabulosa, Josep M/0000-0002-4291-9432; Junque, Carme/0000-0002-6381-3063; Salgado-Pineda, Pilar/0000-0001-7720-0885			BENES FM, 1994, ARCH GEN PSYCHIAT, V51, P477; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FREE SL, 1995, AM J NEURORADIOL, V16, P637; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Gunning-Dixon FM, 1998, AM J NEURORADIOL, V19, P1501; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; JACK CR, 1989, RADIOLOGY, V172, P549, DOI 10.1148/radiology.172.2.2748838; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Primus EA, 1997, BRAIN INJURY, V11, P577; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Verger K, 2000, BRAIN INJURY, V14, P495; Verger K, 2001, BRAIN INJURY, V15, P211	23	59	61	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2005	76	1					129	131		10.1136/jnnp.2004.027631			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	880GQ	WOS:000225777400030	15608014	Bronze, Green Published			2021-06-18	
S	Stein, DG		Singh, M; Simpkins, JW		Stein, DG			The case for progesterone	FUTURE OF HORMONE THERAPY: WHAT BASIC SCIENCE AND CLINICAL STUDIES TEACH US	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on the Future of Estrogen and Hormone Therapy in Postmenopausal Women	NOV 05-07, 2004	Ft Worth, TX	Univ N Texas Hlth Sci Ctr		progesterone; neurosteroids; hormone therapy; menopause; aging; brain damage; recovery	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; HEALTHY POSTMENOPAUSAL WOMEN; FRONTAL CORTICAL CONTUSION; MORRIS WATER MAZE; ESTROUS-CYCLE; OVARIECTOMIZED RATS; LIPID-PEROXIDATION; STEROID-HORMONES; FEMALE RATS	Recent clinical trials in hormone therapy (HT) for women approaching or past menopause have been disappointing. Most women who have been taking conjugated equine estrogens combined with synthetic progestins have been encouraged to stop these supplements because of increased health risks. The results of the clinical trials may be accurate about the risks associated with the synthetic compounds and combinations, but the data do not reflect what might have been the case if 17 beta-estradiol had been tested with natural progesterone instead of synthetic medroxyprogesterone acetate. For the most part, in almost all work on HT, estrogens have been given the primary focus despite the fact that progesterone has important properties that can enhance the repair of neurodegenerative and traumatic injuries to the central nervous system. This article reviews some of those properties and discusses the evidence suggesting that, if HT is to be reconsidered, progesterone should be given more attention as a potent neurotrophic agent that may play an important role in reducing or preventing motor, cognitive, and sensory impairments that can accompany senescence in both males and females.	Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, 1648 Pierce Dr,NE,Evans Bldg Rm 261, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038664, R01NS040825] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS38664, 1 R01 NS40825] Funding Source: Medline		Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Baulieu EE, 2000, HUM REPROD, V15, P1; Baulieu EE, 2000, STEROIDS, V65, P605, DOI 10.1016/S0039-128X(00)00173-2; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Behl C, 1999, TRENDS PHARMACOL SCI, V20, P441, DOI 10.1016/S0165-6147(99)01392-9; BETZ AL, 1990, ACT NEUR S, V51, P256; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Bimonte-Nelson HA, 2004, BEHAV NEUROSCI, V118, P707, DOI 10.1037/0735-7044.118.4.707; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Brass LM, 2004, STROKE, V35, P2644, DOI 10.1161/01.STR.0000143218.20061.ac; Cargill RS, 1999, J NEUROTRAUM, V16, P983; CHAO TC, 1994, AM J REPROD IMMUNOL, V32, P43, DOI 10.1111/j.1600-0897.1994.tb00877.x; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Chesler EJ, 2000, HORM BEHAV, V38, P234, DOI 10.1006/hbeh.2000.1626; de Wit H, 2001, PSYCHONEUROENDOCRINO, V26, P697, DOI 10.1016/S0306-4530(01)00024-5; DIAZVELIZ G, 1994, PSYCHONEUROENDOCRINO, V19, P387, DOI 10.1016/0306-4530(94)90018-3; Djebaili MJ, 2003, J NEUROTRAUM, V20, P1060; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Ehring GR, 1998, J EXP MED, V188, P1593, DOI 10.1084/jem.188.9.1593; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Epting LK, 1998, BEHAV NEUROSCI, V112, P1304, DOI 10.1037/0735-7044.112.6.1304; FULOP Z, 1992, 22 ANN M SOC NEUR AN, V18, P178; Galea LAM, 2000, HORM BEHAV, V37, P86, DOI 10.1006/hbeh.1999.1560; Gangula PRR, 2002, BIOL REPROD, V67, P1881, DOI 10.1095/biolreprod.102.007682; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibbs RB, 2003, J NEUROENDOCRINOL, V15, P477, DOI 10.1046/j.1365-2826.2003.01012.x; Gibbs RB, 1996, J NEUROSCI, V16, P1049; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; HAMPSON E, 1988, BEHAV NEUROSCI, V102, P456, DOI 10.1037/0735-7044.102.3.456; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hunt JS, 1997, J REPROD IMMUNOL, V35, P87, DOI 10.1016/S0165-0378(97)00060-0; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kelly RW, 1997, BIOCHEM BIOPH RES CO, V239, P557, DOI 10.1006/bbrc.1997.7502; Kuebler JF, 2003, ARCH SURG-CHICAGO, V138, P727, DOI 10.1001/archsurg.138.7.727; Li CJ, 2004, P NATL ACAD SCI USA, V101, P2185, DOI 10.1073/pnas.0307313101; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Limmroth V, 1996, BRIT J PHARMACOL, V117, P99, DOI 10.1111/j.1476-5381.1996.tb15160.x; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lowery D. W., 2002, J NEUROTRAUM, V19, P1286; Malcolm Shannon G., 2000, Journal of Neurotrauma, V17, P967; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; MELCANGI RA, 2003, STEROIDS NERV SYST, V1007, P406; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.0.CO;2-E; Pettus EH, 2000, J NEUROCHEM, V75, P383, DOI 10.1046/j.1471-4159.2000.0750383.x; PETTUS EH, IN PRESS BRAIN RES; Robert R, 1997, NITRIC OXIDE-BIOL CH, V1, P453, DOI 10.1006/niox.1997.0157; Roof R. L., 1994, Society for Neuroscience Abstracts, V20, P191; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1997, J NEUROTRAUM, V14, P760; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rubinow MJ, 2004, BEHAV NEUROSCI, V118, P863, DOI 10.1037/0735-7044.118.4.863; Sauerland S, 2004, LANCET, V364, P1291, DOI 10.1016/S0140-6736(04)17202-4; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; SEGARRA AC, 2004, PRINCIPLES GENDER SP, V1, P96; Soares HD, 1995, J NEUROSCI, V15, P8223; Soderpalm AHV, 2004, PSYCHONEUROENDOCRINO, V29, P339, DOI 10.1016/S0306-4530(03)00033-7; Solis-Ortiz S, 2004, PSYCHONEUROENDOCRINO, V29, P1047, DOI 10.1016/j.psyneuen.2003.10.007; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Warren SG, 1997, BEHAV NEUROSCI, V111, P259, DOI 10.1037/0735-7044.111.2.259; Yang SH, 2003, ANN NY ACAD SCI, V1007, P101, DOI 10.1196/annals.1286.010	89	59	61	0	5	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-584-2	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2005	1052						152	169		10.1196/annals.1347.011			18	Endocrinology & Metabolism; Multidisciplinary Sciences; Obstetrics & Gynecology	Endocrinology & Metabolism; Science & Technology - Other Topics; Obstetrics & Gynecology	BDE44	WOS:000233076700011	16024758				2021-06-18	
J	Joseph, DK; Dutton, RP; Aarabi, B; Scalea, TM				Joseph, DK; Dutton, RP; Aarabi, B; Scalea, TM			Decompressive laparotomy to treat intractable intracranial hypertension after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2004	Minneapolis, MN	Amer Assoc Surg Trauma			ABDOMINAL COMPARTMENT SYNDROME; INTRAABDOMINAL PRESSURE	Introduction: Increases in intra-abdominal pressure (IAP) can cause increases in intracranial pressure (ICP). Recently, we noticed that abdominal fascial release could be useful in treating intracranial hypertension (ICH) after traumatic brain injury (TBI). We added this as an option in our treatment of TBI. Methods: In our institution, ICH is treated with an algorithm using osmolar therapy, CSF drainage and barbiturates. Patients with refractory ICH have routine measurement of IAP. If elevated, consideration is given to decompressive laparotomy. We retrospectively reviewed all patients admitted from January 2000 through July 2003 who had abdominal decompression to treat refractory ICH. Results: From 1/00 to 7/03, 17 patients underwent decompressive laparotomy for intractable ICH. Thirteen male and 4 females all sustained blunt injury. All had failed maximal therapy including 14 who had had decompressive craniectomy. Mean ICP was 30 +/- 8.1 mm Hg (range 20-40 mm Hg) before decompression. No patients had evidence of abdominal compartment syndrome (ACS). Before decompression mean IAP was 27.5 (+/- 5.2) mmHg (range 21-35 mm Hg). After abdominal decompression ICP dropped precipitously by at least 10 mm Hg to a mean of 17.5 (+/- 3.2) mmHg (range 10-25 mm Hg). In 6 patients the decrease in ICP was transient. All died. The remaining 11 had sustained decreases in ICP. All survived, made neurologic recovery and were discharged to a rehabilitation facility. Conclusion: Decompressive laparotomy can be a useful adjunct in the treatment of ICH failing maximal therapy following TBI. More work will need to be done to precise the exact indications for this therapy.	Univ Maryland, Med Syst, R Adams Cowley Shock Trauma Ctr, Sch Med,Program Trauma, Baltimore, MD 21201 USA	Scalea, TM (corresponding author), Univ Maryland, Med Syst, R Adams Cowley Shock Trauma Ctr, Sch Med,Program Trauma, 22 S Greene St, Baltimore, MD 21201 USA.	tscalea@umm.edu					ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; BARNES GE, 1985, AM J PHYSIOL, V248, pR208; Bloomfield GL, 1997, CRIT CARE MED, V25, P496, DOI 10.1097/00003246-199703000-00020; Citerio G, 2001, CRIT CARE MED, V29, P1466, DOI 10.1097/00003246-200107000-00027; DIEBEL LN, 1992, J TRAUMA, V33, P45, DOI 10.1097/00005373-199207000-00010; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; HARMAN PK, 1982, ANN SURG, V196, P594, DOI 10.1097/00000658-198211000-00015; HOLTHAUSEN UH, 1997, LANGENBECKS ARCH CHI, V114, P257; JOSEPHS LG, 1994, J TRAUMA, V36, P815, DOI 10.1097/00005373-199406000-00011; Kopelman T, 2000, J TRAUMA, V49, P744, DOI 10.1097/00005373-200010000-00025; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; Meier U, 2003, NEUROSURG QUART, V13, P113, DOI 10.1097/00013414-200306000-00006; Meldrum DR, 1997, AM J SURG, V174, P667, DOI 10.1016/S0002-9610(97)00201-8; MIGLIETTA M, IN PRESS J TRAUMA; MUTOH T, 1991, J APPL PHYSIOL, V70, P2611; Saggi B, 1998, J TRAUMA, V45, P597, DOI 10.1097/00005373-199809000-00033; Saggi BH, 1999, J TRAUMA, V46, P646, DOI 10.1097/00005373-199904000-00014; SAGGI BH, 1998, J TRAUMA, V44, P248; SCHEIN M, 1995, J AM COLL SURGEONS, V180, P745; Schob OM, 1996, AM J SURG, V172, P248, DOI 10.1016/S0002-9610(96)00101-8; STONE HH, 1977, ANN SURG, V186, P343, DOI 10.1097/00000658-197709000-00012; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	23	59	69	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2004	57	4					687	693		10.1097/01.TA.0000140645.84897.F2			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	871EN	WOS:000225112300001	15514520				2021-06-18	
J	Hudak, AM; Trivedi, K; Harper, CR; Booker, K; Caesar, RR; Agostini, M; Van Ness, PC; Diaz-Arrastia, R				Hudak, AM; Trivedi, K; Harper, CR; Booker, K; Caesar, RR; Agostini, M; Van Ness, PC; Diaz-Arrastia, R			Evaluation of seizure-like episodes in survivors of moderate and severe traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						nonepileptic seizures; posttraumatic epilepsy; video-EEG monitoring	TEMPORAL-LOBE EPILEPSY; LATE POSTTRAUMATIC SEIZURES; NONEPILEPTIC SEIZURES; HEAD-INJURY; FEATURES; DIAGNOSIS; ADULTS; RISK	Background: Transient paroxysmal alterations of consciousness or behavior are common sequelae of moderate and severe traumatic brain injury (TBI). Clinicians caring for patients with such episodes often diagnose them as epileptic seizures, a frequent and well-studied complication of TBI. As it is difficult to confirm this diagnosis, antiepileptic drugs are often used empirically. However, as such therapy is frequently ineffective, we studied the usefulness of prolonged video electroencephalogram (VEEG) monitoring in the clinical management of paroxysmal behaviors in TBI survivors. Methods: Records of patients referred evaluation in an epilepsy monitoring unit for management of medically intractable epilepsy were retrospectively reviewed. Patients with a documented history of moderate-to-severe brain injury preceding the onset of epilepsy were identified. These patients were studied by simultaneous videotape and scalp electroencephalographic recordings, and the majority also underwent magnetic resonance imaging and neuropsychologic studies. Results: Of the 1858 consecutive admissions over a 66-month period, 127 (7%) fulfilled enrollment criteria. VEEG monitoring was conducted for an average of 4.6 days. Monitoring was successful in establishing a diagnosis in 82% of the cases referred: 62% had focal seizures, 6% had generalized seizures, and 33% had psychogenic nonepileptic seizures. Of those with temporal lobe epilepsy, 53% had mesial temporal sclerosis, as shown by magnetic resonance imaging. Conclusions: VEEG is a useful procedure in the evaluation of TBI survivors with spells. The yield of diagnoses that may alter treatment is substantial. Additionally, mesial temporal sclerosis is associated with TBI. Given the variety of seizure types found in survivors of moderate-to-severe TBI, obtaining specific diagnosis of seizure type by VEEG monitoring impacts treatment options.	Univ Texas, SW Med Ctr, Dept Phys Med & Rehabil, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA	Hudak, AM (corresponding author), Univ Texas, SW Med Ctr, Dept Phys Med & Rehabil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Anne.Hudak@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD42652] Funding Source: Medline		Annegers J.F., 1996, TREATMENT EPILEPSY P, P165; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Barry E, 1998, EPILEPSIA, V39, P427, DOI 10.1111/j.1528-1157.1998.tb01395.x; BENBADIS SR, 2000, COMPREHENSIVE CLIN N, P468; Cascino GD, 2002, MAYO CLIN PROC, V77, P1111, DOI 10.4065/77.10.1111; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; Cragar DE, 2002, NEUROPSYCHOL REV, V12, DOI 10.1023/A:1015491123070; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; ELOVIC E, 1996, MED REHABILITATION T, P1; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; Krumholz A, 1999, NEUROLOGY, V53, pS76; KUZNIECKY R, 1995, MAGNETIC RESONANCE I; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; Mathern GW, 1996, EPILEPSY RES, V26, P151, DOI 10.1016/S0920-1211(96)00052-6; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MEIERKORD H, 1991, NEUROLOGY, V41, P1643, DOI 10.1212/WNL.41.10.1643; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Sigurdardottir KR, 1998, EPILEPSIA, V39, P749, DOI 10.1111/j.1528-1157.1998.tb01161.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501	24	59	59	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2004	19	4					290	295		10.1097/00001199-200407000-00003			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	839CB	WOS:000222759800003	15263856				2021-06-18	
J	Levin, HS; Zhang, LF; Dennis, M; Ewing-Cobbs, L; Schachar, R; Max, J; Landis, JA; Roberson, G; Scheibel, RS; Miller, DL; Hunter, JV				Levin, HS; Zhang, LF; Dennis, M; Ewing-Cobbs, L; Schachar, R; Max, J; Landis, JA; Roberson, G; Scheibel, RS; Miller, DL; Hunter, JV			Psychosocial outcome of TBI in children with unilateral frontal lesions	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						children; frontal lesions; psychosocial outcome; TBI	CLOSED-HEAD-INJURY; TRAUMATIC BRAIN-INJURY; LOBE DAMAGE; PREFRONTAL CORTEX; DECISION-MAKING; PRACTICAL SCALE; DISORDERS; BEHAVIOR; EMOTION; AGE	To evaluate effects of unilateral frontal lesions on psychosocial and global outcome of traumatic brain injury (TBI) in children, Study 1 compared matched groups of 22 school aged children who had sustained TBI either with or without unilateral frontal lesions. Study 2 evaluated effects of unilateral extrafrontal lesions in 18 TBI patients as compared with 18 nonlesional TBI patients. Communication, Daily Living, and Socialization domains and the Maladaptive Behavior Scale of the Vineland Adaptive Behavior Scales (VABS) were used to assess psychosocial outcome, and the Glasgow Outcome Scale (GOS) measured global outcome. All patients underwent magnetic resonance imaging at least 3 months post injury. Children with frontal lesions had worse scores on the Daily Living and Socialization domains and a higher frequency of maladaptive behavior than those without frontal lesions, but there was no difference in cognitive function. Disability was twice as common in the frontal lesion group relative to children without frontal lesions. Volume of frontal lesion was related to the Socialization domain. Side of lesion had no effect, nor did presence of an extrafrontal lesion (Study 2). Unilateral frontal lesions adversely affect late psychosocial outcome of TBI in children.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX USA; Hosp Sick Children, Dept Psychol, Toronto, ON, Canada; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Childrens Hosp & Hlth Ctr, San Diego, CA USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA	Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Suite 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu		Schachar, Russell/0000-0002-2015-4395	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Blair RJR, 2001, J NEUROL NEUROSUR PS, V71, P727, DOI 10.1136/jnnp.71.6.727; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; Delis D.C., 1994, CVLT C CALIFORNIA VE; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Francis S, 1999, NEUROREPORT, V10, P453, DOI 10.1097/00001756-199902250-00003; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JENNETT B, 1975, LANCET, V1, P480; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; SATTLER JM, 2002, ASSESSMENT CHILDREN, P189; Semel E. M., 1995, CLIN EVALUATION LANG; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Wechsler D., 1991, WECHSLER INTELLIGENC; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	35	59	59	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2004	10	3					305	316		10.1017/S1355617704102129			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	817MB	WOS:000221180500001	15147589				2021-06-18	
J	Brooks, BM; Rose, FD; Potter, J; Jayawardena, S; Morling, A				Brooks, BM; Rose, FD; Potter, J; Jayawardena, S; Morling, A			Assessing stroke patients' prospective memory using virtual reality	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; ENVIRONMENTS	There is a dearth of empirical evidence about prospective memory (remembering to perform actions in the future) in stroke patients. A probable reason for this is that it is difficult to perform a realistic and controlled assessment of prospective memory ability in a rehabilitation setting. Virtual reality may provide a solution to this difficulty by allowing prospective memory to be tested in a simulation of a real-life situation whilst retaining a laboratory level of scientific control. This exploratory study assessed the performance of stroke patients and age-matched control participants on event-, time- and activity-based prospective memory retrieval tasks in a personal computer-based virtual environment. Stroke patients were severely impaired at the event- and activity-based tasks compared with age-matched controls, but only marginally impaired at the time-based task. The additional knowledge gained from this form of assessment could direct rehabilitation more effectively towards specific impairments of individual patients.	Univ E London, Sch Psychol, London E15 4LZ, England; Kent & Canterbury Hosp, Stroke Rehabil Unit, Canterbury, Kent, England	Brooks, BM (corresponding author), Univ E London, Sch Psychol, London E15 4LZ, England.	b.m.brooks@uel.ac.uk					Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Craik F.I.M., 1986, HUMAN MEMORY COGNITI, P409; DAVIES RC, 1998, P 2 EUR C DIS VIRT R, P61; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Maylor E.A., 1996, PROSPECTIVE MEMORY T, P173; MENDOZZI L, 1998, CYBERPSYCHOLOGY BEHA, V1, P79, DOI DOI 10.1089/CPB.1998.1.79; MORRIS RG, 2000, P INT C DIS VIRT REA, P189; NELSON HE, 1982, NATL ADULT READING; Rose D, 1999, PSYCHOLOGIST, V12, P550; Rose FD, 1999, DISABIL REHABIL, V21, P548; Titov N, 2000, BRAIN INJURY, V14, P877; WANN JP, 1997, VIRTUAL REALITY NEUR, P157; Wechsler D., 2011, WECHLSER ABBREVIATED; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	17	59	69	0	14	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2004	18	4					391	401		10.1080/02699050310001619855			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	765VB	WOS:000188304100005	14742152				2021-06-18	
J	Johnston, JJE; McGovern, SJ				Johnston, JJE; McGovern, SJ			Alcohol related falls: an interesting pattern of injuries	EMERGENCY MEDICINE JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; ETHANOL; LEVEL; RATS	Objective: To discover if there is a significant difference in the pattern and severity of injury sustained during falls in patients who have consumed alcohol and those who have not. To determine how pattern and severity of injury correlates with blood alcohol concentration. Method: A prospective quasi-randomised controlled study between November 2001 and July 2002. All healthy adults between 16 and 60 years who had fallen from standing height were included. A systematic history and examination permitted calculation of injury severity scores as per abbreviated injury scale update 1998. Blood alcohol concentrations were obtained from intoxicated patients with consent. Results: 351 healthy adult patients were included in the study, there were 238 in the no alcohol group, 113 had consumed alcohol and blood alcohol intake were obtained for 47. The alcohol group had a higher incidence of head injuries (46(48%) versus 22 (9%)) with a lower incidence of limb injuries (39 (39%) versus 183 (76%)) than the no alcohol group. There was a significant difference in the pattern of injury between the alcohol and no alcohol groups (chi(2), p<0.001) and there was a significant difference in the injury severity scores (p<0.001, Z=-2.5). In the alcohol group severity and pattern correlated with alcohol concentration at the time of injury. Patients with an alcohol concentration <2 g/l had mostly soft tissue limb injuries (58%), 2-2.5 mostly significant limb fractures (55%), and >2.5 mostly significant head injuries (90%). Conclusions: Alcohol related falls are more often associated with severe craniofacial injury. The severity of both limb and head injury is greater and correlates directly with blood alcohol concentration.	Ulster Hosp Dundonald, Dept Accid & Emergency, Belfast, Antrim, North Ireland	Johnston, JJE (corresponding author), Newcastle Gen Hosp, Dept Accid & Emergency, Westgate Rd, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	jeremyjejohnston@doctors.org.uk					*ASS ADV AUT MED, 1990, ABBR INJ SCAL 1990; Biros MH, 1999, ACAD EMERG MED, V6, P1088, DOI 10.1111/j.1553-2712.1999.tb00109.x; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Cook L S, 1994, Acad Emerg Med, V1, P227; HINGSON R, 1993, ADDICTION, V88, P877, DOI 10.1111/j.1360-0443.1993.tb02105.x; HOLDFORD N, 1987, CLIN PHARMACOKINET, V13, P273; HONKANEN R, 1976, ANN CHIR GYNAECOL FE, V65, P287; HONKANEN R, 1990, INJURY, V21, P353, DOI 10.1016/0020-1383(90)90117-D; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kleemann Werner Johann, 1995, Blutalkohol, V32, P162; KNIGHT B, 1996, FORENSIC PATHOLOGY, P544; Roys MS, 2001, APPL ERGON, V32, P135, DOI 10.1016/S0003-6870(00)00049-1; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Tate PS, 1999, BRAIN INJURY, V13, P767; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	16	59	61	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205			EMERG MED J	Emerg. Med. J.	MAR 1	2004	21	2					185	188		10.1136/emj.2003.006130			4	Emergency Medicine	Emergency Medicine	778TB	WOS:000189255900014	14988344	Green Published, Bronze			2021-06-18	
J	Palzur, E; Vlodavsky, E; Mulla, H; Arieli, R; Feinsod, M; Soustiel, JF				Palzur, E; Vlodavsky, E; Mulla, H; Arieli, R; Feinsod, M; Soustiel, JF			Hyperbaric oxygen therapy for reduction of secondary brain damage in head injury: An animal model of brain contusion	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; cerebral contusion; head injury; hyperbaric oxygen; secondary brain damage	CEREBRAL BLOOD-FLOW; EXCITATORY AMINO-ACIDS; CORTICAL IMPACT INJURY; NORMOBARIC HYPEROXIA; COMPUTED-TOMOGRAPHY; HYPOXIA-ISCHEMIA; INFARCT SIZE; CNS INJURY; RAT MODEL; APOPTOSIS	Cerebral contusions are one the most frequent traumatic lesions and the most common indication for secondary surgical decompression. The purpose of this study was to investigate the physiology of perilesional secondary brain damage and evaluate the value of hyperbaric oxygen therapy (HBOT) in the treatment of these lesions. Five groups of five Sprague-Dawley rats each were submitted to dynamic cortical deformation (DCD) induced by negative pressure applied to the cortex. Cerebral lesions produced by DCD at the vacuum site proved to be reproducible. The study protocol entailed the following: (1) DCD alone, (2) DCD and HBOT, (3) DCD and post-operative hypoxia and HBOT, (4) DCD, post-operative hypoxia and HBOT, and (5) DCD and normobaric hyperoxia. Animals were sacrificed after 4 days. Histological sections showed localized gross tissue loss in the cortex at injury site, along with hemorrhage. In all cases, the severity of secondary brain damage was assessed by counting the number of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and caspase 3-positive cells in successive perilesional layers, each 0.5 mm thick. Perilesional TUNEL positive cells suggested the involvement of apoptosis in group 1 (12.24% of positive cells in layer 1). These findings were significantly enhanced by post-operative hypoxia (31.75%, p < 0.001). HBOT significantly reduced the severity and extent of secondary brain damage expressed by the number of TUNEL positive cells in each layer and the volume of the lesion (4.7% and 9% of TUNEL positive cells in layer I in groups 2 and 4 respectively, p < 0.0001 and p < 0.003). Normobaric hyperoxia also proved to be beneficial although in a lesser extent. This study demonstrates that the vacuum model of brain injury is a reproducible model of cerebral contusion. The current findings also suggest that HBOT may limit the growth of cerebral contusions and justify further experimental studies.	Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Div Neurosurg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Acute Brain Res Lab, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Dept Pathol, IL-31096 Haifa, Israel; Israel Def Forces Med Corps, Israel Naval Med Inst, Haifa, Israel	Soustiel, JF (corresponding author), Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Div Neurosurg, POB 9602, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il					Arieli Ran, 1994, Journal of Basic and Clinical Physiology and Pharmacology, V5, P277; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Calvert JW, 2002, BRAIN RES, V951, P1, DOI 10.1016/S0006-8993(02)03094-9; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; DAVIS JN, 1973, SCIENCE, V182, P72, DOI 10.1126/science.182.4107.72; Demchenko IT, 2000, NITRIC OXIDE-BIOL CH, V4, P597, DOI 10.1006/niox.2000.0313; Demchenko IT, 1998, UNDERSEA HYPERBAR M, V25, P147; Eriskat J, 1997, ACT NEUR S, V70, P94; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gwag BJ, 1997, NEUROSCIENCE, V77, P393, DOI 10.1016/S0306-4522(96)00473-3; HUNT RC, 1978, EXP NEUROL, V62, P698, DOI 10.1016/0014-4886(78)90278-9; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; KOHSHI K, 1991, Neurologia Medico-Chirurgica, V31, P575, DOI 10.2176/nmc.31.575; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MATTHEWS DSF, 1995, J NEUROL NEUROSUR PS, V59, P359, DOI 10.1136/jnnp.59.4.359; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; NEUBAUER RA, 1994, SOUTHERN MED J, V87, P933, DOI 10.1097/00007611-199409000-00015; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nighoghossian N, 1997, J NEUROL SCI, V150, P27, DOI 10.1016/S0022-510X(97)05398-7; O'Dell DM, 2000, J NEUROSCI, V20, P4821; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; PukaSundvall M, 1997, BRAIN RES, V750, P325, DOI 10.1016/S0006-8993(97)00024-3; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; ROPER SN, 1991, J NUCL MED, V32, P1684; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Singhal AB, 2002, J CEREBR BLOOD F MET, V22, P861, DOI 10.1097/00004647-200207000-00011; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Teasdale G, 1996, NEUROLOGICAL SURG, P1533; Thomale UW, 2002, ACTA NEUROCHIR SUPPL, V81, P229; Veltkamp R, 2000, BRAIN RES, V853, P68, DOI 10.1016/S0006-8993(99)02250-7; Wada S, 2000, MAR BIOTECHNOL, V2, P285, DOI 10.1007/s101260000006; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	47	59	79	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2004	21	1					41	48		10.1089/089771504772695931			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	766GU	WOS:000188368700005	14987464				2021-06-18	
J	O'Hanlon, GM; Humphreys, PD; Goldman, RS; Halstead, SK; Bullens, RWM; Plomp, JJ; Ushkaryov, Y; Willison, HJ				O'Hanlon, GM; Humphreys, PD; Goldman, RS; Halstead, SK; Bullens, RWM; Plomp, JJ; Ushkaryov, Y; Willison, HJ			Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury	BRAIN			English	Article						Miller Fisher syndrome; neuromuscular junction; anti-ganglioside antibody; alpha-latrotoxin; calpain inhibitor	MILLER-FISHER-SYNDROME; WIDOW SPIDER VENOM; GUILLAIN-BARRE-SYNDROME; TRAUMATIC BRAIN-INJURY; ALPHA-LATROTOXIN; NEUROMUSCULAR-JUNCTION; PERIPHERAL-NERVE; WALLERIAN DEGENERATION; CELL-DEATH; RELEASE	Miller Fisher syndrome-associated anti-GQ1b ganglioside antibodies produce an acute complement-dependent neuroexocytic effect at the mouse neuromuscular junction (NMJ) that closely resembles the effect of alpha-latrotoxin (LTx). This pathophysiological effect is accompanied by morphological disruption of the nerve terminal involving the loss of major cytoskeletal components, including neurofilament. Both LTx and the membrane attack complex of complement form membrane pores that allow free ionic movement and we have previously hypothesized that Ca2+ ingress and the subsequent activation of Ca2+-dependent proteases, calpains, may lead to substrate degradation resulting in structural disorganization of the terminal. Here, we treated mouse NMJs in hemidiaphragm preparations with anti-GQ1b antibodies and complement, or with LTx in the presence and absence of extracellular Ca2+, and studied possible neuroprotective effects of the calpain inhibitors calpeptin and calpain inhibitor V. Both Ca2+ depletion and calpain inhibition protected the cytoskeleton from degradation, as assessed by immunohistological and ultrastructural analysis. Calpain inhibitors may therefore be useful therapeutically in limiting nerve terminal and axonal injury in autoimmune peripheral neuropathy and in human latrodectism.	Univ Glasgow, So Gen Hosp, Dept Neurol, Inst Neurol Sci,Div Clin Neurosci, Glasgow G51 4TF, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London, England; Leiden Univ, Med Ctr, Dept Neurophysiol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RA Leiden, Netherlands	Willison, HJ (corresponding author), Univ Glasgow, So Gen Hosp, Dept Neurol, Inst Neurol Sci,Div Clin Neurosci, Glasgow G51 4TF, Lanark, Scotland.		Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Halstead, Susan/0000-0001-7396-8969			Acosta JA, 1996, MOL MED, V2, P755, DOI 10.1007/BF03401659; Ashton AC, 2000, BIOCHIMIE, V82, P453, DOI 10.1016/S0300-9084(00)00199-1; BADALAMENTE MA, 1995, J RECONSTR MICROSURG, V11, P429, DOI 10.1055/s-2007-1006557; BADALAMENTE MA, 1989, P NATL ACAD SCI USA, V86, P5983, DOI 10.1073/pnas.86.15.5983; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Buchwald B, 2001, NEUROLOGY, V56, P67, DOI 10.1212/WNL.56.1.67; Buchwald B, 1995, NEUROSCI LETT, V201, P163, DOI 10.1016/0304-3940(95)12155-2; Caba E, 2002, J NEUROSCI RES, V67, P787, DOI 10.1002/jnr.10163; Calupca MA, 1999, J NEUROPHYSIOL, V81, P498; Castonguay A, 2001, Prog Brain Res, V132, P227; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Chan SO, 1998, NEUROCHEM RES, V23, P393, DOI 10.1023/A:1022417819356; Chen ZF, 1997, BRAIN RES, V769, P188, DOI 10.1016/S0006-8993(97)00848-2; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; DUCHEN LW, 1981, J PHYSIOL-LONDON, V316, P279, DOI 10.1113/jphysiol.1981.sp013787; Glass JD, 2002, J NEUROL SCI, V196, P9, DOI 10.1016/S0022-510X(02)00013-8; Goodyear CS, 1999, J CLIN INVEST, V104, P697, DOI 10.1172/JCI6837; GORIO A, 1978, J NEUROCYTOL, V7, P193, DOI 10.1007/BF01217918; Henkel AW, 1999, CELL TISSUE RES, V296, P229, DOI 10.1007/s004410051284; Jiang QB, 2000, J NEUROCHEM, V74, P2101, DOI 10.1046/j.1471-4159.2000.0742101.x; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KISHI M, 2001, J PERIPHER NERV SYST, V6, P152; Newsholme P, 1999, BIOCHEM PHARMACOL, V57, P491, DOI 10.1016/S0006-2952(98)00311-6; O'Hanlon GM, 2002, NEUROCHEM RES, V27, P697, DOI 10.1023/A:1020284302718; O'Hanlon GM, 2001, BRAIN, V124, P893, DOI 10.1093/brain/124.5.893; OKAMOTO M, 1971, SCIENCE, V172, P733, DOI 10.1126/science.172.3984.733; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Plomp JJ, 1999, ANN NEUROL, V45, P189, DOI 10.1002/1531-8249(199902)45:2<189::AID-ANA9>3.0.CO;2-T; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; ROBERTS M, 1994, LANCET, V343, P454, DOI 10.1016/S0140-6736(94)92694-8; Rochon D, 2001, J NEUROSCI, V21, P3819, DOI 10.1523/JNEUROSCI.21-11-03819.2001; ROOTS BI, 1983, SCIENCE, V221, P971, DOI 10.1126/science.6192501; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHLAEPFER WW, 1977, BRAIN RES, V136, P1, DOI 10.1016/0006-8993(77)90126-3; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.0.CO;2-T; Volynski KE, 2000, J BIOL CHEM, V275, P41175, DOI 10.1074/jbc.M005857200; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Wang MS, 2000, J NEUROPATH EXP NEUR, V59, P599, DOI 10.1093/jnen/59.7.599; Wells GJ, 1998, EXPERT OPIN THER PAT, V8, P1707, DOI 10.1517/13543776.8.12.1707; Willison HJ, 1999, J NEUROIMMUNOL, V100, P3, DOI 10.1016/S0165-5728(99)00213-1; Willison HJ, 2002, BRAIN, V125, P2591, DOI 10.1093/brain/awf272; Xu Y, 2002, J BIOL CHEM, V277, P21474, DOI 10.1074/jbc.M111689200	45	59	59	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	NOV	2003	126		11				2497	2509		10.1093/brain/awg254			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	735ZL	WOS:000186144800014	12937083				2021-06-18	
J	Goranson, TE; Graves, RE; Allison, D; La Freniere, R				Goranson, TE; Graves, RE; Allison, D; La Freniere, R			Community integration following multidisciplinary rehabilitation for traumatic brain injury	BRAIN INJURY			English	Article							COGNITIVE REHABILITATION; QUESTIONNAIRE; OUTCOMES; PREDICTION; PROGRAM; REGRESSION; DAMAGE	Primary objective : To determine the extent to which participation in a multidisciplinary rehabilitation programme and patient characteristics predict improvement in community integration following mild-to-moderate traumatic brain injury (TBI). Research design : A non-randomized case-control study was conducted employing a pre-test-post-test multiple regression design. Methods and procedures : Archival data for 42 patients with mild-to-moderate TBI who completed the Community Integration Questionnaire (CIQ) at intake and again 6-18 months later were analysed. Half the sample participated in an intensive outpatient rehabilitation programme that provided multi-modal interventions, while the other half received no rehabilitation. The two groups were matched on age, education and time since injury. Results : On the CIQ Home Integration scale, participation in rehabilitation and female gender predicted better outcome. On the Productivity scale, patients with a lower age at injury had better outcome. Outcome on both of these scales, as well as on the Social Integration scale, was predicted by the baseline pre-test score (initial severity). Conclusions : Overall, multidisciplinary rehabilitation appeared to increase personal independence. It is also concluded that: (1) multivariate analysis can reveal the relative importance of multiple predictors of outcome; (2) different predictors may predict different aspects of outcome; and (3) more sensitive and specific outcome measures are needed.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada; Gorge Rd Hosp, Dept Psychol, Victoria, BC, Canada; Gorge Rd Hosp, Dept Rehabil Med, Victoria, BC, Canada	Graves, RE (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.						ARANOW HU, 1987, J HEAD TRAUMA REHAB, V2, P24; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, pCH7; FORSYTHE AB, 1971, J PSYCHIAT RES, V8, P119, DOI 10.1016/0022-3956(71)90013-6; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HELFFENSTEIN DA, 1982, CLIN NEUROPSYCHOLOGY, V4, P139; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MATEER CA, 1996, NEUROPHYSIOLOGY NEUR, V6, P12; NORUSIS MJ, 1999, SPSS BASE 10 0 USERS; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SIVAK M, 1984, INT J REHABIL RES, V7, P389, DOI 10.1097/00004356-198412000-00002; SIVAK M, 1984, ARCH PHYS MED REHAB, V65, P163; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	32	59	59	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2003	17	9					759	774		10.1080/0269905031000088513			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691ML	WOS:000183610000003	12850942				2021-06-18	
J	Zazryn, TR; Finch, CF; McCrory, P				Zazryn, TR; Finch, CF; McCrory, P			A 16 year study of injuries to professional boxers in the state of Victoria, Australia	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							BOXING INJURIES	Objectives: Concerns about the significant injury risks in boxers have been well documented. To inform the continuing debate, updated information about the risk of injury for participants, and suitable means of modifying or preventing these risks, need to be identified. Methods: Data describing all professional boxing fight outcomes and injuries sustained during competition, from August 1985 to August 2001, were obtained from the Victorian Professional Boxing and Combat Sports Board. Results: A total of 107 injuries were recorded from 427 fight participations, corresponding to an injury rate of 250.6 injuries per 1000 fight participations. The most commonly injured body region was the head/neck/face (89.8%), followed by the upper extremities (7.4%). Specifically, injuries to the eye region (45.8%) and concussion (15.9%) were the most common. About three quarters of all injuries were lacerations/open wounds or superficial. No information was available on the mechanism of injury. Conclusions: Future research should collect information on the mechanism of injury, as this is crucial for the development and implementation of effective injury prevention strategies. A suggested boxing injury report form is provided to facilitate this.	Monash Univ, Sch Med, Alfred Hosp, Dept Epidemiol & Prevent Med, Prahran, Vic 3181, Australia	Finch, CF (corresponding author), Monash Univ, Sch Med, Alfred Hosp, Dept Epidemiol & Prevent Med, Commercial Rd, Prahran, Vic 3181, Australia.		McCrory, Paul/Q-8688-2019				*AUSTR SPORTS INJ, 1997, AUSTR SPORTS INJ DAT; Boxing Jordan B, 1996, EPIDEMIOLOGY SPORTS, P113; *BRIT MED ASS, 2002, BOX DEB; ESTWANIK J J, 1984, Physician and Sportsmedicine, V12, P123; FINCH C, 1997, SPORTSAFE AUSTR NATL; GIOVINAZZO VJ, 1987, OPHTHALMOLOGY, V94, P587; JORDAN BD, 1990, PHYSICIAN SPORTSMED, V18, P81, DOI 10.1080/00913847.1990.11709974; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P87, DOI 10.1080/00913847.1988.11709407; MCCOWN IA, 1959, AM J SURG, V98, P509, DOI 10.1016/0002-9610(59)90545-8; MCCRORY P, 2001, CLIN SPORTS MED, P189; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; *NAT HLTH MED RES, 1994, BOX INJ, P38; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Porter M, 1996, CLIN J SPORT MED, V6, P97, DOI 10.1097/00042752-199604000-00006; SCOTT I, 2002, COUNTING INJURIES OU; WELCH MJ, 1986, PHYSICIAN SPORTSMED, V14, P81, DOI 10.1080/00913847.1986.11709169	17	59	63	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	AUG 1	2003	37	4					321	324		10.1136/bjsm.37.4.321			4	Sport Sciences	Sport Sciences	706VB	WOS:000184474800013	12893717	Green Published, Bronze			2021-06-18	
J	Lubisch, W; Beckenbach, E; Bopp, S; Hofmann, HP; Kartal, A; Kastel, C; Lindner, T; Metz-Garrecht, M; Reeb, J; Regner, F; Vierling, M; Moller, A				Lubisch, W; Beckenbach, E; Bopp, S; Hofmann, HP; Kartal, A; Kastel, C; Lindner, T; Metz-Garrecht, M; Reeb, J; Regner, F; Vierling, M; Moller, A			Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: Discovery of potent water-soluble calpain inhibitors with oral bioavailability	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							MU-CALPAIN; CYSTEINE PROTEINASES; BRAIN-INJURY; ACTIVATION; CALCIUM; PROTEOLYSIS; EXPRESSION; PEPTIDES; RAT	Novel benzoylalanine-derived ketoamides were prepared and evaluated for calpain I inhibition. Derivatives carrying vinylbenzyl amino residues in the P-2-P-3 region inhibited calpain in nanomolar concentrations and thus represent a novel class of nonpeptidic calpain inhibitors. Selected examples exhibited an improved pharmacokinetic profile including improved water-solubility and metabolic stability. In particular, these calpain inhibitors showed oral bioavailability in rats as demonstrated by N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethylaminomethylphenyl)ethen-1-yl]benzamide (5d). The closely related derivative N-(1-carbamoyl-1-oxohex-1-yl)-2-[E-2-(4-dimethylaminomethylphenyl)-ethen-1-yl]benzamide (5b) was evaluated for neuroprotective efficacy after experimental traumatic brain injury in a fluid percussion model in rats. When administered after injury, 5b reduced the number of damaged neurons by 41%, and this result would be in line with the suggested neuroprotective efficacy of calpain inhibition.	Abbott GmbH & Co KG, Neurosci Discovery Res, D-67008 Ludwigshafen, Germany	Lubisch, W (corresponding author), Abbott GmbH & Co KG, Neurosci Discovery Res, POB 210805, D-67008 Ludwigshafen, Germany.	wilfried.lubisch@abbott.com					ANGELASTRO MR, 1990, J MED CHEM, V33, P11, DOI 10.1021/jm00163a002; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Baghdiguian S, 1999, NAT MED, V5, P503; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Bort R, 1999, BIOCHEM PHARMACOL, V58, P787, DOI 10.1016/S0006-2952(99)00167-7; Chaterjee S, 1996, BIOORG MED CHEM LETT, V6, P1619, DOI 10.1016/S0960-894X(96)00286-7; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; Dear TN, 2000, GENOMICS, V68, P152, DOI 10.1006/geno.2000.6289; Donkor IO, 2000, CURR MED CHEM, V7, P1171, DOI 10.2174/0929867003374129; FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676; Gabrijelcic-Geiger D, 2001, BIOL CHEM, V382, P1733, DOI 10.1515/BC.2001.209; HARBESON SL, 1994, J MED CHEM, V37, P2918, DOI 10.1021/jm00044a013; HARRIS AL, 1995, BIOORG MED CHEM LETT, V5, P393, DOI 10.1016/0960-894X(95)00042-R; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Iwamoto H, 1999, J CARDIOVASC PHARM, V33, P580, DOI 10.1097/00005344-199904000-00010; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Li ZZ, 1996, J MED CHEM, V39, P4089, DOI 10.1021/jm950541c; Lombardo F, 2001, J MED CHEM, V44, P2490, DOI 10.1021/jm0100990; Lubisch W, 2000, BIOORG MED CHEM LETT, V10, P2187, DOI 10.1016/S0960-894X(00)00430-3; Lubisch W, 2002, BIOORG MED CHEM LETT, V12, P1335, DOI 10.1016/S0960-894X(02)00176-2; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Newcomb-Fernandez JK, 2001, J CEREBR BLOOD F MET, V21, P1281, DOI 10.1097/00004647-200111000-00004; ODA A, 1993, J BIOL CHEM, V268, P12603; Reverter D, 2001, TRENDS CARDIOVAS MED, V11, P222, DOI 10.1016/S1050-1738(01)00112-8; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; Shields DC, 1998, P NATL ACAD SCI USA, V95, P5768, DOI 10.1073/pnas.95.10.5768; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Squier MKT, 1996, CELL DEATH DIFFER, V3, P275; Sreenan SK, 2001, DIABETES, V50, P2013, DOI 10.2337/diabetes.50.9.2013; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; Tagliarino C, 2001, J BIOL CHEM, V276, P19150, DOI 10.1074/jbc.M100730200; Tao M, 1996, BIOORG MED CHEM LETT, V6, P3009, DOI 10.1016/S0960-894X(96)00550-1; Urthaler F, 1997, CARDIOVASC RES, V35, P60, DOI 10.1016/S0008-6363(97)00099-0; VANDERSKLISH PW, 2000, INT J EXP PATHOL, V7, P1171; Volbracht C, 2001, NEUROREPORT, V12, P3645, DOI 10.1097/00001756-200112040-00008; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Wells GJ, 1998, EXPERT OPIN THER PAT, V8, P1707, DOI 10.1517/13543776.8.12.1707; WENCELDRAKE JD, 1991, ARTERIOSCLER THROMB, V11, P882, DOI 10.1161/01.ATV.11.4.882; YOSHII N, 1999, 29 SOC NEUR ABSTR	48	59	60	0	3	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	JUN 5	2003	46	12					2404	2412		10.1021/jm0210717			9	Chemistry, Medicinal	Pharmacology & Pharmacy	684RM	WOS:000183220400016	12773044				2021-06-18	
J	Huebner, RA; Johnson, K; Bennett, CM; Schneck, C				Huebner, RA; Johnson, K; Bennett, CM; Schneck, C			Community participation and quality of life outcomes after adult traumatic brain injury	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article; Proceedings Paper	Annual Conference of the American-Occupational-Therapy-Association	APR   18, 1999	INDIANAPOLIS, INDIANA	Amer Occupat Therapy Assoc		activity limitation; community integration; occupational performance	REHABILITATION; SATISFACTION; INTEGRATION; RECOVERY	OBJECTIVE. This study examined outcomes after traumatic brain injury in adults salient to occupational therapy. METHOD. Demographic data and Functional Independence Measure (FIM) scores from the inpatient rehabilitation stay were first gathered from a retrospective chart review. At follow-up, 25 adults, on average 21 months post-injury, completed measures of disability, community participation, quality of life, and satisfaction with occupational therapy during a telephone interview. Analysis of covariance was used to test the differences between pretest and posttest scores on the FIM; regression analysis and correlations were used to analyze predictions and relationships. RESULTS. Statistically significant improvements in FIM scores during rehabilitation were predictive of the level of long-term disability and community participation among participants. At follow-up, participants were often unemployed, depressed and withdrawn, and experienced limitations in decision making, hand use, bladder control, and community integration. Less disability and more community participation were related to higher quality of life. Satisfaction with occupational therapy, although high, was unrelated to most outcomes. CONCLUSION. Results support the premise that participation is associated with a high quality of lite, yet persons with brain injury have significant needs for long-term occupational therapy.	Eastern Kentucky Univ, Dept Occupat Therapy, Richmond, KY 40475 USA; Stepping Stones Communities, Louisville, KY USA; Mountainland Rehabil, Salt Lake City, UT USA	Huebner, RA (corresponding author), Kentucky Cabinet Families & Children, Off Secretary, Mail Stop 4W-B,275 E Main St, Frankfort, KY 40621 USA.						Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Brandt E. N., 1997, ENABLING AM ASSESSIN; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cohen ME, 2000, ARCH PHYS MED REHAB, V81, pS21, DOI 10.1053/apmr.2000.20620; Corcoran K., 1987, MEASURES CLIN PRACTI; DIJKERS MPJ, 2000, MEASURES SOCIAL O S2, V81, pS63; Evans RW, 1997, ARCH PHYS MED REHAB, V78, pS17, DOI 10.1016/S0003-9993(97)90151-9; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fisher TF, 1998, AM J OCCUP THER, V52, P785, DOI 10.5014/ajot.52.10.785; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; GUST T, 1982, QUALITY LIFE RATING; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Halstead LS, 2001, ARCH PHYS MED REHAB, V82, P149, DOI 10.1053/apmr.2001.22207; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Holm MB, 2000, AM J OCCUP THER, V54, P575, DOI 10.5014/ajot.54.6.575; HUEBNER RA, 1998, J REHABILITATION OUT, V2, P8; JOHNSTON MV, 1994, ARCH PHYSICAL MED RE, V75, P2; Keith RA, 1998, ARCH PHYS MED REHAB, V79, P1122, DOI 10.1016/S0003-9993(98)90182-4; Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6; Macksoud M.S., 1992, J REFUG STUD, V5, P1, DOI [DOI 10.1093/JRS/5.1.1, 10.1093/jrs/5.1.1]; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Nelson DL, 1996, AM J OCCUP THER, V50, P223, DOI 10.5014/ajot.50.3.223; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PANIKOFF LB, 1983, AM J OCCUP THER, V37, P735, DOI 10.5014/ajot.37.11.735; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; SCHWARTZ SM, 1995, AM J OCCUP THER, V49, P655, DOI 10.5014/ajot.49.7.655; *SPSS INC, 2001, STAT PROGR SOC SERV; *STAT U NEW YORK B, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Watts J, 2000, J REHABILITATION OUT, V4, P55; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; *WHO, 1999, INT CLASS FUNCT DIS; Whyte J, 1998, REHABILITATION MED P, P1191; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, BRAIN INJURY REHABIL, P355; YOUNGSTROM MJ, 2000, UNPUB DRAFT 4; 1989, HLTH ACTIVITY LIMITA	41	59	64	0	4	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	MAR-APR	2003	57	2					177	185		10.5014/ajot.57.2.177			9	Rehabilitation	Rehabilitation	654YV	WOS:000181525300007	12674309				2021-06-18	
J	Johnstone, B; Mount, D; Schopp, LH				Johnstone, B; Mount, D; Schopp, LH			Financial and vocational outcomes 1 year after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; cost of illness; rehabilitation; rehabilitation, vocational; treatment outcome		Objective: To characterize financial and vocational outcomes among persons with traumatic brain injury (TBI) in terms of employment status, earned and private income, and public assistance received at the time of injury and at 1 year after injury. Design: Nonexperimental, longitudinal study. Setting: Inpatient TBI rehabilitation unit and participants' community of residence. Participants: Thirty-five persons with new TBI from 1 national Traumatic Brain Injury Model Systems center. Interventions: Not applicable. Main Outcome Measures: Employment status, earned and private monthly income, and public assistance received monthly at the time of injury and at 1-year follow-up. Results: From the time of injury until 1-year follow-up, the percentage of persons employed decreased from 69% to 31%; the percentage unemployed increased from 11% to 49%; the average earned monthly income declined 51% (from $1491 to $726); and the mean total public assistance received per month increased 275% (from $153 to $421). Conclusion: Assuming that this study sample is representative of national statistics for TBI, during the first year after injury, TBI is associated with an estimated $642 million in lost wages, $96 million in lost income taxes, and $353 million in increased public assistance.	Univ Missouri, Dept Hlth Psychol, Sch Hlth Profess, Columbia, MO 65212 USA	Johnstone, B (corresponding author), Univ Missouri, Dept Hlth Psychol, Sch Hlth Profess, 1 Hosp Dr,DC046-46, Columbia, MO 65212 USA.			Johnstone, Brick/0000-0001-8845-9649			[Anonymous], TRAUMATIC BRAIN INJU; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; HURT GD, 2000, NEUROPSYCHOLOGICAL M, P215; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; 1998, NIH CONSENS STATEMEN, V16, P1	5	59	59	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					238	241		10.1053/apmr.2003.50097			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700013	12601655				2021-06-18	
J	Gibson, JB; Maxwell, RA; Schweitzer, JB; Fabian, TC; Proctor, KG				Gibson, JB; Maxwell, RA; Schweitzer, JB; Fabian, TC; Proctor, KG			Resuscitation from severe hemorrhagic shock after traumatic brain injury using saline, shed blood, or a blood substitute	SHOCK			English	Article						swine; hemoglobin-based oxygen carrying compound; diaspirin cross-linked hemoglobin; cerebral perfusion pressure; jugular bulb oximetry	CROSS-LINKED HEMOGLOBIN; SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; HEMODILUTION; OXYGEN; MODEL; RATS; CO2-REACTIVITY; AUTOREGULATION; ISCHEMIA	The original purpose of this study was to compare initial resuscitation of hemorrhagic hypotension after traumatic brain injury (TBI) with saline and shed blood. Based on those results, the protocol was modified and saline was compared to a blood substitute, diaspirin cross-linked hemoglobin (DCLHb). Two series of experiments were performed in anesthetized and mechanically ventilated (FiO(2) = 0.4) pigs (35-45 kg). In Series 1, fluid percussion TBI (6-8 ATM) was followed by a 30% hemorrhage. At 120 min post-TBI, initial resuscitation consisted of either shed blood (n = 7) or a bolus of 3x shed blood volume as saline (n = 13). Saline supplements were then administered to all pigs to maintain a systolic arterial blood pressure (SAP) of >100 mmHg and a heart rate (HR) of <110 beats/min. In Series 2, TBI (4-5 ATM) was followed by a 35% hemorrhage. At 60 min post-TBI, initial resuscitation consisted of either 500 mL of DCLHb (n = 6) or 500 mL of saline (n = 5). This was followed by saline supplements to all pigs to maintain a SAP of >100 mmHg and a HR of <110 beats/min. In Series 1, most systemic markers of resuscitation (e.g., SAP, HR, cardiac output, filling pressures, lactate, etc.) were normalized, but there were 0/7 vs. 5/13 deaths within 5 h (P = 0.058) with blood vs. saline. At constant arterial O-2 saturation (SaO(2)), mixed venous O-2 saturation (SvO(2)), cerebral perfusion pressure (CPP), and cerebral venous O-2 saturation (ScvO(2)) were all higher, intracranial pressure (ICP) was lower, and CO2 reactivity was preserved with blood vs. saline (all P < 0.05). In Series 2, SAP, ICP, CPP, and lactate were higher with DCLHb vs. saline (all P < 0.05). Cardiac output was lower even though filling pressure was markedly elevated with DCLHb vs. saline (both P < 0.05). Neither SvO(2) nor cerebrovascular CO2 reactivity were improved, and ScvO(2) was lower with DCLHb vs. saline (P < 0.05). All survived at least 72 h with neuropathologic changes that included sub-arachnoid hemorrhage, midline cerebellar necrosis, and diffuse axonal injury. These changes were similar with DCLHb vs. saline. Thus, whole blood was more effective than saline for resuscitation of TBI, whereas DCLHb was no more, and according to many variables, less effective than saline resuscitation. These experimental results are comparable to those in a recent multicenter trial using DCLHb for the treatment of severe traumatic shock. Further investigations in similar experimental models might provide some plausible explanations why DCLHb unexpectedly increased mortality in patients.	Univ Miami, Sch Med, Daughtry Family Dept Surg, Miami, FL 33101 USA; Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; E Tennessee State Univ, Quillen Coll Med, Dept Pathol, Johnson City, TN 37403 USA	Proctor, KG (corresponding author), Univ Miami, Sch Med, Daughtry Family Dept Surg, POB 016960 D40,1800 NW 10th Ave, Miami, FL 33101 USA.						*AM COLL SURG, 1997, ADV TRAUM LIF SUPP C; BULLOCK R, 1995, GUIDELINES MANAGEMEN; Burhop KE, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199911001-00030; Chappell JE, 1996, J TRAUMA, V41, P781, DOI 10.1097/00005373-199611000-00003; Chappell JE, 1997, J NEUROSURG, V86, P131, DOI 10.3171/jns.1997.86.1.0131; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohn SM, 1997, CRIT CARE MED, V25, P484, DOI 10.1097/00003246-199703000-00018; COLE DJ, 1993, ANESTHESIOLOGY, V78, P335, DOI 10.1097/00000542-199302000-00018; Cole DJ, 1999, CRIT CARE MED, V27, P972, DOI 10.1097/00003246-199905000-00038; COLE DJ, 1993, CAN J NEUROL SCI, V20, P30, DOI 10.1017/S0317167100047363; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Fischer SR, 1999, AM J PHYSIOL-HEART C, V276, pH2194; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Glass TF, 2001, J NEUROTRAUM, V18, P57, DOI 10.1089/089771501750055776; Hess JR, 1996, SEMIN HEMATOL, V33, P369; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; Intaglietta M, 1999, MICROCIRCULATION, V6, P247, DOI 10.1080/713773960; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; LEFFLER CW, 1986, PROSTAGLANDINS, V31, P183, DOI 10.1016/0090-6980(86)90045-6; MALHOTRA AK, 2000, SHOCK, V13, P60; Maxwell RA, 2000, J TRAUMA, V49, P200, DOI 10.1097/00005373-200008000-00005; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McGrath B J, 1995, New Horiz, V3, P523; Piper IR, 1998, BRIT J ANAESTH, V80, P639; Pope A, 1999, FLUID RESUSCITATION; Prielipp R C, 1995, New Horiz, V3, P456; Rieger A, 1997, NEUROSURGERY, V41, P462, DOI 10.1097/00006123-199708000-00027; ROBERTS SB, 1995, OBES RES, V3, P3, DOI 10.1002/j.1550-8528.1995.tb00002.x; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; TODD MM, 1994, J NEUROTRAUM, V11, P149, DOI 10.1089/neu.1994.11.149; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	37	59	61	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	MAR	2002	17	3					234	244		10.1097/00024382-200203000-00013			11	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	626ML	WOS:000179876600013	11900344				2021-06-18	
J	Greve, KW; Bianchini, KJ; Mathias, CW; Houston, RJ; Crouch, JA				Greve, KW; Bianchini, KJ; Mathias, CW; Houston, RJ; Crouch, JA			Detecting malingered performance with the Wisconsin Card Sorting Test: A preliminary investigation in traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY	The present study examined the classification accuracy of four potential Wisconsin Card Sorting Test malingering indicators (Bernard and Suhr formulas and two types of Unique responses). Participants were 89 traumatic brain-injury (TBI) patients assigned to malingering and nonmalingering groups on the basis of the Slick, Sherman, and Iversion (1999) criteria. Individual Sensitivities were greater than .33 with acceptable Specificity. Combined Sensitivity for two of the indicators was greater than .60. Overall, this study demonstrated three distinct approaches to the WCST used by probable malingerers. The clinical relevance of these findings and directions for future research are discussed.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA; Inst Living, Hartford, CT USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu		Mathias, Charles/0000-0003-1902-673X			Allen LM, 2001, ARCH CLIN NEUROPSYCH, V16, P846; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; DONDERS J, 1999, J FORENSIC NEUROPSYC, V1, P35; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; Greve KW, 2002, J CLIN EXP NEUROPSYC, V24, P48, DOI 10.1076/jcen.24.1.48.968; GREVE KW, IN PRESS ARCH CLIN N; Heaton R. K, 1981, WISCONSIN CARD SORTI; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HEATON SK, 1993, WISCONSIN CORD SORTI; Hennekens CH, 1987, EPIDEMIOLOGY MED; Heubrock D, 1998, EUR J PSYCHOL ASSESS, V14, P211, DOI 10.1027/1015-5759.14.3.211; KNIGHT JA, 1986, 94 M AM PSYCH ASS WA; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; *PSYCH ASS RES, 1993, WISC CARD SORT TEST; Reynolds CR, 2001, ARCH CLIN NEUROPSYCH, V16, P199; Reynolds CR, 1998, CRIT ISS NE, P261; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]	36	59	61	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2002	16	2					179	191		10.1076/clin.16.2.179.13241			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	588KH	WOS:000177700300006	12221480				2021-06-18	
J	Williams, S; Raghupathi, R; MacKinnon, MA; McIntosh, TK; Saatman, KE; Graham, DI				Williams, S; Raghupathi, R; MacKinnon, MA; McIntosh, TK; Saatman, KE; Graham, DI			In situ DNA fragmentation occurs in white matter up to 12 months after head injury in man	ACTA NEUROPATHOLOGICA			English	Article						human traumatic brain injury; white matter damage; TUNEL staining; apoptosis	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; CELL-DEATH; COMPRESSION TRAUMA; TEMPORAL PROFILE; APOPTOSIS; RAT; BCL-2; DEGENERATION	Using the terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick-end labelling (TUNEL) histochemical technique, evidence for DNA fragmentation was sought in the hippocampus, cingulate gyrus and insula from 18 patients who survived for up to 12 months after head injury, and 15 matched controls. Both conventional (haematoxylin and eosin and Luxol-fast blue/cresyl violet) and immunohistochemical (glial fibrillary acidic protein, CD68) staining techniques were used to identify the cellular response and its time course in the regions of interest. Only the occasional TUNEL-positive ((+)) cell/unit area was seen in any area of the control brains. In contrast there were more TUNEL+ cells/unit area in the injured brains. TUNEL+ cells were present in white matter and their average numbers ranged from three to five per unit area for up to 3 months survival in the extreme capsule and the parasagittal white matter, with similar numbers in the hippocampus, and between two and three per unit area in the parasagittal white matter and hippocampus of the cases surviving up to 12 months post injury. Between one and two TUNEL+ cells/unit area were also seen in grey matter, of which most appeared as neurones. About 5% of the TUNEL+ cells in white matter had the morphological features of apoptosis: the corresponding figure in grey matter was less than 1%. In many instances the TUNEL+ cells were also CD68(+) and appeared by light microscopy to be macrophages. It was concluded that, as reflected by TUNEL histochemistry, long-term DNA fragmentation is present in white matter after traumatic brain injury in man.	So Gen Hosp, S Glasgow Univ Hosp NHS Trust, Univ Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Graham, DI (corresponding author), So Gen Hosp, S Glasgow Univ Hosp NHS Trust, Univ Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	D.Graham@clinmed.gla.ac.uk			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS26818] Funding Source: Medline		Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brown A W, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P155; Burek MJ, 1996, BRAIN PATHOL, V6, P427, DOI 10.1111/j.1750-3639.1996.tb00874.x; CharriautMarlangue C, 1996, TRENDS NEUROSCI, V19, P109, DOI 10.1016/S0166-2236(96)80039-7; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; FERRER I, 1990, NEUROSCIENCE, V39, P451, DOI 10.1016/0306-4522(90)90281-8; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; NAMASHIMA K, 1999, J NEUROTRAUM, V16, P143; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Probst-Cousin S, 1998, J NEUROPATH EXP NEUR, V57, P814, DOI 10.1097/00005072-199809000-00002; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Sheng JG, 1998, J NEUROPATH EXP NEUR, V57, P714, DOI 10.1097/00005072-199807000-00008; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Soares HD, 1995, J NEUROSCI, V15, P8223; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Troncoso JC, 1996, J NEUROPATH EXP NEUR, V55, P1134, DOI 10.1097/00005072-199611000-00004; WILLIAMS S, 1998, J NEUROTRAUM, V15, P871; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; YOSHIYAMA Y, 1994, ACTA NEUROPATHOL, V88, P207	53	59	60	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	DEC	2001	102	6					581	590		10.1007/s004010100410			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	495TZ	WOS:000172357600003	11761718				2021-06-18	
J	Newcomb-Fernandez, JK; Zhao, XR; Pike, BR; Wang, KKW; Kampfl, A; Beer, R; DeFord, SM; Hayes, RL				Newcomb-Fernandez, JK; Zhao, XR; Pike, BR; Wang, KKW; Kampfl, A; Beer, R; DeFord, SM; Hayes, RL			Concurrent assessment of calpain and caspase-3 activation after oxygen-glucose deprivation in primary septo-hippocampal cultures	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; calpain; caspases; necrosis; stroke; TBI	CORTICAL IMPACT INJURY; TRAUMATIC BRAIN-INJURY; MAITOTOXIN INDUCES CALPAIN; FOCAL CEREBRAL-ISCHEMIA; DELAYED NEURONAL DEATH; APOPTOTIC CELL-DEATH; ALPHA-SPECTRIN; FODRIN PROTEOLYSIS; DNA FRAGMENTATION; PROTEIN-SYNTHESIS	The contributions of calpain and caspase-3 to apoptosis and necrosis after central nervous system (CNS) trauma are relatively unexplored. No study has examined concurrent activation of calpain and caspase-3 in necrotic or apoptotic cell death after any CNS insult. Experiments used a model of oxygen-glucose deprivation (OGD) in primary septo-hippocampal cultures and assessed cell viability, occurrence of apoptotic and necrotic cell death phenotypes, and protease activation. Immunoblots using an antibody detecting calpain and caspase-3 proteolysis of alpha -spectrin showed greater accumulation of calpain-mediated breakdown products (BDPs) compared with caspase-3-mediated BDPs. Administration of calpain and caspase-3 inhibitors confirmed that activation of these proteases contributed to cell death, as inferred by lactate dehydrogenase. release. Oxygen-glucose deprivation resulted in expression of apoptotic and necrotic cell death phenotypes, especially in neurons. Immunocytochemical studies of calpain and caspase-3 activation in apoptotic cells indicated that these proteases are almost always concurrently activated during apoptosis. These data demonstrate that calpain and caspase-3 activation is associated with expression of apoptotic cell death phenotypes after OGD, and that calpain activation, in combination with caspase-3 activation, could contribute to the expression of apoptotic cell death by assisting in the degradation of important cellular proteins.	Univ Florida, Ctr Traumat Brain Injury Studies, Evelyn F & William McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Houston, TX USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Ann Arbor, MI USA; Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria	Hayes, RL (corresponding author), Univ Florida, Ctr Traumat Brain Injury Studies, Evelyn F & William McKnight Brain Inst, Dept Neurosci, 100 Newell Dr,Box 100244, Gainesville, FL 32610 USA.		Pike, Bruce/K-5562-2014	Pike, Bruce/0000-0001-8924-683X; Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039091, R01NS040182] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40182, R01 NS39091] Funding Source: Medline		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Buki A, 2000, J NEUROSCI, V20, P2825; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; Chen J, 1998, J NEUROSCI, V18, P4914; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Copin JC, 1998, BRAIN RES, V784, P25, DOI 10.1016/S0006-8993(97)00972-4; DiLoreto S, 1997, INT J DEV NEUROSCI, V15, P225; DUGAN LL, 1995, J NEUROSCI, V15, P4545; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Himi T, 1998, EUR J NEUROSCI, V10, P777, DOI 10.1046/j.1460-9568.1998.00073.x; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Kalda A, 1998, NEUROSCI LETT, V240, P21, DOI 10.1016/S0304-3940(97)00914-2; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Lobner D, 1996, NEUROSCIENCE, V72, P335, DOI 10.1016/0306-4522(95)00561-7; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McDonald JW, 1997, BRAIN RES, V759, P228, DOI 10.1016/S0006-8993(97)00248-5; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; Namura S, 1998, J NEUROSCI, V18, P3659; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1998, J NEUROCHEM, V71, P186; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OBERHAMMER F, 1993, J CELL SCI, V104, P317; Pang Z, 1997, J NEUROSCI, V17, P3064; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; PURANAM KL, 1999, CRC METH NEUROSCI S, P129; Rami A, 2000, BRAIN RES, V866, P299, DOI 10.1016/S0006-8993(00)02301-5; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Schmechel D.E., 1999, CRC METH NEUROSCI S, P161; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	60	59	60	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2001	21	11					1281	1294		10.1097/00004647-200111000-00004			14	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	491AZ	WOS:000172087000004	11702043	Bronze			2021-06-18	
J	de Kruijk, JR; Twijnstra, A; Leffers, P				de Kruijk, JR; Twijnstra, A; Leffers, P			Diagnostic criteria and differential diagnosis of mild traumatic brain injury	BRAIN INJURY			English	Article							MODERATE HEAD-INJURY; NEURON-SPECIFIC ENOLASE; COMA-SCALE SCORE; COMPUTED-TOMOGRAPHY; MANAGEMENT; PROTEIN; CT; DAMAGE; SPECT; S-100	Brain injury is classified clinically as severe, moderate or mild brain injury characteristics, including admission Glasgow coma score, duration of unconsciousness and post-traumatic amnesia and any focal neurological findings. Most traumatic brain injuries are classified as mild traumatic brain injury (MTBI). Headache, nausea and dizziness are frequent symptoms after MTBI and may continue for weeks to months after the trauma. MTBI may also be complicated by intracranial injuries. Experimental animal models and post-mortem studies have shown axonal damage and dysfunction in MTBI. This damage is mostly localized in the frontal lobes. Serum S-100 and NSE have been reported to be markers for the severity of brain damage. In the literature, indications for radiodiagnostic evaluation following MTBI have been the subject of debate. Radiographs of the skull are used to exclude skull fractures, but are not useful for an evaluation of brain injury. Computed tomography of the brain seems to be the best way to exclude the development of relevant intracranial lesions. MTBI has a good clinical outcome, although a substantial group of patients develop post-concussional complaints (PCC). There is little information on the effectiveness of various methods suggested for reducing the frequency of PCC.	Univ Hosp Maastricht, Dept Neurol, NL-6229 HX Maastricht, Netherlands; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands	de Kruijk, JR (corresponding author), Univ Hosp Maastricht, Dept Neurol, P Debeylaan 25, NL-6229 HX Maastricht, Netherlands.		Leffers, Pieter/B-8642-2009				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BOHNEN NI, 1993, NEUROLOGY, V42, P103; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; de Louw A, 1994, Ned Tijdschr Geneeskd, V138, P2197; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HADLEY D, 1995, ACTA NEUROLOGY BEL S, V95, P109; Holmes JF, 1997, ACAD EMERG MED, V4, P788, DOI 10.1111/j.1553-2712.1997.tb03786.x; ICHISE M, 1994, J NUCL MED, V35, P217; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; JACOBS A, 1994, J NUCL MED, V35, P942; KAY T, 1992, Neurology, V42, P411; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRUGER J, 1991, NERVENARZT, V62, P226; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Masdeu J C, 1994, J Neuroimaging, V4, P177; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MILLER JD, 1992, BRIT J SURG, V79, P60, DOI 10.1002/bjs.1800790122; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; PERSSON I, 1986, STROKE, V18, P911; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SAUNDERS CE, 1986, ANN EMERG MED, V15, P160, DOI 10.1016/S0196-0644(86)80012-9; SERVADEI F, 1995, J TRAUMA, V39, P696, DOI 10.1097/00005373-199510000-00015; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 1994, Ned Tijdschr Geneeskd, V138, P2279; VANTHOOFT F, 1973, COMOTIO CEREBRI ANDE; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WARREN D, 1989, Pediatric Emergency Care, V5, P83, DOI 10.1097/00006565-198906000-00003; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	55	59	60	0	11	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2001	15	2					99	106		10.1080/026990501458335			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	398BG	WOS:000166733800002	11260760				2021-06-18	
J	Matharu, MS; Goadsby, PJ				Matharu, MS; Goadsby, PJ			Post-traumatic chronic paroxysmal hemicrania (CPH) with aura	NEUROLOGY			English	Article							CLUSTER HEADACHE	The authors describe a patient who developed chronic paroxysmal hemicrania (CPH) in close temporal relationship to a head injury. The subsequent attacks of CPH were associated with a typical migrainous sensory and motor aura. Administration of indomethacin 75 mg daily resulted in isolated occurrence of autonomic and aura symptoms in the absence of pain symptoms. The patient became completely asymptomatic on indomethacin 100 mg daily. Migrainous aura may be seen with trigeminal-autonomic headaches and may represent the expression of an aura-susceptibility gene rather than typical migraine headache biology.	Inst Neurol, Headache Grp, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	Goadsby, PJ (corresponding author), Inst Neurol, Headache Grp, Queen Sq, London WC1N 3BG, England.	peterg@brain.ion.ucl.ac.uk	Goadsby, Peter J/B-2267-2009; Matharu, Manjit/AAN-9786-2020; Goadsby, Peter J/Z-1970-2019	Goadsby, Peter J/0000-0003-3260-5904; Matharu, Manjit/0000-0002-4960-2294			ANTONACI F, 1989, HEADACHE, V29, P648, DOI 10.1111/j.1526-4610.1989.hed2910648.x; Bahra A, 2000, NEUROLOGY, V54, pA20; GEANEY DP, 1983, J NEUROL NEUROSUR PS, V46, P860, DOI 10.1136/jnnp.46.9.860; MEDINA JL, 1981, ARCH NEUROL-CHICAGO, V38, P705, DOI 10.1001/archneur.1981.00510110065010; PAREJA JA, 1995, HEADACHE, V35, P111, DOI 10.1111/j.1526-4610.1995.hed3502111.x; PEARCE SHS, 1987, J NEUROL NEUROSUR PS, V50, P1599; RAPOPORT AM, 1981, CEPHALALGIA, V1, P67, DOI 10.1111/j.1468-2982.1981.tb00011.x; Silberstein SD, 2000, NEUROLOGY, V54, P219, DOI 10.1212/WNL.54.1.219; SJAASTAD O, 1986, HDB CLIN NEUROLOGY, P257; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x	10	59	59	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 23	2001	56	2					273	275		10.1212/WNL.56.2.273			3	Clinical Neurology	Neurosciences & Neurology	393GY	WOS:000166461900029	11160973				2021-06-18	
J	Berman, RF; Verweij, BH; Muizelaar, JP				Berman, RF; Verweij, BH; Muizelaar, JP			Neurobehavioral protection by the neuronal calcium channel blocker Ziconotide in a model of traumatic diffuse brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; calcium channel blocker; neurobehavioral deficit; neurobehavioral protection; rat	N-TYPE; OMEGA-CONOPEPTIDES; MITOCHONDRIAL DYSFUNCTION; CELL-DEATH; ISCHEMIA; RELEASE; ANTINOCICEPTION; ACCUMULATION; INHIBITION; GLUTAMATE	Object. Abnormal accumulation of intracellular calcium following traumatic brain injury (TBI) is thought to contribute to a cascade of cellular events that lead to neuropathological conditions. Therefore, the possibility that specific calcium channel antagonists might exert neuroprotective effects in TBI has been of interest. The focus of this study was to examine whether Ziconotide produces such neuroprotective effects. Methods. The authors report that the acceleration-deceleration model of TBI developed by Marmarou, et al., induces a long-lasting deficit of neuromotor and behavioral function. The voltage-sensitive calcium channel blocker Ziconotide (also known as SNX-111 and CI-1009) exerts neuroprotective effects in this model of diffuse brain injury (DBI) in rats. The dose and time of injection of Ziconotide chosen for the present study was based on the authors' previous biochemical studies of mitochondria. Rats were trained in a series of motor and memory tasks, following which they were subjected to DBI using the Marmarou, ct al., model. At 3, 5, and 24 hours, all rats were injected with 2 mg/kg Ziconotide for a total cumulative dose of 6 mg/kg Ziconotide. Control brain-injured animals were injected with an equal volume of saline vehicle at each of these time points. The rats were tested for motor and cognitive performance at 1,3,7, 14, 21,28, 35, and 42 days postinjury. Saline-treated rats displayed severe motor and cognitive deficits after DBI. Compared with saline-treated control animals, rats treated with Ziconotide displayed better motor performance during inclined plane, beam balance, and beam walk tests; improved memory while in the radial arm maze; and improved learning while in the Morris water maze. Conclusions. These results demonstrated that the acceleration-deceleration model, which had been developed by Marmarou, et al., induces severe motor and cognitive deficits. We also demonstrated that Ziconotide exhibits substantial neuroprotective activity in this model of TBI. Improvement was observed in both motor and cognitive tasks, even though treatment was not initiated until 3 hours after injury. These findings support the development of neuronal N-type calcium channel antagonists as useful therapeutic agents in the treatment of TBI.	Univ Calif Davis, Med Ctr, Dept Neurol Surg, Sacramento, CA 95817 USA	Muizelaar, JP (corresponding author), Univ Calif Davis, Med Ctr, Dept Neurosurg, 4860 Y St,Room 3740, Sacramento, CA 95817 USA.	J.Paul.Muizelaar@UCDMC.ucdavis.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39090] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A20016] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039090] Funding Source: NIH RePORTER		BOWERSOX SS, 1995, J PHARMACOL EXP THER, V273, P248; Bowersox SS, 1996, J PHARMACOL EXP THER, V279, P1243; BUCHAN AM, 1994, J CEREBR BLOOD F MET, V14, P903, DOI 10.1038/jcbfm.1994.121; CHAPLAN SR, 1994, J PHARMACOL EXP THER, V269, P1117; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Folkerts M. M., 1998, J NEUROTRAUM, V13, P610; FOX JA, 1995, PFLUG ARCH EUR J PHY, V429, P873, DOI 10.1007/BF00374813; GAUR S, 1994, NEUROPHARMACOLOGY, V33, P1211, DOI 10.1016/S0028-3908(05)80012-7; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HOVDA DA, 1994, ACTA NEUROCHIR, P521; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; Igelmund P, 1996, EXP BRAIN RES, V109, P22; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MALMBERG AB, 1995, PAIN, V60, P83, DOI 10.1016/0304-3959(94)00094-U; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MILJANICH GP, 1995, ANNU REV PHARMACOL, V35, P707, DOI 10.1146/annurev.pa.35.040195.003423; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NADASDI L, 1995, BIOCHEMISTRY-US, V34, P8076, DOI 10.1021/bi00025a013; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OOBOSHI H, 1992, J NEUROCHEM, V58, P298, DOI 10.1111/j.1471-4159.1992.tb09310.x; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SHAPIRA Y, 1989, Neurological Research, V11, P169; SMITH DH, 1996, NOVEL THERAPIES CNS, P137; SMITH ML, 1993, J CEREB BLOOD FLOW S, V13, pS700; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wu LG, 1997, TRENDS NEUROSCI, V20, P204, DOI 10.1016/S0166-2236(96)01015-6; XIAO WH, 1995, J PHARMACOL EXP THER, V274, P666; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	37	59	61	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2000	93	5					821	828		10.3171/jns.2000.93.5.0821			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	366YL	WOS:000090033800014	11059664				2021-06-18	
J	Fichtenberg, NL; Millis, SR; Mann, NR; Zafonte, RD; Millard, AE				Fichtenberg, NL; Millis, SR; Mann, NR; Zafonte, RD; Millard, AE			Factors associated with insomnia among post-acute traumatic brain injury survivors	BRAIN INJURY			English	Article							HEAD-INJURY; SLEEP; DISTURBANCES; COMPLAINTS; DISORDERS; QUALITY	This study investigated the relationships between insomnia and select demographic, injury and psychosocial variables in post-acute, traumatic brain injury. Clinical assessment of sleep and mood was undertaken via objective measures and a diagnostic interview among 91 consecutive brain injury admissions to an outpatient neurorehabilitation clinic. No associations between insomnia and gender, education, age, and time since injury were found. A logistic regression model of insomnia prediction based upon the Beck Depression Inventory (BDI), sell-reported pain disturbance, litigation and Glasgow Coma Score (GCS) correctly classified 87% of the sample with respect to the presence or absence of insomnia; however, depression and injury severity were the only variables that made a significant unique contribution to the prediction of insomnia. It is concluded that among post-acute traumatic brain injury patients, insomnia is linked with both the presence of depression and a history of milder brain injuries. This suggests that the determinants of insomnia may differ from the acute to the post-acute phase, with neurological factors playing a primary role early in the recovery process and psychosocial factors ascending later. Therefore, assessment and treatment of insomnia must give careful attention to the larger psychosocial context in which the sleep disorder emerges, particularly to role of emotional disturbance.	Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Sch Med, Detroit, MI 48202 USA; Univ Michigan Hosp, Ann Arbor, MI 48109 USA	Fichtenberg, NL (corresponding author), DMC Rehab Ctr Novi, 42005 W 12 Mile Rd, Novi, MI 48337 USA.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beck A.T., 1987, BECK DEPRESSION INVE; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERGSTROM J, 1974, CLIN NEPHROL, V2, P24; BUYSSE DJ, 1994, SLEEP, V17, P630, DOI 10.1093/sleep/17.7.630; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CHATRIAN GE, 1963, ELECTROEN CLIN NEURO, V15, P272, DOI 10.1016/0013-4694(63)90096-8; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; CRAGG JG, 1970, CAN J ECONOMICS, V3, P386, DOI 10.2307/133656; ESTRELLA A, IN PRESS NEW MEASURE; FICHTENBERG NL, 1998, AM J PHYSICAL MED RE, V77, P181; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Hagen C, 1979, REHABILITATION HEAD; HYYPPA MT, 1989, J CLIN EPIDEMIOL, V42, P633, DOI 10.1016/0895-4356(89)90006-1; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; LESSARD CS, 1974, AEROSPACE MED, V45, P664; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MANN NR, 1997, ARCH PHYS MED REHAB, V78, P1055; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; PASSOUANT P, 1965, ELECTROEN CLIN NEURO, V18, P726; Ravesloot C, 1997, REHABIL PSYCHOL, V42, P3, DOI 10.1037/0090-5550.42.1.3; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Zafonte RD, 1996, NEUROREHABILITATION, V7, P189, DOI 10.3233/NRE-1996-7304	24	59	59	0	7	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2000	14	7					659	667					9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	335AV	WOS:000088220600006	10914647				2021-06-18	
J	Wallace, CA; Bogner, J				Wallace, CA; Bogner, J			Awareness of deficits: emotional implications for persons with brain injury and their significant others	BRAIN INJURY			English	Article							COMPETENCE RATING-SCALE; TRAUMATIC HEAD-INJURY; PSYCHOMETRIC PROPERTIES; IMPAIRED AWARENESS; BEHAVIORAL LIMITATIONS; PRIMARY CAREGIVERS; SELF-AWARENESS; FAMILY; RELATIVES; PATIENT	The relationship between emotional distress and differing perceptions of the extent of deficits was investigated with fifty individuals with brain injury and their significant others. Participants completed questionnaires assessing their perceptions of the individual's deficits in various areas (Patient Competency Rating Scale, PCRS). Difference scores were used as markers for awareness of deficits. Emotional distress of the individuals with brain injury and their significant others was assessed with the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI). Forty per cent of persons with brain injury and 34% of significant others reported symptoms suggestive of mild or greater depression, while 54% of persons with brain injury and 39% of significant others reported symptoms suggestive of experiencing mild or greater anxiety. Significant relationships were not found between the emotional distress of significant others and difference scores. Moderate-to-weak relationships were found between difference scores and the emotional distress of individuals with brain injury. The relationship between chronicity and awareness of deficits was in the opposite direction than predicted. The adjustment of significant others appears to be a function of the extent to which they perceive a resolution of deficits, time since injury, and other factors. Implications for rehabilitation and future research are discussed.	Bancroft Neurohlth, Haddonfield, NJ 08033 USA; Ohio State Univ, Columbus, OH 43210 USA	Bogner, J (corresponding author), Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.		Bogner, Jennifer/E-2773-2011				ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Beck A. T., 1993, BECK DEPRESSION INVE; Beck A.T., 1993; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BECK AT, 1979, COGNITIVE THERAPY DE; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; DeLuca J., 1992, NEUROREHABILITATION, V2, P23; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EZBACHI O, 1991, J HEAD TRAUMA REHAB, V6, P71; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fluharty G, 1997, NEUROREHABILITATION, V9, P221, DOI 10.3233/NRE-1997-9307; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; HOUSE A, 1988, J NEUROL NEUROSUR PS, V51, P112, DOI 10.1136/jnnp.51.1.112; KRAMER JJ, 1992, 11 MENTAL MEASUREMEN, P72; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1994, REHABILITATION ADULT, P74; MINTZ MC, 1995, BRAIN INJURY, V9, P173, DOI 10.3109/02699059509008190; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; RIVERA JV, 1996, ARCH PHYSICAL MED RE, V77, P754; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; *SAS I INC, 1985, SAS US GUID BAS VERS; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751	52	59	59	0	21	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2000	14	6					549	562					14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	325WN	WOS:000087699600005	10887888				2021-06-18	
J	Blaha, GR; Raghupathi, R; Saatman, KE; Mcintosh, TK				Blaha, GR; Raghupathi, R; Saatman, KE; Mcintosh, TK			Brain-derived neurotrophic factor administration after traumatic brain injury in the rat does not protect against behavioral or histological deficits	NEUROSCIENCE			English	Article						cortex; hippocampus; learning; memory; neurotrophin	CEREBELLAR GRANULE NEURONS; NERVE GROWTH-FACTOR; TRANSIENT FOREBRAIN ISCHEMIA; SEPTAL CHOLINERGIC NEURONS; RETINAL GANGLION-CELLS; LONG-TERM POTENTIATION; REDUCES INFARCT SIZE; ADULT-RAT; MESSENGER-RNA; FACTOR BDNF	Brain-derived neurotrophic factor has been shown to be neuroprotective in models of excitotoxicity, axotomy and cerebral ischemia. The present study evaluated the therapeutic potential of brain-derived neurotrophic factor following traumatic brain injury in the rat. Male Sprague-Dawley rats (N= 99) were anesthetized and subjected to lateral fluid percussion brain injury of moderate severity (2.4-2.8 arm) or sham injury. Four hours after injury, the animals were reanesthetized, an indwelling, intraparenchymal cannula was implanted, and infusion of brain-derived neurotrophic factor or phosphate-buffered saline vehicle was initiated from a mini-osmotic pump and continued for two weeks. In Study 1 (N= 48), vehicle or 12 mu g/day of brain-derived neurotrophic factor was infused into the dorsal hippocampus. Tn Study 2 (N = 51), vehicle or brain-derived neurotrophic factor at a high (12 mu g/day) or low dose (1.2 mu g/day) was infused into the injured parietal cortex. All animals were evaluated for neurological motor function at two days, one week and two weeks post-injury. Cognitive function (learning and memory) was assessed at two weeks post-injury using a Morris Water Maze. At two weeks post-injury, neuronal loss in the hippocampal CA3 and dentate hilus and in the injured cortex was evaluated. In Study 2, neuronal loss was also quantified in the thalamic medial geniculate nucleus. All of the above outcome measures demonstrated significant deleterious effects of brain injury (P < D.05 compared to sham). However, post-traumatic brain-derived neurotrophic factor infusion did not significantly affect neuromotor function, learning, memory or neuronal loss in the hippocampus, cortex or thalamus when compared to vehicle infusion in brain-injured animals, regardless of the infusion site or infusion dose (P > 0.05 for each). In contrast to previous studies of axotomy, ischemia and excitotoxicity, our data indicate that brain-derived neurotrophic factor is not protective against behavioral or histological deficits caused by experimental traumatic brain injury using the delayed, posttraumatic infusion protocol examined in these studies. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Mcintosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NSO8803, R01-NS26818] Funding Source: Medline		ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; ALTAR CA, 1994, J NEUROCHEM, V63, P1021; ALTAR CA, 1992, P NATL ACAD SCI USA, V89, P11347, DOI 10.1073/pnas.89.23.11347; ANDERSON KD, 1995, J COMP NEUROL, V357, P296, DOI 10.1002/cne.903570209; Baumgartner BJ, 1997, J NEUROSCI, V17, P6504; Baxter GT, 1997, J NEUROSCI, V17, P2683; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Bhave SV, 1999, J NEUROSCI, V19, P3277, DOI 10.1523/jneurosci.19-09-03277.1999; BURKE MA, 1994, EXP NEUROL, V130, P178, DOI 10.1006/exnr.1994.1197; CARTER BD, 1995, J BIOL CHEM, V270, P21751, DOI 10.1074/jbc.270.37.21751; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DUGICHDJORDJEVIC MM, 1995, EUR J NEUROSCI, V7, P1831, DOI 10.1111/j.1460-9568.1995.tb00703.x; Eide FF, 1996, J NEUROSCI, V16, P3123; Ferrer I, 1998, BRAIN PATHOL, V8, P253; Frank L, 1997, EXP NEUROL, V145, P62, DOI 10.1006/exnr.1997.6440; FRIEDMAN B, 1995, J NEUROSCI, V15, P1044; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Houweling DA, 1998, NEUROSCI LETT, V251, P193, DOI 10.1016/S0304-3940(98)00536-9; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, J NEUROSCI, V13, P3394; Jian Z, 1996, CELL SIGNAL, V8, P365, DOI 10.1016/0898-6568(96)00069-1; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Knusel B, 1996, EXP NEUROL, V139, P121, DOI 10.1006/exnr.1996.0087; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; KNUSEL B, 1992, J NEUROSCI, V12, P4391; KOKAIA Z, 1994, NEUROREPORT, V5, P1241, DOI 10.1097/00001756-199406020-00021; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; KUBO T, 1995, DEV BRAIN RES, V85, P249, DOI 10.1016/0165-3806(94)00220-T; LARMET Y, 1995, NEUROREPORT, V6, P1937, DOI 10.1097/00001756-199510020-00027; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Levivier M, 1995, J NEUROSCI, V15, P7810, DOI 10.1523/jneurosci.15-12-07810.1995; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; Liu Y, 1999, J NEUROSCI, V19, P4370; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; Mamounas LA, 1995, J NEUROSCI, V15, P7929; Marsh HN, 1996, J NEUROCHEM, V67, P952; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McTigue DM, 1998, J NEUROSCI, V18, P5354; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORSE JK, 1993, J NEUROSCI, V13, P4146; NAWA H, 1995, EUR J NEUROSCI, V7, P1527, DOI 10.1111/j.1460-9568.1995.tb01148.x; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PATEL MN, 1995, NEUROSCIENCE, V69, P763, DOI 10.1016/0306-4522(95)00281-M; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; PELLEYMOUNTER MA, 1995, EXP NEUROL, V131, P229, DOI 10.1016/0014-4886(95)90045-4; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; SAUER H, 1993, BRAIN RES, V626, P37, DOI 10.1016/0006-8993(93)90560-A; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Schmitt A, 1997, J NEUROSCI, V17, P1, DOI 10.1523/jneurosci.17-01-00001.1997; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sobreviela T, 1996, J COMP NEUROL, V375, P417; SPRANGER M, 1997, J CEREBR BLOOD FL S1, V17, pS370; Taga K, 1997, ANESTHESIOLOGY, V87, P918, DOI 10.1097/00000542-199710000-00027; Tanaka T, 1997, J NEUROSCI, V17, P2959; TSUKAHARA T, 1994, NEUROSURGERY, V34, P323, DOI 10.1227/00006123-199402000-00016; Utley DS, 1996, ARCH OTOLARYNGOL, V122, P407; VENTIMIGLIA R, 1995, EUR J NEUROSCI, V7, P213, DOI 10.1111/j.1460-9568.1995.tb01057.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yamashita K, 1997, METAB BRAIN DIS, V12, P271, DOI 10.1007/BF02674671; Yan Q, 1997, J COMP NEUROL, V378, P135; YAN Q, 1994, EXP NEUROL, V127, P23, DOI 10.1006/exnr.1994.1076; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	91	59	62	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	99	3					483	493		10.1016/S0306-4522(00)00214-1			11	Neurosciences	Neurosciences & Neurology	348TX	WOS:000089003500009	11029540				2021-06-18	
J	Steinsapir, KD; Goldberg, RA; Sinha, S; Hovda, DA				Steinsapir, KD; Goldberg, RA; Sinha, S; Hovda, DA			Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						corticosteroids; methylprednisolone; optic nerve injury; traumatic optic neuropathy; TON	RETINAL GANGLION-CELLS; SPINAL-CORD INJURY; ADULT-RATS; LIPID-PEROXIDATION; CONTROLLED TRIAL; BRAIN INJURY; NEUROPATHY; METABOLISM; RECOVERY; SURVIVAL	Purpose: This study investigates the clinical dogma that very high doses of methylprednisolone helpful in spinal cord injury are also helpful in optic nerve trauma. Methods: The right optic nerve of 29 male rats received a 5 second traumatic crush followed 30 minutes later by one of five intravenous treatments (methylprednisolone 30 mg/kg, 60 mg/kg, 90 mg/kg, 120 mg/kg, or saline). Treatment was continued for three additional administrations at 6 hour intervals. Untreated sham controls (n = 7) were also prepared. 'Six weeks after injury, animals were sacrificed, perfused and optic nerves systematically counted. Results: Axon counts (means +/- s.e.m.) were as follows: Saline = 16,670 +/- 8,900 (n = 5); Methylprednisolone: 30 mg/kg = 8,098 +/- 4,741 (n = 5); 60 mg/kg = 6,925 +/- 6,517 (n = 4); 90 mg/kg = 2,663 +/- 2,653 (n = 4); 120 mg/kg = 6,149 +/- 3,487 (n = 6). Consequently, the data revealed that saline treated animals retained more axons than those that were administered methylprednisolone (p < 0.02). Conclusions: We conclude that methylprednisolone exacerbates axonal loss following crush injury in the rat optic nerve. Based on the results of this study, clinical studies of traumatic optic neuropathy in the future should also examine the possibility that corticosteroid treatment may have an adverse effect on visual outcome following optic nerve trauma.	Jules Stein Eye Inst, Orbital & Ophthalm Plast Surg Div, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Surg, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA	Steinsapir, KD (corresponding author), 537 Newport Ctr Dr,Suite 371, Newport Beach, CA 92660 USA.		Goldberg, Robert/AAE-3046-2019				ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1983, J NEUROSURG, V59, P256, DOI 10.3171/jns.1983.59.2.0256; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; BRAY GM, 1991, ANN NY ACAD SCI, V633, P214; CHO EYP, 1989, EXP BRAIN RES, V78, P567; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; DEJUAN J, 1978, ACTA ANAT, V102, P294; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; FADEN AI, 1984, J NEUROSURG, V60, P712, DOI 10.3171/jns.1984.60.4.0712; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FORRESTER J, 1967, NATURE, V214, P245, DOI 10.1038/214245a0; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GRAHAM LT, 1967, J NEUROCHEM, V14, P465, DOI 10.1111/j.1471-4159.1967.tb09545.x; GROSS CE, 1981, J NEUROSURG, V55, P963, DOI 10.3171/jns.1981.55.6.0963; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HARMAN K, 1991, J NEUROSCI METH, V38, P107, DOI 10.1016/0165-0270(91)90160-2; HUBEL DAVID H., 1963, SCI AMER, V209, P54; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JONES KA, 1991, NEURON, V7, P593, DOI 10.1016/0896-6273(91)90372-7; JOSEPH MP, 1990, ARCH OPHTHALMOL-CHIC, V108, P1091, DOI 10.1001/archopht.1990.01070100047032; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Koeberle PD, 1998, VISION RES, V38, P1505, DOI 10.1016/S0042-6989(97)00364-7; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; Levin LA, 1996, INVEST OPHTH VIS SCI, V37, P2744; MATHESON D F, 1970, Brain Research, V24, P257, DOI 10.1016/0006-8993(70)90105-8; MAURIELLO JA, 1992, BRIT J OPHTHALMOL, V76, P349, DOI 10.1136/bjo.76.6.349; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; Povlishock J T, 1992, Hum Cell, V5, P345; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; RANSOM BR, 1990, NEUROLOGY, V40, P1399, DOI 10.1212/WNL.40.9.1399; Riesen A, 1950, SCI AM, V183, P16; RusselakisCarneiro M, 1996, J NEUROCYTOL, V25, P393, DOI 10.1007/BF02284810; Sabel BA, 1999, RESTOR NEUROL NEUROS, V15, P177; SABEL BA, 1995, EXP BRAIN RES, V106, P93; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; SAPOLSKY RM, 1986, J NEUROSCI, V6, P2240; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SEIFF SR, 1990, OPHTHALMIC SURG LAS, V21, P389; SPOOR TC, 1990, AM J OPHTHALMOL, V110, P665, DOI 10.1016/S0002-9394(14)77065-5; STEINSAPIR KD, 1994, SURV OPHTHALMOL, V38, P487, DOI 10.1016/0039-6257(94)90145-7; STEINSAPIR KD, 1994, INVEST OPHTH VIS SCI, V35, P1544; STEINSAPIR KD, 1993, J CEREBR BLOOD FLOW, V13, pS570; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; VILLEGASPEREZ MP, 1988, J NEUROSCI, V8, P265; WALSH FRANK B., 1966, INVEST OPHTHALMOL, V5, P433; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; Yoles E, 1997, J NEUROTRAUM, V14, P665, DOI 10.1089/neu.1997.14.665; Young W, 1992, J NEUROTRAUMA S1, V9, P9	63	59	61	0	0	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2000	17	4					157	163					7	Neurosciences	Neurosciences & Neurology	456FF	WOS:000170071900001					2021-06-18	
J	Rao, AM; Hatcher, JF; Dempsey, RJ				Rao, AM; Hatcher, JF; Dempsey, RJ			CDP-choline: Neuroprotection in transient forebrain ischemia of gerbils	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						arachidonic acid; leukotriene C-4; CA(1) neuronal death; phosphatidylcholine; hippocampus; S-adenosyl-L-methionine; apoptosis	EXPERIMENTAL FOCAL ISCHEMIA; ADENOSYL-L-METHIONINE; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; FREE FATTY-ACIDS; CEREBRAL-ISCHEMIA; ARACHIDONIC-ACID; PHOSPHOLIPASE A(2); NEURONAL DEATH; RAT-BRAIN	CDP-choline is a rate-limiting intermediate in the biosynthesis of phosphatidylcholine (PtdCho), an important component of the neural cell membrane, The ability of CDP-choline to alter phospholipid metabolism is an important function in the treatment of ischemic injury. Exogenous treatment with CDP-choline stimulates PtdCho synthesis and prevents release of free fatty acids (FFA), especially arachidonic acid (AA), after ischemia/reperfusion. Phase III clinical trials of CDP-choline in the treatment of stroke are currently underway, Here we report the neuroprotection by CDP-choline in transient forebrain ischemia of gerbils, CDP-choline significantly attenuated the blood-brain barrier (BBB) dysfunction after ischemia with 6-hr reperfusion, and considerably reduced the increase of AA in FFA and leukotriene C-4 (LTC4) synthesis at 1 day. Edema was significantly elevated after 1 and 2 days, but attained maximum at 3-day reperfusion, CDP-choline substantially attenuated edema at 3 days, Ischemia resulted in 80 +/- 8% CA(1) hippocampal neuronal death after 6-day reperfusion, and CDP-choline provided 65 +/- 6% neuroprotection, CDP-choline may act by increasing PtdCho synthesis via two pathways: (1) conversion of 1,2-diacylglycerol to PtdCho, and (2) biosynthesis of S-adenosyl-L-methionine, thus stabilizing the membrane and reducing AA release and metabolism to leukotriene C-4 This would result in decreased toxicity due to AA, leukotrienes, oxygen radicals, lipid peroxidation, and altered glutamate uptake, thus limiting BBB dysfunction, edema and providing neuroprotection, (C) 1999 Wiley-Liss, Inc.	Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, Madison, WI 53792 USA; Vet Adm Hosp, Madison, WI USA	Rao, AM (corresponding author), Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, F4-313,600 Highland Ave, Madison, WI 53792 USA.	adibhat1@neurosurg.wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220, R01NS028000] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31220, R01 NS 28000] Funding Source: Medline		ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; ABE K, 1989, ANN NY ACAD SCI, V559, P259; Aronowski J, 1996, NEUROL RES, V18, P570; ARRIGONI E, 1987, BIOCHEM PHARMACOL, V36, P3697, DOI 10.1016/0006-2952(87)90022-0; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; Baskaya MK, 1996, J NEUROSURG, V85, P112, DOI 10.3171/jns.1996.85.1.0112; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CESTARO B, 1994, ACTA NEUROL SCAND, V89, P32, DOI 10.1111/j.1600-0404.1994.tb05407.x; CHAN PH, 1984, FED PROC, V43, P210; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Clark WM, 1997, NEUROLOGY, V49, P671, DOI 10.1212/WNL.49.3.671; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DORLANDO KJ, 1995, NEUROL RES, V17, P281, DOI 10.1080/01616412.1995.11740327; Farooqui AA, 1997, J NEUROCHEM, V69, P889; Fresta M, 1997, LIFE SCI, V61, P1227, DOI 10.1016/S0024-3205(97)00667-X; FRESTA M, 1994, J PHARM PHARMACOL, V46, P974, DOI 10.1111/j.2042-7158.1994.tb03252.x; GALLETTI P, 1991, J NEUROL SCI, V103, pS19; Gimenez R, 1998, EUR J PHARMACOL, V344, P149, DOI 10.1016/S0014-2999(98)00035-1; Hall ED, 1996, ADV NEUROL, V71, P247; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HORROCKS L A, 1981, Progress in Lipid Research, V20, P531; IKEDA M, 1986, J NEUROCHEM, V47, P123; Kasner SE, 1997, ANN EMERG MED, V30, P642, DOI 10.1016/S0196-0644(97)70084-2; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KIRINO T, 1986, STROKE, V17, P455, DOI 10.1161/01.STR.17.3.455; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; Knapp S, 1999, BRAIN RES, V822, P52, DOI 10.1016/S0006-8993(99)01072-0; Lombardi G, 1996, BRIT J PHARMACOL, V117, P189, DOI 10.1111/j.1476-5381.1996.tb15173.x; LOPEZCOVIELLA I, 1995, J NEUROCHEM, V65, P889; MATSUI Y, 1987, EUR J PHARMACOL, V144, P211, DOI 10.1016/0014-2999(87)90521-8; MURPHY EJ, 1993, PHOSPHOLIPIDS SIGNAL, P353; MYKITA S, 1986, J NEUROCHEM, V47, P223; NAKANO S, 1990, J NEUROCHEM, V54, P1911, DOI 10.1111/j.1471-4159.1990.tb04890.x; NISHINO H, 1994, BRAIN RES BULL, V35, P51, DOI 10.1016/0361-9230(94)90215-1; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249; Ohtsuki T, 1996, BRAIN RES, V736, P353, DOI 10.1016/S0006-8993(96)00948-1; Onal MZ, 1997, STROKE, V28, P1060, DOI 10.1161/01.STR.28.5.1060; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Rao AM, 1998, NEUROSCI LETT, V256, P65, DOI 10.1016/S0304-3940(98)00780-0; Rao AM, 1997, MOL BRAIN RES, V44, P134, DOI 10.1016/S0169-328X(96)00245-8; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SATO H, 1988, BIOCHEM BIOPH RES CO, V150, P491, DOI 10.1016/0006-291X(88)90547-5; Schabitz WR, 1996, J NEUROL SCI, V138, P21, DOI 10.1016/0022-510X(95)00341-X; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; SECADES JJ, 1995, METHOD FIND EXP CLIN, V17, P1; TROVARELLI G, 1983, NEUROCHEM RES, V8, P1597, DOI 10.1007/BF00964161; TROVARELLI G, 1981, NEUROCHEM RES, V6, P821, DOI 10.1007/BF00965041; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WATANABE T, 1994, J PHARMACOL EXP THER, V268, P1597; WATANABE T, 1994, J PHARMACOL EXP THER, V271, P1624; WEISS GB, 1995, LIFE SCI, V56, P637, DOI 10.1016/0024-3205(94)00427-T; WERNS SW, 1990, TRENDS PHARMACOL SCI, V11, P161, DOI 10.1016/0165-6147(90)90068-J; Yamaguchi S, 1998, CAN J ANAESTH, V45, P226, DOI 10.1007/BF03012907; Yamamoto T, 1997, BRAIN RES, V762, P240, DOI 10.1016/S0006-8993(97)00490-3; Yen CLE, 1999, FASEB J, V13, P135	70	59	60	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 1	1999	58	5					697	705		10.1002/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.3.CO;2-2			9	Neurosciences	Neurosciences & Neurology	259BM	WOS:000083874200011	10561698				2021-06-18	
J	Ochi, F; Esquenazi, A; Hirai, B; Talaty, M				Ochi, F; Esquenazi, A; Hirai, B; Talaty, M			Temporal-spatial feature of gait after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						gait analysis; temporal-spatial variables; traumatic brain injury	HEMIPLEGIC GAIT; PARAMETERS; WALKING	The temporal-spatial characteristics of the gait of patients with traumatic brain injury (TBI) were investigated and compared with those of normal gait and the gait of stroke survivors. A slower walking velocity is evident in the TBI population when compared with normal. The average walking speed of TBI survivors is faster than that of stroke patients and is mainly related to a longer step length. TBI survivors produce a gait pattern with a prolonged stance period for the unaffected limb, without prolonged stance period for the affected limb, and a shorter step length for the unaffected limb.	MossRehab Hosp, Gait & Mot Anal Lab, Philadelphia, PA 19141 USA; Natl Def Med Coll, Dept Rehabil Med, Tokorozawa, Saitama, Japan	Ochi, F (corresponding author), MossRehab Hosp, Gait & Mot Anal Lab, 1200 Tabor Rd, Philadelphia, PA 19141 USA.						BRANDSTATER ME, 1983, ARCH PHYS MED REHAB, V64, P583; CRAIK RL, 1992, POSTURE GAIT CONTROL, pR2; DUTTER L, 1992, PHYS THER, V72, pS39; Elovic E, 1996, MED REHABILITATION T; ESQUENAZI A, 1993, REHABILITATION MED P; Esquenazi A, 1991, PHYS MED REHABIL CLI, V2, P473, DOI [10.1016/S1047-9651(18)30695-8, DOI 10.1016/S1047-9651(18)30695-8]; HARRIS GF, 1994, ARCH PHYS MED REHAB, V75, P216; LEIPER CI, 1991, PHYS THER, V71, P791, DOI 10.1093/ptj/71.11.791; MAYER N H, 1987, Society for Neuroscience Abstracts, V13, P1174; MIZRAHI J, 1982, SCAND J REHABIL MED, V14, P133; Murray M P, 1970, Arch Phys Med Rehabil, V51, P637; Murray M P, 1966, Am J Phys Med, V45, P8; MURRAY MP, 1964, J BONE JOINT SURG AM, V46, P335, DOI 10.2106/00004623-196446020-00009; PEAT M, 1976, ARCH PHYS MED REHAB, V57, P421; Roth EJ, 1997, AM J PHYS MED REHAB, V76, P128, DOI 10.1097/00002060-199703000-00008; TAYLOR DR, 1980, P INT C REH ENG; WALL JC, 1979, SCAND J REHABIL MED, V11, P95; WALL JC, 1986, ARCH PHYS MED REHAB, V67, P550	18	59	61	0	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1999	14	2					105	115		10.1097/00001199-199904000-00002			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	187DN	WOS:000079771800002	10191370				2021-06-18	
J	Kroppenstedt, SN; Kern, M; Thomale, UW; Schneider, GH; Lanksch, WR; Unterberg, AW				Kroppenstedt, SN; Kern, M; Thomale, UW; Schneider, GH; Lanksch, WR; Unterberg, AW			Effect of cerebral perfusion pressure on contusion volume following impact injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral perfusion pressure; cortical impact injury; hypertension; hypobaric hypotension; intracranial pressure	CONTROLLED CORTICAL IMPACT; TRAUMATIC BRAIN INJURY; BLOOD-FLOW; HEAD-INJURY; HYPOBARIC HYPOTENSION; OXYGEN-SATURATION; RAT; ISCHEMIA; MANAGEMENT; REDUCTION	Object. Although it is generally acknowledged that a sufficient cerebral perfusion pressure (CPP) is necessary for treatment of severe head injury, the optimum CPP is still a subject of debate. The purpose of this study was to investigate the effect of various levels of blood pressure and, thereby, CPP on posttraumatic contusion volume. Methods. The left hemispheres of 60 rats were subjected to controlled cortical impact injury (CCII). In one group of animals the mean arterial blood pressure (MABP) was lowered for 30 minutes to 80, 70, 60, 50, or 40 mm Hg 4 hours after contusion by using hypobaric hypotension. In another group of animals the MABP was elevated for 3 hours to 120 or 140 mm Hg 4 hours after contusion by administering dopamine. The MABP was not changed in respective control groups. Intracranial pressure (ICP) was monitored with an ICP microsensor. The rats were killed 28 hours after trauma occurred and contusion volume was assessed using hematoxylin and eosin-stained coronal slices. No significant change in contusion volume was caused by a decrease in MABP from 94 to 80 mm Hg (ICP 12 +/- 1 mm Hg), but a reduction of MABP to 70 mm Hg (ICP 9 +/- 1 mm Hg) significantly increased the contusion volume (p < 0.05). A further reduction of MABP led to an even more enlarged contusion volume. Although an elevation of MABP to 120 mm Hg (ICP 16 +/- 2 mm Hg) did not significantly affect contusion volume, there was a significant increase in the contusion volume at 140 mm Hg MABP (p < 0.05; ICP 18 +/- 1 mm HE) Conclusions. Under these experimental conditions, CPP should be kept within 70 to 105 mm Hg to minimize post traumatic contusion volume. A CPP of 60 mm HE and lower as well as a CPP of 120 mm HE and higher should be considered detrimental.	Humboldt Univ, Dept Neurosurg, D-13353 Berlin, Germany	Kroppenstedt, SN (corresponding author), Humboldt Univ, Dept Neurosurg, Campus Virchow,Augustenburger Pl 1, D-13353 Berlin, Germany.						ALTURA BM, 1980, BRIT J PHARMACOL, V69, P543, DOI 10.1111/j.1476-5381.1980.tb07900.x; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Busse R, 1997, BRAIN PATHOL, V7, P1377; CHAN KH, 1993, NEUROSURGERY, V32, P547; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DIRNAGL U, 1993, NEUROL RES, V15, P128; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; GRANDE PO, 1998, PATHOPHYSIOLOGICAL P, P123; HEIMANN A, 1994, J CEREBR BLOOD F MET, V14, P1100, DOI 10.1038/jcbfm.1994.144; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Marmarou A, 1994, INTRACRANIAL PRESSUR, P302; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MENDELOW AD, 1993, INTRACRANIAL PRESSUR, V8, P544; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NORDSTROM CH, 1998, PATHOPHYSIOLOGICAL P, P67; Piper I. R., 1995, Journal of Neurotrauma, V12, P470; RINK A, 1995, AM J PATHOL, V147, P1575; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; Unterberg AW, 1997, ACT NEUR S, V70, P106	35	59	61	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1999	90	3					520	526		10.3171/jns.1999.90.3.0520			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	170KX	WOS:000078805800012	10067922				2021-06-18	
J	Levine, B; Freedman, M; Dawson, D; Black, S; Stuss, DT				Levine, B; Freedman, M; Dawson, D; Black, S; Stuss, DT			Ventral frontal contribution to self-regulation: Convergence of episodic memory and inhibition	NEUROCASE			English	Article							TRAUMATIC BRAIN INJURY; HUMAN PREFRONTAL CORTEX; CLOSED-HEAD-INJURY; RECOLLECTIVE EXPERIENCE; ORBITOFRONTAL CORTEX; STRATEGY APPLICATION; RETROGRADE-AMNESIA; LEARNING-DEFICITS; WORKING-MEMORY; OLDER ADULTS	Ventral frontal brain damage is associated with impaired self-regulation of behaviour in unstructured situations (self-regulatory disorder; SRD). This report attempts to integrate this brain-behaviour correlation with earlier animal literature on disinhibition and recent cognitive neuroscience literature on the frontal lobes and episodic memory. Data are presented from patient ML (Levine et at, Brain 1998; 121: 1951-73), who has isolated retrograde amnesia, ventral frontal dysfunction and SRD. Impaired strategic self-regulation of behaviour was documented with psychosocial outcome questionnaires and two laboratory analogues of real-life unstructured situations: a strategy application task and a gambling task. Previous findings of deficits in anterograde episodic memory (i.e. re-experiencing) using the remember/ know distinction were replicated and extended. The role of disinhibition as a mechanism for SRD was supported by ML's severely impaired performance on object alternation, a task with documented sensitivity to disinhibition following ventral frontal dysfunction in non-human primates and humans. It is argued that autonoetic awareness (i.e. awareness of the self as a continuous entity across time) supports self-regulation of behaviour in unstructured situations by providing access to a network of accumulated episodic information. This information is held on-line to facilitate inhibition of inappropriate actions arising from prepotent environmental or internal stimuli. In patients with SRD, these on-line maintenance and inhibition mechanisms are inoperative, resulting in inappropriate behaviour in unstructured situations. Therefore, patients with SRD should be impaired on both tests of episodic re-experiencing and inhibition.	Univ Toronto, Dept Psychol, Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Med Neurol, Baycrest Ctr Geriatr Care,Sunnybrook Hlth Sci Ctr, Rotman Res Inst,Div Neurol, Toronto, ON M6A 2E1, Canada; Univ Toronto, Mt Sinai Hosp, Toronto, ON M6A 2E1, Canada; Univ Toronto, Behav Neurol Program, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Occupat Therapy, Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada		levine@psych.utoronto.ca	Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010; Black, Sandra E./C-7294-2011; Dawson, Deirdre/I-8882-2014	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Black, Sandra/0000-0001-7093-8289; Dawson, Deirdre/0000-0001-7517-6121			Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BLUMER D, 1975, PSYCHIATRIC ASPECTS, V1, P151; BRUTKOWSKI S, 1961, CENTRAL PERIPHERAL M, P133; Burgess P. W., 1997, COGNITIVE MODELS MEM, P247; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Courville C. B., 1937, PATHOLOGY CENTRAL 4; CRAIK FIM, 1990, PSYCHOL AGING, V5, P148, DOI 10.1037/0882-7974.5.1.148; CROVITZ HF, 1974, B PSYCHONOMIC SOC, V4, P517; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DENOBELE E, 1835, ANN MED; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; Dias R, 1997, J NEUROSCI, V17, P9285; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Freedman M, 1998, CEREB CORTEX, V8, P18, DOI 10.1093/cercor/8.1.18; FREEDMAN M, 1986, BEHAV NEUROSCI, V100, P337, DOI 10.1037/0735-7044.100.3.337; FREEDMAN M, 1987, ARCH NEUROL-CHICAGO, V44, P394, DOI 10.1001/archneur.1987.00520160036011; FREEDMAN M, 1989, BRAIN COGNITION, V11, P114, DOI 10.1016/0278-2626(89)90009-2; FUNAHASHI S, 1993, J NEUROSCI, V13, P1479; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; FUSTER JM, 1997, PREFRONTAL CORTEX; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; GARDINER JM, 1988, MEM COGNITION, V16, P309, DOI 10.3758/BF03197041; GARDINER JM, 1991, MEM COGNITION, V19, P617, DOI 10.3758/BF03197157; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; GoldmanRakic PS, 1996, PHILOS T ROY SOC B, V351, P1445, DOI 10.1098/rstb.1996.0129; Grafman J., 1994, HANDB NEUR, V9, P187; Jacobsen C.F., 1936, COMP PSYCHOL, V13, P1, DOI DOI 10.1001/ARCHNEURPSYC.1935.02250150108009; Jacoby LL, 1997, CARN S COGN, P13; JENNETT B, 1975, LANCET, V1, P480; JOHNSON MK, 1993, PSYCHOL BULL, V114, P3, DOI 10.1037/0033-2909.114.1.3; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Keith R, 1987, ADV CLIN REHABILITAT, V1, P10; KNOWLTON BJ, 1995, J EXP PSYCHOL LEARN, V21, P699, DOI 10.1037/0278-7393.21.3.699; Kopelman M D, 1994, Memory, V2, P211, DOI 10.1080/09658219408258945; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LUCCHELLI F, 1995, BRAIN, V118, P167, DOI 10.1093/brain/118.1.167; Markowitsch HJ, 1996, NEUROCASE, V2, P357; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCCOLL MA, 1995, DISABIL REHABIL, V17, P24, DOI 10.3109/09638289509166624; MCINTYRE JS, 1987, CAN J PSYCHOL, V41, P175, DOI 10.1037/h0084154; MISHKIN M, 1964, FRONTAL GRANULAR COR, P219; Norman KA, 1997, MEM COGNITION, V25, P838, DOI 10.3758/BF03211328; NOSEK M, 1982, REHABILITATION COUNS, V36, P21; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OSCARBERMAN M, 1991, FRONTAL LOBE FUNCTIO, P256; Pandya D. N., 1987, FRONTAL LOBES REVISI, P41; Pandya DN, 1996, RES PER NEUROSCI, P13; PETRIDES M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAJARAM S, 1993, MEM COGNITION, V21, P89, DOI 10.3758/BF03211168; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rolls ET, 1996, PHILOS T ROY SOC B, V351, P1433, DOI 10.1098/rstb.1996.0128; RUGG MD, 1998, J MEM LANG, V38, P1; Rushworth MFS, 1997, J NEUROSCI, V17, P4829; Sanides F., 1970, Advances Primatol, V1, P137; SCHACTER DL, 1984, J VERB LEARN VERB BE, V23, P593, DOI 10.1016/S0022-5371(84)90373-6; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; STUSS DT, 1982, J COMP PHYSIOL PSYCH, V96, P913, DOI 10.1037/0735-7036.96.6.913; STUSS DT, 1988, BRAIN COGNITION, V8, P21, DOI 10.1016/0278-2626(88)90036-X; STUSS DT, 1981, BIOL PSYCHIAT, V16, P1085; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; STUSS DT, 1999, IN PRESS FRONTAL LOB; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1985, CAN PSYCHOL, V26, P1, DOI 10.1037/h0080017; Ware JE., 1993, SF 36 HLTH SURVEY MA; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331; WILLER B, 1994, BRAIN INJURY REHABIL; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; Yonelinas AP, 1998, NEUROPSYCHOLOGY, V12, P323, DOI 10.1037/0894-4105.12.3.323	80	59	61	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1355-4794			NEUROCASE	Neurocase		1999	5	3					263	275		10.1080/13554799908402731			13	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	219RU	WOS:000081621500009					2021-06-18	
J	Sugerman, HJ; Bloomfield, GL; Saggi, BW				Sugerman, HJ; Bloomfield, GL; Saggi, BW			Multisystem organ failure secondary to increased intraabdominal pressure	INFECTION			English	Article							INTRA-ABDOMINAL PRESSURE; PLANNED MULTIPLE LAPAROTOMIES; BLOOD-FLOW; INTRACRANIAL-PRESSURE; COMPARTMENT SYNDROME; VOLUME EXPANSION; RENAL-FUNCTION; WALL DEFECTS; CLOSURE; CELIOTOMY	Acutely increased intraabdominal pressure can lead to multisystem organ dysfunction. Organ dysfunction consists of acute pulmonary failure secondary to compressive atelectasis and associated with high peak inspiratory pressures and impaired gas exchange, acute renal failure with marked oliguria without hypernaturia, intestinal and hepatic ischemia possibly leading to bacterial translocation or necrosis with peritonitis, increased intracranial pressures which may cause brain dysfunction or aggravate head injury edema, venous thrombosis and thromboembolism, and abdominal wall ischemia or necrosis. The diagnosis is made clinically in a patient,vith high peak inspiratory pressures, oliguria and an apparently tight abdomen, although urinary bladder pressure greater than or equal to 20 cm H2O pressure is suggestive. However, chronically increased intraabdominal pressure as is seen in the morbidly obese, pregnancy and cirrhosis may be misleading. As to treatment, once the diagnosis is made, the patient's abdomen should be opened and the tension relieved. The intestinal contents need to be protected and evaporative water loss minimized by either closing the skin and not the fascia or, if this is not possible, using an impermeable protective dressing. If the abdomen is difficult to close at the primary operation, it is best to prevent the development of an acute abdominal compartment syndrome by closing only the skin or leaving it open and using an impermeable dressing. In conclusion, the acute abdominal compartment syndrome has become increasingly recognized as a cause for multisystem organ failure. Recognition of the problem or prevention is mandatory for optimal patient survival.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Surg, Gen Surg Trauma Div, Richmond, VA 23298 USA	Sugerman, HJ (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Surg, Gen Surg Trauma Div, POB 980519,MCV Stn, Richmond, VA 23298 USA.						Bloomfield GL, 1996, J TRAUMA, V40, P936, DOI 10.1097/00005373-199606000-00012; Bloomfield GL, 1997, J TRAUMA, V42, P997, DOI 10.1097/00005373-199706000-00002; Bloomfield GL, 1997, CRIT CARE MED, V25, P496, DOI 10.1097/00003246-199703000-00020; Bloomfield GL, 1995, J TRAUMA, V39, P1168, DOI 10.1097/00005373-199512000-00028; CULLEN DJ, 1989, CRIT CARE MED, V17, P118, DOI 10.1097/00003246-198902000-00002; DIAMANT M, 1978, ANESTHESIOLOGY, V48, P23, DOI 10.1097/00000542-197801000-00005; DIEBEL L, 1992, AM SURGEON, V58, P573; DIEBEL LN, 1992, J TRAUMA, V33, P45, DOI 10.1097/00005373-199207000-00010; DIEBEL LN, 1992, J TRAUMA, V33, P279, DOI 10.1097/00005373-199208000-00019; FABIAN TC, 1994, ANN SURG, V219, P643, DOI 10.1097/00000658-199406000-00007; FIETSAM R, 1989, AM SURGEON, V55, P396; HARMAN PK, 1982, ANN SURG, V196, P594, DOI 10.1097/00000658-198211000-00015; HIRSHBERG A, 1994, J TRAUMA, V37, P365, DOI 10.1097/00005373-199409000-00005; IBERTI TJ, 1987, CRIT CARE MED, V15, P1140, DOI 10.1097/00003246-198712000-00014; IRGAU I, 1995, ARCH SURG-CHICAGO, V130, P1011; JOSEPHS LG, 1994, J TRAUMA, V36, P815, DOI 10.1097/00005373-199406000-00011; KASHTAN J, 1981, J SURG RES, V30, P249, DOI 10.1016/0022-4804(81)90156-6; LACEY SR, 1987, J PEDIATR SURG, V22, P1207, DOI 10.1016/S0022-3468(87)80739-X; MELDRUM DR, 1995, AM J SURG, V170, P537, DOI 10.1016/S0002-9610(99)80011-7; Mijangos Jose L., 1994, Surgical Forum, V45, P583; MORRIS JA, 1993, ANN SURG, V217, P576, DOI 10.1097/00000658-199305010-00019; MUTOH T, 1991, J APPL PHYSIOL, V70, P2611; PLATELL CFE, 1990, AUST NZ J SURG, V60, P213, DOI 10.1111/ans.1990.60.3.213; RICHARDS WO, 1983, ANN SURG, V197, P183, DOI 10.1097/00000658-198302000-00010; RICHARDSON JD, 1976, J SURG RES, V20, P401, DOI 10.1016/0022-4804(76)90112-8; Ridings PC, 1995, J TRAUMA, V39, P1071, DOI 10.1097/00005373-199512000-00010; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; SCHEIN M, 1995, J AM COLL SURGEONS, V180, P745; SHELLEY MP, 1981, J SURG RES, V59, P800; SMITH JH, 1985, ARCH INTERN MED, V145, P553, DOI 10.1001/archinte.145.3.553; Sugerman H, 1997, J INTERN MED, V241, P71, DOI 10.1046/j.1365-2796.1997.89104000.x; WITTMANN DH, 1993, EUR J SURG, V159, P75; WITTMANN DH, 1990, WORLD J SURG, V14, P218, DOI 10.1007/BF01664876	33	59	65	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0300-8126	1439-0973		INFECTION	Infection	JAN-FEB	1999	27	1					57	62		10.1007/BF02565176			6	Infectious Diseases	Infectious Diseases	163TB	WOS:000078420700013	10206792				2021-06-18	
J	Kreutz, MR; Bockers, TM; Bockmann, J; Seidenbecher, CI; Kracht, B; Vorwerk, CK; Weise, J; Sabel, BA				Kreutz, MR; Bockers, TM; Bockmann, J; Seidenbecher, CI; Kracht, B; Vorwerk, CK; Weise, J; Sabel, BA			Axonal injury alters alternative splicing of the retinal NR1 receptor: The preferential expression of the NR1b isoforms is crucial for retinal ganglion cell survival	JOURNAL OF NEUROSCIENCE			English	Article						NMDA receptors; NR1; NR2; alternative splicing; retina; antisense targeting; optic nerve crush; in situ hybridization; RT-PCR; Western blots; lesion	EXPERIMENTAL BRAIN INJURY; EXCITATORY AMINO-ACIDS; SUBUNIT MESSENGER-RNA; D-ASPARTATE RECEPTORS; N-TERMINAL DOMAIN; ADULT-RAT RETINA; PROTEIN-KINASE-C; NMDA RECEPTOR; GLUTAMATE-RECEPTOR; OPTIC-NERVE	Cellular-specific splicing of the retinal NMDAR1 receptor (NR1) and expression of NMDAR2 receptor (NR2) subunits in response to optic nerve injury was investigated by in situ hybridization in adult rats. A controlled optic nerve crush led to a clear alteration in the expression of alternatively spliced NR1 variants in the retinal ganglion cell layer (GCL). The NR1-2b and NR1-4b isoforms were preferentially expressed between 2 d and 1 week after injury, whereas expression for all other isoforms remained either unchanged or decreased to barely detectable levels within 4 weeks. Cellular silver grain density for NR2 subunits also declined in the GCL after trauma. To directly test the hypothesis that NR1b expression is crucial for cell survival after axonal trauma, we administered intraocularly an antisense oligonucleotide against the NR1b isoform 2 and 3 d after injury. This led to a drastic loss of retrogradely labeled retinal ganglion cells (RGCs). Antisense targeting clearly reduced retinal NR1 protein levels, as judged by Western blot analysis, but had no effect on the cell number in control retinas. These findings point toward injury-specific changes in alternative splicing of the NR1 receptor, which are crucial for the survival of RGCs after partial axonal trauma. We therefore propose that this reflects an adaptive, rather than a pathogenic, cellular response to neurotrauma.	Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany; Otto Von Guericke Univ, Inst Med Psychol, AG Mol & Cellular Neurobiol, D-39120 Magdeburg, Germany; Univ Munster, Inst Anat, AG Mol Neuroendocrinol, D-48129 Munster, Germany	Kreutz, MR (corresponding author), Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, Brennecke Str 6, D-39118 Magdeburg, Germany.		Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543			ANANTHARAM V, 1992, FEBS LETT, V305, P27, DOI 10.1016/0014-5793(92)80648-Z; AOKI C, 1994, J NEUROSCI, V14, P5202; BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; BIEN A, 1996, SOC NEUR ABSTR, V126, P2; BIEN A, 1998, IN PRESS J NEUROTRAU; BOCKERS TM, 1994, NEUROREPORT, V5, P965; BRANDSTATTER JH, 1994, EUR J NEUROSCI, V6, P1100, DOI 10.1111/j.1460-9568.1994.tb00607.x; BRESNICK GH, 1989, ARCH OPHTHALMOL-CHIC, V107, P339, DOI 10.1001/archopht.1989.01070010349021; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CONDORELLI DF, 1993, J NEUROCHEM, V61, P2133, DOI 10.1111/j.1471-4159.1993.tb07451.x; DELLAVEDOVA F, 1994, NEUROREPORT, V5, P581; Demediuk P, 1990, Adv Neurol, V52, P225; DREYER EB, 1994, NEUROREPORT, V5, P629, DOI 10.1097/00001756-199401000-00024; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUDA Y, 1977, BRAIN RES, V119, P327, DOI 10.1016/0006-8993(77)90314-6; GENNARALLI TA, 1989, J NEUROSURG, V7, P244; GRACY KN, 1995, J COMP NEUROL, V362, P71, DOI 10.1002/cne.903620105; HAMASSAKIBRITTO DE, 1993, J NEUROSCI, V13, P1888; HARTVEIT E, 1995, EUR J NEUROSCI, V7, P1472, DOI 10.1111/j.1460-9568.1995.tb01142.x; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUGHES TE, 1992, VISUAL NEUROSCI, V8, P49, DOI 10.1017/S0952523800006489; KALLONIATIS M, 1993, J COMP NEUROL, V336, P174, DOI 10.1002/cne.903360203; Kraus JE, 1996, MOL BRAIN RES, V41, P97, DOI 10.1016/0169-328X(96)00072-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LAURIE DJ, 1995, MOL BRAIN RES, V32, P94, DOI 10.1016/0169-328X(95)00067-3; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; Massey S.C., 1990, Progress in Retinal Research, V9, P399, DOI 10.1016/0278-4327(90)90013-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MULLER F, 1992, NEUROSCI LETT, V138, P179, DOI 10.1016/0304-3940(92)90500-7; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; PERRY VH, 1982, NATURE, V297, P683, DOI 10.1038/297683a0; PIEHL F, 1995, EUR J NEUROSCI, V7, P2101, DOI 10.1111/j.1460-9568.1995.tb00632.x; SABEL BA, 1995, EXP BRAIN RES, V106, P93; Sambrook J., 1989, MOL CLONING LAB; SANCHEZVIVES MV, 1994, EUR J NEUROSCI, V6, P9, DOI 10.1111/j.1460-9568.1994.tb00243.x; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SCHOBER W, 1977, Zeitschrift fuer Mikroskopisch-Anatomische Forschung (Leipzig), V91, P397; Schwartz M, 1996, INVEST OPHTH VIS SCI, V37, P2245; SIEGEL SJ, 1994, P NATL ACAD SCI USA, V91, P564, DOI 10.1073/pnas.91.2.564; SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666; SILVEIRA LCL, 1994, J NEUROCYTOL, V23, P75, DOI 10.1007/BF01183863; SMITH DH, 1993, J NEUROSCI, V13, P5383; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SUGIOKA K, 1992, J MATER RES, V7, P185, DOI 10.1557/JMR.1992.0185; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TRAYNELIS SF, 1995, SCIENCE, V268, P877; Vezzani A, 1995, EUR J NEUROSCI, V7, P2513, DOI 10.1111/j.1460-9568.1995.tb01050.x; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P2382; Wang JKT, 1996, J NEUROCHEM, V66, P865; WASSLE H, 1991, PHYSIOL REV, V71, P447; YOSHIDA K, 1993, NEURON, V10, P1049, DOI 10.1016/0896-6273(93)90053-T; ZIMMER M, 1995, GENE, V159, P219, DOI 10.1016/0378-1119(95)00044-7; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	66	59	59	0	0	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 15	1998	18	20					8278	8291					14	Neurosciences	Neurosciences & Neurology	126WL	WOS:000076317600016	9763472				2021-06-18	
J	Sick, TJ; Perez-Pinzon, M; Feng, ZZ				Sick, TJ; Perez-Pinzon, M; Feng, ZZ			Impaired expression of long-term potentiation in hippocampal slices 4 and 48 h following mild fluid-percussion brain injury in vivo	BRAIN RESEARCH			English	Article						long-term potentiation; concussion; synaptic plasticity; hippocampus	MODERATE HYPOTHERMIA; SPREADING DEPRESSION; SYNAPTIC PLASTICITY; AFFERENT-FIBERS; NMDA RECEPTORS; HEAD-INJURY; AMINO-ACIDS; CALCIUM; RATS; DEFICITS	The effect of fluid percussion brain injury on hippocampal long-term potentiation (LTP) was investigated in hippocampal slices in vitro. Mild to moderate (1.7-2.1 atm) lateral fluid percussion head injury or sham operation was produced in rats 4 or 48 h prior to harvesting brain slices from the ipsilateral hippocampus. Field excitatory post-synaptic potentials (fEPSPs) were recorded in stratum radiatum of hippocampal subfield CAI in response to electrical stimulation of the Schaffer collaterals. The initial slope of fEPSPs was used to investigate changes in synaptic strength prior to and following 100 or 200 Hz (1 s) tetanic stimulation. TBI significantly inhibited expression of LTP in hippocampal slices in vitro. Post-tetanus fEPSP slopes increased more than 100% in hippocampal slices from sham-operated animals but less than 50% in slices from rats following TBI. The data suggest that changes in functional synaptic plasticity in the hippocampus may contribute to cognitive disorders associated with TBI (traumatic brain injury). The data also indicate that TBI-induced effects on hippocampal LTP are robust and may be investigated in the hippocampal slice preparation in vitro. (C) 1998 Elsevier Science B.V.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33177 USA	Sick, TJ (corresponding author), Univ Miami, Sch Med, Dept Neurol, South Campus Bldg B,12500 SW 152 St, Miami, FL 33177 USA.	tsick@neuron.med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline		BARRIONUEVO G, 1983, P NATL ACAD SCI-BIOL, V80, P7347, DOI 10.1073/pnas.80.23.7347; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; CREPEL V, 1993, J NEUROPHYSIOL, V69, P1774; DEBANNE D, 1994, NEWS PHYSIOL SCI, V9, P256; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMMOND C, 1994, TRENDS NEUROSCI, V17, P497, DOI 10.1016/0166-2236(94)90140-6; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; HANSEN AJ, 1990, CEREBRAL ISCHEMIA RE, P78; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; KRNJEVIC K, 1974, CAN J PHYSIOL PHARM, V52, P852, DOI 10.1139/y74-110; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALTHESORENSSEN D, 1979, NEUROSCIENCE, V4, P1255, DOI 10.1016/0306-4522(79)90155-6; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; REEVES TM, 1995, EXP BRAIN RES, V106, P248; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; ROBERTS EL, 1988, BRAIN RES, V456, P113, DOI 10.1016/0006-8993(88)90352-6; SIEMKOWICZ E, 1981, STROKE, V12, P236, DOI 10.1161/01.STR.12.2.236; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEYLER TJ, 1995, BRAIN SLICES BASIC C, P1; UEMATSU D, 1988, J CEREBR BLOOD F MET, V8, P367, DOI 10.1038/jcbfm.1988.72; YOUNG JN, 1992, BRAIN RES, V573, P70, DOI 10.1016/0006-8993(92)90114-O	38	59	60	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 2	1998	785	2					287	292		10.1016/S0006-8993(97)01418-2			6	Neurosciences	Neurosciences & Neurology	ZJ988	WOS:000073273800011	9518654				2021-06-18	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Neuroprotective effects of MgSO4 and MgCl2 in closed head injury: A comparative phosphorus NMR study	JOURNAL OF NEUROTRAUMA			English	Article						brain; magnetic resonance; trauma; magnesium; treatment	TRAUMATIC BRAIN INJURY; NUCLEAR-MAGNETIC-RESONANCE; DIFFUSE AXONAL INJURY; FREE MAGNESIUM; INTRACELLULAR MAGNESIUM; SMOOTH-MUSCLE; FREE MG-2+; RATS; METABOLISM; ISCHEMIA	Previous studies have shown that free magnesium levels decline after traumatic brain injury and that magnesium salt administration improves posttraumatic outcome. These earlier studies, however, have been limited to models of injury that do not produce a significant degree of diffuse axonal injury and have used either MgSO4 or MgCl2 as the magnesium salt. The present study compares the neuroprotective efficacy of MgSO4 and MgCl2 in a severe model of diffuse axonal injury in rats using phosphorus nuclear magnetic resonance spectroscopy and the rotarod test to monitor effects on metabolism and neurologic outcome, respectively. Both MgSO4 and MgCl2 given as a bolus of 100 mu moles/kg at 30 min after severe, closed head injury significantly improved brain intracellular free magnesium concentration and neurologic outcome. These findings suggest that both salts penetrate the blood-brain barrier after brain trauma, enter injured tissue, and subsequently improve neurologic outcome.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia	Heath, DL (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; Bara M, 1984, MAGNESIUM, V3, P212; Bara Michel, 1994, Magnesium Research, V7, P11; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Corbett RJT, 1996, NEUROREPORT, V8, P287; CUNNINGHAM CC, 1986, ALCOHOL CLIN EXP RES, V10, P246, DOI 10.1111/j.1530-0277.1986.tb05084.x; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FAGIAN MM, 1986, BIOCHIM BIOPHYS ACTA, V852, P262, DOI 10.1016/0005-2728(86)90231-8; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GARFINKEL L, 1985, Magnesium, V4, P60; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRUBBS RD, 1987, MAGNESIUM, V6, P113; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAYES RL, 1992, CENTRAL NERVOUS SYST, P173; HEADRICK JP, 1991, J MOL CELL CARDIOL, V23, P991, DOI 10.1016/0022-2828(91)91635-5; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; HOFFMAN DJ, 1994, BRAIN RES, V644, P144, DOI 10.1016/0006-8993(94)90357-3; HOVDA DA, 1992, CENTRAL NERVOUS SYST, P47; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MULLINS PGM, 1995, NEUROREPORT, V6, P1633, DOI 10.1097/00001756-199508000-00011; PETROFF OAC, 1985, NEUROLOGY, V35, P1681, DOI 10.1212/WNL.35.12.1681; Povlishock JT, 1996, ACT NEUR S, V66, P81; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SCHACHTER M, 1990, BIOCHIM BIOPHYS ACTA, V1035, P378, DOI 10.1016/0304-4165(90)90103-4; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Suzuki M, 1997, GEN PHARMACOL, V28, P119, DOI 10.1016/S0306-3623(96)00148-6; TERASAKI M, 1985, P NATL ACAD SCI USA, V82, P7324, DOI 10.1073/pnas.82.21.7324; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; WALLIS RA, 1996, J NEUROTRAUM, V13, P626; WILLIAMS GD, 1995, MAGNET RESON MED, V33, P853, DOI 10.1002/mrm.1910330618; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	48	59	65	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					183	189		10.1089/neu.1998.15.183			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500003	9528918				2021-06-18	
J	Gerszten, PC; Albright, AL; Barry, MJ				Gerszten, PC; Albright, AL; Barry, MJ			Effect on ambulation of continuous intrathecal baclofen infusion	PEDIATRIC NEUROSURGERY			English	Article						ambulation; baclofen; cerebral palsy; traumatic brain injury	SELECTIVE POSTERIOR RHIZOTOMY; SEVERE SPINAL SPASTICITY; CEREBRAL-PALSY; ORIGIN	Intrathecal baclofen (ITB) infusion has been shown to be an effective treatment for spasticity secondary to both cerebral palsy and spinal cord injury. Its effect on the ambulatory status of individuals with cerebral spasticity, however, has not previously been addressed. We reviewed the effect of ITB on functional ambulation in 24 patients who were ambulatory to some extent, either with or without assistive devices. Twenty-one pumps were placed in patients with spastic cerebral palsy and 3 in patients with spasticity secondary to traumatic brain injury (13 boys and 11 girls, mean age 18 years). The mean ITB dose was 200 mu g/day (range 22-550 mu g/day) and the mean length of follow-up was 52 months. Ambulation was retrospectively graded on four functional levels: community, household, non-functional, and non-ambulatory. The level of ambulation improved by one functional level in 9 patients, did not change for 12 patients, and was worse in 3 patients. Gait was considered to be improved in 20 of 24 patients by the patients or their families. The overall functional improvement not directly related to ambulation was found to be improved in 20 patients, unchanged in 2 patients, and worse in 2 patients. ITB allows for improved ambulation in a certain subset of patients with lower extremity spasticity. It is not contraindicated in patients who rely upon their spasticity for support during ambulation. ITB infusion allows for baclofen dosage titration to balance between extensor tone for support and suppression of hyperactive reflexes which may impede normal locomotion.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA	Albright, AL (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, 375 5th Ave, Pittsburgh, PA 15213 USA.						ALBRIGHT AL, 1995, PEDIATR NEUROSURG, V23, P82; ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; Albright AL, 1996, J CHILD NEUROL, V11, P77, DOI 10.1177/088307389601100202; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Azouvi P, 1996, ARCH PHYS MED REHAB, V77, P35, DOI 10.1016/S0003-9993(96)90217-8; Bodensteiner JB, 1996, J CHILD NEUROL, V11, P75, DOI 10.1177/088307389601100201; BURKE D, 1988, FUNCTIONAL RECOVERY, P401; CAMPBELL SK, 1995, PHYS THER, V75, P352, DOI 10.1093/ptj/75.5.352; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; DIETZ V, 1992, MED SPORT SCI, V36, P225; Feldman RG, 1980, SPASTICITY DISORDERE, P41; GAGE JR, 1991, GAIT ANAL CEREBRAL P, P1; HOFFER MM, 1973, J BONE JOINT SURG AM, VA 55, P137, DOI 10.2106/00004623-197355010-00014; LANDAU WM, 1974, ARCH NEUROL-CHICAGO, V31, P217; LANDAU WM, 1988, NEUROLOGY, V38, P1496, DOI 10.1212/WNL.38.9.1496; LATASH ML, 1990, J NEUROSURG, V72, P388, DOI 10.3171/jns.1990.72.3.0388; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; LOUBSER PG, 1991, PARAPLEGIA, V29, P48, DOI 10.1038/sc.1991.7; MEYTHALER JM, 1992, ARCH PHYS MED REHAB, V73, P794; Ordia JI, 1996, J NEUROSURG, V85, P452, DOI 10.3171/jns.1996.85.3.0452; PEACOCK WJ, 1987, PEDIATR NEUROSCI, V13, P61, DOI 10.1159/000120302; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1984, LANCET, V1, P1078; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Shetter AG, 1996, NEUROSURG QUART, V6, P194, DOI 10.1097/00013414-199609000-00003; SHETTER AG, 1993, PERSPECT NEUROL SURG, V4, P109; STEINBOK P, 1991, CAN J NEUROL SCI, V18, P232	28	59	60	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	JUL	1997	27	1					40	44		10.1159/000121223			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	YV064	WOS:000071786000006	9486835				2021-06-18	
J	Ford, JC; Hackney, DB				Ford, JC; Hackney, DB			Numerical model for calculation of apparent diffusion coefficients (ADC) in permeable cylinders - Comparison with measured ADC in spinal cord white matter	MAGNETIC RESONANCE IN MEDICINE			English	Article						diffusion, MR; white matter; spinal cord	WATER DIFFUSION; RESTRICTED DIFFUSION; SYSTEM; INJURY; MRI; RAT; ISCHEMIA; STROKE; BRAIN; CAT	We have implemented a numerical method for calculation of the apparent diffusion coefficient (ADC) in spinal cord injury, which takes into account the distribution of axon diameters and permeability found in spinal cord white matter, as well as relative axonal volume. We propose a procedure for determining the status of axonal integrity from measured ADC values. These methods have been applied to a well characterized rat spinal cord injury model, affording a prediction of the increase in axonal permeability which is presumed to be closely related to functional deficit. ADC values are compared to those calculated from analytical formulas in the literature, and possible factors underlying the ADC behavior are explored. Calculated results indicate both axonal swelling and cell membrane permeability to be important factors contributing to ADC in traumatic spinal cord injury.		Ford, JC (corresponding author), UNIV PENN,MED CTR,DEPT RADIOL,1 SILVERSTEIN BLDG,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Hackney, David/A-5337-2010		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS25291-06A1.] Funding Source: Medline		Anderson AW, 1996, MAGN RESON MED, V35, P162, DOI 10.1002/mrm.1910350206; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; BIHAN DL, 1991, J MAGN RESON IMAGING, V1, P7; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; FAIRHOLM DJ, 1971, J NEUROSURG, V35, P277, DOI 10.3171/jns.1971.35.3.0277; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; FORD JC, 1994, P 80 M RAD SOC N AM, P306; HAJNAL JV, 1991, J COMPUT ASSIST TOMO, V15, P1, DOI 10.1097/00004728-199101000-00001; LATOUR LL, 1994, P NATL ACAD SCI USA, V91, P1229, DOI 10.1073/pnas.91.4.1229; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; MOONEN CTW, 1991, MAGNET RESON MED, V19, P327, DOI 10.1002/mrm.1910190223; MOSELEY ME, 1991, MAGNET RESON MED, V19, P321, DOI 10.1002/mrm.1910190222; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Neil JJ, 1996, MAGNET RESON MED, V35, P329, DOI 10.1002/mrm.1910350310; NIENDORF T, 1994, MAGNET RESON MED, V32, P672, DOI 10.1002/mrm.1910320520; SEGAWA F, 1993, P SMRM 12 ANN M, V2, P595; STANISZ G, MAGN RESON MED, V37; SYKOVA E, 1994, J CEREBR BLOOD F MET, V14, P301, DOI 10.1038/jcbfm.1994.37; SZAFER A, 1995, MAGNET RESON MED, V33, P697, DOI 10.1002/mrm.1910330516; TANNER JE, 1978, J CHEM PHYS, V69, P1748, DOI 10.1063/1.436751; VANGELDEREN P, 1994, MAGNET RESON MED, V31, P154, DOI 10.1002/mrm.1910310209; VONZIJL PCM, 1991, P NATL ACAD SCI USA, V88, P3228; WAGNER FC, 1971, J NEUROSURG, V35, P272, DOI 10.3171/jns.1971.35.3.0272	26	59	59	0	6	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0740-3194			MAGNET RESON MED	Magn.Reson.Med.	MAR	1997	37	3					387	394		10.1002/mrm.1910370315			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	WJ664	WOS:A1997WJ66400012	9055229				2021-06-18	
J	Pravdenkova, SV; Basnakian, AG; James, SJ; Andersen, BJ				Pravdenkova, SV; Basnakian, AG; James, SJ; Andersen, BJ			DNA fragmentation and nuclear endonuclease activity in rat brain after severe closed head injury	BRAIN RESEARCH			English	Article						closed head injury; head trauma; apoptosis; cell death; Ca/Mg-dependent endonuclease; nucleus; DNA fragmentation	PROGRAMMED CELL-DEATH; APOPTOSIS; MECHANISMS; ACTIVATION; CALCIUM; CYCLE; MODEL	Previous studies have suggested that brain cells undergo apoptotic cell death during several neurodegenerative disorders such as Alzheimer's disease, Parkinsonism and ischemic stroke. In the present study, apoptotic DNA fragmentation and activation of nuclear endonuclease were evaluated in rat brain cells after head trauma. Severe closed head injury was induced in rats by the impact of a 450-g weight dropped from a height of 2 m. A 12% mortality was experienced after head trauma. Brain cell nuclei and DNA were isolated at intervals of 3, 10, 24 h, 3 and 10 days after head trauma. DNA fragmentation was measured by the random oligonucleotide-primed synthesis (ROPS) assay and was significantly increased with the maximum level of DNA fragmentation occurring at 10 h after trauma. The DNA and nuclei yields decreased 10 h after injury and remained at a reduced level at all subsequent sampling intervals. The DNA fragmentation induced after severe head trauma was accompanied by an increase in the activity of the Ca/Mg-dependent endonuclease associated with apoptosis. These data indicate that severe head injury is associated with significant brain cell death by apoptosis.	UNIV ARKANSAS MED SCI HOSP,LITTLE ROCK,AR 72205; NATL CTR TOXICOL RES,DIV NUTR TOXICOL,US FDA,JEFFERSON,AR 72079; NYU MED CTR,NEW YORK,NY 10016							ALLES A, 1991, FASEB J, V5, P2127; ARENDS MJ, 1990, AM J PATHOL, V136, P593; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, V1; BASNAKIAN AG, 1994, NUCLEIC ACIDS RES, V22, P2714, DOI 10.1093/nar/22.13.2714; BASNAKIAN AG, 1995, CURRENT PROTOCOLS MO, P1; BREDESEN DE, 1994, APOPTOSIS, V2, P397; BUDHRAMMAHADEO V, 1994, NEUROSCI LETT, V165, P18, DOI 10.1016/0304-3940(94)90699-8; CALNE DB, 1994, NEUROLOGY, V44, P5; DIGUARDO G, 1993, RES VIROLOGY, V144, P409, DOI 10.1016/S0923-2516(06)80057-9; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FAIRBAIRN DW, 1994, FEMS MICROBIOL LETT, V115, P341, DOI 10.1111/j.1574-6968.1994.tb06661.x; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gennarelli TA, 1993, HEAD INJURY, P137; GRAHAM A, 1993, DEVELOPMENT, V119, P233; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P475, DOI 10.1016/0006-291X(73)90736-5; HOOPER C, 1990, J NIH RES, V2, P46; KESSLER JA, 1993, NEURON, V11, P1223; KHODAREV N N, 1979, Biokhimiya, V44, P622; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MIGHELI A, 1994, J NEUROPATH EXP NEUR, V53, P606, DOI 10.1097/00005072-199411000-00008; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROSE CD, 1993, NEURODEGENERATION, V2, P287; SCHWARTZ LM, 1991, BIOESSAYS, V13, P389, DOI 10.1002/bies.950130805; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; TOMINAGA T, 1992, NEUROSCI LETT, V139, P265, DOI 10.1016/0304-3940(92)90568-R; TOMINAGA T, 1993, BRAIN RES, V608, P21, DOI 10.1016/0006-8993(93)90768-I; WHITE BC, 1993, ANN EMERG MED, V22, P970, DOI 10.1016/S0196-0644(05)82737-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	33	59	64	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 12	1996	729	2					151	155		10.1016/0006-8993(96)00222-3			5	Neurosciences	Neurosciences & Neurology	VE644	WOS:A1996VE64400002	8876983				2021-06-18	
J	Fletcher, JM; Levin, HS; Lachar, D; Kusnerik, L; Harward, H; Mendelsohn, D; Lilly, MA				Fletcher, JM; Levin, HS; Lachar, D; Kusnerik, L; Harward, H; Mendelsohn, D; Lilly, MA			Behavioral outcomes after pediatric closed head injury: Relationships with age, severity, and lesion size	JOURNAL OF CHILD NEUROLOGY			English	Article							FOLLOW-UP; CHILDREN; SEQUELAE; MILD	This study investigated the behavioral outcomes and adaptive functioning of 138 children with mild to severe closed head injury in the 6- to 16-year age range. Each child was evaluated with the Personality Inventory for Children-Revised. A subset of this sample (n = 77) received the Vineland Adaptive Behavior Scales. Results revealed little evidence for group differences based on severity of closed head injury on scales associated with psychopathology on the Personality Inventory for Children-Revised. However, children with severe closed head injury were viewed as experiencing more difficulties than children with mild-moderate closed head injury on those components of the Personality Inventory for Children-Revised most closely associated with cognitive functions. In addition, on the Vineland Adaptive Behavior Scales, severely injured children had lower scores on the Communication and Socialization scales than children with mild-moderate injury, Relationships between the size of frontal and extrafrontal lesions from concurrent magnetic resonance imaging and behavioral outcomes were not apparent. This study suggests that outcome measures assessing adaptive behavior and cognitive functions are more sensitive to severity of closed head injury than parent-based scales of internalizing and externalizing psychopathology.	UNIV TEXAS,SCH MED,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT PSYCHIAT & BEHAV SCI,HOUSTON,TX 77030; UNIV MARYLAND MED SYST,DIV NEUROSURG,BALTIMORE,MD; UNIV TEXAS,MED BRANCH,DEPT SURG,GALVESTON,TX 77550; UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75235	Fletcher, JM (corresponding author), UNIV TEXAS,SCH MED,DEPT PEDIAT,6431 FANNIN,MSB 7142,HOUSTON,TX 77030, USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR02558] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BIJUR PE, 1990, PEDIATRICS, V86, P337; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; BLAU A, 1936, ARCH PSYCHIAT NEUROL, V35, P733; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Damasio H., 1989, LESION ANAL NEUROPSY; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Kahn E, 1934, NEW ENGL J MED, V210, P748, DOI 10.1056/NEJM193404052101405; KLINE RB, 1985, J PEDIATR PSYCHOL, V10, P461, DOI 10.1093/jpepsy/10.4.461; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LACHAR D, 1993, USE PSYCHOL TESTING, P479; Lehr E, 1990, PSYCHOL MANAGEMENT T; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1989, MILD HEAD INJURY, P189; Newby R F, 1986, Arch Clin Neuropsychol, V1, P157, DOI 10.1016/0887-6177(86)90015-6; PEARSON DA, 1994, J SCHOOL PSYCHOL, V32, P33, DOI 10.1016/0022-4405(94)90027-2; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Rourke B. P., 1991, LEARNING DISABILITIE; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; WIRT RD, 1990, MULTIDIMENSIONAL DES	25	59	59	0	1	DECKER PERIODICALS INC	HAMILTON	4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA	0883-0738			J CHILD NEUROL	J. Child Neurol.	JUL	1996	11	4					283	290		10.1177/088307389601100404			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	UV227	WOS:A1996UV22700004	8807417				2021-06-18	
J	Romner, B; Bellner, J; Kongstad, P; Sjoholm, H				Romner, B; Bellner, J; Kongstad, P; Sjoholm, H			Elevated transcranial Doppler flow velocities after severe head injury: Cerebral vasospasm or hyperemia?	JOURNAL OF NEUROSURGERY			English	Article						cerebral blood flow; ischemia; hyperemia; head injury; vasospasm; transcranial Doppler	SEVERE BRAIN INJURY; BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; ARTERIAL SPASM; ULTRASOUND; TOMOGRAPHY; PRESSURE; TIME; COMA	Sixty-seven patients (45 males and 22 females) aged 2 to 70 years (mean 36 years) who had suffered closed head injury were investigated with daily transcranial Doppler (TCD) recordings. A total of 470 TCD recordings (mean 7) were made during Days 1 to 14 after admission. Blood flow velocities were determined in the middle cerebral artery (MCA) and the extracranial internal carotid artery (ICA). Twenty-seven (40%) of the 67 patients demonstrated traumatic subarachnoid hemorrhage (tSAH) on the first computerized tomography (CT) scan after the injury. Flow velocities exceeded 100 cm/second in 22 patients. Eleven (41%) of the 27 patients who showed tSAH on the first CT scan developed velocities greater than 100 cm/second, as compared to 11 (28%) of 40 patients without tSAH on CT. Two patients in whom a thick layer of tSAH was revealed on the first CT scan had MCA flow velocities exceeding 200 cm/second for several days. Measurements of cerebral blood flow (CBF) with single-photon emission CT (SPECT) were performed in six tSAH patients who showed TCD flow velocities exceeding 120 cm/second (uni- or bilaterally) to determine whether the increase in velocity reflected vasospasm or hyperemia. The SPECT studies verified ischemia in five patients but revealed general hyperemia in one. The bilateral increase in MCA flow velocities in the latter case was due to high-volume flow through the MCA secondary to elevated CBF rather than arterial narrowing. In one patient with a thick layer of subarachnoid blood on a CT scan obtained at admission, MCA flow velocities exceeded 220 cm/second bilaterally on Day 8 after the head injury. A SPECT measurement obtained on the same day reflected bilateral ischemia. In this patient flow velocities decreased, with a corresponding normalization of CBF, after 5 days of intravenous nimodipine administration. The MCA/ICA ratio correlated well with the distribution of CBF in the six patients studied using SPECT. This report suggests that vasospasm is an important secondary posttraumatic insult in patients suffering severe head injury and, in some cases, is probably treatable by administration of intravenous calcium channel blockers.	UNIV LUND HOSP,DEPT NEUROPHYSIOL,S-22185 LUND,SWEDEN	Romner, B (corresponding author), UNIV LUND HOSP,DEPT NEUROSURG,S-22185 LUND,SWEDEN.						AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1992, SURG NEUROL, V38, P433, DOI 10.1016/0090-3019(92)90111-Y; CHAN KH, 1993, NEUROSURGERY, V32, P547; CHAN KH, 1992, NEUROSURGERY, V30, P697; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; DEMIRCIVI F, 1993, ACTA NEUROCHIR, V122, P45, DOI 10.1007/BF01446985; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; GROLIMUND P, 1988, LANCET, V1, P1173; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; JAMIESON DG, 1989, COMPUT MED IMAG GRAP, V13, P61, DOI 10.1016/0895-6111(89)90079-7; Kakarieka A., 1995, Journal of Neurotrauma, V12, P375; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KIRKPATRICK PJ, 1994, J NEUROL NEUROSUR PS, V57, P1382, DOI 10.1136/jnnp.57.11.1382; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MASDEU JC, 1994, NEUROLOGY, V44, P1970, DOI 10.1212/WNL.44.10.1970; MUTTAQIN Z, 1993, ACTA NEUROCHIR, V123, P76, DOI 10.1007/BF01476289; PLOUGMANN J, 1994, J NEUROSURG, V81, P822, DOI 10.3171/jns.1994.81.6.0822; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TEASDALE G, 1974, LANCET, V2, P81; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626	31	59	64	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1996	85	1					90	97		10.3171/jns.1996.85.1.0090			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	UT668	WOS:A1996UT66800013	8683288				2021-06-18	
J	Ikonomidou, C; Qin, YQ; Labruyere, J; Kirby, C; Olney, JW				Ikonomidou, C; Qin, YQ; Labruyere, J; Kirby, C; Olney, JW			Prevention of trauma-induced neurodegeneration in infant rat brain	PEDIATRIC RESEARCH			English	Article							METHYL-D-ASPARTATE; ISCHEMIC NEURONAL DEGENERATION; EXCITATORY AMINO-ACIDS; CEREBRAL-ISCHEMIA; NMDA ANTAGONISTS; GLUTAMATE; INJURY; NEUROTOXICITY; DAMAGE; RECEPTORS	Recent evidence implicates the endogenous excitatory neurotransmitters, glutamate (Glu) and aspartate, in the pathophysiology of traumatic injury in the adult CNS, bur it is not known whether similar excitotoxic mechanisms mediate traumatic injury in the immature CNS. Therefore, we developed a model of brain contusion injury in infant rats and used this model to study the nature and evolution of the acute cytopathologic changes and to evaluate the ability of Glu receptor antagonists to protect the immature brain against such changes. Seven-day-old rat pups were subjected to contusion injury and were killed 0, 0.5, 1, 2, 4, and 6 h later for histologic evaluation of the brain. Physical rearing of thr dura and minor disruption of underlying brain tissue was noted at 0 h. At 30 min a discrete zone of neuronal necrosis began to appear at thr bolder of the trauma site; this zone progressively expanded over a period of 1 h. The cytopathologic changes closely resembled the type of changes Glu is known to cause; these changes consisted of swollen dendrites, degenerating neurons with pyknotic nuclei and markedly swollen cytoplasm, and dark cells with vacuolated cytoplasm. The noncompetitive N-metyl-D-aspartate (NMDA) antagonist, dizocilpine maleate, when administered 30 min before or 1 h after trauma, significantly attenuated the lesion. The competitive NMDA antagonist, 3-((2)-carboxypiperazine-1-yl)-propyl-1-phosphonate, was also neuroprotective. The alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate/kainate receptor antagonist 2,3-dihydro-6-nitro-7-sulfamoyl-benzo(f)quinoxaline did not significantly suppress the lesion when given as three treatments (30 mg/kg each) 30 min before plus 15 and 75 min after the insult. These findings suggest that traumatic injury in the infant rat brain is mediated by endogenous excitotoxins (Glu and aspartate) acting at NMDA receptors and can be substantially mitigated by timely treatment with NMDA receptor antagonists.	WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, ST LOUIS, MO 63110 USA; ST LOUIS CHILDRENS HOSP, DEPT PEDIAT NEUROL, ST LOUIS, MO 63110 USA							AKESON J, 1993, ACTA ANAESTH SCAND, V37, P525, DOI 10.1111/j.1399-6576.1993.tb03759.x; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BONDOLI A, 1981, RESUSCITATION, V9, P119, DOI 10.1016/0300-9572(81)90021-6; Corso T. D., 1994, Society for Neuroscience Abstracts, V20, P1531; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; ESCH JSA, 1978, ACTA NEUROCHIR, V45, P15; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farber NB, 1995, BIOL PSYCHIAT, V38, P788, DOI 10.1016/0006-3223(95)00046-1; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; GROTTA J, 1994, STROKE, V25, P255; HENNEBERRY RC, 1989, ANN NY ACAD SCI, V568, P225; Herrling PL, 1994, NEUROPSYCHOPHARMACOL, V10, P5915; HOFFMANN P, 1991, KLIN WOCHENSCHR, V69, P72; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; IKONOMIDOU C, 1989, J NEUROSCI, V9, P1693; IKONOMIDOU C, 1989, Society for Neuroscience Abstracts, V15, P767; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATO N, 1993, P NATL ACAD SCI USA, V90, P7114, DOI 10.1073/pnas.90.15.7114; KAUFMAN BA, 1994, PEDIATR ANN, V23, P18, DOI 10.3928/0090-4481-19940101-07; KLOSE R, 1982, ANAESTHESIST, V31, P33; LANGREHR D, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2269; MARSHALL BE, 1990, PHARMACOL BASIS THER, P285; MCDONALD JW, 1987, EUR J PHARMACOL, V140, P359, DOI 10.1016/0014-2999(87)90295-0; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Olney J W, 1986, Adv Neurol, V44, P857; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1971, J NEUROPATH EXP NEUR, V30, P75, DOI 10.1097/00005072-197101000-00008; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; OLNEY JW, 1989, J NEUROSCI, V9, P1701; OLNEY JW, 1972, J NEUROPATH EXP NEUR, V31, P464, DOI 10.1097/00005072-197207000-00006; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PFENNINGER E, 1984, ANAESTHESIST, V33, P82; Pfenninger E, 1985, Eur J Anaesthesiol, V2, P297; REICHER D, 1987, STROKE, V18, P445, DOI 10.1161/01.STR.18.2.445; SCHWEDLER M, 1982, CAN ANAESTH SOC J, V29, P222, DOI 10.1007/BF03007120; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; STEWART L, 1993, 2 INT NEUR S GLASG, P76; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; THORSEN T, 1980, ACTA ANAESTH SCAND, V24, P1, DOI 10.1111/j.1399-6576.1980.tb01494.x; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q	47	59	63	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	JUN	1996	39	6					1020	1027		10.1203/00006450-199606000-00015			8	Pediatrics	Pediatrics	UN555	WOS:A1996UN55500015	8725264	Bronze			2021-06-18	
J	BACK, W; SCHAMHARDT, HC; HARTMAN, W; BARNEVELD, A				BACK, W; SCHAMHARDT, HC; HARTMAN, W; BARNEVELD, A			KINEMATIC DIFFERENCES BETWEEN THE DISTAL PORTIONS OF THE FORELIMBS AND HIND LIMBS OF HORSES AT THE TROT	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							KINETICS	In literature, it has been hypothesized that the concussion at impact in the equine forelimb is larger than that in the hind limb, and therefore, eventually more clinical lameness may develop in the distal portion of the forelimbs. As the functional anatomy of the distal forelimb and hind limb segments is similar, a study was undertaken to compare the kinematics of hoof and fetlock in the forelimbs and hind limbs. For this purpose, the trot of 24 clinically normal (sound) horses on a treadmill (4 m/s) was recorded, using modem gait analysis equipment. It appeared that vertical hoof velocity at impact and the resulting vertical hoof acceleration were higher in the forelimb than in the hind limb, In contrast, horizontal hoof velocity at impact and the resulting horizontal acceleration were higher in the hind limb. Just after impact the fetlock was more rapidly extended in the forelimb than the hind limb. The peak maximal and minimal accelerations of that joint also were significantly (P < 0.05) higher in the forelimb than in the hind limb. Results of this study indicate that, at the beginning of the stance phase, the distal portion of the forelimb is subjected to more kinematic stress than the distal portion of the hind limb. The higher angular velocity of the fetlock can be interpreted as more rapid loading of this joint, whereas the higher peak accelerations represent the higher oscillatory changes in fetlock movement. It is known from literature that repetitive impulsive joint loading and rapid oscillations in joint movement, even within physiologic limits, contribute to development of osteoarthrosis. Therefore, the differences between distal forelimb and hind limb kinematics found in this study may be related to the generally known higher incidence of chronic lameness in the forelimbs.	UNIV UTRECHT,FAC VET MED,DEPT VET ANAT,3584 CM UTRECHT,NETHERLANDS	BACK, W (corresponding author), UNIV UTRECHT,FAC VET MED,DEPT GEN & LARGE ANIM SURG,YALELAAN 12,3584 CM UTRECHT,NETHERLANDS.						ANTONSSON EK, 1995, J BIOMECH, V18, P39; BACK W, 1995, EQUINE VET J, V27, P39, DOI 10.1111/j.2042-3306.1995.tb03030.x; BACK W, 1995, EQUINE VET J, V27, P31, DOI 10.1111/j.2042-3306.1995.tb03029.x; BACK W, 1994, EQUINE VET J S, V17, P3; Barrey E, 1991, EQUINE EXERC PHYSL, V1, P97; BENOIT P, 1993, ACTA ANAT, V46, P109; CAMPO LJM, 1991, VET COMP ORTHOPAED T, V4, P120; Clayton H M, 1990, Equine Vet J Suppl, P86; CLAYTON HM, 1994, EQUINE VET J, V26, P230, DOI 10.1111/j.2042-3306.1994.tb04375.x; DOW SM, 1991, EQUINE VET J, V23, P266, DOI 10.1111/j.2042-3306.1991.tb03715.x; DYHREPOULSEN P, 1994, EQUINE VET J, V26, P362, DOI 10.1111/j.2042-3306.1994.tb04404.x; FLEISS O, 1984, ARCH TIERARZTL FORTB, V8, P116; Fredricson I, 1972, Acta Vet Scand Suppl, V37, P1; HERRING L, 1992, J EQUINE VET SCI, V12, P172, DOI 10.1016/S0737-0806(06)81476-0; HJERTEN G, 1993, ACTA ANAT, V146, P193; HJERTEN G, 1994, EQUINE VET J S, V17, P48; Johnston C., 1991, EQUINE EXERCISE PHYS, V3, P167; KOBLUK CN, 1989, EQUINE VET J, V21, P48, DOI 10.1111/j.2042-3306.1989.tb02089.x; MERKENS HW, 1994, EQUINE VET J S, V17, P67; RADIN EL, 1991, J ORTHOPAED RES, V9, P398, DOI 10.1002/jor.1100090312; RIEMERSMA DJ, 1988, AM J VET RES, V49, P1344; RIEMERSMA DJ, 1988, AM J VET RES, V49, P1353; ROEPSTORFF L, 1994, EQUINE VET J S, V17, P71; Schamhardt H. C., 1991, EQUINE EXERCISE PHYS, V3, P120; Schamhardt HC, 1994, EQUINE VET J S, V17, P75, DOI DOI 10.1111/J.2042-3306.1994.TB04879.X; Snedecor G.W., 1982, STATISTICAL METHODS; Stashak T S., 1987, ADAMS LAMENESS HORSE, V76, p[88, 102]; VANOLDRUITENBOR.MM, 1995, EQUINE EXER PHYSL, V4, P413; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	29	59	59	0	12	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD, SCHAUMBURG, IL 60173-4360	0002-9645			AM J VET RES	Am. J. Vet. Res.	NOV	1995	56	11					1522	1528					7	Veterinary Sciences	Veterinary Sciences	TC132	WOS:A1995TC13200023	8585667				2021-06-18	
J	YAKOVLEV, AG; FADEN, AI				YAKOVLEV, AG; FADEN, AI			MOLECULAR STRATEGIES IN CNS INJURY	JOURNAL OF NEUROTRAUMA			English	Article						CNS TRAUMA; DIFFERENTIAL DISPLAY; IN SITU HYBRIDIZATION; NORTHERN BLOT ANALYSIS; NUCLEASE PROTECTION ASSAY; POLYMERASE CHAIN REACTION REVERSE TRANSCRIPTION; SUBTRACTIVE HYBRIDIZATION	SPINAL-CORD INJURY; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; POLYMERASE CHAIN-REACTION; EXCITATORY AMINO-ACIDS; DELAYED NEURONAL DEATH; INVIVO GENE-TRANSFER; FACTOR MESSENGER-RNA; C-FOS PROTEIN; RAT-BRAIN	Traumatic or ischemic injuries to the central nervous system (CNS) initiate reactive biochemical changes, some of which are autodestructive and others neuroprotective. Identification of these endogenous factors and their regulation will help to clarify mechanisms of secondary tissue damage and may lead to novel therapies. Recently developed molecular approaches offer opportunities for identifying genes involved in these reactive processes. Three types of molecular strategies are reviewed and examples are provided to demonstrate how each may be applied to elucidate basic mechanisms underlying posttraumatic or postischemic death.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR306634] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER		AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; BABA H, 1994, NEUROCHEM RES, V19, P1091, DOI 10.1007/BF00968721; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; BAKSHI R, 1990, J NEUROSCI, V10, P3793; BALASINGAM V, 1994, J NEUROSCI, V14, P846; BANTLE JA, 1976, CELL, V8, P739; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHAN PH, 1994, BRAIN PATHOL, V4, P59; Chikaraishi D.M., 1979, BIOCHEMISTRY-US, V18, P3250; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1993, CRITICAL REV NEUROBI, P175; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FRIEDMAN WJ, 1992, J NEUROSCI RES, V33, P37, DOI 10.1002/jnr.490330106; GESCHWIND MD, 1994, MOL BRAIN RES, V24, P327, DOI 10.1016/0169-328X(94)90146-5; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; GINZBERG D, 1994, BRAIN RES, V661, P75; GIULIAN D, 1994, NEUROBIOLOGY CNS TRA, P154; GUNN AJ, 1990, BRAIN RES, V531, P105, DOI 10.1016/0006-8993(90)90763-2; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HERRERA DG, 1989, BRAIN RES, V503, P205, DOI 10.1016/0006-8993(89)91665-X; HERRERA DG, 1990, NEUROSCIENCE, V35, P273, DOI 10.1016/0306-4522(90)90081-E; HERRICK CA, 1990, EOS-RIV IMMUNOL, V10, P166; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; HSU CY, 1994, NEUROBIOLOGY CENTRAL, P145; HUGHES P, 1993, NEUROSCIENCE, V57, P319, DOI 10.1016/0306-4522(93)90065-N; HYLDEN JLK, 1992, J NEUROSCI, V12, P1716; IMAI Y, 1994, MOL BRAIN RES, V24, P313, DOI 10.1016/0169-328X(94)90144-9; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; ISAACSON SH, 1994, CELL VIS, V1, P25; KAMII H, 1994, J CEREBR BLOOD F MET, V14, P478, DOI 10.1038/jcbfm.1994.59; KAPLAN BB, 1982, MOL APPROACHES NEURO, P71; LASALLE GL, 1993, SCIENCE, V259, P986; Lemke M, 1990, J NEUROTRAUM, V7, P41, DOI 10.1089/neu.1990.7.41; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; MILNER RJ, 1983, NUCLEIC ACIDS RES, V11, P5497, DOI 10.1093/nar/11.16.5497; NEUMANHAEFELIN T, 1994, J CEREB BLOOD FLOW M, V4, P206; NEVE RL, 1993, TRENDS NEUROSCI, V16, P251, DOI 10.1016/0166-2236(93)90174-K; NUOVO GJ, 1993, AM J SURG PATHOL, V17, P683, DOI 10.1097/00000478-199307000-00005; OUACH TT, 1993, ANN NY ACAD SCI, V679, P418; Panter S. S., 1992, PRINCIPLES PRACTICE, P32; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; RAWE SE, 1981, NEUROSURGERY, V9, P40, DOI 10.1227/00006123-198107000-00007; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; RIDOUX V, 1994, NEUROREPORT, V5, P801, DOI 10.1097/00001756-199403000-00016; ROSEN MB, 1994, TOXICOL METHOD, V4, P135, DOI 10.3109/15376519409061541; SANDLER AN, 1967, J NEUROSURG, V5, P638; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SHARP FR, 1989, NEUROSCI LETT, V100, P117, DOI 10.1016/0304-3940(89)90670-8; SHIGENO T, 1990, NEUROSCI LETT, V120, P117, DOI 10.1016/0304-3940(90)90182-9; SUN FY, 1995, IN PRESS BRAIN RES; SUTCLIFFE JG, 1988, ANNU REV NEUROSCI, V11, P157, DOI 10.1146/annurev.neuro.11.1.157; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; TORTOSA A, 1994, J NEUROL SCI, V121, P10, DOI 10.1016/0022-510X(94)90149-X; Toulmond S., 1994, Society for Neuroscience Abstracts, V20, P193; UEKI K, 1994, ANN NEUROL, V36, P670, DOI 10.1002/ana.410360421; USUI H, 1994, J NEUROSCI, V14, P4915; VINK R, 1991, AM J PHYSIOL, V261, pR1527; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WATSON JB, 1994, J NEUROSCI RES, V39, P108, DOI 10.1002/jnr.490390113; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WORLEY PF, 1990, PROG BRAIN RES, V86, P277; WU G, 1993, BIOCHEM CELL BIOL, V71, P372, DOI 10.1139/o93-055; Yakovlev A., 1994, Society for Neuroscience Abstracts, V20, P423; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; ZIVIN JA, 1976, NEUROLOGY, V26, P99, DOI 10.1212/WNL.26.2.99	83	59	59	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					767	777		10.1089/neu.1995.12.767			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600002	8594206				2021-06-18	
J	MATHIESEN, T; BENEDIKTSDOTTIR, K; JOHNSSON, H; LINDQVIST, M; VONHOLST, H				MATHIESEN, T; BENEDIKTSDOTTIR, K; JOHNSSON, H; LINDQVIST, M; VONHOLST, H			INTRACRANIAL TRAUMATIC AND NONTRAUMATIC HEMORRHAGIC COMPLICATIONS OF WARFARIN TREATMENT	ACTA NEUROLOGICA SCANDINAVICA			English	Article						BRAIN; HEMORRHAGE; ANTICOAGULATION TREATMENT; COMPLICATION	INTRACEREBRAL HEMORRHAGE; ANTICOAGULANT TREATMENT; THALAMIC HEMORRHAGE; THERAPY; POPULATION	An increased referral of patients with anticoagulation related haemorrhages necessitated an analysis of causes and outcome of these complications in a patient group that reflected Swedish therapeutic traditions of anticoagulation treatment. Prospectively, all patients from Stockholm evaluated for warfarin related intracranial haemorrhage occuring during 1987 were analysed and their 6 month outcome recorded. Sixty-eight patients were included. The results of intracranial haemorrhagic complications were catastrophic with a 77% mortality rate. Their incidence was much higher than expected. Forty-one patients had non-traumatic intracerebral haematomas, 1 had a non-traumatic subarachnoid haemorrhage and 26 had traumatic injuries, In the 42 patients with non-traumatic haemorrhages, the indications for anticoagulation were cerebral ischaemic events in a majority (27/42). The remaining 15 patients had different indications for anticoagulation. They also had an increased frequency of hypertension (p<0.05). In the 26 patients with traumatic haematomas, only 6/26 patients had previous cerebral ischaemic injuries (p<0.01). Valvular heart prothesis was their most common indication (11/26) for anticoagulation. Caution in instituting anticoagulation therapy in patients with hypertension or cerebrovascular disease, which is an important indication for anticoagulation in Sweden, is mandatory. Adherence to strict treatment regimens and their continous reevaluation may help to avoid complications. The finding of more patients than expected with haemorrhagic complications is not compatible with the risk evaluations used to justify anticoagulation therapy in the patient groups studied. Clinical practice must have changed with time, showing that risk evaluations from controlled trials or retrospectively collected clinical data from selected patients are not necessarily applicable for long-term clinical practice.	KAROLINSKA HOSP & INST,DEPT NEUROSURG,STOCKHOLM,SWEDEN; KAROLINSKA HOSP & INST,DEPT NEURORADIOL,STOCKHOLM,SWEDEN; KAROLINSKA HOSP & INST,DEPT INTERNAL MED,STOCKHOLM,SWEDEN				Mathiesen, Tiit/0000-0001-9463-1919			BARRAQUERBORDAS L, 1981, STROKE, V12, P524, DOI 10.1161/01.STR.12.4.524; BARRON KD, 1959, NEUROLOGY, V9, P447, DOI 10.1212/WNL.9.7.447; BEWERMEYER H, 1989, NERVENARZT, V60, P268; CERVIN A, 1992, LAKARTIDNINGEN, V89, P208; FISHER CM, 1971, J NEUROPATH EXP NEUR, V30, P536, DOI 10.1097/00005072-197107000-00015; FORFAR JC, 1979, BRIT HEART J, V42, P128; FORSTING M, 1991, CEREBROVASC DIS, V1, P97, DOI 10.1159/000108824; FRANKE CL, 1990, STROKE, V21, P726, DOI 10.1161/01.STR.21.5.726; FREDRIKSSON K, 1992, STROKE, V23, P972, DOI 10.1161/01.STR.23.7.972; HIER DB, 1977, ANN NEUROL, V1, P152, DOI 10.1002/ana.410010209; HIRSH J, 1989, CHEST S, V95, P5; JENNETT B, 1981, MANAGEMENT HEAD INJU, P77; KANAYA M, 1983, HYPERTENSIVE INTRACE, P147; KASE CS, 1985, NEUROLOGY, V35, P943, DOI 10.1212/WNL.35.7.943; Levine M N, 1990, Baillieres Clin Haematol, V3, P815, DOI 10.1016/S0950-3536(05)80029-0; LEVINE MN, 1986, SEMIN THROMB HEMOST, V12, P39, DOI 10.1055/s-2007-1003533; MATTLE H, 1989, J NEUROL NEUROSUR PS, V52, P829, DOI 10.1136/jnnp.52.7.829; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; ROPPER AH, 1980, ANN NEUROL, V8, P141, DOI 10.1002/ana.410080203; SNYDER M, 1977, SURG NEUROL, V7, P31; WALSHE TM, 1977, NEUROLOGY, V27, P217, DOI 10.1212/WNL.27.3.217; WEISBERG LA, 1985, J NEUROL NEUROSUR PS, V48, P1078, DOI 10.1136/jnnp.48.11.1078; WEISBERG LA, 1986, NEUROLOGY, V31, P897; WELLS CE, 1960, ARCH NEUROL-CHICAGO, V3, P553, DOI 10.1001/archneur.1960.00450050073008; WINTZEN AR, 1984, ANN NEUROL, V16, P553, DOI 10.1002/ana.410160505; WINTZEN AR, 1982, ARCH NEUROL-CHICAGO, V39, P69, DOI 10.1001/archneur.1982.00510140003001	26	59	59	0	3	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	MAR	1995	91	3					208	214					7	Clinical Neurology	Neurosciences & Neurology	QQ561	WOS:A1995QQ56100011	7793238				2021-06-18	
J	SCHALEN, W; HANSSON, L; NORDSTROM, G; NORDSTROM, CH				SCHALEN, W; HANSSON, L; NORDSTROM, G; NORDSTROM, CH			PSYCHOSOCIAL OUTCOME 5-8 YEARS AFTER SEVERE TRAUMATIC BRAIN-LESIONS AND THE IMPACT OF REHABILITATION SERVICES	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; SOCIAL-ADJUSTMENT; SELF-REPORT; AGGRESSIVE TREATMENT; RELATIVES; RECOVERY; FAMILY; MANAGEMENT; MORTALITY; PATIENT	This study addresses three questions. First, what is the long-term psychosocial outcome for severely head-injured patients? Second, is an increased survival rate associated with an increase in the number of patients with a poor quality of life? Third, do rehabilitation services affect the final outcome? The long-term outcome was assessed by means of questionnaires for self-ratings, interviews with patients and relatives and neurophysical examinations. One hundred and six patients initially judged as good recovery/moderate disability (GR/MD) 6 months post-injury participated in the study. Forty to 50% of these patients showed co-ordination disturbances; more than 20% had speech disorders and cranial nerve deficits. Twenty-eight per cent had psychiatric symptom scores on the Hopkins Symptom Checklist (HSCL) indicating need of treatment. Social function according to the Social Adjustment Scale-Self-Report (SAS-SR) showed that 40% had problems concerning interpersonal relations and 20-30% had problems within the field of leisure activities, but few problems were reported on work activities and economy. The Comprehensive Psychopathological Rating Scale (CPRS) revealed that hostile feelings, failing memory and fatiguability were common symptoms and were reported by relatives in 71%, 52% and 48%, respectively, but the mean distress levels were moderate. A correlation was seen between quality of life reported by relatives and the degree of mental and social disability according to the Bond Outcome Scale, but the correlation to neurophysical handicap was rather weak. The majority of patients were able to return to a productive social life. The proportion of patients with a poor long-term outcome did not increase after introduction of an aggressive management protocol for head injuries. Data indicated that improvements in facilities for rehabilitation may positively affect psychosocial adjustment.	UNIV LUND HOSP, DEPT NEUROSURG, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT PSYCHIAT, S-22185 LUND, SWEDEN							ASBERG M, 1978, ACTA PSYCHIAT SCAND, V271, P1; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DODWELL D, 1988, J NEUROL NEUROSUR PS, V51, P833, DOI 10.1136/jnnp.51.6.833; EISENBERG HM, 1991, J NEUROSURG, V75, pUS1; GLASS RM, 1978, ARCH GEN PSYCHIAT, V35, P1189; GOLDBERG DP, 1976, BRIT J PSYCHIAT, V129, P61, DOI 10.1192/bjp.129.1.61; Goldberg DP., 1972, DETECTION PSYCHIATRI; HANSSON L, IN PRESS PSYCHIATRIC; HESBACHER PT, 1980, J CLIN PSYCHIAT, V41, P6; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Nordstrom C H, 1989, Brain Inj, V3, P267, DOI 10.3109/02699058909029640; Nordstrom C H, 1989, Brain Inj, V3, P247, DOI 10.3109/02699058909029639; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1987, BRAIN INJURY, V2, P131; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEISSMAN MM, 1981, ARCH GEN PSYCHIAT, V38, P1250; WEISSMAN MM, 1978, J NERV MENT DIS, V166, P317, DOI 10.1097/00005053-197805000-00002; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; WEISSMAN MM, 1975, ARCH GEN PSYCHIAT, V32, P357; WINOKUR A, 1984, BRIT J PSYCHIAT, V144, P395, DOI 10.1192/bjp.144.4.395	43	59	59	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	1994	8	1					49	64		10.3109/02699059409150958			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	MQ291	WOS:A1994MQ29100006	8124317				2021-06-18	
J	GANONG, CA; KAPPY, MS				GANONG, CA; KAPPY, MS			CEREBRAL SALT WASTING IN CHILDREN - THE NEED FOR RECOGNITION AND TREATMENT	AMERICAN JOURNAL OF DISEASES OF CHILDREN			English	Article							ATRIAL-NATRIURETIC-PEPTIDE; SUBARACHNOID HEMORRHAGE; INAPPROPRIATE ANTIDIURESIS; CEREBROSPINAL-FLUID; HYPONATREMIA; HORMONE; SECRETION; HUMANS; BRAIN; PRESSURE	Objectives.-To describe a salt-wasting syndrome in children with central nervous system (CNS) insults and to differentiate it from the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and diabetes insipidus so that it may be more readily diagnosed and treated. Design.-Case reports. Setting.-Community teaching hospital. Patients.-Two inpatients with CNS insults (closed head trauma in one and seizure disorder, spastic diplegia, mental retardation, and hydrocephalus in the other). Selection Criteria.-Evidence of hyponatremia accompanied by elevated urine sodium concentration and excessive urine output. Interventions.-Volume-for-volume urine replacement with 0.9% and/or 3% sodium chloride. Oral salt supplementation was required for brief periods to maintain normal plasma sodium concentration after discharge from the hospital. Measurements and Main Results.-Both patients had hyponatremia, high urine sodium concentrations, hypovolemia, and excessive urine output while receiving maintenance fluids. They also had elevated plasma atrial natriuretic hormone (ANH) concentrations, decreased aldosterone concentrations, and increased plasma renin activity for their degree of hyponatremia and negative fluid balance. Both patients maintained normal serum electrolyte concentrations with appropriate treatment. Conclusions.-These patients showed true salt wasting associated with acute or chronic CNS injury, with hormonal patterns consistent with ''inappropriate'' ANH secretion and distinct from the SIADH. It is important to distinguish cerebral salt wasting (CSW) from the two other major disturbances of water metabolism seen following CNS injury (ie, SIADH and diabetes insipidus), because incorrect diagnosis and treatment could greatly increase morbidity in CSW. The etiologic roles of ANH or brain natriuretic peptide in CSW need to be further elucidated.		GANONG, CA (corresponding author), ST JOSEPHS HOSP,CTR CHILDRENS HLTH,DEPT PEDIAT EDUC,350 W THOMAS RD,PHOENIX,AZ 85013, USA.						ALMUFTI H, 1984, AM J MED, V77, P740, DOI 10.1016/0002-9343(84)90377-2; ANDERSON JV, 1987, CLIN SCI, V72, P305, DOI 10.1042/cs0720305; ANDREWS BT, 1986, NEUROSURGERY, V18, P469, DOI 10.1227/00006123-198604000-00015; BIOLLAZ J, 1987, KIDNEY INT, V32, P537, DOI 10.1038/ki.1987.242; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; BURRELL LM, 1991, AM J PHYSIOL, V260, pR475; COGAN E, 1988, AM J MED, V84, P409, DOI 10.1016/0002-9343(88)90260-4; COOPER WC, 1965, ARCH INTERN MED, V116, P113, DOI 10.1001/archinte.1965.03870010115014; CORT JH, 1954, LANCET, V1, P752; DILLINGHAM MA, 1986, SCIENCE, V231, P1572, DOI 10.1126/science.3006248; DOCZI T, 1988, NEUROSURGERY, V23, P16, DOI 10.1227/00006123-198807000-00003; FOX JL, 1971, J NEUROSURG, V34, P506, DOI 10.3171/jns.1971.34.4.0506; GOLBERG M, 1960, NEW ENGL J MED, V263, P1037; KAMOI K, 1990, J CLIN ENDOCR METAB, V70, P1385, DOI 10.1210/jcem-70-5-1385; KAPPY MS, 1989, CLIN RES, V37, pA193; LARAGH JH, 1985, NEW ENGL J MED, V313, P1330; LEVIN ER, 1988, J CLIN ENDOCR METAB, V66, P1080, DOI 10.1210/jcem-66-5-1080; MANGOONIAN C, 1988, J CLIN ENDOCR METAB, V67, P571; MANGOS JA, 1964, PEDIATRICS, V34, P503; MCGREGOR A, 1990, J CLIN ENDOCR METAB, V70, P1103, DOI 10.1210/jcem-70-4-1103; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; MULROW PJ, 1987, J STEROID BIOCHEM, V27, P941, DOI 10.1016/0022-4731(87)90171-3; NELSON PB, 1984, J NEUROSURG, V60, P233, DOI 10.3171/jns.1984.60.2.0233; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; OSTER JR, 1983, ARCH INTERN MED, V143, P2187, DOI 10.1001/archinte.143.11.2187; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; SAGNELLA GA, 1986, LANCET, V1, P179; SHIMODA M, 1989, ACTA NEUROCHIR, V97, P53, DOI 10.1007/BF01577740; STIDHAM G, 1987, PEDIATR RES, V21, pA207; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; Teran N, 1991, J Cardiothorac Vasc Anesth, V5, P343, DOI 10.1016/1053-0770(91)90157-O; TULASSAY T, 1987, J PEDIATR-US, V111, P329, DOI 10.1016/S0022-3476(87)80449-3; WEIDMANN P, 1986, J CLIN INVEST, V77, P734, DOI 10.1172/JCI112368; WIJDICKS EFM, 1985, ANN NEUROL, V18, P211, DOI 10.1002/ana.410180208; WIJDICKS EFM, 1985, ANN NEUROL, V17, P137, DOI 10.1002/ana.410170206; YAMAMOTO N, 1987, Neurological Surgery, V15, P1019	36	59	60	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0002-922X			AM J DIS CHILD	Am. J. Dis. Child.	FEB	1993	147	2					167	169		10.1001/archpedi.1993.02160260057022			3	Pediatrics	Pediatrics	KL363	WOS:A1993KL36300019	8427239				2021-06-18	
J	GALE, SD; BURR, RB; BIGLER, ED; BLATTER, D				GALE, SD; BURR, RB; BIGLER, ED; BLATTER, D			FORNIX DEGENERATION AND MEMORY IN TRAUMATIC BRAIN INJURY	BRAIN RESEARCH BULLETIN			English	Article						HUMAN; TRAUMATIC BRAIN INJURY; MEMORY; MAGNETIC RESONANCE IMAGING; FORNIX	CLOSED-HEAD-INJURY; ATROPHY; SIZE	Fornix-to-brain ratios (FBR) based on postinjury magnetic resonance (MR) studies were calculated on a group of 27 female traumatic brain injury (TBI) patients and 18 female medical controls by taking the widest aspect of the fornix at the level of the anterior horns and third ventricle and determining a fornix surface area. The FBR was significantly reduced in the TBI group (FBR = 0.1121) as compared to the normal control group (FBR = 0. 1766). Despite these significant FBR findings indicating prominent atrophic changes of the fornix in TBI patients, the FBR did not relate systematically to neuropsychological outcome. These findings clearly indicate fornix vulnerability in TBI and that current quantitative MR methods are sensitive enough to detect such changes. However, fornix degeneration constitutes only one of many contributing factors to the anatomic basis of TBI-induced cognitive disturbances, as fornix atrophy did not relate systematically to neuropsychological outcome.	BRIGHAM YOUNG UNIV, DEPT PSYCHOL, 1086 SWKT, PROVO, UT 84602 USA; LDS HOSP, SALT LAKE CITY, UT 84604 USA							Amaral DG, 1987, HDB PHYSL NERVOUS SY, P211; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bigler E. D., 1989, NEUROPSY NEUROPSY BE, V2, P189; BOTEZMARQUARD T, 1992, ARCH NEUROL-CHICAGO, V49, P321, DOI 10.1001/archneur.1992.00530270141032; CARPENTER MB, 1983, FHUMAN NEUROANATOMY; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DALPAN GJ, 1992, NEUROLOGY, V42, P2125, DOI 10.1212/WNL.42.11.2125; GAFFAN D, 1991, BRAIN, V114, P2611, DOI 10.1093/brain/114.6.2611; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; JESSELL TM, 1991, PRINCIPLES NEURAL SC, P258; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1964, EXAMEN CLIN PSYCHOL; Roberts M, 1970, ATLAS HUMAN BRAIN SE; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SQUIRE LR, 1987, HDB PHYSL 1, V5, P295; SYNEK V, 1976, NEUROLOGY, V26, P231, DOI 10.1212/WNL.26.3.231; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; YEO RA, 1991, J CLIN EXP NEUROPSYC, V13, P63	24	59	59	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.		1993	32	4					345	349		10.1016/0361-9230(93)90198-K			5	Neurosciences	Neurosciences & Neurology	LU134	WOS:A1993LU13400003	8221124				2021-06-18	
J	SEGALOWITZ, SJ; UNSAL, A; DYWAN, J				SEGALOWITZ, SJ; UNSAL, A; DYWAN, J			CNV EVIDENCE FOR THE DISTINCTIVENESS OF FRONTAL AND POSTERIOR NEURAL PROCESSES IN A TRAUMATIC BRAIN-INJURED POPULATION	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							PREFRONTAL CORTEX; DELAYED-RESPONSE; MEMORY; LESIONS; NEURONS; MONKEYS; LOBES	The association between certain behavioral tests of executive functions in humans and the integrity of the prefrontal lobes has rested primarily on studies comparing subjects with frontal versus other loci of damage. Another approach is to compare the within-group variation on a physiological index of frontal functioning with the behavioral tests of interest. ln the present study, subjects with traumatic brain injury (TBI) were given four behavioural measures of executive function, two measures of posterior nonexecutive function, and a Contingent Negative Variation (CNV) task, a proposed electrophysiological index of frontal-lobe functioning. We found that three of the four executive function tests were significantly related to the CNV, accounting for 23-52% of the variance, while the CNV did not correlate at all with the posterior tasks.		SEGALOWITZ, SJ (corresponding author), BROCK UNIV, DEPT PSYCHOL, ST CATHARINES L2S 3A1, ONTARIO, CANADA.						ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; DIPELLEGRINO G, 1991, BRAIN, V114, P951; DREWE E A, 1974, Cortex, V10, P159; DYWAN J, 1990, BRAIN COGNITION, V39, P600; DYWAN JA, 1987, J CLIN EXP NEUROPSYC, V9, P270; FANTI B, 1991, IN PRESS NEUROPSYCHO; Fuster J, 1989, PREFRONTAL CORTEX; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61; FUSTER JM, 1973, BRAIN RES, V61, P79, DOI 10.1016/0006-8993(73)90517-9; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.1111/j.1467-8624.1987.tb01404.x; GROLLKNAPP E, 1980, ELECTROEN CLIN NEURO, P746; HAMSHER KD, 1979, ARCH NEUROL-CHICAGO, V36, P837, DOI 10.1001/archneur.1979.00500490051008; Heaton R. K, 1981, WISCONSIN CARD SORTI; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KOJIMA S, 1984, BRAIN RES, V291, P229, DOI 10.1016/0006-8993(84)91255-1; KOJIMA S, 1982, BRAIN RES, V248, P43, DOI 10.1016/0006-8993(82)91145-3; LEVIN HS, 1982, NEUROBEHAVIOURAL CON, P3; LOVELESS NE, 1976, ELECTROENCEPHALOGR S, V33, P19; Lutzenberger W, 1980, Prog Brain Res, V54, P427, DOI 10.1016/S0079-6123(08)61655-6; MARKOWITSCH HJ, 1977, PSYCHOL BULL, V84, P817, DOI 10.1037/0033-2909.84.5.817; McCallum WC., 1988, HDB ELECTROENCEPHALO, V3, P427; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; MISHKIN M, 1964, FRONTAL GRANULAR COR, P219; MITTENBERG W, 1989, J CLIN EXP NEUROPSYC, V11, P918, DOI 10.1080/01688638908400945; OLBRICH HM, 1986, FORTSCHR NEUROL PSYC, V54, P182, DOI 10.1055/s-2007-1001863; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Rebert CS, 1973, ELECTROENCEPHALOGR S, VS33, P173; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RITTER W, 1980, PSYCHOPHYSIOLOGY, V17, P222, DOI 10.1111/j.1469-8986.1980.tb00138.x; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RUCHKIN DS, 1986, ELECTROEN CLIN NEURO, V63, P445, DOI 10.1016/0013-4694(86)90127-6; SEGALOWITZ SJ, 1990, BRAIN COGNITION, V39, P601; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; STUSS DT, 1982, J COMP PHYSIOL PSYCH, V96, P913, DOI 10.1037/0735-7036.96.6.913; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1981, BIOL PSYCHIAT, V16, P1085; STUSS DT, IN PRESS J NEUROPSYC; TECCE JJ, 1972, PSYCHOL BULL, V77, P73, DOI 10.1037/h0032177; TECCE JJ, 1978, HUMAN EVOKED POTENTI, P475; WALTER WG, 1964, NATURE, V203, P380, DOI 10.1038/203380a0; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1974, WECHSLER ADULT INTEL; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WIEGERSMA S, 1990, NEUROPSYCHOLOGIA, V28, P95, DOI 10.1016/0028-3932(90)90089-7; WOHLBERG GW, 1973, ARCH GEN PSYCHIAT, V28, P533; YAMAMOTO T, 1986, BRAIN WAVES EEG, V14, P103	54	59	60	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	1992	14	4					545	565		10.1080/01688639208402844			21	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	JK552	WOS:A1992JK55200009	1400918				2021-06-18	
J	RUGG, MD; COWAN, CP; NAGY, ME; MILNER, AD; JACOBSON, I; BROOKS, DN				RUGG, MD; COWAN, CP; NAGY, ME; MILNER, AD; JACOBSON, I; BROOKS, DN			EVENT RELATED POTENTIALS FROM CLOSED HEAD-INJURY PATIENTS IN AN AUDITORY ODDBALL TASK - EVIDENCE OF DYSFUNCTION IN STIMULUS CATEGORIZATION	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV GLASGOW,DEPT PSYCHOL MED,GLASGOW G12 8QQ,SCOTLAND; DUNDEE ROYAL INFIRM,DEPT SURG NEUROL,DUNDEE,SCOTLAND	RUGG, MD (corresponding author), UNIV ST ANDREWS,DEPT PSYCHOL,MRC,COGNIT NEUROSCI RES GRP,ST ANDREWS KY16 9JU,FIFE,SCOTLAND.						BRECHER M, 1987, ELECTROEN CLIN NEURO, V66, P369; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; CURRY SH, 1983, THESIS U BRISTOL; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; Donchin E., 1978, EVENT RELATED BRAIN, P349; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FERGUSON GA, 1981, STATISTICAL ANAL PSY; FITZGERALD PG, 1983, BIOL PSYCHOL, V17, P241, DOI 10.1016/0301-0511(83)90003-0; Gronwall DM, 1974, PSYCHOL EFFECTS CONS; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; KESELMAN HJ, 1980, PSYCHOPHYSIOLOGY, V17, P499, DOI 10.1111/j.1469-8986.1980.tb00190.x; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1127, DOI 10.1136/jnnp.38.11.1127; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; MCCLELLAND JL, 1979, PSYCHOL REV, V86, P287, DOI 10.1037/0033-295X.86.4.287; NAATANEN R, 1975, BIOL PSYCHOL, V2, P237, DOI 10.1016/0301-0511(75)90038-1; NAATANEN R, 1986, CEREBRAL PSYCHOPHYSI, P169; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; RITTER W, 1983, PSYCHOPHYSIOLOGY, V20, P168, DOI 10.1111/j.1469-8986.1983.tb03283.x; STEPHENSON WA, 1951, ELECTROEN CLIN NEURO, V3, P237, DOI 10.1016/0013-4694(51)90017-X; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V14, P64	29	59	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	1988	51	5					691	698		10.1136/jnnp.51.5.691			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	N5140	WOS:A1988N514000017	3404166	Green Published, Bronze			2021-06-18	
J	Shahim, P; Tegner, Y; Marklund, N; Blennow, K; Zetterberg, H				Shahim, Pashtun; Tegner, Yelverton; Marklund, Niklas; Blennow, Kaj; Zetterberg, Henrik			Neurofilament light and tau as blood biomarkers for sports-related concussion	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NEUROCHEMICAL AFTERMATH; POSTCONCUSSION SYNDROME; MILITARY PERSONNEL; DAMAGE; PLAYERS; PROTEIN; CHAIN	Objective To compare neurofilament light (NfL) and tau as blood-based biomarkers for acute sports-related concussion (SRC) and determine whether their concentrations at different time points after the injury are associated with prolonged time to return to play (RTP). Methods A total of 288 professional hockey players were followed longitudinally from September 1, 2012, to April 30, 2015. Data collection and biomarker analyses were conducted between 2015 and 2017. Associations were tested between blood concentrations of NfL and tau, and RTP time. Serum concentrations of S100B and neuron-specific enolase (NSE) were also measured for comparison. Results Of 288 players, 105 sustained an SRC. Of these, 87 underwent blood sampling 1, 12, 36, and 144 hours after SRC and at the RTP time point. Serum NfL concentrations 1, 12, 36, and 144 hours after SRC were related to prolonged RTP time, and could separate players with RTP >10 days from those with RTP <= 10 days (area under the receiver operating characteristic curve [AUROC] 0.82). Also, serum NfL 144 hours after SRC discriminated players who resigned from the game due to persistent postconcussion symptoms (PCS) from those who returned to play (AUROC 0.89). Plasma tau 1 hour after SRC was related to RTP but less strongly than NfL, while S100B and NSE showed no such associations. Conclusion Serum NfL outperformed tau, S100B, and NSE as a biomarker for SRC. From a clinical standpoint, serum NfL may be useful to identify individuals at risk of prolonged PCS, and may aid in biomarker-informed decisions with regard to when RTP should be considered.	[Shahim, Pashtun; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden; [Shahim, Pashtun; Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Neurochem Lab, Molndal, Sweden; [Shahim, Pashtun] Lulea Univ Technol, Dept Hlth Sci, Div Med Sci, Lulea, Sweden; [Tegner, Yelverton] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden; [Marklund, Niklas] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England; [Zetterberg, Henrik] UK Dementia Res Inst, London, England	Shahim, P (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden.; Shahim, P (corresponding author), Sahlgrens Univ Hosp, Neurochem Lab, Molndal, Sweden.; Shahim, P (corresponding author), Lulea Univ Technol, Dept Hlth Sci, Div Med Sci, Lulea, Sweden.	pashtun.shahim@gu.se		Tegner, Yelverton/0000-0003-3628-0705	Swedish Research CouncilSwedish Research CouncilEuropean Commission; European Research CouncilEuropean Research Council (ERC)European Commission; Centrum for Idrottsforskning; Torsten Soderberg Foundation; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; VINNOVAVinnova; Frimurarestiftelsen	The study was supported by grants from the Swedish Research Council, the European Research Council, Centrum for Idrottsforskning, the Torsten Soderberg Foundation, the Knut and Alice Wallenberg Foundation, VINNOVA, and Frimurarestiftelsen. The funding source had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Alosco Michael L, 2017, Alzheimers Dement (Amst), V7, P33, DOI 10.1016/j.dadm.2016.11.003; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; Gill J, 2017, NEUROLOGY, V88, P595, DOI 10.1212/WNL.0000000000003587; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Rojas JC, 2016, ANN CLIN TRANSL NEUR, V3, P216, DOI 10.1002/acn3.290; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2017, NEUROLOGY, V88, P1400, DOI 10.1212/WNL.0000000000003816; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wiley CA, 2015, NEUROPATHOLOGY, V35, P95, DOI 10.1111/neup.12158; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	30	58	58	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 15	2018	90	20					E1780	E1788		10.1212/WNL.0000000000005518			9	Clinical Neurology	Neurosciences & Neurology	GN6CO	WOS:000439159900006	29653990	Green Published, Other Gold			2021-06-18	
J	Rizzo, A; Koenig, ST				Rizzo, Albert Skip; Koenig, Sebastian Thomas			Is Clinical Virtual Reality Ready for Primetime?	NEUROPSYCHOLOGY			English	Article						clinical virtual reality; psychology; rehabilitation; neuropsychology	POSTTRAUMATIC-STRESS-DISORDER; COMPUTERIZED COGNITIVE REHABILITATION; PUBLIC-SPEAKING ANXIETY; TRAUMATIC BRAIN-INJURY; MORRIS WATER TASK; EXPOSURE THERAPY; BEHAVIOR THERAPY; GRADED EXPOSURE; SERIOUS GAMES; MOTOR CONTROL	Objective: Since the mid-1990s, a significant scientific literature has evolved regarding the outcomes from the use of what we now refer to as clinical virtual reality (VR). This use of VR simulation technology has produced encouraging results when applied to address cognitive, psychological, motor, and functional impairments across a wide range of clinical health conditions. This article addresses the question, "Is clinical VR ready for primetime?" Method: After a brief description of the various forms of VR technology, we discuss the trajectory of clinical VR over the last 20 years and summarize the basic assets that VR offers for creating clinical applications. The discussion then addresses the question of readiness in terms of the theoretical basis for clinical VR assets, the research to date, the pragmatic factors regarding availability, usability, and costs of clinical VR content/systems, and the ethical issues for the safe use of VR with clinical populations. Results: Our review of the theoretical underpinnings and research findings to date leads to the prediction that clinical VR will have a significant impact on future research and practice. Pragmatic issues that can influence adoption across many areas of psychology also appear favorable, but professional guidelines will be needed to promote its safe and ethical use. Conclusions: Although there is still much research needed to advance the science in this area, we strongly believe that clinical VR applications will become indispensable tools in the toolbox of psychological researchers and practitioners and will only grow in relevance and popularity in the future. General Scientific Summary Virtual reality (VR) technology offers new opportunities for clinical research, assessment, and intervention. Advances in the underlying VR-enabling technologies and methods can now support the creation of low-cost, yet sophisticated, immersive and interactive VR systems, capable of running on consumer-level computing devices. It is predicted that the clinical use of VR will have a significant impact on mental health care in areas where the research demonstrates added value.	[Rizzo, Albert Skip] Univ Southern Calif, Inst Creat Technol, Med Virtual Real Lab, 12015 East Waterfront Dr, Playa Vista, CA 90094 USA; [Koenig, Sebastian Thomas] Katana Simulat Pty Ltd, Human Interface Technol Engineer, Adelaide, SA, Australia	Rizzo, A (corresponding author), Univ Southern Calif, Inst Creat Technol, Med Virtual Real Lab, 12015 East Waterfront Dr, Playa Vista, CA 90094 USA.	rizzo@ict.usc.edu					Adamovich SV, 2009, NEUROREHABILITATION, V25, P29, DOI 10.3233/NRE-2009-0497; Akinwuntan AE, 2012, J STROKE CEREBROVASC, V21, P478, DOI 10.1016/j.jstrokecerebrovasdis.2010.12.001; Albright Glenn, 2016, Mhealth, V2, P44, DOI 10.21037/mhealth.2016.11.02; American Psychological Association, 2003, ETH PRINC PSYCH COD; Anderson PL, 2005, DEPRESS ANXIETY, V22, P156, DOI 10.1002/da.20090; Andrade LH, 2014, PSYCHOL MED, V44, P1303, DOI 10.1017/S0033291713001943; Astur RS, 2006, CYBERPSYCHOL BEHAV, V9, P234, DOI 10.1089/cpb.2006.9.234; Astur RS, 2004, BEHAV BRAIN RES, V151, P103, DOI 10.1016/j.bbr.2003.08.024; Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; Aukstakalnis, 1992, SILICON MIRAGE ART S; Bailenson JN, 2006, COMP SUPP COMP W SER, V34, P1; Banos RM, 2011, INT J HUM-COMPUT ST, V69, P602, DOI 10.1016/j.ijhcs.2011.06.002; Banos RM, 2009, BRIT J GUID COUNS, V37, P347, DOI 10.1080/03069880902957064; Baranowski T, 2016, GAMES HEALTH J, V5, P1, DOI 10.1089/g4h.2015.0026; Barrett J., 2002, ACCESSIBLE INTERFACE; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck JG, 2007, BEHAV THER, V38, P39, DOI 10.1016/j.beth.2006.04.001; Beidel DC, 2017, J ANXIETY DISORD, V50, P23, DOI 10.1016/j.janxdis.2017.05.001; Bermudez i Badia S., 2016, NEUROREHABILITATION, P573, DOI [10.1007/978-3-319-28603-7_28, DOI 10.1007/978-3-319-28603-7_28]; Bickmore TW, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5239; Blascovich J, 2002, PSYCHOL INQ, V13, P103, DOI 10.1207/S15327965PLI1302_01; Blume F, 2017, TRIALS, V18, DOI 10.1186/s13063-016-1769-3; Bogdanova Y, 2016, J HEAD TRAUMA REHAB, V31, P419, DOI 10.1097/HTR.0000000000000203; Bohil CJ, 2011, NAT REV NEUROSCI, V12, P752, DOI 10.1038/nrn3122; Bordnick PS, 2013, RES SOCIAL WORK PRAC, V23, P419, DOI 10.1177/1049731513482377; Botella C, 2015, NEUROPSYCH DIS TREAT, V11, P2533, DOI 10.2147/NDT.S89542; Bouchard S, 2017, BRIT J PSYCHIAT, V210, P276, DOI 10.1192/bjp.bp.116.184234; Bresnahan T., 2016, 2016 P INT C DIS VIR; Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; BROWN DJ, 1998, P 2 EUR C DIS VIRT R, P11; Bryanton C, 2006, CYBERPSYCHOL BEHAV, V9, P123, DOI 10.1089/cpb.2006.9.123; Burgers C, 2015, COMPUT HUM BEHAV, V48, P94, DOI 10.1016/j.chb.2015.01.038; Carlbring P, 2001, BEHAV THER, V32, P751, DOI 10.1016/S0005-7894(01)80019-8; Casutt G, 2014, TRANSPORT RES F-TRAF, V22, P232, DOI 10.1016/j.trf.2013.12.007; Chirico A, 2016, J CELL PHYSIOL, V231, P275, DOI 10.1002/jcp.25117; Chou YH, 2012, VIRTUAL REALITY IN PSYCHOLOGICAL, MEDICAL AND PEDAGOGICAL APPLICATIONS, P203, DOI 10.5772/48445; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Clement S, 2015, PSYCHOL MED, V45, P11, DOI 10.1017/S0033291714000129; CONNOR B, 2002, P 4 INT C DIS VIRT R, P77; Costanzo ME, 2014, PSYCHOSOM MED, V76, P670, DOI 10.1097/PSY.0000000000000109; COSTAS R, 2000, P 3 INT C DIS VIRT R, P305; Cox SM, 2016, J AUTISM DEV DISORD, V46, P1379, DOI 10.1007/s10803-015-2677-1; CROMBY J, 1996, P 1 EUR C DIS VIRT R, P305; Cruz-Neira C., 1993, Computer Graphics Proceedings, P135; Csikszentmihalyi M., 1990, FLOW PSYCHOL OPTIMAL; Cuijpers P, 2008, J BEHAV MED, V31, P169, DOI 10.1007/s10865-007-9144-1; Darejeh Ali, 2013, Journal of Computer Science, V9, P1443, DOI 10.3844/jcssp.2013.1443.1450; Dascal Julieta, 2017, Innov Clin Neurosci, V14, P14; DAVIES RC, 1998, P 2 EUR C DIS VIRT R, P61; Davis E. S., 2000, 8 ANN MED MEETS VIRT; De Vaus D.P., 2015, AAAI SPRING S TURN T, P2, DOI 10.5172/jfs.2011.17.2.126; DeFanti TA, 2011, OPEN ENG, V1, P16, DOI 10.2478/s13531-010-0002-5; Deutsch JE, 2001, PRESENCE-VIRTUAL AUG, V10, P416, DOI 10.1162/1054746011470262; Deutsch JE, 2017, PEDIATR PHYS THER, V29, pS23, DOI 10.1097/PEP.0000000000000387; Difede J, 2007, J CLIN PSYCHIAT, V68, P1639, DOI 10.4088/JCP.v68n1102; Difede J, 2014, NEUROPSYCHOPHARMACOL, V39, P1052, DOI 10.1038/npp.2013.317; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Falconer CJ, 2016, BJPSYCH OPEN, V2, P74, DOI 10.1192/bjpo.bp.115.002147; Faria AL, 2016, J NEUROENG REHABIL, V13, DOI 10.1186/s12984-016-0204-z; Fish JE, 2015, NEUROPSYCHOL REHABIL, V25, P159, DOI 10.1080/09602011.2014.921204; Fleming Theresa M, 2016, Front Psychiatry, V7, P215, DOI 10.3389/fpsyt.2016.00215; Folley BS, 2010, NEUROIMAGE, V49, P3373, DOI 10.1016/j.neuroimage.2009.11.034; Foloppe DA, 2018, NEUROPSYCHOL REHABIL, V28, P709, DOI 10.1080/09602011.2015.1094394; Freeman D, 2017, PSYCHOL MED, V47, P2393, DOI 10.1017/S003329171700040X; Freeman D, 2016, BRIT J PSYCHIAT, V209, P62, DOI 10.1192/bjp.bp.115.176438; Gamito P, 2016, METHOD INFORM MED, V55, P93, DOI 10.3414/ME14-02-0021; Gamito P, 2017, DISABIL REHABIL, V39, P385, DOI 10.3109/09638288.2014.934925; Gartner Inc., 2016, HYP CYCL EM TECHN 20; Gold JI, 2006, CYBERPSYCHOL BEHAV, V9, P207, DOI 10.1089/cpb.2006.9.207; Goldman Sachs, 2016, VIRT AUGM REAL NEXT; Goldman-Sachs, 2006, VIRT AUGM REAL UND R; Granic I, 2014, AM PSYCHOL, V69, P66, DOI 10.1037/a0034857; Gratch J, 2002, IEEE INTELL SYST, V17, P54, DOI 10.1109/MIS.2002.1024753; Harrison A, 2002, DISABIL REHABIL, V24, P599, DOI 10.1080/09638280110111360; Hoffman HG, 2006, CNS SPECTRUMS, V11, P45, DOI 10.1017/S1092852900024202; Hoffman HG, 2011, ANN BEHAV MED, V41, P183, DOI 10.1007/s12160-010-9248-7; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; Howard MC, 2017, COMPUT HUM BEHAV, V70, P317, DOI 10.1016/j.chb.2017.01.013; Hypergrid Business, 2016, 5 VR APPS HELP YOU B; Innes M., 2017, INPSYCH, V39; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Jacobs WJ, 1997, LEARN MOTIV, V28, P521, DOI 10.1006/lmot.1997.0977; Jaffe DL, 2004, J REHABIL RES DEV, V41, P283, DOI 10.1682/JRRD.2004.03.0283; Jentsch F., 2017, SIMULATION AVIATION; Jin WN, 2016, STUD HEALTH TECHNOL, V220, P154, DOI 10.3233/978-1-61499-625-5-154; John N. W., 2017, IEEE T VISUALIZATION; Johnston R., 1995, VIRTUAL REALITY SPEC, V2, P53; Josman N, 2008, INT J DISABIL HUM DE, V7, P49; Josman N, 2014, J STROKE CEREBROVASC, V23, P879, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.013; Kaplan AY, 2013, IEEE T COMP INTEL AI, V5, P141, DOI 10.1109/TCIAIG.2012.2237517; Kato PM, 2010, REV GEN PSYCHOL, V14, P113, DOI 10.1037/a0019441; Keefe RSE, 2016, SCHIZOPHR RES, V175, P90, DOI 10.1016/j.schres.2016.03.038; Klamroth-Marganska V, 2014, LANCET NEUROL, V13, P159, DOI 10.1016/S1474-4422(13)70305-3; Klinger E., 2005, CYB 2005 BAS SWITZ; Kober SE, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-17; Koenig S. T., 2012, THESIS; Koenig S. T., 2010, P INT C SER DIS VIRT; Koenig S. T., 2012, P 9 INT C DIS VIRT R; Krch D., 2013, P INT C VIRT REH PHI; KRUEGER MW, 1993, PRESENCE-TELEOP VIRT, V2, P162, DOI DOI 10.1162/PRES.1993.2.2.162; LAMSON R, 1994, CYBEREDGE J, V4, P6; Lange B, 2009, PHYS THER REV, V14, P355, DOI 10.1179/108331909X12488667117258; Lange B, 2012, DISABIL REHABIL, V34, P1863, DOI 10.3109/09638288.2012.670029; Lange B, 2010, TOP STROKE REHABIL, V17, P345, DOI 10.1310/tsr1705-345; Lanyi CS, 2012, ACTA POLYTECH HUNG, V9, P225; Larson EB, 2014, NEUROREHABILITATION, V34, P759, DOI 10.3233/NRE-141078; Laviola JJ, 2017, 3D USER INTERFACES T; Levin MF, 2015, PHYS THER, V95, P415, DOI 10.2522/ptj.20130579; Levy CE, 2015, AM J PHYS MED REHAB, V94, pE31, DOI 10.1097/PHM.0000000000000248; Liu L, 1999, Cyberpsychol Behav, V2, P53, DOI 10.1089/cpb.1999.2.53; Long CJ., 1996, ECOLOGICAL VALIDITY; Lucas GM, 2014, COMPUT HUM BEHAV, V37, P94, DOI 10.1016/j.chb.2014.04.043; Lumbreras M., 2000, P 3 INT C DIS VIRT R, P129; Madary M, 2016, FRONTIERS ROBOTICS A; Man DWK, 2018, NEUROPSYCHOL REHABIL, V28, P1197, DOI 10.1080/09602011.2016.1251949; Maples-Keller JL, 2017, HARVARD REV PSYCHIAT, V25, P103, DOI 10.1097/HRP.0000000000000138; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; McCall C, 2009, SOC INFLUENCE, V4, P138, DOI 10.1080/15534510802517418; McComas J, 2002, CYBERPSYCHOL BEHAV, V5, P185, DOI 10.1089/109493102760147150; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Merians A. S., 2010, P 2010 INT C DIS VIR, P213; Merians AS, 2002, PHYS THER, V82, P898, DOI 10.1093/ptj/82.9.898; Millan J. R., 2010, FRONTIERS NEUROSCIEN; MindMaze, 2017, MINDMAZE MINDMOTION; Morbini F, 2014, NATURAL INTERACTION, P313; Morina N, 2015, BEHAV RES THER, V74, P18, DOI 10.1016/j.brat.2015.08.010; Morrison J. E., 1999, 42 US ARM RES I BEH; Morrongiello BA, 2015, J PEDIATR PSYCHOL, V40, P697, DOI 10.1093/jpepsy/jsv019; Mosadeghi S, 2016, JMIR MENT HEALTH, V3, DOI 10.2196/mental.5801; MOWAFY L, 1995, ABILITY, V15, P18; Muhlberger A., 2016, J ATTENTION DISORDER; Navarro MD, 2013, NEUROPSYCHOL REHABIL, V23, P597, DOI 10.1080/09602011.2013.806269; Naveh Y., 2000, P 3 INT C DIS VIRT R, P243; Neisser U., 1978, PRACTICAL ASPECTS ME, P3; Neri S. G. R., 2017, CLIN REHABILITATION; Nir-Hadad S. Y., 2015, NEUROPSYCHOL REHABIL, V27, P808; Norcross JC, 2013, PROF PSYCHOL-RES PR, V44, P363, DOI 10.1037/a0034633; Norrholm SD, 2016, BEHAV RES THER, V82, P28, DOI 10.1016/j.brat.2016.05.002; Ogourtsova T., 2015, NEUROPSYCHOL REHABIL, V27, P409, DOI DOI 10.1080/09602; Opris D, 2012, DEPRESS ANXIETY, V29, P85, DOI 10.1002/da.20910; Padgett LS, 2006, J PEDIATR PSYCHOL, V31, P65, DOI 10.1093/jpepsy/jsj030; Papastergiou M, 2009, COMPUT EDUC, V53, P603, DOI 10.1016/j.compedu.2009.04.001; Park S, 2013, INT CONF AFFECT, P423, DOI 10.1109/ACII.2013.76; Parsons S., 2012, 1 INT C INN TECHN AU; Parsons TD, 2008, J BEHAV THER EXP PSY, V39, P250, DOI 10.1016/j.jbtep.2007.07.007; Parsons TD, 2008, CYBERPSYCHOL BEHAV, V11, P17, DOI 10.1089/cpb.2007.9934; Parsons TD, 2017, NEUROPSYCHOL REHABIL, V27, P777, DOI 10.1080/09602011.2015.1109524; Parsons TD, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00660; Parsons TD, 2009, DEV NEUROREHABIL, V12, P224, DOI 10.1080/17518420902991719; Passig D, 2016, COMPUT EDUC, V95, P296, DOI 10.1016/j.compedu.2016.01.009; Pertaub DP, 2002, PRESENCE-TELEOP VIRT, V11, P68, DOI 10.1162/105474602317343668; Pietrzak E, 2014, GAMES HEALTH J, V3, P202, DOI 10.1089/g4h.2014.0013; Piron L, 2002, STUD HEALTH TECHNOL, V85, P355; Powers MB, 2008, J ANXIETY DISORD, V22, P561, DOI 10.1016/j.janxdis.2007.04.006; Proffitt R, 2015, INT J TELEREHABILITA, V7, P23, DOI 10.5195/ijt.2015.6177; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Putrino D, 2014, CURR OPIN NEUROL, V27, P631, DOI 10.1097/WCO.0000000000000152; Regenbrecht H, 2014, P IEEE, V102, P170, DOI 10.1109/JPROC.2013.2294178; Remsik A, 2016, EXPERT REV MED DEVIC, V13, P445, DOI 10.1080/17434440.2016.1174572; Riva Giuseppe, 2011, J Diabetes Sci Technol, V5, P283; Rizzo A., 2016, DIGITAL PATIENT ADV, P257; Rizzo A. A., 2011, INT J VIRTUAL REALIT, V8; Rizzo A. A., 2016, 2016 P INT C DIS VIR, P57; Rizzo AA, 2006, CNS SPECTRUMS, V11, P35, DOI 10.1017/S1092852900024196; Rizzo AA, 2004, TELEMED J E-HEALTH, V10, P184, DOI 10.1089/1530562041641336; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; RIZZO AA, 1994, P 2 INT C VIRT REAL; Rizzo A, 2015, J CONTEMP PSYCHOTHER, V45, P255, DOI 10.1007/s10879-015-9306-3; Rizzo A, 2016, ARTIFICIAL INTELLIGENCE IN BEHAVIORAL AND MENTAL HEALTH CARE, P53, DOI 10.1016/B978-0-12-420248-1.00003-9; Rizzo A, 2010, ANN NY ACAD SCI, V1208, P114, DOI 10.1111/j.1749-6632.2010.05755.x; Rizzo A, 2013, PSYCHIAT ANN, V43, P123, DOI 10.3928/00485713-20130306-08; Rizzo AS, 2002, STUD NEUROPSYCHOL DE, P243; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Rose FD, 2001, PRESENCE-VIRTUAL AUG, V10, P345, DOI 10.1162/1054746011470208; Rosenthal DSH, 2000, USENIX ASSOCIATION PROCEEDINGS OF THE FREENIX TRACK, P129; Rothbaum BO, 2014, AM J PSYCHIAT, V171, P640, DOI 10.1176/appi.ajp.2014.13121625; Rothbaum BO, 2001, J CLIN PSYCHIAT, V62, P617, DOI 10.4088/JCP.v62n0808; Rothbaum BO, 1999, BEHAV MODIF, V23, P507, DOI 10.1177/0145445599234001; ROTHBAUM BO, 1995, BEHAV THER, V26, P547, DOI 10.1016/S0005-7894(05)80100-5; Roy MJ, 2014, STUD HEALTH TECHNOL, V199, P61, DOI 10.3233/978-1-61499-401-5-61; Roy MJ, 2010, ANN NY ACAD SCI, V1208, P142, DOI 10.1111/j.1749-6632.2010.05689.x; Rutten A, 2003, J VISUAL COMP ANIMAT, V14, P233, DOI 10.1002/vis.320; Schell J., 2014, ART GAME DESIGN BOOK; Scherer S, 2014, IMAGE VISION COMPUT, V32, P648, DOI 10.1016/j.imavis.2014.06.001; Schneider SM, 2011, SUPPORT CARE CANCER, V19, P555, DOI 10.1007/s00520-010-0852-7; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; Schwebel DC, 2014, HEALTH PSYCHOL, V33, P628, DOI 10.1037/hea0000032; Shipman SL, 2008, BEHAV BRAIN RES, V187, P433, DOI 10.1016/j.bbr.2007.10.014; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Slater M., 2016, FRONTIERS ROBOTI DEC; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spek V, 2007, PSYCHOL MED, V37, P319, DOI 10.1017/S0033291706008944; Stamm BH, 1998, PROF PSYCHOL-RES PR, V29, P536, DOI 10.1037/0735-7028.29.6.536; Standen P, 2015, PHYS THER, V95, P350, DOI 10.2522/ptj.20130564; Stanton D, 1998, ST HEAL T, V58, P219; STRICKLAND D, 2001, ACM SIGGRAPH 2001 C; Talbot TB, 2012, INT J GAMING COMPUT-, V4, P1, DOI 10.4018/jgcms.2012070101; Tarr MJ, 2002, NAT NEUROSCI, V5, P1089, DOI 10.1038/nn948; TART CT, 1993, CULTIVATING CONSCIOUSNESS, P123; Tashjian VC, 2017, JMIR MENT HEALTH, V4, DOI 10.2196/mental.7387; Tegos S, 2016, INT J COMP-SUPP COLL, V11, P417, DOI 10.1007/s11412-016-9246-2; Thagard P., 2004, COGNITIVE SYSTEMS RE, V5, P269, DOI DOI 10.1016/J.C0GSYS.2004.02.002; Thiebaux M., 2008, P 7 INT JOINT C AUT, P151; Trost Z, 2015, PAIN MANAG, V5, P197, DOI [10.2217/PMT.15.6, 10.2217/pmt.15.6]; Valladares-Rodriguez S, 2016, J BIOMED INFORM, V64, P296, DOI 10.1016/j.jbi.2016.10.019; Valve Corporation, 2017, STEAM; Virtual Reality Society, 2017, APPL VIRT REAL; Wall K. J., 2017, DISABILITY REHABILIT; Wiederhold B.K., 1998, CYBERPSYCHOLOGY BEHA, V1, P45, DOI DOI 10.1089/CPB.1998.1.45; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Wilson JAB, 2008, CYBERPSYCHOL BEHAV, V11, P767, DOI 10.1089/cpb.2008.0071; Yang YJD, 2017, BEHAV RES THER, V93, P55, DOI 10.1016/j.brat.2017.03.014; Yellowlees PM, 2012, TELEMED E-HEALTH, V18, P558, DOI 10.1089/tmj.2011.0195; You SH, 2005, STROKE, V36, P1166, DOI 10.1161/01.STR.0000162715.43417.91; Zhang Z, 2017, PATIENT EDUC COUNS, V100, P1730, DOI 10.1016/j.pec.2017.03.017	223	58	58	1	50	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	NOV	2017	31	8			SI		877	899		10.1037/neu0000405			23	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	FT6JH	WOS:000423259900004	29376669				2021-06-18	
J	Davis, GA; Purcell, L; Schneider, KJ; Yeates, KO; Gioia, GA; Anderson, V; Ellenbogen, RG; Echemendia, RJ; Makdissi, M; Sills, A; Iverson, GL; Dvorak, J; McCrory, P; Meeuwisse, W; Patricios, J; Giza, CC; Kutcher, JS				Davis, Gavin A.; Purcell, Laura; Schneider, Kathryn J.; Yeates, Keith Owen; Gioia, Gerard A.; Anderson, Vicki; Ellenbogen, Richard G.; Echemendia, Ruben J.; Makdissi, Michael; Sills, Allen; Iverson, Grant L.; Dvorak, Jiri; McCrory, Paul; Meeuwisse, Willem; Patricios, Jon; Giza, Christopher C.; Kutcher, Jeffrey S.			The Child Sport Concussion Assessment Tool 5th Edition (Child SCAT5): Background and rationale	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; ZURICH	This article presents the Child Sport Concussion Assessment Tool 5th Edition (Child SCAT5). The Sport Concussion Assessment Tool was introduced in 2004, following the 2nd International Conference on Concussion in Sport in Prague, Czech Republic. Following the 4th International Consensus Conference, held in Zurich, Switzerland, in 2012, the SCAT 3rd edition (Child SCAT3) was developed for children aged between 5 and12 years. Research to date was reviewed and synthesised for the 5th International Consensus Conference on Concussion in Sport in Berlin, Germany, leading to the current revision of the test, the Child SCAT5. This article describes the development of the Child SCAT5.	[Davis, Gavin A.; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Davis, Gavin A.; Makdissi, Michael; McCrory, Paul] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Heidelberg, Vic, Australia; [Purcell, Laura] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Schneider, Kathryn J.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Schneider, Kathryn J.] Univ Calgary, Cumming Sch Med, Alberta Childrens Hosp Res Inst Child & Maternal, Calgary, AB, Canada; [Schneider, Kathryn J.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Alberta Childrens Res Inst, Dept Psychol, Calgary, AB, Canada; [Gioia, Gerard A.] George Washington Univ, Sch Med, Div Pediat Neuropsychol, Childrens Natl Hlth Syst, Washington, DC USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat & Psychiat & Behav Sci, Washington, DC USA; [Ellenbogen, Richard G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Echemendia, Ruben J.] Univ Orthopaed Ctr, Concuss Care Clin, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA; [Makdissi, Michael] Olymp Pk Sports Med Ctr, Melbourne, Vic, Australia; [Sills, Allen] Vanderbilt Univ, Med Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA; [Iverson, Grant L.] Ctr Hlth & Rehabil Res, Dept Phys Med & Rehabil, Harvard Med Sch, Charlestown, MA USA; [Dvorak, Jiri] Schulthess Clin Zurich, Swiss Concuss Ctr, Zurich, Switzerland; [Meeuwisse, Willem] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Patricios, Jon] Univ Pretoria, Fac Hlth Sci, Sect Sports Med, Pretoria, South Africa; [Patricios, Jon] Univ Witwatersrand, Fac Hlth Sci, Dept Emergency Med, Johannesburg, South Africa; [Giza, Christopher C.] UCLA Steve Tisch BrainSPORT Program, Operat MEND TBI Program, Los Angeles, CA USA; [Kutcher, Jeffrey S.] CORE Inst, Sports Neurol Clin, Southfield, MI USA	Davis, GA (corresponding author), Cabrini Med Ctr, Neurosurg, Suite 53, Malvern, Vic, Australia.	gavin.davis@me.com	Yeates, Keith/AAJ-4223-2020; McCrory, Paul/Q-8688-2019; Echemendia, Ruben/R-6939-2019	Schneider, Kathryn/0000-0002-5951-5899; Davis, Gavin/0000-0001-8293-4496; Patricios, Jon/0000-0002-6829-4098; Yeates, Keith/0000-0001-7680-2892; McCrory, Paul/0000-0003-4850-0568; Iverson, Grant/0000-0001-7348-9570	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); AFL; Ad Hoc Committee; International Concussion in Sport Group; Mooney-Reed Charitable Foundation; ImPACT Applications, Inc.; CogState Inc.; Australian Football League; CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; NCAA; DoDUnited States Department of Defense; Today's and Tomorrow's Children Fund; UCLA Brain Injury Research Center; UCLA Faculty Grants Program; UCLA Steve Tisch BrainSPORT program; Avanir; NINDS Neural Analytics SBIR grant	GAD is an honorary member of the Australian Football League Concussion Working Group and has attended meetings organised by sporting organisations including the NFL (USA), National Rugby League (Australia) and FIFA (Switzerland); however, he has not received any payment, research funding or other monies from these groups other than for travel costs. LP is an expert consultant to mdBriefcase in the development of an online concussion education module and has received speaking honoraria/travel expenses for presentations at scientific meetings. KJS has received speaking honoraria for presentations at scientific meetings. She is a physiotherapy consultant at Evidence Sport and Spinal Therapy in Calgary, Alberta, Canada, and for athletic teams. KOY has received grant funding from NIH and Canadian Institutes of Health Research and book royalties from Guilford Press and Cambridge University Press and has occasionally served as an expert witness in forensic cases; he is President-Elect of the International Neuropsychological Society and a member of the Expert Panel on Acute Diagnosis and Management of Mild Traumatic Brain Injury among Children and Adolescents convened by the Centers for Disease Control and Prevention. RGE is a volunteer co-chairman of the NFL Head Neck and Spine Medical Committee. RJE is a consultant to the NHL, Major League Soccer, US Soccer Federation and Princeton University. He has received financial remuneration for these consulting relationships. He has a clinical practice in sport neuropsychology and serves as an expert (neuropsychology, sport neuropsychology) in medico-legal cases involving traumatic brain injury. He at times has received honoraria and reimbursement of expenses to attend professional meetings. MM is Consultant Sport and Exercise Medicine Physician at Olympic Park Sports Medicine Centre, Team Doctor-Hawthorn football club (Australian Football League(AFL)). AFL research grant-funding for research program on concussion in AFL (collaboration between the AFL and the Florey Institute of Neuroscience & Mental Health). Shareholder-Olympic Park Sports Medicine Centre. IOC-travel and accommodation paid as part of Ad Hoc Committee to evaluate rule changes in boxing. FIFA-Travel and accommodation paid as part of International Concussion in Sport Group. AFL-support for travel to NFL concussion 'think tank' August 2014. CogState Pty Ltd-free access to computerised neuropsychological testing program for research purposes. AFL Doctors Association-paid role as executive officer. Honorary member of the Australian Rugby Union Concussion Advisory Group; World Rugby Concussion working group; Concussion in AFL working group; AFL Concussion Scientific Committee and Member and the International Olympic Committee ad hoc group to evaluate rule change in boxing. AS is an unaffiliated neurotrauma consultant, the NFL. GLI acknowledges philanthropic research support from the Mooney-Reed Charitable Foundation and ImPACT Applications, Inc. He has a medical-legal consulting practice, including expert testimony, in the area of neuropsychology and mild traumatic brain injury. PMcC is a co-investigator, collaborator, or consultant on grants relating to mild TBI funded by several governmental organizations. He is directly employed by the National Health & Medical Research Council of Australia and is based at the Florey Institute of Neuroscience and Mental Health.; He is Co-Chair of the Australian Centre for Research into Sports Injury and its Prevention (ACRISP), which is one of the International University Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee (IOC). He is co-chair of the International Concussion in Sport Group and is a member of the scientific advisory boards of the International Concussion & Head Injury Research Foundation (London, UK) and the Sports Surgery Clinic (Dublin, Ireland). He has a clinical and consulting practice in general and sports neurology. He receives book royalties from McGraw-Hill and was employed in an editorial capacity by the British Medical Journal Publishing Group from 2001 to 2008. He has been reimbursed by the government, professional scientific bodies, and sporting bodies for travel costs related to presenting research on mild TBI and sport-related concussion at meetings, scientific conferences, and symposiums. He received consultancy fees in 2010 from Axon Sports (US) for the development of educational material (which was not renewed) and has received research funding since 2001 from CogState Inc. The Australian Football League funds research at the Florey Institute under a legal memorandum and Dr. McCrory does not receive any money from this industry funded research. Dr. McCrory is a cofounder and shareholder in two biomedical companies (involved in eHealth and Compression garment technologies) but does not hold any individual shares in any company related to concussion or brain injury assessment or technology. He did not receive any form of financial support directly related to this manuscript. WM is Medical Director for the National Hockey League. JP is concussion consultant to South African Rugby's BokSmart injury prevention programme and a member of World Rugby's Concussion Advisory Group; both organisations have contributed honoraria towards conference expenses. GAG receives royalties as a test author from Psychological Assessment Resources, receives research funding from the CDC and NIH, receives speaking Honoria for professional lectures, and is on the pediatric mild TBI guidelines panel of the CDC. CCG receives grants/research support from NIH, NCAA, DoD, Today's and Tomorrow's Children Fund, UCLA Brain Injury Research Center, UCLA Faculty Grants Program, UCLA Steve Tisch BrainSPORT program, Avanir (research grant 2016-2017), NINDS Neural Analytics SBIR grant (2016-2018) Consultant: NFL-Neurological Care Program, NHLPA, Neural Analytics Inc (2015-16), is on the advisory panel of LoveYourBrain, MLS, NBA, NCAA, USSF, performs medicolegal work 1-2 cases annually, and speaks on the Medical Education Speakers Network. JSK provides consulting to National Basketball Association, National Football League Players' Association, National Hockey League Players' Association, ElMindA, Ltd. VA and JD have nothing to declare.	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Brooks A, 2015, CLIN J SPORT MED, V25, P214; Davis GA, 2017, BR J SPORTS MED; Echemendia R, 2017, BRIT J SPORTS MED; Echemendia RJ, 2017, REV BR J SPORTS MED; Echemendia RJ., 2017, BR J SPORTS MED; Glaviano NR, 2015, CLIN J SPORT MED, V25, P373, DOI 10.1097/JSM.0000000000000154; Jennings D, 2015, INT J SPORTS PHYS TH, V10, P667; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meeuwisse W, 2017, BR J SPORTS MED; Nelson LD, 2016, CLIN J SPORT MED, P1	13	58	58	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2017	51	11					859	861		10.1136/bjsports-2017-097492			3	Sport Sciences	Sport Sciences	EW3QP	WOS:000402416500005	28446452				2021-06-18	
J	Shahim, P; Tegner, Y; Gustafsson, B; Gren, M; Arlig, J; Olsson, M; Lehto, N; Engstrom, A; Hoglund, K; Portelius, E; Zetterberg, H; Blennow, K				Shahim, Pashtun; Tegner, Yelverton; Gustafsson, Bengt; Gren, Magnus; Arlig, Johan; Olsson, Martin; Lehto, Niklas; Engstrom, Asa; Hoglund, Kina; Portelius, Erik; Zetterberg, Henrik; Blennow, Kaj			Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; CSF BIOMARKERS; INTERNATIONAL-CONFERENCE; HEAD-INJURY; ASSOCIATION; ENCEPHALOPATHY; CONCUSSION; STATEMENT	IMPORTANCE Evidence is accumulating that repeated mild traumatic brain injury (mTBI) incidents can lead to persistent, long-term debilitating symptoms and in some cases a progressive neurodegenerative condition referred to as chronic traumatic encephalopathy. However, to our knowledge, there are no objective tools to examine to which degree persistent symptoms after mTBI are caused by neuronal injury. OBJECTIVE To determine whether persistent symptoms after mTBI are associated with brain injury as evaluated by cerebrospinal fluid biochemical markers for axonal damage and other aspects of central nervous system injury. DESIGN, SETTINGS, AND PARTICIPANTS A multicenter cross-sectional study involving professional Swedish ice hockey players who have had repeated mTBI, had postconcussion symptoms for more than 3 months, and fulfilled the criteria for postconcussion syndrome (PCS) according to the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) matched with neurologically healthy control individuals. The participants were enrolled between January 2014 and February 2016. The players were also assessed with Rivermead Post Concussion Symptoms Questionnaire and magnetic resonance imaging. MAIN OUTCOMES AND MEASURES Neurofilament light protein, total tau, glial fibrillary acidic protein, amyloid beta, phosphorylated tau, and neurogranin concentrations in cerebrospinal fluid. RESULTS A total of 31 participants (16 men with PCS; median age, 31 years; range, 22-53 years; and 15 control individuals [11 men and 4 women]; median age, 25 years; range, 21-35 years) were assessed. Of 16 players with PCS, 9 had PCS symptoms for more than 1 year, while the remaining 7 returned to play within a year. Neurofilament light proteins were significantly increased in players with PCS for more than 1 year (median, 410 pg/mL; range, 230-1440 pg/mL) compared with players whose PCS resolved within 1 year (median, 210 pg/mL; range, 140-460 pg/mL) as well as control individuals (median 238 pg/mL, range 128-526 pg/mL; P =.04 and P =.02, respectively). Furthermore, neurofilament light protein concentrations correlated with Rivermead Post Concussion Symptoms Questionnaire scores and lifetime concussion events (rho = 0.58, P =.02 and rho = 0.52, P =.04, respectively). Overall, players with PCS had significantly lower cerebrospinal fluid amyloid-beta levels compared with control individuals (median, 1094 pg/mL; range, 845-1305 pg/mL; P =.05). CONCLUSIONS AND RELEVANCE Increased cerebrospinal fluid neurofilament light proteins and reduced amyloid beta were observed in patients with PCS, suggestive of axonal white matter injury and amyloid deposition. Measurement of these biomarkers may be an objective tool to assess the degree of central nervous system injury in individuals with PCS and to distinguish individuals who are at risk of developing chronic traumatic encephalopathy.	[Shahim, Pashtun; Gren, Magnus; Arlig, Johan; Olsson, Martin; Hoglund, Kina; Portelius, Erik; Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Clin Neurochem Lab, Inst Neurosci & Physiol, Sahlgrenska Acad,Sahlgrenska Univ Hosp, Molndal, Sweden; [Tegner, Yelverton; Lehto, Niklas; Engstrom, Asa] Lulea Univ Technol, Div Med Sci, Dept Hlth Sci, Lulea, Sweden; [Gustafsson, Bengt] Capio Artro Clin, Stockholm, Sweden; [Zetterberg, Henrik] UCL, Inst Neurol, Dept Mol Neurosci, London, England	Blennow, K (corresponding author), Univ Gothenburg, Molndal Hosp, Sahlgrenska Univ Hosp, Clin Neurochem Lab,Dept Neurosci & Physiol, SE-43180 Molndal, Sweden.	kaj.blennow@neuro.gu.se		Hoglund, Kina/0000-0002-1213-9953; Olsson, Martin/0000-0001-5531-5972; Tegner, Yelverton/0000-0003-3628-0705	Swedish Research CouncilSwedish Research CouncilEuropean Commission; European Research CouncilEuropean Research Council (ERC)European Commission; Centrum for Idrottsforskning; Torsten Soderberg Foundation; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; Frimurarestiftelsen	The study was supported by grants from the Swedish Research Council, the European Research Council, Centrum for Idrottsforskning, the Torsten Soderberg Foundation, the Knut and Alice Wallenberg Foundation, and Frimurarestiftelsen.	Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Blennow K, 2015, TRENDS PHARMACOL SCI, V36, P297, DOI 10.1016/j.tips.2015.03.002; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kvartsberg H, 2015, ALZHEIMERS DEMENT, V11, P1180, DOI 10.1016/j.jalz.2014.10.009; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Mattsson N, 2012, NEUROLOGY, V78, P468, DOI 10.1212/WNL.0b013e3182477eed; Mattsson N, 2009, JAMA-J AM MED ASSOC, V302, P385, DOI 10.1001/jama.2009.1064; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Neselius S, 2015, KNEE SURG SPORT TR A, V23, P2536, DOI 10.1007/s00167-014-3066-6; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Norgren N, 2003, BRAIN RES, V987, P25, DOI 10.1016/S0006-8993(03)03219-0; Palmqvist S, 2016, BRAIN, V139, P1226, DOI 10.1093/brain/aww015; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Portelius E, 2015, BRAIN, V138, DOI 10.1093/brain/awv267; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Skillback T, 2014, NEUROLOGY, V83, P1945, DOI 10.1212/WNL.0000000000001015; Tarawneh R, 2016, JAMA NEUROL, V73, P561, DOI 10.1001/jamaneurol.2016.0086; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Toledo JB, 2015, BRAIN, V138, P2701, DOI 10.1093/brain/awv199; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; WISNIEWSKI K, 1979, ANN NEUROL, V5, P288, DOI 10.1002/ana.410050311; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2016, JAMA NEUROL, V73, P60, DOI 10.1001/jamaneurol.2015.3037	36	58	58	1	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	NOV 1	2016	73	11					1308	1315		10.1001/jamaneurol.2016.2038			8	Clinical Neurology	Neurosciences & Neurology	ED1BL	WOS:000388578600011	27654934	Bronze			2021-06-18	
J	Taylor, DJ; Pruiksma, KE; Hale, WJ; Kelly, K; Maurer, D; Peterson, AL; Mintz, J; Litz, BT; Williamson, DE				Taylor, Daniel J.; Pruiksma, Kristi E.; Hale, Willie J.; Kelly, Kevin; Maurer, Douglas; Peterson, Alan L.; Mintz, Jim; Litz, Brett T.; Williamson, Douglas E.		STRONG STAR Consortium	Prevalence, Correlates, and Predictors of Insomnia in the US Army prior to Deployment	SLEEP			English	Article						anxiety; Army; depression; insomnia; military; PTSD	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; SLEEP DISTURBANCE; PSYCHIATRIC-DISORDERS; LIFE EVENTS; DEPRESSION; MILITARY; SEVERITY; SYMPTOMS; EPIDEMIOLOGY	Study Objectives: To determine the prevalence, correlates, and predictors of insomnia in US Army personnel prior to deployment. Methods: Cross-sectional cohort design assessing insomnia and other psychosocial variables in active duty service members (n = 4,101), at Fort Hood, Texas, prior to military deployment. Insomnia was defined as an Insomnia Severity Index >= 15. Results: The prevalence of insomnia was 19.9%. Enlisted personnel were five times more likely to report insomnia than officers (odds ratio [OR] = 5.17). Insomnia was higher among American Indian/Alaskan Natives than other groups (ORs = 1.86-2.85). Those in the Insomnia Group were older, had longer military careers, and reported more marriages, children, and military deployments (ds = 0.13-0.34) than the No Insomnia group. The Insomnia Group reported more severe mental health symptoms, more recent stressful life events, greater childhood abuse, and lower levels of trait resilience, social support, and unit cohesion (Cohen ds = 0.27-1.29). After controlling for covariates, the Insomnia Group was more likely to have a history of head injuries and clinically significant posttraumatic stress disorder (PTSD), anxiety, depression, alcohol use problems, back pain, extremity pain, headaches, and fatigue (ORs = 1.40-3.30). A simultaneous logistic regression found that greater PTSD, depression, fatigue, stressful life events, headaches, anxiety, alcohol use problems, extremity pain, history of head injury, childhood physical neglect, back pain, number of times married, and lower leader support/unit cohesion and tangible social support were statistically significant predictors of insomnia status. Conclusions: Insomnia occurs in about one of five service members prior to a military deployment and is associated with a wide array of psychosocial stressors and mental and physical health problems.	[Taylor, Daniel J.] Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA; [Pruiksma, Kristi E.; Hale, Willie J.; Peterson, Alan L.; Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Kelly, Kevin; Maurer, Douglas] Carl R Darnall Army Med Ctr, Ft Hood, TX USA; [Peterson, Alan L.] South Texas Vet Healthcare Syst, San Antonio, TX USA; [Peterson, Alan L.] Univ Texas San Antonio, Dept Psychol, San Antonio, TX USA; [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MS USA; [Litz, Brett T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Williamson, Douglas E.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; [Williamson, Douglas E.] Durham VA Med Ctr, Durham, NC USA	Taylor, DJ (corresponding author), Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA.	Daniel.Taylor@unt.edu		Taylor, Daniel/0000-0003-3433-2516; Williamson, Douglas/0000-0002-5310-1716; Litz, Brett/0000-0002-0479-8887	US Department of Defense through the US Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program [W81XWH-08-2-0110, W81XWH-08-02-109, W81XWH-10-1-0828]	The work was performed at the United States Army installation at Fort Hood in Killeen, TX. The views expressed in this article are solely those of the authors and do not reflect an endorsement by or the official policy of the US Army, the US Air Force, the Department of Defense, the Department of Veterans Affairs, or the US Government. Funding for this work was made possible by the US Department of Defense through the US Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program awards W81XWH-08-2-0110 (Dr. Williamson), W81XWH-08-02-109 (Dr. Peterson), and W81XWH-10-1-0828 (Dr. Taylor). There was no other financial support for this research nor are there any conflicts of interest for any of the authors. No off-label or investigational drugs were used in this study. Portions of these findings have previously been presented: Taylor DJ, Pruiksma KE, Kelly K, Maurer D, Litz B, Peterson A, Mintz J, Williamson DE. Insomnia in the military: prevalence and comorbidities. Sleep 2015;38(Abstract Suppl):A614.	Affleck G, 1996, PAIN, V68, P363, DOI 10.1016/S0304-3959(96)03226-5; American Psychiatric Association, 2012, DIAGN STAT MAN MENT; Babson KA, 2010, J ANXIETY DISORD, V24, P1, DOI 10.1016/j.janxdis.2009.08.002; Bader K, 2007, J SLEEP RES, V16, P285, DOI 10.1111/j.1365-2869.2007.00608.x; Baglioni C, 2011, J AFFECT DISORDERS, V135, P10, DOI 10.1016/j.jad.2011.01.011; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT., 1996, BECK DEPRESSION INVE, V2; Bernstein D., 1998, CHILDHOOD TRAUMA QUE; Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Budhiraja R, 2011, SLEEP, V34, P859, DOI 10.5665/SLEEP.1114; Buysse DJ, 2008, SLEEP, V31, P473, DOI 10.1093/sleep/31.4.473; Chambers E, 1998, CHILD ABUSE NEGLECT, V22, P753, DOI 10.1016/S0145-2134(98)00059-3; Chang PP, 1997, AM J EPIDEMIOL, V146, P105; Cohen S, 1983, APPL SOC PSYCHOL, V58, P304; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; DOHRENWEND BS, 1978, J HEALTH SOC BEHAV, V19, P205, DOI 10.2307/2136536; DRYMAN A, 1991, ACTA PSYCHIAT SCAND, V84, P1, DOI 10.1111/j.1600-0447.1991.tb01410.x; Edinger JD, 2004, SLEEP, V27, P1567, DOI 10.1093/sleep/27.8.1567; Farrell EI, 2013, THESIS; FOLEY DJ, 1995, SLEEP, V18, P425, DOI 10.1093/sleep/18.6.425; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; FRIEDMAN GD, 1974, PSYCHOSOM MED, V36, P327, DOI 10.1097/00006842-197407000-00007; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Germain A, 2013, AM J PSYCHIAT, V170, P372, DOI 10.1176/appi.ajp.2012.12040432; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jarrett M, 2000, DIGEST DIS SCI, V45, P952, DOI 10.1023/A:1005581226265; Johnson DC, 2011, MIL MED, V176, P161, DOI 10.7205/MILMED-D-10-00258; Johnson EO, 2006, J PSYCHIATR RES, V40, P700, DOI 10.1016/j.jpsychires.2006.07.008; Katz DA, 1998, ARCH INTERN MED, V158, P1099, DOI 10.1001/archinte.158.10.1099; Kripke Daniel F, 2001, Clin J Womens Health, V1, P244, DOI 10.1053/cjwh.2001.30491; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; KUPPERMANN M, 1995, J GEN INTERN MED, V10, P25, DOI 10.1007/BF02599573; Lavie P, 2001, NEW ENGL J MED, V345, P1825, DOI 10.1056/NEJMra012893; Lehavot K, 2012, AM J PREV MED, V42, P473, DOI 10.1016/j.amepre.2012.01.006; Lichstein KL, 2003, BEHAV RES THER, V41, P427, DOI 10.1016/S0005-7967(02)00023-2; Lichstein KL, 2004, EPIDEMIOLOGY OF SLEEP AGE, GENDER, AND ETHNICITY, P1; LUNDBERG U, 1994, SCAND J PSYCHOL, V35, P315, DOI 10.1111/j.1467-9450.1994.tb00956.x; McCracken Lance M, 2002, Pain Res Manag, V7, P75; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Moldofsky H, 2001, SLEEP MED REV, V5, P387, DOI 10.1053/smrv.2001.0179; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Morin CM, 2006, SLEEP MED, V7, P123, DOI 10.1016/j.sleep.2005.08.008; Morin CM, 2003, PSYCHOSOM MED, V65, P259, DOI 10.1097/01.PSY.0000030391.09558.A3; Morin CM., 1993, INSOMNIA PSYCHOL ASS; Morrow CE, 2013, MIL PSYCHOL, V25, P568, DOI 10.1037/mil0000021; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Nakata A, 2004, SOC SCI MED, V59, P1719, DOI 10.1016/j.socscimed.2004.02.002; National Instutes of Health, 2001, NIH POL REP RAC ETHN; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Oliver LW, 1999, MIL PSYCHOL, V11, P57, DOI 10.1207/s15327876mp1101_4; Pallesen S, 2001, SLEEP, V24, P771; Perlis ML, 1997, J AFFECT DISORDERS, V42, P209, DOI 10.1016/S0165-0327(96)01411-5; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Phillips B, 2007, J CLIN SLEEP MED, V3, P489; Plumb TR, 2014, PSYCHOL SERV, V11, P209, DOI 10.1037/a0034958; Roberts RE, 2000, AM J PSYCHIAT, V157, P81, DOI 10.1176/ajp.157.1.81; ROSS RJ, 1989, AM J PSYCHIAT, V146, P697; ROTH T, 1988, INT CLIN PSYCHOPHARM, V3, P111; Ruiter ME, 2010, BEHAV SLEEP MED, V8, P246, DOI 10.1080/15402002.2010.509251; Sabanayagam C, 2011, J ENV PUBLIC HLTH, V2011; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Schwartz S, 1999, J PSYCHOSOM RES, V47, P313, DOI 10.1016/S0022-3999(99)00029-X; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Spielberger CD., 1988, STATE TRAIT ANGER EX; Spoormaker VI, 2008, SLEEP MED REV, V12, P169, DOI 10.1016/j.smrv.2007.08.008; Tabachnick BG, 2007, USING MULTIVARIATE S; Taylor DJ, 2008, SLEEP, V31, P447, DOI 10.1093/sleep/31.4.447; Taylor DJ, 2007, SLEEP, V30, P213, DOI 10.1093/sleep/30.2.213; Taylor Daniel J, 2003, Behav Sleep Med, V1, P227, DOI 10.1207/S15402010BSM0104_5; Taylor DJ, 2005, SLEEP, V28, P1457, DOI 10.1093/sleep/28.11.1457; Troxel WM, 2015, SLEEP MIL PROM HLTH; Vaitkus MA, 1994, UNIT MANNING SYSTEM; Walsh JK, 2004, J CLIN PSYCHIAT, V65, P13; WATERS WF, 1993, SLEEP, V16, P128, DOI 10.1093/sleep/16.2.128; Weathers F. W., 1993, INT SOC TRAUM STRESS; Weissman MM, 1997, GEN HOSP PSYCHIAT, V19, P245, DOI 10.1016/S0163-8343(97)00056-X; Zhang B, 2006, SLEEP, V29, P85, DOI 10.1093/sleep/29.1.85	82	58	59	1	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0161-8105	1550-9109		SLEEP	Sleep	OCT 1	2016	39	10					1795	1806		10.5665/sleep.6156			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DX4ET	WOS:000384334700004	27450687	Green Published, Bronze			2021-06-18	
J	Greco, T; Glenn, TC; Hovda, DA; Prins, ML				Greco, Tiffany; Glenn, Thomas C.; Hovda, David A.; Prins, Mayumi L.			Ketogenic diet decreases oxidative stress and improves mitochondrial respiratory complex activity	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Traumatic brain injury; juvenile; ketogenic diet; oxidative stress; mitochondria	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; OXYGEN SPECIES PRODUCTION; CORTICAL IMPACT INJURY; D-BETA-HYDROXYBUTYRATE; KETONE-BODIES; ADULT RATS; FREE-RADICALS; MOUSE MODEL; METABOLISM	Cerebral metabolism of ketones after traumatic brain injury (TBI) improves neuropathology and behavior in an age-dependent manner. Neuroprotection is attributed to improved cellular energetics, although other properties contribute to the beneficial effects. Oxidative stress is responsible for mitochondrial dysfunction after TBI. Ketones decrease oxidative stress, increase antioxidants and scavenge free radicals. It is hypothesized that ketogenic diet (KD) will decrease post-TBI oxidative stress and improve mitochondria. Postnatal day 35 (PND35) male rats were given sham or controlled cortical impact (CCI) injury and placed on standard (STD) or KD. Ipsilateral cortex homogenates and mitochondria were assayed for markers of oxidative stress, antioxidant expression and mitochondrial function. Oxidative stress was significantly increased at 6 and 24h post-injury and attenuated by KD while inducing protein expression of antioxidants, NAD(P)H dehydrogenase quinone 1 (NQO1) and superoxide dismutase (SOD1/2). Complex I activity was inhibited in STD and KD groups at 6h and normalized by 24h. KD significantly improved Complex II-III activity that was reduced in STD at 6h. Activity remained reduced at 24h in STD and unchanged in KD animals. These results strongly suggest that ketones improve post-TBI cerebral metabolism by providing alternative substrates and through antioxidant properties, preventing oxidative stress-mediated mitochondrial dysfunction.	[Greco, Tiffany; Glenn, Thomas C.; Hovda, David A.; Prins, Mayumi L.] Dept Neurosurg, Los Angeles, CA USA; [Greco, Tiffany; Glenn, Thomas C.; Hovda, David A.; Prins, Mayumi L.] UCLA Brain Injury Res Ctr, Los Angeles, CA USA; [Hovda, David A.; Prins, Mayumi L.] Interdept Program Neurosci, Los Angeles, CA USA; [Hovda, David A.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA USA	Greco, T (corresponding author), UCLA Dept Neurosurg, 300 Stein Plaza,Suite 562,POB 957039, Los Angeles, CA 90024 USA.	tgreco@mednet.ucla.edu		Glenn, Thomas/0000-0003-4273-3408	NFL Charities; UCLA Brain Injury Research Center; Marilyn and Austin Anderson Fellowship [NS058489-01, NS27544]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: NFL Charities, UCLA Brain Injury Research Center, Marilyn and Austin Anderson Fellowship (grant nos NS058489-01, NS27544).	Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Balietti M, 2010, MICRON, V41, P143, DOI 10.1016/j.micron.2009.08.010; Brookes PS, 2004, MITOCHONDRION, V3, P187, DOI 10.1016/j.mito.2003.10.001; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; GUELDRY S, 1994, J NEUROCHEM, V62, P223; GUIDOUX R, 1991, ARCH BIOCHEM BIOPHYS, V287, P397, DOI 10.1016/0003-9861(91)90495-5; Haces ML, 2008, EXP NEUROL, V211, P85, DOI 10.1016/j.expneurol.2007.12.029; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002; Malinska D, 2010, BBA-BIOENERGETICS, V1797, P1163, DOI 10.1016/j.bbabio.2010.03.001; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Milder JB, 2010, NEUROBIOL DIS, V40, P238, DOI 10.1016/j.nbd.2010.05.030; Nehlig A, 2004, PROSTAG LEUKOTR ESS, V70, P265, DOI 10.1016/j.plefa.2003.07.006; Noh HS, 2006, J NEUROSCI RES, V83, P702, DOI 10.1002/jnr.20736; O'Connell KM, 2013, BIOL RES NURS, V15, P253, DOI 10.1177/1099800411431823; Park EY, 2002, MOL CELL BIOCHEM, V240, P47, DOI 10.1023/A:1020600509965; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins M, 2008, EPILEPSIA, V49, P111, DOI 10.1111/j.1528-1167.2008.01852.x; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; Sadek HA, 2004, BIOCHEMISTRY-US, V43, P8494, DOI 10.1021/bi049803f; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Veech RL, 2004, PROSTAG LEUKOTR ESS, V70, P309, DOI 10.1016/j.plefa.2003.09.007; Veech RL, 2001, IUBMB LIFE, V51, P241; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Xie G, 2014, FREE RADICAL RES, V11, P1; Ziegler DR, 2003, NEUROCHEM RES, V28, P1793, DOI 10.1023/A:1026107405399	43	58	58	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2016	36	9					1603	1613		10.1177/0271678X15610584			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	DV5UU	WOS:000382996800011	26661201	Bronze, Green Published			2021-06-18	
J	Ellis, MJ; Leddy, J; Willer, B				Ellis, Michael J.; Leddy, John; Willer, Barry			Multi-Disciplinary Management of Athletes with Post-Concussion Syndrome: An Evolving Pathophysiological Approach	FRONTIERS IN NEUROLOGY			English	Article						sports-related concussion; post-concussion syndrome; athlete; multi-disciplinary; management; treatment	SPORTS-RELATED CONCUSSION; CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; POSTCONCUSSION SYNDROME; RECOVERY-TIME; VESTIBULAR REHABILITATION; SENSORIMOTOR FUNCTION; PERSISTENT SYMPTOMS	Historically, patients with sports-related concussion (SRC) have been managed in a uniform fashion consisting mostly of prescribed physical and cognitive rest with the expectation that all symptoms will spontaneously resolve with time. Although this approach will result in successful return to school and sports activities in the majority of athletes, an important proportion will develop persistent concussion symptoms characteristic of post-concussion syndrome (PCS). Recent advances in exercise science, neuroimaging, and clinical research suggest that the clinical manifestations of PCS are mediated by unique pathophysiological processes that can be identified by features of the clinical history and physical examination as well as the use of graded aerobic treadmill testing. Athletes who develop PCS represent a unique population whose care must be individualized and must incorporate a rehabilitative strategy that promotes enhanced recovery of concussion-related symptoms while preventing physical deconditioning. In this review, we present our evolving evidence-based approach to evaluation and management of athletes with PCS that aims to identify the pathophysiological mechanisms mediating persistent concussion symptoms and guides the initiation of individually tailored rehabilitation programs that target these processes. In addition, we outline the important qualified roles that multi-disciplinary healthcare professionals can play in the management of this patient population, and discuss where future research efforts must be focused to further evaluate this evolving pathophysiological approach.	[Ellis, Michael J.] Univ Manitoba, Childrens Hosp Res Inst Manitoba, Canada North Concuss Network, Dept Surg Pediat & Child Hlth,Sect Neurosurg,Pan, Winnipeg, MB, Canada; [Leddy, John] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, UBMD Dept Orthopaed & Sports Med, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY 14260 USA	Ellis, MJ (corresponding author), Univ Manitoba, Childrens Hosp Res Inst Manitoba, Canada North Concuss Network, Dept Surg Pediat & Child Hlth,Sect Neurosurg,Pan, Winnipeg, MB, Canada.	mellis3@panamclinic.com			University of Manitoba Department of Surgery Thorlakson Fund	Financial support of this manuscript was provided by the University of Manitoba Department of Surgery Thorlakson Fund.	Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Armstrong B, 2008, SPORTS MED, V38, P101, DOI 10.2165/00007256-200838020-00002; Arunagiri Guruswami, 2003, Curr Opin Ophthalmol, V14, P344, DOI 10.1097/00055735-200312000-00005; Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Balaban CD, 2012, BRAIN RES, V1482, P101, DOI 10.1016/j.brainres.2012.08.040; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bhattacharyya N, 2008, OTOLARYNG HEAD NECK, V139, pS47, DOI 10.1016/j.otohns.2008.08.022; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; Chung S, 2011, J TRAUMA, V70, P873, DOI 10.1097/TA.0b013e3182108823; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Connery AK, 2016, PHYS MED REH CLIN N, V27, P475, DOI 10.1016/j.pmr.2015.12.001; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Covassin T, 2014, J ATHL TRAINING, V49, P462, DOI 10.4085/1062-6059-49.2.03; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Echemendia RJ, 2012, ARCH CLIN NEUROPSYCH, V27, P119, DOI 10.1093/arclin/acr077; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00061; Ellis MJ, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15600; Ellis MJ, 2016, CURR SPORT MED REP, V15, P27, DOI 10.1249/JSR.0000000000000223; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, CURR SPORT MED REP, V14, P20, DOI 10.1249/JSR.0000000000000108; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; ELLIS MJ, 2014, CURR RES CONCUSSION, V1, P33; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Garcia JD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00040; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Hall CD, 2016, J NEUROL PHYS THER, V40, P124, DOI 10.1097/NPT.0000000000000120; Hamon M, 2013, PROG NEURO-PSYCHOPH, V45, P54, DOI 10.1016/j.pnpbp.2013.04.009; Hecht JS, 2004, J HEAD TRAUMA REHAB, V19, P58, DOI 10.1097/00001199-200401000-00006; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry M, 2013, J NEUROSURG-PEDIATR, V12, P30, DOI 10.3171/2013.4.PEDS12477; Hershey Andrew D, 2007, Curr Pain Headache Rep, V11, P390, DOI 10.1007/s11916-007-0222-4; HILLIER SL, 2011, COCHRANE DB SYST REV, V1; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Jull G, 2002, SPINE, V27, P1835, DOI 10.1097/00007632-200209010-00004; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Khan S, 2013, NEUROREHABILITATION, V32, P437, DOI 10.3233/NRE-130866; King ML, 1997, BRAIN INJURY, V11, P445; Koenigs M, 2009, BEHAV BRAIN RES, V201, P239, DOI 10.1016/j.bbr.2009.03.004; Kontos AP, 2016, BRIT J SPORT MED, V50, P139, DOI 10.1136/bjsports-2015-095564; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Losoi H, 2015, J NEUROTRAUM, V32, P942, DOI 10.1089/neu.2014.3799; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Mannix R, 2014, J NEUROTRAUM, V31, P1072, DOI 10.1089/neu.2013.3265; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; Matuszak JM, 2016, SPORTS HEALTH, V8, P260, DOI 10.1177/1941738116641394; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Murdin L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010696.pub2; Mutch WAC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00107; Mutch WAC, 2016, J NEUROSURG, V125, P648, DOI 10.3171/2015.6.JNS15972; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Ota M, 2014, J AFFECT DISORDERS, V165, P59, DOI 10.1016/j.jad.2014.04.032; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Passatore M, 2006, EUR J APPL PHYSIOL, V98, P423, DOI 10.1007/s00421-006-0312-8; Richer L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005220.pub2; Scheiman M, 2011, COCHRANE DATABASE SY, V3; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Starling AJ, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0521-0; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2010, CAN MED ASSOC J, V182, P1173, DOI 10.1503/cmaj.091430; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Treleaven J, 2010, MANUAL THER, V15, P206, DOI 10.1016/j.math.2009.05.001; Ventura RE, 2015, SEMIN NEUROL, V35, P599, DOI 10.1055/s-0035-1563567; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Wang Y., 2014, INT J DISTRIB SENS N, V2014, P9, DOI DOI 10.1371/J0URNAL.P0NE.0110024; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	124	58	58	0	45	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	AUG 24	2016	7								136	10.3389/fneur.2016.00136			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DT9BN	WOS:000381790300001	27605923	DOAJ Gold, Green Published			2021-06-18	
J	Yuan, F; Xu, ZM; Lu, LY; Nie, H; Ding, J; Ying, WH; Tian, HL				Yuan, Fang; Xu, Zhi-Ming; Lu, Li-Yan; Nie, Hui; Ding, Jun; Ying, Wei-Hai; Tian, Heng-Li			SIRT2 inhibition exacerbates neuroinflammation and blood-brain barrier disruption in experimental traumatic brain injury by enhancing NF-kappa B p65 acetylation and activation	JOURNAL OF NEUROCHEMISTRY			English	Article						blood-brain barrier; cerebral edema; inflammation; SIRT2; traumatic brain injury	OXIDATIVE STRESS; MICROGLIAL ACTIVATION; PARKINSONS-DISEASE; GENE-EXPRESSION; CELL-DEATH; IN-VITRO; DEACETYLASE; LIPOPOLYSACCHARIDE; RESPONSES; MODELS	Sirtuin 2 (SIRT2) is a member of the sirtuin family of NAD(+)-dependent protein deacetylases. In recent years, SIRT2 inhibition has emerged as a promising treatment for neurodegenerative diseases. However, to date, there is no evidence of a specific role for SIRT2 in traumatic brain injury (TBI). We investigated the effects of SIRT2 inhibition on experimental TBI using the controlled cortical impact (CCI) injury model. Adult male mice underwent CCI or sham surgery. A selective brain-permeable SIRT2 inhibitor, AK-7, was administrated 30 min before injury. The volume of the brain edema lesion and the water content of the brain were significantly increased in mice treated with AK-7 (20 mg/kg), compared with the vehicle group, following TBI (p < 0.05 at 1 day and p < 0.05 at 3 days, respectively). Concomitantly, AK-7 administration greatly worsened neurobehavioral deficits on days 3 and 7 after CCI. Furthermore, blood-brain barrier disruption and matrix metalloproteinases (MMP)-9 activity increased following SIRT2 inhibition. AK-7 treatment increased TBI-induced microglial activation both in vivo and in vitro, accompanied by a large increase in the expression and release of inflammatory cytokines. Mechanistically, SIRT2 inhibition increased both K310 acetylation and nuclear translocation of NF-kappa B p65, leading to enhanced NF-kappa B activation and up-regulation of its target genes, including aquaporin 4 (AQP4), MMP-9, and pro-inflammatory cytokines. Together, these data demonstrate that SIRT2 inhibition exacerbates TBI by increasing NF-kappa B p65 acetylation and activation. Our findings provide additional evidence of an anti-inflammatory effect of SIRT2.	[Yuan, Fang; Xu, Zhi-Ming; Ding, Jun; Tian, Heng-Li] Shanghai Jiao Tong Univ, Dept Neurosurg, Affiliated Peoples Hosp 6, Sch Med, Shanghai 200030, Peoples R China; [Lu, Li-Yan] Shanghai Jiao Tong Univ, Dept Radiol, Affiliated Peoples Hosp 6, Sch Med, Shanghai 200030, Peoples R China; [Nie, Hui; Ying, Wei-Hai] Shanghai Jiao Tong Univ, Med X Res Inst, Neurosci & Neuroengn Res Ctr, Shanghai 200030, Peoples R China	Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Affiliated Peoples Hosp 6, Sch Med, Shanghai 200030, Peoples R China.; Ying, WH (corresponding author), Shanghai Jiao Tong Univ, Med X Res Inst, Neurosci & Neuroengn Res Ctr, Shanghai 200030, Peoples R China.	415523055@qq.com; tianhlsh@126.com			National Nature and Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271383, 81471245]; Shanghai Science and Technique Committee [13411951400]	This research was supported by funds from National Nature and Science Foundation of China (81271383,81471245) and the Shanghai Science and Technique Committee (13411951400). Lei-Lei Chen is gratefully acknowledged for her assistance with the flow cytometry analyses. The authors declare that they have no conflicts of interest.	Bobrowska A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034805; Chen HY, 2015, NEUROREPORT, V26, P88, DOI 10.1097/WNR.0000000000000305; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen XQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116919; Choi YH, 2013, BIOCHEM BIOPH RES CO, V437, P245, DOI 10.1016/j.bbrc.2013.06.053; Chopra V, 2012, CELL REP, V2, P1492, DOI 10.1016/j.celrep.2012.11.001; de Oliveira RM, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00082; Di Fruscia P, 2015, CHEMMEDCHEM, V10, P69, DOI 10.1002/cmdc.201402431; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donmez G, 2012, J NEUROSCI, V32, P124, DOI 10.1523/JNEUROSCI.3442-11.2012; Eskandarian HA, 2013, SCIENCE, V341, P525, DOI 10.1126/science.1238858; Grall F, 2003, ARTHRITIS RHEUM, V48, P1249, DOI 10.1002/art.10942; Hoffmann G, 2014, J BIOL CHEM, V289, P5208, DOI 10.1074/jbc.M113.487736; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kim MJ, 2013, FREE RADICAL BIO MED, V63, P432, DOI 10.1016/j.freeradbiomed.2013.06.005; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lee AS, 2014, BIOCHEM BIOPH RES CO, V450, P1363, DOI 10.1016/j.bbrc.2014.06.135; Li YX, 2013, NEUROSCI LETT, V544, P36, DOI 10.1016/j.neulet.2013.03.032; Lin JT, 2013, BIOCHEM BIOPH RES CO, V441, P897, DOI 10.1016/j.bbrc.2013.10.153; Lo Sasso G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103573; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Luthi-Carter R, 2010, P NATL ACAD SCI USA, V107, P7927, DOI 10.1073/pnas.1002924107; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Maxwell MM, 2011, HUM MOL GENET, V20, P3986, DOI 10.1093/hmg/ddr326; Nie H, 2014, NEUROREPORT, V25, P838, DOI 10.1097/WNR.0000000000000192; Outeiro TF, 2007, SCIENCE, V317, P516, DOI 10.1126/science.1143780; Pais TF, 2013, EMBO J, V32, P2603, DOI 10.1038/emboj.2013.200; Pallos J, 2008, HUM MOL GENET, V17, P3767, DOI 10.1093/hmg/ddn273; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Qiu XL, 2010, BBA-PROTEINS PROTEOM, V1804, P1576, DOI 10.1016/j.bbapap.2009.09.015; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Rhee JW, 2007, J BIOCHEM MOL BIOL, V40, P88; Rothgiesser KM, 2010, J CELL SCI, V123, P4251, DOI 10.1242/jcs.073783; Taylor DM, 2011, ACS CHEM BIOL, V6, P540, DOI 10.1021/cb100376q; Town T, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-24; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang YP, 2014, EMBO J, V33, P1304, DOI 10.1002/embj.201387224; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	40	58	61	0	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2016	136	3					581	593		10.1111/jnc.13423			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DC3UQ	WOS:000369144800014	26546505	Bronze			2021-06-18	
J	Mychasiuk, R; Hehar, H; Candy, S; Ma, I; Esser, MJ				Mychasiuk, Richelle; Hehar, Harleen; Candy, Sydeny; Ma, Irene; Esser, Michael J.			The direction of the acceleration and rotational forces associated with mild traumatic brain injury in rodents effect behavioural and molecular outcomes	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Concussion; Prefrontal cortex; Hippocampus; qRT-PCR; Sprague Dawley rats	COLLEGIATE FOOTBALL PLAYERS; SEX-DIFFERENCES; WHITE-MATTER; PROFESSIONAL FOOTBALL; EXECUTIVE FUNCTION; AXONAL INJURY; HEAD-INJURY; SHORT-TERM; CONCUSSION; ATTENTION	Background: The translation of research to clinical application is only as good as the modelling platforms employed. This study sought to improve understanding of mild traumatic brain injury (mTBI), by examining the importance of acceleration and rotational force directions on behavioural and molecular outcomes. It is believed that many symptoms associated with concussive forms of mTBI are related to white matter and fibre tract damage. Given that rodents have significantly less white. matter, could changes in acceleration/rotational force directionality alter outcomes?. New method/comparison with existing methods: Comparison of mTBIs with two distinct injury platforms, the lateral impact (LI) device, which produces horizontal acceleration/rotation; or the modified weight drop (WD) device, which produces sagittal or vertical acceleration/rotation. Male and female rats underwent a behavioural test battery followed by analysis of 5 TBI-associated biomarkers (BDNF, Eno2, GFAP, MAPT, TERT) from the prefrontal cortex and hippocampus. Results: Acute behavioural impairments were similar for both injury models; animals exhibited increased time-to-wake, and deficits of balance and motor control. However, as the post-injury interval increased LI animals displayed deficits on tasks related to emotional functioning, whereas WD animals showed impairment in cognitive measures. Biomarker expression varied as a function of injury platform, sex, and brain region. Conclusion: just as with humans, the direction of the acceleration and rotational forces produced injuries in different networks and connections, resulting in altered functional deficits for rodents as well. These findings suggest that rodents are a valuable resource for the study of mTBI, when appropriately modelled. (C) 2015 Elsevier B.V. All rights reserved.	[Mychasiuk, Richelle; Hehar, Harleen; Candy, Sydeny; Ma, Irene; Esser, Michael J.] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Calgary, AB T2N 1N4, Canada	Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Heritage Med Res Bldg Room 274,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	rmmychas@ucalgary.ca			ACHRI; ACHF; Markin USRP for Health and Wellness	The authors would like to thank Craig Good and Lonnie Unger with Collision Analysis, Calgary AB, for their expertise in biomechanical engineering and the development of the Lateral Impact Device. The authors would also like to thank ACHRI, the ACHF, and the Markin USRP for Health and Wellness, for their financial contributions.	Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; Gennarelli T.A., 1987, SAE TECH PAP; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Gur RC, 1999, J NEUROSCI, V19, P4065; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Horch HW, 2002, NAT NEUROSCI, V5, P1177, DOI 10.1038/nn927; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; IQBAL K, 1986, LANCET, V2, P421; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Kanaan RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038272; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Mychasiuk R, 2014, JOVE, V8; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2015, NEUROBIOL DIS, V73, P1, DOI 10.1016/j.nbd.2014.09.003; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sotgiu S, 2006, EUR J NEUROL, V13, P505, DOI 10.1111/j.1468-1331.2006.01280.x; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Ventura-Antunes L, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00003; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Whishaw I. Q., 2005, BEHAV LAB RAT HDB TE; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197; Zilles K, 1985, CORTEL RAT STEREOTAX	56	58	58	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JAN 15	2016	257						168	178		10.1016/j.jneumeth.2015.10.002			11	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CY2FL	WOS:000366224100017	26484783				2021-06-18	
J	Scholz, R; Caramoy, A; Bhuckory, MB; Rashid, K; Chen, M; Xu, HP; Grimm, C; Langmann, T				Scholz, Rebecca; Caramoy, Albert; Bhuckory, Mohajeet B.; Rashid, Khalid; Chen, Mei; Xu, Heping; Grimm, Christian; Langmann, Thomas			Targeting translocator protein (18 kDa) (TSPO) dampens pro-inflammatory microglia reactivity in the retina and protects from degeneration	JOURNAL OF NEUROINFLAMMATION			English	Article						Translocator protein (18 kDa) (TSPO); Microglia; Photoreceptors; Retinal degeneration; Light damage; Age-related macular degeneration	TRAUMATIC BRAIN-INJURY; MACULAR DEGENERATION; MOUSE MODEL; THERAPEUTIC TARGET; AGING RETINA; LIGHT DAMAGE; CELL-DEATH; IN-VIVO; PROGESTERONE; DISEASE	Background: Reactive microglia are commonly seen in retinal degenerative diseases, and neurotoxic microglia responses can contribute to photoreceptor cell death. We and others have previously shown that translocator protein (18 kDa) (TSPO) is highly induced in retinal degenerations and that the selective TSPO ligand XBD173 (AC-5216, emapunil) exerts strong anti-inflammatory effects on microglia in vitro and ex vivo. Here, we investigated whether targeting TSPO with XBD173 has immuno-modulatory and neuroprotective functions in two mouse models of acute retinal degeneration using bright white light exposure. Methods: BALB/cJ and Cx3cr1(GFP/+) mice received intraperitoneal injections of 10 mg/kg XBD173 or vehicle for five consecutive days, starting 1 day prior to exposure to either 15,000 lux white light for 1 h or 50,000 lux focal light for 10 min, respectively. The effects of XBD173 treatment on microglia and Muller cell reactivity were analyzed by immuno-stainings of retinal sections and flat mounts, fluorescence-activated cell sorting (FACS) analysis, and mRNA expression of microglia markers using quantitative real-time PCR (qRT-PCR). Optical coherence tomography (OCT), terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stainings, and morphometric analyses were used to quantify the extent of retinal degeneration and photoreceptor apoptosis. Results: Four days after the mice were challenged with bright white light, a large number of amoeboid-shaped alerted microglia appeared in the degenerating outer retina, which was nearly completely prevented by treatment with XBD173. This treatment also down-regulated the expression of TSPO protein in microglia but did not change the TSPO levels in the retinal pigment epithelium (RPE). RT-PCR analysis showed that the microglia/macrophage markers Cd68 and activated microglia/macrophage whey acidic protein (Amwap) as well as the pro-inflammatory genes Ccl2 and Il6 were reduced after XBD173 treatment. Light-induced degeneration of the outer retina was nearly fully blocked by XBD173 treatment. We further confirmed these findings in an independent mouse model of focal light damage. Retinas of animals receiving XBD173 therapy displayed significantly more ramified non-reactive microglia and more viable arrestin-positive cone photoreceptors than vehicle controls. Conclusions: Targeting TSPO with XBD173 effectively counter-regulates microgliosis and ameliorates light-induced retinal damage, highlighting a new pharmacological concept for the treatment of retinal degenerations.	[Scholz, Rebecca; Caramoy, Albert; Rashid, Khalid; Langmann, Thomas] Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, D-50931 Cologne, Germany; [Bhuckory, Mohajeet B.; Chen, Mei; Xu, Heping] Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, Belfast BT12 6BA, Antrim, North Ireland; [Grimm, Christian] Univ Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8057 Zurich, Switzerland	Langmann, T (corresponding author), Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, D-50931 Cologne, Germany.	thomas.langmann@uk-koeln.de	Xu, Heping/A-4430-2008	Xu, Heping/0000-0003-4000-931X; Grimm, Christian/0000-0001-9318-4352	DFGGerman Research Foundation (DFG)European Commission [LA1203/6-2, LA1203/9-1, LA1203/10-1, FOR2240]; Velux Foundation; Hans und Marlies Stock-Foundation; Pro Retina Foundation; Bayer Graduate Program in Pharmacology; Fight for Sight [1425/1426]; Fight for Sight [1425/26] Funding Source: researchfish	This work was supported by the DFG (LA1203/6-2, LA1203/9-1, LA1203/10-1, and FOR2240), the Velux Foundation, the Hans und Marlies Stock-Foundation, the Pro Retina Foundation, the Bayer Graduate Program in Pharmacology, and Fight for Sight (1425/1426). We thank the members of the Brachvogel Laboratory, Institute of Biochemistry, University of Cologne, for their help with the FACS analyses.	Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Aslanidis A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0296-6; Balasubramaniam B, 2009, EXP EYE RES, V89, P757, DOI 10.1016/j.exer.2009.06.019; Barron AM, 2013, J NEUROSCI, V33, P8891, DOI 10.1523/JNEUROSCI.1350-13.2013; Cascio C, 2000, J STEROID BIOCHEM, V75, P177, DOI 10.1016/S0960-0760(00)00163-1; Chauveau F, 2008, EUR J NUCL MED MOL I, V35, P2304, DOI 10.1007/s00259-008-0908-9; Chen M, 2015, J LEUKOC BIOL; Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; Daugherty DJ, 2013, EMBO MOL MED, V5, P891, DOI 10.1002/emmm.201202124; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Girard C, 2012, J NEUROENDOCRINOL, V24, P71, DOI 10.1111/j.1365-2826.2011.02215.x; Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497; Grimm Christian, 2013, Methods Mol Biol, V935, P87, DOI 10.1007/978-1-62703-080-9_6; Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9; Gut P, 2015, TRENDS ENDOCRIN MET, V26, P349, DOI 10.1016/j.tem.2015.04.001; HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253; Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004; Karlstetter M, 2014, ADV EXP MED BIOL, V801, P207, DOI 10.1007/978-1-4614-3209-8_27; Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3; Karlstetter M, 2010, J IMMUNOL, V185, P3379, DOI 10.4049/jimmunol.0903300; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114; Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Marc RE, 2008, MOL VIS, V14, P782; Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nothdurfter C, 2012, J NEUROENDOCRINOL, V24, P82, DOI 10.1111/j.1365-2826.2011.02166.x; Nothdurfter C, 2012, EUR ARCH PSY CLIN N, V262, pS107, DOI 10.1007/s00406-012-0352-5; Papadopoulos V, 2007, MOL CELL ENDOCRINOL, V265, P59, DOI 10.1016/j.mce.2006.12.004; Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003; Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87; Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Rupprecht R, 2009, SCIENCE, V325, P490, DOI 10.1126/science.1175055; Sanchez-Vallejo V, 2015, PHARMACOL RES, V99, P276, DOI 10.1016/j.phrs.2015.06.019; Schubert T, 2015, CELL MOL LIFE SCI, V72, P3953, DOI 10.1007/s00018-015-1913-3; Selvaraj V, 2015, TRENDS ENDOCRIN MET, V26, P341, DOI 10.1016/j.tem.2015.02.007; Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350; Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015; Veiga S, 2005, NEUROREPORT, V16, P1599, DOI 10.1097/01.wnr.0000179081.39659.7d; Venneti S, 2013, GLIA, V61, P10, DOI 10.1002/glia.22357; Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014; Wei XH, 2013, J NEUROSCI, V33, P1540, DOI 10.1523/JNEUROSCI.0324-12.2013; Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149; Zhang C, 2004, INVEST OPHTH VIS SCI, V45, P2753, DOI 10.1167/iovs.03-1344; Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298	59	58	60	0	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	NOV 2	2015	12								201	10.1186/s12974-015-0422-5			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CV5BX	WOS:000364282300002	26527153	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Siman, R; Shahim, P; Tegner, Y; Blennow, K; Zetterberg, H; Smith, DH				Siman, Robert; Shahim, Pashtun; Tegner, Yelverton; Blennow, Kaj; Zetterberg, Henrik; Smith, Douglas H.			Serum SNTF Increases in Concussed Professional Ice Hockey Players and Relates to the Severity of Postconcussion Symptoms	JOURNAL OF NEUROTRAUMA			English	Article						tau; sports concussion; diffuse axonal injury; mild traumatic brain injury; calpain	TRAUMATIC BRAIN-INJURY; CALPAIN-I; CEREBROSPINAL-FLUID; MILD; BIOMARKERS; TETRODOTOXIN; PROTEOLYSIS; ACTIVATION; MANAGEMENT; STATEMENT	Biomarkers for diffuse axonal injury could have utilities for the acute diagnosis and clinical care of concussion, including those related to sports. The calpain-derived alpha II-spectrin N-terminal fragment (SNTF) accumulates in axons after traumatic injury and increases in human blood after mild traumatic brain injury (mTBI) in relation to white matter abnormalities and persistent cognitive dysfunction. However, SNTF has never been evaluated as a biomarker for sports-related concussion. Here, we conducted longitudinal analysis of serum SNTF in professional ice hockey players, 28 of whom had a concussion, along with 45 players evaluated during the preseason, 17 of whom were also tested after a concussion-free training game. Compared with preseason levels, serum SNTF increased at 1 h after concussion and remained significantly elevated from 12 h to 6 days, before declining to preseason baseline. In contrast, serum SNTF levels were unchanged after training. In 8 players, postconcussion symptoms resolved within a few days, and in these cases serum SNTF levels were at baseline. On the other hand, for the 20 players withheld from play for 6 days or longer, serum SNTF levels rose from 1 h to 6 days postconcussion, and at 12-36 h differed significantly from the less-severe concussions (p=0.004). Serum SNTF exhibited diagnostic accuracy for concussion, especially so with delayed return to play (area under the curve=0.87). Multi-variate analyses of serum SNTF and tau improved the diagnostic accuracy, the relationship with the delay in return to play, and the temporal window beyond tau alone. These results provide evidence that blood SNTF, a biomarker for axonal injury after mTBI, may be useful for diagnosis and prognosis of sports-related concussion, as well as for guiding neurobiologically informed decisions on return to play.	[Siman, Robert; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Shahim, Pashtun; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Clin Neurochem Lab, Inst Neurosci & Physiol, Sahgrenska Acad,Sahlgrenska Univ Hosp, Molndal, Sweden; [Tegner, Yelverton] Lulea Univ Technol, Div Med Sci, Dept Hlth Sci, S-95187 Lulea, Sweden; [Zetterberg, Henrik] UCL, Inst Neurol, London, England	Siman, R (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, 502 Stemmler Hall 36th & Hamilton Walk, Philadelphia, PA 19104 USA.	siman@mail.med.upenn.edu		Tegner, Yelverton/0000-0003-3628-0705	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; Centrum for Idrottsforskning; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS P01 NS056202]; Department of Neurosurgery, University of Pennsylvania School of Medicine; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This work was supported by grants from the Swedish Medical Research Council, the Centrum for Idrottsforskning, and the National Institutes of Health (NINDS P01 NS056202), along with support from the Department of Neurosurgery, University of Pennsylvania School of Medicine. The authors thank the medical staff of the hockey teams: Bengt Gustafsson, MD, Torsten Johansson, MD, Orjan Frojd, MD, Henrik Wretling, MD, Karin Runblad, MD, Goran Thoren, MD, Christer Andersson, MD, Ulf Nordstrom, MD, Stefan Serenius, MD, Mattias Hell, Jonas Kalman, Sina Hedin, Patrik Johansson, and Billy Nilsson for their valuable contributions to the participant enrollment and assessments of PCS. The authors thank Dr. Sean Ren and Samir Sayed of Children's Hospital of Philadelphia for assistance with the electrochemiluminescence-based SNTF immunoassay and Ryan Cocca for outstanding technical assistance.	Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Gatson JW, 2013, J NEUROTRAUM, V30, pA162; Goedert M, 1991, BRAIN PATHOL, V1, P279, DOI 10.1111/j.1750-3639.1991.tb00671.x; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Johnson VE, 2014, J NEUROTRAUM, V31, pA95; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCrea M, 2014, PROG NEUROL SURG, V28, P112, DOI 10.1159/000358769; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryb G. E., 2014, BRAIN INJURY, V9, P1; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xu JL, 2001, BRAIN RES, V898, P171, DOI 10.1016/S0006-8993(01)02156-4; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	44	58	60	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1294	1300		10.1089/neu.2014.3698			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500002	25419578	Green Published			2021-06-18	
J	Farbood, Y; Sarkaki, A; Dianat, M; Khodadadi, A; Haddad, MK; Mashhadizadeh, S				Farbood, Yaghoob; Sarkaki, Alireza; Dianat, Mahin; Khodadadi, Ali; Haddad, Mohammad Khaksari; Mashhadizadeh, Shahram			Ellagic acid prevents cognitive and hippocampal long-term potentiation deficits and brain inflammation in rat with traumatic brain injury	LIFE SCIENCES			English	Article						Traumatic brain injury; Long term potentiation; Ellagic acid; IL-1 beta; IL-6	DENTATE GYRUS; INTRACRANIAL-PRESSURE; SYNAPTIC PLASTICITY; OXIDATIVE STRESS; AMPA RECEPTORS; CA1 REGION; DUAL ROLE; KAPPA-B; INTERLEUKIN-1; MEMORY	Aims: Traumatic brain injury (TBI) remains one of the main clinical problems globally and is a common cause of death among youth. Cognitive defects such as thinking, memory and behavior or mental health disorders are considered as the most frequent effects of severe and moderate TBI. It has been reported that ellagic acid (EA), a natural polyphenol, exhibits protective effects against oxidative damage. This study was performed to examine the EA preventive effects on cognitive impairments, long-term potentiation (LTP) deficits in hippocampus and brain inflammation induced by diffuse TBI in rat. Main methods: Subchronic oral administration of 100 mg/kg EA, 7 consecutive days before induction of trauma (once daily) was used to elucidate the EA effects on passive avoidance memory and hippocampal LTP following TBI. To illustrate the possible mechanisms related to the preventive effects of EA on brain function following TBI, brain content of IL-1 beta, IL-6 and blood-brain barrier (BBB) permeability were determined. Key findings: EA pretreatment significantly (P < 0.001) prevented TBI-induced memory and hippocampal LTP impairments in rat. Furthermore TBI induced elevation in brain content of IL-1 beta, IL-6 and BBB permeability were decreased significantly (P < 0.001) due to EA pre-treatment. Significance: Our findings suggest that EA can prevent cognitive and LTP deficits and also prevent brain inflammation following TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Farbood, Yaghoob; Sarkaki, Alireza; Dianat, Mahin; Mashhadizadeh, Shahram] Ahvaz Jundishapur Univ Med Sci, Sch Med, Physiol Res Ctr, Golestan Blvd,POB 45, Ahwaz 6135715794, Iran; [Farbood, Yaghoob; Sarkaki, Alireza; Dianat, Mahin; Mashhadizadeh, Shahram] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Physiol, Ahwaz 6135715794, Iran; [Khodadadi, Ali] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Immunol, Ahwaz 6135715794, Iran; [Haddad, Mohammad Khaksari] Kerman Univ Med Sci, Sch Med, Physiol Res Ctr, Kerman, Iran; [Haddad, Mohammad Khaksari] Kerman Univ Med Sci, Sch Med, Dept Physiol, Kerman, Iran	Mashhadizadeh, S (corresponding author), Ahvaz Jundishapur Univ Med Sci, Sch Med, Physiol Res Ctr, Golestan Blvd,POB 45, Ahwaz 6135715794, Iran.	mashhadizadeh.s@ajums.ac.ir	Haddad, Mohammad Khaksari/AAB-9025-2019; khodadadi, ali/N-2130-2017; Farbood, Yaghoob/M-3076-2017; Sarkaki, Alireza/Q-8363-2017; Mashhadizadeh, Shahram/AAN-2926-2021	Haddad, Mohammad Khaksari/0000-0003-0770-4281; khodadadi, ali/0000-0003-0442-273X; Farbood, Yaghoob/0000-0002-6390-0079; Sarkaki, Alireza/0000-0001-9272-6228; Mashhadizadeh, Shahram/0000-0003-2614-5657	Ahvaz Physiology Research Center - Vice Chancellor of Research, Ahvaz Jundishapur University of Medical Sciences (Iran) [APRC-147]	This research was supported by a grant (APRC-147) from the Ahvaz Physiology Research Center, funded by the Vice Chancellor of Research, Ahvaz Jundishapur University of Medical Sciences (Iran). Also it was extracted from the Ph.D. thesis of Mr. Shahram Mashhadizadeh. The authors would like to thank of Dr. Soltani Z, Miss Naderi V and Mr. Mirshekar M, our colleagues in Kerman and Ahvaz Universities of Medical Sciences (Iran), for their kind help and technical support.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Arisi G.M., 2014, EPILEPSY BEHAV; Atta-Ur-Rahman, 2001, PLANTA MED, V67, P335, DOI 10.1055/s-2001-14306; BAN E, 1991, NEUROSCIENCE, V43, P21, DOI 10.1016/0306-4522(91)90412-H; BenNasr C, 1996, Z LEBENSM UNTERS FOR, V203, P374, DOI 10.1007/BF01231077; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broutman G, 2001, J NEUROSCI, V21, P27, DOI 10.1523/JNEUROSCI.21-01-00027.2001; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chao PC, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-33; Chen HS, 2011, J FOOD SCI, V76, pT192, DOI 10.1111/j.1750-3841.2011.02373.x; Citri A, 2008, NEUROPSYCHOPHARMACOL, V33, P18, DOI 10.1038/sj.npp.1301559; Clifford MN, 2000, J SCI FOOD AGR, V80, P1118, DOI [10.1002/(SICI)1097-0010(20000515)80:7<1118::AID-JSFA570>3.0.CO;2-9, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1118::AID-JSFA570&gt;3.0.CO;2-9, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1033::AID-JSFA595&gt;3.0.CO;2-T, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1063::AID-JSFA605&gt;3.0.CO;2-Q]; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Edderkaoui M, 2008, WORLD J GASTROENTERO, V14, P3672, DOI 10.3748/wjg.14.3672; Faul M., 2010, TRAUMATIC BRAIN INJU, P7; Festa F, 2001, ANTICANCER RES, V21, P3903; Freir DB, 2003, BRAIN RES, V967, P27, DOI 10.1016/S0006-8993(02)04190-2; Garber J, 2010, GUIDE CARE USE LAB A, V8, P220; Gellerman DM, 1997, J NEUROCHEM, V69, P131; Girish C, 2009, FUND CLIN PHARMACOL, V23, P735, DOI 10.1111/j.1472-8206.2009.00722.x; Goshen I, 2007, PSYCHONEUROENDOCRINO, V32, P1106, DOI 10.1016/j.psyneuen.2007.09.004; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Huh JW, 2011, J NEUROTRAUM, V28, P245, DOI 10.1089/neu.2010.1639; Keshavarzi Z, 2012, IRAN J BASIC MED SCI, V15, P1102; Khaksari M, 2013, IRAN J BASIC MED SCI, V16, P858; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Kostrzewa RM, 2003, NEUROTOX RES, V5, P375, DOI 10.1007/BF03033166; Lai AY, 2006, J NEUROIMMUNOL, V175, P97, DOI 10.1016/j.jneuroim.2006.03.001; Lashgari R, 2006, BEHAV BRAIN RES, V171, P324, DOI 10.1016/j.bbr.2006.04.013; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Manahan-Vaughan D, 1998, NEUROSCIENCE, V86, P709, DOI 10.1016/S0306-4522(98)00111-0; Mansouri MT, 2013, PHARMACOL BIOCHEM BE, V111, P90, DOI 10.1016/j.pbb.2013.09.002; Mansouri MT, 2013, EUR J PHARMACOL, V707, P46, DOI 10.1016/j.ejphar.2013.03.031; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morton LW, 2000, CLIN EXP PHARMACOL P, V27, P152, DOI 10.1046/j.1440-1681.2000.03214.x; Narayanan BA, 1999, CANCER LETT, V136, P215, DOI 10.1016/S0304-3835(98)00323-1; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; O'Connor JJ, 1999, EXP PHYSIOL, V84, P601, DOI 10.1017/S0958067099018928; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Ota Y, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/185463; PARNET P, 1994, MOL BRAIN RES, V27, P63, DOI 10.1016/0169-328X(94)90185-6; Paxinos G., 2006, RAT BRAIN STEREOTAXI; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; REEVES TM, 1995, EXP BRAIN RES, V106, P248; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rogerio AP, 2006, J PHARM PHARMACOL, V58, P1265, DOI 10.1211/jpp.58.9.0014; Ross FM, 2003, J NEUROIMMUNOL, V144, P61, DOI 10.1016/j.jneuroim.2003.08.030; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sakthivel M, 2008, EXP EYE RES, V86, P251, DOI 10.1016/j.exer.2007.10.016; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sarkaki A, 2008, BEHAV BRAIN RES, V186, P72, DOI 10.1016/j.bbr.2007.07.041; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Sarkaki A, 2013, IRAN J BASIC MED SCI, V16, P1004; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Selig DK, 1996, LEARN MEMORY, V3, P42, DOI 10.1101/lm.3.1.42; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Tancredi V, 2000, J NEUROCHEM, V75, P634, DOI 10.1046/j.1471-4159.2000.0750634.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Thomson I.A., 2014, PAK J BIOL SCI, V17, P978; Tsakini N, 2008, MOL CELL NEUROSCI, V37, P110, DOI 10.1016/j.mcn.2007.09.001; Umesalma S, 2010, BASIC CLIN PHARMACOL, V107, P650, DOI 10.1111/j.1742-7843.2010.00565.x; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Viviani B, 2003, J NEUROSCI, V23, P8692; Whitley AC, 2003, BIOCHEM PHARMACOL, V66, P907, DOI 10.1016/S0006-2952(03)00413-1; Ye F, 2014, EXP THER MED, V7, P223, DOI 10.3892/etm.2013.1396; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Yu YM, 2005, J NUTR BIOCHEM, V16, P675, DOI 10.1016/j.jnutbio.2005.03.013; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087241; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	80	58	59	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	MAR 1	2015	124						120	127		10.1016/j.lfs.2015.01.013			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	CE8TX	WOS:000352118100015	25637685				2021-06-18	
J	Fenn, AM; Skendelas, JP; Moussa, DN; Muccigrosso, MM; Popovich, PG; Lifshitz, J; Eiferman, DS; Godbout, JP				Fenn, Ashley M.; Skendelas, John P.; Moussa, Daniel N.; Muccigrosso, Megan M.; Popovich, Phillip G.; Lifshitz, Jonathan; Eiferman, Daniel S.; Godbout, Jonathan P.			Methylene Blue Attenuates Traumatic Brain Injury-Associated Neuroinflammation and Acute Depressive-Like Behavior in Mice	JOURNAL OF NEUROTRAUMA			English	Article						intervention; cytokines; fluid percussion injury; recovery; microglia	QUINOLINIC ACID; NITRIC-OXIDE; AGED MICE; COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; WORKING-MEMORY; HEAD-INJURY; INFLAMMATION; ACTIVATION; EXPRESSION	Traumatic brain injury (TBI) is associated with cerebral edema, blood brain barrier breakdown, and neuroinflammation that contribute to the degree of injury severity and functional recovery. Unfortunately, there are no effective proactive treatments for limiting immediate or long-term consequences of TBI. Therefore, the objective of this study was to determine the efficacy of methylene blue (MB), an antioxidant agent, in reducing inflammation and behavioral complications associated with a diffuse brain injury. Here we show that immediate MB infusion (intravenous; 15-30 minutes after TBI) reduced cerebral edema, attenuated microglial activation and reduced neuroinflammation, and improved behavioral recovery after midline fluid percussion injury in mice. Specifically, TBI-associated edema and inflammatory gene expression in the hippocampus were significantly reduced by MB at 1 d post injury. Moreover, MB intervention attenuated TBI-induced inflammatory gene expression (interleukin [IL]-1 beta, tumor necrosis factor alpha) in enriched microglia/macrophages 1 d post injury. Cell culture experiments with lipopolysaccharide-activated BV2 microglia confirmed that MB treatment directly reduced IL-1 beta and increased IL-10 messenger ribonucleic acid in microglia. Last, functional recovery and depressive-like behavior were assessed up to one week after TBI. MB intervention did not prevent TBI-induced reductions in body weight or motor coordination 1-7 d post injury. Nonetheless, MB attenuated the development of acute depressive-like behavior at 7 d post injury. Taken together, immediate intervention with MB was effective in reducing neuroinflammation and improving behavioral recovery after diffuse brain injury. Thus, MB intervention may reduce life-threatening complications of TBI, including edema and neuroinflammation, and protect against the development of neuropsychiatric complications.	[Fenn, Ashley M.; Skendelas, John P.; Moussa, Daniel N.; Muccigrosso, Megan M.; Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Inst Behav Med Res, Columbus, OH 43210 USA; [Eiferman, Daniel S.] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA; [Lifshitz, Jonathan] Univ Arizona, Phoenix Childrens Hosp, Barrow Neurol Inst, Dept Child Hlth, Phoenix, AZ USA	Eiferman, DS (corresponding author), Ohio State Univ, 395 W 12th Ave,Suite 634, Columbus, OH 43210 USA.	daniel.eiferman@osumc.edu; jonathan.godbout@osumc.edu		Skendelas, John/0000-0002-3491-7568	Ohio State University by the Center for Brain and Spinal Cord Repair; Department of Surgery; College of Medicine Dean's Discovery Grant; OSU Presidential Fellowship	This work was supported by Ohio State University funding by the Center for Brain and Spinal Cord Repair (to JPG), Department of Surgery (to DSE), and a College of Medicine Dean's Discovery Grant (to JPG). AMF was supported by the OSU Presidential Fellowship. The authors thank Christopher Burnsides for his technical assistance, and Dr. Joseph Travers and Dr. Jason Nasse for use of their isoflurane setup and their technical assistance in developing an isoflurane system.	Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Barrientos RM, 2006, NEUROBIOL AGING, V27, P723, DOI 10.1016/j.neurobiolaging.2005.03.010; Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P46, DOI 10.1016/j.bbi.2008.07.002; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cardenas A, 2005, BRAIN RES REV, V50, P1, DOI 10.1016/j.brainresrev.2005.03.006; Chen J, 2008, BRAIN BEHAV IMMUN, V22, P301, DOI 10.1016/j.bbi.2007.08.014; Corona AW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-93; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dantzer R, 2011, PSYCHONEUROENDOCRINO, V36, P426, DOI 10.1016/j.psyneuen.2010.09.012; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; De Palma C, 2008, J NEUROCHEM, V106, P193, DOI 10.1111/j.1471-4159.2008.05351.x; Dibaj P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043963; Fenn A.M., 2013, BIOL PSYCHIAT; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Godbout JP, 2008, NEUROPSYCHOPHARMACOL, V33, P2341, DOI 10.1038/sj.npp.1301649; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Guillemin GJ, 2005, GLIA, V49, P15, DOI 10.1002/glia.20090; Haroon E, 2012, NEUROPSYCHOPHARMACOL, V37, P137, DOI 10.1038/npp.2011.205; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Maslow AD, 2006, ANESTH ANALG, V103, P2, DOI 10.1213/01.ane.0000221261.25310.fe; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Miclescu A, 2010, CRIT CARE MED, V38, P2199, DOI 10.1097/CCM.0b013e3181f26b0c; Miller A.H., 2008, FOCUS, V6, P36; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morganti JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093650; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; NHDS NHAMCS NVSS, 2010, INJ PREV CONTR TRAUM; O'Connor JC, 2009, MOL PSYCHIATR, V14, P511, DOI 10.1038/sj.mp.4002148; Oz M, 2011, MED RES REV, V31, P93, DOI 10.1002/med.20177; Paciullo CA, 2010, PHARMACOTHERAPY, V30, P702, DOI 10.1592/phco.30.7.702; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Peter C, 2000, EUR J CLIN PHARMACOL, V56, P247, DOI 10.1007/s002280000124; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Richwine AF, 2008, PSYCHONEUROENDOCRINO, V33, P1369, DOI 10.1016/j.psyneuen.2008.08.003; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Schirmer RH, 2003, REDOX REP, V8, P272, DOI 10.1179/135100003225002899; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Steiner J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-94; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Vutskits L, 2008, ANESTHESIOLOGY, V108, P684, DOI 10.1097/ALN.0b013e3181684be4; Wang HE, 2013, PREHOSP EMERG CARE, V17, P8, DOI 10.3109/10903127.2012.722178; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Wohleb ES, 2012, PSYCHONEUROENDOCRINO, V37, P1491, DOI 10.1016/j.psyneuen.2012.02.003; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yirmiya R, 2000, ANN NY ACAD SCI, V917, P478; ZEMBOWICZ A, 1992, P NATL ACAD SCI USA, V89, P2051, DOI 10.1073/pnas.89.6.2051; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	77	58	63	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2015	32	2					127	138		10.1089/neu.2014.3514			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AY6QM	WOS:000347690700008	25070744	Green Published			2021-06-18	
J	Des Roches, CA; Balachandran, I; Ascenso, EM; Tripodis, Y; Kiran, S				Des Roches, Carrie A.; Balachandran, Isabel; Ascenso, Elsa M.; Tripodis, Yorghos; Kiran, Swathi			Effectiveness of an impairment-based individualized rehabilitation program using an iPad-based software platform	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						aphasia; stroke; traumatic brain injury; iPad-based rehabilitation; Constant Therapy; impairment-based; individualized rehabilitation	MILD COGNITIVE IMPAIRMENT; WORKING-MEMORY; LANGUAGE THERAPY; APHASIA; STROKE; INTENSITY; DEFICITS; POSTSTROKE; CONVERSION; SEVERITY	The delivery of tablet-based rehabilitation for individuals with post-stroke aphasia is relatively new, therefore, this study examined the effectiveness of an iPad-based therapy to demonstrate improvement in specific therapy tasks and how the tasks affect overall language and cognitive skills. Fifty-one individuals with aphasia due to a stroke or traumatic brain injury (TBI) were recruited to use an iPad-based software platform, Constant Therapy, for a 10 week therapy program. Participants were split into an experimental (N = 42) and control (N = 9) group. Both experimental and control participants received a 1 h clinic session with a clinician once a week, the experimental participants additionally practiced the therapy at home. Participants did not differ in the duration of the therapy and both groups of participants showed improvement over time in the tasks used for the therapy. However, experimental participants used the application more often and showed greater changes in accuracy and latency on the tasks than the control participants; experimental participants' severity level at baseline as measured by standardized tests of language and cognitive skills were a factor in improvement on the tasks. Subgroups of task co-improvement appear to occur between different language tasks, between different cognitive tasks, and across both domains. Finally, experimental participants showed more significant and positive changes due to therapy in their standardized tests than control participants. These results provide preliminary evidence for the usefulness of a tablet-based platform to deliver tailored language and cognitive therapy to individuals with aphasia.	[Des Roches, Carrie A.; Balachandran, Isabel; Ascenso, Elsa M.; Kiran, Swathi] Boston Univ, Speech Hearing & Language Sci Sargent Coll, Aphasia Res Lab, Boston, MA 02215 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA	Des Roches, CA (corresponding author), Boston Univ, Speech Hearing & Language Sci Sargent Coll, Aphasia Res Lab, 635 Commonwealth Ave,Rm 326, Boston, MA 02215 USA.	cadesroc@gmail.com	Des Roches, Carrie/G-3314-2014	Des Roches, Carrie/0000-0001-5593-9347; Tripodis, Yorghos/0000-0003-2190-7608	Coulter Foundation for Translational Research	This project was funded by the Coulter Foundation for Translational Research. The authors thank Stephanie Keifer, Sahil Luthra, and Anna Kasdan for their contributions to the project and for their assistance in data collection.	Akerlund E, 2013, BRAIN INJURY, V27, P1649, DOI 10.3109/02699052.2013.830195; Allen L, 2012, TOP STROKE REHABIL, V19, P523, DOI 10.1310/tsr1906-523; Atticks A. H., 2012, GERONTOLOGY, V17, P84, DOI [10.1044/gero17.3.84, DOI 10.1044/GERO17.3.84]; Bakheit AMO, 2007, CLIN REHABIL, V21, P885, DOI 10.1177/0269215507078486; Barnes DE, 2009, ALZ DIS ASSOC DIS, V23, P205, DOI 10.1097/WAD.0b013e31819c6137; Bhogal SK, 2003, STROKE, V34, P987, DOI 10.1161/01.STR.0000062343.64383.D0; Bowen A, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4407; Cherney LR, 2008, J SPEECH LANG HEAR R, V51, P1282, DOI 10.1044/1092-4388(2008/07-0206); Cherney Leora R., 2010, Seminars in Speech and Language, V31, P42, DOI 10.1055/s-0029-1244952; Doesborgh S, 2004, APHASIOLOGY, V18, P213, DOI 10.1080/02687030344000580; Fink RB, 2002, APHASIOLOGY, V16, P1061, DOI 10.1080/02687030244000400; Finn M, 2011, BRAIN IMPAIR, V12, P187; Goodglass H., 1983, REVISED BOSTON NAMIN; Helm-Estabrooks N., 2001, COGNITIVE LINGUISTIC; Holland AL, 2014, SEMIN SPEECH LANG, V35, P1, DOI 10.1055/s-0033-1362994; Hoover EL, 2014, SEMIN SPEECH LANG, V35, P25, DOI 10.1055/s-0033-1362990; Howard D., 1992, PYRAMIDS PALM TREES; Hussey EK, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00158; Johansson B, 2012, SCAND J OCCUP THER, V19, P176, DOI 10.3109/11038128.2011.603352; Katz RC, 1997, J SPEECH LANG HEAR R, V40, P493, DOI 10.1044/jslhr.4003.493; Kelly H, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000425.pub2, 10.1002/14651858.CD000425.pub3]; Kertesz A, 1982, W APHASIA BATTERY TE; Kiran S, 2005, APHASIOLOGY, V19, P53, DOI 10.1080/02687030444000633; Kiran S, 2001, APHASIOLOGY, V15, P855, DOI 10.1080/02687040143000258; Kiran S, 2014, SEMIN SPEECH LANG, V35, P38, DOI 10.1055/s-0033-1362995; Kohnert K, 2004, BRAIN LANG, V91, P294, DOI 10.1016/j.bandl.2004.04.001; Kurland J, 2014, SEMIN SPEECH LANG, V35, P51, DOI 10.1055/s-0033-1362991; Kurland J, 2014, SEMIN SPEECH LANG, V35, P3, DOI 10.1055/s-0033-1362989; Lee JB, 2009, APHASIOLOGY, V23, P885, DOI 10.1080/02687030802669534; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Palmer R, 2012, STROKE, V43, P1904, DOI 10.1161/STROKEAHA.112.650671; Pedersen PM, 2004, CEREBROVASC DIS, V17, P35, DOI 10.1159/000073896; Pedersen PM, 2001, APHASIOLOGY, V15, P151, DOI 10.1080/02687040042000106; Ralph MAL, 2010, NEUROPSYCHOL REHABIL, V20, P289, DOI 10.1080/09602010903237875; Ramsberger G, 2007, AM J SPEECH-LANG PAT, V16, P343, DOI 10.1044/1058-0360(2007/038); Ramsberger G, 2014, SEMIN SPEECH LANG, V35, P17, DOI 10.1055/s-0033-1362992; Raymer AM, 2008, J SPEECH LANG HEAR R, V51, pS259, DOI 10.1044/1092-4388(2008/020); Slevc LR, 2013, BEHAV BRAIN SCI, V36, P373, DOI 10.1017/S0140525X12002683; Szabo G, 2014, SEMIN SPEECH LANG, V35, P5, DOI 10.1055/s-0033-1362993; Teasell R, 2012, TOP STROKE REHABIL, V19, P457, DOI 10.1310/tsr1906-457; van de Sandt-Koenderman WME, 2011, INT J SPEECH-LANG PA, V13, P21, DOI 10.3109/17549507.2010.502973; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Zickefoose S, 2013, BRAIN INJURY, V27, P707, DOI 10.3109/02699052.2013.775484	43	58	58	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	JAN 5	2015	8								1015	10.3389/fnhum.2014.01015			29	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AY3YO	WOS:000347515500001	25601831	DOAJ Gold, Green Published			2021-06-18	
J	Mangat, HS; Chiu, YL; Gerber, LM; Alimi, M; Ghajar, J; Hartl, R				Mangat, Halinder S.; Chiu, Ya-Lin; Gerber, Linda M.; Alimi, Marjan; Ghajar, Jamshid; Haertl, Roger			Hypertonic saline reduces cumulative and daily intracranial pressure burdens after severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hypertonic saline; mannitol; intracranial pressure; ICP burden	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; BLOOD-FLOW; SODIUM-CHLORIDE; MANNITOL; HYPERTENSION; ICP; HYPERNATREMIA; EXPERIENCE; REDUCTION	OBJECT Increased intracranial pressure (ICP) in patients with traumatic brain injury (TBI) is associated with a higher mortality rate and poor outcome. Mannitol and hypertonic saline (HIS) have both been used to treat high ICP, but it is unclear which one is more effective. Here, the authors compare the effect of mannitol versus HTS on lowering the cumulative and daily ICP burdens after severe TBI. METHODS The Brain Trauma Foundation TBI-trac New York State database was used for this retrospective study. Patients with severe TBI and intracranial hypertension who received only 1 type of hyperosmotic agent, mannitol or HIS, were included. Patients in the 2 groups were individually matched for Glasgow Coma Scale score (GCS), pupillary reactivity, craniotomy, occurrence of hypotension on Day 1, and the day of ICP monitor insertion. Patients with missing or erroneous data were excluded. Cumulative and daily ICP burdens were used as primary outcome measures. The cumulative ICP burden was defined as the total number of days with an ICP of > 25 mm Hg, expressed as a percentage of the total number of days of ICP monitoring. The daily ICP burden was calculated as the mean daily duration of an ICP of > 25 mm Hg, expressed as the number of hours per day. The numbers of intensive care unit (ICU) days, numbers of days with ICP monitoring, and 2-week mortality rates were also compared between the groups. A 2-sample t-test or chi-square test was used to compare independent samples. The Wilcoxon signed-rank or Cochran-Mantel-Haenszel test was used for comparing matched samples. RESULTS A total of 35 patients who received only HTS and 477 who received only mannitol after severe TBI were identified. Eight patients in the HTS group were excluded because of erroneous or missing data, and 2 other patients did not have matches in the mannitol group. The remaining 25 patients were matched 1:1. Twenty-four patients received 3% HTS, and 1 received 23.4% HTS as bolus therapy. All 25 patients in the mannitol group received 20% mannitol. The mean cumulative ICP burden (15.52% [HIS] vs 36.5% [mannitol]; p = 0.003) and the mean (SD) daily ICP burden (0.3 +/- 0.6 hours/day [HIS] vs 1.3 +/- 1.3 hours/day [mannitol]; p = 0.001) were significantly lower in the HIS group. The mean ( SD) number of ICU days was significantly lower in the HIS group than in the mannitol group (8.5 +/- 2.1 vs 9.8 +/- 0.6, respectively; p = 0.004), whereas there was no difference in the numbers of days of ICP monitoring (p = 0.09). There were no significant differences between the cumulative median doses of HIS and mannitol (p = 0.19). The 2-week mortality rate was lower in the HIS group, but the difference was not statistically significant (p = 0.56). CONCLUSIONS HIS given as bolus therapy was more effective than mannitol in lowering the cumulative and daily ICP burdens after severe TBI. Patients in the HIS group had significantly lower number of ICU days. The 2-week mortality rates were not statistically different between the 2 groups.	[Mangat, Halinder S.] Weill Cornell Brain & Spine Ctr, Dept Neurol, New York, NY USA; [Mangat, Halinder S.; Alimi, Marjan; Ghajar, Jamshid; Haertl, Roger] Weill Cornell Brain & Spine Ctr, Dept Neurol Surg, New York, NY USA; [Chiu, Ya-Lin; Gerber, Linda M.] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10065 USA; [Gerber, Linda M.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA; [Mangat, Halinder S.; Alimi, Marjan; Haertl, Roger] NewYork Presbyterian Hosp, New York, NY USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA	Mangat, HS (corresponding author), Weill Cornell Med Coll, Dept Neurol, Div Neurocrit Care, 525 E 68 St,F-610, New York, NY 10065 USA.	hsm9001@med.cornell.edu	Mangat, HALINDER/AAN-9153-2020	Mangat, HALINDER/0000-0003-3426-2001	New York State Department of Health, the Brain Trauma Foundation; NewYork-Presbyterian Hospital TBI fund; Clinical Translational Science Center, National Center for Advancing Translational Sciences [UL1-TR000457-06]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000457] Funding Source: NIH RePORTER	We thank the New York State Department of Health, the Brain Trauma Foundation, and the NewYork-Presbyterian Hospital TBI fund for their financial support. We gratefully acknowledge additional support from Clinical Translational Science Center, National Center for Advancing Translational Sciences, grant no. UL1-TR000457-06.	Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Farahvar A, 2011, J NEUROSURG, V115, P191, DOI 10.3171/2011.4.JNS101116a; FLURY BK, 1986, AM STAT, V40, P249, DOI 10.2307/2684560; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Hartl R, 1997, ZBL CHIR, V122, P181; Hartl R, 1997, ACT NEUR S, V70, P126; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Hartl R, 1997, ACT NEUR S, V70, P40; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Jones PA, 2005, ACT NEUR S, V95, P29; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Marks JA, 2012, J TRAUMA ACUTE CARE, V73, P351, DOI 10.1097/TA.0b013e3182592f76; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NATH F, 1986, J NEUROSURG, V65, P41, DOI 10.3171/jns.1986.65.1.0041; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; ROSENBAUM PR, 1989, J AM STAT ASSOC, V84, P1024, DOI 10.2307/2290079; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Schatzmann C, 1998, ACT NEUR S, V71, P31; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; SMITH HP, 1986, J NEUROSURG, V65, P820, DOI 10.3171/jns.1986.65.6.0820; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Wainwright Mark S, 2012, Acta Neurochir Suppl, V114, P67, DOI 10.1007/978-3-7091-0956-4_12; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Wells DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11678; WILLERSON JT, 1975, CIRCULATION, V51, P1095, DOI 10.1161/01.CIR.51.6.1095; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011	56	58	64	1	14	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2015	122	1					202	210		10.3171/2014.10.JNS132545			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AX5DQ	WOS:000346947600029	25380107	Bronze			2021-06-18	
J	Huang, L; Wong, SN; Snyder, EY; Hamblin, MH; Lee, JP				Huang, Lei; Wong, Sunnie; Snyder, Evan Y.; Hamblin, Milton H.; Lee, Jean-Pyo			Human neural stem cells rapidly ameliorate symptomatic inflammation in early-stage ischemic-reperfusion cerebral injury	STEM CELL RESEARCH & THERAPY			English	Article							BLOOD-BRAIN-BARRIER; MATRIX-METALLOPROTEINASE; PLASMINOGEN-ACTIVATOR; ARTERY OCCLUSION; TRAUMATIC BRAIN; STROKE; RAT; PROTEIN; MICE; MATRIX-METALLOPROTEINASE-9	Introduction: Clinically, a good deal of injury from stroke results from ischemic-reperfusion. There is a loss of cerebral parenchyma and its associated cells, disruption of neuronal connections, compromise of the blood-brain barrier, and inflammation. We tested whether exogenously engrafted human neural stem cells could migrate rapidly and extensively to damaged regions, following transplantation into a neurogenic site where migration cues are already underway during stroke onset, then counteract a number of these pathological processes. Methods: One day post-injury, we injected human neural stem cells (hNSCs) into the ipsilesional hippocampus of a mouse model of stroke with middle cerebral artery occlusion to induce focal ischemia followed by reperfusion (MCAO/R). The time frame for hNSC transplantation corresponded to upregulation of endogenous proinflammatory cytokines. We examined the effect of hNSC transplantation on pathological processes and behavioral dysfunction 48 hours post-injury. Results: Twenty-four hours after transplantation, engrafted hNSCs had migrated extensively to the lesion, and infarct volume was reduced relative to MCAO/R controls. The behavioral deficits seen in MCAO/R controls were also significantly improved. Given this rapid response, we hypothesized that the mechanisms underlying therapeutic activity were anti-inflammatory rather than due to cell replacement. In support of this idea, in hNSC-transplanted mice we observed reduced microglial activation, decreased expression of proinflammatory factors (tumor necrosis factor-alpha, interleukin (IL)-6, IL-1 beta, monocyte chemotactic protein-1, macrophage inflammatory protein-1 alpha) and adhesion molecules (intercellular adhesion molecule-1, vascular cell adhesion molecule-1), and amelioration of blood-brain barrier damage. Conclusions: While long-term effects of engrafted hNSCs on the amelioration of ischemic stroke-induced behavioral dysfunction in a rodent model have been reported, our study is the first to show rapid, beneficial impacts on behavioral function (within 24 hours) upon early delivery of hNSCs into the hippocampus.	[Huang, Lei; Wong, Sunnie; Hamblin, Milton H.; Lee, Jean-Pyo] Tulane Univ, Sch Med, Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70112 USA; [Snyder, Evan Y.; Lee, Jean-Pyo] Ctr Neurosci Aging & Stem Cells, Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA	Lee, JP (corresponding author), Tulane Univ, Sch Med, Ctr Stem Cell Res & Regenerat Med, 1430 Tulane Ave,SL-99, New Orleans, LA 70112 USA.	jeanpyol@tulane.edu			Tulane Center for Stem Cell Research and Regenerative Medicine	We thank Dr. Gary Rosenberg, University of New Mexico, for his helpful scientific discussions and Courtney Louvre and Justin Chen, Tulane University, for technical assistance. This work was supported by startup funds from the Tulane Center for Stem Cell Research and Regenerative Medicine.	Asahi M, 2001, J NEUROSCI, V21, P7724; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Castellanos M, 2003, STROKE, V34, P40, DOI 10.1161/01.STR.0000046764.57344.31; Clark WM, 1997, NEUROL RES, V19, P641; Darsalia V, 2011, J CEREBR BLOOD F MET, V31, P235, DOI 10.1038/jcbfm.2010.81; DEFILIPPI P, 1992, J BIOL CHEM, V267, P18303; Emanueli C, 2003, BRIT J PHARMACOL, V140, P614, DOI 10.1038/sj.bjp.0705458; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hu Xueyou, 2010, J Vis Exp, DOI 10.3791/2445; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jeyakumar M, 2009, STEM CELLS, V27, P2362, DOI 10.1002/stem.163; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kuntz M, 2014, J CEREBR BLOOD F MET, V34, P95, DOI 10.1038/jcbfm.2013.169; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; Lee JP, 2007, NAT MED, V13, P439, DOI 10.1038/nm1548; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mishiro K, 2012, NEUROSCIENCE, V205, P39, DOI 10.1016/j.neuroscience.2011.12.042; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; O'Neill M J, 2001, Curr Protoc Neurosci, VChapter 9, DOI [10.1002/0471142301.ns0905s12, 10.1002/0471142301.ns0906s12]; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Pettigrew LC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-47; Quinn LP, 2007, J NEUROSCI METH, V164, P43, DOI 10.1016/j.jneumeth.2007.03.021; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosell A, 2008, CURR OPIN PHARMACOL, V8, P82, DOI 10.1016/j.coph.2007.12.001; Rossi B, 2011, J LEUKOCYTE BIOL, V89, P539, DOI 10.1189/jlb.0710432; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Tureyen K, 2004, J NEUROSCI METH, V139, P203, DOI 10.1016/j.jneumeth.2004.04.029; Virley D, 2000, J CEREBR BLOOD F MET, V20, P563, DOI 10.1097/00004647-200003000-00015; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212	44	58	61	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1757-6512		STEM CELL RES THER	Stem Cell Res. Ther.	NOV 23	2014	5								129	10.1186/scrt519			16	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	AY2OB	WOS:000347428300001	25418536	DOAJ Gold, Green Published			2021-06-18	
J	Louey, AG; Cromer, JA; Schembri, AJ; Darby, DG; Maruff, P; Makdissi, M; Mccrory, P				Louey, Andrea G.; Cromer, Jason A.; Schembri, Adrian J.; Darby, David G.; Maruff, Paul; Makdissi, Michael; Mccrory, Paul			Detecting Cognitive Impairment After Concussion: Sensitivity of Change From Baseline and Normative Data Methods Using the CogSport/Axon Cognitive Test Battery	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; mTBI; Cognition; Assessment; Injury management; Neuropsychological evaluation	NEUROCOGNITIVE TEST-PERFORMANCE; TEST-RETEST INTERVALS; BIOPSYCHOSOCIAL CHARACTERISTICS; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SPORTS-MEDICINE; RELIABILITY; SCORES; MANAGEMENT; PLAYERS	Concussion-related cognitive impairments are typically evaluated with repeated neuropsychological assessments where post-injury performances are compared with pre-injury baseline data (baseline method). Many cases of concussions, however, are evaluated in the absence of baseline data by comparing post-injury performances with normative data (normative method). This study aimed to compare the sensitivity and specificity of these two methods using the CogSport/Axon test battery. Normative data and reliable change indices were computed from a non-injured athlete sample (n = 235). Test-retest data from non-injured (n = 260) and recently concussed (n = 29) athlete samples were then used to compare the two methods. The baseline method was found to be more sensitive than the normative method, and both methods had high specificity and overall correct classification rates. This suggests that while the normative method identifies most cases of recent concussions, the baseline method remains a more precise approach to assessing concussion-related cognitive impairments.	[Louey, Andrea G.] Univ Melbourne, Melbourne Sch Psychol Sci, Parkville, Vic 3052, Australia; [Cromer, Jason A.; Schembri, Adrian J.; Maruff, Paul] CogState Ltd, Melbourne, Vic 3000, Australia; [Cromer, Jason A.] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA; [Darby, David G.; Maruff, Paul; Makdissi, Michael; Mccrory, Paul] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Makdissi, Michael] Univ Melbourne, Melbourne Physiotherapy Dept, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia	Maruff, P (corresponding author), CogState Ltd, Melbourne, Vic 3000, Australia.	pmaruff@cogstate.com	Maruff, Paul/AAD-2454-2021; McCrory, Paul/Q-8688-2019; Maruff, Paul/ABA-1673-2020	Maruff, Paul/0000-0002-6947-9537; McCrory, Paul/0000-0003-4850-0568	CogState	Paul McCrory has received consultancy fees from CogState.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brown CN, 2007, J ATHL TRAINING, V42, P515; Bruckner CT, 2006, AM J MENT RETARD, V111, P433, DOI 10.1352/0895-8017(2006)111[433:IKIORB]2.0.CO;2; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Crawford JR, 1998, J CLIN EXP NEUROPSYC, V20, P755, DOI 10.1076/jcen.20.5.755.1132; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Gardner A, 2012, APPL NEUROPSYCH-ADUL, V19, P90, DOI 10.1080/09084282.2011.643945; GLAROS AG, 1988, J CLIN PSYCHOL, V44, P1013, DOI 10.1002/1097-4679(198811)44:6<1013::AID-JCLP2270440627>3.0.CO;2-Z; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hinton-Bayre AD, 2012, CLIN J SPORT MED, V22, P105, DOI 10.1097/JSM.0b013e318248a526; Hinton-Bayre AD, 2010, ARCH CLIN NEUROPSYCH, V25, P244, DOI 10.1093/arclin/acq008; Hopkins WG, 2000, SPORTS MED, V30, P1, DOI 10.2165/00007256-200030010-00001; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2011, APPL NEUROPSYCHOL, V18, P197, DOI 10.1080/09084282.2011.595446; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Salinas CM, 2012, J CLIN SPORT PSYCHOL, V6, P363, DOI 10.1123/jcsp.6.4.363; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Solomon GS, 2013, ARCH CLIN NEUROPSYCH, V28, P9, DOI 10.1093/arclin/acs108; Strauss E, 2006, COMPENDIUM NEUROPSYC, P44	38	58	58	0	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2014	29	5					432	441		10.1093/arclin/acu020			10	Psychology, Clinical; Psychology	Psychology	AM6AZ	WOS:000339944200004	24813184	Green Published, Bronze			2021-06-18	
J	Hutchison, MG; Lawrence, DW; Cusimano, MD; Schweizer, TA				Hutchison, Michael G.; Lawrence, David W.; Cusimano, Michael D.; Schweizer, Tom A.			Head Trauma in Mixed Martial Arts	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						mixed martial arts (MMA); knockout; concussion; head injury; technical knockout; video analysis	CONCUSSION; INJURIES; VICTORIA; FOOTBALL; STATE; SPORT	Background: Mixed martial arts (MMA) is a full combative sport with a recent global increase in popularity despite significant scrutiny from medical associations. To date, the empirical research of the risk of head injuries associated with this sport is limited. Youth and amateur participation is growing, warranting investigation into the burden and mechanism of injuries associated with this sport. Purpose: (1) To determine the incidence, risk factors, and characteristics of knockouts (KOs) and technical knockouts (TKOs) from repetitive strikes in professional MMA; and (2) to identify the mechanisms of head trauma and the situational factors that lead to KOs and TKOs secondary to repetitive strikes through video analysis. Study Design: Descriptive epidemiology study. Methods: Competition data and video records for all KOs and TKOs from numbered Ultimate Fighting Championship MMA events (n = 844) between 2006 to 2012. Analyses included (1) multivariate logistic regression to investigate factors associated with an increased risk of sustaining a KO or TKO secondary to repetitive strikes and (2) video analysis of all KOs and TKOs secondary to repetitive strikes with descriptive statistics. Results: During the study period, the KO rate was 6.4 per 100 athlete-exposures (AEs) (12.7% of matches), and the rate of TKOs secondary to repetitive strikes was 9.5 per 100 AEs (19.1% of matches), for a combined incidence of match-ending head trauma of 15.9 per 100 AEs (31.9% of matches). Logistic regression identified that weight class, earlier time in a round, earlier round in a match, and older age were risk factors for both KOs and TKOs secondary to repetitive strikes. Match significance and previously sustained KOs or TKOs were also risk factors for KOs. Video analysis identified that all KOs were the result of direct impact to the head, most frequently a strike to the mandibular region (53.9%). The average time between the KO-strike and match stoppage was 3.5 seconds (range, 0-20 seconds), with losers sustaining an average of 2.6 additional strikes (range, 0-20 strikes) to the head. For TKOs secondary to strikes, in the 30-second interval immediately preceding match stoppage, losers sustained, on average, 18.5 strikes (range, 5-46 strikes), with 92.3% of these being strikes to the head. Conclusion: Rates of KOs and TKOs in MMA are higher than previously reported rates in other combative and contact sports. Public health authorities and physicians should be cognizant of the rates and mechanisms of head trauma. Preventive measures to lessen the risks of head trauma for those who elect to participate in MMA are described.	[Hutchison, Michael G.; Lawrence, David W.; Cusimano, Michael D.; Schweizer, Tom A.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada	Hutchison, MG (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	One or more of the authors has declared the following potential conflict of interest or source of funding: This study was funded through a grant from the Canadian Institutes of Health Research Strategic Teams in Applied Injury Research. The funding agency had no role in the design of the study; the collection, analysis, or interpretation of data; the writing of the report; or the decision to submit the article for publication.	American Medical Association, H 470 965 ULT EXTR F; Australian Medical Association, MIX MART ARTS MUST B; Bearak B, 2011, NY TIMES, pD1; Bledsoe GH, 2006, J SPORT SCI MED, V5, P136; Brown R, 2012, MINNESOTA COMBATIVE; Buse GJ, 2006, BRIT J SPORT MED, V40, P169, DOI 10.1136/bjsm.2005.021295; Canadian Medical Association, MIX MART ARTS MMA BA; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; George C, BOXING UPDATE BOARD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hutchison MG, 2015, BRIT J SPORT MED, V49, P552, DOI 10.1136/bjsports-2013-092235; Kim M, 2010, SPORTS LAW J, V17, P49; Lawrence DW, 2014, CLIN J SPORT MED, V24, P397, DOI 10.1097/JSM.0000000000000047; Martin D, UFC 124 ATTENDANCE R; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Ngai KM, 2008, BRIT J SPORT MED, V42, P686, DOI 10.1136/bjsm.2007.044891; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pishna K, UFC 129 GATE RECEIPT; Rainey Charles E, 2009, N Am J Sports Phys Ther, V4, P190; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Ultimate Fighting Championship, SPORT; Ultimate Fighting Championship, WAYS WIN; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321	28	58	58	1	36	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUN	2014	42	6					1352	1358		10.1177/0363546514526151			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AN6QO	WOS:000340721400018	24658345				2021-06-18	
J	Blaya, MO; Bramlett, HM; Naidoo, J; Pieper, AA; Dietrich, WD				Blaya, Meghan O.; Bramlett, Helen M.; Naidoo, Jacinth; Pieper, Andrew A.; Dietrich, W. Dalton			Neuroprotective Efficacy of a Proneurogenic Compound after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adult hippocampal neurogenesis; functional recovery; hippocampal-dependent memory; neuroprotection; traumatic brain injury	MAJOR TRAUMA; SEVERITY; MORTALITY; MODERATE; PATTERN; CARE; TBI	Traumatic brain injury (TBI) is characterized by histopathological damage and long-term sensorimotor and cognitive dysfunction. Recent studies have reported the discovery of the P7C3 class of aminopropyl carbazole agents with potent neuroprotective properties for both newborn neural precursor cells in the adult hippocampus and mature neurons in other regions of the central nervous system. This study tested, for the first time, whether the highly active P7C3-A20 compound would be neuroprotective, promote hippocampal neurogenesis, and improve functional outcomes after experimental TBI. Sprague-Dawley rats subjected to moderate fluid percussion brain injury were evaluated for quantitative immunohistochemical and behavioral changes after trauma. P7C3-A20 (10?mg/kg) or vehicle was initiated intraperitoneally 30?min postsurgery and twice per day every day thereafter for 7 days. Administration of P7C3-A20 significantly reduced overall contusion volume, preserved vulnerable anti-neuronal nuclei (NeuN)-positive pericontusional cortical neurons, and improved sensorimotor function 1 week after trauma. P7C3-A20 treatment also significantly increased both bromodeoxyuridine (BrdU)- and doublecortin (DCX)-positive cells within the subgranular zone of the ipsilateral dentate gyrus 1 week after TBI. Five weeks after TBI, animals treated with P7C3-A20 showed significantly increased BrdU/NeuN double-labeled neurons and improved cognitive function in the Morris water maze, compared to TBI-control animals. These results suggest that P7C3-A20 is neuroprotective and promotes endogenous reparative strategies after TBI. We propose that the chemical scaffold represented by P7C3-A20 provides a basis for optimizing and advancing new pharmacological agents for protecting patients against the early and chronic consequences of TBI.	[Blaya, Meghan O.; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Bruce W Carter Dept Vet Affairs Med Ctr, Miami, FL USA; [Naidoo, Jacinth] UT Southwestern Med Ctr, Dept Biochem, Dallas, TX USA; [Pieper, Andrew A.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City Dept Vet Affairs, Iowa City, IA 52242 USA; [Pieper, Andrew A.] Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City Dept Vet Affairs, Iowa City, IA 52242 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace, Miami, FL 33136 USA.	andrew-pieper@uiowa.edu; ddietrich@miami.edu	Pieper, Andrew A/R-5552-2016	Pieper, Andrew/0000-0001-6299-6577	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291]; Veterans AffairsUS Department of Veterans Affairs [1 I01 BX000521]; Transformative RO1 grant [NIMH 1RO1MH087986]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH087986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089443] Funding Source: NIH RePORTER	The authors thank Mr. David Sequeira, Mrs. Ofelia Furones-Alonso, and Ms. Jessie Truettner for their technical contributions to this study. The authors also thank Dr. Pantelis Tsoulfas for his critical review of the manuscript. The studies were funded by the National Institutes of Health (NS030291; to W. D. D.), Veterans Affairs (1 I01 BX000521; to H. M. B.), a Transformative RO1 grant (NIMH 1RO1MH087986) awarded to A. A. P. and Steven L. McKnight, and unrestricted endowment funds provided to Steven L. McKnight from an anonymous donor.	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Arregui-Dalmases C, 2010, ACCIDENT ANAL PREV, V42, P1164, DOI 10.1016/j.aap.2010.01.005; Association for the Advancement of Automotive Medicine, 1998, ABBR INJ SCAL UPD 19; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bener A, 2010, BRAIN INJURY, V24, P74, DOI 10.3109/02699050903508192; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Clarke C. F., 2012, NZMJ, V1349, P1; EuroSafe, 2013, INJ EUR UN REP INJ S; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Lanting L. C., 2009, NATL PUBLIC HLTH COM; Leijdesdorff HA, 2012, J TRAUMA ACUTE CARE, V72, P1363, DOI 10.1097/TA.0b013e318250cced; Lin MR, 2009, ACCIDENT ANAL PREV, V41, P710, DOI 10.1016/j.aap.2009.03.010; Liu B, 2008, COCHRANE DATABASE SY, V1; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Majdan M, 2012, EUR J PUBLIC HEALTH, V10, P1; Majdan M, 2011, BRAIN INJURY, V25, P797, DOI 10.3109/02699052.2011.581642; Perez K, 2012, ACCIDENT ANAL PREV, V46, P37, DOI 10.1016/j.aap.2011.12.004; Richards D, 2012, ACCIDENT ANAL PREV, V47, P16, DOI 10.1016/j.aap.2012.01.009; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; SKLAR DP, 1989, AM J EMERG MED, V7, P387, DOI 10.1016/0735-6757(89)90044-2; SWOV Institute for Road Safety Research, 2011, FACT SHEET ROAD FAT; SWOV Institute for Road Safety Research, 2009, FACT SHEET CYCL; SWOV Institute for Road Safety Research, 2007, FACT SHEET MOT MOP H; TEASDALE G, 1974, LANCET, V2, P81; Thompson D.C., 1999, COCHRANE DATABASE SY, V4; Tokdemir M., 2009, MED SCI MONIT, V1, pPI1; Van Camp L A, 1998, Eur J Emerg Med, V5, P207; World Health Organization, 2009, GLOB STAT REP ROAD S	31	58	59	2	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					476	486		10.1089/NEU.2013.3135			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600246	24070637	Green Published			2021-06-18	
J	Su, W; Hopkins, S; Nesser, NK; Sopher, B; Silvestroni, A; Ammanuel, S; Jayadev, S; Moller, T; Weinstein, J; Garden, GA				Su, Wei; Hopkins, Stephanie; Nesser, Nicole K.; Sopher, Bryce; Silvestroni, Aurelio; Ammanuel, Simon; Jayadev, Suman; Moeller, Thomas; Weinstein, Jonathan; Garden, Gwenn A.			The p53 Transcription Factor Modulates Microglia Behavior through MicroRNA-Dependent Regulation of c-Maf	JOURNAL OF IMMUNOLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; IL-10 GENE-EXPRESSION; TUMOR-SUPPRESSOR P53; DIFFERENTIAL REGULATION; CELL-DIFFERENTIATION; SCAVENGER RECEPTOR; C/EBP-BETA; MACROPHAGES; ACTIVATION; DISEASE	Neuroinflammation occurs in acute and chronic CNS injury, including stroke, traumatic brain injury, and neurodegenerative diseases. Microglia are specialized resident myeloid cells that mediate CNS innate immune responses. Disease-relevant stimuli, such as reactive oxygen species (ROS), can influence microglia activation. Previously, we observed that p53, a ROS-responsive transcription factor, modulates microglia behaviors in vitro and in vivo, promoting proinflammatory functions and suppressing downregulation of the inflammatory response and tissue repair. In this article we describe a novel mechanism by which p53 modulates the functional differentiation of microglia both in vitro and in vivo. Adult microglia from p53-deficient mice have increased expression of the anti-inflammatory transcription factor c-Maf. To determine how p53 negatively regulates c-Maf, we examined the impact of p53 on known c-Maf regulators. MiR-155 is a microRNA that targets c-Maf. We observed that cytokine-induced expression of miR-155 was suppressed in p53-deficient microglia. Furthermore, Twist2, a transcriptional activator of c-Maf, is increased in p53-deficient microglia. We identified recognition sites in the 39 untranslated region of Twist2 mRNA that are predicted to interact with two p53-dependent microRNAs: miR-34a and miR-145. In this article, we demonstrate that miR-34a and -145 are regulated by p53 and negatively regulate Twist2 and c-Maf expression in microglia and the RAW macrophage cell line. Taken together, these findings support the hypothesis that p53 activation induced by local ROS or accumulated DNA damage influences microglia functions and that one specific molecular target of p53 in microglia is c-Maf.	[Su, Wei; Hopkins, Stephanie; Nesser, Nicole K.; Sopher, Bryce; Silvestroni, Aurelio; Ammanuel, Simon; Jayadev, Suman; Moeller, Thomas; Weinstein, Jonathan; Garden, Gwenn A.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Jayadev, Suman; Weinstein, Jonathan; Garden, Gwenn A.] Univ Washington, Ctr Human Dev & Disabil, Seattle, WA 98195 USA	Garden, GA (corresponding author), Univ Washington, 1959 North East Pacific St, Seattle, WA 98195 USA.	gagarden@uw.edu	Jayadev, Suman/B-6362-2019; Moller, Thomas/W-8974-2019	Garden, Gwenn/0000-0002-8753-6515; Weinstein, Jonathan/0000-0001-6080-9758	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS073848, R03NS70141, R21NS062269];  [P30-HD02274]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD083091, P30HD002274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS062269, R03NS070141, R01NS073848, R01NS076620] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants R01NS073848, R03NS70141, and R21NS062269 (to G.A.G.), with facilities support from Grant P30-HD02274 to the University of Washington Center on Human Development and Disability.	Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Aktas O, 2007, ARCH NEUROL-CHICAGO, V64, P185, DOI 10.1001/archneur.64.2.185; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Arnaud L, 2006, NEURODEGENER DIS, V3, P313, DOI 10.1159/000095638; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bird L, 2011, NAT REV IMMUNOL, V11, P76, DOI 10.1038/nri2924; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Cao SJ, 2005, J IMMUNOL, V174, P3484, DOI 10.4049/jimmunol.174.6.3484; Cao SJ, 2002, J IMMUNOL, V169, P5715, DOI 10.4049/jimmunol.169.10.5715; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Dai R, 2011, TRANSL RES, V157, P163, DOI 10.1016/j.trsl.2011.01.007; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; Davenport CM, 2010, J NEUROCHEM, V112, P552, DOI 10.1111/j.1471-4159.2009.06485.x; De Haas AH, 2007, GLIA, V55, P1374, DOI 10.1002/glia.20554; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Feng ZH, 2011, J MOL CELL BIOL, V3, P44, DOI 10.1093/jmcb/mjq040; Garden GA, 2004, FASEB J, V18, P1141, DOI 10.1096/fj.04-1676fje; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; Ho IC, 1998, J EXP MED, V188, P1859, DOI 10.1084/jem.188.10.1859; Homma Y, 2007, J INTERF CYTOK RES, V27, P799, DOI 10.1089/jir.2007.0006; Jayadev S, 2007, J NEUROIMMUNE PHARM, V2, P359, DOI 10.1007/s11481-007-9095-x; Jayadev S, 2011, GLIA, V59, P1402, DOI 10.1002/glia.21178; Jebelli JD, 2012, GLIA, V60, P515, DOI 10.1002/glia.22268; Kataoka K, 2007, J BIOCHEM, V141, P775, DOI 10.1093/jb/mvm105; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu FY, 2012, CURR MOL MED, V12, P917; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Louafi F, 2010, J BIOL CHEM, V285, P41328, DOI 10.1074/jbc.M110.146852; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Martinez-Nunez RT, 2011, J BIOL CHEM, V286, P1786, DOI 10.1074/jbc.M110.169367; Mendrysa Susan M, 2011, Genes Cancer, V2, P431, DOI 10.1177/1947601911409736; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Moestrup SK, 2004, ANN MED, V36, P347, DOI 10.1080/07853890410033171; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Muir KW, 2007, CURR OPIN NEUROL, V20, P334, DOI 10.1097/WCO.0b013e32813ba151; Mukhopadhyay S, 2006, EUR J IMMUNOL, V36, P940, DOI 10.1002/eji.200535389; Nakamura M, 2009, GENE, V445, P66, DOI 10.1016/j.gene.2009.06.003; Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528; Perruisseau-Carrier C, 2011, MOL NEUROBIOL, V43, P215, DOI 10.1007/s12035-011-8179-z; Ponomarev ED, 2005, J NEUROSCI RES, V81, P374, DOI 10.1002/jnr.20488; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Rani A, 2011, J IMMUNOL, V187, P3721, DOI 10.4049/jimmunol.1002354; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rickard AJ, 2009, J MOL ENDOCRINOL, V42, P449, DOI 10.1677/JME-08-0144; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Ruffell D, 2009, P NATL ACAD SCI USA, V106, P17475, DOI 10.1073/pnas.0908641106; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Salmina AB, 2009, J ALZHEIMERS DIS, V16, P485, DOI 10.3233/JAD-2009-0988; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Sharabi AB, 2008, PLOS BIOL, V6, P2786, DOI 10.1371/journal.pbio.0060316; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620; Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zambelli F, 2009, NUCLEIC ACIDS RES, V37, pW247, DOI 10.1093/nar/gkp464	78	58	61	0	10	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	JAN 1	2014	192	1					358	366		10.4049/jimmunol.1301397			9	Immunology	Immunology	279HJ	WOS:000328950700037	24319262	Green Accepted, Bronze			2021-06-18	
J	Washington, PM; Morffy, N; Parsadanian, M; Zapple, DN; Burns, MP				Washington, Patricia M.; Morffy, Nicholas; Parsadanian, Maia; Zapple, David N.; Burns, Mark P.			Experimental Traumatic Brain Injury Induces Rapid Aggregation and Oligomerization of Amyloid-Beta in an Alzheimer's Disease Mouse Model	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; beta amyloid	CONTROLLED CORTICAL IMPACT; A-BETA; PRECURSOR PROTEIN; HEAD-INJURY; TRANSGENIC MICE; APOLIPOPROTEIN E4; INDUCED INCREASES; PEPTIDE; DEPOSITION; ACCUMULATION	Soluble amyloid-beta (A) oligomers are hypothesized to be the pathogenic species in Alzheimer's disease (AD), and increased levels of oligomers in the brain subsequent to traumatic brain injury (TBI) may exacerbate secondary injury pathways and underlie increased risk of developing AD in later life. To determine whether TBI causes A aggregation and oligomerization in the brain, we exposed triple transgenic AD model mice to controlled cortical impact injury and measured levels of soluble, insoluble, and oligomeric A by enzyme-linked immunosorbent assay (ELISA) at 1, 3, and 7 days postinjury. TBI rapidly increased levels of both soluble and insoluble A40 and A42 in the injured cortex at 1 day postinjury. We confirmed previous findings that identified damaged axons as a major site of A accumulation using both immunohistochemistry and biochemistry. We also report that soluble A oligomers were significantly increased in the injured cortex, as demonstrated by both ELISA and Western blot. Interestingly, the mouse brain is able to rapidly clear trauma-induced A, with both soluble and insoluble A species returning to sham levels by 7 days postinjury. In conclusion, we demonstrate that TBI causes acute accumulation and aggregation of A in the brain, including the formation of low- and high-molecular-weight A oligomers. The formation and aggregation of A into toxic species acutely after injury may play a role in secondary injury cascades after trauma and, chronically, may contribute to increased risk of developing AD in later life.	[Washington, Patricia M.; Morffy, Nicholas; Parsadanian, Maia; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20007 USA; [Zapple, David N.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA	Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Bldg WP22a,3970 Reservoir Rd NW, Washington, DC 20007 USA.	mpb37@georgetown.edu		Morffy, Nicholas/0000-0003-3170-2032; Burns, Mark P/0000-0003-4750-2000	National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS081068, R03NS067417]; Cosmos Club Foundation's Young Scholars Grant Program; Georgetown University Medical Center Graduate Student Organization's Student Research Grants Program;  [T32NS041218]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS041218, R03NS067417, R01NS081068] Funding Source: NIH RePORTER	The project described above was supported by R01NS081068 and R03NS067417 (to M. P. B.) from the National Institute of Neurological Disorders and Stroke (NINDS) and T32NS041218 (to P. M. W.; principal investigators, Drs. Jean Wrathall and Kathleen Maguire-Zeiss), the Cosmos Club Foundation's Young Scholars Grant Program (to P. M. W.), and the Georgetown University Medical Center Graduate Student Organization's Student Research Grants Program (to P. M. W.). The authors thank Drs. R. Scott Turner and Hyang-Sook Hoe for providing 3 x Tg AD model mice and Dr. Paul Mathews (Nathan S. Kline Institute, Orangeburg, NY) for C1/6.1 Ab.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Deshpande A, 2006, J NEUROSCI, V26, P6011, DOI 10.1523/JNEUROSCI.1189-06.2006; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; Gatson JW, 2013, J NEUROSURG, V118, P1336, DOI 10.3171/2013.2.JNS121771; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hirata-Fukae C, 2008, BRAIN RES, V1216, P92, DOI 10.1016/j.brainres.2008.03.079; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Li SM, 2013, NEURON, V77, P929, DOI 10.1016/j.neuron.2012.12.040; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; OTVOS L, 1993, EUR J BIOCHEM, V211, P249, DOI 10.1111/j.1432-1033.1993.tb19893.x; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pryor NE, 2012, INT J MOL SCI, V13, P3038, DOI 10.3390/ijms13033038; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Savage MJ, 1998, J NEUROSCI, V18, P1743; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Xia WM, 2009, ARCH NEUROL-CHICAGO, V66, P190, DOI 10.1001/archneurol.2008.565	60	58	58	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2014	31	1					125	134		10.1089/neu.2013.3017			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302WJ	WOS:000330635500011	24050316	Green Published			2021-06-18	
J	Winston, CN; Chellappa, D; Wilkins, T; Barton, DJ; Washington, PM; Loane, DJ; Zapple, DN; Burns, MP				Winston, Charisse N.; Chellappa, Deepa; Wilkins, Tiffany; Barton, David J.; Washington, Patricia M.; Loane, David J.; Zapple, David N.; Burns, Mark P.			Controlled Cortical Impact Results in an Extensive Loss of Dendritic Spines that Is Not Mediated by Injury-Induced Amyloid-Beta Accumulation	JOURNAL OF NEUROTRAUMA			English	Article						amyloid beta; brain trauma; controlled cortical impact; dendritic spine; gamma-secretase inhibitor	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; IN-VIVO; PYRAMIDAL NEURONS; GAMMA-SECRETASE; MODEL; MILD; MICE; ACTIVATION; DEPOSITION	The clinical manifestations that occur after traumatic brain injury (TBI) include a wide range of cognitive, emotional, and behavioral deficits. The loss of excitatory synapses could potentially explain why such diverse symptoms occur after TBI, and a recent preclinical study has demonstrated a loss of dendritic spines, the postsynaptic site of the excitatory synapse, after fluid percussion injury. The objective of this study was to determine if controlled cortical impact (CCI) also resulted in dendritic spine retraction and to probe the underlying mechanisms of this spine loss. We used a unilateral CCI and visualized neurons and dendtritic spines at 24 h post-injury using Golgi stain. We found that TBI caused a 32% reduction of dendritic spines in layer II/III of the ipsilateral cortex and a 20% reduction in the dendritic spines of the ipsilateral dentate gyrus. Spine loss was not restricted to the ipsilateral hemisphere, however, with similar reductions in spine numbers recorded in the contralateral cortex (25% reduction) and hippocampus (23% reduction). Amyloid-beta (A beta), a neurotoxic peptide commonly associated with Alzheimer disease, accumulates rapidly after TBI and is also known to cause synaptic loss. To determine if A beta contributes to spine loss after brain injury, we administered a gamma-secretase inhibitor LY450139 after TBI. We found that while LY450139 administration could attenuate the TBI-induced increase in A beta, it had no effect on dendritic spine loss after TBI. We conclude that the acute, global loss of dendritic spines after TBI is independent of gamma-secretase activity or TBI-induced A beta accumulation.	[Winston, Charisse N.; Chellappa, Deepa; Wilkins, Tiffany; Barton, David J.; Washington, Patricia M.; Zapple, David N.; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20057 USA; [Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Loane, David J.] Univ Maryland, Sch Med, Ctr Shock,Trauma & Anesthesiol Res STAR, Natl Study Ctr Trauma & Emergency Med Syst, Baltimore, MD 21201 USA	Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Bldg WP22a,3970 Reservoir Rd NW, Washington, DC 20057 USA.	mpb37@georgetown.edu	Barton, David J/C-9282-2011	Barton, David J/0000-0003-0976-0383; Burns, Mark P/0000-0003-4750-2000; Loane, David/0000-0003-0393-3503	Georgetown University Neural Injury and Plasticity Training Program [T32NS041218]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute for Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS067417, R01NS081068]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS067417, T32NS041218, R01NS081068] Funding Source: NIH RePORTER	This work was supported by grant number T32NS041218 from the Georgetown University Neural Injury and Plasticity Training Program supported by the National Institutes of Health (CNW and PMW, PI: Dr. Jean Wrathall and Dr. Kathleen Maguire-Zeiss) and grants number R03NS067417 & R01NS081068 from the National Institute for Neurological Disorders and Stroke (MPB). We would like to thank Dr. Hyang-Sook Hoe and Dr. Daniel Pak for assistance with the Golgi staining technique.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Bittner T, 2009, J NEUROSCI, V29, P10405, DOI 10.1523/JNEUROSCI.2288-09.2009; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Campbell JN, 2012, J NEUROTRAUM, V29, P218, DOI 10.1089/neu.2011.1762; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; CATALA I, 1988, HUM NEUROBIOL, V6, P255; Comery TA, 1997, P NATL ACAD SCI USA, V94, P5401, DOI 10.1073/pnas.94.10.5401; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Garey LJ, 1998, J NEUROL NEUROSUR PS, V65, P446, DOI 10.1136/jnnp.65.4.446; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kochanski R, 2013, J NEUROCHEM, V126, P113, DOI 10.1111/jnc.12169; Kurz JE, 2008, EPILEPSIA, V49, P1696, DOI 10.1111/j.1528-1167.2008.01616.x; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Murphy TH, 2008, J NEUROSCI, V28, P1756, DOI 10.1523/JNEUROSCI.5128-07.2008; Ng AN, 2008, FASEB J, V22, P2832, DOI 10.1096/fj.07-103903; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rozkalne A, 2011, NEUROBIOL DIS, V41, P650, DOI 10.1016/j.nbd.2010.11.014; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Schulz-Schaeffer WJ, 2010, ACTA NEUROPATHOL, V120, P131, DOI 10.1007/s00401-010-0711-0; Schwartz N, 2009, NEURON, V62, P655, DOI 10.1016/j.neuron.2009.05.007; Spires TL, 2005, J NEUROSCI, V25, P7278, DOI 10.1523/JNEUROSCI.1879-05.2005; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wu HY, 2010, J NEUROSCI, V30, P2636, DOI 10.1523/JNEUROSCI.4456-09.2010	33	58	58	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2013	30	23					1966	1972		10.1089/neu.2013.2960			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AI0FA	WOS:000336520400005	23879560	Green Published			2021-06-18	
J	Lewis, LD; Ching, SN; Weiner, VS; Peterfreund, RA; Eskandar, EN; Cash, SS; Brown, EN; Purdon, PL				Lewis, Laura D.; Ching, ShiNung; Weiner, Veronica S.; Peterfreund, Robert A.; Eskandar, Emad N.; Cash, Sydney S.; Brown, Emery N.; Purdon, Patrick L.			Local cortical dynamics of burst suppression in the anaesthetized brain	BRAIN			English	Article						intracranial electroencephalogram; human; neurophysiology; general anaesthesia	REFRACTORY STATUS EPILEPTICUS; GENERAL-ANESTHESIA; ELECTROENCEPHALOGRAM; PROPOFOL; ISOFLURANE; SLEEP; MODEL; EEG	Burst suppression is an electroencephalogram pattern that consists of a quasi-periodic alternation between isoelectric 'suppressions' lasting seconds or minutes, and high-voltage 'bursts'. It is characteristic of a profoundly inactivated brain, occurring in conditions including hypothermia, deep general anaesthesia, infant encephalopathy and coma. It is also used in neurology as an electrophysiological endpoint in pharmacologically induced coma for brain protection after traumatic injury and during status epilepticus. Classically, burst suppression has been regarded as a 'global' state with synchronous activity throughout cortex. This assumption has influenced the clinical use of burst suppression as a way to broadly reduce neural activity. However, the extent of spatial homogeneity has not been fully explored due to the challenges in recording from multiple cortical sites simultaneously. The neurophysiological dynamics of large-scale cortical circuits during burst suppression are therefore not well understood. To address this question, we recorded intracranial electrocorticograms from patients who entered burst suppression while receiving propofol general anaesthesia. The electrodes were broadly distributed across cortex, enabling us to examine both the dynamics of burst suppression within local cortical regions and larger-scale network interactions. We found that in contrast to previous characterizations, bursts could be substantially asynchronous across the cortex. Furthermore, the state of burst suppression itself could occur in a limited cortical region while other areas exhibited ongoing continuous activity. In addition, we found a complex temporal structure within bursts, which recapitulated the spectral dynamics of the state preceding burst suppression, and evolved throughout the course of a single burst. Our observations imply that local cortical dynamics are not homogeneous, even during significant brain inactivation. Instead, cortical and, implicitly, subcortical circuits express seemingly different sensitivities to high doses of anaesthetics that suggest a hierarchy governing how the brain enters burst suppression, and emphasize the role of local dynamics in what has previously been regarded as a global state. These findings suggest a conceptual shift in how neurologists could assess the brain function of patients undergoing burst suppression. First, analysing spatial variation in burst suppression could provide insight into the circuit dysfunction underlying a given pathology, and could improve monitoring of medically-induced coma. Second, analysing the temporal dynamics within a burst could help assess the underlying brain state. This approach could be explored as a prognostic tool for recovery from coma, and for guiding treatment of status epilepticus. Overall, these results suggest new research directions and methods that could improve patient monitoring in clinical practice.	[Lewis, Laura D.; Ching, ShiNung; Weiner, Veronica S.; Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; [Ching, ShiNung] Washington Univ, Dept Elect & Syst Engn, St Louis, MO 63130 USA; [Peterfreund, Robert A.; Brown, Emery N.; Purdon, Patrick L.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; [Peterfreund, Robert A.; Brown, Emery N.; Purdon, Patrick L.] Harvard Univ, Dept Anaesthesia, Sch Med, Boston, MA 02115 USA; [Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [Eskandar, Emad N.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; [Cash, Sydney S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Cash, Sydney S.] Harvard Univ, Dept Neurol, Sch Med, Boston, MA 02115 USA; [Brown, Emery N.] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Brown, Emery N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA	Purdon, PL (corresponding author), CNY 149-4,149 13th St, Charlestown, MA 02129 USA.	patrickp@nmr.mgh.harvard.edu		Lewis, Laura/0000-0002-4003-0277	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Burroughs-Wellcome FundBurroughs Wellcome Fund; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP1OD003646]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01GM104948, DP2-OD006454]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM104948] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP1OD003646, DP2OD006454] Funding Source: NIH RePORTER; Direct For Mathematical & Physical ScienNational Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS) [1042134] Funding Source: National Science Foundation	This work was supported by a doctoral fellowship from the Canadian Institutes of Health Research to L. D. L., a Career Award at the Scientific Interface from the Burroughs-Wellcome Fund to S. C., and by the National Institutes of Health [Director's Pioneer Award DP1OD003646 to E.N.B., NIH Transformative 1R01GM104948 to E.N.B., NIH New Innovator Award DP2-OD006454 to P.L.P.].	Akrawi WP, 1996, J NEUROSURG ANESTH, V8, P40, DOI 10.1097/00008506-199601000-00010; Amzica F, 2009, EPILEPSIA, V50, P38, DOI 10.1111/j.1528-1167.2009.02345.x; Bokil H, 2010, J NEUROSCI METH, V192, P146, DOI 10.1016/j.jneumeth.2010.06.020; Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281; Cash SS, 2009, SCIENCE, V324, P1084, DOI 10.1126/science.1169626; Chemali JJ, 2011, IEEE ENG MED BIO, P1431, DOI 10.1109/IEMBS.2011.6090354; Ching SN, 2012, P NATL ACAD SCI USA, V109, P3095, DOI 10.1073/pnas.1121461109; Cimenser A, 2011, P NATL ACAD SCI USA, V108, P8832, DOI 10.1073/pnas.1017041108; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; CLARK DL, 1973, ANESTHESIOLOGY, V38, P564, DOI 10.1097/00000542-197306000-00011; Dykstra AR, 2012, NEUROIMAGE, V59, P3563, DOI 10.1016/j.neuroimage.2011.11.046; Ferron JF, 2009, J NEUROSCI, V29, P9850, DOI 10.1523/JNEUROSCI.5176-08.2009; HALL R, 1990, CAN J ANAESTH, V37, P762, DOI 10.1007/BF03006535; Kroeger D, 2007, J NEUROSCI, V27, P10597, DOI 10.1523/JNEUROSCI.3440-07.2007; Lewis LD, 2012, P NATL ACAD SCI USA, V109, pE3377, DOI 10.1073/pnas.1210907109; Lofhede J, 2008, J NEURAL ENG, V5, P402, DOI 10.1088/1741-2560/5/4/005; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; Murphy M, 2011, SLEEP, V34, P283, DOI 10.1093/sleep/34.3.283; Nir Y, 2011, NEURON, V70, P153, DOI 10.1016/j.neuron.2011.02.043; Ohtahara S, 2003, J CLIN NEUROPHYSIOL, V20, P398, DOI 10.1097/00004691-200311000-00003; Purdon PL, 2013, P NATL ACAD SCI USA, V110, pE1142, DOI 10.1073/pnas.1221180110; Rossetti AO, 2004, EPILEPSIA, V45, P757, DOI 10.1111/j.0013-9580.2004.01904.x; Stecker MM, 2001, ANN THORAC SURG, V71, P22, DOI 10.1016/S0003-4975(00)02021-X; STERIADE M, 1994, ELECTROEN CLIN NEURO, V90, P1, DOI 10.1016/0013-4694(94)90108-2; Supp GG, 2011, CURR BIOL, V21, P1988, DOI 10.1016/j.cub.2011.10.017; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006	26	58	58	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP	2013	136		9				2727	2737		10.1093/brain/awt174			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	212EM	WOS:000323965100013	23887187	Other Gold, Green Published			2021-06-18	
J	Ponsford, JL; Parcell, DL; Sinclair, KL; Roper, M; Rajaratnam, SMW				Ponsford, Jennie L.; Parcell, Diane L.; Sinclair, Kelly L.; Roper, Monique; Rajaratnam, Shantha M. W.			Changes in Sleep Patterns Following Traumatic Brain Injury: A Controlled Study	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; sleep disturbance; sleep quality; excessive daytime sleepiness; depression; anxiety	DEPRESSION SCALE; HOSPITAL ANXIETY; DAYTIME SLEEPINESS; QUALITY INDEX; DISTURBANCE; FATIGUE; PREVALENCE; INSOMNIA; REHABILITATION; ASSOCIATION	Background. Sleep changes are frequently reported following traumatic brain injury (TBI) and have an impact on rehabilitation and quality of life following injury. Potential causes include injury to brain regions associated with sleep regulation, as well as secondary factors, including depression, anxiety, and pain. Understanding the nature and causes of sleep changes following TBI represents a vital step in developing effective treatments. Objective. The study aimed to investigate subjective sleep changes in a community-based sample of individuals with TBI in comparison with noninjured age- and sex-matched controls and to explore the impact of secondary factors (pain, anxiety, depression, employment) on these self-reported sleep changes. Methods: A total of 153 participants with mild to severe TBI and 128 noninjured controls completed self-report measures relating to their sleep quality, daytime sleepiness, mood, fatigue, and pain and completed a sleep diary each day for 7 days. Results. Compared with the noninjured controls, participants with TBI reported significantly poorer sleep quality and higher levels of daytime sleepiness; sleep diaries revealed longer sleep onset latency, poorer sleep efficiency, longer sleep duration, and more frequent daytime napping in the TBI group, as well as earlier bedtimes and greater total sleep duration. Anxiety, depression, and pain were associated with poorer sleep quality. Greater injury severity was also associated with a need for longer sleep time. Conclusion. These findings highlight the importance of assessing and addressing pain, anxiety, and depression as part of the process of treating TBI-related sleep disturbances.	[Ponsford, Jennie L.; Parcell, Diane L.; Sinclair, Kelly L.; Rajaratnam, Shantha M. W.] Monash Univ, Clayton, Vic 3800, Australia; [Ponsford, Jennie L.; Sinclair, Kelly L.; Roper, Monique] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Fac Med Nursing & Hlth Sci, Clayton Campus, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu		Rajaratnam, Shantha/0000-0001-7527-8558	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [334002]; Monash UniversityMonash University	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The projects described in the article received funding from the National Health and Medical Research Council (Project ID 334002) and Monash University.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; Braekeland F, 1971, ARCH GEN PSYCHIAT, V24, P548; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Cleeland CS, 1989, ISSUES PAIN MEASUREM, P391; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Harris K, 2007, CLIN ONCOL-UK, V19, P523, DOI 10.1016/j.clon.2007.04.007; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; MONROE LJ, 1967, J ABNORM PSYCHOL, V72, P255, DOI 10.1037/h0024563; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PARSONS LC, 1982, NURS RES, V31, P260; Ponsford J, 2012, TRAUMATIC BRAIN INJU; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sinclair KL, 2014, BEHAV SLEEP MED, V12, P13, DOI 10.1080/15402002.2012.726203; Skilbeck C, 2011, BRAIN IMPAIR, V12, P22, DOI 10.1375/brim.12.1.22; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	46	58	59	0	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	SEP	2013	27	7					613	621		10.1177/1545968313481283			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	190EW	WOS:000322323100004	23549523				2021-06-18	
J	Hussmann, B; Lefering, R; Waydhas, C; Touma, A; Kauther, MD; Ruchholtz, S; Lendemans, S				Hussmann, Bjoern; Lefering, Rolf; Waydhas, Christian; Touma, Alexander; Kauther, Max D.; Ruchholtz, Steffen; Lendemans, Sven		German Soc Trauma Surg	Does increased prehospital replacement volume lead to a poor clinical course and an increased mortality? A matched-pair analysis of 1896 patients of the Trauma Registry of the German Society for Trauma Surgery who were managed by an emergency doctor at the accident site	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Trauma; Prehospital replacement volume; Mortality; Trauma Registry; Haemorrhagic shock; Emergency medicine	RESUSCITATION; IMPACT	Introduction: Severe bleeding after trauma frequently leads to a poor outcome. Prehospital fluid replacement therapy is regarded as an important primary treatment option. Our study aimed to assess the influence of prehospital fluid replacement therapy on the post-traumatic course of severely injured patients in a retrospective analysis of matched pairs. Patients and methods: The data of 51,425 patients of the Trauma Registry of the German Society for Trauma Surgery were analysed. The following patients were included: Injury Severity Score >= 16 points, primary admission, age >= 16 years, no isolated brain injury, transfusion of at least one unit of packed red blood cells (pRBC), systolic blood pressure >= 60 mm Hg at the accident site. The patients were divided into two groups according to the following matched-pair criteria (low-volume: 0-1500 ml prehospital volume replaced; high-volume: >= 1501 ml prehospital volume): intubation at the accident site (yes/no), time from injury to hospital +/- 10 min., means of rescue (emergency helicopter, MICU), Abbreviated Injury Scale (body regions), injury year, systolic blood pressure and age (years). All patients were managed by an emergency doctor at the accident site. Results: A total of 948 patients in each group met the inclusion criteria. Increasing replacement volume was associated with an increased need for transfusion (pRBCs: low-volume: 7 units, high-volume: 8.3 units; p < 0.001) and a reduced ability to coagulate (prothrombin ratio (PR): low-volume: 68%, high-volume: 61.5%; p < 0.001). Patients in shock (systolic BP < 90 mm Hg) upon admission to the hospital were equally in both groups (25.6%; p = 0.98). Significantly higher lethality was observed in cases of increasing volume (low-volume: 22.7%, high-volume: 27.6%; p < 0.01). Conclusions: Excessive prehospital fluid replacement leads to an increased mortality rate. The results of this study support the concept of restrained volume replacement in the prehospital treatment of patients with severe trauma. (C) 2012 Elsevier Ltd. All rights reserved.	[Hussmann, Bjoern; Waydhas, Christian; Touma, Alexander; Kauther, Max D.; Lendemans, Sven] Univ Hosp Essen, Dept Trauma Surg, D-45122 Essen, Germany; [Lefering, Rolf] Witten Herdecke Univ GmbH, Inst Res Operat Med IFOM, Fac Med, Cologne Merheim Med Ctr, Witten, Germany; [Ruchholtz, Steffen] Univ Hosp Marburg, Trauma Dept, Hand & Reconstruct Surg Unit, Marburg, Germany	Hussmann, B (corresponding author), Univ Hosp Essen, Dept Trauma Surg, Hufelandstr 55, D-45122 Essen, Germany.	bjoern.hussmann@uk-essen.de	Kauther, Max/A-1505-2016	Kauther, Max/0000-0003-3795-6068			Malvestio MAA, 2010, REV ESC ENFERM USP, V44, P350; Bernhard M, 2004, ANAESTHESIST, V53, P887, DOI 10.1007/s00101-004-0732-y; Bickell W H, 1998, Curr Opin Anaesthesiol, V11, P177, DOI 10.1097/00001503-199804000-00010; BICKELL WH, 1993, ANN EMERG MED, V22, P225, DOI 10.1016/S0196-0644(05)80208-2; BICKELL WH, 1994, AM J EMERG MED, V12, P36, DOI 10.1016/0735-6757(94)90194-5; BONE RC, 1991, CRIT CARE MED, V19, P973, DOI 10.1097/00003246-199107000-00024; Butler F, 2011, J TRAUMA, V70, pS11, DOI 10.1097/TA.0b013e31821a4b90; Dutton RP, 2002, J TRAUMA, V52, P1141, DOI 10.1097/00005373-200206000-00020; Geeraedts LMG, 2009, INJURY, V40, P11, DOI 10.1016/j.injury.2008.10.007; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Haut ER, 2011, ANN SURG, V253, P371, DOI 10.1097/SLA.0b013e318207c24f; Holcomb JB, 2004, CRIT CARE, V8, pS57, DOI 10.1186/cc2407; Hubetamann Bjorn, 2011, J Emerg Trauma Shock, V4, P465, DOI 10.4103/0974-2700.86630; Hussmann B, 2011, UNFALLCHIRURG, V114, P705, DOI 10.1007/s00113-010-1842-4; Kauvar DS, 2005, CRIT CARE, V9, P1, DOI 10.1186/cc3779; Kreimeier U, 1997, ANAESTHESIST, V46, P309, DOI 10.1007/s001010050406; Kreimeier U, 2002, ACTA ANAESTH SCAND, V46, P625, DOI 10.1034/j.1399-6576.2002.460601.x; Kreimeier U, 2003, NOTFALL RETTUNGSMED, V6, P77; Lefering R, 2009, EUR J TRAUMA EMERG S, V35, P437, DOI 10.1007/s00068-009-9122-0; NASTKOLB D, 1993, CHIRURG, V64, P552; Oestern HJ, 1999, UNFALLCHIRURG, V102, P80, DOI 10.1007/s001130050378; Raum M, 2006, NOTFALL RETTUNGSMED, V9, P485; Sapsford W, 2008, SCAND J SURG, V97, P4, DOI 10.1177/145749690809700102; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Trunkey D D, 2001, Emerg Med Serv, V30, P93; Trunkey DD., 2001, EMERG MED SERV, V30, P98; Trunkey DD, 2001, EMERG MED SERV, V30, P93; Turner J., 2000, HEALTH TECHNOL ASSES, V4, P1, DOI [DOI 10.3310/hta4310, 10.3310/hta4310, DOI 10.3310/HTA4310]; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; White CE, 2009, INJURY, V40, P1023, DOI 10.1016/j.injury.2008.11.023; Williams J G, 2007, J R Army Med Corps, V153 Suppl 1, P70; Yaghoubian A, 2007, AM SURGEON, V73, P1027; Ziegenfuss T, 1996, ZBL CHIR, V121, P924	33	58	59	0	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2013	44	5					611	617		10.1016/j.injury.2012.02.004			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	122VE	WOS:000317345400008	22377276				2021-06-18	
J	Chio, CC; Chang, CH; Wang, CC; Cheong, CU; Chao, CM; Cheng, BC; Yang, CZ; Chang, CP				Chio, Chung-Ching; Chang, Chin-Hong; Wang, Che-Chuan; Cheong, Chong-Un; Chao, Chien-Ming; Cheng, Bor-Chih; Yang, Chung-Zhing; Chang, Ching-Ping			Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-alpha	BMC NEUROSCIENCE			English	Article						Traumatic brain injury; Microglia; Tumor necrosis factor-alpha; Astrocyte; Neuron	CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; TNF-ALPHA; CYTOKINE EXPRESSION; NEUROTROPHIC FACTOR; INTERLEUKIN-6; PLASMA; DEFICIENT; ELEVATION; ISCHEMIA	Background: Tumor necrosis factor-alpha (TNF-alpha) is elevated early in injured brain after traumatic brain injury (TBI), in humans and in animals. Etanercept (a TNF-alpha antagonist with anti-inflammatory effects) attenuates TBI in rats by reducing both microglial and astrocytic activation and increased serum levels of TNF-alpha. However, it is not known whether etanercept improves outcomes of TBI by attenuating microglia-associated, astrocytes-associated, and/or neurons-associated TNF-alpha expression in ischemic brain. A well clinically relevant rat model, where a lateral fluid percussion is combined with systemic administration of etanercept immediately after TBI, was used. The neurological severity score and motor function was measured on all rats preinjury and on day 3 after etanercept administration. At the same time, the neuronal and glial production of TNF-alpha was measured by Immunofluorescence staining. In addition, TNF alpha contents of ischemic cerebral homogenates was measured using commercial enzyme-linked immunosorbent assay kits. Results: In addition to inducing brain ischemia as well as neurological and motor deficits, TBI caused significantly higher numbers of microglia-TNF-alpha double positive cells, but not neurons-TNF-alpha or astrocytes-TNF-alpha double positive cells in the injured brain areas than did the sham operated controls, when evaluated 3 days after TBI. The TBI-induced cerebral ischemia, neurological motor deficits, and increased numbers of microglia-TNF-alpha double positive cells and increased TNF-alpha levels in the injured brain were all significantly attenuated by etanercept therapy. Conclusion: This finding indicates that early microglia overproduction of TNF-alpha in the injured brain region after TBI contributes to cerebral ischemia and neurological motor deficits, which can be attenuated by etanercept therapy. Studies in this model could provide insight into the mechanisms underlying neurological motor disturbance in brain-injured patients.	[Chio, Chung-Ching; Chang, Chin-Hong; Wang, Che-Chuan; Chao, Chien-Ming; Cheng, Bor-Chih] Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan; [Cheong, Chong-Un; Chao, Chien-Ming] Chi Mei Med Ctr, Dept Intens Care Med, Tainan, Taiwan; [Chang, Ching-Ping] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Cheng, Bor-Chih; Yang, Chung-Zhing] Taipei Med Univ, PhD Program Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan	Chang, CP (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.	jessica.cpchang@gmail.com	Bilfinger, Thomas V./J-6392-2019	Chang, Ching-Ping/0000-0003-0890-9414	Taiwan National Science CouncilMinistry of Science and Technology, Taiwan [NSC98-2314-B-218-MY2, NSC99-2314-B-384-004-MY3, NSC100-2314-B-218-001, NSC101-2314-B-218-001-MY3]; Taiwan Department of Health Center of Excellence for Clinical Trials and Research in Neuroscience [DOH99-TD-B-111-003]	This study was funded in part by the Taiwan National Science Council (NSC98-2314-B-218-MY2, NSC99-2314-B-384-004-MY3, NSC100-2314-B-218-001, NSC101-2314-B-218-001-MY3), and the Taiwan Department of Health Center of Excellence for Clinical Trials and Research in Neuroscience (DOH99-TD-B-111-003).	Bao F, 2011, J NEUROTRAUM, V28, P1035, DOI 10.1089/neu.2010.1575; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feuerstein G, 1998, CELL MOL NEUROBIOL, V18, P695, DOI 10.1023/A:1020226020062; Francis J, 2004, AM J PHYSIOL-HEART C, V286, pH2264, DOI 10.1152/ajpheart.01072.2003; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Perry SW, 2002, J NEUROVIROL, V8, P611, DOI 10.1080/13550280290101021; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Taupin V, 1993, J NEUROIMMUNOL, V42, P177; Wang Y, 1997, J NEUROSCI, V17, P4341; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	39	58	60	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	MAR 15	2013	14								33	10.1186/1471-2202-14-33			12	Neurosciences	Neurosciences & Neurology	139WM	WOS:000318615700001	23496862	DOAJ Gold, Green Published			2021-06-18	
J	Siman, R; Giovannone, N; Hanten, G; Wilde, EA; McCauley, SR; Hunter, JV; Li, XQ; Levin, HS; Smith, DH				Siman, Robert; Giovannone, Nicholas; Hanten, Gerri; Wilde, Elisabeth A.; McCauley, Stephen R.; Hunter, Jill V.; Li, Xiaoqi; Levin, Harvey S.; Smith, Douglas H.			Evidence that the blood biomarker SNTF predicts brain imaging changes and persistent cognitive dysfunction in mild TBI patients	FRONTIERS IN NEUROLOGY			English	Article						surrogate marker; concussion; calpain; DTI; spectrin; diffuse axonal injury; prognostic marker; cognitive impairment		Although mild traumatic brain injury (mTBI), or concussion, is not typically associated with abnormalities on computed tomography (CT), it nevertheless causes persistent cognitive dysfunction for many patients. Consequently, new prognostic methods for mTBI are needed to identify at risk cases, especially at an early and potentially treatable stage. Here, we quantified plasma levels of the neurodegeneration biomarker calpain-cleaved alpha ll-spectrin N-terminal fragment (SNTF) from 38 participants with CT-negative mTBI, orthopedic injury (01), and normal uninjured controls (UCs) (age range 12-30 years), and compared them with findings from diffusion tensor imaging (DTI) and long-term cognitive assessment. SNTF levels were at least twice the lower limit of detection in 7 of 17 mTBI cases and in 3 of 13 01 cases, but in none of the UCs. An elevation in plasma SNTF corresponded with significant differences in fractional anisotropy and the apparent diffusion coefficient in the corpus callosum and uncinate fasciculus measured by DTI. Furthermore, increased plasma SNTF on the day of injury correlated significantly with cognitive impairment that persisted for at least 3 months, both across all study participants and also among the mTBI cases by themselves. The elevation in plasma SNTF in the subset of 01 cases, accompanied by corresponding white matter and cognitive abnormalities, raises the possibility of identifying undiagnosed cases of mTBI. These data suggest that the blood level of SNTF on the day of a CT-negative mTBI may identify a subset of patients at risk of white matter damage and persistent disability. SNTF could have prognostic and diagnostic utilities in the assessment and treatment of mTBI.	[Siman, Robert; Giovannone, Nicholas; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Hanten, Gerri; Wilde, Elisabeth A.; McCauley, Stephen R.; Hunter, Jill V.; Li, Xiaoqi; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA	Siman, R (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, 502 Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	siman@mail.med.upenn.edu		Giovannone, Nicholas/0000-0001-5391-8729	National Institute of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS-056202]	This research was supported by a grant from the National Institute of Neurologic Disorders and Stroke (P01 NS-056202 to Douglas H. Smith). We thank Amanda Barnes, Trevor Wu, Ana C. Vasquez, Melisa Frisby, Greg S. Vogt, Joshua Cooper, and Claudia Robertson for their essential contributions to enrolling patients and deriving plasma samples. We gratefully acknowledge the contribution of Ponnada Narayana and Vipulkumar S. Patel in implementation and execution of the imaging sequences, and Zili D. Chu for his role in data processing. We thank Shawn Roberts and Daphne Georlette of Meso Scale Diagnostics for providing the SECTOR Imager 2400 electrochemiluminescence reader and data analysis software, along with advice on their use. We thank the participants and their families for their involvement in this research.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; BIJUR PE, 1990, PEDIATRICS, V86, P337; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Hanten G, 2013, J NEUROTRAUM, V30, P618, DOI 10.1089/neu.2012.2392; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Hasan KM, 2009, BRAIN RES, V1276, P67, DOI 10.1016/j.brainres.2009.04.025; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lebel C, 2012, NEUROIMAGE, V60, P340, DOI 10.1016/j.neuroimage.2011.11.094; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; Mabbott DJ, 2009, BRAIN RES, V1294, P80, DOI 10.1016/j.brainres.2009.07.046; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Siman R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028938; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith A., 1973, SYMBOL DIGIT MODALIT; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Sturgeon CM, 2011, ANN CLIN BIOCHEM, V48, P418, DOI 10.1258/acb.2011.011073; Susuki K, 2008, EXP BIOL MED, V233, P394, DOI 10.3181/0709-MR-243; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Word Medical Association Declaration of Helsinki, 2001, B WORLD HEALTH ORGAN, V79, P373; YNTEMA DB, 1967, ACTA PSYCHOL, V27, P325, DOI 10.1016/0001-6918(67)90075-3; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	63	58	60	1	9	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								190	10.3389/fneur.2013.00190			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QT	WOS:000209629000186	24302918	DOAJ Gold, Green Published			2021-06-18	
J	Ahmed, F; Gyorgy, A; Kamnaksh, A; Ling, G; Tong, L; Parks, S; Agoston, D				Ahmed, Farid; Gyorgy, Andrea; Kamnaksh, Alaa; Ling, Geoffrey; Tong, Lawrence; Parks, Steve; Agoston, Denes			Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury	ELECTROPHORESIS			English	Article						Biomarkers; Blast traumatic brain injury; CSF; Large animal model; Proteins	NEURON-SPECIFIC ENOLASE; ENDOTHELIAL GROWTH-FACTOR; VON-WILLEBRAND-FACTOR; CREATINE-KINASE BB; CSF BIOMARKERS; FACTOR VEGF; S100B; SERUM; PATHOPHYSIOLOGY; DAMAGE	Time-dependent changes of protein biomarkers in the cerebrospinal fluid (CSF) can be used to identify the pathological processes in traumatic brain injury (TBI) as well as to follow the progression of the disease. We obtained CSF from a large animal model (swine) of blast-induced traumatic brain injury prior to and at 6, 24, 72 h, and 2 wk after a single exposure to blast overpressure, and determined changes in the CSF levels of neurofilament-heavy chain, neuron-specific enolase, brain-specific creatine kinase, glial fibrillary acidic protein, calcium-binding protein beta (S100 beta), Claudin-5, vascular endothelial growth factor, and von Willebrand factor using reverse phase protein microarray. We detected biphasic temporal patterns in the CSF concentrations of all tested protein markers except S100 beta. The CSF levels of all markers were significantly increased 6 h after the injury compared to preinjury levels. Values were then decreased at 24 h, prior to a second increase in all markers but S100 beta at 72 h. At 2 wk postinjury, the CSF concentrations of all biomarkers were decreased once again; brain-specific creatine kinase, Claudin-5, von Willebrand factor, and S100 beta levels were no longer significantly higher than their preinjury values while neurofilament-heavy chain, neuron-specific enolase, vascular endothelial growth factor, and glial fibrillary acidic protein levels remained significantly elevated compared to baseline. Our findings implicate neuronal and glial cell damage, compromised vascular permeability, and inflammation in blast-induced traumatic brain injury, as well as demonstrate the value of determining the temporal pattern of biomarker changes that may be of diagnostic value.	[Ahmed, Farid; Gyorgy, Andrea; Kamnaksh, Alaa; Agoston, Denes] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Ling, Geoffrey] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Tong, Lawrence] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA; [Parks, Steve] ORA Inc, Fredericksburg, VA USA	Agoston, D (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu			Defense Advanced Research Projects Agency's (DARPA) Preventing Violent Explosive Neurologic Trauma (PREVENT)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)	The work was funded by the Defense Advanced Research Projects Agency's (DARPA) Preventing Violent Explosive Neurologic Trauma (PREVENT). We thank Dr. Mattias Skold for his input regarding the clinical implications of our findings. The views, opinions, and/or findings contained in this article are those of the authors and should not be interpreted as representing the official views or policies, either expressed or implied, of the Defense Advanced Research Projects Agency (DARPA) or the Department of Defense (DoD). Approved for public release; distribution unlimited.	Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Andersson M, 2011, INT J GERIATR PSYCH, V26, P100, DOI 10.1002/gps.2496; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cooper I, 2011, METHODS MOL BIOL, V762, P347, DOI 10.1007/978-1-61779-185-7_25; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; De Oliveira CO, 2007, J NEUROTRAUM, V24, P1331, DOI 10.1089/neu.2006.0159; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Engelhardt B, 2009, SEMIN IMMUNOPATHOL, V31, P497, DOI 10.1007/s00281-009-0177-0; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Guy R J, 2000, J R Nav Med Serv, V86, P27; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; HAYAKAWA T, 1984, Neurologia Medico-Chirurgica, V24, P13, DOI 10.2176/nmc.24.13; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jiao HX, 2011, J MOL NEUROSCI, V44, P130, DOI 10.1007/s12031-011-9496-4; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; KARKELA J, 1993, J NEUROL SCI, V116, P100, DOI 10.1016/0022-510X(93)90095-G; Kaur C, 2008, CURR NEUROVASC RES, V5, P71, DOI 10.2174/156720208783565645; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kobeissy FH, 2011, PM&R, V3, pS139, DOI 10.1016/j.pmrj.2011.02.012; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Kwon S. K. C., 2011, FRONT NEUROL, V2, P1; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Li R, 1998, AM J FOREN MED PATH, V19, P129, DOI 10.1097/00000433-199806000-00006; Ling G, 2006, NEUROLOGY, V67, P14, DOI 10.1212/01.wnl.0000227781.79800.93; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Lip GYH, 1997, CARDIOVASC RES, V34, P255, DOI 10.1016/S0008-6363(97)00039-4; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Marmarou A, 2003, ACT NEUR S, V86, P7; Matter K, 2003, J CELL BIOL, V161, P459, DOI 10.1083/jcb.200304039; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Merrill MJ, 2005, J NEUROSURG, V103, P853, DOI 10.3171/jns.2005.103.5.0853; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Neufeld G, 1999, FASEB J, V13, P9; NORDBY HK, 1982, ACTA NEUROCHIR, V65, P93, DOI 10.1007/BF01405445; Noubade R, 2008, AM J PATHOL, V173, P892, DOI 10.2353/ajpath.2008.080001; PASAOGLU A, 1989, ACTA NEUROCHIR, V97, P71; Paulinska P, 2009, HAMOSTASEOLOGIE, V29, P32; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Plurad DS, 2011, MIL MED, V176, P276, DOI 10.7205/MILMED-D-10-00147; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Ramasamy A, 2009, J R Army Med Corps, V155, P258; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; SANCHEZRODRIGUEZ VF, 1995, AM J FOREN MED PATH, V16, P210, DOI 10.1097/00000433-199509000-00004; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Schmitt B, 1998, BRAIN DEV-JPN, V20, P536, DOI 10.1016/S0387-7604(98)00046-1; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Sjodin MOD, 2010, J CHROMATOGR B, V878, P2003, DOI 10.1016/j.jchromb.2010.05.036; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Tabaraud F, 2012, ACTA NEUROL SCAND, V125, P416, DOI 10.1111/j.1600-0404.2011.01592.x; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Yates D, 2011, NAT REV NEUROL, V7, P63, DOI 10.1038/nrneurol.2010.190; Zhao BQ, 2009, BLOOD, V114, P3329, DOI 10.1182/blood-2009-03-213264; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	88	58	59	1	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	DEC	2012	33	24			SI		3705	3711		10.1002/elps.201200299			7	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	057FT	WOS:000312548900013	23161535				2021-06-18	
J	Amenta, PS; Jallo, JI; Tuma, RF; Elliott, MB				Amenta, Peter S.; Jallo, Jack I.; Tuma, Ronald F.; Elliott, Melanie B.			A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						controlled cortical impact; blood-brain barrier; cannabinoid-2 receptor; endocannabinoid; traumatic brain injury; microglia	CONTROLLED CORTICAL IMPACT; CEREBRAL ISCHEMIC/REPERFUSION INJURY; FLUID PERCUSSION INJURY; SPINAL-CORD-INJURY; CB2 RECEPTOR; ENDOCANNABINOID SYSTEM; MICROGLIAL ACTIVATION; INFLAMMATORY RESPONSE; CELL-MIGRATION; MOUSE MODEL	After traumatic brain injury (TBI), inflammation participates in both the secondary injury cascades and the repair of the CNS, both of which are influenced by the endocannabinoid system. This study determined the effects of repeated treatment with a cannabinoid type 2 receptor (CB2R) agonist on bloodbrain barrier integrity, neuronal degeneration, and behavioral outcome in mice with TBI. We also looked for the presence of a prolonged treatment effect on the macrophage/microglial response to injury. C57BL/6 mice underwent controlled cortical impact (CCI) and received repeated treatments with a CB2R agonist, 0-1966, or vehicle. After euthanasia at 6 hr or 1, 2, 3, or 7 days postinjury, brains were removed for histochemical analysis. Bloodbrain barrier permeability changes were evaluated by using sodium fluorescein (NaF). Perilesional degenerating neurons, injury volumes, and macrophage/microglia cells were quantified by stereological methods. Rota-rod and open-field testing were performed to evaluate motor function and natural exploratory behavior in mice. 0-1966 Treatment resulted in a significant reduction in NaF uptake and number of degenerating neurons compared with the vehicle-treated group. 0-1966-Treated mice demonstrated improvement on rota-rod and open-field testing compared with vehicle-treated mice. These changes in CCI mice treated with 0-1966 were associated with a prolonged reduction in macrophage/microglia cell counts. In conclusion, repeated treatments with a CB2R agonist, 0-1966, result in attenuated bloodbrain barrier disruption and neuronal degeneration. In addition, repeated treatment with 0-1966 shows prolonged treatment effects on behavior and the macrophage/microglia cell response over several days. (c) 2012 Wiley Periodicals, Inc.	[Amenta, Peter S.; Jallo, Jack I.; Elliott, Melanie B.] Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Tuma, Ronald F.] Temple Univ, Dept Physiol, Philadelphia, PA 19122 USA	Elliott, MB (corresponding author), Thomas Jefferson Univ Hosp, Dept Neurol Surg, 1025 Walnut St,Suite 516, Philadelphia, PA 19107 USA.	melanie.elliott@jefferson.edu		Jallo, Jack/0000-0002-5512-1729			Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Ashton JC, 2011, BRIT J PHARMACOL, V163, P1113, DOI 10.1111/j.1476-5381.2010.01139.x; Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Baty Darric E, 2008, Clin Neurosurg, V55, P172; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Brown AJ, 2007, BRIT J PHARMACOL, V152, P567, DOI 10.1038/sj.bjp.0707481; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584; Cabral GA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000957; Carlisle SJ, 2002, INT IMMUNOPHARMACOL, V2, P69, DOI 10.1016/S1567-5769(01)00147-3; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Correa F, 2005, BRIT J PHARMACOL, V145, P441, DOI 10.1038/sj.bjp.0706215; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Fraga D, 2011, J NEUROIMMUNE PHARM, V6, P566, DOI 10.1007/s11481-011-9291-6; Franklin KB, 2008, MOUSE BRAIN STEREOTA; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lapter S, 2009, ARTHRITIS RHEUM-US, V60, P3744, DOI 10.1002/art.25013; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leong S, 1992, GLIA, V7, P9; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; Liao H, 2005, J BIOL CHEM, V280, P8316, DOI 10.1074/jbc.M412730200; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lombard C, 2007, CLIN IMMUNOL, V122, P259, DOI 10.1016/j.clim.2006.11.002; Malone DT, 2009, PHARMACOL BIOCHEM BE, V93, P91, DOI 10.1016/j.pbb.2009.04.010; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Mo FM, 2004, EUR J PHARMACOL, V489, P21, DOI 10.1016/j.ejphar.2004.02.034; Montecucco F, 2008, AM J PHYSIOL-HEART C, V294, pH1145, DOI 10.1152/ajpheart.01328.2007; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Phares TW, 2007, J IMMUNOL, V178, P7334, DOI 10.4049/jimmunol.178.11.7334; Price DA, 2009, EUR J NEUROSCI, V29, P2177, DOI 10.1111/j.1460-9568.2009.06764.x; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sacerdote P, 2000, J NEUROIMMUNOL, V109, P155, DOI 10.1016/S0165-5728(00)00307-6; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Simard AR, 2007, J COMP NEUROL, V504, P716, DOI 10.1002/cne.21469; Stokely ME, 2007, J NEUROSCI METH, V166, P217, DOI 10.1016/j.jneumeth.2007.07.010; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walter L, 2003, J NEUROSCI, V23, P1398; Wieseler J, 2010, J NEUROSCI METH, V185, P236, DOI 10.1016/j.jneumeth.2009.10.006; Wiley JL, 2002, J PHARMACOL EXP THER, V301, P679, DOI 10.1124/jpet.301.2.679; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zarruk JG, 2012, STROKE, V43, P211, DOI 10.1161/STROKEAHA.111.631044; Zhang M, 2008, NEUROSCIENCE, V152, P753, DOI 10.1016/j.neuroscience.2008.01.022; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447; Zhang M, 2009, MICROVASC RES, V78, P86, DOI 10.1016/j.mvr.2009.03.005; Zhang M, 2009, J NEUROIMMUNE PHARM, V4, P249, DOI 10.1007/s11481-009-9148-4; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	82	58	59	1	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	DEC	2012	90	12					2293	2305		10.1002/jnr.23114			13	Neurosciences	Neurosciences & Neurology	027FM	WOS:000310337300007	22903455				2021-06-18	
J	Wei, J; Pan, XD; Pei, Z; Wang, WM; Qiu, WS; Shi, ZH; Xiao, GM				Wei, Jing; Pan, Xiangdong; Pei, Zhong; Wang, Weimin; Qiu, Wusi; Shi, Zhenghua; Xiao, Guomin			The beta-lactam antibiotic, ceftriaxone, provides neuroprotective potential via anti-excitotoxicity and anti-inflammation response in a rat model of traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Ceftriaxone; neuroprotection; traumatic brain injury; rats	INCREASES GLUTAMATE UPTAKE; TRANSPORTERS; EXPRESSION; OPPORTUNITIES; MECHANISMS; CHALLENGES; PROTEINS; EAAT2	BACKGROUND: The beta-lactam antibiotic, ceftriaxone (CTX), has been reported to induce neuroprotection in animal models of diverse neurologic diseases. Currently, no data have explored the potential for CTX to provide neuroprotection in the animal models of traumatic brain injury (TBI). The aim of this study was to investigate the neuroprotective effect by CTX on TBI and to determine the underlying mechanisms. METHODS: Rats were immediately subjected to a lateral cortical impact injury caused by a free-falling object and divided randomly into three groups: sham-operated, trauma, and trauma + CTX treatment group. The CTX treatment group was given CTX (200 mg/kg of body weight, intravenously) immediately after injury. The cognitive function was assessed by Y-maze testing and cerebral edema was evaluated. Inflammatory cytokines expression was measured using enzyme-linked immunosorbent assay array. The expression of glutamate transporter-1 protein was identified by Western blot analysis. RESULTS: This study shows that the CTX causes attenuation of TBI-induced cerebral edema and cognitive function deficits. CTX treatment significantly reduced levels of the proinflammatory cytokines interleukin-1 beta, interferon-gamma, and tumor necrosis factor-alpha and upregulated glutamate transporter-1 expression after TBI. CONCLUSION: Our results provide in vivo evidence that CTX could exert neuroprotective effect against TBI by improving cognitive function and alleviating brain edema via reducing excitotoxicity and inflammation after TBI. (J Trauma Acute Care Surg. 2012; 73: 654-660. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Wang, Weimin; Qiu, Wusi; Shi, Zhenghua; Xiao, Guomin] Hangzhou Normal Univ, Affiliated Hosp, Dept Neurosurg, Hangzhou 310015, Zhejiang, Peoples R China; [Wei, Jing] Hangzhou Normal Univ, Affiliated Hosp, Med Ctr, Hangzhou 310015, Zhejiang, Peoples R China; [Pan, Xiangdong] Tradit Chinese Med Hosp Linan, Dept Neurosurg, Linan, Peoples R China; [Pei, Zhong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol Lab, Guangzhou 510275, Guangdong, Peoples R China	Xiao, GM (corresponding author), Hangzhou Normal Univ, Affiliated Hosp, Dept Neurosurg, Hangzhou 310015, Zhejiang, Peoples R China.	gxiao@hznu.edu.cn			Health Department of Hangzhou; Science and Technology Department of Lin'an, Zhejiang province, China	Supported by grants from the Health Department of Hangzhou and the Science and Technology Department of Lin'an, Zhejiang province, China.	Anderson CM, 2000, GLIA, V32, P1; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Chu K, 2007, STROKE, V38, P177, DOI 10.1161/01.STR.0000252091.36912.65; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gardoni F, 2010, PROG BRAIN RES, V183, P169, DOI 10.1016/S0079-6123(10)83009-2; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Hedlund E, 2011, EXP NEUROL, V231, P14, DOI 10.1016/j.expneurol.2011.06.002; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Kim K, 2011, J CELL PHYSIOL, V226, P2484, DOI 10.1002/jcp.22609; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li DQ, 2004, NEUROSCI RES, V50, P169, DOI 10.1016/j.neures.2004.06.009; Lipski J, 2007, NEUROSCIENCE, V146, P617, DOI 10.1016/j.neuroscience.2007.02.003; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; McIntosh TK, 1996, LAB INVEST, V74, P315; Miller BR, 2008, NEUROSCIENCE, V153, P329, DOI 10.1016/j.neuroscience.2008.02.004; Nizzardo M, 2011, EXP NEUROL, V229, P214, DOI 10.1016/j.expneurol.2011.01.017; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Thone-Reineke C, 2008, J HYPERTENS, V26, P2426, DOI 10.1097/HJH.0b013e328313e403; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Verma R, 2010, EUR J PHARMACOL, V638, P65, DOI 10.1016/j.ejphar.2010.04.021; Vink R, 2010, NEUROTHERAPEUTICS, V7, P1, DOI 10.1016/j.nurt.2009.12.001; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	37	58	61	2	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2012	73	3					654	660		10.1097/TA.0b013e31825133c0			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	009TK	WOS:000309047900018	22710775				2021-06-18	
J	Yu, FS; Zhang, YM; Chuang, DM				Yu, Fengshan; Zhang, Yumin; Chuang, De-Maw			Lithium Reduces BACE1 Overexpression, Beta Amyloid Accumulation, and Spatial Learning Deficits in Mice with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						beta amyloid; beta-APP-cleaving enzyme-1; learning and memory; lithium; traumatic brain injury	GLYCOGEN-SYNTHASE KINASE-3; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; NEUROTROPHIC FACTOR; CEREBROSPINAL-FLUID; MOUSE MODEL; PHOSPHORYLATION; INHIBITION; EXPRESSION; INCREASES	Traumatic brain injury (TBI) leads to both acute injury and long-term neurodegeneration, and is a major risk factor for developing Alzheimer's disease (AD). Beta amyloid (A beta) peptide deposits in the brain are one of the pathological hallmarks of AD. A beta levels increase after TBI in animal models and in patients with head trauma, and reducing A beta levels after TBI has beneficial effects. Lithium is known to be neuroprotective in various models of neurodegenerative disease, and can reduce A beta generation by modulating glycogen synthase kinase-3 (GSK-3) activity. In this study we explored whether lithium would reduce A beta load after TBI, and improve learning and memory in a mouse TBI model. Lithium chloride (1.5 mEq/kg, IP) was administered 15 min after TBI, and once daily thereafter for up to 3 weeks. At 3 days after injury, lithium attenuated TBI-induced A beta load increases, amyloid precursor protein (APP) accumulation, and beta-APP-cleaving enzyme-1 (BACE1) overexpression in the corpus callosum and hippocampus. Increased Tau protein phosphorylation in the thalamus was also attenuated after lithium treatment following TBI at the same time point. Notably, lithium treatment significantly improved spatial learning and memory in the Y-maze test conducted 10 days after TBI, and in the Morris water maze test performed 17-20 days post-TBI, in association with increased hippocampal preservation. Thus post-insult treatment with lithium appears to alleviate the TBI-induced A beta load and consequently improves spatial memory. Our findings suggest that lithium is a potentially useful agent for managing memory impairments after TBI or other head trauma.	[Yu, Fengshan; Chuang, De-Maw] NIMH, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA; [Yu, Fengshan; Zhang, Yumin; Chuang, De-Maw] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Yu, Fengshan; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Chuang, DM (corresponding author), NIMH, Mol Neurobiol Sect, NIH, 10 Ctr Dr,MSC-1363, Bethesda, MD 20892 USA.	chuang@mail.nih.gov		Yu, Fengshan/0000-0001-8620-3084	Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM); Blast Lethality Injury and Research Program; Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH); NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002468] Funding Source: NIH RePORTER	Support for this work included funding from the Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM), the Blast Lethality Injury and Research Program, and the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH). We are grateful to Drs. Oz Malkesman and Amanda Fu, and to Ms. Laura Tucker from the CNRM for assistance with the behavioral tests and CCI surgery. We would like to thank Drs. Chi-Tso Chiu and Zhifei Wang of the NIMH, and Dr. Flaubert Tchantchou from the Uniformed Services University of the Health Sciences, for their helpful discussions. The authors also wish to gratefully acknowledge the editorial assistance of Peter Leeds and Ioline Henter of the NIMH.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Autry AE, 2012, PHARMACOL REV, V64, P238, DOI 10.1124/pr.111.005108; Barry AE, 2011, J NEUROSCI, V31, P7259, DOI 10.1523/JNEUROSCI.6500-10.2011; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Carter MD, 2010, CLIN PHARMACOL THER, V88, P475, DOI 10.1038/clpt.2010.165; Chiu CT, 2010, PHARMACOL THERAPEUT, V128, P281, DOI 10.1016/j.pharmthera.2010.07.006; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Fukumoto T, 2001, PSYCHOPHARMACOLOGY, V158, P100, DOI 10.1007/s002130100871; Giuffrida ML, 2010, REV NEUROSCIENCE, V21, P83; Hashimoto R, 2002, NEUROPHARMACOLOGY, V43, P1173, DOI 10.1016/S0028-3908(02)00217-4; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; Jacobsen JPR, 2004, BRAIN RES, V1024, P183, DOI 10.1016/j.brainres.2004.07.065; Johnson VE, 2012, EXP NEUROL; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Li XH, 2010, NEUROPSYCHOPHARMACOL, V35, P2143, DOI 10.1038/npp.2010.105; Liu H., 2012, J EXP CLIN MED, V4, P135, DOI [10.1016/j.jecm.2012.04.001., DOI 10.1016/J.JECM.2012.04.001]; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Raby CA, 1998, J NEUROCHEM, V71, P2505; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rockenstein E, 2007, J NEUROSCI, V27, P1981, DOI 10.1523/JNEUROSCI.4321-06.2007; Roggo Silvio, 2002, Current Topics in Medicinal Chemistry, V2, P359, DOI 10.2174/1568026024607490; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Su Y, 2004, BIOCHEMISTRY-US, V43, P6899, DOI 10.1021/bi035627j; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Weiler J, 2011, J COGNITIVE NEUROSCI, V23, P3037, DOI 10.1162/jocn.2011.21633; Yau JLW, 2007, J NEUROSCI, V27, P10487, DOI 10.1523/JNEUROSCI.2190-07.2007; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	49	58	60	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	13					2342	2351		10.1089/neu.2012.2449			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000PU	WOS:000308399900010	22583494	Green Published			2021-06-18	
J	Schreiber, JM; Zelleke, T; Gaillard, WD; Kaulas, H; Dean, N; Carpenter, JL				Schreiber, John M.; Zelleke, Tesfaye; Gaillard, William D.; Kaulas, Himanshu; Dean, Nathan; Carpenter, Jessica L.			Continuous Video EEG for Patients with Acute Encephalopathy in a Pediatric Intensive Care Unit	NEUROCRITICAL CARE			English	Article						Electroencephalogram (EEG); Seizure; Non-convulsive; Status epilepticus; Encephalopathy	NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; CLINICAL-FEATURES; CHILDREN; PREVALENCE; ETIOLOGY	In this study, we aimed to determine the incidence of electrographic seizures among patients in a pediatric intensive care unit (PICU) presenting with acute encephalopathy. Risk factors and duration of continuous EEG monitoring needed to capture electrographic seizures were also assessed. Based on a NeuroICU clinical care pathway, all patients with acute encephalopathy admitted to the PICU are monitored with continuous video electroencephalogram (cVEEG) for 48 h or until the encephalopathy improves. Ninety-four consecutive patients included on the pathway over a year were identified. Mean age was 6.7 years (range 32 days-17.9 years). Data pertaining to patient clinical information and electrographic seizures, including non-convulsive seizures (NCS) and non-convulsive status epilepticus (NCSE), were extracted from a prospective database. Thirty percent (28/94) had seizures captured on cVEEG including 17 patients (18 %) with NCSE. Variables associated with electrographic seizures were age < 24 months and clinical seizure(s) prior to EEG placement. The first seizure captured on cVEEG occurred in the first 24 h for the majority of patients (97 %). Acute brain injury and electrographic seizures were associated with worse outcome. Electrographic seizures are common in pediatric patients with acute encephalopathy. This study supports the practice of cVEEG monitoring for at least 24 h in pediatric patients with acute encephalopathy, particularly if they are less then 24 months of age and/or if a clinical event suspicious for seizure precedes the encephalopathy.	[Schreiber, John M.; Zelleke, Tesfaye; Gaillard, William D.; Kaulas, Himanshu; Carpenter, Jessica L.] George Washington Univ, Sch Med & Hlth Sci, Dept Epilepsy Neurophysiol & Crit Care Neurol, Washington, DC 20010 USA; [Schreiber, John M.; Zelleke, Tesfaye; Gaillard, William D.; Kaulas, Himanshu; Dean, Nathan; Carpenter, Jessica L.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Dean, Nathan] George Washington Univ, Sch Med & Hlth Sci, Dept Crit Care Med, Washington, DC 20010 USA	Carpenter, JL (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Epilepsy Neurophysiol & Crit Care Neurol, 111 Michigan Ave NW, Washington, DC 20010 USA.	jcarpent@cnmc.org		Schreiber, John/0000-0003-0615-2497			Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Garcia-Filion P, 2012, J NEUROTRAUMA; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Husain AM, 2003, J NEUROL NEUROSUR PS, V74, P189, DOI 10.1136/jnnp.74.2.189; Hussain N, 2007, SEIZURE-EUR J EPILEP, V16, P305, DOI 10.1016/j.seizure.2007.01.007; Jaitly R, 1997, J CLIN NEUROPHYSIOL, V14, P326, DOI 10.1097/00004691-199707000-00005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Kuchta J, 2009, CENT EUR NEUROSURG, V70, P176, DOI 10.1055/s-0029-1224168; Narayanan JT, 2007, EPILEPSIA, V48, P900, DOI 10.1111/j.1528-1167.2007.01099.x; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117; Young GB, 1996, NEUROLOGY, V47, P83	27	58	60	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2012	17	1					31	38		10.1007/s12028-012-9715-z			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	976NG	WOS:000306591000004	22565632				2021-06-18	
J	Wise, EK; Hoffman, JM; Powell, JM; Bombardier, CH; Bell, KR				Wise, Elizabeth K.; Hoffman, Jeanne M.; Powell, Janet M.; Bombardier, Charles H.; Bell, Kathleen R.			Benefits of Exercise Maintenance After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Exercise; Rehabilitation; Treatment outcome	RANDOMIZED CONTROLLED-TRIAL; PHYSICAL-ACTIVITY INTERVENTIONS; REHABILITATION OUTCOMES; VIRTUAL-REALITY; DEPRESSION; METAANALYSIS; EFFICACY; PROGRAM; QUALITY; BEHAVIORS	Wise EK, Hoffman JM, Powell JM, Bombardier CH, Bell KR. Benefits of exercise maintenance after traumatic brain injury. Arch Phys Med Rehabil 2012;93: 1319-23. Objective: To examine the effect of exercise intervention on exercise maintenance, depression, quality of life, and mental health at 6 months for people with traumatic brain injury (TBI) with at least mild depression. Design: Treatment group participants were assessed at baseline, after a 10-week exercise intervention, and 6 months after completion of the intervention. Setting: Community. Participants: Participants (N = 40) with self-reported TBI from 6 months to 5 years prior to study enrollment and a score of 5 or greater on the Patient Health Questionnaire-9. Interventions: Ten-week exercise intervention program consisting of supervised weekly 60-minute sessions and unsupervised 30 minutes of aerobic exercises 4 times each week. Telephone follow-up was conducted every 2 weeks for an additional 6 months to promote exercise maintenance for individuals randomized to the intervention group. Main Outcome Measure: Beck Depression Inventory (BD!) comparing participant outcomes over time. Post hoc analyses included comparison among those who exercised more or less than 90 minutes per week. Results: Participants reduced their scores on the BDI from baseline to 10 weeks and maintained improvement over time. Many participants (48%) demonstrated increased physical activity at 6 months compared with baseline. Those who exercised more than 90 minutes had lower scores on the BDI at the 10-week and 6-month assessments and reported higher perceived quality of life and mental health. Conclusions: Exercise may contribute to improvement in mood and quality of life for people with TBI and should be considered as part of the approach to depression treatment.	[Wise, Elizabeth K.] Harborview Med Ctr, Seattle, WA 98104 USA; [Hoffman, Jeanne M.; Powell, Janet M.; Bombardier, Charles H.; Bell, Kathleen R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	Wise, EK (corresponding author), Harborview Med Ctr, Box 359818,325 9th Ave, Seattle, WA 98104 USA.	bwise@u.washington.edu		Bell, Kathleen/0000-0002-0928-2046	National Institute on Disability and Rehabilitation Research [H133A070032]	Supported by the National Institute on Disability and Rehabilitation Research (grant no. H133A070032) funds for the Traumatic Brain Injury Model Systems.	American College of Sports Medicine, 2009, GUID EX TEST PRESCR; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Baillet A, 2010, ARTHRIT CARE RES, V62, P984, DOI 10.1002/acr.20146; Bandura A., 1986, SOCIAL FDN THOUGHT A; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Blake H, 2009, CLIN REHABIL, V23, P589, DOI 10.1177/0269215508101736; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Bopp Melissa, 2007, Prev Chronic Dis, V4, pA87; Borg G., 1998, BORGS PERCEIVED EXER; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Conn VS, 2010, NURS RES, V59, P224, DOI 10.1097/NNR.0b013e3181dbb2f8; Conn VS, 2010, ANN BEHAV MED, V39, P128, DOI 10.1007/s12160-010-9172-x; Conn VS, 2009, NURS RES, V58, P175, DOI 10.1097/NNR.0b013e318199b53a; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Hassett LM, 2011, BRAIN INJURY, V25, P698, DOI 10.3109/02699052.2011.579934; Hassett LM, 2009, J REHABIL MED, V41, P247, DOI 10.2340/16501977-0316; Hoffman JM, 2010, PM&R, V2, P911, DOI 10.1016/j.pmrj.2010.06.008; Jensen M.P., 2001, HDB PAIN ASSESSMENT, P15; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Mossberg KA, 2010, J HEAD TRAUMA REHAB, V25, P173, DOI 10.1097/HTR.0b013e3181dc98ff; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Pinto BM, 2011, AM J PREV MED, V41, P274, DOI 10.1016/j.amepre.2011.04.015; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Randolph C, 1998, REPEATABLE BATTERY A; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rush AJ, 2004, CONTROL CLIN TRIALS, V25, P119, DOI 10.1016/S0197-2456(03)00112-0; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; Sofi F, 2011, J INTERN MED, V269, P107, DOI 10.1111/j.1365-2796.2010.02281.x; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Ware JE, 1995, SF 12 SCORE SF 12 PH; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wycherley TP, 2012, DIABETIC MED, V29, P632, DOI 10.1111/j.1464-5491.2011.03451.x	39	58	60	0	38	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1319	1323		10.1016/j.apmr.2012.05.009			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700004	22840829				2021-06-18	
J	Baker, DG; Nash, WP; Litz, BT; Geyer, MA; Risbrough, VB; Nievergelt, CM; O'Connor, DT; Larson, GE; Schork, NJ; Vasterling, JJ; Hammer, PS; Webb-Murphy, JA				Baker, Dewleen G.; Nash, William P.; Litz, Brett T.; Geyer, Mark A.; Risbrough, Victoria B.; Nievergelt, Caroline M.; O'Connor, Daniel T.; Larson, Gerald E.; Schork, Nicholas J.; Vasterling, Jennifer J.; Hammer, Paul S.; Webb-Murphy, Jennifer A.		MRS Team	Predictors of Risk and Resilience for Posttraumatic Stress Disorder Among Ground Combat Marines: Methods of the Marine Resiliency Study	PREVENTING CHRONIC DISEASE			English	Article							TRAUMATIC BRAIN-INJURY; US MILITARY COHORT; MENTAL-HEALTH; PTSD; IRAQ; DEPLOYMENT; WAR; AFGHANISTAN; DIAGNOSES; SYMPTOMS	The Marine Resiliency Study (MRS) is a prospective study of factors predictive of posttraumatic stress disorder (PTSD) among approximately 2,600 Marines in 4 battalions deployed to Iraq or Afghanistan. We describe the MRS design and predeployment participant characteristics. Starting in 2008, our research team conducted structured clinical interviews on Marine bases and collected data 4 times: at predeployment and at 1 week, 3 months, and 6 months postdeployment. Integrated with these data are medical and career histories from the Career History Archival Medical and Personnel System (CHAMPS) database. The CHAMPS database showed that 7.4% of the Marines enrolled in MRS had at least 1 mental health diagnosis. Of enrolled Marines, approximately half (51.3%) had prior deployments. We found a moderate positive relationship between deployment history and PTSD prevalence in these baseline data.	[Baker, Dewleen G.; Nash, William P.; Nievergelt, Caroline M.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Litz, Brett T.; Vasterling, Jennifer J.] Vet Affairs Boston Healthcare Syst, Boston, MA USA; [Geyer, Mark A.; Risbrough, Victoria B.; O'Connor, Daniel T.] Univ Calif San Diego, San Diego, CA 92103 USA; [Larson, Gerald E.] USN, Hlth Res Ctr, San Diego, CA 92152 USA; [Schork, Nicholas J.] Scripps Translat Sci Inst, La Jolla, CA USA; [Hammer, Paul S.] Def Ctr Excellence Stress & Mental Hlth Traumat B, Arlington, VA USA; [Webb-Murphy, Jennifer A.] USN, Ctr Combat & Operat Stress Control, San Diego, CA 92152 USA	Baker, DG (corresponding author), VA San Diego Healthcare Syst, VA Ctr Stress & Mental Hlth 116A, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	dgbaker@ucsd.edu	Baker, Dewleen/O-4957-2019; Risbrough, Victoria/X-3344-2019	Baker, Dewleen/0000-0002-1736-9838; Litz, Brett/0000-0002-0479-8887; Nievergelt, Caroline/0000-0001-5766-8923; Schork, Nicholas/0000-0003-0920-5013	VA Health Service Research and Development [SDR 09-0128]; Marine Corps and Navy Bureau of Medicine and Surgery; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH093500] Funding Source: NIH RePORTER	This study was funded by VA Health Service Research and Development project no. SDR 09-0128 and by the Marine Corps and Navy Bureau of Medicine and Surgery. We acknowledge special assistance from members of VA Center of Excellence for Stress and Mental Health, VA San Diego Research and Fiscal Services, and the 1st Marine Division and Navy Medicine at 29 Palms and at Camp Pendleton. Acknowledged also are core MRS team members Amela Ahmetovic, Nilima Biswas, William H. Black, Mahalah R. Buell, Teresa Carper, Andrew De La Rosa, Benjamin Dickstein, Heather Ellis-Johnson, Caitlin Fernandes, Susan Fesperman, David Fink, Summer Fitzgerald, Steven Gerard, Abigail A. Goldsmith, Gali Goldwaser, Patricia Gorman, Jorge A. Gutierrez, John A. Hall, Jr, Laura Harder, Pia Heppner, Alexandra Kelada, Jennifer Lemmer, Morgan LeSuer-Mandernack, Manjula Mahata, Arame Motazedi, Elin Olsson, Ines Pandzic, Anjana H. Patel, Dhaval H. Patel, Sejal Patel, Shetal M. Patel, Taylor Perin-Kash, James O.E. Pittman, Stephanie Raducha, Brenda Thomas, Elisa Tsan, Maria Anna Valencerina, Chelsea Wallace, Kate Yurgil, Kuixing Zhang, and the many intermittent on-site MRS clinician-interviewers and data collection staff.	Baker DG, 2012, NEUROPHARMACOLOGY, V62, P663, DOI 10.1016/j.neuropharm.2011.02.027; Baker DG, 2009, MIL MED, V174, P773; Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Brenner LA, 2011, SUICIDE LIFE-THREAT, V41, P416, DOI 10.1111/j.1943-278X.2011.00041.x; Brinton TJ, 1996, HYPERTENSION, V28, P599, DOI 10.1161/01.HYP.28.4.599; Defense Manpower Data Center, 2011, GLOB WAR TERR CAS MI; Highfill-McRoy RM, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-88; Institute of Medicine, 2008, TREATM POSTTR STRESS; Kuehn BM, 2010, JAMA-J AM MED ASSOC, V304, P1427, DOI 10.1001/jama.2010.1327; Larson GE, 2011, PSYCHIAT SERV, V62, P15, DOI 10.1176/ps.62.1.pss6201_0015; LeardMann CA, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1273; Litz BT, 2009, CLIN PSYCHOL REV, V29, P695, DOI 10.1016/j.cpr.2009.07.003; Magruder KM, 2009, PSYCHIAT ANN, V39, P778, DOI 10.3928/00485713-20090728-04; Nash WP, 2010, ARCH PHYS MED REHAB, V91, P1673, DOI 10.1016/j.apmr.2010.06.035; Peleg T, 2006, CNS SPECTRUMS, V11, P589, DOI 10.1017/S109285290001364X; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Risbrough V, 2010, CURR TOP BEHAV NEURO, V2, P205, DOI 10.1007/7854_2009_11; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seasholtz TM, 2006, HYPERTENSION, V47, P937, DOI 10.1161/01.HYP.0000217364.45622.f0; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Talilien T, 2008, INVISIBLE WOUNDS WAR; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	25	58	58	0	25	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1545-1151			PREV CHRONIC DIS	Prev. Chronic Dis.	MAY	2012	9								110134	10.5888/pcd9.110134			11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	977HU	WOS:000306648100005	22575082	Green Published			2021-06-18	
J	Li, YC; Xi, CH; An, YF; Dong, WH; Zhou, M				Li, Y-C.; Xi, C-H.; An, Y-F.; Dong, W-H.; Zhou, M.			Perioperative inflammatory response and protein S-100 beta concentrations - relationship with post-operative cognitive dysfunction in elderly patients	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; MINOR SURGERY; SERUM-LEVELS; ANESTHESIA; NEUROINFLAMMATION; MARKERS; RISK	Background: One major concern in about one third of elder patients after total hip-replacement surgery is post-operative cognitive dysfunction (POCD). Previous studies have suggested that cognitive impairment is accompanied with changes in serum S-100 beta protein (S-100 beta) and inflammatory markers. Thus, the aim of the current study was to investigate the value of serum S-100 beta and interleukin(IL)-1 beta, IL-6, tumour necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP) in reflecting POCD after total hip-replacement surgery. Methods: Forty-two elderly patients were enrolled, and 37 patients completed the follow-up. Serum S-100 beta protein and IL-1 beta, IL-6, TNF-alpha, and CRP were determined pre-operatively, as well as 1 h and 6 h post-operatively. Neuropsychological tests were performed pre-operatively, as well as on day 1, 3, and 7 post-operatively. Results: Seventeen (45.9%, 17/37) patients developed POCD 1 day after surgery, and three (8.1%, 3/37) developed POCD 7 days after surgery. [Correction added after publication 7 February 2012: in the preceding sentence (54.1%, 17/37) was corrected to (45.9%, 17/37)]. Patients with POCD 1 day after surgery had significantly higher serum levels of IL-6 at 6 h (135 +/- 32 pg/ml vs. 91 +/- 29 pg/ml, P < 0.05) and S-100b at 1 h (1872 +/- 385 pg/ml vs. 1289 +/- 143 pg/ml, P < 0.05. No significant post-operative change was detected in levels of TNF-alpha, IL-1, or CRP. Conclusion: The serum levels of pro-inflammatory marker IL-6 and S-100 beta protein increased after total hip-replacement in elderly patients, and such increase may serve as predicting parameters for the occurrence of POCD.	[Li, Y-C.; Xi, C-H.; An, Y-F.; Dong, W-H.; Zhou, M.] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Anesthesiol, Shanghai 200233, Peoples R China	Zhou, M (corresponding author), Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Anesthesiol, 600 Yishan Rd, Shanghai 200233, Peoples R China.	zhoum@sjtu.edu.cn					Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Brickenkamp R., 1994, TEST D2 AUFMERKSAMKE, V8th ed.; Cambell DN, 1993, ANAESTHESIA, V48, P422; Cao XZ, 2010, PROG NEURO-PSYCHOPH, V34, P1426, DOI 10.1016/j.pnpbp.2010.07.027; Cibelli M, 2010, ANN NEUROL, V68, P360, DOI 10.1002/ana.22082; Dijkstra JB, 1999, BRIT J ANAESTH, V82, P867; Evered L, 2011, ANESTH ANALG, V112, P1179, DOI 10.1213/ANE.0b013e318215217e; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Jawa Randeep S, 2011, J Intensive Care Med, V26, P73, DOI 10.1177/0885066610395679; Lemstra AW, 2008, INT J GERIATR PSYCH, V23, P943, DOI 10.1002/gps.2015; [李兴 LI Xing], 2009, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V25, P652; Linstedt U, 2002, ACTA ANAESTH SCAND, V46, P384, DOI 10.1034/j.1399-6576.2002.460409.x; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Norkiene I, 2010, MEDICINA-LITHUANIA, V46, P460, DOI 10.3390/medicina46070066; Oswald W. D., 1997, ZAHLEN VERBINDUNGS T; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Rasmussen LS, 2000, BRIT J ANAESTH, V84, P242; Rohan D, 2005, CAN J ANAESTH, V52, P137, DOI 10.1007/BF03027718; Rosczyk HA, 2008, EXP GERONTOL, V43, P840, DOI 10.1016/j.exger.2008.06.004; SEIDENBERG M, 1981, EPILEPSIA, V22, P75, DOI 10.1111/j.1528-1157.1981.tb04334.x; Sheeran P, 1997, BRIT J ANAESTH, V78, P201; Spath-Schwalbe E, 1998, J CLIN ENDOCR METAB, V83, P1573, DOI 10.1210/jc.83.5.1573; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Sun TS, 2011, INJURY, V42, P707, DOI 10.1016/j.injury.2011.01.010; Tamura A, 2011, ANN THORAC CARDIOVAS, V17, P33, DOI 10.5761/atcs.oa.09.01518; Voronina TA, 2009, B EXP BIOL MED+, V148, P533, DOI 10.1007/s10517-010-0757-y; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wu CL, 2004, REGION ANESTH PAIN M, V29, P257, DOI 10.1016/j.rapm.2003.11.007	31	58	88	2	17	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2012	56	5					595	600		10.1111/j.1399-6576.2011.02616.x			6	Anesthesiology	Anesthesiology	923FD	WOS:000302603900010	22224444				2021-06-18	
J	Lobo, D; Beane, WS; Levin, M				Lobo, Daniel; Beane, Wendy S.; Levin, Michael			Modeling Planarian Regeneration: A Primer for Reverse-Engineering the Worm	PLOS COMPUTATIONAL BIOLOGY			English	Article							GAP-JUNCTIONAL COMMUNICATION; ANTERIOR-POSTERIOR POLARITY; CENTRAL-NERVOUS-SYSTEM; FRESH-WATER PLANARIAN; LEFT-RIGHT ASYMMETRY; STEM-CELLS; INTERCALARY REGENERATION; BETA-CATENIN; TRANSCRIPTION FACTOR; BLASTEMA POLARITY	A mechanistic understanding of robust self-assembly and repair capabilities of complex systems would have enormous implications for basic evolutionary developmental biology as well as for transformative applications in regenerative biomedicine and the engineering of highly fault-tolerant cybernetic systems. Molecular biologists are working to identify the pathways underlying the remarkable regenerative abilities of model species that perfectly regenerate limbs, brains, and other complex body parts. However, a profound disconnect remains between the deluge of high-resolution genetic and protein data on pathways required for regeneration, and the desired spatial, algorithmic models that show how self-monitoring and growth control arise from the synthesis of cellular activities. This barrier to progress in the understanding of morphogenetic controls may be breached by powerful techniques from the computational sciences-using non-traditional modeling approaches to reverse-engineer systems such as planaria: flatworms with a complex bodyplan and nervous system that are able to regenerate any body part after traumatic injury. Currently, the involvement of experts from outside of molecular genetics is hampered by the specialist literature of molecular developmental biology: impactful collaborations across such different fields require that review literature be available that presents the key functional capabilities of important biological model systems while abstracting away from the often irrelevant and confusing details of specific genes and proteins. To facilitate modeling efforts by computer scientists, physicists, engineers, and mathematicians, we present a different kind of review of planarian regeneration. Focusing on the main patterning properties of this system, we review what is known about the signal exchanges that occur during regenerative repair in planaria and the cellular mechanisms that are thought to underlie them. By establishing an engineering-like style for reviews of the molecular developmental biology of biomedically important model systems, significant fresh insights and quantitative computational models will be developed by new collaborations between biology and the information sciences.	[Lobo, Daniel] Tufts Univ, Ctr Regenerat & Dev Biol, Medford, MA 02155 USA; Tufts Univ, Dept Biol, Medford, MA 02155 USA	Lobo, D (corresponding author), Tufts Univ, Ctr Regenerat & Dev Biol, Medford, MA 02155 USA.	michael.levin@tufts.edu	Levin, Michael/A-5918-2011	Levin, Michael/0000-0001-7292-8084; Lobo, Daniel/0000-0003-4666-6118	Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-10-2-0058]; G. Harold and Leila Y. Mathers Charitable Foundation; NSF CDINational Science Foundation (NSF) [EF-1124651]; NIH Kirschstein-NRSAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32 GM08354]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [F32GM083547] Funding Source: NIH RePORTER	This work was supported by the Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC) through award W81XWH-10-2-0058. ML is also grateful for the support of the G. Harold and Leila Y. Mathers Charitable Foundation, and NSF CDI grant - EF-1124651. WSB gratefully acknowledges the support of the NIH Kirschstein-NRSA grant F32 GM08354. The funders had no role in the preparation of the manuscript.	Aboobaker AA, 2011, TRENDS CELL BIOL, V21, P304, DOI 10.1016/j.tcb.2011.01.005; Adams DS, 2008, TISSUE ENG PT A, V14, P1461, DOI 10.1089/ten.tea.2008.0080; Adell T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000505; Adell T, 2009, DEVELOPMENT, V136, P905, DOI 10.1242/dev.033761; Agata K, 2003, CURR OPIN GENET DEV, V13, P492, DOI 10.1016/j.gde.2003.08.009; Agata K, 2003, DEV DYNAM, V226, P308, DOI 10.1002/dvdy.10249; Allen MT, 2005, NEW PHYTOL, V166, P869, DOI 10.1111/j.1469-8137.2005.01348.x; Almuedo-Castillo M, 2011, P NATL ACAD SCI USA, V108, P2813, DOI 10.1073/pnas.1012090108; Andersen T, 2009, ARTIF LIFE, V15, P161, DOI 10.1162/artl.2009.15.2.15201; Aoki R, 2009, NEUROSCIENCE, V159, P908, DOI 10.1016/j.neuroscience.2008.11.011; BAGUNA J, 1981, HYDROBIOLOGIA, V84, P181, DOI 10.1007/BF00026179; BAGUNA J, 1989, DEVELOPMENT, V107, P77; Ball P., 1999, SELF MADE TAPESTRY P; Basanta D, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000030; Beane WS, 2011, CHEM BIOL, V18, P77, DOI 10.1016/j.chembiol.2010.11.012; Bongard J, 2006, SCIENCE, V314, P1118, DOI 10.1126/science.1133687; Brondsted H. V., 1969, PLANARIAN REGENERATI; BRONDSTED HV, 1955, BIOL REV, V30, P65, DOI 10.1111/j.1469-185X.1955.tb00649.x; BROWN F A JR, 1975, International Journal of Chronobiology, V3, P57; BROWN FA, 1975, PHYSIOL ZOOL, V48, P168, DOI 10.1086/physzool.48.2.30155650; BROWN FA, 1966, NATURE, V209, P533, DOI 10.1038/209533b0; BROWN FA, 1964, NATURE, V202, P469, DOI 10.1038/202469a0; Brown FD, 2008, GENESIS, V46, P605, DOI 10.1002/dvg.20471; BROWN HM, 1968, J GEN PHYSIOL, V51, P237, DOI 10.1085/jgp.51.2.237; BROWN HM, 1968, J GEN PHYSIOL, V51, P255, DOI 10.1085/jgp.51.2.255; Cebria F, 2005, DEVELOPMENT, V132, P3691, DOI 10.1242/dev.01941; Cebria F, 2002, NATURE, V419, P620, DOI 10.1038/nature01042; Cebria F, 2008, NEUROSCI RES, V61, P375, DOI 10.1016/j.neures.2008.04.005; Cebria F, 2007, DEV GENES EVOL, V217, P733, DOI 10.1007/s00427-007-0188-6; Cebria F, 2007, DEV BIOL, V307, P394, DOI 10.1016/j.ydbio.2007.05.006; Cebria F, 2007, DEVELOPMENT, V134, P833, DOI 10.1242/dev.02794; CHANDEBOIS R, 1979, DEV GROWTH DIFFER, V21, P195; CHAPLAIN MAJ, 1999, GROWTH FORM SPATIOTE; de Garis H, 1992, DYNAMIC GENETIC CHAO; Devert A, 2007, GECCO 2007: GENETIC AND EVOLUTIONARY COMPUTATION CONFERENCE, VOL 1 AND 2, P982; DIMMITT J, 1952, J CELL COMPAR PHYSL, V40, P11, DOI 10.1002/jcp.1030400103; Molina MD, 2011, CURR BIOL, V21, P300, DOI 10.1016/j.cub.2011.01.016; Eisenhoffer GT, 2008, CELL STEM CELL, V3, P327, DOI 10.1016/j.stem.2008.07.002; Esser AT, 2006, DEV DYNAM, V235, P2144, DOI 10.1002/dvdy.20870; Fernandez-Blanco E, 2007, LECT NOTES ARTIF INT, V4648, P825; Fisher J, 2007, NAT BIOTECHNOL, V25, P1239, DOI 10.1038/nbt1356; Forsthoefel DJ, 2011, DEV BIOL, V356, P445, DOI 10.1016/j.ydbio.2011.05.669; Fraguas S, 2011, DEV BIOL, V354, P87, DOI 10.1016/j.ydbio.2011.03.023; Gautier H, 2000, ANN BOT-LONDON, V85, P359, DOI 10.1006/anbo.1999.1069; Gavino MA, 2011, CURR BIOL, V21, P294, DOI 10.1016/j.cub.2011.01.017; Gentile L, 2011, DIS MODEL MECH, V4, P12, DOI 10.1242/dmm.006692; GLAZIER JA, 1993, PHYS REV E, V47, P2128, DOI 10.1103/PhysRevE.47.2128; Gonzalez-Estevez C, 2007, AUTOPHAGY, V3, P640, DOI 10.4161/auto.4934; Gordon R, 2003, INT J DEV BIOL, V47, P183; Guckenheimer, 2006, DYNAMIC MODELS BIOL; Gurley KA, 2008, SCIENCE, V319, P323, DOI 10.1126/science.1150029; Gurley KA, 2010, DEV BIOL, V347, P24, DOI 10.1016/j.ydbio.2010.08.007; Haddow PC, 2007, GECCO 2007: GENETIC AND EVOLUTIONARY COMPUTATION CONFERENCE, VOL 1 AND 2, P1013; Handberg-Thorsager M, 2008, FRONT BIOSCI-LANDMRK, V13, P6374, DOI 10.2741/3160; Harrison LG, KINETIC THEORY LIVIN; Hogeweg P, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002021; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Iglesias M, 2008, DEVELOPMENT, V135, P1215, DOI 10.1242/dev.020289; Iglesias M, 2011, DEV BIOL, V358, P68, DOI 10.1016/j.ydbio.2011.07.013; Jaeger J, 2009, MOL BIOSYST, V5, P1549, DOI 10.1039/b904722k; Jenkins MM, 1963, BIPOLAR PLANARIANS S, P142; KANATANI HARUO, 1958, JOUR FAC SCI TOKYO UNIV SECT IV ZOOL, V8, P253; Kato K, 1999, DEVELOPMENT, V126, P1031; Kennaway R, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002071; Kobayashi C, 1999, MECH DEVELOP, V89, P25, DOI 10.1016/S0925-4773(99)00192-6; LANGE CS, 1978, DIFFERENTIATION, V11, P1, DOI 10.1111/j.1432-0436.1978.tb00965.x; Larson DE, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000841; Levin M, 2007, PROG BIOPHYS MOL BIO, V94, P186, DOI 10.1016/j.pbiomolbio.2007.03.005; Levin M, 2007, TRENDS CELL BIOL, V17, P261, DOI 10.1016/j.tcb.2007.04.007; Levin M, 2006, DEV NEUROSCI-BASEL, V28, P171, DOI 10.1159/000091915; Levin M, 2009, SEMIN CELL DEV BIOL, V20, P543, DOI 10.1016/j.semcdb.2009.04.013; LINDENMAYER A, 1968, J THEOR BIOL, V18, P280, DOI 10.1016/0022-5193(68)90079-9; Lobo D, 2011, THEOR COMPUT SCI, V412, P6101, DOI 10.1016/j.tcs.2011.07.004; Lobo D, 2010, BIOSYSTEMS, V102, P112, DOI 10.1016/j.biosystems.2010.08.003; Lowe CJ, 2006, PLOS BIOL, V4, P1603, DOI 10.1371/journal.pbio.0040291; MARSH G, 1952, J CELL COMPAR PHYSL, V39, P191, DOI 10.1002/jcp.1030390203; MASON PR, 1975, ANIM BEHAV, V23, P460, DOI 10.1016/0003-3472(75)90095-0; MCWHINNIE MA, 1955, BIOL BULL, V108, P54, DOI 10.2307/1538397; MEINHARDT H, 1978, J THEOR BIOL, V74, P307, DOI 10.1016/0022-5193(78)90078-4; Meinhardt H., 2009, COLD SPRING HARB PER, V1; Meinhardt H., 1982, MODELS BIOL PATTERN; Meinhardt H, 2009, BIOESSAYS, V31, P5, DOI 10.1002/bies.080193; Miller JF, 2004, LECT NOTES COMPUT SC, V3102, P129; MITTENTHAL JE, 1988, DEV BIOL, V126, P315, DOI 10.1016/0012-1606(88)90141-8; MIYAMOTO S, 1985, ZOOL SCI, V2, P389; Molina MD, 2007, DEV BIOL, V311, P79, DOI 10.1016/j.ydbio.2007.08.019; Molina Ma Dolores, 2011, Communicative & Integrative Biology, V4, P498, DOI 10.4161/cib.4.4.15753; MONTGOMERY JR, 1974, T AM MICROSC SOC, V93, P386, DOI 10.2307/3225439; Morgan T. H., 1898, Archiv fuer Entwicklungsmechanik, Vvii, P364; Morgan TH, 1901, ARCH ENTWICKLUNG ORG, V13, P179, DOI 10.1007/BF02161982; Murray J.D., 2002, MATH BIOL; Newmark P, 2001, REGENERATION PLANARI; Newmark PA, 2005, DEV CELL, V8, P623, DOI 10.1016/j.devcel.2005.04.007; Newmark PA, 2002, NAT REV GENET, V3, P210, DOI 10.1038/nrg759; Newmark PA, 1999, PLANARIAN REGENERATI; Nishimura K, 2008, NEUROSCIENCE, V153, P1103, DOI 10.1016/j.neuroscience.2008.03.026; Nishimura K, 2010, NEUROSCIENCE, V168, P18, DOI 10.1016/j.neuroscience.2010.03.038; Nishimura K, 2007, DEV NEUROBIOL, V67, P1059, DOI 10.1002/dneu.20377; Nogi T, 2005, DEV BIOL, V287, P314, DOI 10.1016/j.ydbio.2005.09.002; Nogi T, 2005, LATERALITY, V10, P193, DOI 10.1080/1357650054200001440; Nogi T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000464; Orii H, 2007, DEV GROWTH DIFFER, V49, P345, DOI 10.1111/j.1440-169x.2007.00931.x; Oviedo N, 2008, DIS MOD MECH, V1; Oviedo NJ, 2007, DEVELOPMENT, V134, P3121, DOI 10.1242/dev.006635; Oviedo NJ, 2010, DEV BIOL, V339, P188, DOI 10.1016/j.ydbio.2009.12.012; Oviedo NJ, 2003, DEV DYNAM, V226, P326, DOI 10.1002/dvdy.10228; Palakodeti D, 2008, RNA, V14, P1174, DOI 10.1261/rna.1085008; PASCOLINI R, 1984, CELL TISSUE RES, V236, P345; Pellettieri J, 2007, ANNU REV GENET, V41, P83, DOI 10.1146/annurev.genet.41.110306.130244; Pellettieri J, 2010, DEV BIOL, V338, P76, DOI 10.1016/j.ydbio.2009.09.015; Perkins TJ, 2006, PLOS COMPUT BIOL, V2, P417, DOI 10.1371/journal.pcbi.0020051; Petersen CP, 2008, SCIENCE, V319, P327, DOI 10.1126/science.1149943; Petersen CP, 2011, SCIENCE, V332, P852, DOI 10.1126/science.1202143; Petersen CP, 2009, CELL, V139, P1056, DOI 10.1016/j.cell.2009.11.035; Priami C, 2009, COMMUN ACM, V52, P80, DOI 10.1145/1506409.1506427; Prusinkiewicz P, 2007, SCIENCE, V316, P1452, DOI 10.1126/science.1140429; Reddien PW, 2007, DEVELOPMENT, V134, P4043, DOI 10.1242/dev.007138; Reddien PW, 2011, TRENDS GENET, V27, P277, DOI 10.1016/j.tig.2011.04.004; Reddien PW, 2005, SCIENCE, V310, P1327, DOI 10.1126/science.1116110; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P725, DOI 10.1146/annurev.cellbio.20.010403.095114; Rink JC, 2009, SCIENCE, V326, P1406, DOI 10.1126/science.1178712; Romero R, 2001, INT J DEV BIOL, V45, P669; Rossi L, 2006, DEV GENES EVOL, V216, P335, DOI 10.1007/s00427-006-0060-0; Rubenstein M, 2009, INT J DEV BIOL, V53, P869, DOI 10.1387/ijdb.092937mr; Salo E, 2006, BIOESSAYS, V28, P546, DOI 10.1002/bies.20416; SALO E, 1984, J EMBRYOL EXP MORPH, V83, P63; SALO E, 1985, ROUX ARCH DEV BIOL, V194, P364; Salo E, 2009, INT J DEV BIOL, V53, P1317, DOI 10.1387/ijdb.072414es; Santos FV, 1929, BIOL BULL-US, V57, P188, DOI 10.2307/1536781; SARNAT HB, 1985, CAN J NEUROL SCI, V12, P296, DOI 10.1017/S031716710003537X; Sasaki M, 2000, P NATL ACAD SCI USA, V97, P8617, DOI 10.1073/pnas.97.15.8617; Savill NJ, 1997, J THEOR BIOL, V184, P229, DOI 10.1006/jtbi.1996.0237; Schnell S, 2007, MULTISCALE MODELING; SLACK JMW, 1980, J THEOR BIOL, V82, P105, DOI 10.1016/0022-5193(80)90092-2; Szallasi Z., 2006, SYST MOD CELL BIOL, DOI [10.7551/mitpress/9780262195485.001.0001., 10.7551/mitpress/9780262195485.001.0001]; Takeda H, 2009, ZOOL SCI, V26, P805, DOI 10.2108/zsj.26.805; Tasaki J, 2011, DEVELOPMENT, V138, P2417, DOI 10.1242/dev.060764; Tasaki J, 2011, DEV GROWTH DIFFER, V53, P389, DOI 10.1111/j.1440-169X.2011.01254.x; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; WADDINGTON CH, 1968, NATURE, V218, P525, DOI 10.1038/218525a0; Wagner DE, 2011, SCIENCE, V332, P811, DOI 10.1126/science.1203983; Wenemoser D, 2010, DEV BIOL, V344, P979, DOI 10.1016/j.ydbio.2010.06.017; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; Yang SJ, 2004, EUR J NEUROSCI, V19, P1153, DOI 10.1111/j.1460-9568.2004.03250.x; Yazawa S, 2009, P NATL ACAD SCI USA, V106, P22329, DOI 10.1073/pnas.0907464106; Zhao M, 2006, NATURE, V442, P457, DOI 10.1038/nature04925	146	58	58	1	96	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1553-734X	1553-7358		PLOS COMPUT BIOL	PLoS Comput. Biol.	APR	2012	8	4							e1002481	10.1371/journal.pcbi.1002481			12	Biochemical Research Methods; Mathematical & Computational Biology	Biochemistry & Molecular Biology; Mathematical & Computational Biology	934JM	WOS:000303440400033	22570595	DOAJ Gold, Green Published			2021-06-18	
J	Baguley, IJ; Nott, MT; Howie, AA; Simpson, GK; Browne, S; King, AC; Cotter, RE; Hodgkinson, A				Baguley, Ian J.; Nott, Melissa T.; Howie, Alison A.; Simpson, Grahame K.; Browne, Stuart; King, A. Clayton; Cotter, Rachel E.; Hodgkinson, Adeline			Late mortality after severe traumatic brain injury in New South Wales: a multicentre study	MEDICAL JOURNAL OF AUSTRALIA			English	Article							LONG-TERM SURVIVAL; REHABILITATION; POPULATION; OUTCOMES; TRENDS; DEATH; CARE	Objectives: To determine the long-term mortality pattern of adults with severe traumatic brain injury (TBI), and to identify the risk factors associated with death in this group. Design, patients and setting: Inception cohort study of 2545 adults consecutively discharged from one of three metropolitan tertiary, post-acute inpatient rehabilitation services of the New South Wales Brain Injury Rehabilitation Program from 1 January 1990 to 1 October 2007 after inpatient rehabilitation for primary TBI. Main outcome measure: Survival status at 1 October 2009. Results: 258 deaths were recorded in this sample, yielding a standardised mortality ratio of 3.19 (95% Cl, 2.80-3.60). Risk of death remained elevated above societal norms for at least 8 years after discharge from rehabilitation. Mortality risk was increased by: functional dependence at discharge; age at injury; pre-injury drug and alcohol misuse; pre-injury epilepsy; and discharge to an aged care facility. The risk of death from external causes, and respiratory system and nervous system disorders was six to seven times higher, and the risk of death from disorders of the digestive system, and mental and behavioural disorders was five times higher in adults with severe TBI than in the general population. Conclusions: People who survive to discharge from inpatient rehabilitation following a severe TBI were found to have a sustained increase in risk of death for eight years post discharge. Various demographic and injury-related variables selectively increase mortality risk and may be modifiable in order to reduce the observed increase in mortality.	[Baguley, Ian J.; Nott, Melissa T.; Howie, Alison A.] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia; [Simpson, Grahame K.; Cotter, Rachel E.; Hodgkinson, Adeline] Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Browne, Stuart; King, A. Clayton] Royal Rehabil Ctr Sydney, Brain Injury Rehabil Serv, Sydney, NSW, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia.	Ian.Baguley@swahs.health.nsw.gov.au	Nott, Melissa T/M-6778-2018; Simpson, Grahame K/W-1074-2019; Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Nott, Melissa T/0000-0001-7088-5826; Simpson, Grahame K/0000-0001-8156-9060; Baguley, Ian J/0000-0001-5650-3705; 	New South Wales Government [08157, 10588]	We gratefully acknowledge the statistical advice provided by Karen Byth of Westmead Hospital, and the financial support provided by the New South Wales Government Lifetime Care and Support Authority to complete this study (research grants 08157 and 10588).	Access Economics, 2009, EC COST SPINAL CORD, P31; Australian Bureau of Statistics, 2008, DEATHS AUSTR; Baguley I, 2000, BRAIN INJURY, V14, P505; Baguley IJ, 2008, BRAIN INJURY, V22, P919, DOI 10.1080/02699050802448578; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Harradine PG, 2004, MED J AUSTRALIA, V181, P130, DOI 10.5694/j.1326-5377.2004.tb06202.x; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; NSW Health, NSW BRAIN INJ REH PR; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Strauss D, 2004, NEUROREHABILITATION, V19, P257; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Uniform Data System for Medical Rehabilitation, 1997, GUID UN DAT SET MED; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151	25	58	60	0	5	AUSTRALASIAN MED PUBL CO LTD	PYRMONT	LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA	0025-729X	1326-5377		MED J AUSTRALIA	Med. J. Aust.	JAN 16	2012	196	1					40	45		10.5694/mja11.10090			6	Medicine, General & Internal	General & Internal Medicine	881QH	WOS:000299500700024	22256933	Bronze			2021-06-18	
J	Tham, SW; Palermo, TM; Vavilala, MS; Wang, J; Jaffe, KM; Koepsell, TD; Dorsch, A; Temkin, N; Durbin, D; Rivara, FP				Tham, See Wan; Palermo, Tonya M.; Vavilala, Monica S.; Wang, Jin; Jaffe, Kenneth M.; Koepsell, Thomas D.; Dorsch, Andrea; Temkin, Nancy; Durbin, Dennis; Rivara, Frederick P.			The Longitudinal Course, Risk Factors, and Impact of Sleep Disturbances in Children with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						pediatric; risk factors; sleep disturbances; traumatic brain injury	UNITED-STATES; FOLLOW-UP; POSTCONCUSSIVE SYMPTOMS; PAIN; PARTICIPATION; ADOLESCENTS; RELIABILITY; PERFORMANCE; PREVALENCE; INSOMNIA	This study aimed to examine the prevalence and trajectory of sleep disturbances and their associated risk factors in children up to 24 months following a traumatic brain injury (TBI). In addition, the longitudinal association between sleep disturbances and children's functional outcomes was assessed. This was a prospective study of a cohort of children with TBI and a comparison cohort of children with orthopedic injury (OI). Parental reports of pre-injury sleep disturbances were compared to reports of post-injury changes at 3, 12, and 24 months. Risk factors for sleep disturbances were examined, including severity of TBI, presence of psychosocial problems, and pain. Sleep disturbances were also examined as a predictor of children's functional outcomes in the areas of adaptive behavior skills and activity participation. Both cohorts (children with TBI and OI) displayed increased sleep disturbances after injury. However, children with TBI experienced higher severity and more prolonged duration of sleep disturbances compared to children with OI. Risk factors for disturbed sleep included mild TBI, psychosocial problems, and frequent pain. Sleep disturbances emerged as significant predictors of poorer functional outcomes in children with moderate or severe TBI. Children with TBI experienced persistent sleep disturbances over 24 months. Findings suggest a potential negative impact of disturbed sleep on children's functional outcomes, highlighting the need for further research on sleep in children with TBI.	[Tham, See Wan; Palermo, Tonya M.; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Palermo, Tonya M.; Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.; Wang, Jin; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dorsch, Andrea] Seattle Childrens Hosp, Dept Rehabil Psychol, Seattle, WA USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98195 USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Dept Emergency Med, Philadelphia, PA 19104 USA	Tham, SW (corresponding author), Seattle Childrens Res Inst, M-S CW8-6,POB 5371, Seattle, WA 98145 USA.	see.tham@seattlechildrens.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32GM086270-03]; National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD060068] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM086270] Funding Source: NIH RePORTER	Support for this project was provided by National Institutes of Health grant 5T32GM086270-03, and National Center for Injury Prevention and Control, Centers for Disease Control and Prevention grant R49 CE 001021.	Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bartsch T, 2004, PAIN, V109, P367, DOI 10.1016/j.pain.2004.02.005; Bedell G, 2009, DEV NEUROREHABIL, V12, P342, DOI 10.3109/17518420903087277; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P845, DOI 10.1093/jpepsy/jsm003; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cappuccio FP, 2008, SLEEP, V31, P619, DOI 10.1093/sleep/31.5.619; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chung KF, 2010, SLEEP MED, V11, P752, DOI 10.1016/j.sleep.2009.09.005; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Gregory AM, 2008, ARCH PEDIAT ADOL MED, V162, P330, DOI 10.1001/archpedi.162.4.330; Gregory AM, 2011, J AM ACAD CHILD PSY, V50, P499, DOI 10.1016/j.jaac.2011.02.003; Gregory AM, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200208000-00015; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Huntley ED, 2007, J PEDIATR PSYCHOL, V32, P938, DOI 10.1093/jpepsy/jsm032; Hysing M, 2009, J PEDIATR PSYCHOL, V34, P665, DOI 10.1093/jpepsy/jsn095; Kashikar-Zuck S, 2010, RHEUMATOLOGY, V49, P2204, DOI 10.1093/rheumatology/keq254; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kheirandish L, 2006, DEVELOPMENTAL SCI, V9, P388, DOI 10.1111/j.1467-7687.2006.00504.x; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lautenbacher S, 2006, SLEEP MED REV, V10, P357, DOI 10.1016/j.smrv.2005.08.001; Lewandowski A. S., 2011, PEDIAT CLIN N AM; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Marr A. L., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Murphy M., 1999, AMBULATORY CHILD HLT, V5, P225, DOI DOI 10.1016/J.JURO.2010.11.051; NCIPC, 2003, REP C MILD TRAUM BRA; Ohayon MM, 2005, J PSYCHIAT RES, V39, P151, DOI 10.1016/j.jpsychires.2004.07.001; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Richardson RD, 2005, ASSES EFF INTERV, V30, P51, DOI 10.1177/073724770503000407; Rivara F. P., 2011, PEDIATRICS; Rust J. O., 2004, J PSYCHOEDUCATIONAL, V22, P367; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sivertsen Borge, 2009, Child Adolesc Psychiatry Ment Health, V3, P22, DOI 10.1186/1753-2000-3-22; Smith MT, 2004, SLEEP MED REV, V8, P119, DOI 10.1016/S1087-0792(03)00044-3; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Ward TM, 2010, SLEEP, V33, P252, DOI 10.1093/sleep/33.2.252; Wirrell E, 2005, DEV MED CHILD NEUROL, V47, P754, DOI 10.1017/S0012162205001581; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	55	58	58	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					154	161		10.1089/neu.2011.2126			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300018	22029569	Green Published			2021-06-18	
J	Abend, NS; Topjian, AA; Gutierrez-Colina, AM; Donnelly, M; Clancy, RR; Dlugos, DJ				Abend, Nicholas S.; Topjian, Alexis A.; Gutierrez-Colina, Ana M.; Donnelly, Maureen; Clancy, Robert R.; Dlugos, Dennis J.			Impact of Continuous EEG Monitoring on Clinical Management in Critically Ill Children	NEUROCRITICAL CARE			English	Article						Seizure; Status epilepticus; Pediatric; Critically Ill; Electroencephalogram; EEG monitoring	INTENSIVE-CARE-UNIT; NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; NEONATAL SEIZURES; PATTERNS; ELECTROENCEPHALOGRAPHY; ICU	Continuous EEG (cEEG) monitoring is being used with increasing frequency in critically ill patients, most often to detect non-convulsive seizures. While cEEG is non-invasive and feasible in the critical care setting, it is also expensive and labor intensive, and there has been little study of its impact on clinical care. We aimed to determine prospectively the impact of cEEG on clinical management in critically ill children. Critically ill children (non-neonates) with acute encephalopathy underwent cEEG. Study enrollment and data collection were prospective. 100 children were studied. EEG monitoring led to specific clinical management changes in 59 children. These included initiating or escalating anti-seizure medications in 43 due to seizure detection, demonstrating that a specific event (subtle movement or vital sign change) was not a seizure in 21, or obtaining urgent neuroimaging that led to a clinical change in 3. In the remaining 41 children, cEEG ruled out the presence of non-convulsive seizures but did not lead to a specific change in clinical management. EEG monitoring led to changes in clinical management in the majority of patients, suggesting it may have an important role in management of critically ill children. Further study is needed to determine whether the management changes elicited by cEEG improve outcome.	[Abend, Nicholas S.; Gutierrez-Colina, Ana M.; Donnelly, Maureen; Clancy, Robert R.; Dlugos, Dennis J.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; [Abend, Nicholas S.; Clancy, Robert R.; Dlugos, Dennis J.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Topjian, Alexis A.] Childrens Hosp Philadelphia, Div Anesthesia & Crit Care Med, Philadelphia, PA 19104 USA	Abend, NS (corresponding author), Childrens Hosp Philadelphia, Div Neurol, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	abend@email.chop.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12-NS049453]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K12NS049453] Funding Source: NIH RePORTER	This study is supported by NIH K12-NS049453 to Dr. Abend.	Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2008, PEDIATR EMERG CARE, V24, P705, DOI 10.1097/PEC.0b013e318188fcac; Abend NS, 2008, EPILEPSIA, V49, P349, DOI 10.1111/j.1528-1167.2007.01425.x; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Alehan FK, 2001, J CHILD NEUROL, V16, P484, DOI 10.1177/088307380101600704; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; COEN RW, 1982, J PEDIATR-US, V100, P628, DOI 10.1016/S0022-3476(82)80773-7; de Vos CC, 2008, J CLIN NEUROPHYSIOL, V25, P77, DOI 10.1097/WNP.0b013e31816ef725; Dichter MA, 2009, ARCH NEUROL-CHICAGO, V66, P443, DOI 10.1001/archneurol.2009.10; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Gerber PA, 2008, J CLIN NEUROPHYSIOL, V25, P241, DOI 10.1097/WNP.0b013e318182ed67; Glass HC, 2009, J PEDIATR-US, V155, P318, DOI 10.1016/j.jpeds.2009.03.040; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; Kilbride RD, 2009, ARCH NEUROL-CHICAGO, V66, P723, DOI 10.1001/archneurol.2009.100; Kull LL, 2005, J CLIN NEUROPHYSIOL, V22, P107, DOI 10.1097/01.WNP.0000158361.24544.2D; McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pisani F, 2007, NEUROLOGY, V69, P2177, DOI 10.1212/01.wnl.0000295674.34193.9e; Ronen GM, 2007, NEUROLOGY, V69, P1816, DOI 10.1212/01.wnl.0000279335.85797.2c; Ronner HE, 2009, SEIZURE-EUR J EPILEP, V18, P257, DOI 10.1016/j.seizure.2008.10.010; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Scheuer ML, 2004, J CLIN NEUROPHYSIOL, V21, P353; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Young GB, 1996, NEUROLOGY, V47, P83	36	58	59	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2011	15	1					70	75		10.1007/s12028-010-9380-z			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	789XI	WOS:000292552100011	20499208	Green Accepted			2021-06-18	
J	Hemphill, JC; Andrews, P; De Georgia, M				Hemphill, J. Claude; Andrews, Peter; De Georgia, Michael			Multimodal monitoring and neurocritical care bioinformatics	NATURE REVIEWS NEUROLOGY			English	Article							CEREBRAL PERFUSION-PRESSURE; HEART-RATE-VARIABILITY; TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; BLOOD-FLOW; PROGNOSTIC-SIGNIFICANCE; APPROXIMATE ENTROPY; PHYSIOLOGICAL DATA; DATA-ACQUISITION; CONTINUOUS EEG	Neurocritical care bioinformatics is a new field that focuses on the acquisition, storage and analysis of physiological and other data relevant to the bedside care of patients with acute neurological conditions such as traumatic brain injury or stroke. The main focus of neurocritical care for these conditions relates to prevention, detection and management of secondary brain injury, which relies heavily on monitoring of systemic and cerebral parameters (such as blood-pressure level and intracranial pressure). Advanced neuromonitoring tools also exist that enable measurement of brain tissue oxygen tension, cerebral oxygen utilization, and aerobic metabolism. The ability to analyze these advanced data for real-time clinical care, however, remains intuitive and primitive. Advanced statistical and mathematical tools are now being applied to the large volume of clinical physiological data routinely monitored in neurocritical care with the goal of identifying better markers of brain injury and providing clinicians with improved ability to target specific goals in the management of these patients. This Review provides an introduction to the concepts of multimodal monitoring for secondary brain injury in neurocritical care and outlines initial and future approaches using informatics tools for understanding and applying these data to clinical care.	[Hemphill, J. Claude] San Francisco Gen Hosp, Dept Neurol, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Andrews, Peter] Western Gen Hosp, Dept Crit Care, Edinburgh EH4 2XU, Midlothian, Scotland; [De Georgia, Michael] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Neurol Inst, Ctr Neurocrit Care, Cleveland, OH 44106 USA	Hemphill, JC (corresponding author), San Francisco Gen Hosp, Dept Neurol, Brain & Spinal Injury Ctr, Room 4M62,1001 Potrero Ave, San Francisco, CA 94110 USA.	chemphill@sfgh.ucsf.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	US NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U10 NS058931]; European Society of Intensive Care Medicine; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U10NS058931] Funding Source: NIH RePORTER	J. C. Hemphill is funded in part by grant U10 NS058931 from the US NIH. P. Andrews has received funding from the European Society of Intensive Care Medicine for the Eurotherm3235 Trial.	Ali Tanya, 2010, Med Health R I, V93, P8; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Andrews Peter J D, 2004, Curr Opin Crit Care, V10, P110, DOI 10.1097/00075198-200404000-00006; Andrews PJD, 2005, CRIT CARE, V9, P638, DOI 10.1186/cc3922; Andrews PJD, 2004, INTENS CARE MED, V30, P1730, DOI 10.1007/s00134-004-2376-4; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; *ASTM INT, 2009, F2921 ASTM INT; AXELROD S, 1987, NEPHRON, V45, P202, DOI 10.1159/000184117; Badjatia N, 2009, CRIT CARE MED, V37, pS250, DOI 10.1097/CCM.0b013e3181aa5e8d; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS45; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Buchman T G, 1995, J Intensive Care Med, V10, P234; Buchman TG, 1996, J TRAUMA, V41, P599, DOI 10.1097/00005373-199610000-00002; Buchman Timothy G, 2004, Curr Opin Crit Care, V10, P378, DOI 10.1097/01.ccx.0000139369.65817.b6; Buchman TG, 2010, CRIT CARE, V14, DOI 10.1186/cc8868; Buchman TG, 2009, CRIT CARE MED, V37, P1167, DOI 10.1097/CCM.0b013e3181987bbc; Burr RL, 2008, IEEE T BIO-MED ENG, V55, P2509, DOI 10.1109/TBME.2008.2001286; Burykin A, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.06.013; CARTER LP, 1993, ACTA NEUROCHIR, P43; Chambers IR, 2006, ACTA NEUROCHIR SUPPL, V96, P7; Chambers I, 2008, ACTA NEUROCHIR SUPPL, V102, P223, DOI 10.1007/978-3-211-85578-2_43; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Citerio G, 2004, INTENS CARE MED, V30, P1882, DOI 10.1007/s00134-004-2377-3; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; Cohen MJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8864; Coveney PV, 2005, J R SOC INTERFACE, V2, P267, DOI 10.1098/rsif.2005.0045; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Diedler J, 2010, NEUROCRIT CARE, V12, P313, DOI 10.1007/s12028-010-9350-5; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Fahy Brenda G, 2002, Anesthesiol Clin North Am, V20, P441, DOI 10.1016/S0889-8537(01)00011-6; Forsyth RJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002043.pub2; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; Gawande A, 2007, NEW YORKER      1210; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; GOLDBERGER AL, 1992, APPLIED CHAOS, P321; Goldstein B, 2003, CRIT CARE MED, V31, P433, DOI 10.1097/01.CCM.0000050285.93097.52; GOMEZ H, 2010, C P IEEE ENG MED BIO, V1, P2358; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; Hemphill JC, 2005, NEUROCRIT CARE, V3, P260, DOI 10.1385/NCC:3:3:260; Hornero R, 2005, IEEE T BIO-MED ENG, V52, P1671, DOI 10.1109/TBME.2005.855722; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Jacono FJ, 2010, J HEALTHC ENG, V1, P337, DOI 10.1260/2040-2295.1.3.337; Kim MN, 2010, NEUROCRIT CARE, V12, P173, DOI 10.1007/s12028-009-9305-x; Kirkness CJ, 2008, ACTA NEUROCHIR SUPPL, V102, P105, DOI 10.1007/978-3-211-85578-2_21; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; Kumar S, 2010, HEALTH INFORM J, V16, P306, DOI 10.1177/1460458210380523; Lake DE, 2002, AM J PHYSIOL-REG I, V283, pR789, DOI 10.1152/ajpregu.00069.2002; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; McQuatt A, 2001, METHOD INFORM MED, V40, P373; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; Mussalo H, 2001, CLIN PHYSIOL, V21, P594, DOI 10.1046/j.1365-2281.2001.00359.x; Nakagawa K, 2011, NEUROCRIT CARE, V15, P101, DOI 10.1007/s12028-010-9446-y; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; Otero A, 2009, ARTIF INTELL MED, V47, P219, DOI 10.1016/j.artmed.2009.08.002; Papaioannou VE, 2006, J CRIT CARE, V21, P95, DOI 10.1016/j.jcrc.2005.12.007; Peelen L, 2010, J BIOMED INFORM, V43, P273, DOI 10.1016/j.jbi.2009.10.002; Piper I, 2010, ACTA NEUROCHIR, V152, P1859, DOI 10.1007/s00701-010-0719-1; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROPPER AH, 1992, ANN NEUROL, V32, P564, DOI 10.1002/ana.410320413; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; RYAN SM, 1994, J AM COLL CARDIOL, V24, P1700, DOI 10.1016/0735-1097(94)90177-5; Saeed M, 2011, CRIT CARE MED, V39, P952, DOI 10.1097/CCM.0b013e31820a92c6; SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P137; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; Smielewski P, 2005, ACT NEUR S, V95, P43; Sorani MD, 2007, NEUROCRIT CARE, V7, P45, DOI 10.1007/s12028-007-0043-7; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stuart RM, 2010, NEUROCRIT CARE, V13, P355, DOI 10.1007/s12028-010-9414-6; Stuart RM, 2010, NEUROCRIT CARE, V12, P188, DOI 10.1007/s12028-010-9330-9; Szabo BM, 1997, AM J CARDIOL, V79, P978, DOI 10.1016/S0002-9149(97)00026-X; Tatsuoka C, 2002, J ROY STAT SOC C-APP, V51, P337, DOI 10.1111/1467-9876.00272; Thome C, 2001, J NEUROSURG, V95, P402, DOI 10.3171/jns.2001.95.3.0402; Toweill Daniel L, 2003, Pediatr Crit Care Med, V4, P308, DOI 10.1097/01.PCC.0000074260.93430.6A; TRIEDMAN JK, 1993, HYPERTENSION, V21, P236, DOI 10.1161/01.HYP.21.2.236; Ursino M, 1998, ACT NEUR S, V71, P306; Vajkoczy P, 2003, J NEUROSURG, V98, P1227, DOI 10.3171/jns.2003.98.6.1227; Vajkoczy P, 2001, STROKE, V32, P498, DOI 10.1161/01.STR.32.2.498; van Boven AJ, 1998, AM HEART J, V135, P571, DOI 10.1016/S0002-8703(98)70269-8; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vath A, 2000, ZBL NEUROCHIR, V61, P2, DOI 10.1055/s-2000-8258; Vikman S, 1999, CIRCULATION, V100, P2079, DOI 10.1161/01.CIR.100.20.2079; Wartenberg KE, 2007, CRIT CARE CLIN, V23, P507, DOI 10.1016/j.ccc.2007.06.002; Zenker S, 2007, PLOS COMPUT BIOL, V3, P2072, DOI 10.1371/journal.pcbi.0030204	96	58	63	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-4758	1759-4766		NAT REV NEUROL	Nat. Rev. Neurol.	AUG	2011	7	8					451	460		10.1038/nrneurol.2011.101			10	Clinical Neurology	Neurosciences & Neurology	803YK	WOS:000293618800009	21750522	Bronze			2021-06-18	
J	Bye, N; Carron, S; Han, XD; Agyapomaa, D; Ng, SY; Yan, E; Rosenfeld, JV; Morganti-Kossmann, MC				Bye, Nicole; Carron, Sarah; Han, Xiaodi; Agyapomaa, Doreen; Ng, Si Yun; Yan, Edwin; Rosenfeld, Jeffrey V.; Morganti-Kossmann, M. Cristina			Neurogenesis and Glial Proliferation Are Stimulated Following Diffuse Traumatic Brain Injury in Adult Rats	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neurogenesis; traumatic axonal injury rat model; astrocytes; microglia; polydendrocytes	INTERLEUKIN-6 MESSENGER-RNA; SUBVENTRICULAR ZONE CELLS; FOCAL CEREBRAL-ISCHEMIA; AXONAL INJURY; HIPPOCAMPAL NEUROGENESIS; DENTATE GYRUS; CORTICAL NEUROGENESIS; COGNITIVE RECOVERY; MAMMALIAN BRAIN; STEM-CELLS	Although increased neurogenesis has been described in rodent models of focal traumatic brain injury (TBI), the neurogenic response occurring after diffuse TBI uncomplicated by focal injury has not been examined to date, despite the pervasiveness of this distinct type of brain injury in the TBI patient population. Here we characterize multiple stages of neurogenesis following a traumatic axonal injury (TAI) model of diffuse TBI as well as the proliferative response of glial cells. TAI was induced in adult rats using an impact-acceleration model, and 5-bromo-20-deoxyuridine (BrdU) was administered on days 1-4 posttrauma or sham operation to label mitotic cells. Using immunohistochemistry for BrdU combined with phenotype-specific markers, we found that proliferation was increased following TAI in the subventricular zone of the lateral ventricles and in the hippocampal subgranular zone, although the ultimate production of new dentate granule neurons at 8 weeks was not significantly enhanced. Also, abundant proliferating and reactive astrocytes, microglia, and polydendrocytes were detected throughout the brain following TAI, indicating that a robust glial response occurs in this model, although very few new cells in the nonneurogenic brain regions became mature neurons. We conclude that diffuse brain injury stimulates early stages of a neurogenic response similar to that described for models of focal TBI. (C) 2011 Wiley-Liss, Inc.	[Bye, Nicole; Carron, Sarah; Yan, Edwin; Rosenfeld, Jeffrey V.; Morganti-Kossmann, M. Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Bye, Nicole; Yan, Edwin; Rosenfeld, Jeffrey V.; Morganti-Kossmann, M. Cristina] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Han, Xiaodi] Univ Rochester, Dept Neurosurg, Rochester, NY USA; [Agyapomaa, Doreen] La Trobe Univ, Ctr AgriBiosci, Bundoora, Vic, Australia; [Ng, Si Yun] Natl Univ Singapore, Dept Physiol, Ctr Life Sci, Singapore 117548, Singapore; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic 3004, Australia	Bye, N (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	nicole.bye@monash.edu	Rosenfeld, Jeffrey V/B-7249-2011	Morganti-Kossmann, Cristina/0000-0002-0807-2063	Transport Accident Commission; Victorian Neurotrauma Initiative	Contract grant sponsor: Transport Accident Commission; Contract grant sponsor: Victorian Neurotrauma Initiative.	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; Dayer AG, 2005, J CELL BIOL, V168, P415, DOI 10.1083/jcb.200407053; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Liu JL, 1998, J NEUROSCI, V18, P7768; Liu XS, 2007, J NEUROSCI RES, V85, P2120, DOI 10.1002/jnr.21359; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Magavi SS, 2000, NATURE, V405, P951; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Reimers D, 2008, CURR STEM CELL RES T, V3, P247, DOI 10.2174/157488808786733980; Rhodes JKJ, 2002, NEUROSCI LETT, V335, P1, DOI 10.1016/S0304-3940(02)00811-X; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Schabitz WR, 2007, STROKE, V38, P2165, DOI 10.1161/STROKEAHA.106.477331; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Weinstein DE, 1996, BRAIN RES, V743, P11, DOI 10.1016/S0006-8993(96)00979-1; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x	59	58	60	0	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUL	2011	89	7					986	1000		10.1002/jnr.22635			15	Neurosciences	Neurosciences & Neurology	764IY	WOS:000290624300004	21488090				2021-06-18	
J	MacGregor, AJ; Dougherty, AL; Galarneau, MR				MacGregor, Andrew J.; Dougherty, Amber L.; Galarneau, Michael R.			Injury-Specific Correlates of Combat-Related Traumatic Brain Injury in Operation Iraqi Freedom	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						combat; military; traumatic brain injury	SEVERITY SCORE; AFGHANISTAN; HEAD	Background: The prevalence of traumatic brain injury (TBI) has increased during the wars in Iraq and Afghanistan compared with 20th century military conflicts. The aim of this study was to elucidate injury-specific correlates of combat-related TBI that have yet to be clearly defined. Participants: Predominately Marine US service members who sustained brain injuries in Iraq between March 2004 and April 2008 identified from clinical records completed in the theater of combat operations (n = 2074). Main Outcome Measures: Severity of TBI was classified as mild, moderate, or severe. Injury-specific factors, such as injury mechanism and type, were abstracted from the clinical records and were compared with severity of TBI. Results: Of all TBIs observed in the sample, 89% were mild. Higher severity of TBI was associated with an increased likelihood of sustaining the injury by gunshot and a lower likelihood of helmet use. Improvised explosive devices were associated with a preponderance of mild TBIs, and frequency of injuries in locations in addition to the head was highest among those with moderate and severe TBIs. Concomitant injuries to the spine/back were associated with blast injury mechanisms. Conclusions: Most incidents of TBI occurring during Operation Iraqi Freedom are mild in severity and a result of blast mechanisms. Multiple injuries were common, particularly as severity of TBI increased. Further research is needed to determine effects of combat-related TBI on rehabilitative and adverse health outcomes.	[MacGregor, Andrew J.; Dougherty, Amber L.; Galarneau, Michael R.] USN, Hlth Res Ctr, San Diego, CA 92106 USA	Dougherty, AL (corresponding author), USN, Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	amber.dougherty@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	US Navy Medicine Bureau of Medicine and Surgery, Washington, DC [60808]	This work was supported by the US Navy Medicine Bureau of Medicine and Surgery, Washington, DC, under Work Unit No. 60808. The views and opinions expressed herein are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Commission on Professional Hospital Activities, 1977, INT CLASS DIS 9 REV; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dougherty AL, 2009, INJURY, V40, P772, DOI 10.1016/j.injury.2009.02.014; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2009, GULF WAR HLTH LONG T, V7; Kibby M Y, 1997, Appl Neuropsychol, V4, P34, DOI 10.1207/s15324826an0401_4; LINN S, 1993, INT J EPIDEMIOL, V22, P905, DOI 10.1093/ije/22.5.905; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zeitzer MB, 2008, AAOHN J, V56, P347, DOI 10.3928/08910162-20080801-03	23	58	57	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2011	26	4					312	318		10.1097/HTR.0b013e3181e94404			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	789FZ	WOS:000292501700008	20808241				2021-06-18	
J	Griesbach, GS				Griesbach, Grace S.			Exercise After Traumatic Brain Injury: Is it a Double-Edged Sword?	PM&R			English	Article							NEUROTROPHIC FACTOR EXPRESSION; LONG-TERM POTENTIATION; SENSORIMOTOR CORTEX LESIONS; FLUID PERCUSSION INJURY; NECROSIS-FACTOR-ALPHA; TRKB MESSENGER-RNA; MINOR HEAD-INJURY; VOLUNTARY EXERCISE; SYNAPTIC-PLASTICITY; PHYSICAL-ACTIVITY	This article describes the effects of exercise on neural plasticity after traumatic brain injury (TBI). There is strong evidence that indicates that exercise has neuroprotective effects by activating specific neuronal circuits and increasing molecules that enhance synaptic plasticity. Findings obtained from experimental models of TBI are discussed to support the use of exercise as a rehabilitative tool. These studies indicate that injury characteristics are likely to influence the time window for therapeutic exercise. Results of human and animal studies suggest that premature postconcussive exercise may be deleterious by exacerbating postconcussive symptomatology and disrupting restorative processes. A better understanding of the mechanisms that influence exercise after TBI will contribute to improving guidelines for the return to exercise activities and to the successful use of exercise as a therapeutic tool. PM R 2011;3:S64-S72	[Griesbach, Grace S.] Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Griesbach, Grace S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA	Griesbach, GS (corresponding author), Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N5061960]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061960] Funding Source: NIH RePORTER	Research support: National Institute of Neurological Disorders and Stroke award N5061960 and The UCLA Brain Injury Research Center.	Adlard PA, 2004, NEUROSCIENCE, V124, P985, DOI 10.1016/j.neuroscience.2003.12.039; Adlard PA, 2005, J NEUROSCI, V25, P4217, DOI 10.1523/JNEUROSCI.0496-05.2005; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Ang ET, 2004, NEUROSCIENCE, V129, P337, DOI 10.1016/j.neuroscience.2004.06.087; Ashman TA, 2006, MT SINAI J MED, V73, P999; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Berninger B, 1999, LEARN MEMORY, V6, P232; Booth FW, 2002, J APPL PHYSIOL, V93, P3, DOI 10.1152/japplphysiol.00073.2002; Booth FW, 2000, J APPL PHYSIOL, V88, P774; BRONSTEIN JM, 1993, BRAIN RES REV, V18, P135, DOI 10.1016/0165-0173(93)90011-N; Cammarota M, 2002, CELL MOL NEUROBIOL, V22, P259, DOI 10.1023/A:1020763716886; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Carro E, 2001, J NEUROSCI, V21, P5678; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chu D, 2000, NEUROPEDIATRICS, V31, P63, DOI 10.1055/s-2000-7475; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Desmurget M, 2007, BRAIN, V130, P898, DOI 10.1093/brain/awl300; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Ding YH, 2006, ACTA NEUROPATHOL, V112, P74, DOI 10.1007/s00401-006-0076-6; Ding YH, 2006, CURR NEUROVASC RES, V3, P263, DOI 10.2174/156720206778792911; Ding YH, 2006, CURR NEUROVASC RES, V3, P15, DOI 10.2174/156720206775541787; Dishman RK, 2000, BRAIN RES BULL, V52, P337, DOI 10.1016/S0361-9230(00)00271-9; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; FORDYCE DE, 1993, BRAIN RES, V619, P111, DOI 10.1016/0006-8993(93)91602-O; Friedland RP, 2001, P NATL ACAD SCI USA, V98, P3440, DOI 10.1073/pnas.061002998; Fukunaga K, 1999, JPN J PHARMACOL, V79, P7, DOI 10.1254/jjp.79.7; Garcia C, 2003, NEUROSCIENCE, V119, P721, DOI 10.1016/S0306-4522(03)00192-1; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GomezPinilla F, 1997, BRAIN RES, V764, P1, DOI 10.1016/S0006-8993(97)00375-2; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hansson AC, 2000, EUR J NEUROSCI, V12, P2918, DOI 10.1046/j.1460-9568.2000.00185.x; Hansson AC, 2006, J NEUROENDOCRINOL, V18, P104, DOI 10.1111/j.1365-2826.2005.01390.x; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Itoh T, 2010, J NEURAL TRANSM 1006; Ivanco TL, 2000, NEUROPHARMACOLOGY, V39, P765, DOI 10.1016/S0028-3908(00)00004-6; JACKSON RD, 1989, AM J PHYS MED REHAB, V68, P18, DOI 10.1097/00002060-198902000-00006; Jansen EM, 1996, BRAIN RES, V708, P93, DOI 10.1016/0006-8993(95)01288-5; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; Kozisek ME, 2008, PHARMACOL THERAPEUT, V117, P30, DOI 10.1016/j.pharmthera.2007.07.001; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Kozlowski DA, 1998, BEHAV BRAIN RES, V97, P89, DOI 10.1016/S0166-4328(98)00030-8; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lawlor DA, 2001, BMJ-BRIT MED J, V322, P763, DOI 10.1136/bmj.322.7289.763; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; Lima FD, 2009, BRAIN RES, V1279, P147, DOI 10.1016/j.brainres.2009.04.052; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; Matthews VB, 2009, DIABETOLOGIA, V52, P1409, DOI 10.1007/s00125-009-1364-1; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; MELLONI RH, 1994, NEUROSCIENCE, V58, P683, DOI 10.1016/0306-4522(94)90448-0; Navarro A, 2004, AM J PHYSIOL-REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Nibuya M, 1999, NEUROSCI LETT, V267, P81, DOI 10.1016/S0304-3940(99)00335-3; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; Pan YX, 2007, HYPERTENSION, V49, P519, DOI 10.1161/01.HYP.0000256955.74461.93; Pardridge WM, 2002, ADV EXP MED BIOL, V513, P397; Peng Q, 2008, EXP NEUROL, V210, P154, DOI 10.1016/j.expneurol.2007.10.015; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Pitts EV, 2006, INT ANESTHESIOL CLIN, V44, P21, DOI 10.1097/00004311-200604420-00004; POWELL KE, 1985, PUBLIC HEALTH REP, V100, P118; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512; Rhyu IJ, 2010, NEUROSCIENCE, V167, P1239, DOI 10.1016/j.neuroscience.2010.03.003; Rimmer JH, 2010, AM J PHYS MED REHAB, V89, P249, DOI 10.1097/PHM.0b013e3181c9fa9d; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Russo-Neustadt A, 1999, NEUROPSYCHOPHARMACOL, V21, P679, DOI 10.1016/S0893-133X(99)00059-7; Russo-Neustadt A, 2001, BEHAV BRAIN RES, V120, P87, DOI 10.1016/S0166-4328(00)00364-8; Russo-Neustadt AA, 2000, NEUROSCIENCE, V101, P305, DOI 10.1016/S0306-4522(00)00349-3; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; Schuit AJ, 2001, MED SCI SPORT EXER, V33, P772; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Seifert T, 2010, AM J PHYSIOL-REG I, V298, pR372, DOI 10.1152/ajpregu.00525.2009; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; Szelenyi J, 2001, BRAIN RES BULL, V54, P329, DOI 10.1016/S0361-9230(01)00428-2; Tajiri N, 2010, BRAIN RES, V1310, P200, DOI 10.1016/j.brainres.2009.10.075; Tang SW, 2008, NEUROSCI LETT, V431, P62, DOI 10.1016/j.neulet.2007.11.019; Taylor AN, 2010, J NEUROTRAUM, V27, P1081, DOI 10.1089/neu.2009.1252; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Torres-Aleman I, 2010, DEV NEUROBIOL, V70, P384, DOI 10.1002/dneu.20778; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Ueyama T, 1997, NEUROSCI RES, V28, P103, DOI 10.1016/S0168-0102(97)00030-8; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vaidya VA, 1999, NEUROSCI LETT, V262, P1, DOI 10.1016/S0304-3940(99)00006-3; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266; van Praag H, 2009, TRENDS NEUROSCI, V32, P283, DOI 10.1016/j.tins.2008.12.007; VanLeeuwen JE, 2010, J NEUROSCI RES, V88, P650, DOI 10.1002/jnr.22216; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; ZAFRA F, 1992, J NEUROSCI, V12, P4793	155	58	62	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	JUN	2011	3	6		S			S64	S72		10.1016/j.pmrj.2011.02.008			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	961BB	WOS:000305437800011	21703583				2021-06-18	
J	Gyorgy, A; Ling, G; Wingo, D; Walker, J; Tong, L; Parks, S; Januszkiewicz, A; Baumann, R; Agoston, DV				Gyorgy, Andrea; Ling, Geoffrey; Wingo, Daniel; Walker, John; Tong, Lawrence; Parks, Steve; Januszkiewicz, Adolph; Baumann, Richard; Agoston, Denes V.			Time-Dependent Changes in Serum Biomarker Levels after Blast Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; blast traumatic brain injury; reverse phase protein microarray	NEURON-SPECIFIC ENOLASE; HEAD-INJURY; CARDIAC-ARREST; SPONTANEOUS CIRCULATION; BIOCHEMICAL MARKERS; NEUROFILAMENT; PROTEIN; S-100B; DAMAGE; PREDICTORS	Neuronal and glial proteins detected in the peripheral circulating blood after injury can reflect the extent of the damage caused by blast traumatic brain injury (bTBI). The temporal pattern of their serum levels can further predict the severity and outcome of the injury. As part of characterizing a large-animal model of bTBI, we determined the changes in the serum levels of S100B, neuron-specific enolase (NSE), myelin basic protein (MBP), and neurofilament heavy chain (NF-H). Blood samples were obtained prior to injury and at 6, 24, 72 h, and 2 weeks post-injury from animals with different severities of bTBI; protein levels were determined using reverse phase protein microarray (RPPM) technology. Serum levels of S100B, MBP, and NF-H, but not NSE, showed a time-dependent increase following injury. The detected changes in S100B and MBP levels showed no correlation with the severity of the injury. However, serum NF-H levels increased in a unique, rapid manner, peaking at 6 h post-injury only in animals exposed to severe blast with poor clinical and pathological outcomes. We conclude that the sudden increase in serum NF-H levels following bTBI may be a useful indicator of injury severity. If additional studies verify our findings, the observed early peak of serum NF-H levels can be developed into a useful diagnostic tool for predicting the extent of damage following bTBI.	[Agoston, Denes V.] Uniformed Serv Univ USU, Dept Anat Physiol & Genet, Program Neurosci, Natl Capital Consortium,Neurosurg Program,Sch Med, Bethesda, MD 20814 USA; [Ling, Geoffrey] Uniformed Serv Univ USU, Dept Neurol, Bethesda, MD USA; [Tong, Lawrence; Januszkiewicz, Adolph; Baumann, Richard] Walter Reed Army Inst Res, Div Mil Casualty Res, Silver Spring, MD USA; [Parks, Steve] ORA Inc, Fredericksburg, VA USA	Agoston, DV (corresponding author), Uniformed Serv Univ USU, Dept Anat Physiol & Genet, Program Neurosci, Natl Capital Consortium,Neurosurg Program,Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.mil			DARPA PREVENT	The work was funded by DARPA PREVENT. We thank Mrs. Carla Olsen for her help with the statistical analysis, and Ms. Nicole Draghic and Ms. Alaa Kamnaksh for editorial support.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Ekmektzoglou KA, 2007, RESUSCITATION, V75, P219, DOI 10.1016/j.resuscitation.2007.03.016; Ergun R, 1998, NEUROL RES, V20, P418; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Gyorgy A.B., 2010, J NEUROSCI METHODS; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Korfias S, 2009, MINI-REV MED CHEM, V9, P227, DOI 10.2174/138955709787315994; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Rosen H, 2004, J NEUROL SCI, V221, P19, DOI 10.1016/j.jns.2004.03.003; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Shinozaki K, 2009, CRIT CARE, V13, DOI 10.1186/cc7973; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; THOMAS D G T, 1978, Lancet, V1, P113; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; YAMAZAKI Y, 1995, SURG NEUROL, V43, P270	36	58	65	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					1121	1126		10.1089/neu.2010.1561			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600022	21428721				2021-06-18	
J	Tien, HCN; Jung, V; Pinto, R; Mainprize, T; Scales, DC; Rizoli, SB				Tien, Homer C. N.; Jung, Vincent; Pinto, Ruxandra; Mainprize, Todd; Scales, Damon C.; Rizoli, Sandro B.			Reducing Time-to-Treatment Decreases Mortality of Trauma Patients with Acute Subdural Hematoma	ANNALS OF SURGERY			English	Article							SEVERE HEAD-INJURY; RAPID-SEQUENCE INTUBATION; COMPUTERIZED-TOMOGRAPHY; OUTCOME PREDICTION; COMATOSE PATIENTS; BRAIN-INJURY; CT-SCAN; MORBIDITY; SURVIVAL; IMPACT	Objectives: To determine if reducing prehospital time and time-to-craniotomy is associated with decreased mortality in trauma patients with acute subdural hematomas. Background: Time-to-treatment is an important performance filter for trauma systems, yet very little evidence exists to support its use. Despite the biological rationale supporting the notion of the "Golden Hour" for trauma patients, no evidence exists to support it. Likewise, it remains controversial whether or not time-to-craniotomy is associated with survival in patients with subdural hematomas. Previous studies may have been affected by selection bias. Methods: Retrospective cohort study of all trauma patients who arrived directly from the scene of injury. Study patients were all patients with acute subdural hematomas and without severe torso injuries, who required craniotomy at a Canadian level 1 trauma center from January 1 1996 to December 31 2007. The independent variables of interest were prehospital time and time-to-craniotomy. The primary outcome measure was in-hospital mortality. Results: Of 12,105 trauma patients assessed, 149 patients met inclusion criteria. Overall, 40% (n = 60) patients died. On univariate analysis, there was a strong trend suggesting that patients arriving within the "Golden Hour after trauma" had decreased mortality (37% vs. 53%, P = 0.09). However, there was no difference in mortality for patients undergoing craniotomy within 4 hours and after 4 hours (42% vs. 36%, P = 0.4). On multivariate logistic regression, increased prehospital time was found to be associated with increased mortality (odds ratio 1.03 per minute, 95% CI 1.004-1.05, P = 0.024). Surprisingly, there was a trend showing that increased trauma room to craniotomy times were associated with lower mortality (odds ratio 0.995 per minute, 95% CI 0.99-1.0, P = 0.056). However, patients who quickly had their craniotomy seemed to have more severe neurological injury. Conclusion: Rapid transport of patients with traumatic subdural hematomas hospital is associated with decreased mortality.	[Tien, Homer C. N.; Jung, Vincent; Rizoli, Sandro B.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Gen Surg, Tory Reg Trauma Ctr, Toronto, ON M4N 3M5, Canada; [Pinto, Ruxandra; Scales, Damon C.; Rizoli, Sandro B.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Mainprize, Todd] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Neurosurg, Tory Reg Trauma Ctr, Toronto, ON M4N 3M5, Canada	Tien, HCN (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Gen Surg, Tory Reg Trauma Ctr, 2075 Bayview Ave,Suite H186, Toronto, ON M4N 3M5, Canada.	homer.tien@sunnybrook.ca					*ATLS AM COLL SURG, 2008, ADV TRAUM LIF SUPP D; Austin PC, 2006, J EVAL CLIN PRACT, V12, P601, DOI 10.1111/j.1365-2753.2005.00624.x; BULLARD MJ, REVISIONS CANADIAN E; BULLOCK MR, 2002, SURG MANAG ACUTE SUB, V58; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; *COMM TRAUM TASK F, 2006, RES OPT CAR INJ PAT; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; De Maio VJ, 2003, ANN EMERG MED, V42, P242, DOI 10.1067/mem.2003.266; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; FLETCHER RH, 1996, CLIN EPIDEMIOLOGY; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Johnson JM, 2009, ADV EMERG NURS J, V31, P221, DOI 10.1097/TME.0b013e3181afbf3a; Kleinbaum D. G., 2002, LOGISTIC REGRESSION; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marion DW, 2006, NEUROSURGERY, V58, P655; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; NEWGARD CD, 2009, ANN EMERG MED, V22; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; RAFTOPOULOS C, 1990, CLIN NEUROL NEUROSUR, V92, P57, DOI 10.1016/0303-8467(90)90008-S; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Scales DC, 2008, CRIT CARE MED, V36, P2547, DOI 10.1097/CCM.0b013e31818444a5; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; Taussky P, 2008, SWISS MED WKLY, V138, P281, DOI 2008/19/smw-12056; TIAN HL, 2008, CHIN MED J, V20, P1080; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; van Walraven C, 2004, J CLIN EPIDEMIOL, V57, P672, DOI 10.1016/j.jclinepi.2003.12.008; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212	43	58	58	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	JUN	2011	253	6					1178	1183		10.1097/SLA.0b013e318217e339			6	Surgery	Surgery	764WB	WOS:000290664100020	21494125				2021-06-18	
J	Corrigan, F; Pham, CLL; Vink, R; Blumbergs, PC; Masters, CL; van den Heuvel, C; Cappai, R				Corrigan, Frances; Pham, Chi L. L.; Vink, Robert; Blumbergs, Peter C.; Masters, Colin L.; van den Heuvel, Corinna; Cappai, Roberto			The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains	BRAIN RESEARCH			English	Article						Amyloid precursor protein; Growth factor like domain; E2 domain; sAPP alpha; Traumatic brain injury	ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; HIPPOCAMPAL-NEURONS; SECRETED FORMS; CELL-SURFACE; APP; PATHOPHYSIOLOGY; EXPRESSION; SEQUENCE; FAMILY	The amyloid precursor protein (APP) is known to increase following traumatic brain injury (TBI). This increase in levels of APP may be deleterious to outcome due to the production of neurotoxic A beta. Conversely, this upregulation may be beneficial as cleavage of APP via the alternative non-amyloidogenic pathway produces the soluble alpha form of APP (sAPP alpha), which is known to have many neuroprotective and neurotrophic functions. Indeed it has previously been shown that treatment with sAPP alpha following a diffuse injury in rats improves outcome. However, the exact location within the sAPP alpha molecule which contains this neuroprotective activity has yet to be determined. The sAPP alpha peptide can consist of up to 6 domains, with the main isoform in the brain missing the 4th and 5th. Of the remaining domains, the D1 and D6a domains seem the most likely as they have been shown to have beneficial actions in vitro. This present study examined the effects of in vivo posttraumatic administration via an intracerebroventricular injection of the D1, 02 and D6a domains of sAPP alpha on outcome following moderate-impact acceleration TBI in rats. While treatment with either the D1 or D6a domains was found to significantly improve motor and cognitive outcome, as assessed on the rotarod and Y maze, treatment with the D2 domain had no effect. Furthermore axonal injury was reduced in D1 and D6a domain treated animals, but not those that received the D2 domain. As the D1 and D6a domains contain a heparin binding region while the 02 domain does not, this suggests that sAPP alpha mediates its neuroprotective response through its ability to bind to heparin sulfate proteoglycans. Crown Copyright (C) 2011 Published by Elsevier B.V. All rights reserved.	[Pham, Chi L. L.; Cappai, Roberto] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; [Pham, Chi L. L.; Cappai, Roberto] Univ Melbourne, Mol Sci & BioTechnol Inst Bio21, Melbourne, Vic 3010, Australia; [Masters, Colin L.] Univ Melbourne, Mental Hlth Res Inst, Parkville, Vic 3052, Australia; [Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna] Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA 5005, Australia; [Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna] Inst Med & Vet Sci, Hansen Inst, Adelaide, SA 5000, Australia	Cappai, R (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	r.cappai@unimelb.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012; Cappai, Roberto/B-3347-2010	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Corrigan, Frances/0000-0001-6150-8893; , Corinna/0000-0003-0664-8935; Cappai, Roberto/0000-0002-9505-8496	Brain Foundation (Australia); Neurosurgical Research Foundation (Australia)	This study was supported, in part, by a research grant from the Brain Foundation (Australia), and the Neurosurgical Research Foundation (Australia).	Bell KFS, 2008, NEUROBIOL AGING, V29, P554, DOI 10.1016/j.neurobiolaging.2006.11.004; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Dahms SO, 2010, P NATL ACAD SCI USA, V107, P5381, DOI 10.1073/pnas.0911326107; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Gakhar-Koppole N, 2008, EUR J NEUROSCI, V28, P871, DOI 10.1111/j.1460-9568.2008.06398.x; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Gralle M, 2009, J BIOL CHEM, V284, P15016, DOI 10.1074/jbc.M808755200; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JIN LW, 1994, J NEUROSCI, V14, P5461; MAAS AI, NEUROTHERAPEUTICS, V7, P115; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masliah E, 1997, NEUROSCIENCE, V78, P135, DOI 10.1016/S0306-4522(96)00553-2; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Morimoto T, 1998, J NEUROSCI, V18, P9386; NINOMIYA H, 1994, J NEUROCHEM, V63, P495; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; Ohsawa I, 1997, BIOCHEM BIOPH RES CO, V236, P59, DOI 10.1006/bbrc.1997.6903; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; QIU WQ, 1995, J NEUROSCI, V15, P2157; Reinhard C, 2005, EMBO J, V24, P3996, DOI 10.1038/sj.emboj.7600860; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Sandbrink R, 1996, ANN NY ACAD SCI, V777, P281, DOI 10.1111/j.1749-6632.1996.tb34433.x; SMALL DH, 1994, J NEUROSCI, V14, P2117; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; Williamson TG, 1996, J BIOL CHEM, V271, P31215, DOI 10.1074/jbc.271.49.31215; YAMAMOTO K, 1994, J NEUROBIOL, V25, P585, DOI 10.1002/neu.480250510; Young-Pearse TL, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-15	40	58	59	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 10	2011	1378						137	143		10.1016/j.brainres.2010.12.077			7	Neurosciences	Neurosciences & Neurology	739PN	WOS:000288730300014	21215734				2021-06-18	
J	Lingsma, HF; Roozenbeek, B; Li, BYE; Lu, JA; Weir, J; Butcher, I; Marmarou, A; Murray, GD; Maas, AIR; Steyerberg, EW				Lingsma, Hester F.; Roozenbeek, Bob; Li, Bayoue; Lu, Juan; Weir, James; Butcher, Isabella; Marmarou, Anthony; Murray, Gordon D.; Maas, Andrew I. R.; Steyerberg, Ewout W.			Large Between-Center Differences in Outcome After Moderate and Severe Traumatic Brain Injury in the International Mission on Prognosis and Clinical Trial Design in Traumatic Brain Injury (IMPACT) Study	NEUROSURGERY			English	Article						Center effects; Quality of care; Outcome; Randomized controlled trial; Traumatic brain injury	ACUTE MYOCARDIAL-INFARCTION; ADJUSTMENT METHODS; RISK-ADJUSTMENT; PRACTICAL SCALE; HEAD-INJURY; CARE; QUALITY; EXPERIENCE; MANAGEMENT; MORTALITY	BACKGROUND: Differences between centers in patient outcome after traumatic brain injury are of importance for multicenter studies and have seldom been studied. OBJECTIVE: To quantify the differences in centers enrolling patients in randomized clinical trials (RCTs) and surveys. METHODS: We analyzed individual patient data from 9578 patients with moderate and severe traumatic brain injury enrolled in 10 RCTs and 3 observational studies. We used random-effects logistic regression models to estimate the between-center differences in unfavorable outcome (dead, vegetative state, or severe disability measured with the Glasgow Outcome Scale) at 6 months adjusted for differences in patient characteristics. We calculated the difference in odds of unfavorable outcome between the centers at the higher end vs those at the lower end of the outcome distribution. We analyzed the total database, Europe and the United States separately, and 4 larger RCTs. RESULTS: The 9578 patients were enrolled at 265 centers, and 4629 (48%) had an unfavorable outcome. After adjustment for patient characteristics, there was a 3.3-fold difference in the odds of unfavorable outcome between the centers at the lower end of the outcome distribution (2.5th percentile) vs those at the higher end of the outcome distribution (97.5th percentile; P < .001). In the 4 larger RCTs, the differences between centers were similar. However, differences were smaller between centers in the United States (2.4-fold) than between centers in Europe (3.8-fold). CONCLUSION: Outcome after traumatic brain injury differs substantially between centers, particularly in Europe. Further research is needed to study explanations for these differences to suggest where quality of care might be improved.	[Lingsma, Hester F.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [Li, Bayoue] Erasmus MC, Dept Biostat, NL-3000 CA Rotterdam, Netherlands; [Roozenbeek, Bob; Murray, Gordon D.; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Lu, Juan; Marmarou, Anthony] Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA; [Weir, James; Butcher, Isabella] Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland	Lingsma, HF (corresponding author), Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	h.lingsma@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734; Lu, Juan/0000-0002-5389-7603; Steyerberg, Ewout/0000-0002-7787-0122	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-01923521]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish	Grant support was provided by National Institute of Health (NS-01923521). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Biau DJ, 2008, ANN SURG, V247, P892, DOI 10.1097/SLA.0b013e31816ffa99; Bradley EH, 2006, JAMA-J AM MED ASSOC, V296, P72, DOI 10.1001/jama.296.1.72; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; DeLong ER, 1997, STAT MED, V16, P2645, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2645::AID-SIM696>3.0.CO;2-D; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JENNETT B, 1975, LANCET, V1, P480; Kelly A, 2008, STROKE, V39, P3367, DOI 10.1161/STROKEAHA.108.518738; Krumholz HM, 2008, CIRCULATION, V118, P1885, DOI 10.1161/CIRCULATIONAHA.108.190500; Krumholz HM, 1999, CIRCULATION, V99, P2986, DOI 10.1161/01.CIR.99.23.2986; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES; Steyerberg EW, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.2005.07.008; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1974, LANCET, V2, P81; Timbie JW, 2008, MED DECIS MAKING, V28, P419, DOI 10.1177/0272989X07312476; Wright J, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b569	22	58	60	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2011	68	3					601	607		10.1227/NEU.0b013e318209333b			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	719WN	WOS:000287242300022	21311293				2021-06-18	
J	Palacios, EM; Fernandez-Espejo, D; Junque, C; Sanchez-Carrion, R; Roig, T; Tormos, JM; Bargallo, N; Vendrell, P				Palacios, Eva M.; Fernandez-Espejo, Davinia; Junque, Carme; Sanchez-Carrion, Rocio; Roig, Teresa; Tormos, Jose M.; Bargallo, Nuria; Vendrell, Pere			Diffusion tensor imaging differences relate to memory deficits in diffuse traumatic brain injury	BMC NEUROLOGY			English	Article							WHITE-MATTER INJURY; PREFRONTAL CORTEX; WORKING-MEMORY; AXONAL INJURY; HEAD-INJURY; COGNITIVE DYSFUNCTION; DORSAL HIPPOCAMPUS; CORPUS-CALLOSUM; CEREBRAL-CORTEX; MILD	Background: Memory is one of the most impaired functions after traumatic brain injury (TBI). We used diffusion tensor imaging (DTI) to determine the structural basis of memory deficit. We correlated fractional anisotropy (FA) of the fasciculi connecting the main cerebral regions that are involved in declarative and working memory functions. Methods: Fifteen patients with severe and diffuse TBI and sixteen healthy controls matched by age and years of education were scanned. The neuropsychological assessment included: Letter-number sequencing test (LNS), 2-back task, digit span (forwards and backwards) and the Rivermead profilet. DTI was analyzed by a tract-based spatial statics (TBSS) approach. Results: Whole brain DTI analysis showed a global decrease in FA values that correlated with the 2-back d-prime index, but not with the Rivermead profile. ROI analysis revealed positive correlations between working memory performance assessed by 2-back d-prime and superior longitudinal fasciculi, corpus callosum, arcuate fasciculi and fornix. Declarative memory assessed by the Rivermead profile scores correlated with the fornix and the corpus callosum. Conclusions: Diffuse TBI is associated with a general decrease of white matter integrity. Nevertheless deficits in specific memory domains are related to different patterns of white matter damage.	[Palacios, Eva M.; Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere] Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain; [Palacios, Eva M.; Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere] Inst Biomed Res August Pi I Sunyer IDIBAPS, Barcelona, Spain; [Sanchez-Carrion, Rocio; Roig, Teresa; Tormos, Jose M.] Inst Univ Neurorehabil Guttmann, Dept Neurophysiol, Badalona, Spain; [Bargallo, Nuria] Hosp Clin Barcelona, Ctr Diagnost Imatge, Hosp Clin Barcelona CDIC, Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain.	cjunque@ub.edu	Junque, Carme/B-4400-2011; Vendrell, Pere/B-4392-2011; Bargallo, Nuria/G-6854-2016	Junque, Carme/0000-0002-6381-3063; Vendrell, Pere/0000-0001-8918-5440; Bargallo, Nuria/0000-0001-6284-5402; Tormos Munoz, Jose Maria/0000-0002-8764-2289; Fernandez-Espejo, Davinia/0000-0001-5941-7546	Spanish Ministry of Science and InnovationSpanish Government [SAF2007-66077]; Generalitat de CatalunyaGeneralitat de Catalunya [2009SGR941]; Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) [890003I3]; Spanish Ministry for Education [AP2006-00862]	This work was supported by a grant from the Spanish Ministry of Science and Innovation (SAF2007-66077) and a grant from the Generalitat de Catalunya (2009SGR941) to the Neuropsychology Research Group. Eva M. Palacios was supported by a fellowship from the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) (890003I3). Davinia Fernandez-Espejo was supported by a fellowship from the Spanish Ministry for Education (AP2006-00862).	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2006, BRAIN INJURY, V20, P1053, DOI 10.1080/02699050600909862; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Barbas H, 1995, HIPPOCAMPUS, V5, P511, DOI 10.1002/hipo.450050604; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bonzano L, 2009, NEUROIMAGE, V44, P9, DOI 10.1016/j.neuroimage.2008.08.015; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cabeza R, 2002, NEUROIMAGE, V16, P317, DOI 10.1006/nimg.2002.1063; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; Chumbley JR, 2009, NEUROIMAGE, V44, P62, DOI 10.1016/j.neuroimage.2008.05.021; Ciccarelli O, 2008, LANCET NEUROL, V7, P715, DOI 10.1016/S1474-4422(08)70163-7; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Davachi L, 2002, J NEUROPHYSIOL, V88, P982, DOI 10.1152/jn.2002.88.2.982; Dineen RA, 2009, BRAIN, V132, P239, DOI 10.1093/brain/awn275; Eichenbaum H, 2004, NEURON, V44, P109, DOI 10.1016/j.neuron.2004.08.028; Eickhoff SB, 2007, NEUROIMAGE, V36, P511, DOI 10.1016/j.neuroimage.2007.03.060; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; FERINO F, 1987, EXP BRAIN RES, V65, P421; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Hayasaka S, 2003, NEUROIMAGE, V20, P2343, DOI 10.1016/j.neuroimage.2003.08.003; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Izaki Y, 2008, EUR J NEUROSCI, V27, P3029, DOI 10.1111/j.1460-9568.2008.06284.x; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Jonides J, 1998, J NEUROSCI, V18, P5026; Klingberg T, 1997, CEREB CORTEX, V7, P465, DOI 10.1093/cercor/7.5.465; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laroche S, 2000, HIPPOCAMPUS, V10, P438; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Lee I, 2003, J NEUROSCI, V23, P1517; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S., 2005, MRI ATLAS HUMAN WHIT; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ranganath C, 2001, NEURON, V31, P865, DOI 10.1016/S0896-6273(01)00411-1; Rissman J, 2008, CEREB CORTEX, V18, P1618, DOI 10.1093/cercor/bhm195; ROSENE DL, 1977, SCIENCE, V198, P315, DOI 10.1126/science.410102; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Squire LR, 2004, NEUROBIOL LEARN MEM, V82, P171, DOI 10.1016/j.nlm.2004.06.005; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Thierry AM, 2000, HIPPOCAMPUS, V10, P411, DOI 10.1002/1098-1063(2000)10:4<411::AID-HIPO7>3.0.CO;2-A; Toga AW, 2006, NAT REV NEUROSCI, V7, P952, DOI 10.1038/nrn2012; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; WECHSLER D, 1999, ESCALA INTENTELIGENC; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wills P, 2000, BRAIN INJURY, V14, P693; WILSON B, 1992, J NEUROL NEUROSUR PS, V55, P177, DOI 10.1136/jnnp.55.3.177; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yoon T, 2008, LEARN MEMORY, V15, P97, DOI 10.1101/lm.850808; Zec RF, 2001, J CLIN EXP NEUROPSYC, V23, P671, DOI 10.1076/jcen.23.5.671.1247	84	58	61	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	FEB 23	2011	11								24	10.1186/1471-2377-11-24			11	Clinical Neurology	Neurosciences & Neurology	730VN	WOS:000288063400001	21345223	DOAJ Gold, Green Published			2021-06-18	
J	Koehler, DM; Shipman, J; Davidson, MA; Guillamondegui, O				Koehler, Daniel M.; Shipman, Jason; Davidson, Mario A.; Guillamondegui, Oscar			Is Early Venous Thromboembolism Prophylaxis Safe in Trauma Patients With Intracranial Hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	40th Annual Meeting of the Western-Trauma-Association	FEB 28-MAR 07, 2010	Telluride, CO	Western Trauma Assoc		Traumatic brain injury; Venous thromboembolism prophylaxis; Exacerbation of intracranial hemorrhagic injury	MOLECULAR-WEIGHT HEPARIN; MAJOR TRAUMA; BRAIN-INJURY; COMPRESSION STOCKINGS; PULMONARY-EMBOLISM; ENOXAPARIN; NEUROSURGERY; PREVENTION; MANAGEMENT	Background: Patients with traumatic brain injuries (TBIs) are at high risk for venous thromboembolic sequelae; however, prophylaxis is often delayed because of the perceived risk of intracranial hemorrhagic exacerbation. The goal of this study was to determine whether enoxaparin for early venous thromboembolism (VTE) prophylaxis is safe for hemodynamically stable patients with TBIs. Methods: This is a retrospective cohort study from a Level I Trauma Center of patients with TBIs receiving early (0-72 hours) or late (>72 hours) VTE prophylaxis. Inclusion criteria included evidence of acute intracranial hemorrhagic injury (IHI) on admission computed tomography, head/neck abbreviated injury score >= 3, age >= 16 years, and hospital length of stay >= 72 hours. Exclusion criteria included intracranial pressure monitor/ventriculostomy, current systemic anticoagulation, pregnancy, coagulopathy, history of DVT, ongoing intra-abdominal hemorrhage 24 hours postadmission, and preexisting inferior vena cava filter. Progression of IHI defined as lesion expansion/new IHI on repeat computed tomography. Results: Totally, 669 patients were identified: 268 early (40.1%) and 401 late (59.9%), with a mean injury severity score of 27.8 +/- 10.2 and 29.4 +/- 11, respectively. Head neck abbreviated injury score of 3 (47% vs. 34%), 4 (42% vs. 46%), 5 (11% vs. 19%), and 6 (0% vs. 1%) were reported for the early and late treatment groups, respectively. Mean time to prophylaxis was 2.77 days +/- 0.49 days and 5.31 days +/- 1.97 days. IHI progression before prophylaxis was 9.38% versus 17.41% (p < 0.001) and after prophylaxis was 1.46% versus 1.54% (p > 0.9). Proportions of proximal DVT were 1.5% versus 3.5% (p = 0.117) and pulmonary embolism were 1.5% versus 2.2% (p = 0.49). There were no differences in injury severity score, age, and pelvic and/or long bone fractures. Conclusions: We found no evidence that early VTE prophylaxis increases the rate of IHI progression in hemodynamically stable patients with TBIs. The natural rate of IHI progression observed is comparable with previous studies. Although not powered to detect differences in the incidence of DVT and pulmonary embolism, the data trend toward increased proportions of both VTE outcomes in the late group.	[Koehler, Daniel M.; Shipman, Jason; Davidson, Mario A.; Guillamondegui, Oscar] Vanderbilt Univ, Dept Surg, Nashville, TN 37240 USA	Guillamondegui, O (corresponding author), 1211 21 Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	oscar.guillamondegui@vanderbilt.edu					Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Dickinson LD, 1998, NEUROSURGERY, V43, P1074, DOI 10.1097/00006123-199811000-00039; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Kiphuth IC, 2009, CEREBROVASC DIS, V27, P146, DOI 10.1159/000177923; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Menaker J, 2007, J TRAUMA, V63, P620, DOI 10.1097/TA.0b013e31812f60aa; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; Owings JT, 1997, ARCH SURG-CHICAGO, V132, P862; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87	19	58	62	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2011	70	2					324	329		10.1097/TA.0b013e31820b5d22			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	719FV	WOS:000287187700014	21307729				2021-06-18	
J	Rughani, AI; Dumont, TM; Lu, ZY; Bongard, J; Horgan, MA; Penar, PL; Tranmer, BI				Rughani, Anand I.; Dumont, Travis M.; Lu, Zhenyu; Bongard, Josh; Horgan, Michael A.; Penar, Paul L.; Tranmer, Bruce I.			Use of an artificial neural network to predict head injury outcome	JOURNAL OF NEUROSURGERY			English	Article						artificial neural network; outcome prediction; head trauma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; LOGISTIC-REGRESSION; MODEL	Object. The authors describe the artificial neural network (ANN) as an innovative and powerful modeling tool that can be increasingly applied to develop predictive models in neurosurgery. They aimed to demonstrate the utility of an ANN in predicting survival following traumatic brain injury and compare its predictive ability with that of regression models and clinicians. Methods. The authors designed an ANN to predict in-hospital survival following traumatic brain injury. The model was generated with 11 clinical inputs and a single output. Using a subset of the National Trauma Database, the authors "trained" the model to predict outcome by providing the model with patients for whom 11 clinical inputs were paired with known outcomes, which allowed the ANN to "learn" the relevant relationships that predict outcome. The model was tested against actual outcomes in a novel subset of 100 patients derived from the same database. For comparison with traditional forms of modeling, 2 regression models were developed using the same training set and were evaluated on the same testing set. Lastly, the authors used the same 100-patient testing set to evaluate 5 neurosurgery residents and 4 neurosurgery staff physicians on their ability to predict survival on the basis of the same 11 data points that were provided to the ANN. The ANN was compared with the clinicians and the regression models in terms of accuracy, sensitivity, specificity, and discrimination. Results. Compared with regression models, the ANN was more accurate (p < 0.001), more sensitive (p < 0.001), as specific (p = 0.260), and more discriminating (p < 0.001). There was no difference between the neurosurgery residents and staff physicians, and all clinicians were pooled to compare with the 5 best neural networks. The ANNs were more accurate (p < 0.0001), more sensitive (p < 0.0001), as specific (p = 0.743), and more discriminating (p < 0.0001) than the clinicians. Conclusions. When given the same limited clinical information, the ANN significantly outperformed regression models and clinicians on multiple performance measures. While this paradigm certainly does not adequately reflect a real clinical scenario, this form of modeling could ultimately serve as a useful clinical decision support tool. As the model evolves to include more complex clinical variables, the performance gap over clinicians and logistic regression models will persist or, ideally, further increase. (DOI: 10.3171/2009.11.JNS09857)	[Rughani, Anand I.; Dumont, Travis M.; Horgan, Michael A.; Penar, Paul L.; Tranmer, Bruce I.] Univ Vermont, Div Neurosurg, Burlington, VT USA; [Lu, Zhenyu; Bongard, Josh] Univ Vermont, Dept Comp Sci, Burlington, VT USA	Rughani, AI (corresponding author), 111 Colchester Ave,Fletcher 5, Burlington, VT 05401 USA.	anand.rughani@vtmednet.org					BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; Bongard JC, 2005, IEEE T EVOLUT COMPUT, V9, P361, DOI 10.1109/TEVC.2005.850293; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; Eftekhar Behzad, 2005, BMC Med Inform Decis Mak, V5, P3; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Genkin A, 2007, TECHNOMETRICS, V49, P291, DOI 10.1198/004017007000000245; HAGEN MD, 1995, PRIMARY CARE, V22, P213; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hsu MH, 2005, STUD HEALTH TECHNOL, V116, P241; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Landwehr N, 2005, MACH LEARN, V59, P161, DOI 10.1007/s10994-005-0466-3; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; LU Z, 2008, P 2008 GECCO C COMP, P2047; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Pang BC, 2007, J NEUROTRAUM, V24, P136, DOI 10.1089/neu.2006.0113; Perel P, 2007, J EVAL CLIN PRACT, V13, P464, DOI 10.1111/j.1365-2753.2006.00713.x; Segal ME, 2006, J HEAD TRAUMA REHAB, V21, P298, DOI 10.1097/00001199-200607000-00003; Seung H. S., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P287, DOI 10.1145/130385.130417	19	58	59	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					585	590		10.3171/2009.11.JNS09857			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100023	20020844				2021-06-18	
J	Whelan-Goodinson, R; Ponsford, JL; Schonberger, M; Johnston, L				Whelan-Goodinson, Rochelle; Ponsford, Jennie Louise; Schoenberger, Michael; Johnston, Lisa			Predictors of Psychiatric Disorders Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety disorders; brain injuries; depression; mental disorders; neuropsychology; substance-related disorders	MAJOR DEPRESSION; SUBSTANCE-ABUSE; MOOD DISORDERS; AXIS-I; NATURAL-HISTORY; HEAD-INJURY; ALCOHOL; CONSEQUENCES; DISABILITY; AGE	Objective: To investigate predictors of posttraumatic brain injury psychiatric disorders. Design: Retrospective, cross-sectional design with stratified random sampling of groups of patients on average 1 to 5 years postinjury. DSM-based diagnostic interviews of both traumatic brain injury (TBI) participant and informant. Participants: One hundred community-based participants, aged 19-74 years, with traumatic brain injury sustained 0.05-5.5 years previously. Setting: Community-based patients previously treated at a rehabilitation hospital. Main measure: The Structured Clinical Interview for DSM-IV diagnosis. Results: A psychiatric history was a high-risk factor for having the same disorder postinjury. However, the majority of cases of depression and anxiety were novel, suggesting that significant factors other than pre-TBI psychiatric status contribute to post-TBI psychiatric outcome. Female gender, lower education, and pain were also associated with postinjury depression and unemployment and older age with anxiety. Conclusion: Findings suggest that long-term screening and support are important for individuals with TBI, regardless of preinjury psychiatric status.	[Whelan-Goodinson, Rochelle; Ponsford, Jennie Louise; Schoenberger, Michael] Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton, Vic, Australia; [Johnston, Lisa] Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie Louise] Epworth Med Fdn, Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Bldg 17, Clayton, Vic, Australia.	jennie.ponsford@med.monash.edu.au					Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Burke B. L., 2004, J COGN PSYCHOTHER, V18, P309, DOI [DOI 10.1891/JC0P.18.4.309.64002, 10.1891/jcop.18.4.309.64002]; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; DICKER BG, 1989, J HEAD TRAUMA REHAB, V4, P73; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Drubach D A, 1993, Md Med J, V42, P989; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FIRST MB, 2004, COMPUTER ASSISTED SC; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; PONSFORD J, 2004, MID M INT NEUR SOC A; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Williams JW, 2002, JAMA-J AM MED ASSOC, V287, P1160, DOI 10.1001/jama.287.9.1160; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	48	58	59	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2010	25	5					320	329		10.1097/HTR.0b013e3181c8f8e7			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	649JR	WOS:000281765400004	20042983				2021-06-18	
J	Theus, MH; Ricard, J; Bethea, JR; Liebl, DJ				Theus, Michelle H.; Ricard, Jerome; Bethea, John R.; Liebl, Daniel J.			EphB3 Limits the Expansion of Neural Progenitor Cells in the Subventricular Zone by Regulating p53 During Homeostasis and Following Traumatic Brain Injury	STEM CELLS			English	Article						Traumatic brain injury; Ephrin; Eph; Subventricular zone; p53	CONTROLLED CORTICAL IMPACT; ADULT MAMMALIAN FOREBRAIN; STEM-CELLS; AXON-GUIDANCE; GROWTH-FACTOR; STIMULATES NEUROGENESIS; NEUROBLASTS MIGRATE; NEURONAL MIGRATION; COMMISSURAL AXONS; OLFACTORY-BULB	Ephrins and Eph receptor(s) have recently been implicated in regulating neurogenesis in the adult subventricular zone (SVZ) and rostral migratory stream. Here, we examined the role of ephrinB3-EphB3 signaling in mediating the SVZ response to traumatic brain injury (TBI). Analysis of EphB3 expression showed colocalization with glial fibrillary acidic protein-positive neural stem progenitor cells (NSPCs) and doublecortin-positive neuroblasts, whereas ephrinB3 was expressed outside the neurogenic region. TBI resulted in a significant reduction in EphB3 expression, which coincided with enhanced NSPC survival and proliferation at 3 and 7 days postinjury. Analysis of mice lacking either ephrinB3 (ephrinB3(-/-)) or EphB3 (EphB3(-/-)) showed a significant increase in bromodeoxyuridine (BrdU) incorporation and Ki67 immunoreactivity in the SVZ. Interestingly, cell death was dissimilar between knockout mice, where cell death was reduced in EphB3(-/-) but increased in ephrinB3(-/-) mice. Lateral ventricle infusion of soluble preclustered ephrinB3-Fc reversed the proliferative and cell death defects in ephrinB3(-/-) but not EphB3(-/-) mice and prevented TBI-induced proliferation in wild-type NSPCs. Coincidently, tumor suppressor p53 expression was increased following EphB3 stimulation and is reduced in the absence of either EphB3 or ephrinB3. Furthermore, pharmacological inhibition and siRNA knockdown of p53-attenuated ephrinB3-Fc-mediated growth suppression while having no effect on cell death in cultured NSPCs. These data demonstrate that EphB3 signaling suppresses NSPC proliferation in a p53-dependent manner, induces cell death in the absence of ligand stimulation and is transiently reduced in the SVZ to initiate the expansion and survival of endogenous adult NSPCs following Tin. STEM CELLS 2010:28:1231-1242	[Liebl, Daniel J.] Univ Miami, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Liebl, DJ (corresponding author), Univ Miami, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace,R-48, Miami, FL 33136 USA.	dliebl@med.miami.edu		Ricard, Jerome/0000-0002-9019-4165	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049545, NS30291, NS007459, NS064699]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007459, R01NS051709, P50NS030291, R01NS049545, F32NS064699] Funding Source: NIH RePORTER	We thank Drs. Mark Henkemeyer and Mike Xu for their generous gift of the mutant mice. This work was supported by NIH/NINDS NS049545 (to D.J.L.), NS30291 (to D.J.L.), NS007459 (to M.H.T.), NS064699 (to M.H.T.), and the Miami Project to Cure Paralysis.	ALTMAN J, 1966, J COMP NEUROL, V126, P337, DOI 10.1002/cne.901260302; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arakawa H, 2005, CELL DEATH DIFFER, V12, P1057, DOI 10.1038/sj.cdd.4401601; Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BAIER H, 1994, SCIENCE, V265, P1541, DOI 10.1126/science.8079167; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; Bergemann AD, 1998, ONCOGENE, V16, P471, DOI 10.1038/sj.onc.1201557; Betarbet R, 1996, INT J DEV NEUROSCI, V14, P921, DOI 10.1016/S0736-5748(96)00066-4; Blits-Huizinga CT, 2004, IUBMB LIFE, V56, P257, DOI 10.1080/15216540412331270076; Bose I, 2007, J BIOSCIENCES, V32, P991, DOI 10.1007/s12038-007-0103-3; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Curtis MA, 2007, SCIENCE, V315, P1243, DOI 10.1126/science.1136281; del Rio G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000463; Dempsey RJ, 2003, J NEUROCHEM, V87, P586, DOI 10.1046/j.1471-4159.2003.02022.x; Depaepe V, 2005, NATURE, V435, P1244, DOI 10.1038/nature03651; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Doetsch F, 1997, J NEUROSCI, V17, P5046; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Furne C, 2009, BBA-MOL CELL RES, V1793, P231, DOI 10.1016/j.bbamcr.2008.09.009; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Geng Y, 2010, J HISTOCHEM CYTOCHEM, V58, P265, DOI 10.1369/jhc.2009.954024; Gil-Perotin S, 2006, J NEUROSCI, V26, P1107, DOI 10.1523/JNEUROSCI.3970-05.2006; Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006; Grunwald IC, 2002, CURR OPIN NEUROBIOL, V12, P250, DOI 10.1016/S0959-4388(02)00323-9; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holmberg J, 2005, GENE DEV, V19, P462, DOI 10.1101/gad.326905; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Ivanov AI, 2005, PHYSIOL GENOMICS, V21, P152, DOI 10.1152/physiolgenomics.00043.2004; Jin K, 2002, J CLIN INVEST, V110, P311, DOI 10.1172/JCI200215251; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Kempermann G, 1999, SCI AM, V280, P48, DOI 10.1038/scientificamerican0599-48; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Kuribayashi K, 2008, ADV EXP MED BIOL, V615, P201, DOI 10.1007/978-1-4020-6554-5_10; Li YY, 1998, AM J PHYSIOL-HEART C, V274, pH331, DOI 10.1152/ajpheart.1998.274.1.H331; Li YY, 2001, AM J PHYSIOL-HEART C, V281, pH2738; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Medrano S, 2005, BIOCHEM BIOPH RES CO, V331, P828, DOI 10.1016/j.bbrc.2005.03.194; Medrano S, 2009, NEUROBIOL AGING, V30, P483, DOI 10.1016/j.neurobiolaging.2007.07.016; Mehlen P, 2004, CELL MOL LIFE SCI, V61, P1854, DOI 10.1007/s00018-004-3467-7; Mehlen P, 2004, APOPTOSIS, V9, P37, DOI 10.1023/B:APPT.0000012120.66221.b2; Mehlen P, 1998, NATURE, V395, P801; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Mendes SW, 2006, J NEUROSCI, V26, P882, DOI 10.1523/JNEUROSCI.3162-05.2006; Meulmeester E, 2008, CURR CANCER DRUG TAR, V8, P87, DOI 10.2174/156800908783769337; Middeldorp J, 2010, DEVELOPMENT, V137, P313, DOI 10.1242/dev.041632; Mirzadeh Z, 2008, CELL STEM CELL, V3, P265, DOI 10.1016/j.stem.2008.07.004; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211; Orike N, 1996, CURR BIOL, V6, P108, DOI 10.1016/S0960-9822(02)00435-9; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Ricard J, 2006, MOL CELL NEUROSCI, V31, P713, DOI 10.1016/j.mcn.2006.01.002; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Scheffler B, 2005, P NATL ACAD SCI USA, V102, P9353, DOI 10.1073/pnas.0503965102; Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026; Snapyan M, 2009, J NEUROSCI, V29, P4172, DOI 10.1523/JNEUROSCI.4956-08.2009; Sohur US, 2006, PHILOS T R SOC B, V361, P1477, DOI 10.1098/rstb.2006.1887; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Tauszig-Delamasure S, 2007, P NATL ACAD SCI USA, V104, P13361, DOI 10.1073/pnas.0701243104; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Theus MH, 2008, EXP NEUROL, V210, P656, DOI 10.1016/j.expneurol.2007.12.020; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Wiltrout C, 2007, NEUROCHEM INT, V50, P1028, DOI 10.1016/j.neuint.2007.04.011; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yan YP, 2006, EUR J NEUROSCI, V24, P45, DOI 10.1111/j.1460-9568.2006.04872.x; Yokoyama N, 2001, NEURON, V29, P85, DOI 10.1016/S0896-6273(01)00182-9; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Yoshiya K, 2003, J NEUROTRAUM, V20, P1147, DOI 10.1089/089771503770802844; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang RL, 2001, ANN NEUROL, V50, P602, DOI 10.1002/ana.1249; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou J, 2004, CURR MOL MED, V4, P741, DOI 10.2174/1566524043359926; Zhu DY, 2003, J NEUROSCI, V23, P223	99	58	59	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	JUL	2010	28	7					1231	1242		10.1002/stem.449			12	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	636OF	WOS:000280746400012	20496368	Green Accepted, Bronze			2021-06-18	
J	Klevens, J; Leeb, RT				Klevens, Joanne; Leeb, Rebecca T.			Child maltreatment fatalities in children under 5: Findings from the National Violence Death Reporting System	CHILD ABUSE & NEGLECT			English	Article						Surveillance; Child physical abuse; Inflicted traumatic brain injury; Inflicted childhood neurotrauma; Abusive head trauma	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; UNITED-STATES; ABUSE; IMPACT	Objective: To describe the distribution of child maltreatment fatalities of children under 5 by age, sex, race/ethnicity, type of maltreatment, and relationship to alleged perpetrator using data from the National Violent Death Reporting System (NVDRS). Study design: Two independent coders reviewed information from death certificates, medical examiner and police reports corresponding to all deaths in children less than 5 years of age reported to NVDRS in 16 states. Results: Of the 1,374 deaths for children under 5 reported to NVDRS, 600 were considered attributable to child maltreatment. Over a half of the 600 victims of child maltreatment in this age group were under 1 year old, 59% were male, 42% non-Hispanic Whites, and 38% were non-Hispanic Blacks. Two thirds of child maltreatment fatalities in children under 5 were classified as being due to abusive head trauma (AHT), 27.5% as other types of physical abuse, and 10% as neglect. Based on these data, fathers or their substitutes were significantly more likely than mothers to be identified as alleged perpetrators for AHT and other types of physical abuse, while mothers were more likely to be assigned responsibility for neglect. Conclusions: Among children under 5 years, children under 1 are the main age group contributing to child maltreatment fatalities in the NVDRS. AHT is the main cause of death in these data. These findings are limited by underascertainment of cases and fair inter-rater reliability of coding. Practice implications: The findings suggest the need to develop and evaluate interventions targeting AHT to reduce the overall number of child maltreatment deaths in young children. These interventions should make special efforts to include fathers and their substitutes. Published by Elsevier Ltd.	[Klevens, Joanne; Leeb, Rebecca T.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA	Klevens, J (corresponding author), Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop F-64, Atlanta, GA 30341 USA.						Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Bennett MD, 2006, INJURY PREV, V12, P39, DOI 10.1136/ip.2006.012658; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Brewster AL, 1998, CHILD ABUSE NEGLECT, V22, P91, DOI 10.1016/S0145-2134(97)00132-4; CANIANO DA, 1986, ANN SURG, V203, P219, DOI 10.1097/00000658-198602000-00017; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P187; Crume TL, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.2.e18; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Duggan A, 2004, CHILD ABUSE NEGLECT, V28, P597, DOI 10.1016/j.chiabu.2003.08.007; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Graupman P, 2006, J NEUROSURG, V104, P245, DOI 10.3171/ped.2006.104.4.245; Hahn Robert A, 2003, MMWR Recomm Rep, V52, P1; Herman-Giddens ME, 1999, JAMA-J AM MED ASSOC, V282, P463, DOI 10.1001/jama.282.5.463; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KLEVENS J, 2002, INFLICTED CHILDHOOD, P269; Krugman R D, 1983, Pediatrician, V12, P68; Leeb R. T., 2008, CHILD MALTREATMENT S; MCCLAIN PW, 1993, PEDIATRICS, V91, P338; *NAT CTR INJ PREV, 2006, WISQARS LEAD CAUS DE; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P27; Schnitzer PG, 2008, AM J PUBLIC HEALTH, V98, P296, DOI 10.2105/AJPH.2006.087783; Schnitzer PG, 2005, PEDIATRICS, V116, pE687, DOI 10.1542/peds.2005-0296; Showers J, 1985, Pediatr Emerg Care, V1, P66; Steenkamp M, 2006, INJURY PREV, V12, P3, DOI 10.1136/ip.2006.012518; Stiffman MN, 2002, PEDIATRICS, V109, P615, DOI 10.1542/peds.109.4.615; US Census Bureau, 2007, 2005 2007 AM COMM SU; *UUS DEP HLTH HHS, 2005, CHILD MALTR 2003; *UUS DEP HLTH HHS, 2008, CHILD MALTR 2006; *UUS DEP HLTH HHS, 2007, CHILD MALTR 2005; *UUS DEP HLTH HHS, 2006, CHILD MALTR 2004; *WHO, 1999, INT STAT CLASS DIS R	35	58	58	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	APR	2010	34	4					262	266		10.1016/j.chiabu.2009.07.005			5	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	588LW	WOS:000277072700006	20304491				2021-06-18	
J	Wiesmann, M; Steinmeier, E; Magerkurth, O; Linn, J; Gottmann, D; Missler, U				Wiesmann, M.; Steinmeier, E.; Magerkurth, O.; Linn, J.; Gottmann, D.; Missler, U.			Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP	ACTA NEUROLOGICA SCANDINAVICA			English	Article						cerebrospinal fluid; critical care; head injury; neuroimaging; neurotraumatology	FIBRILLARY ACIDIC PROTEIN; SEVERE HEAD-INJURY; S-100B PROTEIN; SERUM; PROGNOSIS; COMA; DAMAGE; CLASSIFICATION; INDICATORS; STEM	Objective - To investigate the predictive value of early serum levels of S100B and glial fibrillary acidic protein (GFAP) in traumatic brain injury. Methods - Sixty patients admitted within 24 h of trauma were included. Neurological status on admission (Glasgow Coma Scale), initial cranial computed tomography (CCT) studies (Marshall Computed Tomographic Classification), and outcome after 6 months (Glasgow Outcome Scale) were evaluated. S100B and GFAP levels were determined on admission and 24 h after trauma. Results - Blood levels of S100B and GFAP were elevated following head trauma and quantitatively reflected the severity of trauma. S100B levels after 24 h and on admission were of higher predictive value than CCT findings or clinical examination. GFAP, but not S100B levels rapidly declined after trauma. Conclusions - Blood levels of S100B and GFAP indicate the severity of brain damage and are correlated with neurological prognosis after trauma. Both methods can yield additional prognostic information if combined with clinical and CCT findings.	[Wiesmann, M.; Magerkurth, O.; Linn, J.; Gottmann, D.] Univ Munich, Dept Neuroradiol, Munich, Germany; [Wiesmann, M.] Helios Kliniken Schwerin, Dept Neuroradiol, Schwerin, Germany; [Steinmeier, E.] Ernst Moritz Arndt Univ Greifswald, Dept Otorhinolaryngol Head & Neck Surg, Greifswald, Germany; [Missler, U.] Evangel Krankenhaus Duisburg Nord, Dept Neuroradiol, Duisburg, Germany	Wiesmann, M (corresponding author), Univ Klinikum Munchen Grosshadern, Abt Neuroradiol, Marchioninist 15, D-81377 Munich, Germany.	martin.wiesmann@med.uni-muenchen.de	Linn, Jennifer/H-8202-2013; Magerkurth, Olaf/AAH-5482-2020; Linn, Jennifer/AAE-1567-2021	Linn, Jennifer/0000-0003-0797-2761			Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; Hoelper BM, 2000, ACT NEUR S, V76, P265; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KAKARIEKA A, 1997, TRAUMATIC SUBARACHNO; MARION DW, 1996, NEUROTRAUMA, P767; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Missler U, 2000, CLIN CHEM, V46, P993; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Missler U, 1999, CLIN CHEM, V45, P138; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wedekind C, 1999, J TRAUMA, V47, P44, DOI 10.1097/00005373-199907000-00010; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Wiesmann M, 1998, RADIOLOGE, V38, P645, DOI 10.1007/s001170050405; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YAMAURA A, 1981, Neurologia Medico-Chirurgica, V21, P685	37	58	63	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	MAR	2010	121	3					178	185		10.1111/j.1600-0404.2009.01196.x			8	Clinical Neurology	Neurosciences & Neurology	548TV	WOS:000273991300006	19804476				2021-06-18	
S	Maruta, J; Lee, SW; Jacobs, EF; Ghajar, J		Barchas, JD; Difede, J		Maruta, Jun; Lee, Stephanie W.; Jacobs, Emily F.; Ghajar, Jamshid			A unified science of concussion	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	smooth pursuit; attention; prefrontal cortex; diffuse axonal injury (DAI); blast injury	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; WHITE-MATTER INJURY; WORKING-MEMORY; HEAD TRAUMA; COGNITIVE SEQUELAE; PREFRONTAL CORTEX; EYE-MOVEMENTS; REACTION-TIME; ABNORMALITIES	The etiology, imaging, and behavioral assessment of mild traumatic brain injury (mTBI) are daunting fields, given the lack of a cohesive neurobiological explanation for the observed cognitive deficits seen following mTBI. Although subjective patient self-report is the leading method of diagnosing mTBI, current scientific evidence suggests that quantitative measures of predictive timing, such as visual tracking, could be a useful adjunct to guide the assessment of attention and to screen for advanced brain imaging. Magnetic resonance diffusion tensor imaging (DTI) has demonstrated that mTBI is associated with widespread microstructural changes that include those in the frontal white matter tracts. Deficits observed during predictive visual tracking correlate with DTI findings that show lesions localized in neural pathways subserving the cognitive functions often disrupted in mTBI. Unifying the anatomical and behavioral approaches, the emerging evidence supports an explanation for mTBI that the observed cognitive impairments are a result of predictive timing deficits caused by shearing injuries in the frontal white matter tracts.	[Ghajar, Jamshid] Brain Trauma Fdn, World Trade Ctr 7, New York, NY 10007 USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA	Ghajar, J (corresponding author), Brain Trauma Fdn, World Trade Ctr 7, 250 Greenwich St,34th Floor, New York, NY 10007 USA.	ghajar@braintrauma.org	Maruta, Jun/I-3790-2019	Maruta, Jun/0000-0002-5054-6605	Department of DefenseUnited States Department of Defense [W81XWH-08-1-0646, W81XWH-08-2-0177]; James S. McDonnell Foundation; Attention Dynamics Consortium in Traumatic Brain Injury	The work is supported by the Department of Defense Grants W81XWH-08-1-0646, and W81XWH-08-2-0177; James S. McDonnell Foundation grants for the Cognitive Neurobiological Research Consortium in Traumatic Brain Injury and the Attention Dynamics Consortium in Traumatic Brain Injury. Ownership Interest: Sync-Think, Inc. (J.G.).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BARBAS H, 1984, EXP BRAIN RES, V55, P187; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Chen Y, 2002, PROG BRAIN RES, V140, P255; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; *DEF VET BRAIN INJ, 2008, CLIN PRACT GUID; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V35, P217; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jaffee MS, 2009, J REHABIL RES DEV, V46, P655, DOI 10.1682/JRRD.2008.09.0114; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krauzlis RJ, 2005, NEUROSCIENTIST, V11, P124, DOI 10.1177/1073858404271196; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; MARUTA J, 2010, J HEAD TRAU IN PRESS; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McKeag DB, 2009, CLIN J SPORT MED, V19, P343, DOI 10.1097/JSM.0b013e3181b2c114; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; NIOGI SN, 2010, J HEAD TRAU IN PRESS; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Takeuchi H, 2010, J NEUROSCI, V30, P3297, DOI 10.1523/JNEUROSCI.4611-09.2010; TANELIAN T, 2008, INVISIBLE WOUNDS MEN; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; UMEDA Y, 1975, ORL J OTO-RHINO-LARY, V37, P290, DOI 10.1159/000275237; Umile EM, 1998, BRAIN INJURY, V12, P577; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; VANDERSTEEN J, 1983, VISION RES, V23, P1655, DOI 10.1016/0042-6989(83)90180-3; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Warden DL, 2005, J NEUROTRAUM, V22, P1178	96	58	59	0	13	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						58	66		10.1111/j.1749-6632.2010.05695.x			9	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000008	20955326	Green Published, Bronze			2021-06-18	
J	Trabold, R; Eros, C; Zweckberger, K; Relton, J; Beck, H; Nussberger, J; Muller-Esterl, W; Bader, M; Whalley, E; Plesnila, N				Trabold, Raimund; Eroes, Christian; Zweckberger, Klaus; Relton, Jane; Beck, Heike; Nussberger, Juerg; Mueller-Esterl, Werner; Bader, Michael; Whalley, Eric; Plesnila, Nikolaus			The role of bradykinin B-1 and B-2 receptors for secondary brain damage after traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Traumatic brain injury; brain edema; inflammation; bradykinin; Kallikerin-kinin system; neuroptotection	CONTROLLED CORTICAL IMPACT; KALLIKREIN-KININ SYSTEM; MIDDLE CEREBRAL-ARTERY; BINDING-SITES; LF 16-0687MS; RAT MODEL; EDEMA; ANTAGONIST; PERMEABILITY; MEDIATOR	Inflammatory mechanisms are known to contribute to the pathophysiology of traumatic brain injury (TBI). Since bradykinin is one of the first mediators activated during inflammation, we investigated the role of bradykinin and its receptors in posttraumatic secondary brain damage. We subjected wild-type (WT), B-1-, and B-2-receptor-knockout mice to controlled cortical impact (CCI) and analyzed tissue bradykinin as well as kinin receptor mRNA and protein expression up to 48 h thereafter. Brain edema, contusion volume, and functional outcome were assessed 24 h and 7 days after CCI. Tissue bradykinin was maximally increased 2 h after trauma (P < 0.01 versus sham). Kinin B-1 receptor mRNA was upregulated up to four-fold 24 h after CCI. Immunohistochemistry showed that B-1 and B-2 receptors were expressed in the brain and were significantly upregulated in the traumatic penumbra 1 to 24 h after CCI. B2R-/- mice had significantly less brain edema (-51% versus WT, 24 h; P < 0.001), smaller contusion volumes (similar to 50% versus WT 24 h and 7 d after CCI; P < 0.05), and better functional outcome 7 days after TBI as compared with WT mice (P < 0.05). The present results show that bradykinin and its B-2 receptors play a causal role for brain edema formation and cell death after TBI. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 130-139; doi: 10.1038/jcbfm.2009.196; published online 23 September 2009	[Trabold, Raimund; Eroes, Christian; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Dept Neurosurg, Munich, Germany; [Trabold, Raimund; Eroes, Christian; Zweckberger, Klaus; Beck, Heike; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Walter Brendel Ctr Expt Med, Inst Surg Res, Munich, Germany; [Relton, Jane; Whalley, Eric] Biogen Idec Inc, Dept Pharmacol, Cambridge Ctr, Cambridge, MA USA; [Nussberger, Juerg] Univ Lausanne Hosp, Div Hypertens & Vasc Med, Lausanne, Switzerland; [Mueller-Esterl, Werner] Goethe Univ Frankfurt, Inst Biochem, Frankfurt, Germany; [Bader, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany	Plesnila, N (corresponding author), Royal Coll Surgeons Ireland, 123 St Stephens Green, Dublin 2, Ireland.	nikolausplesnila@rcsi.ie	Plesnila, Nikolaus/T-7522-2019	Bader, Michael/0000-0003-4780-4164			Austinat M, 2009, STROKE, V40, P285, DOI 10.1161/STROKEAHA.108.526673; Bartus RT, 1996, IMMUNOPHARMACOLOGY, V33, P270, DOI 10.1016/0162-3109(96)00070-7; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; CHOLEWINSKI AJ, 1991, J NEUROCHEM, V57, P1456, DOI 10.1111/j.1471-4159.1991.tb08314.x; FRANSSON LA, 1992, GLYCOCONJUGATE J, V9, P45, DOI 10.1007/BF00731177; FUJIWARA Y, 1989, LIFE SCI, V44, P1645, DOI 10.1016/0024-3205(89)90481-5; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gorlach C, 1996, PEPTIDES, V17, P1373, DOI 10.1016/S0196-9781(96)00223-9; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; KAMIYA T, 1993, STROKE, V24, P571, DOI 10.1161/01.STR.24.4.571; KARIYA K, 1985, J NEUROCHEM, V44, P1892, DOI 10.1111/j.1471-4159.1985.tb07185.x; Lee DK, 2004, J BIOL CHEM, V279, P7901, DOI 10.1074/jbc.M306377200; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Narotam PK, 1998, ACTA NEUROCHIR, V140, P793, DOI 10.1007/s007010050181; Noda M, 2003, LIFE SCI, V72, P1573, DOI 10.1016/S0024-3205(02)02449-9; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PERRY DC, 1984, J NEUROCHEM, V43, P1072, DOI 10.1111/j.1471-4159.1984.tb12846.x; Plesnila N, 2001, PROG INFLAM RES, P333; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; PRIVITERA PJ, 1992, BRAIN RES, V577, P73, DOI 10.1016/0006-8993(92)90539-L; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V33, P104, DOI 10.1016/0162-3109(96)00021-5; Raidoo DM, 1997, IMMUNOPHARMACOLOGY, V36, P153, DOI 10.1016/S0162-3109(97)00015-5; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; Relton JK, 1997, STROKE, V28, P1430, DOI 10.1161/01.STR.28.7.1430; Sarker MH, 2000, J PHYSIOL-LONDON, V528, P177, DOI 10.1111/j.1469-7793.2000.00177.x; Shughrue PJ, 2003, J COMP NEUROL, V465, P372, DOI 10.1002/cne.10846; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; TODA N, 1977, AM J PHYSIOL, V232, pH267; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; WHALLEY ET, 1983, PFLUG ARCH EUR J PHY, V398, P175, DOI 10.1007/BF00581069; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V323, P66, DOI 10.1007/BF00498830; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	41	58	60	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2010	30	1					130	139		10.1038/jcbfm.2009.196			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	539IL	WOS:000273247500014	19773800	Green Published, Bronze			2021-06-18	
J	Covacu, R; Arvidsson, L; Andersson, A; Khademi, M; Erlandsson-Harris, H; Harris, RA; Svensson, MA; Olsson, T; Brundin, L				Covacu, Ruxandra; Arvidsson, Lisa; Andersson, Asa; Khademi, Mohsen; Erlandsson-Harris, Helena; Harris, Robert A.; Svensson, Mikael A.; Olsson, Tomas; Brundin, Lou			TLR Activation Induces TNF-alpha Production from Adult Neural Stem/Progenitor Cells	JOURNAL OF IMMUNOLOGY			English	Article							TOLL-LIKE RECEPTOR-4; TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DORSAL-VENTRAL POLARITY; INTERFERON-GAMMA; STEM-CELLS; BACTERIAL LIPOPOLYSACCHARIDE; PROGENITOR CELLS; GENE-PRODUCT	Adult neural stem cells (NSCs) are believed to facilitate CNS repair and tissue regeneration. However, it is not yet clear how these cells are influenced when the cellular environment is modified during neurotrauma or neuroinflammatory conditions. In this study, we determine how different proinflammatory cytokines modulate the expression of TLR2 and TLR4 in NSCs and how these cells respond to TLR2 and TLR4 agonists. Primary cultures of neural stem/progenitor cells isolated from the subventricular zone of brains from adult Dark Agouti rats were exposed to 1) supernatants from activated macrophages; 2) proinflammatory cytokines IFN-gamma, TNF-alpha, or both; and 3) agonists for TLR2 and TLR4. Both TLR2 and TLR4 were expressed during basal conditions and their mRNA levels were further increased following cytokine exposure. TLR4 was up-regulated by IFN-gamma and this effect was reversed by TNF-alpha. TLR2 expression was increased by supernatants from activated macrophages and by TNF-a, which synergized with IFN-gamma. TLR agonists induced the expression of TNF-alpha mRNA. Importantly, TNF-alpha could be translated into protein and released into the supernatants where it was quantified by cytokine ELISA. In conclusion, we demonstrate that NSCs constitutively express TLR2 and TLR4 and that their expression is increased as a consequence of exposure to proinflammatory mediators. Additionally, activation of these receptors can induce production of proinflammatory cytokines. These findings suggest that NSCs may be primed to participate in cytokine production during neuroinflammatory or traumatic conditions. The Journal of Immunology, 2009, 182: 6889-6895.	[Covacu, Ruxandra] Karolinska Inst, Karolinska Hosp, Ctr Mol Med,Dept Clin Neurosci, Neuroimmunol Unit,Div Neuroimmunol, S-17176 Stockholm, Sweden; [Arvidsson, Lisa; Svensson, Mikael A.] Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; [Erlandsson-Harris, Helena] Karolinska Inst, Dept Med, Div Rheumatol, Stockholm, Sweden	Covacu, R (corresponding author), Karolinska Inst, Karolinska Hosp, Ctr Mol Med,Dept Clin Neurosci, Neuroimmunol Unit,Div Neuroimmunol, L8-04, S-17176 Stockholm, Sweden.	Ruxandra.Covacu@ki.se	Harris, Robert A./I-6234-2019; Svensson, Mikael/F-8662-2012	Harris, Robert A./0000-0003-4990-509X; Svensson, Mikael/0000-0003-1179-7003; Olsson, Tomas/0000-0002-2938-1877; Khademi, Mohsen/0000-0003-0801-1444; Brundin, Lou/0000-0003-4408-7817; Covacu, Ruxandra/0000-0003-3183-2988	Torsten and Ragnar Soderberg Foundation; Montel Williams Foundation; The Swedish Society for Neurologically; Karolinska InstitutetKarolinska Institutet	This work was supported by Torsten and Ragnar Soderberg Foundation, Montel Williams Foundation, The Swedish Society for Neurologically, Disabled, and Karolinska Institutet.	Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; Andersson A, 2004, J LEUKOCYTE BIOL, V76, P1118, DOI 10.1189/jlb.0704385; Andersson A, 2008, J LEUKOCYTE BIOL, V84, P1248, DOI 10.1189/jlb.1207844; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bosisio D, 2002, BLOOD, V99, P3427, DOI 10.1182/blood.V99.9.3427; Brundin L, 2003, BRAIN PATHOL, V13, P322; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Einstein O, 2003, MOL CELL NEUROSCI, V24, P1074, DOI 10.1016/j.mcn.2003.08.009; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; Hansen BS, 2006, J NEUROIMMUNOL, V172, P94, DOI 10.1016/j.jneuroim.2005.11.006; Hoshino K, 1999, J IMMUNOL, V162, P3749; Imitola J, 2004, AM J PATHOL, V164, P1615, DOI 10.1016/S0002-9440(10)63720-0; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kim SJ, 2007, NEUROCHEM RES, V32, P1399, DOI 10.1007/s11064-007-9323-z; Klassen HJ, 2003, CYTOKINE, V22, P101, DOI 10.1016/S1043-4666(03)00120-0; LI MH, 1994, J SURG RES, V57, P85, DOI 10.1006/jsre.1994.1115; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767; Mita Y, 2001, IMMUNOL LETT, V78, P97, DOI 10.1016/S0165-2478(01)00241-3; Nagai Y, 2006, IMMUNITY, V24, P801, DOI 10.1016/j.immuni.2006.04.008; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Papavasiliou AK, 1996, J NEUROSCI RES, V46, P49, DOI 10.1002/(SICI)1097-4547(19961001)46:1<49::AID-JNR7>3.0.CO;2-F; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pearl-Yafe M, 2007, SHOCK, V27, P226, DOI 10.1097/01.shk.0000239765.80033.37; Pevsner-Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood-2006-06-028704; Phulwani NK, 2008, J IMMUNOL, V181, P3841, DOI 10.4049/jimmunol.181.6.3841; Picard-Riera N, 2002, P NATL ACAD SCI USA, V99, P13211, DOI 10.1073/pnas.192314199; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Rieser C, 1998, BLOOD, V91, P3112, DOI 10.1182/blood.V91.9.3112.3112_3112_3117; Rolls A, 2007, NAT CELL BIOL, V9, P1081, DOI 10.1038/ncb1629; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Sheng WS, 2005, J LEUKOCYTE BIOL, V78, P1233, DOI 10.1189/jlb.0405221; Syed MM, 2007, J NEUROCHEM, V103, P1461, DOI 10.1111/j.1471-4159.2007.04838.x; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Tamandl D, 2003, SHOCK, V20, P224, DOI 10.1097/00024382-200309000-00005; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Ueda Y, 2005, J EXP MED, V201, P1771, DOI 10.1084/jem.20041419; Ueda Y, 2004, J EXP MED, V199, P47, DOI 10.1084/jem.20031104; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zekki H, 2002, BRAIN PATHOL, V12, P308	50	58	63	1	8	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUN 1	2009	182	11					6889	6895		10.4049/jimmunol.0802907			7	Immunology	Immunology	448JG	WOS:000266258300032	19454685	Bronze			2021-06-18	
J	Williams, RF; Magnotti, LJ; Croce, MA; Hargraves, BB; Fischer, PE; Schroeppel, TJ; Zarzaur, BL; Muhlbauer, M; Timmons, SD; Fabian, TC				Williams, Regan F.; Magnotti, Louis J.; Croce, Martin A.; Hargraves, Brinson B.; Fischer, Peter E.; Schroeppel, Thomas J.; Zarzaur, Ben L.; Muhlbauer, Michael; Timmons, Shelly D.; Fabian, Timothy C.			Impact of Decompressive Craniectomy on Functional Outcome After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Decompressive craniectomy; Severe traumatic brain injury; Uncontrollable intracranial hypertension; Glasgow outcome score extended	SURGICAL DECOMPRESSION; MANAGEMENT; SCALE; ICP	Background. The beneficial effect of decompressive craniectomy (DC) in the treatment of traumatic brain injury (TBI) remains controversial. In many centers, it is used as a salvage procedure for uncontrollable intracranial pressure (ICP). It is our contention that DC represents a viable early option for head trauma patients. The purpose of this study was to evaluate the efficacy of DC on functional outcome after severe TBI in the largest single institutional series reported in the literature. Methods: Patients with severe TBI (Abbreviated Injury Score 4-5) treated with DC for the management of increased ICP during 6-year period were identified from the trauma registry. Functional outcome was measured 1 year to 6 years postinjury using the Glasgow Outcome Score Extended (GOSE) via telephone interview and classified as good (GOSE 5-8) or poor (GOSE 1-4, including death). Outcomes were compared using Wilcoxon rank-sum and chi(2) tests where appropriate. Results. One hundred and seventy-one patients were identified: 137 (80%) men and 34 (20%) women. Overall mortality (all in-hospital) was 32% (head-related = 22%). Of the 117 survivors, follow-up was obtained in all but 6 (95%). Good outcome was achieved in 96 patients (56% overall, 82% of survivors). Those with good outcome were younger (26 years vs. 43 years, p = 0.0028) and experienced a greater change in predecompression to postdecompression ICP (ICP reduced by 23 mm Hg vs. 10 mm Hg, p < 0.0001). Not surprisingly, unchanged ICP (predecompression to postdecompression) was associated with poor outcome (p = 0.0031). There was no difference in immediate predecompression ICP between survivors versus nonsurvivors. However, immediate predecompression Glasgow Coma Score was significantly higher in survivors compared with nonsurvivors (7 vs. 5, p < 0.0001). Conclusions: DC resulted in good functional outcome in >50% of patients with severe TBI. The greatest benefit was observed in younger patients with a demonstrable reduction in ICP after decompression. The prospect of improved functional outcome offered by this procedure in the treatment of severe TBI warrants prospective investigation.	[Williams, Regan F.; Magnotti, Louis J.; Croce, Martin A.; Hargraves, Brinson B.; Fischer, Peter E.; Schroeppel, Thomas J.; Zarzaur, Ben L.; Fabian, Timothy C.] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; [Muhlbauer, Michael; Timmons, Shelly D.] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA	Magnotti, LJ (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Surg, 910 Madison Ave,Rm 217, Memphis, TN 38163 USA.	lmagnott@utmem.edu	Zarzaur, Ben/S-6572-2019				Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; *CDC, 2006, MMWR-MORBID MORTAL W, V55, P201; Cooper P R, 1976, Surg Neurol, V5, P25; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; GAAB MR, 1990, ACT NEUR S, V51, P326; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; KOCHER T, 1901, THERAPIE HIRNDRUCKES, P262; Kunze E, 1998, ACT NEUR S, V71, P16; Makino H, 1979, Acta Neurochir Suppl (Wien), V28, P193; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; PEREIRA WC, 1977, ARQ NEURO-PSIQUIAT, V35, P99, DOI 10.1590/S0004-282X1977000200002; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Schneider GH, 2002, ACT NEUR S, V81, P77; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	26	58	61	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2009	66	6					1570	1576		10.1097/TA.0b013e3181a594c4			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	457PN	WOS:000266944500009	19509616				2021-06-18	
J	McCrory, P; Meeuwisse, W; Johnston, K; Dvorak, J; Aubry, M; Molloy, M; Cantu, R				McCrory, Paul; Meeuwisse, Willem; Johnston, Karen; Dvorak, Jiri; Aubry, Mark; Molloy, Mick; Cantu, Robert			Consensus Statement on Concussion in Sport - The 3rd International Conference on Concussion in Sport Held in Zurich, November 2008	PM&R			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; HEAD-INJURIES; PROFESSIONAL FOOTBALL; POSTURAL CONTROL; LONG-TERM; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION		[McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; [Meeuwisse, Willem] Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB, Canada; [Meeuwisse, Willem] Univ Calgary, Dept Community Hlth Sci, Fac Med, Calgary, AB, Canada; [Johnston, Karen] Toronto Rehabil Inst, Sport Concuss Clin, Toronto, ON, Canada; [Dvorak, Jiri] FIFA Med Assessment & Res Ctr F MARC, Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin, Zurich, Switzerland; [Aubry, Mark] Int Ice Hockey Federat & Hockey Canada, Ottawa, ON, Canada; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Molloy, Mick] Int Rugby Board, Dublin 2, Ireland; [Cantu, Robert] Emerson Hosp, Concord, MA USA	McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 2000, SPORT HLTH, V18, P35; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh A, 2005, RUGBY HEADGEAR STUDY; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Peng Rui-yun, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, pS71, DOI 10.1080/02701367.2005.10599291; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	147	58	58	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	MAY	2009	1	5					406	420		10.1016/j.pmrj.2009.03.010			15	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V24LI	WOS:000208411500003	19627927	Green Published			2021-06-18	
J	Purcell, L				Purcell, L.			What are the most appropriate return-to-play guidelines for concussed child athletes?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				SPORT-RELATED CONCUSSION; HIGH-SCHOOL; YOUNG ATHLETE; COLLEGIATE; RECOVERY; MANAGEMENT; INJURY; AGE	Objective: To examine concussion literature for specific guidelines regarding return to play (RTP) following sport-related concussion in child athletes. To make recommendations regarding the most appropriate RTP guidelines for child athletes following sport-related concussion. Design: A literature review of concussion literature. Intervention: A literature search was conducted using Medline and Embase databases from 1998 to 2008. More than 60 articles and two websites were reviewed. Results: There is a paucity of research on sport-related concussion in child athletes, particularly younger children (age 5-12 years). In particular, there is no research on RTP guidelines for child athletes following sport-related concussion. Child athletes take longer to recover from concussions than adults. Concussion symptoms may resolve before cognitive function has completely recovered. Concussion assessment and management in children can be confounded by their growth and development, as well as the lack of trained medical personnel involved with youth sports. There are no child-specific assessment tools for concussion. Conclusions: RTP decisions in children should be made cautiously and should be individualised. No concussed child athlete should be allowed to RTP the same day. Physical and cognitive rest is very important to allow for the resolution of concussion symptoms. Child athletes should remain symptom free for several days before starting a medically supervised stepwise exertion protocol. Further research is needed to elucidate the effects of concussion in children and to determine the most appropriate RTP guidelines. Child-specific concussion assessment tools need to be developed to improve concussion assessment and management in children.	London Hlth Sci Ctr, Childrens Emergency Dept, London, ON N6C 2V5, Canada	Purcell, L (corresponding author), London Hlth Sci Ctr, Childrens Emergency Dept, 800 Commissioners Rd E, London, ON N6C 2V5, Canada.	lpurcell1015@rogers.com					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; *CAN PED SOC, 2006, PEDIAT CHILD HLTH, V11, P420; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Centers for Disease Control and Prevention, WHAT TRAUM BRAIN INJ; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; GIOIA GA, 2004, 2 INT S CONC SPORT 5; Gordon Kevin E, 2006, Semin Pediatr Neurol, V13, P243, DOI 10.1016/j.spen.2006.09.005; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Patel DR, 2002, PEDIATR CLIN N AM, V49, P505, DOI 10.1016/S0031-3955(02)00003-2; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Standaert CJ, 2007, ARCH PHYS MED REHAB, V88, P1077, DOI 10.1016/j.apmr.2007.06.002; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	28	58	58	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I51	I55		10.1136/bjsm.2009.058214			5	Sport Sciences	Sport Sciences	450YO	WOS:000266438100009	19433426				2021-06-18	
J	Immonen, RJ; Kharatishvili, I; Grohn, H; Pitkanen, A; Grohn, OHJ				Immonen, Riikka J.; Kharatishvili, Irina; Grohn, Heidi; Pitkanen, Asla; Grohn, Olli H. J.			Quantitative MRI predicts long-term structural and functional outcome after experimental traumatic brain injury	NEUROIMAGE			English	Article						Diffusion; Fluid percussion model; Head trauma; Long-term; Outcome; Quantitative MRI; T-1 rho; T-2; Traumatic brain injury	FLUID PERCUSSION INJURY; MAGNETIC-RESONANCE; HEAD-INJURY; CEREBRAL-ISCHEMIA; STATUS EPILEPTICUS; REGIONAL PATTERNS; ROTATING-FRAME; MOUSE MODEL; FOLLOW-UP; RATS	In traumatic brain injury (TBI) the initial impact causes both immediate damage and also launches a cascade of slowly progressive secondary damage. The chronic outcome disabilities vary greatly and can occur several years later. The aim of this study was to find predictive factors for the long-term outcome using multiparametric, non-invasive magnetic resonance imaging (MRI) methodology and a clinically relevant rat model of fluid percussion induced TBI. Our results demonstrated that the multiparametric quantitative MRI (T-2, T-1 rho, trace of the diffusion tensor D-av, the extent of hyperintense lesion and intracerebral hemorrhage) acquired during acute and sub acute phases 3 h, 3 days, 9 days and 23 days post-injury has potential to predict the functional and histopathological outcome 6 to 12 months later. The acute D-av changes in the ipsilateral hippocampus correlated with the chronic spatial learning and memory impairment evaluated using the Morris water maze (p<0.05). Similarly, T-1 rho, T-2 and D-av correlated with hippocampal atrophy and with histologically quantified neurodegeneration (p<0.01). The early lesion volume and quantitative MRI changes in the perilesional region prefigured the final lesion extent (p<0.01). Furthermore, the severity of acute intracerebral hemorrhage correlated with the final cortical atrophy (p<0.05), hippocampal atrophy (p<0.01), and also with the water maze performance (p<0.01). We conclude that, assessment of early quantitative MRI changes in the hippocampus and in the perifocal area may help to predict the long-term outcome after experimental TBI. (C) 2008 Elsevier Inc. All rights reserved.	[Immonen, Riikka J.; Grohn, Olli H. J.] Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Biomed NMR Res Grp,Biomed Imaging Unit, FIN-70211 Kuopio, Finland; [Kharatishvili, Irina; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Epilepsy Res Lab, FIN-70211 Kuopio, Finland; [Grohn, Heidi] N Karelia Cent Hosp, Dept Clin Physiol Nucl Med & Neurophysiol, Joensuu, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	Grohn, OHJ (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Biomed NMR Res Grp,Biomed Imaging Unit, POB 1627, FIN-70211 Kuopio, Finland.	olli.grohn@uku.fi			Academy of FinlandAcademy of FinlandEuropean Commission; Emil Aaltonen Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; CURE; Finnish Epilepsy Research Foundation; Finnish Cultural FoundationFinnish Cultural Foundation	This work was supported by the Academy of Finland, the Emil Aaltonen Foundation, the Sigrid Juselius Foundation, CURE (Citizens United for Research for Epilepsy), the Finnish Epilepsy Research Foundation, and the Finnish Cultural Foundation. We thank Mrs. Maarit Pulkkinen, Mr. Jarmo Hartikainen, Mrs. Merja Lukkari and Jari Nissinen, Ph. D., for technical assistance, and Nick Hayward, M. Sc., for revising the language of the manuscript.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; FREUND TF, 1992, BRAIN RES BULL, V28, P27, DOI 10.1016/0361-9230(92)90227-O; Gallagher CN, 2007, CURR OPIN NEUROL, V20, P403, DOI 10.1097/WCO.0b013e32821b987b; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Grohn OHJ, 1999, MAGNET RESON MED, V42, P268; Grohn OHJ, 2000, J CEREBR BLOOD F MET, V20, P1457; HADLEY DM, 1988, CLIN RADIOL, V39, P131; HATASHITA S, 1990, STROKE, V21, P582, DOI 10.1161/01.STR.21.4.582; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; ITO U, 1979, STROKE, V10, P542, DOI 10.1161/01.STR.10.5.542; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Karhunen H, 2003, EPILEPSY RES, V54, P1, DOI 10.1016/S0920-1211(03)00034-2; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Makela HI, 2001, BIOCHEM BIOPH RES CO, V289, P813, DOI 10.1006/bbrc.2001.6058; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Morais DF, 2008, ARQ NEURO-PSIQUIAT, V66, P53, DOI 10.1590/S0004-282X2008000100013; Nairismagi J, 2004, EPILEPSIA, V45, P1024, DOI 10.1111/j.0013-9580.2004.08904.x; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Oh Hyun Soo, 2006, Taehan Kanho Hakhoe Chi, V36, P621; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SEPPONEN RE, 1985, J COMPUT ASSIST TOMO, V9, P1007, DOI 10.1097/00004728-198511000-00002; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smits AJ, 1997, EXP THERM FLUID SCI, V14, P1, DOI 10.1016/S0894-1777(96)00189-6; Soares HD, 1995, J NEUROSCI, V15, P8223; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x	62	58	60	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAR	2009	45	1					1	9		10.1016/j.neuroimage.2008.11.022			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	414KR	WOS:000263862900001	19101638				2021-06-18	
J	Whitney, KA; Shepard, PH; Williams, AL; Davis, JJ; Adams, KM				Whitney, Kriscinda A.; Shepard, Polly H.; Williams, Amanda L.; Davis, Jeremy J.; Adams, Kenneth M.			The Medical Symptom Validity Test in the evaluation of Operation Iraqi Freedom/Operation Enduring Freedom soldiers: A preliminary study	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Neuropsychology; Malingering; Military Veterans; Traumatic brain injury; Test validity; Memory	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; POSTTRAUMATIC-STRESS-DISORDER; EXAGGERATION; PERFORMANCE; MECHANISMS; VETERANS; SEQUELAE	The clinical utility of the Medical Symptom Validity Test (MSVT) for soldiers returning from service in Operation Iraqi Freedom or Operation Enduring Freedom was preliminarily investigated through retrospective chart review. Results showed that 17%, or 4 of 23, Operation Iraqi Freedom/Operation Enduring Freedom patients at a Polytrauma Network Site (Level 2), performed below cut-offs on the MSVT. On "easy" subtests of the MSVT, the group of individuals who failed the MSVT performed significantly worse than the group of individuals who passed. However, there were no significant group differences on the "hard" subtests of the MSVT. When the profiles of individuals who failed the MSVT were examined, none of them met the criteria for the Dementia Profile. These preliminary findings and additional test data supported the conclusion that participants who failed the MSVT were exhibiting diminished symptom validity, suggesting that the specificity of the MSVT was 100%.	[Whitney, Kriscinda A.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; [Whitney, Kriscinda A.; Shepard, Polly H.] Indiana Univ, Sch Med, Indianapolis, IN USA; [Shepard, Polly H.] Profess Psychol Serv, Indianapolis, IN USA; [Williams, Amanda L.] Ball State Univ, Muncie, IN 47306 USA; [Davis, Jeremy J.] Univ Indianapolis, Indianapolis, IN 46227 USA; [Adams, Kenneth M.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA; [Adams, Kenneth M.] Univ Michigan Hlth Syst, Ann Arbor, MI USA	Whitney, KA (corresponding author), Richard L Roudebush Vet Affairs Med Ctr 116P, 1481 W 10th St, Indianapolis, IN 46202 USA.	kamarks@iupui.edu					Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Delis DC, 2000, CALIFORNIA VERBAL LE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; FRERICHS R, 2006, ARCH CLIN NEUROPSYCH, V21, P551; Green, 2004, GREENS MED SYMPTOM V; Green P., 2003, GREENS WORD MEMORY T; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; HOWE LLS, 2009, CLIN NEUROPSYCHOL, V23, P1; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; Merckelbach H, 2003, ARCH CLIN NEUROPSYCH, V18, P145, DOI 10.1016/S0887-6177(01)00191-3; Miller HA, 2004, INT J OFFENDER THER, V48, P268, DOI 10.1177/0306624X03259167; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Pilgrim B M, 1999, Appl Neuropsychol, V6, P243, DOI 10.1207/s15324826an0604_7; REYNOLDS CR, 1998, CLIN ASSESSMENT MALI, P250; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; Rogers R., 1992, SIRS STRUCTURED INTE; Schmidt M., 1996, REY AUDITORY VERBAL; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; *TSGLI, 2007, PROC GUID; *VET BEN ADM, 2006, 21001 VET BEN ADM	30	58	58	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2009	24	2					145	152		10.1093/arclin/acp020			8	Psychology, Clinical; Psychology	Psychology	454TL	WOS:000266705500003	19395348	Green Published, Bronze			2021-06-18	
J	Itoh, T; Satou, T; Ishida, H; Nishida, S; Tsubaki, M; Hashimoto, S; Ito, H				Itoh, Tatsuki; Satou, Takao; Ishida, Hiroyuki; Nishida, Shozo; Tsubaki, Masahiro; Hashimoto, Shigeo; Ito, Hiroyuki			The relationship between SDF-1 alpha/CXCR4 and neural stem cells appearing in damaged area after traumatic brain injury in rats	NEUROLOGICAL RESEARCH			English	Article						Neural stem cell; traumatic brain injury; nestin; SDF-1 alpha; CXCR4	CHEMOKINE RECEPTOR CXCR4; LEUKOCYTE RECRUITMENT; SUBVENTRICULAR ZONE; DENTATE GYRUS; ADULT BRAIN; EXPRESSION; MIGRATION; PROLIFERATION; NEUROGENESIS; LOCALIZATION	Objective: The actual relationship between neural stem cells and SDF-1 alpha/CXCR4 after brain injury has not yet been elucidated, although recent studies have speculated that stromal cell-derived factor-1 alpha (SDF-1 alpha) and its receptor, CXCR4, could contribute to neural stem cells migration after brain injury. In the present study, the temporal relationship between neural stem cells (NSCs) and SDF-1 alpha/CXCR4 around a damaged area was investigated using a rat traumatic brain injury (TBI) model. Methods: We used molecular biology techniques and immunohistochemistry to investigate the relationship between SDF-1 alpha/CXCR4 expression and NSCs existence around a damaged area after TBI in the rat brain. Results: SDF-1 alpha mRNA expression and SDF-1 alpha protein synthesis did not increase after TBI. However, SDF-1 alpha leaked from the injured area and diffused into the cortex 1-3 days after TBI. Subsequently, the levels of CXCR4 mRNA expression and CXCR4 protein synthesis increased significantly. Many small cells with a nestin-positive cytoplasm and fibers also showed immunopositivity for both CXCR4 and SOX-2, but not for GFAP, 3-7 days after TBI. Moreover, a proportion of the CXCR4-positive cells and fibers also showed immunostaining for neurofilaments. Discussion: These results suggest that the leaked SDF-1 alpha attracted CXCR4-positive NSCs as well as elongated nerve fibers. It is considered that the SDF-1 alpha/CXCR4 system in the brain contributes to neural stem cells appearance and maturation after TBI. Therefore, exploitation of the SDF-1 alpha/CXCR4 system around a damaged area may improve the brain dysfunction after TBI. [Neurol Res 2009; 31: 90-102]	[Itoh, Tatsuki; Satou, Takao; Ishida, Hiroyuki; Ito, Hiroyuki] Kinki Univ, Sch Med, Dept Pathol, Osaka 589, Japan; [Satou, Takao] Kinki Univ Hosp, Sch Med, Div Hosp Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ, Inst Life Sci, Div Sports Med, Osaka, Japan; [Nishida, Shozo; Tsubaki, Masahiro] Kinki Univ, Sch Pharmaceut Sci, Osaka, Japan; [Hashimoto, Shigeo] PL Hosp, Dept Pathol, Osaka, Japan	Itoh, T (corresponding author), 377-2 Ohnohigashi, Osakasayama City, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21591871] Funding Source: KAKEN		Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bagri A, 2002, DEVELOPMENT, V129, P4249; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Banisadr G, 2002, EUR J NEUROSCI, V16, P1661, DOI 10.1046/j.1460-9568.2002.02237.x; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Douen AG, 2004, BRAIN RES, V1008, P139, DOI 10.1016/j.brainres.2003.08.070; Dziembowska M, 2005, GLIA, V50, P258, DOI 10.1002/glia.20170; Felszeghy K, 2004, NEUROIMMUNOMODULAT, V11, P404, DOI 10.1159/000080151; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2005, NEUROL RES, V27, P429, DOI 10.1179/016164105X18476; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2006, NEUROCHEM RES, V31, P1381, DOI 10.1007/s11064-006-9186-8; Ji JF, 2004, NEUROSCI LETT, V355, P236, DOI 10.1016/j.neulet.2003.11.024; Kobayashi Y, 2003, BIOL PHARM BULL, V26, P1596, DOI 10.1248/bpb.26.1596; Komitova M, 2005, STROKE, V36, P1278, DOI 10.1161/01.STR.0000166197.94147.59; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Lu M, 2002, P NATL ACAD SCI USA, V99, P7090, DOI 10.1073/pnas.092013799; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Moon C, 2004, BRAIN RES, V1028, P238, DOI 10.1016/j.brainres.2004.09.022; Ni HT, 2004, DEV BRAIN RES, V152, P159, DOI 10.1016/j.devbrainres.2004.06.015; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Piper DR, 2001, J NEUROSCI RES, V66, P356, DOI 10.1002/jnr.1228; Pujol F, 2005, J CELL SCI, V118, P1071, DOI 10.1242/jcs.01694; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Stumm RK, 2003, J NEUROSCI, V23, P5123; Stumm RK, 2002, J NEUROSCI, V22, P5865; Tham TN, 2001, EUR J NEUROSCI, V13, P845, DOI 10.1046/j.0953-816x.2000.01451.x; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tran PB, 2004, J NEUROSCI RES, V76, P20, DOI 10.1002/jnr.20001; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Youn BS, 2000, IMMUNOL REV, V177, P150, DOI 10.1034/j.1600-065X.2000.17701.x; Zeiffer U, 2004, CIRC RES, V94, P776, DOI 10.1161/01.RES.0000121105.72718.5C; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	41	58	63	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	FEB	2009	31	1					90	102		10.1179/174313208X332995			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	415BA	WOS:000263908100013	19228460				2021-06-18	
J	Berger, RP; Ta'Asan, S; Rand, A; Lokshin, A; Kochanek, P				Berger, Rachel P.; Ta'Asan, Shlomo; Rand, Alex; Lokshin, Anna; Kochanek, Patrick			Multiplex Assessment of Serum Biomarker Concentrations in Well-Appearing Children With Inflicted Traumatic Brain Injury	PEDIATRIC RESEARCH			English	Article							TUMOR-NECROSIS-FACTOR; ABUSIVE HEAD TRAUMA; NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; YOUNG-CHILDREN; INFANTS; INTERLEUKIN-6; CYTOKINE; MARKERS; ASSOCIATION	Proper diagnosis of mild inflicted traumatic brain injury (ITBI) is difficult; children often present without a history of trauma and with nonspecific symptoms, such as vomiting. Previous Studies suggest that biomarkers may be able to screen for brain injury in this population, but these studies focused on only a few biomarkers. We hypothesized that using multiplex bead technology we would be able to identify multiple differences in the serum biomarker profile between in children with ITBI and those without brain injury. We compared the concentrations of 44 serum biomarkers in 16 infants with mild ITBI and 20 infants without brain injury. There were significant group differences in the concentrations of nine of the 44 markers. Vascular cellular adhesion molecule (VCAM) (p < 0.00) and IL-6 (IL-6) (p < 0.00) had the most significant group differences; IL-6 was higher after ITBI, whereas VCAM was lower. Using VCAM and IL-6 in classification algorithms, we could discriminate the groups with a sensitivity and specificity of 87% and 90%, respectively. The results suggest significant changes in the serum biomarker profile after mild ITBI. Future research is needed to determine whether these biomarkers can screen for brain injury in infants with nonspecific symptoms. (Pediatr Res 65: 97-102, 2009)	[Berger, Rachel P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; [Lokshin, Anna] Univ Pittsburgh, Luminex Core Facil, Pittsburgh, PA 15213 USA; [Berger, Rachel P.; Kochanek, Patrick] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Ta'Asan, Shlomo; Rand, Alex] Carnegie Mellon Univ, Dept Math Sci, Pittsburgh, PA 15213 USA	Berger, RP (corresponding author), Childrens Hosp Pittsburgh, 3705 5th Ave, Pittsburgh, PA 15217 USA.	rberger@pitt.edu	Ta'asan, Shlomo/B-8366-2017	Ta'asan, Shlomo/0000-0002-6085-7124; Kochanek, Patrick/0000-0002-2627-913X	University of Pittsburgh Center for Injury Research and ControlUniversity of Pittsburgh	Supported by University of Pittsburgh Center for Injury Research and Control [R.B., P.K.]	Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2004, CHILD ABUSE NEGLECT, V28, P739, DOI 10.1016/j.chiabu.2004.01.007; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BREIMAN JR, 1984, CLASSIFICATION REGRE, P18; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brody AS, 2007, PEDIATRICS, V120, P677, DOI 10.1542/peds.2007-1910; Browning JG, 2005, EMERG MED J, V22, P33, DOI 10.1136/emj.2004.016196; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2002, NEUROSURG CLIN N AM, V13, P149, DOI 10.1016/S1042-3680(02)00002-5; Ellaway BA, 2004, ARCH DIS CHILD, V89, P845, DOI 10.1136/adc.2003.035493; ENGEL A, 1994, INFECTION, V22, P160, DOI 10.1007/BF01716695; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; FRIEDMAN J, 2001, ELEMENTS STAT LEARNI, P415; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jiang B, 2003, CLIN DIAGN LAB IMMUN, V10, P995, DOI 10.1128/CDLI.10.6.995-1001.2003; Kaiser L, 2001, J MED VIROL, V64, P262, DOI 10.1002/jmv.1045; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; MANGASARIAN OL, 1995, OPER RES, V43, P570, DOI 10.1287/opre.43.4.570; MANGASARIAN OL, 1990, SIAM PROC S, P22; MANGASARIAN OL, 1965, OPER RES, V13, P444, DOI 10.1287/opre.13.3.444; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; ONEILL JA, 1973, J TRAUMA, V13, P332, DOI 10.1097/00005373-197304000-00012; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Sato M, 2003, PEDIATRICS, V112, P1103, DOI 10.1542/peds.112.5.1103; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777	39	58	60	0	3	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 W CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	JAN	2009	65	1					97	102		10.1203/PDR.0b013e31818c7e27			6	Pediatrics	Pediatrics	386VM	WOS:000261910700017	18787505	Bronze			2021-06-18	
J	Pinzon, A; Marcillo, A; Quintana, A; Stamler, S; Bunge, MB; Bramlett, HM; Dietrich, WD				Pinzon, Alberto; Marcillo, Alexander; Quintana, Ada; Stamler, Sarah; Bunge, Mary Bartlett; Bramlett, Helen M.; Dietrich, W. Dalton			A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model	BRAIN RESEARCH			English	Article						Spinal cord injury; Neuroprotection; Minocycline; Behavioral outcome	FOCAL CEREBRAL-ISCHEMIA; CYTOCHROME-C RELEASE; BRAIN-INJURY; ACTIVATION; RECOVERY; DEATH; EXPRESSION; PROTECTION; CASPASE-1	This study was initiated due to an NIH "Facilities of Research-Spinal Cord Injury" contract to support independent replication of published studies that could be considered for a clinical trial in time. Minocycline has been shown to have neuroprotective effects in models of central nervous system injury, including in a contusive spinal cord injury (SCI) model at the thoracic level. Beneficial effects of minocycline treatment included a significant improvement in locomotor behavior and reduced histopathological changes [Lee, S.M., Yune, T.Y., Kim, S.J., Park, D.O.W., Lee, Y.K., Kim, Y.C., Oh, Y.J., Markelonis, G.J., Oh, T.H., 2003. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma. 20, 1017-1027.] To verify these important observations, we repeated this study in our laboratory. The NYU (MASCIS) Impactor was used to produce a moderate cord lesion at the vertebral level T9-T10 (height 12.5 mm, weight 10 g), (n = 45), followed by administration of minocycline, 90 mg/kg (group 1: minocycline IP, n = 15; group 2: minocycline IV, n = 15; group 3: vehicle IP, n = 8; group 4: vehicle IV, n = 7) immediately after surgery and followed by two more doses of 45 mg/kg/IP at 12 h and 24 h. Open field locomotion (BBB) and subscores were examined up to 6 weeks after SCI and cords were processed for quantitative histopathological analysis. Administration of minocycline after SCI did not lead to significant behavioral or histopathological improvement. Although positive effects with minocycline have been reported in several animal models of injury with different drug administration schemes, the use of minocycline following contusive SCI requires further investigation before clinical trials are implemented. (C) 2008 Elsevier B.V. All rights reserved.	[Pinzon, Alberto; Marcillo, Alexander; Quintana, Ada; Stamler, Sarah; Bunge, Mary Bartlett; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bunge, Mary Bartlett; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, 1095 NW 14th Terrace,LPLC 2-30, Miami, FL 33136 USA.	ddietrich@miami.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Facilities of Research Excellence in Spinal Cord Injury (FORE-SCI) [N01-NS-3-2352]; The Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032352] Funding Source: NIH RePORTER	We would like to thank Diana Ospina, Ileana Oropesa, Denise Koivisto, Andres Maldonado, Rosa Abril, and Monica Stagg for animal care and behavioral analysis; Paulo Diaz and Michael Shumm for performing the contusion injuries; Gladys L. Ruenes and Lyudmila Rusakova for tissue processing; Robert Camarena for photography; and Charlaine Rowlette and Jeremy Lytle for expert editorial assistance and word processing. This work was supported by funds from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Facilities of Research Excellence in Spinal Cord Injury (FORE-SCI) under contract No. N01-NS-3-2352, and The Miami Project to Cure Paralysis.	Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hoang TX, 2008, EXP BRAIN RES, V189, P71, DOI 10.1007/s00221-008-1398-5; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Piao CS, 2003, J NEUROSCI RES, V73, P537, DOI 10.1002/jnr.10671; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Saganova K, 2008, NEUROSCI LETT, V433, P246, DOI 10.1016/j.neulet.2008.01.041; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	26	58	63	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 3	2008	1243						146	151		10.1016/j.brainres.2008.09.047			6	Neurosciences	Neurosciences & Neurology	384YL	WOS:000261780000016	18838063	Green Accepted			2021-06-18	
J	Topal, NB; Hakyemez, B; Erdogan, C; Bulut, M; Koksal, O; Akkose, S; Dogan, S; Parlak, M; Ozguc, H; Korfali, E				Topal, Naile Bolca; Hakyemez, Bahattin; Erdogan, Cuneyt; Bulut, Mehtap; Koksal, Ozlem; Akkose, Sule; Dogan, Seref; Parlak, Mufit; Ozguc, Halil; Korfali, Ender			MR imaging in the detection of diffuse axonal injury with mild traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						Brain injury; axonal injury; magnetic resonance	CLOSED-HEAD INJURY; GRADIENT-RECALLED ECHO; CONCUSSION; DAMAGE; CT	Purpose: To evaluate the occurrence and distribution of mild traumatic brain injury MTBI) caused by diffuse axonal injury DAI) using magnetic resonance MR) imaging and to attempt to correlate MR findings with post-concussion symptoms PCS). Patients and methods: Forty MTBI patients mean age: 32.5 years) with normal cranial computed tomography CT) findings were examined with standard MR protocol including T1-weighted, T(2)-weighted, fluid attenuated inversion recovery FLAIR), gradient echo GRE) and diffusion-weighted DW) sequences. MR imaging was performed within 24 hours of injury. The lesions were classified as DAI based on their location and morphologic appearance. Results: In MR imaging of five 12.5%) of the patients, the lesions compatible with DAI were observed. Four patients 10%) had the foci of low signal intensity compatible with hemorrhagic shear injury on the GRE sequence, and five 12.5%) patients had high signal intensity on FLAIR and DW sequence. Conclusion: MR imaging can be helpful in revealing DAI lesions in patients with normal CT scan findings after MTBI. FLAIR, GRE and DW sequences are superior to conventional spin-echo images in detecting DAI lesions. [Neurol Res 2008; 30: 974-978]	[Topal, Naile Bolca; Hakyemez, Bahattin; Erdogan, Cuneyt; Parlak, Mufit] Uludag Univ, Sch Med, Dept Radiol, TR-16059 Gorukle, Bursa, Turkey; [Bulut, Mehtap; Koksal, Ozlem; Akkose, Sule] Uludag Univ, Sch Med, Dept Emergency Med, TR-16059 Gorukle, Bursa, Turkey; [Dogan, Seref; Korfali, Ender] Uludag Univ, Sch Med, Dept Neurosurg, TR-16059 Gorukle, Bursa, Turkey; [Ozguc, Halil] Uludag Univ, Sch Med, Dept Gen Surg, TR-16059 Gorukle, Bursa, Turkey	Topal, NB (corresponding author), Uludag Univ, Sch Med, Dept Radiol, TR-16059 Gorukle, Bursa, Turkey.	nailebolca@yahoo.com	Topal, Naile Bolca/AAI-2327-2021; Hakyemez, Bahattin/AAI-2318-2021; koksal, ozlem/AAK-8332-2020; dogan, seref/AAI-6531-2021; Parlak, Mufit/AAG-8521-2021	Hakyemez, Bahattin/0000-0002-3425-0740; koksal, ozlem/0000-0003-2271-5659; 			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Ezaki Y, 2006, ACTA NEUROCHIR, V148, P547, DOI 10.1007/s00701-005-0692-2; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Giugni E, 2005, RADIOL MED, V109, P563; Giugni E, 2005, AM J NEURORADIOL, V26, P1140; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; Kushner D, 2002, AM J NEURORADIOL, V23, P1442; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Neumar RW, 2002, ANN EMERG MED, V39, P342, DOI 10.1067/mem.2002.122007; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Sklar EM, 2000, AM J NEURORADIOL, V21, P808; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Zheng WB, 2007, NEURORADIOLOGY, V49, P271, DOI 10.1007/s00234-006-0187-8	30	58	61	1	13	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	NOV	2008	30	9					974	978		10.1179/016164108X323799			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	378LT	WOS:000261323000016	18691451				2021-06-18	
J	Waters, EM; Torres-Reveron, A; McEwen, BS; Milner, TA				Waters, Elizabeth M.; Torres-Reveron, Annelyn; McEwen, Bruce S.; Milner, Teresa A.			Ultrastructural localization of extranuclear progestin receptors in the rat hippocampal formation	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						estrogen-inducible progestin receptors; progesterone; extranuclear	DENDRITIC SPINE DENSITY; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; ESTROUS-CYCLE; SUBCELLULAR-DISTRIBUTION; DIFFERENTIAL REGULATION; BETA IMMUNOREACTIVITY; ISOFORMS EXPRESSION; SEX-DIFFERENCES; PURKINJE-CELLS	Progesterone's effects on hippocampus-dependent behavior and synaptic connectivity maybe mediated through the progestin receptor (PR). Although estrogen induces PR mRNA and cytosolic PR in the hippocampus, nuclear PR immunoreactivity is undetectable by light microscopy, suggesting that PR is present at extranuclear sites. To determine whether this is the case, we used immunoelectron microscopy to examine PR distribution in the hippocampal formation of proestrus rats. Ultrastructural analysis revealed that PR labeling is present in extranuclear profiles throughout the CA1 and CA3 regions and dentate gyrus, and, in contrast to light microscopic findings, in nuclei of a few pyramidal and subgranular zone cells. Most neuronal PR labeling is extranuclear and is divided between pre- and postsynaptic compartments; approximately 30% of labeled profiles were axon terminals and 30% were dendrites and dendritic spines. In most laminae, except in CA3 stratum lucidum, about 15% of PR-immunoreactive profiles were unmyelinated axons. In stratum lucidum, where the mossy fiber axons course, more than 50% of PR-labeled profiles were axonal. The remaining 25% of PR-labeled profiles were glia, some resembling astrocytes. PR labeling is strongly dependent on estrogen priming, insofar as few PR-labeled profiles were detected in ovariectomized, oil-replaced females. Synapses formed by PR-labeled terminals were predominantly asymmetric, consistent with a role for progesterone in directly regulating excitatory transmission. These findings suggest that some of progesterone's actions in the hippocampal formation may be mediated by direct and rapid actions on extranuclear PRs and that PRs are well positioned to regulate progesterone-induced changes at synapses.	[Waters, Elizabeth M.; McEwen, Bruce S.; Milner, Teresa A.] Rockefeller Univ, Harold & Margaret Milliken Hatch Lab Neuroendocri, New York, NY 10065 USA; [Torres-Reveron, Annelyn; Milner, Teresa A.] Weill Cornell Med Coll, Div Neurobiol, Dept Neurol & Neurosci, New York, NY 10021 USA	Waters, EM (corresponding author), Rockefeller Univ, Harold & Margaret Milliken Hatch Lab Neuroendocri, 1230 York Ave, New York, NY 10065 USA.	ewaters@rockefeller.edu	McEwen, Bruce/Z-1630-2019		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS007080, T32 DK07313, DA08259, HL18974]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL018974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T32DK007313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS007080, R01NS011853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA008259] Funding Source: NIH RePORTER	Grant sponsor: National Institutes of Health: Grant number: NS007080 (to B.S.M.): Grant number T32 DK07313 (to B.S.M., E.M.W.); Grant number: DA08259 (to T.A.M, A.T.-R.); Grant number: HL18974 (T.A.M.).	Adams MM, 2004, J COMP NEUROL, V474, P419, DOI 10.1002/cne.20148; Aoki C, 2001, SYNAPSE, V40, P239, DOI 10.1002/syn.1047; Ballare C, 2006, J STEROID BIOCHEM, V102, P2, DOI 10.1016/j.jsbmb.2006.09.030; Camacho-Arroyo I, 1998, NEUROREPORT, V9, P3993, DOI 10.1097/00001756-199812210-00001; Cammarata PR, 2004, EXP EYE RES, V78, P861, DOI 10.1016/j.exer.2003.09.027; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHAN J, 1990, J NEUROSCI METH, V33, P113, DOI 10.1016/0165-0270(90)90015-8; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Drake CT, 2007, PROG BRAIN RES, V163, P245, DOI 10.1016/S0079-6123(07)63015-5; Edwards HE, 2000, NEUROSCIENCE, V101, P895, DOI 10.1016/S0306-4522(00)00439-5; Fitzpatrick SL, 1999, ENDOCRINOLOGY, V140, P3928, DOI 10.1210/en.140.9.3928; Foy MR, 1999, J NEUROPHYSIOL, V81, P925; Frye CA, 2005, PHARMACOL BIOCHEM BE, V81, P907, DOI 10.1016/j.pbb.2005.06.016; Garcia-Segura LM, 2006, GLIA, V54, P485, DOI 10.1002/glia.20404; Gazzaley AH, 1996, J NEUROSCI, V16, P6830; Ghoumari AM, 2005, PROG BRAIN RES, V148, P37, DOI 10.1016/S0079-6123(04)48004-2; Ghoumari AM, 2003, P NATL ACAD SCI USA, V100, P7953, DOI 10.1073/pnas.1332667100; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P313; Guerra-Araiza C, 2003, J NEUROENDOCRINOL, V15, P984, DOI 10.1046/j.1365-2826.2003.01088.x; Guerra-Araiza C, 2000, LIFE SCI, V66, P1743, DOI 10.1016/S0024-3205(00)00497-5; Guerra-Araiza C, 2002, BRAIN RES BULL, V59, P105, DOI 10.1016/S0361-9230(02)00845-6; Hammes SR, 2007, ENDOCR REV, V28, P726, DOI 10.1210/er.2007-0022; Hanekamp EE, 2004, ENDOCR-RELAT CANCER, V11, P831, DOI 10.1677/erc.1.00844; Haywood SA, 1999, ENDOCRINOLOGY, V140, P3255, DOI 10.1210/en.140.7.3255; Herrick SP, 2006, BRAIN RES, V1121, P46, DOI 10.1016/j.brainres.2006.08.084; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JUNGTESTAS I, 1992, J STEROID BIOCHEM, V41, P621, DOI 10.1016/0960-0760(92)90394-X; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; Kurita T, 1998, ENDOCRINOLOGY, V139, P4708, DOI 10.1210/en.139.11.4708; Lacroix-Fralish ML, 2006, NEURON GLIA BIOL, V2, P227, DOI 10.1017/S1740925X07000385; Lange CA, 2007, ANNU REV PHYSIOL, V69, P171, DOI 10.1146/annurev.physiol.69.031905.160319; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; MACLUSKY NJ, 1980, ENDOCRINOLOGY, V106, P192, DOI 10.1210/endo-106-1-192; MACLUSKY NJ, 1978, NATURE, V274, P276, DOI 10.1038/274276a0; Milner TA, 2005, J COMP NEUROL, V491, P81, DOI 10.1002/cne.20724; Milner TA, 2001, J COMP NEUROL, V429, P355; MILNER TA, 2007, NEUROSCI LE IN PRESS; Nilsen J, 2002, NEUROREPORT, V13, P825, DOI 10.1097/00001756-200205070-00018; Nishida H, 2007, J NEUROSCI, V27, P331, DOI 10.1523/JNEUROSCI.4466-06.2007; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; PARSONS B, 1982, J NEUROSCI, V2, P1446; Perea G, 2007, SCIENCE, V317, P1083, DOI 10.1126/science.1144640; Peters A, 1991, FINE STRUCTURE NERVO; Quadros PS, 2007, J COMP NEUROL, V504, P42, DOI 10.1002/cne.21427; Quadros PS, 2002, ENDOCRINOLOGY, V143, P3727, DOI 10.1210/en.2002-211438; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Rosario ER, 2006, BRAIN RES, V1099, P206, DOI 10.1016/j.brainres.2006.03.127; Sandstrom NJ, 2001, BEHAV NEUROSCI, V115, P384, DOI 10.1037//0735-7044.115.2.384; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Scharfman HE, 2003, J NEUROSCI, V23, P11641; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; SIERRA A, 2008, GLIA IN PRESS; Sinchak K, 2001, J NEUROSCI, V21, P5723; Smith CC, 2006, J NEUROSCI, V26, P8517, DOI 10.1523/JNEUROSCI.5279-05.2006; Smith CC, 2005, J NEUROSCI, V25, P7780, DOI 10.1523/JNEUROSCI.0762-05.2005; STEIN DG, 2007, BRAIN RES R IN PRESS; STERNBERGER LA, 1979, IMMUNOHISTCHEMISTRY; Sul JY, 2004, NEURON GLIA BIOL, V1, P3, DOI 10.1017/S1740925X04000031; SWANSON LW, 2000, BRAIN MAPS STRUCTURE; Tabori NE, 2005, NEUROSCIENCE, V130, P151, DOI 10.1016/j.neuroscience.2004.08.048; Tibbetts TA, 1999, P NATL ACAD SCI USA, V96, P12021, DOI 10.1073/pnas.96.21.12021; Tournell CE, 2006, NEUROSCIENCE, V141, P1327, DOI 10.1016/j.neuroscience.2006.05.004; TRAISH AM, 1990, ENDOCRINOLOGY, V127, P1167, DOI 10.1210/endo-127-3-1167; Turner C.D., 1971, GEN ENDOCRINOLOGY; Venkatesan C, 1996, J COMP NEUROL, V365, P79; Villamar-Cruz O, 2006, BRAIN RES BULL, V69, P276, DOI 10.1016/j.brainresbull.2005.12.006; Villoslada P, 2004, PROG BRAIN RES, V146, P403; Wang G, 2006, BRAIN RES, V1094, P163, DOI 10.1016/j.brainres.2006.03.089; WILLIAMS TJ, 2007, ANN M SOC NEUR, V625, P3; Woolley CS, 2007, ANNU REV PHARMACOL, V47, P657, DOI 10.1146/annurev.pharmtox.47.120505.105219; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1994, J NEUROSCI, V14, P7680; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zaborszky L, 2006, NEUROANATOMICAL TRAC	81	58	60	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	NOV 1	2008	511	1					34	46		10.1002/cne.21826			13	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	356PI	WOS:000259789700003	18720413	Green Accepted			2021-06-18	
J	Weichel, ED; Colyer, MH				Weichel, Eric D.; Colyer, Marcus H.			Combat ocular trauma and systemic injury	CURRENT OPINION IN OPHTHALMOLOGY			English	Article						closed-globe injury; combat ocular trauma; enucleation; intraocular foreign body; open-globe injury; traumatic brain injury	EYE INJURIES; WAR INJURIES; IRAQI FREEDOM; DESERT-SHIELD; PROTECTION; MANAGEMENT; STORM	Purpose of review To review the recent literature regarding combat ocular trauma during hostilities in Operations Iraqi Freedom and Enduring Freedom, describe the classification of combat ocular trauma, and offer strategies that may assist in the management of eye injuries. Recent findings Several recent publications have highlighted features of combat ocular trauma from Operation Iraqi Freedom. The most common cause of today's combat ocular injuries is unconventional fragmentary munitions causing significant blast injuries. These explosive munitions cause high rates of concomitant nonocular injuries such as traumatic brain injury, amputation, and other organ injuries. The most frequent ocular injuries include open-globe and adnexal lacerations. The extreme severity of combat-related open-globe injuries leads to high rates of primary enucleation and retained intraocular foreign bodies. Visual outcomes of intraocular foreign body injuries are similar to other series despite delayed removal, and no cases of endophthalmitis have occurred. Despite these advances, however, significant vision loss persists in cases of perforating globe injuries as well as open and closed-globe trauma involving the posterior segment. Summary This review summarizes the recent literature describing ocular and systemic injuries sustained during Operations Iraqi and Enduring Freedom. An emphasis on classification of ocular injuries as well as a discussion of main outcome measures and complications is discussed.	[Weichel, Eric D.] Walter Reed Army Med Ctr, Ophthalmol Serv, Washington, DC 20307 USA; [Weichel, Eric D.] NEI, NIH, Bethesda, MD 20892 USA	Weichel, ED (corresponding author), Walter Reed Army Med Ctr, Ophthalmol Serv, 6900 Georgia Ave, Washington, DC 20307 USA.	eweichel@hotmail.com					Ari Adrienne B, 2006, Optometry, V77, P329, DOI 10.1016/j.optm.2006.03.015; BELKIN M, 1984, ISRAEL J MED SCI, V20, P333; BELLOWS JG, 1947, AM J OPHTHALMOL, V30, P309, DOI 10.1016/0002-9394(47)91977-6; Colyer MH, 2007, OPHTHALMOLOGY, V114, P1439, DOI 10.1016/j.ophtha.2006.10.052; COLYER MH, 2008, OPHTHALMOLOGY; COTTER F, 1991, MIL MED, V156, P126; Duke-Elder S, 1972, SYSTEM OPHTHALMOLOGY; Freidlin J, 2006, OPHTHAL PLAST RECONS, V22, P133, DOI 10.1097/01.iop.0000203495.67894.c7; GOMBOS GM, 1969, AM J OPHTHALMOL, V68, P474, DOI 10.1016/0002-9394(69)90717-X; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Harlan J B Jr, 2002, Ophthalmol Clin North Am, V15, P153, DOI 10.1016/S0896-1549(02)00006-8; HEIER JS, 1993, ARCH OPHTHALMOL-CHIC, V111, P795, DOI 10.1001/archopht.1993.01090060083028; JAFFE NS, 1953, AMA ARCH OPHTHALMOL, V49, P591; Jankovic S, 1998, MIL MED, V163, P423; Jankovic S, 1998, MIL MED, V163, P490; Johnson AJ, 2007, J TRAUMA, V62, pS20, DOI 10.1097/TA.0b013e3180653eb7; Kuhn F, 1996, GRAEF ARCH CLIN EXP, V234, P399, DOI 10.1007/BF00190717; Kuhn Ferenc, 2002, Ophthalmol Clin North Am, V15, P139, DOI 10.1016/S0896-1549(02)00004-4; La Piana FG, 1997, DOC OPHTHALMOL, V93, P29, DOI 10.1007/BF02569045; Lakits A, 1998, OPHTHALMOLOGY, V105, P1679, DOI 10.1016/S0161-6420(98)99038-8; LOWREY A, 1954, Trans Pac Coast Otoophthalmol Soc Annu Meet, V35, P39; Mader TH, 2006, OPHTHALMOLOGY, V113, P97, DOI 10.1016/j.ophtha.2005.07.018; MADER TH, 1993, OPHTHALMOLOGY, V100, P1462; Parsons J., 1941, T OPHTHAL SOC UK, V61, P157; Pieramici DJ, 1997, AM J OPHTHALMOL, V123, P820, DOI 10.1016/S0002-9394(14)71132-8; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SCOTT GI, 1946, BRIT J OPHTHALMOL, V30, P42, DOI 10.1136/bjo.30.1.42; SIMMONS ST, 1984, OPHTHALMOLOGY, V91, P977; Steindorf K, 1914, BERL KLIN WOCHENSCHR, V51, P1789; STONE W, 1950, JAMA-J AM MED ASSOC, V142, P151, DOI 10.1001/jama.1950.02910210007002; Thach AB, 2005, OPHTHALMOLOGY, V112, P1829, DOI 10.1016/j.ophtha.2005.04.024; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; TREISTER G, 1969, AM J OPHTHALMOL, V68, P669, DOI 10.1016/0002-9394(69)91251-3; *US EY INJ REG, SOURC EY INJ; WARD TP, 2007, OPHTHALMOLOGY TIMES, P8; WEICHEL ED, 2007, RETINAL INSIDER, P82; WELCHEL ED, OPHTHALMOLO IN PRESS; Wong TY, 1997, MIL MED, V162, P744; Wong TY, 1997, SURV OPHTHALMOL, V41, P433, DOI 10.1016/S0039-6257(97)00022-2	39	58	59	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1040-8738			CURR OPIN OPHTHALMOL	Curr. Opin. Ophthalmol.	NOV	2008	19	6					519	525		10.1097/ICU.0b013e3283140e98			7	Ophthalmology	Ophthalmology	367WA	WOS:000260582100011	18854697				2021-06-18	
J	Fish, J; Manly, T; Emslie, H; Evans, JJ; Wilson, BA				Fish, J.; Manly, T.; Emslie, H.; Evans, J. J.; Wilson, B. A.			Compensatory strategies for acquired disorders of memory and planning: differential effects of a paging system for patients with brain injury of traumatic versus cerebrovascular aetiology	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							REHABILITATION; PEOPLE; AID; RECOVERY	Background: Previous studies have demonstrated the effectiveness of paging systems in compensating for everyday memory and planning problems after brain injury, including in individuals with traumatic brain injury (TBI). Methods: Here, in addition to further analyses of the TBI data from a previous randomised control crossover trial, results are reported from a sub-group of 36 participants with brain injury from cerebrovascular accident (CVA). Results: Results indicate that, as with the TBI group, the pager was effective. However, the pattern of results following cessation of treatment differed. At a group level, TBI participants demonstrated maintenance of pagerrelated benefits, whereas CVA participants' performance returned to baseline levels. Comparisons of demographic and neuropsychological characteristics of the groups showed that the CVA group was older, had a shorter interval post-injury, and had poorer executive function than the TBI group. Furthermore, within the TBI group, maintenance was associated with executive functioning, such that executive dysfunction impeded maintenance. This correlation remained after controlling for demographic differences between groups. Conclusions: Together, these findings suggest that executive dysfunction may affect treatment-for example, whether or not temporary use of the pager is sufficient to establish a subsequently self- sustaining routine.	[Wilson, B. A.] Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Cambridge CB2 2QQ, England; [Evans, J. J.] Univ Glasgow, Sect Psychol Med, Glasgow, Lanark, Scotland	Wilson, BA (corresponding author), Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Hills Rd,Box 58, Cambridge CB2 2QQ, England.	barbara.wilson@mrc-cbu.cam.ac.uk		Fish, Jessica/0000-0002-9337-1489	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105559837] Funding Source: Medline		Baddeley A.D., 1992, SPEED CAPACITY LANGU; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; CERMAK L S, 1975, Cortex, V11, P163; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Emslie H, 2007, NEUROPSYCHOL REHABIL, V17, P567, DOI 10.1080/09602010701381933; ESLINGER PJ, 1995, NEUROREHABILITATION, V5, P161, DOI 10.3233/NRE-1995-5206; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Everitt B., 1996, MAKING SENSE STAT PS; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Intercollegiate Stroke Working Party, 2004, NAT CLIN GUID STROK; Kapur N, 2004, NEUROPSYCHOL REHABIL, V14, P41, DOI 10.1080/09602010343000138; Kime SK, 1996, BRAIN INJURY, V10, P17; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Robertson IH, 1997, NEUROPSYCHOLOGY, V11, P290, DOI 10.1037/0894-4105.11.2.290; ROBERTSON IH, 1994, TEST EVERDAY ATTENTI; *ROYAL COLL PHYS, 2003, REH FOLL ACQ BRAIN I; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Voinikonis A, 2005, PERS UBIQUIT COMPUT, V9, P284, DOI 10.1007/s00779-004-0332-5; Wilson B.A, 1987, REHABILITATION MEMOR; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Wilson BA, 2003, NEUROREHABILITATION, V18, P3; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	31	58	58	1	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2008	79	8					930	935		10.1136/jnnp.2007.125203			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	328KF	WOS:000257796600017	18039889				2021-06-18	
J	Loder, RT				Loder, Randall T.			The demographics of equestrian-related injuries in the United States: Injury patterns, orthopedic specific injuries, and avenues for injury prevention	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						equestrian; injury; demographics; predictors; body area; location	HORSE-RELATED INJURIES; ACCIDENTS; CHILDREN; SERIES	Background: It was the purpose of this study to review equestrian-related injuries using a large nation wide database and analyze predictors of significant injury. Methods: The National Electronic Surveillance System database was queried for equestrian injuries from 2002 to 2004. The presence of a fracture, dislocation, traumatic brain injury, musculoskeletal injury, orthopedic injury, and spinal injury, as well as injury mechanism, geographical location, and emergency room disposition were noted. Bivariate, cosinor seasonal, and multiple logistic regression analyses were performed. p < 0.01 was considered significant. Results: Emergency room visits because of equestrian-related injuries from 2002 to 2004 from the NEISS database were reviewed; there were 5,033 visits during this time span. The average age was 30.0 +/- 17.0 years; 66% were women. The injuries occurred at home (36%), recreation/sporting facility (30%), on a farm (19%), and other public property (12%). The injury was due to a fall (59%), thrown/bucked from the horse (22.0%), and while riding the horse (9%). The most common injuries were contusion/abrasions (31%), fractures (28%), sprain/strains (18%), traumatic brain injuries (12%), and lacerations (6%). The body area injured was the head and neck (24%), trunk (29%), upper extremity (30%), lower extremity (16%), and multiple locations (11%). Most injuries occurred in the summer. Predictors of hospital admission were age > 18 years, traumatic brain injury, fracture, or occurrence on other public property (odds ratios 1.4, 6.25, 7.7, and 1.5, respectively). Conclusions: The largest number of equestrian injuries occur in white females in the 2nd, 4th, and 5th decades of life. Serious injuries are due to failing or being bucked off a horse and most commonly occur at home or at a recreational/sporting facility. Prevention strategies (educational and passive protection equipment) should be especially targeted to this high risk group.	[Loder, Randall T.] James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA; [Loder, Randall T.] Indiana Univ, Dept Orthopaed Surg, Indiana Sch Med, Indiana, PA USA	Loder, RT (corresponding author), James Whitcomb Riley Hosp Children, Room 4250,702 Barnhill Dr, Indianapolis, IN 46202 USA.	rloder@iupui.edu			Garceau Professorship Endowment; Indiana University, Department of Orthopaedic Surgery; Rapp Pediatric Orthopaedic Research Endowment; Riley Children's Foundation, Indianapolis, Indiana	This research was supported in part by the Garceau Professorship Endowment, Indiana University, Department of Orthopaedic Surgery, and the Rapp Pediatric Orthopaedic Research Endowment, Riley Children's Foundation, Indianapolis, Indiana.	ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BARBER HM, 1973, BRIT MED J, V3, P532, DOI 10.1136/bmj.3.5879.532; BARONE GW, 1989, J TRAUMA, V29, P245, DOI 10.1097/00005373-198902000-00019; BINGHAM C, 1982, CHRONOBIOLOGIA, V9, P397; BIXBYHAMMETT DM, 1992, PEDIATRICS, V89, P1173; BIXBYHAMMETT DM, 1987, AM FAM PHYSICIAN, V36, P209; BOND GR, 1995, PEDIATRICS, V95, P487; BROOKS WH, 1988, PHYSICIAN SPORTSMED, V16, P84, DOI 10.1080/00913847.1988.11709646; Chitnavis JP, 1996, INJURY, V27, P103, DOI 10.1016/0020-1383(95)00176-X; CHRISTEY GL, 1994, J FAM PRACTICE, V39, P148; CONDIE C, 1993, PUBLIC HEALTH REP, V108, P121; Dekker R, 2004, DISABIL REHABIL, V26, P91, DOI 10.1080/09638280310001629688; *DIV HAZ INJ DAT S, 2000, US CONS PROD SAF COM; Exadaktylos AK, 2002, EMERG MED J, V19, P573, DOI 10.1136/emj.19.6.573; FAURE A, 1990, COMPUT BIOL MED, V20, P319, DOI 10.1016/0010-4825(90)90011-D; Fleming PRI, 2001, CLIN EXP OPHTHALMOL, V29, P208, DOI 10.1046/j.1442-9071.2001.00430.x; Frankel HL, 1998, AM SURGEON, V64, P151; Gabbe BJ, 2005, BRIT J SPORT MED, V39, P573, DOI 10.1136/bjsm.2004.015750; Ghosh A, 2000, J PEDIATR SURG, V35, P1766, DOI 10.1053/jpsu.2000.19247; HAMILTON MG, 1993, J TRAUMA, V34, P227, DOI 10.1097/00005373-199302000-00008; Hobbs Gregory D., 1994, Journal of Emergency Medicine, V12, P143, DOI 10.1016/0736-4679(94)90690-4; Holland AJA, 2001, MED J AUSTRALIA, V175, P609, DOI 10.5694/j.1326-5377.2001.tb143746.x; HOPKINS RS, 1989, AM J PREV MED, V5, P104; Jagodzinski Tanya, 2005, WMJ, V104, P50; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; Lim J, 2003, ANZ J SURG, V73, P567, DOI 10.1046/j.1445-2197.2003.02707.x; Mace SE, 2001, ANN EMERG MED, V38, P405, DOI 10.1067/mem.2001.115882; McAbee GN, 1996, PEDIATR NEUROL, V15, P235, DOI 10.1016/S0887-8994(96)00162-2; McCaig Linda F, 2004, Adv Data, P1; MILLS NJ, 1990, P INT RES C BIOM IMP, P155; MOJON A, 1992, CHRONOBIOL INT, V9, P403, DOI 10.3109/07420529209064552; MORBIDITY MWR, 1990, MMWR-MORBID MORTAL W, V39, P329; NELSON DE, 1992, AM J DIS CHILD, V146, P611, DOI 10.1001/archpedi.1992.02160170091022; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Northey Glenda, 2003, N Z Med J, V116, pU601; OFarrell DA, 1997, BRIT J SPORT MED, V31, P249, DOI 10.1136/bjsm.31.3.249; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; REGAN PJ, 1991, INJURY, V22, P124, DOI 10.1016/0020-1383(91)90072-M; Roe D, 2003, AM J ORTHOPSYCHIAT, V73, P336, DOI 10.1037/0002-9432.73.3.334; Sorli J M, 2000, Inj Prev, V6, P59, DOI 10.1136/ip.6.1.59; Tanner JM, 1990, WORLDWIDE VARIATION; Watt GM, 1996, SPORTS MED, V22, P187, DOI 10.2165/00007256-199622030-00005; Whitlock MR, 1999, BRIT J SPORT MED, V33, P212, DOI 10.1136/bjsm.33.3.212	43	58	60	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2008	65	2					447	460		10.1097/TA.0b013e31817dac43			14	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	337US	WOS:000258461600042	18695484				2021-06-18	
J	Ngai, KM; Levy, F; Hsu, EB				Ngai, K. M.; Levy, F.; Hsu, E. B.			Injury trends in sanctioned mixed martial arts competition: a 5-year review from 2002 to 2007	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORT; CONCUSSION; STATEMENT; RISK	Background: Professional mixed martial arts (MMA) competition is a full-contact sport that has risen rapidly in popularity in recent years, However, there is limited information regarding the incidence of competition injuries after sanctioning by an athletic commission. Methods: We conducted a retrospective cohort study to examine MMA injury patterns during a 5 year period after sanctioning in the state of Nevada. Data from all regulated MMA competitions during the study period from March 2002 to September 2007 (1270 fight exposures) was obtained. Injury odds ratios were calculated by conditional logistic regression on match outcome, age, weight, and fight experience, using a pair-matched case-control design (n = 464) and by multiple logistic regression on match outcome, age, fight experience, weight, combat minutes, and scheduled rounds. Results: During the 635 professional MMA matches, 300 of the 1270 athletes sustained documented injuries with an injury rate of 23.6 per 100 fight participations. Most common reported injuries were lacerations and upper limb injuries. Severe concussion rate was 15.4 per 1000 athlete exposures, or 3% of all matches. No deaths or critical sports-related injuries resulted from any of the regulated matches during the study period. Age, weight and fight experience did not statistically increase the likelihood of injuries after controlling for other covariates Conclusions: Injury rates in regulated professional MMA competition are similar to other combat sports; the overall risk of critical sports-related injury seems to be low. Additional study is warranted to achieve a better understanding of injury trends and ways to further lower injury risk in MMA.	[Ngai, K. M.; Levy, F.; Hsu, E. B.] Johns Hopkins Med Inst, Dept Emergency Med, Baltimore, MD 21209 USA	Hsu, EB (corresponding author), Johns Hopkins Med Inst, Dept Emergency Med, 5801 Smith Ave,Davis Bldg,Suite 3220, Baltimore, MD 21209 USA.	ehsu1@jhmi.edu					BLEDSOE GH, 2006, BR J SPORTS MED 0209; BLEDSOE GH, S MED J, V98, P994; Bledsoe GH, 2006, J SPORT SCI MED, V5, P136; *BRIT MED ASS, 2007, BOX UPD BOARD SCI; Buse GJ, 2006, BRIT J SPORT MED, V40, P169, DOI 10.1136/bjsm.2005.021295; Cantu RC, 2000, NEUROSURG FOCUS, V2006, pE3; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Kelly JP, 1997, NEUROLOGY, V48, P581; Kochhar T, 2005, BRIT J SPORT MED, V39, P444, DOI 10.1136/bjsm.2004.011270; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2007, BMJ-BRIT MED J, V335, P781, DOI 10.1136/bmj.39352.454792.80; *NEV STAT ATHL COM, ADV COMM BOX HLTH SA; *NEV STAT ATHL COM, RES; *NEV STAT ATHL COM, NEV TOP MMA GAT; *NEW JERS ATHL CON, LAW PUBL SAF; *NEW JERS STAT ATH, MIX MART ARTS UN RUL; WERTHEIM LJ, 2007, NEW MAIN EVENT; White C, 2007, BRIT MED J, V335, P469, DOI 10.1136/bmj.39328.486100.DB; ZAZRYN TR, BR J SPORTS MED, V37, P448; MIXED MARTIAL ARTS	21	58	62	1	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2008	42	8					686	689		10.1136/bjsm.2007.044891			4	Sport Sciences	Sport Sciences	338UY	WOS:000258536100011	18308883				2021-06-18	
J	Avramescu, S; Timofeev, I				Avramescu, Sinziana; Timofeev, Igor			Synaptic strength modulation after cortical trauma: A role in epileptogenesis	JOURNAL OF NEUROSCIENCE			English	Article						epilepsy; cortical trauma; synaptic efficacy; intrinsic excitability; homeostatic plasticity; in vivo	V PYRAMIDAL NEURONS; EXPLAIN POSTTRAUMATIC EPILEPTOGENESIS; HUMAN TEMPORAL-LOBE; NEOCORTICAL NEURONS; IN-VIVO; HOMEOSTATIC PLASTICITY; ANTIEPILEPTIC DRUGS; NEUROTROPHIC FACTOR; BRAIN-INJURY; RED NUCLEUS	Traumatic brain injuries are often followed by abnormal hyperexcitability, leading to acute seizures and epilepsy. Previous studies documented the rewiring capacity of neocortical neurons in response to various cortical and subcortical lesions. However, little information is available on the functional consequences of these anatomical changes after cortical trauma and the adaptation of synaptic connectivity to a decreased input produced by chronic deafferentation. In this study, we recorded intracellular (IC) activities of cortical neurons simultaneously with extracellular (EC) unit activities and field potentials of neighboring cells in cat cortex, after a large transection of the white matter underneath the suprasylvian gyrus, in acute and chronic conditions (at 2, 4, and 6 weeks) in ketamine-xylazine-anesthetized cats. Using EC spikes to compute the spike-triggered averages of IC membrane potential, we found an increased connection probability and efficacy between cortical neurons weeks after cortical trauma. Inhibitory interactions showed no significant changes in the traumatized cortex compared with control. The increased synaptic efficacy was accompanied by enhanced input resistance and intrinsic excitability of cortical neurons, as well as by increased duration of silent network periods. Our electrophysiological data revealed functional consequences of previously reported anatomical changes in the injured cortex. We suggest that homeostatic synaptic plasticity compensating the decreased activity in the undercut cortex leads to an uncontrollable cortical hyperexcitability and seizure generation.	[Avramescu, Sinziana; Timofeev, Igor] Univ Laval Robert Giffard, Ctr Rech, Quebec City, PQ G1J 2G3, Canada	Timofeev, I (corresponding author), Univ Laval Robert Giffard, Ctr Rech, 2601 Chem Canardiere, Quebec City, PQ G1J 2G3, Canada.	igor.timofeev@phs.ulaval.ca	Timofeev, Igor/E-8828-2012; Timofeev, Igor/AAP-7529-2021	Timofeev, Igor/0000-0002-1389-5857			Abbott LF, 2000, NAT NEUROSCI, V3, P1178, DOI 10.1038/81453; AVRAMESCU S, 2006, SOC NEUR ABSTR, V32; Bausch SB, 2006, J NEUROPHYSIOL, V96, P2151, DOI 10.1152/jn.00355.2006; Berninger B, 1999, LEARN MEMORY, V6, P232; Bladin CF, 2000, ARCH NEUROL-CHICAGO, V57, P1617, DOI 10.1001/archneur.57.11.1617; Burrone J, 2002, NATURE, V420, P414, DOI 10.1038/nature01242; Bush PC, 1999, J NEUROPHYSIOL, V82, P1748; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chen Q, 2007, J NEUROSCI, V27, P542, DOI 10.1523/JNEUROSCI.3607-06.2007; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; Contreras D, 1996, J PHYSIOL-LONDON, V494, P251, DOI 10.1113/jphysiol.1996.sp021488; CONTRERAS D, 1995, J NEUROSCI, V15, P604; Crochet S, 2005, EUR J NEUROSCI, V21, P1030, DOI 10.1111/j.1460-9568.2005.03932.x; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Davis GW, 2001, ANNU REV PHYSIOL, V63, P847, DOI 10.1146/annurev.physiol.63.1.847; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Desai NS, 1999, NAT NEUROSCI, V2, P515; Dinner Dudley S., 1993, P654; ESPLIN MS, 1994, EPILEPSIA, V35, P911, DOI 10.1111/j.1528-1157.1994.tb02533.x; FISHMAN PS, 1993, J NEUROTRAUM, V10, P457, DOI 10.1089/neu.1993.10.457; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; FUKUDA A, 1992, J NEUROPHYSIOL, V68, P28; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Gray CM, 1996, SCIENCE, V274, P109, DOI 10.1126/science.274.5284.109; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; HOUSER CR, 1990, J NEUROSCI, V10, P267; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Jacobs KM, 2000, EPILEPSIA, V41, pS153, DOI 10.1111/j.1528-1157.2000.tb01574.x; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; KUANG RZ, 1990, J COMP NEUROL, V302, P461, DOI 10.1002/cne.903020304; Li HF, 2005, J NEUROPHYSIOL, V93, P146, DOI 10.1152/jn.00665.2004; Lowenstein D H, 1996, Epilepsy Res Suppl, V11, P45; Markram H, 1998, P NATL ACAD SCI USA, V95, P5323, DOI 10.1073/pnas.95.9.5323; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Massimini M, 2001, J NEUROPHYSIOL, V85, P1346; Matsumura M, 1996, J NEUROSCI, V16, P7757; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MCCORMICK DA, 1987, J PHYSIOL-LONDON, V393, P743, DOI 10.1113/jphysiol.1987.sp016851; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; MORRIS ME, 1991, J NEUROPHYSIOL, V65, P157; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; Nita DA, 2006, J NEUROPHYSIOL, V95, P902, DOI 10.1152/jn.00742.2005; Nita DA, 2007, CEREB CORTEX, V17, P272, DOI 10.1093/cercor/bhj145; Perucca E, 1998, EPILEPSIA, V39, P5, DOI 10.1111/j.1528-1157.1998.tb01268.x; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; PURPURA DP, 1961, EXP NEUROL, V4, P377, DOI 10.1016/0014-4886(61)90025-5; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; Rudolph M, 2007, J NEUROSCI, V27, P5280, DOI 10.1523/JNEUROSCI.4652-06.2007; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; SEIGNEUR J, 2007, SOC NEUR ABSTR, V33; Steriade M, 1998, J NEUROPHYSIOL, V79, P483; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Thomson AM, 1996, J PHYSIOL-LONDON, V496, P81, DOI 10.1113/jphysiol.1996.sp021667; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Trasande CA, 2007, J CLIN NEUROPHYSIOL, V24, P154, DOI 10.1097/WNP.0b013e318033787f; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248; TSUKAHARA N, 1975, J NEUROPHYSIOL, V38, P1359; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; VILLABLANCA JR, 1988, BRAIN RES, V453, P17, DOI 10.1016/0006-8993(88)90139-4; Volgushev M, 2006, J NEUROSCI, V26, P5665, DOI 10.1523/JNEUROSCI.0279-06.2006; Waters J, 2006, J NEUROSCI, V26, P8267, DOI 10.1523/JNEUROSCI.2152-06.2006; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	75	58	58	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 2	2008	28	27					6760	6772		10.1523/JNEUROSCI.0643-08.2008			13	Neurosciences	Neurosciences & Neurology	323BF	WOS:000257418300002	18596152	Bronze, Green Published			2021-06-18	
J	Schlenk, F; Nagel, A; Graetz, D; Sarrafzadeh, AS				Schlenk, Florian; Nagel, Alexandra; Graetz, Daniela; Sarrafzadeh, Asita S.			Hyperglycemia and cerebral glucose in aneurysmal subarachnoid hemorrhage	INTENSIVE CARE MEDICINE			English	Article						subarachnoid hemorrhage; cerebral metabolism; microdialysis; glucose; hyperglycemia; hyperglycolysis	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; ISCHEMIC NEUROLOGICAL DEFICITS; COMBINED MICRODIALYSIS; BEDSIDE MICRODIALYSIS; STRESS HYPERGLYCEMIA; HEAD-INJURY; VASOSPASM; METABOLISM; LACTATE	Objective: To determine whether hyperglycemia exerts deleterious effects via cerebral energy metabolism and to illuminate the effects of cerebral high/low glucose in patients with aneurysmal subarachnoid hemorrhage. Design and setting: Prospective, nonrandomized single-center study over a 2-year period in an intensive care unit at a primary-level university hospital. Patients: 28 subarachnoid hemorrhage patients (age 53 +/- 10 years, WFNS grade 2.8 +/- 1.5)classified as asymptomatic (n = 5) or symptomatic with acute focal or delayed ischemic neurological deficits (n = 23). Measurements and results: Hyperglycemia (> 7.8 mmol/l; > 140 mg/dl) was more frequent in symptomatic patients and was reflected in higher glycerol concentrations than in asymptomatic patients. In all patients a microdialysis catheter was inserted into the tissue at risk; dialysates were collected hourly for 10 days. Cerebral low-glucose episodes (< 0.6 mmol/l) and high-glucose episodes (> 2.6 mmol/l) occurred independently of blood glucose levels. During high-glucose episodes cerebral microdialysate levels were normal, while cerebral low glucose, occurring more frequently in symptomatic patients, was associated with severe cellular distress (increase in lactate/pyruvate ratio, glutamate, glycerol) and with unfavorable outcome if combined with hyperglycemia. Conclusions: Although hyperglycemia was more frequent in symptomatic patients and associated with high glycerol levels, hyperglycemia was not related to cerebral high glucose. It appears that the association of adverse outcome with acute-phase hyperglycemia is not mediated by cerebral glucose metabolism. Cerebral low glucose was associated with severe metabolic distress and may present a target for therapy to improve clinical outcome.	[Schlenk, Florian; Nagel, Alexandra; Graetz, Daniela; Sarrafzadeh, Asita S.] Charite Campus Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany	Sarrafzadeh, AS (corresponding author), Charite Campus Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de					Alberti O, 2000, CLIN NEUROL NEUROSUR, V102, P78, DOI 10.1016/S0303-8467(00)00067-6; Allport LE, 2004, STROKE, V35, P1886, DOI 10.1161/01.STR.0000133687.33868.71; Badjatia N, 2005, CRIT CARE MED, V33, P1603, DOI 10.1097/01.CCM.0000168054.60538.2B; Bell DA, 2005, BRIT J NEUROSURG, V19, P21, DOI 10.1080/02688690500089423; BEREK K, 1992, LANCET, V339, P68, DOI 10.1016/0140-6736(92)90202-E; BERGER L, 1986, STROKE, V17, P865, DOI 10.1161/01.STR.17.5.865; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; DRAKE CG, 1988, J NEUROSURG, V68, P985; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; FEIN JM, 1974, J NEUROSURG, V41, P49, DOI 10.3171/jns.1974.41.1.0049; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Frontera JA, 2006, STROKE, V37, P199, DOI 10.1161/01.STR.0000194960.73883.0f; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; JENNETT B, 1975, LANCET, V1, P480; Kerner A, 2007, NEUROL RES, V29, P647, DOI 10.1179/016164107X248983; Lanzino G, 1999, J NEUROSURG, V90, P1018, DOI 10.3171/jns.1999.90.6.1018; LANZINO G, 1993, J NEUROSURG, V79, P885, DOI 10.3171/jns.1993.79.6.0885; Oertel MF, 2007, J CLIN NEUROSCI, V14, P948, DOI 10.1016/j.jocn.2006.11.002; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROBERTSON CS, 1988, J TRAUMA, V28, P1523, DOI 10.1097/00005373-198811000-00002; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schurr A, 2001, J NEUROSCI RES, V66, P782, DOI 10.1002/jnr.10065; Seaquist ER, 2001, DIABETES, V50, P2203, DOI 10.2337/diabetes.50.10.2203; Song EC, 2003, STROKE, V34, P2215, DOI 10.1161/01.STR.0000088060.83709.2C; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wass CT, 1996, MAYO CLIN PROC, V71, P801; WOO E, 1988, STROKE, V19, P1359, DOI 10.1161/01.STR.19.11.1359	40	58	63	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUL	2008	34	7					1200	1207		10.1007/s00134-008-1044-5			8	Critical Care Medicine	General & Internal Medicine	318WL	WOS:000257123400006	18320167				2021-06-18	
J	Dikranian, K; Cohen, R; Mac Donald, C; Pan, Y; Brakefield, D; Bayly, P; Parsadanian, A				Dikranian, K.; Cohen, R.; Mac Donald, C.; Pan, Y.; Brakefield, D.; Bayly, P.; Parsadanian, A.			Mild traumatic brain injury to the infant mouse causes robust white matter axonal degeneration which precedes apoptotic death of cortical and thalamic neurons	EXPERIMENTAL NEUROLOGY			English	Article						mild traumatic brain injury; neuronal apoptosis; caspase-3; axonal degeneration; amyloid precursor protein; electron microscopy	QUANTITATIVE-ANALYSIS; IMMATURE RAT; NEURODEGENERATION; CHILDREN; CORTEX; MODEL; VULNERABILITY; ACTIVATION; TRANSPORT; PATHWAYS	The immature brain in the first several years of childhood is very vulnerable to trauma. Traumatic brain injury (TBI) during this critical period often leads to neuropathological and cognitive impairment. Previous experimental studies in rodent models of infant TBI were mostly concentrated on neuronal degeneration, while axonal injury and its relationship to cell death have attracted much less attention. To address this, we developed a closed controlled head injury model in infant (P7) mice and characterized the temporospatiall pattern of axonal degeneration and neuronal cell death in the brain following mild injury. Using amyloid precursor protein (APP) as marker of axonal injury we found that mild head trauma causes robust axonal degeneration in the cingulum/external capsule as early as 30 min post-impact. These levels of axonal injury persisted throughout a 24 h period, but significantly declined by 48 h. During the first 24 h injured axons underwent significant and rapid pathomorphological changes. Initial small axonal swellings evolved into larger spheroids and club-like swellings indicating the early disconnection of axons. Ultrastructural analysis revealed compaction of organelles, axolemmal and cytoskeletal defects. Axonal degeneration was followed by profound apoptotic cell death in the posterior cingulate and retrosplenial cortex and anterior thalamus which peaked between 16 and 24 h post-injury. At early stages post-injury no evidence of excitotoxic neuronal death at the impact site was found. At 48 h apoptotic cell death was reduced and paralleled with the reduction in the number of APP-labeled axonal profiles. Our data suggest that early degenerative response to injury in axons of the cingulum and external capsule may cause disconnection between cortical and thalamic neurons, and lead to their delayed apoptotic death. (C) 2008 Elsevier Inc. All rights reserved.	[Cohen, R.; Mac Donald, C.; Pan, Y.; Brakefield, D.; Parsadanian, A.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Cohen, R.; Mac Donald, C.; Pan, Y.; Brakefield, D.; Parsadanian, A.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [Dikranian, K.] Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA; [Bayly, P.] Washington Univ, Dept Biomed Engn, St Louis, MO 63110 USA; [Bayly, P.] Washington Univ, Dept Mech & Aerosp Engn, St Louis, MO 63110 USA	Parsadanian, A (corresponding author), Washington Univ, Dept Neurol, 660 S Euclid Ave, St Louis, MO 63110 USA.	parsadaniana@neuro.wustl.edu		Bayly, Philip/0000-0003-4303-0704	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS042794, R01 NS042794-05, R01 NS042794] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042794] Funding Source: NIH RePORTER		Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bailey CDC, 2004, J NEUROCHEM, V91, P1369, DOI 10.1111/j.1471-4159.2004.02825.x; Bayly PV, 2006, BRAIN RES, V1107, P70, DOI 10.1016/j.brainres.2006.05.102; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burek MJ, 1999, CELL DEATH AND DISEASES OF THE NERVOUS SYSTEM, P145; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Conti AC, 1998, J NEUROSCI, V18, P5663; Craig A, 2003, EXP NEUROL, V181, P231, DOI 10.1016/S0014-4886(03)00032-3; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; DOBBING J, 1973, ARCH DIS CHILD, V48, P757, DOI 10.1136/adc.48.10.757; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magill CK, 2007, EXP NEUROL, V207, P64, DOI 10.1016/j.expneurol.2007.05.028; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; Mechawar N, 2001, NEUROSCIENCE, V108, P555, DOI 10.1016/S0306-4522(01)00389-X; Natale JE, 2002, NEUROSCIENCE, V112, P665, DOI 10.1016/S0306-4522(02)00098-2; Paxinos G., 2007, ATLAS DEV MOUSE BRAI; PRICE JL, 1995, RAT NERVOUS SYSTEM; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Repici M, 2003, NEUROSCIENCE, V117, P859, DOI 10.1016/S0306-4522(02)00968-5; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; SHIBATA H, 1993, J COMP NEUROL, V330, P533, DOI 10.1002/cne.903300409; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131	52	58	60	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2008	211	2					551	560		10.1016/j.expneurol.2008.03.012			10	Neurosciences	Neurosciences & Neurology	306UH	WOS:000256272800029	18440507	Green Accepted			2021-06-18	
J	Hoffman, AN; Malena, RR; Westergom, BP; Luthra, P; Cheng, JP; Aslam, HA; Zafonte, RD; Kline, AE				Hoffman, Ann N.; Malena, Rebecca R.; Westergom, Brian P.; Luthra, Pallavi; Cheng, Jeffrey P.; Aslam, Haris A.; Zafonte, Ross D.; Kline, Anthony E.			Environmental enrichment-mediated functional improvement after experimental traumatic brain injury is contingent on task-specific neurobehavioral experience	NEUROSCIENCE LETTERS			English	Article						beam-walking; controlled cortical impact; functional recovery; learning and memory; Morris water maze; neurobehavior; traumatic brain injury	RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; COGNITIVE DEFICITS; RECOVERY; RATS; HYPOTHERMIA; EXERCISE; PROTECTION; 8-OH-DPAT; SURVIVAL; EFFICACY	Environmental enrichment (EE) is superior to standard (STD) housing in promoting functional recovery after traumatic brain injury (TBI). However, whether the EE-mediated benefits after TBI are dependent on exposure to enrichment during neurobehavioral training has not been elucidated. To address this issue, isoflurane-anesthetized adult male rats received either a cortical impact or sham injury and were then randomly assigned to early EE, delayed EE, continuous EE or no EE (i.e., STD conditions). Continuous EE or no EE was initiated immediately after surgery and continued for the duration of the study. Early EE began directly after surgery, continued for I week, and was then followed by STD living (2 rats per cage) for the remainder of the study, while delayed EE commenced I week after early STD housing. Functional outcome was assessed with established motor and cognitive tests on post-injury days 1-5 and 14-18, respectively. CA(1)/CA(3) neurons were quantified at 3 weeks. CA(3) cell loss was significantly attenuated in the TBI +continuous EE group versus the TBI + no EE group. Beam-walking was facilitated in the TBI groups that received either early or continuous EE versus those receiving delayed or no EE. Cognitive training was enhanced in the TBI groups that received continuous or delayed EE versus the early EE or no EE groups. These data suggest that EE-mediated functional improvement after TBI is contingent on task-specific neurobehavioral experience. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	[Hoffman, Ann N.; Malena, Rebecca R.; Westergom, Brian P.; Luthra, Pallavi; Cheng, Jeffrey P.; Aslam, Haris A.; Zafonte, Ross D.; Kline, Anthony E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Hoffman, Ann N.; Malena, Rebecca R.; Westergom, Brian P.; Luthra, Pallavi; Cheng, Jeffrey P.; Aslam, Haris A.; Zafonte, Ross D.; Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700, R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD046700-01A1, R03 HD043851-02, R03 HD043851, HD043851, R03 HD043851-01, R01 HD046700-04, R01 HD069620, R01 HD046700, R01 HD046700-02, R01 HD046700-03, HD046700] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS060005] Funding Source: Medline		BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Nithianantharajah J, 2004, NEUROBIOL LEARN MEM, V81, P200, DOI 10.1016/j.nlm.2004.02.002; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001	22	58	59	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	FEB 6	2008	431	3					226	230		10.1016/j.neulet.2007.11.042			5	Neurosciences	Neurosciences & Neurology	263PK	WOS:000253228800008	18162321	Green Accepted			2021-06-18	
J	Chung, RS; Hidalgo, J; West, AK				Chung, R. S.; Hidalgo, J.; West, A. K.			New insight into the molecular pathways of metallothionein-mediated neuroprotection and regeneration	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; emtin; megalin; metallothionein; neuron	TRAUMATIC BRAIN-INJURY; REACTIVE ASTROCYTES; INFLAMMATORY RESPONSE; ZINC; CNS; EXPRESSION; MEGALIN; COPPER; INTERLEUKIN-6; PROTECT	There is a large body of evidence demonstrating that metallothioneins (MTs) expressed in astrocytes following CNS injury, exhibit both neuroprotective and neuroregenerative properties and are critical for recovery outcomes. As these proteins lack signal peptides, and have well characterized free radical scavenging and heavy metal binding properties, the neuroprotective functions of MTs have been attributed to these intracellular roles. However, there is an increasing realization that the neuroprotective functions of MTs may also involve an extracellular component. In this issue of Journal of Neurochemistry, Ambjorn et al. reveal considerable insight into this novel function of MTs. In this review, we examine the seminal work of Ambjorn et al. in the context of our current understanding of the role of MT in astrocyte-neuron interactions in the injured brain, and also discuss the significant therapeutic potential of their work.	[Chung, R. S.; West, A. K.] Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Hobart, Tas 7001, Australia; [Hidalgo, J.] Autonomous Univ Barcelona, Fac Sci, Anim Physiol Unit, Dept Cellular Biol Physiol & Immunol, Barcelona, Spain; [Hidalgo, J.] Autonomous Univ Barcelona, Fac Sci, Inst Neurosci, Barcelona, Spain	Chung, RS (corresponding author), Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Private Bag 58, Hobart, Tas 7001, Australia.	rschung@utas.edu.au	Hidalgo, Juan/C-9082-2011; Chung, Roger/ABF-8395-2020	Hidalgo, Juan/0000-0003-0921-1122; Chung, Roger/0000-0002-9286-947X			Araque A, 2006, CURR OPIN INVEST DR, V7, P619; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; Carrasco J, 1998, MOL BRAIN RES, V57, P221, DOI 10.1016/S0169-328X(98)00087-4; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562; Chung RS, 2004, J NEUROCHEM, V88, P454, DOI 10.1046/j.1471-4159.2003.02193.x; Chung RS, 2003, J NEUROSCI, V23, P3336; Chung RS, 2004, NEUROSCIENCE, V123, P595, DOI 10.1016/j.neuroscience.2003.10.019; Escartin C, 2006, J NEUROCHEM, V99, P393, DOI 10.1111/j.1471-4159.2006.04083.x; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; FITZGERALD M, 2007, IN PRESS EXP BRAIN R; GASULL T, 1994, AM J PHYSIOL, V266, pE760; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; HANNILA SS, 2007, UNPUB EXP NEUROL; HIDALGO J, 1988, AM J PHYSIOL, V254, pE71; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Klassen RB, 2004, AM J PHYSIOL-RENAL, V287, pF393, DOI 10.1152/ajprenal.00233.2003; Kohler LB, 2003, BRAIN RES, V992, P128, DOI 10.1016/j.brainres.2003.08.049; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Mann JJ, 2005, APOPTOSIS, V10, P369, DOI 10.1007/s10495-005-0811-9; Maret W, 2003, J NUTR, V133, p1460S, DOI 10.1093/jn/133.5.1460S; May P, 2005, CELL MOL LIFE SCI, V62, P2325, DOI 10.1007/s00018-005-5231-z; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; NIELSON KB, 1984, J BIOL CHEM, V259, P4941; NIELSON KB, 1983, J BIOL CHEM, V258, P3063; Penkowa M, 2006, J NEUROSCI RES, V83, P974, DOI 10.1002/jnr.20790; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Penkowa M, 1999, J NEUROSCI, V19, P2535; PENKOWA M, 2006, IN PRESS J NEUROSCI; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; QUINTANA A, 2007, IN PRESS J NEUROSCI; SIDDIQ MM, 2006, SFN ABSTR; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Takahashi Y, 2005, J CELL PHYSIOL, V202, P563, DOI 10.1002/jcp.20158; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; West AK, 2004, REV NEUROSCIENCE, V15, P157; Wolff NA, 2006, J PHARMACOL EXP THER, V318, P782, DOI 10.1124/jpet.106.102574; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984	46	58	62	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2008	104	1					14	20		10.1111/j.1171-4159.2007.05026.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	241QP	WOS:000251671200002	17986229				2021-06-18	
J	Salim, A; Hadjizacharia, P; Brown, C; Inaba, K; Teixeira, PGR; Chan, L; Rhee, P; Demetriades, D				Salim, Ali; Hadjizacharia, Pantelis; Brown, Carlos; Inaba, Kenji; Teixeira, Pedro G. R.; Chan, Linda; Rhee, Peter; Demetriades, Demetrios			Significance of troponin elevation after severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	66th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 27-29, 2007	Las Vegas, NV	Amer Assoc Surg Trauma		troponin; traumatic head injury; beta blocker; outcome	CRITICALLY-ILL PATIENTS; SUBARACHNOID HEMORRHAGE; MYOCARDIAL INJURY; CATECHOLAMINES; ABNORMALITIES; HYPERGLYCEMIA; DYSFUNCTION; MORTALITY; LEVEL; DEATH	Introduction: Elevation of serum troponin (cTnI) after nontraumatic cerebral insult has been associated with an adverse prognosis. This association has not been well documented in traumatic brain injury (TBI). Objective: To evaluate the association and prognostic significance of cTnI elevation in severe TBI. To evaluate the role of beta-blocker (BB) therapy in TBI patients with elevated cTnI. Methods: Retrospective review of all blunt trauma patients with severe TBI (head Abbreviated Injury Scale score [AIS] >= 3) admitted to the intensive care unit (ICU) with serial TnI measurements at a Level I trauma center from January 1998 to December 2005. Patients with AIS score >= 3 to other body regions were excluded. Univariate and multivariate logistic regression was performed to determine prognostic significance of TnI elevation. Results: There were 420 severe blunt TBI patients who had serial cTnI measurements during the study period. One hundred twenty-five (29.8%) had an elevated admission cTnI. TBI patients with an elevated cTnI had a lower admission Glasgow Coma Scale (GCS) score (7.5 vs. 8.7, p < 0.05), higher Injury Severity Score (27.4 vs. 24.8, p < 0.01), and increased hospital mortality (44% vs. 29%, p < 0.05), compared with TBI patients with a normal cTnI. Increasing severity of head injury was associated with an increasing cTnI (TnI level 0.8 mu g/L for head AIS score = 3 vs. TnI Level 10.3 mu g/L for head AIS score = 4, 5, p = 0.09). After adjusting for injury severity, elevated cTnI was an independent predictor for mortality (Odds ratio [OR[: 8.5; 95% confidence interval [CI]: 3.46, 22.15, p < 0.0001). BB therapy was associated with a significant survival advantage (OR: 0.38; 95% CI: 0.15, 0.87, p = 0.03) in TBI patients with any elevation of cTnI. Conclusion: Elevated TnI is frequently observed after severe TBI. The level of TnI correlates with the severity of head injury and is an independent predictor of adverse outcomes. BB therapy is associated with a survival advantage in TBI patients with elevated cTnI.	[Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Hadjizacharia, Pantelis; Brown, Carlos; Inaba, Kenji; Teixeira, Pedro G. R.; Chan, Linda; Rhee, Peter; Demetriades, Demetrios] Univ So Calif, Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA USA; [Brown, Carlos] Bretonneau Hosp, Austin, TX USA; [Rhee, Peter] Univ Arizona, Tucson, AZ USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Teixeira, Pedro/H-2239-2011; INABA, KENJI/AAC-8532-2020	Teixeira, Pedro/0000-0002-7258-7977; 			Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Babuin L, 2005, CAN MED ASSOC J, V173, P1191, DOI 10.1503/cmaj/051291; Banki NM, 2005, CIRCULATION, V112, P3314, DOI 10.1161/CIRCULATIONAHA.105.558239; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COOPER DKC, 1989, ANN ROY COLL SURG, V71, P261; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Di Angelantonio E, 2005, J NEUROL NEUROSUR PS, V76, P76, DOI 10.1136/jnnp.2004.041491; Dixit S, 2000, ARCH INTERN MED, V160, P3153, DOI 10.1001/archinte.160.20.3153; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P115, DOI 10.1007/BF00571658; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hamm CW, 2002, CIRCULATION, V106, P2871, DOI 10.1161/01.CIR.0000044342.50593.63; Hays A, 2006, NEUROLOGY, V66, P1330, DOI 10.1212/01.wnl.0000210523.22944.9b; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Jeremias A, 2005, ANN INTERN MED, V142, P786, DOI 10.7326/0003-4819-142-9-200505030-00015; King DA, 2005, CRIT CARE, V9, pR390, DOI 10.1186/cc3731; KOLIN A, 1984, STROKE, V15, P990, DOI 10.1161/01.STR.15.6.990; Kollef MH, 1997, CHEST, V111, P1340, DOI 10.1378/chest.111.5.1340; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lim W, 2005, CRIT CARE, V9, pR636, DOI 10.1186/cc3816; Lim W, 2006, AM J CRIT CARE, V15, P280; Lindstaedt M, 2002, J TRAUMA, V52, P479, DOI 10.1097/00005373-200203000-00011; Lutz-Dettinger N, 2001, PEDIATR CLIN N AM, V48, P715, DOI 10.1016/S0031-3955(05)70336-9; Maramattom BV, 2006, MAYO CLIN PROC, V81, P192, DOI 10.4065/81.2.192; Martin M, 2005, J TRAUMA, V59, P1086, DOI 10.1097/01.ta.0000190249.19668.37; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; MAYER SA, 1994, NEUROLOGY, V44, P815, DOI 10.1212/WNL.44.5.815; MCLEOD AA, 1982, BRIT HEART J, V47, P221; Naidech AM, 2005, CIRCULATION, V112, P2851, DOI 10.1161/CIRCULATIONAHA.105.533620; NOVITZKY D, 1989, TRANSPLANT P, V21, P2567; NYGAARD CE, 1990, J TRAUMA, V30, P728, DOI 10.1097/00005373-199006000-00013; PILATI CF, 1990, P SOC EXP BIOL MED, V193, P225; Quenot JP, 2005, CHEST, V128, P2758, DOI 10.1378/chest.128.4.2758; Razek T, 2000, SURG CLIN N AM, V80, P1021, DOI 10.1016/S0039-6109(05)70111-0; Roongsritong C, 2004, CHEST, V125, P1877, DOI 10.1378/chest.125.5.1877; Salim A, 2001, J TRAUMA, V50, P237, DOI 10.1097/00005373-200102000-00008; Schuiling WJ, 2005, J NEUROL NEUROSUR PS, V76, P1565, DOI 10.1136/jnnp.2004.060913; Velmahos GC, 2003, J TRAUMA, V54, P45, DOI 10.1097/00005373-200301000-00006; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zaroff JG, 2000, J AM SOC ECHOCARDIOG, V13, P774, DOI 10.1067/mje.2000.105763	41	58	61	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2008	64	1					46	52		10.1097/TA.0b013e31815eb15a			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	250UE	WOS:000252325700012	18188098				2021-06-18	
J	Nakase-Richardson, R; Yablon, SA; Sherer, M				Nakase-Richardson, Risa; Yablon, Stuart A.; Sherer, Mark			Prospective comparison of acute confusion severity with duration of post-traumatic amnesia in predicting employment outcome after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; GALVESTON ORIENTATION; RECOVERY; SCALE	Background: Measurement of the duration of post-traumatic amnesia ( PTA) is common practice, serving as an important index of the severity of traumatic brain injury (TBI) and a predictor of functional outcome. However, controversy exists regarding the nature of PTA; some studies indicate that it is a confusional state with symptoms that extend beyond disorientation and amnesia. Objective: To evaluate the contribution of the severity of acute confusion 1 month after TBI to prediction of employment at 1 year after injury, comparing it with PTA duration. Methods: Prospective study involving 171 participants with complete data, who met the study criteria, from 228 consecutive TBI Model System admissions. Outcome measures included weekly administration of the Delirium Rating Scale-Revised-98 (DeIRS-R98) to measure the severity of acute confusion. Evaluations closest to 1 month after injury were used for study purposes. Duration of PTA was defined as the interval from injury until two consecutive Galveston Orientation and Amnesia Test scores of >= 76 were obtained within a period of 24-72 h. Univariable and multivariable logistic regression were used to predict employment status at 1 year after injury. Results: Age, education and DeIRS-R98 were significant predictors accounting for 34% of outcome variance. Individuals with greater confusion severity at 1 month after injury, older age and lower levels of education were less likely to be employed at 1 year after injury. Severity of confusion was more strongly associated with employment outcome (r(s) = 0.39) than was PTA duration (r(s) = 0.34). Conclusions: In addition to demographic indices, severity of acute confusion makes a unique contribution to predicting late outcome after TBI.	Methodist Rehabil Ctr, Dept Neuropsychol, Brain Injury Program, Jackson, MS 39216 USA	Nakase-Richardson, R (corresponding author), Methodist Rehabil Ctr, Dept Neuropsychol, Brain Injury Program, 1350 E Woodrow Wilson Dr, Jackson, MS 39216 USA.	nakase@aol.com					Ahmed S, 2000, BRAIN INJURY, V14, P765; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P124; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	27	58	59	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2007	78	8					872	876		10.1136/jnnp.2006.104190			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	190IW	WOS:000248053500021	17178822	Green Published			2021-06-18	
J	Koedel, U; Merbt, UM; Schmidt, C; Angele, B; Popp, B; Wagner, H; Pfister, HW; Kirschning, CJ				Koedel, Uwe; Merbt, Ulrike Michaela; Schmidt, Caroline; Angele, Barbara; Popp, Bernadette; Wagner, Hermann; Pfister, Hans-Walter; Kirschning, Carsten J.			Acute brain injury triggers MyD88-dependent, TLR2/4-independent inflammatory responses	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TOLL-LIKE RECEPTOR-4; CLOSED-HEAD INJURY; ISCHEMIA-REPERFUSION INJURY; INNATE IMMUNE-RESPONSE; DENDRITIC CELLS; INTERLEUKIN-1 RECEPTOR; NEUTROPHIL INFILTRATION; SIGNALING PATHWAYS; SCAVENGER RECEPTOR; CEREBRAL-ISCHEMIA	Endogenous molecules released from disrupted cells and extracellular matrix degradation products activate Toll-like receptors (TLRs) and, thus, might contribute to immune activation after tissue injury. Here, we show that aseptic, cold-induced cortical injury triggered an acute immune response that involves increased production of multiple cytokines/chemokines accompanied by neutrophil recruitment to the lesion site. We observed selective reductions in injury-induced cytokine/chemokine expression as well as in neutrophil accumulation in mice lacking the common TLR signaling adaptor MyD88 compared with wild-type mice. Notably, attenuation of the immune response was paralleled by a reduction in lesion size. Neutrophil depletion of wild-type mice and transplantation of MyD88-deficient bone marrow into lethally irradiated wild-type recipients had no substantial impact on injury-induced expression of cytokines/chemokines and on lesion development. In contrast to MyD88 deficiency, double deficiency of TLR2 and TLR4-despite the two receptors being activated by specific endogenous molecules associated to danger and signal through MyD88-altered neither immune response nor extent of tissue lesion size on injury. our data indicate modulation of the neuroinflammatory response and lesion development after aseptic cortical injury through MyD88-dependent but TLR2/4-independent signaling by central nervous system resident non-myeloid cells.	Univ Munich, Klinikum Grosshadern, Dept Neurol, D-81377 Munich, Germany; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany	Koedel, U (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurol, Marchioninistr 15, D-81377 Munich, Germany.	uwe.koedel@med.uni-muenchen.de					Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Babcock AA, 2003, J NEUROSCI, V23, P7922; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Basu A, 2005, J CEREBR BLOOD F MET, V25, P17, DOI 10.1038/sj.jcbfm.9600002; Basu A, 2002, J NEUROSCI, V22, P6071; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Bjorkbacka H, 2004, NAT MED, V10, P416, DOI 10.1038/nm1008; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brentano F, 2005, ARTHRITIS RHEUM-US, V52, P2656, DOI 10.1002/art.21273; Cao CX, 2007, BIOCHEM BIOPH RES CO, V353, P509, DOI 10.1016/j.bbrc.2006.12.057; Carter RJ, 1999, J NEUROSCI, V19, P3248; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; Franke H, 2006, PFLUG ARCH EUR J PHY, V452, P622, DOI 10.1007/s00424-006-0071-8; Fukumoto N, 2004, J IMMUNOL, V173, P1620, DOI 10.4049/jimmunol.173.3.1620; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Iseki K, 2002, GLIA, V39, P1, DOI 10.1002/glia.10078; Ishii KJ, 2001, J IMMUNOL, V167, P2602, DOI 10.4049/jimmunol.167.5.2602; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Johnston B, 2003, J IMMUNOL, V171, P2960, DOI 10.4049/jimmunol.171.6.2960; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kielian T, 2004, J NEUROPATH EXP NEUR, V63, P381, DOI 10.1093/jnen/63.4.381; Klein M, 2006, MICROBES INFECT, V8, P974, DOI 10.1016/j.micinf.2005.10.013; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Leemans JC, 2005, J CLIN INVEST, V115, P2894, DOI 10.1172/JCI22832; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Leker RR, 2003, STROKE, V34, P2000, DOI 10.1161/01.STR.0000079817.68944.1E; Lin M, 2007, J LEUKOCYTE BIOL, V81, P786, DOI 10.1189/jlb.0806502; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Mohamadzadeh M, 1996, J IMMUNOL, V156, P3102; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Nakayama T, 2003, J IMMUNOL, V170, P1136, DOI 10.4049/jimmunol.170.3.1136; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Ni HP, 2002, J BIOL CHEM, V277, P12689, DOI 10.1074/jbc.M110729200; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Oyama J, 2004, CIRCULATION, V109, P784, DOI 10.1161/01.CIR.0000112575.66565.84; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Prince JM, 2006, J AM COLL SURGEONS, V202, P407, DOI 10.1016/j.jamcollsurg.2005.11.021; Prinz M, 2006, J CLIN INVEST, V116, P456, DOI 10.1172/JCI26078; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Ru LB, 2005, ARTHRITIS RHEUM-US, V52, P2936, DOI 10.1002/art.21238; Rupprecht TA, 2007, J IMMUNOL, V178, P1861, DOI 10.4049/jimmunol.178.3.1861; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Scheibner KA, 2006, J IMMUNOL, V177, P1272, DOI 10.4049/jimmunol.177.2.1272; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shen XD, 2005, AM J TRANSPLANT, V5, P1793, DOI 10.1111/j.1600-6143.2005.00932.x; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Shimaoka T, 2003, J IMMUNOL, V171, P1647, DOI 10.4049/jimmunol.171.4.1647; Skoberne M, 2004, TRENDS MOL MED, V10, P251, DOI 10.1016/j.molmed.2004.04.001; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Somersan S, 2001, J IMMUNOL, V167, P4844, DOI 10.4049/jimmunol.167.9.4844; Suzuki Y, 2002, BRAIN DEV-JPN, V24, P1; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tani M, 1996, J CLIN INVEST, V98, P529, DOI 10.1172/JCI118821; Tayag EC, 1996, BRAIN RES, V733, P287, DOI 10.1016/0006-8993(96)00669-5; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Vollmer J, 2005, J EXP MED, V202, P1575, DOI 10.1084/jem.20051696; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Wuttge DM, 2004, ARTERIOSCL THROM VAS, V24, P750, DOI 10.1161/01.ATV.0000124102.11472.36; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; YOUN BS, 1995, J IMMUNOL, V155, P2661; Zhao XY, 2003, J IMMUNOL, V171, P2797, DOI 10.4049/jimmunol.171.6.2797	89	58	61	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2007	171	1					200	213		10.2353/ajpath.2007.060821			14	Pathology	Pathology	185LO	WOS:000247712700021	17591966	Green Published			2021-06-18	
J	Samuelsson, C; Hillered, L; Zetterling, M; Enblad, P; Hesselager, G; Ryttlefors, M; Kumlien, E; Lewen, A; Marklund, N; Nilsson, P; Salci, K; Ronne-Engstrom, E				Samuelsson, Carolina; Hillered, Lars; Zetterling, Maria; Enblad, Per; Hesselager, Goran; Ryttlefors, Mats; Kumlien, Eva; Lewen, Anders; Marklund, Niklas; Nilsson, Pelle; Salci, Konstantin; Ronne-Engstrom, Elisabeth			Cerebral glutamine and glutamate levels in relation to compromised energy metabolism: a microdialysis study in subarachnoid hemorrhage patients	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain; glutamate; glutamine; lactate; microdialysis; pyruvate	TRAUMATIC BRAIN-INJURY; IN-VIVO; INTRACEREBRAL MICRODIALYSIS; NEUROINTENSIVE CARE; AMINO-ACIDS; EXTRACELLULAR METABOLITES; BEDSIDE MICRODIALYSIS; C-13 NMR; RELEASE; HIPPOCAMPUS	Astrocytic glutamate (Git) uptake keeps brain interstitial Git levels low. Within the astrocytes Git is converted to glutamine (Gin), which is released and reconverted to Git in neurons. The Git-Gin cycle is energy demanding and impaired energy metabolism has been suggested to cause low interstitial Gin/Glt ratios. Using microdialysis (MD) measurements from visually noninjured cortex in 33 neurointensive care patients with subarachnoid hemorrhage, we have determined how interstitial Git and Gin, as a reflection of the Git-Gin cycle turnover, relate to perturbed energy metabolism. A total of 3703 hourly samples were analyzed. The lactate/pyruvate (UP) ratios correlated to the Gln/Glt ratios (r = -0.66), but this correlation was not stronger than the correlation between UP and Git (r=0.68) or the correlation between lactate and Glt (r=0.65). A novel observation was a linear relationship between interstitial pyruvate and Gin (r = 0.52). There were 13 periods (404 h) of 'energy crisis', defined by UP ratios above 40. All were associated with high interstitial Git levels. Periods with UP ratios above 40 and low pyruvate levels were associated with decreased interstitial Gin levels, suggesting ischemia and failing astrocytic Gin synthesis. Periods with UP ratios above 40 and normal or high pyruvate levels were associated with increased interstitial Gin levels, which may represent an astrocytic hyperglycolytic response to high interstitial Git levels. The results imply that moderately elevated UP ratios cannot always be interpreted as failing energy metabolism and that interstitial pyruvate levels may discriminate whether or not there is sufficient astrocytic capacity for Glt-Gln cycling in the brain.	Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden	Samuelsson, C (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden.	carolina.samuelsson@neurokir.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Marklund, Niklas/0000-0002-9797-5626; Kumlien, Eva/0000-0002-1952-8791			Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x; Buck CR, 2003, EXP NEUROL, V181, P149, DOI 10.1016/S0014-4886(03)00043-8; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cavus I, 2005, ANN NEUROL, V57, P226, DOI 10.1002/ana.20380; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dohmen C, 2003, STROKE, V34, P2152, DOI 10.1161/01.STR.0000083624.74929.32; Engstrom ER, 2005, NEUROSCI LETT, V384, P7, DOI [10.1016/j.neurlet.2005.04.030, 10.1016/j.neulet.2005.04.030]; HAWKINS RA, 2006, J NUTR, V136; Hertz L, 2006, NEUROCHEM INT, V48, P416, DOI 10.1016/j.neuint.2005.12.021; Hertz L, 2004, NEUROCHEM INT, V45, P285, DOI 10.1016/j.neuint.2003.08.016; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Kanamori K, 2004, J NEUROCHEM, V90, P203, DOI 10.1111/j.1471-4159.2004.02478.x; Kanamori K, 2002, J NEUROCHEM, V83, P682, DOI 10.1046/j.1471-4159.2002.01161.x; Kawai N, 1999, J CEREBR BLOOD F MET, V19, P79, DOI 10.1097/00004647-199901000-00009; Labiner DM, 1999, NEUROCHEM RES, V24, P1379, DOI 10.1023/A:1022528522373; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Magistretti PJ, 1999, NEWS PHYSIOL SCI, V14, P177, DOI 10.1152/physiologyonline.1999.14.5.177; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Petroff OAC, 2002, EPILEPSIA, V43, P703, DOI 10.1046/j.1528-1157.2002.38901.x; Raman L, 2005, DEV BRAIN RES, V156, P202, DOI 10.1016/j.devbrainres.2005.02.013; Ramonet D, 2004, HIPPOCAMPUS, V14, P586, DOI 10.1002/hipo.10188; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Samuelsson C, 2003, EPILEPSY RES, V56, P165, DOI 10.1016/j.eplepsyres.2003.09.004; Sarrafzadeh A, 2005, J NEURORADIOLOGY, V32, P348, DOI 10.1016/S0150-9861(05)83168-2; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh A, 2003, STROKE, V34, P1382, DOI 10.1161/01.STR.0000074036.97859.02; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Shen J, 1999, P NATL ACAD SCI USA, V96, P8235, DOI 10.1073/pnas.96.14.8235; Suarez I, 2002, NEUROCHEM INT, V41, P123, DOI 10.1016/S0197-0186(02)00033-5; Suojaranta-Ylinen R, 1996, Nutrition, V12, P327; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Xu GY, 1998, NEUROSCIENCE, V86, P1011, DOI 10.1016/S0306-4522(98)00063-3	41	58	61	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2007	27	7					1309	1317		10.1038/sj.jcbfm.9600433			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	180OL	WOS:000247375000002	17228333	Bronze			2021-06-18	
J	Reicker, LI; Tombaugh, TN; Walker, L; Freedman, MS				Reicker, Lindsay I.; Tombaugh, Tom N.; Walker, Lisa; Freedman, Mark S.			Reaction time: An alternative method for assessing the effects of multiple sclerosis on information processing speed	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						multiple sclerosis; information processing speed; reaction time; computerized tests of information processing; CTIP	SERIAL ADDITION TEST; CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; WORKING-MEMORY; TEST PASAT; CONCUSSION; ATTENTION; RECOVERY; TASK; IMPAIRMENT	The ability of a newly developed measure of information processing to detect deficits in cognitive functioning associated with multiple sclerosis (MS) was investigated. The Computerized Tests of Information Processing (CTIP; Tombaugh, T., & Rees, L. (1999). Computerized Tests of Information Processing (CTIP). Unpublished test. Ottawa, Ontario, Canada: Carleton University) was administered to 60 clinically definite MS patients and 60 healthy controls. MS patients responded significantly slower than controls on the reaction time tests composing the CTIP. Moreover, as the CTIP tests became more difficult (i.e. as processing demands increased), the difference between the performances of the two groups progressively increased. These results suggest the CTIP is sensitive to the cognitive deficits observed in MS and that this measure has the potential to serve as a viable alternative to traditional measures of information processing speed currently in use with MS patients. (C) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Carleton Univ, Dept Psychol, Ottawa, ON K1S 5B6, Canada; Ottawa Hosp, Ottawa, ON, Canada	Reicker, LI (corresponding author), Carleton Univ, Dept Psychol, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada.	lreicker@connect.carleton.ca	Walker, Lisa/AAH-7842-2019	Walker, Lisa/0000-0001-5865-7257			ALKER L, 2006, C EUR COMM TREATM RE; Archibald CJ, 2000, J CLIN EXP NEUROPSYC, V22, P686, DOI 10.1076/1380-3395(200010)22:5;1-9;FT686; Baird BJ, 2004, THESIS CARLETON U OT; Beck A. T., 1996, BECK DEPRESSION INVE; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; Chronicle EP, 1998, NEUROPSYCHOL REHABIL, V8, P273; DELUCA J, 1993, ARCH NEUROL-CHICAGO, V50, P301, DOI 10.1001/archneur.1993.00540030065016; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Denney DR, 2004, J INT NEUROPSYCH SOC, V10, P948, DOI 10.1017/S1355617704107030; ENTUS A, 1970, PERCEPT PSYCHOPHYS, V7, P143, DOI 10.3758/BF03208643; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Fisk JD, 2001, J INT NEUROPSYCH SOC, V7, P363, DOI 10.1017/S1355617701733103; GODEFROY O, 1994, J NEUROL SCI, V126, P168, DOI 10.1016/0022-510X(94)90268-2; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kail R, 1997, AGING NEUROPSYCHOL C, V4, P157, DOI 10.1080/13825589708256644; Kail R, 1998, J CLIN EXP NEUROPSYC, V20, P98, DOI 10.1076/jcen.20.1.98.1483; KUJALA P, 1994, BRAIN, V117, P1115, DOI 10.1093/brain/117.5.1115; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; MCCAFFREY RJ, 1995, ARCH CLIN NEUROPSYCH, V10, P241, DOI 10.1016/0887-6177(94)00048-U; PROCTOR RW, 1981, PSYCHOL REV, V88, P291, DOI 10.1037/0033-295X.88.4.291; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; RAO SM, 1986, J CLIN EXP NEUROPSYC, V8, P503, DOI 10.1080/01688638608405173; REES L, 2001, NAN RES GRANTS LUNCH; REICKER LI, 2007, UNPUB ABILITY REACTI; Reitan RM., 1985, HALSTEAD REITAN NEUR; Royan J, 2004, ARCH CLIN NEUROPSYCH, V19, P131, DOI 10.1016/S0887-6177(02)00216-0; Rudick R, 1997, ANN NEUROL, V42, P379, DOI 10.1002/ana.410420318; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; Smith AB, 1999, ORG LETT, V1, P2001, DOI 10.1021/ol991166b; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Tombaugh T, 2001, 21 ANN M NAT AC NEUR; TOMBAUGH T, 1999, COMPUTERZIED TESTS I; Tombaugh T. N., 1992, PSYCHOL ASSESSMENT, V4, P193, DOI [10.1037/1040-3590.4.2.193, DOI 10.1037/1040-3590.4.2.193]; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; TOMBAUGH TN, IN PRESS ARCH CLIN N; TOMBAUGH TN, 2006, NORMATIVE DATA COMPU; VANZOMEREN AH, 1978, NEUROLOGY NEUROSURGE, V4, P452; Wechsler D, 1997, WAIS 3 ADM SCORING M; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	47	58	58	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2007	22	5					655	664		10.1016/j.acn.2007.04.008			10	Psychology, Clinical; Psychology	Psychology	191YZ	WOS:000248169200011	17532182	Bronze			2021-06-18	
J	Kalsotra, A; Zhao, J; Anakk, S; Dash, PK; Strobel, HW				Kalsotra, Auinash; Zhao, Jing; Anakk, Sayeepriyadarshini; Dash, Pramod K.; Strobel, Henry W.			Brain trauma leads to enhanced lung inflammation and injury: evidence for role of P4504Fs in resolution	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood brain barrier; cytochrome P450 4Fs; cytokines; leukotriene B4 metabolism; pulmonary inflammation	LEUKOTRIENE B-4; OMEGA-HYDROXYLASES; BIOSYNTHESIS; MOBILIZATION; NEUTROPHILS; CHEMOTAXIS; EXPRESSION; RECEPTOR; RELEASE; SIGNALS	Traumatic brain injury is known to cause several secondary effects, which lead to multiple organ dysfunction syndrome. An acute systemic inflammatory response seems to play an integral role in the development of such complications providing the potential for massive secondary injury. We show that a contusion injury to the rat brain causes large migration of inflammatory cells ( especially macrophages and neutrophils) in the major airways and alveolar spaces at 24 h post-injury, which is associated with enhanced pulmonary leukotriene B-4 (LTB4) production within the lung. However, by 2 weeks after injury, a temporal switch occurs and the resolution of inflammation is underway. We provide evidence that 5-lipoxygenase and Cytochrome P450 4Fs (CYP4Fs), the respective enzymes responsible for LTB4 synthesis and breakdown, play crucial roles in setting the cellular concentration of LTB4. Activation of LTB4 breakdown via induction of CYP4Fs, predominantly in the lung tissue, serves as an endogenous signal to ameliorate further secondary damage. In addition, we show that CYP4Fs are localized primarily in the airways and pulmonary endothelium. Given the fact that adherence to the microvascular endothelium is an initial step in neutrophil diapedesis, the temporally regulated LTB4 clearance in the endothelium presents a novel focus for treatment of pulmonary inflammation after injury.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA	Strobel, HW (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, Vivian L Smith Ctr Neurol Res, POB 20708,6431 Fannin St, Houston, TX 77225 USA.	henry.w.strobel@uth.tmc.edu		Kalsotra, Auinash/0000-0002-1011-0006	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH070054] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS044174, NS35457] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH070054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457, R01NS044174] Funding Source: NIH RePORTER		Bazan NG, 2001, NAT MED, V7, P414, DOI 10.1038/86477; Borovikova LV, 2000, NATURE, V405, P458; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Cui X, 2003, BBA-GEN SUBJECTS, V1619, P325, DOI 10.1016/S0304-4165(02)00491-9; DENZLINGER C, 1985, SCIENCE, V230, P330, DOI 10.1126/science.4048937; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; Kalsotra A, 2003, FEBS LETT, V555, P236, DOI 10.1016/S0014-5793(03)01240-7; KALSOVSKY RA, 1993, AM J PHYSIOL, V264, pL401; Kikuta Y, 2002, PROSTAG OTH LIPID M, V68-9, P345, DOI 10.1016/S0090-6980(02)00039-4; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Marion D W, 1999, Clin Neurosurg, V45, P184; MARTIN TR, 1989, J CLIN INVEST, V84, P1609, DOI 10.1172/JCI114338; Mascia L, 1998, INTENS CARE MED, V24, P1115, DOI 10.1007/s001340050727; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; PAINE R, 1952, JAMA-J AM MED ASSOC, V149, P643, DOI 10.1001/jama.1952.02930240021008; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Serhan CN, 1996, FASEB J, V10, P1147; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stubbe HD, 2004, J CEREBR BLOOD F MET, V24, P1400, DOI 10.1097/01.WCB.0000141516.61418.82; Tarlowe MH, 2003, J IMMUNOL, V171, P2066, DOI 10.4049/jimmunol.171.4.2066; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	40	58	60	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2007	27	5					963	974		10.1038/sj.jcbfm.9600396			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	161FG	WOS:000245999300008	16985506	Bronze			2021-06-18	
J	Phipps, S; Richardson, P				Phipps, Shawn; Richardson, Pamela			Occupational therapy outcomes for clients with traumatic brain injury and stroke using the Canadian occupational performance measure	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article							SELF-IDENTIFIED GOALS; ACHIEVEMENT; ADULTS	The purpose of this study was to determine whether 155 ethnically diverse clients with traumatic brain injury (TBI) and stroke (cerebrovascular accident; CVA) who received occupational therapy services perceived that they reached self-identified goals related to tasks of daily lite as measured by the Canadian Occupational Performance Measure (COPM). This study found that a statistically and clinically significant change in self-perceived performance and satisfaction with tasks of daily life occurred at the end of a client-centered occupational therapy program (p <.001). There were no significant differences in performance and satisfaction between the TBI and CVA groups. However, the group with right CVA reported a higher level of satisfaction with performance in daily activities than the group with left CVA (p =.03). The COPM process can effectively assist clients with neurological impairments in identifying meaningful occupational performance goals, The occupational therapist also can use the COPM to design occupation-based and client-centered intervention programs and measure occupational therapy outcomes.	Rancho Los Amigos Natl Rehabil Ctr, Dept Occupat Therapy & Recreat Therapy, Downey, CA 90242 USA; Calif State Univ Dominguez Hills, Dept Occupat Therapy, Carson, CA 90747 USA; San Jose State Univ, Dept Occupat Therapy, San Jose, CA 95192 USA	Phipps, S (corresponding author), Rancho Los Amigos Natl Rehabil Ctr, Dept Occupat Therapy & Recreat Therapy, 7601 E Imperial Highway, Downey, CA 90242 USA.	sphipps@ladhs.org; pamrichardson@sbcglobal.net					ARNADOTTIR G, 1990, BRAIN BEHAV ASSESING, P188; Baum CM, 1997, AM J OCCUP THER, V51, P277, DOI 10.5014/ajot.51.4.277; Bodiam C., 1999, BR J OCCUP THER, V62, P123, DOI DOI 10.1177/030802269906200310; BOSCH J, 1995, THESIS MCMASTER U HA; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Chenq Ya-Hsin, 2002, Occup Ther Int, V9, P167, DOI 10.1002/oti.163; *COMM ACCR REH FAC, 2006, STAND MAN ORG SERV P; Cup EHC, 2003, CLIN REHABIL, V17, P402, DOI 10.1191/0269215503cr635oa; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Gagne DE, 2003, AM J OCCUP THER, V57, P215, DOI 10.5014/ajot.57.2.215; Guidetti Susanne, 2002, Occup Ther Int, V9, P257, DOI 10.1002/oti.168; Jansa J., 2004, WFOT B, V50, P18; *JOINT COMM ACCR H, 1991, AMH APPL MAN HOSP, V2; Law M, 1994, Can J Occup Ther, V61, P191; LAW M, 1998, CLIENT CENTERED OCCU; Law M., 2005, CANADIAN OCCUPATIONA, V4th ed; Maitra KK, 2006, AM J OCCUP THER, V60, P298, DOI 10.5014/ajot.60.3.298; McColl M A, 2000, Can J Occup Ther, V67, P22; McColl MA., 2003, THEORETICAL BASIS OC; Melville LL, 2002, AM J OCCUP THER, V56, P650, DOI 10.5014/ajot.56.6.650; POLLOCK N, 1993, AM J OCCUP THER, V47, P298, DOI 10.5014/ajot.47.4.298; Rosa SA, 2005, AM J OCCUP THER, V59, P198, DOI 10.5014/ajot.59.2.198; SANFORD J, 1994, C AM SOC AG SAN FRAN; Sumsion T, 2000, Can J Occup Ther, V67, P15; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; Vining Radomski M, 2000, PHYS DISABILITIES SP, V23, P1; Wilkins S, 2001, Can J Occup Ther, V68, P70; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640; Wressle E, 2003, DISABIL REHABIL, V25, P497, DOI 10.1080/0963828031000090560; Youngstrom MJ, 2002, AM J OCCUP THER, V56, P609	31	58	58	0	16	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	MAY-JUN	2007	61	3					328	334		10.5014/ajot.61.3.328			7	Rehabilitation	Rehabilitation	169ML	WOS:000246596200009	17569390				2021-06-18	
J	Rockswold, SB; Rockswold, GL; Defillo, A				Rockswold, Sarah B.; Rockswold, Gaylan L.; Defillo, Archie			Hyperbaric oxygen in traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						cerebral metabolism; hyperbaric oxygen; intracranial pressure; traumatic brain injury	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; FLUID-PERCUSSION INJURY; INTRACRANIAL-PRESSURE; CEREBROSPINAL-FLUID; MITOCHONDRIAL-FUNCTION; MULTICENTER TRIAL; LACTIC-ACIDOSIS; MOLECULAR-BASIS; 2 ATMOSPHERES	Objectives: This critical literature review examines historical and current investigations on the efficacy and mechanisms of hyperbaric oxygen (HBO) treatment in traumatic brain injury (TBI). Potential safety risks and oxygen toxicity, as well as HBO's future potential, are also discussed. Methods: Directed literature review. Results: Historically, cerebral vasoconstriction and increased oxygen availability were seen as the primary mechanisms of HBO in TBI. HBO now appears to be improving cerebral aerobic metabolism at a cellular level, namely, by enhancing damaged mitochondrial recovery. HBO given at the ideal treatment paradigm, 1.5 ATA for 60 minutes, does not appear to produce oxygen toxicity and is relatively safe. Discussion: The use of HBO in TBI remains controversial. Growing evidence, however, shows that HBO may be a potential treatment for patients with severe brain injury. Further investigations, including a multicenter prospective randomized clinical trial, will be required to definitively define the role of HBO in severe TBI.	Univ Minnesota, Dept Surg, Div Neurosurg, Hennepin Cty Med Ctr,Dept Neurosurg, Minneapolis, MN 55415 USA	Rockswold, GL (corresponding author), Univ Minnesota, Dept Surg, Div Neurosurg, Hennepin Cty Med Ctr,Dept Neurosurg, 701 Pk Ave, Minneapolis, MN 55415 USA.	gaylan.rockswold@co.hennepin.mn.us					ARTRU F, 1976, EUR NEUROL, V14, P351, DOI 10.1159/000114759; ARTRU F, 1976, EUR NEUROL, V14, P310, DOI 10.1159/000114753; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bardin H., 1970, QUANTITATIVE METHOD; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bullock MR, 2006, J NEUROSURG, V104, P171; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CONTRERAS FL, 1988, J NEUROSURG, V68, P137, DOI 10.3171/jns.1988.68.1.0137; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; DEATON PR, 1994, AM J PHYSIOL, V267, pL187; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNN JE, 1966, HYPERBARIC MEDICINE, P447; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HARABIN AL, 1990, J APPL PHYSIOL, V69, P328; Hattori N, 2003, J NUCL MED, V44, P1709; HAYAKAWA T, 1971, J NEUROL NEUROSUR PS, V34, P580, DOI 10.1136/jnnp.34.5.580; HOLBACH KH, 1972, EUR NEUROL, V8, P158, DOI 10.1159/000114570; HOLBACH KH, 1974, ACTA NEUROCHIR, V30, P247, DOI 10.1007/BF01405583; HOLBACH KH, 1977, J NEUROL, V217, P17, DOI 10.1007/BF00316313; HOLBACH KH, 1973, ADV NEUROSURG, V1, P158; IKEDA Y, 1990, NEUROSURGERY, V27, P1; ILLINGWORTH C, 1962, Br Med J, V2, P1271; INGVAR DH, 1965, ACTA NEUROL SCAND, V41, P92, DOI 10.1111/j.1600-0404.1965.tb04282.x; JACOBSON I, 1963, LANCET, V2, P549; JACOBSON I, 1963, J NEUROSURG, V20, P849, DOI 10.3171/jns.1963.20.10.0849; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KLEIN J, 1990, ANESTH ANALG, V70, P195; Krause G. S., 1986, AM HEART J, V16, P1200; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Mantell LL, 1999, ANN NY ACAD SCI, V887, P171, DOI 10.1111/j.1749-6632.1999.tb07931.x; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; METZEL E, 1971, ACTA NEUROCHIR, V25, P177, DOI 10.1007/BF01809099; MILLER JD, 1971, ARCH NEUROL-CHICAGO, V24, P210, DOI 10.1001/archneur.1971.00480330038003; MILLER JD, 1970, J NEUROSURG, V33, P287, DOI 10.3171/jns.1970.33.3.0287; MINK RB, 1995, STROKE, V26, P2307, DOI 10.1161/01.STR.26.12.2307; MOGAMI H, 1969, J NEUROSURG, V31, P636, DOI 10.3171/jns.1969.31.6.0636; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; MOODY RA, 1970, J NEUROSURG, V32, P51, DOI 10.3171/jns.1970.32.1.0051; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Muehstedt SG, 2001, SURGERY, V130, P602, DOI 10.1067/msy.2001.117105; MUIZELAAR JP, 1989, TXB HEAD INJURY, P221; Murr R, 1996, ACTA NEUROCHIR, V138, P928, DOI 10.1007/BF01411281; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NODA Y, 1983, J NEUROCHEM, V40, P1329, DOI 10.1111/j.1471-4159.1983.tb13574.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ORTEGA BD, 1972, STEROIDS BRAIN EDEMA, P167; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; PUGLIA CD, 1984, TOXICOL APPL PHARM, V75, P258, DOI 10.1016/0041-008X(84)90208-4; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROCKSWOLD G L, 1985, HYPERBARIC OXYGEN RE, V6, P161; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; SALTZMAN HA, 1965, MONOGR SURG SCI, V2, P1; Siddiqui A, 1997, PLAST RECONSTR SURG, V99, P148, DOI 10.1097/00006534-199701000-00023; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; SMITH G, 1961, SURG GYNECOL OBSTET, V113, P13; Springer JE, 1998, BRAIN RES PROTOC, V2, P259, DOI 10.1016/S1385-299X(97)00045-7; SUKOFF MH, 1967, SURGERY, V62, P40; SUKOFF MH, 1968, J NEUROSURG, V29, P236, DOI 10.3171/jns.1968.29.3.0236; SUKOFF MH, 1982, NEUROSURGERY, V10, P29, DOI 10.1227/00006123-198201000-00006; Tindall G T, 1965, Surg Forum, V16, P414; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; WAXMAN SG, 1991, TRENDS NEUROSCI, V14, P461, DOI 10.1016/0166-2236(91)90046-W; Weaver L K, 1999, Respir Care Clin N Am, V5, P51; WEAVER LK, 1988, J HYPERBARIC MED, V3, P215; WEAVER LK, 1999, HYPERBARIC MED PRACT, P245; WHALEN RE, 1966, ARCH NEUROL-CHICAGO, V14, P15, DOI 10.1001/archneur.1966.00470070019002; WISPE JR, 1987, CLIN PERINATOL, V14, P651; WRIGHT WB, 1972, 272 US NAV EXP DIV U; WULLENWEBER R, 1969, CEREBRAL BLOOD FLOW, P270; Young W, 1992, J NEUROTRAUMA S1, V9, P9; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; ZHOU Z, 2006, IN PRESS J NEUROSURG	95	58	77	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR	2007	29	2					162	172		10.1179/016164107X181798			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	165JI	WOS:000246301000008	17439701				2021-06-18	
J	Spanos, GK; Wilde, EA; Bigler, ED; Cleavinger, HB; Fearing, MA; Levin, HS; Li, X; Hunter, JV				Spanos, G. K.; Wilde, E. A.; Bigler, E. D.; Cleavinger, H. B.; Fearing, M. A.; Levin, H. S.; Li, X.; Hunter, J. V.			Cerebellar atrophy after moderate-to-severe pediatric traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							DIFFUSE AXONAL INJURY; PREFRONTAL CORTEX; HEAD-INJURY; CHILDREN; VULNERABILITY; PROJECTIONS; PROTEIN; IMPACT; RAT; MRI	BACKGROUND AND PURPOSE: Although the cerebellum has not attracted the same degree of attention as cortical areas and the hippocampus in traumatic brain injury (TBI) literature, there is limited structural and functional imaging evidence that the cerebellum is also vulnerable to insult. The cerebellum is emerging as part of a frontocerebellar system that, when disrupted, results in significant cognitive and behavioral consequences, We hypothesized that cerebellar volume would be reduced in children following TBI and wished to examine the relation between the cerebellum and known sites of projection, including the prefrontal cortex, thalamus, and pons. MATERIALS AND METHODS: Quantitative MR imaging was used to measure cerebellar white and gray matter and lesion volumes 1-10 years following TBI in 16 children 9-16 years of age and 16 demographically matched typically developing children 9-16 yeas of age. Cerebellar volumes were also compared with volumetric data from other brain regions to which the cerebellum projects. RESULTS: A significant group difference was found in cerebellar white and gray matter volume, with children in the TBI group consistently exhibiting smaller volumes, Repeating the analysis after excluding children with focal cerebellar lesions revealed that significant group differences still remained for cerebellar white matter (WM). We also found a relation between the cerebellum and projection areas, including the dorsolateral prefrontal cortex, thalamus, and pons in 1 or both groups. CONCLUSION: Our finding of reduced cerebellar WM volume in children with TBI is consistent with evidence from experimental studies suggesting that the cerebellum and its related projection areas are highly vulnerable to fiber degeneration following traumatic insult.	Texas Childrens Hosp, Dept Diagnost Imaging, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA; Dartmouth Coll Sch Med, Dept Psychiat, W Lebanon, NH USA; Boston VA Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Wilde, EA (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 1790 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ewilde@bcm.tmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19HD035476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19 HD035476, U19 HD35476] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS021889, NS-21889] Funding Source: Medline		Allen G, 2005, NEUROIMAGE, V28, P39, DOI 10.1016/j.neuroimage.2005.06.013; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Diamond A, 2000, CHILD DEV, V71, P44, DOI 10.1111/1467-8624.00117; Finnie JW, 2001, J COMP PATHOL, V124, P159, DOI 10.1053/jcpa.2000.0446; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Haber S, 2001, NEUROSCIENTIST, V7, P315, DOI 10.1177/107385840100700408; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hardan AY, 2001, J AM ACAD CHILD PSY, V40, P666, DOI 10.1097/00004583-200106000-00011; Kinuya K, 2004, NUCL MED COMMUN, V25, P333, DOI 10.1097/00006231-200404000-00004; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Liu JS, 2000, NEUROSCI LETT, V282, P85, DOI 10.1016/S0304-3940(00)00865-X; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; Schmahmann JD, 1997, J NEUROSCI, V17, P438; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Sullivan EV, 2003, ALCOHOL CLIN EXP RES, V27, P1409, DOI 10.1097/01.ALC.0000085586.91726.46; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333	29	58	58	0	3	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2007	28	3					537	542					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	149PW	WOS:000245160100035	17353332				2021-06-18	
J	Gill, HS; Campbell, PA; Murray, DW; De Smet, KA				Gill, H. S.; Campbell, P. A.; Murray, D. W.; De Smet, K. A.			Reduction of the potential for thermal damage during hip resurfacing	JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME			English	Article							RETRIEVED FEMORAL HEADS; BONE-CEMENT; REPLACEMENT; POLYMETHYLMETHACRYLATE; ARTHROPLASTY; INTERFACE; INJURY	Resurfacing arthroplasty of the hip is being used increasingly as an alternative to total hip replacement, especially for young active patients. There is concern about necrosis of the femoral head after resurfacing which can result in fracture and loosening. Most systems use a cemented femoral component, with the potential for thermal necrosis of the cancellous bone of the reamed femoral head. We used thermal probes to record temperatures close to the cement-bone interface during resurfacing arthroplasty. The maximum temperature recorded at the cement-bone interface in four cases was approximately 68 degrees C which was higher than that reported to kill osteocytes. A modified surgical technique using insertion of a suction cannula into the lesser trochanter, generous pulsed lavage and early reduction of the joint significantly reduced the maximum recorded cancellous bone temperature to approximately 36 degrees C in five cases (p=0.014). We recommend the modified technique since it significantly reduces temperatures at the cement-bone interface.	Univ Oxford, Nuffield Orthopaed Ctr, Botnar Res Ctr, Dept Orthopaed Surg, Oxford OX3 7LD, England; Orthoped Hosp, Univ Coll Los Angeles, J Vernon Luck Res Ctr, Implant Retrieval Lab, Los Angeles, CA 90007 USA; Anca Med Ctr, B-9000 Ghent, Belgium	Gill, HS (corresponding author), Univ Oxford, Nuffield Orthopaed Ctr, Botnar Res Ctr, Dept Orthopaed Surg, Windmill Rd, Oxford OX3 7LD, England.	richie.gill@ndos.ox.ac.uk	Gill, Harinderjit S/A-9808-2011; Murray, David W/D-7117-2011	Gill, Harinderjit S/0000-0002-7740-2062; 			AMSTUTZ HC, 1996, CLIN ORTHOP S, V329, P511; Andersen K H, 1998, Ugeskr Laeger, V160, P4905; AUST JC, 1981, ARCH SURG-CHICAGO, V116, P345; BERMAN AT, 1984, CLIN ORTHOP RELAT R, V186, P284; CAMPBELL P, 2006, IN PRESS CLIN ORTHOP; CHARNLEY J, 1970, Journal of Bone and Joint Surgery British Volume, V52, P340; DIPISA JA, 1976, CLIN ORTHOP RELAT R, P95; Huiskes R, 1980, Acta Orthop Scand Suppl, V185, P1; LEESON MC, 1993, CLIN ORTHOP RELAT R, V295, P239; Little CP, 2005, J BONE JOINT SURG BR, V87B, P320, DOI 10.1302/0301-620X.87B3.15330; McMinn D, 2006, P I MECH ENG H, V220, P239, DOI 10.1243/095441105X68944; MJOBERG B, 1984, ACTA ORTHOP SCAND, V55, P597, DOI 10.3109/17453678408992403; Morberg P, 1993, J Arthroplasty, V8, P617, DOI 10.1016/0883-5403(93)90009-S; Shimmin AJ, 2005, J BONE JOINT SURG BR, V87B, P463, DOI 10.1302/0301-620X.87B4; Stanczyk M, 2004, J BIOMECH, V37, P1803, DOI [10.1016/j.biomech.2004.03.002, 10.1016/j.jbiomech.2004.03.002]; Stelnicki EJ, 1996, J CRANIOFAC SURG, V7, P192, DOI 10.1097/00001665-199605000-00006; WILLERT HG, 1974, J BONE JOINT SURG AM, VA 56, P1368, DOI 10.2106/00004623-197456070-00005; CONSERVE PLUS TOTAL	18	58	61	0	5	BRITISH EDITORIAL SOC BONE JOINT SURGERY	LONDON	22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND	0301-620X	2044-5377		J BONE JOINT SURG BR	J. Bone Joint Surg.-Br. Vol.	JAN 1	2007	89B	1					16	20		10.1302/0301-620X.89B1.18369			5	Orthopedics; Surgery	Orthopedics; Surgery	130IJ	WOS:000243793000004	17259409				2021-06-18	
J	Nolin, P; Heroux, L				Nolin, Pierre; Heroux, Louise			Relations among sociodemographic, neurologic, clinical, and neuropsychologic variables, and vocational status following mild traumatic brain injury - A follow-up study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; MTBI; return to work; subjective complaints; vocational status	MINOR HEAD-INJURY; POST-CONCUSSION SYMPTOMS; MOTOR-VEHICLE ACCIDENTS; WORK; RETURN; COMPLAINTS; QUESTIONNAIRE; COMPENSATION; RECOVERY; SEQUELAE	objectives: To explore the long-term relations among sociodemographic, neurologic, clinical, and neuropsychologic variables, and vocational status in persons with mild traumatic brain injury (MTBI), and to identify the symptoms that determine whether or not these individuals return to work. Design: Longitudinal quasi-experimental between-groups design. Participants: Eighty-five MTBI subjects aged between 16 and 65 years. Setting: The emergency ward of the TroisRivieres Regional Hospital Centre in Quebec, Canada. Main Outcome Measures: Age, gender, Glasgow Coma Scale score, duration of posttraumatic amnesia, duration of retrograde amnesia, total of symptoms at emergency, time elapsed since the trauma, Paced Auditory Serial Addition Task, Stroop, Color Word Test, California Verbal Learning Test, and the number of symptoms at follow-up (12 to 36 months posttrauma). Results: Only the total number of symptoms reported at follow-up was related to vocational status. The majority of individuals had returned to work 1 year or more post-MTBI. Individuals who had not returned to work reported the greatest number of symptoms, which could be linked to their affective status. Six affective symptoms, 5 cognitive symptoms, 6 physical symptoms, and 8 symptoms relating to social and daily life activities differentiated the participants who had returned to work from those who had not. Conclusions: Patient characteristics, injury severity indicators, and cognitive functions were not associated with vocational status. To better understand post-MTBI vocational status, it is important to focus on subjective complaints that arise following the injury.	Univ Quebec Trois Rivieres, Dept Psychol, Child & Family Dev Res Unit, Trois Rivieres, PQ G9A 5H7, Canada	Nolin, P (corresponding author), Univ Quebec Trois Rivieres, Dept Psychol, Child & Family Dev Res Unit, POB 500, Trois Rivieres, PQ G9A 5H7, Canada.	Pierre.Nolin@uqtr.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bartelski J, 1996, ACTA PHYS POL B, V27, P911; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN N, 1992, J NEUROL NEUROSUR PS, V55, P222, DOI 10.1136/jnnp.55.3.222; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; EDNA TH, 1987, ACTA NEUROCHIR, V85, P40, DOI 10.1007/BF01402368; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HURT DH, 2000, NEUROPSYCHOLOGICAL M, P215; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Nolin P., 2000, Annales de Readaptation et de Medecine Physique, V43, P236, DOI 10.1016/S0168-6054(00)89087-X; Nolin P, 2001, REV NEUROPSYCHOL, V11, P23; NOLIN P, 1999, REV QUEBECOISE PSYCH, V20, P39; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WRIGHT JC, 1996, CLIN REHABIL, V10, P334, DOI DOI 10.1177/026921559601000412; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	50	58	60	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					514	526		10.1097/00001199-200611000-00006			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400006	17122682				2021-06-18	
J	Ramic, M; Emerick, AJ; Bollnow, MR; O'Brien, TE; Tsai, SY; Kartje, GL				Ramic, Maya; Emerick, April J.; Bollnow, Melanie R.; O'Brien, Timothy E.; Tsai, Shih-Yen; Kartje, Gwendolyn L.			Axonal plasticity is associated with motor recovery following amphetamine treatment combined with rehabilitation after brain injury in the adult rat	BRAIN RESEARCH			English	Article						neurite outgrowth; sensorimotor cortex; psychostimulant; physical therapy; basilar pons; motor recovery	NEURITE GROWTH-INHIBITORS; MONOCLONAL-ANTIBODY IN-1; USE-DEPENDENT PLASTICITY; FUNCTIONAL RECOVERY; CORTICOFUGAL PLASTICITY; BEHAVIORAL RECOVERY; LOCOMOTOR FUNCTION; PROMOTES RECOVERY; NUCLEUS-ACCUMBENS; CORTICAL-LESIONS	Clinical and laboratory studies have suggested that amphetamine treatment when paired with rehabilitation results in improved recovery of function after stroke or traumatic brain injury. In the present study, we investigated whether new anatomical pathways developed in association with improved motor function after brain damage and amphetamine treatment linked with rehabilitation. Following a unilateral sensorimotor cortex lesion in the adult rat, amphetamine (2 mg/kg) was administered in conjunction with physiotherapy sessions on postoperative days two and five. Physiotherapy was continued twice daily for the first 3 weeks after injury, and then once daily until week six. Performance on skilled forelimb reaching and ladder rung walking was used to assess motor improvement. Our results show that animals with sensorimotor cortical lesions receiving amphetamine treatment linked with rehabilitation had significant improvement in both tasks. Neuroanatomical tracing of efferent pathways from the opposite, non-damaged cortex resulted in the novel finding that amphetamine treatment linked with rehabilitation, significantly increased axonal growth in the deafferented basilar pontine nuclei. These results support the notion that pharmacological interventions paired with rehabilitation can enhance neuronal plasticity and thereby improve functional recovery after CNS injury.	Edward Hines Jr Vet Adm Hosp, Res Serv, Hines, IL 60141 USA; Loyola Univ, Med Ctr, Neurosci Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Cell Biol, Maywood, IL 60153 USA; Loyola Univ, Dept Math & Stat, Ctr Stat Consulting, Chicago, IL 60626 USA	Emerick, AJ (corresponding author), Edward Hines Jr Vet Adm Hosp, Res Serv, 5th Ave & Roosevelt Rd, Hines, IL 60141 USA.	april.emerick@med.va.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS040960] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000828] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56 NS040960] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [40960] Funding Source: Medline; RRD VA [I01 RX000828] Funding Source: Medline		Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Butefisch CM, 2002, ANN NEUROL, V51, P59, DOI 10.1002/ana.10056; CARR LA, 1969, SCIENCE, V164, P322, DOI 10.1126/science.164.3877.322; CASTRO AJ, 1972, BRAIN RES, V37, P173, DOI 10.1016/0006-8993(72)90665-8; Cauraugh JH, 2005, PROG NEUROBIOL, V75, P309, DOI 10.1016/j.pneurobio.2005.04.001; Cramer SC, 2004, RESTOR NEUROL NEUROS, V22, P231; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Emerick AJ, 2004, BEHAV BRAIN RES, V152, P315, DOI 10.1016/j.bbr.2003.10.010; Emerick AJ, 2003, J NEUROSCI, V23, P4826; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; Flores C, 2000, NEUROSCIENCE, V98, P287, DOI 10.1016/S0306-4522(00)00115-9; Foltys H, 2003, CLIN NEUROPHYSIOL, V114, P2404, DOI 10.1016/S1388-2457(03)00263-3; GOLD PE, 1984, BRAIN RES, V305, P103, DOI 10.1016/0006-8993(84)91124-7; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Herzog A, 1997, J NEUROSCI METH, V72, P57, DOI 10.1016/S0165-0270(96)00156-2; HOFFSCHMIDT B, 2001, P 5 COL SOL S JUN 21, P51; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; Jones TA, 1999, J NEUROSCI, V19, P10153; Kartje GL, 1999, ANN NEUROL, V45, P778, DOI 10.1002/1531-8249(199906)45:6<778::AID-ANA12>3.0.CO;2-B; KOMITOVA M, 2006, EXP NEUROL; KONRADI C, 1994, J NEUROSCI, V14, P5623; Li YL, 2003, NEUROPSYCHOPHARMACOL, V28, P1082, DOI 10.1038/sj.npp.1300115; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Mueller D, 2006, NEUROSCIENCE, V137, P727, DOI 10.1016/j.neuroscience.2005.09.038; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; Nelles G, 1999, STROKE, V30, P1510, DOI 10.1161/01.STR.30.8.1510; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; Park YH, 2002, BRAIN RES, V951, P43, DOI 10.1016/S0006-8993(02)03103-7; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x; Sawaki L, 2002, NEUROLOGY, V59, P1262, DOI 10.1212/WNL.59.8.1262; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; Sonde L, 2001, CEREBROVASC DIS, V12, P253, DOI 10.1159/000047712; Song YM, 2005, ARCH NEUROL-CHICAGO, V62, P809, DOI 10.1001/archneur.62.5.809; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; Tegenthoff M, 2004, ACTA NEUROL SCAND, V109, P330, DOI 10.1046/j.1600-0404.2003.00235.x; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Treig T, 2003, CLIN REHABIL, V17, P590, DOI 10.1191/0269215503cr653oa; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Wenk CA, 1999, J COMP NEUROL, V410, P143, DOI 10.1002/(SICI)1096-9861(19990719)410:1<143::AID-CNE12>3.0.CO;2-#; WHISHAW IQ, 1991, BEHAV BRAIN RES, V42, P77, DOI 10.1016/S0166-4328(05)80042-7; WHISHAW IQ, 2005, BEHAV LAB RAT HDB TE, P162; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744	51	58	60	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 21	2006	1111						176	186		10.1016/j.brainres.2006.06.063			11	Neurosciences	Neurosciences & Neurology	089TY	WOS:000240905200022	16920088				2021-06-18	
J	Armstead, WM; Nassar, T; Akkawi, S; Smith, DH; Chen, XH; Cines, DB; Higazi, AA				Armstead, William M.; Nassar, Taher; Akkawi, Saed; Smith, Douglas H.; Chen, Xiao-Han; Cines, Douglas B.; Higazi, Abd Al-Roof			Neutralizing the neurotoxic effects of exogenous and endogenous tPA	NATURE NEUROSCIENCE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; CENTRAL-NERVOUS-SYSTEM; BRAIN; INHIBITOR; THERAPY; STROKE; INJURY; CEREBROVASODILATION; FIBRINOLYSIS; IMPAIRMENT	The clinical use of tissue-type plasminogen activator (tPA) in the treatment of stroke is profoundly constrained by its serious side effects. We report that the deleterious effects of tPA on cerebral edema and intracranial bleeding are separable from its fibrinolytic activity and can be neutralized. A hexapeptide (EEIIMD) corresponding to amino acids 350-355 of plasminogen activator inhibitor type 1 (PAI-1) abolished the tPA-induced increase in infarct size and intracranial bleeding in both mechanical and embolic models of stroke in rats, and reduced brain edema and neuronal loss after traumatic brain injury in pigs. These experiments suggest mechanisms to reduce the neurotoxic effects of tPA without compromising its fibrinolytic activity, through the use of selective antagonists and new tPA formulations.	Hadassah Univ Hosp, Dept Clin Biochem, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91120 Jerusalem, Israel; Univ Penn, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Higazi, AA (corresponding author), Hadassah Univ Hosp, Dept Clin Biochem, IL-91120 Jerusalem, Israel.	higazi@mail.med.upenn.edu	smith, douglas/A-1321-2007		NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL06831, HL076206, HL82545, HL076406, HL67381] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL076406, R01HL076206, R01HL067381] Funding Source: NIH RePORTER		Adams H, 2005, STROKE, V36, P916, DOI 10.1161/01.STR.0000163257.66207.2d; AKKAWI S, 2006, AM J PHYSIOL-HEART C, DOI DOI 10.1152/A4PHEART.01042.2005; Armstead WM, 2004, J NEUROTRAUM, V21, P1204, DOI 10.1089/0897715041953849; Armstead WM, 2005, DEV BRAIN RES, V156, P139, DOI 10.1016/j.devbraines.2005.02.012; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P452, DOI 10.1097/00004647-200003000-00002; Atochin DN, 2004, STROKE, V35, P2177, DOI 10.1161/01.STR.0000137412.35700.0e; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; BUCKLEY NM, 1986, COMP BIOCHEM PHYS A, V83, P1, DOI 10.1016/0300-9629(86)90080-0; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Ding-Zhou L, 2002, EUR J PHARMACOL, V457, P137, DOI 10.1016/S0014-2999(02)02686-9; Duhaime AC, 1999, EXP TOXICOL PATHOL, V51, P172, DOI 10.1016/S0940-2993(99)80091-8; Felix B, 1999, BRAIN RES BULL, V49, P1, DOI 10.1016/S0361-9230(99)00012-X; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Higazi AA, 1998, BLOOD, V92, P2075, DOI 10.1182/blood.V92.6.2075.418k08_2075_2083; HIGAZI AAR, 1995, J BIOL CHEM, V270, P9472, DOI 10.1074/jbc.270.16.9472; Higazi AAR, 2005, BLOOD, V105, P1021, DOI 10.1182/blood-2004-03-0995; Lapchak PA, 2001, CNS DRUGS, V15, P819, DOI 10.2165/00023210-200115110-00001; LAPCHAK PA, 2002, CURR NEUROL NEUROSCI, V2, P1, DOI DOI 10.1007/s11910-002-0051-0; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Nagai N, 2001, BLOOD, V97, P3086, DOI 10.1182/blood.V97.10.3086; Nagai N, 1999, CIRCULATION, V100, P2541, DOI 10.1161/01.CIR.100.25.2541; Nassar T, 2004, BLOOD, V103, P897, DOI 10.1182/blood-2003-05-1685; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; REBICH S, 1995, AM J PHYSIOL-HEART C, V268, pH1071; THOMAS JM, 1971, GROWTH, V35, P259; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; WAGERLE LC, 1986, PEDIATR RES, V20, P131, DOI 10.1203/00006450-198602000-00007; Zhang LT, 1997, J BIOL CHEM, V272, P27053, DOI 10.1074/jbc.272.43.27053; Zhang ZG, 2002, CIRCULATION, V106, P740, DOI 10.1161/01.CIR.0000023942.10849.41; Zivin JA, 1999, NEUROLOGY, V53, P14, DOI 10.1212/WNL.53.1.14	32	58	58	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	SEP	2006	9	9					1150	1155		10.1038/nn1757			6	Neurosciences	Neurosciences & Neurology	078DE	WOS:000240080800016	16936723				2021-06-18	
J	Bennett, PC; Ong, B; Ponsford, J				Bennett, PC; Ong, B; Ponsford, J			Assessment of executive dysfunction following traumatic brain injury: Comparison of the BADS with other clinical neuropsychological measures	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						neuropsychological assessment; dysexecutive syndrome; behavioral assessment ofthe dysexecutive syndrome; ED; BADS; cognitive impairment	DYSEXECUTIVE SYNDROME; FRONTAL LOBES; BEHAVIORAL-ASSESSMENT; VALIDITY; TESTS	Traditional neuropsychological measures of executive dysfunction (ED) are widely believed to lack adequate sensitivity and selectivity. This may indicate that existing measures are poorly designed and Constructed, although an alternative explanation is that executive cognition is multifactorial. such that its assessment necessarily requires administration of multiple measures. This possibility led to the development of it test battery, the Behavioural Assessment of the Dysexecutive Syndrome (BADS). To investigate the sensitivity of the BADS to ED, it and various other measures of ED were administered to 64 persons who had sustained traumatic brain injury. The treating clinical neuropsychologist and occupational therapist for each participant also completed a behavioural rating scale, the Dysexecutive Questionnaire (DEX). Four factors were found to underlie scores on the neuropsychological measures, but few tests were sufficiently powerful to make a significant unique contribution to predicting scores on the DEX. This confirms that multiple tests, drawn from both the BADS and other sources, may be necessary to detect ED in a clinical population.	Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, Caulfield, Vic 3145, Australia; La Trobe Univ, Sch Psychol Sci, Bundoora, Vic, Australia	Bennett, PC (corresponding author), Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, POB 197, Caulfield, Vic 3145, Australia.	p.bennett@med.monash.edu.au	Bennett, Pauleen/C-2138-2016	Bennett, Pauleen/0000-0001-5864-4464			ALDERMAN N, 1993, J CLIN EXP NEUROPSYC, V15, P69; Ardila A, 2000, ARCH CLIN NEUROPSYCH, V15, P31, DOI 10.1016/S0887-6177(98)00159-0; Axelrod B. N., 1994, ASSESSMENT, V1, P269, DOI DOI 10.1177/107319119400100307; Banich M. T, 1997, NEUROPSYCHOLOGY NEUR; BENNETT PC, 2005, J INT NEUROPSYCH SOC, V11, P1; Bryan J, 2000, J CLIN EXP NEUROPSYC, V22, P40, DOI 10.1076/1380-3395(200002)22:1;1-8;FT040; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Crawford JR, 2000, AGING NEUROPSYCHOL C, V7, P9, DOI 10.1076/anec.7.1.9.806; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Handler J., 1994, HANDB NEUR, P125; Heaton R. K, 1981, WISCONSIN CARD SORTI; Kafer K L, 1997, J Int Neuropsychol Soc, V3, P108; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Obonsawin MC, 2002, NEUROPSYCHOLOGIA, V40, P970, DOI 10.1016/S0028-3932(01)00171-3; Porteus S.D., 1965, PORTEUS MAZE TEST 50; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; Shallice T., 2002, PRINCIPLES FRONTAL L, P261, DOI [10.1093/acprof:oso/9780195134971.003.0017, DOI 10.1093/ACPROF:OSO/9780195134971.003.0017]; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Wilson BA, 1996, BEHAV ASSESSMENT DYS	25	58	59	0	13	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2005	11	5					606	613		10.1017/S1355617705050721			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	968TJ	WOS:000232185000012	16212688				2021-06-18	
J	Eilander, HJ; Wijnen, VJM; Scheirs, JGM; De Kort, PLM; Prevo, AJH				Eilander, HJ; Wijnen, VJM; Scheirs, JGM; De Kort, PLM; Prevo, AJH			Children and young adults in a prolonged unconscious state due to severe brain injury: Outcome after an early intensive neurorehabilitation programme	BRAIN INJURY			English	Article						severe brain injury; children; young adults; outcome; early intensive neurorehabilitation; vegetative state; minimally consciousness	CLOSED HEAD-INJURY; VEGETATIVE STATE; SENSORY STIMULATION; COMA AROUSAL; MANAGEMENT; CHILDHOOD; RECOVERY	Primary objective. The Rehabilitation Centre Leijpark in the Netherlands provides an Early Intensive Neurorehabilitation Programme (EINP) to children and young adults in a prolonged unconscious state after severe brain injury. In an extensive research project the effects of EINP were studied. This part of the project focused on the outcome in terms of level of consciousness (LOC) in relation to the specific characteristics of a retrospectively studied cohort. Research design. This study was executed according to a one-group archived pre-test-post-test design. Subjects. Subjects were all consecutively admitted patients (n = 145, 72% male) between December 1987-January 2001. Inclusion criteria were: age 0-25 years, within 6 months after injury, LOC at admission vegetative state (VS) or minimally conscious state (MCS). One hundred and four patients (72%) suffered a traumatic injury and 41 patients (28%) a non-traumatic injury. Methods and procedures. All patients had received EINP until they reached consciousness or until it was concluded that no progress was achieved during 3 months after the start of EINP. Medical files were investigated to collect the patients' characteristics and injury data, to determine the LOC at admission and at discharge and to determine the discharge destination. Results. Almost two-thirds of the patients reached full consciousness. LOC at admission, aetiology and interval since injury were found to be significant prognostic factors. Traumatic patients had a much better outcome than non-traumatic patients. A comparison with earlier outcome studies showed a more favourable outcome than expected. It is argued that a multi-centre study is needed to confirm possible effects of EINP.	Rehabil Ctr Leijpk, Div Res, Project VLB NAH, NL-5004 EA Tilburg, Netherlands; Tilburg Univ, Fac Social Sci, Dept Psychol & Hlth, NL-5000 LE Tilburg, Netherlands; St Elizabeth Hosp, Div Neurol, Tilburg, Netherlands; UMC Utrecht, Rudolf Magnus Inst Neurosci, Rehabil Ctr De Hoogstraat, Utrecht, Netherlands	Eilander, HJ (corresponding author), Rehabil Ctr Leijpk, Div Res, Project VLB NAH, POB 5022, NL-5004 EA Tilburg, Netherlands.	h.j.eilander@hccnet.nl	Eilander, Henk/D-9643-2016; Wijnen, Viona/G-1328-2016	Wijnen, Viona/0000-0001-7797-1882			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bach-y-Rita P, 2003, ARCH PHYS MED REHAB, V84, P1100, DOI 10.1016/S0003-9993(03)00312-5; BACHYRITA P, 1980, RECOVERY FUNCTION TH; BACHYRITA P, 2000, CEREBRAL REORGANIZAT, P357; BARIN JJ, 1985, HEAD INJURY REHABILI, P101; BARKER RA, 1999, NEUROPSY REHABIL MOD, P1; BONTKE CF, 1992, J HEAD TRAUMA REHAB, V7, P115; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; CUMMINS RA, 1992, AUST PSYCHOL, V27, P71, DOI 10.1080/00050069208257582; DeYoung S, 1987, Rehabil Nurs, V12, P121; DOMAN G, 1993, NEUROPSYCHOL REHABIL, V3, P203; DOMAN RJ, 1960, JAMA-J AM MED ASSOC, V174, P257, DOI 10.1001/jama.1960.03030030037007; EILANDER HJ, 2003, KINDERREVALIDATIE, P302; Faverjon S, 2002, NEUROLOGY, V59, P1356, DOI 10.1212/01.WNL.0000033588.59005.55; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Giacino JT, 1996, NEUROREHABILITATION, V6, P69, DOI 10.3233/NRE-1996-6108; GILLIES JD, 1980, DEV MED CHILD NEUROL, V22, P642; Grafman J, 2000, J COMMUN DISORD, V33, P345, DOI 10.1016/S0021-9924(00)00030-7; JAFFE MB, 1985, HEAD INJURY REHABILI, P167; KOLB B, 1996, RECOVERY TRAUMATIC B, P199; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; Kriel RL, 1995, J NEUROL REHABIL, V9, P145; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Lombardi F, 2002, CLIN REHABIL, V16, P464, DOI 10.1191/0269215502cr519oa; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; PIERCE J P, 1990, Brain Injury, V4, P191, DOI 10.3109/02699059009026165; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Rader M A, 1989, Brain Inj, V3, P141, DOI 10.3109/02699058909004545; Renner M.J., 1987, ENRICHED IMPOVERISHE; Schwartz CE, 1997, PSYCHOSOM MED, V59, P362, DOI 10.1097/00006842-199707000-00005; Servadei F, 2000, NEUROSURGERY, V46, P70; SMITH GJ, 1985, HEAD INJURY REHABILI, P275; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; STEIN DG, 1995, BRAIN REPAIR; Steindler DA, 2002, LANCET, V359, P1047, DOI 10.1016/S0140-6736(02)08096-0; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; SZEKERES SF, 1985, HEAD INJURY REHABILI, P219; TEASDALE G, 1974, LANCET, V2, P81; van Praag H, 1999, NAT NEUROSCI, V2, P266; WEBER PL, 1984, ARCH PHYS MED REHAB, V65, P457; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112; Wilson SL, 1996, BRAIN INJURY, V10, P807, DOI 10.1080/026990596123927; YLVISAKER M, 1985, HEAD INJURY REHABILI; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU; ZASLER ND, 1996, RECOVERY TRAUMATIC B, P185	63	58	58	1	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2005	19	6					425	436		10.1080/02699050400025299			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	932JI	WOS:000229549600004	16101265				2021-06-18	
J	Bulger, EM; Copass, MK; Sabath, DR; Maier, RV; Jurkovich, GJ				Bulger, EM; Copass, MK; Sabath, DR; Maier, RV; Jurkovich, GJ			The use of neuromuscular blocking agents to facilitate prehospital intuhation does not impair outcome after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 29-OCT 02, 2004	Maui, HI	Amer Assoc Surg Trauma		prehospital; endotracheal intubation; neuromuscular blocking agents; paralytics	RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURIES; HYPOTENSION; FIELD; HYPOXIA	Background: Several studies have demonstrated that the success rate of prehospital intubation is improved by the use of neuromuscular blocking agents (NMBAs). However, a recent study has reported that prehospital intubation with NMBAs worsens outcome after traumatic brain injury (TBI). We sought to determine the effect of the use of NMBAs to facilitate prehospital intubation on outcome after TBI. Methods: All patients admitted to our Level I trauma center with a head Abbreviated Injury Scale score >= 3 were identified by the trauma registry (January 1998-June 2003). Patient records were matched with prehospital databases. Patients were further stratified on the basis of prehospital Glasgow Coma Scale (GCS) score into mild (GCS score of 14115), moderate (GCS score of 9-13), and severe (GCS score < 9) TBI. Outcome included mortality and good outcome (survival to discharge with a GCS score of 14/15). Results: There were 3,052 patients who were identified as having been transported directly from the field. Complete prehospital data were available for 2,012 patients (66%). Of these, 920 were mild TBI (intubation rate, 17.4%), 293 moderate TBI (intubation rate, 57.7%), and 799 severe TBI (intubation rate, 95%). Overall, 72% of intubated patients received NMBAs. There were no significant differences in demographics or injury severity between the groups. Patients not receiving NMBAs were more likely to be hypotensive and have prehospital cardiopulmonary resuscitation (p = 0.001). The unadjusted mortality for the patients intubated with NMBAs was 25% versus 37% for those not receiving NMBAs (p < 0.001). When adjusted for confounding variables, patients intubated with NMBAs were more likely to survive (odds ratio, 0.63; 95% confidence interval, 0.41-0.97; p = 0.04) and have a good outcome (odds ratio, 1.7; 95% confidence interval, 1.2-2.6; p = 0.006) than those in the no-NMBA group. Conclusion: The use of NMBAs to facilitate prehospital intubation improves outcome for patients with TBI. The value of prehospital intubation for TBI remains to be determined; however, any trial evaluating nonintubation for TBI must be compared with NMBA-facilitated intubation to be valid.	Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Dept Neurol, Seattle, WA 98104 USA	Bulger, EM (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, Box 359796,325 9Th Ave, Seattle, WA 98104 USA.	ebulger@u.washington.edu					Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Krisanda T J, 1992, Prehosp Disaster Med, V7, P121; LAVERY RF, 1992, PREHOSP DISASTER MED, V7, P144; Ma OJ, 1998, AM J EMERG MED, V16, P125, DOI 10.1016/S0735-6757(98)90027-4; McDonald C C, 1998, Prehosp Emerg Care, V2, P29, DOI 10.1080/10903129808958836; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	20	58	59	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2005	58	4					718	723		10.1097/01.TA.0000159239.14181.BC			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	919VS	WOS:000228646300016	15824647				2021-06-18	
J	Schuknecht, B; Graetz, K				Schuknecht, B; Graetz, K			Radiologic assessment of maxillofacial, mandibular, and skull base trauma	EUROPEAN RADIOLOGY			English	Article						computed tomography; cranial nerve; magnetic resonance; mandibula; maxillofacial injury; orbit; temporal bone; trauma	FRACTURES; CT; CLASSIFICATION; DIAGNOSIS; INJURIES	Cranio-maxillofacial injuries affect a significant proportion of trauma patients either in isolation or concurring with other serious injuries. Contrary to maxillofacial injuries that result from a direct impact, central skull base and lateral skull base (petrous bone) fractures usually are caused by a lateral or sagittal directed force to the skull and therefore are indirect fractures. The traditional strong role of conventional images in patients with isolated trauma to the viscerocranium is decreasing. Spiral multislice CT is progressively replacing the panoramic radiograph, Waters view, and axial films for maxillofacial trauma, and is increasingly being performed in addition to conventional films to detail and classify trauma to the mandible as well. Imaging thus contributes to accurately categorizing mandibular fractures based on location, into 11 alveolar, mandibular proper, and condylar fractures-the last are subdivided into intracapsular and extracapsular fractures. In the midface, CT facilitates attribution of trauma to the categories central, lateral, or combined centrolateral fractures. The last frequently encompass orbital trauma as well. CT is the imaging technique of choice to display the multiplicity of fragments, the degree of dislocation and rotation, or skull base involvement. Transsphenoid skull base fractures are classified into transverse and oblique types; lateral base (temporal bone) trauma is subdivided into longitudinal and transverse fractures. Supplementary MR examinations are required when a cranial nerve palsy occurs in order to recognize neural compression. Early and late complications of trauma related to the orbit, anterior cranial fossa, or lateral skull base due to infection, brain concussion, or herniation require CT to visualize the osseous prerequisites of complications, and MR to define the adjacent brain and soft tissue involvement.	Univ Zurich Hosp, Inst Neuroradiol, CH-8091 Zurich, Switzerland; MRI Med Radiodiagnost Inst, CH-8044 Zurich, Switzerland; Univ Zurich Hosp, Dept Maxillofacial Surg, CH-8091 Zurich, Switzerland	Schuknecht, B (corresponding author), Univ Zurich Hosp, Inst Neuroradiol, Frauenklin Str 10, CH-8091 Zurich, Switzerland.	image-solution@ggaweb.ch					ASSAEL LA, 1993, RADIOL CLIN N AM, V31, P209; Chacon GE, 2003, J ORAL MAXIL SURG, V61, P668, DOI 10.1053/joms.2003.50134; Donat TL, 1998, ARCH OTOLARYNGOL, V124, P1306, DOI 10.1001/archotol.124.12.1306; ERNST A, 2004, TRAUMATOLOGIE KOPFHA; Fabian TS, 1999, J TRAUMA, V47, P275, DOI 10.1097/00005373-199908000-00009; Freund M, 2002, EUR RADIOL, V12, P1127, DOI 10.1007/s00330-001-1167-3; Gassner R, 2003, J CRANIO MAXILL SURG, V31, P51, DOI 10.1016/S1010-5182(02)00168-3; GRAETZ K, 1986, THESIS BASEL; HAUG RH, 1993, CRANIOMAXILLOFACIAL, P90; Ho VT, 1996, AM J NEURORADIOL, V17, P134; Kuhn F, 1996, Eur J Ophthalmol, V6, P464; LeFort R., 1901, REV CHIR PARIS, V23, P208; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; LEVY RA, 1992, AM J NEURORADIOL, V13, P885; Linnau KF, 2003, EUR J RADIOL, V48, P5, DOI 10.1016/S0720-048X(03)00203-1; Linneau KF, 2003, EUR J RADIOL, V48, P17, DOI 10.1016/S0720-048X(03)00205-5; Manson PN, 1999, PLAST RECONSTR SURG, V103, P1287, DOI 10.1097/00006534-199904040-00031; Martello JY, 1997, ANN PLAS SURG, V38, P223, DOI 10.1097/00000637-199703000-00006; MATHOG RH, 1984, MAXILLOFACIAL TRAUMA; Resnick DK, 1997, NEUROSURGERY, V40, P1177, DOI 10.1097/00006123-199706000-00012; Rhea JT, 1999, RADIOL CLIN N AM, V37, P489, DOI 10.1016/S0033-8389(05)70108-1; Salvolini U, 2002, EUR RADIOL, V12, P1253, DOI 10.1007/s00330-002-1445-8; SartorettiSchefer S, 1997, AM J NEURORADIOL, V18, P1115; Schuknecht B, 2003, NEUROIMAG CLIN N AM, V13, P605, DOI 10.1016/S1052-5149(03)00044-3; Schuknecht B, 1996, NEURORADIOLOGY, V38, P470; Stone JA, 1999, AM J NEURORADIOL, V20, P706; WEST OC, 1993, RADIOLOGY, V188, P329, DOI 10.1148/radiology.188.2.8327674; Yeakley J W, 1999, Curr Probl Diagn Radiol, V28, P65, DOI 10.1016/S0363-0188(99)90002-6; ZINGG M, 1992, J ORAL MAXIL SURG, V50, P778, DOI 10.1016/0278-2391(92)90266-3	29	58	64	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	MAR	2005	15	3					560	568		10.1007/s00330-004-2631-7			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	912OT	WOS:000228089500017	15662492	Green Accepted			2021-06-18	
J	Steudel, WI; Cortbus, F; Schwerdtfeger, K				Steudel, WI; Cortbus, F; Schwerdtfeger, K			Epidemiology and prevention of fatal head injuries in Germany - trends and the impact of the reunification	ACTA NEUROCHIRURGICA			English	Article						head injury; epidemiology; incidence rates; mortality rates; age group-specific data	TRAUMATIC BRAIN INJURY; DEATHS; POPULATION; COMMUNITY; MORTALITY; FEATURES; COUNTY	A review of the data published on the epidemiology of traumatic brain injuries (TBI) reveals that the data of almost all studies are drawn from local or regional series. Nationwide data are rarely available, or are extrapolated from regional data. In Germany, there has been a nationwide mortality register with ICD-9-coded diagnoses since 1968. In addition, it has been compulsory since 1994 that all hospitals in Germany provide ICD-9 data on all admissions and discharges. Based on data provided by the Federal Bureau of Statistics (Statistisches Bundesamt) in Wiesbaden, all head injuries between 1972 and 1998 were analyzed according to ICD-9 and after 1998 according to the updated ICD-10. The data of hospitalized cases and fatal cases were correlated with population data to calculate incidences and mortality rates. Age-group specific data were also available and analyzed. Head injuries in Germany accounted in 1998 for 19.59% of all injuries. The incidence is 337/100,000. The incidence rate of serious head injury is 33.5/100,000. Mortality decreased continuously from 27.2/100,000 in 1972 to 9.0/100,000 in 2000. The mortality is highest in the group older than 75 years. 68.4% of persons with head injury die before admission to a hospital. After the reunification in 1989/1990, the number of fatal head injuries showed a temporary increase. The number of patients treated in-hospital remained essentially unchanged (276/564 patients in 1998). The majority of hospitalized patients suffered minor head injury. Conclusion: Analysis of the admission/discharge data of all German hospitals reveals surprising inside views of age group-related incidence and mortality rates of head injuries in this country. Future research should be focused on patients with minor head injuries who account for nearly 200,000 cases of in-hospital treatment.	Neurochirurg Univ Klin, D-66421 Homburg, Germany	Steudel, WI (corresponding author), Neurochirurg Univ Klin, D-66421 Homburg, Germany.	ncwste@uniklinik-saarland.de					ADELOYE A, 1976, INT SURG, V61, P478; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; CORTBUS F, 1999, KLINIK FORSCHUNG, V5, P4; CORTBUS F, 2002, NEUROTRAUMA, P69; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; FIELD FG, 1996, EPIDEMIOLOGY HEAD IN; Firsching R, 2001, WORLD J SURG, V25, P1221; GRONWALL D, 1974, LANCET, V2, P605; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KARLSBECK WD, 1981, J NEUROSURG S, V53, P19; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KOCH G, 1996, UNFALLURSACHEN BEIM; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; LILLARD PL, 1978, SURG NEUROL, V9, P79; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MacKenzie E J, 1989, Md Med J, V38, P725; MacMillan R, 1979, Health Bull (Edinb), V37, P75; PHONPRASERT C, 1980, J TRAUMA, V20, P679, DOI 10.1097/00005373-198008000-00008; PLAUT MR, 1976, MIL MED, V141, P244; RAIMONDI A, 1979, J NEUROSURG, V32, P647; SELECKI BR, 1982, AUST NZ J SURG, V52, P93, DOI 10.1111/j.1445-2197.1982.tb05297.x; Servadei F, 2002, J Neurosurg Sci, V46, P111; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V268, P791, DOI 10.1001/jama.1992.03490060127048; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Turazzi S, 1975, J Neurosurg Sci, V19, P215; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; 1983, SCI AM, V249, P20	34	58	59	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2005	147	3					231	242		10.1007/s00701-004-0441-y			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	905YW	WOS:000227608700002	15627922				2021-06-18	
J	Van Goethem, JWM; Maes, M; Ozsarlak, O; van den Hauwe, L; Parizel, PM				Van Goethem, JWM; Maes, M; Ozsarlak, O; van den Hauwe, L; Parizel, PM			Imaging in spinal trauma	EUROPEAN RADIOLOGY			English	Article						spine, trauma; spine, fractures; spine, injuries; spine, MR; spine, CT	FLEXION-EXTENSION RADIOGRAPHS; LOW-RISK CRITERIA; CERVICAL-SPINE; BLUNT TRAUMA; CORD-INJURY; HELICAL CT; COMPUTED-TOMOGRAPHY; DECISION RULE; FRACTURES; CHILDREN	Because it may cause paralysis, injury to the spine is one of the most feared traumas, and spinal cord injury is a major cause of disability. In the USA approximately 10,000 traumatic cervical spine fractures and 4000 traumatic thoracolumbar fractures are diagnosed each year. Although the number of individuals sustaining paralysis is far less than those with moderate or severe brain injury, the socioeconomic costs are significant. Since most of the spinal trauma patients survive their injuries, almost one out of 1000 inhabitants in the USA are currently being cared for partial or complete paralysis. Little controversy exists regarding the need for accurate and emergent imaging assessment of I e traumatized spine in order to evaluate spinal stability and integrity of neural elements. Because clinicians fear missing occult spine injuries, they obtain radiographs for nearly all patients who present with blunt trauma. We are influenced on one side by fear of litigation and the possible devastating medical, psychologic and financial consequences of cervical spine injury, and on the other side by pressure to reduce health care costs. A set of clinical and/or anamnestic criteria, however, can be very useful in identifying patients who have an extremely low probability of injury and who consequently have no need for imaging studies. Multidetector (or multislice) computed tomography (MDCT) is the preferred primary imaging modality in blunt spinal trauma patients who do need imaging. Not only is CT more accurate in diagnosing spinal injury, it also reduces imaging time and patient manipulation. Evidence-based research has established that MDCT improves patient outcome and saves money in comparison to plain film. This review discusses the use, advantages and disadvantages of the different imaging techniques used in spinal trauma patients and the criteria used in selecting patients who do not need imaging. Finally an overview of different types of spinal injuries is given.	Univ Antwerp, Univ Ziekenhuis Antwerpen, Dept Radiol, B-2650 Edegem, Belgium; Algemeen Ziekenhuis Maria Middelares, Dept Radiol, B-9100 St Niklaas, Belgium	Van Goethem, JWM (corresponding author), Univ Antwerp, Univ Ziekenhuis Antwerpen, Dept Radiol, Wilrijkstr 10, B-2650 Edegem, Belgium.	johan.vangoethem@ua.ac.be		Parizel, Paul M./0000-0002-0221-2854			Belanger E, 2000, J NEUROSURG, V93, P294, DOI 10.3171/spi.2000.93.2.0294; Bensch FV, 2004, EUR RADIOL, V14, P618, DOI 10.1007/s00330-003-2090-6; Besman A, 2003, AM SURGEON, V69, P1010; Blackmore CC, 2003, NEUROIMAG CLIN N AM, V13, P283, DOI 10.1016/S1052-5149(03)00024-8; Bogduk N, 2001, CLIN BIOMECH, V16, P267, DOI 10.1016/S0268-0033(01)00003-1; Chiu WC, 2001, J TRAUMA, V50, P457, DOI 10.1097/00005373-200103000-00009; Cirak B, 2004, J PEDIATR SURG, V39, P607, DOI 10.1016/j.jpedsurg.2003.12.011; CROWE H, 1964, Calif Med, V100, P12; Daffner RH, 2001, AM J ROENTGENOL, V177, P677, DOI 10.2214/ajr.177.3.1770677; Dai LY, 2004, J TRAUMA, V56, P348, DOI 10.1097/01.TA.0000035089.51187.43; DENIS F, 1983, SPINE, V8, P817, DOI 10.1097/00007632-198311000-00003; Dickinson G, 2004, ANN EMERG MED, V43, P507, DOI 10.1016/j.annemergmed.2003.10.036; Dwek JR, 2000, AM J ROENTGENOL, V174, P1617, DOI 10.2214/ajr.174.6.1741617; ELKHOURY GY, 1992, CLIN NEUR, V38, P261; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; FALCONE S, 1994, AM J NEURORADIOL, V15, P747; FLANDERS AE, 1990, RADIOLOGY, V177, P25, DOI 10.1148/radiology.177.1.2399326; GEBHARD JS, 1994, ORTHOP REV S, V23, P9; Geck MJ, 2001, J SPINAL DISORD, V14, P371, DOI 10.1097/00002517-200110000-00001; Goldberg W, 2001, ANN EMERG MED, V38, P17, DOI 10.1067/mem.2001.116150; Griffen MM, 2004, J TRAUMA, V56, P457; Gunzburg R, 2003, Pain Res Manag, V8, P24; Hanson JA, 2000, AM J ROENTGENOL, V174, P713, DOI 10.2214/ajr.174.3.1740713; Harris JH, 1996, RADIOLOGY ACUTE CERV; Hoffman JR, 2000, NEW ENGL J MED, V343, P1339; Hoffman JR, 1998, ANN EMERG MED, V32, P461, DOI 10.1016/S0196-0644(98)70176-3; Holmes JF, 2002, J TRAUMA, V53, P524, DOI 10.1097/00005373-200209000-00021; Insko EK, 2002, J TRAUMA, V53, P426, DOI 10.1097/00005373-200209000-00005; Jackson R Sean, 2002, J Am Acad Orthop Surg, V10, P271; Jenkins M G, 1999, Eur J Emerg Med, V6, P215; Linsenmaier U, 2002, EUR RADIOL, V12, P1728, DOI 10.1007/s00330-001-1225-x; Mann FA, 2003, EUR J RADIOL, V48, P39, DOI 10.1016/S0720-048X(03)00196-7; Mower WR, 2002, J TRAUMA, V53, P1198, DOI 10.1097/00005373-200212000-00039; Obenauer S, 2002, EUR RADIOL, V12, P2107, DOI 10.1007/s00330-001-1253-6; Oner FC, 1999, EUR SPINE J, V8, P194, DOI 10.1007/s005860050156; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; Pollack CV, 2001, ANN EMERG MED, V38, P8, DOI 10.1067/mem.2001.116810; Potter K, 2003, BRIT J RADIOL, V76, P347, DOI 10.1259/bjr/11881183; ROGERS LF, 1971, AMER J ROENTGENOL RA, V111, P844, DOI 10.2214/ajr.111.4.844; Sagiuchi T, 2002, J COMPUT ASSIST TOMO, V26, P654, DOI 10.1097/00004728-200207000-00032; SCHAEFER DM, 1992, J NEUROSURG, V76, P218, DOI 10.3171/jns.1992.76.2.0218; Stiell IG, 2003, NEW ENGL J MED, V349, P2510, DOI 10.1056/NEJMoa031375; Stiell IG, 2001, JAMA-J AM MED ASSOC, V286, P1841, DOI 10.1001/jama.286.15.1841; Stiell IG, 2000, ACAD EMERG MED, V7, P566; Taylor J R, 1993, Ann Acad Med Singap, V22, P187; Touger M, 2002, ANN EMERG MED, V40, P287, DOI 10.1067/mem.2002.125708; Van Goethem J W M, 2003, JBR-BTR, V86, P230; VanGoethem JWM, 1996, EUR J RADIOL, V22, P30, DOI 10.1016/0720-048X(95)00696-N; Vellman WP, 2003, SPINE, V28, P941; Wallis BJ, 1996, PAIN, V66, P223, DOI 10.1016/0304-3959(96)03044-8; Weisskopf M, 1999, UNFALLCHIRURG, V102, P942, DOI 10.1007/s001130050508; Wilmink JT, 1999, EUR RADIOL, V9, P1259, DOI 10.1007/s003300050832; WOODRING JH, 1993, J TRAUMA, V34, P32, DOI 10.1097/00005373-199301000-00006; WOODRING JH, 1992, J TRAUMA, V33, P698, DOI 10.1097/00005373-199211000-00019; Yue JJ, 2004, SPINE, V29, pE181, DOI 10.1097/00007632-200405010-00021	55	58	58	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	MAR	2005	15	3					582	590		10.1007/s00330-004-2625-5			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	912OT	WOS:000228089500019	15696292				2021-06-18	
J	Serbest, G; Horwitz, J; Barbee, K				Serbest, G; Horwitz, J; Barbee, K			The effect of Poloxamer-188 on neuronal cell recovery from mechanical injury	JOURNAL OF NEUROTRAUMA			English	Article						membrane damage; neuronal cells; Poloxamer; shear stress; traumatic brain injury	IN-VITRO MODEL; TRAUMATIC BRAIN-INJURY; STRAIN-RATE; PC12 CELLS; GROWTH; APOPTOSIS; GLUTAMATE; CALCIUM; DEATH; DIFFERENTIATION	Neuronal injury resulting from mechanical deformation is poorly characterized at the cellular level. The immediate structural consequences of the mechanical loading lead to a variety of inter- and intra-cellular signaling events that interact on multiple time and length scales. Thus, it is often difficult to establish cause-and-effect relationships such that appropriate treatment strategies can be devised. In this report, we showed that treating mechanically injured neuronal cells with an agent that promotes the resealing of disrupted plasma membranes rescues them from death at 24 h post-injury. A new in vitro model was developed to allow uniform mechanical loading conditions with precisely controlled magnitude and onset rate of loading. Injury severity increased monotonically with increasing peak shear stress and was strongly dependent on the rate of loading as assessed with the MTT cell viability assay, 24 h post-injury. Mechanical injury produced an immediate disruption of membrane integrity as indicated by a rapid and transient release of LDH. For the most severe injury, cell viability decreased approximately 40% with mechanical trauma compared to sham controls. Treatment of cells with Poloxamer 188 at 15 min post-injury restored long-term viability to control values. These data establish membrane integrity as a novel therapeutic target in the treatment of neuronal injury.	Drexel Univ, Sch Biomed Engn, Sci & Hlth Syst, Philadelphia, PA 19104 USA; Pharmacol Drexel Univ, Coll Med, Philadelphia, PA USA	Barbee, K (corresponding author), Drexel Univ, Sch Biomed Engn, Sci & Hlth Syst, Philadelphia, PA 19104 USA.	barbee@coe.drexel.edu	Barbee, Kenneth/F-4333-2014		ODCDC CDC HHS [R49/CCR316574-01-3] Funding Source: Medline		Allen RT, 1997, J PHARMACOL TOX MET, V37, P215, DOI 10.1016/S1056-8719(97)00033-6; BARBEE KA, 1995, AM J PHYSIOL-HEART C, V268, pH1765; Blackman BR, 2000, ANN BIOMED ENG, V28, P363, DOI 10.1114/1.286; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Colowick S. C., 1993, METHODS ENZYMOLOGY; Das KP, 2004, NEUROTOXICOL TERATOL, V26, P397, DOI 10.1016/j.ntt.2004.02.006; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; EDLICH RF, 1973, J SURG RES, V14, P277, DOI 10.1016/0022-4804(73)90029-2; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; Hannig J, 2000, RADIAT RES, V154, P171, DOI 10.1667/0033-7587(2000)154[0171:SSOMPB]2.0.CO;2; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Heneka MT, 1998, J NEUROCHEM, V71, P88; KABANOV AV, 1995, MACROMOLECULES, V28, P2303, DOI 10.1021/ma00111a026; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; KESHMIRIAN J, 1989, J NEUROCYTOL, V18, P491, DOI 10.1007/BF01474545; Kitazawa M, 2004, NEUROTOXICOLOGY, V25, P589, DOI 10.1016/j.neuro.2003.09.014; Kobayashi N, 1998, CELL TISSUE RES, V291, P163, DOI 10.1007/s004410050988; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; LEE RC, 1994, ANN NY ACAD SCI, V720, P239, DOI 10.1111/j.1749-6632.1994.tb30453.x; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Mills JC, 1997, EXP CELL RES, V231, P337, DOI 10.1006/excr.1997.3474; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Nakayama Y, 2001, J NEUROTRAUM, V18, P545, DOI 10.1089/089771501300227341; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; PADANILAM JT, 1994, ANN NY ACAD SCI, V720, P111, DOI 10.1111/j.1749-6632.1994.tb30439.x; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; SCHMOLKA IR, 1977, J AM OIL CHEM SOC, V54, P110, DOI 10.1007/BF02894385; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; TAHIR SK, 1992, BIOCHEM CELL BIOL, V70, P1159, DOI 10.1139/o92-162; Terry MA, 1999, ANN NY ACAD SCI, V888, P274, DOI 10.1111/j.1749-6632.1999.tb07962.x; Ulloth JE, 2003, J NEUROCHEM, V84, P655, DOI 10.1046/j.1471-4159.2003.01571.x; Verma A, 2000, J HEAD TRAUMA REHAB, V15, P1149, DOI 10.1097/00001199-200010000-00008; Yang E, 2004, CELL MOL NEUROBIOL, V24, P181, DOI 10.1023/B:CEMN.0000018615.84358.33; ZHELEV DV, 1993, BIOCHIM BIOPHYS ACTA, V1147, P89, DOI 10.1016/0005-2736(93)90319-U	58	58	61	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2005	22	1					119	132		10.1089/neu.2005.22.119			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	889OF	WOS:000226451600008	15665607				2021-06-18	
J	Gooch, JL; Oberg, WA; Grams, B; Ward, LA; Walker, ML				Gooch, JL; Oberg, WA; Grams, B; Ward, LA; Walker, ML			Care provider assessment of intrathecal baclofen in children	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							GROSS MOTOR FUNCTION; CEREBRAL-PALSY; SPASTICITY; INFUSION; ORIGIN; TRIAL	Intrathecal baclofen is used increasingly to manage severe spasticity in children. Before implanting the baclofen pump, care providers typically ask how it will benefit their child. The purpose of this study was to describe the perceptions of care providers about intrathecal baclofen for management of spasticity in 80 individuals (52 males, 28 females). The individuals were younger than 22 years at the time of implantation (mean age 11 years, SD 5 years; range 3 to 21 years). Participants had been implanted with the pump for a minimum of one year at the time of evaluation. The most common diagnoses were quadriplegic and diplegic cerebral palsy and traumatic brain injury. Most participants were at level IV and V on the Gross Motor Function Classification System. After pump implantation most participants had tone reduction on the Ashworth scale of 1 to 1.9 in the lower extremities and 0 to 0.9 in the upper extremities. Lower extremity range of motion was maintained in 43 of 51 individuals (84%) and lost in 8 participants (16%). Complications requiring surgery occurred in 63 of a larger group of 152 patients (incidence per patient-year of follow-up was 0.19). Thirty-one of the 80 children had orthopedic procedures after pump placement. Only one of these was unexpected and none had rapid progression of scoliosis. Most treatment goals were achieved. Goals most commonly chosen (decreased pain, prevention of worsening of deformity, and improved ease of care) were improved in 91%, 91%, and 88% of participants respectively. Ninety-five per cent of care providers agreed that they would have this procedure performed again (81% strongly agreed, 14% slightly agreed). All care providers reported improvement in scores on the Caregiver Questionnaire. This information has been helpful to families considering intrathecal baclofen therapy.	Univ Utah, Hlth Sci Ctr, Primary Childrens Med Ctr, Salt Lake City, UT 84113 USA	Gooch, JL (corresponding author), Univ Utah, Hlth Sci Ctr, Primary Childrens Med Ctr, 100 N Med Dr, Salt Lake City, UT 84113 USA.	pcjgooch@IHC.com					ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; Armstrong RW, 1997, J NEUROSURG, V87, P409, DOI 10.3171/jns.1997.87.3.0409; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Campbell WM, 2002, DEV MED CHILD NEUROL, V44, P660; Gerszten PC, 1997, PEDIATR NEUROSURG, V27, P40, DOI 10.1159/000121223; Gilmartin R, 2000, J CHILD NEUROL, V15, P71, DOI 10.1177/088307380001500201; Gooch JL, 2003, PEDIATR NEUROSURG, V39, P1, DOI 10.1159/000070870; HALEY SM, 1991, PHYS MED REHABIL CLI, V2, P698; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; PENN RD, 1987, J NEUROSURG, V66, P181, DOI 10.3171/jns.1987.66.2.0181; RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341; Schneider JW, 2001, DEV MED CHILD NEUROL, V43, P601, DOI 10.1017/S0012162201001098	13	58	61	1	3	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	AUG	2004	46	8					548	552		10.1017/S001216220400091X			5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	842EW	WOS:000222987100008	15287246				2021-06-18	
J	Stranjalis, G; Korfias, S; Papapetrou, C; Kouyialis, A; Boviatsis, E; Psachoulia, C; Sakas, DE				Stranjalis, G; Korfias, S; Papapetrou, C; Kouyialis, A; Boviatsis, E; Psachoulia, C; Sakas, DE			Elevated serum S-100B protein as a predictor of failure to short-term return to work or activities after mild head injury	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; MHI; mild or minor or ultra-mild head injury; outcome; S-100B; TBI	BRAIN INJURY; CLASSIFICATION; CONCUSSION; MANAGEMENT	Protein S-100B is an established serum marker of primary and secondary brain damage and stroke. A group of patients after mild head injury (MHI) develop post-concussion symptoms that interfere with the ability in the short-term to return to work or undertake certain activities. The aim of this study was to examine the correlation of serum S-100B with short-term outcome after MHI. We studied 100 subjects who were referred to the Emergency Department (ED) after a MHI. All subjects had a GCS of 15 either with or without loss of consciousness (LOC) and/or post-traumatic amnesia (PTA). Serum S-100B was collected within 3 h from the injury and a value of greater than or equal to0.15 mug/L was considered as abnormal. Subjects with other injuries, including scalp or cervical spine, were excluded, as well as those with alcohol/narcotic drug consumption or history of serious physical/mental illness. An independent observer measured the return to work/activities within one week. Thirty-two (32%) subjects had elevated S-100B. The failure to return to work/activities was significantly correlated with elevated S-100B: subjects with increased S-100B had a failure rate of 37.5% versus 4.9% of those with normal values (p = 0.0001). In MHI, the elevated S-100B seemed to correlate with an unfavorable short-term outcome. This might be useful in (1) selecting patients who need closer observation, hospitalization, and further investigations (such as CT scan or MRI), and (2) the prognosis of genuine post-concussion symptoms, that interfere with return to work or activities, versus other causes such as premorbid personality, labyrinthine dysfunction, whiplash syndrome, post-injury stress, occupational injury, litigation, and malingering.	Univ Athens, Evangelismos Hosp, Dept Neurosurg, Athens, Greece; Evangelismos Med Ctr, Dept Biochem, Athens, Greece	Stranjalis, G (corresponding author), 32 Skoufa St, Athens 10673, Greece.	stranjal@otenet.gr	Pillay, Nischalan/F-9536-2012				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1996, NEUROTRAUMA, P13; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MARION D, 1991, TRAUMATIC BRAIN INJU, P24; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	20	58	60	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2004	21	8					1070	1075		10.1089/0897715041651088			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	846AK	WOS:000223286800009	15319006				2021-06-18	
J	Osteen, CL; Giza, CC; Hovda, DA				Osteen, CL; Giza, CC; Hovda, DA			Injury-induced alterations in N-methyl-D-aspartate receptor subunit composition contribute to prolonged (45)calcium accumulation following lateral fluid percussion	NEUROSCIENCE			English	Article						calcium; glutamate; ifenprodil; MK-801; N-methyl-D-aspartate receptor; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPONTANEOUSLY HYPERTENSIVE-RATS; TRANSIENT CEREBRAL-ISCHEMIA; MESSENGER-RNA EXPRESSION; LONG-TERM POTENTIATION; AGE-RELATED-CHANGES; NMDA-RECEPTOR; IN-VITRO; POSTSYNAPTIC DENSITY-95; SYNAPTIC-TRANSMISSION	Cells that survive traumatic brain injury are exposed to changes in their neurochemical environment. One of these changes is a prolonged (48 h) uptake of calcium which, by itself, is not lethal. The N-methyl-D-aspartate receptor (NMDAR) is responsible for the acute membrane flux of calcium following trauma; however, it is unclear if it is involved in a flux lasting 2 days. We proposed that traumatic brain injury induced a molecular change in the NMDAR by modifying the concentrations of its corresponding subunits (NR1 and NR2). Changing these subunits could result in a receptor being more sensitive to glutamate and prolong its opening, thereby exposing cells to a sustained flux of calcium. To test this hypothesis, adult rats were subjected to a lateral fluid percussion brain injury and the NR1, NR2A and NR2B subunits measured within different regions. Although little change was seen in NR1, both NR2 subunits decreased nearly 50% compared with controls, particularly within the ipsilateral cerebral cortex. This decrease was sustained for 4 days with levels retuning to control values by 2 weeks. However, this decrease was not the same for both subunits, resulting in a decrease (over 30%) in the NR2A:NR2B ratio indicating that the NMDAR had temporarily become more sensitive to glutamate and would remain open longer once activated. Combining these regional and temporal findings with (41)calcium autoradiographic studies revealed that the degree of change in the subunit ratio corresponded to the extent of calcium accumulation. Finally, utilizing a combination of NMDAR and NR2B-specific antagonists it was determined that as much at 85% of the long term NMDAR-mediated calcium flux occurs through receptors whose subunits favor the NR2B subunit. These data indicate that TBI induces molecular changes within the NMDAR, contributing to the cells' post-injury vulnerability to glutamatergic stimulation. (C) 2004 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr,Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Interdept Program Mol Cellular & Integrat Physiol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Neurol, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA	Hovda, DA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr,Dept Surg, Room 18-228 NPI,Box 957039, Los Angeles, CA 90095 USA.	dhovda@mednet.ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, NS02197, NS27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; ARAKI T, 1990, BRAIN RES, V528, P114, DOI 10.1016/0006-8993(90)90202-M; BEHE P, 1995, P ROY SOC B-BIOL SCI, V262, P205, DOI 10.1098/rspb.1995.0197; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BETZ AL, 1989, BASIC NEUROCHEMISTRY, P591; Bi XN, 2000, METH MOL B, V144, P203; Boyce S, 1999, NEUROPHARMACOLOGY, V38, P611, DOI 10.1016/S0028-3908(98)00218-4; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chizh BA, 2001, NEUROPHARMACOLOGY, V40, P212, DOI 10.1016/S0028-3908(00)00148-9; Clayton DA, 2002, J NEUROSCI, V22, P3628; Clayton DA, 2001, NEUROBIOL AGING, V22, P165, DOI 10.1016/S0197-4580(00)00196-2; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Coughenour LL, 2001, J PHARMACOL EXP THER, V296, P150; Dawson DA, 2001, BRAIN RES, V892, P344, DOI 10.1016/S0006-8993(00)03269-8; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; DIENEL GA, 1984, J NEUROCHEM, V43, P913, DOI 10.1111/j.1471-4159.1984.tb12825.x; Dingledine R, 1999, PHARMACOL REV, V51, P7; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dravolina OA, 2000, PHARMACOL BIOCHEM BE, V65, P611, DOI 10.1016/S0091-3057(99)00232-4; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Flint AC, 1997, J NEUROSCI, V17, P2469; GASS P, 1993, J CEREBR BLOOD F MET, V13, P337, DOI 10.1038/jcbfm.1993.42; Ghosh S, 1997, NEUROL RES, V19, P403, DOI 10.1080/01616412.1997.11740833; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GORMAN LK, 1995, J NEUROTRAUM, V12, P120; Guzikowski AP, 2000, J MED CHEM, V43, P984, DOI 10.1021/jm990428c; Healy DJ, 2000, SYNAPSE, V38, P294, DOI 10.1002/1098-2396(20001201)38:3<294::AID-SYN8>3.0.CO;2-U; HENS JJH, 1997, NEUOTRANSMITTER METH, P61; HEURTEAUX C, 1994, BRAIN RES, V659, P67, DOI 10.1016/0006-8993(94)90864-8; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOVDA DA, 1996, NEUROTRAUMA, P1459; Hsu JC, 1998, J CEREBR BLOOD F MET, V18, P768, DOI 10.1097/00004647-199807000-00008; Husi H, 2000, NAT NEUROSCI, V3, P661; Husi H, 2001, TRENDS NEUROSCI, V24, P259, DOI 10.1016/S0166-2236(00)01792-6; Husi H, 2001, J NEUROCHEM, V77, P281, DOI 10.1046/j.1471-4159.2001.00248.x; ISHII T, 1993, J BIOL CHEM, V268, P2836; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kew JNC, 1996, J PHYSIOL-LONDON, V497, P761, DOI 10.1113/jphysiol.1996.sp021807; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lu XY, 2001, J NEUROCHEM, V77, P1553, DOI 10.1046/j.1471-4159.2001.00359.x; Luo JH, 1997, MOL PHARMACOL, V51, P79; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Magnusson KR, 2002, MOL BRAIN RES, V99, P40, DOI 10.1016/S0169-328X(01)00344-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Migaud M, 1998, NATURE, V396, P433; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Murray F, 2000, EUR J PHARMACOL, V397, P263, DOI 10.1016/S0014-2999(00)00263-6; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NAGASAWA H, 1990, BRAIN RES, V524, P196, DOI 10.1016/0006-8993(90)90690-D; Nash JE, 1999, EXP NEUROL, V155, P42, DOI 10.1006/exnr.1998.6963; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Quinlan EM, 1999, P NATL ACAD SCI USA, V96, P12876, DOI 10.1073/pnas.96.22.12876; RAPPAPORT ZH, 1987, STROKE, V18, P760, DOI 10.1161/01.STR.18.4.760; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Samii A, 1999, J NEUROTRAUM, V16, P879, DOI 10.1089/neu.1999.16.879; SCHEETZ AJ, 1994, FASEB J, V8, P745; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Seeburg P., 1994, NMDA RECEPTOR, P147; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; SHIROTANI T, 1994, J CEREBR BLOOD F MET, V14, P831, DOI 10.1038/jcbfm.1994.104; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Small DL, 1997, NEUROSCI LETT, V232, P87, DOI 10.1016/S0304-3940(97)00592-2; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Takagi N, 1997, J NEUROCHEM, V69, P1060; Tang YP, 1999, NATURE, V401, P63; THOMAS M J, 1990, Society for Neuroscience Abstracts, V16, P777; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; VEZZANI A, 1989, J PHARMACOL EXP THER, V249, P278; WANG YH, 1995, J NEUROCHEM, V65, P176; Watanabe H, 1998, J CEREBR BLOOD F MET, V18, P686, DOI 10.1097/00004647-199806000-00011; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Yamakura T, 1999, PROG NEUROBIOL, V59, P279, DOI 10.1016/S0301-0082(99)00007-6; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang L, 1997, J NEUROCHEM, V69, P1983	96	58	61	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2004	128	2					305	322		10.1016/j.neuroscience.2004.06.034			18	Neurosciences	Neurosciences & Neurology	855AJ	WOS:000223944900009	15350643				2021-06-18	
J	Turkstra, LS; Dixon, TM; Baker, KK				Turkstra, LS; Dixon, TM; Baker, KK			Theory of Mind and social beliefs in adolescents with traumatic brain injury	NEUROREHABILITATION			English	Article						brain injury; adolescent; theory of mind; social	PRAGMATIC LANGUAGE-SKILLS; HEAD-INJURY; CHILDREN; INDIVIDUALS; CHILDHOOD; DAMAGE	Impairments in social performance are common consequences of TBI, yet the neuropsychological basis of these impairments is not well understood. This is particularly true for adolescents, who have the highest incidence of TBI and are at a critical stage of developing social and relationship skills. To address this, adolescents with TBI were compared to their typically developing peers on a social cognition task that included Theory of Mind (ToM) questions. As ToM may be necessary for the development of culture-specific social knowledge, the two groups also were compared in regard to their social beliefs. There were significant differences between injured and uninjured adolescents in social cognition, with group differences increasing as a function of the requirement for ToM. There were few differences in self-reported social knowledge and social beliefs. The implication of this discrepancy for the rehabilitation of adolescents with TBI is discussed.	Case Western Reserve Univ, Cleveland, OH 44106 USA	Turkstra, LS (corresponding author), Univ Wisconsin, Dept Communicat Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	lsturkstra@wisc.edu			NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC-00163] Funding Source: Medline		Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Baron-Cohen S, 2000, NEUROSCI BIOBEHAV R, V24, P355, DOI 10.1016/S0149-7634(00)00011-7; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Csikszentmihalyi M., 1984, BEING ADOLESCENT CON; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DAMON W, 1982, CHILD DEV, V53, P841, DOI 10.2307/1129122; Damon W., 1983, SOCIAL PERSONALITY D; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DEPOMPEI R, 1999, REHABILITATION ADULT, P393; Dunn J., 1994, CHILDRENS EARLY UNDE, P297; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Flanagan S., 1998, AWARENESS SOCIAL INF; GARCIA L, 1997, DEV SOCIAL COGNITION, P365; GERACI RI, 1980, SOCIAL KNOWLEDGE INT; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Hartley L. L., 1995, COGNITIVE COMMUNICAT; JENNETT B, 1975, LANCET, V1, P480; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; LAPSLEY DK, 1986, DEV PSYCHOL, V22, P800, DOI 10.1037/0012-1649.22.6.800; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lewis JK, 2000, J HEAD TRAUMA REHAB, V15, P930, DOI 10.1097/00001199-200006000-00006; Marschark M, 2000, J CHILD PSYCHOL PSYC, V41, P1067, DOI 10.1017/S0021963099006496; McDonald S, 1998, CLIN LINGUIST PHONET, V12, P237, DOI 10.3109/02699209808985224; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; MCDONALD S, 1998, UNPUB FIELD TEST DAT; McNeny R., 1999, REHABILITATION ADULT, P242; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; RAFFAELLI M, 1989, J YOUTH ADOLESCENCE, V18, P567, DOI 10.1007/BF02139074; Rosenberg M., 1979, CONCEIVING SELF; Russell PA, 1998, J CHILD PSYCHOL PSYC, V39, P903, DOI 10.1111/1469-7610.00390; Shaffer D.R., 2000, SOCIAL PERSONALITY D; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Steinberg L., 1999, ADOLESCENCE; STRUCHEN M, 2003, SOCIAL COMMUNICATION; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 1998, APHASIOLOGY, V12, P421, DOI 10.1080/02687039808249541; Turkstra LS, 2001, J COMMUN DISORD, V34, P151, DOI 10.1016/S0021-9924(00)00046-0; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; *WH ORG, 2001, INT CLASS FUNCT DIS; Ylvisaker M., 1998, COLLABORATIVE BRAIN	51	58	58	0	22	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2004	19	3					245	256					12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	883HU	WOS:000226003000007	15502257				2021-06-18	
J	Urbahns, K; Horvath, E; Stasch, JP; Mauler, F				Urbahns, K; Horvath, E; Stasch, JP; Mauler, F			4-phenyl-4H-pyrans as IKCa channel blockers	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article							RAT CEREBRAL-CORTEX; BINDING; BRAIN; RECEPTORS; ANTAGONISTS; INHIBITION	4.Phenyl-4H-pyrans have been identified as potent and specific IKCa channel blockers. Their synthesis and structure-activity relationships are described. A selected derivative, rac-11, reduces the infarct volume in a rat subdural hematoma model of traumatic brain injury after iv administration. (C) 2003 Elsevier Ltd. All rights reserved.	Bayer AG, Pharma Res Ctr, Inst Med Chem, D-42096 Wuppertal, Germany; Pharma Res Ctr, Inst CNS Res, D-42096 Wuppertal, Germany; Pharma Res Ctr, Inst Cardiovasc Res, D-42096 Wuppertal, Germany	Urbahns, K (corresponding author), Bayer Yakuhim Ltd, Res Ctr Kyoto, 6-5-1-3 Kunimidai, Kyoto 6190219, Japan.	klaus.urbahns.ku1@bayer.co.jp					ANGEL I, 1991, FUNDAM CLIN PHARM, V5, P107, DOI 10.1111/j.1472-8206.1991.tb00704.x; [Anonymous], 1991, ANGEW CHEM, V103, P1587; BROWN GB, 1986, J NEUROSCI, V6, P2064; ELLORY JC, 1994, BRIT J PHARMACOL, V111, P903, DOI 10.1111/j.1476-5381.1994.tb14823.x; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P147; HUGUES M, 1982, J BIOL CHEM, V257, P2762; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796; LEE HR, 1984, LIFE SCI, V35, P721, DOI 10.1016/0024-3205(84)90340-0; LEWIN AH, 1989, MOL PHARMACOL, V35, P189; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REYNOLDS IJ, 1986, J PHARMACOL EXP THER, V237, P731; SCHOEMAKER H, 1985, EUR J PHARMACOL, V111, P273; Schwab A, 2001, AM J PHYSIOL-RENAL, V280, pF739; SCHWAB A, 1998, CURR RES ION CHANNEL, V3, P126; SORENSEN RG, 1989, MOL PHARMACOL, V36, P689; TAS PWL, 1988, NEUROSCI LETT, V94, P279, DOI 10.1016/0304-3940(88)90031-6; TRIGGLE DJ, 1989, MED RES REV, V9, P123, DOI 10.1002/med.2610090203; URBAHNS K, 1997, Patent No. 0758648; WAGNER JA, 1988, J NEUROSCI, V8, P3354; Wegner M, 1996, Hypertens Res, V19, P229, DOI 10.1291/hypres.19.229; WOLINSKY J, 1969, J ORG CHEM, V34, P3169, DOI 10.1021/jo01262a077	24	58	59	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	AUG 18	2003	13	16					2637	2639		10.1016/S0960-894X(03)00560-2			3	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	709AQ	WOS:000184602900004	12873483				2021-06-18	
J	Diaz-Parejo, P; Stahl, N; Xu, WB; Reinstrup, P; Ungerstedt, U; Nordstrom, CH				Diaz-Parejo, P; Stahl, N; Xu, WB; Reinstrup, P; Ungerstedt, U; Nordstrom, CH			Cerebral energy metabolism during transient hyperglycemia in patients with severe brain trauma	INTENSIVE CARE MEDICINE			English	Article						hyperglycemia; head injury; cerebral microdialysis; glucose; lactate; glutamate	ISCHEMIC CELL-DAMAGE; FOREBRAIN ISCHEMIA; LACTIC-ACIDOSIS; GLUCOSE LEVEL; PREISCHEMIC HYPERGLYCEMIA; DIABETES-MELLITUS; SKELETAL-MUSCLE; CYCLOSPORINE-A; HEAD-INJURY; RAT-BRAIN	Objective: To study whether transient hyperglycemia adversely affects cerebral energy metabolism in patients with severe traumatic brain lesions. Design and setting: Prospective, nonrandomized study in the neurosurgical intensive care unit of a university hospital. Patients: 108 patients treated for severe traumatic brain lesions. Interventions: All patients were treated according to neurosurgical intensive care routine including monitoring of, intracranial pressure. One microdialysis catheter was inserted via a burr hole frontally to that used for the intraventricular catheter ("better" position). In patients with focal lesions one or more catheters were inserted into cerebral cortex surrounding an evacuated focal contusion or underlying an evacuated hematoma ("worse" position). Perfusion rate was 0.3 mul/min and samples were taken every. 30 or 60 min. The levels of glucose, pyruvate, lactate, glutamate, and glycerol were analyzed and displayed bedside. Measurements and results: There were 18 episodes of moderate (12-15 mmol/1) and 6 episodes of pronounced (>15 mmol/1) hyperglycemia. Moderate hyperglycemia did not change intracerebral levels of lactate, pyruvate, glutamate, glycerol, or lactate/pyruvate ratio. Lactate concentrations increased during pronounced hyperglycemia. Pronounced cerebral lactic acidosis and a moderate increase in interstitial glycerol concentration indicating cell membrane degradation was observed in a single patient with pronounced, long-lasting hyperglycemia. Conclusions: Cerebral energy metabolism was affected by transient hyperglycemia only at blood glucose concentration above 15 mmol/l as shown by a moderate increase in interstitial lactate level.	Univ Lund Hosp, Dept Clin Neurosci, S-22185 Lund, Sweden; Univ Hosp Virgen Rocio, Dept Intens Care, Seville, Spain; Kunming Med Coll, Intens Care Unit, Kunming, Peoples R China; Univ Lund Hosp, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden	Nordstrom, CH (corresponding author), Univ Lund Hosp, Dept Clin Neurosci, S-22185 Lund, Sweden.			Stahl, Nils/0000-0003-2077-8103			BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BENVENISTE H, 1989, J NEUROCHEM, V52, P1741, DOI 10.1111/j.1471-4159.1989.tb07252.x; BERTRAND N, 1992, NEUROSCI LETT, V148, P81, DOI 10.1016/0304-3940(92)90809-L; Bruno A, 1999, NEUROLOGY, V52, P280, DOI 10.1212/WNL.52.2.280; Cherian L, 1997, CRIT CARE MED, V25, P1378, DOI 10.1097/00003246-199708000-00027; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; EKHOLM A, 1995, EXP BRAIN RES, V104, P462; Forsyth R, 1996, DEV NEUROSCI-BASEL, V18, P360, DOI 10.1159/000111429; Forsyth RJ, 1996, NEUROCHEM INT, V28, P231, DOI 10.1016/0197-0186(95)00094-1; Fray AE, 1996, J PHYSIOL-LONDON, V496, P49, DOI 10.1113/jphysiol.1996.sp021664; GERCKEN G, 1973, PFLUG ARCH EUR J PHY, V344, P207, DOI 10.1007/BF00588461; Gisselsson L, 1999, J CEREBR BLOOD F MET, V19, P288, DOI 10.1097/00004647-199903000-00007; GISSELSSON L, 1992, J CEREBR BLOOD F MET, V12, P809, DOI 10.1038/jcbfm.1992.112; HICKNER RC, 1992, ACTA PHYSIOL SCAND, V146, P87, DOI 10.1111/j.1748-1716.1992.tb09396.x; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; JANSSON PA, 1988, AM J PHYSIOL, V255, pE218; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; KATSURA K, 1992, EUR J NEUROSCI, V4, P166, DOI 10.1111/j.1460-9568.1992.tb00863.x; KRAIG RP, 1985, BRAIN RES, V342, P281, DOI 10.1016/0006-8993(85)91127-8; KRISTIAN T, 1996, LIFE SCI, V59, P57; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; LI PA, 1995, NEUROBIOL DIS, V2, P97, DOI 10.1006/nbdi.1995.0010; Li PA, 2000, STROKE, V31, P183, DOI 10.1161/01.STR.31.1.183; Li PA, 1999, FREE RADICAL BIO MED, V27, P1033, DOI 10.1016/S0891-5849(99)00152-5; Li PA, 1998, BRAIN RES, V804, P36, DOI 10.1016/S0006-8993(98)00651-9; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; Mitchell A J, 1997, J Stroke Cerebrovasc Dis, V6, P377, DOI 10.1016/S1052-3057(97)80038-9; NORDSTROM C, 1976, ACTA PHYSL SCAND, V98, P248; OPPENHEIMER SM, 1985, BRIT MED J, V291, P1014, DOI 10.1136/bmj.291.6501.1014-a; PALJARVI L, 1983, ACTA NEUROPATHOL, V60, P232, DOI 10.1007/BF00691871; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; PENTELENYI T, 1977, INJURY, V8, P264, DOI 10.1016/0020-1383(77)90099-7; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROSDAHL H, 1993, J PHYSIOL-LONDON, V471, P637, DOI 10.1113/jphysiol.1993.sp019920; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Schinder AF, 1996, J NEUROSCI, V16, P6125; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P253, DOI 10.1038/jcbfm.1985.32; SIESJO BK, 1978, BRAIN ENERGY METABOL, P192; TEASDALE G, 1974, LANCET, V2, P81; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; VANDENBERGHE, 2001, N ENGL J MED, V345, P1359; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; WOO J, 1990, ARCH NEUROL-CHICAGO, V47, P1174, DOI 10.1001/archneur.1990.00530110028011; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	51	58	60	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	APR	2003	29	4					544	550		10.1007/s00134-003-1669-3			7	Critical Care Medicine	General & Internal Medicine	676NY	WOS:000182759600007	12655390				2021-06-18	
J	Martin, LJ; Price, AC; McClendon, KB; Al-Abdulla, NA; Subramaniam, JR; Wong, PC; Liu, ZP				Martin, LJ; Price, AC; McClendon, KB; Al-Abdulla, NA; Subramaniam, JR; Wong, PC; Liu, ZP			Early events of target deprivation/axotomy-induced neuronal apoptosis in vivo: oxidative stress, DNA damage, p53 phosphorylation and subcellular redistribution of death proteins	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's disease; amyotrophic lateral sclerosis; cell death; DNA damage; Parkinson's disease; traumatic brain injury	LATERAL GENICULATE-NUCLEUS; PROGRAMMED CELL-DEATH; SUPEROXIDE-DISMUTASE; CEREBRAL-ISCHEMIA; GANGLION-CELLS; BAX; BRAIN; DEGENERATION; MITOCHONDRIA; ACTIVATION	The mechanisms of injury- and disease-associated apoptosis of neurons within the CNS are not understood. We used a model of cortical injury in rat and mouse to induce retrograde neuronal apoptosis in thalamus. In this animal model, unilateral ablation of the occipital cortex induces apoptosis of corticopetal projection neurons in the dorsal lateral geniculate nucleus (LGN), by 7 days post-lesion, that is p53 modulated and Bax dependent. We tested the hypothesis that this degenerative process is initiated by oxidative stress and early formation of DNA damage and is accompanied by changes in the levels of pro-apoptotic mediators of cell death. Immunoblotting revealed that the protein profiles of Bax, Bak and Bad were different during the progression of neuronal apoptosis in the LGN. Bax underwent a subcellular redistribution by 1 day post-lesion, while Bak increased later. Bad showed an early sustained increase. Cleaved caspase-3 was elevated maximally at 5 and 6 days. Active caspase-3 underwent a subcellular translocation to the nucleus. A dramatic phosphorylation of p53 was detected at 4 days post-lesion. DNA damage was assessed immunocytochemically as hydroxyl radical adducts (8-hydroxy-2-deoxyguanosine) and single-stranded DNA. Both forms of DNA damage accumulated early in target-deprived LGN neurons. Transgenic overexpression of superoxide dismutase-1 provided significant protection against the apoptosis but antioxidant pharmacotreatments with trolox and ascorbate were ineffective. We conclude that overlapping and sequential signaling pathways are involved in the apoptosis of adult brain neurons and that DNA damage generated by superoxide derivatives is an upstream mechanism for p53-regulated, Bax-dependent apoptosis of target-deprived neurons.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ Hosp, Wilmer Eye Inst, Baltimore, MD 21287 USA	Martin, LJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, 558 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	martinl@jhmi.edu		Subramaniam, Jamuna/0000-0003-0343-2469	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG016282] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG16282] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34100] Funding Source: Medline		Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; Al-Abdulla NA, 1998, AM J PATHOL, V153, P447, DOI 10.1016/S0002-9440(10)65588-5; Al-Abdulla NA, 2002, NEUROSCIENCE, V115, P7, DOI 10.1016/S0306-4522(02)00363-9; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Aust AE, 1999, P SOC EXP BIOL MED, V222, P246, DOI 10.1046/j.1525-1373.1999.d01-141.x; BARRON KD, 1967, J NEUROPATH EXP NEUR, V26, P300, DOI 10.1097/00005072-196704000-00007; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; Burke RE, 1998, ANN NEUROL, V44, pS126, DOI 10.1002/ana.410440719; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Carr A, 1999, FASEB J, V13, P1007; Castagna V, 1999, NEUROSCIENCE, V93, P313, DOI 10.1016/S0306-4522(99)00138-4; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; Conti AC, 1998, J NEUROSCI, V18, P5663; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DEL PL, 1997, SCIENCE, V278, P687; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frankfurt OS, 1996, EXP CELL RES, V226, P387, DOI 10.1006/excr.1996.0240; GIOLLI RA, 1971, J COMP NEUROL, V142, P351, DOI 10.1002/cne.901420306; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kermer P, 1998, J NEUROSCI, V18, P4656; Kitamura Y, 1999, JPN J PHARMACOL, V79, P1, DOI 10.1254/jjp.79.1; Klocker N, 1998, J NEUROSCI, V18, P1038; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; KOHN KW, 1991, PHARMACOL THERAPEUT, V49, P55, DOI 10.1016/0163-7258(91)90022-E; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lashley KS, 1941, J COMP NEUROL, V75, P67, DOI 10.1002/cne.900750105; Lesuisse C, 2002, J CEREBR BLOOD F MET, V22, P935, DOI 10.1097/00004647-200208000-00005; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lok J, 2002, J NEUROTRAUM, V19, P815, DOI 10.1089/08977150260190410; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; Martin LJ, 1999, J NEUROBIOL, V40, P185, DOI 10.1002/(SICI)1097-4695(199908)40:2<185::AID-NEU5>3.0.CO;2-#; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; Martin LJ, 2002, NEUROCHEM RES, V27, P1093, DOI 10.1023/A:1020961006216; Martin LJ, 2002, J NEUROBIOL, V50, P181, DOI 10.1002/neu.10026; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Martin LJ, 2000, NEUROBIOL DIS, V7, P613, DOI 10.1006/nbdi.2000.0314; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Mattacola CG, 1999, ATHLET THER TODAY, V4, P13; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Natale JE, 2002, NEUROSCIENCE, V112, P665, DOI 10.1016/S0306-4522(02)00098-2; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Salgo MG, 1996, ARCH BIOCHEM BIOPHYS, V333, P482, DOI 10.1006/abbi.1996.0418; Sefton A. J., 1985, RAT NERVOUS SYSTEM, V1, P169; SHANGARY S, 2000, J BIOL CHEM, V275; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Usuki F, 2001, NEUROSCI LETT, V304, P199, DOI 10.1016/S0304-3940(01)01764-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	61	58	61	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2003	85	1					234	247		10.1046/j.1471-4159.2003.01659.x			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	657EF	WOS:000181651900024	12641745				2021-06-18	
J	Okonkwo, DO; Melon, DE; Pellicane, AJ; Mutlu, LK; Rubin, DG; Stone, JR; Helm, GA				Okonkwo, DO; Melon, DE; Pellicane, AJ; Mutlu, LK; Rubin, DG; Stone, JR; Helm, GA			Dose-response of cyclosporin A in attenuating traumatic axonal injury in rat	NEUROREPORT			English	Article						calcineurin; cyclosporin A; diffuse axonal injury; mitochondria; traumatic brain injury	POSTTRAUMATIC BRAIN INJURY; CYTOCHROME-C RELEASE; DAMAGE; PERMEABILITY; MITOCHONDRIA; INHIBITION	Cyclosporin A has emerged as a promising therapeutic agent in traumatic brain injury (TBI), although its precise neuroprotective mechanism is unclear. Cyclosporin A, given as a single-dose intrathecal bolus, has previously been shown to attenuate mitochondrial damage and reduce axonal injury in experimental TBI. We assessed the effect of a range of intravenous cyclosporin A doses upon axonal injury attenuation to determine the ideal dose. Rats were subjected to experimental TBI and given one of five intravenous doses of cyclosporin A. At 3 h post-injury, brains were processed for brain tissue cyclosporin A concentration. In a second set of animals, at 24 h postinjury, brains were processed for amyloid precursor protein immunoreactivity, a widely used marker of axonal injury. Intravenous administration produced therapeutic levels of cyclosporin A in brain parenchyma. Higher concentrations were achieved with equivalent doses given intrathecally; this is consistent with the reported poor blood-brain barrier permeability of cyclosporin A. Cyclosporin A 10 mg/kg i.v. produced the greatest degree of neuroprotection against diffuse axonal injury; cyclosporin A 50 mg/kg i.v. was toxic. Intravenous cyclosporin A administration achieves therapeutic levels in brain parenchyma and 10 mg/kg is the most effective dose in attenuating axonal damage after traumatic brain injury.	Univ Virginia, Dept Neurosci, Charlottesville, VA 22908 USA; Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22908 USA	Okonkwo, DO (corresponding author), Univ Virginia, Dept Neurosci, POB 800212, Charlottesville, VA 22908 USA.						Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; SANGHVI A, 1988, CLIN CHEM, V34, P1904; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	22	58	61	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	MAR 3	2003	14	3					463	466		10.1097/01.wnr.0000058958.85541.d3			4	Neurosciences	Neurosciences & Neurology	656ZW	WOS:000181641800033	12634504				2021-06-18	
J	Velazquez, JLP; Frantseva, MV; Naus, CC				Velazquez, JLP; Frantseva, MV; Naus, CC			Gap junctions and neuronal injury: Protectants or executioners?	NEUROSCIENTIST			English	Article						brain; connexins; gap junctions; ischemia; trauma	INTERCELLULAR COMMUNICATION; HYPOXIA-REOXYGENATION; ISCHEMIA; CELLS; BRAIN; RAT; CONNEXIN43; DAMAGE; HYPERCONTRACTURE; VULNERABILITY	The authors review concepts and recent experimental observations that relate gap junctional communication to the pathophysiology of neuronal injury, specifically ischemic or traumatic damage. The role played by this type of direct intercellular communication during the progression of the injuries can be conceived to be either detrimental or beneficial, depending on the arguments employed. The data indicate that, far from being a simple matter of judgment, the contribution of gap junctions to cell injury is a complicated phenomenon that depends on the specific insult and network in which it operates.	Hosp Sick Children, Dept Neurol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Paediat, Div Neurol, Brain & Behav Program, Toronto, ON M5S 1A1, Canada; Univ British Columbia, Dept Anat, Vancouver, BC V5Z 1M9, Canada		jose-luis.perez-velazquez@sickkids.ca					Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Blanc EM, 1998, J NEUROCHEM, V70, P958; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Castejon OJ, 1998, BRAIN INJURY, V12, P409, DOI 10.1080/026990598122539; Chandross KJ, 1996, MOL CELL NEUROSCI, V7, P501, DOI 10.1006/mcne.1996.0036; Chang QA, 2000, J NEUROSCI, V20, P674, DOI 10.1523/JNEUROSCI.20-02-00674.2000; Cotrina ML, 1998, J NEUROSCI, V18, P2520; Daleau P, 1999, J MOL CELL CARDIOL, V31, P1391, DOI 10.1006/jmcc.1999.0973; DAVIDSON JS, 1988, J PHARMACOL EXP THER, V246, P1104; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; GarciaDorado D, 1997, CIRCULATION, V96, P3579; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Li WEI, 1998, EUR J NEUROSCI, V10, P2444, DOI 10.1046/j.1460-9568.1998.00253.x; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Martinez AD, 2000, BRAIN RES REV, V32, P250, DOI 10.1016/S0165-0173(99)00086-7; Nagaoka T, 1999, J HISTOCHEM CYTOCHEM, V47, P937, DOI 10.1177/002215549904700711; Nishida M, 2000, ENDOTHELIUM-NEW YORK, V7, P279, DOI 10.3109/10623320009072214; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; Oguro K, 2001, J NEUROSCI, V21, P7534; Ozog MA, 2002, J NEUROPATH EXP NEUR, V61, P132, DOI 10.1093/jnen/61.2.132; Rami A, 2000, EXP NEUROL, V170, P297, DOI 10.1006/exnr.2001.7712; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; ROHLMANN A, 1993, NEUROSCI LETT, V154, P206, DOI 10.1016/0304-3940(93)90208-3; Rozental R, 2000, BRAIN RES REV, V32, P189, DOI 10.1016/S0165-0173(99)00097-1; ROZENTAL R, 2001, METHODS MOL BIOL, V154; Ruiz-Meana M, 1999, CIRC RES, V85, P280, DOI 10.1161/01.RES.85.3.280; Sai KM, 2001, CANCER LETT, V173, P163, DOI 10.1016/S0304-3835(01)00616-4; Scemes E, 1998, GLIA, V24, P74, DOI 10.1002/(SICI)1098-1136(199809)24:1<74::AID-GLIA8>3.0.CO;2-0; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Sutor B, 2000, CEREB CORTEX, V10, P684, DOI 10.1093/cercor/10.7.684; Trosko JE, 1998, TOXICOL LETT, V103, P71, DOI 10.1016/S0378-4274(98)00288-4; Velazquez JLP, 1997, J NEUROSCI, V17, P9085; WARNER DS, 1995, ANESTHESIOLOGY, V82, P1237, DOI 10.1097/00000542-199505000-00019	36	58	61	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	FEB	2003	9	1					5	9		10.1177/1073858402239586			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	639RD	WOS:000180642300009	12580335				2021-06-18	
J	Berger, RP; Pierce, MC; Wisniewski, SR; Adelson, PD; Kochanek, PM				Berger, RP; Pierce, MC; Wisniewski, SR; Adelson, PD; Kochanek, PM			Serum S100B concentrations are increased after closed head injury in children: A preliminary study	JOURNAL OF NEUROTRAUMA			English	Article						child abuse; pediatrics; S100B; traumatic brain injury	S-100 PROTEIN MEASUREMENTS; TRAUMATIC BRAIN-DAMAGE; MARKERS; AGE	Traumatic brain injury (TBI) is a leading cause of death and disability in children. The current gold standards for diagnosis of TBI after closed head injury (CHI) have limitations, particularly in cases of inflicted injury. S100B is a protein that is specific to astrocytes. Serum S100B concentrations are increased in adults after CHI; there are no studies of serum S100B after CHI in children. The goal of this study was to measure the serum concentrations of S100B in children inflicted and noninflicted mild, moderate, and severe CHI. CHI severity was defined by initial Glasgow Coma Scale score. Forty-five children aged 0-13 years with mild (n = 27), moderate (n = 6), and severe (n = 12) CHI were enrolled prospectively. Blood was obtained as soon as possible after injury (range: 0.5-15.25 h) and every 12 h for up to 5 days when vascular access was available. Single control samples were obtained from 16 children aged 0-11 years with isolated long-bone fractures. Twenty-two patients (49%), including both patients with inflicted CHI, had an abnormal initial serum S100B concentration where an abnormal concentration was defined as greater than mean control concentration plus two standard deviations. S100B was detectable more than 12 h after injury only in patients with severe CHI. We conclude that serum S100B is increased in almost half of children after mild, moderate, and severe inflicted and noninflicted CHI. The increase is transient, lasting less than 12 h after injury, except in children with severe injury. Future research will focus on the possibility of using serum S100B as a screening test for inflicted CHI.	Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Berger, RP (corresponding author), Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Kochanek, Patrick M/D-2371-2015; Pierce, Mary Clyde/AAQ-3509-2021; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00084] Funding Source: Medline		DUHAIME AC, 1992, PEDIATRICS, V90, P179; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976	12	58	58	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1405	1409		10.1089/089771502320914633			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500001	12490005				2021-06-18	
J	Ruchholtz, S; Waydhas, C; Lewan, U; Piepenbrink, K; Stolke, D; Debatin, J; Schweiberer, L; Nast-Kolb, D				Ruchholtz, S; Waydhas, C; Lewan, U; Piepenbrink, K; Stolke, D; Debatin, J; Schweiberer, L; Nast-Kolb, D			A multidisciplinary quality management system for the early treatment of severely injured patients: implementation and results in two trauma centers	INTENSIVE CARE MEDICINE			English	Article						quality management; early clinical therapy; multiple injuries; severe blunt trauma; penetrating trauma; emergency operation	ACUTE SUBDURAL-HEMATOMA; MISSED INJURIES; PREVENTABLE DEATHS; COMATOSE PATIENTS; CARE; IMPROVEMENT; MORBIDITY; MORTALITY; DIRECTIONS; ALGORITHM	Objective: The impact of a multidisciplinary quality management system (MQMS) on the early treatment of severely injured patients was tested. Design and setting: Prospective clinical study in two level I trauma centers. Methods and materials: MQMS comprised a protocol for documentation, 20 assessment criteria, and the judgement of data by a quality circle. After implementation in Munich (1st period, n=90; 2nd period, n=77) the validation took place in Essen (1st period, n=175; 2nd period, n=150). Results: Improvements in diagnostics were shown by significant time savings in radiological diagnostics and before computed tomography in severe traumatic brain injury. In patients with hemorrhagic shock there was a reduction in time before transfusion (49 to 14 min in Munich; 31 to 22 min in Essen) and before emergency operation (74 to 43 min in Munich; 69 to 45 min in Essen). The time before craniotomy was reduced from 97 to 67 min in Munich. The incidence of delayed diagnosis of life-threatening lesions was diminished from 6% to 3% in Munich (not found in Essen). The TRISS technique showed a reduction in mortality in both hospitals in the second period (Munich: 15.4% TRISS vs. 9.1% observed mortality; Essen: 17.8% vs. 11.3%). Conclusions: MQMS improved early clinical treatment in severe injury with respect to therapeutic effectiveness and outcome. The effectiveness of the MQMS was shown at two different hospitals.	Univ Hosp Essen, Dept Trauma Surg, D-45122 Essen, Germany; Univ Hosp Essen, Dept Anesthesiol, D-45122 Essen, Germany; Univ Hosp Essen, Dept Neurosurg, D-45122 Essen, Germany; Univ Hosp Essen, Dept Radiol, D-45122 Essen, Germany; Univ Munich, Klinikum Innenstadt, Dept Surg, D-8000 Munich, Germany	Ruchholtz, S (corresponding author), Univ Hosp Essen, Dept Trauma Surg, Hufelandstr 55, D-45122 Essen, Germany.						*AM COLL SURG COMM, 1993, RES OPT CAR INJ PAT; BISHOP M, 1991, AM SURGEON, V57, P736; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CAMPBELL S, 1989, AM SURGEON, V55, P478; CAYTEN CG, 1991, ANN SURG, V214, P510, DOI 10.1097/00000658-199110000-00015; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHAMPION HR, 1992, ARCH SURG-CHICAGO, V127, P333; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; COPES WS, 1995, J TRAUMA, V38, P432, DOI 10.1097/00005373-199503000-00027; DAVIS JW, 1991, J TRAUMA, V31, P813, DOI 10.1097/00005373-199106000-00012; DEMING WE, 1985, OUT CRISIS; DRAAISMA JMT, 1989, J TRAUMA, V29, P1552; ESPOSITO TJ, 1995, ARCH SURG-CHICAGO, V130, P171; HIRSHBERG A, 1994, AM J SURG, V168, P299, DOI 10.1016/S0002-9610(05)80152-7; HOYT DB, 1992, J TRAUMA, V33, P586, DOI 10.1097/00005373-199210000-00016; HOYT DB, 1994, J TRAUMA, V36, P377, DOI 10.1097/00005373-199403000-00017; Ishikawa K, 1985, WHAT IS TOTAL QUALIT; Juran J., 1989, JURAN LEADERSHIP QUA; KREIS DJ, 1986, J TRAUMA, V26, P649, DOI 10.1097/00005373-198607000-00010; LIU M, 1988, CRIT CARE MED, V16, P1191, DOI 10.1097/00003246-198812000-00004; MACKENZIE EJ, 1992, J TRAUMA, V33, P292, DOI 10.1097/00005373-199208000-00021; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; McDermott FT, 1996, J TRAUMA, V40, P520, DOI 10.1097/00005373-199604000-00003; MUCKART DJJ, 1991, AM J SURG, V162, P457, DOI 10.1016/0002-9610(91)90260-K; NASTKOLB D, 1994, UNFALLCHIRURG, V97, P292; Robertson R, 1996, AM J SURG, V172, P564, DOI 10.1016/S0002-9610(96)00247-4; Ruchholtz S, 1998, INJURY, V29, P115, DOI 10.1016/S0020-1383(97)00150-2; SCHWARTZ ML, 1991, J TRAUMA, V31, P962, DOI 10.1097/00005373-199107000-00013; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHACKFORD SR, 1987, J TRAUMA, V27, P866, DOI 10.1097/00005373-198708000-00004; STOCCHETTI N, 1994, J TRAUMA, V36, P401, DOI 10.1097/00005373-199403000-00022; STOTHERT JC, 1990, J TRAUMA, V30, P1021, DOI 10.1097/00005373-199008000-00012; Sung CK, 1996, J TRAUMA, V41, P276, DOI 10.1097/00005373-199608000-00013; TRUNKEY D, 1991, NEW ENGL J MED, V324, P1259; WENNEKER WW, 1990, AM J SURG, V160, P655, DOI 10.1016/S0002-9610(05)80768-8; WEST JG, 1979, ARCH SURG-CHICAGO, V114, P455; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILSON DS, 1992, J TRAUMA, V32, P45, DOI 10.1097/00005373-199201000-00010; Zintl B, 1997, UNFALLCHIRURG, V100, P811, DOI 10.1007/s001130050198	39	58	62	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	OCT	2002	28	10					1395	1404		10.1007/s00134-002-1446-8			10	Critical Care Medicine	General & Internal Medicine	641PG	WOS:000180753500006	12373463				2021-06-18	
J	Yount, R; Raschke, KA; Biru, M; Tate, DF; Miller, MJ; Abildskov, T; Gandhi, P; Ryser, D; Hopkins, RO; Bigler, ED				Yount, R; Raschke, KA; Biru, M; Tate, DF; Miller, MJ; Abildskov, T; Gandhi, P; Ryser, D; Hopkins, RO; Bigler, ED			Traumatic brain injury and atrophy of the cingulate gyrus	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							ANTERIOR CINGULATE; AXONAL INJURY; CORTEX; MR; DEFICITS; ANATOMY; REGIONS; DAMAGE	The medial surface areas of the cingulate gyrus (CG) and other midline structures (corpus cal-losum, thalamus, lateral ventricle) were examined in 27 traumatically brain injured (TBI) and 12 age- and gender-matched control subjects from an established TBI data base. Significant atrophy, primarily in the posterior CG, was found in TBI patients. Degree of atrophy was related to severity of injury. TBI subjects also had significantly reduced corpus callosum and thalamic cross-sectional surface areas with associated increased lateral ventricular volume, as well as reduced brain volume and increased ventricle-to-brain ratio. Despite significant atrophy of the posterior CG, neuropsychological performance was not related to changes in CG cross-sectional surface area in the TBI subjects. This apparent discrepancy is discussed.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Univ Maryland, Dept Biol, College Pk, MD 20742 USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; LDS Hosp, Dept Phys Med & Rehabil, Salt Lake City, UT USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu	Tate, David/G-5166-2011	Tate, David/0000-0003-0213-1920			Beck A.T., 1987, BECK DEPRESSION INVE; Beck AT., 1990, BECK ANXIETY INVENTO; Berman KF, 1999, NEUROBIOLOGY MENTAL, P246; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bigler ED, 2000, AM J NEURORADIOL, V21, P1857; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Carter CS, 1997, AM J PSYCHIAT, V154, P1670, DOI 10.1176/ajp.154.12.1670; CLARK DL, 2000, BRAIN BEHAV INTRO BE; CONNOR PD, 1995, THESIS BRIGHAM YOUNG; CUMMINGS JL, 2000, TXB GERIATRIC NEUROP, P81; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GEN AD, 1994, IMAGING HEAD TRAUMA; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GLUHBEGOVIC N, 1980, HUMANBRAIN PHOTOGRAP; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; Hinnant D.W., 1999, TRAUMATIC BRAIN INJU, P187; Killiany RJ, 2000, ANN NEUROL, V47, P430, DOI 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.3.CO;2-9; Levin H.S., 1996, TRAUMATIC BRAIN INJU, P105; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LONG CJ, 1978, J NEUROSURG, V49, P264, DOI 10.3171/jns.1978.49.2.0264; MALAMUD N, 1967, ARCH NEUROL-CHICAGO, V17, P113, DOI 10.1001/archneur.1967.00470260003001; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; Mesulam MM, 2000, PRINCIPLES BEHAV COG, P1; Ono M, 1990, ATLAS CEREBRAL SULCI; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; RASBAND W, 1994, NIH IMAGE 155; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A., 1958, LEXAMEN CLINIQUE PSY; Roberts M, 1970, ATLAS HUMAN BRAIN SE; Saykin AJ, 1999, BRAIN, V122, P1963, DOI 10.1093/brain/122.10.1963; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; SUTHERLAND RJ, 1993, NEUROBIOLOGY CINGULA, P461; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; VALENSTEIN E, 1987, BRAIN, V110, P1631, DOI 10.1093/brain/110.6.1631; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; VOGT BA, 1993, NEUROBIOLOGY CINGULA, P19, DOI DOI 10.1007/978-1-4899-6704-6_2; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wu J, 1999, AM J PSYCHIAT, V156, P1149	48	58	59	0	4	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2002	14	4					416	423		10.1176/appi.neuropsych.14.4.416			8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	611ZB	WOS:000179047300004	12426409				2021-06-18	
J	Engelberts, NHJ; Klein, M; Ader, HJ; Heimans, JJ; Trenite, DGAKN; van der Ploeg, HM				Engelberts, NHJ; Klein, M; Ader, HJ; Heimans, JJ; Trenite, DGAKN; van der Ploeg, HM			The effectiveness of cognitive rehabilitation for attention deficits in focal seizures: A randomized controlled study	EPILEPSIA			English	Article						cognitive rehabilitation; epilepsy; attention deficits; randomized controlled study	CLOSED-HEAD-INJURY; HEALTH SURVEY; BRAIN-INJURY; EPILEPSY; PROGRAM; MEMORY; RELIABILITY; EDUCATION; DISEASE; SF-36	Purpose: Cognitive deficits are one of the major limiting factors in the everyday life functioning of patients with focal Seizures. Although cognitive rehabilitation methods have been successfully applied to patients with other central nervous system (CNS) lesions, these methods have not yet been evaluated in cognitively impaired patients with epilepsy. The present study evaluated the effectiveness of two commonly used methods for attention deficits: (a) the Retraining Method, aimed at retraining impaired cognitive functions; and (b) the Compensation Method, aimed at teaching compensatory strategies while taking neuronal loss for granted. Methods: Fifty adult Outpatients with focal seizures and attention impairments receiving carbamazepine (CBZ) monotherapy were randomly assigned to the Retraining Method, the Compensation Method, or to a waiting-list control group. Established and self-reported neuropsychological outcomes and self-reported quality of life of these groups were evaluated at pretraining, posttraining, and at a 6-month follow-up measurement point and were completed by 44 patients. Results: Neuropsychological outcomes related to training, self-reported neuropsychological outcomes, and quality of life at the 6-month follow-up measurement point improved both in the Retraining Method group (n = 19) and the Compensation Method group (n = 17) relative to the waiting-list control group (n = 8). The Compensation Method was more effective in improving self-reported neuropsychological outcomes and quality of life, especially for patients with less education. The patients with active epilepsy benefited more from both methods than did the seizure-free patients. Conclusions: These data show that cognitive rehabilitation programs are effective for patients with focal seizures and attention deficits and should, therefore, be incorporated into comprehensive care programs.	Dutch Epilepsy Clin Fdn, Meer & Bosch, NL-2103 SW Heemstede, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Med Psychol, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Neurol, NL-1081 HV Amsterdam, Netherlands; Med Ctr Alkmaar, Dept Neurol, Alkmaar, Netherlands	Engelberts, NHJ (corresponding author), Dutch Epilepsy Clin Fdn, Meer & Bosch, Achterweg 5, NL-2103 SW Heemstede, Netherlands.	nengelberts@sein.nl	Klein, Martin/C-4192-2012; Trenite, Dorothee Nolst/ABG-5804-2020	Klein, Martin/0000-0003-4160-5746; Klein, Martin/0000-0001-5553-7911			Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Aldenkamp AP, 1991, NEUROPSYCHOL REHABIL, V1, P199; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CONNOR A, 1988, INT J CLIN NEUROPSYC, V10, P1; CORCORAN R, 1993, BRIT J CLIN PSYCHOL, V32, P199, DOI 10.1111/j.2044-8260.1993.tb01044.x; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Dixon R.A., 1999, COGNITIVE NEUROREHAB, P59; Engel J, 2001, EPILEPSIA, V42, P316, DOI 10.1046/j.1528-1157.2001.t01-1-36500.x; FIMM B, 1988, THESIS; Franzen M D, 1987, Arch Clin Neuropsychol, V2, P265, DOI 10.1016/0887-6177(87)90014-X; Giovagnoli AR, 1997, EPILEPSY RES, V28, P119, DOI 10.1016/S0920-1211(97)00036-3; HAYES RL, 2000, COCHRANE DB SYST REV, V3; Hendriks MPH, 2001, CURR PROB E, V16, P87; HOUX PJ, 1993, PERCEPT MOTOR SKILL, V76, P195, DOI 10.2466/pms.1993.76.1.195; Johanson M, 2001, CURR PROB E, V16, P203; Kalviainen R, 1992, Seizure, V1, P255; Lincoln NB, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002842; LOISEAU P, 1984, ACTA NEUROL SCAND, V69, P31, DOI 10.1111/j.1600-0404.1984.tb05666.x; LUTEIJN F, 1982, HANDLEIDING GRONINGE; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; McNair DM, 1981, PROFILE MOOD STATES; Milders M, 1998, MEMORY, V6, P21, DOI 10.1080/741941597; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Perrine K, 1999, NEUROLOGY, V53, pS39; Plohmann A, 1994, Schweiz Arch Neurol Psychiatr (1985), V145, P35; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; ROBERTSON IH, 1993, CURR OPIN NEUROL, V6, P756, DOI 10.1097/00019052-199310000-00013; RYAN R, 1980, EPILEPSIA, V21, P433, DOI 10.1111/j.1528-1157.1980.tb04091.x; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Sturm W, 1991, NEUROPSYCHOL REHABIL, V1, P259, DOI DOI 10.1080/09602019108402258; TRENITE DGAK, 1987, ELECTROEN CLIN NEURO, V67, P167; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY	39	58	61	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUN	2002	43	6					587	595		10.1046/j.1528-1157.2002.29401.x			9	Clinical Neurology	Neurosciences & Neurology	573KH	WOS:000176828400004	12060017				2021-06-18	
J	Ricker, JH; Rosenthal, M; Garay, E; DeLuca, J; Germain, A; Abrahan-Fuchs, K; Schmidt, KU				Ricker, JH; Rosenthal, M; Garay, E; DeLuca, J; Germain, A; Abrahan-Fuchs, K; Schmidt, KU			Telerehabilitation needs: A survey of persons with acquired brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acquired brain injury; telemedicine; telerehabilitation		Objective: To survey individuals with acquired brain injury to assess multiple facets of interest, access, and familiarity necessary to implement new telerehabilitation technologies. Design: Anonymous mail survey. Setting: Community. Participants: Seventy-one respondents to a survey. These individuals had experienced acquired brain injury (predominantly severe traumatic brain injury [TBI]) and were living in the community. Surveys were mailed by a state chapter of the Brain Injury Association to a random selection of members with acquired brain injury. Main Outcome Measure: Survey designed specifically for this investigation. Results: The survey responses indicate that there is great interest in the possibility of accessing telerehabilitative services among individuals with acquired brain injury. In particular, there was strong interest expressed in services that could be used to assist with problems in memory, attention, problem-solving, and activities of daily living. Conclusions: Telemedicine, and more specifically telerehabilitation, holds great promise as an adjunct to traditional clinical service delivery. Little research in thus area has been applied, however, to individuals with acquired brain injuries. Although on the surface, telerehabilitation seems to be an appropriate assessment and treatment modality for individuals with brain injury, it will only succeed if those individuals have the interest-and tine access-necessary to use new and evolving technologies.	KMRREC Neuropsychol, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Siemens Corp Res Inc, Strateg Business Dev Grp, Princeton, NJ USA; Siemens AG, Siemens Med Solut, D-8520 Erlangen, Germany	Ricker, JH (corresponding author), KMRREC Neuropsychol, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	jricker@kmrrec.org		Ricker, Joseph/0000-0003-3415-991X			Burdea G, 2000, IEEE T REHABIL ENG, V8, P430, DOI 10.1109/86.867886; Burns RB, 1998, ASSIST TECHNOL, V10, P126, DOI 10.1080/10400435.1998.10131970; Girone M, 2000, Stud Health Technol Inform, V70, P89; Grimes G J, 2000, Stud Health Technol Inform, V70, P113; Hufford BJ, 1999, REHABIL PSYCHOL, V44, P176, DOI 10.1037/0090-5550.44.2.176; Lathan CE, 1999, TELEMED J, V5, P169, DOI 10.1089/107830299312131; Liu LL, 2000, J TELEMED TELECARE, V6, P47, DOI 10.1258/1357633001935554; Mathewson C, 2000, J Wound Ostomy Continence Nurs, V27, P269; Palsbo S E, 2000, Manag Care Q, V8, P56; Popescu VG, 2000, IEEE T INF TECHNOL B, V4, P45, DOI 10.1109/4233.826858; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; Vesmarovich S, 1999, Adv Wound Care, V12, P264	12	58	60	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2002	17	3					242	250		10.1097/00001199-200206000-00005			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	552WE	WOS:000175642400005	12086577				2021-06-18	
J	Ginsberg, SD; Martin, LJ				Ginsberg, SD; Martin, LJ			Axonal transection in adult rat brain induces transsynaptic apoptosis and persistent atrophy of target neurons	JOURNAL OF NEUROTRAUMA			English	Article						afferent-derived trophic support; apoptosis; axotomy; deafferentation; mammillary nucleus; transneuronal injury; traumatic brain injury; fimbria-fornix	FIMBRIA-FORNIX TRANSECTION; MAMMILLARY BODY LESIONS; HIPPOCAMPAL EFFERENTS; GLUTAMATE RECEPTORS; DEPOLARIZING AGENTS; BASAL FOREBRAIN; MAMILLARY BODY; INJURY; SEPTUM; HYPOTHALAMUS	We used the fimbria-fornix (FIT) transection model of axonal injury to test the hypothesis that transneuronal degeneration occurs in the adult central nervous system in response to deafferentation. The medial mammillary nucleus, pars medialis (MMNm) was analyzed by light and electron microscopy at 3, 7, 14, and 30 days, and 6 months after unilateral FIT transection in adult rat to identify the time course of neuronal responses in a remote target. Presynaptic terminals and neuronal cell bodies degenerated in the MMNm ipsilateral to FF transection. Terminal degeneration occurred predominantly at 3 and 7 days postlesion. Between 14 and 30 days postlesion, neuronal number in the MMNm decreased (similar to 20 %). Two forms of neuronal degeneration were found in the MMNm after deafferentation. Some neurons died apoptotically. Other neurons underwent vacuolar degeneration. In these latter neurons, somatodendritic pathology occurred at 14 and 30 days and 6 months postlesion. The ultrastructure of this vacuolar degeneration was characterized by disorganization of the cytoplasm, formation of membrane-bound vacuolar cisternae and membranous inclusions, loss of organelles, cytoplasmic pallor, and chromatin alterations. This study shows that both anterograde axonal degeneration and transneuronal degeneration occur in a fornical target after FF axon transection. This transneuronal degeneration can be classified as sustained neuronal atrophy or transsynaptic apoptosis.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Martin, LJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, 558 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.			Ginsberg, Stephen/0000-0002-1797-4288	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG043375, AG16282] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34100] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG043375, R01AG016282] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; ALLEN GV, 1988, J COMP NEUROL, V275, P39, DOI 10.1002/cne.902750105; ALLEN GV, 1989, J COMP NEUROL, V286, P311, DOI 10.1002/cne.902860303; Allen WF, 1944, J COMP NEUROL, V80, P283, DOI 10.1002/cne.900800208; Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; Amaral DG, 1987, HDB PHYSL NERVOUS SY, P211; BLEIER R, 1969, BRAIN RES, V15, P365, DOI 10.1016/0006-8993(69)90162-0; Buki A, 2000, J NEUROSCI, V20, P2825; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; CANTERAS NS, 1992, J COMP NEUROL, V324, P195, DOI 10.1002/cne.903240205; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GAFFAN D, 1991, BRAIN, V114, P2611, DOI 10.1093/brain/114.6.2611; Ginsberg SD, 1996, J NEUROCHEM, V67, P1208; GINSBERG SD, 1995, J COMP NEUROL, V353, P539, DOI 10.1002/cne.903530406; Ginsberg SD, 1998, NEUROSCIENCE, V86, P1259, DOI 10.1016/S0306-4522(98)00136-5; Ginsberg SD, 1999, NEUROSCIENCE, V88, P1059, DOI 10.1016/S0306-4522(98)00288-7; Golden JP, 1998, J COMP NEUROL, V398, P139, DOI 10.1002/(SICI)1096-9861(19980817)398:1<139::AID-CNE9>3.0.CO;2-2; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GUDDEN B, 1880, ARCH PSYCHIAT NERVEN, V11, P428; GUILLERY RW, 1956, J ANAT, V90, P350; Heymach JV, 1997, NATURE, V389, P789, DOI 10.1038/39743; Krieg WJS, 1932, J COMP NEUROL, V55, P19, DOI 10.1002/cne.900550104; LANGLAIS PJ, 1990, J NEUROSCI, V10, P1664; MACLEAN PD, 1952, ELECTROEN CLIN NEURO, V4, P407, DOI 10.1016/0013-4694(52)90073-4; MAHUT H, 1972, NEUROPSYCHOLOGIA, V10, P65, DOI 10.1016/0028-3932(72)90043-7; MAIR WGP, 1979, BRAIN, V102, P749, DOI 10.1093/brain/102.4.749; MARTIN LJ, 1993, J NEUROSCI, V13, P2249; Martin LJ, 1999, J NEUROBIOL, V40, P185, DOI 10.1002/(SICI)1097-4695(199908)40:2<185::AID-NEU5>3.0.CO;2-#; Martin LJ, 2001, INT J MOL MED, V7, P455; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Moudgil SS, 2000, STROKE, V31, P1418, DOI 10.1161/01.STR.31.6.1418; MOUNT HTJ, 1993, J NEUROSCI, V13, P3173; NAMURA S, 1994, BRAIN RES BULL, V35, P221, DOI 10.1016/0361-9230(94)90126-0; NAUTA W J H, 1969, P136; NAUTA WJH, 1956, J COMP NEUROL, V104, P247, DOI 10.1002/cne.901040205; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Peters A, 1991, FINE STRUCTURE NERVO; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; RAMNATH RR, 1992, NEUROSCIENCE, V51, P931, DOI 10.1016/0306-4522(92)90530-F; RAZ N, 1992, NEUROREPORT, V3, P713, DOI 10.1097/00001756-199208000-00016; Rose J, 1939, J ANAT, V74, P91; SAUNDERS RC, 1989, BEHAV BRAIN RES, V35, P85, DOI 10.1016/S0166-4328(89)80109-3; SCHRAMM M, 1990, P NATL ACAD SCI USA, V87, P1193, DOI 10.1073/pnas.87.3.1193; SQUIRE LR, 1990, J NEUROSCI, V10, P3106; STICHEL CC, 1995, EUR J NEUROSCI, V7, P401, DOI 10.1111/j.1460-9568.1995.tb00336.x; STORMMATHISEN J, 1978, NEUROSCI LETT, V9, P65, DOI 10.1016/0304-3940(78)90049-6; SWANSON LW, 1975, SCIENCE, V189, P303, DOI 10.1126/science.49928; SWANSON LW, 1977, J COMP NEUROL, V172, P49, DOI 10.1002/cne.901720104; TAKATA M, 1995, INTEGR COMPUT-AID E, V2, P249; TONKISS J, 1992, EXP BRAIN RES, V90, P572; WALAAS I, 1980, NEUROSCIENCE, V5, P1691, DOI 10.1016/0306-4522(80)90088-3; ZHANG SX, 1995, J NEUROPATH EXP NEUR, V54, P255, DOI 10.1097/00005072-199503000-00012	57	58	58	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2002	19	1					99	109		10.1089/089771502753460277			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	517LD	WOS:000173611300009	11852982				2021-06-18	
J	Machamer, J; Temkin, N; Dikmen, S				Machamer, J; Temkin, N; Dikmen, S			Significant other burden and factors related to it in traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							BLUNT HEAD-INJURY; DEPRESSIVE SYMPTOMS; RANDOMIZED TRIAL; CAREGIVER BURDEN; RELATIVES VIEW; DISTRESS; VALPROATE; SCALE	Feelings of burden and factors related to it were examined in a sample of 180 relatives of moderately to severely traumatically brain injured (TBI) subjects 6 months postinjury. Relatives were enrolled onto the study based on their family member's head injury and not on outcome. The results indicate that although both positive and negative experiences were common, the majority of the relatives reported an overall positive experience. The significant other's (SO's) experience was significantly and systematically related to many factors with overall negative experience associated with increased brain injury severity, worse neuropsychological functioning, increased dependency on others, SO's report of changes in the TBI subject, changes in the SO's life as a result of caregiving and SO depression.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Machamer, J (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	machamer@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19643] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980023] Funding Source: Medline		ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Chiu Wen-Ta, 1993, Journal of the Formosan Medical Association, V92, P255; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JENNETT B, 1975, LANCET, V1, P480; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A., 1972, REHABILITATION, V38, P33; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reitan R.M., 1993, HALSTEADREITAN NEURO; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Teri L, 1997, J GERONTOL B-PSYCHOL, V52, pP159, DOI 10.1093/geronb/52B.4.P159; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Wechsler D., 1955, MANUAL WECHSLER ADUL; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	37	58	58	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2002	24	4					420	433		10.1076/jcen.24.4.420.1040			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	568ZJ	WOS:000176574600002	12187456				2021-06-18	
J	Orihara, Y; Ikematsu, K; Tsuda, R; Nakasono, I				Orihara, Y; Ikematsu, K; Tsuda, R; Nakasono, I			Induction of nitric oxide synthase by traumatic brain injury	FORENSIC SCIENCE INTERNATIONAL			English	Article						inducible nitric oxide synthase; cerebrovascular smooth muscle cell; neutrophil; microglia; traumatic brain injury	SMOOTH-MUSCLE CELLS; CEREBRAL BLOOD-FLOW; HEAD-INJURY; HUMAN-NEUTROPHILS; L-ARGININE; RATS; EXPRESSION; IMMATURE	We investigated the dynamic induction/expression of inducible nitric oxide synthase (iNOS) using human brains made available through death by traumatic brain injury (TBI). Astrocytes. micro.-lia. and neutrophils were identified in tissue using immunohistochemical staining with antibodies against glial fibrillary acidic protein (GFAP). MHC class II antigen, and neutrophil elastase. respectively. The localization of iNOS protein in each of these cell types was evaluated using immunohistochemistry. Within 2 days of injury, iNOS immunoreactivity was not detected. However, after 2 days, immunoreactivity was detected in the traumatized brain. The iNOS immunoreactivity was localized on neutrophils and microglia/macrophages in the areas around the tissue necrosis in the traumatized cortical hemisphere, in the deep part of the cortex and the dentate gyri of the hippocampi adjacent to the hemorrhage, and within the cytoplasm of vascular smooth muscle cell of a small artery or arteriole surrounding the injured region. This reactivity was absent after 8 days post-injury, These observations confirmed the prolonged induction of iNOS within various cells in the injured brain. These responses suggest that iNOS plays a crucial role in cerebrovascular damage and/or secondary brain damage subsequent to traumatic brain injury. Furthermore. the dense nitric oxide (NO) generated by iNOS may play a role in neuronal cell death after injury. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Nagasaki Univ, Sch Med, Dept Legal Med, Nagasaki 8528523, Japan	Orihara, Y (corresponding author), Nagasaki Univ, Sch Med, Dept Legal Med, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.						Akaike T, 1996, METHOD ENZYMOL, V268, P211; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; CHAO CC, 1992, J IMMUNOL, V149, P2736; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682; DING AH, 1988, J IMMUNOL, V141, P2407; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; KANNO K, 1993, HYPERTENSION, V22, P34, DOI 10.1161/01.HYP.22.1.34; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MCCALL TB, 1991, EUR J IMMUNOL, V21, P2523, DOI 10.1002/eji.1830211032; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; THOMAS WE, 1992, BRAIN RES REV, V17, P116; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; WANG XK, 1995, STROKE, V26, P661, DOI 10.1161/01.STR.26.4.661; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0; YAN L, 1994, J IMMUNOL, V153, P1825	32	58	63	1	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	DEC 1	2001	123	2-3					142	149		10.1016/S0379-0738(01)00537-0			8	Medicine, Legal	Legal Medicine	504ZW	WOS:000172887100009	11728740				2021-06-18	
J	Zhang, L; Abreu, BC; Masel, B; Scheibel, RS; Christiansen, CH; Huddleston, N; Ottenbacher, KJ				Zhang, L; Abreu, BC; Masel, B; Scheibel, RS; Christiansen, CH; Huddleston, N; Ottenbacher, KJ			Virtual reality in the assessment of selected cognitive function after brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						virtual reality; traumatic brain injury; cognitive function; assessment	SEVERE HEAD-INJURY; REHABILITATION; TECHNOLOGY; ADULTS; STATE	Objective: To assess selected cognitive functions of persons with traumatic brain injury using a computer-simulated virtual reality environment. Study Design: A computer-simulated virtual kitchen was used to assess the ability of 30 patients with brain injury and 30 volunteers without brain injury to process and sequence information. The overall assessment score was based on the number of correct responses and the time needed to complete daily living tasks. Identical daily living tasks were tested and scored in participants with and without brain injury. Each subject was evaluated twice within 7 to 10 days. A total of 30 tasks were categorized as follows: information processing, problem solving, logical sequencing, and speed of responding. Results: Persons with brain injuries consistently demonstrated a significant decrease in the ability to process information (P = 0.04-0.01), identify logical sequencing (P = 0.04-0.01), and complete the overall assessment (P < 0.01), compared with volunteers without brain injury. The time needed to process tasks, representing speed of cognitive responding, was also significantly different between the two groups (P < 0.01). Conclusion: A computer-generated virtual reality environment represents a reproducible tool to assess selected cognitive functions and can be used as a supplement to traditional rehabilitation assessment in persons with acquired brain injury.	Transit Learning Ctr Galveston, Galveston, TX 77550 USA; Univ Texas, Med Branch, Galveston, TX 77550 USA	Zhang, L (corresponding author), Transit Learning Ctr Galveston, 1528 PO St, Galveston, TX 77550 USA.		, Charles/V-6218-2019	Christiansen, Charles/0000-0003-0542-1042; Ottenbacher, Kenneth/0000-0001-5990-3982			Abreu BC, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P51; BERG EA, 1948, J GEN PSYCHOL, V39, P22; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Christiansen C, 1996, J MED VIRTUAL REALIT, V1, P6; Dellasega C, 1994, J Community Health Nurs, V11, P129, DOI 10.1207/s15327655jchn1103_1; ELIS DC, 1987, CALIFORNIA VERBAL LE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HETTINGER LJ, 1992, PRESENCE-TELEOP VIRT, V1, P306; Kennedy R., 1992, PRESENCE TELEOPER VI, V1, P295, DOI [10.1162/pres.1992.1.3.295, DOI 10.1162/PRES.1992.1.3.295]; Lackner J. R., 1992, PRESENCE-TELEOP VIRT, V1, P319; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; NEISTADT ME, 1994, AM J OCCUP THER, V48, P431, DOI 10.5014/ajot.48.5.431; Ottenbacher KJ, 1998, AM J EPIDEMIOL, V147, P615; Owen AM, 1997, PROG NEUROBIOL, V53, P431, DOI 10.1016/S0301-0082(97)00042-7; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Puls I, 1999, STROKE, V30, P2291, DOI 10.1161/01.STR.30.11.2291; REGAN EC, 1994, AVIAT SPACE ENVIR MD, V65, P527; Riva G, 1998, ST HEAL T, V58, P120; Rizzo A.A., 1998, CYBERPSYCHOLOGY BEHA, V1, P59, DOI [10.1089/cpb.1998.1.59, DOI 10.1089/CPB.1998.1.59]; Rizzo AA, 1997, ST HEAL T, V44, P123; Rose FD, 1996, CURR OPIN NEUROL, V9, P461, DOI 10.1097/00019052-199612000-00012; Schuttler J, 1995, ANAESTHESIST, V44, P850, DOI 10.1007/s001010050221; SINGBARTL G, 1985, ANASTH INTENSIV NOTF, V20, P251, DOI 10.1055/s-2007-1003119; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; *STAT U NY BUFF, 1997, GUID UN DAT SET MED; STEIN DG, 1995, BRAIN REPAIR; WECSHLER D, 1939, MEASUREMENT ADULT IN; WILKINSON GS, 1984, WIDE RANGE ACHIEVEME; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530	30	58	62	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2001	80	8					597	604		10.1097/00002060-200108000-00010			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	454BR	WOS:000169953000009	11475481				2021-06-18	
J	Ballard, JC				Ballard, JC			Assessing attention: Comparison of response-inhibition and traditional continuous performance tests	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	106th Annual Convention of the American-Psychological-Association	AUG 14-18, 1998	SAN FRANCISCO, CALIFORNIA	Amer Psychol Assoc			CLOSED-HEAD INJURY; SUSTAINED ATTENTION; EVENT RATE; COMPUTERIZED ASSESSMENT; VIGILANCE; CHILDREN; NOISE; ANXIETY; ALCOHOL	The purpose of this study was to compare a recently developed response-inhibition task (Conners, 1995) to slow- and fast-event-rate versions of the traditional A-X Continuous Performance Test (CPT). Among 146 normal adults, results revealed significant differences between tasks in omission and commission error rates, reaction time, reaction time variability, and responses to critical signals. Effects of environmental noise and participant anxiety also differed for the three tasks. Traditional CPTs produced time-related performance decrements, but the response-inhibition task produced improvement across initial blocks of trials. The response-inhibition task may measure "executive control" rather than sustained attention, and therefore may represent functions of different brain systems.	SUNY Geneseo, Dept Psychol, Coll Geneseo, Geneseo, NY 14454 USA	Ballard, JC (corresponding author), SUNY Geneseo, Dept Psychol, Coll Geneseo, Geneseo, NY 14454 USA.						BAKER CH, 1959, BRIT J PSYCHOL, V50, P30, DOI 10.1111/j.2044-8295.1959.tb00678.x; Ballard JC, 1996, J CLIN EXP NEUROPSYC, V18, P864, DOI 10.1080/01688639608408308; Ballard JC, 1996, J CLIN EXP NEUROPSYC, V18, P843, DOI 10.1080/01688639608408307; BEALE IL, 1987, J ABNORM CHILD PSYCH, V15, P229, DOI 10.1007/BF00916351; BERCH DB, 1984, SUSTAINED ATTENTION, P143; BROADBENT DE, 1965, HUM FACTORS, V7, P155, DOI 10.1177/001872086500700207; CAMPBELL JW, 1991, J SCHOOL PSYCHOL, V29, P143; CHEE P, 1989, J ABNORM CHILD PSYCH, V17, P371, DOI 10.1007/BF00915033; Conners C. K., 1995, CONNERS CONTINUOUS P; COONS HW, 1987, PSYCHOPHYSIOLOGY, V24, P572; DAVIES DR, 1966, BRIT J PSYCHOL, V57, P381, DOI 10.1111/j.2044-8295.1966.tb01039.x; DAVIES DR, 1984, VARIETIES ATTENTION, P395; EARLEBOYER EA, 1991, PSYCHIAT RES, V37, P47, DOI 10.1016/0165-1781(91)90105-X; EDLEY RS, 1987, J PSYCHOEDUCATIONAL, V4, P340; GIAMBRA LM, 1988, PSYCHOL AGING, V3, P75, DOI 10.1037/0882-7974.3.1.75; GOETSCH VL, 1990, J PSYCHOPATHOL BEHAV, V12, P329, DOI 10.1007/BF00965987; GOLOMBOK S, 1988, PSYCHOL MED, V18, P365, DOI 10.1017/S0033291700007911; HANCOCK PA, 1984, SUSTAINED ATTENTION, P103, DOI DOI 10.1016/8978-032302588-1.50009-9; HOCKEY R, 1984, VARIETIES ATTENTION, P395; Joschko M., 1991, CLIN NEUROPSYCHOL, V5, P53; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KNOPF IJ, 1975, MERRILL PALMER QUART, V21, P195; KOELEGA HS, 1986, HUM FACTORS, V28, P465; KRUEGER GP, 1989, WORK STRESS, V3, P129, DOI 10.1080/02678378908256939; LEVY F, 1980, J CHILD PSYCHOL PSYC, V21, P72; LINNOILA M, 1978, J STUD ALCOHOL, V39, P745, DOI 10.15288/jsa.1978.39.745; Loeb M, 1984, SUSTAINED ATTENTION, P179; Loeb M., 1986, NOISE HUMAN EFFICIEN; MACKWORTH NH, 1950, MED RES COUNCIL SPEC, V268, P174; McGrath J. J., 1968, STUDIES HUMAN VIGILA, P1; MCGRATH JJ, 1968, STUDIES HUMAN VIGILA, P295; MCGRATH JJ, 1968, STUDIES HUMAN VIGILA, P235; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MIRSKY AF, 1992, J PSYCHIAT RES, V26, P383, DOI 10.1016/0022-3956(92)90042-M; NORMAN DA, 1980, 99 CTR HUM INF PROC; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Parasuraman, 1993, HUM PERFORM, V6, P71, DOI DOI 10.1207/S15327043HUP0601_; PARASURAMAN R, 1991, PSYCHOL AGING, V6, P155, DOI 10.1037/0882-7974.6.2.155; Parasuraman R, 1998, ATTENTIVE BRAIN, P221; Parasuraman R, 1998, ATTENTIVE BRAIN, P3; PARASURAMAN R, 1979, SCIENCE, V205, P924, DOI 10.1126/science.472714; PARASURAMAN R, 1987, PERCEPT PSYCHOPHYS, V41, P17, DOI 10.3758/BF03208208; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Parasuraman R., 1984, SUSTAINED ATTENTION, P61; Parasuraman R., 1993, NEUROPSYCHOLOGY, V7, P242, DOI DOI 10.1037/0894-4105.7.3.242; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; Posner M.I., 1994, IMAGES MIND; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Posner MI, 1998, ATTENTIVE BRAIN, P401; RAPPORT MD, 1993, J AM ACAD CHILD PSY, V32, P333, DOI 10.1097/00004583-199303000-00014; ROHRBAUGH JW, 1988, PSYCHOPHARMACOLOGY, V96, P442, DOI 10.1007/BF02180021; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SCHIFF AR, 1985, CHILD DEV, V56, P621; SMITH A, 1989, SCAND J PSYCHOL, V30, P185, DOI 10.1111/j.1467-9450.1989.tb01082.x; SMITH AP, 1992, NEUROPSYCHOBIOLOGY, V26, P198, DOI 10.1159/000118920; Spielberger C.D., 1980, STRESS ANXIETY, P95; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; TARVER SG, 1974, J LEARN DISABIL, V7, P560, DOI 10.1177/002221947400700906; Warm JS, 1984, SUSTAINED ATTENTION, P15; WARNER HD, 1972, HUM FACTORS, V14, P181, DOI 10.1177/001872087201400208	61	58	61	1	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	2001	23	3					331	350		10.1076/jcen.23.3.331.1188			20	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	439JG	WOS:000169112900008	11404811				2021-06-18	
J	Hawley, CA				Hawley, CA			Return to driving after head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						driving; brain injury	TRAUMATIC BRAIN INJURY; FIM+FAM; STROKE	Objectives-To determine whether patients who return to driving after head injury can be considered safe to do so and to compare the patient characteristics of those who return to driving with those who do not. Methods - In a multicentre qualitative study 10 rehabilitation units collectively registered 563 adults with traumatic brain injury during a 2.5 year period. Recruitment to the study varied from immediately after hospital admission to several years after injury, Patients and their families were interviewed around 3 to 6 months after recruitment. A total of 383 (67.5%) subjects were interviewed within 1 year of injury, of whom 270 (47.6%) were interviewed within 6 months of injury. Main outcome measures were the presence or absence of driving related problems reported by drivers and ex-drivers, and scores on driving related items of the functional independence/functional assessment measure (FIM+FAM). Result - Of the 563 patients 381 were drivers before the injury and 139 had returned to driving at interview. Many current drivers reported problems with behaviour (anger, aggression, irritability; 67 (48.2%)), memory (89(64%)), concentration and attention (39 (28.1%)), and vision (39 (28.1%)). Drivers reported most driving related problems as often as ex-drivers, main exceptions were epilepsy and community mobility. Current drivers scored significantly higher on the FIM+FAIM (were more independent), than ex-drivers. The driving group had sustained less severe head injuries than ex-drivers; nevertheless, 78 (56.2%) current drivers had received a severe head injury. Few (61 (16%)) previous drivers reported receiving formal advice about driving after injury. Conclusions - The existence of problems which could significantly affect driving does not prevent patients returning to driving after traumatic brain injury. Patients should be assessed for both mental and physical status before returning to driving after a head injury, and systems put in place to enable clear and consistent advice to be given to patients about driving.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England	Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				*BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; *DRIV MED GROUP, 1996, MED PRACT GLANC GUID; Fisk GD, 1998, BRAIN INJURY, V12, P683; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; HAWLEY CA, 2000, BRIT J THERAPY REHAB, V7, P116; *HEADW, 1989, DRIV HEAD INJ; JENNETT B, 1995, MED ASPECTS FITNESS; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCMILLAN T, 1991, REHABILITATION PROGR; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MORTIMER RG, 1986, ISION VEHICLES; MUNTON G, 1995, MED ASPECTS FITNESS; *NHS HLTH ADV SERV, 1996, THERM REV MENT HLTH; PIDIKITI RD, 1991, ARCH PHYS MED REHAB, V72, P109; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; RIMEL RW, 1990, REHABILITATION ADULT; SCHUTTE P, 1995, MED ASPECTS FITNESS; SHUTE RH, 1990, OPHTHAL PHYSL OPT, V10, P327, DOI 10.1111/j.1475-1313.1990.tb00878.x; *SOC SERV INSP SOC, 1995, INF STRAT SYST REF C; *STAT U NEW YORK B, 1989, FAM DEC TREE; STILWELL J, 1998, REPORT NATL TRAUMATI; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TAYLOR JF, 1995, MED ASPECTS FITNESS; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	31	58	63	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2001	70	6					761	766		10.1136/jnnp.70.6.761			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	443RV	WOS:000169354900012	11385010	Green Published, Bronze			2021-06-18	
J	Chistyakov, AV; Soustiel, JF; Hafner, H; Trubnik, M; Levy, G; Feinsod, M				Chistyakov, AV; Soustiel, JF; Hafner, H; Trubnik, M; Levy, G; Feinsod, M			Excitatory and inhibitory corticospinal responses to transcranial magnetic stimulation in patients with minor to moderate head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; silent period; motor evoked potential; transcranial magnetic stimulation	MOTOR CORTEX EXCITABILITY; SILENT PERIOD; BRAIN-STIMULATION; PARKINSONS-DISEASE; CORTICAL STIMULATION; DISSOCIATION; STROKE; HUMANS; FACILITATION; POTENTIALS	Objectives-The changes in excitatory and inhibitory responses to transcranial magnetic stimulation (TMS), as attested by motor evoked potential (MEP) and silent period (SP) parameters, were compared in patients who sustained minor to moderate head injury. Methods-A total of 38 patients with brain concussion, and diffuse, focal, and combined brain injury and 20 healthy volunteers were examined. The MEPs and SPs were recorded from the abductor pollicis brevis muscle after single pulse TMS 2 weeks after head trauma. The parameters assessed were the MEP resting threshold, the MEP/M wave amplitude ratio, the central motor conduction time (CMCT), the SP threshold, the interthreshold difference (ITD), and the SP duration (SPD). Results-The main finding was an increase in the ITD in patients with mild and moderate head injury due to the relatively greater augmentation of the MEP threshold. This was associated with a reduction of the MEP/M wave amplitude ratio. The degree of MEP and SP changes depended on severity of head injury and was not related to the type of brain lesions. The SPD did not differ significantly in brain concussion, or diffuse, focal and combined brain injury groups compared with the control group. The CMCT was prolonged in patients with diffuse and combined brain lesions. Among subjective complaints only fatigue was significantly related to ITD, MEP, and SP threshold abnormalities. Conclusions-The results suggest that mechanisms involved in MEP and SP generation are differently affected in head injury, the first being impaired more severely. The increase of the ITD accompanied by reduction of the MEP/M wave amplitude ratio may reflect a dissociated impairment of inhibitory and excitatory components of central motor control in head trauma.	Rambam Maimonides Med Ctr, Dept Neurosurg, Ctr Treatment & Appl Res Head Injury, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Chistyakov, AV (corresponding author), Rambam Maimonides Med Ctr, Dept Neurosurg, Ctr Treatment & Appl Res Head Injury, POB 9602, IL-31096 Haifa, Israel.						Ashby P, 1999, CLIN NEUROPHYSIOL, V110, P550, DOI 10.1016/S1388-2457(98)00082-0; CANTELLO R, 1992, NEUROLOGY, V42, P1951; Catano A, 1997, ELECTROMYOGR MOTOR C, V105, P29, DOI 10.1016/S0924-980X(96)96515-7; Catano A, 1997, ELECTROMYOGR MOTOR C, V105, P290, DOI 10.1016/S0924-980X(97)00021-0; Chen R, 1997, NEUROLOGY, V49, P881, DOI 10.1212/WNL.49.3.881; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; CHIAPPA KH, 1991, NEUROLOGY, V41, P1154, DOI 10.1212/WNL.41.7.1154; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; CHISTYAKOV AV, 1995, SPINE, V20, P2135, DOI 10.1097/00007632-199510000-00012; Classen J, 1997, BRAIN, V120, P605, DOI 10.1093/brain/120.4.605; CLAUS D, 1991, ELECTROENCEPHALOGR C, V81, P342; DAVEY NJ, 1994, J PHYSIOL-LONDON, V477, P223, DOI 10.1113/jphysiol.1994.sp020186; FUHR P, 1991, ELECTROEN CLIN NEURO, V81, P257, DOI 10.1016/0168-5597(91)90011-L; George MS, 1999, ARCH GEN PSYCHIAT, V56, P300, DOI 10.1001/archpsyc.56.4.300; Inghilleri M, 1996, EXP BRAIN RES, V109, P467; Lewko JP, 1996, BRAIN TOPOGR, V8, P397, DOI 10.1007/BF01186915; Liepert J, 2000, CLIN NEUROPHYSIOL, V111, P671, DOI 10.1016/S1388-2457(99)00312-0; MAVROUDAKIS N, 1994, ELECTROEN CLIN NEURO, V93, P428, DOI 10.1016/0168-5597(94)90149-X; PRIORI A, 1994, MOVEMENT DISORD, V9, P178, DOI 10.1002/mds.870090209; PRIORI A, 1994, BRAIN, V117, P317, DOI 10.1093/brain/117.2.317; ROICK H, 1993, EXP BRAIN RES, V94, P489, DOI 10.1007/BF00230207; SchulzeBonhage A, 1996, ELECTROEN CLIN NEURO, V99, P267; VALLSSOLE J, 1994, NEUROLOGY, V44, P735, DOI 10.1212/WNL.44.4.735; VALZANIA F, 1996, ELECTROENCEPHALOGR C, V105, P37; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WASSERMANN EM, 1993, ELECTROEN CLIN NEURO, V89, P424, DOI 10.1016/0168-5597(93)90116-7; Young MS, 1997, NEUROLOGY, V49, P1278, DOI 10.1212/WNL.49.5.1278; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	28	58	59	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2001	70	5					580	587		10.1136/jnnp.70.5.580			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	426AE	WOS:000168326200003	11309450	Bronze, Green Published			2021-06-18	
J	Lyeth, BG; Gong, QZ; Shields, S; Muizelaar, JP; Berman, RF				Lyeth, BG; Gong, QZ; Shields, S; Muizelaar, JP; Berman, RF			Group I metabotropic glutamate antagonist reduces acute neuronal degeneration and behavioral deficits after traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						metabotropic glutamate receptor; fluid percussion; traumatic brain injury; rat; AIDA	SIGNAL-TRANSDUCTION PATHWAY; FLUID-PERCUSSION MODEL; EXCITATORY AMINO-ACIDS; 1-AMINOINDAN-1,5-DICARBOXYLIC ACID; PHENYLGLYCINE DERIVATIVES; SPATIAL DISCRIMINATION; RECEPTOR SUBTYPES; NMDA-RECEPTORS; FLUORO-JADE; DEATH	Recent studies indicate that acute activation of Group I mGluRs following traumatic brain injury (TBI) contributes to the ensuing pathophysiology. The present study examined the effects of post-TBI administration of the selective mGluR1 antagonist (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA) on acute neuronal degeneration in the hippocampus and longterm sensorimotor and learning/memory outcome. In Experiment 1, 26 rats received 0.4, 2.0, or 10.0 nmol AIDA or artificial CSF vehicle infusion into the hippocampus starting 5 min postinjury. At 24 h after TBI characteristic pyramidal cell degeneration was observed in Fluoro-Jade-stained coronal sections of the CA2/3 sectors of the dorsal hippocampus. The mean (+/- SERI) number of Fluoro-Jade-positive neurons in the 10 nmol AIDA group (184 +/- 32) was significantly less (P < 0.05) than the vehicle group (310 <plus/minus> 47). In Experiment 2, 20 rats were trained on sensorimotor and memory tasks prior to parasagittal fluid percussion TBI. Rats were administered 10 nmol AIDA or vehicle as in Experiment 1. Rats were assessed on beam walking and radial arm maze (RAM) performance weekly for 6 weeks after TBI. Acquisition of a Morris water maze (MWM) task was assessed on days 11-15 after TBI. The AIDA-treated group had significantly reduced deficits in beam walk, MWM, and RAM performance compared to the vehicle-treated group. These data indicate that injury-induced acute activation of mGluR1 receptors contributes to both the cellular pathology and the behavioral morbidity associated with TBI. (C) 2001 Academic Press.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA.			Shields, Shannon/0000-0002-8006-7103; Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER		CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Gong QZ, 1999, J NEUROTRAUM, V16, P893, DOI 10.1089/neu.1999.16.893; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HAYES RL, 1988, J NEUROTRAUM, V5, P287; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Jiang ZW, 2000, BRAIN RES, V852, P37, DOI 10.1016/S0006-8993(99)02230-1; Johnson MP, 1999, BRAIN RES, V821, P539, DOI 10.1016/S0006-8993(99)01065-3; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KESNER RP, 1982, SCIENCE, V218, P173, DOI 10.1126/science.7123228; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; OLTON DS, 1978, PHYSIOL BEHAV, V20, P597, DOI 10.1016/0031-9384(78)90252-4; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; OPITZ T, 1995, NEUROSCIENCE, V68, P989, DOI 10.1016/0306-4522(95)00195-O; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Pellegrini-Giampietro DE, 1999, EUR J NEUROSCI, V11, P3637, DOI 10.1046/j.1460-9568.1999.00786.x; Pellegrini-Giampietro DE, 1999, NEUROPHARMACOLOGY, V38, P1607, DOI 10.1016/S0028-3908(99)00097-0; PELLICCIARI R, 1995, J MED CHEM, V38, P3717, DOI 10.1021/jm00019a002; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; ROBERTS PJ, 1995, NEUROPHARMACOLOGY, V34, P813, DOI 10.1016/0028-3908(95)00094-M; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715	43	58	64	0	3	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2001	169	1					191	199		10.1006/exnr.2001.7643			9	Neurosciences	Neurosciences & Neurology	431KD	WOS:000168629600020	11312571				2021-06-18	
J	Nesbitt, AD; Cooper, PJ; Kohl, P				Nesbitt, AD; Cooper, PJ; Kohl, P			Rediscovering commotio cordis	LANCET			English	Article							CHEST-WALL IMPACT; SUDDEN-DEATH; CARDIAC CONCUSSION; SPORTS		Univ Oxford, Physiol Lab, Cardiac Mechanoelect Feedback Grp, Oxford OX1 3PT, England; Univ Oxford, John Radcliffe Hosp, Sch Med, Oxford OX3 9DU, England	Kohl, P (corresponding author), Univ Oxford, Physiol Lab, Cardiac Mechanoelect Feedback Grp, Parks Rd, Oxford OX1 3PT, England.			Kohl, Peter/0000-0003-0416-6270			Albers A, 1966, Lebensversicher Med, V18, P9; BERNSTEIN R, 1896, Z KLIN MED, V29, P519; BRUNNER W, 1939, ZB CHIRURG, V39, P2145; CASPER J, 1857, PRACTISCHES HDB GERI; COOPER GJ, 1982, J TRAUMA, V22, P994, DOI 10.1097/00005373-198212000-00004; DEUTSCH F, 1930, WIEN ARCH INTERN MED, V20, P279; Dickman Gerald L, 1978, Phys Sportsmed, V6, P85, DOI 10.1080/00913847.1978.11948393; EDLICH R F JR, 1987, Journal of Emergency Medicine, V5, P181, DOI 10.1016/0736-4679(87)90176-4; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; FROEDE RC, 1979, J FORENSIC SCI, V24, P752; GLATZEL H, 1936, DEUT MED WOCHENSCHR, V10, P377; GOGLER E, 1962, UNFALLOPFER STRASSEN, P51; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; GREINER H, 1953, Monatsschr Unfallheilkd Versicherungsmed, V56, P90; HADOM W, 1940, SCHWEIZ Z UNFALLHEIL, V1, P156; HADOM W, 1940, SCHWEIZ Z UNFALLHEIL, V1, P227; ISFORT A, 1969, MON UNFALL VERISCH-V, V72, P409; JACOBI, 1937, ARCH ORTHOPAD UNFALL, V42, P418; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; Kohl P, 2001, CARDIOVASC RES, V50, P280, DOI 10.1016/S0008-6363(01)00194-8; Kohl P, 1999, PROG BIOPHYS MOL BIO, V71, P91, DOI 10.1016/S0079-6107(98)00038-8; Kohl P, 1999, HEART, V82, P397, DOI 10.1136/hrt.82.3.397; Link MS, 1999, CIRCULATION, V100, P413, DOI 10.1161/01.CIR.100.4.413; Link MS, 1998, NEW ENGL J MED, V338, P1805, DOI 10.1056/NEJM199806183382504; Link MS, 1999, HEART, V81, P109, DOI 10.1136/hrt.81.2.109; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; Maron BJ, 1999, J CARDIOVASC ELECTR, V10, P114, DOI 10.1111/j.1540-8167.1999.tb00648.x; Meola F, 1879, GIORNALE INT SCI MED, V1, P923; Michalodimitrakis EN, 1997, AM J FOREN MED PATH, V18, P282, DOI 10.1097/00000433-199709000-00010; NELATON A, 1876, ELEMENTS PATHOLOGIE; NORDMANN M, 1942, Z KREISLAUFFORSCH, V11, P361; RIEDINGER F, 1903, HDB PRAKTISCHEN CHIR, P373; RIEDINGER F, 1882, BRUSTERSCHUTTERUNG F, P221; Schlomka G., 1934, ERG INN MED KINDERHK, V47, P1, DOI 10.1007/ 978-3-642-90672-5_1.; SELVIN P, 1998, WASHINGTON POST 0530; SPUHLER O, 1937, SCHWEIZ MED WOCHENSC, V26, P571; Walther G, 1968, Lebensversicher Med, V20, P136; Wirth E, 1973, Beitr Gerichtl Med, V30, P458	38	58	61	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 14	2001	357	9263					1195	1197		10.1016/S0140-6736(00)04338-5			3	Medicine, General & Internal	General & Internal Medicine	423RX	WOS:000168192100033	11323067				2021-06-18	
J	Engberg, AW; Teasdale, TW				Engberg, AW; Teasdale, TW			Traumatic brain injury in Denmark 1979-1996. A national study of incidenceand mortality	EUROPEAN JOURNAL OF EPIDEMIOLOGY			English	Article						epidemiology; primary prevention; traumatic brain injury	HEAD-INJURY; EPIDEMIOLOGY; TRENDS	In order to describe and analyse the development of the incidence of traumatic brain injury (TBI) in Denmark for different age groups of the two genders from 1979 through 1993 (for fatal injuries through 1996), a computerised search corresponding to diagnoses ICD 8th ed., 800, 801, 803, 850-854 from 1979 through 1993 was carried through in the national hospital register. Each person was counted only once, according to the most serious injury during the study period. For fatal cases, the search was extended till 1996. From 1979-1981 to 1991-1993, the total age-adjusted incidence of persons hospitalised under diagnoses ICD 800, 801, 803, 850-854 decreased 41% from 265 to 157 per 100,000 of the population per year. Decreases were 42% for ICD 850, brain concussion, 56% for ICD 800, 801, 803, cranial fractures, and 16% for ICD 851-854, structural brain injury. The percentage of cases with ICD 851-854 increased from 8.4 to 11.7% of the total. From 1979-1981 to 1985-1987 there was a 2% decrease in fatal TBI in and outside hospital (from 14.68 to 14.35 per 100,000), against a total 27% decrease to 10.67 in 1994-1996. For diagnoses ICD 851-854 and for fatal cases, significantly accelerating decreases from 1985-1987 were found only for the younger age groups. Consequently, in the period from 1979 to 1993, the mean age at injury increased by 10 years for persons hospitalised under diagnoses ICD 851-854. Decreases may be explained partly by changing admission and other hospital practices, and partly by the effect of comprehensive national preventive programs launched at the middle of the study period, the effect of which seemed to vary by age group and gender.	Univ Copenhagen Hosp, Hvidovre Hosp, Div Neurol Rehabil 231, Ctr Med, DK-2650 Hvidovre, Denmark	Engberg, AW (corresponding author), Univ Copenhagen Hosp, Hvidovre Hosp, Div Neurol Rehabil 231, Ctr Med, DK-2650 Hvidovre, Denmark.						ALS E, 1958, Ugeskr Laeger, V120, P857; Andersen TF, 1999, DAN MED BULL, V46, P263; ANNEGERS JF, 1980, NEUROLOGY, V30, P186; Annoni J M, 1992, Disabil Rehabil, V14, P23; BAY NH, 1991, 1 EHLASS FORBR; *BORNS SIKK, 1988, CAMP ORG NAT CONS AG; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Engberg A W, 2001, Ugeskr Laeger, V163, P3755; Engberg A W, 2001, Ugeskr Laeger, V163, P3757; Engberg Aase, 1995, Acta Neurologica Scandinavica, V92, P1; *FAERDS, 1988, 1157 FAERDS; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MCKENZIE EJ, 1989, MARYLAND MED J, V38, P725; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; *NAT BUR HLTH, 1981, SUNDH DODS KONG DANM; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1996, WESTERN J MED, V165, P192; WHO, INT CLASS DIS	23	58	58	0	1	KLUWER ACADEMIC PUBL	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0393-2990			EUR J EPIDEMIOL	Eur. J. Epidemiol.		2001	17	5					437	442		10.1023/A:1013733107520			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	510KZ	WOS:000173208400007	11855577				2021-06-18	
J	Chiaretti, A; De Benedictis, R; Polidori, G; Piastra, M; Iannelli, A; Di Rocco, C				Chiaretti, A; De Benedictis, R; Polidori, G; Piastra, M; Iannelli, A; Di Rocco, C			Early post-traumatic seizures in children with head injury	CHILDS NERVOUS SYSTEM			English	Article						pediatric head injury; post-traumatic seizures	POSTTRAUMATIC SEIZURES; EPILEPSY; PREDICTORS	Post-traumatic seizures (PTS) can be a serious complication of head injury, because they can cause secondary brain damage through increased metabolic requirements, raised intracranial pressure, cerebral hypoxia, and/or excessive release of neurotransmitters. In children, early PTS are more frequent than late ones. In this retrospective study we conducted an epidemiological analysis and tried to identify potential risk factors for the onset of early PTS in children hospitalized for head injury in our Paediatric Intensive Care Unit. The severity of injury was assessed using the Glasgow Coma Scale (GCS), while the outcome of traumatized children was defined using the Glasgow Outcome Score (GOS). Early PTS were diagnosed in 15 out of the 125 children hospitalized (12%). Most of the children (73.3%), developed seizures within 24 h of the trauma (immediate PTS). Among the risk factors, a very important role was played by the severity of the injury; in fact, the incidence of early PTS among patients with GCS less than or equal to8 was ten times greater than that among children with GCS 13-15. Other risk factors that significantly influenced the onset of early PTS, were age (60% of children with early PTS were less than 3 years old) and severe cerebral edema. Overall, children with early PTS had a worse outcome than the other patients. In fact, 53% had a GOS of less than or equal to3 compared to 19.1% of those without early PTS (P<001). In particular, considering children with severe head injury, 80% of those with early PTS had a GOS of <less than or equal to> 3, compared to 41% of those without early PTS (P<0.05). In conclusion, PTS can be a serious complication of head injury in children, because they can worsen secondary brain damage. Appropriate management of head-trauma patients must include suitable and immediate prophylaxis with anti-epileptic drugs.	Univ Cattolica Sacro Cuore, Pediat Intens Care Unit, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Dept Pediat Neurosurg, Rome, Italy	Chiaretti, A (corresponding author), Univ Cattolica Sacro Cuore, Pediat Intens Care Unit, Largo A Gemelli 8, I-00168 Rome, Italy.	raffdebe@tin.it					Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Black P, 1975, CIBA F S, V34, P215; DALESSANDRO R, 1988, ARCH NEUROL-CHICAGO, V45, P42, DOI 10.1001/archneur.1988.00520250048019; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HENDRICK EB, 1968, J TRAUM, V8, P547; JENNETT B, 1975, LANCET, V1, P480; Lee ST, 1997, CAN J NEUROL SCI, V24, P40, DOI 10.1017/S0317167100021077; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Moshe S L, 1987, Epilepsia, V28 Suppl 1, pS3, DOI 10.1111/j.1528-1157.1987.tb05753.x; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983	19	58	58	1	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	DEC	2000	16	12					862	866		10.1007/s003810000368			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	383MR	WOS:000165887000008	11156302				2021-06-18	
J	Clark, WM; Raps, EC; Tong, DC; Kelly, RE				Clark, WM; Raps, EC; Tong, DC; Kelly, RE		Cervene Stroke Study Invest	Cervene (nalmefene) in acute ischemic stroke - Final results of a phase III efficacy study	STROKE			English	Article						narcotic antagonists; stroke; therapy	RECEPTOR ANTAGONIST NALMEFENE; CEREBRAL-ISCHEMIA; SPINAL-CORD; GLUTAMATE ANTAGONIST; RANDOMIZED TRIAL; TRAUMATIC INJURY; BRAIN ISCHEMIA; NALOXONE; TOLERABILITY; DEFICITS	Background and Purpose-The goals of the present study were to assess the efficacy and safety of nalmefene (Cervene) in patients with acute (less than or equal to 6 hours) ischemic stroke and to investigate the safety of combined recombinant tissue plasminogen activator and nalmefene in a separate subset of patients. Nalmefene. an opioid antagonist with relative kappa receptor selectivity, has shown neuroprotective effects in multiple experimental central nervous system injury and ischemic models. Results from an earlier phase II study in patients with acute ischemic stroke suggested that nalmefene was safe and tolerable and may be effective for patients (<70 years old. Methods-This investigation was a phase III, placebo-controlled, double-blind, randomized study of a 24-hour infusion of nalmefene. Patients with acute ischemic stroke who had an onset of symptoms within 6 hours and a baseline score of greater than or equal to 4 on the NIH Stroke Scale were randomized to receive either 60 mg nalmefene administercd as a ID-mg bolus over 15 minutes and then a 50-mg infusion over 23.75 hours or placebo, The primary efficacy outcome was the proportion of patients achieving a score of greater than or equal to 60 on the Bathel Index and a rating of "moderate disability" or better on the Glasgow Outcome Scale at 12 weeks. Assessments were performed at baseline iprcdose), hours 12 and 24, days 2 and 7, and week 12, Results-A total of 368 patients were randomized at 42 centers, including 32 patients treated with recombinant tissue plasminogen activator and study drug. Nalmefene was well tolerated. Overall, there was no significant difference in 3-month functional outcome for nalmefene treatment compared with placebo on any of the planned analyses. A prospective secondary analysis also failed to find a treatment effect in patients <70 years old, Conclusions-Although nalmeferne appears to be safe and well tolerated. this study failed to find any treatment benefit in stroke patients treated within 6 hours.	Oregon Hlth Sci Univ, Oregon Stroke Ctr, Portland, OR 97201 USA; Stanford Stroke Ctr, Palo Alto, CA USA; Louisiana State Univ, Ctr Med, Shreveport, LA 71130 USA	Clark, WM (corresponding author), Oregon Hlth Sci Univ, Oregon Stroke Ctr, UHS 44,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.						ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ALBERS G, 1997, STROKE, V28, P271; ALBERS GW, 1995, STROKE, V26, P254, DOI 10.1161/01.STR.26.2.254; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Clark W, 1999, J Stroke Cerebrovasc Dis, V8, P224, DOI 10.1016/S1052-3057(99)80071-8; Clark W M, 1996, J Stroke Cerebrovasc Dis, V6, P35, DOI 10.1016/S1052-3057(96)80024-3; Clark WM, 1999, STROKE, V30, P2592, DOI 10.1161/01.STR.30.12.2592; CLARK WM, 1994, NEUROLOGY, V44, pA270; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Davis Stephen M., 1997, Stroke, V28, P271; EDWARDS K, 1996, NEUROLOGY, V46, P424; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P451; FADEN AI, 1985, REGUL PEPTIDES, V11, P35, DOI 10.1016/0167-0115(85)90029-1; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FADEN AI, 1990, PROTECTION BRAIN ISC, P265; FALLIS RJ, 1984, STROKE, V15, P627, DOI 10.1161/01.STR.15.4.627; GRAHAM SH, 1993, BRAIN RES, V632, P346, DOI 10.1016/0006-8993(93)91175-R; GROTTA J, 1995, STROKE, V26, P602, DOI 10.1161/01.STR.26.4.602; Grotta James, 1997, Stroke, V28, P271; HAHN EF, 1975, J MED CHEM, V18, P259, DOI 10.1021/jm00237a008; HARIRI RJ, 1986, J NEUROSURG, V64, P780, DOI 10.3171/jns.1986.64.5.0780; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; JENNETT B, 1975, LANCET, V1, P480; KRUMINS SA, 1986, ANN NEUROL, V19, P498, DOI 10.1002/ana.410190514; LESKO L, 1997, STROKE, V28, P232; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; MAHONEY F I, 1965, Md State Med J, V14, P61; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MICHEL ME, 1984, PHARMACOLOGIST, V26, P201; NAMBA S, 1986, JPN J PSYCHIAT NEUR, V40, P61; OLNEY JW, 1983, EXCITOTOXINS, P92; PERRARO F, 1984, LANCET, V1, P915; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SANDOR P, 1986, J CEREBR BLOOD F MET, V6, P553, DOI 10.1038/jcbfm.1986.101; SCAVINI C, 1990, STROKE, V21, P943, DOI 10.1161/01.STR.21.6.943; VINK R, 1990, J NEUROSCI, V10, P3524; YUM SW, 1990, ARCH NEUROL-CHICAGO, V47, P277, DOI 10.1001/archneur.1990.00530030043014; ZIVIN JA, 1991, SCI AM, V265, P56, DOI 10.1038/scientificamerican0791-56	38	58	60	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	JUN	2000	31	6					1234	1239		10.1161/01.STR.31.6.1234			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	319HJ	WOS:000087335200006	10835438	Bronze			2021-06-18	
J	Bareyre, FM; Saatman, KE; Helfaer, MA; Sinson, G; Weisser, JD; Brown, AL; McIntosh, TK				Bareyre, FM; Saatman, KE; Helfaer, MA; Sinson, G; Weisser, JD; Brown, AL; McIntosh, TK			Alterations in ionized and total blood magnesium after experimental traumatic brain injury: Relationship to neurobehavioral outcome and neuroprotective efficacy of magnesium chloride	JOURNAL OF NEUROCHEMISTRY			English	Article						ionized magnesium; fluid percussion; magnesium; rats; traumatic brain injury	INTRACELLULAR FREE MG-2+; FLUID-PERCUSSION MODEL; SEVERE HEAD-INJURY; CALCIUM; RATS; METABOLISM; STROKE; CATECHOLAMINES; HEPATOCYTES; ANTAGONIST	Experimental evidence suggests that magnesium plays a role in the pathophysiological sequelae of brain injury. The present study examined the variation of blood ionized and total magnesium, as well as potassium, sodium, and ionized calcium, after experimental fluid percussion brain injury in rats. Blood ionized magnesium concentration significantly declined from 0.45 +/- 0.02 to 0.32 +/- 0.02 mM by 30 min postinjury and stayed depressed for the 24-h study period in vehicle-treated rats. Blood total magnesium concentration was 0.59 +/- 0.01 mM and remained stable over time in brain-injured vehicle-treated animals. When magnesium chloride (125 mu mol/rat) was administered 1 h postinjury, ionized magnesium levels were restored by 2 h postinjury and remained at normal values up to 24 h following brain trauma. Magnesium treatment also significantly reduced posttraumatic neuromotor impairments 1 and 2 weeks after the insult, but failed to attenuate spatial learning deficits. A significant positive and linear correlation could be established between ionized magnesium levels measured 24 h postinjury and neuromotor outcome at 1 and 2 weeks. We conclude that acute ionized magnesium measurement may be a predictor of long-term neurobehavioral outcome following head injury and that delayed administration of magnesium chloride can restore blood magnesium concentration and attenuate neurological motor deficits in brain-injured rats.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NSO8803, R01-NS26818] Funding Source: Medline		ALTURA B M, 1985, Magnesium, V4, P245; Altura B. M., 1992, Magnesium and Trace Elements, V10, P122; Altura B T, 1984, Magnesium, V3, P195; Altura B. T., 1992, Magnesium and Trace Elements, V10, P90; ALTURA BM, 1994, SCAND J CLIN LAB INV, V54, P5, DOI 10.3109/00365519409095206; ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; ALTURA BM, 1981, FED PROC, V40, P2672; ALTURA BM, 1995, ALCOHOL, V12, P433, DOI 10.1016/0741-8329(95)00026-N; ALTURA BM, 1995, ALCOHOL, V12, P131, DOI 10.1016/0741-8329(94)00072-7; ALTURA BM, 1997, FRONT BIOSCI, V2, P9; Altura BT, 1997, NEUROSCI LETT, V230, P37, DOI 10.1016/S0304-3940(97)00471-0; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P21, DOI 10.3109/00365519409095208; ALTURA BT, 1980, NEUROSCI LETT, V20, P323, DOI 10.1016/0304-3940(80)90168-8; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P53, DOI 10.3109/00365519409095211; ALTURA BT, 1980, MED HYPOTHESES, V6, P753, DOI 10.1016/0306-9877(80)90093-6; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P83, DOI 10.3109/00365519409095214; Bara M, 1984, MAGNESIUM, V3, P212; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BROUGHTON A, 1968, LANCET, V2, P1156; Cavaliere F, 1985, Recenti Prog Med, V76, P563; CHAUDRY IH, 1982, AM J PHYSIOL, V242, pR604; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLOWES GHA, 1957, ANN SURG, V146, P530, DOI 10.1097/00000658-195710000-00002; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Ema M, 1991, Magnes Trace Elem, V10, P269; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FINK R, 1992, MAGNES TRACE ELEM, V10, P1; FLINK EB, 1981, ARCH INTERN MED, V141, P441, DOI 10.1001/archinte.141.4.441; GUNTHER T, 1995, MOL CELL BIOCHEM, V144, P141, DOI 10.1007/BF00944393; Gurevich B, 1998, J NEUROSURG, V88, P1066, DOI 10.3171/jns.1998.88.6.1066; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; HENROTTE JG, 1985, J AM COLL NUTR, V4, P165, DOI 10.1080/07315724.1985.10720073; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; JOBORN H, 1985, CLIN ENDOCRINOL, V23, P219, DOI 10.1111/j.1365-2265.1985.tb00217.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KING LR, 1965, SURG GYNECOL OBSTETR, V120, P761; KING LR, 1973, ANN SURG, V177, P126, DOI 10.1097/00000658-197301000-00022; MARK JB, 1961, SURG GYNECOL OBSTET, V113, P213; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McLaurin R L, 1972, Clin Neurosurg, V19, P281; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Regan RF, 1998, J NEUROCHEM, V70, P77; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SAWYER RB, 1970, ARCH SURG-CHICAGO, V100, P343; SEELIG MS, 1994, J AM COLL NUTR, V13, P429; SHAPIRA Y, 1989, Neurological Research, V11, P169; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1990, J NEUROSCI, V10, P3524; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1991, MG2PLUS EXCITABLE ME, P125; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	75	58	61	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	1999	73	1					271	280		10.1046/j.1471-4159.1999.0730271.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	207PV	WOS:000080946000032	10386980				2021-06-18	
J	Chatzipanteli, K; Wada, K; Busto, R; Dietrich, WD				Chatzipanteli, K; Wada, K; Busto, R; Dietrich, WD			Effects of moderate hypothermia on constitutive and inducible nitric oxide synthase activities after traumatic brain injury in the rat	JOURNAL OF NEUROCHEMISTRY			English	Article						hypothermia; nitric oxide; constitutive nitric oxide synthase; inducible nitric oxide synthase; fluid-percussion brain injury	CEREBRAL BLOOD-FLOW; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; RADICAL PRODUCTION; NEUROTOXICITY; TEMPERATURE; PROTECTION; INHIBITION; ISCHEMIA; PHOSPHORYLATION	We investigated the effects of therapeutic hypothermia (30 degrees C) on alterations in constitutive (cNOS) and inducible (iNOS) nitric oxide synthase activities following traumatic brain injury (TBI). Male Sprague-Dawley rats were anesthetized with 0.5% halothane and underwent moderate (1.8-2.2 atm) parasagittal fluid-percussion (F-P) brain injury. In normothermic rats (37 degrees C) the enzymatic activity of cNOS was significantly increased at 5 min within the injured cerebral cortex compared with contralateral values (286.5 +/- 68.9% of contralateral value; mean +/- SEM). This rise in nitric oxide synthase activity was significantly reduced with pretraumatic hypothermia (138.8 +/- 17% of contralateral value; p < 0.05). At 3 and 7 days after normothermic TBI the enzymatic activity of cNOS was decreased significantly (30 +/- 8.4 and 28.6 +/- 20.9% of contralateral value, respectively; p < 0.05). However, immediate posttraumatic hypothermia (3 h at 30 degrees C) preserved cNOS activity at 3 and 7 days (69.5 +/- 23.3 and 78.6 +/- 7.6% of contralateral value, respectively; mean +/- SEM; p < 0.05). Posttraumatic hypothermia also significantly reduced iNOS activity at 7 days compared with normothermic rats (0.021 +/- 0.06 and 0.23 +/- 0.06 pmol/mg of protein/min, respectively; p < 0.05). The present results indicate that hypothermia (a) decreases early cNOS activation after TBI, (b) preserves cNOS activity at later periods, and (c) prevents the delayed induction of iNOS. Temperature-dependent alterations in cNOS and iNOS enzymatic activities may participate in the neuroprotective effect of hypothermia in this TBI model.	Univ Miami, Sch Med, Dept Neurol & Neurol Surg, Miami, FL 33101 USA	Chatzipanteli, K (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline		Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; ALBINA JE, 1993, J IMMUNOL, V150, P5080; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1995, ANN NEUROL, V37, P115, DOI 10.1002/ana.410370122; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SUZUKI S, 1995, J NEUROSURG, V83, P862, DOI 10.3171/jns.1995.83.5.0862; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; ZILLES L, 1985, CORTEX BRAIN STEREOT	46	58	60	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	1999	72	5					2047	2052		10.1046/j.1471-4159.1999.0722047.x			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	186WJ	WOS:000079753400030	10217283	Bronze			2021-06-18	
J	Mathias, JL; Coats, JL				Mathias, JL; Coats, JL			Emotional and cognitive sequelae to mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; FRONTAL-LOBE DYSFUNCTION; PSYCHOSOCIAL FUNCTION; CROSS-VALIDATION; PERSONALITY; DISTURBANCE; SYMPTOMS; MODERATE; SCALE	This study compared the emotional functioning and cognitive abilities (i.e., verbal fluency, executive functioning, memory, and attention) of 27 patients with mild traumatic brain injury (MTBI) to that of 27 controls. With the exception of verbal fluency, the cognitive abilities of the MTBI group appeared to be intact. Emotional functioning was assessed using the Neuropsychology Behavior and Affect Profile (NBAP), a revised version of the Neurobehavioural Rating Scale and the Headley Court Psychosocial Rating Scale. The NBAP demonstrated good internal reliability, criterion validity, and construct validity. The MTBI group showed significantly higher levels of post injury depression than controls on the NEAR Pre injury levels of depression in the MTBI group were also higher than the controls but both the patient reports and those of family members confirmed an increase in depression following MTBI.	Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia	Mathias, JL (corresponding author), Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia.	psyj-mat@psychology.adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594			ABSHER JR, 1995, APHASIOLOGY, V9, P181, DOI 10.1080/02687039508248705; ALFANO DP, 1991, NEUROPSYCHOLOGY, V5, P35; Bennett TL, 1989, COGNITIVE REHABILITA, V7, P20; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; FOS LA, 1995, INT NEUR SOC AUSTR S; Gass CS, 1997, ARCH CLIN NEUROPSYCH, V12, P199, DOI 10.1016/S0887-6177(96)00032-7; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GOLDSTEIN FC, 1989, INTEGRATING THEORY P, P217; GRONWALL D, 1974, LANCET, V2, P605; HAMILTON JM, 1995, BRAIN INJURY, V9, P479, DOI 10.3109/02699059509008207; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JENKINS A, 1986, LANCET, V2, P445; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin H. S., 1991, FRONTAL LOBE FUNCTIO; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levin HS, 1989, MILD HEAD INJURY; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Nelson HE, 1982, NATL ADULT READING T; NELSON L, 1994, NEUROBEHAVIORAL BEHA; Nelson LD, 1995, PSYCHOL ASSESSMENT, V7, P404, DOI 10.1037/1040-3590.7.3.404; NELSON LD, 1989, J CONSULT CLIN PSYCH, V1, P266; NELSON LD, 1993, PSYCHOL ASSESSMENT, V5, P374; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RANSEN J, 1990, COGNITIVE REHABILITA, V8, P8; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Satz P, 1996, PSYCHOL ASSESSMENT, V8, P115; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TEASDALE G, 1974, LANCET, V2, P81; *WHO, 1989, ALC US DIS ID TEST	54	58	59	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1999	21	2					200	215		10.1076/jcen.21.2.200.930			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	226CL	WOS:000082002700005	10425517				2021-06-18	
J	Armstead, WM				Armstead, WM			Superoxide generation links protein kinase C activation to impaired ATP-sensitive K+ channel function after brain injury	STROKE			English	Article						cerebral circulation; newborn; nitric oxide	PIAL ARTERY VASODILATION; CEREBRAL ARTERIOLES; SMOOTH-MUSCLE; HEAD-INJURY; RESPONSES; DISMUTASE; ISCHEMIA; NEWBORN; PIGLETS; OXYGEN	Background and Purpose-Endothelin-1, in concentrations similar to that present in cerebrospinal fluid after fluid percussion brain injury (FPI), increases superoxide anion (P-2(-)) production. Endothelin-l also contributes to altered cerebral hemodynamics after FPI through impairment of ATP-sensitive K+ (K-ATP) channel function through protein kinase C (PKC) activation. Generation of O-2(-) additionally occurs after FPI. Nitric oxide and cGMP elicit pial artery dilation through K-ATP channel activation. The present study was designed to determine whether PKC activation generates O-2(-), which, in turn, could link such activation to impaired K-ATP channel function after FPI. Methods-Injury of moderate severity (1.9 to 2.1 atm) was produced by the lateral FPI technique in anesthetized newborn pigs equipped with a closed cranial window. Superoxide dismutase-inhibitable nitroblue tetrazolium (NBT) reduction was determined as an index of O-2(-) generation. Results-Phorbol 12,13-dibutyrate (10(-6) mol/L), a PKC activator, increased superoxide dismutase-inhibitable NET reduction from 1+/-1 to 37+/-5 pmol/mm(2). Staurosporine (10(-7) mol/L), a PKC antagonist, blocked the NET reduction after phorbol 12,13-dibutyrate and blunted the NET reduction observed after FPI (1+/-1 to 15+/-2 versus 1+/-1 to 5+/-1 pmol/mm(2) after FPI in the absence versus presence of staurosporine). Exposure of the cerebral cortex to a xanthine oxidase O-2(-)-generating system increased NET reduction in a manner similar to FPI and blunted pial artery dilation to the K-ATP channel agonists cromakalim and calcitonin gene-related peptide, the nitric oxide releasers sodium nitroprusside and S-nitroso-N-acetylpenicillamine, and the cGMP analogue 8-bromo-cGMP (10+/-1% and 21+/-1% versus 4+/-1% and 9+/-1% for 10(-8) and 10(-6) mol/L cromakalim before and after activated oxygen-generating system exposure). Conclusions-These data show that PKC activation increases O-2(-) production and contributes to such production observed after FPI. These data also show that an activated system that generates an amount of O-2(-) similar to that observed with FPI blunted pial artery dilation to K-ATP channel agonists and nitric oxide/cGMP. These data suggest, therefore, that O-2(-) generation links PKC activation to impaired K-ATP channel function after FPI.	Childrens Hosp Philadelphia, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	Armstead, WM (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesia, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	armsteaw@mail.med.upenn.edu					Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH423; Bari F, 1996, STROKE, V27, P1874, DOI 10.1161/01.STR.27.10.1874; Bari F, 1996, J CEREBR BLOOD F MET, V16, P1158, DOI 10.1097/00004647-199611000-00010; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; Kasemsri T, 1997, AM J PHYSIOL-HEART C, V273, pH2639; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; KITAZONO T, 1993, AM J PHYSIOL, V265, pH581; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kontos HA, 1996, AM J PHYSIOL-HEART C, V271, pH1498; Lange A, 1997, J BIOL CHEM, V272, P27345, DOI 10.1074/jbc.272.43.27345; LEFFLER CW, 1989, STROKE, V20, P541, DOI 10.1161/01.STR.20.4.541; LEFFLER CW, 1989, PEDIATR RES, V25, P180; LEFFLER CW, 1990, AM J PHYSIOL, V259, pH1230, DOI 10.1152/ajpheart.1990.259.4.H1230; LESCOHIER I, 1993, PEDIATRICS, V91, P721; MILLER JD, 1994, LANCET, V344, P421; MIYOSHI Y, 1992, CIRC RES, V70, P612, DOI 10.1161/01.RES.70.3.612; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MURRAY MA, 1992, AM J PHYSIOL, V32, pH1643; Satoh H, 1995, GEN PHARMACOL, V26, P1549, DOI 10.1016/0306-3623(95)00046-1; SHANKAR V, 1995, AM J PHYSIOL-HEART C, V269, pH997; SMITH NC, 1991, PARASITOL RES, V77, P521, DOI 10.1007/BF00928421; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; THOROGOOD MC, 1995, AM J PHYSIOL-HEART C, V269, pH1776; WEI EP, 1986, AM J PHYSIOL, V251, pH693; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781	33	58	60	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JAN	1999	30	1					153	159		10.1161/01.STR.30.1.153			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	155EW	WOS:000077934200032	9880404	Bronze			2021-06-18	
J	Bernard, SA; Jones, BM; Buist, M				Bernard, SA; Jones, BM; Buist, M			Experience with prolonged induced hypothermia in severe head injury	CRITICAL CARE			English	Article						hypokalaemia; ileus; induced hypothermia; neutropenia; nosocomial pneumonia; septic shock; thrombocytopenia; traumatic brain injury	INTRACRANIAL HYPERTENSION; MODERATE HYPOTHERMIA; BRAIN INJURY; TRAUMA	Background: Recent prospective controlled trials of induced moderate hypothermia (32-34 degrees C) for relatively short periods (24-48 h) in patients with severe head injury have suggested improvement in intracranial pressure control and outcome. It is possible that increased benefit might be achieved if hypothermia was maintained for more periods longer than 48 h, but there is little in the literature on the effects of prolonged moderate hypothermia in adults with severe head injury. We used moderate induced hypothermia (30-33 degrees C) in 43 patients with severe head injury for prolonged periods (mean 8 days, range 2-19 days). Results: Although nosocomial pneumonia (defined in this study as both new chest radiograph changes and culture of a respiratory pathogen from tracheal aspirate) was quite common (45%), death from sepsis was rare (5%). Other findings included hypokalaemia on induction of hypothermia and a decreasing total white cell and platelet count over 10 days. There were no major cardiac arrhythmias. There was a satisfactory neurological outcome in 20 out of 43 patients (47%). Conclusion: Moderate hypothermia may be induced for more prolonged periods, and is a relatively safe and feasible therapeutic option in the treatment of selected patients with severe traumatic brain injury. Thus, further prospective controlled trials using induced hypothermia for longer periods than 48 h are warranted.	Dandenong Hosp, Intens Care Unit, Dandenong, Vic 3175, Australia	Bernard, SA (corresponding author), Dandenong Hosp, Intens Care Unit, David St, Dandenong, Vic 3175, Australia.						BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; BLOCH M, 1967, BRAIN, V90, P769, DOI 10.1093/brain/90.4.769; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONTEN MJM, 1994, CRIT CARE MED, V22, P1683; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CANCIO LC, 1994, RESUSCITATION, V28, P9, DOI 10.1016/0300-9572(94)90049-3; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CURRY DL, 1970, ENDOCRINOLOGY, V87, P750, DOI 10.1210/endo-87-4-750; DARBY J M, 1992, Anesthesiology (Hagerstown), V77, pA295, DOI 10.1097/00000542-199209001-00295; DARBY JM, 1994, CRIT CARE MED, V22, pA71; DELANEY KA, 1989, ANN EMERG MED, V18, P72, DOI 10.1016/S0196-0644(89)80319-1; DEMARIA EJ, 1985, ANN SURG, V202, P248, DOI 10.1097/00000658-198508000-00017; EPSTEIN FM, 1987, HEAD INJURY, P391; FAY T, 1945, RES PUBL ASS NERV ME, V24, P611; Fay T, 1940, NY STATE J MED, V40, P1351; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; KOHT A, 1983, INTENS CARE MED, V9, P275, DOI 10.1007/BF01691254; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; MACLEAN D, 1974, BMJ-BRIT MED J, V2, P59; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MICHENFELDER JD, 1965, SURG CLIN N AM, V45, P889; ORLOWSKI JP, 1984, CRIT CARE MED, V12, P367, DOI 10.1097/00003246-198404000-00006; PATT A, 1988, SURG CLIN N AM, V68, P775; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHAPIRO HM, 1974, J NEUROSURG, V40, P90, DOI 10.3171/jns.1974.40.1.0090; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SPRUNG J, 1991, CRIT CARE MED, V19, P1545, DOI 10.1097/00003246-199112000-00018; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; SWAIN JA, 1993, NEW ENGL J MED, V329, P1119, DOI 10.1056/NEJM199310073291511; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012	38	58	61	0	4	CURRENT SCIENCE LTD	LONDON	34-42 CLEVELAND STREET, LONDON W1P 6LE, ENGLAND	1466-609X			CRIT CARE	Crit. Care		1999	3	6					167	172		10.1186/cc371			6	Critical Care Medicine	General & Internal Medicine	271JJ	WOS:000084590200009		DOAJ Gold, Green Published			2021-06-18	
J	Philips, MF; Muir, JK; Saatman, KE; Raghupathi, R; Lee, VMY; Trojanowski, JQ; McIntosh, TK				Philips, MF; Muir, JK; Saatman, KE; Raghupathi, R; Lee, VMY; Trojanowski, JQ; McIntosh, TK			Survival and integration of transplanted postmitotic human neurons following experimental brain injury in immunocompetent rats	JOURNAL OF NEUROSURGERY			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Neurological-Surgeons	APR 25-30, 1998	PHILADELPHIA, PENNSYLVANIA	Amer Assoc Neurol Surgeons		traumatic brain injury; fluid-percussion injury; neuronal development; neural transplantation; inflammation; postmitotic human neuron cells; rat	NEURAL PROGENITOR CELLS; LONG-TERM SURVIVAL; REGION-SPECIFIC DIFFERENTIATION; FETAL MESENCEPHALIC TISSUE; EMBRYONAL CARCINOMA-CELLS; FLUID-PERCUSSION MODEL; CENTRAL-NERVOUS-SYSTEM; PARKINSONS-DISEASE; GROWTH-FACTOR; MOUSE-BRAIN	Object. Limitations regarding cell homogeneity and survivability do not affect neuronlike hNT cells, which are derived from a human teratocarcinoma cell line (Ntera2) that differentiates into postmitotic neurons with exposure to retinoic acid. Because NT2N neurons survive longer than 1 year after transplantation into nude mice brains, the authors grafted these cells into the brains of immunocompetent rats following lateral fluid-percussion brain injury to determine the long-term survivability of NT2N cell grafts in cortices damaged by traumatic brain injury (TBI) and the therapeutic effect of NT2N neurons on cognitive and motor deficits. Methods. Seventy-two adult male Sprague-Dawley rats. each weighing between 340 and 370 g, were given an anesthetic agent and subjected to lateral fluid percussion brain injury of moderate severity (2.2-2.5 atm in 46 rats) or to surgery without TBI (shamoperation, 26 rats). Twenty-four hours postinjury, 10(5) NT2N cells (24 injured animals) or 3 mu l of vehicle (22 injured and 14 control animals) was stereotactically implanted into the periinjured or control cerebral cortex. Motor function was assessed at weekly intervals and all animals were killed at 2 or 4 weeks after their posttraumatic learning ability was assessed using a Morris water maze paradigm. Viable NT2N grafts were routinely observed to extend human neural cell adhesion molecule-(MOC-1)immunoreactive processes into the periinjured cortex at 2 and 4 weeks posttransplantation, although no significant improvement in motor or cognitive function was noted. Inflammation identified around the transplant at both time points was assessed by immunohistochemical identification of macrophages (ED-1) and microglia (isolectin B4). Conclusions. Long-term survival and integration of NT2N cells in the periinjured cortex of immunocompetent rats provides the researcher with an important cellular system that can be used to study maturation, regulation, and neurite outgrowth of transplanted neurons following TBI.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG09215] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG009215] Funding Source: NIH RePORTER		ANDREWS PW, 1984, LAB INVEST, V50, P147; Belkadi AM, 1997, EXP NEUROL, V144, P369, DOI 10.1006/exnr.1997.6414; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRUNDIN P, 1988, EXP BRAIN RES, V70, P192; BRUNDIN P, 1985, EXP BRAIN RES, V60, P204; Butcher SP, 1997, J NEUROSCI, V17, P6939; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Drake M, 1996, ACTA PHYSIOL SCAND, V158, P155, DOI 10.1046/j.1365-201X.1996.535298000.x; Duan WM, 1996, BRAIN RES, V712, P199, DOI 10.1016/0006-8993(95)01409-8; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FRODL EM, 1994, BRAIN RES, V647, P286, DOI 10.1016/0006-8993(94)91328-5; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Galpern WR, 1996, EXP NEUROL, V140, P1, DOI 10.1006/exnr.1996.0109; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRABOWSKI M, 1993, ANN NEUROL, V34, P362, DOI 10.1002/ana.410340310; Gritti A, 1996, J NEUROSCI, V16, P1091; HADANI M, 1992, J NEUROTRAUM, V9, P107, DOI 10.1089/neu.1992.9.107; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Honey C R, 1990, Neuroreport, V1, P247, DOI 10.1097/00001756-199011000-00019; Iacovitti L, 1997, NEUROREPORT, V8, P1471, DOI 10.1097/00001756-199704140-00029; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KLEPPNER SR, 1995, J COMP NEUROL, V357, P618, DOI 10.1002/cne.903570410; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; LEE VMY, 1986, J NEUROSCI, V6, P514; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; LINDVALL O, 1997, NEUROREPORT, V8, P3; Lundberg C, 1996, NEUROBIOL DIS, V3, P33, DOI 10.1006/nbdi.1996.0004; Lundberg C, 1996, EXP NEUROL, V139, P39, DOI 10.1006/exnr.1996.0079; MANTIONE JR, 1995, BRAIN RES, V671, P333, DOI 10.1016/0006-8993(94)01400-C; MARTINEZSERRANO A, 1995, NEURON, V15, P473, DOI 10.1016/0896-6273(95)90051-9; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYAZONO M, 1995, LAB INVEST, V73, P273; Miyazono M, 1996, J COMP NEUROL, V376, P603, DOI 10.1002/(SICI)1096-9861(19961223)376:4<603::AID-CNE8>3.0.CO;2-5; MOLENAAR WM, 1991, ACTA NEUROPATHOL, V83, P46, DOI 10.1007/BF00294429; Munir M, 1996, J PHARMACOL EXP THER, V276, P819; Munir M, 1995, J NEUROSCI, V15, P7847; Onizuka K, 1996, EXP NEUROL, V137, P324, DOI 10.1006/exnr.1996.0033; Peschanski M, 1996, NEUROSCIENCE, V71, P899, DOI 10.1016/0306-4522(95)00575-7; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; Rothwell NJ, 1996, PHARMACOL THERAPEUT, V69, P85, DOI 10.1016/0163-7258(95)02033-0; Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574; SAKAI K, 1991, BRAIN RES, V565, P167, DOI 10.1016/0006-8993(91)91750-U; SHIHABUDDIN LS, 1995, J NEUROSCI, V15, P6666; Shihabuddin LS, 1996, EXP NEUROL, V139, P61, DOI 10.1006/exnr.1996.0081; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Snyder Evan Y., 1994, Current Opinion in Neurobiology, V4, P742, DOI 10.1016/0959-4388(94)90018-3; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Soares HD, 1995, J NEUROSCI, V15, P8223; Sorensen JC, 1996, EXP NEUROL, V138, P227, DOI 10.1006/exnr.1996.0061; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; SPENCER L, 1996, SIGHT SOUND, V6, P47; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Trojanowski JQ, 1997, EXP NEUROL, V144, P92, DOI 10.1006/exnr.1996.6393; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Wu P, 1996, GENE THER, V3, P246; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	76	58	60	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	1999	90	1					116	124		10.3171/jns.1999.90.1.0116			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	168TH	WOS:000078708400016	10413164				2021-06-18	
J	Stover, JF; Stocker, R				Stover, JF; Stocker, R			Barbiturate coma may promote reversible bone marrow suppression in patients with severe isolated traumatic brain injury	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						head injury; barbiturate coma	BETA-LACTAM ANTIBIOTICS; ANESTHETICS; METABOLISM; INVITRO; PHARMACOKINETICS; METRONIDAZOLE; COMPLICATIONS; INHIBITION; THERAPY; DISEASE	Objectives: Barbiturate coma is employed in brain-injured patients whenever increases in intracranial pressure remain unresponsive to less aggressive therapeutic regimens. Barbiturate-mediated neuroprotection, however, is weakened by an increased infection rate related to barbiturate-induced immunosuppression. Coadministration of barbiturates with antibiotics known to induce bone marrow suppression could, in turn, potentiate barbiturate-mediated immunosuppression. Adverse drug reactions and interactions of thiopental with antibiotics in terms of leukopenia, infection rate, and bone marrow suppression were investigated. Methods: White blood cells were measured daily, tracheobronchial secretion and urine were examined for bacterial growth twice a week or if an infection was suspected. Results: A total of 52 patients with severe isolated head injury were consecutively investigated. Due to increased intracranial pressure (ICP), which did not respond to analgosedation, barbiturate coma was performed in 23 cases. The other 29 patients remained analgosedated. Leukocytes and neutrophils were reversibly and significantly decreased in all patients, mostly sustained under thiopental. The pulmonary infection rate due to Gramnegative organisms was nearly doubled during barbiturate coma. Reversible agranulocytosis and bone marrow suppression attributed to antibiotics developed in six patients after thiopental administration. Mortality rate, however, was not increased by these adverse effects. Conclusions: Barbiturate coma may cause reversible leukopenia and an increased infection rate. Long-term administration of thiopental may also promote reversible antibiotic-induced bone marrow suppression. The mechanisms and site of interaction between thiopental and antibiotics cannot be assessed by the present study and remain to be clarified. However, during and after barbiturate coma, close monitoring of leukocytes and infections and careful selection of antibiotics is required.	Univ Zurich Hosp, Div Trauma Surg, CH-8091 Zurich, Switzerland	Stover, JF (corresponding author), Univ Zurich Hosp, Div Trauma Surg, Ramistr 100, CH-8091 Zurich, Switzerland.						BONDY SC, 1993, FREE RADICAL BIO MED, V14, P633, DOI 10.1016/0891-5849(93)90144-J; BURCH PG, 1983, ANESTHESIOLOGY, V58, P146, DOI 10.1097/00000542-198302000-00008; CHIU PJS, 1977, ANTIMICROB AGENTS CH, V11, P821, DOI 10.1128/AAC.11.5.821; COHEN PJ, 1973, ANESTHESIOLOGY, V39, P153, DOI 10.1097/00000542-197308000-00007; DONEGAN JH, 1985, AM J PHYSIOL, V249, pH421; EBERHARDT KEW, 1992, INFECTION, V20, P16; EPSTEIN B, 1955, J CLIN INVEST, V34, P500; FARRELL G, 1984, HEPATOLOGY, V4, P722, DOI 10.1002/hep.1840040427; HORBER FF, 1989, EUR J CLIN PHARMACOL, V36, P389, DOI 10.1007/BF00558301; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KRESS HG, 1989, ACTA ANAESTH SCAND, V33, P122, DOI 10.1111/j.1399-6576.1989.tb02873.x; KRESS HG, 1987, ANAESTHESIST, V36, P356; LEBOWITZ PW, 1983, ANESTHESIOLOGY, V59, P381, DOI 10.1097/00000542-198311000-00003; Mandl DL, 1997, ANN PHARMACOTHER, V31, P1321, DOI 10.1177/106002809703101109; MICHENFE.JD, 1974, ANESTHESIOLOGY, V41, P231, DOI 10.1097/00000542-197409000-00004; MILLER JD, 1971, BRAIN RES, V34, P411; MOUDGIL GC, 1981, CAN ANAESTH SOC J, V28, P597, DOI 10.1007/BF03007159; NEFTEL KA, 1985, J INFECT DIS, V152, P90, DOI 10.1093/infdis/152.1.90; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; OLAISON L, 1990, J ANTIMICROB CHEMOTH, V25, P449, DOI 10.1093/jac/25.3.449; ROSENBERG PJ, 1977, ANESTHESIOLOGY, V46, P322, DOI 10.1097/00000542-197705000-00003; ROWLAND M, 1990, CLIN PHARMACOKINET, V18, P184, DOI 10.2165/00003088-199018030-00002; SATO M, 1989, RESUSCITATION, V17, P233, DOI 10.1016/0300-9572(89)90039-7; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; SCHNEIDER MU, 1984, CHEMOTHERAPY, V30, P345, DOI 10.1159/000238292; SINGH N, 1993, AM J MED, V94, P251, DOI 10.1016/0002-9343(93)90056-U; STOCKER R, 1995, INTEGRATED APPROACH, P196; SUTTON LN, 1987, J NEUROSURG, V67, P381, DOI 10.3171/jns.1987.67.3.0381; TABURET AM, 1989, CLIN PHARMACOL THER, V45, P373, DOI 10.1038/clpt.1989.43; TODD MM, 1987, NEUROSURGERY, V20, P559, DOI 10.1227/00006123-198704000-00009; WHITE CM, 1980, BRIT MED J, V280, P647, DOI 10.1136/bmj.280.6214.647-b; WISE R, 1991, ANTIMICROB AGENTS CH, V35, P1081, DOI 10.1128/AAC.35.6.1081	32	58	60	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0031-6970			EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	SEP	1998	54	7					529	534		10.1007/s002280050508			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	134NL	WOS:000076749400007	9832294				2021-06-18	
J	Thatcher, RW; Biver, C; McAlaster, R; Camacho, M; Salazar, A				Thatcher, RW; Biver, C; McAlaster, R; Camacho, M; Salazar, A			Biophysical linkage between MRI and EEG amplitude in closed head injury	NEUROIMAGE			English	Article						EEG; MRI; T2 relaxation times; cognition; traumatic brain injury	MAGNETIC-RESONANCE IMAGES; RELAXATION-TIMES; DELTA WAVES; BRAIN; NMR; MECHANISMS; DIFFUSION; SEGMENTATION; DIAGNOSIS; SEQUENCES	Nuclear magnetic resonance of brain water proton (H-1) T2 relaxation times and measures of absolute amplitude of EEG were obtained from 19 closed head injured patients. The relationship between EEG and T2 relaxation time differed as a function of both EEG frequency and gray matter versus white matter. White matter T2 relaxation time was positively correlated with increased EEG amplitude in the delta frequency band (0.5-3.5 Hz). In contrast, lengthened gray matter T2 relaxation time was inversely correlated with EEG amplitude in the alpha and beta frequency bands (7-22 Hz). These findings are consistent with clinical EEG studies in which white matter lesions are related to increased EEG delta amplitude and gray matter lesions are related to decreased EEG alpha and beta frequency amplitude. Estimates of the severity of injury were obtained by neuropsychological measurements, in which lengthened T2 relaxation times in both the neocortical gray and white matter were correlated with diminished cognitive function. Decreased EEG beta and alpha amplitude and increased EEG delta amplitude were also correlated with diminished cognitive function. The findings imply a biophysical linkage between the state of protein-lipid structures of the brain as measured by the MRI and the scalp-recorded EEG. (C) 1998 Academic Press.	Vet Adm Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33744 USA; Def & Vet Head Injury Program, Washington, DC 20307 USA	Thatcher, RW (corresponding author), Vet Adm Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33744 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADVANI SH, 1982, OXFORD MED ENG SERIE, P3; Barlow JS, 1993, ELECTROENCEPHALOGRAM; BENSAID AM, 1994, P SOC PHOTO-OPT INS, V2167, P454, DOI 10.1117/12.175079; BEZDEK JC, 1993, MED PHYS, V20, P1033, DOI 10.1118/1.597000; BLOCH F, 1946, PHYS REV, V70, P460, DOI 10.1103/PhysRev.70.460; BOTTOMLEY PA, 1987, MED PHYS, V14, P1, DOI 10.1118/1.596111; BOTTOMLEY PA, 1984, MED PHYS, V11, P425, DOI 10.1118/1.595535; Braitenberg V, 1978, ARCHITECTONICS CEREB, P443; BRAITENBERG V, 1972, SYNCHRONIZATION EEG, P47; CARPENDER MB, 1983, HUMAN NEUROANATOMY; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; Cohen J., 1983, APPL MULTIPLE REGRES; COOPER R, 1981, EEG TECHNOLOGY; DARWIN RH, 1986, RADIOLOGY, V160, P375, DOI 10.1148/radiology.160.2.3726116; DASILVA FL, 1991, ELECTROEN CLIN NEURO, V79, P81, DOI 10.1016/0013-4694(91)90044-5; DIXON RL, 1982, MED PHYS, V9, P807, DOI 10.1118/1.595189; DOES MD, 1995, MAGN RESON IMAGING, V13, P575, DOI 10.1016/0730-725X(94)00138-S; FULLERTON GD, 1992, MAGNETIC RESONANCE I, P88; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GLOOR P, 1968, BRAIN, V91, P779, DOI 10.1093/brain/91.4.779; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; GOLDENSOHN ES, 1979, CURRENT PRACTICE CLI; GRAHAM DI, 1993, HEAD INJURY; HICKEY DS, 1986, BRIT J RADIOL, V59, P565, DOI 10.1259/0007-1285-59-702-565; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; HUS EW, 1996, AM J PHYSIOL, V40, pC1895; JASPER H, 1953, ELECTROENCEPHALOGR S, V4, P168; KJOS BO, 1985, AM J ROENTGENOL, V144, P1165, DOI 10.2214/ajr.144.6.1165; KOENIG SH, 1991, MAGNET RESON MED, V20, P285, DOI 10.1002/mrm.1910200210; KROEKER RM, 1986, J MAGN RESON, V69, P218, DOI 10.1016/0022-2364(86)90074-0; LEBIHAN D, 1991, JMRI-J MAGN RESON IM, V1, P7, DOI 10.1002/jmri.1880010103; LEE Y-C, 1970, Mathematical Biosciences, V6, P473, DOI 10.1016/0025-5564(70)90080-5; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MILLS CM, 1984, RADIOLOGY, V150, P87, DOI 10.1148/radiology.150.1.6689792; NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981; NICHOLSON C, 1980, NEUROSCI RES PROG B, V18, P177; Nunez P., 1981, ELECT FIELDS BRAIN; Nunez P. L., 1995, NEOCORTICAL DYNAMICS; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Ommaya AK, 1968, J BIOMECH; Otnes R. K., 1972, DIGITAL TIME SERIES; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; Sano K, 1967, Neurol Med Chir (Tokyo), V9, P21, DOI 10.2176/nmc.9.21; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; SZAFER A, 1995, MAGNET RESON MED, V33, P697, DOI 10.1002/mrm.1910330516; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R W, 1995, J Neuroimaging, V5, P35; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; VANZIJL PCM, 1991, P NATL ACAD SCI USA, V88, P3228, DOI 10.1073/pnas.88.8.3228; VELLEMAN PF, 1995, DATA DESK VERSION 5; Wehrli F. W, 1992, MAGNETIC RESONANCE I, P3	59	58	59	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAY	1998	7	4	1				352	367		10.1006/nimg.1998.0330			16	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	ZT101	WOS:000074048500008	9626675				2021-06-18	
J	Al-Adawi, S; Powell, JH; Greenwood, RJ				Al-Adawi, S; Powell, JH; Greenwood, RJ			Motivational deficits after brain injury: A neuropsychological approach using new assessment techniques	NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; BROMOCRIPTINE; BEHAVIOR; SCALE	Deficits of motivation art: recognized as a significant clinical problem following brain injury, and a neuropsychological model is postulated linking such deficits with cognitive deficits of a frontal type. However, few, if any, quantitative assessment measures exist; most descriptions in the literature are qualitative, and this has limited the scope and robustness of research into the problem. The authors in the present research have developed new tools for assessing patients' level of motivation in therapy (percent participation index) and their behavioral responsiveness to experimental incentive (the card-arranging reward responsivity objective test). Relationships among poor motivation, reward responsiveness, frontal lobe function, and mood were explored in a sample of 54 patients with nonfocal vascular or traumatic brain injury; the results were consistent with the neuropsychological model. Preliminary reliability and validation data on the new measures are reported.	Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; Inst Psychiat, Dept Psychol, London SE5 8AF, England; Homerton Hosp, Reg Neurol Rehabil Unit, London, England	Powell, JH (corresponding author), Univ London Goldsmiths Coll, Dept Psychol, Lewisham Way, London SE14 6NW, England.	psa01jhp@gold.ac.uk	Al-Adawi, Samir/A-9663-2016	Al-Adawi, Samir/0000-0002-9858-5582			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ALADAWI S, IN PRESS ADDICTION; AMMONS R. B., 1962, QUICK TEST; BENTON AL, 1986, NEUROPSYCHOLOGIA, V6, P63; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; COLLIN C, 1988, J NEUROL NEUROSUR PS, V141, P68; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; FRITH CD, 1983, PSYCHOL MED, V13, P779, DOI 10.1017/S0033291700051485; FRITH CD, 1992, J ROY SOC MED, V85, P222; Frith CD., 1992, COGN NEUROPSYCHOL; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GILES GM, 1993, BRAIN INJURY REHABIL; Hair J., 1992, MULTIVARIATE DATA AN; KATZMANN S, 1994, AM J OCCUP THER, V48, P259, DOI 10.5014/ajot.48.3.259; KLINE P, 1983, ADV BEHAV RES THER, V5, P141, DOI 10.1016/0146-6402(83)90017-6; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Liddle P F, 1993, Behav Neurol, V6, P5, DOI 10.3233/BEN-1993-6102; MULLER U, 1994, PROG NEURO-PSYCHOPH, V18, P1103, DOI 10.1016/0278-5846(94)90114-7; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; PICKERING AD, IN PRESS SCI STUDY P; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; Raven J. C., 1965, GUIDE USING COLOURED; RICHARDS PM, 1989, J CONSULT CLIN PSYCH, V57, P396, DOI 10.1037/0022-006X.57.3.396; SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8; Savournin R, 1995, BRIT J MED PSYCHOL, V68, P353, DOI 10.1111/j.2044-8341.1995.tb01843.x; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; Seligman M., 1981, BEHAVIOR THERAPY DEP, P123; SHAKOW D, 1963, BEHAV SCI, V8, P275; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Vikki Juhani, 1994, Journal of Clinical and Experimental Neuropsychology, V16, P325; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Wilson, 1991, NATL ADULT READING T; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	58	59	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	1998	12	1					115	124		10.1037/0894-4105.12.1.115			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	YR430	WOS:000071494500010	9460739				2021-06-18	
J	LeRoux, PD; Newell, DW; Lam, AM; Grady, MS; Winn, HR				LeRoux, PD; Newell, DW; Lam, AM; Grady, MS; Winn, HR			Cerebral arteriovenous oxygen difference: A predictor of cerebral infarction and outcome in patients with severe head injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; arteriovenous oxygen difference; intracranial pressure; cerebral ischemia; outcome	EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; ACUTE SUBDURAL-HEMATOMA; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; COMATOSE PATIENTS; METABOLISM; SATURATION; CIRCULATION	Jugular bulb oxygen monitoring can be used to estimate the adequacy of cerebral blood flow to support cerebral metabolism after severe head injury. In the present study, the authors studied the cerebral arteriovenous oxygen difference (AVDO(2)) before and after treatment in 32 head-injured patients (Glasgow Coma Scale scores less than or equal to 8) to examine the relationships among AVDO(2) and cerebral perfusion pressure (CPP), delayed cerebral infarction, and outcome. Fifteen patients (Group A) underwent craniotomy for hematoma evacuation and 17 (Group B) received mannitol for sustained intracranial hypertension (intracranial pressure > 20 mm Hg, > 10 minutes). Radiographic evidence of delayed cerebral infarction was observed in 14 patients. Overall, 17 patients died or were severely disabled. Cerebral AVDO(2) was elevated before craniotomy or mannitol administration; the mean AVDO(2) for all patients before treatment was 8.6 +/- 1.8 vol%. Following craniotomy or mannitol administration, the AVDO(2) decreased in 27 patients and increased in five patients (mean AVDO(2) 6.2 +/- 2.1 vol% in all patients; 6 +/- 1.9 vol% in Group A; and 6.4 +/- 2.4 vol% in Group B). The mean CPP was 75 +/- 9.8 mm Hg and no relationship with AVDO(2) was demonstrated. Before treatment, the AVDO was not associated with delayed cerebral infarction or outcome. B; contrast, a limited improvement in elevated AVDO(2) after craniotomy or mannitol administration was significantly associated with delayed cerebral infarction (Group A: p < 0.001; Group B: p < 0.01). Similarly, a limited improvement in elevated AVDO(2) after treatment was significantly associated with an unfavorable outcome (Group A: p < 0.01; Group B: p < 0.001). In conclusion, these findings strongly indicate that, despite adequate cerebral perfusion, limited improvement in elevated cerebral AVDO(2) after treatment consisting of either craniotomy or mannitol administration may be used to help predict delayed cerebral infarction and poor outcome after traumatic brain injury.	UNIV WASHINGTON,DEPT NEUROSURG,HARBORVIEW MED CTR,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT ANESTHESIOL,HARBORVIEW MED CTR,SEATTLE,WA 98195							BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1993, NEUROSURGERY, V32, P547; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CRUZ J, 1992, J TRAUMA, V32, P629, DOI 10.1097/00005373-199205000-00015; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GIBBS EL, 1945, AM J PSYCHIAT, V102, P184, DOI 10.1176/ajp.102.2.184; Gibbs FA, 1934, ARCH NEURO PSYCHIATR, V32, P257, DOI 10.1001/archneurpsyc.1934.02250080003001; GOETTING MG, 1991, INTENS CARE MED, V17, P195, DOI 10.1007/BF01709876; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JAKOBSEN M, 1989, J CEREBR BLOOD F MET, V9, P717, DOI 10.1038/jcbfm.1989.101; JENNETT B, 1975, LANCET, V1, P480; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; KURODA Y, 1992, NEUROSURGERY, V30, P687; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARTIN NA, 1995, N JEUROTRAUMA, V12, P879; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MOULTON RJ, 1994, CLIN INVEST MED, V17, P187; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHENKIN HA, 1948, ARCH NEURO PSYCHIATR, V60, P240, DOI 10.1001/archneurpsyc.1948.02310030021002; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; SUTTON LN, 1987, J NEUROSURG, V67, P381, DOI 10.3171/jns.1987.67.3.0381; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; TEASDALE G, 1974, LANCET, V2, P81	51	58	60	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1997	87	1					1	8		10.3171/jns.1997.87.1.0001			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XF331	WOS:A1997XF33100001	9202258				2021-06-18	
J	Lomnitski, L; Kohen, R; Chen, Y; Shohami, E; Trembovler, V; Vogel, T; Michaelson, DM				Lomnitski, L; Kohen, R; Chen, Y; Shohami, E; Trembovler, V; Vogel, T; Michaelson, DM			Reduced levels of antioxidants in brains of apolipoprotein E-deficient mice following closed head injury	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article; Proceedings Paper	2nd European Pharmacology Biochemistry and Behavior Conference	JAN 05-12, 1997	MORZINE, FRANCE			Alzheimer's disease; apolipoprotein; head trauma; apolipoprotein E-deficient mice; reducing currents; antioxidants	FAMILIAL ALZHEIMERS-DISEASE; OXIDATIVE STRESS; METABOLISM; EXPRESSION	Recent animal model studies using apolipoprotein E (apoE)-deficient (knockout) mice revealed that these mice have memory deficits and neurochemical derangements and that they recover from closed head injury less adequately than control mice. In the present study, we examined the possibility that the diminished recovery of apoE-deficient mice from head injury is related to a reduction in their ability to counteract oxidative damage. Measurements of reducing agents by cyclic voltammetry revealed that cortical homogenates of apoE-deficient and control mice contain similar levels of these compounds, whose oxidation potentials for the two groups of mice are at 400 +/- 40 mV and 900 +/- 50 mV. The responses of the apoE-deficient and control groups to closed head injury were both biphasic and were composed of initial reductions followed by subsequent increases in the levels of reducing antioxidant equivalents. However, the two groups differed markedly in the magnitude of their response. This difference was most pronounced with the 400-mV reducing compounds, such that at 4 h after injury their levels in injured control mice increased over twofold relative to the noninjured control mice, whereas the corresponding anodic current of the apoE-deficient mice recovered only to its original level and did not increase further even by 24 h after injury. In vitro studies using recombinant apoE allele E3 and beta very low density lipoprotein revealed that this lipoprotein can delay Cu2+-induced lipid peroxidation. This suggests that the inability of the apoE-deficient mice to respond to brain injury by a surge in brain reducing compounds may be related, at least in part, to direct antioxidant activity of apoE. (C) 1997 Elsevier Science Inc.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT NEUROBIOCHEM,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,DEPT PHARMACEUT,JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT PHARMACOL,JERUSALEM,ISRAEL; GEN BIOTECHNOL,REHOVOT,ISRAEL							BEITYANNAI E, 1995, J CEREBR BLOOD FL S1, V15, pS713; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BONDY SC, 1995, P SOC EXP BIOL MED, V208, P337; CHEN Y, IN PRESS NEUROSCIENC; CHEVION S, 1997, IN PRESS FREE RADIC; CLARKE GA, 1993, EUR J CELL BIOL, V61, P108; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; FAINARU M, 1988, ARTERIOSCLEROSIS, V8, P130, DOI 10.1161/01.ATV.8.2.130; GENIS I, 1995, NEUROSCI LETT, V199, P5, DOI 10.1016/0304-3940(95)12007-Q; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; GUTTERIDGE JMC, 1990, ARCH BIOCHEM BIOPHYS, V283, P223, DOI 10.1016/0003-9861(90)90635-C; KOHEN R, 1993, J HARM TOXICOL METHO, V29, P485; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LOMNITSKI L, 1997, NEUROCHEMISTRY; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; Pinchuk I, 1996, FREE RADICAL RES, V24, P351, DOI 10.3109/10715769609088033; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696	25	58	60	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	APR	1997	56	4					669	673		10.1016/S0091-3057(96)00412-1			5	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	WV401	WOS:A1997WV40100018	9130293				2021-06-18	
J	Priebe, MM; Sherwood, AM; Graves, DE; Mueller, M; Olson, WH				Priebe, MM; Sherwood, AM; Graves, DE; Mueller, M; Olson, WH			Effectiveness of gabapentin in controlling spasticity: A quantitative study	SPINAL CORD			English	Article						surface electromyography; spasticity; gabapentin; Neurontin; spinal cord injury; assessment		The purpose of this investigation was to study the effectiveness of gabapentin in controlling spasticity in persons with spinal cord injury (SCI) using a surface EMG-based quantitative assessment technique called the brain motor control assessment (BMCA). Six men from a Veterans Affairs Medical Center with spasticity due to traumatic SCI were studied as part of a multi-center, placebo-controlled, cross-over, clinical trial of gabapentin. Spasticity was evaluated using multi-channel surface EMG recordings of muscles in the lower extremities, abdomen and low back before and during treatment with oral gabapentin or placebo. Gabapentin or placebo was given orally in doses 400 mg three times daily for 48 h. Following a 10 day wash-out period subjects were crossed-over to receive the medication not received the first time. This was followed by an elective open-label extension. Group results during the controlled trial did not reach statistical significance at the dosage used. One subject demonstrated a dramatic improvement in spasticity that was apparent both clinically and with the BMCA. Other subjects demonstrated modest improvements which were seen in the BMCA but not recognized clinically. During the open label extension, the four subjects who participated experienced important clinical improvements with higher doses (to 3600 mg/day). These improvements were often in components of spasticity in which the BMCA had detected subclinical changes during the cross-over trial. A seventh subject was studied using the BMCA at doses of 1200 mg T.I.D. gabapentin, off gabapentin and 800 mg T.I.D. gabapentin and demonstrated quantitatively a dose-related effect with higher doses of gabapentin which matched clinical observations. Gabapentin at doses of 400 mg T.I.D. may be effective in controlling some features of spasticity in persons with SCI. Higher doses provide greater control of spasticity, and controlled studies using higher doses are needed to evaluate gabapentin's efficacy.	VET AFFAIRS MED CTR, SPINAL CORD INJURY SERV, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV RESTORAT NEUROL & HUMAN NEUROBIOL, HOUSTON, TX 77030 USA; UNIV KENTUCKY, DEPT PHYS MED & REHABIL, LEXINGTON, KY USA; UNIV LOUISVILLE, DEPT NEUROL, LOUISVILLE, KY 40292 USA	Priebe, MM (corresponding author), BAYLOR COLL MED, DEPT PHYS MED & REHABIL, HOUSTON, TX 77030 USA.			Graves, Daniel/0000-0002-1389-5216; Sherwood, Arthur/0000-0002-0110-4317			DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; KATZ RT, 1989, ARCH PHYS MED REHAB, V70, P144; Petroff OAC, 1996, ANN NEUROL, V39, P95, DOI 10.1002/ana.410390114; Sherwood AM, 1996, MUSCLE NERVE, V19, P966, DOI 10.1002/(SICI)1097-4598(199608)19:8<966::AID-MUS5>3.0.CO;2-6; SHERWOOD AM, 1996, IN PRESS J ELECTROPH; YOUNG RR, 1994, NEUROLOGY, V44, P12	6	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	MAR	1997	35	3					171	175		10.1038/sj.sc.3100366			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WM369	WOS:A1997WM36900008	9076868	Bronze			2021-06-18	
J	McMillan, TM				McMillan, TM			Post-traumatic stress disorder following minor and severe closed head injury: 10 single cases	BRAIN INJURY			English	Article							DISASTER; SCALE	Post-traumatic stress disorder (PTSD) was found to occur after minor or severe closed head injury in 10 single cases which are reported in detail. They were drawn from 312 cases of closed head injury who were referred for neuropsychological assessment or neurorehabilitation. All cases which had been given both diagnoses are presented. Information was collected retrospectively from case notes and reports. It is argued that a continuum of experience, which represents the entirety of an event, is not necessary for PTSD to occur, but that a 'window' of real or imagined experience which results from loss of consciousness and post-traumatic amnesia after closed head injury need not prevent the symptoms of PTSD from arising, although they may make them less likely and the phenomenon of the dual diagnoses relatively rare. The issue of whether PTSD found following closed head injury is a subclassification of PTSD is raised.	ST GEORGES HEALTHCARE, ATKINSON MORLEYS HOSP, LONDON SW20 0NE, ENGLAND	McMillan, TM (corresponding author), ST GEORGES HEALTHCARE, WOLFSON MED REHABIL CTR, COPSE HILL, LONDON SW20 0NE, ENGLAND.						*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P424; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, P247; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Baddeley A.D., 1992, SPEED CAPACITY LANGU; Beck A.T., 1987, BECK DEPRESSION INVE; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; COUGHLAN AK, 1985, ADULT MEMORY INFORMA; DAVIDOFF DA, 1988, COGNITIVE REHABILITA, V6, P8; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; EVERLY GS, 1989, PERCEPT MOTOR SKILL, V68, P807, DOI 10.2466/pms.1989.68.3.807; GERSONS BPR, 1992, BRIT J PSYCHIAT, V161, P742, DOI 10.1192/bjp.161.6.742; GREENWOOD RJ, 1994, BRIT MED J, V308, P1199, DOI 10.1136/bmj.308.6938.1199; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; HORTON AM, 1988, ARCH CLIN NEUROPSYCH, V6, P8; Jennett B, 1981, MANAGEMENT HEAD INJU; JOSEPH S, 1993, BRIT J CLIN PSYCHOL, V32, P327, DOI 10.1111/j.2044-8260.1993.tb01063.x; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KOLB LC, 1987, AM J PSYCHIAT, V144, P989; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Middelboe T., 1992, European Psychiatry, V7, P183; Nelson H. E., 1991, NATIONAL ADULT READI; Peterson L G, 1986, Adv Psychosom Med, V16, P84; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SBORDONE RJ, 1992, NEUROLAW LETT, V3; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; THOMPSON J, 1994, BRIT J CLIN PSYCHOL, V33, P75, DOI 10.1111/j.2044-8260.1994.tb01096.x; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WATSON IPB, 1988, BRIT J PSYCHIAT, V152, P164; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	33	58	59	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	1996	10	10					749	758		10.1080/026990596124016			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VH730	WOS:A1996VH73000005	8879665				2021-06-18	
J	Alsop, DC; Murai, H; Detre, JA; McIntosh, TK; Smith, DH				Alsop, DC; Murai, H; Detre, JA; McIntosh, TK; Smith, DH			Detection of acute pathologic changes following experimental traumatic brain injury using diffusion-weighted magnetic resonance imaging	JOURNAL OF NEUROTRAUMA			English	Article						magnetic resonance imaging; traumatic brain injury; diffusion; diffuse axonal injury	AXONAL INJURY; HEAD-INJURY; RAT; ARTIFACTS; MODEL; MRI	Standard magnetic resonance imaging (MRI) has been shown to be remarkably insensitive to acute changes following traumatic brain injury. Because diffusion-weighted MRI has recently demonstrated excellent sensitivity to acute ischemic injury and other CNS abnormalities, we evaluated the use of diffusion MRI for the detection of pathologic changes in the rat brain during the first hours following parasagittal fluid percussion brain injury. Diffusion MRI was able to demonstrate a significant diffusion decrease in the primary cortical contusion injury and a comparable decrease in the ipsilateral thalamus. Tissue damage in the thalamus region is much weaker than in the cortex, but the thalamus is a primary site of axonal and dendritic injury in this model. T2 imaging in the same subjects showed slight enhancement in the neighborhood of the injured cortex but was unable to demonstrate injury elsewhere. Diffusion imaging was superior to T2 at demonstrating injury and the prominent diffusion decrease in the thalamus suggests that diffusion MRI is preferentially sensitive to axonal or dendritic injury.	UNIV PENN,MED CTR,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT NEUROL,PHILADELPHIA,PA 19104	Alsop, DC (corresponding author), UNIV PENN,MED CTR,DEPT RADIOL,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		smith, douglas/A-1321-2007; Alsop, David C/J-5764-2013	Alsop, David C/0000-0002-8206-1995	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803, P01NS008803, R55NS026818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ANDERSON AW, 1994, MAGNET RESON MED, V32, P379, DOI 10.1002/mrm.1910320313; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTRY LR, 1994, RADIOLOGY, V191, P1; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; KARLICEK RF, 1980, J MAGN RESON, V37, P75, DOI 10.1016/0022-2364(80)90095-5; LATOUR LL, 1994, MAGNET RESON MED, V32, P189, DOI 10.1002/mrm.1910320207; LEBIHAN D, 1991, JMRI-J MAGN RESON IM, V1, P7, DOI 10.1002/jmri.1880010103; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MORI S, 1994, P SOC MAGN RES 1994, P135; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; ORDIDGE RJ, 1994, MAGN RESON IMAGING, V12, P455, DOI 10.1016/0730-725X(94)92539-9; Pierce JES, 1996, J NEUROSCI, V16, P1083; SKLAR EML, 1992, RADIOL CLIN N AM, V30, P353; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; WONG EC, 1994, P SMR 2 ANN M SAN FR, P136; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; ZHONG J, 1993, MAGN RESON MED, V30, P241, DOI 10.1002/mrm.1910300214	27	58	60	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1996	13	9					515	521		10.1089/neu.1996.13.515			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VP266	WOS:A1996VP26600004	8913968				2021-06-18	
J	Tepper, S; Beatty, P; DeJong, G				Tepper, S; Beatty, P; DeJong, G			Outcomes in traumatic brain injury: Self-report versus report of significant others	BRAIN INJURY			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; HEAD-INJURY; PSYCHOSOCIAL RECOVERY; DISABILITY; STABILITY; RETURN; WORK	This paper examines the inter-rater reliability of 148 persons with traumatic brain injury (PwTBI) and their significant others (SO) on the Functional Independence Measure (FIM), and the Community Integration Questionnaire (CIQ). Results reveal that agreement differs across instruments and subscales, with greatest response comparability on the productivity CIQ subscale, followed by the motor FIM, social integration CIQ, cognitive FIM, and home integration CIQ. These findings have important implications for the future of TBI outcomes studies.		Tepper, S (corresponding author), NATL REHABIL HOSP RES CTR,WASHINGTON,DC 20010, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR304550] Funding Source: Medline		BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; BURTON LA, 1993, J REHABILITATION OCT, P34; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Data Management Service of the Uniform Data System for Medical Rehabilitation and the Center for Functional Assessment Research, 1990, GUIDE USE UNIFORM DA; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Helmstadter G.C., 1964, PRINCIPLES PSYCHOL M; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MAGAZINER J, 1988, J CLIN EPIDEMIOL, V41, P1065, DOI 10.1016/0895-4356(88)90076-5; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; OTTENBACHER KJ, 1994, ARCH PHYS MED REHAB, V75, P1297; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; WARE JE, 1993, SF36 HLTH SURV MAN I; Willer B, 1994, BRAIN INJURY REHABIL, P355; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	27	58	58	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1996	10	8					575	581		10.1080/026990596124142			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UZ656	WOS:A1996UZ65600003	8836514				2021-06-18	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Impact acceleration-induced severe diffuse axonal injury in rats: Characterization of phosphate metabolism and neurologic outcome	JOURNAL OF NEUROTRAUMA			English	Article						magnetic resonance; trauma; magnesium; bioenergetics	TRAUMATIC BRAIN INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; EXPERIMENTAL HEAD-INJURY; VOLTAGE-DEPENDENT BLOCK; MAGNESIUM; PH; DAMAGE; MG-2+; POTASSIUM; RESPONSES	Diffuse axonal injury (DAI) occurs in over half of all severe cases of traumatic brain injury and has been associated with the development of a persistent vegetative state. Although a number of studies have examined the biochemical and physiological events following brain trauma, none of these has concentrated on events associated with the occurrence of severe DAI, The present study has used phosphorus magnetic resonance spectroscopy (MRS) and the rotarod motor test to characterize metabolic and neurologic consequences of severe diffuse axonal injury in rats induced by impact acceleration. Traumatic brain injury was induced in male rats by dropping a 450-g brass weight a distance of 2 m onto a 10-mm stainless-steel disc (3 mm wide) attached to the closed skull, Changes in brain intracellular pH, free magnesium concentration, cytosolic phosphorylation ratio, and mitochondrial oxidative metabolism after injury were monitored by phosphorus MRS while neurologic motor outcome over 1 week was assessed using the rotarod test, Impact acceleration-induced injury resulted in a highly significant decline in free magnesium concentration, cytosolic phosphorylation ratio, and an increased rate of mitochondrial oxidative phosphorylation, but no significant change in pH, These changes were associated with the occurrence of a significant neurologic deficit over 1 week postinjury, The similarity in metabolic events associated with production of neurologic deficits in this and other models of traumatic brain injury suggests that these bioenergetic changes may be common to all models of brain trauma.	JAMES COOK UNIV N QUEENSLAND,DIV BIOCHEM & HUMAN PHYSIOL,TOWNSVILLE,QLD 4811,AUSTRALIA			AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Bara M, 1984, MAGNESIUM, V3, P212; BRAUGHLER JM, 1992, 1991 MA LIEB INC CEN, P1; BROWN AM, 1991, MG2 PLUS EXCITABLE M, P21; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; COHN M, 1962, J BIOL CHEM, V237, P176; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; EMERSON CS, 1992, NEUROREPORT, V11, P957; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GUNTHER T, 1986, MAGNESIUM, V5, P53; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAYES RL, 1992, 1991 CENTR NERV SYST, P173; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HOVDA DA, 1990, ACT NEUR S, V51, P331; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; JOHNSON JW, 1990, BIOPHYS J, V57, P1085, DOI 10.1016/S0006-3495(90)82626-6; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KRAMER RS, 1979, 1979 CENTR NERV SYST, P70; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; SALZMAN SK, 1987, J NEUROSURG, V66, P431, DOI 10.3171/jns.1987.66.3.0431; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, J NEUROTRAUMA, V5, P365; WONG PP, 1994, BRAIN INJURY, V8, P509, DOI 10.3109/02699059409151003; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG W, 1994, NEUROBIOLOGY CENTRAL, P123	51	58	60	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1995	12	6					1027	1034		10.1089/neu.1995.12.1027			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TU518	WOS:A1995TU51800003	8742131				2021-06-18	
J	RAGHUPATHI, R; MCINTOSH, TK; SMITH, DH				RAGHUPATHI, R; MCINTOSH, TK; SMITH, DH			CELLULAR-RESPONSES TO EXPERIMENTAL BRAIN INJURY	BRAIN PATHOLOGY			English	Article							IMMEDIATE-EARLY GENES; HEAT-SHOCK PROTEIN; RAT-BRAIN; C-FOS; STATUS EPILEPTICUS; NERVOUS-SYSTEM; EXPRESSION; HIPPOCAMPUS; ISCHEMIA; JUN	Little is known regarding the molecular (genomic) events associated with the pathophysiology of traumatic brain injury (TBI). This review focusses on the experimental efforts to date elucidating the acute alterations in expression of immediate early genes (IEGs), heat shock proteins (HSPs) and cytokines following experimental brain injury. The immediate early genes, c-fos, c-jun and junB were observed to be bilaterally induced in the cortex and hippocampus as early as 5 min following lateral fluid-percussion (FP) brain injury in the rat. While levels of c-fos and junB mRNA returned to control levels by 2h, c-jun mRNA remained elevated up to 6h post-injury. Increased levels of mRNA for the inducible heat-shock protein (hsp72) were observed up to 12h following injury and were restricted to the cortex ipsilateral to the impact site. Mild induction of the glucose-regulated proteins (grp78 and grp94), which share sequence homology with hsp72, was apparent in the ipsilateral cortex. The cytokines IL-1 beta and TNF alpha were induced at 1h following FP brain injury and remained elevated up to 6h post-injury. These data, while indicative of the complex genomic response to TBI, are also suggestive of the trauma-induced activation of multiple signal transduction pathways.		RAGHUPATHI, R (corresponding author), UNIV PENN,DEPT SURG,DIV NEUROSURG,7 HAYDEN HALL,3320 SMITH WALK,PHILADELPHIA,PA 19104, USA.		smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803, R01NS026818, R55NS026818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 08803, NS 26818] Funding Source: Medline		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; BENJAMIN IJ, 1989, J CLIN INVEST, V89, P1685; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHOPP M, 1993, CURR OPIN NEUROL NEU, V6, P6; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; D'MELLO SR, 1991, MOL BRAIN RES, V11, P255, DOI 10.1016/0169-328X(91)90034-U; DASH PK, 1995, J NEUROSCI, V15, P2030; Dekosky S. T., 1994, Society for Neuroscience Abstracts, V20, P193; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; FAN L, 1994, J NEUROTRAUM, V11, P108; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GASS P, 1993, EUR J NEUROSCI, V5, P933, DOI 10.1111/j.1460-9568.1993.tb00944.x; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; KINOUCHI H, 1994, J CEREBR BLOOD F MET, V14, P808, DOI 10.1038/jcbfm.1994.101; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH T, 1989, Society for Neuroscience Abstracts, V15, P132; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NEUMANNHAEFELIN T, 1994, J CEREBR BLOOD F MET, V14, P206, DOI 10.1038/jcbfm.1994.27; NOWAK TS, 1990, STROKE, V21, P107; NOWAK TS, 1990, CEREBROVAS BRAIN MET, V2, P345; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PIERCE JES, 1995, J NEUROTRAUM, V12, P134; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Rink A. D., 1994, Society for Neuroscience Abstracts, V20, P250; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; SHENG M, 1989, NEURON, V4, P477; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SIMONATO M, 1991, MOL BRAIN RES, V11, P115, DOI 10.1016/0169-328X(91)90113-C; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SUN FY, 1995, BRAIN RES, V661, P63; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; WELSH FA, 1992, J CEREBR BLOOD F MET, V12, P204, DOI 10.1038/jcbfm.1992.30; WESSEL TC, 1991, BRAIN RES, V567, P231, DOI 10.1016/0006-8993(91)90800-B; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; YOUNG B, 1992, J NEUROTRAUM, V9, pS375	51	58	59	0	1	INT SOC NEUROPATHOLOGY	ZURICH	ISN JOURNAL PO BOX, CH-8033 ZURICH, SWITZERLAND	1015-6305			BRAIN PATHOL	Brain Pathol.	OCT	1995	5	4					437	442		10.1111/j.1750-3639.1995.tb00622.x			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	TK374	WOS:A1995TK37400010	8974626				2021-06-18	
J	SAKAS, DE; BULLOCK, MR; PATTERSON, J; HADLEY, D; WYPER, DJ; TEASDALE, GM				SAKAS, DE; BULLOCK, MR; PATTERSON, J; HADLEY, D; WYPER, DJ; TEASDALE, GM			FOCAL CEREBRAL HYPEREMIA AFTER FOCAL HEAD-INJURY IN HUMANS - A BENIGN PHENOMENON	JOURNAL OF NEUROSURGERY			English	Article						HYPEREMIA; CEREBRAL BLOOD FLOW; ISCHEMIA; INFARCTION; SUBDURAL HEMATOMA; HEAD INJURY; SINGLE-PHOTON EMISSION COMPUTERIZED TOMOGRAPHY	ACUTE SUBDURAL-HEMATOMA; BLOOD-FLOW; INTRAVENTRICULAR PRESSURE; GLUCOSE HYPERMETABOLISM; SPECT; METABOLISM; MECHANISMS; CHILDREN; RAT; AUTOREGULATION	To assess the relationship between posttraumatic cerebral hyperemia and focal cerebral damage, the authors performed cerebral blood flow mapping studies by single-photon emission computerized tomography (SPECT)) in 53 patients within 3 weeks of brain injury. Focal zones of hyperemia were present in 38% of patients. Hyperemia was correlated with clinical features and early computerized tomography (CT) and magnetic resonance (MR) imaging performed within 48 hours of the SPECT study and late CT and MR studies at 3 months. The hyperemia was observed primarily in structurally normal brain tissue (both gray and white matter), as revealed by CT and MR imaging, immediately adjacent to intraparenchymal or extracerebral focal lesions; it persisted for up to 10 days, but was never seen within the edematous pericontusional zones. The percentage of patients in the hyperemic group having brief (< 30 minutes) or no loss of consciousness was significantly higher than in the nonhyperemic group (twice as high, p < 0.05). Other clinical parameters were not significantly more common in the hyperemic group. The mortality of patients with focal hyperemia was lower than that of individuals without it, and the outcome of survivors with hyperemia was slightly better than patients without hyperemia. These results differ from the literature, which suggests that global post traumatic hyperemia is primarily an acute, malignant phenomenon associated with increased intracranial pressure, profound unconsciousness, and poor outcome. The current results agree with more recent studies which show that post traumatic hyperemia may occur across a wide spectrum of head injury severity and may be associated with favorable outcome.	SO GEN HOSP, INST NEUROL SCI, GLASGOW G51 4TF, LANARK, SCOTLAND; UNIV GLASGOW, DEPT NEUROSURG, GLASGOW, LANARK, SCOTLAND					Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ANDERSEN A R, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P288; ANDERSON WF, 1988, BIOESSAYS, V8, P69, DOI 10.1002/bies.950080206; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BULLOCK R, 1991, STROKE, V22, P1284, DOI 10.1161/01.STR.22.10.1284; BULLOCK R, 1994, INTRACRANIAL PRESSUR, P264; BULLOCK R, 1995, IN PRESS J NEUROTRAU; BULLOCK R, 1989, INTRACRANIAL PRESSUR, V7, P637; ENDOH K, 1991, AM J PHYSIOL, V261, pG1037; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; Eriksson L, 1986, Acta Radiol Suppl, V369, P453; FARACI FM, 1991, HYPERTENSION, V17, P917, DOI 10.1161/01.HYP.17.6.917; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FUMEYA H, 1990, ACT NEUR S, V51, P283; GEMMELL HG, 1990, J NUCL MED, V31, P1595; HEISS WD, 1990, J CEREBR BLOOD F MET, V10, P687, DOI 10.1038/jcbfm.1990.122; INGLIS F, 1992, J NEUROTRAUM, V9, P75, DOI 10.1089/neu.1992.9.75; JENNETT B, 1975, LANCET, V1, P480; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; KURODA Y, 1992, NEUROSURGERY, V31, P1062, DOI 10.1227/00006123-199212000-00012; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; MACFARLANE R, 1991, J NEUROSURG, V75, P845, DOI 10.3171/jns.1991.75.6.0845; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MOSKOWITZ MA, 1989, AM J PHYSIOL, V257, pH1736; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NEIRINCKX RD, 1987, J NUCL MED, V28, P191; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; OVERGAARD J, 1976, J NEUROSURG, V45, P292, DOI 10.3171/jns.1976.45.3.0292; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PAULSON OB, 1972, NEUROLOGY, V22, P286, DOI 10.1212/WNL.22.3.286; PELLIGRINO DA, 1992, AM J PHYSIOL, V262, pE447; POHL U, 1991, AM J PHYSIOL, V261, pH2016; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SAKAS DE, 1989, P NATL ACAD SCI USA, V86, P1401, DOI 10.1073/pnas.86.4.1401; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SCHUTTA HS, 1968, BRAIN, V91, P281, DOI 10.1093/brain/91.2.281; SPERLING B, 1993, STROKE, V24, P193, DOI 10.1161/01.STR.24.2.193; TEASDALE G, 1974, LANCET, V2, P81; TSUDA Y, 1988, EUR J NUCL MED, V14, P546; WALDEMAR G, 1989, BRIT J CLIN PHARMACO, V28, pS177, DOI 10.1111/j.1365-2125.1989.tb03593.x; ZUPPING R, 1970, J NEUROSURG, V33, P498, DOI 10.3171/jns.1970.33.5.0498	50	58	58	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	1995	83	2					277	284		10.3171/jns.1995.83.2.0277			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	RL110	WOS:A1995RL11000015	7616274				2021-06-18	
J	ZINK, BJ; FEUSTEL, PJ				ZINK, BJ; FEUSTEL, PJ			EFFECTS OF ETHANOL ON RESPIRATORY-FUNCTION IN TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC BRAIN INJURY; RESPIRATORY FUNCTION; VENTILATION; ETHANOL; PIG	NERVOUS-SYSTEM TRAUMA; ALCOHOL-INTOXICATION; HEAD-INJURY; NALOXONE; POTENTIATION; DEPRESSION; RESPONSES; OXYGEN; DAMAGE; CAT	It has been observed that traumatic brain injury (TBI) increases the susceptibility of the brain to subsequent hypoxia, and prolonged apnea occurs in ethanol (EtOH)-treated animals following brain injury. This investigation tests the hypothesis that EtOH suppresses ventilation and hypercapnic respiratory drive following TBI. Immature pigs were anesthetized with halothane and received a 2 to 3 atm fluid-percussion brain injury. Respiratory parameters, including tidal volume, frequency, ventilation (V-E), and arterial blood gases were measured on 100% O-2 and on 5% to 6% inspired CO2 in O-2 prior to and at 1O, 60, 120, and 180 minutes after TBI. Hypercapnic response sensitivity (S) was measured as the change in V-E per mm Hg increase in PaCO2. Intracranial pressure, mean arterial blood pressure, heart rate, brain temperature, glucose, and EtOH levels were also monitored. Three groups were studied: the first group of six received EtOH (3.5 gm/kg, intragastrically) without brain injury; the second group of six received TBI without EtOH; the third group of eight received EtOH and TBI. Ethanol levels were 121 +/- 13 (standard error of the mean) mg/dl in the EtOH/TBI group (136 +/- 25 in the EtOH group) at the time of injury, and 175 +/- 12 mg/dl in the EtOH/TBI group (200 +/- 20 mg/dl in the EtOH group) at 120 minutes after injury. The EtOH/TBI animals had significantly lower V-E and S, and higher PaCO2 following brain injury (p < 0.05, repeated-measures analysis of variance). No significant differences were identified between groups for pH, PaCO2, intracranial pressure, heart rate, brain temperature, or glucose levels. Ethanol intoxication leads to significant impairment of respiratory control following traumatic brain injury and may contribute to brain injury in intoxicated trauma victims.	ALBANY MED COLL,DEPT SURG,ALBANY,NY	ZINK, BJ (corresponding author), UNIV MICHIGAN,MED CTR,DEPT SURG,EMERGENCY SURG SECT,UH B1C255,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.						ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; BAZOR D, 1982, NEW ENGL J MED, V306, P1363; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; BUNEGIN L, 1986, CRIT CARE MED, V14, P387, DOI 10.1097/00003246-198604000-00151; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DILUZIO NR, 1969, EXP MOL PATHOL, V11, P38, DOI 10.1016/0014-4800(69)90069-0; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FELL JC, 1990, 34 ANN P ASS ADV AUT, P69; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GORDIS E, 1989, ALCOHOL ALERT NAT I, V3, P1; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JEFFCOATE WJ, 1979, LANCET, V2, P1157; JEFFERYS DB, 1980, LANCET, V1, P308; JOHNSTONE RE, 1973, CLIN PHARMACOL THER, V14, P501; KAZEMI H, 1991, J APPL PHYSIOL, V70, P1, DOI 10.1152/jappl.1991.70.1.1; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; LOVINGER DM, 1993, ALCOHOL CLIN EXP RES, V17, P19, DOI 10.1111/j.1530-0277.1993.tb00720.x; MARSHALL BE, 1985, PHARMACOL BASIS THER, P276; MELTON JE, 1990, J APPL PHYSIOL, V69, P1296; MICHIELS TM, 1983, J APPL PHYSIOL, V55, P929; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MOSS IR, 1981, J APPL PHYSIOL, V50, P1011; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SAHN SA, 1975, CLIN SCI MOL MED, V49, P33, DOI 10.1042/cs0490033; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; SELIGMAN ML, 1977, LIPIDS, V12, P945, DOI 10.1007/BF02533316; STEWART JR, 1988, 32 ANN P ASS ADV AUT, P319; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; ZINK BJ, 1988, CIRC SHOCK, V24, P19	38	58	59	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1995	82	5					822	828		10.3171/jns.1995.82.5.0822			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	QU325	WOS:A1995QU32500016	7714608				2021-06-18	
J	KOTAPKA, MJ; GRAHAM, DI; ADAMS, JH; GENNARELLI, TA				KOTAPKA, MJ; GRAHAM, DI; ADAMS, JH; GENNARELLI, TA			HIPPOCAMPAL PATHOLOGY IN FATAL HUMAN HEAD-INJURY WITHOUT HIGH INTRACRANIAL-PRESSURE	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; AMINO-ACIDS; DAMAGE; RAT	Traumatically induced hippocampal damage is a frequent sequela of fatal human head injury and is traditionally considered to be the result of decreased cerebral perfusion secondary to raised intracranial pressure (ICP). However, in previous studies employing an experimental model of acceleration head injury, hippocampal lesions have been observed in the absence of high ICP. To further elucidate the role of raised ICP in the production of posttraumatic hippocampal neuronal damage, 14 cases of fatal human nonmissile head injury, in which the measured ICP was less than 20 mm Hg, were subjected to light microscopic evaluation for the frequency and anatomic distribution of hippocampal damage. The mean maximal ICP of the 14 patients was 17.6 mm Hg. Detailed light microscopic evaluation revealed hippocampal lesions in 12 of the 14 cases studied (86%). These lesions were typically bilateral foci of selective neuronal loss in the CA1 subfield of the hippocampus. The nature and distribution of hippocampal lesions were similar to those previously reported both in fatal human head injury associated with elevated ICP and in experimental acceleration head injury without raised ICP. These results provide further evidence that the occurrence of hippocampal neuronal loss following head injury is not exclusively dependent on elevated PCP. Other mechanisms, such as pathologic excitation of neurons, may be involved.	UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA; UNIV GLASGOW,DEPT NEUROPATHOL,GLASGOW,SCOTLAND							ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Brown A W, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P155; BULLOCK R, 1990, ACT NEUR S, V51, P274; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; INGLIS FM, 1990, ACT NEUR S, V51, P277; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1993, J NEURTRAUMA S1, V10, P142; LORENTEDENO R, 1934, J PSYCHOL NEUROL LPZ, V46, P113; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001	26	58	59	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1994	11	3					317	324		10.1089/neu.1994.11.317			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PF221	WOS:A1994PF22100007	7996585				2021-06-18	
